,ticker,content
0,JNJ,medtech player stryker syk say wednesday isn discussion acquire boston scientific bsx prod stryker share pop boston scientific stock topple stryker be not discussion boston scientific corporation regard potential acquisition firm say filing security exchange commission stock market today stryker share climb close stock have slide previous session boston scientific other hand tumble reversed day gain rbc analyst glenn novarro note recent stock decline have make potential boston deal less favorable financially have expect medical supplier have pay share more deal get newsletter deliver inbox more info product service privacy policy term use assume split debt equity deal estimate decline stryker share post wall street journal story have force stryker issue additional share potential boston scientific deal say note overall be strategic rationale deal create value have be challenge novarro say reiterate outperform rating stryker also call pullback monday tuesday buy opportunity dow jone component johnson johnson jnj be better acquirer boston say further valuation potential pure play spine target move higher stryker still have firepower appetite deal say related chart read basic buy point mark time real much money do need start investing sell great stock take profit regularly mostly
1,JNJ,stock turn lower just midday tuesday hurt decline share micron technology mu china court temporarily ban sale micron chip china ruling favor unite microelectronic umc patent infringement lawsuit less hour remain tuesday shorten session dow jone industrial average be blue chip component johnson johnson jnj coca cola ko merck mrk lead way gain nasdaq composite be give back small cap be bright spot russell rise meanwhile crude oil top barrel level first time late quickly turn tail hit intraday high barrel crude oil future reversed sharply lower august crude oil be recently trading barrel stock market result today volume be heavy conocophillip cop share rise work flat base buy point share roku roku jump help oppenheimer upgrade outperform just handle entry heavy volume gainer include health care leader amedisys am share gap new high rise help upgrade bank america buy neutral amedisys be well extend price base march medical software space marketsmith growth name medidata solution mdso look poise extend winning streak session share rise cup handle base buy point medidata have form handle alternate entry royal gold rgld pop lengthy consolidation rise buy interest amarillo gold mara rosa gold project brazil elsewhere share facebook fb be pressure nearly news widen probe regard cambridge analytica datum scandal tuesday downdraft facebook chart still look hold buy point get instant access more trading idea exclusive stock list ibd proprietary rating only also ibd tipp poll economic optimism surge stock nvidia start listsu auto sale ford fiat chrysler top view gm tap
2,JNJ,kris bakowski be diagnosed alzheimer disease georgia resident feel relieve finally put name fog be slowly envelop brain even be viable alzheimer treatment month forget own phone number have trouble colleague name mapping route home work become chore day find alone mall recollection be get biopharma company believe be able help soon analyst say biogen biib be first crack code disease modify alzheimer treatment slow disease progression indeed biogen tokyo base eisai announce late thursday phase test alzheimer drug slow progression disease month news send biogen stock soar more point friday novartis nvs roche rhhby amgen amgn other also be develop potential alzheimer drug number development stage biotech company victory be not certain number big pharma company include merck mrk eli lilly lly johnson johnson jnj have be road abandon plan alzheimer treatment least expert see success next decade wouldn come too soon bakowski other alzheimer patient get newsletter deliver inbox more info product service privacy policy term usebakowski now have be blog alzheimer experience year blog post alzheimer association describe month testing lead diagnosis subsequent relief hopeful cure son lifetime family isn so optimistic husband liken titanic ship be sink son be go survive wasn write son reflect be mother be death row innocent crime potential alzheimer market be massive estimate american be live alzheimer other form dementia way intervene alzheimer association expect cost care person disease hit today dollar be estimate bakowski many expert be hopeful privately hold proclara bioscience be cadre biotech company aim develop alzheimer treatment chief medical officer david michelson call field pretty vibrant michelson have hold position merck lilly say steady drumbeat bad news alzheimer treatment reflect not so much failure affect specific target brain issue such side effect specific test recently speak webinar host endpoint news lot really tremendous work ongoing enable new approach be become possible generate promising new target say be actually very hopeful optimistic next year hold research alzheimer several drug have be approve treat dementia alzheimer type include eisai namenda allergan agn treat symptom alzheimer disease neither cure disease elliot goldstein chief executive promis neurosciences count type treatment hand none slow progression disease tell investor business daily promis be also work alzheimer treatment trade toronto stock exchange doesn have sale earning yet goldstein previously work novartis be also develop alzheimer drug biogen strongest hope be drug now dub aducanumab goldstein predict drug come market aducanumab have high potential approval have show small improvement decline patient alzheimer symptom say biogen do not respond request comment article visit ibd stock checkup see biogen rate now key fundamental technical metric total biogen have potential alzheimer treatment pipeline aducanumab be farthest late stage study likely have datum analyst say biogen eisai thursday announcement involved drug know ban test involved patient diagnosed early alzheimer company say drug antibody achieve statistical significance key predefined endpoint evaluate effectiveness month biogen stock jump close have surge intraday high gain point still messy field biogen stock plunge valentine day year add new patient ongoing study aducanumab move catch investor guard also week merck scrap late stage alzheimer treatment study risk look likely outweigh benefit be volatile area canaccord analyst sumant kulkarni tell investor business daily have be very spectacular failure past component investor think next work help stock point view then again say nothing else have work past trouble alzheimer treatment research be scientist aren exactly sure cause disease prevailing theory ty disease buildup toxic plaque brain happen protein call beta amyloid structurally change beta amyloid be sticky clump together become plaque pharmaceutical company be look approach beta amyloid essentially boil remove prevent bace inhibitor work prevent buildup monoclonal antibody biogen aducanumab aim remove promis goldstein note adverse event also be sidestep alzheimer treatment come side effect know amyloid related imaging abnormality aria refer swell brain goldstein say promis alzheimer treatment set begin clinical study doesn cause mizuho analyst salim sy say possible help patient get past aria common idiom industry be don get aria be really treat plaque tell ibd then trouble determine study be design well proclara michelson say first evidence show drug engage intend target beta amyloid second patient be proven actually have alzheimer third study be big appropriate duration turn look back history aren many study many drug have be study way really fulfill element say argue only study have hit design goal be merck now fail bace inhibitor know verubecestat biogen aducanumab february merck scrap study alzheimer treatment patient prodromal very early stage alzheimer disease year earlier say same drug have virtually chance find positive effect patient mild moderate form disease meanwhile field be thin stop midstage test bace inhibitor group patient liver safety concern january pfizer pfe stop research alzheimer parkinson disease lilly alzheimer treatment failure late be acutely painful company monoclonal antibody call solanezumab lose late stage study last study be patient mild form alzheimer promis alzheimer treatment bound several toxic misfold protein cause alzheimer goldstein say function theory be other target alzheimer disease outside beta amyloid drug be also testing theory tangle protein call tau be root cause privately hold unite neurosciences hope come vaccine alzheimer goal be use drug treatment early alzheimer preventive measure physician administer drug too late rescue brain unite neurosciences chief medical officer ajay verma tell investor business daily verma background be biogen direct development drug include aducanumab be merck novartis verma expect aducanumab get approval several sell side analyst model likelihood aducanumab appease food drug administration verma see possibility aducanumab be expensive be first treatment slow progression alzheimer disease think challenge be be solution just rich say verma ultimately expect solution treat alzheimer disease lie combination drug be key treat cancer hiv cardiovascular disease metabolic disease high cholesterol say intervention number alzheimer patient triple james hendrix say endpoint news webinar hendrix be director global science initiative alzheimer association need better therapy need sooner rather later hendrix say alzheimer treatment study be tricky unite neurosciences verma say barrier blood brain make get drug brain difficult animal model aren particularly predictive study run long period time further complicate matter science isn sure stage be best treat reason be center approval rate fda alzheimer treatment accord paper present hendrix industry average be research be improve hendrix say scientist be aware potential impact beta amyloid tau well number approach target different stage end be enough alzheimer treatment just delay begin disease several year say be possible delay onset die something else say also stock market forecast next month build long term profit stock take gain robotic surgery revolution be just get term retirement investing strategy etfsnew option strategy limit risk earning
3,JNJ,roche rhhby have mixed news tuesday cancer drug tecentriq succeed lung cancer study celgene celg abraxane fail mashup johnson johnson jnj share roche dip month low stock market today roche stock slide close share dow jone component decline celgene lose broadly stock pharmaceutical company tick study roche test tecentriq chemotherapy include celgene abraxane patient advanced form lung cancer regimen help never treat patient live significantly longer compare chemo alone tecentriq combination also reduce risk disease worsening death compare chemotherapy alone roche say news release get newsletter deliver inbox more info product service privacy policy term piece study news pockmarked roche stock janssen unit terminate study testing drug darzalex tecentriq patient advanced type lung cancer accord news release weekend patient be previously treat decision follow review independent datum monitoring committee find observed benefit regimen vs tecentriq alone addition committee note numerical increase patient death receive combination base finding janssen also decide discontinue study evaluate darzalex drug similar tecentriq patient multiple myeloma janssen have license genmab develop manufacture commercialize darzalex be disappoint study be discontinue genmab fully support janssen decision patient safety be paramount drug development genmab chief executive jan van winkel say prepared statement related trade stock most penny stock fail make investor richsell take profit hold here be several guideline followwhat be inflation do matter fed
4,JNJ,astrazeneca azn eli lilly lly become latest tuesday series pharmaceutical company scrap study potential alzheimer disease treatment appear unlikely work drugmaker discontinue phase study drug call lanabecestat independent datum monitoring committee predict lanabecestat miss goal study early alzheimer disease mild alzheimer dementia complexity alzheimer disease pose most difficult medical challenge time lilly research lab president daniel skovronsky say written statement be grateful contribution study participant family lanabecestat belong class drug call bace inhibitor work prevent buildup substance call beta amyloid plaque brain researcher believe toxic substance be center alzheimer disease get newsletter deliver inbox more info product service privacy policy term useastrazeneca lilly be far only pharmaceutical company frustrated pursuit alzheimer disease treatment dow jone component merck mrk end study drug verubecestat mild moderate early alzheimer disease earlier year fellow dow jone stock pfizer pfe abandon research treatment alzheimer parkinson disease johnson johnson jnj stop study bace inhibitor patient late stage alzheimer disease liver worry lilly stock crash drug miss goal phase study lilly study drug solanezumab patient mild alzheimer disease market be increasingly look biogen be work monoclonal antibody drug know aducanumab work remove beta amyloid plaque brain analyst expect biogen have datum key study lilly say tuesday doesn expect significant cost associate decision end study potential alzheimer disease treatment reaffirm guidance midterm guidance remainder decade be commit ensure finding be used inform further research alzheimer community give importance find treatment disease say astrazeneca spokesperson menela pangalos statement stock market today lilly sank fraction close share be consolidate buy point astrazeneca lose collectively share pharmaceutical company be flat related invest stock free new apps aim buy stock ahead earning report be inflation do matter fed
5,JNJ,artificial intelligence now firmly entrench many hospital operate room field robotic surgery be start get competitive giant company alphabet googl johnson johnson jnj medtronic mdt be training sight intuitive surgical isrg king robotic surgery company analyst say boom medical technology segment have lot room run robotic surgery be area grow billion dollar more machine be used treat patient intuitive command space annual sale signature da vinci robotic surgeon however be limit type procedure handle multus limb da vinci be used variety procedure include cardiac colorectal gynecological head neck thoracic urologic surgery only long re minimally invasive big market be be still unclear yet analyst agree potential have yet be tap so more player be move quickly get newsletter deliver inbox more info product service privacy policy term use think investor need understand robotic ai artificial intelligence revolution be happen touch sector economy say jeremie capron director research manage partner robo global index advisory firm specialize robotic industry investment be technological revolution investor afford miss analyst say march auris health become first company formidable threat intuitive catheter base monarch platform gain approval intuitive counterpunch seek approval flexible catheter similar auris device likely year rbc analyst brandon henry say recent report meanwhile other be work area intuitive surgical doesn have foothold nephew snn have robotic assistant knee replacement stryker syk have robotic joint replacement system mazor robotic mzor zimmer biomet zbh have robotic offering brain spinal surgery mazor alone see sale just system player have long way go take intuitive surgical throne intuitive have market cap today worth nearly capron call intuitive amazing stock think investment community have be scratch head try figure impact new entrant intuitive surgical tell investor business daily feel pretty relax size be big enough small player come share medical tech company have be relatively insulate wo frustrate biotech pharmaceutical stock late stock medical equipment maker such intuitive mazor have collectively spiked year date intuitive blowout quarter april help spur excitement evercore analyst vijay kumar say recent note client recent investor day medtronic be help drive frenzy robotic surgery be topic currently medtech blowout quarter intuitive surgical hint pace manual robotic transition be pick kumar say topic competition elicit various response investor intuitive surgical stock be year climb kumar expect intuitive surgical competition become more apparent next month intuitive da vinci surgical system now boast patient count da vinci system be also move deeper hernias be see early stage adoption bariatric surgery perform induce weight loss myriam curet executive vice president chief medical officer intuitive note email ibd estimate prostatectomy be perform robotic assist surgery same be true malignant hysterectomy general surgery be fastest grow specialty be still early stage adoption procedure such ventral inguinal hernia repair colorectal bariatric surgery say believe be substantial opportunity expand robotic usage category be develop additional tool technology do so year intuitive guide first quarter earning conference call growth number procedure perform system year follow many consider strong fourth quarter recur revenue include instrument accessory da vinci system grow recur revenue represent sale pie still even intuitive surgical see early innings expect robotic surgery present huge total addressable market number da vinci procedure perform year grow nearly other robotic surgery company intuitive closest competitor auris doesn trade publicly recently be stealth mode kumar say medical technology company sign agreement division agreement come month auris monarch system grab approval monarch be flexible catheter surgeon thread patient mouth lung remote control approval investor believe credible competitor intuitive be year away kumar say monarch get approval month ahead view intuitive surgical plan seek approval own flexible catheter later year auris say monarch first target be lung cancer expert estimate half lung biopsy be perform year surgeon also use flexible catheter urinary tract procedure number roughly procedure year intuitive isn sweat competition auris chief executive interestingly be frederic moll founder intuitive surgical intuitive current ceo gary guthart joined medical technology firm take ceo have build technology make decision architecture base first principle not look shoulder other person be do really engage customer deeply understand clinical need guthart say recent earning call rbc henry note auris monarch have larger catheter intuitive allow camera intuitive see benefit smaller catheter move deeper lung henry write recent report allow surgeon potentially use remove diseased tissue meanwhile have team google company call verb surgical analyst be unsure system team be create do expect enter robotic surgery market same time medtronic be partner mazor medtronic also expect own robotic surgery system launch not unreasonable suggest intuitive keep market evercore kumar tell ibd new robotic surgery company have differentiate have straightforward too product say investor have put pretty punchy marketable valuation intuitive surgical re still early stage robotic conversation add market be big enough sustain multiple player company mazor zimmer biomet make system call rosa come have system surgeon use brain spinal procedure other mazor ceo ori hadomi say sizing opportunity robotic surgery company be difficult surgeon use mazor system spinal surgery company renaissance system perform spinal brain surgery cost disposable instrument material comprise mazor revenue hadomi tell ibd surgery perform mazor list price be term disposable item estimate half procedure generate stakeholder expect spine procedure grow rapidly person be be more more active say meaning suffer more injury require surgery more often procedure become less invasive safer procedure become more patient be willing interested be treat be operated benefit robotic surgery be plentiful hadomi say revision surgery surgery correct mistake tweak prior surgery be significantly lower robot assist precision robot help curb potential error say last october mazor unveil result patient study find fivefold reduction complication surgery perform mazor robotic surgery technology notably be also sevenfold reduction revision surgery compare freehand lumbar fusion surgery doubt patient perspective not consider go surgery robot know chance go revision surgery be time higher say revision surgery be also costly hospital face reimbursement hurdle agree robotic surgery win replace human surgeon hadomi liken system other toolbox surgeon be simply medical technology tool make operate easier surgeon safer patient say benefit be also grow investor say robo global capron really exciting be fact be inflection point technology enable robotic surgery price point be attractive say now lot action medtronic see confirmation be substantial addressable market related look best stock buy watch start herecan crispr small biotechs cure disease amazon vs walmart locking horn battle retail futurechart read basic buy point mark time real marijuana industry overtake beer legalization spur innovation
6,JNJ,intuitive surgical isrg break past buy point heavy volume hit record high wednesday knock park once again first quarter analyst say share intuitive jump close stock market today stock break consolidation begin form late january buy point intuitive also joined investor business daily leaderboard sign point strong canaccord analyst jason mill say note client firm continue produce best class result large cap medtech knock park once again first quarter say lion share first quarter metric handily eclipse expectation get newsletter deliver inbox more info product service privacy policy term analyst be more split procedure growth expectation quarter number procedure used intuitive da vinci surgical system rise intuitive cite grow demand general surgery worldwide urologic procedure number da vinci procedure perform grow growth be rest world intuitive raise bottom line outlook growth procedure placement new da vinci system hospital also be highlight grow year year ultimately procedure growth remain key focus investor procedure volume growth have historically be lead indicator additional system placement mill say intuitive expect still early innings large hernia repair market mill say hernia general surgery be expect be biggest procedure volume bucket mill see intuitive fire cylinder evercore analyst vijay kumar note intuitive didn raise top end outlook procedure volume procedure grow say note client question come valuation intuitive stock kumar say hospital be fact purchasing da vinci system anticipation future procedure demand then lofty price earning ratio be justified however give historical comment procedure be lead indicator system placement procedure come line expectation argue greater time price earning ratio capital expenditure revenue beat say maintain high valuation also depend intuitive maintain standing predominant player market kumar say auris health recently launch monarch platform lung biopsy same time dow jone component johnson johnson jnj medtronic mdt be move robotic surgery market investor be more comfortable pay premium price earning ratio asset perceive have monopoly power say other entrant come make case sustenance monopoly power bull argue intuitive have technological lead rival debate be likely come head next month kumar say meantime kumar say be stay sideline canaccord mill up price target intuitive keep hold rating related much volume look stock look best stock buy watch start basic analyze stock cup handle
7,JNJ,consumer health giant johnson johnson jnj nudge sale guidance higher tuesday even blockbuster drug remicade continue face competitive pressure demand cancer treatment surge first quarter oncology be grow field first quarter sale cancer drug grow unit include brand drug account total pharmaceutical sale rise respectively prior quarters result boost full year sale view range midpoint beat consensus view dow jone component also reaffirm adjust profit target share analyst have modeled rbc analyst glenn novarro note beat expectation board get newsletter deliver inbox more info product service privacy policy term use pharma upside drive higher revenue guidance subdue expectation drive share higher say note client sale segment be estimate pharmaceutical segment be primary source upside stock market today share slide close first quarter report adjust profit share sale metric rise vs year earlier period sale easily top consensus analyst poll zack investment research adjust profit beat nickel share pharmaceutical unit bring beat novarro view cancer drug zytiga be single biggest source upside say zytiga generate revenue novarro estimate darzalex treat multiple myeloma adult also beat expectation say sale fellow cancer drug imbruvica be just line respectively sale drug grow vs last year same time sale inflammation drug remicade decline bring just total pharmaceutical sale remicade face competition biologic copy know biosimilar make dow merck mrk pfizer pfe consumer unit make product baby shampoo neutrogena grow sale biggest upside come beauty product rise meanwhile sale wound care product fall medical device sale rise beating novarro model orthopedic sale spine product decline lead dip sale knee replacement evercore analyst vijay kumar call result soft segment think most be due tougher sequential comparison say note normalize think first quarter sequential volume trend slow base point related unitedhealth top earning view hike outlook do spot major market top easy look heavy best stock buy watch start buy stock ahead earning report
8,JNJ,start stock dow jone industrial average djia now include america largest company wide range industry include apple aapl exxon mobil xom intel intc nike nke goldman sachs gs general electric ge have be only remain original dow stock be just replace walgreen boot alliance wba conjunction nasdaq composite dow jone index dow stock serve bellwether general market american economy help investor gauge current environment future outlook bookmark page ongoing coverage dow stock benchmark index scroll see list component stock dow jone industrial average index get newsletter deliver inbox more info product service privacy policy term useclick symbol get latest news stock quote company get instant access more trading idea exclusive stock list ibd proprietary rating only related best stock buy stock be ibd big cap
9,JNJ,rumore buyout drugmaker tesaro tsro swiss drugmaker roche rhhby send share tesaro soar wednesday make little sense strategic standpoint analyst say rbc analyst kennen mackay see combination unlikely give see lack compelling strategic rationale tesaro make ovarian cancer drug call zejula compete rival drug astrazeneca azn clovis oncology clvs mackay note tesaro guidance zejula sale be trouble rivalry grow ovarian cancer drug sale expect tesaro lower full year outlook make potential acquirer hesitant say report client spanish intereconomia com say late tuesday roche be interested acquire tesaro announce plan buy foundation medicine fmi site report roche announce acquisition tesaro next few day get newsletter deliver inbox more info product service privacy policy term useat close bell stock market today tesaro stock rocket stock pop much earlier trading roche lift same time biotech stock rise less further tesaro already have ongoing collaboration dow jone component merck mrk treat form breast cancer ovarian cancer also partner johnson johnson jnj develop zejula treat prostate cancer roche other hand be collaborate roche rival clovis treat gynecological tumor clovis make ovarian cancer drug call rubraca duo be testing rubraca roche immuno oncology drug call tecentriq roche focus develop acquire best class molecule see rubraca line effectiveness superior safety vs zejula potentially better fit context strategy zejula mackay say tesaro too already have partnership zejula market outside detract value acquire global pharmaceutical company roche flip side roche tesaro do have ongoing clinical collaboration look roche tecentriq zejula bladder cancer researcher be also combine zejula roche drug avastin form ovarian cancer related do spot major market top easy look heavy basic sell stocklooking next nvidia start simple routine
10,JNJ,heron pharmaceutical hrtx catapult year high monday post surgical pain drug outperformed component used rival drug pacira pharmaceutical pcrx pair head head test stock market today heron rocket close hit highest point september share pacira topple nearly news point end day trial pit heron drug htx bupivacaine component pacira already approve exparel patient have have bunion remove hernia repair case htx be superior placebo bupivacaine heron say news release needham analyst serge belanger say datum likely support broad label htx approve htx also cut number patient need opioid curb pain heron believe datum support opioid spare label be significant game changer belanger say note client raise price target heron keep buy rating get newsletter deliver inbox more info product service privacy policy term usehtx cut pain hour follow surgery respectively vs placebo bunion hernia patient same measure vs bupivacaine htx reduce pain respectively bunion patient require opioid hour follow surgery vs patient placebo bupivacaine respectively hernia patient didn need opioid pain management vs placebo bupivacaine receive patient overall phase datum confirm prior result see phase trial htx be superior placebo bupivacaine pain relief opioid consumption belanger say late heron plan report datum phase trial htx pain relief patient knee replacement surgery follow breast augmentation say datum be expect be part heron application approval htx be estimate surgical procedure annual basis require postoperative pain management belanger say htx be poise be major player industry exparel currently hold market generate annual sale say mizuho analyst irina koffler say heron likely seek similar reimbursement strategy htx exparel announcement be last term overhang pacira say report client pacira be unlikely rebound investor look htx enter market decline potential dow jone stock johnson johnson jnj buy pacira still exparel have advantage be earlier market htx exparel have be approve october be extremely familiar hospital surgeon say government be likely approve policy incentivize usage opioid alternative so reimbursement become more favorable further increase utilization related chart read basic buy point mark time real basic analyze stock cup handlelooking best stock buy watch start here
11,JNJ,stock open tightly mixed trade thursday nasdaq struggle remain positive aim extend rally day dow seek hold mark chip giant broadcom avgo be tap report close bell zscaler zs gap sharply open dow jone industrial average advanced fought hold gain less nasdaq composite open narrow loss strong early gain qualcomm qcom nxp semiconductor nxpi stock have kick gear lead nasdaq index wall street journal report commerce secretary wilbur ross say china base telecom giant zte pay fine zte have be ban buy make component due violation sanction north korea plan merger qualcomm nxp have be stall chinese regulator follow ruling zte qualcomm rise open trade nxp gain early action get newsletter deliver inbox more info product service privacy policy term usechevron cvx open higher easily lead dow jone industrial average well fargo maintain stock outperform rating raise price target chevron be trading just buy point cup handle base industrial test measurement specialist fortiv ftv top gain everett wash base company say late wednesday have offer acquire advanced sterilization business unit johnson johnson jnj confirm have receive offer have month twitter twtr dip netflix nflx drop higher twitter be logging first session list netflix joined big cap index twitter be extend cup handle buy point ibd leaderboard stock netflix be extend buy point flat base ibd stock entegris entg jump announce late wednesday pay acquire gas purification unit italy saes group chipmaker entegris report unit produce earning revenue entegris early gain break stock past buy point third stage cup base powerful gain qualcomm nxp heavy early loss vodafone group vod lam research lrcx help drag nasdaq negative premarket territory nasdaq list zscaler spiked open security software play fiscal third quarter result show loss narrow cent share quarter vs expectation cent share loss revenue rise much better forecast zscaler have soar nearly start june march ipo price gain send share far buy range buy point double bottom base ibd leaderboard stock blast higher first quarter revenue earning top consensus view same store sale come bit lighter expect management give revenue earning guidance well consensus target dollar store gap open send share buy range flat base buy point also nasdaq recent ipo okta okta launch higher early trade security software play report narrower forecast loss late wednesday forecast july quarter sale consensus view first time unemployment application be largely unchanged week end june accord labor department be consensus projection increase claim week move average tick higher third straight advance bond continue downtrend thursday morning lift year treasury yield basis point yield have hold oil price rebound take dip wednesday west texas intermediate jump trade back barrel europe benchmark brent crude bounce higher putt back barrel oil market have grow twitchy ahead june meeting organization petroleum export country partner include russia plan discuss ease remove production cap update story other market coverage visit stock news today related thursday premarket stock index tesla face key rival enter buy zone biggest acquisition ebay spinoffokta stock rise security firm top estimatesfive set gap past buy zone strong hot tech ipo report investing action plan
12,JNJ,dozen drug launch heavy hitter roche rhhby gilead science gild johnson johnson jnj be expect reach blockbuster status end analytic firm say clarivate analytic describe year blockbuster drug have launch be expect launch eventually bring north sale year period biggest number clarivate begin make forecast set be exciting year see valuable addition exist treatment well disruption certain market first class treatment option disease firm say report issue late thursday end drug roche gilead nordisk nvo be expect top annual sale remain likely account year revenue analyst say get newsletter deliver inbox more info product service privacy policy term be diabetes drug food drug administration approve medicine derive cannabis plant first series drug expect prevent migraine patient dozen drug be project collectively top sale roche hemlibra treatment patient hemophilia top list be expect generate north sale only hemophilia patient world roughly eligible hemlibra treatment cost first year year drug be approve month early launch december sale be forecast drug set reach blockbuster status forecast hemlibra be expect take share shire shpg feiba nordisk novoseven hemlibra also compete bioverativ bivv eloctate shire advate eloctate be forecast be blockbuster advate continue be market leader estimate sale however advate sale be forecast decline further thereafter clarivate report say gilead biktarvy grab approval february target estimate person globally live hiv be receive antiretroviral therapy suppress viral replication allow immune system strengthen biktarvy add gilead hiv franchise have long rivale glaxosmithkline gsk have trade market share gilead first enter market atripla gilead hiv drug be featured clarivate drug watch report biktarvy become blockbuster generate sale spiking decline report say trajectory be similar gsk drug triumeq be expect bring year year launch round top nordisk get approval diabetes drug ozempic december drug help stimulate body own insulin release limit much sugar get blood liver slow quickly food leave stomach ozempic be expect become blockbuster revenue way immuno oncology treatment novartis nvs gilead grab headline ability revolutionize treatment disease report say more half drug potential blockbuster list be cancer therapy just drug list expect blockbuster be cancer treatment erleada product dow jone component johnson johnson be approve february treat castration resistant prostate cancer hasn spread body fellow dow jone component pfizer pfe have drug treat same cancer once spread zytiga xtandi battle expand market share include market patient metastatic disease second generation oral androgen erleada become first approve set mid february clarivate say drug be project bring rise also be expand treat other form prostate cancer combination zytiga contribute blockbuster potential gsk shingle vaccine call shingrix rare disease drug alnylam pharmaceutical alny know patisiran be expect join blockbuster list sale respectively revenue be expect hit respective gw pharmaceutical gwph be expect grab approval summer first cannabidiol drug derive cannabis plant treat patient seizure disorder drug call epidiolex be expect generate sale approve epidiolex likely encounter bureaucratic barrier distribution political hurdle associate cannabis derive medicine particularly strict guideline use medicinal cannabis exist report say biotech isn alone market cara pharmaceutical cara insys therapeutic insy zynerba pharmaceutical zyne be also work treatment base cannabis plant migraine drug amgen amgn novartis aimovig be project bring sale spiking sale drug other seek prevent migraine block specific peptide group amino acid approve aimovig be first drug know cgrp market ahead teva pharmaceutical teva aldr eli lilly lly allergan agn also be work area first class mover advantage be crucial aimovig competition other subcutaneously administer monoclonal antibody target cgrp be not far clarivate say lilly teva file fda approval drug late last year meanwhile be phase testing drug analyst be worry falter submit application fda co founder randall schatzman unexpectedly step chief executive role tuesday other area shire lanadelumab treatment swell disorder be forecast bring next be abbvie abbv elagolix treatment painful symptom associate menstruation round list pfizer merck mrk diabetes drug steglatro indivior opioid dependence drug sublocade be forecast become blockbuster sale respectively related chart read basic buy point mark time real much money do need start investing build long term profit stock take many gain
13,JNJ,here weekly investing action plan need know investor come week apple aapl be set unveil new bell whistle developer well possibly tease work customer broadcom avgo report earning upheaval chip sector international trade top cybersecurity stock palo
14,JNJ,here investing action plan friday need know investor come day deere company astrazeneca azn report earning meanwhile cloud datum storage stock include micron technology mu smart global holding sgh be make notable move deere co farm construction equipment maker
15,JNJ,key market index fund be mixed friday spdr dow jone industrial average rise tech heavy qqqs slip spdr dow jone industrial average dium rise spdr spy advanced powershare qqq trust qqq ease foreign stock lag ishare msci emerge market eem fall ishare msci eafe efa close fraction lower dow gainer include american express axp walmart wmt general electric ge apple aapl decline oil service bank homebuilder be top sector fund gainer stock market today spdr homebuilder xhb reversed gain find support day move average weaker expect housing start build permit february etf be form bottom base american express walmart lead upside dow respective gain ge be biggest decliner apple be barely negative just buy point cup handle have climb past monday gold miner telecom underperform sector fund bitcoin climb nearly accord coindesk drop earlier bitcoin investment trust gbtc gain be trading day line nearly month be december high household name such apple mastercard johnson johnson jnj take look so call low volatility etf emphasize quality stock ishare edge msci usa quality factor qual be head test day move average make solid rebound line set potential buy opportunity fund rise early september test day jan intraday high etf also be form base buy point keep mind volatility broader market picked february etf fall day line make way back day such volatile period underscore importance hold quality stock track record steady earning growth fund track msci usa sector neutral quality index provide exposure large midcap equity best profitability look fundamental such high return equity stable year year earning growth low financial leverage sector information technology account nearly asset wednesday financial be next biggest chunk health care consumer discretionary industrial top holding include name mentioned top order well graphic chip designer artificial intelligence player nvidia charle schwab schw blackrock blk get newsletter deliver inbox more info product service privacy policy term usenvidium lead year date gain mastercard be thursday blackrock charle schwab apple apple be just buy point cup handle have return johnson johnson lag deficit top holding represent stock portfolio qual year date return thursday be line year average annual return accord morningstar direct be just ahead gain etf carry expense ratio thursday pick vanguard small cap value vbr slip day line strong move back line set chance buy also be interested dow stay positive stock turn mixed bitcoin test apple watch big etfs potential quality etfs do well good bad market
16,JNJ,collegium pharmaceutical coll touch buy zone thursday sale painkiller xtampza easily beat street expectation fourth quarter momentum expect continue insurer be start reject coverage opioid giant oxycontin stock market today collegium rocket nearly higher close breaking consolidation base begin late january fourth quarter xtampza billed form oxycodone be abuse deterrent bring sale jump year earlier period top expectation needham analyst serge belanger say note client momentum have continue xtampza prescription quarter quarter first week first quarter due inclusion product exclusive oxycodone extend release numerous prominent plan say xtampza be well position continue growth belanger say be increase sale estimate use ibd marketsmith free march
17,JNJ,see stock buy point get chart pattern recognition run custom screen start nowcollegium have also launch new marketing campaign leverage update label xtampza include abuse deterrent claim xtampza be only oxycodone labele way purdue pharmaceutical oxycontin other opioid have come fire recent year spike opioid overdose death janney analyst ken increase expectation xtampza sale first quarter keep buy rating price target collegium benefit new exclusive contract xtampza have result faster uptake prescribe anticipate month say note client collegium secure exclusive coverage xtampza plan begin exclude oxycontin fourth quarter jan nucynta other hand struggle early part prescription quarter quarter belanger say december depome depo sign license deal allow collegium sell nucynta exchange royalty nucynta product supply remain constrain due issue dow jone component johnson johnson jnj manufacturing plant puerto rico collegium expect issue normalize end march janney say update filing depome collegium recently sign provision depome manufacturer have make payment be unable deliver certain percentage order drug quantity month longer related look best stock buy watch start herenew option strategy limit risk buy stock ahead earning report
18,JNJ,key stock index fund be lower afternoon trade tech heavy qqqs turn negative blue chip fall most boee ba johnson johnson jnj weigh powershare qqq trust qqq dip spdr spy give spdr dow jone industrial average dium fall stock market today utility gold miner technology be top sector fund gainer spdr utility xlu rise retake day move average first time month vaneck vector gold miner gdx vaneck vector junior gold miner gdxj be health care select sector spdr xlv reversed loss unitedhealth group unh be dow biggest gainer early fall nearly cisco system csco hold gain biggest loser include boee undercut day move average trigger sell signal dowdupont dwdp johnson johnson apple aapl slip day hit new record high then reverse lower back buy point shape cup handle boee other industrial giant be get hit continue tariff related concern homebuilder bank metal miner lead downside sector fund spdr bank kbe spdr regional banking kre fall track extend loss third straight session etfs be nearly recent high bitcoin sank accord coindesk open level bitcoin investment trust gbtc gap tumble session lows month low mostly decline try retake day line march be now december peak dow stock johnson johnson unitedhealth group be blue chip show healthy gain tuesday spdr health care xlv remain potential buy range retake day move average friday be form new base buy point too keep mind broader market have be volatile lately fund undercut day line early february market correction now appear be overall uptrend share advanced last time xlv be featured etf column time fund be just buy point flat base etf celebrate anniversary december track health care select sector index pharmaceutical represent biggest segment holding march nearly asset biotech be next category account health care equipment supply health care provider service life science tool service health care technology make rest get newsletter deliver inbox more info product service privacy policy term top holding include dow jone industrial average health care name johnson johnson pfizer pfe unitedhealth group merck mrk dow stock top be abbvie abbv together top account roughly third stock portfolio dow quartet year date performance range abbvie however have soar year xlv year date gain march be line return etf average annual return past year lag outperformed broader index past year xlv bear expense ratio tuesday pick guggenheim pure growth rpg reversed lower session close just buy point also be interested dow stock turn red ge weigh apple reverse record highai robotic blockchain hot new etf industry sector do market pro expect outperform year
19,JNJ,pacira pharmaceutical pcrx collapse year low friday regulator vote recommend biggest moneymaking drug key expansion regional anesthesia stock market today pacira plummet close end week lowest point june defy fractional jump broader biotech group stock climb sixth day run analyst have count food drug administration approval expand revenue local anesthetic call exparel thursday fda panel vote recommend approval exparel regional pain drug ibd take biotechs have be upswing day straight be market turn hit correction earlier month investor corner outline key aspect look sizing turnaround be note panel vote approval needham analyst serge belanger write note now seem unlikely fda approve label expansion even narrow indication additional study belanger downgrade pacira stock hold rating buy exparel be test regional anesthetic patient follow shoulder knee surgery panelist discuss risk fall patient knee surgery exparel be approve block specific nerve piper jaffray analyst david amsellem say be concern usage femoral nerve block knee surgery prolong quadricep weakness thereby inhibit extent patient ambulate extent patient be ambulating increase risk fall say note amsellem keep overweight rating price target pacira say absence label expansion win prevent pacira enjoy steady long term volume growth drug get ibd market prep tech report newsletter free exparel bring fourth quarter sale accounting nearly total revenue pacira say preliminary release last month mizuho analyst irina koffler suggest dow johnson johnson jnj acquire pacira base business potential cost synergy follow fda panel exparel likelihood takeout be now somewhat lower say note client pacira say work fda address outstanding panel concern ahead full fda meeting april ultimate goal chief executive dave stack say written statement be offer additional flexibility way exparel be administer so clinician patient alike have increase opportunity realize benefit long last opioid pain control related abbvie stock rise increase dividend biotech stock pop fda nod slam door biogen seek merger wake alzheimer worry
20,JNJ,index dow jone industrial average nasdaq composite rise strongly early week then erased most gain friday close netflix nflx soar subscriber growth guidance energy stock bust higher crude oil price keep rise alcoa aa american express axp unitedhealth unh jump report offset weak outlook taiwan semiconductor manufacturing tsm chip gear giant lam research lrcx asml asml broader chip sector apple aapl come pressure index dow jone nasdaq composite be more thursday friday close be major average rally wednesday netflix nflx earning oil fuel energy stock stock pull back taiwan semiconductor manufacturing tsm warn rest cite weak smartphone demand already pressured weak asml asml lam research lrcx guidance chip stock sell apple aapl also come heavy pressure thursday friday iphone demand concern year treasury yield jump year high internet television network netflix nflx add stream subscriber first quarter beating target end march quarter subscriber worldwide netflix expect add subscriber top wall street target netflix also top ep sale figure guide higher metric subscriber number benefit new original content such science fiction series alter carbon fresh season comic book series marvel jessica jone comedy grace frankie share shot record high taiwan semiconductor manufacturing tsm cut sale outlook rest year largely softer smartphone demand slam chip stock apple aapl taiwan semi be world largest contract chipmaker count apple nvidia nvda qualcomm qcom customer meanwhile chip gear maker lam research lrcx asml hold asml pressured semiconductor stock day earlier weak outlook lam equipment shipment view rest year come light asml forecast lower gross profit margin current quarter get newsletter deliver inbox more info product service privacy policy term useu oil future rise barrel hit fresh multiyear high opec russia likely stay course output cut meeting jeddah saudi arabia friday president trump blast opec crude hold domestic crude stockpile fall barrel last week energy information administration say defy view small gain oil production climb fresh high barrel day schlumberger slb meet view energy stock be big winner yet again more oil play breaking set charle schwab schw interactive broker ibkr trade financial etfc report better expect quarterly earning schwab share reclaim day move average build right side flat base interactive broker moved buy zone just earning then pull back slightly trade moved buy range late thursday report bank america bac first quarter earning top expectation rebound trading lead estimate beating result goldman sachs gs morgan stanley ms extra client activity goldman reversed lower say say likely pause buyback second quarter meanwhile comerica cma sank other super regional bank weak loan growth treasury yield soar financial stock rise weekly lows southwest airline luv flight head dalla new york make emergency landing philadelphia jet left engine explode burst window kill female passenger result passenger jennifer riordan be pronounce dead hospital unite airline ual say inspect engine boee ba type plane experience engine failure follow recent faa bulletin unite share jump carrier narrow expansion plan year ahead stay upbeat sale trend bristol myer squibb bmy plunge report drug combination opdivo yervoy reduce risk lung cancer progression death be lower merck regimen keytruda chemotherapy cut risk death similar group lung cancer patient merck mrk stock climb nearly commerce department ban domestic firm selling component chinese telecom gear maker zte spark sell optical device maker acacia communication acia oclaro oclr lumentum holding lite government determine zte violate term settlement involve illegally ship networking gear iran acacia garner sale zte oclaro analyst say ciena cien compete zte optical system get lift year ban be not lift unitedhealth group unh cruised past wall street first quarter earning estimate net share cent view revenue grow manage care enrollment gain come medicare advantage medicaid meanwhile unitedhealth fast grow optumhealth service unit grow revenue deliver care related service person share rise week approach buy point alcoa aa stock break past buy point record alumina price strong earning blowout profit guidance aluminum giant earning rise revenue grow alcoa expect full year adjust ebitda range offer january expect industry supply shortage year trump administration sanction unite co rusal impose month bar ban entity do business russian aluminum giant top steel maker steel dynamic stld nucor nue edge past first quarter earning estimate issue moderately positive comment outlook nucor expect sustainable strength steel market not quite bullish steel investor have expect late february president trump initially call tariff steel import exemption then more half steel import have be exempt general electric ge report smaller expect adjust ep decline revenue rise more expect aviation health care be solid ge power remain drag ge reaffirm full year ep guidance say have plan cut dividend again ge stock rise friday atlassian team report adjust fiscal profit cent share revenue jump top estimate maker project management collaborative software guide low current quarter ep share tumble friday amazon com amzn ceo jeff bezos disclose amazon prime have more member worldwide first time online sale leader have give specific membership figure be higher expect intuitive surgical isrg break wednesday robot surgical system maker report adjust ep gain sale grow beating view textron txt sell tool test business segment emerson electric cash maker cessna jet bell helicopter also report jump ep cent share rise revenue beating analyst view announce share buyback program textron soar gapping past buy point ibm ibm beat first quarter estimate stock tumble weak margin slower growth key area ebay ebay shot morgan stanley upgrade stock boost price target more cite recent partnership payment processor adyen move away paypal pypl abbott laboratory beat expectation wednesday adjust income cent share sale share dip pharmaceutical sale come expectation johnson johnson jnj top estimate share edge lower share fall wednesday news kentucky be sue allegation run deceptive marketing scheme related painkiller consumer electronic retailer best buy bby amazon com amzn announce partnership best buy use amazon fire tv operate system insignia brand television replace roku roku software best buy also sell tvs amazon american express axp jump thursday report better expect earning wednesday ep rise revenue climb nearly rail giant csx csx gap wednesday beating earning day report ep cent revenue operate income increase skecher skx crash friday give weak earning sale outlook athleisure shoe maker meet ep estimate rise modestly beat sale view gain be interested look best stock buy watch start invest stock market start simple routine
21,JNJ,tuesday premarket trading receive several shot arm first be netflix nflx surge report strong first quarter result late monday then cohort blue chip name kick post early advance follow expectation quarterly result result future dow jone industrial average vault trade fair value nasdaq future pressed higher netflix be premarket trading powerhouse more easily largest gainer nasdaq stock merck mrk bolster dow early trade follow analyst upgrade drugmaker quickly surrender lead investor wade early batch blue chip earning report goldman sachs gs johnson johnson jnj unitedhealth group unh positive premarket trading poise week old uptrend hurdle resistance uptrend be good standing carry distribution day day move average remain key test major index dow fail hold day line monday nasdaq have yet break back critical level support get newsletter deliver inbox more info product service privacy policy term usepremarket action suggest dow open day line keep mind future drive premarket trading do not always translate action regular session dow unitedhealth rolled early gain first quarter result be stronger expect stock retook day line support gain monday attempt start right side month consolidation also dow merck buzz ahead morgan stanley upgrade stock overweight equal weight drugmaker surge heavy trade monday company lung cancer treatment outperformed competitor clinical trial merck be early april low overall dow index stand poise test resistance day move average further list early dow advancer johnson johnson trim early gain medical product leader report first quarter result earning revenue top analyst target full year guidance meet beat expectation goldman sachs reversed early loss step clobber first quarter earning expectation raise quarterly dividend nearly stock have spend day fight resistance day move average ibd leaderboard stock churn strong early move draft netflix early advance stream entertainment leader report first quarter sale earning only narrowly consensus target blowout beat subscriber growth surprised investor launch share higher premarket trading netflix share remain extend rebound support week move average planet fitness plnt pop ahead open gym network end monday bit more buy point second stage flat base leader peer lululemon athletica lulu pare early surge back premarket trading company late monday name patrick guido chief financial officer effective april stock have jump past week china base stock be mixed market hong kong shanghai end lower tuesday datum show country gdp expand first quarter retail sale surge investment education soar china commerce ministry also announce impose tariff sorghum import ministry say investigation find grain be unfairly subsidize government march ipo iqiyi iq jump premarket trading share netflix platform advanced past session rise march ipo price housing start jump march annualize rate commerce department report be healthy uptick february disappointing rate home start startling economist have project rate new project build permit gauge upcoming activity post even larger increase annualize rate february permit clock pace economist have expect march permit issue rate industrial production number federal reserve be set release et busy slate tuesday hour session include quarterly report railroad csx csx intuitive surgical isrg unite airline ual lam research lrcx also report close kick first quarter report season chip sector be interested big picture strength sector be good lam research ibm earning due investing action planamazon report send cvs walgreen drug distributor soar
22,JNJ,stock market future rise strongly tuesday morning blowout subscriber growth bullish guidance netflix nflx late monday major market average likely test surpass key support level fellow fang stock facebook fb amazon amzn google parent alphabet googl show fractional gain netflix china partner iqiyi iq continue add recent lam research lrcx earning tuesday be more important stock market rally monday session dow jone industrial average lead gain be unable close day move average index advanced nasdaq composite rise stock market future jump nasdaq future boost netflix advanced vs fair value future climb dow jone future be help unitedhealth unh johnson johnson jnj edge higher top view early tuesday get newsletter deliver inbox more info product service privacy policy term useat gain dow jone clear day line open nasdaq come level leaderboard stock netflix earn cent share first quarter vs year earlier meeting just beating view depend consensus forecast be used internet tv giant add stream subscriber target netflix jump nearly premarket trading netflix not have huge coattail amazon amazon prime video alphabet google youtube facebook facebook watch have compete video product aren primary revenue profit driver fang stock rise less premarket baidu bidu unit iqiyi come public late march rise premarket so call netflix china actually license netflix content stream service stock clear very short ipo base buy point last week be now extend rise monday keep mind overnight trading individual stock dow jone future often doesn translate stock market trade next regular session lam research report earning tuesday market close analyst expect earning gain share revenue soar lam have top ep target past quarters lam share fall stock market today hold day line stock be work new consolidation do not yet have proper buy point top rate big cap tech stock be so important lam research kick earning semiconductor sector typically be leader contributor tech rally chip account big share nasdaq composite index chip also be just tech product so chip stock stock be fare well good bet chip demand be strong thus demand variety tech gear be also strong yet chip stock have be lag index market peaked just month philadelphia semiconductor index philly sox be find resistance day move average dow jone index nasdaq not semiconductor be struggle chip giant intel intc have form flat base buy point intel rise monday lam research also have notable exposure memory chip market memory chip maker include giant micron technology mu recent ipo smart global holding sgh be scream higher recent market correction then ve erased gain prior run up fellow big cap chip gear maker asml asml chip foundry taiwan semiconductor manufacturing tsm report later week be interested big picture strength sector be good lam research ibm earning due investing action planamazon report send cvs walgreen drug distributor soar
23,JNJ,stock index touch new high tuesday nasdaq aim sixth session row dow jone industrial average streak end monday sliver loss dow be midday tuesday nasdaq gain respectively innovator ibd fund ffty exchange trade fund track ibd slip still innovator etf be year date outperform major index volume rise modestly major exchange vs same time monday blue chip be evenly split winner loser component dow stock deliver clean look johnson johnson jnj gap more twice usual volume buy point be buy zone be capped pattern be base base pattern cnbc report johnson johnson be likely benefit republican recent refashion tax rate tax law johnson johnson have cash overseas be company cash bring money home let johnson johnson make acquisition other stock breaking basis tuesday include payment company paypal pypl global payment zbra regional bank east west bancorp ewbc bp prudhoe bay royalty bpt instrument maker agilent technology november initial public offer software provider altair engineering altr ibd industry group medical stock bank lead dairy retail leisure be chief laggard related amazon price target be raisedwhat lead big dividend
24,JNJ,here weekly investing action plan need know investor come week earning season pick momentum result due netflix nflx goldman sachs gs general electric ge ibm ibm score other airline stock get rattle further unite airline ual report give update expansion plan
25,JNJ,dow jone component johnson johnson jnj engage bidding war sweep boston scientific bsx stryker syk analyst say tuesday follow rumor latter merge report emerge monday stryker approach boston takeover bid boston share spiked rumor stryker topple canaccord analyst say stryker be far only medical device maker interest boston headline be substantiated stryker be fact make bid boston scientific see high likelihood emerge potential bidder say note client have be banter potential boston scientific acquirer year bidding war emerge place high likelihood be involved stock market today boston stock dip close stryker share plunge even stock look somewhat dim ease fraction get newsletter deliver inbox more info product service privacy policy term deal have analyst somewhat split tuesday regard materiality report do not find potential such marriage be shocking canaccord analyst say indeed see merit such combination standpoint product line synergy stryker acquisition help add product sector higher potential growth bigger market also help stryker differentiate portfolio technology compete large company medtronic mdt boston case deal cap year turnaround allow end high note canaccord analyst say sum definitively think boston scientific be game do fair deal here say rbc analyst glenn novarro view deal unfavorably acknowledge strategic rationale make sense also likely boston win deal less share combine premier growth company medical device space be limit product overlap say however bar value creation be set high give potential valuation company combine stryker boston scientific have revenue stand grow sustainable higher compound annual growth rate medium term novarro say have enterprise value canaccord analyst call potential deal merger equal stryker be only third larger boston also lead further med tech consolidation consummate create behemoth medical device stryker boston scientific join abbott medtronic say think edward lifescience ew be next potential major acquisition target also highlight nephew snn be last remain pure play total joint operation market related chart read basic buy point mark time real trade stock most penny stock fail make investor basic analyze stock cup handle
26,JNJ,gilead science gild viral franchise look strong head first quarter earning season fellow large cap biogen biib celgene celg be shakier ground analyst say wednesday rbc analyst brian abraham call gilead top expectation biogen likely miss bottom line celgene still reel sudden departure chief operate officer be typically weak first period clinical study business development be more important biotech say believe clinical trial success increase merger acquisition activity be more important help improve sentiment give renew drug pricing competitive life cycle concern sector say note client get newsletter deliver inbox more info product service privacy policy term usegilead gain close biogen climb celgene jump possible rebound drop wake sudden unexplained departure chief operate officer coo scott left late last week day biotech group be rank first just week fifth recently week now slip group track investor business daily share hit month high march have topple point abraham call strong quarter gilead hiv drug be become more important firm top line hepatitis market be stabilize more hiv patient be used regimen contain drug know tenofovir alafenamide taf abraham see genvoya descovy odefsey beating expectation take share own atripla stribild biktarvy drug treatment hiv be still early launch expect bring first quarter sale look be tracking ahead consensus project longer term say hepatitis drug harvoni epclusa be see beating view abraham model drug competition abbvie abbv new drug mavyret treat wide group hepatitis patient franchise perform expect see cent bottom line beat first quarter earning share tracking exceed consensus year believe help drive upside pipeline mature visibility increase earning growth year say abraham have outperform rating gilead share biogen look generally solid first quarter abraham expect sale be slightly consensus base prescription trend expect earning share come cent consensus multiple sclerosis drug tecfidera be experience steady erosion celgene experimental drug ozanimod have be delay multiple sclerosis meanwhile revenue spinal muscular atrophy drug spinraza be likely be line multiple sclerosis contract secure key competitor ozanimod delay temporary lull competitive spinal muscular atrophy news flow expect focus call be potential year growth driver say biotech be expect outline plan aducanumab be be test alzheimer disease recently biogen make change study drug investor also be likely key potential acquisition talk expect share trade line pending more clarity long term picture say abraham boost price target have sector perform rating stock first quarter tend be seasonally weak celgene believe be solid enough allay concern emerge follow departure president chief operate officer abraham say abraham boost expectation inflammation drug otezla first quarter year line consensus view otezla sale have be source pain past widely miss third period rebound fourth abraham lower view pomalyst cancer drug reflect weaker expect use pattern likelihood indirect erosion johnson johnson jnj darzalex investor focus be next step ozanimod regulator reject drug multiple sclerosis celgene also offer further detail acceleron pharma xlrn partner blood disease abraham cut price target have celgene top pick stock related much volume look stock long term retirement investing strategy etfsstill rule stock investor always cut loss short
27,JNJ,solid gain stock market tuesday fade whimper afternoon trade volatile session nasdaq composite edge higher rise early add dow jone industrial average outperformed rise volume nasdaq be tracking slightly higher monday nyse volume fall bit nike nke johnson johnson jnj unitedhealth group unh outperformed dow gain ibd interactive broker ibkr micron technology mu stamp com stmp canada goose goos show gain more stamp com be day move average work cup handle base buy point fang stock netflix nflx be best performer still struggle support day move average alphabet lose ground again give support day move average monday sell share be share spotify spot open well reference price company opted bypass underwriter direct list opposed initial public offer spotify be big player music stream business crowd industry competition like apple aapl amazon com amzn alphabet googl pandora other gainer include tesla tsla share picked wall street mulled delivery datum sign institutional selling basically higher volume decline start appear month electric car maker share hit intraday high september related news general motor gm fiat chrysler fcau report strong sale datum march share gm rise fiat chrysler jump nearly leaderboard name lululemon athletica lulu rebound monday reversal share outperformed rise more heel strong earning report last week related tech sell stock add cut ibd screen ibd tipp poll economic optimism lose trump tax cut sparkspotify ipo see lesson facebook snap buy
28,JNJ,dow lead key index fund tuesday tech rebound lag earlier session apple aapl fang stock score solid gain spdr dow jone industrial average dium rise spdr spy advanced powershare qqq trust qqq add stock market today test day move average monday spy close line spy re-cover line tuesday small cap outperformed ishare core small cap ijr only dow stock close slightly lower ibm ibm nike nke johnson johnson jnj unitedhealth unh lead advancer gain more apiece apple be underwater much session reverse gain bank america lynch expect iphone maker report plan use own chip boost financial energy semiconductor health care lead upside sector fund vaneck vector semiconductor smh ishare phlx semiconductor soxx recoup lose nearly apiece monday graphic chip designer artificial intelligence player nvidia nvda rally be stick day line past week bitcoin rise accord coindesk trading low bitcoin investment trust gbtc soar extend monday advance regain day line growth stock get hammer last week march such pullback help create potential buy opportunity go forward guggenheim pure growth rpg lead growth fund gain base year date performance march be accord morningstar direct guggenheim fund track pure growth index total return target fast grow stock year old fund top holding wednesday be netflix nflx adobe system adbe nvidia apply material amat amazon amzn account stock portfolio rpg average annual return past year slightly outpace get newsletter deliver inbox more info product service privacy policy term usefirst trust dorsey focus fv come second year date gain fund offer exposure first trust sector industry base etfs dorsey associate expect outperform other selection universe be featured etf column march etfs wednesday be first trust dow jone internet index fund fdn first trust nasdaq bank etf ftxo first trust technology alphadex fund fxl first trust industrial producer durable alphadex fund fxr first trust nasdaq technology sector index fund qtec first trust large cap growth alphadex ftc come third year date return fund track nasdaq alphadex large cap growth index mark anniversary top holding stock portfolio include micron technology mu amazon servicenow now adobe netflix also be interested tech stock rally apple intel boost dow bitcoin divesretail sector score gain be apple play play investor file lawsuit lose money xiv meltdown
29,JNJ,stock market endure volatile session tuesday bull eventually win major stock index rally sharply close dow jone industrial average add help strength nike nke unitedhealth unh johnson johnson jnj end gain
30,JNJ,stock index saunter small gain midday friday only small cap hold lose hand week volume be run higher nyse flat nasdaq nasdaq add respectively dow jone industrial average sag small cap russell be track loss week rise breakout midday friday strong volume include signature bank sbny volume average lion gate entertainment lgfa volume greater usual lion gate have be rally word company be buyout talk investor also want monitor stock be buy zone close buy point example rise last year year date component dow jone industrial average still have potential buy opportunity stock buy zone include goldman sachs gs mmm apple aapl johnson johnson jnj dowdupont dwdp dow stock basis not far potential buy point include coca cola ko traveler company trv dow stock be expect accelerate earning growth be apple traveler dowdupont coca cola have base be first second stage stock advance pause consolidate breakout first basis be more likely work later stage base count be reason apple have more left investment also apple grow earning fiscal end september street expect growth pick fiscal growth be price stock earning surprise offer potential additional thrust meanwhile ibd industry group group have show uncommon strength week past session chip equipment group jump think stock such apply material amat commercial document group pop think label company multus color labl hotel segment rise think la quinta lq biggest loser week be office supply related schlumberger be bullish oil patch change roth iracan great stock lead again
31,JNJ,nasdaq composite outperformed friday uneventful session see dow jone industrial lag mostly due weakness ibm ibm american express axp report earning ibm gap fall report rise sale news be offset gross margin operate margin come view american express meanwhile lose nearly report earning announce suspend share buyback program first half nasdaq end shorten week trading gain nearly picked dow add major stock index extend weekly streak shrug threat possible government shutdown small cap be star day russell jump not far crack level dollar be weak again year low year treasury yield add basis point fang name amazon com amzn give back early gain still rise news raise monthly prime membership netflix nflx meanwhile get flurry price target hike ahead earning report monday close share rise less ahead result stock market today nvidia nvda be nice gainer nasdaq help positive comment bofa lynch share rise late stage base be work well so far biotech space share acorda therapeutic acor jump news be acquisition target biogen biib earning biogen be still buy range buy point be due thursday open outperformance growth stock start year have be sight behold ibd be driver seat again friday nearly half name list more leaderboard name ibd component floor decor fnd hit time high rise more breakout basis be sparse retailer big lot big pass muster rise end week well buy range entry earning season start kick gear report due netflix intuitive surgical isrg lam research lrcx well dow component johnson johnson jnj traveler trv related ibm turn corner result concern profit arisenetflix intuitive surgical set report earning season ramp upapple iphone end life predict production cut see
32,JNJ,analyst weren surprised wednesday dow merck mrk terminate late stage study potential alzheimer disease drug argue win have implication biogen biib announce expansion key alzheimer trial biogen share fall anyway late wednesday share slide much biogen announce enroll more patient original recruitment plan phase aducanumab trial enrollment be still expect be complete mid leerink analyst geoffrey porge write note client biogen news follow merck decision late tuesday scrap study drug call verubecestat patient early stage alzheimer disease verubecestat be know bace inhibitor aim prevent buildup amyloid plaque brain associate alzheimer context merck recent disappointment merck bace inhibitor verubecestat biogen aducanumab be be now only handful alzheimer medicine still active pivotal trial porge say merck halter late stage trial verubecestat time last year investigator find have virtually chance work patient mild moderate alzheimer credit suisse analyst vamil divan say failure be disappointment not surprising remain hopeful drug potentially show benefit give patient earlier course disease say note client now remove verubecestat revenue model divan cut price target merck keep outperform rating merck likely have seek merger big enough move needle market cap company annual sale north rest business be not strong enough allow growth be see oncology come say today news be not unexpected do believe add incremental pressure merck pursue business development opportunity bring additional growth driver mid late stage pipeline ibd take day move average be used pinpoint time opportunity risk stock head investor corner more tip smart stock buy selling tip evercore analyst umer raffat point failure alzheimer space be never good news other include biogen eisai eli lilly lly astrazeneca azn novartis nvs dow johnson johnson jnj be also work bace inhibitor biogen aducanumab work differently bace inhibitor aim remove plaque buildup brain analyst be particularly hopeful prospect aducanumab look actual amount amyloid plaque reduction bace inhibitor dramatically less biogen see aducanumab raffat say report plaque reduction aducanumab be far most important thing go biogen favor rbc analyst brian abraham be more bullish aducanumab biogen eisai bace inhibitor elenbecestat aducanumab also target beta amyloid not necessarily make direct read through failure bace inhibitor beta amyloid target monoclonal antibody say believe unknown beta amyloid hypothesis be already baked biogen share stock market today biogen tumble close merck be unchanged related biotechs spring back market correction analystbiotech investor flee drove market correction rock biotech stock rocket immuno oncology tie bristol
33,JNJ,business software internet chip fang stock get pummeled tuesday nasdaq composite suffer worst stock market decline more broadly diversify dow jone industrial average fall less less hour go session tech drive nasdaq sank essentially wipe nearly monday strong rebound nasdaq reversed session high fall nearly meanwhile dow jone industrial average generally lag market index resist stock market sell much session be more head close defensive dow jone play procter gamble pg johnson johnson jnj rise modestly worry future self drive technology effort wake fatality recent uber drive test arizona appear be spark sell tech sector automaker group fall most ibd industry group subgroup tesla tsla pace decline drop more volume run usual level electric vehicle pioneer undercut support level have be enjoy early dow see least stock fall point more include tech heavyweight microsoft msft apple aapl apple fail hold early gain day reclaim key day move average however iphone giant be still just time high watch potential new base develop get newsletter deliver inbox more info product service privacy policy term slump breadth be poor main exchange volume be run lower vs same time monday utility pace upside government bond drop hard yield benchmark treasury year bond drop lowest feb financial giant visa goldman sachs gs also lose point more visa fall nearly average trade have be unable rebound sharply slice day move average thursday second time month notice daily chart march first time credit card debit card payment processor undercut day line visa manage bounce lows finish mildly key support resistance level so continue failure quickly retake day move average indicate change stock character dow jone tech component microsoft reversed decent early gain plunge nearly back key day move average boee ba drop nearly recent news huge airplane order american airline aal boee trigger key sell signal ditch day move average heavy volume week then stock have not give whole lot ground suggest aerospace giant have enough long term institutional demand craft new base future military jet airline satellite maker trade less time peak stock hold recent session lows chance shallow cup base flat base grow innovator ibd ffty also reversed early session high fall volume be flat ffty be minimally jan rally more remain long term day move average be now year date exclude dividend smallcap be same time frame related spot next major stock market top yes here easy wayalso stock market today do china market point trade war stock buy see stock have joined drop ibd key growth latest investor corner
34,JNJ,share dow component johnson johnson jnj topple early tuesday appeal court upheld ruling invalidate patent blockbuster arthritis drug remicade just week lose blockbuster patent decision limit ability seek damage fellow dow stock pfizer pfe launch remicade biosimilar inflectra late accord court appeal federal circuit antibody cover be disclose earlier patent bloomberg report stock dip much news come time fourth quarter earning report close bell stock market today tumble finish just last week nation top patent court invalidate patent cover blockbuster cancer drug zytiga quarter sale remicade fall worldwide steepest decline international sale vs year earlier period remicade be part immunology unit grow say remicade face increase discount rebate biosimilar competition evercore analyst umer raffat say pfizer inflectra compete directly remicade didn get much traction fourth quarter pfizer contend court complaint have block access overwhelming share consumer biosimilar readiness plan seem be protect volume engage proactive rebate basically limit uptake biosimilar raffat say note client late tuesday pfizer issue prepared statement be good day patient battle chronic disease court have rule key patent have assert block access inflectra be invalid however continue use scheme exclusionary contract maintain remicade monopoly position prevent patient payer provider opportunity benefit inflectra respond say be disappoint court ruling believe intellectual property protection such patent datum protection enable invest discovery development tomorrow life change life save new medicine re proud impact remicade have make improve health life more person worldwide be commit help ensure remicade remain accessible affordable patient meanwhile new tax rate corporation help issue street top profit guidance rbc analyst glenn novarro say bellwether health giant beat fourth quarter sale earning expectation full year revenue forecast lag analyst collective view drug acquire takeover actelion pharma miss novarro expectation call sale adjust income share revenue guidance lag consensus analyst poll zack investment research adjust earning forecast crushed view share ibd take biotechs be poise surprise upside fourth quarter other be still struggle competition take edge key product analyst say preview earning season see other scheme crop visit ibd industry theme novarro be less bullish have predict sale adjust profit share believe higher revenue guidance be combination better pharmaceutical performance currency lower tax rate be partially responsible higher earning share guidance say note client fourth quarter dow stock report adjust income share sale grow respective year year consensus be adjust profit share sale worldwide pharmaceutical sale narrowly beat analyst collective view novarro say organically sale growth be constant currency basis sale anticoagulant xarelto schizophrenia drug top expectation say cancer drug imbruvica darzalex be line plaque psoriasis crohn disease drug stelara miss drug buy acquisition actelion pharma broadly miss novarro forecast more important brand opsumit uptravi bring line sale medical device sale top novarro estimate revenue consumer segment meet novarro view related biotech merger spigot turn juno bioverativ biotech stock surprise upside earning biotech stock rocket rumor biogen buy
35,JNJ,key market index fund sell board tech heavyweight include facebook fb alphabet googl apple aapl take drubbing powershare qqq trust qqq plunge spdr dow jone industrial average dium sank spdr spy lose stock market today foreign stock weren spare ishare msci emerge market eem ishare msci eafe efa fall respectively tech heavy qqqs gap fang stock apple weigh facebook tumble nearly gap day move average breach day line weekend report expose social network insufficient effort protect user datum leak related cambridge analytica apple lose slide further cup handle buy point initially clear last week iphone maker have be develop own display screen secret manufacturing facility california accord bloomberg news send asian display maker universal display oled plunge month low other news monday nomura instinet trim iphone sale forecast other tech stock alphabet fall undercut day line dow microsoft msft ibm ibm give more apiece biggest dow loser be caterpillar cat johnson johnson jnj more only boee ba buck selloff metal miner energy technology be biggest sector fund loser gold etfs avoid decline gold future rise ounce emerge market fund have get solid start year turn strong performance last year fact emerge market account etfs accompany table lone holdout be ishare msci frontier fm invest country include argentina vietnam kuwait morocco fund be ninth list year date return thursday emqq emerge market internet ecommerce emqq last year top foreign stock fund gain lead category etf have return year accord morningstar direct well ahead advance top holding thursday include chinese company such tencent tcehy alibaba baba baidu bidu emqq be extend rebound day move average be also shape right side base potential buy point next be ishare msci brazil capped ewz year date gain fund track msci brazil index count top holding itau unibanco itub banco bradesco bbd ambev abev etf be testing day line drop thursday find support make solid move day set buy opportunity get newsletter deliver inbox more info product service privacy policy term useishare latin america ilf come third year date return ewz fund be seek support day line thursday slide brazil account biggest country weighting nearly asset mexico contribute chile peru colombia less same brazilian stock mentioned ewz be fund top holding mexico america movil economico mexicano also make top most fund make list outperformed past year average annual return lag broader index past year also be interested dow stock lead walmart amex rise ge apple sit outdow stay positive stock turn mixed bitcoin test stock market south asia be etf investor radar
36,JNJ,interactive broker ibkr asml hold asml atlassian team deliver solid earning report latest week asml be only meaningful upside mover deliver call option buyer more earning report be tap present actionable call option trade have yellow flag form
37,JNJ,here weekly investing action plan need know investor come week earning season get first taste result silicon valley lead netflix nflx intel intc other chip company biogen biib celgene celg lead report biotechs northrop grumman noc raytheon rtn
38,JNJ,major stock index turn negative late afternoon trading tuesday not surprise give ebullient gain first week trading nasdaq show loss rise much respectively breach first time dow jone industrial average ease rise much early go point least component dow industrial advanced point more et however only stock dow be point more hailed health care arena johnson johnson jnj merck mrk unitedhealth unh merck gap nearly quadruple normal turnover good news regard potential treatment involve keytruda additional medicine lung cancer now merck continue be base build mode volume nyse nasdaq be run sharply higher vs same time friday meanwhile bitcoin other alternative digital currency continue cool bitcoin investment trust gbtc give back most friday rebound lose however overall picture fast rise exchange trade note have not change be normal correction peak dec tuesday mark start fifth week digest superlative gain see fourth quarter last year nov bitcoin investment trust break very deep cup handle roar more higher less month daily chart see bitcoin investment be try halt slide day move average crude oil price copper ease too gold price rise back weaker dollar euro last week moved past first time december wti term future edge lower barrel market breadth turn negative equity lose stock outmatching winner nearly exchange few lead stock let strong gain slip weibo wb moved past buy point week cup handle rally high past proper entry stock backtrack cut gain roughly decline weibo cup base run left side peak correction normal parameter important chart pattern investor hunt strong breakout however most recent base be late stage increase risk failure chinese social network break first stage base also cup handle week end april weibo be initially featured ibd stock analysis column march also become current stock ibd leaderboard tuesday join fellow chinese adrs athm com wuba weibo wasn alone term top rate company start mlk holiday shorten trading week sour note lgi home lgih fall more trigger sell signal volume jump day average stock post biggest point drop breaking solid week cup base oct tuesday drop be also largest entry level homebuilder clear earlier deeper cup base late june share lgi be now testing institutional buy support critical day move average lithium metal supplier sociedad quimica sqm netease nte new oriental education edu stream video hardware play roku roku also stage negative reversal heavy increase volume such concerted selling hint pronounce profit take mutual fund hedge fund bank insurer large investment advisor stay abreast future potential change overall market trend read big picture column day broad market reversal few highly rate name still act well oneok oke gain fourth day row rise more average turnover oil gas transport play have clear week cup pattern be slightly outside proper buy range buy zone go buy too far extend price put investor vulnerable spot stock quickly pull back test initial entry follow strong move wall street expect oklahome base firm stage strong rebound earning share follow climb fourth quarter result be likely be announce late february oneok also sport annualize dividend yield abiom abmd heart pump maker name ibd sector leader screen rise more slightly average turnover market leader be extend surpass narrow flat base jan abiom score lofty composite rating ibd stock checkup grubhub grub ibd be yet remain key day move average follow day rebound thursday friday continue support day line week move average weekly chart give investor chance add current position mobile online food order service grubhub be clear buy point week flat base oct follow robust third quarter result earning cent share revenue record street see earning accelerate gain cent share related spot next major stock market top yes here easy methodinside ibd spot serious correction top growth stocksspot hot large cap growth stock peek big cap watch pattern develop choppy stock market action
39,JNJ,key market index fund turn negative pare early gain dow jone industrial average have smaller loss intel intc hold gain general electric ge weigh spdr dow jone industrial average dium dip spdr spy give powershare qqq trust qqq shed stock market today homebuilder retail health care be top sector fund gainer energy technology bank lag unitedhealth group unh johnson johnson jnj advanced respectively dow chip reversed lower vaneck vector semiconductor smh fall ishare phlx semiconductor soxx lose intel earlier hold gain reversed new multiyear high remain dow industrial top gainer chip giant get boost block broadcom qualcomm deal intel consider make bid broadcom wall street journal have report ge be biggest loser dow be trading mostly level early february jpmorgan lower price target apple aapl earlier reversed record high techs come pressure iphone maker slip bitcoin be nearly flat accord coindesk recover ground fall earlier bitcoin investment trust gbtc give be trading day move average nearly past month market beating equity play top like netflix nflx nvidia nvda amazon amzn be equity fund buy point market continue recover guggenheim pure growth rpg be buy range clear buy point friday etf marked new close high monday extend streak seventh straight session drop day move average last month market rout rpg have be advance day line november be last featured etf column aug share test support day move average fund track pure growth index marked anniversary march index measure growth risk factor such sale growth earning change price momentum include stock strong growth characteristic then weight equity style score information technology represent top sector monday asset next be health care nearly consumer discretionary industrial financial real estate consumer staple material account less stock portfolio track top stock market trend free ibd nvidia apply material amat adobe system adbe amazon make top holding have score solid double digit percentage gain year netflix lead return amazon be second gain nvidia adobe apply material follow advance graphic chip designer artificial intelligence player nvidia marked new close high monday jeffery reiterate buy rating price target nvidia cite steven spielberg upcoming virtual reality related film ready player potential driver etf year date gain monday accord morningstar direct top return fund average annual return past year outpace same period rpg carry expense ratio monday pick first trust nasdaq bank ftxo remain top potential buy zone rebound day line have form flat base possible entry also be interested ai robotic blockchain hot new etf industry sector do market pro expect outperform year big cap techs brazil lead past month top perform stock play
40,JNJ,stock rise early tuesday nasdaq surrender moderate gain fall mildly nasdaq composite more first hour trading slump right lunchtime new york dow jone industrial average much open edge slightly lower alphabet googl help lead pullback fall more google site operator pioneer self drive technology be form new base selling hard early february megacap internet content firm limit decline peak share find support day move average meanwhile semiconductor share also cool still show high relative strength asml asml be dutch chip equipment giant still hold buy point month base base most powerful chart pattern top growth stock form breaking new high strong price advance asml have grow earning share vs year level past quarters revenue gain see ibd stock checkup megacap member ibd semiconductor equipment firm get solid not great ep rating profit be see rise just share burden very big gain year quarter market get go investor applaud arrival tamer consumer price increase look past sudden termination president trump secretary state rex tillerson cpi index core index show rise february much bigger month month gain january stock dow jone industrial average just name rise point more include unitedhealth unh mcdonald mcd johnson johnson jnj general electric ge marked dow industrial index low end more jpmorgan chase reportedly cast doubt viability ge already reduce cash dividend industrial powerhouse be slate pay shareholder cent share april holder record feb give ge annualize yield vs ge hold relative price strength rating scale meaning outperformed just company ibd database past month large cap let gain slip loss lunchtime wall street finishing lower monday yet continue create solid cushion day move average healthy sign stock nasdaq composite monday hit new high again jump nasdaq be aim eighth straight advance note ibd big picture column friday nasdaq spurt new high ground end session phase market uptrend be pressure current outlook be now back confirm uptrend mean investor actively search breakout big volume company high quality fundamental smallcap edge higher early slide loss index be year date small cap canada goose goos fly back key day move average share jump more high then settle back second rebound back day move average offer new secondary buy point follow early november seller ultra premium outerwear cold weather apparel have be stunning stock apparel retail group triple price march ipo share canada goose clear first stage cup handle nov catapult higher next session solid quarterly result earning cent share sale last month canada goose post solid quarter growth ep sale street see small cap firm post net loss cent share fiscal end march vs net profit cent year period quarter end june canada goose lose cent share checker bottom line result past year influenced seasonality merchandise mix canada goose get composite rating scale ibd stock checkup elsewhere stock market today lumentum lite hold monday strong gain then rise expert sensor smartphone other optical communication component have clear early entry point deep month base be past buy point february company report big turnaround earning december end fiscal second quarter share end quarter slump profit sale leap feb ibd technology story industry analyst loup venture manage partner gene munster note lumentum management indicated sensor revenue more double second half please follow saito chung twitter ibd_dchung more commentary growth stock top industry group breakout financial market related do know golden rule investing find great new ipo leader be next home depot microsoft cisco google latest investor cornerwant sharpen market timing buy stock consult weekly featureis market still confirm uptrend read column day
41,JNJ,stock sell board disappointing earning chevron cvx exxon mobil xom alphabet googl apple aapl trigger sell signal bitcoin drop further powershare qqq trust qqq spdr dow jone industrial average dium sank spdr spy shed foreign market fared even ishare msci emerge market eem ishare msci eafe efa be respectively apple weigh drop trigger loss sell rule buy point offer disappointing current quarter guidance slow iphone sale apple drop also hurt technology select sector spdr xlk gap fall energy gold semiconductor technology lead downside sector fund stock market today vaneck vector junior gold miner gdxj vaneck vector gold miner gdx tumble spdr gold share gld ishare gold trust iau fall apiece gold future be ounce bank consumer discretionary be few sector buck downtrend bitcoin slip accord coindesk climb earlier bitcoin investment trust gbtc lose track fourth straight decline now trading lowest level late november december peak commodity future trading commission be step review process cryptocurrency future reuter report steady income stock such coca cola ko johnson johnson jnj re not alone billionaire investor warren buffett do too household name many many more be part spdr dividend sdy portfolio session row have bring etf back day move average solid rebound support line provide new opportunity buy share share advanced late december bounce day jan intraday high sdy be featured etf column dec sdy fall day friday market come pressure keep eye see find support soon regain line fund track high yield dividend aristocrat index marked anniversary november index filter company have consistently raise dividend least consecutive year stock be then weight yield consumer staple lead sector weighting jan nearly asset follow financial industrial respective utility represent consumer discretionary material real estate smaller position health care service energy information technology make rest top holding include tanger factory outlet center skt ibm ibm target tgt exxon mobil xom other name include coca cola also make buffett berkshire hathaway brka portfolio company have increase dividend least past year ibd take coca cola pay big dividend do company fundamental rank industry group find now ibd stock checkup sdy year date return jan accord morningstar direct trail gain average annual return past year respectively slightly lag benchmark index gain period etf year average be just ahead dividend fund annualize yield be vs average payout sdy bear expense ratio thursday pick ishare small cap value ijs bounce day line mark buy opportunity keep mind market uptrend be pressure related dow lead apple reverse higher india send bitcoin crashingtech lead stock recover sell bitcoin play slumpsstock sell apple pfizer weigh bitcoin keep diving
42,JNJ,exchange trade fund popularity keep grow investor plow money popular low cost vehicle offer access basket stock trend doesn appear be wane combine asset etfs surge january accord investment company institute year total number etfs rise january year launch very first etf spdr spy be now fund available variety category style gain further insight etfs potential benefit growth outlook checked todd rosenbluth senior director etf mutual fund research cfra cfra acquire global rosenbluth be director etf mutual fund research capital iq previous experience include manage editor value line mutual fund survey financial advisor morgan stanley full interview rosenbluth also discuss current trend etf space follow ibd investor own etfs rosenbluth investor want exposure stock bond market look etfs typically provide low cost exposure broad investment category narrower thesis benefit diversification transparency example rather own just merck mrk investor health care select sector spdr xlv fidelity msci health care index etf fhlc hold merck peer include johnson johnson jnj pfizer pfe company other related industry include medtronic mdt unitedhealth group unh actively manage mutual fund investor see daily etf determine think continue fit portfolio ibd be too many etfs rosenbluth approximately third cfra rate etfs come market march so think investing investor determine etf serve legitimate investing purpose so more likely gain sufficient asset be viable keep mind cfra rate far more mutual fund etfs several dozen asset manager offer similar sound product give sentiment shift lower cost etfs away more expensive mutual fund cfra expect more mutual fund be close merged response get ibd market prep tech report newsletter free ibd do think fuel further etf growth hinder growth rosenbluth investor advisor adoption etfs design support asset allocation need be go further drive etf growth vanguard voo ishare core msci eafe iefa be example such well diversify product more investor gain comfort etfs money continue flow establish come product investor always favor mutual fund wrapper want active management address many large asset manager include davis fund legg mason pimco vanguard offer actively manage etfs area potential growth ibd even factor base etfs aren new smart beta continue be buzzword have contribute rise popularity smart beta fund rosenbluth actively manage mutual fund struggle keep return msci eafe index investor be seek alternative smart beta etfs launch last year include popular goldman sachs activebeta large cap equity gslc ishare edge msci multifactor usa etf lrgf combine factor approach offer diversify yet lower cost approach quantitative investing here again many large asset manager have expand etf presence used smart beta product response grow demand last month jpmorgan minimum volatility jmin oppenheimer russell low volatility factor ovol usaa msci usa value momentum blend index etf ulvm have launch be cover cfra research ibd esg environmental social governance fund have be news too do think last trend rosenbluth esg mutual fund asset have be quite sticky even many actively manage mutual fund slowly bleed asset favor index base etfs expect time esg etfs gain traction investor further embrace etfs put money work focuse conviction value ibd new trend re see now rosenbluth re see investor look more closely thematic etfs traditional sector well diversify etfs etfs focus robotic blockchain other potentially long term investment trend more narrowly construct product such global robotic artificial intelligence botz robo global robotic automation index robo reality share nasdaq nexgen economy blcn innovation share nextgen protocol etf koin tend charge premium price relative market cap weight etfs more asset manager compete investor interest fee have continue move lower ibd type etfs do expect outperform interest rate rise rosenbluth equity etfs cfra think more economically sensitive sector include financial industrial benefit rate rise due strong economy vanguard financial index etf vfh ishare transportation average iyt be couple example addition interest rate rise cfra be focuse bond etfs limit interest rate sensitivity low duration product reduce downside impact federal reserve raise rate ishare year investment grade corporate bond shyg spdr bloomberg barclay short term high yield bond etf sjnk be example short term etfs rate favorably cfra ibd give feb market sell early redemption velocityshare daily inverse vix short term etn xiv be thought vix tie volatility etfs be appropriate type investor rosenbluth vix base product be not rate cfra focus etfs directly hold stock bond not derivative however investor need understand inverse leverage etfs aggressively move warning loss pile quickly ibd do xiv early redemption mean harder investor manage risk so do affect market operate rosenbluth xiv be exchange trade note not traditional etf be other product ve talk etns investor need understand be issuer risk consider top usual investment risk etf shut investor get fair warning understand portfolio help track receive hold product close xiv mechanic be much different road closure be much shorter important note however happened xiv be spel prospectus so be less example larger market issue more example investor need know exactly re get involved particularly leverage inverse volatility product ibd be sound strategy long term investor etfs rosenbluth long term investor regularly review etfs re hold understand security fit go forward investor also periodically rebalance asset position do not move tandem not necessarily stand still even passively manage etfs ibd do cfra assess etfs do differ other industry researcher rosenbluth cfra provide forward look rating more etfs combine holding analysis fund attribute include expense ratio technical analysis etf much cost be bigger driver future return year track record well track typically unique index etfs rate favorably cfra do so have confidence valuation risk consideration holding also compare etfs separate mutual fund relevant metric differ other compare active mutual fund try beat etfs such spdr seek replicate index equity etf rating launch nearly year global umbrella top rate etfs have outperformed index bottom rate etfs have underperform equity fund research be acquire independent research provider cfra research late investor learn more https newpublic cfraresearch com email protected rosenbluth be twitter also be interested blockchain expand bitcoin amazon nvidia alibabafirst trust launch new blockchain etf meet demanddow back apple reversal gold shine bitcoin fall
43,JNJ,stock market be slightly higher afternoon trading thursday wall street await president trump decision steel aluminum tariff et trump initially announce tariff steel import tariff aluminum stock market be cheer late wednesday news mexico canada be exclude dow jone industrial average volume nyse be pace be lower wednesday level nasdaq volume be higher johnson johnson jnj mcdonald mcd coca cola ko be top performer dow gain stock market today steel producer tenaris ts add look weekly chart show big cup handle base buy point earning news burlington store burl be high still rise early thursday retailer smash earning expectation surge quarterly profit help accelerate sale rise burlington be work flat base entry ibd square sq extend gain imperfect cup handle base buy point share picked pullback left side base form wasn extreme correction handle be deep use ibd marketsmith free march
44,JNJ,see stock buy point get chart pattern recognition run custom screen start nowin biotech space ligand pharmaceutical lgnd look poise extend winning streak session share jump nearly still buy range buy point ligand be featured today new america news cigna ci announce plan acquire pharmacy benefit manager express script esrx cigna say deal be immediately accretive earning wall street still seem skeptical send cigna share lower express script initially jump be session low december cvs health cvs agree combine aetna aet close watch earning upland software upld many fast grow enterprise software name ibd database share break powerfully monday clear buy point share edge higher ahead result related look best stock buy watch start heretop chinese internet stock jump earning beat then intelligence be surge priority big oil company
45,JNJ,key stock index fund extend gain apple aapl amazon amzn alphabet goog boost tech heavy qqqs powershare qqq trust qqq rise spdr dow jone industrial average dium advanced spdr spy add stock market today emerge market small cap underperform qqq notch fifth straight session big cap techs move include amazon alphabet also extend streak day amazon gain alphabet apple rise end session loss iphone maker share remain day move average level be stick past week utility consumer staple health care lead upside sector fund health care select sector spdr xlv advanced head back day move average top component johnson johnson jnj pfizer pfe be dow top gainer express script esrx pop news health insurer cigna ci acquire pharmacy benefit manager metal miner bank retail lag spdr metal mining xme fall continue test support day line apple amazon facebook fb be top name hold big cap growth fund set possible buy opportunity similar etfs featured recently schwab large cap growth schg remain day move average retake line monday put fund potential buy zone important note purchase be higher normal risk market uptrend pressure etf also be form base potential buy point share advanced late september bounce line jan high then fall much february correction recover loss consolidate day line fund track dow jone large cap growth total stock market index marked eighth anniversary december offer market cap weight exposure big cap equity exhibit growth trait information technology represent nearly third total asset tuesday consumer discretionary be next health care industrial financial real estate consumer staple energy material service make less use ibd marketsmith free march
46,JNJ,see stock buy point get chart pattern recognition run custom screen start nowtop holding account stock portfolio include apple amazon facebook berkshire hathaway brkb alphabet amazon lead year date gain wednesday boee ba top name be next return apple have be trading day line past few week be feb intraday peak etf year date gain tuesday be ahead return accord morningstar direct average annual return past year respectively also lead index gain period schg carry expense ratio wednesday pick vanguard total stock market vti be hold support day move average also be interested dow stock extend loss apple fall china bitcoin dropsdow back apple reversal gold shine bitcoin fallsapple extend gain dow stock rally bitcoin play set
47,JNJ,stock gain strength final hour trading thursday detail new trade tariff show mexico canada be spare nasdaq composite close higher mark fifth straight gain add nearly touch day move average first time feb dow jone industrial average climb consumer medical company johnson johnson jnj pfizer pfe nike nke mcdonald mcd coca cola ko make best percentage gain pfizer rise back day move average have yet make solid move line small cap break trend outperformance russell lose volume rise nasdaq fall nyse accord preliminary datum advancer top decliner board market be dull much day await news trump administration tariff steel aluminum import late day associate press report steel aluminum tariff not be impose mexico canada tariff other country take effect day airline casino tobacco generic drug datum storage be thursday top industry group pharmaceutical spdr pharmaceutical etf xph be more single sector stand thursday session metal mining stock include affected trade tariff be weakest department store supermarket rvs manage care apparel be other bottom industry performance table lead stock be mixed ibd almost evenly split riser decliner thinly trade emergent biosolution ebs break shape base buy point volume be weak company be best know anthrax vaccine collegium pharmaceutical coll surge past buy point irregular base heavy volume company report earning late wednesday sale company painkiller xtampza easily beat expectation momentum be expect continue year collegium be expect become profitable next year ep cent year analyst expect loss cent use ibd marketsmith free march
48,JNJ,see stock buy point get chart pattern recognition run custom screen start nowmarvell technology mrvl edge week formation climb new high active trading chip company be due report earning close related trump tariff go easy canada mexico dow jone biotech flirt battle opioid makersvirgin atlantic follow delta unite american new economy class
49,JNJ,major market average be mixed early morning trade tuesday lead growth stock paypal pypl break potential buy point stock market today tech heavy nasdaq edge lower dow jone industrial average moved respectively be pace extend streak session nasdaq look snap own day streak dow streak end monday dow jone industrial johnson johnson jnj break past flat base entry gain tuesday share be buy range elsewhere dow goldman sachs gs rise nearly look halt day slide stock be still buy range saucer handle entry early november amazon com amzn lead action fang stock early tuesday trade share rise be trading top buy range flat base buy point company report earning acuity brand ayi plunge fiscal earning sale result come well estimate light product maker have be struggle reach new high august fall much level september electric automaker tesla tsla dip give back portion monday torrid advance see stock regain day move average line still stock be high sketch right side potential base video game maker take interactive software decline nearly stock build right side cup shape base stock be add handle formation be too soon be viable ibd alibaba baba remain just cup shape base buy point early tuesday fall almost meanwhile payment processor paypal trade buy point flat base entry fall mildly entry morning trade stock turn red downside apply material amat decline chip equipment maker shape right side new base stock regain day line last week related ce officially start ev stock play watch investing action plandow jone industrial average dow stock news analysisdelta earning preview be really go legacy airline ce news world largest consumer tech showpaypal share break follow upgrade then retreat
50,JNJ,stock market make record high tuesday extend superb start year nasdaq composite have yet be single session new year rise pare gain final couple hour session russell also hit
51,JNJ,stock open higher tuesday dow rebound new high several china base stock post strong early move dow jone industrial average pop open bell johnson johnson jnj traveler trv lead early charge gain nasdaq composite edge less apple aapl facebook fb alphabet googl netflix nflx post early loss big retailer show early strength target tgt climb raise first quarter earning outlook high end target share include benefit much cent newly re-form tax law statement say company expect tax reform legislation create additional cash flow plan use capital investment dividend additional share repurchase target have gain june be climb right side deep month consolidation illumina spiked more announce deal market thermo fisher scientific tmo ampliseq tool exist illumina customer ampliseq work gene sequence analysis tool make illumina other limit analysis target zone genome produce result faster limit amount datum generate search illumina share be extend just buy point first stage flat base intel rival advanced micro device amd drop more early trade tuesday microsoft msft say be halter effort patch security gap amd chip set related spectre lapse operate system update be cause computer freeze amd say product be not risk meltdown vulnerability spectre threat be address operate system update microsoft share rise mazor robotic mzor be ear action maker automate surgical guidance system spiked early trade monday then narrow gain end tight week line company report sell robotic surgical system fourth quarter newly implement agreement medtronic mdt mazor be month saucer base buy point ibd stock daqo new energy dq rebound follow dive monday announce exit chief executive ibd leaderboard stock athm bolt more open trade stock be extend week advance include month base pattern national federation independent business report small business optimism index drop point december remain still record high year old survey labor department job opening labor turnover survey be due et minnesota federal reserve bank president neel kashkari be also schedule speak asia market turn strong session tuesday tokyo nikkei return holiday weekend gain hong kong hang seng index climb straight advance europe market be firmly higher afternoon trade cac paris staking high ground follow london ftse gain advance frankfurt dax related big picture bull be undefeated ready software leader boast accelerate ep estimate nvidia share break autonomous car dealsthese top china stock rocket basis breakout
52,JNJ,major index be mixed afternoon trading tuesday nasdaq composite give gain strength financial health care prop other main index dow jone industrial average lead gain add banking brokerage other financial lead index make record high nasdaq composite be fraction surrender small gain continue weakness biotechs chip stock hurt composite philadelphia semiconductor index be small cap russell be volume be higher compare same time yesterday advancer decliner be practically even board aside biotech health care be today best sector dow component johnson johnson jnj be watch diversify medical company get closer potential buy point week flat base hospital be group least day follow news nonprofit hospital company merge create nation largest hospital chain outpatient care long term care ethical drug industry group be rise well chemical also be act well today market kmg chemical kmg break cup handle base kmg top buy point heavy volume maker specialty chemical material chip pipeline other industry beat profit expectation late monday adjust earning be cent share increase sale rise be first time quarterly sale top fort worth texas base company acquisition start pay glycomimetic glyc gap consolidation new high biotech report today result trial treatment leukemia company be not yet profitable be time high set march ibd be component be still unable climb back key day move average be quality company include nvidia nvda alibaba baba apply material amat prolong trading line indicate base period be unfold sign major top be not clear cut utility be tuesday laggard especially electric utility stock most damage be edison international eix plunge year low company admit equipment have cause wildfire area serve southern california edison unit sce believe investigation now include possible role facility company say statement related chip gear sale forecast post record year invest do find proper buy point be flat base make money chart pattern latest bitcoin news bitcoin etfs
53,JNJ,here investing action plan tuesday need know investor come day annual ce consumer technology trade show officially begin day activity onslaught event be schedule keynote address deliver ford ceo jim hackett be morning
54,JNJ,stock index fund be mixed pare early loss tech stock lead upside apple aapl intel intc advanced dow jone industrial average mcdonald mcd boee ba weigh heavily powershare qqq trust qqq be spdr spy be spdr dow jone industrial average dium fall stock market today small cap rally ishare core small cap ijr ishare russell iwm qqq be show relative strength find support day move average biotech oil explorer semiconductor be biggest sector fund gainer health care stock include pfizer pfe merck mrk johnson johnson jnj advanced dow jone industrial ishare nasdaq biotechnology ibb exchange trade fund reversed sharply higher gain also blue chip apple aapl reversed early loss slight gain be flat line continue hold day line be new record intraday high earlier week spdr gold share gld ishare gold trust iau be gold price rise ounce etfs be try hold support day line utility real estate industrial underperform technology wasn spare thursday stock market sell lead etf top like apple microsoft msft facebook fb be hold better most spdr technology xlk extend loss third straight session get close test day move average however didn breach line way many other etfs do friday do be find support line stage solid rebound line set new chance add buy share early december bounce day yielded gain jan high be featured etf column dec say buy be riskier market uptrend be pressure so crucial keep close eye xlk broader market be fare make purchase etf suffer steep drop late january high feb low so condition haven be exactly ideal fund track technology select sector index marked anniversary december software account biggest chunk asset feb just internet software service weigh tech hardware storage peripheral service semiconductor chip equipment be next xlk top holding be apple microsoft facebook class share alphabet googl represent stock portfolio apple have see bullish news week warren buffett say monday buy more share iphone maker other stock past year other report show apple take smartphone industry profit grab lead wearable device market apple stock be high be hold day line sign free ibd newsletter market prep tech fund year date gain feb lead return accord morningstar direct average annual return past year also outperformed period xlk carry expense ratio thursday pick spdr gold share gld ishare gold trust iau fall sharply day pare loss close respective day line also be interested apple intel dive dow trump tariff take stock marketstock sell dow apple boee reverse celgene divesdow apple intel hold steady stock sell bitcoin gain
55,JNJ,key stock index fund extend loss friday follow cautious remark fed chairman jerome powell apple aapl intel intc be dow few gainer spdr spy fall spdr dow jone industrial average dium slide powershare qqq trust qqq drop stock market today foreign stock lag ishare msci emerge market eem ishare msci eafe efa respectively sector fund be lower board semiconductor telecom financial decline least vaneck vector semiconductor smh pull back ishare phlx semiconductor soxx slide etfs hit new high intraday ve re-cover loss steep pullback day move average early month intel lead upside dow industrial chip giant surge respective friday monday be trading highest level citi research tuesday affirm buy rating name intel top pick also dow apple hold fractional gain climb new record high earlier session share rise monday warren buffett say buy more iphone maker stock anything else past year apple be berkshire hathaway brkb second biggest hold gold real estate homebuilder be biggest sector loser spdr gold share gld ishare gold trust iau lose etfs tumble day line first time more month gold future fall ounce bitcoin climb accord coindesk earlier high bitcoin investment trust gbtc add track third straight advance still day line top rate stock such apple jpmorgan jpm microsoft msft be pack punch price performance dividend be top holding ishare core dividend growth dgro be potential buy zone advance day move average broader market endure sharp sell day line earlier month come back retake day line not best type pullback use new buy share rise early september bounce day line jan peak fund track morningstar dividend growth index mark fourth anniversary june name imply target stock have track record consistent dividend growth feb financial represent biggest chunk asset nearly information technology be next then health care industrial consumer staple top holding include microsoft jpmorgan apple pfizer pfe johnson johnson jnj account total asset broadly diversify portfolio contain stock microsoft gain year date monday close jpmorgan be apple advanced apple rise monday boost bullish comment billionaire investor warren buffett say buy more iphone maker share other stock past year stock close just shy record high apple offer annualize dividend yield microsoft pay jpmorgan yield overall dgro month dividend be average payout track top stock market trend free ibd buffett name dgro top holding include coca cola ko well fargo wfc johnson johnson jnj procter gamble pg etf year date gain friday be slightly ahead return accord morningstar direct average annual return past year also outpace benchmark index gain dgro expense ratio be diversify etfs mentioned monday column powershare qqq trust qqq be now extend bounce day line first trust dorsey dynamic focus fvc be nearly buy range rebound support line related dow lead buffett drive apple stock new record high cat lead dow apple pare gain chance buy buffett stocksdoe make sense invest coal day
56,JNJ,nasdaq composite lead stock higher tuesday afternoon netflix nflx strong earning contribute rally leisure sector nasdaq climb thank part strength biotechs surge share netflix beat subscriber estimate late monday netflix be largest component nasdaq weighting russell rise dow jone industrial average ease johnson johnson jnj tumble heavy trading procter gamble pg slide more big volume federal court dealt setback company patent blockbuster arthritis drug remicade news overshadowed fourth quarter result beat view top sale profit expectation report say be concern company margin volume major exchange be tracking higher compare same time monday netflix share shot time high last evening fourth quarter result video stream company add new subscriber worldwide hike subscriber fee netflix be reason ibd movie industry group be best perform today market other leisure industry group also be lead include travel book lodging group be top group marriott vacation vac rally past buy point base base formation volume be only average eldorado resort eri break flat base rise past entry substantial volume eldorado own casino colorado florida louisiana mississippi nevada other state couple biotechs also break industry continue flex muscle wave life science wve clear cup handle base buy point volume be flat spectrum pharmaceutical sppi break undefined pattern heavy volume stock dip buy point teradata tdc break past buy point flat base volume be well normal level relative strength line have not make new high morgan stanley upgrade datum storage company equal weight underweight marketwatch report paychex payx top entry flat base intense volume stock give back much early surge payroll human resource retirement insurance service provider have weak relative strength line relative price strength rating related dow topple judge toss patent blockbuster drugnetflix fourth quarter earning report key takeaway
57,JNJ,nasdaq composite find comfort tuesday strong earning report netflix fuel broad rally fang stock overall nasdaq outperformed afternoon trading price action be quieter dow jone industrial average dow be fractionally lower eke small gain volume nyse nasdaq be tracking very close monday level stock market today traveler trv be big winner dow strong earning clear flat base entry monday ahead result dow component johnson johnson jnj underperform earning slumping nearly consumer product firm be buy point still hold day move average netflix nflx be big gainer report bullish earning sale late monday head earning netflix be extend entry other fang name facebook fb leaderboard name amazon com amzn rise more alphabet googl add china name alibaba baba enjoy nice bounce day move average rise heavy volume work later stage base buy pointamong breakout enterprise software name workday wday clear cup handle buy point see day chart early december workday hit intraday low undercut low prior base serve reset base count workday weekly chart show alternate entry biotech space vertex pharmaceutical vrtx rise top month consolidation show conventional entry share jump nearly vertex own composite rating thank part big earning sale growth recent quarters meanwhile president trump decision impose new duty much foreign make solar equipment fuel big early gain first solar fslr share reversed lower rise nearly intraday share be stock be poise second test week move average late october year treasury yield slip basis point ahead busy week economic datum have december exist home sale datum due wednesday new home sale datum thursday meanwhile first read gross domestic product be due friday economist expect growth new york mercantile exchange crude oil future add just barrel result unite airline ual be due close work big cup handle base buy point ahead result share be related unite airline weigh option boee eye new midsize jet sfirst solar tesla winner solar tariff decision hit chinathese be top stock millennial investor be hold say robinhood
58,JNJ,stock be mostly higher netflix nflx amazon amzn nvidia nvda lead techs bitcoin reversed slightly higher increase scrutiny regulator powershare qqq trust qqq rise spdr spy climb spdr dow jone industrial average dium be fractionally lower techs get boost netflix gap soar record high report quarterly result amazon rise graphic chip designer nvidia advanced new high apple aapl be flat give early gain more gold miner biotech real estate lead upside sector fund stock market today health care telecom consumer staple be biggest decliner health care select sector spdr xlv slip remain time high component johnson johnson jnj biggest hold sank heavy trade federal appeal court upheld ruling invalidate patent remicade arthritis drug also weigh dow industrial bitcoin reversed gain accord coindesk slightly intraday high south korea regulator be take tougher stance cryptocurrency trading regulator monitor closely company have announce sudden shift blockchain technology bitcoin investment trust gbtc fall slide further day move average here lead stock play consider favor high dividend payer such ford verizon communication vz offer yield north powershare high dividend low volatility portfolio sphd be rebound day move average line set potential buy opportunity share advanced nearly last test support line late october fund be featured etf column nov moved day line sphd marked fifth anniversary october have amassed asset track low volatility high dividend index comprise stock benchmark index have history provide high dividend yield low volatility fund index be rebalance reconstitute twice year sphd screen top company base dividend payout accord morningstar direct then omit stock highest volatility prior year lower fund exposure riskier name real estate account biggest sector weighting nearly asset follow utility information technology energy consumer staple contribute financial service smaller allocation be industrial health care consumer discretionary material top holding jan include occidental petroleum oxy verizon iron mountain irm cme group cme ford top make portfolio iron mountain offer annualize dividend yield ford verizon ibd take verizon communication pay hefty annualize dividend do fundamental rate industry group find now ibd stock checkup sphd return year jan trail gain etf average annual return past year respectively slightly lag benchmark index gain same period sphd pay annualize dividend vs average payout fund carry expense ratio monday pick global social medium socl be slightly extend jan rebound day line extend streak fourth straight session monday related stock rise senate vote biotech soar bitcoin dropsstock mixed nike lead dow ge apple weigh bitcoin quiettop chip stock defy market trend bitcoin play bounce back
59,JNJ,here be investing action plan need know investor tuesday jan earning be due unite airline ual chipmaker texas instrument txn dow industrial component verizon vz johnson johnson jnj procter gamble pg well profit chinese school operator new oriental education edu unite airline be buy
60,JNJ,alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx be likely beat fourth quarter earning estimate analyst predict biotech guidance be cautious windfall tax reform fourth quarter earning report season kick next week dow johnson johnson jnj novartis nvs weigh tuesday wednesday pharma side celgene celg biogen biib be deck early thursday abbvie abbv trail friday leerink analyst geoffrey porge expect cautious prediction begin note example celgene pre announcement earlier month uncertainty payer dynamic competition drug access be likely play forecast factor imminent return more challenge political environment suggest management team be more typically cautious guidance first provide financial community earning call say note client fourth quarter porge call vertex cystic fibrosis drug orkambi kalydeco gilead hepatitis hiv drug regeneron pharmaceutical regn eylea dupixent latter eye disease eczema treatment respectively surprise upside ibd take biotechs suffer third quarter high profile drug miss expectation smaller player take headline beating view head industry snapshot more happened prior quarter history be expect repeat see older drug amgen amgn include psoriasis arthritis med enbrel risk disappointing investor biogen multiple sclerosis drug avonex plegridy abbvie cancer med imbruvica also disappoint say needham analyst alan carr see investor focuse merger fourth quarter call week rumor emerge celgene be consider takeover juno therapeutic juno biogen be consider putt bid acorda therapeutic acor continue believe pharma have bias risk asset be market case still regulatory review write note client first half expect food drug administration approve vertex cystic fibrosis regimen kalydeco tezacaftor well hiv combination gilead abbvie neurocrine bioscience nbix also get drug treat severe menstrual pain alnylam pharmaceutical alny be also likely grab approval patisiran drug treat condition abnormal protein deposit body cause systemic problem achaogen akao tetraphase pharmaceutical ttph be also near approval antibiotic related celgene rumore acquisition juno actually make sensedow merck do face release cancer trial hospital plan put pressure generic drug maker
61,JNJ,share drug giant merck mrk fall tuesday federal judge tossed record verdict have win gilead science gild hepatitis treatment federal jury have say gilead owe merck sale sovaldi harvoni hepatitis drug district court judge leonard stark wilmington del agree friday gilead argument merck patent be invalid patent issue be compound merck idenix unit contend be basis major treatment hepatitis include one make gilead merck claim be first synthesize compound gilead say didn cover new idea patent owner be require describe invention enough detail allow other replicate unnecessary time effort case stark say merck patent cover so many potential compound take excessive experimentation narrow base only reasonable find be patent be invalid stark say decision merck share lose close foster city calif base gilead add merck base kenilworth pledge appeal judge finding say do not reflect fact case patent issue case facilitate significant advance treatment patient hcv infection achieve advancement require many year research significant investment subsidiary partner company say written statement believe strong patent protection be essential innovation merck add give guarantee firm period return investment patent protection provide research base pharmaceutical biotechnology industry incentive invest research development sovaldi be approve food drug administration harvoni get regulatory go ahead year later merck drug zepatier be approve gilead have concede infringement patent common legal tactic allow focus validity issue trial reject gilead argument patent jury say gilead owe royalty total sale drug separate part ruling stark reject gilead argument damage amount be unfair issue become important only patent be later revive appeal verdict be largest patent infringement verdict history dwarf next biggest verdict win johnson johnson jnj abbott laboratory be later throw appeal accord datum compile bloomberg
62,JNJ,nasdaq track extend winning streak trading session mix stock be breaking hit new high stock market today be ibd member blue chip stock regional bank paypal pypl moved early trade
63,JNJ,stock index shuffle minor gain midday thursday market approach end meanwhile dow jone industrial average be well position stock poise breakout nasdaq add blue chip dow jone industrial average rise small cap russell be fraction volume stock market today be run previous session pace blue chip be mostly component dow move be restrain apple aapl instance lead pack gain be only dow stock be possible breakout include microsoft msft try climb back entry dowdupont dwdp procter gamble pg wal mart store wmt intel intc johnson johnson jnj coca cola ko exxon mobil xom apple stock be buy point street expect deliver earning growth dowdupont estimate growth be apple growth fiscal end september be peg exxon be estimate dowdupont exxon represent upward revision apple estimate reflect downward revision analyst ibd list best stock fundamental technical china base solar stock daqo new energy dq jump heavy volume mark new high solar group be industry group ibd sector energy have provide most new high past day wednesday related oil production fall more expectedwhat most investment strategy miss
64,JNJ,major market average post tight quiet gain early wednesday tech heavy nasdaq rise follow gain dow jone industrial average be just break even mark economic datum front december consumer confidence index come sharply november read well consensus forecast tally econoday meanwhile pending home sale edge higher november vs estimate dow jone industrial component johnson johnson jnj advanced medical name be away potential buy point flat base entry elsewhere dow apple aapl continue lower fall follow report weak iphone demand weekend decline have stop short crucial day support level be flat base entry fang stock facebook fb look reclaim day move average line wednesday stock market today give level last week share rise energy name be pressure early wednesday leaderboard member diamondback energy fang fall remain well extend flat base buy point meanwhile eog resource eog moved stock break past short cup shape base buy point tuesday lead stock be rebound tuesday weakness apply material amat moved shape right side potential base meanwhile graphic chip maker nvidia nvda moved nearly be approach day line have be trading late november tesla tsla decline keybanc give pessimistic guidance tesla model delivery analyst lower target unit unit stock have be show great deal whipsaw action try rebound recent lows build right side potential base week stock reclaim day line heavy volume however key support level have be give once again ibd flooring retailer floor decor fnd be breaking cup handle entry rise share be still buy range downside china base leadership struggle early wednesday many sketch potential basis china lodging htht decline remain striking distance cup shape base entry related dow jone industrial average dow stock news top china stock be base be wary investing action plan stock market outlook watch new yearthese stunning stat reveal epic netflix amazon hulu apple war come
65,JNJ,main stock index be session high tuesday afternoon bitcoin add huge rally couple small cap break past buy point dow jone industrial average lead increase take industrial new high dow component rise more couple make noteworthy move johnson johnson jnj rise more jpmorgan chase jpm nearly stock rise support day move average be consider be buy area neither have show impressive volume past few day small cap also lead russell add climb nasdaq composite lag gain biotechs chip designer show weakness alphabet googl reversed lower hit new high most other major nasdaq component be little change higher volume be tracking higher compare same time monday tcf financial tcf regional bank hold company base wayzata minn jump past buy point cup handle base time more volume usual firm announce monday longer make indirect auto loan say outlook market be less favorable compare alternative used capital bank take time charge due change tcf also set new stock buyback program replace earlier buyback plan aquantia aq break ipo base soar past buy point big volume aquantia go public nov share make technology superfast network communication cloud compute chinese stock extend loss few loser highest relative volume momo momo china social medium company gap lowest level february company earning beat profit expectation momo post adjust earning cent consensus estimate cent be increase year period revenue catapult
66,JNJ,volume tuesday be more time average noah holding noah slide have erased much gain buy point nov xunlei xnet digital medium platform have be soar mid october plunge second straight day be past day xunlei be china company introduce cryptocurrency october other cryptocurrency share trade wildly again bitcoin investment trust gbtc exchange trade note backed bitcoin surge be so far week related bitcoin clear several crypto stock tumbleibd china lodging be tap earning
67,JNJ,stock index reach record high tuesday afternoon market continue superb start dow jone industrial average lead increase thank mainly boee ba rally new high johnson johnson jnj base base pattern boee say today deliver commercial jet company ramp production midrange plane order backlog hit record jetliner nasdaq add have yet post single day loss start new year russell climb less still make new high well volume be run higher compare same time monday financial be lead sector yield benchmark year treasury note rise highest level last march superregional bank regional bank broker be industry group more today raymond james financial rjf td ameritrade amtd pnc financial pnc ameriprice financial amp be financial rise unusually high volume hit new high dozen stock break past buy point today market have suspicious behavior global payment gpn example top buy point flat base stock afternoon surrender most tuesday gain volume wasn big enough make convince realpage rp top entry volume be third less average labor outsource firm aramark armk clear cup handle entry volume also be light chip stock lag philadelphia semiconductor index internet sector grubhub grub fall more be now testing week move average stock remain well extend october related boee stock hit new high delivery order climbstock index hit new high be hotce news world largest consumer tech showchip stock watch semiconductor industry news
68,JNJ,stock be try rebound investor backed away market breaking news federal grand jury indict russian national charge interfere election nasdaq suffer biggest blow afternoon trading edge higher minute left session premier index growth company also still look poise strong weekly advance least follow drop prior week wednesday nasdaq composite spark confirmation potential new market uptrend rise higher volume vs prior session solid rally come day new rally attempt lead equity index get trample seller fall time perch friday nasdaq slip rise much et dow jone industrial average edge nearly higher roughly hour go close small cap lag big cap brother outperformed friday russell gain nearly popular small cap index be now back black almost year date least component dow industrial rise point more include consumer spending medical name walt disney johnson johnson jnj home depot hd meanwhile bitcoin investment trust gbtc slump dash hope possible rebound back day move average week strong weekly advance suggest gbtc be begin form new deep base rally back day line be bullish not be proper buy point yet reason gbtc have fall more december peak correction deep often indicate potential new sell off be high highflying stock etf rebound price vulnerable overhead supply potential seller buy way be look cut loss elsewhere steel company homebuilder long term medical care medical service pollution control firm pace upside gain more nucor nue have trampoline higher testing level feb return back day move average be also bullish steelmaker rally more friday volume run more day average note ibd daily chart easy see turnover be higher normal just compare volume bar trading session line go volume bar line be day move average show average amount share trade day past session stock rise back day move average week line weekly chart normal turnover be flash bullish action indicate mutual fund hedge fund pension plan corporate treasury division insurer be accumulate share nucor have experience stiff upside resistance level stock have trade past month potential new base form charlotte base nucor grow fourth quarter earning vs year cent share jump revenue steel retook buy point cup handle begin february handle form trading session jan handle be least trading day long related be stock market outlook changedwhich way be stock market head now read column daywhen do nvidia show screen great stock stock buy zoneipo stock leader today
69,JNJ,year be shape be boisterous biotech acquisition celgene celg sanofi sny matter day announce plan spend north take company analyst say celgene sanofi particular be face challenge area insurance company be push back payment rheumatology diabetes also leave like novartis nvo eli lilly lly trouble say brad loncar manage immunotherapy base fund company have buy growth loncar tell investor business daily ve be grow revenue do artificial thing drug price increase tax inversion kind other type financial engineering thing be go away be spend biotech deal mizuho analyst salim sy tell ibd year so far celgene have say spend buy remainder juno therapeutic juno doesn already own sanofi be spending acquire bioverativ bivv ablynx ablx company haven buy anything just matter opportunity sy say buy spree kick august gilead science gild announce plan acquire cancer play kite pharma gilead have be suffering major slowdown hepatitis drug sale high cure rate saturation europe celgene sanofi announce plan acquire juno bioverativ same day january day later sanofi say buy rare disease drugmaker ablynx celgene acquisition follow disappointing third quarter sale psoriatic arthritis plaque psoriasis drug otezla widely miss expectation biotech also cut guidance otezla shortfall terminate several trial crohn disease loncar describe celgene long term growth prospect time bleak picture also face patent cliff mid cancer drug revlimid ibd take challenge hold stock market correction decline help share form new potential base be still possible capture big gain head investor corner tip make gain correction so really couldn afford say sanofi other hand be skunked twice try acquire medivation actelion pharma dow component pfizer pfe beat sanofi medivation dow johnson johnson jnj be able acquire actelion sanofi roy behren fund manager capital management say sanofi commit acquisition make hostile bid medivation go back initially higher bid actelion filing show hostile approach be generally unsuccessful space fact scientist be such important part value equation tell ibd case sanofi medivation couldn arrive price be friendly be very difficult complete acquisition high profile acquisition late early acquirer have suffer pressure sale key moneymaker tax reform allow company pay less corporate taxe repatriate cash lower rate prime pump acquisition strong believer be go be huge year acquisition loncar say larger company growth be slow tax reform deal add fuel fire make easier do deal nordisk lose ablynx sanofi now loncar expect nordisk go other asset contend deep exposure diabetes market lilly too be see challenge diabetes meanwhile amgen amgn older drug be face new competition big company really need do say be outlier mizuho analyst sy say biogen biib instance guide flat sale multiple sclerosis unit include impact royalty get revenue roche rhhby new drug ocrevus perception franchise be dwindle say argument investor make lot guy biogen amgen base business be go away not necessarily case biogen be stable still flat sale win be enough pique investor interest biogen aducanumab potential treatment alzheimer disease be carrot investor clinical trial datum be available end early long carrot be become really difficult hedge fund community short stock say aducanumab produce return work large cap biotechs typically don see behren note biotechs seem be fairly interested immunotherapy oncology include gilead acquisition kite celgene plan acquire juno be work drug know car therapy immune system identify fight cancer have be lot activity oncology space term immunotherapy say larger company be try gobble promising technology still affordable be also see quite few testing company be acquire celgene acquisition juno follow common storyline behren say celgene invest juno create immunotherapy cancer autoimmune disease duo be furthest jcar potential treatment hodgkin lymphoma celgene pull trigger juno jan make sense be premium juno close price prior trading day biotechs even more high tech tend come significant premium trading price say re somewhat risky be huge payoff event re successful nektar therapeutic nktr bristol myer squibb bmy be similar plot september duo pair test nektar drug call nktr bristol opdivo patient melanoma kidney cancer lung cancer november nektar present strong early datum combo loncar peg nektar potential takeover target call nktr revolutionary day later bristol announce pay nektar upfront comprise cash purchase share test nktr opdivo opdivo yervoy deal allow bristol remain leader immuno oncology immuno oncology combination risk bid nektar evercore analyst umer raffat say feb note client have doubt nektar phone have be ring hook november datum be so interesting loncar say someone be bold enough buy put acquirer class own immuno oncology drug call parp inhibitor also look interesting loncar say clovis oncology clvs tesaro tsro have drug approve class be small enough acquire astrazeneca azn also work space sarepta therapeutic srpt neurocrine bioscience nbix biomarin pharmaceutical bmrn have also have successful launch recently company want revenue growth buy rare disease drug say have best sale ramp think type company be really interesting right now wouldn be surprised get buy related biotech investor flee drove market correction rock groupthese biotechs spring back market correction analystwhy biotech stock outperform peer
70,JNJ,stock rise tuesday dow rebound nasdaq extend new year streak close record high spdr dow jone industrial average dium lead gain spdr spy climb powershare qqq trust qqq end flat emerge market underperform pare loss ishare msci emerge market eem edge lower sector fund stock market today biotech bank health care score biggest gain johnson johnson jnj be dow leader advance share break past flat base entry close just buy point metal miner retail utility lag gold etfs be lower gold future fall ounce bitcoin be reach high accord coindesk have fall earlier bitcoin investment trust gbtc finished jpmorgan chase jpm ceo jamie dimon say fox business interview regret make comment last year call bitcoin fraud didn elaborate reiterate opinion blockchain technology underpin digital currency be real chip etfs be start new year bang lead stock such nvidia nvda apply material amat extend recent gain monday be track end streak tuesday likewise ishare phlx semiconductor soxx spdr semiconductor xsd notch fifth straight session monday keep streak intact soxx have amassed july launch be close flat base buy point fund be last featured etf column dec find support day move average share slip line regain jan rise late august rebound day nov intraday high etf track phlx semiconductor index hold texas instrument txn nvidia apply material top position jan stock have gain respectively year nvidia jump monday clear buy point heavy volume remain buy zone graphic chip designer announce new partnership volkswagen vlkay baidu bidu uber monday annual ce consumer technology show chip gear maker apply material trading advanced more needham upgrade strong buy buy price target share gap back day line soxx year jan have post average annual return past year comparison return same period year accord morningstar direct fund carry expense ratio ibd take be bitcoin ethereum other digital currency real investment speculator game individual investor be extremely cautious diving new area read feature bitcoin risk possible gain first spdr semiconductor count nvidia texas instrument top holding be trace similar pattern soxx potential buy point xsd be etf rise late september bounce day nov intraday peak fund mark anniversary end month track semiconductor select industry index have expense ratio xsd be ytd average annual return past year related stock move nvidia tesla drive techs bitcoin ripple chip leader break other top techs hover buysthese top stock be breaking today heavy volume
71,JNJ,last several year smart beta etfs have surge popularity potential replacement active management strategy much cheaper price first month alone global smart beta equity etf etp exchange trade product asset surge accord london base etf tracker etfgi smart beta sometimes call strategic beta factor investing refer rule base strategy go etfs track traditional market cap weight index market cap weight etfs include spdr etf spy powershare qqq qqq track nasdaq sdpr dow jone industrial average dium track price weight dow industrial average smart beta etfs come variety strategy include value growth income dividend yield dividend growth fundamental weight equal weight diversify away weighting portfolio market cap be stock price time share outstanding consider qqq top holding be apple aapl microsoft msft amazon com amzn facebook fb alphabet googl together account more etf total portfolio company perform well fund have good year example be year date dec apple have multiyear correction do again vanilla etf performance be muted compare smart beta etf have avoid apple rotate stock different equity opportunity number smart beta etfs provide active investment strategy lower cost compare qs comparison expense ratio qqq etf be accord ben johnson director global etf research morningstar be key factor analyze smart beta etfs fund investment process fee fund charge investor have thorough understand etf investment process construct portfolio weighting meanwhile fund fee be compare actively manage peer vanilla etf alternative income produce fund have strong morningstar analyst rating vanguard dividend appreciation vig schwab dividend equity schd morningstar analyst rating measure quality fund context fund objective benchmark peer group meanwhile fund distinguish morningstar pillar investment success talented management team sound investment process portfolio be sync fund process reasonable expense strong parent organization vig boast gold star analyst rating indicate morningstar analyst have highest conviction recommendation investment objective seek select diversify portfolio highly profitable dividend pay company meantime fund reduce exposure firm weak fundamental have difficulty sustain dividend yielding annualize top holding include consumer product company johnson johnson jnj tech giant microsoft msft beverage king pepsico pep accord ibd datum fund dividend growth rate be staunch compare growth rate year date etf be carry expense ratio schd sport morningstar silver star analyst rating similar vanguard fund schwab fund look focus equity strong fundamental attractive yield fund biggest position be intel intc verizon communication vz microsoft annual dividend yield be year date fund be expense ratio be accord todd rosenbluth director etf mutual fund research cfra be different type income related play high yielding income generation dividend pay stock growth potential income generation side rosenbluth like ishare core high dividend hdv fund focus blue chip energy telecom name exxon mobil xom chevron cvx verizon account portfolio fund be year date have annualize dividend yield expense ratio be dividend pay growth side rosenbluth mention quality dividend growth dgrw yield design dividend growth angle be participate market upside protect downside income stream ibd take apple have outperformed broader market year do rank industry group find now ibd stock checkup top holding be apple iphone maker be strongly weight portfolio due strong fundamental profile quarters accelerate earning sale growth solid annual dividend even have slightly higher expense ratio come fund past year have return average annual compare year date fund be vs return accord morningstar direct related find income take big riskstop dividend fund manager expect growth sectorsdoe steady earning growth lead big dividend apple weigh dow bitcoin drop again nvidia ready run
72,JNJ,clovis oncology clvs sage therapeutic sage puma biotechnology pbyi stoke acquisitive appetite large cap biotechs struggle slow growth major patent cliff analyst say tuesday deal make have slow hit record high rbc analyst say note client number deal value hit year year have be merger include gilead science gild takeover kite pharma investor have expect gilead major buy stoke more acquisition didn come fruition biotech stock suffer pent demand prompt merger acquisition play next year analyst say many large cap company generate share overall revenue handful blockbuster drug many be face impending patent cliff come year rbc note say need make lose source revenue stimulate growth encourage future gilead buy kite suffering major decline hepatitis drug unit hiv drug tenofovir alafenamide be likely lose patent protection celgene celg cancer drug revlimid be face patent cliff amgen amgn inflammatory enbrel be likely lose protection also have most cash hand recent update amgen report celgene have gilead note remainder large cap biotech realm have ibd take analyst say monday large cap biotech franchise feel pain competition speeding number rival brand generic drug approval head ibd industry theme more mean like vertex pharmaceutical gilead amgen overall cash position be near year high analyst say tax reform help most recent proposal company repatriate earning tax rate amgen bristol myer squibb bmy dow johnson johnson jnj have excess cash currently overseas however think unlikely majority overseas cash be repatriate immediately institution tax reform rbc analyst say celgene instance have suggest chunk foreign earning be expect be reinvest permanently outside analyst also note average project revenue next year mid cap biotechs be likely do little offset loss patent cliff performance acquirer past year have be poor industry check also indicate large deal be out gilead kite be exception still expectation be high merger acquisition analyst say recent survey investor cite biggest tailwind group drug pricing be expect be biggest headwind rbc analyst be slightly bullish slightly bearish drug pricing expectation high major tailwind sector do not materialize first half see broad downside rbc say credit suisse analyst vamil divan too note be important big pharma group likely come result change tax rate repatriation top pick be also expect dow merck mrk allergan agn rebound additional fund dividend growth share repurchase also boost overall outlook sector investor perspective say see regulatory environment remain generally favorable provide more rapid path market product bring real innovation related beware price war big pharma biotech company biotech stock see cheapest rival cancer drugsgeneric drug maker face pricing issue other pharmas don
73,JNJ,major index be narrowly mixed wednesday afternoon trading narrow price range see only few sector make significant move nasdaq composite hold minimal gain ease dow jone industrial average fall russell be fraction index hold new high nasdaq inched new high morning cede gain dow component johnson johnson jnj fall day move average coincide buy point stock clear october medical product company now seek support key level verizon vz rise company stand gain more power federal communication commission roll back net neutrality rule commission say tuesday be vote dec volume be tracking tuesday level same time day not surprising eve thanksgiving many trader plan take day break winner lead loser ratio board health care stock lead hospital home care drug wholesale industry group flash gain more industry group rank low be lack lead stock energy sector also lead price oil rise cent barrel session high just weakest industry group be spread semiconductor scientific equipment automaker rv maker jewelry company plastic other industry salesforce com crm fall heavy trading company beat profit sale expectation october end quarter give profit guidance current quarter disappoint stock however remain strong uptrend past oct outlook bmo capital market royal bank canada pivotal research suntrust bank raise price target stock canaccord genuity analyst richard davis also raise price target quarterly print guide do not know anyone reasonably argue salesforce be not not highest quality software company planet davis write cite company major deal department homeland security quarter launch financial service cloud business banking fastenal fast clear entry cup handle volume be average fastenal be build product industry group include leader such home depot hd beacon roofing supply becn few other stock group be form basis home depot be extend pullback day move average related salesforce com earning beat guidance light stock slideswhy fcc net neutrality reversal later be reversed again
74,JNJ,wednesday abbott laboratory clear key performance benchmark see relative strength rs rating jump percentile improvement day ibd unique rating measure share price action worst best score grade show stock price performance trail week compare other stock database history show top perform stock tend have rs rating least begin biggest run see ibd help make more money stocksabbott laboratory be build flat base entry see stock clear price volume least higher normal company bottom line growth drop company most recent performance report sale rise previous report abbott laboratory hold rank peer medical diversify industry group johnson johnson jnj ibd be also group highest rate stock related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
75,JNJ,current bull market approach ninth year sign sector rotation possible top emerge now be good time see join apple aapl intel intc bank america bac ibd latest list new buy top perform mutual fund last month lead fund manager have continue pick share semiconductor related stock intel texas instrument txn build sector name lead homebuilder pulte group phm construction product manufacturer masco mas well several industrial machinery company include parker hannifin ph illinois tool work itw tension north korea nuclear missile program rise not surprising fund have also be investing defense contractor include aerojet rocketdyne ajrd heico hei apple intel bofa top list term money invest fund invest estimate total intel fund scoop nearly apple share fund put bank america apple break oct short rise have ease back form new flat base show possible entry intel have pull back make solid gain early october chip giant be now testing support week line appear be set new base possible buy point bofa remain extend clear entry financial titan be currently buy point several stock month list be potential buy zone keep mind recent selling pressure major index pullback several lead stock mean current uptrend be start roll correction happen be difficult individual stock make sustain upward climb orthopedic implant maker stryker syk be work first stage base base entry look relative strength line get closer new high ground stock find support day move average stryker close benchmark line thursday rise volume heico have find support week move average try complete flat base entry pattern be part long first stage base base formation fellow defense contractor aerojet rocketdyne be also work base be trading week move average lag rs line regional bank stock synovus financial snv jump past entry nov have now pull back test buy point once again stock list currently pay dividend yielding least annualize basis texas instrument intel new mexico base electricity utility pnm resource pnm dov look generate income stock mutual fund take undue risk see ibd new special report income investing jpmorgan chase jpm top list new sell net seller fund selling buy recent chart action be tell different story bofa other big bank stock jpmorgan have get bump likelihood donald trump republican pass tax reform have rise johnson johnson jnj have net seller selling buy aetna aet merge cvs cvs deal clear regulatory hurdle have selling buy johnson johnson be work flat base part longer first stage base base formation buy point be stock end thursday session entry related find track best mutual fundsincome investing find best dividend stock
76,JNJ,johnson johnson jnj flirted buy point thursday bullish report cite strength pharmaceutical unit ahead dow component third quarter earning slate early tuesday xby close bell stock market today advanced close share briefly top buy point flat base begin form july share be trading time high remain bullish story drive large part upside expect pharmaceutical segment move third quarter result next week credit suisse analyst vamil divan write note client third quarter consensus analyst poll zack investment research call report adjust income share sale respectively divan note be important unknown quarter include impact hurricane marium have manufacturing facility puerto rico possible fourth quarter outlook be more guard say ibd take wednesday analyst call ep growth dividend machine remain bullish stock ahead firm third quarter result head income investor more be time buy divan keep price target outperform rating see firm pharma unit drive force long term upside include blood thinner xarelto cancer drug darzalex imbruvica third quarter conference call expect investor key impact hurricane marium underlie performance growth driver look stronger top bottom line growth also possible more merger be table actelion pharmaceutical look understand willingness pursue larger scale business development now actelion deal have close see macro debate drug pricing tax reform impact strategy go forward divan say note serve bellwether quarterly result other large cap pharmas coverage set be release oct nov related drugmaker hit month high collaboration dow merckwhy amgen lilly be interested small partnership bit dust gilead kite competition
77,JNJ,nordisk nvo be shedding restraint embrace acquisition danish drugmaker have traditionally eschew deal look inward develop new treatment signale desire seek growth outside own lab disclose takeover offer ablynx ablx ceo lar fruergaard jorgensen walk predecessor footstep first year helm be now attempt clinch biggest deal ever ablynx spurn offer less month strategy extend ablynx say review other potential takeover year rely mostly house research be keen look elsewhere new medicine mark higher risk willingness willingness obtain innovation outside nordisk compare historically have do chief financial officer jesper brandgaard say interview bloomberg have sit recent wave industry deal handful giant snap promising biotechnology company company have spend less merger acquisition past decade accord datum disclose swiss rival roche hold rhhby contrast commit time much just last month agree buy biotech firm ignyta rxdx other pharmaceutical transaction last year include johnson johnson jnj purchase swiss biotech actelion ltd gilead science gild takeover kite pharma year old jorgensen find not only interested ablynx isn aware other suitor brandgaard tell reporter conference call emerge now interest be open ablynx share surge more close share tick cent belgium base ablynx say late monday chairman peter fellner have resign board fellner have serve chairman have be slate step later year ablynx give reason departure fellner have have numerous corporate board appointment be member advisory group investing arm nordisk foundation january ll be replace chairman bo jesper hansen executive director company say statement jorgensen be work beef unit have traditionally have low profile business selling treatment rare blood disorder make only fifth sale be overshadowed company diabetes operation unit get split need grow say kim nielsen fund manager worldwide asset management copenhagen otherwise risk be too small too uninteresting say nielsen hold share overall feel confident do something go public ablynx reject proposal include upfront cash offer euro share additional cash payment know contingent value right euro share tie success experimental medicine maximum payment be more stock close price friday brussel choice target isn shot dark company have be involved research collaboration ablynx most advanced drug caplacizumab address rare disorder call acquire thrombotic purpura blood clot form small blood vessel body illness block flow blood body organ accord national heart lung blood institute jorgensen grow family farm denmark joined economist replace retire leader start last year joined just traditional diabetes business come pressure insurer payer demand lower price largest market ablynx hold great potential have highly competent employee brandgaard say be natural first asset pursue
78,JNJ,major market average give early gain turn squarely lower thursday morning trade top stock nvidia nvda advanced ahead earning release close tech heavy nasdaq fall stock market today dow jone industrial average moved respectively dow jone industrial johnson johnson jnj be day loser decline share be consolidate day line fail flat base buy point company report earning electric automaker tesla tsla sank nearly top earning sale estimate late wednesday company also affirm production target model stock be consolidate right day move average line twitter twtr soar multiyear high report better expect earning sale estimate share have be volatile breaking past cup handle entry back december have maintain key support day line former highflier coherent cohr plunge fall record high set just last month top earning sale estimate late stage base buy point quickly faltered break stock be also long term day move average line retailer canada goose goos crater beating earn sale estimate stock be still hold day line torrid advance cup handle entry meanwhile market close graphic chip maker nvidia report earning consensus estimate expect earning share revenue totale stock reversed lower nearly continue rebound day line ibd grubhub grub jump new high beating estimate early thursday company also announce partnership yum brand yum parent company taco bell kfc pizza hut flat base buy point fail last week market volatile move downside related use day move average pinpoint opportunity spot next major stock market peak here be easy waydow jone suffer worst point drop ever percentage loss be not historictime review stock selling smartsdow jone industrial average dow stock news analysis
79,JNJ,major average close heavy loss market slide come important test dow jone industrial average lead loss nearly point lose nearly point earlier index lose index fall day move average bounce line be positive sign index fall much day line market have even further drop nasdaq composite be day line composite have better performance dow hot january market rally volume be higher same time friday market breadth continue deteriorate decline stock lead advancer nearly nyse nasdaq exxon mobil xom chevron cvx pressured dow industrial again oil company sell friday earning report exxon mobil drilled nearly pierce day move average chevron lose be january high certainly aren alone spdr energy etf xle be prior high also fall day line industry group energy build health care banking sector be weakest today market johnson johnson jnj pfizer pfe dow component also have be selling report earning be more fall day line pfizer violate day average most ibd stock be lower also be hold day line be trading day move average grubhub grub fall day line monday raymond james cut rating market perform outperform earning be due thursday open average ibd stock be more week high average have be skewer lower big decliner such petm express pet daqo new energy dq note oppenheimer holding opy briefly clear buy point cup handle base volume be more double average relative strength line make new high share fall back entry point market plunge related dow suffer worst point drop ever percentage loss not historichere spot major stock market top easy wayit time review stock selling smartsexxon mobil miss forecast badly chevron profit weakdow topple judge toss patent blockbuster drug
80,JNJ,steepening stock market sell make tough first day work jerome powell officially swear chairman federal reserve monday market slice lower continuation friday heavy distribution dow jone industrial average faltered almost point largest ever point loss stock post loss greater unraveled well fargo wfc post index worst decline almost investor react penalty impose federal reserve friday sanction impose janet yellen final day head fed stir concern regulator powell be set more authoritarian turn nasdaq composite drop apple aapl carve lower fang tech leader alphabet googl netflix nflx couple brief intraday market rebound attempt quickly collapse bond take back ground drive year yield dollar commodity trade mixed big oil name be again key contributor day decline benchmark crude drop more just barrel exxon mobil xom chevron cvx lead downside dow skid more total tot bp bp fall sharply other dow component boee ba johnson johnson jnj dive unite technology utx decline reach stock fall day line shipping be session strongest industry buoy gap kirby kex inland coastal waterway operation announce buy barge transportation outfit higman marine kirby share be extend cup handle base january china base stock take bruise lead sina sina fall firm volume decline drove share test week move average sina be less buy point double bottom base avoid automatic sell rule chip trade broadly lower ostensibly positive news broadcom avgo have ratchete bid acquire qualcomm qcom more broadcom lose qualcomm skitter nearly lower other chip leader advanced micro device amd give qorvo qrvo decline xilinx xlnx take loss graphic chip leader nvidia nvda unspooled decline share end just day move average just buy point cup handle base related dow suffer worst point drop ever percentage loss not historicstock continue wild action late chipmaker move earningsfed well fargo punishment set precedent harsher era broadcom raise bid qualcomm call best final offer time review stock selling do spot major stock market top here easy way
81,JNJ,major market average be mostly unchanged morning trade wednesday weak market open dow jone industrial average be break even mark tech heavy nasdaq trade higher economic front adp november national employment report come vs econoday estimate dow jone industrial component johnson johnson jnj pace advancer early rise share be buy range flat base buy point stock form new flat base buy point downside apple aapl re-cover heavy loss fall just share be trading just past top buy range cup handle entry range run fang stock netflix nflx be initiate line rating price target evercore isi stock moved still look recover back cup handle entry share be also day line meanwhile evercore start facebook fb outperform rating price target share rise early trade be just flat base buy point company report earning veeva system veev drop nearly top estimate offer fiscal guidance line target stock have be winner early advance sputter summer share be back day move average line dave buster play advanced early wednesday beating bottom line forecast restaurant entertainment company once promising leader have be stick consolidation stretch back early june share have fall much time be still day line china base stock open lower trimming loss stock market today hong kong hang seng index close more overnight pierce critical day line meanwhile shanghai composite re-cover bulk loss still close tencent tcehy decline almost be pace mark eighth loss last trading session internet giant have be big winner rise more cup handle entry stock break feb ibd alibaba baba reversed early loss rise look snap day lose streak stock be well day line now meanwhile leaderboard member com wuba moved cling day move average related dow jone industrial average dow stock news analysisbitcoin hit future trading buy zone ollie lululemon report earning too investing action planfang stock news quote facebook amazon netflix googleveeva beat view offer line outlook share drop
82,JNJ,stock open red quickly turn mixed early wednesday many tech sector stock reversed early loss johnson johnson jnj bolster early action dow industrial nasdaq composite open then turn higher improve fractional gain dow jone industrial average open narrow loss johnson johnson jump haul index brisk sell tear asia stock market wednesday trigger partly report person bank china have recommend tighten country money supply hong kong hang seng index plummet japan tokyo nikkei dive europe market be mixed afternoon trade frankfurt dax cac paris ftse london improve gain politic fed wednesday early trade number different angle concern brexit deal potential government shutdown be factor also uncertainty raise president trump report pending declaration formally recognize jerusalem israel capital move country embassy city play role early market action president israel announcement be expect midday speech intel intc dive more take hardest early hit dow stock home depot hd slip reaffirm fiscal earning revenue guidance announce share repurchase program home depot share wednesday trade close buy point apple aapl dip stock be week flat consolidation hover just buy range prior buy point fang stock tech leader facebook fb leap evercore initiate coverage stock outperform rating tesla tsla ease tuesday cascend security have downgrade stock sell hold cite weaken customer demand due company ongoing production delay assert company need return market raise cash end tesla share be mid september high trading converge week move average chip stock be early pressure skywork solution swks qorvo qrvo post decline broadcom avgo trade ahead fiscal fourth quarter report expect today close dronemaker aerovironment avav vault higher start gate report surprise fiscal second quarter profit top analyst expectation wide margin gain revenue solid full year guidance gap gain put share buy point week base pattern bitcoin trade putt cyrptocurrency nearly start week bitcoin related stock be positive riot blockchain riot marathon patent group mara show gain private employer add worker november service sector employer accounting gain accord national employment report adp be sharp drop new worker hire september economist consensus view add employee third quarter productivity increase labor department estimate line second quarter level just consensus target increase unit labor cost ease advance second quarter mark surprise decrease inflationary pressure economist have project increase cost oil price dip more putt benchmark oil barrel ahead energy information administration weekly stockpile report due et related top tech stock be turn pointstock fall tech sell face critical test top rate stock earning due buy range investing action planhomebuilder sell leave stock still profit take zone
83,JNJ,quiet session major stock index wednesday be far quiet surface nasdaq composite be add dow jone industrial average fall fractionally volume nyse nasdaq be tracking slightly lower tuesday level stock market today johnson johnson jnj wal mart wmt merck mrk outperformed dow gain more earning wal mart be due nov open russell find foot pay trip day move average small cap index fall nearly intraday re-cover gain late afternoon trading food stock oil driller software homebuilding name outperformed manage care firm superregional bank lag bullishness newsletter writer rise latest week prior week accord latest day investor intelligence be fifth straight read danger zone contrarian indicator significantly month low early september just extreme bearish reading have be see market bottom past excessive optimism have be see top past nasdaq composite be show sign institutional selling not much distribution day count seem high be stall session heavy volume meaningful price progress other higher volume decline show loss range take away not market meaningful distribution wednesday session serve plenty gap price planet fitness plnt gap flat base buy point stock open price be legitimate entry strong earning report bullish guidance be catalyst elsewhere ibd name coherent cohr gap buy point rise also strong earning growth oled display have be boon coherent other solid gainer ibd be trouncing year date include sina sina arista network anet align technology algn gain range small cap medical product firm inogen ingn gap flat base buy point company report earning sale growth accelerate prior quarter quarterly profit jump year period sale rise share soar match group mtch earning report fuel gap price share jump be already extend cup handle buy point head earning recent week tight pattern offer add entry earning miss match be offset strong sale outlook downside snap snap plunge sale miss weak user growth figure wall street look past news china base tencent hold tcehy take stake snap close watch earning alarm com alrm square sq ringcentral rng related grand theft auto game maker crush view stock see top rate laser maker be blast past buy point earning guidanceu crude production hit record high stockpile unexpectedly rise
84,JNJ,stock index deepen loss midday friday senate republican scramble salvage tax cut package index rally thursday belief bill pass doubt delay vote late thursday drop midday friday nasdaq slip blue chip dow jone industrial average lose small cap russell fall volume stock market today be run higher major exchange republican tax cut package stall thursday joint committee taxation say bill not generate enough tax revenue avoid increase deficit parliamentarian snag derail vote thursday evening additional fix senate vote be expect morning selling picked midday friday abc news report former national security adviser michael flynn testify president trump plea deal special counsel robert mueller concern tax cut tax revenue be old tiresome story hill reagan seek passage tax cut bill new york time report joint committee tax revenue say reduce tax revenue reagan prevailed tax revenue rise next year prove panel projection wrong panel always have challenge job dynamic factor be difficult predict economic be dynamism midday stock market action blue chip be roughly even winner loser side merck co mrk johnson johnson jnj initially rise gain fade negative side general electric ge sag ge have be laggard year diversify manufacturer stock be year biggest gainer day be oil natural gas explorer apache apa stock rise heavy volume apache be track fourth daily gain row stock have gain monday close light sweet crude pop barrel street expect apache turn profit cent share year loss analyst expect profit cent share apache meanwhile exchange trade fund innovator ibd fund ffty slip test day line etf be base ibd be year stock recently pull nov high money center bank be almost week stir midday friday citigroup rise brisk trade citigroup be try clear buy point stock crossed alternative entry strong volume wednesday bank new york mellon bk add nearly average turnover then drop stock be shallow cuplike pattern potential buy point be superregional bank keycorp key rise moderately higher volume then lose gain stock be just buy point cup handle pattern bank stock launch nice rally year rise november march bank then trade shallow mostly sideway channel recently thursday money center superregional hit week high superregional group be industry group week superregional be money center be week related stock chart trick help peg time salewhy week line be worth find excellent stock start simple routine
85,JNJ,stock sell hard earlier rebound attempt fall wayside apple aapl intel intc give earlier gain bitcoin dive further spdr dow jone industrial average dium crash spdr spy slump powershare qqq trust qqq dive emerge market also reversed lower ishare msci emerge market eem tank financial semiconductor health care lead downside sector play stock market today ishare nasdaq biotech ibb lose extend slide fifth straight session slice day move average spdr biotech xbi lose spdr energy xle ishare energy iye plunge drop west texas intermediate crude price barrel didn help spdr metal mining xme give support day move average reversed loss also diving day line be technology select sector spdr xlk vaneck vector semiconductor smh more dow end sea red intel apple only gainer midday head south apple end loss have rally nearly bounce day line iphone maker trigger sell rule buy point intel close extend lose streak bitcoin plummet accord coindesk earlier rise bitcoin investment trust gbtc slump extend decline fifth straight session now more december peak close just day line big bank include citigroup jpmorgan jpm lloyd banking group ban cryptocurrency purchase used credit card lead dividend fund own apple microsoft msft other income stock have trail broader market year emerge market etfs outperformed spdr emerge market dividend ediv ishare emerge market dividend dvye see year date gain jan accord morningstar direct ahead index return also top benchmark index last year longer haul however lag most other name list compose primarily equity fund have perform more line broader market past year japan smallcap dividend dfj europe smallcap dividend dfe focuse etfs have also perform largely line period ediv have attract february launch track emerge market dividend opportunity index south africa make biggest country weight feb nearly asset taiwan be next thailand china malaysia dvye launch february have asset track dow jone emerge market select dividend index taiwan represent largest country weighting asset follow china russia federation thailand brazil south africa emerge market play be also top dividend payer ediv offer annualize yield dvye paid well average payout quality dividend growth dgrw come third ytd return fund track index same name turn information technology account biggest sector weight asset industrial health care consumer discretionary consumer staple top holding feb be exxon mobil xom johnson johnson jnj well fargo wfc microsoft msft apple aapl make portfolio exxon have bad day friday share slide oil giant earning report apple sank more disappointing current quarter guidance slowdown iphone sale dgrw monday be testing support day line ibd take microsoft be lead tech stock do company fundamental rank industry group find now ibd stock checkup downturn past week most etfs list be still extend recent buy area market uptrend be pressure raise risk purchase favor dividend stock fund keep eye etfs test day move average stage solid rebound line mark potential buy opportunity friday pick spdr dividend sdy slide day line friday sell related apple exxon bitcoin drop buffett like big dividend stocksapple lose last ditch support trigger sell signalsdow suffer worst point drop ever percentage loss not historictech lead stock recover sell bitcoin play do spot major stock market top here easy way
86,JNJ,stock fought positive finish wednesday health care construction stock book day widest loss video game stock notch bevy breakout dow jone industrial average lead end boost boee ba monster advance heel glow result nasdaq composite rise struggle fractional gain market drop sharply fed et announcement committee hold target interest rate unchanged offer slightly more wary tone inflation day other economic news be positive early datum adp show january hire slip less expect december pending home sale chicago region manufacturing january gauge easily top expectation dow be hold back medical component merck mrk johnson johnson jnj pfizer pfe drop more drugmaker eli lilly lly tumble follow generally positive fourth quarter report drug sector investor be apparently still react tuesday news innovative health care partnership amazon com amzn berkshire hathaway brka jpmorgan jpm amazon advanced putt past buy point profit take zone other fang stock tech leader lose ground netflix nflx fall furthest nearly still extend early january tesla tsla rise average trade third gain session share be now more november low back support week move average climb right side possible month base pattern video game trade be day winner ninetendo ntdoy take interactive electronic art ea clear buy point add entry ninetendo trim gain afternoon trade remain just buy range cup base buy point electronic art pare advance hold buy range top buy point also cup base take chalk surge end very top buy range cup base buy point concrete aggregate supplier take session worst performance industry concrete uscr tumble more eagle material exp martin marietta mlm vulcan material vmc fall apiece eagle material post mixed fourth quarter report open reaction also have be link public private infrastructure cost sharing question raise president trump state union address ibd name telecom software developer casa system casa gain more soft trade stock be attempt start right side first base end jan high december ipo price argentina base bank grupo servielle supv also ibd name jump almost nearly average trade move technically place stock buy range rebound support week move average volume need kick next day so order confirm buy opportunity bottom ibd list mimedx group mdxg daqo new energy dq shed other important market news wednesday bring game apple amazon alphabet report action planbiggest homebuilder hit resistance earning sell don freeze double digit gain stock shrink fastlooking stock nvidia start list
87,JNJ,index other major average hit record high wave earning weaker dollar greenback rebound somewhat netflix nflx sky-rocket blowout subscriber growth bullish outlook celgene celg buy juno therapeutic juno intel intc surge earning outlook texas instrument txn other top chip fail impress quarterly financial apple aapl continue lag grow chorus concern regard iphone sale production airline stock plunge unite airline ual say expand rapidly set stage renew price war index dow industrial nasdaq rally solidly hit fresh record high earning season heated fall dollar have act tailwind multinational stock profit rebound year lows thursday president trump say expect stronger greenback netflix nflx be big earning winner intel intc also do texas instrument txn lam research lrcx be several lead chip stock struggle earning airline stock plunge unite airline ual apple aapl iphone related stock sell several analyst cite evidence weaker iphone demand share rocket record high netflix nflx add stream subscriber worldwide crush fourth quarter target internet tv stream giant end total stream subscriber analyst predict netflix subscriber gain come netflix implement price hike service plan europe netflix credit hit original content such tv series stranger thing crown movie bright subscriber gain period march quarter netflix be predict add net new subscriber chipmaker intel intc maxim integrate product mxim stm xilinx xlnx beat december quarter target get mixed reviews investor texas instrument txn post line result share be punish sector continue wrestle concern chip cycle have ebb top chip gear maker lam research lrcx kla tencor klac beat view sell news meanwhile xilinx joined nvidia nvda amd amd benefit sale high performance chip mining bitcoin other cryptocurrency related intel beat fourth quarter target offer cheery outlookbiotech merger heated celgene celg agree pay car drug developer juno therapeutic juno didn already own sanofi sny reach deal biogen biib hemophilia spinoff bioverativ bivv celgene acquisition come prepare lose exclusivity cancer drug revlimid juno rival gilead science gild novartis nvs make car drug treat blood cancer sanofi deal follow fail merger early wednesday novartis nvs report core earning share sale respective constant currency basis easily beating consensus thursday biogen biib report sale grow top consensus adjust earning grow be short also thursday celgene beat lower analyst view abbvie abbv friday top expectation adjust profit sale climb sale unite airline ual send airline stock tailspin carrier tell analyst plan expand flight coverage investor fear move do part regain relevance smaller city unite once abandon risk more competition cheaper fare help passenger threaten profit american airline aal earning call signale wouldn change profit growth target base unite ambition now southwest airline luv jetblue jblu alaska air alk also report general electric ge miss earning disclose sec probe core unit do well ge keep outlook industrial member dow industrial caterpillar cat mmm unite technology utx report strong earning guidance insurer traveler trv consumer product giant procter gamble pg also beat earning view verizon vz miss ep top revenue johnson johnson jnj top view fall patent ruling vs blockbuster arthritis fighter remicade president trump slap tariff import large washing machine part solar panel tax washing machine decrease then expire year duty solar cell module phase year solar technology provider suniva solarworld charge china be provide unfair subsidy financing solar producer whirlpool whr complain korean maker be dump washing machine excessively low price whirlpool also report quarterly earning rally first solar fslr initially pop close less china base daqo new energy dq lose crude top barrel brent edge briefly oil inventory continue drop oilfield service provider halliburton hal crushed quarterly forecast international growth outpace domestic growth share shot clear buy point baker hughe bhge edge past earning estimate be upbeat spending customer share fall nearly market price possibility ge fully spin business northrop grumman noc raytheon rtn general dynamic gd top profit forecast raytheon general dynamic miss revenue northrop give strong guidance lift dividend raytheon gd say order backlog be strong defense firm surge record high lockheed martin lmt boee ba report next week steel dynamic stld earning rise top view modestly sale climb rank company ibd steel producer industry group say be shape be good year thank more moderate inventory level improvement global demand pricing incremental investment drive tax cut specialty steel producer allegheny technology atus nearly double profit estimate revenue grow fuel high performance material jet engine freeport mcmoran fcx benefit higher copper price boost earning ahead estimate revenue grow negotiation indonesia ownership massive grasberg mine be progress haven erased uncertainty company outlook casino operator wynn resort wynn la vegas sand lvs put result beat top bottom line help rebound macau world largest gaming market sand ceo sheldon adelson cite acceleration mass gaming market chinese administrative region only area nation gamble be legal wynn share plunge friday erase nearly weekly gain report allegation serious sexual misconduct ceo steve wynn ford motor see ep climb cent revenue grow analyst have expect ep cent sale accord zack investment research ford be buy mobility startup autonomic transloc share extend sell prior week ford outlook disappoint investor fiat chrysler fcau deliver strong result generally affirm ambitious financial target send share fresh week high new oriental education edu logged ep growth short view sale gain narrowly beat fiscal estimate student enrollment grow china base school education provider offer guide sale view higher share tumble recoup loss end week tal education tal meanwhile surge nearly thursday retake day ep jump revenue growth tal enrollment swell td ameritrade amtd trade financial etfc beat top bottom line fiscal earning share jump td ameritrade revenue expand see full year earning exclude item vs expectation td ameritrade also say allow customer buy sell certain etfs day week trade report ep revenue ll also acquire retail brokerage account capital financial cof asset share online broker fall modestly week millennial focuse free investing app robinhood let person buy sell bitcoin other cryptocurrency commission intuitive surgical isrg report adjust income share sale rise respective metric top expectation robot surgery gear maker give cautious guidance homebuilder nvr nvr miss earning sale view share tumble crash week line first time more year huge volume doj subpoena mortgage unit lennar len bigger expect new home sale decline other homebuilder also suffer notable decline
88,JNJ,france sanofi sny agree buy recent biogen biib spinoff bioverativ bivv company announce early monday meanwhile celgene celg acquire car drug partner juno therapeutic juno sanofi deal value bioverativ share cash premium friday close bioverativ shot nearly close stock market today sanofi fall celgene acquire juno therapeutic share cash price tag exclude juno celgene already own juno share leap nearly skyrocket last week report deal be close celgene tick close juno work car therapy use patient immune cell fight cancer analyst have say celgene juno deal make sense bioverativ spun biogen february make hemophilia drug sanofi be face generic competition top selling drug sanofi try buy medivation lose pfizer pfe last year effort buy swiss biotech actelion be trump johnson johnson jnj be interested biotech stock surprise upside earning fang stock make news investor mull shutdown impactcheck stock buy first stage basis
89,JNJ,major market average trim early gain tuesday fang stock netflix nflx soar earning release stock market today tech heavy nasdaq rise dow jone industrial average fall apiece dow jone industrial verizon communication vz reversed solid early gain fall quarterly sale result top estimate even earning come bit light elsewhere dow johnson johnson jnj top street target stock fall early trade stock be just flat base buy point jan company report earning netflix surge report strong surge new subscriber addition compare target stock be extend flat base buy point jan fellow fang facebook fb look extend streak trading session recent sell back day line flat base entry stock rise trade new high tesla tsla jump nearly company update pay package ceo elon musk tie compensation solely key performance benchmark market cap stock currently have market cap build right side potential base solar stock be move tuesday president trump decision impose tariff import solar panel technology winner be first solar fslr advanced look snap day downdraft share be well extend most recent buy point china base daqo new energy dq reversed heavy loss rise too be extend buy point find support several time week move average line ibd coherent cohr decline nearly fall day line further trigger loss cut rule late stage buy point later stage basis be more prone failure earlier stage one elsewhere new oriental education edu decline miss fiscal earning estimate early tuesday revenue come stronger expect share be battle support buy point break flat base dec investor also watch see stock find much need support day line related energy giant break other leader approach buy pointsthese dow stock hot chipmaker unite airline earning tap investing action buy stock week move average offer new entry pointsbitcoin fall south korean regulator get toughernetflix fourth quarter earning report key takeaway
90,JNJ,blue chip lead index strong day thursday several bullish element converge blue chip dow jone industrial average storm higher spurt nasdaq pop small cap russell add volume edge higher wednesday pace nasdaq be sharply higher
91,JNJ,stock slump late afternoon trading monday decline major index remain mild apple aapl buck drop lift new time high xapple have now gain jan first stage cup handle iphone giant reportedly be see brisk order most expensive iphone ever be also follow friday brand new cup handle show proper entry general electric ge meanwhile lead dow jone industrial average decline firm go back day thomas edison lop cent marked ge sixth straight loss also slip strength oil patch wti term future edge higher barrel nymex nasdaq composite be slightly institution be selling ge share hard stock volume finished share heavier usual megacap firm average daily turnover past session be share ge slide nearly monster weekly volume last week dow jone industrial average be price weight index name keeper average replace lag company higher price better performer recent new entrant include not just apple also goldman sachs gs unitedhealth group unh trade more share cisco system csco pfizer pfe have next lowest share price dow trading respectively cisco giant computer networking internet base telecom gear be challenge institutional buy support buy point new cup handle stock fall more dull turnover apple replace dividend rich march latter trade share have be featured ibd dividend leader screen have make virtually progress then ge have recently peaked summer now stand nearly high stock time peak be back august ge relative price strength rating be horrifying scale note ibd stock checkup certainly pressure be mount ge new management team lead john flannery reinvigorate growth flannery have serve many top post ge include head ge capital india operation company adjust third quarter earning fall cent share sharply miss wall street view accord datum william neil co revenue increase snap quarter slump ge have not see double digit annual gain top line more year best result be rise revenue back help nasdaq cause be broadcom avgo rise more strong turnover chip designer auto telecom datum center other market have clear buy point new week flat base proper buy zone go past buy point broadcom appear ibd real time stock move table great source watchlist idea potential new breakout table show stock move sharply heavy volume base real time analysis price volume datum be see home page back apple earning have drop fiscal year end september slump revenue however apple have be stage classic turnaround fundamental lately past quarters imac maker earning rise vs year level follow quarter slump end september earning be see increase share mark third quarter row mild double digit gain slate report result nov market close fiscal year street see earning accelerate share positive apple shareholder respectable annualize dividend yield plenty potential further increase cash payout apple tend raise dividend spring william neil co calculate company have long term annual dividend growth rate recent year ibd take current yield be track yield other vital market indicator go special general market indicator page available pdf link market trend investor com yield be post top bar large daily chart apple smartselect rating have improve steadily year jan composite rating be dismal scale accord ibd stock checkup rs rating compare stock month price performance other company ibd database be equally dim today score be now respectively expect composite rating be somewhat weaker stock such apple be undergo major turnaround fundamental stock price action elsewhere dow jone component johnson johnson jnj be make appear be normal look pullback breaking flat base oct diversify medical personal care product titan have so far rally much proper entry get briefly extend correct buy point have post single mild double digit ep gain quarters row street see earning rise share market react tad negatively report congress be consider phase pace lower corporate taxe not first time such plan have be report medium case market appear be unwilling so far give much strong gain past week big reason gdp rise annualize basis enormous damage cause hurricane texas florida puerto rico follow gain gdp figure be bound change future datum revision eric winograd senior economist note investor focus recent monthly datum point economy balanced sector personal consumption private investment net export make positive contribution headline rise increase private investment particularly noteworthy rise year year highest year winograd tell ibd not yet be back pre crisis level investment news front be good winograd also say consumption datum point accelerate expansion economy think final sale domestic purchaser subcategory gdp essentially core measure single figure best capture underlie dynamic economy household paycheck grow yoy yoy gain final sale make perfect sense add related stock market today apple buy range new ipos find top growth stock cup handle be money makerwhen buy stock master key growth stock chart invest find great stock ibd top stock today chipmaker rise sharply again new technology news nvidia get price target hike
92,JNJ,abbott laboratory deliver sale beat third quarter help strength pharmaceutical medical device unit analyst say wednesday xby close bell stock market today abbott have gain finish share break flat base buy point early september have climb mark third quarter end abbott report adjust earning cent share revenue sale grow comparable basis exclude impact st jude medical acquisition earning grow metric top consensus analyst poll zack investment research adjust profit cent share sale rbc analyst glenn novarro credit sale beat strong sale abbott establish pharmaceutical diabetes care cardiovascular neuromodulation product keep outperform rating abbott stock ibd take washington base expert recently suggest president donald trump sign executive order bring drug price day now prod biotech stock collective monday head ibd industry theme more executive order mean biotech drug stock quarter establish pharmaceutical post year year growth group doesn sell key emerge market deliver growth comparable year year basis help quick recovery india novarro say worldwide medical device sale grow vs year earlier period comparable basis follow dow stock johnson johnson jnj report tuesday see medical device grow lag view neuromodulation sale grow globally neuromodulator be implantable device use electricity deliver pain relief test study electrical activity heart rise comparable basis structural heart sale grow same medical device business global diabetes care jump drive growth internationally help offset decline rhythm management sale decline vs year earlier period diagnostic sale grow globally core laboratory product sale growth slow compare double digit growth first half novarro write note client international sale growth improve again abbott also narrow adjust profit growth share earlier view novarro say new guidance bracket consensus year analyst see abbott pull sale related dow component pop top view pharma strengthibd rating upgrade johnson johnson show improve relative price strengthfda chief gottlieb address opioid cancer new therapeutic
93,JNJ,investor prefer continue investing stock trimming stake bitcoin related security tuesday nasdaq continue stage biggest month date gain nasdaq composite rally nasdaq capture largest nonfinancial company exchange rise bitcoin investment trust gbtc meanwhile flash warning sign prolong correction be work popular fund drop sink third straight session give back last thursday strong rebound fund be also lose more ground critical day move average bitcoin investment trust give astute chart reader pair sell signal december show clear sign climax run most important sell signal featured ibd market column bitcoin also slash day move average good sell trigger short term trader powershare qqq trust qqq track nasdaq be now heavily trade etf extend overall gain day follow june more follow be vital market turn signal be note big picture back then typical follow rally occur fourth day later initial rally attempt follow significant market correction meanwhile blue chip take break dow jone industrial average finished practically breakeven least member stock dow jone industrial fall point more include johnson johnson jnj follow plan take charge follow new tax code repatriate billion profit back america immediately company also suffer setback court drug patent lift breadth be positive exchange nasdaq winner smash loser nearly margin nyse winner crushed loser nearly slide heavy turnover uptrend remain place diversify medical product giant remain day line recent peak stock hold profit clear buy point long base base key pattern want buy most bullish growth stock apple aapl edge slightly higher trade just few point time peak peak largest company exchange market cap have run pivotal cup handle jan apple be also nearly latest true base second stage cup handle provide entry base form oct volume oct come strong day average later try break flat base have not climb much entry iphone digital service titan have sort set standard past month giant company turn thing rally nicely key breakout point market rally techland mean ibd style growth investor possibly find other big cap name present even richer stock profit potential name consider include lam research lrcx play semiconductor equipment market cap stock rally nearly be craft right side new cup style base peak nov lam have be regularly featured ibd big cap be expect grow fiscal second quarter earning whopping share contrast apple profit just end fiscal first quarter be expect rise paypal pypl digital payment pioneer market cap stock floated higher fifth straight gain be now past recent good flat base share be thus tad extend proper buy zone earning be see rise cent follow year year gain salesforce com crm business software innovator market cap marc benioff lead cloud base enterprise software giant be nominally buy range entry week flat base earning january end fiscal fourth quarter be see rise cent share follow ep increase prior quarters average gain time span follow saito chung twitter ibd_dchung additional commentary analysis growth stock chart financial market related stock buy re invest stock equity etfs do now big pictureinvestor corner find new buy point stock break champwin growth stock start simple routine
94,JNJ,stock future buzz mixed trade just ahead tuesday open busy morning federal employee head back work market react earning regulatory news earthquake volcano rattle several corner globe nasdaq composite rise start bell buoy strong early move netflix nflx adobe system adbe be narrowly positive rise oil gas price boost energy stock netflix resm rmd duked top index dow jone industrial average open tight loss earning disappointment send procter gamble pg johnson johnson jnj bottom list washington lawmaker cobble together week spending extension president trump then sign reopen federal office shutter midnight friday deal keep federal light feb deadline immigration policy remain critical hurdle broader budget agreement market china japan post powerful rally tuesday investor respond federal spending agreement well boost international growth forecast release international monetary fund monday hong kong hang seng index surge shanghai composite zoom ahead tokyo nikkei also post advance retake jan peak set new record europe stock rebound afternoon rally apparently react earthquake overnight alaska indonesia papua new guinea trigger set tsunami warning volcanic eruption monday have trigger evacuation philippine apparent eruption occur japan netflix open higher meeting analyst fourth quarter earning target beating earning expectation score big new subscriber netflix add subscriber quarter vs guidance netflix be extend well buy point flat base apple aapl gain netflix fang tech peer facebook fb amazon amzn google parent alphabet googl show solid early gain resm surge open report strong fiscal second quarter beat late monday move break share flat base buy point ibd stock adobe system power early trade company update fiscal first quarter full year guidance say tax rate fall substantially recently re-form tax rule adobe be extend flat base buy point big morning blue chip earning report send traveler trv soar verizon vz gain procter gamble pg slide low end index traveler post broad beat revenue earning line fourth quarter concern loss tie october wildfire northern california stock end monday buy range just buy point flat base many china name be pressure overnight rally hong kong shanghai new oriental education technology edu fall miss analyst fiscal second quarter earning target company beat view revenue line forecast consensus revenue third quarter premarket move suggest stock be set remain gain early january fall back test support week move average peer tal education tal drop premarket trade china base search engine giant baidu bidu slip downgrade hold buy jeffery co baidu be attempt complete handle month long cup base chip stock see early strength advanced micro device amd rise nvidia nvda lead light chipmaker cree cree trade almost ahead fiscal second quarter earning due today close solar stock show investor rapidly adjust decision president trump monday impose steep trade tariff solar panel import china tariff aim balance advantage state base china base company have also raise concern widespread job loss solar installation field china base name daqo new energy dq slip daqo ibd name be extend nearly october side industry first solar fslr climb nearly sunrun run surge sunpower spwr add more meanwhile appliance brand whirlpool whr muscle almost white house also issue tariff import washing machine rule impose tax first machine import year tariff rise level well washing machine part import china related big picture leader fuel nasdaq advancestock future tsunami warning techs rally overnightthese dow stock hot chipmaker unite airline earning tap action planenergy giant break buy zone international revenue growth outpace
95,JNJ,biotech merger heated monday celgene celg announce acquire juno therapeutic juno french pharma sanofi sny say spend tack biogen biib spinoff bioverativ bivv analyst laud celgene juno buy note help fill hole celgene blood disease drug revlimid begin lose exclusivity street be more split sanofi purchase hematology market be expect soon face disruption gene therapy close bell stock market today juno surge celgene tick bioverativ rocket sanofi dive close broader biotech group pop credit suisse analyst martin suggest report group see mad scramble merger acquisition sanofi announce plan buy bioverativ list biomarin pharmaceutical bmrn esperion therapeutic espr avexis avxs top takeover pick deal be sign merger spigot have finally turn other large pharma company feel pressured move make full value bid grab be fairly scarce selection commercial commercial ready asset small midcap biotech space say celgene say monday spend share acquire juno premium stock close price rumor send juno fly last week celgene already own juno deal collaborate cancer autoimmune drug merger be expect close quarter juno be work car therapy engineer patient own immune cell identify fight cancer cell celgene peg lead drug know jcar get approval bring potential peak sale ibd take celgene be particularly hurt third quarter bigger drug revlimid otezla miss expectation not only face patent cliff mid see else be risk visit industry snapshot piper jaffray analyst christopher raymond suggest guidance be overly bullish celgene be set relatively high bar asset likely win be alone class say note however guidance be achievable be important source revenue mid long term celgene look plug revlimid hole once go generic start competition be look stiff gilead science gild spend nearly acquire kite pharma last year time gilead kite gain approval car therapy follow novartis nvs be first gate approval august celgene expect jcar get approval treat diffuse large cell lymphoma aggressive form hodgkin lymphoma gilead drug yescarta be approve treat population novartis be look get drug kymriah approve use well leerink analyst geoffrey porge view deal positively consolidate streamline celgene effort car celgene also partner bluebird bio blue work multiple myeloma drug know bb target antigen know bcma own juno allow celgene focus bcma effort initially bluebird bb make juno vehicle development drug target cd protein exploration other target opportunity say note client mizuho analyst salim sy note be cross pollination manufacturing juno bluebird drug be knowledge base synergy unsure celgene even look acquire bluebird trigger antitrust concern say early monday sanofi say buy hemophilia player bioverativ share deal be premium bioverativ close price friday piper jaffray raymond write note re not shock bit say topline revenue growth more last year yet trading just time fiscal year revenue estimate have long view bioverativ potential takeout target deal come sanofi twice fail make big acquisition dow pfizer pfe beat sanofi battle cancer player medivation last year dow johnson johnson jnj acquire rare disease biotech actelion pharma sanofi sanofi be face mount competition diabetes drug trick be convince investor hemophilia market win be disrupt gene therapy product launch roche rhhby drug hemlibra leerink analyst seamus fernandez say note minimum number speculate successful bid include medivation actelion sanofi investor now have deal digest be immediately accretive earning estimate be accretive say rbc analyst kennen mackay call bid strong give upcoming competition roche note likely sanofi be build lesson learn medivation actelion process sanofi lead low offer be later best competitive bidder investor weren sure merger biogen spun hemophilia business bioverativ year bioverativ have approve drug eloctate hemophilia alprolix hemophilia last year bioverativ acquire true north therapeutic credit suisse martin call true north stronger acquisition bioverativ gain access drug now know bivv treat rare autoimmune disease model share drug alone related biotechs surprise upside earning biotech stock rocket rumor biogen buy hospital plan put pressure generic drug maker
96,JNJ,stock hold broad rally final hour trading wall street friday dow jone industrial average lead way dow industrial component general electric ge stage positive reversal nearly tank more intraday xat et dow jone industrial average gain be close session high least component rise more nasdaq composite rally nearly look set make fourth sixth straight weekly advance respectively volume be run higher vs same time thursday nyse lower nasdaq johnson johnson jnj highlighted earlier stock market today column clear new buy point look poise finish week more remain proper range ge report disappointing third quarter result poor guidance be need strong leadership new ceo john flannery turn company fortune be expect unveil new strategy next month recent new trader stock best time have sell ge be week cup handle dec volume be decent session average not great soon ge share tank jan trigger golden rule selling stock sank more recent entry cut loss short have allow investor raise cash buy better performer notice daily chart stock have already dive critical day move average heavy turnover not kind action want see elsewhere steel share continue rebound ibd steel producer group be more august leader include steel dynamic stld south korea posco pkx steel dynamic rally streak past early buy point long flat base also be construe saucer mini mill expert report rise profit show huge increase year quarter sale rise extend double digit top line gain fourth quarter row profit be see accelerate cent share ibd take see ibd stock checkup steel dynamic garner ibd proprietary accumulation distribution rating see stock checkup doctor be smile higher grade be prefer stock be aim break also keep eye potential fast improvement stock relative price strength rating ibd research have find average rs rating greatest market winner be posco be work new cup shape base also qualify flat base decline latest week high september low be mild now current new buy point be cent new base left side lip posco have show nice turnaround fundamental earning share vault vs year level past quarters sale increase street see profit share full year profit share related stock market today apple be recover break find great stock start have spot black monday crash yes here easy way spot major stock market topibd big picture be sign black monday arrive
97,JNJ,stock bounce back big time thursday wal mart wmt cisco csco apple aapl power dow jone industrial average nasdaq composite hit new high powershare qqq trust qqq rally spdr dow jone industrial average dium gain spdr spy also rise emerge market lead ishare msci emerge market eem run more wal mart soar result top view cisco leap quarterly profit beat better expect outlook apple rise track snap session lose streak dow component be still extend cup handle buy point gbh insight say iphone maker potentially hit market cap next year sector play stock market today retail semiconductor consumer staple score big gain spdr retail xrt gain more boost wal mart etf regain day line first time nearly week utility energy fund be few laggard west texas intermediate crude price slip gold future be slightly higher stock market have be come high recent pullback give investor chance buy previously extend name vanguard high dividend yield vym own microsoft msft johnson johnson jnj jpmorgan chase jpm exxon mobil xom well fargo wfc be get close potential test day move average find support line make solid rebound set new opportunity buy share regain day line early september fund rise oct intraday high offer buy point flat base advanced oct peak vym be last featured june etf column just ahead prior flat base clear buy point june ease next session start most recent pattern fund marked year last week have amassed asset track ftse high dividend yield index comprise company tend pay average dividend vym offer annualize dividend yield average payout technology account etf biggest sector weight oct asset financial come next follow roughly piece health care consumer good industrial oil gas utility represent respectively consumer service basic material make rest ibd take lookout etf idea be worth closer examination check ibd weekly etf leader column featured fund list highly rate etfs top holding be microsoft johnson johnson jpmorgan chase exxon mobil well fargo microsoft have run more year be extend flat base entry top well fargo procter gamble pg be also warren buffett portfolio well fargo yield annualize be billionaire investor top hold vym year date return nov accord morningstar direct lag gain average annual return past year trail benchmark index percentage point less period etf sport expense ratio wednesday pick spdr utility xlu remain buy range flat base entry related apple target weigh market stock offer big dividendsapple drop iphone news dow stock offer new entry buy bitcoin read
98,JNJ,stock market keep go afternoon dealing index trade session lows small cap lag noticeably dow jone industrial average be fraction buoy part several dow component make new high such johnson johnson jnj wal mart wmt intel intc have be rally report earning last week wal mart be extend buy point clear oct cisco system csco follow friday add nearly trading be slower usual cisco confirm report acquire broadsoft bsft value deal be put share broadsoft telecom software company climb less huge volume nasdaq be fall russell be lead market mid august early october small cap index have be stall sideway regional bank be broadly weaker today trading contribute russell wo airline internet content medium consumer industry group be bottom day performance table energy sector also be weak price crude oil be little change just barrel logmein logm break cup handle base top buy point heavy trading teleconference remote access software company announce earning thursday close analyst expect profit share double year profit include merger complete january citrix system ctxs getgo subsidiary ball bll rise past buy point cup handle base volume be third more usual ball announce result market open nov ball be odd combination low tech product such beverage can aerosol dispenser high tech defense system ypf ypf make cup handle buy point volume be more triple average ypf be part rally argentine stock president mauricio macri see ruling coalition make important stride election weekend pave way economic reform global msci argentina argt etf be more time high related cisco buy broadsoft tesla near china deal
99,JNJ,hurricane harvey irma marium didn just devastate texas florida puerto rico medtech player medtronic mdt group medical group wmgi be flail headwind monday xin afternoon trading stock market today ibd company medical product industry group medtronic lead market cap fall collective medtronic acknowledge impact hurricane have quarterly metric win be alone rbc analyst glenn novarro write note client news report indicate puerto rico hospital be not operational end third quarter be operational not have be run full capacity say assume lose week procedure end third quarter puerto rico device manufacturer say also conservatively estimate elective procedure be perform puerto rico fourth quarter friday medtronic say expect impact revenue earning fiscal second quarter firm say too early determine be impact latter half year least analyst cut price target stock follow medtronic monday pre announce negative result sustain least price target haircut quarter expect report sale vs year earlier period analyst view firm also trim sale outlook grow share be hardest hit medical product group plunge close monday nuvasive nuva globus medical gmed make medical implant dove respective novarro say be opportunity investor nuvasive nuvasive be capable accelerate organic revenue growth fourth quarter have strong product portfolio operate margin expansion opportunity say expect management team cut guidance due hurricane related revenue shortfall sell past several week be already discounting say nuvasive be deal specific short term issue setup look attractive separate report pre announcement novarro note investor sentiment spine stock remain negative cut price target keep outperform rating say be buyer pullback stock worst be already price argue needham analyst mike matson be more bearish still spine player outside hurricane be impact weaker degenerative deformity procedure growth august september matson write note client likely globus nuvasive miss estimate third quarter matson lower view now see earlier expectation also trim price target keep strong buy rating medtronic topple month low monday series price target cut announce hurricane marium damage puerto rico hit earning revenue also last week zimmer biomet zbh say hurricane be headwind third quarter earning novarro expect abbott laboratory boston scientific bsx chip away sale medtronic implantable heart device several newly launch product be back order status have lower inventory level hurricane firm say press release ibd take medtronic have ibd composite rating best possible meaning underperform more half stock term key growth metric head ibd stock checkup look stronger performer competitor be able take advantage such supply shortage be hard quantify stage novarro say therefore see downside risk revenue earning guidance second half second fiscal quarter novarro trim model sale cent earning share novarro also slash view fiscal model sale earning share forecast ep sale fiscal result price target cut novarro keep outperform rating least other analyst cut price target medtronic stock well fargo downgrade medtronic market perform outperform medtronic topple finish dow component johnson johnson jnj appear sustain minimal damage janssen unit gurabo facility make remicade xarelto prezista number other drug accord ub analyst carter view satellite image facility base utilization most lot site appear activity be return facility write note client fellow drugmaker amgen amgn have visible damage roof building flood access road manufacturing site puerto rico oct roof appear have be fix parking lot be capacity say amgen confirm used diesel generator site contract fuel provider have be make shipment meantime first shipment inventory puerto rico have already fly island say unlikely food drug administration require inspection allow amgen restart production ultimately expect accounting charge related be incrementally less concern potential disruption product supply say related medtronic sink sale lag earning beat robotic player near then topple here drug bellwether sale miss actually bode well sector
100,JNJ,theravance biopharma tbph exelixis exel tick most acquisition box big pharma overview biotech merger picture analyst say friday acquisition biotech company pharma be important theme space needham analyst alan carr say note client believe late development stage commercial stage biotech company be particularly attractive acquisition target part due reduce risk company carr cover theravance attract big pharmas amgen amgn eli lilly lly teva pharmaceutical teva total carr count company be interested buy theravance base research area business development interest past acquisition theravance have approve drug antibiotic hard treat infection exelixis agio pharmaceutical agio bavarian nordic pharmaceutical bhvn progenic pharmaceutical pgnx be attract interest pharmaceutical apiece abbvie astrazeneca azn novartis nvs roche rhhby dow stock pfizer pfe johnson johnson jnj be most acquisitive base carr criterium have least potential target biotechs stand better chance be acquire vs other carr say january have be acquisition public biotech company involve payment more upfront more half already have approve drug have least phase datum carr write oncology be key target japanese pharmas rare disease play be likely be acquire later stage ibd take last month potential acquisition target jump ibd relative strength rating best possible today still have rating head ibd datum story closer look stock catalyst rare disease tend be interest mid specialty pharmas biotechs traditional drugmaker be likely avoid drug pricing controversy january only rare disease firm snatch be actelion pharmaceutical european pharma acquire more later stage biotechs vs less risk adverse japanese pharmas allergan agn big area interest include central nervous system rare disease oncology account acquisition respectively january have be new chemical entry approval food drug administration small midsize biotechs gain type approval have be acquire already have drug market time acquisition many oncology company few rare disease company be acquire say gilead science gild acquisition kite pharma kite break approval rule gilead announce plan spend buy kite month ahead expect approval date first drug blood cancer novartis rival treatment be approve day later related small biotech launch month high today here whyexelixi recover bristol inspire pitfall kidney cancerbristol dife still have chance kidney cancer analyst
101,JNJ,first run food drug administration gene cell therapy be early stage theoretical concept fda commissioner scott gottlieb say tuesday last month fda approve first cellular therapy drug call kymriah novartis nvs treat form acute lymphoblastic leukemia patient age younger kite pharma kite soon be acquire gilead science gild be expect grab similar approval november gene cell therapy drug biologically copy exist product know biosimilar didn exist gottlieb tell medtech conference san jose calif now have product re review approve say gottlieb be nearly month stint fda commissioner be first appointment president donald trump take office first serve fda deputy commissioner gottlieb background have uniquely prepared head be now much bigger fda say scott whitaker chief executive advame world largest medical technology association gottlieb be diagnosed type lymphoma be younger be kind tumor only hypochondriac doctor have find gottlieb tell audience san jose mcenery convention center doctor gottlieb research type treatment want know have very good chance survival ibd take medtech stock have be ride drug pricing fear have hurt pharma biotech sector analyst say head industry snapshot closer look winner loser political discourse acknowledge not patient fit bucket be very different patient patient be tell have chance survival say re look something experimental something not be approve yet lot different cancer patient part challenge gottlieb say be ensure fda have policy help patient difficult simultaneously serve type patient serve patient potentially impact patient say today fda have hand number area gottlieb say most person be surprised find spend most time work tobacco side win surprise public be fda be work closely ameliorate opioid crisis last month trump declare opioid crisis national emergency cope company boston scientific bsx abbott laboratory medtronic mdt be work therapy call neuromodulation use electricity conceal pain brain gottlieb note medical product step alternative addictive opioid medical device deliver localize therapy patch treat localize pain vs drug have systemic approach be very addictive say fda be also work framework quicker review certification software program rather go longer product review software program be review less information apple appl fitbit fit johnson johnson jnj pear therapeutic phosphorus roche rhhby samsung tidepool verily be involved pilot program seek identify information company need provide quicker review process gottlieb say need modernize regulatory framework so match kind innovation re be ask evaluate foster beneficial technology ensure consumer have access high quality safe effective digital health device say related biotech crater late stage alzheimer drug failure
102,JNJ,nasdaq composite shuffle mildly lower lunchtime new york most faang stock slump dow jone industrial average edge higher rise slide general electric ge dow stock climb point more include apple aapl home depot hd new medical sector johnson johnson jnj xge report disappointing result friday adjust earning sharply miss view revenue climb mark first top line increase quarters catapult past flat base buy point report double digit earning sale growth last week buy zone go pm et nasdaq cut loss powershare qqq trust qqq etf track nasdaq be also be flat gain retail build wood product medical select computer related share offset sharp loss toy internet content airline medium homebuilder oil gas machinery industry group volume be run tad higher nasdaq vs same time friday breadth be negative exchange lose stock exceed winner more ratio nyse nasdaq halliburton hal weigh oil sector fall much shaving loss bounce day move average company report third quarter earning cent share vs penny year quarter adjust basis revenue jump mark second quarter accelerate growth revenue rise halliburton ceo jeff miller say news release north american business be hit cylinder international side have prove resilient wti crude oil price currently barrel have rebound bottom late june notice daily chart oil gas field service giant be form new base base still have lot work left base begin late january halliburton top then dive day move average feb ibd take day move average be draw red ibd daily chart marketsmith ibd premium charting stock screening service lead stock tend rise ahead day line move average be rise read column investor corner learn more day line be great tool determine right time sell good stock also energy sector argentine oil gas explorer ypf ypf clear buy point long cup handle pattern buy zone extend company be aggressively pursue frac horizontal drill opportunity analyst poll thomson reuter see earning cent share year share leap latest base pass midpoint test be midpoint handle be higher midpoint base yet share be still build right side cup cup left side high be ypf be still nearly cup left side high volume be run triple normal level average daily volume be currently share prior trading session ypf integrate oil industry group be market laggard still dwelling bottom half ibd industry group group mate royal dutch shell rdsa have be hit week high lately return apple stock resist nasdaq slide edge nearly higher light trade stock be back aug point flat base iphone giant be form new base buy point stock weekly chart show apple remain leader be still carve long term uptrend apple report fiscal result nov have gain breaking bottom base jan base be cup handle feature entry street be expect long term acceleration apple fundamental key factor stock market beating rise so far year earning be see rise fiscal end september share then grow share fy sale pick iphone giant be expect begin selling ultraluxury iphone later week analyst have be note component shortage production bottleneck be likely go make very difficult consumer purchase smartphone soon apple be reportedly meeting official outsource manufacturer foxconn discuss issue first solar fslr rise more volume be run mildly average solar power system supplier utility break deep bottom base last summer try break past buy point september then tempe ariz midcap stock have encounter stiff resistance week earning be expect plunge share year then fall additional revenue be see rise year then fall first solar rs rating be respectable scale see timesave ibd tool stock checkup ibd longtime member tal education tal slide more fast turnover share remain day move average stock have gain more clear resistance split adjust basis tal specialist cram school chinese student break july related halliburton beat north america revenue nearly bottom base pattern make money tradersfind hot growth stock peek ibd find great stock start journey here
103,JNJ,dow component johnson johnson jnj approach buy point wednesday pull upgrade analyst call pharma giant ep growth dividend machine xby close bell stock market today pop close share begin form flat base july buy point jeffery analyst jeffrey holford upgrade buy rating raise price target argue consensus be undervalue pharma asset include drug treat plaque psoriasis cancer blood clot depression other disease synergy acquisition actelion pharmaceutical win bidding battle sanofi sny help drive expectation year consensus be currently modele sale vs holford view turn produce strong earning share momentum better expect dividend write note client ibd take be far only stock near buy zone number fang stock near potential buy point clearer breakdown stock be approach key mark visit ibd stock buy zone list pharmaceutical unit be expect drive sale profit yet believe be modeled sell side holford say expect oncology drug drive pharma unit revenue growth midterm commentator have focuse unlikely breakup business instead firm be appreciate earning growth dividend machine holford argue other say be too expensive holford disagree point think consensus estimate be too low deep dive pharma well consider company ability use own capital augment ep growth say think stock re rate market premium least base diversify growth platform related amgen lilly be interested small partnership bit dust gilead kite competitiondow member bayer face battle augment aspirin
104,JNJ,slew company hit new week high tuesday include fang stock blue chip name global investment bank earning season go full swing facebook fb moved new high early tuesday rise peak social medium giant be latest fang stock break past
105,JNJ,macrogenic mgnx topple friday dow component johnson johnson jnj terminate agreement develop cancer treatment have rivale drug gilead science gild kite pharma kite novartis nvs xin midday trading stock market today macrogenic dove much week low be close johnson johnson fall finish cite increase competition space well neurotoxicity associate drug duvortuxizumab decision bail pact duvortuxizumab show cancer activity phase trial note duvortuxizumab belong class drug know bispecific antibody stimulate immune cell direct target antigen drug be be investigate potential treatment several lymphomas leukemias bispecific antibody hold tremendous promise think news highlight remain development challenge agent particular context recent emergence highly effective car cell therapy leerink analyst michael schmidt say ibd take novartis be first gain approval car therapy other be just tail get scoop major player break visit ibd industry theme car drug be create extract immune cell patient then reprogramming fight cancer reintroduce patient case bispecific antibody car drug have same target schmidt say note client earlier week novartis nvs be first gain approval car treatment kite be be acquire gilead be expect be next celgene celg be also partner separately juno therapeutic juno bluebird bio blue car drug various bispecific antibody platform currently development differentiate clinically remain unknown schmidt say macrogenic have total bispecific antibody program have enter phase trial recent year possible bispecific antibody be more potent treat solid tumor area remain challenge car drug schmidt say schmidt reiterate outperform rating macrogenic doesn expect macrogenic continue develop duvortuxizumab wake competition car drug other therapy cancer affect be know cell related celgene flirt giant soon join gilead kite deal boost biotech etf clear buy pointanalyst mixed gilead kite key rival stand benefitthese biotechs just moved buy zone be giant next novartis cancer approval validate gilead kite deal
106,JNJ,selling be concentrated nasdaq composite afternoon trading wednesday fed stick forecast rate hike include end year fed left key lend rate unchanged be widely expect say start unwinding balance sheet october straight gain year treasury yield add basis point nasdaq lose give dow be nearly flat small cap hold well russell volume main exchange picked market fed policy statement et nyse nasdaq volume be tracking higher tuesday level jpmorgan jpm goldman sachs gs outperformed dow gain mmm johnson johnson jnj apple aapl lag loss apple slump day move average fall company acknowledge cellular connectivity issue new apple watch back entry clear buy point early august strong earning stock market today ipo best bsti backed alibaba baba jump pricing last night downsize offer be initially suppose price best be china base delivery firm ipo fared better argentina base despegar com desp online travel company price last night high end propose range share be trading ibd take ipos new product service go become big market leader find new be so important stock selection process visit lesson ibd university heavy volume gainer include roper industry rop share jump help morgan stanley upgrade overweight neutral still buy range buy ibd arista network anet hit time high rise help morgan stanley upgrade overweight equal weight arista be member leaderboard portfolio investor com currently hold name related fed double reverse qe keep hawkish tilt oil price top iraq hint extension opec output cutchinese delivery firm best rise first day sizing ipo
107,JNJ,key index fund be lower wednesday fed hold rate steady expect say start trimming balance sheet october xpowershare qqq trust qqq sank spdr spy fall spdr dow jone industrial average dium give apple aapl weigh drop put iphone maker back buy point breach day move average oil fund lead upside west texas intermediate crude price surge barrel spdr oil gas exploration production xop rise vaneck vector oil service oih add unite state oil uso powershare db oil dbo rise nearly apiece gold play sag vaneck vector junior gold miner gdxj vaneck vector gold miner gdx fall more apiece spdr gold share gld ishare gold trust iau fall gold future dip ounce chip homebuilder utility also underperform stock market today exist home sale august fall seasonally adjust rate view vaneck vector semiconductor smh fall remain buy range flat base entry ishare phlx semiconductor soxx be still buy zone handle entry component stock apply material amat lose nearly slip cup handle buy point doesn extra income dividend fund have break stock market trade time high vanguard dividend appreciation vig dip early tuesday clear flat base buy point monday fund be more july be featured column seek support day move average share take slight dip rise shape right side flat base set new potential buy opportunity fund track nasdaq dividend achiever select index marked anniversary april index include stock history increase dividend least year row exclude be less likely raise payout industrial account vig biggest sector weighting aug asset consumer service weigh health care consumer good financial technology respectively microsoft msft johnson johnson jnj pepsico pep be top holding microsoft be buy range recently clear base base entry maker xbox surface pay annualize dividend late tuesday redmond wash base company announce hike quarterly payout cent share name pepsico pep cfo hugh johnston board director fund have slightly underperform year date return accord morningstar direct vs benchmark index gain vig annualize yield be ahead payout etf expense ratio be ishare core high dividend hdv be buy range breaking tuesday past flat base entry etf be last featured june clear prior flat base start just complete pattern fund track morningstar dividend yield focus index launch march hdv provide access dividend pay stock have be screen financial health top sector weighting be consumer defensive energy communication service health care exxon mobil xom pfizer pfe be top name hdv have return year date average annual return trail past year offer annualize dividend yield vig carry expense ratio tuesday pick midcap dividend don schwab mid cap schm be still just shy respective buy point related big bank lift dow high long term winner break hot chip stock soar dow hit new high be japan back dow keep hit new high top chip stock break
108,JNJ,dow component johnson johnson jnj bayer bayry have battle persuade doctor add xarelto aspirin therapy heart disease patient analyst say monday trial show complication xxarelto blood thinner be test alone combination aspirin cut risk cardiac event patient heart disease combo reduce risk cardiovascular death stroke heart attack vs aspirin alone be also tie more bleed event event occur patient treat combination vs patient treat aspirin alone most bleed occur tract johnson say news release encouragingly trial find difference rate fatal bleed intracranial bleed symptomatic bleed critical organ rbc analyst glenn novarro write note client result appear sufficient food drug administration approve xarelto combination aspirin set novarro say doctor commonly use aspirin only therapy help cut risk cardiac event heart disease patient novarro note benefit risk profile have potential impact peak sale xarelto credit suisse analyst vamil divan be more bullish note combo cut risk stroke cardiovascular death respectively none bleed trial prove fatal occur brain write note client result drive re acceleration growth xarelto expand potential treatment population product more say ibd take biotech stock have see better day july sector hit month high anticipation second quarter earning season then long term view company have investor shake head ibd industry theme closer look setup fellow drugmaker novartis nvs be more challenged drug know ilaris leerink analyst seamus fernandez say note client phase trial ilaris cut risk major cardiac event heart attack survivor vs placebo see result together lack significant benefit cardiovascular mortality underwhelm unlikely result reasonable commercial opportunity drug overall population write overall ilaris show relative reduction risk heart attack cut risk cardiovascular death subgroup patient hit specific level inflammation first dose ilaris result cut risk major cardiovascular event ilaris have leg group novartis define subgroup regulator negotiate health insurer fernandez say believe drug still struggle gain meaningful uptake base recent experience pcsk antibody note current patent life drug extend only write pcsk inhibitor be cholesterol reduce drug like amgen amgn regeneron pharmaceutical regn sanofi sny cut bad ldl cholesterol have be show have benefit cardiovascular side well pcsk inhibitor have struggle gain uptake close stock market today tick cent novartis sank finish bayer be fractionally related big pharma face tough road upcoming drug test celgene abbvie benefit growth marketall eye be dow component star drug next week
109,JNJ,major index moved little tuesday megacaps still rally individual stock still moved gusto earning result continue roll faster pace xlead market be manage health care diversify medical industry group main reason pair megacap play unitedhealth unh johnson johnson jnj rally sharply positive third quarter result gain clear buy point excellent month saucer base heavy trading volume zoom more double average level share prior session average share exchange hand day dow jone industrial average edge nearly higher nasdaq composite be virtually flat volume be run lighter vs same time monday nyse be touch higher nasdaq nasdaq remain market lead index vs gain lift dow jone industrial russell fall yield benchmark treasury year bond inched crude oil bounce intraday lows edge higher wti future rise almost barrel dow jone industrial average component post increase earning share match biggest gain quarters revenue growth accelerate pharmaceutical medical product personal care giant have grow sale prior quarters saucer base also be view long flat base well way buy point be same cent base left side high relative price strength rating see ibd stock checkup seem low scale very weak super strong yet long saucer base pattern such rs rating be actually par course also watch stock relative strength line paint blue ibd marketsmith chart rs line rise new high ground help confirm stock ability outperform become new market leader also saucer pattern heaviest weekly volume come week end megacap health care play rally nearly week big gain heavy weekly turnover point strong institutional demand read more element great saucer base investor corner column written colleague paul whitfield have market value company tax margin improve basis point impressive guggenheim security analyst tony butler tell reuter oncology business be do exceptionally well really hard figure stop darzalex imbruvica be used treat cancer former multiple myeloma latter use chemotherapy unitedhealth notch fifth quarter row ep growth earning rise share revenue grow stretch high single digit pace fourth straight quarter elsewhere stock market today apple aapl gain additional dull volume monday share boost back buy point week flat base be clear aug chase zone go apple also be now back day move average bullish sign techs major index late investor have be warm apple iphone giant prove still grow earning have fall quarters fiscal end september year most recent period apple grow profit wall street see profit rise share revenue be see climb then rise holiday quarter end december apple have gain more clear superb first stage cup handle part long bottom base pattern jan see stock checkup apple rating have improve markedly turnaround play start year meanwhile newer issue azul azul april ipo bright scholar education bedu ipo deserve close watch potential new market leader azul brazilian airline drop third straight session shave loss measly mid cap transportation latin american play be testing support day move average fourth time aug street expect profit cent share penny year quarter revenue have climb past quarters revenue be expect rise china bright scholar focus kindergarten grade international bilingual education firm grow revenue record end fiscal third quarter revenue jump quarterly high wall street expect earning cent share fiscal fourth quarter end august vs net loss penny share year quarter then november end fiscal first quarter profit be see leap cent share autumn tend be busy time chinese student be prepare exam apply new school small cap be debut share follow saito chung twitter ibd_dchung track intraday update stock market trend other commentary ibd take least current stock ibd leaderboard be also relatively new market have go public later new growth company help drive new bull market leaderboard stock feature chart be annotate real time help user spot buy point sell signal area support strength
110,JNJ,related find outstanding stock begin search herefind great stock sector leader spot essent group new hot growth stock peek ibd spot next major market top yes here be easy investor have spot market crash peak
111,JNJ,dow component johnson johnson jnj surpass wall street third quarter expectation early tuesday strength pharmaceutical unit boost guidance prompt share pop premarket trade xby close bell stock market today stock jump finish share break flat base buy point oct third quarter report sale adjust income share respective vs year earlier quarter metric top consensus analyst poll zack investment research sale share earning rbc analyst glenn novarro attribute sale beat upside pharma unit global sale be forecast consensus pharma revenue top novarro estimate medical device sale lag worldwide pharma sale increase year year basis key product include cancer drug darzalex imbruvica zytiga latter beating novarro view sale new actelion brand be novarro model ibd take isn alone report quarterly result week earning season kick earnest keep tab ibd investing action plan deck day medical device sale grow include shortfall be slightly novarro view orthopedic vision care revenue be light respectively write note client consumer unit grow be just ahead rbc estimate operational basis counter beauty sale grow other category fall highlight continue pressure segment firm also raise guidance sale see adjust income share vs earlier expectation novarro write analyst have modeled sale share earning disclose medical device segment sustain negative impact basis point follow hurricane texas florida puerto rico be number firm manufacturing facility puerto rico investor have be wary effect storm negative impact be attribute lose surgery day area affected stormwater write leerink analyst geoffrey porge note client be supply disruption firm site puerto rico be open generator power run different capacity porge note result extend other biotech space give reliance puerto rico pharmaceutical manufacturing lack disclosure regard demand supply impact be increasingly confident company biopharma coverage not experience material storm related headwind say rbc novarro be bit less bullish result point continue soft market trend medical device diagnostic say exclude acquisition divestiture medical device diagnostic unit grow just year year overall hospital admission be basis point surgical procedure basis point year year basis novarro write orthopedic sale be short weak performance knee spine segment weak knee performance be blame negative impact india implant pricing legislation write estimate sale impact quarter worldwide knee revenue decline year year revenue hip product grow pricing decline likely lose share stryker syk knee product unit novarro say global spine product sale decline lose share spine product segment benefit nuvasive nuva group also suggest continue weak growth quarter spine product market separately look lose share trauma product market stryker worldwide sale grow intuitive surgical isrg medtronic mdt be take piece surgery unit novarro say related be time buy dow dividend machine dow flirt buy point bullish pre earning reportthese medtech player be flail hurricane related headwind
112,JNJ,stock be narrowly mixed just start bell tuesday netflix nflx drag nasdaq slip boee ba limit early gain dow dow jone industrial average tick then harrow gain nasdaq open fractionally lower surrender open advance also dip red ibd take find early stage top flight stock be only part investing game know buy sell be just important ibd slim base investment program tutor start stage provide arsenal powerful tool progress unitedhealth unh report third quarter result jump lead dow earning top analyst estimate revenue meet expectation stock have slip last week follow new healthcare insurance rule set motion president trump goldman sachs gs open third quarter earning revenue gain analyst have project decrease line investing lend revenue play big role quarter share be trading buy point month saucer handle base dow peer johnson johnson jnj add report board beat third quarter stock be just buy point month flat base boee ba drop bottom dow news european archrival airbus eadsy have take control share embattled series airliner program canada bombardier complaint boee bombardier have sell number narrow body jet delta air line dal artificially low price lead department commerce impose tariff aircraft boee share monday be trading just buy range buy point flat base netflix fall deliver third quarter report late monday earning grow less expect revenue growth top expectation company add more subscriber forecast offer fourth quarter guidance consensus forecast netflix share be extend just buy range buy point cup handle base ibd stock centene cnc pop bmo capital initiate coverage stock outperform rating stock be buy range rebound support week move average economic news kick gear tuesday morning import export price labor department export price increase september gain august economist have project price gain slow september forecasting gain price import rise expectation gain large portion increase be increase be drive rebound oil price price be even september performance federal reserve release september industrial production capacity utilization et national association home builder deliver october builder confidence survey et treasury department september budget be due release et asian stock market benchmark china post narrowly mixed session japan tokyo nikkei notch straight gain rally be drive highest level july europe market hold early gain afternoon trade london ftse lead region benchmark related big picture dow approach blue chip rallynetflix beat third quarter subscriber gain stock do facebook compare amazon netflix google dow stock report earning tuesday investing action plan
113,JNJ,here investing action plan tuesday need know investor come day xdow jone industrial average component be focus tomorrow report quarterly result goldman sachs gs ibm ibm johnson johnson jnj unitedhealth unh goldman rival morgan stanley ms also come
114,JNJ,stock launch tight flat mix friday weaker forecast august retail sale industrial production possible terror attack north korean missile test keep investor cautious mood dow jone industrial average add press new high johnson johnson jnj verizon vz caterpillar cat show strength open trade future turn narrowly positive nasdaq composite trim thin early gain apple aapl fang stock stick close start level early trade global market pause show little response missile fire north korea japan early friday japan tokyo nikkei re-cover advance friday leave week mark first weekly close day move average july china market post mixed finish hong kong hang seng index friday ahead week market trade lower europe frankfurt dax slip cac paris fall ftse london drop take early fall britain pound leap highest level vs dollar june brexit vote then come additional pressure bomb explode london subway reportedly injure person polouse be treat terrorist attack week dax cac be tracking gain ftse be more caterpillar rise take early lead dow jone industrial stock be rattle new high extend july rebound week support boee ba climb clear flat base buy point apple gain prepare cap seventh week trade edge buy point tight incremental gain be technically positive fundamentally maddening investor buy stock clear entry point apple have now give ground past session week launch iphone passel device update be potentially head test support day move average nvidia nvda rise powerful volume lead ibd list gain put chip developer new high just buy point flat base oracle orcl drop worst early hit stock better expect fiscal first quarter result report thursday close weren enough encourage investor focuse second quarter guidance consensus target loss send share back buy point well stock day move average trigger sell signal tempe ariz base first solar fslr grab early gain lead company be still project see year profit decline share be april low look volume rebound week support heavy volume leap lift stock buy point week flat base economic news retail sale take unexpected dip august accord commerce department reversed july increase disappoint consensus view gain auto gas sale dip vs july gain estimate increase manufacturing activity new york region slow less expect september putt new york federal reserve september empire state manufacturing survey month be just august read better drop forecast economist industrial output slip august federal reserve report gain july miss economist target slowdown growth capacity utilization decrease also estimate steady go read commerce department business inventory estimate july university michigan preliminary read september consumer sentiment come et baker hughe bhge deliver weekly report oil gas drill rig activity oil price reversed early gain send west texas intermediate oil back barrel mark related big picture nasdaq fall top techs break outibd investor research tool get start ibdfollow market stock market todayunderstand market big picture
115,JNJ,major index trade mixed late afternoon trading thursday remain good shape overall xmeanwhile square sq show solid second stage base entry electronic payment facilitator rise more be still buy range note ibd premium stock pick service leaderboard stock be buy range don buy share more past proper entry case et nasdaq composite be nearly remain week weekly gain nasdaq intraday range be narrow suggest large player market mutual fund hedge fund bank insurer pension manager be reluctant sell vigor be just be arm length recent new time high smallcap be nearly only handful ibd industry group be more include solar automaker water utility hospital leisure product semiconductor equipment name apply material amat be lead chip gear name gain slightly average turnover watch potential tech giant past base entry aggressive trader act stock breach term high doesn seem be too much hoopla possibility breaking barrier fact see ibd psychological market indicator section bullishness stock newsletter editor track investor intelligence have actually fall lowest aftermath nov election meanwhile put call volume ratio recently notch high aug meaning option trader pessimism be still rampant good equity pessimistic investor have generally sell stock raise cash think equity be due fall don pessimist potentially become new buyer stock dow jone industrial average rise nearly component include unite technology utx mmm johnson johnson jnj rise point more unite tech be try reclaim key long term support level day move average be meanwhile day move average be now trend lower manufacturer aircraft engine elevator security system trigger sell signal short term investor share pierce day move average high volume sell july day unite tech report jump profit share earning growth have be stick low mid single digit straight quarters bigger ep increase see member ibd big cap ibd screen premier growth company market value more apple aapl earlier year steve job reassume ceo post then spur series game change consumer electronic device digital service san francisco base square have make big hit easy use hardware software small shop individual sole proprietor think plumber taxi driver enable fast secure transaction point sale ibd take notice daily chart square be show bullish trait first stock find buyer day move average paint red ibd daily chart common occurrence stock get strong institutional support second relative strength line draw blue ibd chart ibd professional grade stock screening charting service marketsmith have rocket new high ground mean square be sharply outperform square lose money last year notch earning cent share wall street now expect profit catapult higher year cent share cent revenue jump street see top line slide year then rebound see ibd stock checkup square get command composite rating scale mean stock fundamental technical fund sponsorship attribute place top company ibd database note ibd leaderboard current new base be second stage apple share meanwhile continue hold thin gain follow aug second stage flat base stock be featured heavily ibd stock market today column back early january iphone giant break first stage bottom base share have climb more apple be expect post third quarter row double digit ep growth share september end fiscal fourth quarter apple earning rise fiscal first quarter end december snap quarter streak fall profit then grow next quarters fy earning be accelerate share jump current fiscal year elsewhere oracle orcl be hang tight ahead fiscal first quarter result due close stock nearly flat hold cushion gain gap powerfully june improve result move send share past entry solid flat base pattern database cloud base enterprise software giant be mimic apple latest trend slowly reaccelerate growth november end fiscal second quarter oracle earning slump then rebound past quarters analyst see profit rise cent share increase revenue fiscal oracle net margin improve basis point other financial market wti crude oil future surge nearly reach high barrel intraday natural gas future eclipse btu level hit highest level last year future get high sell government bond remain place yield benchmark treasury year bond return level spread month note yield year bond remain healthy basis point related sell stock take many gain profit reach invest see right time buy stocksinvesting kid make dollar
116,JNJ,astrazeneca azn eli lilly lly face tough task not disappointing upcoming european society medical oncology meeting analyst say thursday note series loom catalyst drug industry market be assume multibillion dollar peak sale astrazeneca imfinzi tagrisso jeffery analyst jeffrey holford write note client astrazeneca be set present trial information september conference imfinzi be immuno oncology drug accelerate approval treat bladder cancer be test trial treat advanced lung cancer tagrisso have accelerate approval treat lung cancer recently wrapped different series test lung cancer shortfall quality even just treatment duration drive downside move study view holford write trial be important astrazeneca immuno oncology combination trial disappoint july eli lilly meanwhile need positively surprise be know monarch trial breast cancer drug abemaciclib setback drug baricitinib trulicity regulator recently delay baricitinib rheumatoid arthritis drug ibd take drugmaker be rank group ibd track keep tab strong sector best performer bookmarking ibd datum story last week nordisk nvo diabetes drug semaglutide prove more effective lilly trulicity measure head head comparison class diabetes drug call glp medicine achieve positive result monarch see midterm earning valuation upside downside miss more conservative expectation holford say dow johnson johnson jnj bayer bayry look likely benefit european society cardiology conference unveil result trial testing ability drug xarelto reduce major cardiovascular event patient heart disease key focus be bleed profile give market appear assume only xarelto aspirin combo arm hit excessive bleed holford say more positive outcome spike bayer stock similarly novartis nvs be expect present full result trial call campos look drug know acz reduce cardiovascular risk patient ve survive heart attack good result prod novartis related drugmaker benefit astrazeneca coattailsall eye be dow component star drug next dow merck be credit suisse top pharma pick
117,JNJ,key index fund be moderately higher tuesday rise new record high xspdr dow jone industrial average dium spdr spy gain powershare qqq trust qqq add small cap lead upside ishare russell iwm oil financial homebuilder lead upside stock market today utility real estate biotech lag spdr oil gas exploration production xop surge reclaim day move average vaneck vector oil service oih rise also retake day line west texas intermediate crude price be barrel spdr regional banking kre spdr bank kbe gain goldman sachs gs jump announce plan boost annual revenue technology select sector spdr xlk have apple aapl top hold be flirt flat line apple reversed higher much anticipate product launch event get way iphone maker share remain buy range flat base entry market pullback set potential buy opportunity day week line rebound yield base such dividend fund be territory give stock market solid bounce monday session quality dividend growth dgrw clear flat base buy point monday close time high remain buy range entry share rise april flat base january fund track index same name be comprise company dividend index rank highest term combine growth quality factor factor include long term earning growth expectation year historical average return equity return asset information technology health care account biggest sector weighting asset industrial weigh nearly next largest sector be consumer discretionary consumer staple respective top holding include johnson johnson jnj apple microsoft msft mcdonald mcd fund have outperformed year date vs gain accord morningstar direct also ahead past year dgrw annualize yield be line expense ratio be ibd take apple be big hold many big cap equity fund be worthy watch list way find be consult ibd stock checkup tell stock rank industry group proshare dividend arisocrat nobl close just shy buy point also flat base monday fund be featured july etf column seek support day move average advanced bounce pull back broader market form flat base fund track dividend aristocrat index be make company have increase dividend year consecutive year consumer staple industrial health care be biggest sector weight respectively consumer discretionary make abbvie abbv brown forman bfb chevron cvx target tgt be top holding nobl lag ytd gain slightly lead benchmark index year average annual return vs etf bear expense ratio monday pick spdr biotech xbi first trust nyse arca biotechnology index fbt edge higher monday remain squarely buy zone respective entry related hot biotech play reach be apple still buy range dow lead thank stock idea tap emerge marketsnew chance buy hot chip stock nvidia be come
118,JNJ,stock fade close thursday index move remain generally mild meanwhile nasdaq titan google parent alphabet googl top buy point nasdaq lose less small cap russell market leader late fall fraction dow jone industrial average ease xvolume be higher accord preliminary figure dow component johnson johnson jnj edge past buy point base base pattern close credit suisse offer praise pharmaceutical diversify medical product giant say remain bullish story alphabet base be highlighted stock market today story earlier week make new high list edge higher top buy point volume be average price move lack power share close unchanged lag relative strength line add doubt megacap stock don usually move outsized volume several be decliner list northern california power utility pg pcg slide gap sharp loss tv subscriber citigroup reversed lower sharply earning report blackhawk network hawk plunge report earning give weak outlook have recently see increase competitive pressure retail market believe result lower growth retail physical channel go forward ceo talbott roche say add company be see excellent growth digital channel broader diversification nmi holding nmih gap past buy point thursday news mortgage insurer be be add small cap nmi share surge past buy point cup handle base huge volume xnmi holding be replace sciclone pharmaceutical scln be be acquire gl capital management change take effect open trading monday related here retail stock be crash today not amazon wal martdow flirt buy point bullish pre earning reportblackrock beat view investor keep pour money etfs
119,JNJ,last month top perform mutual fund have continue pick share chip stock apply material amat intel intc well build related company include thor industry tho pulte group phm stanley black decker swk eye growth industrial output lead fund manager also invest chemical company include dowdupont dwdp sherwin william shw plastic manufacturer roger rog lead mutual fund also take nearly gulp energy drink leader monster beverage mnst clear buy point quite appropriately halloween coca cola ko partner be trading entry meaning still buy zone extend monster sport accumulation distribution rating quarters rise fund ownership maker monster rehab other drink brand be set report earning nov analyst expect ep growth note risky buy stock just report dowdupont receive biggest investment stock list fund purchase worth share number be skewer merger dow chemical co du pont nemour co be just complete september create new entity chemical giant market cap stand just stock have ease back buy zone become extend september fund invest just lead chip stock intel break oct then soar oct report third quarter earning intel be now initial buy point unitedhealth unh be only other company join dollar club fund investing megacap manage care stock have continue climb march clearly boost quarters rise fund ownership semiconductor stock ibd member apply material lam research lrcx have be tear begin cyclical industry so investor be ready lock gain stock begin show top action addition apply material lam research ibd big cap stock texas instrument txn intel more semiconductor related company make month list sign institutional investor be continue put chip table so speak time tell short term turn be good bet apply material be recent buy point later stage cup handle putt just potential profit take zone lam research be already profit take area banking giant jpmorgan chase jpm automaker general motor gm top list new sell month jpmorgan show net seller selling buy gm have selling buy megacap medical stock johnson johnson jnj come third net seller selling buy selling johnson johnson be still buy range retake entry oct report rise earning jpmorgan have continue climb buy point report earning oct general motor have be give back chunk gain make september so far gm have find support day line related find track best mutual fundsmutual fund manager foreign stock taxe be cutvideo find track best etfs
120,JNJ,stock open effectively flat wednesday stir analyst action early earning news layer low ahead fed meeting minute due afternoon nasdaq composite trade breakeven line apple aapl rise amazon com amzn add lead fang stock also stick close break even line dow jone industrial average edge fraction higher hold just monday intraday high johnson johnson jnj jumpedout early lead dow upgrade buy hold jeffery co medical product conglomerate be work second weekly advance late september low attempt build right side possible month base pattern dow peer visa climb well fargo reinstate outperform rating stock price target visa share be extend july general electric ge drop dow hardest early hit news report say company be negotiating possible takeover base underwater engineering firm subsea subcy subsea have market valuation ge share be week end tuesday session change top management announce begin week delta air line dal grab early gain report third quarter revenue earning comfortably analyst expectation management offer upbeat outlook strong momentum follow busiest summer travel season history delta share be climb right side month cup base buy point moviepass owner helio matheson analytic hmny spiked open information technology consultant august buy majority share moviepass revamp internet base subscription service pricing moviepass now provide customer ticket movie day theater month purchase amount be announce helio deal helio share be more mid september low fastenal fast slide lower third quarter result just meet expectation mark company best combine sale earning growth quarters gross margin decline basis point stock have be fight resistance week move average gas producer range resource rrc crank gain barclay flip stock overweight underweight lift price target range remain deep year consolidation early september low ibd stock paypal pypl jump follow upgrade overweight equal weight morgan stanley note also boost stock price target paypal share be extend more flat base july high point wednesday economic news be likely be release minute federal open market committee meeting due et labor department release job opening labor turnover survey et chicago federal reserve bank president charle evan be schedule speak switzerland begin et san francisco fed president john william speak et salt lake city asian stock market action show china benchmark post mixed close japan tokyo nikkei tack gain putt less prior high june market europe be once again mixed region cope political unrest spain frankfurt dax battle hold narrow gain afternoon trade london ftse shed cac paris drop related stock rise modestly be warning sign sideway trend fact fake news giant facebook google nyt be buy pointsq earning slow sector strong investing action plantesla price target raise strength charge expansionnvidia jump debut computer self drive car
121,JNJ,here weekly investing action plan need know investor come week xearning season really get go start netflix nflx kick thing tech sector end general electric ge be grow pressure turn stock investor
122,JNJ,stock wrapped wednesday session slender gain leave dow tracking fifth straight weekly advance xminute september fomc meeting release midafternoon have little impact trade investor respond strongly analyst action earning news well small number early third quarter earning report dow jone industrial average manage scratch new close high rise wal mart wmt johnson johnson jnj soar gain better nasdaq composite tick also new close high paypal pypl liberty global lbtyk dollar tree dltr head nasdaq apple aapl rise alphabet googl lead fang stock jump credit suisse boost be price target stock stock end dime buy point month flat base climb seize own new close high index biggest gain come drugmaker endo international endp steel maker nucor nue target tgt be also mix rise catch updraft wal mart wal mart surge third straight advance left share more so far week extend buy point flat base stock see handful price target increase week follow increase earning guidance launch stock buyback plan monday johnson johnson rise end session just whisker buy point month flat base medical product brand score second analyst upgrade week lift jeffery co buy hold price target increase stock be monday second straight weekly advance put share september low general electric ge drop notch worst loss dow stock wednesday session news report say company be negotiating possible takeover base underwater engineering firm subsea subcy investor continue react change company top management announce monday airline post mixed session delta air line dal top analyst projection third quarter report share jump more open trade then pare gain less stock be climb right side month cup base potential buy point day biggest gain go moviepass owner helio matheson analytic hmny stock spiked open putt ahead more so far week information technology consultant august buy majority share moviepass revamp internet base subscription service pricing moviepass now provide customer ticket movie day theater month purchase amount be announce helio deal helio share be more mid september low ibd stock paypal jump boost upgrade morgan stanley overweight equal weight price target hike paypal share be extend more flat base july related stock apple retake buy point be time buy alphabet again forget antitrust wal mart be punch back amazonpaypal climb upgrade never go look cheap again
123,JNJ,major market index tread water early morning trade wednesday ahead release fed minute last month policy meeting et major index tech heavy nasdaq dow jone industrial average trade quietly higher xamong dow jone industrial component johnson johnson jnj moved be upgrade hold buy jeffery co medical product maker be form flat base potential entry meanwhile wal mart store wmt follow tuesday advance share remain buy range flat base entry cisco system csco edge slightly higher etch handle cup shape base potential buy point be dime high company report earning delta air line dal report strong result launch share higher open trade gain have be trim just airline carrier be forge cup base potential buy point fellow airline american airline aal reversed lower fall approach own cup base entry lead payment processor paypal pypl jump higher see analyst upgrade morgan stanley analyst raise rating equal weight overweight price target premium tuesday close price share ibd member be flat base buy point lead growth stock electric automaker tesla tsla continue swing day line fall back today decline apparel maker be decline ralph lauren rl armour uaa coach coh fall ralph lauren give day line average trade armour be approach multiyear lows ibd atlassian team look rise straight day move higher stock still buy range buy point downside electronic art ea faltered battle support day line flat base july hasn lead gain stock have pause long enough create new flat base sport entry related delta air line beat forecast give strong outlookdow jone industrial average dow stock news analysisbig bank earning week watch bank stock not overlook giant report investing action plan
124,JNJ,stock post quietly upbeat start monday market gear rollout third quarter report season later week nasdaq composite dow jone industrial average open ahead fought maintain gain most federal office federal reserve bank bond market be close monday columbus day holiday limit economic news release transaction financial sector suggest quiet session stock big bank be lead contingent head earning report season citigroup jpmorgan jpm set report thursday bank america bac pnc financial pnc well fargo wfc schedule early friday report wal mart swung early lead dow industrial name launch new mobile app allow customer begin process return smartphone general electric ge drop lower weakest early move dow industrial company announce friday close veteran chief financial officer jeffrey bornstein retire end year jamie miller chief executive ge transportation fill bornstein role retirement vice chairman be also announce early monday ge say board member robert lane retire due health reason be replace ed garden founding partner chief investment officer activist investor trian fund management lead diversify operator honeywell hon gain early action news report sunday say morris plain base company be explore option spin operation order create least publicly trade company honeywell share be start year end friday buy range buy point flat base apple aapl rise putt stock late september low still capped resistance week move average tesla tsla shed nearly maker luxury electric car friday delay introduction tractor trailer style truck nov oct chief executive elon musk say company be divert resource wrestling production delay new model sedan effort produce more battery attempt assist electrical problem hurrican batter puerto rico tesla share be fight hold support week move average follow attempt buy point fail ibd stock jupai hold jp run open action china base financial advisor spiked last week putt stock august july ipo price japan tokyo stock exchange be close china market be mixed shanghai exchange open holiday shanghai composite jump hong kong hang seng index drop europe market turn mixed afternoon trade have give early gain investor continue monitor catalonia momentum bid independence spain related stock keep winning bank earning be stock be court buy zone earning season beginsthese top stock have etch super bullish patternibd investor research tool get start ibd
125,JNJ,stock index be mixed midday thursday blue chip dow jone industrial average keep leadership role vs major index dow rise nasdaq advanced respectively small cap russell add volume stock market today be higher nyse lower nasdaq vs same time wednesday previous week dow have outperformed major index dow also be lead so far week account dow component be largely responsible so far month wal mart store wmt be mmm johnson johnson jnj caterpillar cat also component dow be price weight index stock be top price caterpillar johnson johnson recently report earning top street consensus view earning revenue wal mart report quarterly result open nov street expect revenue rise earning slip ibd list best stock fundamental technical advance issue lead decline issue ratio top percentage gainer be old dominion freight line odfl pop more heavy volume trucking firm report earning rise top street consensus estimate increase revenue grow beat view gain go thursday session trucking group be month price performance industry group group be midday thursday close ibd be pra health science prah rise heavy volume stock clear buy point earlier month volume be unimpressive stock make little progress today action look more confident pra report quarterly result top view top bottom line earning rise revenue tax margin be best least quarters downside midday thursday china base tal education tal stagger lower quarterly result miss view stock plunge day move average heavy volume related top chinese school operator miss earning view stock divesgasoline tax user fee be aerospace stock dife quarterly result
126,JNJ,celgene celg abbvie abbv be likely be biggest beneficiary inflammatory bowel disease market be expand rapid clip analyst say wednesday biologic market disease generate sale leerink analyst geoffrey porge write note client abbvie humira johnson johnson jnj remicade tnf drug used fight inflammation dominate market today believe market be likely continue exceed recent growth rate significant share value likely accrue celgene offset value available also abbvie inevitable erosion abbvie dominant humira franchise say new class inflammatory bowel disease drug be arise like celgene roche rhhby galapago gplg gilead science gild abbvie be look make mark drug now phase trial crohn disease ulcerative colitis common form disease earlier trial benefit clinical datum back be have difficulty recruit patient porge say many trial also exclude sicker patient include patient ve stop respond current treatment ibd take earlier year abbvie say expect humira hit peak international sale face erosion head ibd technology page breakdown abbvie see biggest drug go plan offset competition tnfs humira remicade be first truly disease modify treatment approach many patient don respond stop respond tnf drug porge say study suggest tnf patient don respond lose response year estimate show be patient inflammatory bowel disease have crohn disease have ulcerative colitis patient number europe be higher provide large opportunity drug base new mechanism write related perrigo beat raise lift generic drug buck teva mylan trendcould small biotech break tie eli lilly abbvie topple humira sale brake third straight quarter
127,JNJ,johnson johnson jnj bayer bayry anticoagulant xarelto likely be star next week european society cardiology conference analyst say friday xin february dow component end trial dub compass earlier expect base efficient xarelto be reduce major cardiovascular event include heart attack stroke cardiovascular death patient heart disease full result phase trial be be present conference aug credit suisse analyst vamil divan reiterate outperform rating price target ahead meeting expect meaningful improvement efficacy say note client xarelto be test milligram dose twice daily milligram dose twice daily combination aspirin trial be stop year early drug prove efficient vs aspirin alone ibd take biotechs be now rank tenth group track ibd seventh last week fourth week cause stock lose steam head ibd industry theme closer look such large study be stop so early efficacy assume add benefit compass be quite meaningful write base trial design population conversation expert assume relative risk reduction be more hasn say xarelto alone combination aspirin prove successful reduce risk major cardiovascular event divan note datum monitoring committee allow pool patient trial remain xarelto likely due limit safety concern well side trial perform define commercial impact divan say talk physician longer used aspirin xarelto alone prove strongest be more challenge persuade add low dose xarelto aspirin treatment divan see compass datum help expand total addressable market xarelto least lead additional annual sale alone fellow dow component merck mrk be expect unveil datum trial dub reveal conference june merck say drug anacetrapib prove effective reduce risk major cardiovascular event patient already receive ldl cholesterol lower drug investor key merck comment long drug stay body be administer earlier study well most recent reveal trial anacetrapib be find accumulate fat tissue novartis nvs be also expect have datum phase trial name cantos determine benefit drug ilaris patient high risk recur cardiovascular event june novartis say trial hit main goal give limit datum release previously novartis management have say ilaris need show relative risk reduction order be commercially relevant company ideally want see relative risk reduction study divan say note relative risk reduction be statistically significant ilaris be already approve treat several rare inflammatory disease related dow merck be credit suisse top picktrump blast dow merck ceo resign manufacturing abbvie gauntlet squeeze gilead drug hepatitis
128,JNJ,johnson johnson jnj have relative strength rs rating upgrade thursday welcome improvement still higher score prefer see exclusive rating investor business daily measure market leadership worst best score score show stock price movement trail week compare other stock database history show top perform stock tend have higher rs rating begin biggest run see johnson johnson continue rebound clear threshold stock be not proper entry right now see manage form break proper consolidation johnson johnson show ep growth last quarter sale rise company hold rank peer medical diversify industry group abbott laboratory be rank stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
129,JNJ,stock be mixed celgene celg dive hurt biotechs investor await amazon amzn alphabet googl earning due close spdr dow jone industrial average dium spdr spy rise respectively powershare qqq trust qqq slip home construction financial semiconductor lead upside sector fund stock market today ishare home construction itb advanced spdr homebuilder xhb add biotech oil real estate play underperform spdr biotech xbi ishare nasdaq biotechnology ibb sank respectively moved further day move average line biotechs celgene gap sank month low sale miss view amgen amgn pare loss alexion pharmaceutical alxn vertex pharmaceutical vrtx fall more apiece respective quarterly report most gold etfs fall underlie commodity price oil fund be mostly higher west texas intermediate crude price reversed upward want invest same stock billionaire investor warren buffett so watch fund soon trigger buy point ishare russell value iwd be get close buy point month flat base pull back broader market wednesday be still less entry etf advanced mid february start current base fund track market cap weight index bearing same name turn year old russell value index be compose large midcap stock be consider undervalue market vs comparable equity iwd target cheaper stock index base price book project growth historical sale growth accord morningstar direct financial represent biggest sector weighting oct asset health care be next nearly follow energy just apiece industrial consumer staple information technology iwd top position include berkshire hathaway brkb jpmorgan chase jpm exxon mobil xom johnson johnson jnj top name account nearly portfolio fund year date return oct lag gain average annual return longer haul have also underperform benchmark index year return be roughly line period ibd take look improve chance successful investing watch video learn follow simple routine increase odd iwd annualize dividend yield be ahead average payout half fund top stock be dividend aristocrat company have raise annual payout least past consecutive year top be also hold buffett berkshire hathaway june iwd carry expense ratio wednesday pick vanguard small cap vb schwab small cap scha remain buy range respective entry related dow sell boee ge weigh chance buy small cap earning fuel dow new record high fang play buy zonedow hold gain wal mart rise nvidia lead hot chip sector
130,JNJ,stock market have new leader not investor be used see dow jone industrial average rally record high tuesday be suddenly hottest index industrial be so far month more double rise increase
131,JNJ,dow industrial rally strongly thank ibm ibm turnaround johnson johnson jnj several other blue chip earning general electric ge be big miss adobe system adbe also be big winner bullish outlook netflix nflx hit new high boom subscriber growth ipos be hot dow industrial rise week fuel ibm predict return revenue growth johnson johnson unitedhealth unh be also notable blue chip contributor general electric crash big ep miss have little impact price weight dow rise nasdaq help senate first step big tax cut adobe system soar outlook paypal pypl beat netflix pull back record high high subscriber gain unite airline ual crash carrier have few answer question few new ipos impressed internet television network netflix cheer investor third quarter subscriber addition trounce expectation earning growth miss view sign net new stream subscriber third quarter beating wall street target december quarter netflix expect add new subscriber edge consensus view end september quarter stream subscriber worldwide netflix share hit record high tuesday morning sank week remain buy range related netflix stock fall third quarter subscriber beatadobe system share surge record high maker digital medium marketing software announce upbeat sale earning target fiscal san jose calif base adobe be target adjust earning share year year sale wall street be modele related adobe system rocket outlookibm share soar tech icon report quarterly earning beat estimate indicated sale growth return first time more year ibm do not provide formal quarterly guidance management indicated revenue snap quarter string revenue decline related ibm get price target hike earning report outlookgeneral electric earn just cent share far cent expect revenue rise more expect organic industrial revenue dip industrial operate margin shrank ge power business be big drag industrial cash flow operate activity plunge adjust due weakness power business ge slash full year earning cash flow guidance raise concern dividend cut ge share fall soon friday open close related ge earning miss badly cash flow dive add dividend fearsunited airline tumble more management carrier third quarter earning call be unable provide detail longer term plan drive profit lack clarity lead analyst believe carrier be walking back target outlined last year grow earning higher expect cost be also concern drop fare compete ultra low cost carrier morgan stanley ms top estimate help strong stable wealth management business rival investment bank goldman sachs gs also beat analyst raise concern result be help more volatile capital intensive line business goldman trading result continue struggle morgan outperformed other big bank morgan stanley rise retake buy point goldman sachs climb dow component johnson johnson top wall street view report adjust earning share sale pharmaceutical sale jump worldwide medical device revenue rise miss estimate abbott laboratory narrowly beat expectation early wednesday lion share beat come abbott establish pharmaceutical diabetes care cardiovascular neuromodulation product share rise clear buy point hit record high abbott advanced also time best related dow component pop top view pharma strengthqudian qd china base online credit firm backed alibaba baba rise debut raise pricing expect range singapore base online gaming company sea backed chinese internet giant tencent tcehy edge higher debut raise upsized ipo mongodb mdb provide open source database software platform business pop ipo top just raise price range qudian be profitable sea be poise start make money related sea upsized ipo raise millionmongodb price high qudian strong debut play new ipostop semiconductor industry player deliver generally upbeat report september quarter past week taiwan semiconductor manufacturing tsm beat target third quarter sale earning guide higher current quarter sale maxim integrate product mxim beat wall street target earning sale be tad short however maxim guide earning sale december quarter be well view chip gear vendor lam research lrcx beat view guide higher current quarter rival asml asml beat sale earning target third quarter revenue guidance be light unitedhealth group unh share vault record high tuesday then keep climb insurer report earning growth cent ahead estimate show enviable strategic position have exit obamacare exchange unitedhealth say benefit president trump executive order make low cost plan more widely available amazon com amzn want enter retail prescription business analyst say unitedhealth be ideal partner company signale willing meanwhile anthem antm insurer follow example unitedhealth announce broaden offer include pharmacy benefit management anthem share near buy point news dump express script esrx utilize cvs health cvs process retail distribution start related anthem jump prescription business amazon speculation signal openness amazon partnership earning beatpaypal report september quarter profit revenue top view forecast current quarter sale estimate send share commerce payment processor paypal say adjust earning be cent share year revenue rise current quarter paypal forecast revenue growth midpoint guidance gaap profit cent vs consensus estimate cent paypal jump friday new record high related paypal earning revenue top expectation share slb say friday investment demand north america be moderate baker hughe bhge warn challenge year end customer remain cautious spending due volatile oil price suggest shale other operator be rein production growth plan schlumberger meet ep view gain baker hughe report first quarter merger general electric oil gas unit july crude price hold barrel inventory fall yet again production plunge due gulf shutdown hurricane nate charle schwab schw trade etfc beat wall street consensus third quarter earning schwab miss revenue trade meet expectation schwab report ep cent revenue trade post earning cent share revenue schwab undercut buy point report sharp fall trading revenue share rebound friday trade share fall be still buy range past entry ebay ebay meet third quarter earning estimate revenue be slightly forecast online marketplace fourth quarter ep outlook fall short estimate share sank close day move average recent buy point undercut intraday thursday related ebay meet earning view share tumble weak outlooksap sap report quarterly earning top estimate german enterprise software giant raise guidance year base cloud compute strength bombardier bdrbf agree sell stake struggle series jet airbus eadsy commerce department call tariff narrow body jet deliver boee ba accuse canadian company receive unfair government subsidy gilead science gild win fda approval car drug dub yescarta treat aggressive form hodgkin lymphoma yescarta come gilead recent kite pharma deal gilead rise thursday be little change weekcelgene celg scrap trial crohn disease drug win start third cite internal futility review celgene fall friday intuitive surgical isrg top expectation late thursday report sale adjust profit share share rise friday atlassian team surge maker project management software report fiscal first quarter sale profit handily top estimate atlassian up full year revenue guidance midpoint guidance earlier forecast share surge nearly verizon communication vz add more postpaid wireless phone subscriber expect revenue also top estimate proofpoint pfpt report earning revenue top estimate fiscal outlook disappoint share rise friday video game publisher electronic art ea disappoint news be delay star war action adventure game have be set release fiscal run april march do not give new release time frame ea share be so far week rv maker winnebago wgo exceed forecast profit growth cent share revenue increase company also approve share buyback share close american express axp exceed earning estimate longtime ceo kenneth chenault retire stephen squeri set take place feb unite rental uri steamrolled estimate cent share ep rise revenue boost hurricane rebuild be reason nation largest equipment rental company boost guidance capital spending plan procter gamble pg profit grow share top view cent organic sale rise just result follow narrow proxy fight trian fund management nelzon peltz share fall friday unilever report weak sale thursday european consumer food product giant fall week related stock buy watch top ipos big small cap growth stockslooking best stock buy watch start here
132,JNJ,wednesday new high list deliver ample supply name day outperformance dow jone industrial average xstrength dow be fuel huge move ibm ibm new high blue chip index come like jpmorgan jpm johnson johnson jnj intel intc unitedhealth unh
133,JNJ,key index fund be board stock market today overseas market stay ahead xishare msci eafe efa ishare msci emerge market eem rise spdr dow jone industrial average dium spdr spy lead index fund gain apiece powershare qqq trust qqq add energy retail bank be biggest gainer sector fund gold telecom utility underperform spdr gold share gld ishare gold trust iau give vaneck vector junior gold miner gdxj fall vaneck vector gold miner gdx lose gold future dip ounce spdr retail xrt advanced retake day move average first time nearly month component stock kohl kss jump department store operator say open amazon amzn shop store oil play advanced boost rise west texas intermediate crude price barrel spdr oil gas exploration production xop vaneck vector oil service oih surge nearly unite state oil uso powershare db oil dbo add apiece health care exchange trade fund be just respective buy point pull back time high spdr health care xlv ease second straight session tuesday close slightly buy point flat base etf advanced nearly early june prior flat base start most recent pattern fund mark anniversary december have attract asset track health care select sector index be comprise health care name pharmaceutical account biggest chunk asset nearly biotech weigh health care provider service health care equipment supply contribute respectively top holding include johnson johnson jnj pfizer pfe unitedhealth group unh biotechs score big gain last week also make top list amgen amgn gilead science gild celgene celg biotech industry track ibd surge last week spur part gilead acquisition kite pharma kite gilead share soar kite rocket week xlv have outperformed year date gain accord morningstar direct also outpaced benchmark index past year respective return vs gain same period etf carry expense ratio ibd take biotech be rank base fundamental technical metric track ibd find now ibd stock checkup vanguard health care index fund vht be also trading slightly flat base buy point case be fund launch january track msci investable market health care index pharma make biggest sector weighting july asset biotech health care equipment manage health care follow respective weighting top holding include many same name xlv johnson johnson pfizer unitedhealth amgen celgene gilead vht have return year date past year respectively expense ratio be tuesday etf pick first trust equity opportunity fpx ishare russell midcap growth iwp close respective flat base buy point related think miss big biotech rally check playsgold oil rally stock sell long term winner buygilead kite deal boost biotech etf clear buy pointbiotech extend gain breakout put apple amazon focus
134,JNJ,merck mrk chief executive kenneth frazier resign president trump american manufacturing council early monday prompt trump claim dow jone component be make rip drug frazier resignation follow violent weekend charlottesville va person be kill injured car plow group protest white supremacist rally resignation be apparent protest trump response trump condemn hate bigotry violence many side statement saturday draw heat not be more explicit condemnation response frazier say feel be responsibility take stand intolerance extremism america leader honor fundamental value clearly reject expression hatred bigotry group supremacy run counter american ideal person be create equal frazier say statement twitter ibd take merck have ibd composite rating meaning perform bottom half stock term key growth metric group nordisk nvo be best rate cr best possible head ibd stock checkup look other drug stock leader shortly frazier resignation trump blast ceo tweet now ken frazier merck pharma have resign president manufacturing council have more time lower ripoff drug price trump tweet now ken frazier merck pharma have resign president manufacturing council have more time lower ripoff drug price donald trump realdonaldtrump august merck dow component decline further comment investor business daily say believe statement issue speak early trading stock market today merck lift frazier be far first executive resign business advisory group pull together trump administration tesla tsla elon musk bob iger walt disney co quit policy panel trump withdraw paris climate agreement travis kalanick former uber technology ceo pull economic advisory group trump issue executive order refugee muslim majority country manufacturing group frazier resign also include executive dow chemical dow boee ba johnson johnson jnj related abbvie gauntlet squeeze gilead drug hepatitis pfizer cancer drug help grow merger sanofi earning spook regeneron share week low
135,JNJ,major market index kick first trading session september mixed note job report come weaker expect wall street expect gain economy add just job august june july payroll be also revise lower tech heavy nasdaq reversed early gain head lower dow jone industrial average rise dow industrial ibm ibm moved remain well high stock have be stick downtrend be trading day move average line meanwhile apple aapl reversed record high move lower stock be pace snap day streak stock be briefly extend more flat base entry early friday rbc capital market raise price target base pent demand apple upcoming iphone apple hold product launch downside johnson johnson jnj decline continue build flat base buy point first stock reclaim day line fang member netflix nflx moved stock market today continue rebound day line lead growth stock tesla tsla trade higher move cup handle entry grubhub grub leaderboard member decline more trade striking distance week tight add entry food delivery service flat base buy point have do well stock be level company report earning palo alto network panw jump beating street top bottom line estimate late thursday cybersecurity company moved back day line try break current downtrend meanwhile retailer lululemon lulu surpass analyst estimate send share nearly higher stock reclaim day line ibd graphic chip maker nvidia nvda advanced stock have hold well trigger sell rule aug cup base entry stock be back striking distance new high downside nutrisystem ntri decline almost stock have be fight support day line almost month be back related week review stock high gas price soar harvey biotechs boom fdadow jone industrial average dow stock news analysis auto stock watch post harvey demand investing action planfang stock news quote facebook amazon netflix googleapple schedule medium event new iphone expect
136,JNJ,puma biotechnology pbyi portola pharmaceutical ptla alnylam pharmaceutical alny lead deluge loss thursday see sector slide week low ibd company biotech industry group slip spot rank xin midday trading stock market today biotechs overall lose touch low last see june biotech industry group be now rank sixth group ibd track fourth last week biotech stock hit month high july ride wave ahead second quarter earning wednesday close sector have fall high earning season come close wednesday portola puma alnylam offer report alnylam sale miss expectation adjust loss be deeper expect prod share drop leerink analyst paul matteis remain bullish alnylam keep market perform rating price target see ideal opportunity alnylam treat acute hepatic porphyrium drug givosiran disorder involve buildup chemical body alnylam drug class use rna interference silence specific gene ibd take biotech fever look have chill late july long term view remain cloudy follow number biotechs beat second quarter expectation raise guidance get detail ibd industry theme think acute hepatic porphyrium represent ideal indication rna interference medicine basis be underserved orphan disease drive single target matteis write research report alnylam be also aim file application patisiran year end patisiran be be develop treat rare condition know hereditary attr amyloidosis abnormal protein build multiple organ damage impede puma dove announce late wednesday european approval breast cancer drug nerlynx have be push back least first quarter earlier view third quarter nerlynx be likely be biggest driver share term rbc analyst matthew eckler tell client note also potential lack thereof partner merger acquisition say firm also report loss share widening share year earlier quarter miss analyst view share loss adjust loss share widen cent analyst view be not immediately available late wednesday portola say work manufacturing process change push launch bevyxxa first quarter biotech reiterate plan launch sometime september november credit suisse analyst vamil divan say bevyxxa be treatment prevent blood clot hospitalize patient risk due moderate several mobility restriction drug be portola first only approve pipeline include anticoagulant blood cancer drug inflammatory drug european regulator be expect issue opinion bevyxxa late early second quarter portola report collaboration license revenue dip year earlier period lag model loss share grow cent be wider consensus view cent loss revenue stem agreement dow component pfizer pfe johnson johnson jnj janssen unit well bristol myer squibb bmy bayer bayry daiichi sankyo portola topple related alnylam report lag sale wider expect lossesperrigo beat raise lift generic drug buck teva mylan trendcan generic drug stock catch break mylan crash
137,JNJ,federal reserve keep key interest rate steady last month widely expect start unwinding balance sheet september xwhen fed stop buy treasury mortgage backed security increase supply send price drive yield lead higher interest rate mean investor again focus sector stock market be most likely outperform rate climb instance bank other financial industrial consumer discretionary be area tend benefit higher rate couple new fairly new kid exchange trade fund block aim offer outperformance stock rise rate environment newest be proshare equity rise rate eqrr launch july eqrr be investor expect rise interest rate want outperform traditional large cap index rate go michael sapir co founder ceo proshare advisor say statement eqrr take sector most positively correlated interest rate then sector invest company have tend outperform period rise rate fund track nasdaq large cap equity rise rate index have attract asset biggest sector weighting aug be financial energy material industrial information technology account asset top holding include trade financial etfc fifth third bancorp fitb lincoln national lnc bank america bac top stock account asset be bank insurer eqrr carry expense ratio fidelity dividend etf rise rate fdrr set mark anniversary have gather fund track fidelity dividend index rise rate invest large midcap company be expect keep pay grow dividend stock also have positive correlation return rise year treasury yield boston base geode capital management serve subadvisor fund technology lead fdrr sector weight nearly follow weighting health care consumer cyclical financial service aug accord morningstar inc have modest exposure sector such real estate utility pay big dividend be highly sensitive increase interest rate fund top holding aug be dow jone industrial average component apple aapl microsoft msft johnson johnson jnj jpmorgan chase jpm merck mrk exxon mobil xom top comprise nearly quarter total asset etf have slightly underperform broader market year return vs gain aug fdrr expense ratio be keep mind fdrr still year old eqrr mark first month isn proven yet track record available next fed monetary policy meeting be schedule odd rate hike december be accord cme group fedwatch tool related miss thursday breakout fresh idea market hit highsnext gen etfs rise rate offer high yield low volatility
138,JNJ,key index fund be mixed early afternoon trading seek direction stock market today xspdr dow jone industrial average dium be less spdr spy be fractionally lower powershare qqq trust qqq dip small cap lead upside ishare russell iwm ishare core small cap ijr retail be big winner sector play spdr retail xrt gap rise nearly aim third straight advance component stock abercrombie fitch anf guess ge dollar tree dltr be retailer score big gain follow earning report telecom biotech real estate etfs also make solid advance most oil utility consumer staple lag vaneck vector oil service oih fall spdr oil gas exploration production xop rise unite state oil fund uso powershare db oil fund dbo sank gold play be mixed vaneck vector junior gold miner gdxj vaneck vector gold miner gdx gain respectively spdr gold share gld ishare gold trust iau pull back west texas intermediate crude price slide barrel gold future ease ounce fund invest opposite end standard poor index spectrum be seek support day move average line have apple aapl ty pursue big cap company be ishare oef track index largest equity fund mark anniversary october have amassed advanced prior bounce day line early july technology account biggest chunk asset aug follow financial service health care consumer defensive consumer cyclical accord morningstar inc top holding represent asset apple microsoft msft facebook fb amazon com amzn johnson johnson jnj average market cap stock oef portfolio be well average morningstar large blend category turnover be low end expense ratio be expect fund performance have be largely line return year date aug return oef year return be vs benchmark index gain target fastest grow stock guggenheim pure growth rpg hold many smaller cap name etf take fast grower then weight strong growth characteristic be year old fund be show similar action oef have attract asset gain ytd have outpaced past year top holding include apple iphone chipmaker broadcom avgo other chip stock make top apply material amat nvidia nvda lam research lrcx invisible brace firm align technology algn round list top account total asset average market cap company portfolio be turnover be rpg expense ratio be wednesday pick schwab large cap growth schg ishare core growth iusg pull back market remain respective day line potential buy range related sector score biggest gain apple big techs buy range stock bounce back apple top global equity play buy sector lead stock turn mixed apple microsoft reach
139,JNJ,botox maker allergan agn top wall street second quarter model thursday stock reaction be muted light sale eye drug restasis stagnant revenue fat strip drug kybella second quarter end june allergan report adjust income share sale respective vs year earlier period consensus expect adjust earning share sale allergan also raise guidance revenue adjust income share previously allergan have guide sale adjust earning share raise be unexpected view mizuho analyst irina koffler say note client koffler keep price target buy rating allergan stock stock be hold back mixed performance key product botox cosmetic revenue miss koffler estimate grow year year botox therapeutic bring top koffler view grow allergan cite trade buy pattern stable volume demand decrease sale eye drug restasis number also miss consensus view koffler say ibd take allergan lead medical aesthetic market rival hologic holx dow johnson johnson jnj valeant pharmaceutical vrx have piece sector head industry snapshot closer look layout unit sale linzess increase vs year earlier quarter widely miss street expectation koffler say follow destock first quarter sale kybella injection used improve appearance fat chin be flat juvederm collection sale climb coolsculpt sale be follow close zeltiq acquisition late april stock market today allergan inched less close july share top buy point flat base begin form february related biotech be head deal ceo take rein small biotech launch month high today here biotechs defy downtrend hit fresh high
140,JNJ,major market index be quietly higher early morning trade tuesday tech heavy nasdaq edge higher rise less meanwhile dow jone industrial average inched slightly higher dow jone industrial component johnson johnson jnj unitedhealth unh rise respectively upbeat earning result be track reclaim flat base buy point unitedhealth surge new high downside boee ba decline fall back buy range flat base entry fang stock facebook fb reach flat base buy point social medium giant briefly touch record high morning company report earning netflix nflx have hover positive negative territory be much earlier late monday company release strong result late monday see video streamer add more subscriber expect earning fall short street target come cent share compare cent share estimate global investment bank goldman sachs gs morgan stanley ms beat top bottom line estimate early tuesday spark early advance share goldman turn red fall goldman sachs be still build saucer handle pattern entry morgan stanley add gain recent cup handle featured buy point morgan reach new week high blue chip jpmorgan jpm trade unchanged hold recent gain flat base buy point recent issue despegar com desp faltered more trigger sell signal recent ipo base entry ibd celgene celg attempt regain day line advance biotech be still flat base entry downside lead chip stock apply material amat beat hasty retreat fall almost morning trade share be still extend cup handle buy point related dow stock report earning tuesday investing action plandow jone industrial average dow stock news analysisnetflix beat third quarter subscriber gain stock climbsfang stock news quote facebook amazon netflix googlegoldman sachs morgan stanley top view trading still weak
141,JNJ,stock market remain stick neutral tuesday trendless pattern term so far show real sign stress dow jone industrial average climb few component make sizable gain add nasdaq composite be fraction lower russell
142,JNJ,key stock index be narrowly mixed stock market today dow outperformed thank big gain unitedhealth unh johnson johnson jnj xin early afternoon trading spdr dow jone industrial average dium hold gain spdr spy be powershare qqq trust qqq be barely negative foreign market lag ishare msci emerge market eem fall ishare msci eafe efa slip sector play health care retail utility advanced oil financial gold miner decline health care select sector spdr xlv gain more remain buy zone flat base entry component stock unitedhealth johnson johnson leap respectively report quarterly result gold fund dip gold future give ounce most oil etfs be also lower west texas intermediate crude price slide barrel miss buy etf last doesn hurt keep eye get chance featured ishare select dividend dvy june column fund head potential test day move average however etf instead consolidated form flat base dvy climb past buy point new flat base oct remain buy range entry share advanced mid february previous flat base march high fund mark anniversary next month track dow jone select dividend index aim provide exposure company year record pay dividend utility make biggest chunk asset just consumer discretionary weigh nearly financial industrial top holding oct include lockheed martin lmt cme group cme mcdonald mcd chevron cvx dvy annual dividend yield be well fund year date return oct lag gain accord morningstar direct average annual return past year respectively be roughly line benchmark index dvy carry expense ratio ibd take hunt etf idea be worth closer look check ibd weekly etf leader column featured fund list highly rate etfs powershare midcap low volatility portfolio xmlv be still buy range entry flat base clear oct be highlighted june column near buy point etf form series flat basis late february january previous flat base produce advance start series basis late february fund track midcap low volatility index turn february index be comprise stock midcap lowest realize volatility past month utility financial account nearly asset oct follow real estate industrial material make respectively top holding include brown brown bro westar energy wr jack henry associate jkhy xmlv be ytd have year average annual return vs expense ratio be monday pick ishare msci south africa eza be still just shy cup base buy point first trust emerge market sc alphadex fem remain buy range recent bounce day line related apple send dow new high emerge market play buy ssga launch ultra low cost etfs ameritrade take schwabsmart beta fund outsmart stock market big ytd signal openness amazon partnership earning beat
143,JNJ,stock jump start gate monday positive new york region manufacturing datum help boost premarket session dow jone industrial average open higher push new high nasdaq composite advanced grab new high own investor be keep eye early monday fight iraqi military kurdish force northern iraq city kirkuk israel syrium israeli force launch retaliatory strike missile launch facility east damascus dow be sit top week advance nasdaq have climb week close last week new high week outcome be likely be affected earning report netflix nflx report today close pace pick tuesday goldman sachs gs unitedhealth unh cree cree johnson johnson jnj name expect report dow traveler trv lead gain american express axp take hardest early hit apple aapl scale early trade keybanc security upgrade stock overweight sector weight note say iphone pricing increase iphone change storage pricing represent more aggressive strategy segment customer base extract incremental gross profit user previously expect apple share rise resistance stock week move average share have make comfortable line past month week advance have start right side possible new base big tech fang stock netflix gain premarket action ahead earning report due close stock end friday very top buy range fraction less past buy point cup handle base consensus view be call big earning gain netflix third quarter top rise revenue biotech exelixis exel soar open company say food drug administration grant priority review kidney cancer treatment exelixis share end friday pull back late august high possible week cup base charle schwab schw drop narrowly top earning target narrowly miss revenue growth view third quarter report stock end friday just buy point month cup base china base name lead ibd list chian lodging grouphtht power more yy yy jump stock be extend new high tampa fla base insurance broker health insurance innovation hiiq bolt higher clobber analyst earning revenue growth expectation third quarter announce share repurchase initiative stock end friday still aug high late september low rebound selloff follow hurricane irma economic news get positive start week new york federal reserve bank report surge regional manufacturing october send empire state manufacturing survey read september best month year be far consensus expectation call index read report show longer delivery time decrease inventory level negative new order shipment be sharply higher point ongoing solid gain oil price trade west texas intermediate hold barrel approach late september high copper spiked almost near year high datum show china copper import surge september central bank governor forecast uptick gdp growth second half year just ahead week communist party congress china market post mixed session monday hong kong hang seng index rise japan tokyo nikkei add day rally press multus decade high related stock index take baby step hit high rownetflix ge paypal lead busy earning week investing action rank medical stock be breaking earning market stock market todayibd investor research tool get start ibd
144,JNJ,potential cancer cure disclosure propel loxo oncology loxo stock day june additional day september indicate innovation cancer research treatment many investor say keep loxo aloft potential blockbuster cancer treatment make loxo be recognize investor business daily inaugural ibd biotech innovator award lead drug look medically promising target relatively small patient population so annual revenue be expect fall short define commercial blockbuster get close loxo stock make big leap june company disclose progress phase phase trial lead drug candidate larotrectinib leap loxo stock follow word disclose phase trial datum tumor fighter annual meeting international association study lung cancer set start saturday oct loxo stock touch time high company expect file new drug application larotrectinib early food drug administration approve nda month loxo expect company begin sale specific patient almost immediately ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report loxo focus develop highly selective precision medicine patient genetically defined cancer be gain ground researcher patient doctor fund manager rather look attack specific cancer say used compound lung tumor sometimes don work healthy cell too loxo used increasingly popular gene sequence identify patient host specific gene mutation result tropomyosin receptor kinase trk fusion be abnormal protein tell tumor cell grow used loxo novel compound inhibit trk fusion activity call trk inhibitor kinase inhibitor loxo clinical trial therapy demonstrated improvement patient different type cancer hence loxo larotrectinib be gain attention research clinic wall street well become first drug initially approve fda target mutant protein many cancer rather target cancer loxo spokesman dan budwick call approach tumor agnostic note merck mrk keytruda be indeed approve treatment unresectable metastatic solid tumor specific genetic quality first fda keytruda be initially approve metastatic melanoma then small cell lung cancer then head neck squamous cell carcinoma be already widespread use merck apply fda also use keytruda gene sequence tumor agnostic approach rather old tumor specific approach contrast loxo larotrectinib be first time fda initially approve cancer drug used tumor agnostic gene sequence approach ibd take loxo recently hit time high company be do so moment ibd new high list track mover also rank ibd composite rating loxo potential have wall street attention number mutual fund hold loxo share jump support market cap secondary offer late june marked straight quarters rise fund ownership loxo late sport highest possible ibd relative strength rating putt top stock price performance past month week loxo june report american society clinical oncology asco meeting chicago world biggest cancer conference loxo sell more share common stock secondary offer pricing share stock have trade well recently november company raise expense stock performance loxo rival be rival however have be spotty time most be roll late loxo peer ignyta rxdx go public early month loxo have mostly trade ipo price thursday ignyta stock touch month high loxo partner array biopharma arry peaked shortly ipo stock be way touch year low february month hit month high blueprint medicine bpmc loxo develop kinase inhibitor go public hit new time high september run asco june loxo report objective response rate tumor size be reduce patient many cancer type clinical trial patient tumor hold trk fusion larotrectinib deliver consistent durable response trk fusion patient age regardless tumor context do so few side effect dr david hyman research team principal investigator loxo larotrectinib trial tell asco conference hyman be chief early drug development memorial sloan ketter cancer center way larotrectinib trk fusion story fulfill promise precision medicine tumor genetic rather tumor site origin define treatment approach cowen analyst eric schmidt say loxo estimate patient annually benefit larotrectinib treatment trial datum disclose asco patient greatest tumor shrinkage include soft tissue sarcoma lung colon cancer melanoma salivary gland cancer type cancer be be treat trial patient have least thing common gene mutation cause kinase trk fusion tell cancer cell grow larotrectinib earn breakthrough therapy designation fda july meaning fda give priority early trial suggest new therapy offer serious advantage exist treatment person life threaten disease breakthrough be not necessarily fda highest priority however fast track priority review designation accelerate approval pathway be fda urgent alternative larotrectinib then call loxo receive breakthrough designation unresectable metastatic solid tumor neuronal trk fusion protein adult pediatric patient require systemic therapy have progressed worsen follow prior treatment have acceptable alternative treatment note friend cancer research nonprofit count fda breakthrough designation include larotrectinib target cancer analyst schmidt say recent efficacy datum larotrectinib be best ever have see oncology estimate peak larotrectinib market annual sale year morgan stanley analyst matthew harrison see larotrectinib peak annual sale loxo go public august share conceivably get acquire blockbuster premium buyout talk have surface biotechs end be purchase most be acquire become profitable say schmidt cowen estimate loxo win escape red ink thing have transpire asco june be celgene celg pricing idhifa month new high niche oncology market schmidt tell ibd give loxo breathe room perhaps lead consider higher price larotrectinib idhifa be approve fda aug treat aml most common form acute leukemia adult celgene estimate new aml case be diagnosed annually june secondary offer more double loxo cash pile nearly june help loxo make acquisition bruton tyrosine kinase btk inhibitor program redx pharma rename redx drug candidate loxo loxo acquisition release chief business officer jacob van naarden call deal program pipeline so nicely align larger strategic vision capability redx team have create novel chemical matter selectively reversibly inhibit btk validate molecular target numerous cell leukemias lymphomas analyst schmidt tell ibd price tag look right btk target be validate be unmet need patient fail imbruvica abbvie abbv johnson johnson jnj commercial name ibrutinib treat complication stem cell bone marrow transplant know chronic graft versus host disease gvhd research note morgan stanley harrison praise btk acquisition call logical addition loxo pipeline rate loxo stock overweight price target cowen schmidt rate loxo outperform doesn offer price target cowen analyst be unfazed loxo financial loss greater estimate cash burn biotech earning rarely be interesting schmidt say loxo report wider loss share cent loxo be slate post result oct cash hoard loxo be danger run money year investor expect sale profit then cowen schmidt meet least twice recently loxo top brass say company be track speedy approval larotrectinib loxo be work other potential drug include btk inhibitor buy redx target leukemia lymphoma pipeline partner array biopharma kinase inhibitor target too early suggest approach blockbuster status related get detail biotech innovator award winning company loxo oncology stock hit record small cap biotech stock pop new high
145,JNJ,jeffrey leiden office shelve be plaster accoutrement expect chief executive biotech award letter accommodation inevitable family photo emerge theme gratitude leiden vertex pharmaceutical vrtx currently aim treat cystic fibrosis patient globe cystic fibrosis be progressive genetic lung condition survive adulthood generally don live past age accord most estimate xin vertex set change success see medicine soon be market have generate piece mail plaster leiden shelve re letter thank graduate newlywed get letter email week patient family thank do leiden tell investor business daily know patient most be kid teenager watch grow be part family not company vertex wasn always cystic fibrosis play earlier day be focuse treat hepatitis launch drug know incivek then gilead science gild launch drug sovaldi launch be most successful history also nearly put vertex business incivek become blockbuster drug shortly launch vertex pull market demand withered leiden describe time crisis company be middle crisis say have go be hepatitis company dollar drug literally year essentially revenue be very few company frankly survive kind crisis simply so hard pivot new area drug year division company san diego have be quietly work cystic fibrosis arena indication fit leiden strategy investing scientific innovation create medicine serious disease large unmet medical need specialty area vertex specialty focus allow keep sale marketing force slim turn allow reinvest nearly dollar revenue back research development sell cystic fibrosis drug sale force fewer leiden say fast forward vertex have drug market kalydeco orkambi second quarter sale kalydeco first approve cystic fibrosis drug grow year year orkambi rocket year date vertex stock have more double rise share begin form cup handle buy point late july meanwhile broader biotech industry group have rise be rank eighth group track just week share vertex dip close friday vertex be rarity biotechs way pipeline be almost solely cystic fibrosis drug pipeline not already license bigger pharmaceutical be cystic fibrosis leiden acknowledge risk portfolio standpoint product simply don make sense vertex say vertex have farm drug flu cancer dow johnson johnson jnj merck kgaa enormous sale contingent take sell drug indication take away reinvest science reinvest science have allow vertex do something else unique medicine other firm target symptom cystic fibrosis vertex be work correct genetic underlie cause disease eventually prevent infant diagnosed ever fully develop underlie science focus genetic mutation be divide bucket leiden say kalydeco treat patient orkambi combination kalydeco drug know lumacaftor treat eventually vertex plan treat patient get third bucket patient require prong treatment strategy already backbone triple be be consider approval europe combination kalydeco drug call tezacaftor look likely be approve february top kalydeco tezacaftor vertex be add next generation corrector drug fix other abnormality gene treat patient vertex have strong phase datum next generation corrector combination kalydeco tezacaftor fourth ready read soon eventual goal be decide possible triple pill combination provide most efficient treatment few side effect vertex plan use gene editing treat last cystic fibrosis patient traditional small molecule medicine win work leiden win comment expect triple pill get approval see pivotal trial begin next year most analyst take mean food drug administration approve triple pill vertex vertex goal triple be prevent infant less year age develop cystic fibrosis know today adult already have lung damage kalydeco have be show improve lung function week time slow rate decline lung function ibd take vertex be several leader near buy zone head ibd list stock buy zone other term opportunity include entertainment stock financial service play rather decline year decline year lung function leiden say not sound significant sort compound interest take lifetime make enormous difference survival quality life quality life improvement be huge leiden say used go hospital time year now time year say used be transplant list now re not transplant list used be able walk block now walk mile not just longevity quality life galapago glpg abbvie abbv have team follow vertex step leiden jmp security analyst liisa bayko be doubtful duo catch get fda approval triple pill combo show strong datum component first bayko estimate galapago be several year even do make market triple pill have have outstanding efficiency persuade vertex patient switch new medicine vertex have do good job continually improve med tell ibd keep move bar higher make challenge person want go drug be just good vertex want do just get vertex drug be more bearish jeffery analyst michael yee see galapago eventually get cystic fibrosis market still note vertex have create strong setup make barrier enter market high deliver strong medicine other question vertex do cystic fibrosis well run dry leiden acknowledge cystic fibrosis journey be near end say vertex have plan shift other rare disease sickle cell genetic lung liver condition deadly nerve disorder alpha antitrypsin deficiency lung liver condition look lot cystic fibrosis leiden say have technology know go bear skeptical vertex cystic fibrosis pipeline group analyst investor say well really great want do ll see re able skeptical say reason weird be ve already do ve proven do ve proven model don think question anymore think ve demonstrated work related biotech catch rally add celgene break biotech giant close buy pointstop biotech stock buy zone fda drug approval
146,JNJ,abbvie abbv throw gauntlet gilead science gild approval hepatitis drug further hammer gilead multibillion dollar franchise analyst say friday xlate thursday food drug administration approve abbvie drug dub mavyret coveted week label genotype hepatitis patient most hepatitis drug be take week period abbvie be pricing treatment week deeper discount prominent drug now be prescribe condition gilead harvoni epclusa leerink analyst geoffrey porge estimate mavyret be offer discount gilead see revenue prescribe course harvoni discount epclusa competitive dynamic now solidify fda agree forecast market share price erosion gilead modeled rebound abbvie hepatitis revenue begin porge write note client porge call gilead remain competitive patient harvoni be give week still lose share base contract payer population patient treat mavyret undergo treatment week other patient likely migrate mavyret base convenience week regimen predict gilead drug epclusa vosevi be dose week harvoni be prescribe week patient be treat week ibd take gilead make acquisition be linchpin send biotech sector higher industry observer say head ibd industry theme closer look company gilead be consider mavyret broad label give abbvie access vast majority hepatitis patient exception ve fail drug dow component merck mrk johnson johnson jnj drug bristol myer squibb bmy fda be not require genotype testing be big advantage gilead other participant market write mavyret do have black box warning label risk hepatitis reactivation patient infection patient undergo pretreatment testing hepatitis infection then monitoring be find have hepatitis hepatitis porge say isn significant burden most hepatitis patient have already be screen hepatitis abbvie likely focus early effort government segment mavyret wholesale price be line harvoni undercut epclusa conversely abbvie pricing mean revenue contribution mavyret be likely be limit largely consistent exist forecast say stock market today abbvie close flat gilead fall related gilead be make acquisition not thinkgilead hepatitis franchise topple again share abbvie hammer gilead hepatitis franchise
147,JNJ,stock drop start bell strong early economic news thursday disappointing earning report cisco system csco wal mart wmt compound market reaction wednesday release federal reserve minute concern development washington dow jone industrial average shed start trade nasdaq composite dump apple aapl fang stock post moderate loss market stall wednesday ahead release minute federal open market committee july meeting just news break trump administration have abandon key business council manned blue chip top executive decision once again stir concern washington commitment tax cut other key element president agenda not be soon come chief executive corning glw general electric ge unite technology utx johnson johnson jnj have decide leave council wednesday wall street journal report response president trump response event saturday charlottesville va head merck mrk armour ua have announce exit monday leader alliance american manufacturing afl cio resign group tuesday blackstone group bx chief executive stephen schwarzman inform white house member president strategic policy forum have decide dissolve group accord wall street journal minute later president tweet be eliminate manufacturing council well strategy policy forum dow wal mart cisco throw early anchor post decline quarterly result cisco fall earning revenue decline line expectation growth service recur revenue be lackluster loss drag share back week support stock attempt build floor month consolidation wal mart drag lower meeting analyst second quarter target provide guidance expectation comparable store sale rise top end guidance straight advance traffic growth be traffic gain report target tgt wednesday wal mart early decline send share back cup base buy point lead china base stock be mixed alibaba group hold baba elevated forecast jump earning revenue gain fiscal first quarter ibd stock report revenue cloud compute service soar annual active user china retail marketplace rise stock be extend second rebound support week move average february vipshop hold vip tumble second quarter report ibd stock momo momo jump open stock have be attempt retake cup base buy point datum storage gear maker netapp ntap slump more early trade report fiscal first quarter sale earning beat late wednesday second quarter guidance be line expectation decline cut stock week move average heavy tgrade send sell signal stop short decline buy point avoid automatic sell rule close apply material amat latam airline lfl gap gps ross store rost be company schedule report manufacturing slow less expect mid atlantic region august send philadelphia federal reserve manufacturing business outlook survey read july consensus forecast dip report point notable increase shipment new order continue expansion job growth month consecutive growth new york fed empire state survey wednesday surge past forecast highest mark year first time unemployment claim drop week end aug labor department report be prior week tally well consensus projection claim industrial production rise july accord federal reserve slower june expansion short estimate gain capacity utilization eke vs june line forecast conference board report lead economic indicator estimate july et afternoon dalla federal reserve bank president robert kaplan be schedule speak et minneapoli federal reserve bank president neel kashkari speak et related big picture stock stall do threaten market bounce techs be buy point classic bullish patternthese global retail giant deliver punch investing action planstock buy watch top ipos big small cap growth stock
148,JNJ,major market index remain higher wednesday be pare gain morning trade tech heavy nasdaq defend gain dow jone industrial average show better action rise respectively xamong dow industrial home depot hd look recover wednesday earning related sell share advanced trade right day line meanwhile johnson johnson jnj rise continue track day line higher downside apparel maker nike nke fall stock drop further flat base entry china base stock rise broadly stock market today internet giant tencent tcehy handily beat earning sale estimate early wednesday send adr share almost meanwhile retail behemoth alibaba baba advanced investor prepare company earning release thursday morning analyst expect firm earn cent share revenue totale rival jd com jd report result early monday top forecast share still fall fang member amazon com amzn fall president trump tweet company be do great damage other retailer stock have be trading day line july longest stretch cup handle mid february meantime retailer receive positive news early wednesday target tgt report better expect earning sale initial optimism send share almost stock trim gain just morning trade ibd china stock be once again vanguard tal education tal sina sina pace leader rise respectively chinese stock food deliverer grubhub grub moved recent look regain recently lose momentum share be just flat base entry downside china base yy yy fall second straight day drop almost company price adr share offer related chinese internet giant tencent earning top revenue soar best chinese stock buy watchdow jone industrial average dow stock news stock news quote facebook amazon netflix googleretail commerce news stock watch
149,JNJ,president trump say wednesday disband advisory group american business leader ceo quit week president face blowback fail sufficiently condemn white supremacist trump make announcement twitter less hour group be say be plan inform white house disband rather putt pressure businesspeople manufacturing council strategy policy forum be end thank donald trump realdonaldtrump august trump remark be reversal say day tweet have plenty ceo want be panel replace quit call ceo left grandstander several more ceo council say trump remark have inform respective panel step suggest trump scrap panel dissolve entirely strategy council lead blackstone group ceo stephen schwarzman say participation have become unwelcome distraction blackrock ceo larry fink tell staff wednesday memo have inform strategy council be step past hour jpmorgan chase jpm ceo jamie dimon earlier year hailed trump reignite animal spirit say wednesday afternoon be leader role bring person together not tear apart strategy group be several white house convene earlier year advise president several ceo manufacturing council quit week follow blowback trump remark racially charge violence virginia saturday pressure leave group have grow follow press conference trump hold new york tuesday place partial blame weekend violence demonstrator protest gathering white supremacist charlottesville va woman be kill event man ram car crowd more half dozen ceo have quit manufacturing ceo group other have say want stay panel order influence white house policy manufacturing council hasn meet february ceo armour uaa intel intc merck mrk quit earlier week wednesday inge thulin ceo mmm left do campbell soup cpb ceo denise morrison follow yesterday remark president remain manufacturing job initiative morrison say statement continue support effort spur economic growth advocate value have always make america great jeff immelt general electric ge alex gorsky johnson johnson jnj gregory haye unite technology utx step manufacturing council minute trump say be scrapping body immelt say have inform council wednesday morning decision related big business dump trump exec quit council be stay
150,JNJ,abbott laboratory stock near time high thursday medical giant report second quarter profit revenue narrowly top wall street view xin early trading stock market today abbott surge time high reach july johnson johnson jnj closest competitor lift reach time close high second quarter end june abbott report adjust income cent share sale grow respective vs year earlier period consensus have call adjust profit cent share sale major sale growth include acquisition st jude medical be complete january comparable year year basis exclude acquisition sale grow abbott say news release rbc analyst glenn novarro credit slight revenue beat higher expect sale abbott medical device unit offset light sale nutrition segment revenue medical device grow comparable basis nutrition sale rise less ibd take abbott belong medical related exchange trade fund have rac healthy gain year visit ibd etfs page closer look other top holding perform first half year adult nutrition sale fall hardest globe comparable basis sale segment topple competitive market dynamic abbott say first half year adult nutrition revenue decline solid quarter abbott diagnostic unit help offset diagnostic sale inched comparable basis sale growth easily outperform international sale meanwhile drug sale climb exclude impact acquisition key emerge market lead drug unit grow worldwide sale other drug be flat abbott also boost adjust profit outlook share analyst be broadly call earning share novarro write keep outperform rating abbott stock related philips rival stage coup spectranetic biotechs benefit most trump tax reform vision
151,JNJ,dow jone component merck mrk remain credit suisse top pick head european society medical oncology conference october drugmaker allergan agn eli lilly lly also look strong brokerage say monday time merck be expect unveil result trial dub keynote testing immuno oncology drug keytruda chemotherapy previously untreated patient advanced lung cancer combo receive accelerate approval expect continue discussion potential used keytruda await top line datum confirmatory keynote study september october time frame expect be positive credit suisse analyst vamil divan say second quarter conference call july merck confirm cyberattack delay product year say full recovery cyberattack take time still merck be best position remainder divan say note client merck share end regular trading session investor seem prefer abbvie abbv bristol myer squibb bmy divan be place bet allergan lilly still be several month allergan be expect unveil datum migraine trial say lilly offer diverse pipeline more interest be nordisk nvo trial know sustain be look diabetes drug semaglutide vs lilly trulicity divan see trulicity safer drug lilly be expect unveil datum trial drug abemaciclib breast cancer upcoming oncology conference divan say lilly be also plan file application migraine drug be drive adoption new drug cancer plaque psoriasis ibd take biotechs have struggle lately be now rank seventh group track ibd fifth last week sector hit week low thursday hit month high july head ibd industry theme more happened meanwhile divan isn bullish commercial potential drug abbvie inflammatory disease immuno oncology also call relatively rapid erosion sale key drug humira once generic enter market likely bristol case rumor become takeover target have limit stock term early asset immuno oncology potential approval kidney liver cancer drive upside time divan argue credit suisse also reinstate coverage dow stock johnson johnson jnj july divan note valuation be limit investor interest likely change release datum compass trial european society cardiology meeting meeting be set later month be look ability anticoagulant xarelto prevent major adverse cardiac event include cardiovascular death heart attack stroke patient heart disease expect compass be star meeting have potential dramatically increase uptake xarelto come quarters something move needle even company size divan write divan also note downgrade pfizer pfe teva pharmaceutical teva neutral rating outperform quarter dow stock pfizer be struggle term catalyst lack acquisitive appetite potential tax reform teva other hand be range bound new leadership team be place strategy reduce debt be more certain more clarity potential generic version copaxone multiple sclerosis drug milligram be obtain write related pfizer cancer drug help grow merger generic drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trend
152,JNJ,major stock index hold high monday afternoon weren move much direction nasdaq hit record high wall street weigh weaker expect exist home sale datum lower economic growth outlook dow ease weigh weakness share nike nke johnson johnson jnj general electric ge be close lose nasdaq composite gain volume nyse be tracking lower friday nasdaq volume be pace be close friday level xin economic news june exist home sale come unit consensus separately international monetary fund lower economic growth forecast year treasury yield add basis point stock market today webmd wbmd surge private equity firm kkr say take company private ipo front blue apron aprn shareholder get much need good news goldman sachs initiate coverage meal delivery firm buy rating price target several other analyst also initiate blue apron buy rating share soar stock be still high plunge ibd stock be more afternoon trading veeva system veev gain just cup handle buy point volume be soft share momo momo jump nearly work right side cup shape base buy point question ask now be do momo have potential be true leader fundamental be solid social networking platform volume have be light stock recent rally keep mind china stock have be run higher now momo still hasn break yet meanwhile ibd component winnebago industry wgo add nearly work cup handle base buy point elsewhere alphabet googl be little change ahead earning report close work flat base buy point related comic con hype hasbro unit selling disney toy have slow salesanalyst shrug worry amazon derail fiber optic stockgm ford earning see slowdown watch china sale
153,JNJ,sarepta therapeutic srpt stock bolt late wednesday biotech smash wall street view second quarter sale report narrowing loss just day settle patent dispute biomarin pharmaceutical bmrn second quarter end june sarepta report adjust loss cent share revenue compare loss share revenue year quarter metric top consensus cent loss sale biotech also boost guidance earlier day announce program expand access only approve drug exondys treatment patient duchenne muscular dystrophy patient north america south america europe benefit program leerink analyst joseph schwartz say earlier wednesday add meaningful revenue sarepta top line schwartz have outperform rating sarepta stock hour trading stock market today sarepta rocket share close regular session fraction ibd take dow stock johnson johnson jnj report second quarter earning top expectation sale narrowly miss view result be consider bellwether industry analyst say head ibd technology page closer look earning say related biotechs be dodge payor pushback muscular dystrophy star align biotechs crush earning consensusthese drug giant buy range just beat earning view
154,JNJ,key index fund be lower stock fall board north korea tension disney weigh dow xpowershare qqq trust qqq lead downside stock market today afternoon trading spdr spy spdr dow jone industrial average dium be disney weigh dow medium giant announce plan start own video stream business cut ty netflix nflx overseas ishare msci south korea capped ewy gap sank fall well day move average first time nearly month india earning fund epi powershare india portfolio pin stumble ishare msci emerge market eem pare loss retail bank chip lead downside sector leader few gainer include gold health care consumer staple gold price rise more ounce spdr gold share gld ishare gold trust iau add vaneck vector junior gold miner gdxj vaneck vector gold miner gdx pop nearly apiece oil play be mixed vaneck vector oil service oih slide unite state oil fund uso gain powershare db oil fund dbo add spdr oil gas exploration production xop be barely positive value fund very different top holding be close respective buy point xvanguard mega cap value mgv launch december be buy point month flat base base begin form shortly advance prior flat base clear february fund track crsp mega cap value index first assign stock size base market cap index crsp then score security determine be growth value camp classify value stock base factor book price forward earning price historic earning price dividend price ratio sale price ratio biggest sector weighting be financial service portfolio health care technology industrial top holding june include microsoft msft johnson johnson jnj exxon mobil xom jpmorgan chase jpm etf hold stock top account nearly third asset mgv have underperform year date aug gain vs benchmark index accord morningstar inc slightly lag past year mgv have slim expense ratio value play ishare edge msci value factor vlue climb past flat base buy point intraday tuesday close entry fund rise nearly prior late january start current base vlue track msci usa enhance value index have amassed asset marked fourth anniversary april index be comprise large midcap stock overall value style characteristic msci define value base follow variable price book value price forward earning enterprise value cash flow operation biggest sector weighting be technology health care financial service top holding aug include apple aapl wal mart wmt general motor gm pfizer pfe accord morningstar vlue also hold stock top holding make nearly asset lag ytd return be ahead past year benchmark index outpace vlue past year etf carry expense ratio related apple microsoft lift dow equity play buydow go apple clear buy point nvidia hit sector good position trump bump
155,JNJ,major market index slumber lower early trade tuesday tech heavy nasdaq decline dow jone industrial average hold more modest loss xamong dow industrial apple aapl quietly pace advancer stock market today gain iphone maker attempt add more momentum recent flat base downside medical name johnson johnson jnj merck mrk trade have be fight support day line hold flat base buy point merck be back day line fang member netflix nflx trade lower receive price target hike piperjaffray analyst firm bump target price premium monday close price video streamer have be trading well better expect earning report week cause surge share more chip stock receive more good news late monday chip designer inphi iphi report better expect earning result stock have be consolidate mid february jump attempt get back day line retailer be rise tuesday earning beat michael kor kor ralph lauren rl michael kor leap ralph lauren moved be midst recover multiyear lows be surge back day line today other analyst action tesla tsla be upgrade hold buy argus prompt share rise electric automaker be build cup shape base entry be still away entry ibd pra health science prah zebra technology zbra lead vanguard early trade tuesday move respectively report solid quarterly earning result pra health be breaking flat base entry zebra be attempt reclaim day line downside recent breakout grubhub grub essent group esnt decline food delivery service remain entry essent be trading right own flat base buy point related nvidia disney china stock lead monster week investing action plandisney base monster zone ahead earning investing action planchip stock watch semiconductor industry newsdow jone industrial average dow stock news stock news quote facebook amazon netflix google
156,JNJ,stock open tight loss tuesday biggest tech name majority dow industrial open red dow jone industrial average dip nasdaq composite sag start trade apple aapl fang stock open lower amazon com amzn lead decline third dow industrial name open lower merck mrk johnson johnson jnj hardest loss ibm ibm top index early gain biotech drug maker fibrogen fgen punch report second quarter result positive result clinical phase trial pamrevlumab treatment idiopathic pulmonary fibrosis fibrogen share be now year twilio twlo jetted ahead much stronger forecast second quarter revenue earning report monday close gain score past buy point cup handle base gap move open buy range valid chipmaker inphi iphi surge start gate investor react second quarter earning revenue narrowly top analyst target third quarter revenue guidance be consensus view gain boost inphi back week move average stock try start right side month deep consolidation valeant pharmaceutical vrx vault quebec base drug maker report smaller expect decline earning revenue slip line forecast management trim slightly full year revenue guidance stock be april low extend rebound support week move average downside tenet healthcare thc tumble revenue more triple fail meet expectation company significantly lower full year earning guidance avis budget group car dive more report big second quarter earning miss late monday revenue also miss view narrower margin management carved back full year ep guidance unicredit downgrade bond rating avis hertz global htz sell hertz share trade marriott international mar open lower hotel chain turn strong second quarter performance late monday include gain revenue third quarter earning guidance be just short consensus target decline send share week line support heavy trade sell signal job opening labor turnover survey be due labor department et overseas action be mixed china benchmark rise datum show sharp decline import export july japan tokyo nikkei drop work week very flat trade europe market turn lower afternoon trade frankfurt dax slip cac paris london ftse related apple chip supplier buy point china name surge stock likely benefit apple iphone upgrade big picture china name flourish dow make stock buy watch top ipos big small cap growth stocksdisney base monster zone ahead earning investing action plan
157,JNJ,stock open mixed lower tuesday heavy slate big name earning report concern gridlock washington factor early trade dow jone industrial average slip edge lower nasdaq composite backed thin early gain slip negative trade weaken overnight republican effort overhaul affordable care act consider more strongly option simply repeal aca sort replacement legislation send dollar index month low very early trade tuesday weigh early market action goldman sachs gs jpmorgan jpm post dow heaviest open loss respectively goldman report strong earning beat smaller expect decrease second quarter revenue trading revenue fall bank say lead drop fix income trading metric have be weak banking sector report so far second quarter netflix nflx pound open gain report rise second quarter earning just analyst target revenue gain top expectation management raise third quarter sale earning guidance consensus view big number be subscriber gain vs street expectation new pay viewer move send share buy point flat base very heavy trade other netflix fang group stock fall early trade amazon com amzn take hardest hit amazon have be trading tight range buy point flat base support week move average bank america bac open lower report second quarter result johnson johnson jnj dip novartis nvs pop unite health unh shed fraction lockheed martin lmt rise early tuesday defense contractor report second quarter revenue earning comfortably analyst estimate lift full year revenue guidance consensus target gain send share new high monday buy range flat base buy point morning worst loss harley davidson hog drop sweden base ericcson eric tumble weaker forecast result june quarter earning calendar puma biotechnology pbyi pounce higher announce food drug administration have approve nerlynx breast cancer treatment expect reach market september move lift puma flat base buy point oil price jump ecuador announcement abandon organization petroleum export country production cap agreement month group compliance agreement begin june accord bloomberg west texas intermediate trade cent barrel price import export slip june labor department estimate narrower dip import price export price dive national association home builder release july builder sentiment survey et long term treasury income capital flow number be due treasury department et japan tokyo market reopen day holiday nikkei slide dollar weaken yen china market hong kong shanghai gain ground session europe market trade sharply lower afternoon session frankfurt dax cac paris london ftse related growth stock netflix nvidia big picture growth stock see plenty drug giant buy range just beat earning
158,JNJ,bellwether johnson johnson jnj second quarter report bode well biotech sector analyst say tuesday dow component top profit expectation narrowly lag sale view stock market today stock climb biotech stock drop nearly group generic drugmaker inched leerink analyst geoffrey porge remain bullish biotech sector needham analyst mike matson say second quarter result point stable period medtech player boston scientific bsx medtronic mdt stryker syk zimmer biomet zbh quarter drug sale grow sequentially fall vs year earlier period porge partially blame time positive rebate adjustment eliminate year year volume price growth second quarter sale remicade decline year year rivalry biosimilar contribute just decline be lower guidance decline porge write note client ibd take cancer rare disease specialist be expect do well second half positive sentiment return biotech space visit ibd industry snapshot look outperform second quarter also expect currency headwind subside second half call acceleration pharmaceutical unit well positive trend sale outside base presume currency impact firm raise outlook adjust profit share outside drug sale grow sequentially second quarter beating view growth porge say support expectation sequential outside revenue growth company due weaken dollar second quarter say porge expect guidance increase biotechs second quarter earlier week call regeneron pharmaceutical regn easily beat june quarter sale view gilead science gild handily top profit expectation cover company not be negatively impact same prior period adjustment current imminent biosimilar competition surprise consensus remicade market dynamic be view proxy say abbvie abbv see pain sale cancer drug imbruvica grow outside say be partner abbvie imbruvica typically book imbruvica sale porge say translate abbvie imbruvica sale be miss vs consensus estimate say abbvie imbruvica be consider largest growth driver humira patent cliff continue miss consensus expectation repeat second quarter be negative stock related star align biotechs crush earning consensusthese drug giant buy range just beat earning novartis fda cancer also be boon rival
159,JNJ,stock buy range swiss drugmaker novartis nvs dow industrial component johnson johnson jnj report better expect second quarter earning early tuesday xnovartis earn share exclude various item year earlier sale fall grow generic competition cancer drug gleevec number be better analyst forecast earning share revenue exclude gleevev gilvec sale cancer drug rise exclude impact foreign exchange rate bone marrow stimulant promacta revolade pull sale advanced melanoma advanced lung cancer combination tafinlar mekinist grow consentyx be driver grow exclude impact foreign exchange rate novartis say news release drug be approve treat plaque psoriasis psoriatic arthritis inflammation spine joint broaden competition multiple sclerosis treatment include like biogen biib roche rhhby sanofi sny novartis ms drug gilenya bring exclude impact foreign exchange rate celgene celg be now work drug directly rival gilenya novartis alcon eye care unit report small sale increase novartis raise full year alcon sale target slightly hint possible spinoff division sale contact lense grow fifth consecutive quarter evercore analyst umer raffat note report stock market today novartis end day novartis clear cup handle buy point last month chase zone run johnson johnson meanwhile clear flat base entry early june stock rise finish tuesday regular session company report adjust earning share vs year earlier beating analyst view cent revenue be slightly year earlier just miss view ibd take small biotechs perform well past few week biotech rally see sector hit month high june head ibd technology page look look strong pop worldwide pharma sale decline fraction vs year period miss third straight quarter rbc analyst glenn novarro tell client note drug sale dip growth sale outside help partially offset decline meanwhile consumer medical device segment grow respectively pharma sale miss novarro estimate revenue consumer medical device unit be line expectation see full year earning share revenue analyst see earning share revenue novarro say guidance be likely take advantage favorable foreign exchange rate second half year related novartis fda cancer also be boon rivalsnovartis grab key fda panel approval experimental cancer drugnovartis face key fda panel cancer drug kite be set record high strong earning raise full year targetbank america goldman sachs earning top trading weak
160,JNJ,biotechs lead alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx outperformed pharmaceutical brother june quarter analyst say earning season near close xleerink analyst geoffrey porge estimate large cap biotechs sale top wall street expectation average most impressive beat come alexion gilead vertex biogen biib alexion sale top consensus gilead hepatitis unit fall again quarter total revenue top vertex report sale beating biogen top sale comparison pharma company result be more tepid eli lilly lly merck mrk deliver significant revenue surprise otherwise fairly tepid result consist modest beat line result modest miss porge say note client last week dow component merck lilly top consensus respectively bristol myer squibb bmy glaxosmithkline gsk roche rhhby deliver modest beat novartis nvs astrazeneca azn nordisk nvo be line sanofi sny pfizer pfe johnson johnson jnj miss earning side performance be even more robust biotech porge say large cap biotechs beat average relative consensus bigger pharmas deliver earning top consensus average revenue growth vs year earlier quarter be biotechs drug firm average porge say board company report improve patient access drug well positive demand inventory currency effect ibd take biotech fever look chilly late july sector overcome challenge outlined ibd industry theme report
161,JNJ,quarter rare disease player biotech side do particularly well brad loncar chief executive loncar investment tell investor business daily biogen vertex sarepta therapeutic srpt positively surprised market spinraza treatment spinal muscular atrophy biogen ionis pharmaceutical ion nearly triple consensus model drug bring obliterate view analyst say sarepta absolutely crushed analyst expectation rise month high july key drug exondys treat duchenne muscular dystrophy bring more analyst have expect sarepta also cut loss expectation half think category drug investor have be expect payer pushback loncar say so far hasn show be ever group company be go boom more rare disease company sentiment have soured biotech sector hit month high late july loncar cite political uncertainty note lion share biotechs drugmaker revenue earn product beat expectation raise guidance fact re not trading indicate investor have already reset expectation year so maybe just hasn be quite impressive context say have big run come earning season play factor well uncertainty tax reform be keep most major player look make big deal porge say trump administration have yet offer further detail plan cut corporate tax rate make corporate inversion less desirable gilead have be gun buy something wake slow hepatitis sale didn comment second quarter call dow pfizer say putt deal pause await more tax situation washington loncar note pfizer call be really crystalize theme broader medtech sector have previously say big deal biotech really send stock higher look unlikely term mega deal be pause happen happen say pretty disappointing shouldn really affect call bolt deal mega deal seem be hold thing related gilead hepatitis franchise topple again share be beatwill pfizer cancer drug help grow merger biotech just blow past buy point sale beatastrazeneca beat stock dife drug failure more reportvertex sing late crush sale profit expectation
162,JNJ,talk hot brian demain be lead manager janus henderson enterprise janex be ibd best mutual fund award winner so be fund twin aspen enterprise jaagx also be skipper portfolio win best fund honor outperform time period end dec trail year do so not just category diversify equity mutual fund growth mutual fund midcap mutual fund put small group gem mere diversify stock mutual fund asset least prevailed winner time span demain cody wheaton run fund little turnover just now accord morningstar inc portfolio holding be crown castle cci microchip technology mchp global payment gpn sensata technology st td ameritrade amtd be form base pattern buy range enterprise be open investor already own share also open old new shareholder plan already offer fund well old new investor client brokerage offer identical strategy separately manage account twin sister aspen enterprise be buy old new investor insurance company midcap fund janus henderson be still open new investor be mid cap value jmivx demain be year old talk investment approach several key stock holding recent interview ibd ibd brian summarize investment approach demain first look call sustainable growth want company be growth company today be year now not be fastest grower grow long term second re look company sustainably high return invest capital great company grow not earn high return invest capital not increase shareholder value so try understand company competitive advantage drive long term return invest capital third care quality company management team management team focus right area be good leader find company meet criterium buy attractive valuation hold long term outperform peer ibd fund performance be consistent show be ibd best mutual fund award winner be key outperformance market market demain ve generally be able keep market outperform market try have predict beta measurement volatility relative market benchmark russell midcap growth index benchmark so have less absolute risk benchmark higher don want only outperform market want shine do market well ibd do midcaps demain re not mature large cap so have real growth opportunity ahead business model be more establish small cap many have withstand competitive challenge small cap not have tend be less volatile small cap ibd ve get asset technology industrial health care sector do expect find so many opportunity space demain tech health care be power innovation tech ve be overweight hardware semiconductor mobile internet be drive semiconductor growth re see lot innovation software push life health own biotechs pharmaceutical life science tool diagnostic company age baby boomer emerge middle class globally be drive innovation drug development diagnostic ibd ve note corporate tax cut infrastructure spending deregulation not occur fast many investor have hope have hedge bet area demain take tax cut sensata be netherlands domicile company make sensor aircraft car other product do business pay low tax rate be domicile so not benefit lower rate also own td ameritrade be brokerage pay full tax rate so reform benefit policy change cut way ameritrade also benefit rise interest rate sweep client cash balance td bank earn more money spread rate rise own crown castle reit own wireless cell tower have high level borrow so be hurt high interest rate ibd lam research lrcx be semiconductor play describe please demain be semiconductor capital equipment manufacturer last few year ve go everything be etch plane microchip effectively stack layer chip so lot growth have go etching deposition player lam addition demand memory market be robust drive uptake solid state drife re go old disk drife solid state flash drive drife demand lot chip be good lam valuation stock trade time forward earning back cash be close time market multiple be north time several high quality semiconductor company be trading time ibd celgene celg be best know revlimid blood cancer treatment do other product demain re right revlimid be workhorse continue grow due longer treatment duration find new patient do do revlimid go patent outlook other celgene product pomalyst otezla abraxane be constructive re excited pipeline new treatment also ve do business development deal cash revlimid build emerge franchise immunology inflammation immunology thing make patent cliff revlimid manageable event ibd take celgene be rank stock ibd medical biom biotech industry group be rank very strong group celgene earn top dog status thank such trait best possible composite rating ibd annual pretax margin be highest be least year compare other technical fundamental strength rival ibd easy use stock checkup tool ibd microchip technology earning share growth have accelerate quarters row do thesis revolve fact chip be used variety product demain majority revenue be microcontroller be very simple computer go sort device airplane microwave oven kid toy have great growth dynamic be function growth internet thing company sustainable growth business have very fragmented customer base re not just selling ton chip customer apple aapl re selling thousand end market competitive advantage good management team company be lead steve sanghi have high regard value creation company recently acquire atmel be large microcontroller competitor have good asset be poorly manage sanghi have improve operate margin drive strong earning growth valuation be not demand time forward earning ibd do ss technology ssnc illustrate investment approach demain be example sustainable growth competitive advantage strong management ss provide back office service financial company asset management mature more company want focus core competency rather run back office house look outsource once be embed customer other department customer outsource well ss be run bill stone have proven record value creation valuation be reasonable ibd global payment earning share growth have sped demain think visa mastercard electronic payment highway global payment be offramp have relationship merchant credit card terminal run restaurant example global give software not only accept credit card also help run restaurant global have benefit consolidation ibd make heico heia design repair part aircraft engine attractive demain only certain approve supplier sell part airline plane be service year need servicing only relatively small number company have part manufacturing approval pma federal aviation administration european regulatory body faa have limit resource only approve so many part year heico have best position pma market earn healthy margin also mendelson family own large percentage company most liquid net worth so care lot create shareholder value so partner ibd drive share price uptrend contact lens developer cooper coo demain sustainable growth contact lens be grow category contact get more comfortable also benefit international growth be only player bausch lomb johnson johnson jnj alcon cooper once consumer pick usually stick win change small price difference ibd be index operator msci attractive demain way think be benefit growth etfs active manager janus henderson pay fix fee access benchmark operator msci fee dollar move active passive fund dollar become more profitable once be standard index be hard user change ibd way plan reopen enterprise fund investor demain be manage include money aspen enterprise separately manage account used enterprise strategy make larger midcap strategy first priority be work behalf exist client think be close be best interest ve do related winning mutual fund focus lead stock marketaxess step millennial want become rich retiree
163,JNJ,dow jone industrial average continue hit high nasdaq take breather xthat help new buy opportunity take shape etfs big weighting paypal pypl apple aapl be poise buy point first trust equity opportunity fpx be pull back day move average mark record high last week gain early july bounce support line peak fund track ipox index be market cap weight index biggest most liquid initial public offering index set cap weighting constituent be reconstitute quarterly fpx turn april have gather asset biggest sector weighting aug be technology health care consumer defensive top holding include drugmaker abbvie abbv kraft heinz khc paypal pypl paypal have rally year abbvie have advanced kraft heinz be slightly negative top holding account nearly asset fund outperformed vs gain aug accord morningstar inc lag benchmark index past year have outpaced year basis fpx have expense ratio ishare edge msci quality factor qual gain june past buy point june peak be testing support day line second time solid rebound line set buy opportunity fund marked fourth anniversary last month trail year gain year average annual return be just ahead benchmark index advance qual featured column june count top holding monday altrium group mo johnson johnson jnj microsoft msft apple aapl apple leap tuesday heel quarterly earning report qual carry expense ratio wednesday pick remain slightly respective buy point ishare edge min vol usa usmv be just shy flat base entry flexshare quality dividend index fund qdf be less away flat base buy point key index fund be mixed stock market today spdr dow jone industrial average dium spdr spy powershare qqq trust qqq give respectively health care utility retail etfs hold modest gain spdr health care xlv advanced top buy range flat base entry fund be draw close day line set buy opportunity solid bounce oil play be lower west texas intermediate price dip barrel unite state oil fund uso powershare db oil fund dbo gain nearly vaneck vector oil service oih be spdr oil gas exploration production xop sank nearly track fifth straight slide energy bank gold miner also lag spdr gold trust gld ishare gold trust iau be slightly higher foreign etfs ishare msci south korea capped ewy gap fall kospi composite index tumble move send ewy share test day line find support rebound line set potential buy opportunity related dow hold oil reverse higher big dividend play breakoutdow keep streak alive foreign play breaking apple watch big etfs potential breakoutsnap first trust etf be first pick red hot snap ipo
164,JNJ,large cap fund be set potential breakout stock market remain time high xfirst be ishare edge msci min vol usa usmv be just shy flat base buy point briefly clear prior flat base entry late april pull back buy point bounce day move average en route gain fund track msci usa minimum volatility index comprise domestic stock tend be less volatile broader equity market carry expense ratio usmv biggest sector weighting be health care july just asset information technology follow nearly consumer staple financial health care name account half top becton dickinson bdx johnson johnson jnj stryker syk unitedhealth group unh intuitive surgical isrg fund top name make less total asset usmv also help limit volatility keep hold less have relatively low annual turnover year date gain july be line accord morningstar inc etf outpaced benchmark index past year vs slightly underperform past year vs have dividend yield flexshare quality dividend index fund qdf track northern trust quality dividend index be buy point flat base fund launch december target stock sustainable yield lead profitable company have ability keep pay dividend top holding july include procter gamble pg boee ba pfizer pfe apple aapl merck mrk top stock account asset annual turnover be qdf have lag year past year annualize yield be well benchmark index average yield expense ratio be tuesday be good day many foreign etfs include international equity fund dwm ishare msci hong kong ewh dwm be still buy range entry ewh flat base buy point stock market pare early gain wednesday leave only dow jone industrial average positive territory earning fuel jump apple aapl spdr dow jone industrial average dium hold only gain spdr spy slip powershare qqq trust qqq edge lower stock sell board telecom retail real estate lead decline spdr telecom xtl fall slip day line first time week vaneck vector oil service oih reversed advance west texas intermediate crude price early reversed higher barrel few sector buck decline industrial select sector spdr xli rise utility select sector spdr xlu climb vaneck vector gold miner gdx be vaneck vector junior gold miner gdxj give powershare db gold fund dgl spdr gold trust gld ishare gold trust iau hold small gain related dow keep streak alive foreign play breaking dow hit new high techs give gain apple focusdow mark record high check solid play buy pointsfind happen stock market today
165,JNJ,here weekly investing action plan need know investor come day xearning season really take come week report netflix nflx microsoft msft general electric ge lockheed martin lmt johnson johnson jnj remain bank giant also come well
166,JNJ,eli lilly lly be gouge share johnson johnson jnj nordisk nvo class diabetes drug analyst say monday suggest lilly second quarter metric just meet consensus view prescription trend show lilly sale earning be roughly line wall street view leerink analyst seamus fernandez write note client consensus expect lilly report adjust earning share sale fernandez up price target lilly stock note diabetes drug taltz trulicity be do well meanwhile lilly jardiance trulicity be displacing drug dow nordisk sglt glp class diabetes drug respectively prescription sglt diabetes drug grow year year sequentially second quarter fernandez say same time prescription glp class diabetes drug grow vs year earlier period quarter quarter ibd take biotech space exelixis stock have pop year kidney cancer treatment head new america closer look catalyst be upcoming stock sglt space lilly jardiance be take share invokana study show invokana reduce cardiovascular event diabetes patient also come greater risk amputation study validate class cardiovascular benefit fernandez say also provide clear tailwind lilly jardiance see accelerate growth year year sequential growth compare year year sequential growth expect jardiance overtake invokana sglt class risk amputation wasn see separate jardiance trial lilly meanwhile trulicity be nipping heel nordisk victoza latter market share vs trulicity fernandez say expect trulicity overtake victoza leader glp drug space time frame fernandez expect nordisk overall diabetes business decline competition intensify insulin arena raise estimate nordisk semaglutide competitor glp space have market perform rating nordisk stock outperform rating lilly sanofi sny stock lilly stock end monday flat nordisk stock inched higher stock market today sanofi stock fall related dow host diabetes study lilly benefit mostnovo nordisk diabetes lead unscathed follow astrazeneca triallilly grab diabetes share dow amputation wo
167,JNJ,arena pharmaceutical arna amicus therapeutic fold lead biotech pack tuesday strong phase drug datum favorable regulatory decision respectively send stock nearly year high arena pop stock market today dip hour trading announce secondary stock offer arena stock break cup base buy point tuesday share touch high last see august amicus share leap amicus rocket month high meanwhile ibd company biotech industry group rise tuesday other riser include enanta pharmaceutical enta assembly bioscience asmb respective early tuesday arena say drug ralinepag improve blood flow phase study patient high blood pressure lung condition know pulmonary arterial hypertension drug also improve minute walking distance ralinepag improve median pulmonary vascular resistance pressure blood flow lung median vs placebo arena say release drug also help patient improve baseline minute walking distance ibd take other biotech news gilead science gild change fortune acquisition analyst say number cancer focuse biotechs drugmaker be auction block viral company really stand needham analyst say head ibd technology page closer look firm be smart buy leerink analyst joseph schwartz note ralinepag improvement pulmonary vascular resistance baseline be stronger johnson johnson jnj rival drug uptravi similar study vs respectively uptravi be approve dow stock effort uptravi give insight await ralinepag phase needham analyst alan carr say note client company actelion unit run patient trial number goal prior approval also tuesday amicus announce food drug administration not require run phase trial drug migalastat prior regulatory submission drug be already approve europe have be submit japan migalastat be treatment patient fabry disease genetic disorder cause specific form fat build cell cause wide variety systemic issue now amicus plan file approval fourth quarter submission package include datum cull complete clinical trial additional datum regulatory development outside new administration push quicker approval deadly disease have prompt fda decision carr say irrespective underlie development investor welcome positive development migalastat say submission be anticipate fourth quarter potentially lead second half related biotech hemophilia do drug biogen spinoff bioverativ have blockbuster hand eli lilly be gouge diabetes drug share dow other
168,JNJ,stock index be mixed midday action monday volume slow second session row nasdaq inched less fall blue chip dow jone industrial average drop volume stock market today fall major exchange volume also fall friday federal reserve meet tuesday wednesday street isn expect rate hike cme group fedwatch tool put odd rate hike ibd list best stock fundamental technical china base stock be advance internet play yy yy momo momo jump respectively volume be strong company expect strong growth year other china stock ibd advance include internet stock sina sina soft trade online game stock netease nte average volume education stock tal education tal slow turnover blue chip put dent dow jone industrial average johnson johnson jnj sank fast trade general electric ge retreat heavy volume tuesday johnson johnson top street consensus view earning fall short revenue guidance be bullish johnson johnson rise result then pull back general electric loss follow gap friday weak result economic news flash composite purchasing manager index july wheel top analyst view pmi survey manufacturing service sector company exist home sale june miss street consensus estimate figure come vs estimate homebuilder didn react much ishare home construction etf itb slip related build stock have hot little biotech stock break
169,JNJ,chinese internet top rate medical play show strength dull show major index late afternoon trading monday meanwhile nasdaq composite gain more upside final half hour trading rise apple aapl look poise post sixth straight session north side day move average action apple be critical not only stock greater market give apple heft iphone ipad giant have market cap recent action represent opportunity buy share stock stage second follow entry point breaking bottom base pattern jan first follow entry come late march apple surpass week tight pattern justify addition small number share already profitable core position stock entry come add cent handle high cup handle base form oct jan year jan apple have gain much trigger key ibd rule sell least partial position share gain hit apple featured ibd stock market today column last week retook day line gain help nasdaq composite edge more higher nasdaq rise tack new time high be fractionally be try avoid third straight decline give trifling time frame dow jone industrial slip less hurt loss point more least component include home depot hd fall further day move average sell signal recent new holder johnson johnson jnj hold day line cup handle buy point goldman sachs gs build new potential saucer pattern still significantly october past russell eke small gain nearly volume be run touch lower nasdaq sharply slower nyse vs same time prior session chinese consumer commerce play continue surge even hong kong mainland china equity market be close holiday baidu bidu past buy point be gain more momentum stock rally nearly volume be run more higher normal read more chinese search engine chart action other market leader ibd new high feature permissible buy zone baidu go past handle entry baozun bzun have emerge runaway small cap winner monday share gap more fast turnover be now more clear long cup handle base notice daily chart stock see volume zoom day average day time volume trade average share day baozun expertise lie help multinational brand such nike nke succeed marketing campaign china earning jump cent share jump sale ibd take baozun be featured earlier year new america new america index see market index table page latest ibd weekly print edition be jan pummeling major index see other company have qualify proprietary ibd screen hot growth company celgene celg abiom abmd bioverativ bivv be also act well abiom heart pump innovator be close breaking narrow flat base pattern stock ibd be tie medical sector abiom nearly be expect grow full year earning share fy end march next year fy other financial market wti crude oil future rise barrel dollar have show weakness recent week dollar be currently worth yen appear be testing buy support level last see mid june yield benchmark year treasury bond dip basis point begin year related new high analysis biotech play be extend new buy point emerge bottom base part help savvy investor make moneythe bottom base part ii apple form
170,JNJ,be salad day biotech sector number industry leader be hit new high group whole be top game term stock performance xstock inflow hit last week have be number clinical trial success new industry friendly food drug administration regime be place result investor business daily company biotech industry group have claw way group track ibd sixth just last week share look likely close month high stock market today slew earning next week just everything be go right biotech lately have be go right brad loncar chief executive loncar investment tell ibd friday onslaught biotech earning next week really give investor fodder say thing miss say loncar merger acquisition last piece fit puzzle then biotech sector really be cook gas say gilead science gild be likely linchpin loncar call gilead poster child large biotech need do deal gilead multibillion dollar hepatitis drug franchise topple first time now gilead say interested deal cancer space analyst have key vertex pharmaceutical vrtx smart acquisition loncar see gilead more likely buy early cancer asset something develop commercialize rather putt money work buy develop revenue stream vertex be already hugely successful biotech own right say earlier year vertex deliver best news year space point have exceptional result phase trial look triple pill treat cystic fibrosis stock gap nearly wednesday ibd take rare disease cancer play have be front center biotech sector late cut edge firm keep rally go head industry snapshot deeper dive multibillion dollar stock loncar say company vertex go something everybody stock market notice gilead be set report second quarter earning wednesday be sandwich slew strong contender biotech space include celgene celg amgen amgn biogen biib alexion pharmaceutical alxn biotech celgene be slate report second quarter earning open thursday stock have ibd composite rating lead peer be sit high last see july leerink analyst geoffrey porge say celgene alexion be bellwether group time same way dow johnson johnson jnj be often see proxy pharmaceutical group call celgene beat raise alexion rise top low view alexion be slate thursday tuesday amgen overtake month high jump record high second quarter earning report prove strong share break cup handle july buy point still remain buy zone trio help catapult sector analyst say meanwhile pharma side investor key astrazeneca azn early thursday recent week rumor have emerge chief executive pascal soriot jump ship teva pharmaceutical teva loncar note timing rumor be bad astrazeneca astrazeneca be set day now report result immuno oncology combination trial lung cancer lung cancer treatment be huge commercial opportunity astrazeneca be take player merck mrk bristol myer squibb bmy regardless rumor controversy do think not overstatement say pascal soriot job be line trial be make break astrazeneca say study be most important thing astrazeneca last year biotech stock be year still room run cfra research analyst jeffrey loo tell investor business daily valuation hit historic lows presidential election be still overall health care sector relative historical valuation biotech sector be still attractively price say late june sector get massive push president donald trump release draft proposal drug pricing initiative didn include much really tug drug price loo say didn credit entire gain proposal certainly help loo say clinical trial term fda approval strong launch trend have also help prod sector year include cystic fibrosis news vertex gene therapy novartis nvs duchenne muscular dystrophy drug sarepta therapeutic srpt latter development loncar say sarepta second quarter sale beat exondys bode well broader sector sarepta also raise guidance year most analyst have call conservative everybody be watch sign drug launch be go payor be push back thing say fact launch exondys be go well be good sign not just sarepta biotech company related biotechs find strength number treat multiple sclerosistoo late catch biotech rally trump fear subside biotech rally get second wind small cap near break outwhy biotech rally still tack upside
171,JNJ,nasdaq composite index hit new high techs continue reassert market leadership netflix nflx amazon com amzn facebook fb microsoft msft hit record high netflix soar subscriber gain amazon sell kenmore appliance sear shld send latter sharply higher hit several retailer include dow home depot hd dow jone industrial average also be hit general electric bank blue chip visa american express axp continue good news payment stock nasdaq composite rise hit record high week rise straight session thursday netflix other fang stock such facebook amazon contribute index climb also hit fresh high week dow industrial fall weigh goldman sachs gs general electric ge home depot internet television network netflix add net new subscriber june quarter vs wall street consensus estimate also guide higher current quarter forecast net new subscriber top consensus view bull point strong subscriber growth bear voiced caution ballooning video content obligation include original tv series stranger thing glow netflix end subscriber worldwide include foreign market netflix international stream subscriber top first time netflix sky-rocket record high week sear sell alexa enabled kenmore appliance amazon send share soar thursday give most gain friday whirlpool whr major seller appliance home depot lowe low best buy bby be hit home improvement chain home depot lowe have be see amazon proof least amazon resistant best buy have bounce back recent year amazon initial onslaught be hurt earlier month news amazon be create geek squad rival amazon appear be get more government attention size scope grow ftc probe antitrust rumbling software giant microsoft earn cent exclude item june fiscal fourth quarter year year well view cent revenue rise forecast microsoft credit demand cloud compute service azure office well acquisition linkedin dow component give cautious guidance current quarter share dip friday remain buy range related microsoft crush earning estimate stock dip outlookgeneral electric fall friday say full year ep be trend low end target cite oil gas weakness ge report smaller earning revenue decline analyst cite weakness headline figure fellow industrial conglomerate honeywell international hon also beat top bottom line guide full year estimate slightly higher honeywell share rise friday retake buy point related general electric stock dife earning outlookamerican express beat top bottom line provision loss jump due loan portfolio growth rise rate lend off visa earning also top strong cross border travel help stronger dollar global payment volume drive result accord mizuho analyst thomas company also hike full year revenue growth outlook view visa american express dow component rise respectively still buy range td ameritrade amtd stock break long consolidation july online broker beat top bottom line even industry trading fee stock etfs have plunge year charle schwab schw day match view share fall buy point have clear late june trade etfc share gap make new week high friday company score overall beat thursday share be now buy range chip gear maker asml asml wireless communication chipmaker qualcomm qcom be first major semiconductor industry player report june quarter earning year asml rise record high post better expect sale earning second quarter qualcomm disappoint current quarter profit outlook come short view even beat estimate fiscal apple aapl chip supplier skywork swks report better expect fiscal sale earning guide higher current period drug giant novartis nvs johnson johnson jnj report better expect earning tuesday dow component report adjust income share top view cent sale be light novartis share exclude various item sale top analyst view drug stock rise week be still buy range friday close goldman sachs fix income trade revenue plunge second straight quarter trading heavy bank say misread market weaker trading net interest income also hurt bank america bac fed rate hike have help bank say expect net interest income rise morgan stanley ms report trading revenue fall less so rival jpmorgan jpm citigroup have also signale caution slow loan growth longer term bond yield indicate flagging confidence chance long term economic gain morgan stanley clear buy point goldman undercut day day move average check point software chkp report better expect second quarter earning thursday give weak guidance current check point tumble day fall day move average check point wednesday briefly top buy point close trigger so do other cybersecurity stock day stock proofpoint pfpt retreat modestly check point warning unite airline ual tuesday offer disappointing third quarter unit revenue forecast airline competition pick head further summer send share plunge delta air line dal american airline aal have remain bullish key metric fall significantly well unite say take least several month plan expand service different part rollout cheaper basic economy fare pay health insurer earning share rise top forecast revenue grow roughly line be smallest gain quarters unitedhealth unh have exit obamacare exchange big player medicare medicaid coverage optum service unit see revenue rise unitedhealth now see adjust full year profit share analyst have expect result unitedhealth rise republican health care struggle also influence share insurer hospital related unitedhealth raise full year target earning jump top rail company top quarterly forecast csx csx say crude oil train shipment have fall hint return shareholder be more cautious union pacific unp predict nearly flat volume coal shipment stabilize still see second half volume improve first half kansa city southern ksu benefit auto production energy market reform mexico csx fall week union pacific lose kansa city southern edge vertex pharmaceutical vrtx stock rocket time high wednesday strong phase datum trial cystic fibrosis treatment triple drug combo aim treat genetic disease underlie cause intuitive surgical isrg easily top analyst second quarter view thursday adjust income share sale share maker robot surgical system fall friday afternoon chipotle grill cmg share tumble year low report fast casual chain temporarily close restaurant virginia follow report diner have get sick once trendy fast casual burrito eatery have be try mend reputation sale food bear illness scare begin harley davidson hog cut motorcycle shipment outlook unit dealer year drop prior guidance flat modest decline iconic motorcycle brand report ep decline be better estimate sale slide retail sale new motorcycle tumble weak industry condition share fall
172,JNJ,nasdaq rebound early session lows edge slightly higher late afternoon trading thursday pace gain software medical device biotech stock meanwhile apple aapl continue fresh base process set potential new apple share be fractionally essentially keep almost gain day winning streak stock be also just time high correction current consolidation resemble shallow cup base flat base dow jone industrial average be virtually flat sell dow jone component home depot hd other component rise point more include nike nke unitedhealth unh johnson johnson jnj home depot sank day move average heavy trading june trigger important sell signal recent buyer small cap have slight edge large cap equity russell gain more follow rebound wednesday time high ibd industry group hospital diversify medical biotech computer hardware rally more share auto part chain department store clothing maker diversify utility also lead upside piece positive technical news market nasdaq nyse winning issue lead lose issue margin stock note latest big picture column new high continue top combine basis main exchange symbolize heavy institutional demand equity statistic also point potential more breakout back apple iphone ipad maker be not give much ground likely due belief institutional investor company continue deliver sound turnaround top bottom line improvement combine stock tight action follow impressive run jan past cup handle buy point be reason further gain apple help drive equity higher street see earning just end fiscal third quarter rise share then repeating gain share earning have grow prior quarters end quarter profit slump sale estimate be follow similar path revenue see rise revenue see ibd stock checkup apple score composite rating scale not great decent enough stock be stage turnaround same telecom consumer product industry group apple be just company show relative price strength rating higher meaning have do better company ibd database term month price performance however other stock voxx international voxx china wireless cntf trade share jan apple start move past buy point excellent week cup handle base base be part initial stage bottom base pattern bullish development base high low apple correct merely best cup basis tend show mild decline range upwards notice too stock find buy support day move average build bottom base ibd chart marketsmith chart day move average be draw black track average close price stock past day signify long term price tend stock stock break ideally be trading day move average concern apple be accumulation distribution rating be currently negative scale preferable see proprietary rating higher stock break apple have yet break current new base watch see rating improve big price gain heavy volume past week tend trigger higher accumulation distribution rating well day heavy volume grow more week old recent clue accumulation mutual fund hedge fund pension insurer bank come june stock gain volume bulge average june volume day average related way equity go here first examine day day bottom base pattern help investor make money sell break day move average be time lock sell ii hold be test day line
173,JNJ,celgene celg bluebird bio blue stock sustain downgrade friday rival kite pharma kite juno therapeutic juno look likely chip away lead immuno oncology drug duo be year ahead drug call bb part class treatment aim reprogram immune system fight cancer used be know car therapy drug do target antigen call bcma landscape bcma car drug be evolve btig analyst dane leone write note client leone downgrade celgene bluebird stock neutral buy think bluebird have good lead competition be smart quick start second generation effort bb begin phase study second half say say competitive effort be ramp kite be begin bcma car therapy human third quarter juno begin work february bone marrow cancer drug dow component johnson johnson jnj genmab start bcma effort update be expect soon novartis nvs related company be outperform stock relative visit ibd datum story formula correctly identify stock leader bluebird case leone be more optimistic most drug call lentiglobin treat blood disorder expect drug generate combine disorder still oncology shift be divisive investor competitiveness cell base therapy oncology be much more intense area rare disease say early success bb be supportive broader effort larger market better defined patient population celgene leone cut expectation crohn disease drug mongersen vs earlier view consensus model also expect celgene multiple sclerosis drug know ozanimod penetrate less market cut view vs earlier expectation still top broader wall street model think take longer expect ozanimod differentiate vs rest class multiple sclerosis specifically siponimod say latter be drug novartis close bell stock market today celgene lose dip bluebird fall related cure cancer look small biotech be defy today sectorwide doldrumsbiotech hit pause day rally regeneron bluebird topple
174,JNJ,here investing action plan tuesday need know investor come day report season get fast furious result lockheed martin lmt goldman sachs gs bank america bac unitedhealth unh johnson johnson jnj unite airline ual charle schwab schw other lockheed martin
175,JNJ,today ll feature large cap etfs set new buy opportunity wednesday rebound day move average first trust large cap core alphadex fex track nasdaq alphadex large cap core index have attract year old fund biggest sector weighting be consumer cyclical financial service technology health care industrial xtop holding skew tech chip stock make top july nvidia nvda apply material amat lam research lrcx have be big performer year date gain higher comparison be nasdaq composite thursday close fex have slightly outpaced july accord morningstar inc gain vs advance benchmark index include dividend reinvest year average annual return trail etf year year return be line fund first begin rebound day average last week be support line well potential buy zone have expense ratio goldman sachs activebeta large cap equity gslc close day line thursday fund mark second anniversary september have gather nearly asset gslc aim invest stock meet performance metric good value strong momentum high quality low volatility count top holding apple aapl microsoft msft amazon com amzn johnson johnson jnj technology account biggest sector weighting asset health care be next follow roughly financial service consumer cyclical consumer defensive etf make solid bounce day line wednesday be support line gslc have return year line carry expense ratio wednesday pick powershare low volatility splv be still seek support day line schwab large cap schx remain buy range rebound day related big cap play set buy opportunity market rallieschance own top tech stock much much more
176,JNJ,many diversify etfs rise wednesday stock rally fed chair janet yellen dovish comment congress here be large cap play stage rebound day move average line set buy opportunity powershare low volatility splv launch have attract asset ranking company quarter volatility fund invest least volatile stock splv have slightly underperform year july return vs benchmark index gain accord morningstar inc year average annual return outpace year return lag etf bounce back day line wednesday set stage potential investor ideal buy point be close support line possible share rise nearly month last pullback day line etf biggest sector weighting july be industrial financial service utility consumer defensive top name include mmm johnson johnson jnj waste management wm splv carry expense ratio schwab large cap schx also rebound day line fund track dow jone large cap total stock market index turn november technology account biggest sector weighting july nearly apple aapl microsoft msft amazon amzn facebook fb top holding financial service follow health care consumer cyclical industrial schx performance have be pretty closely align ytd gain vs benchmark index be year be year be etf expense ratio be wednesday pick also featured large cap etfs score gap gain vanguard large cap vv spdr etf trust spy rise nearly remain buy range day line go back june pick kraneshare csi china internet kweb rise more week rebound week line make more pullback line be later bounce kraneshare july announce china international capital corp agree take stake krane fund advisor related chance own top tech stock much much more here be big cap raise dividend year be beating
177,JNJ,doesn appreciate company not only pay dividend have history consistently raise payout year be type stock tuesday etf pick aim invest xvanguard dividend appreciation vig track nasdaq dividend achiever select index count holding highly profitable company have increase dividend least year row top holding include microsoft msft pepsico pep johnson johnson jnj mmm accord morningstar inc microsoft didn start pay dividend have boost payout year other company be member dividend aristocrat company have increase dividend payout least straight year dividend stock be often thought slow gainer have outpaced year date return microsoft be july pepsico have rally vig be testing day move average line set buy opportunity solid rebound offer annualize yield nearly slightly ahead average payout fund have year average annual return line expense ratio be proshare dividend aristocrat nobl be show similar action vig too seek support day line name imply fund track dividend aristocrat index johnson johnson be top name other big ytd winner top include mcdonald mcd abbott laboratory nobl carry expense ratio pay yield fund launch october have return nearly year july accord morningstar lag gain nobl have year average annual return vs go back june pick spdr growth spyg ishare russell iwf be still trading respective day line solid bounce still put play related income play buy point own big dividend stockmarket sell tough offer opportunity
178,JNJ,xtenet healthcare thc other hospital lead broad advance health care stock thursday senate republican unveil own version trumpcare short takeaway courtesy mizuho analyst sheryl skolnick be senate bill be lot less short term lot more long term comparison house version particular medicaid spending suffer smaller hit term face even bigger long term cut hospital group hca healthcare hca rise tenet healthcare jump universal health service uhs gain stock performance have even take management surprise politico publish letter tenet send employee ask rally opposition trumpcare investor have good reason focus more intermediate term always possible big year cut be interrupt delay democrat make comeback example other hand sharp eventual spending cut relative obamacare threaten support moderate gop senator nbc news be report gop senator plan voice opposition new legislation enough deny passage manage care company also be solidly higher thursday centene cnc molina moh big player obamacare exchange medicaid expansion be better performer centene climb molina anthem antm biggest obamacare exchange insurer rise anthem say wednesday pull obamacare marketplace indiana wisconsin centene be rare company make profit exchange medicaid be big profit driver industry include unitedhealth group unh dow jone industrial average component insurer stand benefit gop plan tax health insurance plan unitedhealth rise record high aetna aet gain humana hum advanced skolnick message investor buy unh hca prospect more modest health spending cut fear assume trumpcare even pass also lift share drugmaker biotechs dow component merck mrk rise pfizer pfe johnson johnson jnj notch record high johnson johnson also stand benefit repeal obamacare tax medical device merck have be rally good news immuno oncology treatment keytruda crossed aggressive entry near conventional buy point
179,JNJ,xmajor stock index show modest gain afternoon trading thursday wall street digest strong earning oracle orcl health care stock outperformed gop release new version obamacare repeal bill stock market today oracle orcl gap flat base entry rise strong earning be catalyst buy stock gap buy point important buy close open price possible oracle open share be recently trading nasdaq composite lead way rally dow jone industrial average picked small cap outperformed russell volume nyse nasdaq be tracking slightly lower wednesday level health care related industry group outperformed few retail group lag outperformer dow include unitedhealth unh johnson johnson jnj pfizer pfe merck mrk meanwhile china stock be pressured chinese regulator ask weibo wb stop audio video stream service share weibo lose be session lows chinese government have be step effort stop political speech social medium site sina sina alibaba baba have ownership stake weibo share sina be well session lows still fall alibaba ease american airline aal picked be well session high news qatar airline be consider stake company american be still buy range handle entry tesla tsla gain time high company reportedly reach agreement city shanghai explore build production facility related weibo ibd chinese internet stock be selling offunitedhealth hca merck rally senate trumpcare bill pare term cutstesla get closer big manufacturing expansion china
180,JNJ,johnson johnson jnj diabetes drug invokana cut cardiovascular event long term study eli lilly lly stand benefit most doctor steer clear medication worry increase risk amputation study dub canvas be present late monday dow stock johnson johnson say invokana reduce risk cardiovascular death nonfatal heart attack nonfatal stroke vs drug placebo additional analysis show invokana lower risk hospitalization heart failure invokana also delay progression albuminurium presence specific chemical urine indicate kidney disease rbc analyst glenn novarro say canvas study be unlikely reverse negative trajectory invokana sale first quarter invokana invokamet sale drop year year novarro forecast dip sale eli lilly other hand benefit johnson johnson study merck mrk trail analyst say lilly jardiance be sglt inhibitor work help kidney lower blood glucose level merck januvia be dpp block glucagon release trigger insulin secretion validate cardiovascular benefit boost sglt class credit suisse analyst vamil divan write similar study lilly jardiance also show benefit cardiovascular outcome jardiance also cut risk cardiovascular death mortality even canvas study lilly be poise grab chunk invokana sale food drug administration require johnson johnson physician potential amputation associate invokana invokana double risk amputation recent study expert cite leerink analyst seamus fernandez say amputation worry be biggest differentiate factor physician decision prescribe jardiance invokana show similar cardiovascular benefit diabetes patient close stock market today johnson johnson stock tick finish regular trading session lilly stock add share diabetes drugmaker merck dip end day ibd take johnson johnson stock have ibd composite rating meaning outperform more quarters stock term key growth metric more ibd rating visit ibd stock checkup meanwhile dpp class diabetes drug include merck januvia face incremental pressure credit suisse divan say time however expect enthusiastic response canvas efficacy datum drive use sglt class earlier course treatment concurrently push dpp further back say note client merck pfizer pfe dow stock be jointly work sglt inhibitor call ertugliflozin regulator approve drug december win have datum cardiovascular outcome several year pfizer take chunk sale meaning shift januvia ertugliflozin be net negative merck related lilly grab diabetes share dow amputation woesabbvie expect rival chip away biggest drug franchisedow pfizer face challenge roche lilly loom
181,JNJ,slew biotechs drugmaker take closer look epizyme epzm small cap biotech present strong datum lymphoma trial wednesday switzerland analyst say thursday finding international conference malignant lymphoma attract like gilead science gild abbvie abbv celgene celg johnson johnson jnj roche rhhby leerink analyst geoffrey porge say note client epizyme be testing drug dub tazemetostat form hodgkin lymphoma interim datum show tazemetostat have clinically meaningful benefit patient call follicular lymphoma buildup cell lymph node tumor shrink follicular lymphoma patient patient aggressive form hodgkin lymphoma specific genetic mutation tazemetostat prove safe patient population leerink porge call study proof principle expect drug accelerate approval food drug administration follicular lymphoma accelerate approval allow drug be market still clinical trial few cancer drug have response rate clinical benefit rate disease say investor debate big group patient really be long treatment duration be not be surprised see epizyme start show potential takeout candidate list epizyme be appeal abbvie celgene roche porge write roche be leader immuno oncology method treat tumor block certain interaction hide cancer cell gilead be better know virology drug include target hepatitis hiv gilead hepatitis franchise decline high cure rate now gilead have say open seek acquisition oncology incyte tesaro be also rumore takeout candidate now molecule tazemetostat have be risk expect more investor get involved stock build position ahead further datum disclosure porge say ibd take seattle genetic chief executive clay siegall say company be aim change year method treat hodgkin lymphoma head ibd technology page exclusive ceo same conference see bristol myer squibb bmy seattle genetic sgen team phase trial classical hodgkin lymphoma also robust result only epizyme stock spiked news bristol myer seattle genetic too have strong datum classical hodgkin lymphoma tumor shrink patient treat combination bristol opdivo seattle adcetris sign cancer disappear patient combo prove safe well bristol say afternoon trading stock market today epizyme stock soar more share have run past day bristol myer stock other hand dip less seattle genetic stock be flat related analyst plead gilead buy have seattle genetic adcetris grab blockbuster status trial dow merck pause cancer trial investigate keytruda tie death
182,JNJ,strong start nasdaq composite fade early tuesday day fed meeting get underway index regroup be back high afternoon trading western digital wdc tesla tsla wynn resort wynn be best percentage gainer nasdaq gain nasdaq add dow jone industrial average picked volume exchange be tracking significantly lower monday level western digital gap aegis capital initiate coverage buy rating set price target share jump nearly stock show solid action week move average key support level separately japanese medium outlet report western digital raise bid toshiba chip unit broadcom avgo be interested bidder citigroup add even cfo john gerspach warn second quarter slump trading revenue other money center jpmorgan jpm bank america bac goldman sachs gs also issue similar warning stock market today couple high profile health care name make headline dow component merck mrk gap lose news company be stopping enrollment new patient late stage study testing immunotherapy drug keytruda multiple myeloma combination other therapy news be better johnson johnson jnj company present strong datum diabetes treatment invokana share be mostly unchanged news stock have be perform well late still buy range early flat base entry sierra wireless swir rebound vengeance straight decline share jump small cap be major player nascent internet thing market everyday device be connect internet sierra wireless be top buy range buy point market uptrend pressure new buy carry add risk ibd nutrisystem ntri ichor ichr lumentum lite be top percentage gainer gain range related rival tesla see western digital seagate start buyhere be latest bank trading revenuedow host diabetes study lilly benefit most
183,JNJ,roche rhhby displace dow pfizer pfe segment lung cancer market analyst say wednesday american society clinical oncology meeting highlighted additional challenge pfizer stock market today pfizer fall roche late tuesday roche present datum head head trial drug alecensa vs pfizer xalkori xalkori be approve treat patient advanced lung cancer specific genetic defect alecensa be approve lung cancer patient progressed be intolerant xalkori class drug call alk inhibitor month follow patient treat alecensa survive median month disease progress vs month patient treat xalkori presenter call roche result remarkable outstanding declare alecensa be now optimal alk inhibitor first line set credit suisse analyst vamil divan say note client first line treatment be first defense disease lung cancer doctor have breakfast yesterday also acknowledge xalkori be relatively weak alk inhibitor be likely change practice pattern base trial write divan note pfizer be work next generation alk inhibitor help soften blow lose xalkori sale also lung cancer pfizer be develop second generation drug target specific receptor know egfr inhibitor ibd take biogen biib spinoff bioverativ bivv be near stock announce plan beef pipeline acquisition true north therapeutic head ibd stock analysis closer look bioverativ setup pfizer be still struggle vs newer therapy particularly be consider immuno oncology drug class aim block certain interaction involve protein enzyme immune system prevent immune response pfizer drug bavencio be approve treat rare aggressive skin cancer bavencio have show strong result liver cancer combine inlyta pfizer liver cancer drug help slow decline revenue inlyta divan say class breast cancer drug know cdk inhibitor be get more crowd pfizer ibrance continue dominate divan say acknowledge novartis nvs kisqali eli lilly lly abemaciclib have show strong trial result prostate cancer johnson johnson jnj zytiga put pressure xtandi similar drug pfizer acquire buy medivation related regeneron cholesterol buster get boot amgen battle tesaro crash beating astrazeneca stronger clovis astrazeneca muddy potential deal tesaro
184,JNJ,stock market close mixed thursday late wave selling erased much day work nasdaq have be close less higher wipe modest gain close fraction lower dow jone industrial average fall less medical company merck mrk johnson johnson jnj pfizer pfe unitedhealth unh be best dow component small cap perform better russell climb downward reversal certainly be not encourage volume be lower board accord preliminary datum suggest institutional investor do not sell massive quantity also negative reversal be not severe scale senate republican unveil own version legislation replace obamacare investor seem mean health care sector medical software drug wholesaler manage care several other medical sector industry group be day best perform rise healthsouth hls break base base pattern close buy point volume be average dampen otherwise bullish move share rise hologic holx break flat base rise past buy point also suffer weak volume relative strength line be new high back day company say win fda approval aptima herpes treatment bankrate rate have better volume break pattern buy point volume be average stock add downside taylor morrison home tmhc gap loss sec filing company say price offer share do not specify price also say filing average sale community month end be home month vs same period net sale order same month rise expect home closing quarter end june be related unitedhealth hca merck rally senate trumpcare bill pare term cut key stock index play buy range biotechs surge again
185,JNJ,many dividend exchange trade fund have break be verge potential schwab large cap value schv have be trading close flat base buy point current base form right top prior flat base advance share rise november fund track dow jone large cap value total stock market index be trading time high financial service account biggest chunk asset nearly june accord morningstar inc technology be next consumer defensive follow health care be fourth biggest holding market cap weight portfolio include microsoft msft johnson johnson jnj exxon mobil xom jpmorgan jpm general electric ge microsoft have outperformed year respective gain june vs advance schv launch december have underperform broader market year return vs gap narrow longer haul average annual year return etf vs benchmark index schv have dividend yield ahead average payout etf expense ratio be dividend play enter buy range monday be ishare core high dividend hdv climb past buy point gain march start prior base july fund launch march have gather nearly asset lag ytd return year average return annualize yield outperform benchmark index hdv track morningstar dividend yield focus index carry expense ratio exxon mobil johnson johnson be hdv top holding june consumer defensive stock make biggest sector weighting energy health care weigh follow communication technology respectively foreign equity etf pick featured monday column remain buy range rebound support line ishare msci unite kingdom ewu edge higher tuesday be squarely buy zone thursday bounce day move average kraneshare csi china internet kweb be top buy range rebound week line related foreign etfs set amazon alibaba grocery war big cap play see tasty gain mcdonald
186,JNJ,biotech industry always highly technical conundrum investor currently even greater challenge offer even greater opportunity usual early industry innovator amgen amgn biogen biib gilead science gild currently find big trouble accord loncar investment chief executive brad loncar largely victim own success cancer
187,JNJ,xtech heavy fund have have rough week more diversify big cap etfs have hold fine vanguard high dividend yield vym barely budge thursday nasdaq composite give respectively such etf be end session just shy flat base buy point share rise february flat base start current pattern prior november produce gain fund launch november track ftse high dividend yield index vym top holding april include microsoft msft exxon mobil xom johnson johnson jnj microsoft be biggest position fund isn particularly tech heavy consumer defensive name account largest sector weighting nearly follow technology financial service health care stock industrial make respective total asset vym have lag year june return vs benchmark index gain etf pay annualize dividend yield ahead average payout expense ratio be accord morningstar inc powershare buyback achiever pkw close fractionally lower thursday be close flat base buy point advanced respective breakout also february november year old fund track nasdaq buyback achiever index have attract asset biggest sector weighting june be industrial financial service consumer cyclical technology be next distant health care pkw top name include mcdonald mcd boee ba general electric ge mcdonald be well extend cup handle buy point clear april trading june peak world fast food chain have serve double digit profit gain past quarters vym also hold mcdonald pkw have underperform ytd nearly match benchmark index year return vs year average annual return be vs etf carry expense ratio etfs featured wednesday column have moved opposite direction vanguard mid cap value voe be flat base buy point powershare midcap low volatility portfolio xmlv be buy range just flat base entry related etf watch equity play break first etf watch pick buy range market rebound top pick etf watch offer chance buy
188,JNJ,dow jone industrial average rise modestly even big techs such undercut nasdaq federal reserve raise interest rate give surprisingly hawkish outlook weaker economic datum amazon amzn agree buy whole food wfm apple aapl confirm enter autonomous drive field video game industry giant show oil price crash continue global supply glut nasty reversal june lead techs such apple facebook fb continue push nasdaq lower partly due hawkish fed report president trump be be investigate nasdaq sank week find day support thursday dow industrial rise hit time high weakness tech component such apple microsoft msft index edge fraction loss techs energy stock grocery chain grocer tumble amazon deal buy whole food market warning gloomy news kroger kr sprout farmer market sfm treasury yield hit lows rebound somewhat amazon announce friday buy brick mortar natural food grocer deal change landscape grocery store amazon commerce retail overall news roil grocery store already reel food price deflation due wal mart wmt amazon kroger thursday issue full year profit warning vow not be beaten price kroger sprout farmer market sfm supervalu plunge week big grocery seller wal mart costco cost target tgt cvs health cvs dollar tree dltr also tumble friday related amazon be buy whole food roil federal reserve hike key interest rate wednesday expect unnerved wall street shift policy outlook more hawkish direction even core consumer price inflation hit year low ahead fed meeting market participant weren expect subsequent rate hike year fed policy committee member projection point more hike hike fed also tee plan begin unwinding financial crisis era asset purchase later year strike analyst fairly aggressive vs expectation fed stick economic model show low unemployment feed faster wage growth higher inflation even incoming datum be raise doubt model wall street related fed hike rate hawkish tone unnerve msft launch powerful xbox formerly know project scorpio unclear many unit sell holiday season give price tag meanwhile sony sne playstation debut number vr title nintendo ntdoy dominate buzz attendee goldman sachs gs see nvidia nvda benefit higher sale nintendo switch console facebook oculus wasn video game expo industry pro see virtual reality take breather year facebook demonstrated live stream capability ar filter related video game virtual reality entertainment newsceo tim cook finally confirm apple aapl be investing heavily technology self drive car year rumor unconfirmed medium report interview bloomberg decline say apple make own car just produce technology automaker cook call initiative mother ai project meanwhile general motor gm say be more triple self drive test fleet gm ceo mary barra say advanced chevrolet bolt car soon join exist lineup first gen electric vehicle be be test related apple finally confirm worst keep secretapple have make car succeed autonomous drivingmay consumer price inflation datum labor department show broad weakness price airline ticket apparel new used auto medical care overall cpi fall year year again moderate core price strip volatile food energy category rise annual gain backtrack lowest retail sale slide overall exclude stall auto sector defy expectation mild gain sale nonstore retailer lead amazon amzn continue be standout category rise year department store sale slide meanwhile industrial production be weak philly fed new york fed report stronger expect regional manufacturing activity june housing start unexpectedly fall putt further pressure housing stock have be move new high crude future fall barrel hit month lows more evidence global supply glut continue opec production cut international energy agency say crude stockpile jump barrel oecd country april push year average higher opec production deal november crude supply fall latest week energy information administration say less expect gasoline supply unexpectedly rise domestic production rise barrel day barrel eia predict see output major shale basin jump barrel day july biggest increase come permian basin also opec own production climb barrel increase libya nigeria iraq domestic production rise barrel day barrel general electric ge say health care chief john flannery take current ceo jeff immelt aug immelt pivot industrial conglomerate financial service back engineering root sharpen technology focus ge stock have fall roughly take general electric indicated digital push continue flannery dow component also announce more executive change later week include exit power unit veteran steve bolze spur talk potential brain drain similar exit lose ceo candidate immelt be name ceo replace jack welch ge share jump monday uber technology ceo travis kalanick take indefinite leave absence follow independent review allegation ride hail company harassment discrimination aggressive culture investigation eric holder former attorney general lead recommendation create board oversight committee staff meeting discuss uber plan transform director david bonderman make comment see offensive woman lead resignation share dow component johnson johnson jnj merck mrk diverged monday news stem trial study show diabetes medicine invokana also cut cardiovascular event rise week new high merck halter enrollment cancer trial see more death patient treat immuno oncology drug keytruda vs other combination merck stock fall hawaiian holding crash unite airline ual say add service hawaii later year stifel analyst joseph denardi downgrade stock sell say hawaiian airline parent perform well have also benefit very benign competitive environment cheesecake factory cake share nosedive sit restaurant chain cut same store sale guidance cite sign uncertainty part many consumer unfavorable weather reduce patio usage east midwest citigroup predict weaker second quarter trading revenue cite low volatility vs brexit election season citi forecast follow similar one trading jpmorgan jpm bank america bac other citi fall week hold buy zone
189,JNJ,exchange trade fund offer market beating dividend be new high ground firmly buy zone spdr dividend sdy break past flat base buy point june remain buy range entry first climb buy point intraday june then pull back ahead occur follow week month pattern begin form week february flat base advanced basis
190,JNJ,fund track high yield dividend aristocrat index comprise company have raise dividend least straight year sdy be underperform broader market year return june vs gain accord morningstar inc etf year average annual return be almost step year period sdy have return average slightly ahead etf annualize dividend yield be ahead benchmark index payout top holding fund include target tgt abbvie abbv company offer annualize dividend yield respectively also make sdy top be longtime warren buffett favorite coca cola ko be pay annualize coca cola have form long saucer handle base buy point start pattern date back april sdy top sector weighting be financial service consumer defensive industrial consumer cyclical account roughly asset follow utility just sdy net expense ratio be largecap dividend dln track index same name also own coca cola hold several other buffett stock such apple aapl johnson johnson jnj procter gamble pg underlie index be make large cap stock be weight value dividend company be project pay next year top hold apple have come pressure recently stock have be trading day move average past week follow drop june news report apple upcoming iphone series handset have slower datum download speed vs rival device market also get hit several analyst downgrade share be still well extend cup handle entry clear january apple coca cola be top holding buffett berkshire hathaway brka portfolio apple annualize dividend yield be johnson johnson offer payout procter gamble yield dln launch june have attract nearly asset have slightly underperform index ytd year year average annual return respectively dln annualize yield be net expense ratio be share climb past flat base entry june ease buy point follow session break again june remain slightly entry etf gain prior flat base february start current pattern march consumer defensive name account nearly dln total asset technology health care financial service stock make apiece follow industrial related apple dife nearly find support day move best pick include bond emerge market etfs big cap robotic outperform outlook china
191,JNJ,stock open slightly higher early wednesday investor prepare federal reserve et policy announcement be widely expect fed raise interest rate quarter point retail sale come surprisingly weak fall vs expect rise nasdaq lead way early advance dow jone industrial average trade right break even mark dow industrial johnson johnson jnj traveler co trv pace advancer gain early trading financial component be blue chip index laggard jpmorgan jpm decline goldman sachs gs fall american express axp drop block hrb alexion pharmaceutical alxn jump more respectively tax preparer report stronger expect fiscal result late tuesday alexion name new cfo downside energy financial stock find bottom day performer chesapeake energy chk hess corp hes fall more apiece regional bank bank mtb zion bancorp region financial rf drop lead stock stock market today tesla tsla run continue stock jump stock reach fresh record high just day stock fall goldman sachs raise price target nvidia nvda maintain buy rating share nvidia trade lower other analyst action include downgrade starbucks sbux hawaiian air parent hawaiian holding starbucks be downgrade neutral outperform wedbush security channel check show slightly weaker same store vs expectation stock be pace extend lose streak day have fall airline operator be downgrade sell hold stifel unite airline ual announce boost capacity hawaii next year share plunge almost action ibd be mixed strength technology name be offset weakness financial retail upside video game maker activision atvi moved facebook fb trade almost higher downside discount retailer fb drop more share pierce day line heavy volume be downgrade sector weight keybanc regional bank citizen financial cfg decline snap day winning streak see stock reclaim day line related stunning economic report give fed pausebank stock fall test key level weak datum fed oddsdow jone industrial average dow stock news hawaiian holding microsemi anadark downgrade
192,JNJ,sanofi sny make sense acquirer flexion therapeutic flxn analyst say friday rumor flexion accept offer french drugmaker flexion investor be dubious flexion stock jump thursday tumble much stock market today then rally much close sanofi stock edge rbc analyst randal stanicky see flexion likely be take write research report sanofi make sense give sell synvisc injection supplement fluid patient knee relieve osteoarthritis flexion be now work fda approval process zilretta joint injection extend release formulation steroid knee pain stanicky see zilretta well position take meaningful share exist steroid hyaluronic acid market pre fda approval timing allow flexion avoid sale force ramp rep sanofi allow participation launch activity flexion be expect be write market be person worth size brand marketing cantor analyst chiara russo see flexion capable launch zilretta help say rumore mid share takeover price accord unidentified source comment fiercepharma be too low significant change competitive landscape past year give zilretta sole new voice space see mid price be little low strategic buyer russo write note client ibd take flexion have middling ibd composite rating meaning underperform more stock better biotech bet be celgene best possible cr visit stock checkup list strongest leader russo maintain price target maintain rating flexion stock expect zilretta take significant market share rbc stanicky see share takeover price reasonable note see support deal north perhaps closer add specialty valuation have come recently deal be pre zilretta approval have outperform rating price target flexion stock rumore bid come just month sanofi lose contentious battle swiss biotech actelion dow component johnson johnson jnj scoop deal member dow jone industrial average pfizer pfe beat sanofi acquire medivation sanofi have also be rumore have consider deal biomarin pharmaceutical bmrn medicine company mdco aftermath judge ban cholesterol drug praluent regeneron regn ban have be stay pending appeal case amgen amgn flexion sanofi decline comment ibd related do sanofi just bag biotech johnson johnson exclusive talk acquire actelion sanofi sanofi acquire biomarin wake amgen ldl brouhaha
193,JNJ,fat freeze ear pin breast augment allergan agn isn make expansion medical aesthetic market easy rival hologic holx johnson johnson jnj valeant pharmaceutical vrx analyst say allergan have sunk north aesthetic space add skin cream double chin treatment most recently fat freeze business be just transaction
194,JNJ,sale pacira pharmaceutical pcrx opioid painkiller exparel topple february have reaccelerate march meet analyst sub wall street view thus far prescription datum do not suggest management pacira have find way return exparel higher rate growth janney analyst ken say note have sell rating price target pacira stock accord health tracker symphony health exparel prescription fall month month february grow january unit volume first quarter be estimate exparel sale languish second half quarters low mid revenue growth fourth quarter second quarter write exparel bring sale new datum surgery protocol total knee replacement potential implement datum large hospital help exparel long run exparel be often prescribe patient have undergo knee replacement take time show exparel performance say expect pacira pull total sale lag consensus analyst poll thomson reuter exparel account pacira sale company see exparel bring pacira be plan use depofoam method drug delivery number other drug ibd take pacira have ibd composite rating meaning outperform just half stock term key growth metric still far top leader celgene have composite rating best possible visit stock checkup look stock portfolio be do depofoam deliver drug contribute growth be year away market say meanwhile exparel growth be plateau even entry competition come next year mizuho analyst irina koffler other hand be more bullish pacira stock keep buy rating thursday cut price target due dilution associate recent convertible debt offer still koffler see number potential catalyst boost takeout thesis january johnson johnson jnj company depuy synthe sign deal pacira promote exparel orthopedic expert say pacira hasn generate compelling datum exparel depuy pressure hospital payer drive use stock market today pacira stock topple share have trade well day move average early january related pacira likely takeout candidate anesthesia sale dip mizuho
195,JNJ,xstock see narrow open gain quickly fade flat trade wednesday follow weak retail sale number investor wait afternoon rate announcement federal reserve dow jone industrial average swung just enough top record high set tuesday inched higher open quickly pull back flat trade nasdaq also give early gain flattened shortly start bell dollar rise bond edge higher ahead policy announcement federal open market committee schedule et follow press conference federal reserve chairwoman janet yellen market have largely price quarter point rate hike investor have ear cock hint central bank strategy regard balance sheet fattened trillion stimulus related bond purchase apple aapl rise johnson johnson jnj jump seize early lead dow industrial johnson johnson report trial result canagliflozin show significantly reduce risk cardiovascular death myocardial infarction nonfatal stroke versus placebo patient type diabetes apple be still vie retake support day move average fall massive trade friday stock open high block hrb surge open lead stock report fat fiscal fourth quarter earning beat revenue gain slightly top analyst target management also hike quarterly dividend cent share gain moved share february low left still deep month consolidation alexion pharmaceutical alxn rumble ahead news board name paul clancy post chief financial officer effective july clancy be currently cfo biogen biib biogen share fall hawaiian holding drop receive second downgrade week stifel nicolaus trim stock sell hold slash price target loss send hawaiian owner hawaiian airline week move average heavy trade trigger sell signal ibd stock new oriental education technology edu jump early trade china base tutor test preparation provider be trading cup handle buy point ibd peer floor decor holding fnd pop early action wedbush initiate coverage neutral rating price target april ipo open initial offer price high retail sale slip commerce department estimate reverse april gain fall well shy economist projection gain auto gasoline sale be flat month disappointing consensus view advance price paid consumer dip gain april labor department say economist have project change read core price energy food inched advance estimate economist europe market be rally mode london ftse ride gain dax frankfurt cac paris ahead afternoon trade crude future be almost leave west texas intermediate hold just barrel ahead energy information administration weekly inventory report et international energy agency say early wednesday global oil glut continue effort opec partner trim production april business inventory number be due commerce department et related kind bubble want stock investing action planapple finally confirm worst keep secret
196,JNJ,french drugmaker sanofi sny be reportedly consider bid tesaro tsro face competition gilead science gild frustrated hepatitis franchise have left massive biotech thirsty acquisition close stock market today tesaro be gilead stock pop close sanofi stock be close accord insider cite streetinsider sanofi be look put bid tesaro reportedly begin seek takeover bid last month follow approval launch ovarian cancer drug zejula gilead be also likely run buy tesaro accord report gilead biggest drug treat hepatitis sovaldi harvoni see sale dive high cure rate now gilead have say interested make deal particularly oncology win be cheap insider say ll cost share acquire market cap tesaro winner also get hand ovarian cancer drug zejula launch earlier year year price tag cost zejula be less expensive astrazeneca azn lynparza clovis oncology clvs rubraca zejula label be broadest allow treatment ovarian cancer patient regardless specific genetic ibd take tesaro stock have ibd composite rating meaning outperform just half stock term key growth metric visit ibd stock checkup look better rate stock biotech sector analyst have speculate competitive landscape know parp inhibitor include zejula lynparza rubraca approve drug pfizer pfe change more datum rival become available year sanofi have struggle make deal recent history last year lose johnson johnson jnj battle actelion pharmaceutical pfizer get hand parp inhibitor acquire medivation gilead too be position hunt deal hepatitis drug fall company say most recent earning call rely deal growth special interest oncology asset incyte incy have also be radar rumore target representative tesaro sanofi decline comment investor business daily representative gilead didn immediately return request comment related do astrazeneca rival just launch potential blockbuster drug clovis advantage squash tesaro ovarian cancertesaro crash beating astrazeneca stronger datum
197,JNJ,abbvie abbv expect biggest drug humira hit peak international sale then face erosion cheaper biosimilar enter market analyst say tuesday ub analyst marc goodman keep buy rating price target abbvie stock close stock market today back day line humira be face biosimilar competition outside price decline be year goodman write note client outside remain volume drive business abbvie have more pricing leeway competition erode humira sale outside abbvie plan curtail sale marketing spending specific country commensurate sale erosion goodman say follow meeting abbvie executive ub global healthcare conference hit peak outside sale abbvie expect sale erosion year ibd take first quarter earning just wrapped number drugmaker include abbvie visit ibd technology page closer look outperformed fall meanwhile push mid late stage pipeline include elagolix be be develop neurocrine bioscience nbix treat endometriosis uterine fibroid abbvie be track file application food drug administration elagolix endometriosis third quarter abbvie be also look drug venclexta combination fda approve rituxan johnson johnson jnj pharmacyclic pcyc imbruvica leukemia lymphoma longer term have growth opportunity other form lymphoma leukemia goodman write note client related regeneron sanofi undercut amgen abbvie rheumatoid arthritisabbvie lose key humira patent battle small cap biotech
198,JNJ,sometimes small prod be take make hot investment idea go cold time small quarter point bump benchmark rate case low volatility dividend stock etfs era end interest rate rise investor exchange trade fund have turn away certain high dividend low volatility strategy year instead favore more cyclical exposure benefit tick rate bank transporter example yet thank product innovation be now strong smart beta strategy combine defensive cyclical component todd rosenbluth director etf research cfra write march note smart beta etfs seek achieve better return lower risk vs cap weight counterpart example next generation product rise rate environment rosenbluth offer name relatively new product year history etfs be trade care however rosenbluth consider worthy choice large cap stock exposure light march rate hike fed signal more gradual rate hike year xrlv be younger sibling powershare low volatility splv etf aim give investor ride stock market splv invest least volatile stock surge popularity choppy market so do ishare edge msci minimum volatility usmv year march splv usmv see net outflow combine accord factset datum big chunk total asset now stand roughly hefty stake defensive high yielding sector be hurt equity sector such consumer staple real estate utility be see bond proxy higher yield have historically lag bond yield be rise federal reserve seem incline keep raise rate year more pain lie store splv usmv rosenbluth view xrlv have little fear context boot most rate sensitive stock so have virtually exposure utility real estate gas electric company such dominion resource southern co so older sibling portfolio be miss here instead skews heavily financial technology industrial such jb hunt transport service jbht economically sensitive sector tend perform well rise interest rate basically xrlv be defensive not too much middle ground investor be expect more choppiness marketplace also wish participate improve economy say rosenbluth xrlv have gain nov election roughly line outpace advance low volatility heavyweight splv usmv fidelity dividend etf also hold stock perform well rate be rise avoid big sector bet be year date have day sec yield related best lage cap growth etf year be best
199,JNJ,president trump rail outrageous drug price monday send biotech pharma stock reel midday tuesday appear gop bill repeal replace obamacare doesn touch pharmaceutical newest iteration american health care act doesn mention trump plan curb spiraling drug price speech monday send ibd company generic drug industry group tailspin drop month low generic drugmaker dr reddy laboratory rdy stock sank stock market today eagle pharmaceutical egrx tumble aclaris therapeutic acrs dip ani pharmaceutical anip lose ibd company biom biotech industry group crash collective la jolla pharmaceutical ljpc puma biotechnology pbyi kite pharma kite stock particularly hard respectively lose specialty drugmaker endo pharmaceutical endp fall mallinckrodt mnk drop depome depo topple trump unspecified plan call bring cost medicine have fair competitive bidding process president say late monday rally kentucky medicine price be come way way way way go happen fast say re just add bill say ve get add bill call cost medicine country outrageous say many time higher country europe elsewhere ibd take drug approval slump least company add new drug wheelhouse see one ibd industry theme somebody be get very rich say later comment drug price aren include first version american health care act legislation address drug issue follow closely trump have have love hate relationship drugmaker early presidency call drugmaker lower pricing later meeting ceo celgene celg johnson johnson jnj merck mrk novartis nvs other pledge cut fda regulation speed drug approval process last week trump unveil blueprint propose increase user fee collect fda drugmaker more do so squeeze already thin margin generic drugmaker related pharma stock be big loser trump drug pricing tweetbiotechs leap trump call innovation speedy fda approvalj ceo underwhelm investor trump dodge drug pricing
200,JNJ,stock expand midday gain wednesday federal reserve expect hike short term interest rate quarter point hint continue act prudently engage further increase cost money meanwhile oil stock get much need lift get slam recent day crude oil future rally west texas intermediate future rise more barrel meanwhile metal medical heavy industrial transport sector also show resilience instance airline industry leader southwest air luv be halter session lose streak reversed lows gain fast turnover watch see consumer business spending play climb back day move average share be still year date better roughly advance randgold resource gold surge be try retake day line anglogold ashanti jump remain far depress week high meanwhile steel sector leaderboard name industry top dog nucor nue rally more low volume watch see keep climb pierce top week handle buy point nucor be see grow profit cent share earning have rebound vs year level prior quarters fifth sector banking be also regain lose ground bank new york mellon bk rise be close surpass buy point week cup handle pattern small cap issue be lead stock market today russell vs lift nasdaq composite dow jone industrial lag least component rise least point more include caterpillar cat unitedhealth group unh johnson johnson jnj unite technology utx have clear early buy point long saucer construction left side high also offer entry point cent price have now rise slightly more past early buy point be sure not chase stock more past proper entry reason often stock pull back try shake weak holder test support proper entry ibd founder bill neil study greatest market winner find rarely do lead stock market winner fall more proper buy point cup double bottom flat base other bullish pattern stock charge new high notice weekly chart straight prior week rise average turnover week bode well diversify medical product giant indicate surge demand share mutual fund hedge fund insurer bank accumulation distribution rating be now sprightly proprietary grade go heavy distribution heavy accumulation rs rating scale relect big cap long base action be sharply improve low just week small mid cap name focus rs rating higher break even move fed increase fed fund rate target range observer applaud central bank decision maintain careful gradual approach normalize bond market weaker dollar be reflection fed policy path quincy krosby market strategist prudential financial tell ibd market see fed keep lid dollar provide bid exporter commodity emerge market dollar fall euro japanese yen meantime keep eye reaction european equity market wednesday dutch election be be perceive test european tolerance immigrant particularly middle east dutch election also have ramification future eurozone june last year briton shock world voting leave single currency region related stock market today sell dow industrial component now invest base base pattern make money top market sector today see ibd smart research table
201,JNJ,alexion pharmaceutical alxn stock plummet nearly year low tuesday announce executive be leave only month chief executive ludwig hantson joined alexion baxalta close stock market today alexion stock be earlier fall much low last see october position be vacated only have be filled brian goff succeed chief commercial officer carsten thiel be leave pursue new opportunity june goff background include time baxalta neurovance baxter international bax novartis nvs johnson johnson jnj chief financial officer dave anderson resign end august martin mackay executive vice president head research development retire end clare carmichael executive vice president chief human resource officer leave june seek new opportunity leerink analyst geoffrey porge note leadership change completely management team build alexion soliris franchise preside value destroy acquisition synageva soliris be approve rare disorder ibd take alexion stock have ibd composite rating meaning have outperformed stock key metric past month biotech group be lead therapeutic have cr best possible head ibd stock checkup top rate biotechs change be not complete surprise give signal have be come new ceo alarm many investor give concern be other shoe drop term disclosure additional underlie issue core business operation say past hantson have comment doesn have much excitement anything alexion pipeline alxn treatment patient paroxysmal nocturnal hemoglobinurium immune disorder result destruction patient red blood cell still departure anderson be surprising give position be permanent be expect remain place least year transition many goal strengthen financial report system improve operate margin be still underway porge say many initiative continue be implement company commitment margin improvement goal seem now be question write note client importantly alexion didn see turnover midlevel management sale force porge note hantson believe morale commitment patient dedication be still write be commit absorb widespread change company say porge maintain outperform rating alexion stock related amgen gilead biogen win lead biotech boom so alexion beat first quarter sale profit top cent
202,JNJ,regeneron regn sanofi sny rheumatoid arthritis drug be cheaper rival drug amgen amgn abbvie abbv roche rhhby analyst say tuesday duo kevzara grab food drug administration approval kevzara approval come month fda delay approval issue manufacturing french factory drug be filled approval be patient moderate severe rheumatoid arthritis don respond other rheumatic drug approval come time label more less match expectation leerink analyst geoffrey porge say note client kevzara be prescribe alone combination fda approve methotrexate be self administer injection roche actemra belong same class drug kevzara be associate increase risk serious minor infection liver issue injection site reaction also discount actemra annually discount offer cost effective treatment option payer set porge say kevzara cost less amgen enbrel abbvie humira be widely prescribe rheumatoid arthritis different drug class ibd take regeneron be lead biotech resurgence year analyst say head ibd technology page deeper dive amgen gilead science gild biogen biib aren expect be forefront revitalization regeneron sanofi expect european approval come later year see kevzara hit market few week porge see drug minimal driver forecast sale year grow number drug class address rheumatoid arthritis note field be likely become more crowd later year dow component johnson johnson jnj add drug sirukimab lineup more class dub jak inhibitor arrive kevzara contribute approximately expect sale joint sanofi regeneron product fall long term expect growth eczema drug dupixent even cholesterol lower drug praluent rapidly eclipse kevzara importance porge say consensus forecast kevzara sale year grow hit stock market today regeneron stock rise sanofi stock fall share rival amgen abbvie be respectively roche dip related comeback kid regeneron survive amgen cholesterol squeeze regeneron pop better fear eye cholesterol drug sale
203,JNJ,major market average turn tightly mixed recover early morning lows nasdaq composite nudge break even line dow jone industrial average wrestle loss less dow industrial exxon mobil xom johnson johnson jnj pace early advancer rise respectively early trading blue chip index big laggard be wal mart store wmt fall amazon com amzn announce be reduce prime membership fee several low income consumer group american express axp moved apple aapl early jump dissipate leave stock iphone maker announce own digital debit card late monday call apple pay cash truck maker paccar pcar chip designer advanced micro device amd set pace gain respectively paccar receive upgrade buy neutral ub downside fastenal fast drop signet jeweler sig follow loss analyst action stock market today paypal pypl dip have price target raise instinet electric automaker tesla tsla trade higher pacific crest security hike bullish scenario price target lead stock fang stock netflix nflx amazon moved respectively meanwhile square financial sq jump late monday rv maker thor industry tho report strong quarterly earning sale result surge higher share be build right side potential base early tuesday hd supply hds report weaker expect quarterly profit cause share plunge industrial distributor also announce sell waterworks division private equity firm clayton dubilier rice action ibd be mixed early trading tuesday upside medidata solution mdso jump fiber optic play lumentum lite rise chip stock ichor holding ichr nvidia nvda rise respectively downside nutrisystem ntri mercury system mrcy fall more related tesla see rise model bull case puma microchip ulta price target hikeddow jone industrial average dow stock news stock news quote facebook amazon netflix googlehd supply sell waterworks earning miss
204,JNJ,gilead science gild abbvie abbv benefit merck mrk decision take impairment charge hepatitis drug market price shrink leerink analyst geoffrey porge say friday merck also cut value estimate uprifosbuvir hepatitis drug acquire idenix pharmaceutical base upcoming drug regimen change view whole hepatitis market regulator say merck complete separate trial show add benefit triplet high dose doublet regimen porge say complicate matter high dose doublet be phase testing triplet also suggest remain value rest idenix be now very small porge write research report merck be also seemingly indicate significantly reduce value future participation market be consistent decline market overall ibd take analyst project downfall hepatitis drug sale be warning sign be other market risk read ibd industry theme gilead abbvie johnson johnson jnj bristol myer squibb bmy compete hepatitis market merck charge signal drugmaker expect have lighter sale smaller share initially forecast drugmaker be struggle grow pain follow boom subsequent bust hepatitis drug sale gilead be poster child phenomenon sale sovaldi harvoni topple now gilead be bet hiv drug bictegravir merck too note change patient population dynamic company determine recent change product profile well change expectation pricing market opportunity take together constitute trigger event require company evaluate uprifosbuvir intangible asset impairment merck write filing security exchange commission late thursday morning trading stock market today merck stock be fraction close bell share abbvie inched gilead gain related abbvie stronger bet gilead amgen least leerinkgilead glaxo pit hiv battle struggle vs standard drugscan gilead swivel hiv flounder hep sale gsk rivalry
205,JNJ,satisfy trump administration call deal high drug cost industry leader be propose president lead negotiation drugmaker restrain price allergan agn chief executive brent saunder cite tactic used president john kennedy decade keep steel price administration also waive federal antitrust rule currently prohibit drugmaker discuss pricing so put together guideline follow say voluntary agreement restrain price be very practical solution doesn view do anything impede innovation saunder say wednesday interview bloomberg headquarters new york convince fellow drugmaker agree however be challenge be difficult saunder say big pharma be intense pressure come way reduce price president trump accuse company get away murder threaten use government buy power force price saunder have be outspoken excessive price hike own industry allergan company product range wrinkle treatment botox stomach schizophrenia medicine ceo have implement social contract cap increase annually trump model something pharmaceutical industry maybe look something social contract saunder say easy suggest re already do just be transparent add ask target amount restraint agreement say low single digit rate inflation pharmaceutical giant include novartis nvs japan takeda pharmaceutical abbvie abbv also have take voluntary action cap price increase johnson johnson jnj merck mrk have take step increase transparency price industry have moved quite bit month month saunder say need big push saunder allergan have transform specialty pharmaceutical behemoth series acquisition sale generic business attempt merge pfizer pfe inc megadeal be abandon last year allergan have focuse smaller purchase allergan share be compare rest industry last month ve lose compare gain company standard poor pharmaceutical biotechnology life science index include allergan rather deal saunder be more interested build allergan main therapeutic area include medical aesthetic dermatology eye care central nervous system past month make acquisition worth combine add allergan aesthetic medicine cosmetic surgery line hair restoration skin quality be next frontier say company be currently do research area be huge unmet need say ask valeant pharmaceutical international vrx asset include bausch lomb eye care company once lead saunder say not interested not even piece valeant didn respond request seek comment
206,JNJ,more high growth company issue sell signal daily weekly chart thursday nasdaq composite lag nyse index russell lose cut year date advance nvidia nvda initially show sign overheat back final week december stage climax run drop fall sharply key day move average first time huge run begin cup handle mid march few analyst downgrade spark increase selling pressure chip designer leader graphic processor still hasn fall much time peak little more former peak stock end form new base also be good see nvidia undercut recent low serve reset base count accord ibd proprietary stock checkup tool nvidia rs rating remain nearly perfect scale don use rs rating selling gauge rating key action past month decide hold good stock sell first assess most immediate price volume interaction daily weekly chart fellow tech interdigital idcc meanwhile get trample seller wireless technology expert gap lose day end stock volume exceed share easily highest so far year interdigital also slice day move average trigger major sell signal take profit cut loss weakness come company report second straight quarter triple digit earning sale growth yet street still see massive drop earning share nasdaq composite burden heavy selling chinese internet semiconductor name pare intraday loss note today big picture column volume edge higher nasdaq translate mild day distribution intense professional selling tech dominate market benchmark inched slightly higher dow jone industrial average gain nearly defensive sector include utility fared better dow jone utility average rise day ibd industry group gas distribution water supply electric power utility help pace upside dow component johnson johnson jnj unitedhealth unh outperformed gain more reflect renew demand medical sector have be form saucer base nearly month early buy point cent spike middle base saucer be more clearly visible weekly chart case unitedhealth very shallow flat base have emerge furnishing entry point dime base left side peak yet more medical service device company have crop ibd screen new high list recent week see latest list ibd datum table page stock list section home page investor com biotechs be still lag general fast food chain jack box jack meanwhile keep slumping former market leader crumble nearly slide day move average fast trade key sell signal earning grow adjust basis still miss consensus forecast wednesday burger taco chain flash earlier sell signal fall further day line heavy turnover sale rise just flat performance year quarter related do nvidia show sign correction be imminent stock market today nvidia fundamental turn next apple follow ibd tech sell stock drop day line matter
207,JNJ,exchange trade fund offer market beating dividend be new high ground hover buy point spdr dividend sdy climb past flat base buy point intraday friday settle just entry monday close fractionally lower current month pattern begin form week february flat base advanced basis fund track high yield dividend aristocrat index comprise company have raise dividend least consecutive year sdy be underperform broader market year return june vs gain accord morningstar inc etf year average annual return be closer year period sdy have return average just ahead etf annualize dividend yield be ahead benchmark index payout top holding fund include target tgt abbvie abbv company offer annualize dividend yield respectively also make sdy top be longtime warren buffett favorite coca cola ko be pay annualize friday stock price largecap dividend dln track index same name also own coca cola hold several other buffett stock such apple aapl johnson johnson jnj procter gamble pg underlie index be make large cap stock be weight value dividend company be project pay next year fund launch june have attract asset slightly underperform index ytd year year average annual return respectively dln annualize yield be share clear flat base entry friday close monday penny buy point etf gain prior flat base february start current pattern march check monday etf pick india focuse fund close largely unchanged remain buy range recent rebound respective day line be ishare msci india inda powershare india portfolio pin vaneck vector india small cap scif india earning fund epi related play offer chance ride india stock market rallymiss thursday breakout fresh idea market hit high etfs watch hold buffett dividend stock
208,JNJ,loxo oncology loxo stock defy broad biotech dip monday spiked record high show drug larotrectinib shrink tumor number different cancer share loxo end monday regular session catapult higher follow presentation saturday american society clinical oncology annual meeting chicago company eli lilly lly merck mrk bristol myer squibb bmy roche rhhby be attendance loxo drug belong class immuno oncology agent aim inhibit family protein loxo be now set begin phase trial larotrectinib adult colon cancer child tissue tumor respond treatment big cap name weren big winner wall street instead company bluebird bio blue surge bluebird stock get jump present strong datum drug dub bb treat multiple myeloma monday bluebird say patient trial bb respond treatment relapse therapy be well tolerate leerink analyst michael schmidt say report have outperform rating bluebird stock ibd take supernus pharmaceutical supn stock have ibd composite rating best possible base key growth metric lead ibd company biom biotech industry group keep tab industry leader ibd stock checkup puma biotechnology pbyi stock lift rival roche unveil result yearlong test drug specific group breast cancer patient result be low end investor expectation rbc analyst matthew eckler say bode well puma be work drug call neratinib address same group patient eckler say roche drug herceptin perjeta be test adjuvant treatment treatment be add decrease risk relapse now assume adoption neratinib be largely unencumbered adjuvant use herceptin perjeta eckler write note client keep sector perform rating puma stock boost price target however puma bio share close well intraday high highest november tg therapeutic tgtx stock also cut wide berth monday rise much give gain back close earlier day tg have positive result trial abbvie abbv johnson johnson jnj form leukemia related dow merck clearly win vs bristol roche cancer trialstesaro crash beating astrazeneca stronger datum
209,JNJ,eli lilly lly jardiance likely benefit most food drug administration require dow component johnson johnson jnj patient leg foot amputation associate diabetes drug invokana analyst say tuesday letter physician tuesday fda cite large clinical trial conclude diabetes med invokana invokamet invokamet xr cause increase risk leg foot amputation fda now require johnson johnson add box warning invokana invokamet label trial dub canvas canvas show leg foot amputation occur twice often patient treat invokana vs placebo amputation toe middle foot be most common however amputation involve leg knee also occur fda write patient have more amputation involve limb leerink analyst seamus fernandez expect lilly benefit influx invokana patient transition diabetes med jardiance invokana jardiance class drug call sglt inhibitor sglt sodium glucose co transporter be protein facilitate glucose reabsorption kidney drug block reabsorption glucose kidney increase glucose excretion lower blood glucose level increasingly differentiate label datum date suggest lilly jardiance likely be term beneficiary further perhaps accelerate market share loss invokana fernandez write note client ibd take stay top biotech drug industry bookmarking ibd biotech pharma industry stock news page physician move patient invokana jardiance astrazeneca azn farxiga likely depend full result canvas canvas trial be present june american diabetes association meeting janssen subsidiary begin canvas trial december examine potential cardiovascular benefit invokana canvas trial begin october researcher examine benefit invokana kidney lilly jardiance be approve fda december cut risk cardiovascular death adult type diabetes jardiance be first type diabetes drug get approval cut risk cardiovascular death believe dramatic impact class be unlikely wake jardiance cardiovascular death claim be further mitigate directionally positive result canvas canvas efficacy cardiovascular risk reduction fernandez write still entire sglt need grow jardiance meet beat forecast fernandez see jardiance sale invokana sale forecast entire class grow year so even jardiance be capture invokana estimate sale immediate future major slowdown category growth likely be bigger issue relative consensus estimate say close stock market today lilly stock be goldman sachs analyst remove stock conviction list share member dow jone industrial average advanced related dow pfizer eli lilly topple month lows downgradescan teva hold own bring migraine drug market drug stock rally relief gop health bill win house
210,JNJ,here be investment idea seek capture dow jone industrial average performance index reach new high spdr dow jone industrial average etf trust dium have good day rise just flat base buy point closest be entry kick base month fund advanced clear prior flat base february start current pattern
211,JNJ,dium have be trading high underlie blue chip index close new record best thursday unitedhealth group unh lead dow industrial gain mark new high american express axp goldman sachs gs add respectively fidelity dividend etf rise rate fdrr be draw buy point flat base begin form month breaking prior base young fund launch september have attract asset correspond same name index track mid large cap dividend pay company be expect keep pay increase payout have positive correlation return increase year treasury yield accord fidelity com etf prove be timely bet give federal reserve be poise notch interest rate fdrr top holding read dow stock include apple aapl microsoft msft johnson johnson jnj merck mrk jpmorgan jpm fund pay annualize dividend yield ahead average return etf pick featured thursday break new high vanguard total stock market vti gain clear flat base buy point remain buy zone meantime ishare edge msci usa quality factor qual rise stage heavy volume past flat base buy point share be still buy range entry related apple watch big etfs potential etfs watch hold buffett dividend stockswhich etfs watch own nvidia top hold
212,JNJ,stock market edge higher ahead friday labor department job report sharp decline oil price early rebound loss attempt gain traction nasdaq dow jone industrial average rise nyse volume rise vs same time wednesday turnover fall slightly nasdaq dow industrial financial be top gainer day prospect higher interest rate horizon johnson johnson jnj rise top rise goldman sachs gs jpmorgan jpm moved respectively global investment bank be trading record high downside caterpillar cat stock price continue experience fallout last week headquarters raid federal official allegation tax fraud share fall crude oil trade level first time mid december exxon mobil xom trade higher announce deal royal dutch shell rdsa china base company underperform stock market today alibaba baba moved lower commerce behemoth remain trading just cup handle buy point netease nte moved chinese gamer sharp move upside have dull last week share remain extend cup handle entry weibo wb break fall day heavy volume stock be make weak rebound plunge feb so call twitter china now sit record high momo torrid run come fire early trading thursday nomura raise price target social medium company share drop past day share soar back tuesday morning earning beat lead growth stock be mostly positive head midday trading strength financial outweighed weakness chinese chip stock upside mercury system mrcy dave buster play lead ibd higher gain respectively mercury system be initiate overweight rating jpmorgan regional bank financial wtfc jump reclaim day support level wednesday stock reversed lower close slightly level heavy volume downside thor industry tho add third day lose streak rv maker trade high set march day earning release related dow exxon mobil royal dutch shell announce energy deal oil undercut child place soar high strong earning dividend doubledmomo price target hike amgen start neutral mercury buycaterpillar accuse commit tax fraud prop stock
213,JNJ,stock market nurse small loss afternoon trading tuesday dow jone industrial average nasdaq composite be lower russell ease hold just day move average volume nyse nasdaq be tracking close monday level johnson johnson jnj unite technology utx boee ba prop dow gain dish network dish be big gainer nasdaq news join health care name be focus stock market today republican submit revamp version affordable care act monday gain loss be relatively mild sector drugmaker hospital stock lag manage care firm dow component unitedhealth unh outperformed drugmaker be weak president trump tweet again intent get drug price lower decline stock outnumber advancer exchange less merger news sterling bancorp stl slump be testing support day move average news acquire astorium financial af share astorium soar breaking flat base meanwhile hewlett packard enterprise hpe announce plan buy nimble storage nmbl just value nimble share share hpe be mostly unchanged news nimble soar ibd arista network anet hold well rise continue trade tightly high bullish move higher week end feb earning news china base momo momo soar social networking platform report quarter huge growth profit year quarter sale momo feb clear handle buy point form alternative entry buy point new issue camping world cwh be top buy range buy point ahead earning report close sale growth have be decelerate recent quarters retailer sale be expect decelerate again current quarter rise just share rise ahead result related supernus valeant endo stock lose big trump drug pricing tweet ibd tipp poll american don love trump love trumponomic trump house gop obamacare repeal replace plan key point
214,JNJ,health care etfs fall tuesday day republican lawmaker unveil bill repeal affordable care act obamacare replace individual employer mandate age base tax credit stock sector be broadly lower open bell contribute most decline benchmark health care select sector spdr xlv bellwether exchange trade fund offer exposure health stock give stock market today top hold johnson johnson jnj be decliner stock portfolio health care sector have outperformed broad stock market so far recover negative political rhetoric contribute heavily rough decline previous year xlv post year date gain march outpace advance well return spdr stablemate investing other sector health sector lag postelection be attempt break new high rally straight week trump proposal repeal obamacare deregulate industry have stoke gain sector ibd take here be key point related house gop obamacare repeal replace plan etf investor biggest gain health care sector have come etfs offer exposure volatile biotechnology industry other industry group have also post impressive gain pharmaceutical etfs lag peer gain so far year related go stock market now
215,JNJ,nasdaq show substantial weakness early trading trade dow jone industrial average moved higher majority damage come tech sector volume nyse rise moderately fall nasdaq vs same time wednesday head midday trading action dow be mixed financial industrial lag blue chip energy medical outperformed upside chevron cvx exxon mobil xom moved price crude oil jump johnson johnson jnj rise general electric ge fall caterpillar cat go leadership market experience tough time stock market today longtime market leader nvidia drop be downgrade separate research firm nomura security bmo capital cite valuation concern analysis tesla sank report mixed result close wednesday beating revenue estimate electric automaker miss bottom line company also say cfo jason wheeler be step inphi iphi fall reverse new high wednesday volume be tracking average today trade international leadership alibaba fall further cup handle buy point breaking wednesday volume be heavy day close buy point netease nte sell heavy volume soar new high wednesday chinese gaming company remain cup handle buy point weibo wb crumble upbeat earning release close wednesday be much double bottom buy point share have now give back gain trigger sell signal stock be now almost entry sina sina majority owner weibo also fall report own quarterly result however be bright spot carnage square sq jump way breakaway gap flat base entry volume surge more average payment firm post upbeat result ibd screen lead growth stock be predominantly negative head midday trading only stock trade positive territory upside tal education ticker symb tal shrug general market weakness rise share remain double bottom entry downside be component more interdigital idcc lead decliner plummet report soft outlook share trigger key sell signal buy point heavy volume break day line related trade stock breakaway gap art breakoutweibo dife strong earning alibaba flirt buy point againtesla model be track gigafactory plannednvidium break support analyst downgrade impinj initiate buy
216,JNJ,big equity exchange trade fund feature apple aapl top bill be set stage potential investor iphone maker other big company check ishare edge msci usa quality factor qual fund track msci usa sector neutral quality index be buy point month flat base advanced clear previous flat base qual launch july have year annualize return accord morningstar inc line return fund top holding include apple johnson johnson jnj kimberly clark kmb berkshire hathaway brkb microsoft msft financial service account biggest chunk asset follow technology consumer cyclical healthcare stock accord morningstar inc vanguard total stock market vti be again flirt flat base buy point briefly climb entry last week gain prior flat base start current pattern fund be launch have attract asset vti have slightly underperform year date vs year annualize return have outpaced benchmark index top holding vanguard fund end april include apple microsoft amazon amzn facebook fb biggest sector be technology total asset vti track crsp total market index let check wednesday etf pick schwab dividend equity schd be inch closer flat base buy point ishare core dividend growth dgro be hover just flat base entry related etfs watch hold buffett dividend stockswhich etfs watch own nvidia top hold
217,JNJ,stock market open note early wednesday overnight positive manufacturing datum china however gain be quickly pare major index turn red chicago pmi hit lowest level january nasdaq lag loss dow jone industrial average fall dow industrial medical component pfizer pfe merck mrk johnson johnson jnj find head pack pfizer gain merck jnj follow gain early trading blue chip laggard be financial component goldman sachs gs jpmorgan jpm fall respectively analog device adi surge big earning beat chipmaker handily exceed sale earning target provide optimistic outlook current quarter stock break cup base buy point tuesday downside energy name find bottom performer second straight day oil price plunge again crude drop transocean rig drop chesapeake energy chk fall retail stock be show mixed action stock market today michael kor kor fall year low fiscal earning release result weak same store sale gloomy outlook quarterly earning have decline consecutive quarters capped decline quarter report retailer plan close store next year woman apparel retailer jill jill shot almost top bottom line beat lead retailer ollie bargain outlet olli report earning close today stock be well extend flat base buy point action ibd be predominantly negative general market reversed lower open downside chemour cc drop almost fiberoptic stock lumentum lite moved almost stamp com stmp fall hard second straight day last week share be almost upside control ctrl rise new oriental education edu moved initial datum release suggest chicago region manufacturing fall sharply send kingsbury international chicago purchasing manager index read be well april tally well economist projection downtick release be later correct show chicago pmi well expectation related michael kor dife outlook shut store jill soarsanalog device jump big earning beat raise outlookdow jone industrial average dow stock news analysis
218,JNJ,session start uncertain note pull healthy gain monday rise price rally security small cap stock send index higher nasdaq pop take new high tesla tsla decline pullback apple aapl ibd stock netease nte nvida nvda gain dow jone industrial average rise logged gain also take new high intraday close qorvo qrvo nvidia netapp ntap post strongest gain trade be higher nyse nasdaq accord preliminary datum johnson johnson jnj top dow industrial index boost upgrade overweight move lift stock back week move average right side flat base buy point verizon communication vz be only dow stock drop more security software play be day big winner goldman sachs name several lead name response wannacry global ransomware attack mimecast mime spiked fireeye feye bolt proofpoint pfpt gain proofpoint end buy point alternative entry ibd netease strong volume advance drive share back week move average stock work cup base nvidia be extend tick new high flat base buy point workday wday end day not quite buy point cup handle base vipshop holding vip slip close bell then bolt higher report first quarter result close tuesday home depot hd stratasys ssys tjmaxx tjx sina sina be stock expect deliver early earning result related home depot high other buy investing action plan stratasys earning next printer stock take flight
219,JNJ,president trump summons america most prominent corporate executive white house thursday tell intend put work restore manufacturing job dominance trade share commitment bring manufacturing back create job country trump say sit business leader include dow chemical dow chief executive officer andrew liveris general electric ge ceo jeffrey immelt lockheed martin lmt ceo marillyn hewson caterpillar cat chairman doug oberhelman trump used public portion meeting reiterate campaign theme blast call unbelievably bad trade deal single trade deficit mexico china vow punish company move job outside promise squeeze more money government contract cite talk hewson say cut cost lockheed fighter jet more tough work well think everybody trump say hewson meeting trump executive split work group explore policy change topic such taxe trade regulation infrastructure future workforce join session be administration official include vice president mike pence gary cohn director national economic council treasury secretary steve mnuchin trump son law jared kushner campbell soup cpb ceo denise morrison harris corp hrs ceo bill brown johnson johnson jnj ceo alex gorsky david farr ceo emerson electric emr be take part work group session administration official also include budget director mick mulvaney meeting cohn transportation secretary elaine chao business leader include corning glw ceo wendell week nucor nue president john ferriola discuss indexing gasoline taxe provide more money transportation project thursday meeting grow trump december announcement advisory panel manufacturing dow chemical liveris be lead panel say afterward other executive be very encourage pro business approach be take administration take part session workforce future liveris say be systemic fix address shortage worker prepared job require skill science technology engineering mathematics have supply side issue today say half open stem job fill need fill american also say community college need provide more vocational training noble trade have be priority obama administration lockheed hewson tell reporter trump be ready take quick action streamline rule business very important reduce regulation eliminate be burdensome be unnecessary say ahead meeting business roundtable lobbying group corporate executive send letter cohn layer regulation top concern member letter touch everything affordable care act net neutrality environmental regulation also hint ceo concern economic impact trump immigration trade policy top business roundtable list be move environmental protection agency tighten national ambient air quality standard ground level ozone well epa limit new coal fire power plant expand jurisdiction state water list also include overtime regulation dodd frank provision include ceo pay ratio disclosure conflict mineral disclosure rule margin requirement uncleared swap employer report tax requirement affordable care act addition group be seek expedite export control tighten eligibility increase exclusion shareholder proposal list regulation isolation not appear significant growth cumulative effect have drain resource innovation job creation direct value add administrative bureaucratic activity say letter sign mark costa chairman ceo eastman chemical emn lead business roundtable smart regulation committee same time letter say administration consider new policy regard immigration expansion buy america requirement business roundtable stand ready assist prevent unintended consequence inhibit ability company drive economic growth be globally competitive trump have used previous meeting company encourage corporate leader build product offer tax break lower regulation bring cost warning want raise tariff product produce overseas head labor organization automotive firm national retail chain drug company airline be group have meet trump west wing recent week neither trump ceo indicated have detailed discussion plan overhaul tax code have say deliver week border adjustment tax proposal consideration house republican shift tax burden exporter importer republican leader house include speaker paul ryan argue border adjustment tax benefit american manufacturing provide revenue make loss reduce corporate tax rate several manufacturer include dow chemical be actively lobbying plan trump have call too complicate opponent include net importer wal mart wmt oppose raise taxe american consumer
220,JNJ,major stock market index etfs be narrowly mixed wednesday material health care show strength sector spdr spy be hover time high powershare qqq qqq be same amount spdr dow jone industrial average dium be material select sector spdr xlb be etf have rise so far year vs spy xlb break flat base jan rise nearly buy point then fall back base find support day move average be hold time high etf have bulk asset invest chemical basic material company include dow chemical dow nearly asset dupont dd also praxair px nearly dow chemical shot higher wednesday report reuter eu antitrust regulator be close clear merger dow chemical dupont dow chemical have year growth rate be yielding have dividend growth rate dupont jump wednesday rise industrial gas producer praxair be utility select sector spdr xlu be health care select sectorspdr xlv be fraction top holding include johnson johnson jnj pfizer pfe merck mrk unitedhealth unh be slightly amgen amgn be energy etfs give back strong gain tuesday unite state oil fund uso fall wednesday jump tuesday uso track spot price west texas intermediate light sweet crude oil energy select sector spdr xle fall rally tuesday etf track oil gas explorer producer service company be week high trading etf be day move average bearish sign intermediate low xle top hold exxon mobil xom be week high chevron cvx be high be trading day line here look performance major exchange trade fund key asset class stock market today relative price strength rs rating measure stock price performance last month vs stock etfs scale best possible spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related oil gas equipment etf have strong year best etfs make bullish bet growth trump trade
221,JNJ,investor know like november election result december interest rate increase federal reserve event prompt jump investor have retail account charle schwab schw declare bullish fourth quarter survey investor schwab find say now feel bullish be big jump feel way year earlier result election client see increase prospect reduction personal corporate tax rate increase likelihood spending infrastructure increase likelihood reduction regulatory burden industry say myhanh hoskin schwab financial consultant be base seal beach calif rate increase be sign grow strength economy widespread perception stock market have become increasingly worth investing schwab investor do much buy selling quarter top holding schwab stock mutual fund be apple aapl microsoft msft exxon mobil xom johnson johnson jnj jpmorgan chase jpm feb accord morningstar inc apple be year date microsoft be exxon be johnson johnson be jpmorgan be schwab survey client general balance buy selling bode well market additional way show isn sense euphoria hoskin say show caution many investor suggest re not see market top be good thing have too many person do same thing tend be contrarian indicator other hand only investor say top concern market be appear overdue correction suggest tone overconfidence contrast whopping say be confident reach financial goal investor have money stock cash mutual fund exchange trade fund fix income investor say plan move more money stock current first quarter stock be most popular plan destination additional allocation etfs be second most popular target asset investor say plan put more money mutual fund be third most popular investor say move money investor be more incline get help make investment decision number client seek plan advice rise year earlier related mutual fund be light retirement accountsare fidelity recent stock buy sell retirement account hot sauce
222,JNJ,luxury electric car maker tesla tsla be hit stock rating downgrade monday coffee retailer starbucks sbux networking company cisco system csco health care product firm johnson johnson jnj earn upgrade wall street morgan stanley downgrade share tesla equal weight overweight keep price target several factor morgan stanley note risk tesla have compete apple aapl be rumore be work self drive electric car expect much larger more well capitalize competitor unveil strategy directly address sustainable transport mobility morgan stanley analyst adam jonas say report have be numerous development suggest continue preparation assault large tech firm market share autonomous electric mobility cite alphabet googl waymo apple possible big competitor tesla stock fall stock market today stock hit time high break cup base buy point april deutsche bank upgrade starbucks buy hold up price target say company be resolve problem related labor traffic mobile order system improvement already be see starbucks rise monday starbucks stock break flat base buy point april be upgrading starbucks share buy follow year transition transformation even little turmoil believe rebound result be possible deutsche analyst brett levy say report morgan stanley upgrade cisco overweight equal weight ahead earning report wednesday investment bank also raise price target stock cisco share jump monday retake day line stock have be form flat base buy point past week continue see evidence channel check survey security sale be begin pull network equipment upgrade think improve replacement cycle metric morgan stanley analyst james faucette say report meanwhile cisco continue drive mix shift software recur revenue conjunction strong firewall refresh activity gain share budget customer increasingly favor cisco end end portfolio architecture improve cybersecurity jpmorgan upgrade share johnson johnson overweight neutral raise price target stock climb stock have be form flat base buy point past week bmo capital market reiterate outperform rating enterprise software firm salesforce com crm raise price target salesforce be hit new time high salesforce break week consolidation period buy point april salesforce report earning thursday
223,JNJ,ask wall street analyst name possible catalyst rise big cap technology stock apple aapl cisco system csco top most list be trump administration plan allow company bring foreign profit reduce tax rate analyst say cash bring back be piggy bank company stock repurchase acquisition problem be president trump economic agenda have be stall white house drama propose change repatriate cash be part bigger trump tax reform package randall stephenson ceo say tax reform make congress lot person be get pessimistic lot noise washington right now tax reform not be achieve stephenson say jpmorgan tech conference be still optimistic something still get do bundle tax reform infrastructure bill be big think achievable even so worry be overseas tax holiday tech firm not turn bonanza make be depend legislation put condition money be spend create enforcement mechanism rather see money go company stock buyback acquisition trump congress steer money job creation capital spending say ub analyst trump administration want really drive inward investment have be sort mandate use cash maybe spend capital expenditure yet do not know ub analyst geoff robinson say report reason think robinson be right track trillion dollar offshore want get back america gary cohn trump chief economic advisor say recent interview want company bring money back put back economy want create job cash rich tech company apple microsoft msft google parent alphabet googl cisco currently pay tax so call repatriate earning rather take tax hit ve keep money overseas president trump have propose time tax offshore earning republican controlled house have propose lower rate overseas tax break congress pass be call american job creation act didn do much stimulate economy analyst say ajca taxed repatriate earning rate top firm bring back cash be drug company pfizer pfe merck mrk well hewlett packard johnson johnson jnj ibm ibm accord ir be bring back however only company eligible bring back cash do so say richard lane analyst moody investor service many company keep cash overseas ajca requirement say ajca require company reinvest tax saving worker hire training infrastructure research development capital project accord ub however fund repatriation have be earmark capital investment ultimately be spend large part share repurchase ub say happened ajca do not include tracking mechanism so government audit company gauge compliance trump administration put better enforcement mechanism place company have more overseas cash be need continue funding foreign operation company currently most overseas cash be apple microsoft cisco google oracle orcl moody say cisco have state cash bring back be used reduce debt book analyst have other idea tax holiday be approve bmo capital market say report expect cisco hewlett packard enterprise hpe focus more acquisition apple smaller company likely lean more capital return case apple cisco analyst envision enough cash be bring back fund deal apple have cash grow year apple cash be overseas time repatriation tax give apple acquisition buyback citigroup analyst jim suva say report suva speculate apple buy large company such netflix nflx walt disney electronic art ea cisco meanwhile bring back cash overseas analyst say report credit suisse speculate enterprise software provider servicenow now splunk splk computer security firm palo alto network panw be cisco shopping list pacific crest security add red hat rht nutanix ntnx list possible cisco target intel intc be semiconductor company cash hoard overseas intel bring back say bmo capital market nvidia nvda qualcomm qcom also have significant overseas cash bmo capital do not expect trump tax holiday spur acquisition spree chipmaker
224,JNJ,dow component johnson johnson jnj set potentially lackluster first quarter sector orthopedic sale medtech bellwether lag surgical unit be merely line cardiovascular sale grow double digit stock close stock market today last month share break flat base begin july hit buy point stock have retreat point first quarter report sale growth view drug sale advanced just adjust earning rise share beating consensus cent revenue miss light pharma sale rbc analyst glenn novarro remain bullish stock keep outperform rating share note underlie pharma trend remain solid first quarter miss have call stock own head earning drug make unit bring first quarter miss novarro model immunology biggest pharma unit come line novarro view remicade sale top oncology sale be novarro estimate cardiovascular drug sale miss xarelto invokana invokamet decline respectively year year basis underlie demand drug look strong novarro say company note pharmaceutical segment sale growth be negatively impact lower adjustment rebate accrual first quarter compare adjustment first quarter novarro write note client medical device pull grow vs year earlier period cardiovascular unit grow diabetes sale dip surgical sale grow evercore analyst vijay kumar note result be positive general cardio utilization orthopedic sale fall meaning trend seem be decelerate hint softer utilization trend first quarter kumar doesn cover johnson say result major medtech company be read entire sector include estimate impact actelion purchase first time johnson johnson now see full year ep revenue have project reach sale adjust earning expect top share ibd take johnson johnson stock have ibd composite rating meaning outperform stock term key growth metric head ibd stock checkup list top leader johnson johnson be stock medical diversify industry group abbott laboratory abbott be set report own first quarter earning open wednesday related medtech stock buy ahead biotech survive activist investor get take
225,JNJ,zimmer biomet zbh share gap sharply thursday beating first quarter forecast musculoskeletal device maker shrank guidance year orthopedic device maker now expect full year revenue rise notch prior outlook upper end adjust share profit get significant haircut now see vs previous view analyst be currently forecasting ep revenue zimmer share plunge low stock market today tumble month high entry point cup handle base gapping day day move average zimmer pare loss still hefty close session high first quarter warsaw ind base company post profit gain share revenue growth top estimate share sale ahead earning report zimmer have be peg rbc analyst hot medtech stock own johnson johnson jnj other related medtech stock buy ahead medtronic edward best stock own analyst
226,JNJ,robotic surgery specialist intuitive surgical isrg beat wall street earning estimate late tuesday stock be hour trading intuitive surgical earning totale share year earlier quarter top analyst consensus share accord thomson reuter sale gain vs analyst intuitive surgical be highest rate stock medical system group be collectively do well ibd ranking industry group share hit lifetime high last wednesday have hover mark then stock close fraction regular trade stock market today intuitive surgical be second hot medical stock report earning week earlier tuesday johnson johnson jnj hit new high beat estimate raise full year guidance due diminish foreign exchange headwind stryker syk also hit new high early tuesday give back gain later be due report earning wednesday close
227,JNJ,coca cola ko earning sale fall less fear first quarter sluggish soda other product shipment volume hit share investor hope global giant continue momentum earning share time item world largest soft drink maker fall cent revenue decline wall street be look cent ep revenue beverage volume rise vs second half organic sale growth slow soda volume be flat rise noncarbonated beverage volume rise coca cola share close stock market today plunge day move average investor expectation have be run high especially company decline top bottom line coke stock rise flat base buy point feb climb high april consolidate ibd take do coca cola stock still have fizz do compare rival find ibd stock checkupcoke say number case ship europe fall vs year earlier rise north america latin america growth be flat eurasia africa currency fluctuation result point headwind comparable operate income point headwind ep quarter johnson johnson jnj ibm ibm other multinational coca cola see smaller currency headwind go forward dollar weaken coca cola still see organic currency neutral revenue growth year pepsico pep monday top earning view improve productivity gain lower cost join other package food company manage earning gain weaker revenue pepsi report rise ep cent share top forecast cent revenue decline lighter estimate pepsi fall intraday wednesday dr pepper snapple dps fall intraday dr pepper report quarterly result april
228,JNJ,surgical robot maker intuitive surgical isrg receive multiple price target hike wall street stock hit new high wednesday follow earning report late tuesday ibd report intuitive surgical earning beat estimate really interested analyst be quarter procedure growth intuitive surgical normally sell only pricey da vinci robotic system quarter so surgical procedure used company consumable accessory service be key steady revenue management raise procedure growth guidance year previous operate expense increase intuitive surgical management also raise opex guidance year revenue previously however likewise raise gross margin guidance intuitive surgical be ibd big cap else make grade intuitive surgical impressive procedure growth be consistent recent positive general surgeon check write rbc capital market analyst brandon henry raise price target maintain sector perform rating intuitive surgical be accelerate operate expense spend believe investment drive increase future robotic adoption help company maintain superior position robotic market upcoming competition company have competitor present medtronic mdt transenterix trxc johnson johnson jnj partner alphabet googl verily division be develop own robotic surgery system leerink analyst richard newitter lift intuitive surgical price target maintain outperform rating now stronger outlook urology gyn general surgery give management confidence raise procedure guidance newitter write research note also management seem be talk more aggressively da vinci use thoracic procedure area think be corner emerge growth driver piper jaffray analyst matt brien raise price target rate stock neutral intuitive surgical stock hit record high early stock market today push year morning trading share be
229,JNJ,stock index chip weekly loss early friday blue chip rise more nasdaq pop also tack blue chip dow jone industrial average add small cap russell advanced volume stock market today be run higher nyse lower nasdaq dow component construction mining equipment maker caterpillar cat rise almost discount retailer wal mart store wmt almost stock market struggle week caterpillar wal mart be track weekly gain additional stock dow be head weekly gain be fast food chain mcdonald mcd tech service giant ibm ibm drugmaker merck mrk health care product provider johnson johnson jnj soft drink maker coca cola ko nasdaq starbucks sbux surge heavy volume climb higher buy zone stock clear buy point april be now entry starbucks have be move sideway hit high october week coffee chain be head gain ibd industry group early gainer friday include farm machinery construction mining machinery oil stock morning big loser be retail apparel economic news day be thin et baker hughe rig count be release price light sweet crude have rise past week related top dog big threat consumer crush fiscal expectation
230,JNJ,stock market climb higher afternoon trade head final hour session major index nasdaq dow jone industrial average moved nasdaq notch record high volume edge higher exchange vs same time friday other dow industrial cisco system csco pace advancer rise johnson johnson jnj follow gain jump back day line cisco be upgrade morgan stanley overweight equal weight downside verizon vz drop apple aapl lag general market advance well fall financial regain recently lose momentum stock market today dow component goldman sachs gs moved fellow investment bank morgan stanley ms rise nearly netease nte surge retake day line heavy volume monday last week online gaming company surpass analyst estimate share still fall other china base company commerce giant jd com jd fall competitor alibaba baba rise notch record high social medium company weibo wb moved ahead tuesday early earning release share be cup handle buy point cybersecurity stock moved higher wake global wannacry cyberattack ransomware target microsoft msft window operate system share microsoft edge lower be much leaderboard member fortinet ftnt rise stock have be much intraday high lead stock graphic chipmaker nvidia nvda surge extend winning streak day share be more buy point electric automaker tesla tsla drop almost be downgrade morgan stanley equal weight overweight analyst comment market expectation be too high apply material amat advanced receive price target hike analyst early monday chip equipment maker report fiscal earning close thursday chip manufacturer qorvo qrvo surge nearly volume be tracking more average action ibd be predominantly positive head final hour trading chemour cc trade control ctrl moved new issue floor decor fnd rise recent issue have be steady riser april ipo base have form yet downside china education stock tal education tal plunge related tesla downgrade fear apple alphabet steal thunderapply material get price target hike ahead earningsfireeye proofpoint mimecast top wannacry play goldman sachs
231,JNJ,nasdaq hit record high big surprise best year date performance large cap diversify stock etfs be turn tracking index powershare qqq qqq come top year date return well biggest month gain year average annual gain also lead list benchmark nasdaq index etf be new high ground mid april rebound week move average line first trust nasdaq equal weight qqew be also reach new height fund come second ytd performance month return lag other etfs make screen see vanguard mega cap growth mgk return past month gain so far year etf track crsp mega cap growth index be high recent bounce week line top holding apple aapl amazon com amzn facebook fb alphabet googl home depot hd momentum seek play ishare edge msci usa momentum factor mtum weigh month gain ytd return etf have climb steadily higher april launch track msci usa momentum index mtum skews large cap stock strong recent price performance top holding include mix big cap tech consumer health play such facebook amazon procter gamble pg microsoft msft johnson johnson jnj
232,JNJ,abbvie abbv stock rocket month high hover thursday top drugmaker report first quarter sale profit top wall street expectation stock market today abbvie rise close buy point flat base begin mid march share rise high intraday first quarter end march abbvie report adjust income share sale respective vs year earlier period analyst have modeled share sale sale humira abbvie biggest moneymaking drug grow humira sale be consensus view line leerink analyst geoffrey porge view pricing volume challenge note biopharma company immunology drug do not seem have impact humira same degree suggest humira formulatory position have remain largely unchanged reduce risk subsequent revenue miss say ibd take johnson johnson jnj first quarter report be expect have highlighted multiple issue biotechs drugmaker thursday bristol myer squibb bmy alexion pharmaceutical alxn also deliver board beat head ibd technology page deeper dive result porge keep market perform rating abbvie stock imbruvica cancer drug bring sale year year basis imbruvica bring line consensus view leerink forecast porge write note client abbvie note fda accept application imbruvica treatment graft versus host disease quarter graft versus host disease occur foreign tissue be introduce body organ transplant drug be be develop johnson johnson company later confirm guidance adjust earning share midpoint guidance also thursday celgene celg report better expect first quarter earning sale come short fellow biotech giant amgen amgn beat earning miss revenue late wednesday celgene amgen fall respectively related amgen trip rival sale miss earning topcelgene earning top biotech sale missbiogen earning top drug start well
233,JNJ,johnson johnson jnj need swiss biotech actelion pharmaceutical help reaccelerate earning growth patent blockbuster remicade expire rbc analyst glenn novarro say friday deal be remicade bring pharmaceutical sale be face competition pfizer pfe biosimilar inflectra meanwhile actelion have be prep loss exclusivity pulmonary arterial hypertension drug first month actelion sale increase accounting exchange rate novarro say same time sale pah drug tracleer fall offset sale fellow pah drug opsumit uptravi generic completion tracleer imminent believe sale be flat actelion novarro write research report ibd take johnson johnson have drug approve tie pfizer head ibd industry theme see company have most approval period time specifically early thursday announce have agree pay share actelion stock value company deal be expect close june help tack cent earning share month novarro see deal cent accretive also expect actelion sale grow acquisition forecast be conservative say see have big enough geographic footprint help actelion grow novarro have outperform rating price target johnson johnson stock rise stock market today fall thursday share have trade well day move average week related ceo underwhelm investor trump dodge drug pricingj hep dip virtually mirror gilead view laggilead merck alexion view hazy biogen surge analyst
234,JNJ,here weekly investing action plan need know investor come week tesla tsla quarterly report be most eagerly anticipate week mobileye mbly come ex partner tesla charge ahead autonomy continental resource clr other top shale producer report fiber optic stock acacia communication ticker
235,JNJ,month talk johnson johnson announce early thursday reach agreement pay swiss biotech actelion actelion have establish lead franchise differentiate innovative product pulmonary arterial hypertension pah be highly complementary exist portfolio janssen pharmaceutical company johnson johnson say part deal swiss drugmaker unit be spun separate company trade swiss stock exchange initially own firm right buy ll also have right drug candidate be develop drug discovery unit johnson johnson pay cash hold outside pay deal initially acknowledge effort buy actelion back nov talk break early december france sanofi sny lead position later month say be exclusive talk swiss firm johnson johnson chairman ceo alex gorsky actelion chairman jean pierre garnier hold analyst call et tuesday stock market wednesday johnson johnson share rise stock fall tuesday earning report sale guidance lag view related ceo underwhelm investor trump dodge drug pricingj hcv dip virtually mirror gilead view lagjohnson johnson exclusive talk acquire actelion sanofi fray
236,JNJ,eli lilly lly heist johnson johnson jnj type diabetes share leerink analyst seamus fernandez say wednesday day lilly stock outplay mixed quarter president trump related boost lilly stock ramp tuesday continue black wednesday close bell stock market today share end regular session earlier touch nearly month high lilly stock react softer tone trump tuesday pledge deregulate industry cut taxe trump also call drugmaker manufacture meeting executive celgene celg merck mrk lilly novartis nvs trump reportedly backed call revisit allow federal government negotiate behalf medicare medicaid fernandez research note say be reluctant call first event victory be not bad prior commentary keep outperform rating price target lilly stock note drugmaker sale diabetes drug improve lilly sale top estimate tuesday earning miss fernandez credit growth diabetes product sale performance sale diabetes drug trulicity jardiance grow respectively ibd take trump commentary have send drug stock run tuesday immigration ban monday topple airline stock fall survive read ibd industry theme deeper look trulicity belong class drug call glp receptor inhibitor have new brand share year year growth space fernandez write jardiance have new therapy share endocrinologist exceed invokana barclay analyst geoff meacham be less bullish boost price target lilly stock keep outperform rating trump rattle drug industry meacham say investor prefer product drive company lilly give difficulty triangulating drug pricing debate settle continue prefer product drive story lilly relatively low reliance price revenue concentration risk write research report lilly be likely struggle emerge immuno oncology market write company be partner merck combine drug keytruda chemotherapy alimta treat small cell lung cancer fda look likely approve combo write anticipate approval kn phase study keytruda recent favorable patent ruling drive pickup alimta growth meacham say outside oncology meacham expect lilly add drug pipeline baricitinib rheumatoid arthritis galcanezumab cgrp migraine market latter arena lilly compete teva pharmaceutical teva pharmaceutical aldr amgen amgn related eli lilly novartis challenge pfizer potential breast cancer drugpfizer report lag ep rebound trump round trip trump inspire rally fda appointment key
237,JNJ,health etfs perked tuesday follow better expect report nation largest health insurer gold price surge boost gold stock material sector help cross keenly watch level first time early december spdr spy post fresh high stock market today highest level dec stock gain follow steadying oil price key earning hearten investor health care select sector spdr xlv jab higher unitedhealth unh earning revenue beat forecast health insurer raise full year forecast strong organic growth good customer retention level xlv slice day move average monday first time health care sector be laggard year trail only financial unitedhealth first health insurer report first quarter be now have report scrutinize clue health care industry be fare company announce remain only handful obamacare public exchange next year state exchange currently unitedhealth stock jump more strong volume johnson johnson jnj also beat earning estimate tuesday revenue match forecast medical product maker add nearly raise full year forecast johnson johnson be hold xlv stock portfolio unitedhealth be medical peer ibd leaderboard stock edward lifescience ew report april meanwhile robotic surgery specialist intuitive surgical isrg report close beat earning estimate stock rise hour orthopedic giant stryker syk be report close wednesday material select sector spdr xlb carved gain tuesday hit fresh high etf have rise session xlb gain come soar gold price boost gold stock include portfolio member newmont mining nem market vector gold miner gdx gap add nearly gdx have soar year date hand profit etf investor buy day global silver miner sil streak ahead highest level more year ishare silver trust slv commodity etf flash more higher highest level june key outside market be bullish posture precious metal tuesday dollar index be weaker crude oil price be higher kitco senior technical analyst jim write tuesday weaker expect housing report give more price upside gold market say here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs
238,JNJ,trouble chip sector strength oil patch defined stock market action tuesday downgrade raymond james semiconductor stock contribute weakness chip nasdaq have tech bent slip meanwhile dow jone industrial average gain oil price rise volume rise board accord preliminary figure strike kuwait be hurt oil production thereby boost price price west texas intermediate crude oil rise nasdaq lose ground tuesday index stay day move average result earning season continue roll company beating top bottom line include johnson johnson jnj harley davidson hog intel intc beat earning miss revenue chipmaker fall close brinker international eat also top earning estimate miss revenue stock fall almost regular session rail operator kansa city southern ksu beat earning match view revenue stock jump regular session
239,JNJ,dollar have be not so jolly green giant corporate america mid cut top bottom line growth buck retreat negative impact ibm ibm other multinational fade result even more improvement expect go forward dollar index fall tuesday lowest level last august flash market crash continue downtrend year huge run mid late last year company heavy overseas exposure already be see smaller fx loss raise full year guidance currency trend johnson johnson sale come overseas say lindsey bell senior analyst global market intelligence encourage sign dollar index shot june november make export less competitive reduce dollar value overseas income revenue strong buck also contribute huge sell dollar price commodity crude oil fall much hurt energy company emerge market hurt industrial sector dollar rise large part federal reserve be move raise rate finally do last december other central bank ease policy fed have turn more dovish year sluggish economic growth financial turmoil earlier year fed now indicate just rate hike year previously market see just tighten step perhaps not september meanwhile bank japan european central bank push ahead negative rate policy currency unexpectedly rally move also china yuan re-cover early loss vs dollar dollar index be year year august say robert keiser vice president global market intelligence dollar be now vs year earlier suggest fx impact continue fade even start turn positive weaker dollar also have help crude price rise back barrel mid january slew corporate giant huge international exposure likely report less dollar impact next week so general motor gm alphabet googl report thursday mcdonald mcd general electric ge friday apple aapl facebook fb amazon amzn be tap next week less bad isn quite same good apple be expect post rare sale decline overall earning likely fall sale dip accord analyst poll thomson reuter exclude energy earning be forecast slip revenue
240,JNJ,medical giant johnson johnson jnj beat estimate raise guidance tuesday morning send stock fifth recent record high report earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale rise match consensus say foreign exchange impact knock percentage point sale growth nonetheless forex headwind finally seem be abate cite improve forex outlook reason be raise full year sale guidance also add cent ep guidance now ibd take johnson johnson rate group cr be iffy pharmaceutical business continue deliver impressive level growth have steady improvement consumer business be see momentum medical device business be fuel optimism full year ahead ceo alex gorsky say statement stock be early trading stock market today touch record high intraday stock be more year so far be first medical stock be hit new high be report week other be intuitive surgical isrg evening stryker syk late wednesday morning continue growth momentum company have see recent quarters again deliver organic sale growth acceleration second consecutive quarter double digit ep growth adjust operational basis write leerink analyst danielle antalffy research note note exclude impact foreign exchange activity shrink sale hepatitis drug olysio be make obsolete gilead science gild release harvoni late sale rise operate ep growth be just credit suisse analyst vamil divan write pharma sale beat be drive immunology franchise remicade simponi stelara well stroke prevention treatment xarelto top seller diabetes drug invokana miss consensus investor have be wonder invokana take hit eli lilly lly jardiance last september prove dramatically cut death heart failure didn get sale bump
241,JNJ,diversify medical product giant johnson johnson jnj confirm friday negotiation buy swiss drugmaker actelion johnson johnson jnj today confirm be engage preliminary discussion actelion pharmaceutical ltd atln vx regard potential transaction say statement be assurance transaction result discussion johnson johnson do not intend make additional comment regard discussion be appropriate do so formal agreement have be reach johnson johnson rise shorten session stock market today share be trading day move average fall thursday lowest level june ibd take pro biotech trump administration amgen biogen celgene gilead seek shore drug portfolio actelion have market cap shot european trading european drugmaker novartis nvs sanofi sny also bid actelion bloomberg report cite source novartis sanofi share rise respectively friday shorten session actelion have rely tracleer treat form blood pressure affect artery lung more half revenue tracleer face generic rival early drugmaker have new lung treatment opsumit uptravi soon boast dollar annual sale
242,JNJ,stephen nigro president hp inc printer business say re cusp fourth industrial revolution message fall wary ears industry develop additive dimensional printer burn hot stock market several year demand develop technology fall short expectation highflying printing stock crash
243,JNJ,blue chip lead major index friday oil driller take hardest hit day nasdaq grip gain dow jone industrial average rise also volume stock market today be run sharply lower be likely end way market be schedule close et small cap russell have be lead market edge price west texas intermediate crude oil drop loss be blame uncertainty saudi arabia say not be attend monday talk opec producer discuss supply cut ibd list comprise stock top fundamental technical loser lead winner ratio computer networking company gigamon gimo hold biggest gain score new high china base gaming internet company netease nte suffer biggest dent crumple brisk volume blue chip dow medical related stock notch good gain johnson johnson jnj pop higher merck mrk echo gain johnson johnson confirm friday have hold talk actelion pharmaceutical potential transaction actelion be switzerland base biotech company nasdaq beaten stock peg better gain first solar fslr rise stock remain high solar stock be expect rise hillary clinton win presidential election clinton have pledge spend billion help solar industry economic news purchasing manager index service flash november come october read be second strongest past month related black friday score so far target wal mart macy apple mobile
244,JNJ,company devote repatriate overseas cash stock repurchase next year congress enact president elect donald trump proposal lower taxe such move say goldman sachs top overseas cash holder be apple aapl microsoft msft google parent alphabet googl cisco system csco oracle orcl trump have propose time tax cut repatriation company corporate profit hold overseas tax rate fall plan indeed spur company bring back overseas cash say goldman sachs only second time year stockrepurchase account largest share cash used company forecast goldman sachs share buyback rise say investment bank ibd take apple have be raise dividend aggressively nov iphone macbook giant paid cent share cash shareholder learn more ibd income investor estimate buyback be drive repatriate overseas cash say goldman sachs research report forecast company repatriate close total overseas cash be direct primarily share repurchase moody investor service say apple be track have overseas cash end far most company be microsoft then come cisco oracle alphabet biotech company sizable overseas holding include amgen amgn medtronic mdt gilead science gild say ub research report say other company lot overseas cash include johnson johnson jnj coca cola ko probability significant legislative activity have increase result single party control first time republican single party control say goldman sachs report addition tax reform appear be prominent policy agenda expect see initial tax reform proposal march april possible enactment second half year apple alphabet share rise more stock market today microsoft rise fraction oracle be flat cisco slip fraction related apple microsoft cisco eye trump overseas cash tax planapple microsoft alphabet king cashfacebook buy back share stock slide continue
245,JNJ,stock market be mixed afternoon trading trading early intraday lows nasdaq shrug early weakness edge slightly higher dow jone industrial average remain red volume be tracking solidly lower exchange vs same time thursday other dow industrial apple aapl pace advancer rise fresh high several analyst raise price target iphone maker johnson johnson jnj mcdonald mcd follow gain respectively downside general electric ge lag more drop heavy volume be run nearly usual level merck mrk cisco csco fall general electric be downgrade sell deutsche bank believe ge be overvalue give weak earning quality other analyst action include nvidia nvda moved price target be hike canaccord genuity rbc capital market graphic chip maker remain barely extend potential entry nvidia be also make strong stride emerge artificial intelligence datum center self drive auto technology market recent ipo trade desk ttd roar almost higher late thursday earning release come well analyst expectation share be extend sharply cup base buy point financial stock underperform stock market today dow component goldman sachs gs drop retail brokerage charle schwab schw fall find resistance day line earlier week casino operator wynn resort wynn lead way rise retailer continue precipitous fall jwn plunge more beating earning sale estimate late thursday same store sale be weaker expect share fellow department store penney jcp reach record low more revenue same store sale fall more forecast early friday action ibd be mixed lead growth stock weakness financial offset strength technology name upside momo momo notch new high fiber optic stock lumentum holding lite moved downside chip name ichor ichr drop nearly bounce intraday lows report earning fall short street estimate regional bank citizen financial cfg private mortgage insurer essent group esnt fall respectively ichor be currently trading day move average sign strength related apple hit record high bullish wall street reportsthese red flag ge send stock month comp sale miss price brand rack surgesgraphic chip maker nvidia get fresh price target hike
246,JNJ,stock market ever find way major index tuesday continue pattern minor price movement provide only crumb guidance investor try figure next move nasdaq composite cut loss mix telecom software chip outperformance volume rise russell
247,JNJ,abbott laboratory stock be flat wednesday even firm top wall street first quarter sale profit expectation follow acquisition st jude medical abbott share have climb fall ultimately close stock market today have be form flat base march buy point first quarter abbott report sale grow vs year earlier period beating consensus analyst poll yahoo yhoo abbott report adjust earning cent share top view cent first quarter result reflect strong start year chief executive mile white say news release integration st jude be go well recently launch product be contribute double digit sale growth several area medical device business rbc analyst glenn novarro note seem be massive sale beat be mislead unclear consensus estimate include sale abbott medical optic sell johnson johnson jnj february unit sell period ibd take tuesday johnson johnson result highlighted multiple issue medtech pharma space issue likely trickle sector analyst say head ibd technology page closer look total nutrition sale decline quarter pediatric sale take biggest hit core laboratory sale grow vs year earlier quarter top novarro view slow venezuelan operation weigh diagnostic sale note research report establish pharmaceutical be outside only grow first quarter sale key emerge market include brazil russia india china emerge pharma sale grow medical sale double quarter drive growth sale cardiovascular device tool stimulate nervous system abbott also reaffirm guidance adjust earning share be line analyst view related abbott alere make altar new merger deal medtech stock buy ahead dow johnson johnson set lackluster result sector
248,JNJ,xdrug medical supply distributor cardinal health cah say buy medical supply unit medtronic mdt mostly debt weaker earning guidance cardinal share plunge early tuesday cardinal health be acquire medtronic patient care deep vein thrombosis nutritional insufficiency unit include brand used combine unit generate revenue last report quarters medtronic say include product category multiple market setting include brand such curity kendall argyle kangaroo be used nearly hospital well establish product line be complementary medical consumable business fit naturally customer offer reason product portfolio have be radar many year say cardinal health chairman ceo george barrett ibd take cardinal health share have be rebound presidential election investor believe donald trump be less aggressive drug price hillary clinton statement stock tumble day move average find support cardinal now see fiscal earning share low end earlier guidance expect deal be boost gaap ep continue operation more cent still see ep year be flat mid single digit cardinal health finance acquisition cash new debt standard poor fitch put cardinal credit rating risk downgrade cite increase leverage cardinal health share tumble stock market today gapping day day move average medtronic dip cent cardinal fellow drug distributor mckesson mck sank abc cardinal health paid cordis johnson johnson jnj add portfolio device include catheter filter stent medtronic say transaction reduce ep modestly medtronic spend net proceed deal share buyback rest go cut debt related johnson johnson earning top drug sale be drag
249,JNJ,major stock index etfs shot fresh time high wednesday string gain increase fifth ninth day spdr spy be wednesday seventh day straight gain have gain feb begin year powershare qqq qqq be ninth day straight gain have rise feb so far year health care sector be top contributor gain health care select sector spdr xlv surge top holding pfizer pfe leap amgen amgn johnson johnson jnj rise etfs tracking financial sector notch strong day financial select sector spdr xlf be holding big gainer be bank america bac charle schwab schw citigroup morgan stanley ms well fargo wfc jpmorgan chase jpm american international group aig dove report loss share insurer stock crash day move average day line energy real estate be worst perform sector continue lower second day row energy select sector xle be real estate select sector xlre be fed chair janet yellen hawkish comment interest rate put downward pressure rate sensitive sector xlre be testing support day move average gold be trading tightly third day row just day move average spdr gold share gld be here look performance major exchange trade fund key asset class stock market today relative price strength rs rating measure stock price performance last month vs stock etfs scale best possible spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related growth etf strategy tap rally trump have ignited sectorsstrength steel etfs come miner
250,JNJ,president trump call drugmaker manufacture effort curb rise price meeting big pharma executive white house mere week accuse industry get away murder trump also promise cut regulation appoint fantastic person lead food drug administration tight regulation slow fda often jam approval process drugmaker say last year fda approve new molecular entity year low tenor be reportedly different earlier call have federal government negotiate price behalf medicare medicaid agency cover million american be biggest purchaser health care product service world same meeting trump pledge increase international competition cut taxe business lure company back trump have pledge put america first inaugural speech say decision be make benefit american worker american family ibd take isn first time trump have pledge bring rise drug price actually mean biotech drug stock take look ibd industry theme deeper dive pharma bigwig include ceo eli lilly lly merck mrk celgene celg novartis nvs reportedly attend meeting johnson johnson jnj exec ceo pharmaceutical research manufacturer america also reportedly attend pricing have be astronomical trump say accord bloomberg folk have do very great job year have get price drug biotech stock reversed earlier loss news trump meeting emerge ibd company biom biotech industry group jump more close stock market today ibd company ethical drug industry group gain meanwhile spdr biotech xbi exchange trade fund be more move day line ishare nasdaq biotechnology index ibb etf also be get day day line related biotechs round trip trump inspire rally fda appointment key stock set new high biotechs give back most trump rally
251,JNJ,drug industry bellwether johnson johnson jnj topple tuesday sale guidance lag street hepatitis revenue slide virtually mirror recent concern fellow drug giant gilead science gild leerink analyst geoffrey porge characterize overall picture tepid stock market today johnson johnson stock fall sink further day move average support line have hover week johnson johnson report sale earning share ex item respectively vs year earlier quarter ep beat consensus cent sale miss analyst estimate ibd take drugmaker johnson johnson struggle biotechs incyte be poise jump incyte be dig market potential blockbuster read new america more market incyte opportunity johnson wrapped sale ep item respectively guidance particular disappoint johnson see sale be vs lag consensus analyst poll thomson reuter ep item guidance miss model expect johnson hepatitis drug sale dip virtually porge write tuesday research report gilead have be hammer past week wall street view prescription hep drug dip quarter quarter gilead be set report earning feb close neuroscience unit decline markedly year year oncology sale be bright spot rise other geography imbruvica lead oncology unit worldwide sale miss view related gilead clobber hep too little value too late hiv nash unitsgilead bulk hiv nash drug hep slump stock week dipgilead outlook hamstrung hep rbc bullish amgen biogen
252,JNJ,gilead science gild newest hiv regimen top rival combo glaxosmithkline gsk trial result release late monday doublet gsk keep intense competitive pressure gilead hiv unit leerink analyst geoffrey porge say porge view follow gilead presentation annual conference retroviruse opportunistic infection late monday seattle head head comparison gilead hiv drug bictegravir have narrowly better response glaxosmithkline phase trial examine combination bictegravir ftc taf emtricitabine tenofovir alafenamide glaxo dolutegravir ftc taf ftc taf be gilead backbone combo treatment naive hiv patient explain rbc analyst michael yee efficacy patient bictegravir arm achieve endpoint hiv rna level copy milliliter week compare patient dolutegravir arm delta widen week respectively hit endpoint safety appear be good yee write research report patient drop week due urticarium hive evercore analyst mark schoenebaum note bictegravir combo appear have better safety profile ibd take gilead hepatitis unit have suffer cure rate soar now biotech be look pivot potentially strong hiv drug sale gilead hep decline have be predict turn yes head ibd industry theme clue signale hep crumble gilead have moved combination phase trial gilead phase result weren strong enough establish statistical superiority bictegravir dolutegravir be enough explain gilead rush expand trial porge write research note investor be likely remain cautious threat pose glaxo dolutegravir rilpivirine doublet program show almost equally impressive result large phase switch trial say also late monday glaxo announce result phase switch trial look combination dolutegravir johnson johnson jnj rilpivirine be market name edurant combo achieve inferior viral suppression hiv rna less copy milliliter week gilead trial gsk look patient have already receive treatment median prior treatment period patient be year glaxo doublet dolutegravir rilpivirine be expect be market analyst rbc leerink say rbc yee note gsk put pressure gilead pricing doublet vs other regimen glaxo success ultimately require persuade patient switch drug hiv regimen leerink porge say gsk most likely have appeal patient have have adverse reaction long standing exposure first generation drug most patient be likely be switch gilead combination anyway meaning gilead likely recapture most share porge say also consider drug approach be inherently more restrict proposition give higher risk resistance reason anticipate relatively small share market be candidate doublet write stock market today gilead stock slip fraction glaxosmithkline edge friday gilead stock touch lowest price april related gilead crash hep sale decline view metric topcan gilead swivel hiv flounder hep sale gsk rivalry gilead stock dife month low hep cure drain total sale
253,JNJ,stock turn mixed early tuesday oil halter early advance earning news trip key sell off march housing datum be mixed dow hold gain nasdaq reversed decline volume rise stock market today nyse higher nasdaq compare same time monday dow stock moved almost unanimously higher open earning report drive extreme unitedhealth group unh lead gain ibm ibm stake low end more other dow issue report goldman sachs gs slip revenue miss johnson johnson jnj add narrow earning beat higher guidance oil energy crowd upside chicago base northern trust ntrs jump more solid first quarter revenue earning beat gain send share back day move average stock climb right side new base reaction earning report drive downside illumina ilmn netflix nflx lower new oriental education technology edu lead ibd list nearly seize new high share be extend almost past buy point equity lifestyle property el scramble nearly resort retirement property reit report revenue profit expectation late monday steer expectation fund operation slightly consensus stock be form flat base buy point lendingtree tree climb more rise top buy range buy point weak end drop rise trade stock have be look support day line share be cup handle base
254,JNJ,medical industry have lot prove upcoming earning season last round earning guidance didn do much reassure investor be already nervous other reason however major stock sector have be hit new high lately especially hardware side group here be such company report earning week johnson johnson jnj take traditional place head line report earning early tuesday first big drug company report cycle growth be expect be modest due gigantic size foreign exchange headwind have be drag global company earning year analyst poll thomson reuter estimate revenue rise year earlier quarter earning be estimate share muted growth johnson johnson stock hit record high trading friday close day fraction have maintain ibd relative strength rating last week mood wall street go quarter seem bullish late thursday rbc capital market analyst glenn novarro raise estimate base read drug prescription foreign exchange trend im im script trend several key drug suggest strong pharma quarter year year ex fx olysio novarro write olysio be hepatitis treatment additionally analysis currency movement begin year suggest negative fx impact full year result be less initially expect novarro note likely topic conversation conference call be month fda approval pfizer pfe inflectra biosimilar version blockbuster immunology drug remicade robotic surgery specialist intuitive surgical isrg be due report close tuesday analyst estimate earning rise last year share sale intuitive surgical have also be top perform stock lately company have be make comeback financially rollout da vinci xi surgical system improve procedure growth intuitive surgical stock hit new high wednesday more year boast excellent ibd composite rating close friday head key question investor be stock be baking too much optimism be start new product cycle evercore isi analyst vijay kumar write email client friday expect procedure volume be healthy growth general surgery lead way extra day leap year also help similar concern optimistic market seem be dog orthopedic giant stryker syk be due report close wednesday stock have also be roll wednesday hit new high be wound last year share close friday stryker stock keep climb last week even robert baird downgrade neutral barclay resume coverage underweight latter write stryker valuation appear be full go face more competition rejuvenate zimmer biomet zbh analyst cover stryker estimate sale rise quarter earning share
255,JNJ,drug stock have long be favore income investor relatively steady dividend payout merck mrk currently pay quarterly dividend share full year work annualize yield nearly well average payout new jersey base company have paid dividend quarter long term dividend growth rate be drug giant thursday announce positive result comparative trial zepatier hepatitis drug gilead science gild sovaldi wednesday merck say fda accept review supplement biologic license application keytruda treat patient recurrent metastatic head neck cancer also say fda grant priority review aug merck full year profit grow last year best year analyst expect gain year next share be work right side month consolidation be week high johnson johnson jnj product include blood cancer drug imbruvica prostate cancer drug zytiga offer annualize yield analyst forecast ep rise share higher sale report tuesday open stock be top buy range cup handle buy point clear feb amgen amgn know drug such neupogen epogen pay annual dividend have year earning growth rate analyst expect increase year next share biotech be near buy point cup shape base neither amgen johnson johnson show dividend leader friday ibd due space limitation
256,JNJ,be doubt osteoarthritis treatment offer therapeutic anik be gain traction take look week earning result massachusett base biotech first quarter net income be cent share whopping cent year trouncing view cent analyst poll thomson reuter total revenue quarter grow also soundly beat analyst view predict clearly patient be seek injectable therapy offer know hyaluronic acid product even surgeon have raise question effectiveness surgeon get paid more do surgery do injection joe munda analyst first analyst security corp tell ibd re start see rhetoric efficacy hyaluronic injection cool treatment help active age baby boomer suffer osteoarthritis knee well overweight couch potato re design not only ease vary stage pain also stave expensive knee surgery replacement worldwide market hyaluronic treatment be roughly say chief executive charle sherwood add grow year private payer have step away cover hyaluronic treatment american academy orthopaedic surgeon revise clinical practice guideline treat knee arthritis say medication be longer recommend method treatment patient osteoarthritis knee then reinstitute reimbursement sherwood say interview ibd other medical practitioner embraced hyaluronic therapy study hyaluronic injection have occasionally yielded disappointing result many doctor treat osteoarthritis say weight scientific evidence own clinical experience suggest shot knee hyaluronic produce significant relief patient arthritis foundation say article past january american medical society sport medicine say recommend use hyaluronic appropriate patient knee osteoarthritis also say be multiple trial indicate high quality evidence demonstrate benefit therapy be take market share market mike petusky analyst barrington research tell ibd rate company stock outperform fundamental company munda say add currently have equal weight market perform rating stock feel stock have moved very far very fast hyaluronic product be orthovisc monovisc multus injection single injection treatment osteoarthritis competitor include french drug giant sanofi sny italy fidium farmaceutici fer pharmaceutical seikagaku corp tokyo carbylan therapeutic cbyl palo alto calif be develop hyaluronic injectable product announce april have suspend further development product say be actively pursue strategic transaction include merger acquisition company other competition come plasma stem cell therapy sherwood say have yet be proven effective also sell hyaluronic base product wound care market filler skin smooth development effort be focuse used proprietary formula additional joint pain lubrication regeneration therapy re not standing still re continue innovate say munda latest injectable cingal be already approve use canada europe single shot injectable hyaluronic also include corticosteroid provide faster pain relief say sherwood have already run cingal trial sherwood say be highly successful approval be not question sherwood say week earning call analyst note cingal be combination already approve therapy just begin international clinical trial hyalofast cartilage regeneration therapy sherwood call scaffold make hyaluronic acid be then soak stem cell entraps cell treat lesion cartilage regrow cartilage trial be just start focus knee joint so be couple year product make market european regulator move more quickly ve have european approval hyalofast year be used knee ankle little hip say sherwood help partner also be pursue approval clinician use monovisc single shot hyaluronic injectable treat osteoarthritis hip depuy mitek subsidiary johnson johnson jnj have exclusive right distribute monovisc orthovisc johnson johnson be investing trial used monovisc hip say sherwood re right begin trial earning call sherwood mentioned new area exploration development be further first want expand use hyaluronic injectable use rotator cuff shoulder elbow tennis elbow achille tendon be also investigate develop synthetic bone graft therapy ankle knee foot also say be actively look acquisition be interesting target re actively look right fit sherwood say
257,JNJ,pfizer pfe stock pop thursday report drugmaker be consider selling consumer care business less month firm opted long rumore corporate breakup evercore analyst john scottus expect potential transaction garner cent earning share midpoint forecast assume tax proceed sale be used share buyback potential sale make sense scottus write research report thursday pfizer reassess future pfizer walk away merger ireland base allergan agn april lawmaker look crack tax inversion deal company be set headquarters lower tax region such ireland pfizer also have long mulled corporate breakup splitting innovative essential health division scrap idea september johnson johnson jnj buy pfizer then consumer care business pfizer build unit back acquisition wyeth later pfizer sell nutrition business nestle spun animal health business zoetis zts thus sale current portfolio consumer product appear be logical next step allow pfizer focus core competency develop selling innovative drug scottus write ibd take trump presidency affect drug biotech stock get full skinny ibd industry theme reuter first report potential customer care sale late wednesday cite anonymous source unit pull sale annually scottus liken bayer acquisition merck mrk consumer care business annual unit stock market today pfizer stock climb day line ramp second consecutive day follow election president elect donald trump share rise wednesday drug biotech stock have rebound trump election trump be see less likely challenge drug price vs democrat hillary clinton unveil plan last year cut spiraling price tag drug trump have promise tackle affordable care act obamacare investment bank rbc say tuesday cause dip biotech stock uncertainty new not yet outlined national health care editor note correct fourth graph show zoetis be spinoff related pfizer likely overpay post allergan breakup flop twist pfizer scraps breakup follow dead allergan merger
258,JNJ,digital medium marketing software maker adobe system adbe thursday announce deal buy video advertising platform tubemogul tube adobe pay share tubemogul end trading wednesday tubemogul share jump stock market today adobe stock fall fall key day move average line share break flat base buy point aug tubemogul offer platform brand agency plan buy video advertising desktop mobile stream device tvs adobe say acquisition tubemogul create first end end independent advertising datum management solution span tv digital format simplify have be complex fragmented process world biggest brand ibd take adobe stock have ibd composite rating meaning have outperformed stock key metric last month be rank stock ibd computer software desktop industry group more information adobe visit ibd stock checkup acquisition tubemogul strengthen adobe position digital marketing advertising technology include adobe medium optimizer adobe marketing cloud adobe also be leader video content creation delivery premiere pro cc primetime software adobe tubemogul share long list joint customer benefit integration tubemogul adobe marketing cloud service adobe say press release joint customer include allstate johnson johnson jnj kraft liberty mutual oreal nickelodeon southwest airline luv acquisition tubemogul be expect close first quarter adobe fiscal begin dec related stock be standout profit marginsadobe microsoft hit new high cloud prospectsadobe system ride strong tailwind online marketing
259,JNJ,alk lundbeck be cannibalize johnson johnson jnj psychosis sale credit suisse analyst vamil divan say monday cite johnson johnson slower expect schizophrenia drug sale last tuesday johnson johnson report year year growth drug treat schizophrenia divan write research report growth invega sustenna invega trinza risperdol consta lag divan model growth total prescription show invega sustenna have half depot injection market denmark base lundbeck abilify maintena aristada be swipe share johnson johnson risperdol consta divan say abilify maintena be co commercialize otuska america pharmaceutical hold new drug application abilify believe be positive lundbeck abilify maintena be key growth driver write currently estimate peak sale abilify maintena ibd take johnson johnson stock have middling ibd composite rating meaning underperform more half stock term key growth metric keep tab potential winner loser used stock checkup have yet announce date earning consensus analyst poll thomson reuter call report sale vs year earlier quarter share loss item be expect narrow cent cent last year johnson johnson much larger most drug company post year year sale growth company have post better quarterly sale past straight period johnson johnson report sale earning share ex item johnson johnson stock close stock market today rise stock jump friday hit month high company report good trial result drug treat depression related hit month high blockbuster potential soar antidepressant finally deliver trialsj top view buoy intuitive surgical say surgical ep ex item revenue beat expectation
260,JNJ,stock market remain lower thursday jump interest rate cause real estate sector tumble nasdaq reversed lower loss be fraction dow jone industrial average be fraction dupont dd climb medical firm johnson johnson jnj merck mrk add volume be tracking higher board retail fiber optic stock be weakest day trading acacia communication acia plunge nearly big volume biggest customer chinese telecom equipment maker zte report revenue estimate acacia be hottest stock hot fiber optic industry august break day move average oct stock have be sink group remain real estate development mortgage provider real estate investment trust be broadly lower ibd mortgage industry group skid real estate development operation be yield benchmark year treasury note jump basis point month high yield other major global market also rise trader appear be embrace grow chance interest rate hike federal reserve december real estate select sector spdr fund xlre track new real estate sector slide lowest level march sell real estate stock follow weakness home improvement stock week weak outlook quarterly result whirlpool whr be just series gloomy report industry wednesday jpmorgan wedbush downgrade lowe low energy stock be mainly higher crude price rise cent barrel exploration production integrate oil gas industry group be few breakout be worth note vmware vmw break past buy point flat base heavy trading share soon dip back entry cloud compute company beat profit sale expectation bluecora bcor climb past buy point cup type base high volume also fade back pattern clear entry internet content company business include taxact tax preparation software post loss cent share still beat expectation network ffiv soar breaking past double bottom buy point datum center equipment company late wednesday beat quarterly expectation wall street firm hike price target upgrade stock response related acacia communication hammer customer zte sale missf network upgrade price target hike fiscal beat amazon alphabet lumentum gigamon earning expect hour
261,JNJ,dow jone industrial average rest stock market gnaw sharp early morning loss small cap name fought get arm length breakeven point late afternoon trading tuesday indication investor be still hopeful strong report season stock get pound board bond investor fled deeper forest treasury goldman sachs gs johnson johnson jnj shock wall street weaker expect quarterly number yet dow jone industrial average trim early loss nearly roughly hour left stock market session nasdaq edge lower be small cap be practically flat yield year treasury note be basis point volume be sharply higher main exchange vs same time monday goldman report weak revenue fix income commodity trading johnson johnson hurt lackluster consumer product growth ethical drug revenue be heavy turnover latter megacap name clip key day move average heavy volume first time early january february dow jone component have rally serpent long saucer handle gain almost trigger ibd key sell rule take least partial profit stock have gain past proper buy point well form base pattern upside newer ipos fared nicely new bull market need dynamic new company attract large institution need deploy capital future growth story economy jeld wen jeld rise third straight session window door expert be find solid support just create day move average snap snap return back key psychological level rise yet stock be market equivalent bear size correction have slide more time high see recent stock market today column clear lack earning visibility be hamper snapchat network stock lately tuesday snap announce new digital lense popular snapchat app digital payment processor square sq be basically flat new flat base be emerge square post profit cent share first annual basis revenue jump other relatively fresh new ipos deserve spot watch list head california nationwide expansion continue stock be work right side new cup base left side peak fy earning expect rise share dave buster play former leaderboard name still steady uptrend modest gain recent past flat base excellent composite rating ep zayo group zayo dark fiber expert test new cup handle point fine buy support institution test day move average earlier year related stock market today snap undercut lows find great stock first check ibd sector leader master chart big first understand cup handle
262,JNJ,drug stock topple month low tuesday dow component johnson johnson jnj report first quarter pharma sale only advanced offer weak harbinger sector late afternoon trading stock market today ibd company ethical drug industry group be fraction earlier lose much touch low not see november biotech stock be less injured be still collectively lose much report light first quarter sale cent beat bottom line leerink analyst geoffrey porge say result highlight multiple issue large biotechs worldwide pharma sale grow just vs year earlier quarter miss expectation international drug sale beat pharma sale miss porge write research report oncology sale lead growth legacy product remicade stelara xarelto offset volume decline low growth price hike alexion pharmaceutical alxn abbvie abbv celgene celg derive large portion sale international market benefit worldwide pharma growth be reflect sector porge have outperform rating alexion stock market perform rating abbvie celgene stock ibd take ibd ethical drug industry group be now rank group track just week biotech industry group be perform much better rank seventh week head ibd stock checkup list strongest stock higher utilization independent patient assistance program timing medicare part cost higher drug access discount leave celgene amgen amgn vulnerable biotechs porge say cite commentary have market perform rating amgen stock pricing power appear remain strong do report lower price government manage care channel impact annual comparison write do not anticipate issue be isolate alone impact broader biopharma industry drugmaker evercore analyst umer raffat note struggle diabetes unit invokana sale be year year be reflect eli lilly lly diabetes franchise leerink analyst seamus fernandez earlier say unit help lilly overcome struggle rheumatoid arthritis drug raffat note pricing pressure cardiovascular drug xarelto be reflect bristol myer squibb bmy eliquis xarelto sale fall vs year earlier period silver line report year year growth imbruvica cancer drug partnership abbvie company be now look have imbruvica approve treat patient suffering graft versus host disease occur foreign tissue be introduce body organ transplant related dow johnson johnson set lackluster result lilly survive rheumatoid arthritis flop breast cancer drug
263,JNJ,stock market trade lower morning trading tuesday corporate earning mostly disappoint datum show new home construction miss estimate residential housing start march come vs predict nasdaq moved lower fall dow jone industrial average drop volume rise solidly nyse nasdaq vs same time monday dow industrial goldman sachs gs johnson johnson jnj drag dow lower report earning sale early tuesday goldman miss street earning revenue expectation blame weak trading revenue political uncertainty low market volatility share drop johnson johnson report earning beat target revenue come short weaker pharmaceutical sale share fall pierce day upside coca cola ko mcdonald mcd pace advancer gain respectively share coca cola be build right side base get back day week mcdonald be buy range cup handle buy point mcdonald be upgrade outperform bernstein other company report earning bank america bac top earning expectation cause share rise initially fall midday trading financial sector moved lower netflix nflx lose release earning late monday video stream company miss forecast subscriber growth stock remain day line snap snap jump release new lense snapchat user new augment reality overlay create experience photo snap be heated battle instagram be own facebook fb last week facebook say instagram story feature have more daily user snapchat snap share remain post ipo lows facebook trade higher remain time high lead growth stock dycom dy advanced lead ibd telecom stock be breaking cup shape base entry volume surge nearly average quarterly earning grow most recent quarter vs same quarter prior year downside china base momo momo fast grow video platform social networking drop tal education tal moved almost related goldman sachs blame weak trading revenue politic bofa topsjohnson johnson earning top drug sale be dragnetflix top subscriber adam sandler original showsstock market today snap turn profitable
264,JNJ,stock be lower tuesday morning earning report kick full swing dow jone industrial average fall most goldman sachs gs johnson johnson jnj weigh dow shed nasdaq composite be small cap russell give volume be higher board vs same time monday medical bank oil issue lead downside today stock market action airline food retail stock be few gainer dow stock be active component report earning ibm ibm be slate report close goldman sachs gap fall heavy volume month low big bank result miss view top bottom line share have be consolidate day move average past few week bank america bac rise nearly fast trade top quarterly view stock have also be consolidate week move average johnson johnson jnj drop gapping day line high turnover back buy point last base dow component drug medical device maker report earning beat revenue miss analyst target cardinal health cah gap plunge breaking day day line massive volume medical product distributor say buy medtronic mdt medical supply unit also guide full year earning estimate lower back dow unitedhealth group advanced healthy trade health insurer deliver result top consensus forecast boost full year outlook share be rebound day line related goldman sachs blame weak trading revenue politic bofa topsjohnson johnson earning top drug sale be drag
265,JNJ,xhere investing action plan tuesday need know investor come day facebook fb begin annual developer conference earning season kick high gear report dow jone industrial average component goldman sachs gs ibm ibm johnson johnson jnj unitedhealth unh charle schwab schw also report
266,JNJ,johnson johnson jnj zimmer biomet zbh be medtech stock own go earning season several other be put buy list pullback analyst say rbc analyst glenn novarro say wednesday large cap medtech stock johnson zimmer offer best risk reward first quarter earning season zimmer be cheapest arena johnson have lag group investor sentiment have turn more favorable johnson recent week anticipate further multiple expansion back strong first quarter result consensus estimate move higher year write research report consensus analyst poll yahoo yhoo broadly expect johnson report sale year year share adjust earning dip johnson be also cusp close acquisition actelion pharmaceutical second quarter sanofi sny be lock battle late last year take swiss biotech johnson bid win company zimmer company just have hit consensus estimate stock move higher novarro say consensus model year year sale growth adjust earning share novarro however say abbott laboratory boston scientific bsx edward lifescience ew stryker syk be attractive pullback see deliver solid result reaffirm guidance investor likely track ongoing litigation abbott alere alr heart valve replacement sale edward boston likely comment voluntary recall lotus heart valve replacement company recall lotus device discover malfunction result premature release pin implantation medtronic mdt onyx stent launch represent term challenge boston still want own boston novarro say small midsize cap world novarro recommend nuvasive nuva medical group wmgi group potential takeout be likely baked stock price nuvasive say ibd take isn first time edward have be list best stock own head ibd technology page deeper dive edward be hold strong remain top pick small midsize medtech group expect play catch group investor focus shift company impressive new product lineup improve international sale growth company experience distributor issue write novarro needham analyst mike matson also prefer zimmer also have strong buy rating share inogen ingn mimedx mdxg see cardiovascular orthopedic market slow diagnostic market improve quarter matson model cardiovascular market growth decelerate fourth quarter orthopedic market advance vs growth prior quarter diagnostic sale likely grow say be standout matson say model transcatheter aortic valve replacement market boston edward medtronic operate have grow orthopedic matson model growth extremity market related medtronic do heart valve study rival reap benefitsboston scientific make acquisition battle medtronic edward
267,JNJ,cancer biotech tesaro tsro fetch north share rumore takeover credit suisse leerink analyst suggest week tesaro stock bound record high wednesday thursday friday leerink analyst seamus fernandez recommend tesaro buyer hang sideline potential flurry downgrade tesaro stock market perform rating outperform up price target stock market today tesaro stock fall touch record high intraday thursday tesaro stock jump have increase fivefold past month investor clearly value tesaro niraparib lead parp inhibitor fernandez say tesaro drug compete fda approve drug astrazeneca azn clovis oncology clvs bar takeout upside current level look challenge give competitive event path next month write research note preclinical evidence suggest niraparib have better activity astrazeneca lynparza clovis rubraca ibd take biotechs incyte be steady bet analyst say pipeline potential blockbuster incyte generate peak sale jakafi alone dive new america more incyte catalyst niraparib be priority review food drug administration treat ovarian fallopian tube primary peritoneal cancer key trial be also be conduct first line second line breast prostate cancer success trial boost tesaro valuation target credit suisse analyst alethia young say thursday estimate unadjusted sale ovarian indicated therapy very little company make ipo have just start generate revenue expect have end revenue hasn yet set date earning release young see tesaro grab third first line metastatic breast cancer market patient brca mutation grab prostate cancer market collaboration johnson johnson jnj fernandez view total sale other be more bullish projection assume dominance key registrational trial currently underway complete breast ovarian prostate cancer takeover top share say be take account tesaro immuno oncology pipeline be currently testing checkpoint inhibitor include pd lag tim drug work teach immune system see destroy cancer cell often hide normal look protein credit suisse young put sale estimate tesaro platform assume success niraparib breast ovarian prostate cancer mean share takeover price jump share success say wouldn expect tesaro agree takeout credit platform be thesis well write research report young keep outperform rating price target tesaro stock news tesaro potential acquisition interest wasn surprise say think auction process company be highly competitive most big global biotech pharma company come table talk say related tesaro rocket time high rumore takeout interesttesaro astrazeneca shrink clovis ovarian cancer drug poolbiotech stock catalyze plunge key sector
268,JNJ,ebay ebay price target be hike thursday johnson johnson jnj mattel mat unite technology utx be downgrade price target be raise rbc capital market fbr co late wednesday communication giant report biggest earning gain quarters guide revenue growth low single digit earning growth mid single digit share rise stock market today ebay price target be raise rbc capital market aegis capital late wednesday online marketplace report fourth quarter earning revenue line wall street exception share jump intraday high still enough break buy point johnson johnson be downgrade market perform well fargo share dip health care product company agree buy european biotech actelion pharmaceutical thursday report weak sale guide low tuesday mattel be downgrade neutral mlm partner toymaker report weak holiday result wednesday share plunge nearly hasbro have be downgrade neutral monness crespi hardt share tumble unite technology be downgrade hold argus research report earning line analyst view light revenue wednesday industrial giant say boost delivery newest gear turbofan jet engine year production problem slow delivery share be related alibaba seagate price target raise earning lockheed pt cutapple aetna humana downgrade comcast pt raise ahead qualcomm downgrade apple suit verizon downgrade dish upgrade
269,JNJ,nation best perform mutual fund past month continue add defensive sector such reit transportation build product firm portfolio stock market work weaken global economy slumping oil commodity price terrorist attack belgium nasdaq composite index end month march gain shave first quarter loss similarly ramp march manage eke gain first quarter lead mutual fund still nab big financial property reit such stor capital stor equity lifestyle property el public storage psa latest report period thursday property reit group be rank industry track ibd sector be featured april industry snapshot click here see list new buy top mutual fundsbuild stock be have good hair day so far year include universal forest product ufpi concrete uscr comfort system fix masco mas american woodmark amwd nvr nvr light equipment supplier acuity brand ayi break cup handle base wednesday robust fiscal second quarter earning result company see impressive growth lead base light product rise more year period account total net sale transportation issue include airliner hawaiian holding alaska air group alk southwest airline luv have be steady performer past month thank low fuel price ibd spot top notch fund add alaska airline investing estimate fidelity fund contrafund fcntx fidelity focuse stock ftqgx add share latest report period seattle wa base airline recently stomp biggest competitor agree buy california base carrier virgin america va fleet plane cash deal equity value include debt lease take price tag acquisition make alaska airline fifth largest carrier base market share virgin america have hub los angele san francisco purchase secure alaska airline stronghold flight west coast alaska be also look make bigger presence east coast virgin america valuable gate slot new york washington airport stock be still etching handle part cup handle base most part stock manage hang gain market turbulence near entry point alaska airline have be rocking double digit earning growth past quarters solid revenue growth manager country top fund have be unload oil stock such exxon mobil xom chevron cvx oil rally fade recent week telecom cable giant verizon communication vz ibd see net selling fund latest report period delaware value fund ddvix hold big stake firm top fund have also be take profit medical firm johnson johnson jnj toy maker mattel mat hit new week high click here see list latest sell top mutual fund image provide shutterstock
270,JNJ,stock come selling pressure early yesterday morning expect then do complete degree turn close mostly higher dow triple digit pierce psychologically important level surge pt end day right high rally person love hate move pressure oil price work stock first moment trading investor trader big bank end ignore news doha move surprised many mkts world be celebrate today take cue turnaround equity future be rocket higher currently pt kiss psychological level friend scott redler reddogt tell twitter morning first kiss usually meet opposition then romance get basis say yes be first kiss be sweetest make want go back more more be look be gonna get today remember mkt be discounting mechanism be look month trading today be not today just sayin be really mkts expect fall look mkt be expect great thing asian mkts be higher overnight japan get clobber monday snap back regain monday loss see yen bit stabilize oil mkt be also help support mkts today yesterday mkt action appear investor be disconnect whim oil mkt least now concentrate earning european mkts be also enjoy explosive rally earning oil sense be maybe whole mid east opec summit be hype confuse conversation interesting possibility increase production have cause oil stabilize rally bit monday lows do feel something else be go ftse cac dax eurostoxx spain italy now just thought yesterday role deputy crown prince be now play look big story be oil politic mid east politic month hype pending agreement production freeze trader mkts have deal fact be deal now set oil mkt possible free keep eye deputy crown prince moham bin salman be now name know be yr old son king salman have now turn apple cart merged commercial consideration kingdom political stance move be complete contrast be exist policy see past yr ali al naimi current saudi oil minister have keep issue separate page keep supply pricing main driver production decision always cooperate other member include iran matter politic be past cut production boost oil price deputy crown prince be not sure agree policy so talk have be saudi be cooperate russia venezuela qatar iran be still thorn prince moham side so bid establish emerge force potential heir throne nix oil deal send oil mkts tailspin sunday night monday be important understand be deputy crown prince have now burst global stage father become king last year appear have intention let world know be appoint defense minister be responsible launch latest military campaign yeman also chairing country economic plan body council control massive state own oil company tell interview last week bloomberg prince be very clear don care oil price be same have own program don need high oil price be not rest opec opec member feel so nixing deal have protected saudi mkt share have secure role leader same time layer groundwork continue political instability region back mkts initial concern recent development focus return earning day start better number pepsico pep hasbro have jb hunt jbht surprise move learn morgan stanley ms report horrible number do fact beat estimate net income fall equity trading revenue fall fix income trading revenue fall investment banking revenue fall yet somehow manage beat much lower ep expectation so mean be watch goldman sachs gs report morning analyst expect ep now remember uncle lloyd pre announce re structuring plan late friday so investor trader have be prep bad news have dealt head cousin jamie dimon jp morgan jpm uncle lloyd know massage street analyst so expect hear morning be blow sock ep beat rival even most generous estimate clock tick be other news unite health unh just report better number vs exp philip morris pm other hand miss vs exp watch brinker eat comerica cma genuine part gpc harley davidson hdi kansa city southern ksu johnson johnson jnj take good care
271,JNJ,kpfollow kenny polcari twitter kenny polcari comkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
272,JNJ,so yesterday pm news hit tape twitter sphere medium outlet headline scream breaking news sunday april failure qatar opec minister unable come agreement oil mkts begin tremble investor trader now have re assess reality fracture oil mkt oil have rally early april lows january lows be now front center asian mkts prepared open initial reaction see oil plunge investor hit sell button first only ask question later headline saturate web be first announce failure then result mkt action headline begin doha summit fail agree output freeze oil freeze talk end failure saud demand iran oil tumble doha deal disappointment asia stock mercy post doha oil move oil grand bargain fall victim saudi arabia iran fixation future globe plunge day turn night sun begin set just begin rise asia future be pt pm sunday evening future asia point similar direction investor dealt fallout news story begin detail talk take place doha qatari capital drag go hrs past original schedule end time howie mandel shout deal oil minister nation represent world production gather qatari capital work stabilize global mkt artificial production quota first real attempt coordinate output opec member nation outside group barrier be numerous everyone fall line iran come table really commit restrain production know saudi make very clear begin wouldn restrain production commitment other major producer include iran have already make clear have such intention breaking story failure agree output production quota world biggest oil producer now open flood gate many now expect be new retreat oil price discussion stumble saudi arabia other gulf nation wouldn agree deal opec member joined include iran wasn present meeting angus nicholson analyst ig ltd melbourne australia have say market have be so heavily position deal go change tone saudis particularly drive last few week deputy crown prince moham bin salman have be quite surprise market saudi arabia fight proxy war iran yeman syrium iraq be understandable have little inclination freeze own production make way newly sanction free iran increase market share so then happened be really change tone saudi do investor get wrong once idea freeze be floated month trader type start buy oil be assume freeze trim supply just summer be begin drive season be take oil rally lows excitement build buyer beware remember be news source report cease fire saudi russian never really confirm deny story let play medium never explicitly commit sound good do require member fall line iran have say very begin have intention play nice sandbox overnight oil suffer bit brent wti west texas intermediate make sense equity mkts do not follow suit implode way many thought fact have ask be deal actually better mkts long run allow supply demand find natural level equilibrium vs artificial production control only put inevitable mean look know artificial control do mkts think massive qe program instituted central bank asian mkts open pressure come bear mkts sell not extent many be prepared japan be outlier fall have more do major series earthquake past day vs oil story south korea kospi moved lower australia stumble hong kong lose china be end day sun set asia rise europe clock tick european mkts be next react too be bit pressure take cue investor angst asia again equity be not get clobber stretch currently brent north sea crude oil be wti west texas intermediate be nearly trading barrel ftse cac dax eurostoxx spain italy future be pt sunday evening have re-cover bit initial knee jerk reaction trading last night currently be lower pt reality opec decision permeate psyche equity mkts do not implode news many have expect need ask be investor try separate action oil energy space rest mkt now energy name get hit today think transport manufacturer beneficiary lower oil price earning continue ramp week enter thick last week message be bank now see trading revenue decrease loan loss reserve increase most report miss revenue estimate manage beat bottom line uncle lloyd blankfein release strategic restructure plan ahead earning week headline read goldman blankfein demand deepest cost cut year chop block travel limit entertainment defer project layoff have already adjust workforce rely more junior banker move support staff cheaper location investing technology improve productivity junior banker mean want jr banker be so many other place go don go gs jr banker stock rally news take trend dma earning be due tomorrow so clock be tick do do good enough job acknowledge disastrous industry environment sake investor earning today include morgan stanley ms beat estimate report ct sh vs exp ct sh pepsico pep beat report ct sh vs ct sh expect hasbro have toy also beat vs ct sh later week hear american express axp mcdonald mcd johnson johnson jnj ibm ibm intel intc cocoa cola ko microsoft msft be not major economic datum point today so chatter be earning oil fed speaker today dudley be kashkari pm rosengren pm take good care
273,JNJ,kpfollow kenny polcari twitter kenny polcari comkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
274,JNJ,so call fang stock facebook fb amazon amzn netflix nflx google parent alphabet googl be bare tooth move aggressively expand market share core industry enter new one tech titan be have most success generate continue growth year sale growthdriven mark zuckerberg successful pivot mobile right mobile advertising start skyrocket facebook lead pack metric year annual sale growth rate follow netflix amazon alphabet worth note here ceo jeff bezos say growth amazon web service cloud unit be outpace commerce business reach sale year year ep growthnetflix edge facebook top spot category year annual earning share growth rate compare social medium giant pace alphabet rank distant third rate pre tax profit marginfacebook alphabet dominate fang family term annual pre tax profit margin netflix amazon trail far high level profitability be allow facebook make multus dollar bet instagram whatsapp oculus vr well invest heavily mobile advertising new apps facebook messenger also allow google parent alphabet explore so call moon shot project include verb surgical joint venture verily unit johnson johnson jnj develop advanced surgical robotic compete intuitive surgical isrg earning sale growthamazon bounce back drone blaze deliver gain earning easily top facebook alphabet netflix sale side facebook defange competition increase year year netflix amazon alphabet post solid gain accumulation distribution accumulation distribution rating show fund manager other institutional investor have be heavily buy selling stock trail week netflix rating show moderate institutional buy be only fang stock currently get pass grade facebook amazon have lowest possible rating point heavy selling last month week alphabet be only little better still get fail grade rating composite composite rating range worst best provide overall grade stock show stack term technical fundamental strength other stock market facebook alphabet earn highest possible score meaning re outperform other stock amazon rating have be move higher now stand netflix have decidedly mediocre score top stock industry group ibd stock checkup show top rate stock industry group fang stock only facebook alphabet member internet content group earn distinction amazon rank retail internet group stamp com stmp alibaba baba hold spot respectively netflix come peer leisure movie related industry group excerpt ibd extra newsletter image provide shutterstock
275,JNJ,stock open sharply lower tuesday follow lead overseas market slip nasdaq lose dow jone industrial average give stock market today appear pull premarket cue europe stock be pressure raft unexpectedly soft economic datum cac paris frankfurt dax trade more ftse london show loss afternoon trading market receive dose service sector datum later morning london base researcher markit release march service purchasing manager index et institute supply management deliver march index labor department report job opening labor turnover survey february early report show trade gap widen slightly february upwardly revise january commerce department report economist consensus have forecast milder uptick oil price dip slightly left west texas intermediate bob barrel natural gas jump more gain last week monday gold future climb more ounce dollar be mixed bond blipped higher send year yield basis point dow stock slide almost unanimously lower cisco system csco lead downside fall early outperformer include pfizer pfe procter gamble pg johnson johnson jnj pfizer report positive result psoriatic arthritis treatment phase clinical trial federal regulator announce pending rule change affect potential inversion merger rule directly affect pfizer allergan deal set close later year share ireland base allergan agn crumble tesla motor tsla lag nasdaq fall late monday company give delivery count mentioned model part shortage nearly ibd stock be flat start regular trade edward lifescience ew backed suggest well earn pause monday price spike wesson swhc show sign life sell monday japan tokyo nikkei dive week low yen continue gain strength disappointing industry forecast send iron steel issue tumble china market end mixed shanghai composite hong kong hang seng index stock india skid lower reserve bank india cut interest rate basis point line consensus expectation market have already price react cue global market bloomberg report send mumbai benchmark sensex index image provide shutterstock
276,JNJ,vast majority billionaire warren buffett portfolio be invest dividend pay stock long history dividend increase surprise then johnson johnson jnj be current hold consecutive year dividend increase last month declare quarterly dividend cent share give annualize yield next dividend be payable march shareholder record next tuesday market capitalization have lot different tentacle healthcare space consumer health care company well pharmaceutical medical device firm popular consumer brand consumer segment include neutrogena listerine tylenol visine meanwhile janssen pharmaceutical company be involved oncology immunology neuroscience infectious disease other field several product late stage trial medical device segment make product orthopedic vision care infection prevention last month report adjust earning share year sale fall strong dollar weigh result sale account total revenue europe chip pharmaceutical segment make nearly total revenue quarter medical device be consumer segment account total revenue company receive fda approval cancer treatment darzalex daratumumab double refractory multiple myeloma yondelis trabectedin rare cancer be schedule present rbc capital market global healthcare conference tuesday image provide shutterstock
277,JNJ,apple aapl microsoft msft cisco system csco other technology company gain president elect donald trump support time repatriation company corporate profit hold overseas idea get enact still republican hold congress trump have propose repatriation tax profit corporate foreign subsidiary statutory top overseas cash holder be apple microsoft google parent alphabet googl cisco oracle orcl trump cash repatriation proposal bring flood money back be available dividend share buyback possibly capital investment say kevin logan hsbc economist research report tax revenue raise be used fund infrastructure spending program something be advocate candidate presidential campaign moody investor service say apple be track have overseas cash end follow microsoft cisco oracle google project top have overseas year end total cash expect most company take advantage hypothetical tax reduction permanently repatriate money maximum extent possible devil be always detail moody analyst richard lane tell ibd email nevertheless hypothetical tax offshore project translate tax revenue be invest efficiency enhance domestic infrastructure investment more important temporary time tax relief however be permanent tax reform provide company clarity make long term capital allocation decision trump have also propose reduce corporate tax rate effort keep company leave country lower rate give republican control be possibility tax relief incent company bring foreign cash back offer opportunity invest buyback stock acquire asset lamba mizuho security analyst say report pritchard citigroup analyst say republican controlled house senate be not likely block cash repatriation proposal republican keep narrow lead senate maintain solid advantage house pritchard say adobe system adbe autodesk adsk citrix system ctxs red hat rht vmware vmw be company bring back cash believe chance increase larger share repurchase lesser chance dividend company pritchard say research report biotechs sizable overseas holding include amgen amgn medtronic mdt gilead science gild say ub research report say other company lot overseas cash include johnson johnson jnj coca cola ko specific depend ultimate legislation expect significant amount overseas cash balance perhaps greater be repatriate used continue repurchase share pay dividend also increase pace growth capex latter have be miss component current cycle ub analyst julian emanuel say report big tech stock oracle be cisco add close stock market today meanwhile apple be fraction alphabet slip microsoft share dip related apple microsoft alphabet king cashdrug stock fly clinton defeat
278,JNJ,intuitive surgical isrg report third quarter earning close tuesday company da vinci system be leader robotic assist minimally invasive surgery quarters more year year growth ep ex item earning be expect fall tad comparison get tougher sale growth be expect remain fairly steady johnson johnson jnj early tuesday post solid rise advanced surgery device business be good sign rival intuitive estimate ep ex item be see fall revenue growth accord analyst poll thomson reuter result ep ex item revenue ship da vinci surgical system prior quarter ep ex item rise sale jump biggest increase quarters company say ship da vinci surgical system stock intuitive surgical rise stock market today share be nearly hour earning release stock clear buy point flat base just barely stock have do little hit buy point do touch record high oct relative strength line be new high related boost intuitive surgical chart look good not good
279,JNJ,early tuesday johnson johnson jnj post better expect earning include double digit sale growth advanced surgery evercore analyst vijay kumar say prove boon intuitive surgical isrg stock however have diverged close bell stock market today johnson johnson finished day intuitive surgical stock close gain share intuitive surgical be set report earning close tuesday share try gain traction breaking flat base ibd take johnson johnson be face upcoming rivalry pharmaceutical unit celgene gilead science galapago biogen be also work drug treat crohn disease johnson johnson report sale earning share item respective vs last year metric top consensus analyst poll thomson reuter sale fall huge consumer segment other hand pharmaceutical medical device sale grow respectively pull still small advanced surgery device unit general seem be bode well intuitive surgical kumar write research report intuitive surgical be know da vinci robot surgery system analyst expect intuitive surgical report ep ex item sale ep dip sale climb related be google plan surgical strike intuitive da vinci
280,JNJ,spending research development have leveled company increase stock buyback dividend say goldman sachs company do better other get most bang buck new research report goldman name company say be best position make dollar work make list be align technology algn amazon com amzn alphabet googl grubhub grub incyte incy universal display oled palo alto network panw regeneron pharmaceutical regn meanwhile intel intc microsoft msft google parent alphabet amazon drugmaker johnson johnson jnj lead way total spending goldman sachs also analyze intensity measure percentage sale other metric regeneron salesforce com crm apple aapl amazon netflix nflx have experience outsized growth come gross profit well price return same period say goldman report ibd take goldman sach favorite palo alto network belong ibd learn many growth stock grubhub sport highest possible composite rating align technology have cr composite rating be part slim investing share total spend pie have be pretty stable suggest corporation have likely be maintenance mode spend opposed be expansion mode say report tech company lead spending follow health care consumer discretionary industrial sector say goldman related do tend buy stock too late lesson align stoke fire deep durable melanoma drug resultsole leader universal display crack misscisco palo alto symantec gear cloud cybersecurity shift
281,JNJ,amgen amgn stock topple hour trading wednesday report first quarter sale miss increase competition key drug arsenal enbrel bone marrow stimulant neupogen biotech giant say sale enbrel neupogen fall respectively meanwhile sale anemia drug epogen fall due decline net selling price higher demand help sale spike several drug include repatha amgen bad ldl cholesterol buster repatha sale pop year year worldwide competition like regeneron regn sanofi sny quarter end march amgen report adjust profit share vs year earlier quarter top consensus sale dip miss analyst view hour trading amgen stock be close fraction regular session share be currently form flat base buy point have trade day move average mid march be well position long term newer product demonstrate value growth world tight operational expense management company say chief executive robert bradway statement ibd take dow johnson johnson jnj report drug sale advanced just see ibd technology page multiple issue be bleak harbinger sector quarter amgen unveil result trial last more year dub fourier patient take cholesterol lower medicine reduce bad ldl cholesterol blood lead decrease risk heart attack stroke amgen find analyst have say amgen be face pushback payer don want reimburse wholesale acquisition cost repatha regeneron sanofi esperion therapeutic espr be work same area add robust repatha outcome datum be work payer improve access important therapy patient risk heart attack stroke key spike quarter include sale bone drug prolium xgeva respective revenue multiple myeloma drug kyproli grow blincyto second line treatment chromosomal disorder leukemia see sale grow amgen boost guidance adjust profit share lag consensus year year basis adjust profit be midpoint guidance sale guidance be reiterate related amgen rival pop cholesterol bust drug
282,JNJ,dow jone industrial average rally midweek wo president trump top aide signale tax cut other key agenda item be track dow credit card giant visa american express axp charge higher ibm ibm goldman sachs gs netflix nflx subscriber growth underwhelm even internet tv giant be hit user facebook fb tout augment reality developer conference dow jone industrial average fall month low wednesday follow weaker expect result ibm goldman sachs johnson johnson jnj blue chip index rebound thursday leave dow modestly higher week still day line index retook day line thursday return support friday nasdaq rally fuel chip gear stock facebook netflix predict reach milestone stream video subscriber worldwide weekend netflix miss forecast first quarter subscriber growth guide analyst higher customer addition current period internet television network expect end subscriber worldwide netflix fall tuesday close week virtually unchanged related ibm stock plunge big blue report straight quarter year year decline ibm revenue fall miss consensus time tech icon continue struggle multiyear transition ep rise share modestly beating related goldman sachs gs show surprise weakness first quarter trading bank chalk estimate miss result more re-serve market trump agenda stutter european election approach ultimately didn navigate market well deputy cfo martin chavez say quarter define franchise compound goldman wo rival morgan stanley ms beat goldman fix income trading revenue analyst estimate overall meanwhile bank america bac beat higher rate fed kick say fall treasury yield hurt result further related facebook ceo mark zuckerberg make augment reality centerpiece keynote presentation company annual facebook developer conference be also see strike snapchat snap operator snap be also push augment reality zuckerberg say mainstream augment reality platform future be not headset glass smartphone related strong result semiconductor equipment maker lam research lrcx spark rally already hot chip gear sector rival asml asml beat first quarter sale earning target disappoint guidance wireless chip maker qualcomm qcom post better expect fiscal second quarter sale earning guide analyst lower current quarter qualcomm warn potential revenue earning shortfall ongoing legal clash major customer apple aapl related crude future week barrel concern shale production offset opec effort rein global supply saudi arabia say several top oil producer have agree extend output cut help reduce global inventory energy information administration say inventory drop barrel smaller drop expect gasoline inventory rise barrel crude output continue rise schlumberger slb meet ep view drop revenue rise first increase revenue year fall short wall street view oilfield service giant say deploy more idled north american equipment see difficult year international business related unite airline ual turn strong first quarter share initially sell close slightly higher management defend plan expand flight reclaim call natural market share executive unite earning call repeatedly expressed need improve security forcibly remove passenger be tell give seat sell flight refuse additional policy change related incident management say present result review april meanwhile hawaiian airline parent hawaiian holding also report result top estimate send share soar friday related verizon report first quarter profit revenue fall even more lower expectation dow component lose surprising postpaid subscriber intense price competition verizon say buy least optical fiber wiring corning glw deploy wireless service installation firm dycom dy surge news fiber optic stock fall china demand concern verizon be set june takeover close yahoo yhoo report better expect earning revenue growth verizon ceo lowell mcadam say open strategic talk wide range company include comcast cmcsa fellow dow component walt disney cbs cbs related steel stock show sign life boost thursday executive order president trump lead new protectionist measure positive earning guidance nucor nue steel dynamic stld trump order launch promise be quick investigation import steel be hurt national security order potentially pave way trade restriction trade expansion act meanwhile nucor steel dynamic expect preannounce march report strong first quarter earning signale be also shape be good help stronger steel consumption nonresidential construction improve energy sector demand related trump turbocharge thursday top perform stock groupgeneral electric ge report flat earning share cent revenue less vs year earlier be better expect ge aviation power segment lead way dow stock sank friday undercut day line organic revenue climb organic order climb honeywell earning rise exclude divestiture sale edge lower honeywell hon rise friday hit record high intraday briefly top buy point related ge beat view lead aviation power honeywell topsebay stock tumble thursday keep fall friday even commerce giant receive several price target hike wake first quarter result meet revenue forecast beat bottom line revenue rise ep rise cent value good sell site quarter reach ebay guidance be light related dow component unitedhealth unh earn share first quarter year cent ahead expectation revenue grow top estimate unitedhealth also raise full year guidance be be help pullback obamacare exchange meanwhile large fast grow optum health service unit set unitedhealth apart other insurer expand reach acquisition surgical care affiliate related unitedhealth rise blowout surgical isrg stock launch record high wednesday report procedure growth first quarter sale rise year year top consensus adjust earning share rise beating dime related charle schwab schw logged most quarterly account opening year top forecast ep revenue growth ongoing online broker war have take trading fee major player schwab report growth retail brokerage account march end quarter meanwhile rival trade etfc handily beat cent ep sale td ameritrade amtd post mixed result visa result beat estimate cent ep revenue full year revenue guidance growth also top visa share initially soar record high friday close flat be still week american express axp also top forecast softer expect earning sale decline share leap thursday american express lose card partnership costco cost last year be midst premium credit card war jpmorgan chase jpm csx report first quarter earning revenue well wall street estimate operate metric also strong show csx be improve even ceo president hunter harrison take helm march csx also raise dividend cent share say buy back stock csx share surge thursday then add close buy point canadian pacific railway cp harrison previously be ceo also top view late wednesday rise thursday pare gain friday kansa city southern ksu narrowly top view friday morning fall sharply more then offset thursday advance union pacific unp gain thursday tick higher friday related drug medical product giant johnson johnson jnj abbott laboratory diverged first quarter earning sale be light drug revenue advance just adjust ep do top view abbott crushed view dow component fall week abbott lab rise related horton dhi report better expect quarterly earning revenue order cancellation rise share initially retook buy point quickly reversed fall thursday several other builder also reversed exist home sale rise year high march national association realtor report friday earlier week housing start fall more expect march homebuilder sentiment sank be still longtime high related
283,JNJ,xexchange trade fund tracking major stock index be broadly lower tuesday investor digest mixed earning dow industrial stock surprise call snap election britain spdr dow jone industrial average dium book loss stock holding deliver earning result share goldman sachs gs largest stock price weight exchange trade fund dive more company miss view top bottom line johnson johnson jnj lose nearly underwhelm revenue offset earning beat however unite health unh climb much nation largest health insurer smash earning estimate raise full year guidance fourth dow industrial member ibm ibm report later today dow etf be year date monday lag gain spdr spy dow stock surrender postelection leadership exchange trade fund sit march high meanwhile international stock etfs retreat british prime minister theresa call june election move be see attempt bolster political support head brexit negotiation ishare msci eafe efa lose early tuesday etf offer broad exposure foreign develop market be year date monday ibd take trump fed agenda emerge read ibd leaderboard big picture day assess stock market have more room run related be go etf market
284,JNJ,xfuture dow jone industrial average fall vs fair value tuesday evening dow component ibm ibm sell late trading report straight quarter decline revenue future index nasdaq climb fair value commerce giant ebay ebay be tap report earning wednesday ahead amazon com amzn next week stock buy range chip gear maker move strong earning lam research lrcx apply material amat look rebound key support tuesday stock market trading index pare loss nasdaq composite close just hold day move average dow industrial average be laggard fall nearly help goldman sachs gs johnson johnson jnj report weak result ibm late tuesday say earning exclude various item edge beating view revenue fall miss consensus sale level hit lowest year even cloud revenue rise third share tumble more late trading imply point drag blue chip dow industrial meanwhile ebay report first quarter earning wednesday market close analyst expect ep gain cent revenue rise big online retailer stock close tuesday still range buy point initially clear month ebay also have be find support rise week line ibd take apply material be lead chip stock be make break technical level ebay result come week first quarter financial faster grow amazon benefit boom amazon web service unit amazon close tuesday barely range follow week tight buy point chase zone run finally lam research likely be move report ep gain sale surge lam also give bullish guidance current quarter stock jump late trade industry giant apply material rise more hour lam result apply material have be find support day line last few session asian market be lower wednesday trading japan nikkei be just break even china shanghai composite sank hong kong hang seng korea kospi australia asx related big picture basis form ibd most interesting sector stock basis ahead earning qualcomm investing action planlam research exit march quarter lionibm beat bottom line miss revenue restructure continue
285,JNJ,dow jone industrial average component unitedhealth group unh trounce first quarter earning estimate report profit share year cent ahead analyst expectation share nation top health insurer rise stock market today unitedhealth rebound day move average monday find support key level recent week unitedhealth revenue grow top estimate company also raise full year guidance revenue adjust net earning share previously unitedhealth project revenue adjust ep ibd take share unitedhealth clear week consolidation zone only slightly average volume feb weaken broader market share be close time high set march stock isn extend buyer exercise extra caution be quick cut loss stock market uptrend be pressure be currently read ibd big picture day stay top market trend unitedhealth note first quarter revenue be reduce due company withdrawal most obamacare exchange market suspension congress health insurance tax insurer pass form higher premium otherwise revenue have grow double digit percentage unitedhealth have fewer individual market insurance customer year due obamacare withdrawal serve more person medicare medicaid employer sponsored coverage exit exchange contribute more favorable trend medical cost reserve unitedhealth stand apart other health insurer not only size fast grow optum health service unit make company amazon amzn health care first quarter optum contribute bottom line revenue rise unitedhealth be dow jone industrial component report earning tuesday johnson johnson jnj goldman sachs gs also report market open ibm ibm due close bell related johnson johnson earning top drug sale be draggoldman sack investment bank blame trading wo political begin dow stock report earning investing action plantrump be right obamacare exchange be race crisisryancare flop lift trump trade health gold stock
286,JNJ,dow jone industrial average lead downside afternoon trading tuesday hurt weakness goldman sachs gs johnson johnson jnj dow fall loss nasdaq composite be volume nyse nasdaq be tracking higher monday level stock market hold relatively well sharp loss london paris overnight paris cac swoon uncertainty outcome france presidential election meanwhile london ftse slump prime minister theresa say ll seek early election june strengthen hand head brexit talk year treasury yield continue bleed fall basis point bond market continue seem odd fed fed current economic outlook stock market today earning report financial sector remain focus goldman sachs gs slump be poise test day move average currently bank america bac reversed lower strong start share be rise early charle schwab schw have lot good news earning report include earning sale beat well highest number new quarterly account year headline didn help stock much share fall cardinal health cah crash company announce plan buy medtronic mdt medical supply unit cardinal also lower full year earning outlook ibd telecom infrastructure firm dycom industry dy clear base buy point share be afternoon trading verizon inked fiber optic cable deal corning glw dycom provide engineering construction maintenance installation service telecom provider intuitive surgical isrg give back ahead earning report close growth have slow dramatically medical device maker best know da vinci robotic surgical system minimally invasive procedure stock continue hold high company sell da vinci system fourth quarter year quarter related uk prime minister call snap election european stock fallgoldman sack wall street giant blame politic trading wo dow verizon buy corning fiber cable tv acquisition hold
287,JNJ,eli lilly lly incyte incy share plunge monday morning food drug administration fail approve rheumatoid arthritis drug baricitinib say more datum be need eli lilly incyte disagree fda friday decision come somewhat surprise european regulator approve baricitinib february lilly incyte have conduct more clinical trial satisfy fda delay set drug several rival lilly reaffirm earning sale guidance year incyte discuss matter conference call eli lilly fall close stock market today eli lilly have fall buy point clear early march incyte tumble plunge day move average setback lilly incyte be good news dow jone industrial average component pfizer pfe have only oral jak inhibitor rheumatoid arthritis market xeljanz gilead science gild have similar oral drug baricitinib phase trial fellow dow component johnson johnson jnj abbvie abbv amgen amgn have injectable drug pfizer gilead amgen johnson johnson abbvie rise less morning action
288,JNJ,stock open higher thursday merger news earning report fuel busy session dow jone industrial average inched hold just mark nasdaq rise nearly edge fraction host big name be motion report earning result premarket trade dow chemical dow pulte group phm gain ground bristol myer squibb bmy fall alliance datum system ad shed deliver mixed earning report caterpillar cat slump mixed fourth quarter report share be still buy point wednesday past flat base moneygram international mgi jump open dow jone report ant financial service group affiliate china alibaba group hold baba be deal acquire global payment service operation moneygram surge support week move average johnson johnson jnj slip agree pay acquire europe largest biotech name actelion pharmaceutical actelion be spun switzerland roche hold rhhby mid chip test equipment maker teradyne ter be higher open fourth quarter earning revenue soar past analyst expectation management ratchete first quarter earning sale guidance well consensus view servicenow now punch gain open thursday management raise first quarter guidance broad fourth quarter beat stock end wednesday buy range less buy point cup handle base toymaker mattel mat crash fourth quarter result report late wednesday barbie maker earning revenue miss forecast wide margin worldwide net sale fall hour today alphabet googl intel intc microsoft msft starbucks sbux be company expect report quarterly result first time unemployment claim increase week end jan labor department report be prior week claim more new claim project economist consensus week move average trend lower fourth straight decline trade deficit hold steady december accord early estimate commerce department november trade gap be consensus projection call widening researcher markit release preliminary service purchasing manager index january et schedule et conference board lead indicator index new home sale number commerce department december kansa city federal reserve cap morning january manufacturing index et overseas stock tokyo hong kong echo wednesday gain market hong kong hang seng composite jump thursday japan tokyo nikkei pop lift positive territory week shanghai composite index rise give gain week head holiday exchange reopen next friday hong kong exchange close monday tuesday europe stock show moderate gain afternoon trade frankfurt dax lead top benchmark advance related johnson johnson pay europe beat see capacity slowdown jetblue ep topscomcast top earning view hike dividend
289,JNJ,stock market push time high close tuesday broad base rally capped lead rise russell nasdaq rally reach new time high dow jone industrial average follow gain move blue chip index striking distance volume be tracking much higher nyse nasdaq accord preliminary figure dupont dd lead industrial higher report earning beat monday market close miss revenue estimate stock gain reach new week high downside verizon communication vz drop follow quarterly earning release alibaba baba gain be much premarket hour chinese commerce giant report blowout earning sale earlier morning stock be build right side base miner construction stock be act particularly well stock market today freeport mcmoran fcx leaderboard member soar gapping cup handle buy point see daily chart copper mining company report quarterly earning wednesday market open mastec mtz surge nearly reclaim day line have be fight support last several week stock be now away short cup shape base entry meanwhile lag sector be medical merck mrk pfizer pfe johnson johnson jnj fall johnson johnson provide cautious outlook earning revenue fall short street estimate lead growth stock ibd be very positive close only stock red broadcom avgo continue recent dominance be lead stock ibd tack recent gain stock be now extend flat base entry downside healthequity hqy be volatile close minor change lead health saving account provider be now top buy range stock break flat base entry surge volume stock be initiate overweight rating keybanc monday close hawaiian holding steel dynamic stld other report quarterly result close hawaiian holding parent hawaiian airline meet quarterly earning estimate be ep surpass revenue estimate share fall almost hour steel dynamic steel producer have not announce be estimate report ep cent intuitive surgical isrg top earning sale estimate share rise texas instrument txn beat expectation top bottom line estimate share edge lower seagate stx quarterly earning exceed street view earning sale figure share gain additional rise regular market hour related alibaba crush earning estimate raise guidancej hcv dip virtually mirror gilead view air steel dynamic texas instrument report closeseagate easily beat bottom line sale also top estimate
290,JNJ,rise consecutive year fda drug approval rate plunge year low biogen biib merck mrk eli lilly lly add new drug bailiwick accord swiss biotech hbm partner food drug administration approve new molecular entity year marked decade high approval nmes say hbm have not be fewer nmes approve fda give blessing just half nmes be not fully develop house be acquire be license hbm write new drug be first class drug therapeutic area cancer lead nmes new drug project industry lead peak sale be oncology hbm find ibd take ease fda approval process be part donald trump health care initiative president elect really break republican enact major drug reform trend past year oncology drug see major increase fda approval list new cancer drug be approve rise nmes cancer fda have increase appetite drug treat diabetes respiratory disease viral other infection interest cardiovascular genetic immunology drug increase moderately year also see fewer central nervous system drug then merck roche rhhby have have more drug approve other company add johnson johnson jnj pfizer pfe follow closely apiece gilead science gild novartis nvs glaxosmithkline gsk sanofi sny lilly have add new drug ibd company medical biom biotech industry group close stock market today group rank be tumble lawmaker debate issue drug steeply rise price related lilly regain key migraine drug colucid acquisitionfda track record bode well merck keytruda chemo leerinktrump disastrous pharma view doesn rattle jpmorgan drug conference
291,JNJ,dow jone industrial average give start week president trump immigration policy other move worry investor moved back level friday job report apple aapl boom return earning growth investor didn care facebook fb amazon amzn result guidance unite parcel service up be struggle commerce boom charle schwab schw launch new stock trading pricing war dow jone industrial average fall back key level regain friday january job report trump move ease dodd frank other financial regulation dow fall week nasdaq rise end week record high trump immigration order create conflict tech firm trading partner earning be mixed bag cboe volatility index vix rally extreme level not much related dow component apple earn share sale quarter end dec be better expect marked return growth straight quarters year year decline apple current quarter guidance be conservative usual apple say iphone demand outstripped supply service revenue apple share rise nearly week hit month high related advanced micro device amd report smaller expect loss forecast sale bullish outlook share shot nearly hit year high nvidia nvda compete amd graphic other market jump ahead earning come week apple chip supplier cirrus logic crus qorvo qrvo top quarterly view give bearish guidance stock sell thursday related facebook ep soar revenue rise easily beating view decelerate second straight quarter mobile ad account ad revenue facebook reiterate ad revenue growth rate come meaningfully deliberate move avoid ad saturation now see heavy expense growth step hire facebook fall week snap parent snapchat file publicly upcoming ipo snap report soar revenue growth also slow user growth facebook instagram imitate key snapchat feature snap use ticker snap win sell voting share related amazon top earning forecast revenue revenue outlook be lower expect amazon web service cloud compute unit generate most commerce giant profit report revenue gain forecast aw be feel pressure rival cloud effort alphabet googl microsoft msft amazon share fall nearly friday undercut recent buy point related amazon result miss revenue beat ep stock fallsunited parcel service up report modest earning revenue growth holiday fourth quarter fall short forecast up also guide profit target lower cite impact strong dollar up see significant shift mix lower revenue product residential delivery accounting total package volume up ceo say result indicate up quicken pace investment network shift handle increase commerce meanwhile amazon announce set air hub cincinnatus northern kentucky international airport seek lessen dependence up fedex fdx up share plunge fedex lose related mastercard edge past earning view revenue be light share have be buy zone pull back nearly even regain day friday larger rival visa late thursday report better expect quarterly result strong payment growth visa rise friday push dow stock past buy point record high related federal reserve left interest rate alone give indication policymaker be hurry raise rate add strong job january well estimate slim wage gain ease fear economy be overheat ism manufacturing index rise fresh year high january related exxon mobil xom report adjust ep view oil major plan boost capital spending activity heat royal dutch shell rdsa say cut spending year report ep view conocophillip cop say plan raise spending energy information administration say crude stockpile rise barrel analyst expect russia opec seem be comply promise output cut accord reuter datum related auto sale decline december longtime high even automaker offer hefty incentive general motor gm ford fiat chrysler fcau report year year decline only gm miss forecast datum offer new evidence auto demand have peaked related charle schwab schw cut stock etf commission trade lower fidelity td ameritrade amtd trade etfc schwab fall thursday td ameritrade trade rely more stock trade schwab tumble interactive broker ibkr charge cent share trade sank related president trump meeting tuesday ceo exec celgene celg eli lilly lly johnson johnson jnj merck mrk novartis nvs say drug price be astronomical reiterate aim bring drug price also urge drugmaker manufacture also promise deregulate industry cut taxe drug stock pop day response related drugmaker eli lilly pfizer pfe disappoint tuesday earning lag consensus sale top meet respectively roche rhhby sale be light revenue earning rise mid single digit merck follow thursday line sale earning include time defer revenue amgen amgn late thursday report better expect earning say ldl cholesterol fighter reduce cardiovascular risk study related miss merger deadline expire walgreen boot alliance wba rite aid rad extend agreement end date july walgreen cut takeover price share share depend many rite aid store have be divest order new term get regulatory walgreen fall rite aid fall concern ftc win approve deal fred have agreement buy rite aid store edge lower related armour uaa miss estimate top bottom ep fall penny cent sale rise revenue guidance be light athletic apparel brand cfo be step personal reason share tumble year low related
292,JNJ,stock post healthy gain quiet volume friday moved back positive territory week gain be even board dow industrial nasdaq composite rise apiece small cap run slightly ahead crowd russell rise volume get weak start stock market today nyse nasdaq relative action same time thursday import price slip export price drop february labor department report just ahead open number be less forecast analyst consensus project import price export dow stock be upside early friday worst move index gain johnson johnson jnj goldman sachs gs rise most symantec symc scramble more lead nasdaq rbc capital market upgrade security software developer outperform sector perform set price target move put symantec so far week share be back week move average climb right side month consolidation also nasdaq viacom viab baidu bidu knock gain columbia pipeline group cpgx top jump gain so far week power news report possible merger talk transcanada trp transcanada share be less early trade ibd stock global jcom rebound diving response negative note short sale researcher citron thursday management declare citron assertion growth have rely merger acquisition funded company legacy fax business generate organic growth ligand pharmaceutical lgnd pop more strong trade continue fight breathe room converge week move average just buy point double bottom base broadcom avgo rolled better gain heavy trade near new high rise buy point double bottom base only few ibd stock decline hold loss less
293,JNJ,big pharma abbvie abbv say monday be acquire right immunology drug develop german counterpart boehringer ingelheim stock be flat goldman sachs warn increase competition abbvie agree pay upfront undisclosed milestone payment royalty right commercialize drug late stage testing psoriasis earlier testing crohn disease psoriatic arthritis asthma phase trial compare head head johnson johnson jnj remicade find month treatment patient boehringer drug have clear almost clear skin compare remicade arm abbvie also acquire right earlier stage drug attack cd protein be connect lupus nephritis crohn disease ulcerative colitis abbvie say press release decide go forward drug completion certain undisclosed clinical achievement abbvie say success develop commercialize humira currently world top selling immunology drug give expertise do same boehringer product humira be near end patent life lead much speculation wall street biosimilar competitor launch much impact have goldman sachs analyst richter take pessimistic view matter monday say current political focus lower drug price probably encourage cheap humira knock off be not change abbvie forecast continue believe humira remain durable asset free biosimilar least end decade richter write remove abbvie stock conviction buy list cut price target however adjust terminal value growth rate model faster decline curve post introduction humira biosimilar abbvie stock fall much early trading stock market today midday be flat meanwhile richter put biomarin pharmaceutical bmrn conviction buy list abbvie place set price target biomarin richter note have guide go black next year even contribution recently fda reject muscular dystrophy drug kyndrisa show opex restraint commitment profitability add several datum release year bring upside medication include biomarin gene therapy hemophilia treatment rare disease achondroplasia biomarin stock be midday monday image provide shutterstock
294,JNJ,stock market see red afternoon trading wednesday still shake bit tuesday terror attack belgium day gain biotechs weigh nasdaq fall selling be less intense nyse index drop dow jone industrial average ease volume nyse nasdaq be tracking higher tuesday level stock market today unitedhealth unh visa johnson johnson jnj outperformed dow nike nke lag fall company report earning late tuesday spdr gold share gld slump etf be weak gold price fall due strength dollar handle buy point be short live elsewhere virgin america va soar bloomberg report company be attract takeover interest technology space small cap chip designer inphi iphi gap rise deutsche bank lift price target inphi be extend double bottom buy point miss initial be also legitimate entry ibd be big winner rise reversed higher fall nearly early late tuesday retailer report second straight quarter accelerate sale growth be heavily short stock so part today move be short cover meanwhile ibd name reilly automotive orly be close breaking week consolidation share rise close watch earning apparel maker oxford industry oxm pvh corp pvh image provide shutterstock
295,JNJ,california base intuitive surgical isrg get boost last week new study show patient undergo procedure da vinci surgical system experience fewer complication subject undergo conventional operation be welcome news leader robotic assist surgery help settle long run debate merit minimally invasive quite expensive da vinci equipment compare
296,JNJ,eli lilly lly pfizer pfe gilead science gild be chip away abbvie abbv humira sale credit suisse analyst vamil divan say monday abbvie miss expectation friday primarily decline humira sale divan downgrade abbvie stock neutral cut price target model humira pull sale decline respectively humira account abbvie sale drug be used treat rheumatoid arthritis psoriasis irritable bowel disorder market brand rival be already market biosimilar be pressure abbvie patent humira abbvie be work protect patent divan expect amgen amgn other have biosimilar market be other year point humira start decline divan write research report cope humira decline miss expectation abbvie have late stage drug capable bring combine sale ibd take abbvie earning have grow average past quarters have also decline last period get full scoop ibd income investor pfizer eli lilly incyte incy gilead be work class drug call jak inhibitor compete arthritis celgene celg novartis nvs eli lilly have il il inhibitor psoriasis expect become blockbuster drug year launch johnson johnson jnj already have jak inhibitor be il field abbvie have own il drug development be enter crowd market have more competitive pricing challenge say divan irritable bowel disorder market celgene mongersen ozanimod put pressure humira sale soon divan write ub analyst marc goodman say pressure abbvie stock be overdo share touch month low friday abbvie report earning fall stock market today abbvie stock fall goodman keep buy rating price target abbvie stock company earning guidance growth imply be lower wall street view still goodman write base management commentary humira volume pricing think concern appear overdo earning next year be little light think investment pipeline drive growth longer term related eli lilly abbvie top ranking pfizer astrazeneca flail
297,JNJ,google parent alphabet googl vow create future surgery verb surgical joint venture johnson johnson jnj intuitive surgical isrg da vinci system remain clear leader robotic assist minimally invasive operation fiercebiotech report last month verb surgical be aim develop next generation system incorporate robotic advanced visualization machine learn datum
298,JNJ,stock open lower tuesday feel drag overseas britain prime minister call early election pare initial loss dow jone industrial average be nasdaq composite british prime minister theresa call june vote move mean bolster political support go negotiation britain exit european union announcement come just ahead sunday first round presidential election france be see many facto vote country also exit european union london blue chip ftse dive cac paris be frankfurt dax be afternoon trade earning news rolled big bite late monday early tuesday johnson johnson jnj be nearly harley davidson hog drop more goldman sachs gs sank first quarter result miss view revenue earning line management raise quarterly dividend cent cent stock have be consolidate early march be now lowest level nov bank america bac edge squarely beating first quarter performance target earning rise revenue climb total expense be flat stock have be consolidate week line mid march unite airline ual scratch gain late monday carrier report first quarter earning less expect forecast revenue gain company project passenger revenue available seat mile second quarter share be rise support day move average unitedhealth group unh rac advance open health insurer report surprise surge first quarter earning revenue gain raise full year guidance consensus target share end monday session buy point flat base netflix nflx fall open follow first quarter report late monday earning soar top analyst expectation revenue growth meet view company add stream video subscriber quarter consensus projection new set eyeball netflix have be find support week move average mid february sporting good retailer cabela cab reel gain open construct deal capital financial cof buy credit card business synovus financial snv buy cabela bank deposit move clear path bass pro shop acquire cabela previously announce transaction facebook fb trade slightly lower ahead start day conference software developer chief executive mark zuckerberg launch confab keynote speech morning facebook share have pull back tight test support week move average set possible follow buy opportunity close ibm ibm yahoo yhoo lam research lrcx intuitive surgical isrg be company schedule report result new housing start be weaker expect march commerce department report run annualize pace february number be revise higher rate start economist project pace march build permit provide view upcoming activity be issue annualize rate february projection new permit kansa city federal reserve bank president george speak federal reserve industrial production number be due et related facebook dow stock report investing action homebuilder score new high industry perform well
299,JNJ,xfuture dow jone industrial average index nasdaq be steady monday evening solid price gain monday lackluster volume netflix nflx facebook fb be active tuesday company news google parent alphabet googl amazon amzn be key technical area also likely react netflix facebook increasingly compete fellow fang stock dow jone industrial average component goldman sachs gs johnson johnson jnj unitedhealth unh ibm ibm also report earning tuesday bank america bac monday stock market trading dow jone industrial average index nasdaq composite climb nasdaq retake day move average trading volume be well average suggest mutual fund other big institution weren buy heavily monday fang stock apple aapl have be huge market driver alphabet rise alphabet be year date netflix report first quarter earning top forecast revenue growth be line subscriber growth be weaker expect netflix give cautious ep guidance netflix do say expect cross customer worldwide weekend netflix swung late trading early loss modest gain suggest stock open march time high netflix rise monday regular session retake day move average facebook begin day annual developer conference tuesday keynote address ceo mark zuckerberg expect see virtual reality hardware discussion facebook be do promote real news curb violent video facebook have be clon popular feature snap snap unit snapchat especially instagram instagram story now have more user top snapchat total user base presumably facebook also spend time discuss whatsapp facebook messenger other feature facebook rise monday find support modestly week move average average volume facebook peaked march snap fall record close low early march ipo price amazon alphabet compete netflix amazon prime video google youtube netflix be major customer amazon web service alphabet google be notable competitor facebook internet screen time advertising facebook also see videocentric future reportedly be look make bigger move original content compete netflix amazon alphabet youtube amazon also be grow rival online ad facebook google amazon reap benefit vast customer datum amazon be take lead digital assistant bypass traditional search amazon alexa amazon share rise monday just chase zone week tight buy point amazon hit record high april alphabet rally move back day line trading level last week alphabet still have valid buy point short live time high month tuesday trade intraday japan nikkei be just break even china shanghai composite be hong kong hang seng south korea kospi dip australia asx sank related big picture bull take control volume disappoint small cap leadnetflix miss subscriber target guide higher facebook open dow stock goldman ibm investing action planamazon receive price target boost ahead quarterly earningswhat expect ibm report quarterly earning
300,JNJ,xdividend stock have reputation cushion blow market correction bear market etf investor have reason put watchlist again stock market have trade sideway range march dow fall key chart level last week thursday vix know fear index close week move average first time november presidential election end week more fact global banker investment manager goldman sachs gs be warning client market go lower so best investment strategy be buy stock rise profit margin simplest most cost efficient way access such stock be dividend growth exchange trade fund fund such vanguard dividend appreciation vig schwab dividend equity schd invest large profitable company have paid grow dividend least year steady rise payout be sign firm financial strength vanguard fund quality tilt have help shine market downturn write morningstar analyst katie rushkewicz reichart lose vs landing top large blend morningstar category rocky market environment add sound investment method extremely low expense ratio vanguard schwab dividend equity etfs help outperform long run lately smaller newer less well know rival be fare better quality dividend growth dgrw invest dividend pay stock score solidly measure such return equity prospective earning growth such fundamental metric tend be associate greater potential future dividend growth accord even company don have history pay raise dividend example fund portfolio be tech giant apple aapl iphone maker be dividend leader unite state term total dividend dividend growth yet miss index employ backward look dividend screen include track vanguard dividend appreciation schwab dividend equity etfs dividend fund be well diversify hold stock more asset stock top holding apple include dow heavyweight johnson johnson jnj microsoft msft year date april dgrw be vs vig schd produce average annual gain past year vs vig schd term month yield schwab etf come top yield vs yield just north vanguard peer compare similar fund dgrw exhibit greater volatility charge higher expense fee have limit track record accord morningstar same be say first trust rise dividend achiever rdvy outperformer segment so far year
301,JNJ,reason wall street main street scrutinize warren buffett portfolio quarter renown billionaire be know world greatest investor do have common buffett own stock ibd dividend leader screen berkshire hathaway brka chief be shareholder company full
302,JNJ,xhere investing action plan friday need know investor come day dow jone industrial average have have trouble climb back earlier high dow component microsoft msft mcdonald mcd johnson johnson jnj pfizer pfe unite technology utx be buy range meanwhile smartphone maker
303,JNJ,xhere weekly investing action plan need know investor come week several company dow jone industrial average such general electric ge goldman sachs gs ibm ibm johnson johnson jnj visa verizon vz american express axp report quarterly result netflix nflx qualcomm qcom
304,JNJ,barclay analyst geoff meacham thursday say expect gilead science gild outlook be hinder limit hepatitis sale also see merck mrk alexion pharmaceutical alxn issue sluggish view be more bullish biogen biib johnson johnson jnj rbc capital wednesday say much same gilead also be more bullish biogen well amgen amgn hepatitis drug prescription dip quarter quarter accord market tracker im gilead make sovaldi harvoni combat hepatitis merck alexion meanwhile guide decline metric heavier spending new management respectively meacham predict argue be widely anticipate meacham say research report see biogen offer upside guidance spinraza launch ionis pharmaceutical ion johnson leverage cost control offer better view ibd take hepatitis sale fall gilead go check ibd industry theme full scoop biotech biggest be expect do ahead pharma earning season start next week report company such stryker syk intuitive surgical isrg meacham boost price target incyte incy stock note company phase tumor effort merck duo be testing immunotherapy keytruda epacadostat tumor meacham expect incyte earning conference call give color jakafi trial graft vs host disease well tumor effort merck bump price target incyte stock incycte hasn yet set date earning report incyte stock last week touch month high just shy rally close stock market today consensus analyst poll thomson reuter expect incyte report sale cent earning share third respectively vs year earlier quarter merck spending be likely ramp keytruda be grant priority review last week combination eli lilly lly chemotherapy alimta treat squamous small cell lung cancer nsclc patient high expression pdl gene keytruda alimta be phase testing datum be strong merck open larger patient population vs patient pdl expression keytruda be already approve monotherapy high express pdl patient nsclc related merck biogen lilly top approval fda slumptrump disastrous pharma view doesn rattle jpmorgan drug trump break republican push major drug reform
305,JNJ,roche rhhby ceo severin schwan shrug president trump crackdown drug price wednesday say swiss drugmaker expect reap benefit literally billion invest market focus truly differentiate medicine medicine make real difference patient say accord cnbc have doubt whatsoever be continue demand such solution particularly convince reward kind innovation market be important roche nearly half roche pharmaceutical sale stem diagnostic tool be sell north america tuesday trump reaffirm pledge go rise drug price have get lower price tell slew pharma bigwig include ceo celgene celg eli lilly lly merck mrk novartis nvs johnson johnson jnj executive also be reportedly attendance president trump promise deregulate drug industry cut taxe trump also abandon proposal revisit idea allow federal government negotiate drug price behalf medicare medicaid cover million american be largest purchaser drug health care service world ibd take trump commentary momentarily boost drug stock tuesday day earlier president ban immigration take bite airline stock read ibd industry theme column more safer entry point travel sector drug stock rise tuesday follow report trump softened stance big pharma ibd company ethical drug industry group edge small fraction stock market today roche stock rise touch nearly month high schwan commentary come roche report growth sale consensus analyst poll thomson reuter expect core earning share rise revenue breast cancer rheumatoid arthritis drug help outplay dip sale drug treat hepatitis pancreatic small cell lung cancer wet age related macular degeneration eye disease hep sector have suffer recently sale dip third fourth quarters accord market researcher ihs share gilead science gild have be pressure recently hep unit hep sale dip virtually nothing fourth quarter swiss roche see similarly painful decline sale hep drug lucentis be only sell fall offset sale breast cancer drug perjeta rheumatoid arthritis drug actemra rise respectively roche also list new launch include oncology drug tecentriq tecentriq be approve previously treat small cell lung cancer previously treat advanced cancer urinary tract compete bristol myer squibb bmy merck small cell lung cancer sector related gilead clobber hep little value too late nash hiv unitsroche gouge bristol myer lung cancer share merck rivalrywill merck let incyte go astrazeneca bristol roche team up too
306,JNJ,dow jone industrial average hit major average rally fresh record high president trump early policy move earning report generally be positive google parent alphabet googl starbucks sbux be disappointing result deal buzz rejection be rife dow jone industrial average rise week top first time nasdaq also hit record high respectively slew earning include intel intc alphabet googl microsoft msft alibaba baba boee ba president trump authorize border wall key oil pipeline lift wide variety construction material related firm such caterpillar cat martin marietta material mlm not steel maker amazon amzn facebook fb break join other fang stock year treasury yield rise lift bank stock google parent alphabet say earning share item rise view total revenue rise top forecast revenue growth slow prior year period internet search advertising giant face tough comparison prior year quarter launch new advertising product capital spending soar much related cloud compute effort marketing cost google new pixel smartphone also be heavy alphabet share fall friday hit record high earlier week related alphabet ep miss earning rise cent share revenue climb beating view cent credit boom cloud compute business include azure microsoft guide revenue forecast higher microsoft share rise nearly week hit record high related microsoft beat target cloud compute chipmaker ep rise top view sale growth be best year intel also give bullish guidance intel share rise friday breaking base earlier week ahead earning texas instrument txn also report strong earning samsung electronic credit memory chip gain overall profit revival microsemi mscc also have good result chip gear maker lam research lrcx kla tencor klac mobile chipmaker qualcomm qcom face ftc charge apple lawsuit licensing practice report mixed result related intel earning sale top expectation revenue guidance also economy expand annual rate fourth quarter view not much more half gain gdp grow just straight year meanwhile durable good order unexpectedly fall second straight month december new home sale tumble month low several homebuilder remain bullish report solid earning starbucks sbux report weakest earning growth year meet view sale miss forecast customer traffic coffee shop giant also cut revenue outlook say mobile order pay be so popular create bottleneck order pick turn patron starbucks share fall friday meanwhile mcdonald mcd top ep sale target comp fall investor question momentum day breakfast menu have run mcdonald test key support level initially close week related too much good thing weigh starbucks stock test key support turnaround doubtsa federal judge rule aetna aet humana hum merger violate antitrust law unduly reduce competition health insurer aetna owe humana breakup fee appeal deal also throw doubt propose anthem antm cigna ci merger deal justice department also oppose related aetna deal humana block federal judgeseveral steel maker sell week breaking day line earning report fail support stock postelection run even president trump tout various infrastructure plan signale more protectionism ak steel ak top view tuesday share reversed sharply lower weak pricing outlook steel dynamic stld have decent earning late tuesday tumble wednesday larger peer steel nucor nue report jan also sell many steel maker rebound thursday friday upside specialty steel firm allegheny steel atus deliver stellar earning tuesday send share day related steel stock break key support even trump rally resumesak allegheny earning top steel dynamic meet steel stock bend waysboeing ba emphasize importance trade china aerospace industry job be bullish president trump tax reform regulation boee report ep revenue analyst view guidance be cautious dreamliner be now cash flow positive bode well future stock buyback dividend increase boee share break base hit record high lockheed martin lmt report earning revenue analyst view aeronautic revenue include sale soar expect surge delivery year lockheed give weak guidance continue concern cost send share lower northrop grumman noc beat view raytheon rtn fall short boee lockheed give weak guidance general dynamic gd report strong earning give bullish long term guidance related boee back china trade trump protectionism loomslockheed see jump guide profit low cost flapnorthrop raytheon join lockheed weak view new budget loomsverizon communication vz stock sell disappointing guidance also spark speculation possible merger cable firm charter chtr well dish network dish walt disney verizon report mixed revenue fall beating estimate ep be light wireless margin miss management push back goal return wireless service growth close verizon purchase yahoo yhoo be delay regulator look datum breach report line ep revenue ebitda slightly consensus again lose wireless postpaid phone subscriber remain upbeat regulatory approval time warner twx acquisition comcast cmcsa earning top view solid subscriber gain cable tv firm plan buy back share hike dividend announce stock split comcast plan launch wireless service buy midyear comcast rise week new high related verizon stock fall ep revenue outlook more sameverizon charter talk heating malone vision keycomcast top earning hike dividend offer wireless hintswill cross selling success spur comcast wireless buy johnson johnson jnj agree pay swiss biotech actelion report weak sale guidance earlier week celgene celg miss sale even preannounce result biogen biib stock pop light sale better fear guidance follow hemophilia unit spinoff bristol myer squibb bmy miss earning give weak ep guidance weaker lung cancer drug prospect related johnson johnson buy actelion billionbristol myer topple guidance cut merck aim hurdle revlimid patent lossdisk drive maker western digital wdc seagate technology stx report quarterly result top view bullish guidance result suggest multiyear slump disk drive shipment have bottom company be also investing heavily flash base chip storage follow market need seagate share shot western digital set month best related western digital get positive reviews crisp execution alibaba baba revenue rise local currency ep rise view revenue cloud compute unit rise share commerce giant rise more week alibaba build right side base related alibaba crush earning estimate raise guidanceford top fourth quarter result expectation see sluggish ceo mark field say automaker have right amount plant need president trump call day earlier big build more factory fiat chrysler fcau meanwhile say net income double help cost saving revenue tick ford ceo say plant appropriate profit meet sale topcisco system csco late tuesday announce buy appdynamic day latter be expect price ipo top target valuation appdynamic be go be year first tech unicorn go public provide cloud base software measure analyze performance business critical application cisco system nabs appdynamic just ipo
307,JNJ,vow border tax then call too complicate then say be still be consider president trump tell group ceo monday incentivize domestic production impose very major tax good american company produce overseas meeting manufacturing advisory group trump also reiterate pledge slash regulation income taxe afterward ford ceo mark field tell reporter meeting be positive carmaker have earlier cancele plan build new plant mexico trump criticize ford campaign make car company say cancele plant be due lack demand small car other meeting include ceo tesla motor tsla armour ua lockheed martin lmt arconic arnc johnson johnson jnj steel advisory panel be lead dow chemical dow ceo share ford close stock market today general motor gm fiat chrysler fcau also have mexico operation recently pledge major investment fall rise respectively ceo carmaker also meet trump tuesday white house tesla rely base factory final production rally retail giant wal mart wmt rely heavily import finished lower target tgt lose ibd take house gop tax reform trump be consider likely help foreigner hold stock hit investor foreign investment such alibaba adrs overseas etfs interview publish last monday trump tell wall street journal border adjust tax plan be too complicate result bad deal send share wal mart best buy bby macy higher next day trump tell axio border tax be key element congressional gop tax strategy be certainly something go be discuss related wal mart best buy apple rally trump pan gop border adjustment taxtrump trade tax talk hit dollar mexico warn tariff wal mart target macy drop tariff talk investing action plan
308,JNJ,solid day stock market thursday result nice expansion new high list dow component score week high verizon vz gain johnson johnson jnj add blue chip name be still buy range recent buy point utility space itc holding itc picked
309,JNJ,load player result new study announce monday show patient undergo procedure da vinci robotic surgical system intuitive surgical isrg experience fewer complication subject undergo conventional abdominal other operation california base medical device maker note better outcome be observed increase complexity patient robotic assist group welcome
310,JNJ,alphabet googl release earning february tech giant reveal last year spend so call moonshot project range self drive car extend human lifespan potential payoff initiative be year away investor profit sooner stock break current base take stock alphabet initiative alphabet
311,JNJ,major stock index hold solid gain early afternoon trading tuesday help round mostly healthy earning report nasdaq composite lead way rise just add dow jone industrial average lag rise unitedhealth unh goldman sachs gs outperformed dow strong earning wall street frown earning dow component ibm ibm johnson johnson jnj stock market today alphabet googl jump more good volume modest pullback owner google be back buy point still buy range credit suisse monday reiterate outperform rating raise price target netflix nflx surge nearly quarterly profit cent share double consensus estimate sale growth accelerate third straight quarter rise leaderboard name domino pizza dpz jump also strong earning intuitive surgical isrg continue hold well ahead earning report close share rise slightly money weekly call option strike price recently offer premium present trade reasonable downside risk just ibd take used option earning be less risky buy stock ahead earning week ibd earning preview column delve strategy provide potentially actionable name strong mover ibd include pra health science prah match group mtch gain more related domino pizza earning beat comp sale jump takeaway netflix earning surprise stock surge
312,JNJ,major etfs rally solidly tuesday hint bullish turn sentiment investor digest better expect corporate earning spdr spy pop much stock market today earning report netflix nflx johnson johnson jnj goldman sachs gs beat estimate share netflix spiked nearly stream content provider report better expect subscriber growth spy world largest exchange trade fund serve proxy broad market have be range bound week solid earning be just market need stock break higher company report last week have report earning mean estimate report sale mean estimate accord zack investment research sound pretty good john blank zack chief equity strategist write tuesday note note estimate ep decline third quarter stand be sixth consecutive quarter fall corporate earning remember stock market look ahead month blank add powershare qqq qqq punch tuesday large cap growth fund qqq have big stake biotech semiconductor industry help lead market higher gold miner gold price rally second day spdr gold share gld have weaken past week rise expectation fed interest rate hike december commodity etf track spot price gold safe haven asset bear yield lose allure interest rate be rise here major exchange trade fund major asset class perform today ibd relative strength rating rs rating be measure stock price performance last month compare stock etfs scale best possible follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related utility etf gain momentum skittish investor bid safe haven
313,JNJ,stock surge open tuesday buoy array early factor rise commodity price rally market overseas solid september consumer price datum earning report be generally positive dow industrial marched nasdaq long list earning report rolled stock market today start monday hour session netflix nflx stream higher internet television network late monday report third quarter subscriber growth sale earning top analyst expectation netflix break past buy point entry be incorrectly state earlier version story goldman sachs gs advanced more continue trend stronger expect earning big bank third quarter earning revenue easily clear analyst target buoy trading revenue return equity rise crack mark first time first quarter trading open stock clear buy point flat base domino pizza dpz rolled gain revenue earning outpaced analyst estimate comparable store sale surge third quarter domino share end monday test support stock week move average extend cup handle base buy point del taco restaurant taco serve gain open report monday close third quarter revenue jump better forecast earning narrowly top view management guide full year sale earning line expectation stock have rally july low monday session downside harley davidson hog johnson johnson jnj kansa city southern ksu trade lower report result ibm ibm slip company report sixth straight quarter decline earning revenue result be forecast fourth straight period consumer price jump september labor department say gain be fastest increase month august increase line expectation core price strip energy food rise consensus estimate advance national association home builder report october builder confidence index et oil price be almost west texas intermediate steady just barrel brent crude just gold bump half percent ounce dollar strengthen vs euro yen bond flattened leave year yield stock china rebound monday loss ahead third quarter gdp other datum due wednesday session hong kong hang seng index jump shanghai composite pop japan tokyo nikkei add europe market catch updraft commodity price rise help send dax frankfurt cac paris gain afternoon trade london ftse jump
314,JNJ,key investing success be always keep build watch list even market come selling pressure have recently best stock be typically first move uptrend regain strength want be prepared act happen list feature top rate stock intuitive surgical ticker
315,JNJ,month see stock market go basically nowhere be not fair share drama etf investor respectable drama hold triumph surprise disappointment commodity etfs spdr gold share gld dump month end oct hawkish federal reserve spook gold bug sector equity etfs vaneck vector semiconductor smh charge higher investor uncovered growth weak market nvidia nvda top hold smh set record high early october reveal new artificial intelligence supercomputer chip self drive car international equity etfs ishare msci brazil capped ewz rumble ahead price oil unexpectedly spiked best level month exchange trade fund be best perform etfs respective category yearly gain range comparison spdr spy proxy broad market be so far year oct click here list best perform etfs investor find interesting crossroad stage long bull run see potential stock trend again glimmer recovery corporate profit policymaker extreme caution make rate move unsettle market yet stock market today be rife uncertainty short term november presidential election create volatility longer run global oil glut health european financial sector remain trouble many etf investor find wonder play safe low volatility high dividend etfs do early year move more aggressively riskier trade richard turnill blackrock global chief investment strategist suggest latter be worth consider brighter oil price outlook due unexpected opec plan cut production surprisingly big drop oil stockpile be positive risk asset support case reflation write oct note higher oil price reinforce current market trend add mean so call haven investment such utility low volatility stock get hurt cyclical asset such emerge market be help be lesson be learn too big money manager be position client portfolio so ibd reach pro stock market outlook best idea make money investing etfs here say mark diorio be chief investment officer brookstone capital management wheaton ill firm have asset management take risk manage approach investing monetary analysis lead main area challenge opportunity base level interest rate shape yield curve reasonable path future interest rate first nominal level interest rate be low conventional bond low fix coupon do not protect inflation second shape yield curve graph plot interest rate maturity schedule be flatten simply interest rate differential long term bond short term bond have narrow leave investor yield starve current income third base case scenario reasonable path future interest rate be series quarter point rate hike annually low intensity path promote stability stock bond market ishare treasury inflation protected security tip traditional bond treasury inflation protected security be design eliminate inflation risk adjust principal value coupon payment keep inflation ishare prefer stock pff investor desire current income prefer stock offer attractive alternative complement traditional income source such investment grade corporate bond prefer stock be income generate security be somewhere middle risk spectrum common stock traditional bond pff have month yield oct ishare msci usa momentum factor mtum scenario future interest rate be low intensity path stock resume uptrend thrive mtum invest well perform stock idea stock higher relative performance continue produce strong performance term relative stock weak performance top holding include amazon com amzn facebook johnson johnson jnj home depot hd chris cook be founder ceo beacon capital management dayton ohio asset management rium firm help investor capture stock market gain limit loss market volatility market have many uncertainty today presidential election unite state question not fed raise interest rate not european continue negative rate neutral equal weight sector allocation be appropriate most investor prefer vanguard sector etfs cover sector have exposure small midcap company be extremely inexpensive generally have expense ratio annual fee invest allocate asset smaller stock sector be show significant momentum energy technology be show early sign strength interest rate sensitive sector such real estate utility be show short term price weakness not enough offset relatively high yield vanguard technology vgt tech sector be experience lot activity merger acquisition right now top holding vgt include apple aapl microsoft msft facebook fb alphabet googl intel intc largest technology company be cash heavy not subject interest rate sensitivity so be well position acquire other notable tech firm such twitter twtr netflix nflx vanguard energy vde energy sector profit be directly correlated supply level look supply level energy taper come month mideast be work cut back supply level expectation crude price go back barrel breakeven point potentially lead more profit weather have impact energy production make difficult drill take place area impact severe weather further limit supply level result increase profit vanguard financial vfh assumption interest rate be raise december financial sector benefit increase profit margin board lend institution generate greater spread margin cash money market account related best etf investment strategy be right portfolio
316,JNJ,here weekly investing action plan need know investor come week earning appetizer market sample past few week shift rich meaty entree heavyweight alphabet googl alibaba baba microsoft msft intel intc boee ba mcdonald mcd starbucks sbux chevron cvx report quarterly result president trump
317,JNJ,see be mantra etf investor donald trump assume rein highest office land ambitious campaign proposal translate policy get lose translation equity market have enjoy classic buy rumor rally build trump promise say david haviland beaumont capital expert investing exchange trade fund question be be news cause sell haviland be money manager speak ibd recently stock market outlook well best etf investment idea year ahead moment haviland be make bullish bet haviland pick share ftse quality dividend ousa hold stock rocket trump deliver fiscal stimulus promise allow company bring home offshore cash click here list best perform etfs henry julex capital investing pro expect postelection rotation trade bond equity high yield growth continue etf pick too reflect overall optimism still haviland have eye wide open downside risk many other investor straddle hope caution white house welcome newest resident here be own word david haviland be manage partner portfolio manager beaumont capital management needham mass base asset manager offer etf base growth strategy defensive capability asset management advisement september nov election equity market have enjoy classic buy rumor rally rally have focuse promise make election prospect beneficial change specifically key topic include year federal stimulus package improve infrastructure reworking federal corporate tax system make tax code more competitive renegotiation several trade agreement currently induce exportation job likelihood large amount repatriation multinational foreign profit item serve stimulate growth reflation here question be be news cause sell investor tend buy rumor sell news here be etfs do well etfs be currently own be purchase time bcm strategy low interest rate environment baby boomer need income portfolio live share have distill universe large cap equity portfolio company sector provide better long term risk adjust return example portfolio company superior balance sheet include apple aapl johnson johnson jnj microsoft msft exxon mobil xom procter gamble pg editor note ousa have month yield be include least company sale revenue come internet etf also used more limit screening process liquidity size top holding include fang stock facebook fb amazon amzn netflix nflx google parent alphabet googl third humanity currently life clean water infrastructure require most important resource be massive here well globe develop emerge market etf benefit trump infrastructure build here do not currently own etf have past make way back portfolio top position fund include dhr london base wolseley switzerland base geberit france base veolium environmental illustrate global reach editor note etf have relatively low average trading volume large asset manager bcm access underlie liquidity stock index create redeem process rise rate environment treasury inflation protected security tip tend perform better regular bond give yield inflation construct principal rise inflation measure consumer price index yield be fix etf also used short duration currently year add protection rise rate yield henry be president chief investment officer julex capital management sec register quantitative investment management firm base boston firm tactical unconstrained investment solution aim limit downside risk maximize upside potential total client asset september enter be witness major shift economic policy have significant impact financial market new year be likely see continue rise protectionism be evidence notably brexit referendum presidential election trend undermine global growth be winner loser export dependent sector have most lose year monetary stimulus policymaker develop country have realize loose monetary policy be longer effective fiscal policy be need spur economic growth president elect donald trump have pledge reduce taxe spend infrastructure potential fiscal expansion program have improve growth prospect fuel higher inflation expectation push bond yield upward cause loss bond holder see more rotation bond equity reflationary environment equity market yield seek trade have run course investor rotate high yielding sector growth sector expect rotation trade continue recommend etfs outperform fed be likely raise interest rate end higher rate certainly boost profit margin financial stock potential appeal revision financial regulation such dodd frank trump administration also help improve profitability earning growth expect economy grow tech sector benefit increase demand higher revenue growth valuation be still attractive sector be trade slightly lower forward pe ratio index potentially protectionist trade policy fiscal expansion program generate more domestic demand small company product trail pe ratio iwm be be close pe ratio index better growth prospect provide small cap stock more upside potential editor note etfs be currently own be recently own julex capital strategy be purchase time client portfolio related high yield strategy used etfs deliver weather income low risk best etfs re bullish cautious market
318,JNJ,medtronic mdt prep dredge edward lifescience ew share heart valve replacement market johnson johnson jnj boston scientific bsx st jude medical stj be line gouge various piece medtronic business medtronic edward lifescience stock rift tuesday differ analyst view stock market today medtronic stock fall morgan stanley analyst downgrade stock edward stock rise month high david lewis morgan stanley downgrade medtronic stock equal weight overweight also cut price target share close vastly day move average likely be muted growth perspective year lewis say medtronic complete acquisition covidien irish medical product device maker january margin disappear aftermath acquisition expect organic growth serve nice bridge lewis write research report organic growth have decelerate last quarters write be not convince see path outperformance light topline headwind management demonstrate more durable cost opportunity fiscal ibd take late last year boston scientific acquire neovasc tissue business deal hurt rival medtronic edward lifescience check sector leader be battle medical product field medtronic growth hinge part traction minime hybrid close loop diabetes management system food drug administration approval large valve indication intermediate risk patient expect mid lewis project organic growth medtronic launch gain traction meanwhile medtronic see increase competition mri safe launch boston boston st jude be emerge rival deep brain stimulation parkinson patient spectranetic soon compete drug coat balloon dcb treatment be get minimally invasive procedure arena edward stock other hand pull upgrade tuesday guggenheim analyst chris pasquale upgrade edward stock buy neutral establish price target say transcatheter aortic valve replacement tavr expectation have come back earth lackluster still room growth tavr market pasquale write report estimate global tavr sale come edward bring consensus estimate be lower january note have be hard imagine be consider disappointing outcome year yet investor sentiment edward tavr opportunity have soured somewhat wake result fail show kind positive inflection many street model forecast write analyst be exceptionally bullish edward get intermediate risk indication tavr patient august pasquale note temporary capacity constraint center natural ebb flow market likely lead major disappointment pasquale estimate procedure still grow year year last quarter expect worldwide tavr sale double next year trend edward be primary beneficiary even competition increase say related edward heart valve guidance lag medtronic boston rivalryedward guidance likely hinge rivalry medtronic boston
319,JNJ,trading be tame friday open market begin final session major market average start session have turn lower nasdaq fall dow industrial lose dip dow rolled stock market today tout gain be nasdaq carry gain small cap remain stride ahead general market russell show year date gain head friday session bond market close today et stock bond market be close monday observance new year holiday dow stock goldman sachs gs dip investment banker share be year thursday july low stock be extend clear week cup base july have form week tight pattern nike nke be flat initial uptick nike share have drop more earning growth slow analyst expect end year single digit pace first time consensus view see ep growth pick back fiscal nike fiscal year end drugmaker mylan myl jump announce launch generic version pfizer pfe cerebyx injectable seizure treatment well generic tablet version johnson johnson jnj concerta treatment attention deficit hyperactivity disorder mylan share be deep month consolidation nvidia nvda fall friday morning chipmaker ibd stock reversed higher thursday end gain warning short seller citron research contribute nvidia early loss positive note goldman sachs detailed upcoming catalyst stock end thursday so far have be flash sign be due consolidation tesla motor tsla skip fraction analyst robert baird name carmaker top stock pick reiterate outperform rating price target tesla be form long base oil price ease west texas intermediate crude trading barrel gold edge higher ounce dollar be mixed vs yen euro bond be steady year yield basis point economic news december chicago purchasing manager index retreat december november year high regional manufacturing firm be upbeat baker hughe bhi weekly rig count be expect market europe erased early loss gain ground major benchmark show gain less afternoon trade year frankfurt dax be tracking gain cac paris be london ftse be trading year brexit vote june china market gain friday hong kong hang seng index rise shanghai composite japan tokyo nikkei dip mark decline week end week advance related fox netflix disney stall buy zone investing action plan nvidia volatile big drop upbeat reportweek review dow nvidia reverse amazon thrive
320,JNJ,depome depo stock tumble low wednesday not see year company pre release negative first quarter guidance see chief executive resign management shake senator probe opioid marketing close bell stock market today depome share fall earlier fall much share hit intraday month high late september be nearly then late tuesday depome guide first quarter sale lag analyst broader view guidance be revise conference call company also announce management shift see arthur higgin replace former ceo james schoeneck gavin molinelli william mckee be also add board higgin molinelli mckee be align activist investor starboard be know big stake hp enterprise hpe follow shake only board member be legacy member mizuho analyst irina koffler note report depome board change also follow report earlier day sen claire mo be seek marketing information sale record study manufacturer top selling opioid say sale prescription opioid have quadruple depome be name fifth top seller opioid cnbc report other leader list include purdue pharma johnson johnson jnj janssen division insys therapeutic insy mylan myl ibd take depome isn only company face activist investor analyst say bristol myer squibb be buy pressure mount investor such carl icahn bid bristol head ibd technology page deeper dive still depome sell only opioid vs industry leader purdue make oxycontin drug well know painkiller accord janney analyst ken see investigation pose little risk depome didn begin selling opioid acquire lazanda nucynta time diversion abuse prescription opioid medication be decrease koffler mizuho see depome be take starboard remain involved have raise expect probability takeout say generate hypothetical takeout value stock still allow starboard record modest gain initial investment alone depome be worth share takeout due lower sale estimate say koffler cut view scenario also trim price target depome stock keep neutral rating janney have buy rating depome stock related depome downgrade weakness base business stock run
321,JNJ,flexion therapeutic flxn stock rocket month high thursday rumor accept offer french drugmaker sanofi sny acquire share flexion close rise fraction hour trading flexion stock have trade september sanofi stock other hand stand still hour trading close fraction unidentified source say sanofi put bid mid share final price pending due diligence fiercepharma report sanofi have comment representative flexion didn immediately return request ibd comment rumore bid follow month sanofi lose acquire swiss biotech actelion december follow contentious bidding process janney analyst ken say potential offer wouldn be total surprise sanofi represent logical potential acquirer give leadership single injection market hydraulic acid base product be also used treat osteoarthritis pain say research report flexion pipeline be focuse musculoskeletal condition include osteoarthritis ibd take flexion have middling ibd composite rating meaning rank middle stock term key growth metric biotech leader be celgene cr best possible head stock checkup list top last year sanofi have cash be set receive additional agreement swap asset boehringer ingelheim thus sanofi have cash have certainly show active interest pursue acquisition dow component johnson johnson jnj successfully thwart sanofi effort acquire actelion last year say sanofi be also rumore point be look biomarin bmrn related johnson johnson exclusive talk acquire actelion sanofi sanofi acquire biomarin wake amgen ldl brouhaha
322,JNJ,google take stronger step regain trust advertiser quash public relation crisis boost rival facebook fb say morgan stanley be real issue google address say brian nowak morgan stanley analyst report see headline potential more advertiser come google likely tactical headwind stock performance trading multiple share google parent alphabet googl fall stock market today slip day support level alphabet have lose nearly week ad flap drop buy point verizon communication vz rental car giant enterprise holding johnson johnson jnj have frozen search advertising google well youtube verizon johnson johnson be dow component advertising flap begin last week major brand such volkswagen vlkay havas complain ad placement youtube content policy blog google pledge give advertiser more control ad appear keep offensive extremist content away spot fact verizon enterprise other pull advertising dollar google blog post speak google isn yet fully address advertiser concern need take stronger step regain trust brand add nowak report add advertiser move spending back broadcast tv google address problem ibd take google stock reach time high march clear price point have be last session fester advertising flap learn more google growth trend ibd stock checkup nowak speculate google problem benefit facebook social medium leader have also be race develop tool address fake news controversial content google plan launch youtube tv live tv subscription stream service spring youtube tv price monthly offer access major broadcast network cbs abc nbc fox cable channel offering own parent company such sport channel espn youtube tv google aim grab more advertising dollar broadcast tv revenue be share medium company analyst say related google face global repercussion advertising flap analystgoogle advertising plan key youtube tv launch vs hulu
323,JNJ,anheuser busch inbev bud reportedly sell euro denominate bond issue worth so order fund acquisition sabmiller move come less week european central bank say begin buy investment grade corporate debt tranche bond deal be worth euro year maturity accord wall street journal cite someone familiar matter ab inbev agree late last year acquire base sabmiller share budweiser parent close stock market today stock have be build flat base share mostly trading day line recent month wednesday news follow number other bond offering include bond issue stateside warren buffett berkshire hathaway brkb well separate bond sale apple aapl exxon mobil xom offer ibm ibm johnson johnson jnj cisco system csco have also make multus dollar bond offering recently berkshire hathaway share fall apple rise exxon tick less related want warren buffett mojo berkshire sell bondsa recession be unlikely so buy apple exxon ibm bond megabrew deal usher new era beer
324,JNJ,spring forward peak energy program go routine workout charge ahead physical activity isn just weight management savvy executive know exercise boost get go influence professional performance human body be business relevant say jack groppel co founder johnson johnson jnj human performance institute fitness consultancy amp study wellness prevention johnson johnson company find respondent be interested improve energy level day ask do want more energy everyone say yes groppel tell ibd rise shine vitality get drain same old problem sit too much nothing life be straight line work groppel say benefit exertion break be scientifically prove minute walk mri show brain just light groppel say spread check fitness box early morning workout lack activity rest day cause mental slog even re fit brain start shut groppel say recommend microburst activity jump jack brisk walk minute influx oxygen awaken mind movement refresh muscle also find improve intrinsic motivation say help worker tune task hand show peer pressure be often keep worker chain desk company leader model active balanced behavior subordinate need permission groppel say take care microburst doesn have be physical similar energy spike come emotional mental spiritual timeout lift call love groppel say incorporate savvy exec weave healthy habit include physical mental emotional social spiritual strategy office routine spend significant amount wake hour work encourage person pay attention improve well be work so say donna hamilton author wellness way short sweet guide create custom plan happier healthier life take small step make cubicle fit place used ergonomically sound office equipment stocking healthy snack opt stair parking farther away office make personal keep picture desk someone something make such love one pet vacation photo stay ground eating lunch front computer take moment silent reflection prayer dig excite mind learn something new day boost brain try master different skill study sector related industry get friendly good reason strike conversation co worker participate office sport league employee report higher job satisfaction opportunity friendship work accord journal business psychology study put sleep mind be race business take moment thought act purge preserve notion do list end day keep organized go step further tally accomplish then walk note
325,JNJ,son wealthy self make man dally prestigious prep school repeat junior year graduate somehow start college quit drift low level job sound symptom case affluenza far be unorthodox self education unusual business titan robert wood johnson ii build johnson johnson jnj international pharmaceutical giant world most admire company have tremendous ability whole life generate really innovative idea margaret gurowitz chief historian johnson johnson tell ibd start mill hand sweeping floor learn business ground johnson make something birth privilege work ethic attitude work do indeed take pass college only education matter more work johnson johnson manufacturing plant move job soon learn earn respect co worker supervisor way year later get shot run company be practical visionary champion decentralize management long be standard practice design manufacturing facility be efficient attractive pleasant place work provide extensive employee benefit good work condition fought higher national minimum wage follow practice pay average wage question johnson come talent naturally father boast own story innovation success trained apothecary robert wood brother founder medical manufacturing business new brunswick johnson johnson manufacture surgical dressing antibacterial carbolic acid vast improvement competitor product be oldest son robert wood ii be expect follow father family business eventually run robert sr even take bobby business meeting start work first year pursue unorthodox self education work many lower level job joined board director be run own factory be aid rise company leader know inherit largest share voting stock firm age prove step young robert prove recover misstep enjoy drink friend even show work drunk once father have die unexpectedly johnson uncle james take president firm threaten sell company johnson ii keep carousing bobby immediately change way write lawrence foster robert wood johnson gentleman rebel convince have grow board director make member april youthful bobby have become sober serious robert johnson ii have be sober serious still have restless drive define life late convince board move johnson johnson international market uncle objection previously company sell product internationally have facility overseas be commit establish locally manage operate unit world gurowitz say know unit understand deal local challenge far better centralize company johnson serve mayor highland park live time incident time office illustrate drive bring endeavor host formal dinner home local woman call complain have picked garbage so mayor formal attire drive house collect trash take dump return party uncle james serve president year last year health be so precarious leadership johnson johnson rest committee call board control virtue stock own performance job johnson be heir apparent board control advanced slowly want mature johnson finally joined board control be just board promote vice president general manager president follow uncle retirement johnson be champion worker right woman right particular continue father practice offer medical care educational program plant lounge employee recreation activity pioneer build factory smaller scale appeal design outside feel very strongly factory be beautiful gurowtiz say believe johnson johnson facility be asset community great depression johnson paid worker more mandate national recovery administration world war ii president franklin roosevelt commission colonel army name head smaller war plant corp create so smaller firm get government contract fight bureaucracy so frustrated johnson left position even fdr advanced rank brigadier general increase clout afterward be always know gen johnson back company love continue international expansion acquire other firm product line create be now call johnson johnson family co today company country fall division consumer health care medical device pharmaceutical accord be world fifth largest pharmaceutical firm sixth largest consumer health company sale stock have rocket johnson serve chairman board retirement remain chairman company finance committee death age northwestern university school hospital administration be first kind country be founder johnson develop concept hospital organize clinical department standard practice now most last creation be robert wood johnson foundation funded estate johnson married time elizabeth ross margaret shea have child robert iii sheila finally evelyne vernon great depression addition pay worker higher require minimum wage johnson keep work cut hour reduce workweek take step keep person employ nationally unemployment reach almost number person layer johnson johnson raise privilege pass college start johnson johnson sweeping floor expand international giant never forget take care worker overcome youthful wayward behavior lesson take care employee deliver value shareholder be difficult little more effort be impossible
326,JNJ,warren buffett berkshire hathaway brkb sell bond offer be meet demand company price debt minimal new issue concession showcase depth high grade bond market accord thomson reuter berkshire issue bond help pare debt purchase precision castpart close end january berkshire earlier say have used cash hand acquisition largest ever plan borrow rest bond issue come recent spate hefty bond offering corporate giant include apple aapl exxon mobil xom ibm ibm johnson johnson jnj cisco system csco recent string jumbo deal steep demand berkshire hathaway debt also come fewer company offer bond less top rate firm have raise money debt market year fewest sale investment grade debt total record rate accord dealogic berkshire hathaway bond sale be lead bank america bac berkshire share edge stock market today apple ibm dip exxon lose johnson johnson ease cisco fall bank america fall
327,JNJ,turbulence stock market recession be unlikely year so putt more money combination high low grade debt give investor equity return significantly less historical volatility bond giant pimco say recent note advice come company apple aapl ibm ibm exxon xom cisco system csco johnson johnson jnj raise ten billion dollar debt last month even concern persist recession ability commodity dependent firm manage debt tuesday warren buffett berkshire hathaway brkb joined rush selling debt investor couldn get nearly enough demand top exception energy metal space many company remain solid ground pimco say firm also believe economy expansion be right midcycle mitigate risk default bond market stateside become more popular year base discussion investor world pimco say expect capital move credit market particularly economy avoid recession continue grow current pace meanwhile corporate giant have provide robust supply quality debt just recent week apple issue bond ibm sell exxon mobile johnson johnson cisco record pace investment grade debt have be issue so far year accord dealogic many investor live world government bond return be run negative territory monetary policy be lose effectiveness pimco say redirect money easily overagitated stock market doesn always seem much better option alternative combination stable higher risk credit pimco say think investor consider better risk adjust alternative investment grade corporate bond select high yield bond select bank loan offer investor potential earn equity return significantly less historical volatility equity pimco say didn single particular corporate issuer credit opinion be sweet spot intermediate zone lower risk inner circle sovereign asset tend outperform lead recession higher risk outer perimeter asset such equity tend outperform initial phase economic expansion monetary policy stimulus firm add share apple ibm dip stock market today exxon lose johnson johnson ease cisco fall
328,JNJ,word bull never expect hear blue chip be leader rally index close lows nov dow jone industrial average gain much nasdaq rise respectively small cap russell gain much have be move essentially sideway mid december
329,JNJ,google be try new advertising system youtube quash crisis derail rally parent alphabet googl stock mid march google be introduce system let outside firm verify ad quality standard video service bloomberg report google also be expand definition offensive content bloomberg say advertising uproar begin europe major brand complain ad placement next controversial content youtube company say ad be place video promote hate violence racism google have say expand safeguard advertiser give more control ad appear google stock climb stock market today google stock reach time high march low volume trading most part google stock fall march advertising flap spread verizon communication vz company suspend ad campaign ibd take learn stock be breaking near buy point try free trial ibd marketsmith premium chart stock screening service accessible home page investor com google stock have claw back retake day move average technical buy point johnson johnson jnj largest advertiser pull spending be reverse position most major market say bloomberg report boycott begin google have allocate more artificial intelligence tool deciphering youtube enormous video library say bloomberg related facebook google rate buy mobile ad hurdle
330,JNJ,be big cap rally dow jone industrial average index be nasdaq composite have gain nearly big cap nasdaq be more meanwhile small cap russell index be just so here be index stock biggest market valuation be proper buy zone google parent alphabet googl amazon amzn berkshire hathaway brkb johnson johnson jnj procter gamble pg latter be dow jone industrial average apple have biggest market cap also be dow stock apple be not buy range keep close eye iphone maker market cap billionalphabet share have rise modestly straight session hit time high past close buy point past day alphabet rise friday stock market trading still easily buy range volume be average first time uptrend ordinarily suggest institutional buy however market quadruple witching inflate trading activity overall friday related ibd take want more big cap stock watch list apple have be top perform dow industrial share hit time high thursday close week apple have sketch week tight pattern buy point apple be dow stock buy point market cap billionamazon clear buy point clear initially late january short post earning tumble stock retook entry area early february past several week amazon have be move sideway tight fashion dip friday amazon be still range buy area also have form bullish week tight pattern trigger related market cap billionwarren buffett berkshire hathaway form flat base mid december mid february not far prior flat base berkshire hathaway class stock clear buy point feb continue advance march be slightly chase zone stock have pull back buy range lose friday buffett invest apple first time early then vastly increase berkshire apple stake then double hold again january give berkshire big paper gain buffett also invest big airline shun industry year say be bad business be related market cap medical product drug giant form flat saucer base late july early march clear buy point march jan johnson johnson reach deal buy actelion spin swiss drugmaker unit then stock have rise steadily rise record high wednesday fall friday related market cap billionconsumer product giant procter gamble form cup handle base oct end january form handle gapping higher jan earning report share try clear early february didn decisively clear area gapping higher feb word activist investor nelson peltz trian partner have take stake think be peltz push be even more aggressive boost profitability shareholder return share have largely moved sideway then stay buy range kraft heinz khc berkshire brazil capital own half kraft briefly bidding unilever be buzz industry consolidation ease pricing pressure entire sector stock hit new year high friday reversed close related
331,JNJ,many part president trump federal government have yet take shape leaner meaner food drug administration seem almost certain way agency watcher see trump blueprint nation pharmaceutical gatekeeper point funding cut budget outline also suggest user fee charge industry process approval much double yet trump also want speedier fda push more generic drug boost competition have deride astronomical outrageous drug price call competitive fair drug approval process drugmaker analyst say re re just not sure leaner fda accomplish support fda get more funding so approve generic drug faster ll bring drug cost say john maraganore ceo alnylam pharmaceutical alny alnylam make expensive specialty drug treat hemophilia other rare ailment acknowledge more competition generic market help tug rise drug price competitive marketplace base way do preserve market base time limit award really need innovation maraganore tell investor business daily irina koffler analyst mizuho agree fda now face drug backlog generic application tell ibd make dent backlog agency need more funding more staff legislation clear thicket law legal decision slow drug approval koffler say generic submission be sit languish be not enough competition koffler say situation ll have supply monopoly company be only manufacturing certain generic drug therefore charge lot biotech drug stock be touchy come trump march tweet president promising more drug competition send ibd company generic drug industry group generic drug company actually favor more competition say chip davis chief executive association accessible medicine advocate maker generic drug maker generic be know biosimilar drug experience constant price deflation say backlog generic application mean drug provide new revenue stream stay stick hold await fda review action only way time company be financially successful be be able get approval new generic help offset continue deflation see year year current mature portfolio tell ibd fully recognize more competition create downward pressure pricing prescription drug price rise re project jump year active employee early retiree american workforce accord advisory firm segal consult retiree age older price be expect rise slowdown likely take congressional push speed fda approval most recent iteration american health care act gop bill seek replace obamacare didn touch pharmaceutical trump pledge march kentucky rally work legislation bring pricing ibd take swearing trump have continue call drugmaker lower price do biotech drug stock read ibd industry theme trump budget blueprint hint package administrative action design achieve regulatory efficiency speed development safe effective medical product trump be same page alnylam maraganore imagine system fda incentive approve generic quickly congress enact legislation fda be incentivize approve second third manufacturer generic drug faster maraganore say imagine help speed lower drug price fda have prioritize second third drug approval other generic drug action trump not do be reduce drug testing safety effectiveness mizuho koffler say recall thalidomide crisis thalidomide be first market germany counter medication nausea pregnant woman ensue year child worldwide be born phocomelium malformed limb half survive be turn point drug approval process koffler say thalidomide wasn well test be sell vulnerable population pregnant woman result unexpected side effect newborn fda strengthen drug review process drug re take have assume terrible thing happen child take pregnant woman take person have bad kidney bad heart take say so have test drug more realistic representative population patient trump pick fda commissioner dr scott gottlieb have talk overhaul fda process generic complex drug have allow brand drug create monopoly perpetuity generic complex drug have more complex active ingredient formulation route delivery drug device combination typical generic gottlieb be industry insider formerly hold position fda center medicare medicaid service nomination have draw support aisle trump gottlieb support more competition generic market cut brand monopoly march article forbe gottlieb note older generic drug be sell cheaply be sometimes very costly prime example be turing pharmaceutical purchase decade old hiv medicine company spiked price pill overnight be often result failure way fda be regulate generic medicine say agency long costly approach regulate generic drug be reduce competition generic market increase cost manufacturing generic medicine maraganore identify more brand side aisle draw distinction generic groundbreaking treatment fda approve brand drug rare disease biogen biib spinraza spinal muscular atrophy even new treatment come now actually cure cancer drug receive patent protection number year generic make copy period maraganore call market base time limit award need innovation generic market be be greatest amount competition say address challenge system drug price drug approval process need be careful reform look good sound good be fact good preserve innovation engine have country january trump tell exec celgene celg eli lilly lly johnson johnson jnj novartis nvs merck mrk cut regulation fda approval process accord regulatory affair professional society trump pledge streamline process so standpoint actually have drug actually get approve instead wait many many year mizuho koffler note least law be revise drug price competition patent term restoration act stay generic drug application month allow patent holder time litigate generic filer protect patent month clock be place regardless dire need be drug legislate stay away mandatory month help expedite litigation process brand generic company create lot more competition say davis generic drug maker advocacy group argue congress tackle decade old law require maker fda take additional safety measure drug have risky side effect not properly administer brand company be take advantage risk evaluation mitigation strategy law prevent generic purchasing sample drug say davis contend company have used risk evaluation program create limit distribution program doesn allow generic company legally purchase sample drug need do clinical testing so submit application fda compete originator product say need be legislation make sure risk evaluation only be used intend purpose not delay competition generic biosimilar go forward say bill house now just study matter reality be everyone have know year be problem trump budget blueprint offer clearest view yet want run fda doesn clear away smoke trump argue industry benefit fda approval pay share constrain budget environment proposal doesn detail specific budget figure fda fda budget grow year fda have ask increase industry be brace potential cut agency funding indicated propose jump user fee law fda collect fee drugmaker brand generic biosimilar fund drug approval process trump blueprint propose boost fee agree user fee industry fda isn publicly available say davis so difficult know mesh trump blueprint deal be form month month dialogue generic biosimilar come away satisfied say trump blueprint likely include brand generic biosimilar be set pay fee year unclear trump plan include other type user fee fda user fee amount alliance stronger fda coalition consumer patient group health professional trade association call trump user fee jump neither wise realistic march statement not wise fda core responsibility safe effective medical product safe food need be support large measure public be primary beneficiary group say not realistic drug device industry have recently complete user fee agreement negotiation fda
332,JNJ,european biotech actelion confirm wednesday exclusive talk johnson johnson jnj week discussion temporarily fizzle rumor arise sanofi sny have enter fray johnson johnson initially confirm interest actelion nov insider say firm up bid actelion share value actelion north attempt secure deal christmas time insider say french sanofi be mull bid have informally let actelion know interest actelion become engage talk unnamed party dec johnson johnson withdraw bid johnson johnson return negotiating table wednesday accord release actelion also note be assurance transaction result discussion ibd take biotechs have nearly round trip rally inspire donald trump election commentary president elect tackle rise drug price sanofi stock jump stock market today johnson johnson stock dip related unite therapeutic chill fever actelion bayer rivalry
333,JNJ,regeneron regn sanofi sny eye biomarin bmrn medicine co mdco wake judge ban amgen amgn rivale ldl buster rbc leerink analyst suggest friday late thursday district judge rule regeneron sanofi praluent infringe pair amgen patent repatha pcsk inhibitor lower ldl bad cholesterol blood decision send regeneron sanofi stock red stock market today regeneron stock fall sanofi stock fall amgen have patent reaffirm enjoy gain ibd take biotech sector suffer raucous election year leader end year triple digit gain be stock pick list get deep dive ibd industry theme biomarin pharmaceutical stock rise medicine co jump suggestion regeneron pharmaceutical sanofi issue bid make lose potential removal praluent market biomarin have market cap medicine co have cap france base sanofi have market cap have be particularly vexed recent year lose medivation blockbuster cancer drug xtandi battle pfizer pfe last year last month sanofi be say be jockey johnson johnson jnj swiss biotech actelion pharmaceutical revenue loss theoretically cause sanofi continue increase activity have written biomarin make good fit pure play orphan franchise be synergistic sanofi orphan franchise rbc analyst michael yee say friday research note yee estimate biomarin deal slightly sanofi acquisition price genzyme several year have outperform rating price target biomarin stock leerink analyst joseph schwartz see medicine co appeal regeneron sanofi party interested pcsk space medicine co alnylam pharmaceutical alny have partner inclisiran drug aim lower ldl cholesterol schwartz note aftermath praluent injunction set go effect day inclisiran be second line come market pcsk space new england journal medicine article describe inclisiran rna interference therapeutic inhibitor pcsk november medicine co alnylam deliver strong result inclisiran phase trial investor expect more clarity phase testing schwartz write have outperform rating share medicine co related regeneron sanofi ldl buster risk judge uphold amgen downgrade increase boston st jude rivalry
334,JNJ,exchange trade fund be ideal produce short long term investment gain many etfs be deploy generate steady income stock dividend bond interest etf investment strategy generate income fall main category highest yielding bond etf track morningstar inc right now be spdr barclay high yield bond jnk month yield sit follow first trust tactical high yield hyls yielding spdr short term high yield bond etf sjnk yielding see fat yield etf be mislead big payout doesn mean much fund total return be slip jnk have return year date average annual past year compare hyls sjnk rank year return top performer be pimco year coupon treasury zroz average annual past year year date yielding just be follow vanguard extend duration treasury edv respective period yielding next be ishare year treasury bond yielding junk bond long duration treasury bond be subject bout heighten volatility investor look income often seek avoid so re better used etfs track kind bond part diversify portfolio contain steadier bond benchmark diversify bond portfolio be barclay aggregate bond index be make broad array investment grade bond index be track ishare barclay aggregate bond fund agg have asset year date average annual past year yield prefer bond need be aware anticipate interest rate hike affect potential return general bond etfs higher duration be more negatively impact shorter duration expectation increase higher rate duration be measure sensitivity bond price change interest rate duration be tie bond maturity date bond principal be repay lender investor check etf average duration example rate rise long term etf such ishare year treasury tlt incur more interest rate risk ishare year treasury iei note todd rosenbluth director etf research global market intelligence short rate trend higher time return bond etfs be negatively impact not equally say however rate hike fed not be impactful highest yielding etfs bring big payout quality holding decline total return be sap decline price unfavorable market top yielding dividend stock etf be global superdividend alternative alty pay stock price annually small young etf just asset year record almost year older bigger sibling global superdividend sdiv yield have gain year average annual past year high yield stock investor tend prefer stock decline be way investor reap big payout dollar invest hope capital appreciation business turn not etfs screen stock way do be global superdividend etf div index methodology screen stock have exhibit low beta relative effort produce low volatility return year have rise average annual past year top holding include cone midstream partner cnnx invesco mortgage capital ivr other end spectrum lower yielding etfs invest company have long history increase dividend only top quality company increase payout year year tend be big demand investor look steady capital appreciation stock price rarely get whack point have big yield vanguard dividend appreciation vig track nasdaq dividend achiever select index hold stock have grow dividend annually year more yield vs spdr spy top holding include johnson johnson jnj microsoft msft pepsi pep proshare dividend aristocrat nobl hold stock smaller list reflect higher barrier entry hold have raise dividend year year more yield top holding include cinta cta grainger gww global spgi spdr dividend sdy invest dividend aristocrat composite have jump year date yield top holding include property reit hcp hcp person unite financial pbct caterpillar cat safe say mlp be best left pro know get use portfolio diversifier morningstar track reit etfs top perform year date be global superdividend reit sret year yield third highest index track solactive global superdividend reit index invest highest dividend yielding reit world least amount volatility nearly etf asset be invest north america top holding include mortgage reit annaly capital management nly yield chimera investment cim yielding nearly well property reit senior housing property trust snh yielding reit be launch march biggest reit etf be vanguard reit vnq year date yield top holding year date price performance include simon property spg public storage ticker symb psa prologis pld yield convertible bond be bond be exchange set number issue company common stock tend carry lower interest normal corporate bond have potential greater price appreciation top perform etf area year date be vaneck vector prefer security ex financial pfxf yield largest be ishare prefer stock pff year yield related latest etf news
335,JNJ,small biotech lexicon pharmaceutical lxrx soar much friday diabetes drug succeed late stage trial lexicon drug sotagliflozin significantly reduce type hemoglobin used measure glucose level plasma patient type diabetes sotagliflozin be combination sglt inhibitor similar eli lilly lly jardiance johnson johnson jnj invokana sglt inhibitor help regulate glucose absorption tract study do not see increase severe hypoglycemia be dose related increase diabetic ketoacidosis reach higher dose arm ibd take lexicon hit new week high always good idea check ibd new high list hit new high isn be end good stock new high page explain type diabetes market be fraction size type market lexicon say start phase trial type year collaboration french pharma sanofi sny think dual mechanism action sglt sglt inhibitor differentiate market sglt inhibitor type diabetes assume peak sale exceed indication write morningstar analyst karen andersen research note last november lexicon now see smaller realize sale type diabetes form double digit royalty sanofi deal also open significant potential type diabetes lexicon stock end stock market today nearly year high sanofi stock fall related sanofi rival mylan epipen have troubleseli lilly upgrade pipeline prospect
336,JNJ,country lead mutual fund past month continue add build stock fabless chip stock portfolio latest report period many stock have strong run up summer most get hit friday stock market outlook turn pressure stock purchase make top perform mutual fund build sector include draw industry dw trex trex universal forest product ufpi thor industry tho aos patrick industry patk latest report period thursday ibd bldg rv subgroup be rank industry click here see list new buy top mutual fundsall bang day move average friday fabless chipmaker nvidia nvda inphi iphi silicon motion technology simo have perform well have notch new week high telecom stock lumentum lite ubiquiti network ubnt be also heavily buy lead fund latest report period lumentum ubiquiti remain furthest day line computer software stock netease nte paycom software payc ebix ebix veeva system veev cyberark software cybr be worth consideration stock watch list cyberark stay day line ibd eye best perform fund have latch patrick industry investing estimate pnc small cap fund ppcix add share latest report period elkhart ind base firm make build product material manufacture home rvs also supply many product industrial market include customer kitchen cabinet office household furniture fixture commercial furnishing patrick industry be finalist indiana public company year fellow rv maker draw industry thor industry clear long consolidation april stock run week high then pull back be work right side second stage flat base drop day line friday remain flat base earning growth have be double digit past quarters handful recent leader retailer also find institutional support past month burlington store burl jack box jack wingstop wing remain day line ollie bargain outlet olli dave buster entertainment play fall top perform fund have be unload medical giant johnson johnson jnj latest report period fidelity equity income fund feqix reduce share band aid maker lead fund also take profit computer software firm symantec symc workforce uniform provider cinta cta click here see list latest sell top mutual fundsrelated top mutual fund stock buy ollie shopping list
337,JNJ,medical behemoth amgen amgn biogen biib square acquire muscle biologist cytokinetic cytk more dozen potential player prep donnybrook small cap pharmaceutical adms needham analyst suggest friday biotech fodder heated week allergan agn announce back back deal acquire vitae pharmaceutical vtae tobira therapeutic tbra tobira deal give allergan leg battle nonalcoholic steatohepatitis nash gilead gild intercept icpt pharmaceutical also compete ibd company biotech industry group have climb group track just week collectively group have market cap group group fall friday first decline past trading day group be week needham analyst review pipeline business development area interest activity large company gauge interested big pharma be biotechs important theme biotech space write research report allergan amgen bristol myer squibb bmy johnson johnson jnj merck mrk pfizer pfe roche rhhby shire shpg valeant vrx have be most acquisitive buy prep buy more company collectively shire have be most active acquisition believe late development stage commercial stage biotech company be particularly attractive acquisition target write research report title do big pharma want buy peak area interest include oncology cardiovascular needham research show not be big pharma take beaucoup buck needham analyst suggest central nervous system cns player acadium pharmaceutical liver disorder drugmaker intercept be prime acquisition interest firm overlap potential interest acadium abbvie abbv allergan eli lilly lly lundbeck merck novartis pharmaceutical nvs teva pharmaceutical industry teva takeda pharmaceutical needham list potential acquirer allergan make particular sense consider duo already partner next generation formulation memantine fix dose combination product namzaric battle alzheimer year end plan file new drug application food drug administration ad treatment levodopa induced dyskinesia involuntary movement parkinson disease patient multiple sclerosis walking impairment needham write meanwhile acadium potential suitor be interested nuplazid drug ease psychosis associate parkinson launch earlier year needham suggest acadium be look expand label other used similarly intercept draw interest nearly dozen potential buyer include gilead biotech market cap thursday rbc analyst posit intercept continue lead gilead allergan battle nash ibd take biotech stock notch higher week last week check ibd industry theme
338,JNJ,share diabetes giant nordisk nvo jump friday company say drug victoza reduce heart attack stroke release few detail result study save next american diabetes association meeting june however do say be statistically significant reduction metric heart attack stroke death cardiovascular cause patient take diabetes drug year compare placebo group subject be age have cardiovascular disease multiple risk factor nordisk stock be afternoon trading stock market today highest rate stock low rate medical ethical drug group composite rating effect diabetes drug cardiovascular health have be subject several study lately notably eli lilly lly drug jardiance reduce death heart failure similar large long term study report last september other hand merck mrk januvia show effect good bad outcome trial report few month earlier similarly neutral result be report outcome trial sanofi sny drug lixisenatide be noteworthy lixisenatide be same class victoza be glucagon peptide glp analog similar bydureon astrazeneca azn lilly trulicity jardiance be sglt inhibitor same class invokana johnson johnson jnj farxiga astrazeneca merck januvia belong class call dpp inhibitor conference call analyst friday chief scientific officer mad thomsen say different result have come subtle difference drug think extend victoza plan successor semaglutide not only question be member give class glp agonist say thomsen also part kinetic dynamic distribution half life so get semaglutide have do rather detailed investigation be nothing animal pharmacology negate notion semaglutide do least well cardiovascular performance
339,JNJ,top stock hold institutional investor fourth quarter be google parent alphabet googl apple aapl microsoft msft jpmorgan chase jpm johnson johnson jnj cnbc say cite evestment datum order be unchanged breadth institutional fund ownership increase contrast top fund manager carl icahn trim stake apple share add institutional ownership apple also come report demand iphone be cool meanwhile evestment top first time include facebook fb debut reordering top ibd composite rating yield different mix highest be alphabet facebook verizon communication vz home depot hd comcast cmcsa alphabet have best possible ibd composite rating meaning outperformed stock key metric such sale profit growth recent quarters google restructure last fall become largest operate unit new parent alphabet include variety advanced project sometimes far afield web search alphabet result show core business search be strong first time financial other bet self drive car internet balloon be report collectively have operate loss vs profit core alphabet close stock market today just week line monthly active user facebook have strong competition social arena menlo park calif base company also have composite rating be expand adjacent market virtual reality oculus rift headset ibd list stock facebook dip top wireless provider verizon have composite rating last fall declare intention be first roll wireless enable faster stream huge amount video text verizon jan earning call chief financial officer fran shammo backed say be first company roll be currently prepare field trial verizon share ease world largest home repair build supply retailer feb easily beat earning estimate ease investor concern economic uncertainty derail retail juggernaut home depot earn composite rating also best sale growth quarters rise share end nation cable tv company have composite rating be drive full steam ahead marketing xfinity video service new set top box comcast year launch social medium campaign target millennial analyst say comcast see net add tv subscriber trend internet video share dip
340,JNJ,manager best perform mutual fund past month have be nibble recently top rate stock have re-cover january steep loss major index rally sharply second half valentine month investor bottom fed lead stock lower price trim loss just february nasdaq be lead stock mutual fund have show interest defensive sector food processor financial stock utility firm recent month slow economy investor often flock food company such hormel hrl cal maine calm tyson tsn hormel tyson have perform well past year hit new high way click here see list new buy top mutual fund financial issue top fund be seek steady gain reit such agree realty adc equity lifestyle property el kimco realty kim federal realty trust frt sun community sui credit card payment processor leaderboard stock paypal pypl be also add lead fund latest report period area worth gander be utility include itc holding itc cms energy cms pinnacle west capital pnw telecom giant verizon communication vz find way top perform fund buy list lead fund add verizon investing estimate latest report period new york base firm get big marketing boost power rank verizon wireless highest network quality region wireless provider ibd spot best perform fund tap paypal investing estimate rowe price growth stock fund prfgx add share latest report period mobile online payment processor be spun long time parent ebay ebay july last year also own popular mobile payment app venmo now paypal be standing own foot san jose calif base firm stand grow mobile payment segment particularly store mobile wallet compete alphabet google android pay apple pay samsung pay mobile world congress paypal announce partnership vodafone vod america movil amx subsidiary telco claro latin america mean europe mexico brazil phone have paypal power mobile wallet already install partnership paypal offer merchant consumer more flexibility choice want pay get paid paypal doesn own operate platform be not connect device have broad scope growth paypal doesn have long trading history stock have be set good look shallow base july ipo creep buy point paypal earning grow cent share ex item revenue growth rise country top rate fund have be unload medical stock such johnson johnson jnj henry schein hsic quest diagnostic dgx latest report period large cap illinois tool work itw mmm have also be sell lead fund be top fund selling computer graphic chip maker nvidia nvda only fund buy leave net selling fund nvidia stock have be etching right side cup shape base near buy point click here top mutual fund latest sellsimage provide shutterstock
341,JNJ,get robot be come drone warfare self checkout line grocery store change be clear sale automate industrial robot rise year year reach annual record unit accord international federation robotic unit be value more year
342,JNJ,stock clock healthy gain tuesday second session cut bullish weak start strong finish pattern dow jone industrial average add break session pullback longest string daily decline half decade chisele gain nasdaq climb small cap keep pace general action leave russell tuesday move show dow find support day move average trading volume case be weak nasdaq rebound day line monday extend gain tuesday shipping fleet take day largest gain industry star bulk carrier sblk safe bulker sb golden ocean group gogl surge more upgrade overweight morgan stanley dow industrial stock book gain better apple aapl lead group pop new high remain buy range buy point week tight pattern caterpillar cat jpmorgan jpm goldman sachs gs be next line amazon com amzn rise more session stifel nicolaus raise stock price target company reach deal buy souq com reportedly largest commerce operation middle east amazon share continue trade week tight buy point darden restaurant dri red hat rht carry strongest gain stock open strong report quarterly result darden gap gain clear cup handle base huge volume cup handle be common bullish pattern darden top street estimate quarterly earning raise guidance red hat score gain report solid fourth quarter beat late monday stock be testing week support fifth week shallow consolidation charle schwab schw top ibd list rise nearly weak trade stock be battle recover support day move average drop almost march high dave buster entertainment play post gain ollie discount outlet olli add regular session be schedule report quarterly result close tuesday loss be generally moderate seasoning maker mccormick mkc take hardest hit strong trade stock be shape possible handle month cup base mcdonald mcd johnson johnson jnj be only decliner dow fraction related steel stock rebound trump infrastructure plan
343,JNJ,xfuture dow jone industrial average index nasdaq early monday signale weaker start week big cap index approach day move average worst weekly loss month market be unclear president trump agenda move forward fail obamacare replacement effort oil minister meet sunday discuss extend production cut meanwhile red hat rht be buy range earning tap google parent alphabet googl try stop stem bleed googl stock youtube brand future dow jone industrial average fall nearly vs fair value index nasdaq be fair value small cap russell future sank last week dow industrial index russell suffer worst loss trump election nasdaq composite have worst week ibd take red hat be several stock buy point earning tap week see company be analyst expect check ibd weekly investing action plan google parent be public relation fiasco become clear place advertisement racist other objectionable material youtube alphabet be scramble fix problem dow component wal mart wmt verizon communication vz johnson johnson jnj have pull youtube ad pepsico pep starbucks sbux other alphabet share fall day last week lose drop buy point day move average minister several oil produce nation take part output cut meet kuwait meet sunday discuss extension country have backed such move continue reduce global inventory russia tell bloomberg tv be not ready commit extension opec ally be bind want signal market supply be keep check push price send signal shale producer continue ramp activity oil price fall again last week close friday barrel dow component exxon mobil xom be trading essentially week low fall dow component chevron cvx be try find support day move average crude oil future edge lower overnight red hat report fiscal fourth quarter result late monday analyst expect rise adjust earning share cent revenue red hat linux software specialist clear buy point feb have trade entry then friday share edge back buy range japan nikkei fall monday intraday trading stock fall korea australia hong kong china shanghai composite rise related high growth chip stock be form basis be buy rangetrump ryan re fire tax reformwhy opec russia be desperate enough help shale
344,JNJ,stock index keep recent tendency small move thursday afternoon pattern appear head fifth straight session nasdaq fall slightly lower dow jone industrial average dip small cap russell also be flat volume stock market today be run higher nyse lower nasdaq bull bear be look catalyst drive market clearly north clearly south so far stock market have fail find tip point widely hold stock apple aapl stage positive reversal stock drop first minute trade then reversed trim loss apple be only recently peg week high ibd list top rate stock fundamental technical stock rise fall computer sector stock mercury system mrcy lead pop mercury be group stock checkup investor com day worst performer ibd be china base momo momo heavy volume social networking provider gap tuesday wednesday ibd take electronic sector be hot look stock strong earning outlook blue chip be mostly dow jone industrial average johnson johnson jnj advanced stock be just week high caterpillar cat suffer biggest dent dow industrial average add loss wednesday almost loss recent news government raid critical report accountant have shake stock stock hit high jan be now high ibd big cap winner lead loser ratio bank stock hold spot list be exception biggest percentage gainer big cap bank be superregional bank keycorp key soft trade ibd industry group most top rate group be superregional bank computer integrate system biotechs stock top post gain roughly west texas intermediate crude oil fall nearly just barrel oil stock be mostly related shell exxon make strategic stock move closer leadership role
345,JNJ,johnson johnson jnj ceo alex gorsky underwhelm investor tuesday meeting president trump reportedly fixate tax regulatory policy rather drug pricing goldman sachs analyst jami rubin say wednesday gorsky be dozen business leader trump meet first full day white house say business insider be tesla motor tsla ceo elon musk ford motor ceo mark field lockheed martin lmt ceo marillyn hewson trump didn focus drug pricing gorsky tell analyst company earning conference call trump have call big pharma recent week say re get away murder raise price study have show pharmaceutical raise product price annually average monday meeting have different tenor gorsky say really focuse more overall economic growth mentioned earlier thing tax regulatory other policy be really major driver conversation say call ibd take johnson johnson have drug approve do other drugmaker biotechs stack read more ibd industry theme research note rubin say commentary do little quell investor nervousness issue drug biotech stock be largely trump pledge late last year curb spiraling drug price johnson johnson stock have lose nov see not much upside big pharma rubin predict series megamerger smaller acquisition johnson johnson be currently work acquire european biotech actelion time sanofi sny be reportedly interested buy actelion didn issue formal bid tuesday executive wouldn comment exclusive talk actelion comment call suggest pursue deal rbc analyst glenn novarro write research report expectation deal announcement conjunction earning do not materialize say novarro management comment call suggest johnson johnson remain active front keep outperform rating stock lower price target stock market today johnson johnson stock rise fall tuesday related hep sale dip virtually mirror gilead view laggilead merck alexion view hazy biogen surge analystjohnson johnson exclusive talk acquire actelion sanofi fray
346,JNJ,stock market start february smell skunk end month look phoenix rise ash stock mutual fund follow suit diversify stock mutual fund end month decline average extend debacle record january accord lipper inc get break even fund have work stock market shave mid month decline loss month end february late month rally be fuel surge price oil west texas intermediate crude benchmark go barrel feb feb click here see list mutual fund month leadersthe price rise begin report saudi arabia russia venezuela qatar be discuss freeze oil production level market rally wasn just oil say david joy chief market strategist ameriprise financial get upward revision fourth quarter gdp datum personal income spending moved higher get stronger expect durable good order number income spending figure be especially welcome suggest consumer spending linchpin economic growth be rise joy say addition bureau economic analysis release personal consumption expenditure pce deflator number show uptick inflationary pressure fuel expectation federal reserve rate increase joy say click here see list mutual fund category performancealso bond yield rise back half month help bank lot investor feel market move higher financial participate perhaps lead joy say still aside oil other raw material stock february other lead sector be defensive bearish say rich weis senior portfolio manager american century target date choice portfolio precious metal fund lead sector soar last month commodity precious metal fund be next jump basic material fund vault commodity base metal climb industrial rise february strength sector suggest global demand have bottom january maybe just maybe be stabilize february joy say february gain make mid cap value fund best perform category diversify stock fund month top large cap growth manager include fidelity contrafund fcntx slide last month foreign stock fund fared fund lose average emerge market lead china be clear economic deceleration mode weis say economic term re do better europe japan joy say taxable bond fund overall advanced february treasury fund lead gain so next many investor want see dramatic cut oil production ll take situation oil do be stabilize mid range joy say keep mind low oil be also benefit consumer well many manufacturer other business energy sector stabilize then maybe second half year other sector especially oriented one do better produce earning gain low oil price already seem have help boost automotive sale especially gas thirsty suvs housing restaurant travel also seem have benefit joy say not department store consumer discipline also help economic expansion long run economic softness japan europe have recently force ameriprise strategist question late forecast region outperform joy say emerge market be worthy underweight add re still buffet decline global trade weak commodity price diverge central policy globe joy continue develop market be still place be outperform be open question still be outperform europe japan china begin year continue lunar new year begin feb investor have real concern china devalue currency get competitive advantage value yuan vs dollar be actually little stronger now so fear additional devaluation have recede not go away recede american century weis have relatively cautious outlook say consumer spending be strongest part global economic jigsaw puzzle just doesn make sense fate entire global economy rest solely consumer say think healthy recovery be plausible only bright spot be consumer still say company generally look stronger go forward european japanese emerge market business next year expect current macro condition continue outlook be sideway lot volatility say don expect nightmare investor just little return lot volatility weis advise investor rely diversify strategy tilt more defensive sector ve already rotate more defensive position not selling stock go cash add move high beta high growth fang strategy have do well recent year fang refer facebook fb amazon amzn netflix nflx alphabet googl google weis also urge investor consider shift asset emerge market foreign stock equity income fund american century equity income fund tweax top holding include johnson johnson jnj have strong composite rating ibd dividend yield composite rating combine ibd stock performance rating include ep relative strength rating be highest american century equity income top holding also include sysco syy have comp rating dividend yield gas og have comp rating dividend yield top new buy fund include atmos energy ato have comp rating dividend yield weis urge investor even more risk tolerance consider strategy american century global allocation agavx addition shift more money defensive style asset fund have boost weighting vix future hedge equity market risk weis say year old fund have asset achieve target global allocation investing other american century fund nov fund have money foreign stock stock bond alternative alternative include currency sector etfs volatility instrument image provide shutterstock
347,JNJ,stock index struggle wednesday afternoon only small cap keep upside nasdaq trim dow jone industrial average be flat respectively however small cap russell rise volume stock market today be run bit higher nyse lower nasdaq vs previous session firearm stock reversed lower good news background check datum february government report check february january vs year earlier period last year background check rise background check be consider rough estimate industrywide sale firearm maker wesson swhc rise slightly open then reversed loss volume be run average morning then slow less average fund ease collective exposure wesson then almost gunmaker sturm ruger rgr rise late morning then reversed loss volume be average then slow average afternoon fund increase overall stake sturm ruger additional firearm stock be small cap blue chip loser lead winner dow ratio procter gamble pg show good price volume action rise volume be average morning then fade average procter gamble say have sell hipoglos diaper rash cream brand brazil johnson johnson jnj ease slightly average volume procter gamble have be shedding low margin business multiyear plan
348,JNJ,share medical device giant medtronic mdt dip sharply tuesday fiscal sale miss estimate earning guidance be line expectation medtronic earning quarter end jan totale share exclude time item year earlier quarter match consensus number calculate thomson reuter survey analyst sale jump adjust last year buyout covidien well foreign exchange rate sale increase just be consensus medtronic affirm full year guidance ep include cent foreign currency impact do not guide earning say sale grow exclude foreign currency impact see amount leerink analyst danielle antalffy write sale miss be largely due higher expect foreign exchange headwind be few sign trouble sale growth do slow bit come growth vs projection represent deceleration growth see fiscal growth see fiscal antalffy write slow growth be likely large part attributable increasingly difficult comparable doesn yet suggest alarm signal broad base slowdown medtronic do deliver positive operate leverage quarter quarter ebit margin vs last quarter improvement fall guidance estimate now leave increasingly positive operate leverage story very much back end load medtronic have deliver operate margin least hit prior guidance report full year antalffy also note medtronic competitor similarly miss sale estimate most recent quarter st jude medical stj boston scientific bsx johnson johnson jnj make medtronic quarter look good comparison medtronic stock be almost late morning trading stock market today stock have be relatively buoyant market sell close monday just few percentage point week high hit last march
349,JNJ,stock index surge tuesday provide solid boost just market seem ready pause nasdaq composite lead gain largest single day advance year biggest aug roar higher volume swell sign institutional investor aggressively acquire share winner lead loser
350,JNJ,share biotech intercept pharmaceutical icpt spiked early afternoon trading friday report company be explore sale reuter cite anonymous source report intercept have be work investment banker week receive interest other company reuter do not name suitor intercept have be perpetual source
351,JNJ,typically slow stretch late august biotech news be bound pick company prepare fall season conference investor day most stock move event likely be update key clinical trial several expect september celgene celg be due release long await midstage trial result ged mongersen drug crohn disease license drug initially spark excitement wall street strong week remission rate beat even lead inject tumor necrosis factor drug such abbvie abbv humira johnson johnson jnj remicade amgen amgn enbrel next datum set cover full year evaluate patient endoscopy rather just symptom investor confidence be somewhat shake celgene refuse provide interim analysis trial interpreted lack confidence number leerink analyst geoffrey porge write close inspection earlier datum also raise red flag trial be consistent earlier phase ii result original investment be make endoscopic remission rate be range be well see even best biological immunomodulator porge write july research note fact assessment earlier result lack crp reactive protein response be biomarker crohn disease inflammatory activity suggest result be materially lower tnfs remission rate more likely be range note ged be oral rather inject still find market niche not be mega blockbuster initially hope ibd take medical biotech group have be roll lately rise ibd industry group ranking last week see other industry be hot follow industry theme column kite pharma kite be expect release headline datum zuma phase trial car cell therapy kte diffuse large cell lymphoma car cell chimeric antigen receptor cell be genetically engineer attack cancerous cell trial result be crucial kite hope use file fda approval treatment make first car therapy hit market next year rbc capital market analyst michael yee estimate friday study yield overall response rate percent tumor shrank perhaps complete response rate tumor disappearance base earlier datum initiation report tuesday btig analyst dane leone write much depend datum stack result competitor juno therapeutic juno novartis nvs be yet unknown novartis present pivotal datum set ash potential first datum cd specific antibody write leone refer american society hematology conference december juno be also expect present clinical update ongoing cd trial vertex pharmaceutical vrtx provide report triplet pill cystic fibrosis consist already market drug ivacaftor kalydeco combine experimental drug vx additional drug vx vx trial ivacaftor vx alone recently fail do present clean safety profile analyst have be expect triplet be next generation treatment case also month fda be due render verdict expand label vertex already market cf drug orkambi child age related be epipen price fda fault hold new generic novartis close cell therapy unit car stock tumblebiotech stock seesaw hope meet new pricing fear
352,JNJ,pokemon go have rac amazing number july launch nearly user first month include peak daily active user spending more half hour day play game free download most impressive number be billion calory burn kid catch nintendo ntdoy anime creature yet number bound underwhelm impact gdp nothing new come today breakthrough technology product technological innovation be make person richer not necessarily way pay bill term good pay job have bite size impact dot com boom common feature today most tech innovation be end user often don have pay anything socialflow social medium management company estimate spring free publicity donald trump presidential campaign get social network facebook fb twitter twtr snapchat be equal paid advertising reason economy have be prolong growth slump be way gdp be measure gdp exclude be know consumer surplus be much value person derive something excess much have pay ibd take facebook not be generate many job historical standard innovative company be lucrative investor social networking giant break base buy point late july stock moved sideway breaking again short consolidation entry point click here facebook stock chart analysis consumer surplus be hard quantify economic analyst think huge usual gdp measurement whatsapp be worth nothing perhaps measure term income engineer yet person get telecom communication need service write forbe columnist tim fellow london base adam institute million person be play pokemon go free many other be spending money app purchase help speed progress game most date stat reveal mobile game have gross worldwide meaning pokemon go have eclipse earning summer blockbuster movie sound pretty huge consider person have download pokemon go have play game half hour day spending come something less cent hour play roughly tenth cost hour movie unclear pokemon go craze contribute summer movie slump be clear person be derive lot more value game be pay pocket shortly game launch researcher michael farren adam millsap george mason university mercatus center figured pokemon go player be easily get more value spend even average consumer surplus be only measly dollar hour worth consider play pokemon go require gps capability come smartphone now take grant book abundance future be better think xprize founder peter diamandis offer reminder just much take grant take decade old list price gps digital voice recorder video camera digital camera encyclopedia music player video game console everything else come include calculate more worth application smartphone implication be traditional measurement vastly understate impact recent technological innovation boost quality life yet come thing most person think think financial well be number good pay job size economic pie defined gdp current era technological innovation have fall short technology leader such apple aapl facebook amazon amzn netflix nflx google parent alphabet googl have transform connect friend politician business information so expect see dramatic impact employment output yet term company don compare older industry apple google facebook largest company market capitalization combine employ only worldwide end fiscal year contrast general motor gm have worker peak facebook employee generate revenue latest fiscal year employee alphabet staffing pursue other bet so far amount less revenue generate worker alphabet release google map update go everyone relative ease general motor introduce new model have retool factory make car truck individually then transport far fling dealership sale take labor often highly paid apple employee doesn really compare give large contract manufacturing workforce meanwhile average microsoft msft employee generate more moderate revenue outside tech sector revenue employee be lower still general electric ge be johnson johnson jnj general motor be exclude network independent dealer ibd take high revenue worker generally translate high profit margin look company margin be high relative competitor steady grow primer read investor corner ibd make research easier proprietary smr rating combine sale growth profit margin return equity visit ibd stock checkup see stock rate tech employment overall sector take year finally top dot com peak job add nearly job now employ person compute technology industry association say earlier year reason take so long be big shift tech manufacturing dot com bust china emergence lead wave outsource end tech industry shed more factory job more half job be go end context slow economic growth weak wage gain anger lose factory job donald trump have make campaign speech staple pledge elect apple make iphone not china logistic shift production china foxconn worker assemble iphone be daunting entail intensive training worker be feasible substantially raise cost iphone even worker make little more minimum wage instead tech job boom job health care social assistance leisure hospitality retail government account net employment gain date back end labor department datum show mid sector government account net new nonfarm job help explain productivity gain have be so weak recession say lakshman economic cycle research institute economic growth such be have be skewer growth number hour work largely lower wage service sector job capital investment have take huge hit aftermath great recession write company outside tech sector have bolster tech employment internally surprising truth be latest wave innovation have benefit relatively few worker directly economywide impact also have be limit fact help explain weak economic growth weak wage growth rise political populism productivity measure output worker hour have continue grow pre rate economy be bigger calculate university chicago economic professor chad syverson household have be case imagine election cycle sound whole lot less angry instead productivity growth have crawl average year past half decade labor department datum show compare annual gain prior decade even strip productivity drag fall capital intensity be amount capital worker modest lift tech sector be clear multifactor productivity be component productivity growth serve measure innovation contribution growth reflect efficiency gain aren directly explain capital labor input explain economist robert gordon professor northwestern university digital revolution do help produce decade rapid multifactor productivity growth average year acceleration die quickly most economy have already benefit internet revolution gordon argue rise fall american growth rise cloud compute app economy social medium past decade multifactor productivity growth slow year george mason university economist tyler cowen write information technology remain most likely source future breakthrough silicon valley have not save just yet technology have give entrepreneur low cost platform innovation let relatively few person do big thing also help individual connect person want have offer spare room airbnb back seat uber handyman taskrabbit fact augment reality technology pokemon go let player see pikachu offline environment be view likely source future productivity gain ar pokemon go hype be actually primarily business tool application facilitate increase productivity work group write tim mulligan midium research internal study boee ba find trainee assemble wing be faster more accurate initial attempt thank get instruction augment reality instead desktop computer productivity growth be sluggish decade steve job introduce mac innovation build give way internet era so too early rule productivity boom
353,JNJ,seller come stock market tuesday be conviction selling index basically mirror performance european stock index dick sporting good dks be earning winner retail leader home depot hd tjx tjx succumb selling nasdaq lose hurt part weakness biotech techs also fall do dow jone industrial average weigh weakness johnson johnson jnj microsoft msft volume nyse nasdaq be tracking slightly higher monday level new york mercantile exchange wti crude oil september delivery rise fourth straight session settle barrel year treasury yield add basis point wall street get barrage economic datum earlier session consumer price be flat housing start come tad better expect industrial production notch best monthly gain november stock market today retail stock be spotlight dow component home depot reversed lower flirt buy point share fall earning slightly beat sale miss meanwhile dick sporting good power higher close earning beat impressive same store sale growth quarter profit rise year sale growth accelerate second straight quarter rise same store sale exclude sale newly open store rise well company prior forecast range tjx gap day move average fall earn sale top expectation outlook fall short expectation hain celestial group hain fall sky share dive close company delay release fiscal year financial result sort accounting issue ibd take hain composite rating rank ibd package food group see leader group be ibd stock checkup top performer ibd include cyberark cybr netease nte netease report earning wednesday close profit be take former leaderboard name tuesday gain buy point hit monday
354,JNJ,stock stage late rally friday lift major market index positive finish dow jone industrial average extend streak nasdaq lead advance add dow eke fractional gain small cap underpeformed russell slip volume be lighter board vs thursday accord preliminary number oil bank gold miner lead downside stock market today department store apparel retailer heavy construction stock outperformed west texas intermediate crude future slide nearly barrel wal mart wmt johnson johnson jnj be dow biggest winner rise apiece financial energy lag goldman sachs gs jpmorgan jpm chevron cvx exxon mobil xom nearly more apple aapl fall nearly early pare loss close higher iphone maker share have rally breaking cup handle buy point early last month buy point nvidia nvda also stage upside reversal gain nearly slumping much early share plunge thursday several analyst cut rating price target say graphic chipmaker be overvalue mizuho security ub reiterate buy rating call pullback buy opportunity universal display oled surge time high company report result beat forecast initiate dividend cent share share be now more extend handle buy point profit take range jwn pop reclaim day line fast trade announce mixed result weak earning guidance close thursday department store retailer shrug price target cut telsey advisory group downside acacia communication acia gap month low continue descent september peak needham lower price target fiber optic product maker result top view earning outlook disappoint mobileye mbly more heavy volume be ibd biggest loser sell signal be trigger stock be just week high share slip back buy range handle entry short seller citron research give driver assistance technology company wednesday beat earning sale estimate price target economic datum tap monday include durable good order pending home sale index january fed robert kaplan be also slate speak oil producer eog resource eog priceline pcln workday wday be company schedule report quarterly earning monday related mobileye become citron short sale target second timenvidia fall stem reassure analyst comment
355,JNJ,celgene celg biotech market cap rival johnson johnson jnj galapago glp gilead science gild biogen biib crohn disease drug top efficacy expectation company say sunday prompt boost share monday stock market today celgene stock lift briefly slip month low share be year rbc analyst michael yee say politic be tamp biotech stock ibd take biotechs be worst perform group last wednesday supernus pharmaceutical prothena stock topple keep tab industry theme best stock bet yee be bullish ged celgene drug combat crohn recent study patient ged show improvement cdai crohn disease activity index se cd simple endoscopic score crohn disease wall street eye be more tune latter week trial patient show least reduction se cs be clinically meaningful endoscopic improvement say yee cdai metric show response be remission week be good higher expect doctor expert say datum patient achieve be good particularly convenient oral drug yee write research report monday gilead galapago filgotinib be phase testing phase didn look se cd endpoint so be compare celgene ged yee write stelara show same improvement patient week study include placebo biogen also have mt drug treat inflammatory bowel disorder go phase testing crohn well ulcerative colitis be major category inflammatory bowel disorder yee model ged add sale time celgene world move pill treat crohn stelara be injection believe celgene promising early endoscopic improvement get better time ged be otezla crohn disease meaning even not most potent drug still be drug celgene well tolerate good safety convenient good efficacy write credit suisse analyst alethia young model peak sale ged have price target outperform rating celgene stock next catalyst celgene stock likely be firm present week datum young say provide important clue sustainability mucosal heal write research report see effect early be positive have suggest mucosal heal be therapeutic endpoint testing crohn drug mucosal heal endoscopic remission be associate increase rate clinical remission accord national library medicine related celgene biotechs top wall worry trio new celegene drug bring
356,JNJ,major index continue back forth hour left thursday session small cap continue sell hard russell drop more top slide wednesday contrast dow jone industrial poke slightly lower solid gain component such ibm ibm dupont dd johnson johnson jnj dupont be approach cup long handle entry be not far cup left side high be bit more nasdaq fall house largest firm market cap be slightly volume be run more higher nasdaq nyse vs same time wednesday real estate related play slump stock market today bank attract more buy yield year treasury bond rise almost higher interest rate generally enable lender expand profit margin loan product wall street giant jpmorgan chase jpm dow component rise nearly dull volume stock continue rise further past buy point narrow cup handle pattern build much larger base structure investor have also buy share jpmorgan clear secondary handle second buy point permissible buy zone extend jpmorgan rival morgan stanley ms be nearly rise nearly past entry bottom style cup handle base super regional be also rally suntrust sti atlanta rally nearly more past cup long handle entry ease chase zone go suntrust last week report quarter single digit top bottom line growth boast ultrareliable profitability annualize dividend better yield wednesday close suntrust score excellent year earning stability factor scale stable wild steady profit give corporate board confidence raise maintain cash payout shareholder ibd super regional banking group be so far stock market today also pace upside be ship transport trucking water supply utility education dairy product industry group more ibd take cup handle base be most important chart pattern investor learn time buy great stock basic take free online course ibd university related spot cup handle winning pattern growth investorssee sector rotation money move defense firmswhat be bottom base pattern
357,JNJ,angiodynamic ango power triple usual trade monday give serious boost stock rebound support day move average latham base small cap provide array catheter base product most be used minimally invasive image guide procedure then throw away product include vacuum suck clot
358,JNJ,stock market open lower keep fall go noon hour friday nasdaq trade be new close low year correction begin last summer nasdaq fall dow jone industrial average stock market today volume surprisingly be tracking
359,JNJ,stock open lower friday heel weak january job datum key earning report nasdaq fall hardest backed dow stick loss volume be soft nyse lower nasdaq relative trading same time thursday
360,JNJ,broad market rally week end jan be diversify stock fund rise average end week pullback accord lipper inc week see number conventional diversify stock mutual fund notch advance be contrast prior week not single diversify stock fund more asset do not rely heavily shorting other hedge tactic borrow huge cash stake gain ground latest week be good news investor general especially pay attention retirement plan top performer diversify stock fund week be nuance concentrated value fund ncavx have only holding oct reward investor jump latest week nuance investment call classic value investment firm concentrated value fund typically hold stock various market capitalization fund have money work stock accord morningstar inc be foreign stock balance be cash midcap value fund have portfolio midcaps fund consist small micro cap stock large cap account portfolio giant cap stock make fund show industrial be largest sector asset dec energy be next financial edge utility third fourth spot asset respectively correction corp america cxw top hold be reit hold correctional detention facility federal state local authority state district columbia share be week stock have so so composite rating ibd composite rating combine ibd stock performance rating include ep rs rating be highest cameron international cam maker oil gas machinery equipment rise week energy stock have comp rating cameron be drive week key driver overall market rally oil price rise week talk russia saudi arabia opec possible production cut solid stock market news more offset investor concern raise midweek federal reserve give cautious assessment global economy central bank say growth have slow diageo deo british booze maker rise week also top hold diageo have comp rating other holding johnson johnson jnj jump week sporting good comp rating health care product maker post fourth quarter earning share growth week be improvement quarters ep decline sale be shy analyst consensus expectation adjust ep gain beat view cent share equity income fund lead diversify stock fund category gain week natural resource top sector category gain week japanese fund gain lead foreign stock fund category taxable bond fund gain week investor show appetite risk emerge market local currency fund be top perform taxable bond fund group treasury fund edge week tax exempt bond fund lose week
361,JNJ,load player market confirm new uptrend tuesday wall street cheer big jump oil price well couple blue chip earning report gain amount follow day rally attempt nasdaq picked dow outperformed rise volume nyse nasdaq
362,JNJ,stock hold nice gain early afternoon trading tuesday couple blue chip earning report take center stage rise oil price didn hurt dow jone industrial average outperformed rise mmm johnson johnson jnj chevron cvx rise more earning report lift share chevron be beneficiary
363,JNJ,spectacular rise even more spectacular collapse valeant pharmaceutical have multiple cause heart story be much biotech company rely big drug price increase growth not only do price hike make valeant vrx politically unpopular also meant business be ultimately unsustainable money manager prefer biotechs pharmas produce drug grow customer demand signale growth sale volume think preferable avenue revenue growth be volume significant price increase have see past year only be repeat few year leonard yaffe health care portfolio manager kessef capital tell ibd email more revenue increase be due volume more value be assign drug re hunting big growth stock biotechs catch eye look past headline revenue number help see company have more sustainable even accelerate growth volume growth lag sale increase company be lean price not last most price increase be far more moderate valeant price hike heart drug nitropress isuprel respectively many company regularly lift price well past inflation rate prop revenue disguise actual demand ibd take big cap deliver still deliver big gain often less volatility smaller cap stock also true biotech have strong big cap company amgen biogen be current resident ibd big cap compare volume revenue be worthwhile reason volume growth be more overall revenue growth signal company be have rebate more list price do last year move product be roll drug country extract lower price be often case europe investor don signal insurer other payor be putt thumbscrew company payor mix obviously be very critical well large consolidated payor cover many many life have negotiating power pick choose rationalize product base price efficacy alternative etc thomas vandeventer portfolio manager tocqueville asset management tell ibd email second quarter earning report conference call comment reveal biotech giant hot stock rely almost solely price increase growth other expand mostly volume increase still other credit mix amgen amgn be classic example lean price revenue rise volume growth be much stem age amgen lead drug top seller rheumatoid arthritis drug enbrel be decade old volume shrank quarter still contribute growth thank pricing drug be even older epogen neupogen shrank price volume re face new biosimilar competition newer drug prolium xgeva make difference grow front be reason fact beat estimate raise guidance amgen stock initially drop earning report contrast amgen celgene celg revenue rise percentage point come volume growth accord company didn break percentage individual drug amgen do company say demand be good board celgene also beat forecast raise guidance future sale profit stock jump report medivation mdvn demonstrate sneaky power rebate list price prostate cancer drug xtandi now medivation only market drug rise second quarter revenue overall rise bit less analyst expect volume grow growth underlie demand xtandi be partially offset lower net price xtandi due year year increase gross net rate say cfo jennifer jarrett earning conference call gross net be industry speak rebate level xtandi have be tight competition johnson johnson jnj zytiga prostate cancer market have be undercut price cvs health cvs recently release drug formulary pass xtandi zytiga reason follow report here rundown other big biotechs be fare price vs volume question unite state lion share change year year basis be price be pretty stable unit trend tecfidera pretty stable unit trend tysabri modest gradual decline interferon franchise include avonex plegridy clancy say ex unite state be not see pricing increase year year basis gain be attributable volume unit expansion biogen overall revenue rise quarter beating expectation lead drug soliris provide vast majority revenue volume rise hike sale rest top line come newly launch drug have year year comparison incyte revenue jump year year beating expectation related be biotechs make comeback stock watchbiotech be make case leadership be good
364,JNJ,do invest successfully fidelity investment do help game know large cap stock fidelity approximately stock stock bond mutual fund make biggest second quarter add sell todd rosenbluth global market intelligence director mutual fund research pore newly release sec holding disclosure second largest mutual fund manager compare past filing boston base behemoth have long term asset june snapshot trade give insight stock fidelity manager thought be worth get be willing trim information technology remain fund giant largest sector collective asset june be case even many fidelity manager sell share tech titan microsoft msft apple aapl second quarter fidelity trim microsoft share count compare stake peel apple back microsoft stock fall have rally june word yet fidelity resume buy apple share sank have rally then contrast fidelity beef share home entertainment software stock activision blizzard atvi feburary atvi complete purchase king digital report first second quarter result ahead capital iq consensus rosenbluth report client thursday afternoon share be close end stock end june higher begin quarter be flat then health care sector fidelity be net buyer seller fidelity like prognosis biotech firm vertex pharmaceutical vrtx enough graft additional exist share count turn be good call july vertex get fda approval new cystic fibrosis drug rosenbluth note now share be end go other director fidelity slice johnson johnson jnj stake unitedhealth group unh hold be end other sector fidelity add stake cell tower owner american tower amt cable provider charter communication chtr carmaker tesla motor tsla fidelity add position american tower be be june charter be stock be see solid earning estimate revision activity analyst say zack equity research still charter telecom service integrate industry group be rank week tesla be fractionally close stock fidelity trim be amazon amzn cut visa shave fidelity largest stock mutual fund continue hold many largest megacap stock even fund family group trim rosenbluth say blue chip growth fbgrx have top holding apple visa other top stock include tesla complex add blue chip growth be year go thursday vs large cap growth peer track morningstar inc dividend growth fdgfx hold trim target apple johnson johnson microsoft dividend growth be year separate datum morningstar inc highlight stock fund have add recently fidelity contrafund fcntx manage have interesting add contrafund be largest stock mutual fund available have add gold canadian base gold producer run mine globally midday friday share be so far year earning share grow past quarters note share be trading just have never reach contrafund hold dozen mining stock have boost stake recently half itau unibanco itub be name contrafund have raise stake brazilian bank hold company adrs be so far year ep have decline quarters row analyst see expect gain current quarter increase company have so so composite rating ibd composite rating start run combine ibd performance rating include ep relative price strength rating stock poise move higher often have high comp rating look stock rating be higher mean ve outperformed other stock term composite rating ibd take alan elliot explain high comp rating be not always buy signal itau also have ibd smr rating smr rating be best contrafund open stake apply material amat latest disclosure ep go decline quarters growth most recent frame ep gain be report thursday top wall street expectation apply revenue be slightly analyst consensus maker chipmake equipment post revenue period fall short street forecast analyst survey zack expect current quarter end october apply material expect share earning range cent cent stock gap huge volume friday semiconductor equipment maker share be so far year
365,JNJ,dow jone industrial average hit time high july be blue chip index blue chip performer top dow stock winner year be diverse group unitedhealth group unh johnson johnson jnj caterpillar cat wal mart store wmt mmm health care product service giant johnson johnson continue rise report third straight quarter earning growth july consensus be earning share climb current quarter be acceleration mild increase new brunswick base company be grow organically acquisition july conclude cash purchase vogue international privately hold salon influenced maker hair care other personal product johnson johnson stock be monday fall stock market today share nation largest manage health care provider rise report outstanding earning revenue growth past year unitedhealth grow serve more person domestic medical benefit market include more person add second quarter unitedhealth be relatively conservative enter obamacare exchange market have say exit most state peer have announce similar withdrawal unitedhealth be year date monday fall just tuesday ibd take unitedhealth be top performer dow year bull ahead gain so far see other medical stock be top performer year go ibd stock checkup sale largest maker mining construction equipment be weak last year early low price metal caterpillar continue sell construction equipment slowly recover housing industry rbc capital market raise price target caterpillar july base success restructure so far position seem be improve not deep mine shaft yet tuesday july caterpillar report drop ep revenue ep beat estimate revenue miss caterpillar share rise monday dip tuesday world biggest retailer continue hold own upstart amazon com amzn be grow fast still just fourth wal mart size revenue wal mart be scramble add feature entice shopper july announce walmart pay card swipe technology be now available walmart superstore nationwide walmart pay work apple aapl iphone alphabet own googl google android device wal mart stock have climb year monday fall tuesday nation largest tape adhesive maker purveyor medical supply office equipment surveillance communication device other product caterpillar enter buy zone last week continue trade report health care sale rise nearly last quarter lead beat estimate raise guidance july however share fall say electronic energy sector sale plunge quarter rise year monday rise cent tuesday
366,JNJ,higher oil price earning report positive economic datum boost stock big gain tuesday ahead federal reserve wednesday policy statement dow jone industrial average take lead gain rally nasdaq rise volume be mixed slightly lower nyse higher nasdaq
367,JNJ,stock future chalk modest gain ahead tuesday open investor prepared welter notable earning report launch day federal open market committee meeting dow future trade nearly point fair market value nasdaq future eke premarket action stock market today resist undertow china tuesday picked oil fed decline monday add fresh momentum hong kong hang seng tumble shanghai composite slice lower stock europe hold mild loss midday none major benchmark slip further dollar rise euro yen oil price bob higher almost hang barrel bond most commodity edge federal office remain close washington follow most northern hemisphere consider run mill winter storm federal reserve announce fomc conduct plan day meeting accord schedule end wednesday policy statement due et afternoon schedule et release house price index probably not occur due federal housing finance agency closure case shiller be due report city composite home price index researcher markit deliver preliminary january service purchasing manager index january consumer confidence number be expect conference board richmond federal reserve release january manufacturing index mmm johnson johnson jnj post mild gain follow quarterly result procter gamble pg jump nearly sprint spiked mixed fiscal performance end monday loss january trading share dupont dd slip fraction earning revenue meet estimate guidance be par lockheed martin lmt trade more report forecast revenue earning guide full year ep consensus view management also announce have agree divest information system global solution unit cash stock deal reston va base leido holding ldo biotech relypsa tlyp shot ahead open redwood city calif base drug maker report positive result drug interaction trial regard blood potassium treatment veltassa volatile not thinly trade stock end monday so far january action lead stock be tame open centene cnc drop almost st loui mo provider manage healthcare service announce late monday be conduct international search computer hard drife contain vital personal information patient treat period centene have be attempt climb right side possible base have encounter resistance
368,JNJ,drug stock have be take beating hard east coast lately last year worry drug pricing compound so so pre announcement forecast last month week however big drugmaker haven pre announce result have chance beat expectation usual johnson johnson jnj kick season
369,JNJ,economy be enter recession stock consumer staple health care telecom be best place hide say barclay glionna name tobacco giant philip morris international pm reynold american rai drug giant merck mrk pfizer pfe meanwhile include general electric ge stock buy recovery doesn see recession term be red flag such collapse oil price retreat so far year slow growth global economy china report monday glionna joined grow number analyst provide list recession resistant stock take slightly different tack other offer list recession playbook recovery playbook other top pick recession playbook be campbell soup cpb coca cola ko johnson johnson jnj procter gamble pg hormel food hrl philip morris stock close tuesday reynold american maker camel cigarette add merck gain pfizer rise campbell soup climb johnson johnson procter gamble end flat glionna say recovery playbook best perform sector previous period economic recovery used exit recession indicative recovery have be energy material industrial consumer discretionary stock list ford motor general electric general motor gm harley davidson hog viacom ford end gm lose tuesday ge tick harley davidson fall viacom plunge more expect result december end quarter meanwhile cowen analyst put own list recession stock tuesday say believe stock appeal low end consumer have minimal global exposure appear well suit weather economic downturn top pick price clothing retailer ross store rost wal mart store wmt ross store climb wal mart fall
370,JNJ,medical giant johnson johnson jnj say tuesday restructure device division bid save annually end didn provide many detail press release say discuss project further report earning jan however do specify
371,JNJ,health care behemoth johnson johnson jnj decide last year use veeva system veev software gathering datum clinical trial need get new drug approve veeva rival take notice good reason thank wasn long veeva content management application turn head potential customer well say re go standardize globally month have customer biggest drugmaker do exact same thing veeva chief financial officer timothy cabral tell stifel technology conference june case imitation wasn just sincerest form flattery be pretty much accord plan cloud base software company insider call veeva way mean rapidly develop industry specific application functionality be mile ahead legacy offering then use positive customer outcome take market storm chief executive peter gassner left salesforce com crm start veeva launch company primary goal mind replace biopharma company legacy system cloud base software design make painstaking regulatory requirement lot less painful veeva first product be customer relationship management offer pharma sale rep then start target research development side business clinical trial content management application now rapid month development period launch new application track quality control process drug manufacturing veeva drug biotech customer be race time direction gassner tell investor business daily hand need expedite regulatory approval bring cure market keep person suffering die then be business drive reason fully capitalize market opportunity patent expire race have become even more critical time cost develop new drug have soar inflation adjust dollar accord pharmaceutical research manufacturer america stake be so high more large drug developer have decide rapid succession junk prior technology investment embrace veeva critical ally race clock glaxosmithkline gsk be ramp adoption veeva customer relationship management product drug sale team member most customer relationship deployment aren yet global scale most big drug biotech company be now veeva customer company have be roughly market provide customer relationship solution global sale rep rep be tasked teach doctor prescribe drug effectively customer embrace veeva sale geography company market share approach relatively new customer relationship feature veeva be call approve email allow drug sale rep send marketing educational material doctor email have be rare regulatory concern veeva provide template let communication happen compliant way dominant veeva customer relationship product look track become management think company vault content management platform have even bigger advantage competition pharmaceutical giant have person outside company collaborate clinical trial different drug candidate time sharing comment update record keep action involved trial drug application used involve courier multiple file sharing system document repository be hard participant access now vault make possible have central hub cloud everyone connect way streamline regulatory compliance vault launch generate subscription revenue year vault generate subscription revenue double accord william blair analyst bhavan suri alper tuken re winning better usability suri tell ibd note vault revenue be grow so fast veeva continue see revenue growth accelerate little overall revenue rise year first quarter veeva announce revenue now come ongoing subscription adjust earning rise share basis earning rise cent share cent ibd take share veeva system surge earning news breaking long base pattern remain level hit just ipo share be still close enough buy point merit consideration closer look right timing buy stock see investor corner be more confident ever be track achieve state revenue run rate target selling just current solution life science alone gassner tell analyst veeva first quarter earning call accord seek alpha transcript share break well past late build base then surge again eclipse mark early july close monday share be incrementally key veeva success be have bring together enterprise software expertise industry specific expertise expertise application don just permit regulatory compliance fda regulatory body world veeva revenue come outside now company be just begin expand industry expertise life science have tremendous platform involved build application rapidly ve do qms veeva drug manufacturing quality management application many application be applicable outside life science gassner say gassner announce latest earning call veeva have small team now dedicate selling vault other industry plan undertake new effort veeva way growth profit customer success say veeva strong suit be ease use heavily regulate industry lot investor think have future provide cloud base application financial service industry include brokerage business needham co analyst scott berg tell ibd berg see more term potential industry fda actually work namely food manufacturing be vulnerable costly reputation damage recall mentioned hormel food hrl possibility suri see johnson johnson exist relationship veeva candidate adopt vault platform manage quality other regulate industry baby food manufacturer such nestle also be natural market vault penetrate suri say
372,JNJ,stock show mild action friday dow snap week winning run general market maintain positive bent week jam packed earning report datum show weaker expect growth economy advance gdp report didn seem horrible headline number overall gain far miss econoday consensus forecast increase government also revise figure sharply higher growth latest read consumer spending jump strongly reflect positive impact relatively high employment lower gas price world economy dow jone industrial average slip less lag gain nearly nasdaq composite latter hit new time high rise high stock market today dow loss week pale comparison gain prior week respectively nasdaq rally week fifth straight weekly advance edge lower fewer point less stock be perform best dow way view be compare relative strength rating measure stock performance past month vs rest stock market action past month carry higher weighting score johnson johnson jnj unitedhealth group unh lead dow component rs rating respectively rise padding impressive gain clear long saucer handle even large advance annualize dividend yield still exceed payout continue rise recently post third quarter row modest earning growth earning be see rise share be acceleration increase medical personal care product titan see second quarter year earning share be see rise pick revenue unitedhealth have have masterful performance break shallow double bottom base late february manage care behemoth rise proper pivot point ranking third rs rating dow component be dupont dd chemical giant be cozy price level have trouble pierce higher earlier week dupont marked jump earning best result quarters sale slide however investor seek company faster growth need look ibd various high growth screen include today ipo leader column screen look outstanding performer aspect ibd slim investment paradigm latest story highlight china yirendai yrd ep see rise veeva system veev ep see gain ibd stock lgi home lgih ep see rise ibd take ibd big cap stock spotlight sector leader column locate ibd stock list investor com hunt company average fundamental keep eye company offer something new form fantastic new product new industry new market condition new management stock hit new high price be slim next week keep eye quarterly result big datum software expert tableau datum cvs health cvs procter gamble pg tuesday tesla motor tsla electronic art ea first solar fslr wednesday ibd leaderboard member monster beverage mnst priceline group pcln thursday
373,JNJ,type diabetes be battle best selling drug world biggest drugmaker company be eyee even bigger sale new generation treatment change field have prove more evolutionary revolutionary several event next few month start soon monday eventually move billion dollar make compliance treatment easier even prevent death heart disease diabetes drug provide single best selling product johnson johnson jnj merck mrk almost nordisk nvo annual revenue come diabetes treatment health care research firm globaldata say diabetes treatment bring nearly re get better better manage diabetes general say funtleyder health care portfolio manager square asset management have more option next phase be go be get person adhere regimen work diabetes patient type diabetes be world most common disease sticking treatment be difficult medication routine get increasingly complicate disease progress diet exercise fail patient go oral drug start cheap generic such metformin prove insufficient doctor add newer brand oral medicine come class dpp inhibitor lead merck januvia more recent sglt inhibitor lead invokana class work different mechanism be sometimes combine yet further intervention be require patient move injectable drug nowadays glucagon peptide glp analog be usually first line attack class include nordisk victoza eli lilly lly trulicity ibd take eli lilly stock have nice year run end year now sport weak composite relative strength rating respectively shouldn get much stock pick attention company aim rebound ceo tell ibd exclusive year come most familiar treatment diabetes insulin modern insulin come different variety include long act version sanofi sny lantus tresiba need be inject only once day faster act one use mealtime such lilly humalog novolog pile med patient have trouble keep so approach simplify routine be create combination drug be do successfully hiv market sanofi nordisk be await fda decision combination insulin glp back back fda advisory panel recommend approval xultophy win unanimous support sanofi lixilan have couple dissenter due safety issue related pen injector used administer drug fda deadline decide xultophy be monday sanofi decision be due next month hasn reveal specific deadline leerink analyst seamus fernandez see blockbuster potential drug expect ll take year hit peak sale have see other recent major primary care launch such pcsk sanofi regeneron regn amgen amgn entresto novartis nvs breo ellipta glaxosmithkline gsk expect slow initial launch class first few year fernandez write research note view xultophy have slight upper hand drug device profile position treatment algorithm lead better physician acceptance market uptake say overall diabetes model forecast peak sale xultophy peak sale lixilan fda decision much anticipate wall street be already approve drug lilly sglt inhibitor jardiance last year lilly stunned industry large year trial show jardiance significantly extend lifespan diabetes patient reduce death rate death cardiovascular cause also sharply reduce hospitalization heart failure analyst say jardiance see instant uptick sale so spectacular be result didn happen lilly closely study issue say enrique conterno president lilly diabetes realize potential thing need happen conterno tell ibd first be need datum label second be need new treatment guideline be establish canada already make change relevant medical society treatment guideline conterno say expect same early next year get label change mean lilly sale rep be able talk cardiovascular benefit customer be important primary care doctor most diabetes prescription aren always specialist research lilly have apply expand label include information least put clinical trial result packaging approval however isn quite slam dunk expect trial result way lilly design trial primary endpoint be normally most important fda be composite different measurement cardiovascular health produce mixed result specific finding heart failure overall death be exploratory endpoint thus fda advisory panel only narrowly recommend change label meet june change label basis secondary endpoint set precedent so remain so unclear fda do analyst compare coin flip view approval actual cv death indication have coin flip odd give unprecedented nature result trial write evercore isi analyst mark schoenebaum email june say also feel better chance fda allow datum be add label also remain be see competition shape last month nordisk report glp call victoza also reduce cardiovascular death not quite much jardiance jardiance be oral victoza be injectable occupy slightly different position treatment regimen jardiance most direct competitor invokana be also subject cardiovascular outcome trial due completion february initial result possibly come earlier different variable company do best diabetes be broadest portfolio funtleyder say cite lilly nordisk have have particularly comprehensive program give advantage salesforce leverage basis same sale guy sample multiple drug say have benefit payer bundle drug together big bill instead pbms pharmacy benefit manager have negotiate separate pill eli lilly share rise stock market today best level late january nordisk climb dip
374,JNJ,intuitive surgical isrg maker robotic surgery system late tuesday post earning revenue handily beat wall street expectation send share rise hour earning share item rise year earlier quarter sale rise analyst poll thomson reuter have expect maker da vinci surgical system minimally invasive surgery didn provide guidance earning release analyst expect ep ex item quarter sale intuitive surgical stock be nearly hour trading company release result share rise fraction tuesday regular session intuitive stock hit time high july move flat base buy point june so share remain buy range da vinci success have spawn more competition alphabet googl verily unit formerly google life science have team johnson johnson jnj advanced surgical robot early tuesday post earning beat johnson johnson stock hit record high tuesday close medtronic mdt make big move field acquisition last year covidien company say number da vinci procedure rise nearly vs ship da vinci system vs pre earning research note leerink analyst richard newitter say intuitive be increasingly benefit next leg growth da vinci xi system launch
375,JNJ,alphabet world internet search leader be prospect core business strike success health care world company glucose monitoring contact lens diabetic be inch closer drugstore shelve sale self stabilize spoon design help person uncontrollable hand tremor eat comfortably top first month google restructure last year become largest operate unit new parent alphabet googl buy biotech company lift lab just few month health focuse startup begin product sale point broaden emphasis other health medical advancement alphabet last month rename google life science division verily life science division bring together clinician scientist be focuse understand improve chronic condition impact massive number person health issue include cardiovascular disease diabetes cancer disease mental health be development health care think be far reach be long last be see period convergence technology company health care company california life science association trade group ceo sara radcliffe tell ibd say change drive health care tech firm partnership include explosion big datum result demand way manage patient information growth access datum internet cloud mobile technology such fitbit fit wearable be shift health care maintain tracking health rather simply treat disease say company team uprecent notable health tech partnership include alphabet verily division team last month johnson johnson jnj develop surgical robot news follow september announcement google life science spinoff calico have enter year collaboration north chicago ill base pharmaceutical firm abbvie abbv research age related disease verily have partner too medical device firm dexcom link verily create new class disposable glucose monitoring system be faster cheaper smaller product be currently available johnson johnson verily announce last year have create verb surgical develop new surgical robotic device smaller less expensive intuitive surgical isrg da vinci system now control minimally invasive surgery segment other look join force health tech divide include medical device maker medtronic mdt be collaborate big datum solution provider ibm ibm watson health analyze wave information glean diabetes insulin pump datum vs be not only tech heavyweight seek blend medical altruism big datum big moneymaking plan apple aapl microsoft msft other be also used deep technology expertise create medical related product service year apple introduce health tracking tool monitor user footstep heart rate sleep activity microsoft samsung already offer number so call wearable device also allow person monitor daily movement advance mobile compute artificial intelligence new analytic software be drive effort recent year have be increase interest health care application company traditionally be see be consumer focuse company say iain simpson drug delivery specialist cambridge consultant company such google apple facebook fb amazon com amzn have build consumer focuse business base creation compelling sustainable user experience now simpson say various tech company be head health drive increase relevance capability market create new high value business opportunity particularly work collaboration establish health care player such pharma medical device company health care spending weigh project reach accord california health care foundation profit potential be obvious incentive other factor be also work part reason alphabet focus move needle parkinson treatment be personal google co founder now alphabet president sergey brin mother eugenia have parkinson brin be diagnosed carry mutation lrrk gene have be associate higher rate degenerative disorder central nervous system generally pace medical research be glacial compare used internet brin tell wire interview google amplify process be look lot place collect lot information see pattern lead somewhere legislative change be factor have help open door tech firm put massive compute muscle health care datum drive medicine be key element affordable care act federal law ushered president barack obama health care reform be major force center boom new health technology law provide major financial incentive doctor hospital prove care be effective value base payment rule be spark demand new software track analyze patient datum say lynne dunbrack research vice president idc health insight patient prescribe example dunbrack say hospital be find cheaper send medicare patient have congestive heart failure home weight scale electronic tablet connect app rather risk too many readmission day discharge result hospital get federal reimbursement rate cut have be real financial incentive health care organization purchase use technology be then help drive demand be company be now see new opportunity dunbrack say shift value base care other top area focus health care industry include sequence human genome digitize health care datum say cowen co analyst john blackledge september report alphabet health care strategy health care trend be not occur vacuum be be accommodate technology advance area such social mobile analytic cloud compute be area google expertise blackledge say swirl change tech advance be also help fuel medical ambition tech heavyweight apple annual worldwide developer conference june apple introduce new healthkit app monitor user heart rate sleep weight blood pressure other health related measurement let home health device such heart monitor fitness monitor exchange datum healthkit allow clinician mayo clinic send health information user app turn transmit datum user physician healthkit be logical extension apple exist product digital ecosystem keep user engage increase apple app store business also keep apple product service relevant grow increasingly competitive consumer health market say simpson cambridge consultant apple tech framework researchkit let person want remotely participate clinical medical trial do so used specially design apps iphone instead have show person march apple display apps say help diagnose range condition diabetes heart disease apple say win see datum transmit person opt sharing researcher want researchkit help address few problem medical research current state such limit patient participation infrequent datum sampling apple jeff william now chief operate officer say time person sign single medical study stanford university first hour release researchkit apple ceo tim cook tell cnbc march put perspective stanford have tell have take normally medical center entire year sign many participant so researchkit be absolute game changer say cook call discover cure disease push life expectancy much longer currently be alphabet google have own initiative call fit include developer tool online platform collect datum connect michele chandler twitter ibd_mchandler facebook
376,JNJ,weak january payroll report send stock future narrow gain loss ahead friday open dow future dim fair market value nasdaq future backed future show loss stock market today launch nasdaq week be big cap have fared better send dow friday session deficit week small cap have bear more share selling leave russell nonfarm payroll expand worker january labor department estimate sharply december downwardly revise new hire economist have forecast new job unemployment rate dip december hourly earning increase better expect trade deficit widen slightly december commerce department report afternoon federal reserve release december consumer credit figure et dollar bond rise buck remain track largest weekly drop oil price propel large share week sloshy market change bob slightly higher gain hold less gold inched copper platinum slip oil price feel effect baker hughe bhi release weekly rig count report dow stock drop flattish mixed trade moderate loss job report johnson johnson jnj slip lead decline big datum analytic specialist tableau software datum crack fall premarket action seattle base company report late thursday strong revenue growth smaller expect decline profit licensing revenue growth disappoint analyst revenue guidance be weaker expect tableau end thursday session july high double dip consolidation linkedin lnkd unraveled ahead open professional networking site report late thursday show strong earning beat healthy rise revenue management full year earning revenue guidance come far consensus expectation linkedin have spend past week week move average work fashion bottom month consolidation symantec symc scale top fiscal earning forecast announce strategic investment private equity fund silver lake symantec have be deepen consolidation jan lead stock be predominately flat ahead payroll report lead exception hanesbrand hbi topple report earning revenue consensus view full year revenue guidance also undercut analyst expectation stock have be try retake week move average climb right side tight month pattern overseas china market wrapped mixed session friday mixed week ahead next week lunar new year holiday shanghai composite slip friday end week ahead hong kong hang seng index rise friday logged loss week hong kong exchange close monday thursday shanghai exchange shut entire week japan tokyo nikkei fall leave loss index have fall recent week europe market paris frankfurt turn negative job report london ftse hold fraction positive territory midday week ftse be tracking decline frankfurt dax paris cac be apiece image provide shutterstock
377,JNJ,stock future punch higher then begin trimming gain early tuesday overseas market oil price have say early action dow jone industrial average keep gain open advance nasdaq show gain also open high trade be weak nasdaq lower nyse compare trade same time friday option expiration boost friday volume gdp report china monday wasn bad expect trip global market rally help lift early trade stock market today oil price place drag early action west texas intermediate reverse earlier gain fractional loss trading barrel brent crude trade more remain nickel wti price economic news national association homebuilder january housing market index slip december consensus expectation increase gauge builder confidence have averaged first half hit high october oil related stock crowd low end exxon mobil xom chevron cvx dupont dd be only decliner dow unitedhealth unh top blue chip index more fourth quarter sale earning clear analyst consensus full year earning guidance be line view revenue guidance come bit short estimate unitedhealth be week line support october high chipmaker nvidia nvda lead gain johnson johnson jnj rise more announce lay workforce medical product division part effort trim annual cost unit management say take restructure charge eventually book charge johnson johnson share be key level support dec high china base stock top ibd list tal education xrs spiked open chain student tutor center have pull back straight week end friday week move average acceptable range possible flat base netease nte claw way back week move average share have correct week pullback bottom list equity midstream partner eqm slip more oil pipeline operator have pull back fail retake week move average late december
378,JNJ,come surgery intuitive surgical isrg chief executive gary guthart seek follow old camper motto leave campsite be ever trauma involved open patient end be almost damage difficult recover ailment surgery aim remove thus
379,JNJ,stock be mixed late afternoon trading tuesday dow jone industrial average be lead mcdonald mcd johnson johnson jnj netflix nflx weigh nasdaq dow add nasdaq composite lose ease distribution day be take shape nasdaq hold be tech index first confirm new uptrend june volume nyse be tracking slightly lower monday level mcdonald rise breaking past buy point double bottom base johnson johnson rise report earning open bell stock market today lockheed martin lmt rise maker report second quarter earning share increase year earlier cent estimate sale rise company increase guidance lockheed rise morning then reversed briefly turn negative concern cash burn await government payment ibd facebook fb add top flat base entry elsewhere new oriental education edu rise nearly work cup handle base buy point new oriental education report quarterly earning wednesday couple retailer moved higher heavy volume ollie bargain outlet olli gain try clear first stage double bottom base buy point meanwhile allen interior eth add still buy range base base buy point downside netflix crash company report earning late monday netflix top ep view subscription gain fall short view intuitive surgical isrg fall ahead earning report due close be hold gain reclaim buy point light volume slightly money weekly call option july expiration strike price currently offer premium offer trade downside risk check latest earning preview column learn more used option earning
380,JNJ,stock open minor loss tuesday strong read june housing activity dow industrial fall nasdaq ease big earning report rolled late monday early tuesday lead netflix nflx goldman sachs gs ibm ibm johnson johnson jnj stock market be so far enjoy healthy july nasdaq be month monday best performance october gain be strongest march small cap russell have gain month also best march market pause pull back however few tell factor clue investor institutional investor be head next commerce department say june housing start rise almost annualize rate vs tally be revise downward economist have project rate build permit guide future activity rise more annualize basis consensus have forecast permit issue pace reaction homebuilding stock be muted pulte home phm rise open toll brother tol add lennar len horton dhi lgi home lgih post small gain pulte horton report result thursday netflix open loss second quarter subscriber growth fall far short company new subscriber target earning growth blow past analyst expectation revenue meet estimate netflix share have be consolidate december goldman sachs slip open report second quarter earning revenue fall less project ibm edge report upside second quarter result late monday aid gain cloud base revenue johnson johnson rise beating analyst second quarter earning revenue forecast well raise full year guidance consensus view vmware vmw spiked open strong second quarter result super micro computer smci topple server system computer component manufacturer management sharply reduce fiscal fourth quarter sale earning guidance late monday auto part retailer genuine part gpc drop open atlanta base chain report sale earning analyst target guide full year earnign low end consensus range oil trade west texas intermediate future just barrel gold inched fraction ounce dollar gain vs euro yen pound bond tick higher trimming year treasury yield basis point overseas china market take modest loss tokyo nikkei jump japan market reopen day holiday europe stock be morning lows afternoon trade london ftse have flattened cac paris be germany dax trim loss
381,JNJ,drug industry earning season launch week biggest name johnson johnson jnj novartis nvs biogen biib broad portfolio give investor preview business general be do big kahuna johnson johnson tuesday morning be expect report year year sale growth modest decline ep share stock hit record high intraday friday be year credit strong pharma trend flight safety yield write rbc capital market analyst glenn novarro july preview note analyst be expect good quarter pharma business novarro write base prescription datum im health im biggest drug remicade imbruvica invokana xarelto beat consensus credit suisse analyst vamil divan july preview lower estimate invokana raise remicade xarelto say be concern entry cheaper biosimilar version remicade later year pfizer pfe remicade biosimilar be approve fda april ibd take most drug stock have take pound year have prove be exception last month stock market today column highlighted standout defensive dow stock only go higher then biosimilar also probably be topic discussion novartis conference call also tuesday morning wednesday swiss drug giant biosimilar version amgen amgn enbrel win unanimous back fda advisory panel make likely be novartis second biosimilar launch version amgen neupogen enter market last year investor also likely be interested performance novartis newest potential blockbuster drug cosentyx psoriasis entresto heart failure be first class drug be approve last year entresto so far have miss expectation cosentyx have enjoy stronger uptake cosentyx also face new competition however eli lilly lly launch drug same class call taltz monday credit suisse analyst cut ep estimate launch drug appear be cost more expect however write long term outlook drug look good estimate peak annual entresto sale peak cosentyx estimate have be run same analyst expect novartis financial suffer loss patent protection leukemia drug gleevec sale be see fall earning share novartis stock be slowly recover long slide july peak april low share find support day line recent week have moved just day close friday thursday open biogen be expect report quarter stronger growth lower expectation multiple sclerosis franchise have miss expectation last several report nonetheless rbc analyst michael yee see potential upside ms drug tecfidera expect biogen raise ep guidance current ep more consensus depend expense cut represent significant improvement last year analyst estimate earning grow share revenue gain biogen stock crash last july have be trading still slide day line most month biogen do close day line friday aside brief late early june stint biogen have not be day nearly year
382,JNJ,stock give gain early afternoon trading thursday hunger blue chip seem increase dow jone industrial average pace gain popular index dow jone industrial average be add advance claim prior session component blue chip index be now year date nasdaq composite thursday afternoon have climb oil steel banking fertilizer railroad semiconductor stock help hoist higher volume be run higher nasdaq nyse dow jone industrial average seem relish role perennial laggard market bottom october index post impressive gain peak march paled vs nasdaq composite run roughly same period time however individual action stock dow continue get better take health care sector pfizer pfe be act big cap leader lately big pharma play rise month saucer handle notice week long handle begin june stock pull back lightly volume dry most session ideal action stock set potential pfizer case take place july volume be quiet ibd research have find case volume come strong few week move new high wall street seem convince pfizer have return growth track profit be see rise nearly cent share pickup sale week ethical drug giant reportedly close deal sell medicine russian market also get label extension prevnar vaccine pneumonia doctor now prescribe vaccine adult year old also dow johnson johnson jnj insurer unitedhealth group unh be act well recent breakout former be flat extend recent past buy point relative price strength line have be rise june indicate have be outperform unitedhealth be intraday stock remain flat base entry flat base decline head toe not exceed unitedhealth week flat base feature very mild drop indicate reluctance institutional investor sell share buy zone extend unitedhealth company earn respectable composite rating maximum ibd stock checkup second only manage care industry peer centene cnc johnson johnson unite health report earning next week fellow dow stock jpmorgan chase jpm gap lead money center bank gain volume be run more double normal level wall street bank post rise profit beating analyst consensus view revenue lift ceo jamie dimon earlier week announce plan raise minimum pay large number bank employee stock still need work build right side potential new base jpmorgan rs rating lag pfizer unitedhealth ibd name stock market today datum center operator coresite realty cor cool third day row investor appear cash more gain dividend pay reit nursing physician staff outsourcer amn healthcare highest ranking medical name ibd jump nearly dull turnover stock have rise more past handle entry long double bottom base general least profit be take stock rise past proper pivot point see wednesday big picture column market pulse table market be currently confirm uptrend mean investor have higher probability make money buy breakout high quality growth stock proper buy point market follow june be stock be best class industry group term profit growth margin sale return equity institutional fund sponsorship relative price strength check investor com exclusive tool ibd stock checkup
383,JNJ,market continue downward march new high be become scarcer intuitive surgical isrg attempt buck trend stage cup handle wednesday intuitive surgical be leader robotic surgery dominant da vinci system robot assist surgical procedure allow surgeon greater precision quicker recovery patient
384,JNJ,stock market kick stub toe intuitive surgical isrg get upgrade overweight morgan stanley maker da vinci surgical system try buck downturn break first stage base intuitive surgical be clear leader robotic surgery platform enable surgeon perform precise minimally
385,JNJ,do snowstorm take much east coast cause untold damage life property also cause snow job defined mkts last thursday friday see snow job be defined deception effort overwhelm persuade attempt flatter be
386,JNJ,slow global economy many mutual fund strategist expect value oriented fund top growth fund have lag past year so far earliest day volatile new year value fund be do exactly even be lose less growth counterpart value mutual fund averaged
387,JNJ,trekky beware be year borg fittingly so shift chip landscape resistance be futile harvard university wyss institute develop organ chip today program be more tangible institute picked partnership johnson johnson jnj pre clinical trial testing drug company be take notice
388,JNJ,earning season be full swing week netflix nflx intel intc microsoft msft general motor gm report elon musk unveil new tesla motor tsla master plan meanwhile japan softbank sftby announce buy chip designer arm holding armh justice department block big health insurance merger deal dow hit fresh high nasdaq set new best rise modestly fourth straight weekly gain facebook fb domino pizza dpz new oriental education technology edu be slew stock hit buy point facebook low volume struggle several other highly rate big name be close entry point oil price retreat barrel internet television network netflix attract just new customer second quarter vs target netflix expect add new subscriber vs analyst estimate netflix blame slow subscriber growth increase churn related price increase longtime subscriber also say summer olympic put brake new subscriber gain august netflix top profit view share sank nearly week tesla motor ceo elon musk unveil ambitious long term plan electric car company combination solarcity scty tesla aim acquire offer plan include new kind pickup minibus well compact suv commercial truck tesla struggle meet production goal expansive report give indication tesla be consistently profitable tesla stock fall more thursday masterplan be release rise close week hold day line tesla hold grand open event july gigafactory reno nev battery plant be far finished ibd take tesla stock be still try recover company have report several quarters loss mobileye maker driver assistance technology used tesla many other automaker have strong fundamental mbly clear new handle entry point friday detailed rating mobileye go ibd stock checkup software giant earn cent share ex item fiscal fourth quarter vs year earlier revenue climb analyst have expect ep fall cent sale microsoft credit strong sale cloud compute software service beat just start fiscal year vow improve profitability cloud business include office azure microsoft share rise week close buy point japan softbank pay acquire arm holding design chip apple aapl iphone well most other smartphone boom internet thing market deal occur brexit vote cause british pound tumble vs yen softbank plan expand arm overseas headcount next year analyst wonder softbank maintain arm vendor neutral approach arm share have soar so far week softbank fall nearly sprint majority own softbank slide chipotle grill cmg ep sank cent revenue fall miss view still chipotle share rise week retake day line domino pizza dpz beat view ep cent revenue growth domino stock break new high leap papa john pzza pop keybanc say pizza delivery be fare well civil unrest starbucks sbux disappoint revenue miss line ep adjust profit grow cent sale growth weaker expect americas comp be anomaly say ceo howard schultz starbucks rally friday hit month high dunkin brand dnkn turn mixed result share fall thursday rise week ebay ebay gap base spiking week record high report ep growth cent beating view penny revenue rise also top top bottom line guidance be light ebay full year projection be strong yahoo yhoo ep miss penny revenue revenue guidance easily beat forecast report say verizon vz announce yahoo buyout deal few day intel intc qualcomm qcom skywork solution swks report mixed earning intel cent earning share ex item edge top consensus respectively intel share fall month high weaker expect datum center sale close week just qualcomm report sale ep ex item fiscal beating wall street expectation respective cent qualcomm share rise nearly month high fiscal skywork report sale ep item vs year earlier quarter narrowly beating consensus expectation skywork slide friday week long review justice department file block aetna aet humana hum anthem antm cigna ci merger say hurt competition consumer share rise news investor have price skepticism deal approval meanwhile humana raise ep guidance say exit many obamacare exchange market next year unitedhealth unh largest manage care firm top ep view say profit improve exit nearly exchange unite airline ual beat estimate cut full year carry capacity growth international uncertainty weigh carrier also say reduce winter flight delta air line dal say prior week do same follow nation brexit vote southwest luv forecast unit revenue decline be first year carrier also miss estimate spirit airline save indicated heavy lower fare competition persist good customer bad airline financial result american airline aal report profit drop wasn bad expect american also say brexit help not hurt global carrier season kick solid report big cap drugmaker johnson johnson jnj beat estimate raise guidance drive strength pharma division novartis nvs also beat estimate stock fall warn rise expense related new drug launch also say fda have reject biosimilar version amgen amgn drug neulasta biogen biib rise beat raise ceo george scango say be quit year stock rise modestly fresh high novartis advanced slightly biogen jump nearly biotech stock try recover general motor gm report strong profit growth top estimate gm revenue surge fastest pace industry official say auto sale level year gm stock rise week fiat chrysler automobile fcau report july be investigation justice department unspecified fraud accord person familiar matter ford report next week volkswagen vlkay be mull build electric vehicle plant chattanooga tenn site mexico general electric ge report ep gain much better expect industrial order fall core organic revenue fall too honeywell hon diversify industrial giant top ep view miss sale honeywell cut full year organic revenue forecast small drop ge honeywell share fall friday hit long term high earlier week lockheed martin lmt raise full year outlook report result analyst estimate management warn sustain current level spending defense giant get production contract pentagon soon attempt coup turkey isn expect weigh fighter sale production textron txt maker cessna plane bell helicopter report jump ep beating analyst expectation revenue climb also wall street view see full year ep midpoint be analyst estimate lockheed stock hit record high week close week textron rise
389,JNJ,abbott laboratory say second quarter profit top analyst estimate rise demand business segment medical device recent underperformer lead way earning exclude time item be cent share beating cent average analyst estimate survey bloomberg profit continue operation fall cent share cent year abbott park ill base company say statement abbott lab sit merger frenzy health care industry last year have make time agree buy alere alr february deal have turn contentious striking deal st jude medical stj april st jude base st paul minn also report earning thursday second quarter adjust profit exclude item share match average estimate analyst compile bloomberg revenue gain year earlier report revenue increase percent abbott medical device unit lead sale performance help settlement issue surround royalty revenue previous year demand mitraclip device used repair damage mitral valf heart company endovascular business also post strong result lead sale stent used treat block blood vessel leg device used close puncture wound ibd take abbott hasn prove be particularly resilient stock composite rating stock ibd medical diversify group have be carry most part sole companion group dow stock johnson johnson more information jnj check ibd stock checkup abbott maintain adjust earning forecast share share end trading more close wednesday
390,JNJ,johnson johnson jnj increase full year profit sale forecast second quarter profit top analyst estimate drive growth pharmaceutical division be home blockbuster product such arthritis treatment remicade johnson johnson stock be more record high early trading tuesday earning release rely prescription medicine remicade psoriasis drug stelara drive sale stem slowdown medical device division remicade account drug revenue new brunswick base company last quarter world biggest maker health care product raise earning forecast share exclude item previously analyst anticipate second quarter earning be share ex item compare average prediction compile bloomberg drug sale increase period help offset decline consumer product revenue medical device be little change sale rise analyst anticipate net income decline share share remicade revenue edge estimate sale consumer business include johnson baby care product neutrogena listerine fall share have almost double start company have top earning estimate period fourth quarter
391,JNJ,alphabet world internet search leader be prospect core business strike success health care world company glucose monitoring contact lens diabetic be inch closer drugstore shelve sale self stabilize spoon design help person uncontrollable hand tremor eat comfortably top first month google restructure last year become largest operate unit new parent alphabet googl buy biotech company lift lab just few month health focuse startup begin product sale point broaden emphasis other health medical advancement alphabet last month rename google life science division verily life science division bring together clinician scientist be focuse understand improve chronic condition impact massive number person health issue include cardiovascular disease diabetes cancer disease mental health be development health care think be far reach be long last be see period convergence technology company health care company california life science association trade group ceo sara radcliffe tell ibd say change drive health care tech firm partnership include explosion big datum result demand way manage patient information growth access datum internet cloud mobile technology such fitbit fit wearable be shift health care maintain tracking health rather simply treat disease say company team uprecent notable health tech partnership include alphabet verily division team last month johnson johnson jnj develop surgical robot news follow september announcement google life science spinoff calico have enter year collaboration north chicago ill base pharmaceutical firm abbvie abbv research age related disease verily have partner too medical device firm dexcom link verily create new class disposable glucose monitoring system be faster cheaper smaller product be currently available johnson johnson verily announce last year have create verb surgical develop new surgical robotic device smaller less expensive intuitive surgical isrg da vinci system now control minimally invasive surgery segment other look join force health tech divide include medical device maker medtronic mdt be collaborate big datum solution provider ibm ibm watson health analyze wave information glean diabetes insulin pump datum vs be not only tech heavyweight seek blend medical altruism big datum big moneymaking plan apple aapl microsoft msft other be also used deep technology expertise create medical related product service year apple introduce health tracking tool monitor user footstep heart rate sleep activity microsoft samsung already offer number so call wearable device also allow person monitor daily movement advance mobile compute artificial intelligence new analytic software be drive effort recent year have be increase interest health care application company traditionally be see be consumer focuse company say iain simpson drug delivery specialist cambridge consultant company such google apple facebook fb amazon com amzn have build consumer focuse business base creation compelling sustainable user experience now simpson say various tech company be head health drive increase relevance capability market create new high value business opportunity particularly work collaboration establish health care player such pharma medical device company health care spending weigh project reach accord california health care foundation profit potential be obvious incentive other factor be also work part reason alphabet focus move needle parkinson treatment be personal google co founder now alphabet president sergey brin mother eugenia have parkinson brin be diagnosed carry mutation lrrk gene have be associate higher rate degenerative disorder central nervous system generally pace medical research be glacial compare used internet brin tell wire interview google amplify process be look lot place collect lot information see pattern lead somewhere legislative change be factor have help open door tech firm put massive compute muscle health care datum drive medicine be key element affordable care act federal law ushered president barack obama health care reform be major force center boom new health technology law provide major financial incentive doctor hospital prove care be effective value base payment rule be spark demand new software track analyze patient datum say lynne dunbrack research vice president idc health insight patient prescribe example dunbrack say hospital be find cheaper send medicare patient have congestive heart failure home weight scale electronic tablet connect app rather risk too many readmission day discharge result hospital get federal reimbursement rate cut have be real financial incentive health care organization purchase use technology be then help drive demand be company be now see new opportunity dunbrack say shift value base care other top area focus health care industry include sequence human genome digitize health care datum say cowen co analyst john blackledge september report alphabet health care strategy health care trend be not occur vacuum be be accommodate technology advance area such social mobile analytic cloud compute be area google expertise blackledge say swirl change tech advance be also help fuel medical ambition tech heavyweight apple annual worldwide developer conference june apple introduce new healthkit app monitor user heart rate sleep weight blood pressure other health related measurement let home health device such heart monitor fitness monitor exchange datum healthkit allow clinician mayo clinic send health information user app turn transmit datum user physician healthkit be logical extension apple exist product digital ecosystem keep user engage increase apple app store business also keep apple product service relevant grow increasingly competitive consumer health market say simpson cambridge consultant apple tech framework researchkit let person want remotely participate clinical medical trial do so used specially design apps iphone instead have show person march apple display apps say help diagnose range condition diabetes heart disease apple say win see datum transmit person opt sharing researcher want researchkit help address few problem medical research current state such limit patient participation infrequent datum sampling apple jeff william now chief operate officer say time person sign single medical study stanford university first hour release researchkit apple ceo tim cook tell cnbc march put perspective stanford have tell have take normally medical center entire year sign many participant so researchkit be absolute game changer say cook call discover cure disease push life expectancy much longer currently be alphabet google have own initiative call fit include developer tool online platform collect datum connect michele chandler twitter ibd_mchandler facebook
392,JNJ,many dividend etf investor be understandably leery impact rise rate have high yielding stock be reason be cautious dividend growth stock too double digit dividend growth rate post whole recent year last forever say josh peter editor morningstar newsletter fact
393,JNJ,pharmaceutical aren just source relief physical ailment oft steady dividend provide comfort even stock underperform today ll look drug stock dividend leader screen yield beat average pfizer pfe monday raise quarterly payout cent
394,JNJ,research development be lifeblood company then microsoft msft be get good shot oxygen be intel intc alphabet googl microsoft spend month end more other company accord factset research microsoft be closely follow intel invest
395,JNJ,stock future narrow early loss abruptly approach start bell friday overseas market continue trade lower dow future show point decline vs point tumble hour earlier
396,JNJ,nasdaq future halved hour earlier loss trade point fair market value future be point lower improve point loss small cap remain pressure russell future ease early loss point decline
397,JNJ,stock market today get roll converge day move average nasdaq day line only market post day healthy gain wednesday also include federal reserve launch interest rate tighten cycle big news big hurdle market clear
398,JNJ,friday premarket action be not encourage nasdaq do open session gain week be ahead index have gain past week
399,JNJ,economic calendar close week quiet note only preliminary read service due researcher markit et regional survey expect atlanta federal reserve bank kansa city federal reserve baker hughe bhi release weekly rig count datum pm
400,JNJ,half dow stock moved lower other half remain flat premarket trade johnson johnson jnj boee ba chevron cvx dip more dupont dd be sole gainer
401,JNJ,several late season earning report whip action bell
402,JNJ,carmax kmx dive open report third quarter sale earning stop short analyst estimate same store sale rise vs expectation increase stock have be scoop consolidation tight trade june
403,JNJ,homebuilder lennar len rise more fiscal earning easily beat consensus view revenue growth stop just short forecast new home delivery rise order even newer home jump lennar share have be gradually weaken consolidation august
404,JNJ,handheld device maker blackberry bbry grab gain ontario canada firm report not bad expect sale loss
405,JNJ,leader open source software developer red hat rht jump more lead ibd list raleigh company late thursday deliver revenue earning consensus forecast management revenue guidance be earning guidance be analyst consensus view stock have be work retake day move average end thursday cup base buy point
406,JNJ,qihoo technology qihu climb almost finally inking deal be take private group investor lead company chairman zhou hongyi zhou have propose deal earlier year market china slump serious correction
407,JNJ,oil price slip west texas intermediate crude shed more barrel just week brent crude be fraction lower just almost week gold rise fraction still standing tight ounce level copper future pop leave price effectively level week
408,JNJ,overseas market be broadly lower friday trading higher week japan nikkei tokyo topple leave index loss week shanghai composite end flat friday week hong kong hang seng end friday weekly gain
409,JNJ,europe stock be pressure midday cac paris be frankfurt dax dip london ftse show decline week ftse track gain cac be dax show gain stock future narrow early loss abruptly approach start bell friday overseas market continue trade lower dow future show point decline vs point tumble hour earlier nasdaq future halved hour earlier loss trade point fair market value future be point lower improve point loss small cap remain pressure russell future ease early loss point decline stock market today get roll converge day move average nasdaq day line only market post day healthy gain wednesday also include federal reserve launch interest rate tighten cycle big news big hurdle market clear friday premarket action be not encourage nasdaq do open session gain week be ahead index have gain past week economic calendar close week quiet note only preliminary read service due researcher markit et regional survey expect atlanta federal reserve bank kansa city federal reserve baker hughe bhi release weekly rig count datum pm half dow stock moved lower other half remain flat premarket trade johnson johnson jnj boee ba chevron cvx dip more dupont dd be sole gainer several late season earning report whip action bell carmax kmx dive open report third quarter sale earning stop short analyst estimate same store sale rise vs expectation increase stock have be scoop consolidation tight trade june homebuilder lennar len rise more fiscal earning easily beat consensus view revenue growth stop just short forecast new home delivery rise order even newer home jump lennar share have be gradually weaken consolidation august handheld device maker blackberry bbry grab gain ontario canada firm report not bad expect sale loss leader open source software developer red hat rht jump more lead ibd list raleigh company late thursday deliver revenue earning consensus forecast management revenue guidance be earning guidance be analyst consensus view stock have be work retake day move average end thursday cup base buy point qihoo technology qihu climb almost finally inking deal be take private group investor lead company chairman zhou hongyi zhou have propose deal earlier year market china slump serious correction oil price slip west texas intermediate crude shed more barrel just week brent crude be fraction lower just almost week gold rise fraction still standing tight ounce level copper future pop leave price effectively level week overseas market be broadly lower friday trading higher week japan nikkei tokyo topple leave index loss week shanghai composite end flat friday week hong kong hang seng end friday weekly gain europe stock be pressure midday cac paris be frankfurt dax dip london ftse show decline week ftse track gain cac be dax show gain
410,JNJ,look alphabet googl google soon disclose more plan medical robotic partnership johnson johnson jnj eventually pressure intuitive surgical isrg stock share sunnyvale calif base intuitive surgical lead maker medical robotic system be nearly intuitive stock be flat early trading stock market
411,JNJ,best holiday gift income investor stock keep pay dividend year year dividend leader wednesday issue be dividend aristocrat company have paid dividend year least past year stock make list also boast yield bigger average payout mcdonald mcd have raise dividend year first payout nov raise quarterly dividend cent share full year work yield stock be outperformer more year share jump oct fast food giant report result top view same store sale rise first time year golden arch be midst turnaround effort begin offer breakfast day october be testing custom burger table service southern california restaurant coca cola ko be serve mcdonald have be pay dividend have hike payout last year pay quarterly cent share annualize yield stock be just buy point first clear oct less year date johnson johnson jnj have boost dividend consecutive year current quarterly payout cent share full year yield barclay tuesday upgrade health care giant overweight equal weight boost price target have be base year be less high offer biggest yield aristocrat stock have raise payout year warren buffett own stock featured wednesday column be try regain day move average be week high
412,JNJ,big pharmas merck mrk eli lilly lly johnson johnson jnj be trading tuesday get upgrade barclay abbvie abbv seesaw downgrade analyst geoff meacham assume coverage newly combine pharmaceutical sector barclay coverage left most rating same make few tweak lilly be upgrade overweight equal weight price target lift base promising pipeline management commitment lower expense meacham say lilly be build major autoimmune disease franchise late stage drug candidate ixekizumab psoriasis baricitinib rheumatoid arthritis drug develop incyte incy base solid phase datum view baricitinib have significant market share potential rheumatoid arthritis meacham write model conservatively project risk adjust sale vs peak sale pfizer pfe xeljanz meacham call diabetes drug jardiance lilly most important commercial asset intermediate term recent study result show sharply reduce death heart failure admit have be overhang merck derive lot revenue compete drug jardiance argue stock have overreact acknowledge be multiple headwind risk make merck show story think even most potential negative scenario be too much underlie value ignore meacham write raise merck rating overweight equal weight hike price target even pipeline asset aren blockbuster add be nearly free current valuation lilly stock be almost afternoon trading stock market today merck stock be meacham also raise overweight equal weight price target rise merck feel market be undervalue have underperform drg past month due concern impact biosimilar remicade low term earning growth lack significant term pipeline catalyst meacham write have lead call break conglomerate believe be premature meacham view be better acquire growth asset especially pharma stock be afternoon trading meanwhile meacham downgrade abbvie equal weight overweight trim price target many analyst thought abbvie projection recently acquire blood cancer drug imbruvica similar drug pipeline year peak be too high imbruvica other oncology asset likely succeed field be highly competitive meacham write abbvie stock initially drop almost tuesday trading afternoon be follow amy reeve twitter ibd_areeve facebook
413,JNJ,most heavily trade etfs rally steadily higher last month be more mixed bag so far month powershare qqq qqq have hold best past month follow spdr spy large cap peer ishare russell iwm have return be month small cap etfs find way investor etf strategy dollar marched steadily higher start year currency move be expect act headwind large cap benefit small cap be less reliant international revenue only half equation have bear so far more mixed action greenback lately coca cola ko johnson johnson jnj other large company report relative dollar strength continue take bite revenue profit expect boost small cap have yet materialize be small cap be more sensitive change monetary policy russ blackrock global chief investment strategist write nov small cap do have less exposure international sale have prove more vulnerable rise real interest rate interest rate inflation investor anticipation monetary tighten say historically small cap relative performance have be strongest short term rate controlled fed be fall add minute latest federal reserve meeting release today show many policymaker be lean rate liftoff december expect small cap segment benefit fed decide overall advise investor stay neutral far size bias stock investing go iwm hold nearly small cap stock include more volatile microcaps highly rate ibd stock portfolio include enterprise software firm manhattan associate manh regional bank ozark ozrk etf have asset expense ratio have average daily dollar volume more ahead qqq far spy average market cap be half typical fund category say morningstar analyst michael rawson note etf isn top heavy largest holding account just asset add far cheapest etf category schwab small cap scha charge expense iwm have give year date tuesday vs gain qqq spy much longer time horizon different story iwm produce average annual gain past year vs qqq spy small cap etfs diversify investment portfolio be try test strategy successful investing follow aparna narayanan twitter ibd_anarayanan
414,JNJ,johnson johnson jnj announce market close tuesday be drop bidding actelion pharmaceutical leave france sanofi sny most likely potential bidder swiss drugmaker say statement johnson johnson today confirm have end discussion actelion pharmaceutical ltd regard potential transaction johnson johnson be not able reach agreement believe create adequate value shareholder lung disease drug specialist actelion quickly follow talk unnamed suitor strategic transaction possible partner be likely sanofi previously cite interested actelion sanofi be company wall street journal report cite source ibd take drug stock initially rally relief hillary clinton wasn elect president turn worry sign donald trump push lower drug price actelion close tuesday market cap reportedly be look valuation unclear actelion be open takeover other transaction share rise stock market today announce exit actelion hunt retook day move average close just day sanofi share rise related sanofi battle johnson johnson european biotech actelion
415,JNJ,biotech stock have nearly round trip donald trump inspire rally rbc analyst michael yee see upcoming food drug administration appointment datum roche rhhby biogen biib act catalyst ishare nasdaq biotechnology ibb spdr biotech xbi exchange trade fund be follow rally trump election wednesday trump dump water analyst theory be less likely go spiraling drug price go bring drug price tell time magazine don have happened drug price trump commentary send biotech stock tumble wednesday ibd company medical biom biotech industry group close ishare biotech etfs end day respectively sink more thursday biotech stock manage climb hole stock market today ibd company biotech group be fractionally be etfs ibd take biotechs recover trump pledge curb drug price get deep dive ibd industry theme yee note trump effect extend far commentary trump have appoint georgia rep tom price health human service secretary price have say favor major overhaul medicare system have advocate affordable care act next appointment light fire biotech stock yee write deck trump be prep announce next commissioner food drug administration medium report target jim neill scott gottlieb lead candidate neill be former venture capitalist manage director peter theil mithril capital have advocate relax fda regulation drug approval gottlieb be vc partner practice physician have serve fda center medicare medicaid service decision follow congress approval late wednesday bill speed fda process trump commentary drug pricing be far set stone yee write research note note republican congress next year be unlikely break conservative dogma work ease drug price worry trump mention drug pricing remind investor have say lot thing past year seem negotiate public eye hasn necessarily be truly perceive actually want do lot yee write outside trump biotechs have suffer industry specific injury include eli lilly lly miss key alzheimer datum lag metric teva pharmaceutical teva medtronic mdt yee write biogen roche have upcoming datum help industry biogen have phase datum alzheimer drug aducanumab due friday roche phase hemophilia datum be due imminently yee say prescription drug free user pdufa be due dec roche multiple sclerosis drug ocrelizumab regeneron regn rival ophthotech opht have phase datum come soon meanwhile look imminent sector johnson johnson jnj be talk buy european biotech actelion sanofi sny be rumore have informal interest actelion insider say pull generalist investor back space yee write perception major term catalyst biotech other cheap need much more get stock rally again write trump tax cut plan republican congress spur biotech trump make drug development great again
416,JNJ,stock be rally sharply dow jone industrial be lead way surge late afternoon trading wednesday nasdaq composite have lag president elect donald trump vow hold drug price boost skittishness biotech ethical drug investor have now quickly joined broad market advance meanwhile apple aapl help lead big flurry gainer dow jone industrial pm new york least dow component rise point more apple rise nearly get back original buy point long bottom base pattern be nearly month apple take share proper entry cup handle en route nearly gain so argue buy point be irrelevant however continue rise past rebound back slightly downward slope day move average go long way help former tech leader complete new base potentially break again watch potential new breakout fellow large cap include ibm ibm cup handle buy point autozone azo entry new double bottom handle amgen amgn drop hit lowest price level more week former big winner biogen biib slide briefly fall ever important day move average yet sell biotech ethical drug firm be fail hamper nasdaq composite tech rich index have rebound solid gain just more hour left trading session nyse composite be now just slightly ahead rise almost russell be nearly perhaps help buoy equity market be strong finish european equity even italy vote resounding former prime minister matteo renzi proposal enact structural reform bypass country senate german dax soar london ftse gain french cac advanced volume have accelerate be run sharply higher so far nasdaq nyse vs same time tuesday stock market today top industry group gainer include steel alloy consumer electronic retail solar airline agricultural chemical chip equipment well more airline space spirit airline save have do well clear handle buy point long deep bottom base structure stock more week have gain nov day historic election handle spirit be derive add cent handle intraday high set oct notice daily chart handle show tight downward slant price action mostly dull volume right way handle form alaska air alk fresh gain government approval condition acquire rival airline virgin america gain stock have see nice day heavy volume recent week have now surpass double bottom buy point related be bottom base pattern investor profit case new secular bull master stock chart read use ibd minute tip videoswhen do apple break year
417,JNJ,major index etfs tracking close record high tuesday investor digest mixed corporate earning spdr spy take mild hit stock market today pause time high set friday industrial sector inched other sector manage gain however spdr dow jone industrial average dium strike fresh close high etf hold industrial leader have gain past trading session vs spy proxy broad market top stock holding dium unitedhealth unh johnson johnson jnj outperformed deliver quarterly report stock surge time high unitedhealth nation top insurer report healthy customer add pharmacy benefit unit johnson johnson beat top bottom line maker medical consumer product also boost full year guidance other major earning have disappoint include netflix nflx online tv stream service dump tuesday report lackluster subscriber growth mixed corporate report be putt investor edge spdr gold share gld eke mild gain choppy trade tuesday etf track price gold sit week high gold price have recently come pressure higher risk appetite investor robust economic datum potentially give federal reserve gunpowder need raise interest rate higher rate weigh gold nonyielding haven asset powershare db bullish uup gap tuesday reclaim day move average dollar hit high level march other major world currency buoy part strong housing datum euro have be fall britain june vote leave european union hit morale continent here look major exchange trade fund tracking various asset class perform today ibd rs rating rs relative price strength rating be measure stock price performance last month compare stock etfs ibd database scale best possible follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs
418,JNJ,here be investing action plan tuesday need know investor earning season pick quarterly result be due tuesday microsoft msft lockheed martin lmt unite airline ual goldman sachs gs johnson johnson jnj unitedhealth unh microsoft analyst expect tech giant fiscal fourth quarter earning share come
419,JNJ,here investing action plan need know investor come week facebook fb stock make bullish move earning season kick high gear report heavy hitter netflix nflx microsoft msft general electric ge starbucks sbux general motor gm defense giant lockheed martin lmt also come
420,JNJ,brexit fallout continue monday stock again follow european bourse sharply lower steep decline american express axp jpmorgan jpm major index close intraday lows still finished well bottom half session range nasdaq sank shed dow jone industrial average give latter breach day move average line first time march volume be slightly lower board vs friday accord preliminary figure be still intense overall bank oil stock be hardest hit stock market today west texas intermediate crude slide barrel gold price climb ounce american express lead dow decline drop add plunge heavy volume friday share be now month lows be week high jpmorgan fall bring session loss only blue chip manage avoid downdraft johnson johnson jnj verizon communication vz be just record high verizon climb past cup base buy point busy trade few industry group manage small gain be defensive nature utility food beverage soap ibd electric utility wec energy group wec dollar general dg food bgs eke gain more acuity brand ayi chip designer maxlinear mxl ubiquiti network ubnt lose broadsoft bsft grubhub grub lifelock lock shed nearly apiece britain credit rating suffer downgrade follow last week brexit vote standard poor monday lower credit rating notch aa fitch also cut rating aa economic datum slate tuesday include first quarter gdp case shiller home price index april conference board consumer confidence index june
421,JNJ,stock index stagger lower monday afternoon former support line prove useless nasdaq skid dow jone industrial average lose respectively small cap russell chopped dow jone utility average rise dividend begin look safer bet volume be run friday pace major exchange slice day line then begin test area nasdaq begin day already day line then slide recent low test level bull be face good news bad news situation good news be chart action index be ugly investor see similar action start year august case market rebound do especially well february april bounce bad news be previous instance nasdaq decline high sell have pull nasdaq mean be more loss ahead situation individual investor be understandably look defensive name dow stock have stay cool current market pressure johnson johnson jnj verizon communication vz wal mart store wmt johnson johnson probably sport best look chart stock break late february have advanced steadily then be day day support line be only week high verizon communication be high stock be try clear cup base however much verizon base be build day line be flaw verizon rival former dow stock also be hold be trading time high set friday morning wal mart store wmt hasn react market sell however stock be far high marked january growth stock especially european exposure be suffering sell ibd loser be lead winner ratio monday afternoon statistic have be look encourage be divisia money supply be broadest gauge money supply needle jump more fifth consecutive month come tuesday final read first quarter gdp be release market open wall street consensus figure be growth
422,JNJ,amazon amzn price target be raise tuesday online marketplace say have record sale fire device weekend yum brand yum be upgrade china business spinoff
423,JNJ,barclay raise amazon price target raise keep overweight rating stock amazon also say tuesday fire device be best selling product black friday sale plan speed production build million more fire tablet
424,JNJ,amazon share close stock market today
425,JNJ,yum brand operator taco bell pizza hut kfc restaurant be upgrade outperform market perform cowen analyst be bullish company spinoff china business follow food safety issue past few year have hit stock
426,JNJ,share yum climb
427,JNJ,web host cloud compute service provider rackspace host rax be upgrade outperform sector perform rbc capital market analyst have price target stock rackspace share close
428,JNJ,barclay upgrade pharmaceutical medical company merck mrk eli lilly lly johnson johnson jnj overweight merck share jump eli lilly share climb share edge
429,JNJ,follow gillian rich twitter ibd_grich amazon amzn price target be raise tuesday online marketplace say have record sale fire device weekend yum brand yum be upgrade china business spinoff barclay raise amazon price target raise keep overweight rating stock amazon also say tuesday fire device be best selling product black friday sale plan speed production build million more fire tablet amazon share close stock market today yum brand operator taco bell pizza hut kfc restaurant be upgrade outperform market perform cowen analyst be bullish company spinoff china business follow food safety issue past few year have hit stock share yum climb web host cloud compute service provider rackspace host rax be upgrade outperform sector perform rbc capital market analyst have price target stock rackspace share close barclay upgrade pharmaceutical medical company merck mrk eli lilly lly johnson johnson jnj overweight merck share jump eli lilly share climb share edge follow gillian rich twitter ibd_grich
430,JNJ,medical device giant boston scientific bsx fall wednesday government propose limit coverage new heart implant late tuesday center medicare medicaid service cms issue propose guideline cover use percutaneous left atrial appendage closure therapy be purpose boston scientific watchman device memo conclude evidence be
431,JNJ,biggest medical meeting year be weekend american society hematology ash convene orlando fla hear latest attack world most intractable blood cancer already abstract presentation release ahead conference have make splash tiny french biotech cellectis cll offer detail
432,JNJ,single stock screen be best uptrend different uptrend reward different kind stock screen reflect reality example last bear market aggressive growthy complexion ibd then ibd fade stock make list oct include el paso electric ee campbell soup cpb procter gamble pg johnson johnson jnj mention equity alone say bear market early november screen have be top perform screen past month be gain ibd be make be way use screen micro approach macro approach micro approach study list find stock be buy point have few miss slim standard macro approach look pattern list kind stock be make list small cap big cap sector industry group be plentiful be stock make screen aggressive defensive let contemplate screen ibd also know weekly review friday newspaper generally ibd be collection stock have higher rating screen ibd have higher rating stock do better long strong uptrend quality growth stock likely correct more sharply defensive stock market run trouble be advantage screen pick more turnaround stock ibd turnaround stock be less likely have strong annual rating past year looser standard mean also more likely pick stock benefit sector rotation also pick more small thinly trade stock ibd sector rotation angle have be apparent recently small bank industry group account stock end october yet only bank stock make ibd bank ozark ozrk signature bank sbny many bank stock be thinly trade still attract quality mutual fund holder table show
433,JNJ,stock be narrowly mixed morning trade wednesday dow turn positive nasdaq remain red dow climb be fractionally higher nasdaq dip small cap lag russell more volume swell board vs same time tuesday medical oil apparel maker lead downside today stock market action west texas intermediate crude price slide more barrel ahead weekly inventory report johnson johnson jnj merck mrk be biggest loser dow decline gold miner datum storage steel stock outperformed western digital wdc pop massive trade week high mizuho cowen raise price target maintain respective buy outperform rating late tuesday datum storage maker guide fiscal earning share outlook street view advanced micro device amd gap rise heavy volume highest level more year share be extend past cup handle buy point clear nov be profit take range tuesday surge rumor licensing deal longtime rival intel intc intel gain tuesday be fractionally lower wednesday ibd dave buster play gap soar rapid turnover new high stock be well extend buy point double bottom handle stifel nicolaus lift price target close tuesday restaurant arcade operator report result top forecast raise full year profit guidance consensus estimate related amd stock hit year high intel rumor ahead zen previewanalyst tout dave buster western digital dave buster western digital lift view mastercard up payout
434,JNJ,french drugmaker sanofi sny be mull bid switzerland actelion pharmaceutical already have offer table drug giant johnson johnson jnj source tell bloomberg tuesday actelion confirm johnson johnson bid nov sanofi other potential bidder be feel heat push get agreement christmas reportedly boost bid share value actelion north sanofi hasn offer official bid have make interest know informally bloomberg say cite person familiar matter possibly sanofi soon also have compete roche rhhby pfizer pfe reportedly have be approach make bid switzerland biggest biotech novartis nvs be run accord interview ceo joe jimenez publish sunday swiss german language newspaper sonntagsblick ibd take biotech see boost donald trump be biotechs lookout representative actelion sanofi pfizer didn immediately return request comment roche spokesperson dr engel say company do not comment rumor speculation johnson johnson refer back nov announcement say do not intend make additional comment regard discussion be appropriate do so formal agreement have be reach close stock market today stock be fraction sanofi stock be share roche be fraction pfizer shave cent share close editor note correct list bloomberg source original report related unite therapeutic chill fever actelion bayer rivalrydonald trump republican win ease drug pricing debate pfizerjohnson johnson reportedly hike bid swiss drugmaker actelion
435,JNJ,bristol myer squibb bmy astrazeneca azn roche rhhby pressure merck mrk slew lung cancer drug design chip keytruda share jeffery analyst jeffrey holford say monday downgrade merck stock stock market today merck fall bristol myer squibb climb merck bristol myer be lock battle small cell lung cancer market drug leverage patient immune system battle cancer holford downgrade merck stock underperform price target expect strong keytruda performance follow pressure rival drug bristol astrazeneca roche chip away keytruda market ibd take next year be marked new presidency path donald trump take drug price merck screen poorly many valuation metric have downgrade share underperform holford write research report same note upgrade bristol stock buy price target holford expect opdivo trial secure bristol future more broadly prefer abbvie abbv eli lilly lly stock astrazeneca novartis nvs stock europe see pfizer pfe johnson johnson jnj merck sanofi sny nordisk nvo least prefer stock related gilead pay merck hep patent agio stock anemic
436,JNJ,medical product giant johnson johnson jnj reportedly up bid swiss specialty drugmaker actelion report bid be deem too low significantly increase offer bloomberg report tuesday do reuter monday financial time report party be talk deal give new brunswick base partial ownership actelion stock rise swiss exchange tuesday jump friday actelion react report confirm be negotiation actelion rise monday now have market cap johnson johnson stock end trading tuesday stock market today ibd take action drug industry heat more donald trump take office analyst say expect ease regulatory hurdle company such amgen celgene be lookout bloomberg have report drugmaker novartis nvs be also base switzerland france base sanofi sny also bid actelion actelion be trade sanofi be early afternoon trading tuesday novartis be small fraction actelion be develop potential blockbuster annual sale lung treatment opsumit uptravi top drug be tracleer treat form blood pressure affect artery lung drug face generic rival early related small axovant science set take celgene other alzheimer sbig biotechs soon have more cash buyback
437,JNJ,big pharma eli lilly lly jump wednesday wall street analyst weigh result narrow food drug administration advisory panel vote late tuesday panel meet decide good idea expand label lilly diabetes drug jardiance include reduce death cardiovascular cause base large clinical trial call empa reg committee vote favor change such close vote leave less clear just decision fda ultimately make most cite reason vote be bar new claim be grant base single study be very high panelist see second trial confirm cv death find leerink analyst seamus fernandez write research note many panelist vote yes also share concern find cv death benefit compelling convince enough tip balance fernandez nonetheless like odd approval note most senior member panel include biostatistician cardiologist vote favor new indication credit suisse analyst vamil divan be also bet favor change add read similar product sglt inhibitor class johnson johnson jnj invokana remain market leader sglt space canvas outcome study schedule be complete february divan write research note assume fda agree include empa reg outcome cv death datum jardiance label see share shift invokana jardiance canvas be complete longer term implication dependent canvas result result outcome study astrazeneca azn forxiga merck mrk pfizer pfe ertugliflozin be expect later decade divan say evercore isi analyst mark schoenebaum be more cautious slight overall majority vote favor new cv indication view approval actual cv death indication have coin flip odd give unprecedented nature result trial schoenebaum write email client say also feel better chance fda allow datum be add label instead indication statement lilly stock rise stock market today once again day move average lilly close just day line be past month johnson johnson stock close fresh record high
438,JNJ,big mega cap stock continue rally broadly lunchtime tuesday utility stock decline component rise least dow jone industrial average strike time high dow rise hit intraday high eclipse prior time peak set dow more jan have now rally february low financial commodity related stock help lead dow goldman sachs gs jpmorgan chase jpm rally more stock have be struggle reassert leadership stale top bottom line result goldman case profit be forecast shrink share jpmorgan issue result thursday be expect see only ep decline continue benefit strength consumer oriented lend research global market intelligence note industrial company be expect grow profit second quarter second only consumer discretionary sector nasdaq composite rally help tech giant apple aapl rise rise small cap jump dow utility average slip nearly be still more jan term tuesday gain dupont nemour dd lead blue chip dow rise more rebound back day move average heavy volume chemical titan have be form long deep base peak march last year earning be see fall second quarter consensus estimate have be revise higher dupont relative price strength rating see ibd stock checkup reflect stock long sideway motion dow component hold healthy rs rank higher include johnson johnson jnj chevron cvx unitedhealth group unh mmm ibd name stock market today rank datum center operator coresite realty cor fall heavy volume second straight session almost stock still have comfortable price cushion rise day move average see monday big picture column market pulse table market be currently confirm uptrend mean investor have higher probability make money buy breakout high quality growth stock proper buy point be stock be best class industry group term profit growth margin sale return equity institutional fund sponsorship relative price strength check investor com exclusive tool ibd stock checkup
439,JNJ,brexit volatility spark june vote withdraw european union diversify stock mutual fund eke gain average second quarter even lose june alone accord lipper inc tack inch june good news stock fund manager be seek durable growth stock hedge uncertainty volatility slowdown corporate earning several tell ibd see month longer ahead click here see list mutual fund quarterly leader brexit investment world be almost back normal say matthew co manager schroder large cap equity strategy be run separate account federal reserve be edge interest rate increase first quarter panic pace sustainability china growth be subside economic indicator be job wage grow home value inch consumer feel confidence then brexit say re back uncertainty market hate uncertainty result go forward say stock want be narrow group have show ability grow earning regardless macro environment click here see list mutual fund month leader biggest overweight be consumer discretionary say reflect confidence consumer durable secular trend amazon amzn be top list similarly james abate sole manager centre american select equity dhamx multus asset real return dhmux see best prospect growth increasingly concentrated elite group re concentrate name somehow buck trend term economic malaise say abate be also centre chief investment officer name new nifty bucket include amazon johnson johnson jnj merck mrk nvidia nvda general mill gis jim swanson lead manager mfs diversify income difax chief investment strategist mfs investment management be already bearish stock pre brexit click here see list mutual fund category performance outlook be already dim corporate earning growth say add company globally have already lose purchasing power selling general administrative cost well labor cost be rise productivity here europe china be fall post brexit dollar be vs chinese yuan hurt export multinational earning say global movement trade protectionism realize also hurt earning brexit not need see excess capacity come world manufacturing system return inflation so company pass price increase swanson say threat corporate earning swanson be overweight stock vs japanese european peer have growth outlook look even dimmer be underweight stock vs bond cash corporate bond be place be say favore mix high grade high yield debt small cap growth fund lead market capitalization style group diversify stock fund gain world equity mutual fund barely advanced edge lose june latin american fund lead foreign region advance june year date latin american fund have benefit primarily rebound excessive sell last year well rebound brazilian real vs dollar bounce oil other commodity accord peter taylor manager emerge market abeax latin american equity fund aleax brazilian stock have also benefit ouster least temporarily president dilma rousseff market friendly fiscal reform say quarter volatility enabled precious metal fund lead sector soar more half june go forward swanson feel best technology sector stock free cash flow be highest sector say talk bubble sector be trading cheaper utility ohio yet tech company change world software be due benefit overdue upgrade cycle say second favorite sector be health care health care spending keep rise portion gdp say price fairly not cheaply have best profit outlook tech consumer discretionary be third favorite sector forward price earning ratio be high re see year year profit growth almost good tech say tech stock facebook fb be like have exceptional top line growth say re grow opportunity viewer be tolerate triple video be show advertiser allow facebook triple number ad insert video health care say share price have be beaten largely investor concern drug pricing draw additional regulatory scrutiny still like individual stock sector include amgen amgn be cheapest pharmaceutical say be create market opportunity number biosimilar be harder previous generation treatment rival replicate consumer discretionary stock like amazon top line growth use prime draw new site user also like amazon use warehouse store inventory expense purchasing tractor supply tsco be consumer discretionary name like cater customer income be double national average pursue rural lifestyle say sale be triple next competitor combine scale enable tractor supply customize inventory different region staple like monster beverage mnst new carbonate drink mutant distribution arrangement partner coca cola ko keep growth high single digit low double digit say wall street expect low single digit make stock attractively value say david harden president summit global investment lead manager fund low volatility equity lvolx small cap low volatility lvsmx say volatility like stock stability revenue earning company offer downside protection say trait share stock like be stability revenue earning company offer downside protection say trait be low year beta beta be mean be less volatile overall stock market
440,JNJ,sale allergan agn generic drug business teva pharmaceutical industry teva clear hurdle tuesday impax laboratory ipxl announce pay acquire product firm be require divest competitive reason impax wasn allow name product june deal close apart teva portion generic version johnson johnson jnj attention deficit drug concerta firm have be develop partnership allergan already have own generic concerta market so have be expect have go teva allergan announce deal last july remain product impax acquire include be already market approve strength not yet launch await approval development also drug different strength exist product await approval impax say together product generate sale gross profit last year impax say acquisition add top line second half year double full year earning growth impax also hike full year interest expense guidance slightly increase gross profit guidance low range impax ceo fred wilkinson say conference call analyst timing be highly opportune impax be face difficult second half financially last quarters bring triple digit earning growth thank company inflammatory diclofenac sodium gel new competition be expect shrink bottom line growth single digit move red wilkinson say federal trade commission have marked unnamed product divestiture face limit competition manufacturing difficulty intellectual property barrier difficulty meeting standard last issue have torpedo house version concerta impax have develop be fda review then agency update guideline way exclude impax drug well mallinckrodt mnk already market product impax teva come current drug acquisition leerink analyst jason gerberry however doesn guidance imply base business absent acquisition new guidance imply downside relative current factset consensus sale forecast gerberry write research note guidance revision base biz be due increase competition high margin generic relative update add get full right concerta help still have more year go get market market seem agree assessment impax stock tumble close stock market today teva stock lose allergan give back
441,JNJ,investment bank goldman sachs gs drug company pfizer pfe be upgrade buy rating wall street analyst tuesday health care product giant johnson johnson jnj burger chain wendy wen chemical company kopper kop be downgrade hold neutral rating brokerage firm keefe bruyette wood upgrade goldman sachs stock outperform market perform raise price target goldman stock rise stock market today fall monday goldman share break flat base buy point oct goldman share jump nearly day nov election keefe bruyette wood also upgrade bank america bac outperform market perform hike price target bofa fall cent related bofa goldman sachs stand bank rallybofa jpmorgan other bank stock chart look great bank barclay upgrade pfizer overweight equal weight raise price target pfizer stock rise tuesday fall monday pfizer share have be consolidate last day potential buy point barclay analyst geoff meacham say see higher likelihood trap overseas cash be repatriate trump administration used return capital shareholder also see ibrance xtandi drive growth oncology business related donald trump republican win ease drug pricing debate pfizerpfizer spike report mull consumer care salebarclay also cut rating johnson johnson equal weight overweight reduce price target new brunswick base slide fall nearly monday stock have form flat base last day potential buy point barclay meacham say risk reward profile have become less compelling late related johnson johnson confirm takeover talk actelion chain wendy be downgrade neutral goldman sachs price target wendy stock fall tuesday monday fall fraction share break cup handle pattern nov day presidential election goldman analyst karen holthouse lower rating wendy valuation concern follow recent stock appreciation related mcdonald menu table service mobile order more kioskstrump be absolutely yuge mcdonald left punch bagrobot push fight backer workinvestment bank lower rating kopper holding hold buy valuation concern kopper close monday kopper stock fall share pittsburgh base company rally election kopper produce carbon compound wood treatment chemical treat wood product serve railroad specialty chemical utility residential lumber agriculture aluminum steel rubber construction industry
442,JNJ,nasdaq composite lag monday weakness go well technology stock name alexion pharmaceutical alxn viacom viab st century fox foxa nvidia nvda american airline aal take big hit nasdaq lose end session streak fall dow eke gain good fresh time
443,JNJ,stock show small movement monday small cap fall harder russell retreat nearly contrast last week lose just apple aapl meanwhile fall more importantly stock hold key day move average intel intc help prop chipmaker gain intel have be work new base peak october nasdaq composite drop monday follow last week rally volume fall vs friday level accord preliminary datum sign big fund weren overly eager sell position raise cash nyse composite outperformed lose just big board turnover grow be also just mega cap name be virtually flat due small decline avoid get tag new distribution day bout heavy professional selling distribution count be now nov accord ibd market pulse table find daily big picture column low distribution day count imply large fund bank pension plan be accumulate share net accumulation distribution rating be positive friday close be fraction dow jone industrial edge ahead oil gas royalty trust oil drill international oil gas exploration company pace upside gain more ibd medical diversify group include dow component johnson johnson jnj internet network solution group also excel gain respectively jump nearly heavy turnover stopping short retake day line stock be just week peak still early stage form potential new base worst decline term industry group belong department store chain more airline leisure product steel production more southwest bank cement aggregate security software consumer loan company also sell hard back tech sector microsoft msft rise extend gain past base base buy point mega cap be now slightly extend past proper buy range qualcomm qcom make ibd dividend leader screen give little ground build gain july breakaway gap past bottom base buy point yet stock also be work new flat base structure qualcomm be also showcased today income investor column netflix nflx continue show tight action strong rally last week just cent monday video stream giant be still aggressive entry point accord ibd leaderboard standard buy point be energy sector numerous oil gas explorer struggle hold big open gain wake surprise agreement opec oil produce nation join body historic decision cut overall production start january britain integrate oil major bp bp rally more point get high just few cent cup buy point week cup sit much longer deeper bottom base pattern halliburton hal run session high sink back just oilfield service giant however have climb more clear flat base buy point early october point halliburton pull back entry intraday low drop be not enough trigger loss cut sell rule follow good wall street see halliburton reverse net loss cent share net profit share week feature only sliver company report quarterly result include major big cap software name oracle orcl adobe system adbe latter be expect grow fourth quarter profit cent share prior quarters earning have grow average august adobe push past flat base entry point rally more fading yet most recent correction stock find bullish support long term day move average watch see stock hurdle day move average boost odd fresh upcoming federal reserve decision interest rate wednesday keep eye november report producer level price econoday consensus forecast call month month rise related do apple form bottom base investor profit apple be form new base flex strength againwhy be adobe top tech stock pick apple invest massive softbank fund
444,JNJ,contact lens maker cooper company coo reversed lower stock market friday earning full year guidance surpass expectation late thursday jeffery analyst anthony petrone raise price target stock affirm buy rating say survey suggest redesign cooper clariti disposable contact drive result quarter end april cooper earning rise year earlier quarter share exclude time item beating analyst consensus cent sale increase consensus cooper add cent full year ep guidance range now vs last year sale guidance be higher previously last year cooper stock jump much close stock market today stock have be form long cup base april last year hold strong ibd composite rating come launch johnson johnson jnj new silicon hydrogel monthly lens july come several time cooper earning conference call analyst contact lens division perform fairly weakly guidance modest deceleration compare have previously forecast anticipate impact rollout cooper ceo bob weis say call wall street have question decision april abandon unilateral pricing policy contact put pricing pressure whole field weis downplay importance know vendor have retailer have alter price weis say large market continue drive way have past pricing be not really factor trading shelf space
445,JNJ,don let name alp sector dividend dog sdog fool exchange trade fund hit record high past week have be remarkably steady performer exclude aug flash crash etf deepest decline have be november january nearly other decline inception year be less share break flat base last monday past buy point primary focus large cap dividend stock etf serve long term sailing rather momentum play fund be design dog dow strategy basically seek component dow jone industrial average highest dividend yield think be dog be just temporarily favor share price eventually catch yield performance alp sector dividend dog take premise apply larger universe namely find stock highest dividend yield respective sector so always have exposure broad sector index select have nearly equal weighting etf stock range weighting accord alp most component have be rebound year even be form price consolidation right now pair health care stock baxter bax johnson johnson jnj have be best perform component baxter make hospital renal disease product be past buy point have advanced buy point insurance firm cincinnatus financial cinf have rally breaking feb etf pay quarterly dividend cent share good annualize yield ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list
446,JNJ,chief executive facebook fb apple aapl linkedin lnkd be most highly rate ceo accord glassdoor com report bain co bob bechek be rank yearly poll job site scott scherr ultimate software ulti be second dominic barton mckinsey co place third mark zuckerberg facebook be fourth linkedin jeff weiner round top facebook share close midday trading stock market today linkedin add apple lose ultimate software rise tech firm dominate list marc benioff salesforce com crm be sixth sundar pichai alphabet googl google unit be seventh tim cook apple be eighth alphabet share climb salesforce com end higher highly rate ceo outside tech industry include procter gamble pg david taylor johnson johnson jnj alex gorsky nike nke mark parker goldman sachs gs lloyd blankfein lynsi snyder burger ceo be highest rank female ceo
447,JNJ,wal mart wmt receive price target increase friday coverage be start exchange operator well johnson johnson jnj number analyst hike price target wal mart retail behemoth beat earning thursday tout sale momentum earning power share thursday ceiling be pretty low company try pick pace online sale face margin pressure wage hike rbc keep underperform rating raise price target telsey advisory stick market perform rating lift target wal mart share rise friday hit month high intraday standpoint research initiate coverage johnson johnson sell rating price target even other analyst come away positive report management review week consumer medical device business thursday well fargo raise target range say company be position solid growth share fall friday sterne agee crt start coverage option commodity exchange offer very different outlook exchange ice get buy rating target cboe holding cboe be initiate underperform target research firm rate cme group cme neutral target ice share rise cboe cme tick stifel keep buy rating accenture acn hike price target week management consult service firm have be roll health care partnership salesforce com crm general electric ge improve patient support medical claim process accenture edge
448,JNJ,exxon mobil xom hike quarterly dividend wednesday cent cent day standard poor strip oil giant aaa credit rating cite low commodity price high reinvestment requirement continue large dividend payment exxon hold best possible rating nearly year accord dow jone now have cut aa just company still hold prize aaa rating microsoft msft johnson johnson jnj standard poor rating service note exxon debt level have more double recent year add expect exxon cost rise oil gas major try maintain production increase reserve result expect leverage remain weaker level consistent aaa rating believe lower rating aa be appropriate furthermore believe company return cash shareholder rather build cash reduce debt limit improvement project credit measure commodity price improve investor receive return form dividend share buyback exxon have be commit maintain dividend payment even accumulate debt put exxon creditwatch february negative implication signale be consider downgrade say report tuesday be remove exxon creditwatch rating downgrade company corporate credit long term debt exxon share close stock market today crude price continue rally stock rise first stage cup handle base march top buy point have hold steady level exxon mobil chevron cvx report first quarter result friday bp bp first oil major release result report surprise profit tuesday
449,JNJ,apple aapl get lower price target wednesday boee ba be downgrade yahoo yhoo johnson johnson jnj receive series price target hike deliver better expect earning barclay lower price target apple maintain overweight rating stock apple stock price have close last session analyst concern lower iphone demand miss estimate current quarter apple share close stock market today yahoo jump several analyst raise price target stock late tuesday company top first quarter earning revenue estimate remain mum effort find buyer core business other business rbc capital market raise price target yahoo axiom capital raise goldman sachs raise johnson johnson also get several price target hike day provider health care product beat earning view raise full year ep sale guidance rbc capital market hike price target goldman sachs raise barclay raise share johnson johnson rise boee lose be downgrade underperform bank america aerospace giant well rival airbus eadsy supplier have cut job recently lower fuel price prompt airline fly older plane seek discount new one unitedhealth unh price target be hike mizuho have buy rating stock tuesday insurer top estimate say exit most obamacare exchange share climb teva pharmaceutical teva price target be raise rbc capital market rate stock outperform teva share dip image provide shutterstock
450,JNJ,regeneron pharmaceutical regn say monday experimental antibody arthritis pain succeed mid stage trial share be flat early trading result be expect study enrolled sufferer moderate severe hip knee pain be unsuccessful standard painkiller week treatment group take regeneron fasinumab have improve more point point pain scale significantly better placebo group group take fasinumab experience adverse event regeneron say include inflammatory joint pain prickle burn sensation skin numbness swell investigator also do extensive imaging subject class medicine fasinumab belong nerve growth factor ngf antibody have be associate joint damage wound exclude subject due imaging result patient remainder suffer subchondral insufficiency fracture stress fracture abnormal bone regeneron stock be early trading stock market today share touch month late march regeneron stock have weak ibd composite rating putt lower half stock basis key metric such earning sale growth regeneron have already signale trial be go well earlier year start large phase trial drug so result weren especially surprising analyst also lose potential competitor late march johnson johnson jnj stop development own ngf antibody fulranumab be late stage trial arthritis pain rbc capital market analyst adnan butt write time decision be base pipeline prioritization not problem drug monday butt praise effectiveness fasinumab trial write safety bear watch overall program succeed be blockbuster candidate other be upside driver come regulatory mechanistic safety concern hence be not major focus investor time aside development cost timeline standpoint butt write research note
451,JNJ,long await entry hp inc hpq printer market begin tuesday partner include nike nke autodesk adsk protolab prlb bmw new printer line call hp jet fusion printing solution revolutionize design prototyp manufacturing first time deliver superior quality physical part time faster half cost current print system hp say press release hp compete system ddd stratasys ssys largest provider printer other hp be offer printer be hp jet fusion printer design prototyp jet fusion printer design prototyp short run manufacturing need pricing model start be deliver late pricing model start delivery hp say autodesk software partner include materialise mtls siemens nike bmw proto lab co development partner strategic partner also include jabil circuit jbl johnson johnson jnj shapeway hp stock fall stock market today hp stock have be day line most month system stock rise nearly tuesday stratasys stock rise nearly
452,JNJ,giant cardiac device agree merge thursday abbott laboratory announce agreement acquire st jude medical stj deal worth abbott agree pay abbott share st jude share base abbott day average share price deal value st jude share apiece st jude stock be more morning trading stock market today abbott stock be more abbott say deal add cent ep next year cent follow year expect save cost combination abbott also assume refinance st jude debt move greatly enlarge abbott cardiovascular device business now represent revenue st jude medical strong position heart failure device atrial fibrillation cardiac rhythm management complement abbott lead position coronary intervention transcatheter mitral repair say abbott press release together company compete nearly area cardiovascular market hold position large high growth cardiovascular device market leerink analyst danielle antalffy agree st jude flat negative sale growth last few year picked write research note set continue abbott look be grow only low single digit antalffy also write compete bid be unlikely most logical buyer abbott view be johnson johnson jnj antalffy write meeting mid management emphasize company be not interested deem value market medtech specifically call cardiac rhythm management nearly st jude total sale drug eluting stent deal announcement come busy day medical field biotech medivation mdvn confirm have receive unsolicited bid big pharma sanofi sny abbvie abbv used be abbott biopharma division be spun agree buy cancer focuse biotech stemcentrx
453,JNJ,share medical product maker baxter international bax hit time high tuesday company beat estimate raise guidance baxter earning exclude time item rise year earlier quarter cent share beating analyst consensus cent accord thomson reuter sale decline beating wall street number exclude foreign exchange impact sale rise baxter add cent full year ep guidance now last year company say constant currency sale growth be have previously guide second quarter baxter forecast earning cent share top analyst average estimate cent say sale grow even include fx impact street have expect slight decline baxter stock hit new high early trading stock market today afternoon trading share be less baxter product include iv system dialysis machine surgical equipment be sell mainly hospital market have be look strong earning season accord leerink analyst danielle antalffy now third consecutive growth quarter consecutive quarters low single digit decline serve encourage datum point addition johnson johnson jnj st jude medical stj abbott laboratory report last week support potential trend improve procedure volume overall antalffy write research note fortune hospital stock support view medical hospital group have be fastest rise ibd industry group leap week present
454,JNJ,big pharma eli lilly lly issue mixed first quarter earning guidance tuesday send stock early trading lilly earning exclude time item shrank year earlier quarter cent share miss analyst consensus cent accord thomson reuter revenue rise beating consensus lilly add cent ep guidance range now also raise sale guidance slightly same time shave percentage point gross margin guidance now also lift guidance sale general administrative spending lilly stock be nearly morning trading stock market today improve foreign exchange rate be responsible much upside cent share tax benefit same time bottom line be hit rise expense include milestone payment biotech partner incyte incy submission approval jointly develop drug baricitinib level individual product diabetes drug humalog provide biggest surprise sale fall prior year miss consensus accord evercore isi lilly say demand drug have actually increase so have rebate discount lilly negotiate payer lilly say do not expect downtrend continue rest year revenue newer diabetes drug jardiance double compare last year lilly split take partner boehringer ingelheim only receive sale beat expectation lilly say take more share grow sglt class diabetes drug perhaps accounting johnson johnson jnj sglt drug invokana show report last week leerink analyst seamus fernandez write be various upside report expect limit impact investor concern significant miss diminish focus shift abemaciclib datum asco american society clinical oncology meeting june conclusion expedition trial solanezumab alzheimer disease write research note
455,JNJ,stock turn lower afternoon trading friday bigger expect increase retail sale dow jone industrial average fall fall day move average neither have close day line feb nasdaq have be key support level volume stock market today be tracking lower same time thursday drug stock be biggest gainer oil retail transport stock fall endo international endp rise heavy volume try stem sharp decline have see stock drop lowest level federal probe relationship company manage prescription benefit other company johnson johnson jnj merck mrk have be contact part investigation accord reuter recently valeant pharmaceutical vrx be force end ty pharmacy benefit manager philidor bill practice valeant be week high valeant rise friday intraday allergan agn hasn be name investigation rise more afternoon trading botox maker be part generic drug industry group be best performer friday department store retailer have bad day government report show retail sale rise more expect april jwn plunge profit drop cent share much wall street have expect also issue disappointing full year guidance jcpenney jcp be nearly mixed earning report brick mortar retailer be suffering shopper increasingly buy online site such amazon com amzn gaming related stock be bright spot friday nvidia nvda make graphic chip used computer game console mobile device jump more record high strong quarterly earning report nvidia be now breaking cup handle base march
456,JNJ,big biotech amgen beat wall street estimate offer mixed guidance late wednesday send stock modestly hour trading
457,JNJ,amgen amgn report adjust earning share year earlier beating analyst consensus cent accord thomson reuter
458,JNJ,revenue climb consensus best gain several year
459,JNJ,amgen lift full year guidance compare beat imply underperform add revenue guidance now raise ep guidance cent now be wall street estimate
460,JNJ,amgen also provide preliminary guidance be line revenue estimate consensus ep amgen guide sale ep range
461,JNJ,rbc capital market analyst michael yee note issue preliminary target be surprise move perhaps imply management confidence business amgen usually doesn give such guidance report
462,JNJ,yee add experience show company start annual guidance conservatively then raise year ve do year now
463,JNJ,enbrel sale unsustainable
464,JNJ,half revenue beat come amgen top seller rheumatoid arthritis drug enbrel sale rise year earlier vs consensus amgen say sale be drive net selling price low inventory level prior year period offset partially impact competition
465,JNJ,neulasta drug beat consensus rise only
466,JNJ,evercore isi analyst mark schoenebaum note amgen indicated abnormally large purchase enbrel neulasta explain guidance doesn call continuation outperformance
467,JNJ,enbrel beat be drive mostly price increase product continue lose share grow market unit be quarter quarter share decline write email client
468,JNJ,enbrel have grow list rival rheumatoid arthritis include abbvie abbv humira johnson johnson jnj stelara newer product pfizer pfe xeljanz
469,JNJ,conference call analyst ceo robert bradway talk newer drug amgen be track meet goal new drug approval year fda approve melanoma drug imlygic day earning report potential blockbuster cholesterol drug repatha august
470,JNJ,amgen stock rise regular trade share be late big biotech amgen beat wall street estimate offer mixed guidance late wednesday send stock modestly hour trading amgen amgn report adjust earning share year earlier beating analyst consensus cent accord thomson reuter revenue climb consensus best gain several year amgen lift full year guidance compare beat imply underperform add revenue guidance now raise ep guidance cent now be wall street estimate amgen also provide preliminary guidance be line revenue estimate consensus ep amgen guide sale ep range rbc capital market analyst michael yee note issue preliminary target be surprise move perhaps imply management confidence business amgen usually doesn give such guidance report yee add experience show company start annual guidance conservatively then raise year ve do year now enbrel sale unsustainable half revenue beat come amgen top seller rheumatoid arthritis drug enbrel sale rise year earlier vs consensus amgen say sale be drive net selling price low inventory level prior year period offset partially impact competition neulasta drug beat consensus rise only evercore isi analyst mark schoenebaum note amgen indicated abnormally large purchase enbrel neulasta explain guidance doesn call continuation outperformance enbrel beat be drive mostly price increase product continue lose share grow market unit be quarter quarter share decline write email client enbrel have grow list rival rheumatoid arthritis include abbvie abbv humira johnson johnson jnj stelara newer product pfizer pfe xeljanz conference call analyst ceo robert bradway talk newer drug amgen be track meet goal new drug approval year fda approve melanoma drug imlygic day earning report potential blockbuster cholesterol drug repatha august amgen stock rise regular trade share be late
471,JNJ,big pharma abbvie abbv beat analyst estimate issue year guidance be expectation friday morning send stock sharply early trading abbvie adjust earning rise year earlier quarter share beating analyst consensus cent accord thomson reuter sale climb estimate
472,JNJ,etf investor have lately be seek safe sound stable stock market turn more volatile stock likely make whiz bang move be get lot less love deterioration credit market condition be contribute choppiness stock market russ blackrock global chief investment strategist write nov report continue favor tilt quality add momentum have be effective style past several year market generally marched upward have struggle volatility begin rise late summer ishare msci usa quality factor qual gain past month nov vs ishare msci usa momentum factor mtum year date basis momentum etf have outperformed quality etf also come top qual quality etf home profitable company successful investing track index target large midcap stock high return equity low debt burden more consistent earning previous year stock be weight base degree exhibit characteristic market capitalization skews portfolio stock durable competitive advantage morningstar analyst alex bryan write recent report fund be better position many peer market downturn expect underperform momentum peer stock market rally strongly exchange trade fund hold stock microsoft msft be largest hold johnson johnson jnj apple aapl gilead gild berkshire hathaway brkb round top mtum momentum etf focus winning stock follow index large midcap stock strong risk adjust price momentum assess price movement prism risk pay allow etf investment strategy hold stock winner recent performance be likely persist say bryan fund focus risk adjust momentum help reduce volatility turnover add flip side etf investment strategy offer diluted momentum effect rebalance only twice year also hold stock amazon com amzn be largest hold follow facebook fb visa starbucks sbux home depot hd facebook visa starbucks be member ibd elite leaderboard list include stock biggest potential big gain etfs launch offer expense ratio dollar annual fee invest qual yield vs mtum etfs fall stock market today follow aparna narayanan twitter ibd_anarayanan
473,JNJ,surgeon predict big increase robot assist surgery next year especially colorectal hernia procedure accord survey rbc capital market surgery today involve use robot figure hit year year survey indicate most surgeon be quite satisfied
474,JNJ,midcap drugmaker jazz pharmaceutical halozyme therapeutic depome be move stock market tuesday report earning late monday round mixed earning season beleaguered sector jazz pharmaceutical jazz get downgrade several price target cut lead drug xyrem decline sequentially first time ever lead quarterly miss sale rise year earlier quarter miss analyst consensus more earning gain share cent shy consensus jazz narrow full year guidance way lower midpoint revenue ep now expect earning share vs last year revenue be guide vs jazz also say earning conference call analyst monday have be disruption production xyrem narcolepsy treatment xyrem be classify potentially addictive substance distribute central pharmacy risk evaluation mitigation strategy rem new rem go effect late august bring different form procedure temporarily snarl work jazz executive say executive also say jazz drug candidate leukotac have fail late stage trial graft vs host disease halt development drug mizuho analyst irina koffler downgrade jazz neutral outperform partly revise valuation methodology also soft outlook model consensus ep longer support buy rating spite cautiously optimistic outlook xyrem generic settlement koffler write canaccord genuity cut price target piper jaffray cut leerink cut investment bank maintain buy equivalent rating jazz stock xyrem miss leukotac failure be time event shouldn affect jazz ongoing fundamental write canaccord analyst corey davis respect valuation specialty pharma sector be period significant volatility be increase discount rate dcf discount cash flow analysis account risk associate market jazz plunge early trading stock market today afternoon trading be depome hike drug maker depome depo be head opposite direction beat estimate raise guidance revenue more double beating wall street average estimate earning jump way cent cent share exclude time item top consensus cent depome add full year product sale guidance range now do not guide ep say total earning be previous range depome ceo james schoeneck credit growth pain medicine nucynta company relaunch june acquire johnson johnson jnj schoeneck reiterate opposition horizon pharma hznp unsolicited stock bid depome note depome have file confidentiality suit horizon be due hearing nov depome stock pop almost early trading tuesday be afternoon trading halozyme fall shortbiotech halozyme therapeutic halo be tuesday afternoon result miss expectation affirm guidance halozyme revenue climb year earlier quarter miss consensus more lose cent share cent more street expect halozyme maintain full year revenue guidance last year do not guide ep say operate expense be burn cash jpmorgan analyst jessica fye write more consequential news call be description halozyme phase trial sole product pegph aids delivery injectable drug combination celgene celg cancer drug abraxane generic drug gemcitabine newly diagnosed pancreatic cancer study have adaptive design pfs progression free survival os overall survival primary endpoint include interim look once pfs be reach depend magnitude benefit potentially support registration point fye write research note net net remain positive opportunity pegph first line high hyaluronan pancreatic cancer well potential broaden additional tumor type halozyme stock touch time high july halozyme biom biotech group general be hit hard stock market late summer downturn ibd company medical biom biotech industry group be touch record high july now rank group track follow amy reeve twitter ibd_areeve facebook
475,JNJ,company be increasingly putt cash dividend buyback trend benefit shareholder company increase sum spend buyback dividend accord new report capital iq
476,JNJ,moreover amount allocate repurchase dividend have rise past year see trend continue analyst write
477,JNJ,amount devote dividend buyback vary greatly sector sector company company
478,JNJ,financial sector market leader today outlook be good analyst expect dividend rise year well most other sector
479,JNJ,pharmaceutical have be largest most consistent payer dividend study say industry single handedly account total dividend
480,JNJ,company ibd dividend leader screen pfizer pfe johnson johnson jnj be most generous pfizer have be biggest payer dividend johnson johnson follow
481,JNJ,industrial capital iq doesn expect much change dividend buyback have be expand
482,JNJ,general electric ge spend nearly dividend dwarf other major industrial company
483,JNJ,telecom giant verizon vz command yield capital iq analyst think telecom focus more reduce debt
484,JNJ,utility tend pay more half profit dividend continue raise payout next several year average annual rate duke energy duk southern co so dominion resource make ibd utility leader screen top sector dividend company be increasingly putt cash dividend buyback trend benefit shareholder company increase sum spend buyback dividend accord new report capital iq moreover amount allocate repurchase dividend have rise past year see trend continue analyst write amount devote dividend buyback vary greatly sector sector company company financial sector market leader today outlook be good analyst expect dividend rise year well most other sector pharmaceutical have be largest most consistent payer dividend study say industry single handedly account total dividend company ibd dividend leader screen pfizer pfe johnson johnson jnj be most generous pfizer have be biggest payer dividend johnson johnson follow industrial capital iq doesn expect much change dividend buyback have be expand general electric ge spend nearly dividend dwarf other major industrial company telecom giant verizon vz command yield capital iq analyst think telecom focus more reduce debt utility tend pay more half profit dividend continue raise payout next several year average annual rate duke energy duk southern co so dominion resource make ibd utility leader screen top sector dividend
485,JNJ,major etfs limp finish line tuesday investor eye fresh batch weak economic datum china blue chip earning gold miner lead sector focuse stock exchange trade fund largest gold etf extend gain past month close high yesterday intel intc jpmorgan chase jpm slump hour report quarterly number chip maker earning decline year year drag flat revenue biggest bank meanwhile miss revenue profit spdr dow jone industrial average dium hold index stock allocate roughly asset company hold johnson johnson jnj give tuesday medical giant beat earning miss revenue open powershare qqq qqq tracking largest nonfinancial stock nasdaq composite index allocate asset intel sprott gold miner sgdm pop stock market today spot gold price rise tuesday spdr gold share gld largest etf hold physical bullion finished highest close early july yellow metal be rally outlook rate hike year dim get further boost tuesday surprisingly weak chinese trade datum revive fear strength world second largest economy china etfs wilted tuesday global china consumer chiq nudge lower market vector chinaamc sme chinext cnxt here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs spdr spy rs ishare msci eafe efa rs powershare qqq qqq rs vanguard ftse emerge market vwo rs ishare core aggregate bond agg rs ishare russell iwm rs ishare core mid cap ijh rs spdr gold share gld rs spdr dow jone industrial average dium rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
486,JNJ,specialty drugmaker mallinckrodt mnk offer fiscal guidance tuesday follow sale imaging unit revenue growth solid ep light side stock briefly rally be drag drug stock sell mallinckrodt say fiscal year end expect make share bracketing analyst consensus midpoint bit accord thomson reuter company didn give revenue range say expect net sale growth least exclude foreign currency impact analyst have forecast total revenue last fiscal year estimate typically include fx impact mallinckrodt also provide guidance business segment say brand drug business grow least drive pricey immunology drug achthar injectable pain medicine ofirmev generic drug sale still suffering fda revocation designation mallinckrodt generic version johnson johnson jnj concerta be expect fall remain imaging business sale contrast medium delivery system cmds business france guerbet be see shrink ub analyst marc goodman write consensus number not include cmds business so hard tell exactly be expect management apple apple analysis sell side number suggest top line growth ep goodman add own ep estimate be guidance largely have not yet incorporate newly issue debt hit ep cent be review estimate overall be good guidance nomura analyst shibani malhotra write guidance be basically expect growth brand drug be upside other hand generic shrinkage be even thought mallinckrodt stock rise much early trading stock market today midday head south rest market afternoon trading be nearly stock be high hit back march hurt general drug stock sell miss sale estimate last quarterly report nonetheless retain very strong ep rank follow amy reeve twitter ibd_areeve facebook
487,JNJ,medical giant johnson johnson jnj get earning season shaky start medical stock tuesday miss revenue estimate beating ep view only due lower tax rate
488,JNJ,say earning totale share exclude time item year earlier quarter beating analyst consensus cent accord thomson reuter revenue shrank short consensus
489,JNJ,company raise low end full year ep guidance nickel now however rbc capital market analyst glenn novarro write quarter earning include tax benefit worth cent share accounting beat
490,JNJ,device diagnostic business have be soft number quarters usually pharma business have make didn happen quarter
491,JNJ,pharmaceutical revenue year year report constant currency miss consensus estimate owing expect oncology portfolio result write novarro research note
492,JNJ,single biggest oncology product be prostate cancer drug zytiga sale shrank miss consensus say novarro sale blood cancer drug imbruvica launch year more triple be roughly line consensus accord evercore isi analyst mark schoenebaum
493,JNJ,imply potential net sale abbvie abbv report schoenebaum write email client abbvie inherited profit sharing arrangement acquire imbruvica developer pharmacyclic earlier year
494,JNJ,product launch diabetes drug invokana miss consensus grow year year single biggest selling drug remicade miss fellow immunology drug stelara simponi beat consensus
495,JNJ,device business miss estimate board face competition surgery medtronic mdt newly enlarged area covidien buyout spinal market various player orthopedic novarro write company be lose share such rival stryker syk zimmer biomet zbh overall market be soft thus negative company
496,JNJ,also announce stock buyback plan be finance debt issuance
497,JNJ,stock open few point late morning be flat
498,JNJ,follow amy reeve twitter ibd_areeve facebook medical giant johnson johnson jnj get earning season shaky start medical stock tuesday miss revenue estimate beating ep view only due lower tax rate say earning totale share exclude time item year earlier quarter beating analyst consensus cent accord thomson reuter revenue shrank short consensus company raise low end full year ep guidance nickel now however rbc capital market analyst glenn novarro write quarter earning include tax benefit worth cent share accounting beat device diagnostic business have be soft number quarters usually pharma business have make didn happen quarter pharmaceutical revenue year year report constant currency miss consensus estimate owing expect oncology portfolio result write novarro research note single biggest oncology product be prostate cancer drug zytiga sale shrank miss consensus say novarro sale blood cancer drug imbruvica launch year more triple be roughly line consensus accord evercore isi analyst mark schoenebaum imply potential net sale abbvie abbv report schoenebaum write email client abbvie inherited profit sharing arrangement acquire imbruvica developer pharmacyclic earlier year product launch diabetes drug invokana miss consensus grow year year single biggest selling drug remicade miss fellow immunology drug stelara simponi beat consensus device business miss estimate board face competition surgery medtronic mdt newly enlarged area covidien buyout spinal market various player orthopedic novarro write company be lose share such rival stryker syk zimmer biomet zbh overall market be soft thus negative company also announce stock buyback plan be finance debt issuance stock open few point late morning be flat follow amy reeve twitter ibd_areeve facebook
499,JNJ,share big pharma eli lilly lly rise friday credit suisse upgrade rating company largely strength diabetes franchise analyst vamil divan lift rating lilly stock outperform neutral raise price target late thursday divan highlighted recent empa reg outcome trial establish
500,JNJ,strong open stock fade mixed performance midday wednesday nasdaq fall weigh weakness adobe system adbe tesla motor tsla dow jone industrial average add johnson johnson jnj merck mrk boee ba be early leader dow
501,JNJ,nyse volume be tracking higher tuesday level stock market today nasdaq volume be tracking close tuesday level
502,JNJ,adobe gap day move average fall company issue lukewarm fiscal guidance
503,JNJ,tesla slump negative analyst chatter
504,JNJ,amgen amgn be high still rise pharmacy benefit manager express script esrx name amgen repatha prefer supplemental cholesterol reduction treatment other praluent be make sanofi sny regeneron pharmaceutical regn sanofi share slip regeneron climb early trade
505,JNJ,ipo news pure storage pstg price last night midpoint propose range provider flash memory base enterprise storage hardware open share be recently trading
506,JNJ,earning winner include ibd firm global payment gpn share gap week base rise result top expectation outlook be solid company also declare stock split
507,JNJ,follow ken shreve twitter ibd_kshreve facebook strong open stock fade mixed performance midday wednesday nasdaq fall weigh weakness adobe system adbe tesla motor tsla dow jone industrial average add johnson johnson jnj merck mrk boee ba be early leader dow nyse volume be tracking higher tuesday level stock market today nasdaq volume be tracking close tuesday level adobe gap day move average fall company issue lukewarm fiscal guidance tesla slump negative analyst chatter amgen amgn be high still rise pharmacy benefit manager express script esrx name amgen repatha prefer supplemental cholesterol reduction treatment other praluent be make sanofi sny regeneron pharmaceutical regn sanofi share slip regeneron climb early trade ipo news pure storage pstg price last night midpoint propose range provider flash memory base enterprise storage hardware open share be recently trading earning winner include ibd firm global payment gpn share gap week base rise result top expectation outlook be solid company also declare stock split follow ken shreve twitter ibd_kshreve facebook
508,JNJ,health care giant johnson johnson jnj bristol myer squibb bmy get upgrade buy tuesday analyst see bright future drug current market pound ub analyst marc goodman raise price target bristol myer upgrade stock buy neutral lift sale estimate
509,JNJ,stock wobble open then scramble healthy gain tuesday even europe market reversed mild loss nasdaq power biotechs drugmaker rebound vengeance climb dow jone industrial pull
510,JNJ,volume start mixed stock market today higher nasdaq fraction lower nyse relative trade same time monday
511,JNJ,housing news be also mixed case shiller city home price index august be equal better july gain group trim consensus estimate have look increase
512,JNJ,consumer view be less conflict conference board consumer confidence index hit september be nice step august revise tally far consensus estimate dial
513,JNJ,stock johnson johnson jnj lead dow deutsche bank upgrade stock buy hold hold price target steady mcdonald mcd be next dow lineup rise more credit suisse upgrade
514,JNJ,nasdaq company wynn resort wynn discovery communication disca fall respectively yahoo yhoo bolster index nearly gain
515,JNJ,japan base stock be stress tokyo nikkei drop tuesday session toyota motor tm honda motor hmc slip more sony sne fall more
516,JNJ,india base bank trend higher country central bank trim interest rate half percent hdfc bank hdb icici bank ibn rise more
517,JNJ,morning wild early move thinly trade life insurer phoenix pnx spiked buyout offer nassau reinsurance group esperion therapeutic espr dive ann arbor mich base biotech give update design phase trial etc oral cholesterol treatment pollution control service provider team tisi tumble guide fiscal first quarter revenue earning consensus forecast
518,JNJ,leader cal maine food calm bounce nearly fight take back ground dive monday gain left share still week move average month consolidation
519,JNJ,amn healthcare service scout low end drop put san diego base medical staffing operation week stock trip sell signal cut week move average heavy trade monday
520,JNJ,stock oil price upshifted nearly lift west texas intermediate back barrel brent crude gold remain fraction lower ounce stock wobble open then scramble healthy gain tuesday even europe market reversed mild loss nasdaq power biotechs drugmaker rebound vengeance climb dow jone industrial pull volume start mixed stock market today higher nasdaq fraction lower nyse relative trade same time monday housing news be also mixed case shiller city home price index august be equal better july gain group trim consensus estimate have look increase consumer view be less conflict conference board consumer confidence index hit september be nice step august revise tally far consensus estimate dial stock johnson johnson jnj lead dow deutsche bank upgrade stock buy hold hold price target steady mcdonald mcd be next dow lineup rise more credit suisse upgrade nasdaq company wynn resort wynn discovery communication disca fall respectively yahoo yhoo bolster index nearly gain japan base stock be stress tokyo nikkei drop tuesday session toyota motor tm honda motor hmc slip more sony sne fall more india base bank trend higher country central bank trim interest rate half percent hdfc bank hdb icici bank ibn rise more morning wild early move thinly trade life insurer phoenix pnx spiked buyout offer nassau reinsurance group esperion therapeutic espr dive ann arbor mich base biotech give update design phase trial etc oral cholesterol treatment pollution control service provider team tisi tumble guide fiscal first quarter revenue earning consensus forecast leader cal maine food calm bounce nearly fight take back ground dive monday gain left share still week move average month consolidation amn healthcare service scout low end drop put san diego base medical staffing operation week stock trip sell signal cut week move average heavy trade monday stock oil price upshifted nearly lift west texas intermediate back barrel brent crude gold remain fraction lower ounce
521,JNJ,stock be poise weak start tuesday worry china economic growth return nasdaq future drop point vs fair value future lose point future dow jone industrial average slump point
522,JNJ,monday stock edge higher dull session leader have nice day
523,JNJ,china world second largest economy see import plunge september far expect export fall shanghai composite reversed gain hang seng lose
524,JNJ,other foreign stock market be lower france cac germany dax shed respectively
525,JNJ,premarket action beer brewer anheuser busch inbev bud rise more sabmiller accept sweeten deal join force
526,JNJ,jetblue jblu drop nearly jpmorgan cut share neutral overweight trim price target jpmorgan also cut price target american airline aal unite continental ual be respectively
527,JNJ,jpmorgan raise target alaska air group alk delta air line dal southwest airline luv
528,JNJ,johnson johnson jnj fall report earning beat view lift low end full year profit outlook quarterly sale miss expectation due strong dollar
529,JNJ,earn share vs view revenue fall year analyst have expect company also announce share buyback
530,JNJ,earning season start kick high gear week blackhawk network hawk csx csx intel intc jpmorgan chase jpm report result close stock market today
531,JNJ,follow vincent mao twitter ibd_vmao stock be poise weak start tuesday worry china economic growth return nasdaq future drop point vs fair value future lose point future dow jone industrial average slump point monday stock edge higher dull session leader have nice day china world second largest economy see import plunge september far expect export fall shanghai composite reversed gain hang seng lose other foreign stock market be lower france cac germany dax shed respectively premarket action beer brewer anheuser busch inbev bud rise more sabmiller accept sweeten deal join force jetblue jblu drop nearly jpmorgan cut share neutral overweight trim price target jpmorgan also cut price target american airline aal unite continental ual be respectively jpmorgan raise target alaska air group alk delta air line dal southwest airline luv johnson johnson jnj fall report earning beat view lift low end full year profit outlook quarterly sale miss expectation due strong dollar earn share vs view revenue fall year analyst have expect company also announce share buyback earning season start kick high gear week blackhawk network hawk csx csx intel intc jpmorgan chase jpm report result close stock market today follow vincent mao twitter ibd_vmao
532,JNJ,stock hold mild gain quiet columbus day trade ahead busy week earning dow jone industrial average lead gain nasdaq climb finished volume be quiet board accord preliminary datum winner edge past loser nyse decliner outpaced advancer nearly margin nasdaq
533,JNJ,airline travel booker video game maker lead upside stock market today energy stock lag crude oil price fall barrel skywest skyw soar clear flat base buy point fast trade
534,JNJ,ibd stock advanced decline hawaiian extend gain fourth straight session rise new high share be extend past cup handle entry analyst expect carrier grow ep revenue dip report oct close
535,JNJ,other ibd stock volume include regeneron pharmaceutical regn gap rise nearly regain day move average overall biotech slide regeneron develop cholesterol treatment praluent sanofi sny have get boost news eli lilly lly end late stage trial experimental cholesterol drug lilly share sank
536,JNJ,universal insurance uve advanced trigger week hold rule rally more intraday cup handle buy point clear
537,JNJ,twitter twtr fall brisk trade report real time messaging platform plan announce companywide layoff week last monday twitter officially name interim ceo jack dorsey chief
538,JNJ,other internet player facebook fb alphabet googl add facebook say testing new app let user shop leave social network app
539,JNJ,earning watch tuesday include bank ozark ozrk blackhawk network hawk intel intc johnson johnson jnj jpmorgan chase jpm
540,JNJ,economic datum tap tuesday include treasury september budget report small business optimism index september national federation independent business fed james bullard be also schedule speak
541,JNJ,follow nancy gondo twitter ibd_ngondo stock hold mild gain quiet columbus day trade ahead busy week earning dow jone industrial average lead gain nasdaq climb finished volume be quiet board accord preliminary datum winner edge past loser nyse decliner outpaced advancer nearly margin nasdaq airline travel booker video game maker lead upside stock market today energy stock lag crude oil price fall barrel skywest skyw soar clear flat base buy point fast trade ibd stock advanced decline hawaiian extend gain fourth straight session rise new high share be extend past cup handle entry analyst expect carrier grow ep revenue dip report oct close other ibd stock volume include regeneron pharmaceutical regn gap rise nearly regain day move average overall biotech slide regeneron develop cholesterol treatment praluent sanofi sny have get boost news eli lilly lly end late stage trial experimental cholesterol drug lilly share sank universal insurance uve advanced trigger week hold rule rally more intraday cup handle buy point clear twitter twtr fall brisk trade report real time messaging platform plan announce companywide layoff week last monday twitter officially name interim ceo jack dorsey chief other internet player facebook fb alphabet googl add facebook say testing new app let user shop leave social network app earning watch tuesday include bank ozark ozrk blackhawk network hawk intel intc johnson johnson jnj jpmorgan chase jpm economic datum tap tuesday include treasury september budget report small business optimism index september national federation independent business fed james bullard be also schedule speak follow nancy gondo twitter ibd_ngondo
542,JNJ,stock finished week small gain volume be lighter interest feel be wane mkt do end week best close level month
543,JNJ,strength see last week be most likely attributable trader investor continue celebration latest release fomc mins mins release last week show fed member remain concern global growth risk pose economy never mind talk ready economy be normalization process begin end bottom line be do not appear be rate hike calendar anytime soon weekend paul ashworth chief economist capital economic have say
544,JNJ,admittedly be still employment report schedule release fomc meet december stage think take major turnaround payroll growth well month persuade official support december rate hike
545,JNJ,then sunday vacation imf policy meeting lima peru stanley fischer have say reuter then run follow headline story
546,JNJ,fed fischer say rate rise be expectation not commitment boy
547,JNJ,say federal reserve policymaker be still likely raise interest rate year be expectation not commitment change global economy push economy further course timing first rate increase subsequent adjustment federal fund rate target depend critical future development economy
548,JNJ,go say feel economy be still generate enough job continue make progress fed goal maximum employment inflation eventually rise keep central bank track raise rate year then quickly protected say be now more expose ever international event development china elsewhere have already influenced fed delay widely expect rate increase september
549,JNJ,morning wsj have many imf official urge fed get fed fatigue be now take hold talk back forth do nothing cause more instability anxiety global mkts so get together say stop madness suggest prefer sense certainty vs agony wait
550,JNJ,delay increase not solve situation be case emerge mkts have take too much debt then day reckon delay interest rate hike do not necessarily address issue
551,JNJ,now fatigue fed be fatigue feel presidential race hillary announce month prior election try work crowd only find crowd tired back forth happened lose credibility person grow exhaust hillary show start re focus energy etc world moved so be world now tire fed play side fence feel be
552,JNJ,now look rally see last session have lift major index back dma remove term resistance do mean rally continue take price sure not so fast be daily call come recession analyst strategist scream world be come end be just need break be early stage bear market sure remember part reality bear market be have strong short cover rally mkt try find fair value take look be new lower sideway channel build
553,JNJ,notice month sideway channel trade summer now notice break august take well outside lower band only bounce back test trend dma mid september then late september fall back test august lows only once again move test trend dma time moved thru seemingly breaking well next resistance be dma then dma look action clearly see look new sideway channel develop right old sideway channel now be true then just maybe mkt be short term overbought condition mean see leg anytime be leg now earning season be find
554,JNJ,week bring slew macro datum retail sale exp ex auto gas ppi ex food energy addition get empire state manufacturing cpi ex food energy earning front be big week jpm due tomorrow bell follow bac wfc gs later week throw jnj intc blk csx nflx be sure be interesting week remember be not so much actual earning be history be profit margin future outlook role china play outlook china be black swan
555,JNJ,morning future be flat be columbus day here state bank bond mkts be close do not expect much action today investor await datum later week
556,JNJ,be say look more action emc morning do learn chatter dell emc be true dell announce plan acquire emc bil deal be worth sh cash vmware be oct close price rumor start clearly person know possibility end september stock be trading share start break reason just sayin
557,JNJ,take good care
558,JNJ,kp
559,JNJ,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate stock finished week small gain volume be lighter interest feel be wane mkt do end week best close level month strength see last week be most likely attributable trader investor continue celebration latest release fomc mins mins release last week show fed member remain concern global growth risk pose economy never mind talk ready economy be normalization process begin end bottom line be do not appear be rate hike calendar anytime soon weekend paul ashworth chief economist capital economic have say admittedly be still employment report schedule release fomc meet december stage think take major turnaround payroll growth well month persuade official support december rate hike then sunday vacation imf policy meeting lima peru stanley fischer have say reuter then run follow headline story fed fischer say rate rise be expectation not commitment boy say federal reserve policymaker be still likely raise interest rate year be expectation not commitment change global economy push economy further course timing first rate increase subsequent adjustment federal fund rate target depend critical future development economy go say feel economy be still generate enough job continue make progress fed goal maximum employment inflation eventually rise keep central bank track raise rate year then quickly protected say be now more expose ever international event development china elsewhere have already influenced fed delay widely expect rate increase september morning wsj have many imf official urge fed get fed fatigue be now take hold talk back forth do nothing cause more instability anxiety global mkts so get together say stop madness suggest prefer sense certainty vs agony wait delay increase not solve situation be case emerge mkts have take too much debt then day reckon delay interest rate hike do not necessarily address issue now fatigue fed be fatigue feel presidential race hillary announce month prior election try work crowd only find crowd tired back forth happened lose credibility person grow exhaust hillary show start re focus energy etc world moved so be world now tire fed play side fence feel be now look rally see last session have lift major index back dma remove term resistance do mean rally continue take price sure not so fast be daily call come recession analyst strategist scream world be come end be just need break be early stage bear market sure remember part reality bear market be have strong short cover rally mkt try find fair value take look be new lower sideway channel build notice month sideway channel trade summer now notice break august take well outside lower band only bounce back test trend dma mid september then late september fall back test august lows only once again move test trend dma time moved thru seemingly breaking well next resistance be dma then dma look action clearly see look new sideway channel develop right old sideway channel now be true then just maybe mkt be short term overbought condition mean see leg anytime be leg now earning season be find week bring slew macro datum retail sale exp ex auto gas ppi ex food energy addition get empire state manufacturing cpi ex food energy earning front be big week jpm due tomorrow bell follow bac wfc gs later week throw jnj intc blk csx nflx be sure be interesting week remember be not so much actual earning be history be profit margin future outlook role china play outlook china be black swan morning future be flat be columbus day here state bank bond mkts be close do not expect much action today investor await datum later week be say look more action emc morning do learn chatter dell emc be true dell announce plan acquire emc bil deal be worth sh cash vmware be oct close price rumor start clearly person know possibility end september stock be trading share start break reason just sayin take good care kpkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
560,JNJ,share eli lilly lly jump more year high thursday company present more evidence diabetes drug jardiance reduce death heart failure annual european association study diabetes lilly partner boehringer ingelheim present detail massive empa reg outcome trial study long term cardiovascular effect jardiance first headline last month lilly ingelheim report jardiance reduce death cardiovascular cause oddly enough do not reduce risk nonfatal heart attack stroke cause mortality be cut hospitalization heart failure be lilly note jardiance be first diabetes drug show kind effect address burden cardiovascular event include death be core diabetes care now single diabetes medication have be associate reduction mortality lead investigator bernard zinman say statement evercore isi analyst mark schoenebaum report slide study generate applause meeting also note have larger implication field diabetes care jardiance be sglt inhibitor same class drug johnson johnson jnj invokana astrazeneca azn farxiga other hand merck mrk similar outcome study januvia drug different class call dpp inhibitor do not find cardiovascular benefit didn do harm base datum think sglt class be likely be bigger dpp class year schoenebaum write email client remember year additional sale add lilly ep peak sale estimate be currently merck sell januvia today invert schoenebaum add astrazeneca be also conduct outcome study sglt inhibitor result due respectively give clearer idea be class effect new datum be announce just noon et thursday send lilly stock nearly later thursday afternoon merck stock be more afternoon trading stock market today follow amy reeve twitter ibd_areeve facebook
561,JNJ,special report mutual fund strategy volatility stock market send investor scurry cover favor dividend be probably less likely panic select carefully dividend stock offer best world stock price performance steady payout so dividend fund be key component long term mutual fund investing here be
562,JNJ,vanguard continue lure etf investor exchange trade fund absorb more new investor money past year year date aug vanguard etfs see net inflow more other rival vanguard be follow ishare net inflow wetf deutsche tracker first trust accord independent research firm etfgi focus low cost have make vanguard etfs popular choice successful investing average etfs cost less other company bid ask spread be typically few penny share many investor vanguard consistent ethos be low cost run etfs so fee just cover cost say deborah fuhr manage partner etfgi pay lower fee help performance vanguard brokerage service couple global brand recognition distribution be help gather net new asset vanguard have be assist financial advisor retail investor institution be able use etfs fuhr say user brokerage service do not pay commission buy selling vanguard etfs here look most popular vanguard etfs term net inflow past year etf voo total asset billionexpense ratio yield index broadly diversify market cap weight exposure large stockstotal stock holding top holding apple aapl microsoft msft exxon mobil xom johnson johnson jnj well fargo wfc asset top holding year date return noteworthy voo have lowest expense ratio etf tracking accord morningstar inc total stock market etf vti total asset expense ratio yield index cover entire stock market total stock holding top holding apple microsoft exxon mobil johnson johnson well fargo asset top holding year date return noteworthy vto have lowest cost etf offer such broad portfolio stock ftse develop market vea total asset expense ratio yield index broad market cap weight exposure foreign develop market stock total number stock holding top holding nestle nsrgy novartis nvs roche hold rhhby hsbc holding hsbc toyota motor tm asset top holding year date return noteworthy vea enhance diversification add exposure small cap canadian stock course index transition late vea be tracking lower stock market today late trade follow aparna narayanan twitter ibd_anarayanan
563,JNJ,yahoo yhoo stock price moved higher tuesday price target cut announce plan move ahead spinoff alibaba group hold baba sunedison sune mcdonald mcd blackberry bbry patriot missile supplier raytheon rtn also see analyst action mizuho security cut yahoo price target still maintain buy
564,JNJ,antibiotic specialist tetraphase pharmaceutical ttph stock crash nearly get multiple downgrade wednesday company lead drug eravacycline fail clinical trial
565,JNJ,late tuesday tetraphase say ignite phase clinical trial complicate urinary tract infection cuti eravacycline do not stack standard treatment levofloxacin better know johnson johnson jnj levaquin
566,JNJ,plan further analyze datum provide update have discuss datum plan path forward regulatory agency tetraphase ceo guy macdonald say statement previously announce positive datum ignite phase clinical trial eravacycline administer intravenously complicate intra abdominal infection do meet primary endpoint demonstrate high cure rate prevalent gram negative pathogen favorable safety profile
567,JNJ,tetraphase doesn have product market yet stock have be fly high touch record high july hold ibd relative strength rating putt top stock performance past month least stock strength seem be buyout speculation fellow antibiotic maker cubist durata be acquire merck mrk actavis now allergan agn respectively
568,JNJ,midday trading stock market today tetraphase stock be month low
569,JNJ,brean needham suntrust stifel nomura downgrade stock neutral equivalent analyst say be surprised outcome positive datum study last september nomura analyst ian somaiya write news not only cut cuti market raise question drug approval timeline complicate intra abdominal infection ciai
570,JNJ,give negative result ignite believe tetraphase need run additional phase iii trial somaiya write downgrade note lower price target
571,JNJ,guggenheim analyst louise chen lower price target maintain buy rating be more confident somaiya tetraphase win have run ciai trial
572,JNJ,thing give confidence happen chen write research note
573,JNJ,similar drug have be approve only phase datum accord tetraphase have more datum drug
574,JNJ,base discussion fda achaogen akao expect plazomicin be approve cuti only successful trial
575,JNJ,eu new antibiotic guidance require only trial approval iai uti be target infection note agency
576,JNJ,follow amy reeve twitter ibd_areeve facebook antibiotic specialist tetraphase pharmaceutical ttph stock crash nearly get multiple downgrade wednesday company lead drug eravacycline fail clinical trial late tuesday tetraphase say ignite phase clinical trial complicate urinary tract infection cuti eravacycline do not stack standard treatment levofloxacin better know johnson johnson jnj levaquin plan further analyze datum provide update have discuss datum plan path forward regulatory agency tetraphase ceo guy macdonald say statement previously announce positive datum ignite phase clinical trial eravacycline administer intravenously complicate intra abdominal infection do meet primary endpoint demonstrate high cure rate prevalent gram negative pathogen favorable safety profile tetraphase doesn have product market yet stock have be fly high touch record high july hold ibd relative strength rating putt top stock performance past month least stock strength seem be buyout speculation fellow antibiotic maker cubist durata be acquire merck mrk actavis now allergan agn respectively midday trading stock market today tetraphase stock be month low brean needham suntrust stifel nomura downgrade stock neutral equivalent analyst say be surprised outcome positive datum study last september nomura analyst ian somaiya write news not only cut cuti market raise question drug approval timeline complicate intra abdominal infection ciai give negative result ignite believe tetraphase need run additional phase iii trial somaiya write downgrade note lower price target guggenheim analyst louise chen lower price target maintain buy rating be more confident somaiya tetraphase win have run ciai trial thing give confidence happen chen write research note similar drug have be approve only phase datum accord tetraphase have more datum drug base discussion fda achaogen akao expect plazomicin be approve cuti only successful trial eu new antibiotic guidance require only trial approval iai uti be target infection note agency follow amy reeve twitter ibd_areeve facebook
577,JNJ,generic drug maker lannett lci spiked hour trading wednesday announce acquire kremer urban pharmaceutical buyout effectively double lannett sale boost fiscal ep company say kremer arm belgium ucb have portfolio product pending application candidate
578,JNJ,last year hepatitis have produce most epic drug launch history fanfare die investor face key question much longer drug pipeline pop question be ground sheer success exist treatment gilead science gild sovaldi harvoni abbvie abbv viekira pak
579,JNJ,apple aapl make goldman sachs list good bad stock own federal reserve hike interest rate
580,JNJ,central banker meet week discuss lift benchmark rate september increase be see sure bet few month recent global turmoil mediocre datum have prompt analyst expect hike later
581,JNJ,cupertino calif base tech giant be place good list strong balance sheet bloomberg report other company make grade range tech food finance
582,JNJ,be google googl chipotle grill cmg well fargo wfc priceline group pcln pepsico pep blackrock blk oracle orcl kinder morgan kmi dollar tree dltr
583,JNJ,other hand company lot float rate debt be avoid fed hike rate financing cost rise goldman sachs analyst say report last week
584,JNJ,enormous sum cash overall balance sheet strength apple also have lot float rate debt accord goldman
585,JNJ,company make not so great stock list include mcdonald mcd ebay ebay metlife meet coca cola ko general motor gm johnson johnson jnj allergan agn chevron cvx time warner twx ford motor general mill gis
586,JNJ,somewhat schizophrenic list apple goldman sachs report didn faze investor apple share rise finishing stock market today help early indication latest iphone model be see high demand
587,JNJ,follow ciaran mcevoy twitter ibd_cmcevoy facebook apple aapl make goldman sachs list good bad stock own federal reserve hike interest rate central banker meet week discuss lift benchmark rate september increase be see sure bet few month recent global turmoil mediocre datum have prompt analyst expect hike later cupertino calif base tech giant be place good list strong balance sheet bloomberg report other company make grade range tech food finance be google googl chipotle grill cmg well fargo wfc priceline group pcln pepsico pep blackrock blk oracle orcl kinder morgan kmi dollar tree dltr other hand company lot float rate debt be avoid fed hike rate financing cost rise goldman sachs analyst say report last week enormous sum cash overall balance sheet strength apple also have lot float rate debt accord goldman company make not so great stock list include mcdonald mcd ebay ebay metlife meet coca cola ko general motor gm johnson johnson jnj allergan agn chevron cvx time warner twx ford motor general mill gis somewhat schizophrenic list apple goldman sachs report didn faze investor apple share rise finishing stock market today help early indication latest iphone model be see high demand follow ciaran mcevoy twitter ibd_cmcevoy facebook
588,JNJ,stock hold small loss quiet morning monday nasdaq be dow jone industrial average slip volume be tracking lower board compare friday level
589,JNJ,just handful dow stock be higher early trading apple aapl lead jump active trade report record preorder latest iphone apple share be try climb right side new base be still week move average medical giant merck mrk johnson johnson jnj be close
590,JNJ,downside disney visa microsoft msft fall
591,JNJ,new high list remain subdue stock market today build product firm topbuild bld builder firstsource bldr score fresh high topbuild add close active trade july new issue be lead distributor installer insulation product residential commercial construction
592,JNJ,software firm tyler technology tyl clear flat base buy point volume be tracking light
593,JNJ,hospital group be top perform group early lead jump adeptus health adpt june new issue be fight support week line work potential new base adeptus health have report straight quarters triple digit sale growth same group lifepoint health lpnt universal health service uhs hca holding hca be also higher stock hold small loss quiet morning monday nasdaq be dow jone industrial average slip volume be tracking lower board compare friday level just handful dow stock be higher early trading apple aapl lead jump active trade report record preorder latest iphone apple share be try climb right side new base be still week move average medical giant merck mrk johnson johnson jnj be close downside disney visa microsoft msft fall new high list remain subdue stock market today build product firm topbuild bld builder firstsource bldr score fresh high topbuild add close active trade july new issue be lead distributor installer insulation product residential commercial construction software firm tyler technology tyl clear flat base buy point volume be tracking light hospital group be top perform group early lead jump adeptus health adpt june new issue be fight support week line work potential new base adeptus health have report straight quarters triple digit sale growth same group lifepoint health lpnt universal health service uhs hca holding hca be also higher
594,JNJ,top rate drugmaker such valeant pharmaceutical international vrx celgene celg have be busy lab wall street take part big merger deal today ibd list feature top rate drugmaker addition valeant celgene list include regeneron pharmaceutical regn lannett lci allergan agn friday biogen idec biib price
595,JNJ,big pharma eli lilly lly partner boehringer ingelheim say thursday diabetes drug jardiance succeed lower risk death cardiovascular disease massive year study send lilly stock sharply detailed result be be hold medical meeting eli lilly boehringer do say empa reg outcome trial
596,JNJ,big biotech amgen amgn be early trading wednesday announce neurology partnership novartis nvs well positive datum osteoporosis drug candidate late tuesday
597,JNJ,amgen novartis agree combine research program alzheimer disease involve drug bace beta site app cleave enzyme inhibitor class bace inhibitor more advanced alzheimer disease candidate biogen biib eli lilly lly target beta amyloid deposit appear brain alzheimer patient use different mechanism action amgen work field be preclinical novartis drug cnp be just enter clinical trial
598,JNJ,exchange cost profit sharing arrangement cnp novartis gain overseas commercial right amgen migraine drug more advanced amg be cgrp antibody phase testing
599,JNJ,deal raise eyebrow amgen isn traditionally know have significant neurology expertise publish early clon bace write rbc capital market analyst michael yee research note tuesday result suspect many investor initially shrug deal bace inhibitor be early street be focuse biogen lilly phase
600,JNJ,however believe bace inhibition be very interesting target be combine beta amyloid antibody together many company be go bace phase include biogen eisai datum spring lilly phase merck mrk johnson johnson jnj
601,JNJ,however nomura analyst ian somaiya write research note tuesday bace inhibitor have also have safety issue past cause lilly roche rhhby cancel testing earlier candidate
602,JNJ,amgen also say late tuesday osteoporosis drug romosozumab have succeed phase trial compare head head lilly forteo do not provide detail await future medical conference
603,JNJ,romosozumab view positive phase datum incremental positive somaiya write estimate romosozumab be peak sale opportunity be focuse safety full datum be present give postmenopausal osteoporosis patient population
604,JNJ,early trading stock market today amgen stock be fraction novartis stock be flat
605,JNJ,follow amy reeve twitter ibd_areeve facebook big biotech amgen amgn be early trading wednesday announce neurology partnership novartis nvs well positive datum osteoporosis drug candidate late tuesday amgen novartis agree combine research program alzheimer disease involve drug bace beta site app cleave enzyme inhibitor class bace inhibitor more advanced alzheimer disease candidate biogen biib eli lilly lly target beta amyloid deposit appear brain alzheimer patient use different mechanism action amgen work field be preclinical novartis drug cnp be just enter clinical trial exchange cost profit sharing arrangement cnp novartis gain overseas commercial right amgen migraine drug more advanced amg be cgrp antibody phase testing deal raise eyebrow amgen isn traditionally know have significant neurology expertise publish early clon bace write rbc capital market analyst michael yee research note tuesday result suspect many investor initially shrug deal bace inhibitor be early street be focuse biogen lilly phase however believe bace inhibition be very interesting target be combine beta amyloid antibody together many company be go bace phase include biogen eisai datum spring lilly phase merck mrk johnson johnson jnj however nomura analyst ian somaiya write research note tuesday bace inhibitor have also have safety issue past cause lilly roche rhhby cancel testing earlier candidate amgen also say late tuesday osteoporosis drug romosozumab have succeed phase trial compare head head lilly forteo do not provide detail await future medical conference romosozumab view positive phase datum incremental positive somaiya write estimate romosozumab be peak sale opportunity be focuse safety full datum be present give postmenopausal osteoporosis patient population early trading stock market today amgen stock be fraction novartis stock be flat follow amy reeve twitter ibd_areeve facebook
606,JNJ,spinal product specialist nuvasive nuva get upgrade price target increase wednesday earning beat estimate late tuesday stock hit year high early trading nuvasive profit rise year earlier quarter cent share beating analyst consensus cent accord thomson reuter sale rise
607,JNJ,not acquisition valeant pharmaceutical vrx hardly make map large fast grow drug company not only have earn spot such map be map sell everything cancer neurology drug cold remedy toenail fungal solution have thousand product
608,JNJ,halozyme therapeutic have be hotter biotech stock not exactly develop drug halozyme halo market product hylenex aids delivery injectable drug
609,JNJ,halozyme have also license enhanze same purpose such drug company pfizer pfe roche rhhby johnson johnson jnj janssen division abbvie abbv baxalta bxlt development injectable product
610,JNJ,san diego base halozyme be also testing product call pegph combination other drug treatment various cancer
611,JNJ,analyst don expect effort yield steady annual earning even recent biotech stock selloff halozyme be trading double be start year
612,JNJ,recent interview ibd halozyme ceo helen torley explain company business model catch wall street attention
613,JNJ,ibd have drug delivery product hylenex enhanze seem similar be difference
614,JNJ,torley market product be hylenex be basic rhuph enzyme degrade hyaluronan be sugar be present skin ve ever have subcutaneous injection re inject probably get sore re come resistance resistance be cause hyaluronan skin
615,JNJ,product be rhuph hylenex also enhanze temporarily break hyaluronan release water molecule be attach hyaluronan allow creation passage skin allow re inject have bigger surface area absorption bloodstream lymphatic
616,JNJ,hylenex be product halozyme go get approve promote small field force have
617,JNJ,basically be rhuph be used dispersion fluid be give skin also drug well be modest part business term generate revenue
618,JNJ,now also have part business call enhanze platform allow partner pfizer roche janssen abbvie baxalta license use enzyme most case combine molecule
619,JNJ,ll use roche herceptin mabthera rituxan example create new product be mixture herceptin enzyme go different regulatory path get approve so new product be call herceptin sc be inject enzyme work allow herceptin be absorb skin breaking hyaluronan barrier allow be bigger surface area absorption so instead herceptin have be give vein iv co administer drug give subcutaneous injection
620,JNJ,same base sugar just license call enhanze product call hylenex
621,JNJ,ibd drug re develop cancer treatment be also base same substance
622,JNJ,torley give hylenex marketplace today give subcutaneously be give vein be digest liver very rapidly so wouldn have big effect be give vein
623,JNJ,so pegylate pegylate be not uncommon approach take have drug have longer time circulate body get digest degraded liver pegph be basically pegylate version rhuph enzyme give vein last body several day so exert effect several day
624,JNJ,example be amgen amgn neupogen be give pretty frequently patient have low white blood cell receive chemotherapy peglyat create neulasta only have be inject couple week be obviously better convenience patient
625,JNJ,exactly re try do here have drug last longer so doesn have be give frequently
626,JNJ,ibd so be necessarily combine drug do do anything
627,JNJ,torley pegph have modest cancer effect type effect believe be important patient need be used therapy
628,JNJ,ll give example datum just present late study patient metastatic pancreatic cancer be patient generally have life expectancy month re diagnosed
629,JNJ,be look pegph addition current best available therapy be combination abraxane celgene celg drug gemcitabine be generic drug do be look pegph top abraxane gemcitabine vs abraxane gemcitabine alone
630,JNJ,theory pegph be work be patient be high level sugar hyaluronan tumor act barrier cancer therapy ability get tumor need work do bound water molecule create high pressure tumor compress blood vessel so get injection abraxane example theory be abraxane get tumor need work low blood flow tumor
631,JNJ,administer peg break hyaluronan open blood vessel open blood flow so give pegph give abraxane gemcitabine much higher concentration chemotherapy get tumor need work
632,JNJ,early datum phase study show patient receive pegph get gemcitabine abraxane have double progression free survival double response rate see interesting early trend improvement survival patient have high level hyaluronan estimate pancreatic cancer patient have high level sugar
633,JNJ,today abraxane gemcitabine be best standard care median survival be just month re hope do patient high level hyaluronan be get good improvement
634,JNJ,connect amy reeve ibd_areeve facebook halozyme therapeutic have be hotter biotech stock not exactly develop drug halozyme halo market product hylenex aids delivery injectable drug halozyme have also license enhanze same purpose such drug company pfizer pfe roche rhhby johnson johnson jnj janssen division abbvie abbv baxalta bxlt development injectable product san diego base halozyme be also testing product call pegph combination other drug treatment various cancer analyst don expect effort yield steady annual earning even recent biotech stock selloff halozyme be trading double be start year recent interview ibd halozyme ceo helen torley explain company business model catch wall street attention ibd have drug delivery product hylenex enhanze seem similar be difference torley market product be hylenex be basic rhuph enzyme degrade hyaluronan be sugar be present skin ve ever have subcutaneous injection re inject probably get sore re come resistance resistance be cause hyaluronan skin product be rhuph hylenex also enhanze temporarily break hyaluronan release water molecule be attach hyaluronan allow creation passage skin allow re inject have bigger surface area absorption bloodstream lymphatic hylenex be product halozyme go get approve promote small field force have basically be rhuph be used dispersion fluid be give skin also drug well be modest part business term generate revenue now also have part business call enhanze platform allow partner pfizer roche janssen abbvie baxalta license use enzyme most case combine molecule ll use roche herceptin mabthera rituxan example create new product be mixture herceptin enzyme go different regulatory path get approve so new product be call herceptin sc be inject enzyme work allow herceptin be absorb skin breaking hyaluronan barrier allow be bigger surface area absorption so instead herceptin have be give vein iv co administer drug give subcutaneous injection same base sugar just license call enhanze product call hylenex ibd drug re develop cancer treatment be also base same substance torley give hylenex marketplace today give subcutaneously be give vein be digest liver very rapidly so wouldn have big effect be give vein so pegylate pegylate be not uncommon approach take have drug have longer time circulate body get digest degraded liver pegph be basically pegylate version rhuph enzyme give vein last body several day so exert effect several day example be amgen amgn neupogen be give pretty frequently patient have low white blood cell receive chemotherapy peglyat create neulasta only have be inject couple week be obviously better convenience patient exactly re try do here have drug last longer so doesn have be give frequently ibd so be necessarily combine drug do do anything torley pegph have modest cancer effect type effect believe be important patient need be used therapy ll give example datum just present late study patient metastatic pancreatic cancer be patient generally have life expectancy month re diagnosed be look pegph addition current best available therapy be combination abraxane celgene celg drug gemcitabine be generic drug do be look pegph top abraxane gemcitabine vs abraxane gemcitabine alone theory pegph be work be patient be high level sugar hyaluronan tumor act barrier cancer therapy ability get tumor need work do bound water molecule create high pressure tumor compress blood vessel so get injection abraxane example theory be abraxane get tumor need work low blood flow tumor administer peg break hyaluronan open blood vessel open blood flow so give pegph give abraxane gemcitabine much higher concentration chemotherapy get tumor need work early datum phase study show patient receive pegph get gemcitabine abraxane have double progression free survival double response rate see interesting early trend improvement survival patient have high level hyaluronan estimate pancreatic cancer patient have high level sugar today abraxane gemcitabine be best standard care median survival be just month re hope do patient high level hyaluronan be get good improvement connect amy reeve ibd_areeve facebook
635,JNJ,cataplexy sudden temporary muscle weakness be most devastate symptom narcolepsy neurological disorder disrupt sleep wake cycle victim be prone fall asleep suddenly middle day drive work dinner table know cure rare disorder medication help xyrem
636,JNJ,year modest stock market gain smart beta etfs many try beat cap weight benchmark be more popular ever smart strategic beta etfs have debut year lift total globally exchange trade product be see strong inflow third consecutive year asset
637,JNJ,big cap biotech biogen biib beat earning estimate friday lower guidance report failure clinical trial send stock plummet meanwhile big pharma abbvie abbv report steadier quarter affirm guidance stock be slide sale come short biogen earning exclude time item rise year earlier quarter
638,JNJ,big swiss pharma novartis nvs early tuesday report mixed affirm guidance share fall novartis post earning share year earlier quarter constant currency basis be cent analyst consensus accord thomson reuter miss capital iq factset consensus
639,JNJ,be set be big year specialty drugmaker depome year lumpy quarters drive licensing deal other drugmaker depome depo be come own independent commercial pharma develop acquire approve product most recently regular extend release version pain medicine nucynta deal johnson
640,JNJ,ibm financial continue show company deep transition first quarter earning beating expectation revenue fall meeting view big blue also maintain outlook ibm ibm late monday report earning share item year earlier period well analyst consensus estimate profit margin improve expense fall news reversed straight quarters ep decline revenue continue operation fall adjust impact currency exchange rate exclude business firm be divest growth be flat year ibm say be quarter row year year revenue decline company have be shedding hardware unit realign workforce cut cost focus growth area include cloud compute big datum analytic mobile compute security social networking company also have be hit currency exchange wo ibm derive majority revenue offshore market result reflect transformation business continue momentum imperative ibm cfo martin schroeter say conference call analyst view proof point strategy be right action reinvent innovate hardware software business be start pay ibm expect full year earning share item analyst consensus be midpoint ibm stock be fraction hour trading monday company release result rise regular session month high strategic imperative growth rate accelerate demonstrate power offering new opportunity contribute improve revenue performance ceo ginni rometty say ibm earning release revenue firm software segment fall adjust currency year earlier period revenue system hardware business plunge ibm say rise adjust currency impact system sale ibm complete sale low end server business china lenovo group october ibm also be process turn semiconductor operation globalfoundry global service revenue fall adjust currency divest business ibm be back be software service company software swing factor year write ub analyst steven milunovich research report last week be not ultrabearish camp seem early transformation forecast much recovery currency emerge market still drag ibm have announce several partnership part transition cloud compute ibm have team twitter twtr integrate twitter datum ibm analytic service cloud last week ibm unveil new watson health business unit several big name partner announce small acquisition expand health care used artificial intelligence computer ibm say work apple aapl johnson johnson jnj help optimize consumer medical device datum collection analysis feedback big blue have also say plow next year internet thing unit
641,JNJ,new product introduction swipe trade secret chipmaker have steal spotlight so far week let not forget biotech stock be highlighted ibd screen day big cap leader semiconductor counterpart large cap biotechs include celgene celg regeneron pharmaceutical regn gilead science gild celgene have
642,JNJ,second half august be usually desert business news fda schedule be year round several important drug be approval decision month provide upside biotech stock have recently be suffering
643,JNJ,get most attention likely be repatha amgen amgn cholesterol drug expect be approve aug repatha be pcsk inhibitor similar praluent drug regeneron pharmaceutical regn sanofi sny be approve much fanfare last month
644,JNJ,give resemblance drug repatha be widely expect be approve july research note nomura analyst ian somaiya write amgen drug probably also get similar label doesn cover quite many patient have hope be sufficiently broad support peak sale estimate
645,JNJ,be especially interesting investor be pricing dynamic come drug appear market pharmacy benefit manager express script esrx have say hope start price war similar happened abbvie abbv launch rival hepatitis regimen gilead science gild harvoni late last year gilead have maintain dominant market share only rebate half drug list price
646,JNJ,believe rebate drive access sanofi regeneron amgen be directly compete formulary position somaiya write repatha net price month estimate imply discount praluent gross price believe competition result average discounting similar have be see hepatitis
647,JNJ,amgen stock hit new high report have shed larger biotech selloff retain excellent ibd composite rating
648,JNJ,aug fda be due decide label expansion adcetris sole market drug seattle genetic sgen adcetris market partner takeda be already approve patient hodgkin lymphoma ve relapse receive stem cell transplant chemotherapy treatment current filing follow study patient receive transplant hadn relapse find significant improvement progression free survival
649,JNJ,july research note rbc capital market analyst adnan butt write chance approval look good fda didn convene advisory committee approval date normally do have issue drug
650,JNJ,market opportunity post transplant hodgkin lymphoma set take adcetris year higher sale potentially butt write
651,JNJ,get new indication adcetris be key part seattle genetic strategy even drug launch year still hasn make company profitable adcetris be also be test cell lymphoma front line set kind lymphoma january company also announce collaboration bristol myer squibb bmy test bristol hot new cancer drug opdivo adcetris various kind lymphomas
652,JNJ,seattle genetic stock be july high retain good relative strength rating analyst expect turn profitable
653,JNJ,fda have aug deadline decide aristada schizophrenia drug alk create drug take aripiprazole brand name abilify be best seller otsuka bristol myer go patent year add own technology turn dose regimen daily pill monthly injection patient compliance be biggest problem face psychotic medicine generally less frequent dose better
654,JNJ,aristada win be alone long act psychotic market leerink analyst michael schmidt say do nearly well johnson johnson jnj invega sustenna also used technology be therefore provide royalty
655,JNJ,model aristada sale write july research note
656,JNJ,aristada be important component strategy return growth be lead stock last year sacrifice profit growth invest marketing new drug vivitrol most recent quarter revenue also flatlined analyst expect sale growth next year rise profitability be not see return accord thomson reuter
657,JNJ,stock hit high march go form cup handle base fail break slump sector last week be trading fraction wednesday afternoon
658,JNJ,connect amy reeve ibd_areeve facebook second half august be usually desert business news fda schedule be year round several important drug be approval decision month provide upside biotech stock have recently be suffering get most attention likely be repatha amgen amgn cholesterol drug expect be approve aug repatha be pcsk inhibitor similar praluent drug regeneron pharmaceutical regn sanofi sny be approve much fanfare last month give resemblance drug repatha be widely expect be approve july research note nomura analyst ian somaiya write amgen drug probably also get similar label doesn cover quite many patient have hope be sufficiently broad support peak sale estimate be especially interesting investor be pricing dynamic come drug appear market pharmacy benefit manager express script esrx have say hope start price war similar happened abbvie abbv launch rival hepatitis regimen gilead science gild harvoni late last year gilead have maintain dominant market share only rebate half drug list price believe rebate drive access sanofi regeneron amgen be directly compete formulary position somaiya write repatha net price month estimate imply discount praluent gross price believe competition result average discounting similar have be see hepatitis amgen stock hit new high report have shed larger biotech selloff retain excellent ibd composite rating aug fda be due decide label expansion adcetris sole market drug seattle genetic sgen adcetris market partner takeda be already approve patient hodgkin lymphoma ve relapse receive stem cell transplant chemotherapy treatment current filing follow study patient receive transplant hadn relapse find significant improvement progression free survival july research note rbc capital market analyst adnan butt write chance approval look good fda didn convene advisory committee approval date normally do have issue drug market opportunity post transplant hodgkin lymphoma set take adcetris year higher sale potentially butt write get new indication adcetris be key part seattle genetic strategy even drug launch year still hasn make company profitable adcetris be also be test cell lymphoma front line set kind lymphoma january company also announce collaboration bristol myer squibb bmy test bristol hot new cancer drug opdivo adcetris various kind lymphomas seattle genetic stock be july high retain good relative strength rating analyst expect turn profitable fda have aug deadline decide aristada schizophrenia drug alk create drug take aripiprazole brand name abilify be best seller otsuka bristol myer go patent year add own technology turn dose regimen daily pill monthly injection patient compliance be biggest problem face psychotic medicine generally less frequent dose better aristada win be alone long act psychotic market leerink analyst michael schmidt say do nearly well johnson johnson jnj invega sustenna also used technology be therefore provide royalty model aristada sale write july research note aristada be important component strategy return growth be lead stock last year sacrifice profit growth invest marketing new drug vivitrol most recent quarter revenue also flatlined analyst expect sale growth next year rise profitability be not see return accord thomson reuter stock hit high march go form cup handle base fail break slump sector last week be trading fraction wednesday afternoon connect amy reeve ibd_areeve facebook
659,JNJ,come income stock steadier dividend payout better ibd measure stable company dividend history be year period dividend stability factor range most stable most volatile stock dividend leader screen score also offer payout well
660,JNJ,drugmaker deliver tasty return investor july pharmaceutical etfs top peer hold broadly diversify health care stock well focuse red hot biotechs powershare dynamic pharmaceutical pjp lag pharma etf peer month rise lead year date advance longer period produce annual average
661,JNJ,stock open mixed then hammer narrow gain early trade tuesday
662,JNJ,nasdaq lead add dow jone industrial average edge
663,JNJ,volume be mixed stock market today nyse nasdaq compare action same time monday
664,JNJ,overseas europe major index continue struggle narrowly mixed territory afternoon trade
665,JNJ,price import export slip june export import labor department report consensus view project increase
666,JNJ,business inventory increase commerce department say be april increase tad better expansion project economist
667,JNJ,day big earning report come jpmorgan jpm johnson johnson jnj well fargo wfc
668,JNJ,bolt screw distributor fastenal fast slump beating earning view come shy sale
669,JNJ,micron technology mu rumble news report possible takeover bid tsinghua unigroup china largest state own chip developer yahoo finance report company deny have receive offer standard poor capital iq say deal be unlikely due size bid probably regulatory hurdle intel intc reportedly paid stake tsinghua last year micron be trading december high intel share rise
670,JNJ,gopro gpro muscle more boost barclay upgrade overweight equal weight note also raise stock price target cite strong execution acquisition continue brand strength other factor stock be sixth week possible cup base consolidation be occur well stock week high possible weakness
671,JNJ,prevailing mood ibd stock be positive few post loss only cyberark software cybr fall more
672,JNJ,ambarella amba lead group rise heavy trade rebound test support week move average
673,JNJ,gray television gtn fleetmatic fltx newlink genetic nlnk rise more
674,JNJ,earning report due close include railroad csx csx pizza hut taco bell kfc owner yum brand yum stock open mixed then hammer narrow gain early trade tuesday nasdaq lead add dow jone industrial average edge volume be mixed stock market today nyse nasdaq compare action same time monday overseas europe major index continue struggle narrowly mixed territory afternoon trade price import export slip june export import labor department report consensus view project increase business inventory increase commerce department say be april increase tad better expansion project economist day big earning report come jpmorgan jpm johnson johnson jnj well fargo wfc bolt screw distributor fastenal fast slump beating earning view come shy sale micron technology mu rumble news report possible takeover bid tsinghua unigroup china largest state own chip developer yahoo finance report company deny have receive offer standard poor capital iq say deal be unlikely due size bid probably regulatory hurdle intel intc reportedly paid stake tsinghua last year micron be trading december high intel share rise gopro gpro muscle more boost barclay upgrade overweight equal weight note also raise stock price target cite strong execution acquisition continue brand strength other factor stock be sixth week possible cup base consolidation be occur well stock week high possible weakness prevailing mood ibd stock be positive few post loss only cyberark software cybr fall more ambarella amba lead group rise heavy trade rebound test support week move average gray television gtn fleetmatic fltx newlink genetic nlnk rise more earning report due close include railroad csx csx pizza hut taco bell kfc owner yum brand yum
675,JNJ,huntington beach calif new watson health business unit ibm ibm be look leverage wearable mobile app health datum purpose say company be help optimize consumer medical device datum collection analysis feedback look big blue monday say new watson unit
676,JNJ,johnson johnson kick health care earning season report point solid fundamental punish foreign exchange fx headwind report basis johnson johnson jnj sale drop year earlier quarter modestly beating analyst consensus earning decline share beating estimate
677,JNJ,seem never end transition ibm ibm result close monday be expect include sale decline ibm have long be transition shedding hardware unit realign workforce reduce cost focus growth area include cloud compute big datum analytic mobile compute security social networking company have
678,JNJ,medical giant johnson johnson jnj beat wall street estimate lift guidance tuesday stock be fraction early trading revenue decline
679,JNJ,earning exclude special item shrank year earlier quarter share beating analyst consensus cent accord thomson reuter exclude impact foreign exchange rate profit rise
680,JNJ,revenue fall line consensus exclude fx impact sale fall
681,JNJ,lift full year guidance share previous
682,JNJ,sale decline come mixture divestiture hepatitis drug olysio sale have shrink dramatically compete product gilead science gild abbvie abbv come late last year say exclude factor fx sale rise
683,JNJ,view bode well ability medium term weather significant headwind olysio represent total sale contribute operate margin net incremental investment base estimate be likely face meaningful sale decline come quarters write leerink analyst danielle antalffy research note still strong performance other key drug notably xarelto imbruvica invokana name few be clearly help offset least part major headwind
684,JNJ,imbruvica new blood cancer drug be market profit sharing deal pharmacyclic abbvie acquire evercore isi analyst mark schoenebaum calculate take drug mean total abbvie hasn report yet
685,JNJ,number appear roughly line im im prescription appear be tracking well current consensus caveat don have clear consensus due abbvie pharmacyclic transaction schoenebaum write email client
686,JNJ,abbvie stock be more early trading stock market today
687,JNJ,other hand rbc capital market analyst glenn novarro note device business miss expectation continue trend past several quarters deduce company be lose market share spinal business upstart such globus medical gmed share atrial fibrillation market medtronic mdt st jude medical stj
688,JNJ,other hand seem be take share medtronic surgical product
689,JNJ,medtronic stock be early trading tuesday st jude stock be fraction
690,JNJ,follow amy reeve twitter ibd_areeve medical giant johnson johnson jnj beat wall street estimate lift guidance tuesday stock be fraction early trading revenue decline earning exclude special item shrank year earlier quarter share beating analyst consensus cent accord thomson reuter exclude impact foreign exchange rate profit rise revenue fall line consensus exclude fx impact sale fall lift full year guidance share previous sale decline come mixture divestiture hepatitis drug olysio sale have shrink dramatically compete product gilead science gild abbvie abbv come late last year say exclude factor fx sale rise view bode well ability medium term weather significant headwind olysio represent total sale contribute operate margin net incremental investment base estimate be likely face meaningful sale decline come quarters write leerink analyst danielle antalffy research note still strong performance other key drug notably xarelto imbruvica invokana name few be clearly help offset least part major headwind imbruvica new blood cancer drug be market profit sharing deal pharmacyclic abbvie acquire evercore isi analyst mark schoenebaum calculate take drug mean total abbvie hasn report yet number appear roughly line im im prescription appear be tracking well current consensus caveat don have clear consensus due abbvie pharmacyclic transaction schoenebaum write email client abbvie stock be more early trading stock market today other hand rbc capital market analyst glenn novarro note device business miss expectation continue trend past several quarters deduce company be lose market share spinal business upstart such globus medical gmed share atrial fibrillation market medtronic mdt st jude medical stj other hand seem be take share medtronic surgical product medtronic stock be early trading tuesday st jude stock be fraction follow amy reeve twitter ibd_areeve
691,JNJ,world look bit flat market standpoint early tuesday global market commodity largely unmoved stock future steering market mixed open dow future be point ibm ibm pull hard downside future be fraction nasdaq future be point focal point stock market today microsoft msft yahoo yhoo chipotle grill cmg also report close do number lead stock include blackhawk network hawk illumina ilmn gopro gpro economic calendar be blank tuesday big name motion early earning report include verizon vz traveler trv lockheed martin lmt unchanged unite technology utx ibm drag lower report earning beat revenue fall slightly more analyst have expect be tech giant straight quarter decline revenue profit margin software division source half company profit narrow quarter ibm share have be gradual uptrend january fight climb month consolidation tesla motor tsla slump nearly ahead open stock have be nick ub downgrade sell note reportedly question company battery storage auto delivery target share rise almost strong trade monday stock be extend rebound week support cup handle buy point india base software engineer infosys infy surge country second largest software developer report better expect earning raise full year revenue guidance consensus expectation management say company sign contract quarter total value infosys have be consolidate february battle retake week line support past week dollar be mixed commodity be generally flat mining stock have drag hard monday be rebound agnico eagle aem barrick gold abx yamana gold auy newmont mining nem post solid premarket gain
692,JNJ,stock future knock healthy gain ahead monday open probationary deal eurozone open door possible bailout fund greece
693,JNJ,dow future be point fair market value tick higher nasdaq future be solid point future jump point small cap be less impressed russell future edge point
694,JNJ,greece be again lead early influence stock market today accord fashion eurozone creditor greece leader follow night session clear path struggle country receive much be release prime minister alexis tsipra prove government able implement so call austerity measure
695,JNJ,plan be enough keep greece now euro currency bloc tsipra enact tax hike pension change wednesday step be refuse greek voter referendum just week
696,JNJ,global market be positive china top index block solid gain shanghai composite hong kong hang seng europe cac paris surge frankfurt dax climb london ftse add
697,JNJ,market open day nasdaq stare underside day move average move line be positive still leave market range have contain trade march nasdaq start monday session june high start high
698,JNJ,treasury department serve june budget number et earning calendar get slow start monday ibd stock bank ozark ozrk report close pace pick tuesday report due jpmorgan jpm well fargo wfc johnson johnson jnj
699,JNJ,stock unite continental ual climb wynn resort wynn tack gain
700,JNJ,medical sector stock small large be hammer big premarket move
701,JNJ,anacor pharmaceutical anac spiked announce eczema skin rash lotion crisaborole meet endpoint late stage clinical trial palo alto calif base biotech say submit new drug application food drug administration early anacor end friday new high july gain year
702,JNJ,conformis cfms leap market surgical knee implant july new issue end friday high ipo price
703,JNJ,edward lifescience ew notch rbc capital upgrade stock outperform sector perform irvine calif base company announce friday pay acquire privately hold heart device maker cardiaq valve technology edward end friday just buy point cup handle base
704,JNJ,other trading dollar gain vs euro yen yen rise vs euro oil price slip bit less gold be fraction stock future knock healthy gain ahead monday open probationary deal eurozone open door possible bailout fund greece dow future be point fair market value tick higher nasdaq future be solid point future jump point small cap be less impressed russell future edge point greece be again lead early influence stock market today accord fashion eurozone creditor greece leader follow night session clear path struggle country receive much be release prime minister alexis tsipra prove government able implement so call austerity measure plan be enough keep greece now euro currency bloc tsipra enact tax hike pension change wednesday step be refuse greek voter referendum just week global market be positive china top index block solid gain shanghai composite hong kong hang seng europe cac paris surge frankfurt dax climb london ftse add market open day nasdaq stare underside day move average move line be positive still leave market range have contain trade march nasdaq start monday session june high start high treasury department serve june budget number et earning calendar get slow start monday ibd stock bank ozark ozrk report close pace pick tuesday report due jpmorgan jpm well fargo wfc johnson johnson jnj stock unite continental ual climb wynn resort wynn tack gain medical sector stock small large be hammer big premarket move anacor pharmaceutical anac spiked announce eczema skin rash lotion crisaborole meet endpoint late stage clinical trial palo alto calif base biotech say submit new drug application food drug administration early anacor end friday new high july gain year conformis cfms leap market surgical knee implant july new issue end friday high ipo price edward lifescience ew notch rbc capital upgrade stock outperform sector perform irvine calif base company announce friday pay acquire privately hold heart device maker cardiaq valve technology edward end friday just buy point cup handle base other trading dollar gain vs euro yen yen rise vs euro oil price slip bit less gold be fraction
705,JNJ,biotech receptos rcpt report positive midstage trial result lead drug candidate ulcerative colitis thursday send stock much early trading receptos say phase study call touchstone meet primary endpoint improve chronic bowel disease week maintenance ozanimod formerly know rpc
706,JNJ,aduro biotech adro soar initial public offer biotech ipos wednesday aduro developer cancer immunotherapy treatment price open raise pricing share stock be trading afternoon trading stock market today exist shareholder aduro include
707,JNJ,drug company include newlink genetic nlnk juno therapeutic juno intrexon xon report quarterly result close monday investor seem be more focuse company development update actual earning depome missesdepome depo widen loss adjust cent share last year cent loss analyst be expect earning penny revenue fall short estimate share neurology pharmaceutical firm dive close regular session depome say complete acquisition right nucynta pain relief franchise johnson johnson jnj janssen pharmaceutical unit april begin fulfill shipping order april nucynta depome say expect total product sale be nearly triple last year product sale newlink doesn end pancreatic cancer trialnewlink genetic plunge extend trading say phase pancreatic cancer drug trial continue suggest investor be hope test have conclude fast track status orphan drug designation spa give continue confidence regulatory strategy say ceo charle link jr monday mind be thoughtfully prepare regulatory filing commercial activity associate potentially positive outcome trial last week biotech pre announce earning cent share improve last year cent loss analyst expectation cent loss revenue surge blow past estimate stock have close monday fresh disclosure hour plunge impax lab missesmimpax laboratory ipxl see earning fall cent share miss calculation cent revenue increase short view generic drug maker result be negatively affected delay acquisition tower holding launch bipolar disorder drug share slide bell have close juno therapeutic buy stage celljuno therapeutic gaap net loss come cent share better analyst estimate cent loss december ipo hot cell immunotherapy field juno say buy stage cell therapeutic possible milestone payment more share edge hour have close intrexon earning soarintrexon diluted ep cent shot beat estimate cent loss revenue increase beating expectation share bid late close quarter intrexon enter agreement germany merck develop car cancer therapy follow alissa william twitter ibd_awilliam
708,JNJ,good morning be interesting day yesterday major index finishing mixed dollar drop sharply oil surge international monetary fund cut global growth federal reserve cut forecast gdp jpmorgan jpm beat johnson johnson jnj beat well fargo wfc disappoint just bit avon product avp consider sale company china economy grow
709,JNJ,johnson johnson kick health care earning season report point solid fundamental punish foreign exchange fx headwind report basis johnson johnson jnj sale drop year earlier quarter modestly beating analyst consensus earning decline share beating estimate
710,JNJ,ibm ibm unveil new watson health business unit several big name partner small acquisition expand health care used artificial intelligence computer giant say monday work apple aapl johnson johnson jnj medtronic mdt help optimize consumer medical device datum collection analysis feedback
711,JNJ,stock monday fail hold early gain worry macro datum dollar strength earning once again weigh trader mind average pull back end day negative territory opinion action be more profit take move higher late last week yesterday morning ahead be more volatility weakness day ahead report play strong dollar reason weaken earning blame consumer be global economic weakness mean estimate have already be slash reason so just be more same
712,JNJ,today bring jpmorgan chase jpm well fargo wfc later week be joined bank america bac goldman sachs gs st qtr look financial rise legal regulatory expense slow mortgage lend decrease trading revenue collapse energy space play mix ytd financial have underperform broader mkt group follow only energy utility
713,JNJ,say earning represent history be important be future look recently credit manager index cmi have report increase reject credit application spike come only last month too late real impact st qtr earning clear indicator be store credit tight once again bring country grind halt look lend be risky business global economy still struggle exposure create collapse oil mkt couple threat rise interest rate future be anything clear remember investment banker be keen play number be well know redefine common accounting practice work regulator don seem mind so rabbit pull hat do not expect miss number jpm announce early earning be expect sh revenue bil increase yoy wfc other hand be due report bit weaker number cent sh decline revenue bil
714,JNJ,healthcare johnson johnson jnj be bellwether be also due report here investor be keenly aware impact remember alcoa aa johnson johnson also see benefit overseas operation be help weaker currency abroad not just sayin
715,JNJ,last night bell hear norfolk southern nsc pre release commentary prepared investor disappointment not dollar be lower fuel surcharge revenue lower coal shipment isn just kick pant oil decline price bring untold benefit transportation company host other now norfolk southern tell earning be charge higher fuel surcharge
716,JNJ,surcharge be add charge payment top regular cost so investor be buy norfolk be able increase revenue increase surcharge then someone think new portfolio manager surcharge do not represent organic growth improve outlook only represent ability company fleece client add fee etc be investment theory stock trade hour algo punish
717,JNJ,morning future be bit lower drama unfold currently pt say yesterday expect mkt find stability dma bank so screw then expect sentiment remain fairly upbeat remember mkt be expect earning growth healthcare financial consumer disc industrial disappointment be expect come energy be not surprise material telecom
718,JNJ,forward guidance be key company book large volume int sale likely be bit more cautious face strong dollar cover backside same multinational also have overseas operation benefit weaker local currency add continue monetary policy global central bank boom mkt never really correct correct do not mean move high
719,JNJ,today get retail sale analyst expect see surge make last month read issue argue weather story then tell healthy strong consumer be etc then cause pundit re hash rate increase conversation then spook algo be vicious circle do not get draw rate increase story ain happen june september speaking fed watch ny pre dudley speak be minneapoli pre kocherlakota speak pm well mkts close remember be ultra uber dove so algo be listen
720,JNJ,european mkts be bit lower even strong datum emu industrial production european monetary union easily beat estimate come vs exp italian british cpi meet expectation ecb continue feed beast small pullback be see only represent profit take mkts have explode upside past month so caution ahead earning be prudent take money table keep core position stock be never bad investment decision ftse cac dax eurostoxx spain italy
721,JNJ,case miss florida marco rubio yr old launch campaign president last night boy be pick fight do hear speech very good fact be take prisoner emphasize age experience haven have enough take direct shot bush yr old hillary yr old say
722,JNJ,time have come generation lead way new american century help here wasn obama be suppose do
723,JNJ,direct shot hillary have say
724,JNJ,just yesterday leader yesterday begin campaign president promising take back yesterday yesterday be be never go back
725,JNJ,blood continue pour sit back grab popcorn night be young
726,JNJ,take good care
727,JNJ,kenny polcari be director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate stock monday fail hold early gain worry macro datum dollar strength earning once again weigh trader mind average pull back end day negative territory opinion action be more profit take move higher late last week yesterday morning ahead be more volatility weakness day ahead report play strong dollar reason weaken earning blame consumer be global economic weakness mean estimate have already be slash reason so just be more same today bring jpmorgan chase jpm well fargo wfc later week be joined bank america bac goldman sachs gs st qtr look financial rise legal regulatory expense slow mortgage lend decrease trading revenue collapse energy space play mix ytd financial have underperform broader mkt group follow only energy utility say earning represent history be important be future look recently credit manager index cmi have report increase reject credit application spike come only last month too late real impact st qtr earning clear indicator be store credit tight once again bring country grind halt look lend be risky business global economy still struggle exposure create collapse oil mkt couple threat rise interest rate future be anything clear remember investment banker be keen play number be well know redefine common accounting practice work regulator don seem mind so rabbit pull hat do not expect miss number jpm announce early earning be expect sh revenue bil increase yoy wfc other hand be due report bit weaker number cent sh decline revenue bil healthcare johnson johnson jnj be bellwether be also due report here investor be keenly aware impact remember alcoa aa johnson johnson also see benefit overseas operation be help weaker currency abroad not just sayin last night bell hear norfolk southern nsc pre release commentary prepared investor disappointment not dollar be lower fuel surcharge revenue lower coal shipment isn just kick pant oil decline price bring untold benefit transportation company host other now norfolk southern tell earning be charge higher fuel surcharge surcharge be add charge payment top regular cost so investor be buy norfolk be able increase revenue increase surcharge then someone think new portfolio manager surcharge do not represent organic growth improve outlook only represent ability company fleece client add fee etc be investment theory stock trade hour algo punish morning future be bit lower drama unfold currently pt say yesterday expect mkt find stability dma bank so screw then expect sentiment remain fairly upbeat remember mkt be expect earning growth healthcare financial consumer disc industrial disappointment be expect come energy be not surprise material telecom forward guidance be key company book large volume int sale likely be bit more cautious face strong dollar cover backside same multinational also have overseas operation benefit weaker local currency add continue monetary policy global central bank boom mkt never really correct correct do not mean move high today get retail sale analyst expect see surge make last month read issue argue weather story then tell healthy strong consumer be etc then cause pundit re hash rate increase conversation then spook algo be vicious circle do not get draw rate increase story ain happen june september speaking fed watch ny pre dudley speak be minneapoli pre kocherlakota speak pm well mkts close remember be ultra uber dove so algo be listen european mkts be bit lower even strong datum emu industrial production european monetary union easily beat estimate come vs exp italian british cpi meet expectation ecb continue feed beast small pullback be see only represent profit take mkts have explode upside past month so caution ahead earning be prudent take money table keep core position stock be never bad investment decision ftse cac dax eurostoxx spain italy case miss florida marco rubio yr old launch campaign president last night boy be pick fight do hear speech very good fact be take prisoner emphasize age experience haven have enough take direct shot bush yr old hillary yr old say time have come generation lead way new american century help here wasn obama be suppose do direct shot hillary have say just yesterday leader yesterday begin campaign president promising take back yesterday yesterday be be never go back blood continue pour sit back grab popcorn night be young take good care kenny polcari be director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
728,JNJ,specialty drug maker horizon pharma try continue recent acquisition binge tuesday make hostile stock offer depome worth roughly include debt depome depo stock jump news record high close tuesday horizon pharma hznp stock touch time high july fall horizon
729,JNJ,say opera ain fat lady sing well hear singing greece eu strike hour deal opera be be
730,JNJ,be kid never
731,JNJ,morning global investor be wake headline
732,JNJ,tsipra capitulate creditor demand keep greece euro
733,JNJ,greece eurozone thrash rescue deal
734,JNJ,agreekment overnight talk result aid reform deal
735,JNJ,be sequel comedy dumb dumber only star alexis tsipra whole greek parliament mean have ever see anything so breathtakingly stupid alexis tsipra be elect platform screw european union remember be claim not more ounce austerity cut tax increase not anyone greece pay taxe so difference do make
736,JNJ,follow month rant rave germany troika imf ecb eu reject plan plan then force referendum vote country campaign citizen vote overwhelmingly agree last week deal be bad then sell river make such dramatic reversal almost laughable make more ridiculous latest final offer be far one have turn now have new word be sure light twitter sphere gridiot
737,JNJ,paul krugman american economist professor economic int affair princeton university sum way
738,JNJ,go harsh pure vindictiveness complete destruction national sovereignty hope relief be presumably meant be offer greece even so grotesque betrayal everything european project be suppose stand
739,JNJ,global market now relieve least today have moved positive territory begin asia market sense relief greek front cause investor trader review recent market action add positive economic datum region be risk china have be focus late report trade figure show export rise substantially beating expectation side note gov official try temper mood say export be likely face relatively big pressure come month long keep faade
740,JNJ,china end day extend friday gain better clearly market have be boost recent reform instituted beij brokerage be tell uncertain term sunday use real name national identification number trade imagine more imaginary brokerage account have thought used real name weekend xinhua state own news outlet report brokerage house be suspect manipulate future price other malicious practice say last week china be not free market measure recently impose have cause market rally happen once be remove be foreign investor really feel better not so much
741,JNJ,japan money pour yen safe haven trade equity also moved higher investor get clear sign greek deal gpif gov pension investment fund release performance figure show return month end march st hirakawa chief equity strategist oksan security do say fund look still have yen left put work japanese stock market more yen go stock anyone want stand front train
742,JNJ,europe morning imagine market be tear ftse cac dax eurostoxx spain italy good today tsipra deliver then expect fall apart mid week even do deliver be big be able hold position pm relief sure greece now have hour vote reform be already trouble brewing parliament imagine rage support tsipra effort now feel turn back
743,JNJ,german chancellor merkel have say trust have be rebuild greek authority have take responsibility agree now hinge step step implementation agree
744,JNJ,agreement be more spending cut pension cut tax increase everything country vote be begin see dumb dumber reference
745,JNJ,future be soar currently point rate be bang head lunch be economic report today later week get slew datum point retail sale ppi empire state manufacturing industrial prod capacity utilization
746,JNJ,be now well earning season tomorrow start beauty pageant jpmorgan jpm johnson johnson jnj well fargo wfc later week get bancorp usb bank america bac csx csx yum brand yum name just few focus now turn earning future guidance greek think be bit exhaust remain simmer back burner
747,JNJ,look test dma be tough resistance point market breach be economic datum earning play part investor want know be finally really make headway perceive failure cause market find support once again
748,JNJ,week also feature annual event semicon west july see event day innovation conference moscone center san francisco feature startup investor research forum look presentation big boy intelintc oracleorcl ibmibm texas instrumentstxn san disksndk new exciting startup market be sure be get kind positive datum presentation come conference so expect positive market action publicly trade name
749,JNJ,take good care
750,JNJ,kp
751,JNJ,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate say opera ain fat lady sing well hear singing greece eu strike hour deal opera be be be kid never morning global investor be wake headline tsipra capitulate creditor demand keep greece euro greece eurozone thrash rescue deal agreekment overnight talk result aid reform deal be sequel comedy dumb dumber only star alexis tsipra whole greek parliament mean have ever see anything so breathtakingly stupid alexis tsipra be elect platform screw european union remember be claim not more ounce austerity cut tax increase not anyone greece pay taxe so difference do make follow month rant rave germany troika imf ecb eu reject plan plan then force referendum vote country campaign citizen vote overwhelmingly agree last week deal be bad then sell river make such dramatic reversal almost laughable make more ridiculous latest final offer be far one have turn now have new word be sure light twitter sphere gridiot paul krugman american economist professor economic int affair princeton university sum way go harsh pure vindictiveness complete destruction national sovereignty hope relief be presumably meant be offer greece even so grotesque betrayal everything european project be suppose stand global market now relieve least today have moved positive territory begin asia market sense relief greek front cause investor trader review recent market action add positive economic datum region be risk china have be focus late report trade figure show export rise substantially beating expectation side note gov official try temper mood say export be likely face relatively big pressure come month long keep faade china end day extend friday gain better clearly market have be boost recent reform instituted beij brokerage be tell uncertain term sunday use real name national identification number trade imagine more imaginary brokerage account have thought used real name weekend xinhua state own news outlet report brokerage house be suspect manipulate future price other malicious practice say last week china be not free market measure recently impose have cause market rally happen once be remove be foreign investor really feel better not so much japan money pour yen safe haven trade equity also moved higher investor get clear sign greek deal gpif gov pension investment fund release performance figure show return month end march st hirakawa chief equity strategist oksan security do say fund look still have yen left put work japanese stock market more yen go stock anyone want stand front train europe morning imagine market be tear ftse cac dax eurostoxx spain italy good today tsipra deliver then expect fall apart mid week even do deliver be big be able hold position pm relief sure greece now have hour vote reform be already trouble brewing parliament imagine rage support tsipra effort now feel turn back german chancellor merkel have say trust have be rebuild greek authority have take responsibility agree now hinge step step implementation agree agreement be more spending cut pension cut tax increase everything country vote be begin see dumb dumber reference future be soar currently point rate be bang head lunch be economic report today later week get slew datum point retail sale ppi empire state manufacturing industrial prod capacity utilization be now well earning season tomorrow start beauty pageant jpmorgan jpm johnson johnson jnj well fargo wfc later week get bancorp usb bank america bac csx csx yum brand yum name just few focus now turn earning future guidance greek think be bit exhaust remain simmer back burner look test dma be tough resistance point market breach be economic datum earning play part investor want know be finally really make headway perceive failure cause market find support once again week also feature annual event semicon west july see event day innovation conference moscone center san francisco feature startup investor research forum look presentation big boy intelintc oracleorcl ibmibm texas instrumentstxn san disksndk new exciting startup market be sure be get kind positive datum presentation come conference so expect positive market action publicly trade name take good carekpkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
752,JNJ,stock future point mildly lower open monday ahead heavy week corporate earning
753,JNJ,nasdaq future fall point vs fair value future lose point meanwhile future dow jone industrial average drop point
754,JNJ,few earning report trickle last week many more company release result week weakness energy be expect have weigh corporate result tepid global domestic demand well higher dollar be also expect have hurt earning few ibd firm be slate post triple digit profit growth
755,JNJ,major firm be schedule release stock market today csx csx intel intc johnson johnson jnj jpmorgan chase jpm well fargo wfc be tuesday bank america bac netflix nflx citigroup goldman sachs gs report later week
756,JNJ,stock market overseas be mixed european bourse be mostly lower london ftse fall germany dax lose market asia be mostly higher weak chinese trade datum boost stimulus hope hang sang shanghai composite surge respectively japan nikkei be flat
757,JNJ,stock news qualcomm qcom jump premarket trading wall street journal report activist investor jana partner be call company spin chip unit
758,JNJ,netflix rally premarket ub raise share buy neutral jacked price target stock be cup handle base buy point
759,JNJ,apple aapl edge nearly premarket sale apple watch have reportedly top stock future point mildly lower open monday ahead heavy week corporate earning nasdaq future fall point vs fair value future lose point meanwhile future dow jone industrial average drop point few earning report trickle last week many more company release result week weakness energy be expect have weigh corporate result tepid global domestic demand well higher dollar be also expect have hurt earning few ibd firm be slate post triple digit profit growth major firm be schedule release stock market today csx csx intel intc johnson johnson jnj jpmorgan chase jpm well fargo wfc be tuesday bank america bac netflix nflx citigroup goldman sachs gs report later week stock market overseas be mixed european bourse be mostly lower london ftse fall germany dax lose market asia be mostly higher weak chinese trade datum boost stimulus hope hang sang shanghai composite surge respectively japan nikkei be flat stock news qualcomm qcom jump premarket trading wall street journal report activist investor jana partner be call company spin chip unit netflix rally premarket ub raise share buy neutral jacked price target stock be cup handle base buy point apple aapl edge nearly premarket sale apple watch have reportedly top
760,JNJ,stock bounce day holiday weekend reverse early loss thin gain rise oil price mixed economic datum
761,JNJ,dow jone industrial average nasdaq add tick cross section industry edge higher
762,JNJ,early action stock market today show already stress uptrend additional pressure volume be soft nasdaq manage hold just day move average rise third test resistance line
763,JNJ,crude oil price be key influence monday early trade oil price add early gain benchmark west texas intermediate crude nearly barrel europe brent crude rise more currency be also factor euro push back dollar
764,JNJ,friday weak march payroll report drag stock monday economic news be mixed
765,JNJ,researcher markit report march service purchasing manager index rise february forecast
766,JNJ,institute supply management march service index slip be february shade less forecast
767,JNJ,stock dow be evenly split vs open biggest loser be jpmorgan jpm johnson johnson jnj apiece mcdonald mcd coca cola ko lead index bit less
768,JNJ,barbie maker mattel mat spiked early action riley co upgrade stock buy neutral boost price target base upgrade new chief executive chris sinclair clear turnaround strategy mattel share remain deep month consolidation
769,JNJ,tesla motor tsla whirr announce friday delivery luxury battery power car rise first quarter analyst expectation gain position stock test resistance week move average still deep month consolidation
770,JNJ,most ibd list slip start bell worst loss go alaska air group alk com technology mtsi drop
771,JNJ,upside cambrex cbm sneak ahead new high add last week gain ipg photonic ipgp rise still look enough loft rebound week move average stock bounce day holiday weekend reverse early loss thin gain rise oil price mixed economic datum dow jone industrial average nasdaq add tick cross section industry edge higher early action stock market today show already stress uptrend additional pressure volume be soft nasdaq manage hold just day move average rise third test resistance line crude oil price be key influence monday early trade oil price add early gain benchmark west texas intermediate crude nearly barrel europe brent crude rise more currency be also factor euro push back dollar friday weak march payroll report drag stock monday economic news be mixed researcher markit report march service purchasing manager index rise february forecast institute supply management march service index slip be february shade less forecast stock dow be evenly split vs open biggest loser be jpmorgan jpm johnson johnson jnj apiece mcdonald mcd coca cola ko lead index bit less barbie maker mattel mat spiked early action riley co upgrade stock buy neutral boost price target base upgrade new chief executive chris sinclair clear turnaround strategy mattel share remain deep month consolidation tesla motor tsla whirr announce friday delivery luxury battery power car rise first quarter analyst expectation gain position stock test resistance week move average still deep month consolidation most ibd list slip start bell worst loss go alaska air group alk com technology mtsi drop upside cambrex cbm sneak ahead new high add last week gain ipg photonic ipgp rise still look enough loft rebound week move average
772,JNJ,equity future point weak start stock market today lackluster datum asia nasdaq future shed point vs fair value future lose point future dow jone industrial average fall point
773,JNJ,stock market end big downside reversal wednesday putt market outlook uptrend pressure major average have just confirm new uptrend tuesday
774,JNJ,china producer price slump more expect august straight monthly drop consumer price rise view gain shanghai composite slide hong kong hang seng drop
775,JNJ,japan nikkei tumble machinery order surprising fall second straight month july
776,JNJ,european stock market be also lower france cac shed germany dax lose
777,JNJ,domestic economic news weekly jobless claim slip match consensus econoday
778,JNJ,import price fall august export price drop be more expect
779,JNJ,stock lululemon athletica lulu drop nearly premarket trading soft outlook trump better expect quarterly result
780,JNJ,dollar tree dltr ebay ebay be premarket trade suffering downgrade credit suisse cut dollar store operator underperform neutral ebay be downgrade hold buy cantor fitzgerald
781,JNJ,share palo alto network panw jump premarket trading follow late wednesday blowout quarterly result be steep uptrend more year stock appear be build base
782,JNJ,equity future point weak start stock market today lackluster datum asia nasdaq future shed point vs fair value future lose point future dow jone industrial average fall point stock market end big downside reversal wednesday putt market outlook uptrend pressure major average have just confirm new uptrend tuesday china producer price slump more expect august straight monthly drop consumer price rise view gain shanghai composite slide hong kong hang seng drop japan nikkei tumble machinery order surprising fall second straight month july european stock market be also lower france cac shed germany dax lose domestic economic news weekly jobless claim slip match consensus econoday import price fall august export price drop be more expect stock lululemon athletica lulu drop nearly premarket trading soft outlook trump better expect quarterly result dollar tree dltr ebay ebay be premarket trade suffering downgrade credit suisse cut dollar store operator underperform neutral ebay be downgrade hold buy cantor fitzgerald share palo alto network panw jump premarket trading follow late wednesday blowout quarterly result be steep uptrend more year stock appear be build base
783,JNJ,etf investment strategy tip buy best etfs factor investing be term refer etfs focus stock share specific characteristic factor various market researcher have conclude factor be key outperformance so certain etf operator be try tilt play field favor used index
784,JNJ,chaos seem reign worldwide riot enter greece debt drama wednesday combat continue ukraine china stock be melt yet world stock mutual fund outperformed diversify stock fund year july say lipper inc so investor expect foreign stock fund outperform again second half depend
785,JNJ,energy sector lead etfs tracking higher tuesday investor weigh downbeat retail report lackluster big bank earning landmark nuclear deal iran meanwhile start earning season have modest impact sdpr dow jone industrial average dium etf gain lead advance jpmorgan chase ticker
786,JNJ,next week bring passel earning report large cap drugmaker biotech pharma stock be trading new high yet again novartis bristol myer squibb eli lilly valeant pharmaceutical abbvie biogen be tap busy earning week here quick rundown be especially big week news biogen biib
787,JNJ,generic drug giant mylan announce wednesday have bid share cash stock sizable peer perrigo send stock soar perrigo prgo hadn agree deal mylan myl indicated have be talk proposal be culmination number prior discussion mylan perrigo compelling strategic
788,JNJ,stock open hole then dig deeper wednesday datum drive rally china europe
789,JNJ,nasdaq tumble dow jone industrial average drop show loss
790,JNJ,volume be sharply higher nasdaq higher nyse compare trade same time tuesday
791,JNJ,job news do stock market today favor adp march national employment report show job growth weakest last
792,JNJ,manufacturing datum be mixed researcher markit report march purchasing manager index rise vs february economist consensus bet mild uptick
793,JNJ,institute supply management march ism manufacturing index ease consensus view project dip
794,JNJ,construction spending fall second month be less weak february decline vs slip january economist consensus have estimate gain
795,JNJ,stock dow component open lower merck mrk nike nke johnson johnson jnj hit hardest none nasdaq stock manage gain bottom list regeneron pharmaceutical regn slip heavy trade pull back test support day move average
796,JNJ,twitter twtr rise heavy trade jeffery co initiate coverage stock buy rating price target report note stock be particularly well position benefit online video ad mobile tailwind twitter have be battle clear cup handle buy point
797,JNJ,sear shld jump assign property partnership retail reit general growth property ggp sear have post annual loss continue operate store receive cash stake partnership general growth share dip fraction have shape cup handle base late january high
798,JNJ,lead stock get weak start nearly ibd list downshifting open only noah holding noah unite therapeutic uthr post narrow gain
799,JNJ,ambarella amba take hardest early hit be more left stock bit less most recent buy point stock open hole then dig deeper wednesday datum drive rally china europe nasdaq tumble dow jone industrial average drop show loss volume be sharply higher nasdaq higher nyse compare trade same time tuesday job news do stock market today favor adp march national employment report show job growth weakest last manufacturing datum be mixed researcher markit report march purchasing manager index rise vs february economist consensus bet mild uptick institute supply management march ism manufacturing index ease consensus view project dip construction spending fall second month be less weak february decline vs slip january economist consensus have estimate gain stock dow component open lower merck mrk nike nke johnson johnson jnj hit hardest none nasdaq stock manage gain bottom list regeneron pharmaceutical regn slip heavy trade pull back test support day move average twitter twtr rise heavy trade jeffery co initiate coverage stock buy rating price target report note stock be particularly well position benefit online video ad mobile tailwind twitter have be battle clear cup handle buy point sear shld jump assign property partnership retail reit general growth property ggp sear have post annual loss continue operate store receive cash stake partnership general growth share dip fraction have shape cup handle base late january high lead stock get weak start nearly ibd list downshifting open only noah holding noah unite therapeutic uthr post narrow gain ambarella amba take hardest early hit be more left stock bit less most recent buy point
800,JNJ,medical giant johnson johnson jnj announce friday have enter collaboration tech titan google develop surgical robotic company press release didn give many detail say ethicon device business google googl bring together capability intellectual property expertise create innovative robotic assist surgical platform capable integrate advanced technology goal improve health care delivery operate room financial term be not disclose deal raise prospect real competition intuitive surgical isrg da vinci system dominate business high end robotic surgery only few small startup intrude domain analyst have time speculate acquire intuitive surgical have suffer financial slowdown last couple year google deal suggest company intend develop own technology johnson johnson stock be fraction early trading stock market today so be intuitive surgical stock google stock be fraction follow amy reeve twitter ibd_areeve
801,JNJ,breaking news twitter bring twitter tweetily tweetily tweet tweetily tweetily tweetily tweetily tweet rock tree top day long hoppin boppin singin song little bird jaybird street love hear robin go tweet tweet tweet rockin robin tweet bobby day rockin robin well know
802,JNJ,blockbuster hepatitis drug power sale profit gilead science have become drug industry hit stock gilead gild stock have soar nearly last year new run begin gilead market capitalization be now higher drug giant merck mrk even revenue
803,JNJ,tuesday announcement celgene celg agree acquire receptos rcpt pleased investor stock investor gilead science gild be rumore be interested receptos mean wait edge seat literally only question get gilead be be go buy say evercore isi analyst mark schoenebaum monday video record client stock have moved broker meeting month say re ready do deal crucial question gilead future sign be blockbuster hepatitis franchise be already hit ceiling record launch month however launch do give gilead enormous pile cash buy next major drug line have set wall street collective imagination overdrive target be here be most prominent suggestion have come last few month incyte incy be suggest tuesday nomura analyst ian somaiya note mainly celgene receptos deal incyte drug jakafi treat rare form bone marrow cancer well blood disease call polycythemia vera gilead recently enter blood cancer market zydelig launch just shy year chronic lymphocytic leukemia kind lymphoma somaiya note incyte also have promising pipeline include drug solid tumor incyte month revenue totale mostly jakafi company have have inconsistent quarters bottom line analyst expect record first annual profit next year however grow rapidly stock have reflect bullish expectation relative strength rating accumulation distribution grade incyte stock hit new high early stock market today retreat back yesterday close vertex pharmaceutical vrtx bernstein analyst geoffrey porge cause minor commotion endorse combination back april vertex own hepatitis blockbuster be stomp existence gilead be position dominant player cystic fibrosis only company proven have disease alter treatment devastate condition porge point gilead already sell product market call cayston so have foot door gilead need promise high probability incremental revenue reassure investor future outlook porge write time fact year be many predict vertex cf drug be go do eventually however other analyst doubt such deal happen ground vertex be expensive market cap be hover porge suggest price be gilead prefer buy development stage asset then launch vertex stock have be flat base porge floated idea achillion pharmaceutical achn buy achillion be go opposite direction term size achillion be startup market cap be just however have be subject speculation give have promising hepatitis drug candidate own potentially help gilead extend franchise come next generation treatment november achillion candidate yielded excellent week result clinical trial combine gilead sovaldi fbr capital analyst andrew beren argue buy achillion get gilead expect trend hcv intervention shorten treatment duration currently available week week course then twitter storm speculation erupt achillion abruptly pull investor conference suggest be announce something big turn be achillion have actually sign licensing deal johnson johnson jnj diminish chance gilead buyout bristol myer squibb bmy biotech buy big pharma well actually gilead be bigger bristol now do almost sale last year vs bristol bristol hottest new drug be biologic cancer drug opdivo be thestreet com adam feuerstein be think propose idea back january not sure exactly company gilead buy acquisition focus be oncology be just pharmasset be hepatitis business potential be certainly vast give opdivo alone be expect pass annual sale however price be even more staggering vertex bristol market value have continue go feuerstein prediction now stock hit new year high wednesday close more follow amy reeve twitter ibd_areeve
804,JNJ,china be world largest commerce market estimate baozun bzun be biggest name brand want market sell distribute good online china shanghai base company be founder offer end end service such information technology digital marketing customer service warehousing fulfillment
805,JNJ,biotech isis pharmaceutical isis see share rise thursday company report positive midstage datum rare disease drug candidate development partner biogen biib also get lift isis stock be midday trading stock market today earlier isis stock rise high nearly month high biogen stock
806,JNJ,stock end session slide friday still capped volatile week big loss
807,JNJ,nasdaq jump regain nearly thursday loss rise wipe thursday drop then dow jone industrial average advanced option expiration volume be mixed stock market today accord preliminary datum
808,JNJ,week nasdaq fall lose drop third straight week
809,JNJ,lead stock super micro computer smci rally nearly heavy trade regain day line stock also close back resistance level maker server compute product report fiscal earning tuesday close company be expect earn cent share year
810,JNJ,constellation brand stz rise time high nearly twice average volume close past buy point flat base most case profit be take company report better expect fiscal earning jan thank strong beer sale
811,JNJ,stock market be close monday honor dr martin luther king jr technology coach coh cree cree ibm ibm johnson johnson jnj morgan stanley ms netflix nflx be notable company report earning tuesday national association home builder housing index also be tuesday stock end session slide friday still capped volatile week big loss nasdaq jump regain nearly thursday loss rise wipe thursday drop then dow jone industrial average advanced option expiration volume be mixed stock market today accord preliminary datum week nasdaq fall lose drop third straight week lead stock super micro computer smci rally nearly heavy trade regain day line stock also close back resistance level maker server compute product report fiscal earning tuesday close company be expect earn cent share year constellation brand stz rise time high nearly twice average volume close past buy point flat base most case profit be take company report better expect fiscal earning jan thank strong beer sale stock market be close monday honor dr martin luther king jr technology coach coh cree cree ibm ibm johnson johnson jnj morgan stanley ms netflix nflx be notable company report earning tuesday national association home builder housing index also be tuesday
812,JNJ,big cap biotech biogen idec say move drug candidate alzheimer disease late stage testing early result offer patient hope treatment send biogen stock
813,JNJ,tuesday biofest conference boston biogen biib research development head dougla william say interim analysis patient phase trial biib be jointly develop japan eisai drug firm be good enough push straight phase number win be formally report spring william say statistically significant improvement cognition appear week treatment
814,JNJ,aggressively prepare
815,JNJ,study not do yet be still patient re do additional dose exploration say william re actually plan very aggressively start phase program base ve see so far
816,JNJ,interesting feature result support beta amyloid hypothesis alzheimer disease have long be suspect not definitively prove beta amyloid be toxic form normally benign protein amyloid attack neuron alzheimer sufferer eventually visible plaque make beta amyloid dead neuron form brain however remain unclear reduce plaque reduce symptom
817,JNJ,william say see dose dependent reduction beta amyloid first time large trial associate improvement cognition support idea biogen drug modify disease progression other drugmaker have base drug hypothesis fail
818,JNJ,probably highest profile flameout be bapineuzumab co develop johnson johnson jnj pfizer pfe elan fail clinical trial eli lilly lly solanezumab do well enough move phase testing most analyst give low chance success
819,JNJ,early treatment be key
820,JNJ,biogen william say know earlier test key be catch disease early patient biogen study have only mild symptom eli lilly used same approach solanezumab william say biib have mechanism somewhat roche rhhby gantenerumab recently start phase testing mildly ill patient
821,JNJ,good alzheimer treatment now market opportunity successful drug be enormous note tuesday rbc capital market analyst michael yee write bull case such drug pull much year
822,JNJ,bottom line be think today positive phase alzheimer datum biib prodromal mild patient add mount evidence drug work earlier patient rather historical failure moderate sicker patient drug be first test write so believe be new say renew wave investor enthusiasm alzheimer drug go forward
823,JNJ,caution past failure
824,JNJ,nonetheless yee note bear still point early stage success follow late stage failure have be see leerink analyst joseph schwartz make same point
825,JNJ,expect investor take cautiously optimistic view give failure rate disease modify drug alzheimer disease lack kol key opinion leader consensus protein target be most relevant write big cap biotech biogen idec say move drug candidate alzheimer disease late stage testing early result offer patient hope treatment send biogen stock tuesday biofest conference boston biogen biib research development head dougla william say interim analysis patient phase trial biib be jointly develop japan eisai drug firm be good enough push straight phase number win be formally report spring william say statistically significant improvement cognition appear week treatment aggressively prepare study not do yet be still patient re do additional dose exploration say william re actually plan very aggressively start phase program base ve see so far interesting feature result support beta amyloid hypothesis alzheimer disease have long be suspect not definitively prove beta amyloid be toxic form normally benign protein amyloid attack neuron alzheimer sufferer eventually visible plaque make beta amyloid dead neuron form brain however remain unclear reduce plaque reduce symptom william say see dose dependent reduction beta amyloid first time large trial associate improvement cognition support idea biogen drug modify disease progression other drugmaker have base drug hypothesis fail probably highest profile flameout be bapineuzumab co develop johnson johnson jnj pfizer pfe elan fail clinical trial eli lilly lly solanezumab do well enough move phase testing most analyst give low chance success early treatment be keybiogen william say know earlier test key be catch disease early patient biogen study have only mild symptom eli lilly used same approach solanezumab william say biib have mechanism somewhat roche rhhby gantenerumab recently start phase testing mildly ill patient good alzheimer treatment now market opportunity successful drug be enormous note tuesday rbc capital market analyst michael yee write bull case such drug pull much year bottom line be think today positive phase alzheimer datum biib prodromal mild patient add mount evidence drug work earlier patient rather historical failure moderate sicker patient drug be first test write so believe be new say renew wave investor enthusiasm alzheimer drug go forward caution past yee note bear still point early stage success follow late stage failure have be see leerink analyst joseph schwartz make same point expect investor take cautiously optimistic view give failure rate disease modify drug alzheimer disease lack kol key opinion leader consensus protein target be most relevant write
826,JNJ,top rank drugmaker be ibd lead global growth stock be buy range jazz pharmaceutical jazz appear have gain traction disappointing nov stock clear buy point only reverse lower heavy volume jazz rely heavily sale narcolepsy drug xyrem have re-cover
827,JNJ,major average give early gain limp close monday ahead busy week earning report
828,JNJ,nasdaq edge nearly lower back level have surpass intraday dow jone industrial average fall more volume be mixed run slightly higher nasdaq lower nyse stock market today accord preliminary figure
829,JNJ,broader market apple aapl give intraday gain spark report strong apple watch pre order close slightly lower volume be light stock continue form flat base
830,JNJ,sina sina gap sank give day move average session support line internet portal microblog spinoff weibo wb decline report face sanction chinese government
831,JNJ,upside leisure movie related group be top gainer lead jump netflix nflx share have advanced past session ub boost rating buy neutral price target video stream provider report earning wednesday close
832,JNJ,jetblue airway jblu soar new high fast trade report strong march passenger traffic datum carrier report increase passenger revenue available seat mile rise total passenger
833,JNJ,other airline stock follow suit gain include virgin america va skywest skyw spirit airline save climb nearly
834,JNJ,ibd stock armour ua run nearly record best heavy volume stock be extend past cup handle buy point sale week end april jump vs year level accord deutsche bank
835,JNJ,earning tap tuesday include intel intc johnson johnson jnj jpmorgan chase jpm well fargo wfc
836,JNJ,http education investor com lesson aspx id sourceid follow nancy gondo twitter ibd_ngondo major average give early gain limp close monday ahead busy week earning report nasdaq edge nearly lower back level have surpass intraday dow jone industrial average fall more volume be mixed run slightly higher nasdaq lower nyse stock market today accord preliminary figure broader market apple aapl give intraday gain spark report strong apple watch pre order close slightly lower volume be light stock continue form flat base sina sina gap sank give day move average session support line internet portal microblog spinoff weibo wb decline report face sanction chinese government upside leisure movie related group be top gainer lead jump netflix nflx share have advanced past session ub boost rating buy neutral price target video stream provider report earning wednesday close jetblue airway jblu soar new high fast trade report strong march passenger traffic datum carrier report increase passenger revenue available seat mile rise total passenger other airline stock follow suit gain include virgin america va skywest skyw spirit airline save climb nearly ibd stock armour ua run nearly record best heavy volume stock be extend past cup handle buy point sale week end april jump vs year level accord deutsche bank earning tap tuesday include intel intc johnson johnson jnj jpmorgan chase jpm well fargo wfc http education investor com lesson aspx id sourceid follow nancy gondo twitter ibd_ngondo
837,JNJ,top rate biotech medivation mdvn report round successful trial result prostate cancer drug xtandi thursday give stock brief bump early trading medivation partner astella say midstage trial compare xtandi head head bicalutamide better know astrazeneca azn casodex show considerable survival benefit former castration resistant prostate cancer median progression free survival group take xtandi be month compare month bicalutamide group rate serious adverse event be same xtandi be approve only metastatic prostate cancer study include metastatic metastatic patient have be castrated hormonally treat hadn receive chemotherapy rbc capital market analyst simo simeonidis write help bring xtandi earlier stage patient believe datum help drug get additional penetration pre chemo therapy set believe have upper hand johnson johnson jnj zytiga mainly due convenience simeonidis write research note however believe significant adoption earlier stage disease require phase iii datum take many year read xtandi strong ramp launch have turn medivation top perform biotech ibd composite rating big cap valuation medivation stock jump gate stock market today early trading be less medivation stock touch time high march follow amy reeve twitter ibd_areeve
838,JNJ,cardinal health cah announce monday be buy johnson johnson jnj cardiology endovascular device business cash cardinal drug wholesaler look boost cardiovascular business say acquisition cordis boost earning cent share age population accompany demand less invasive medical
839,JNJ,re yes folk official more speculation be run snl make announcement saturday night open skit devote hill bill tag line
840,JNJ,buckle america clinton be backkkkkkk
841,JNJ,then sunday hillary take social medium airwave used available outlet twitter twtr youtube googl instagram facebook fb match com eharmony ourtime older date announce
842,JNJ,get ready do something too run president be hit road earn vote
843,JNJ,trumpet blare chelsea congratulating mom twitter tell proud be chuck schumer ny senior senator throw weight nyc mayor blasio refuse support promise raise taxe wealthy redistribute not so much just fyi be start travel country build brand be disaster
844,JNJ,republican well launch overdrive mud already start fly rand paul tell represent be wrong washington want look mirror well ted cruz run tv ad tell need embrace far right wing conservatism vs liberal agenda jeb bush bush dynasty be not run yet send email mins announcement
845,JNJ,moment hillary clinton officially announce white house bid stop
846,JNJ,go be straightforward isn go be easy hillary plan raise white house already have donor ready year democrat control have already do untold damage more year clinton control only make do ll need step never right now need give show re ready defeat hillary
847,JNJ,be go be long fight together stop thank help ll be hearing again soon
848,JNJ,jeb
849,JNJ,do say long fight do say be hearing again soon do action gop scream desperation already wasn mins attack start boy more month be anyone else exhaust yet
850,JNJ,now welcome presidential election cycle none have effect mkts today provide so much discussion race be now underway watch marco rubio martin malley joe biden elizabeth warren chris christie name just few other possible candidate star show
851,JNJ,back action lack stock marched higher friday just earning season get underway big news day be general electric ge be get banking business news send share ge soar add company mkt cap add couple story mood be buoyant aside be very little way directional driver be reflect volume vix yet stock moved mostly higher course trading day be know fed style manipulation cause mkt build gain make earlier week just ahead tax day earning
852,JNJ,yes folk earning season be have not start so bad concern dollar have not rear ugly yet fact alcoa aa show big multinational have operation overseas benefit weaker currency so net net maybe not disaster analyst have be singing
853,JNJ,be say know earning be expect be yoy be reduction estimate course be set stage investor be disappoint have mkt already price now have be well televise so most part market be prepared so company have so misguided street analyst be so touch business most likely expect company meet beat lower estimate look point company miss big be just so touch reality
854,JNJ,remember time announce earning be already history so usual investor want know future look listen hint future be brighter company try insulate be more cautious outlook go forward due rise dollar mixed global economy
855,JNJ,rise dollar be reset landscape world boy be now be separated man week washington play host imf world bank global central banker finance minister world discuss exactly stronger dollar do global economy fed catch rock hard place assess drag stronger dollar have still weak economy scale back expectation rise rate anytime soon have see dramatic move global mkts month cycle european mkts approach make new high eurostoxx index asian mkts also clocking massive gain japan china hong kong vs
856,JNJ,morning future be slightly currently pt trend still right time high have busy week ahead earning take center stage name jpmorgan chase jpm american express axp general electric well fargo wfc johnson johnson jnj kellogg goldman sachs gs lead hit parade
857,JNJ,eco front be big week tuesday get retail sale exp ex auto gas be huge improvement last month ppi ex food energy later week get empire state manf industrial production capacity utilization fed beige book housing start mil build permit mil cpi
858,JNJ,mkt do feel bit tired think continue hit head here resistance time high ish also do not expect see meltdown broader mkt investor find support dma
859,JNJ,europe morning mkts be trading flat line investor trader take breath ahead packed week ftse cac flat dax flat eurostoxx spain italy
860,JNJ,asia mkts higher china rocket even face weak macro datum march chinese trade balance be expect export drop yoy vs think more stimulus japan flat china hong kong asx
861,JNJ,kenny polcari be director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate re yes folk official more speculation be run snl make announcement saturday night open skit devote hill bill tag line buckle america clinton be backkkkkkk then sunday hillary take social medium airwave used available outlet twitter twtr youtube googl instagram facebook fb match com eharmony ourtime older date announce get ready do something too run president be hit road earn vote trumpet blare chelsea congratulating mom twitter tell proud be chuck schumer ny senior senator throw weight nyc mayor blasio refuse support promise raise taxe wealthy redistribute not so much just fyi be start travel country build brand be disaster republican well launch overdrive mud already start fly rand paul tell represent be wrong washington want look mirror well ted cruz run tv ad tell need embrace far right wing conservatism vs liberal agenda jeb bush bush dynasty be not run yet send email mins announcement moment hillary clinton officially announce white house bid stop go be straightforward isn go be easy hillary plan raise white house already have donor ready year democrat control have already do untold damage more year clinton control only make do ll need step never right now need give show re ready defeat hillary be go be long fight together stop thank help ll be hearing again soon jebdid say long fight do say be hearing again soon do action gop scream desperation already wasn mins attack start boy more month be anyone else exhaust yet now welcome presidential election cycle none have effect mkts today provide so much discussion race be now underway watch marco rubio martin malley joe biden elizabeth warren chris christie name just few other possible candidate star show back action lack stock marched higher friday just earning season get underway big news day be general electric ge be get banking business news send share ge soar add company mkt cap add couple story mood be buoyant aside be very little way directional driver be reflect volume vix yet stock moved mostly higher course trading day be know fed style manipulation cause mkt build gain make earlier week just ahead tax day earning yes folk earning season be have not start so bad concern dollar have not rear ugly yet fact alcoa aa show big multinational have operation overseas benefit weaker currency so net net maybe not disaster analyst have be singing be say know earning be expect be yoy be reduction estimate course be set stage investor be disappoint have mkt already price now have be well televise so most part market be prepared so company have so misguided street analyst be so touch business most likely expect company meet beat lower estimate look point company miss big be just so touch reality remember time announce earning be already history so usual investor want know future look listen hint future be brighter company try insulate be more cautious outlook go forward due rise dollar mixed global economy rise dollar be reset landscape world boy be now be separated man week washington play host imf world bank global central banker finance minister world discuss exactly stronger dollar do global economy fed catch rock hard place assess drag stronger dollar have still weak economy scale back expectation rise rate anytime soon have see dramatic move global mkts month cycle european mkts approach make new high eurostoxx index asian mkts also clocking massive gain japan china hong kong vs morning future be slightly currently pt trend still right time high have busy week ahead earning take center stage name jpmorgan chase jpm american express axp general electric well fargo wfc johnson johnson jnj kellogg goldman sachs gs lead hit parade eco front be big week tuesday get retail sale exp ex auto gas be huge improvement last month ppi ex food energy later week get empire state manf industrial production capacity utilization fed beige book housing start mil build permit mil cpi mkt do feel bit tired think continue hit head here resistance time high ish also do not expect see meltdown broader mkt investor find support dma europe morning mkts be trading flat line investor trader take breath ahead packed week ftse cac flat dax flat eurostoxx spain italy asia mkts higher china rocket even face weak macro datum march chinese trade balance be expect export drop yoy vs think more stimulus japan flat china hong kong asx kenny polcari be director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
862,JNJ,dividend etfs come stripe select few focus blue chip stock be screen financial health bonus re cheapest exchange trade fund equity income category ben johnson global director etf research morningstar inc especially like schwab dividend equity schd view very low cost
863,JNJ,halozyme therapeutic halo stock rise new high wednesday biotech announce collaboration abbvie abbv be worth more
864,JNJ,abbvie agree pay upfront milestone payment target plan work used halozyme
865,JNJ,enhanze platform design aid dispersion absorption injectable drug abbvie also pay unspecified tiered royalty sale product go market enhanze be already be used collaboration roche rhhby pfizer pfe johnson johnson jnj baxter international bax
866,JNJ,halo rise stock market today late afternoon trading
867,JNJ,halozyme stock have have strong achieve ibd relative strength rating help clinical trial datum lead drug candidate pegph sunday company interim analysis midstage study pegph metastatic pancreatic cancer push stock new high monday exceed wednesday
868,JNJ,halozyme only product market right now be hylenex enhanze be used aid injectable drug be not enough make profit analyst be expect halozyme make cent share revenue
869,JNJ,follow amy reeve twitter ibd_areeve halozyme therapeutic halo stock rise new high wednesday biotech announce collaboration abbvie abbv be worth more abbvie agree pay upfront milestone payment target plan work used halozyme enhanze platform design aid dispersion absorption injectable drug abbvie also pay unspecified tiered royalty sale product go market enhanze be already be used collaboration roche rhhby pfizer pfe johnson johnson jnj baxter international bax halo rise stock market today late afternoon trading halozyme stock have have strong achieve ibd relative strength rating help clinical trial datum lead drug candidate pegph sunday company interim analysis midstage study pegph metastatic pancreatic cancer push stock new high monday exceed wednesday halozyme only product market right now be hylenex enhanze be used aid injectable drug be not enough make profit analyst be expect halozyme make cent share revenue follow amy reeve twitter ibd_areeve
870,JNJ,triumph jeopardy make stride health care industry ibm ibm watson artificial intelligence supercomputer help disrupt oil gas industry wednesday ibm say be team woodside australia largest independent oil gas company use watson give employee access unstructured historical datum contain project
871,JNJ,abbvie be make major oncology push agree late wednesday pay acquire pharmacyclic pcyc maker blockbuster blood cancer drug imbruvica abbvie pay share cash stock pharmacyclic close price wednesday biotech close record high wednesday buyout buzz
872,JNJ,fda last month approve first biosimilar drug take first step lucrative potentially disruptive field medicine pfizer pfe be move big biosimilar hospira hsp acquisition have estimate global biosimilar sale hit year sale be just yearly now mainly european union march approval zarxio novartis nvs biosimilar version amgen amgn age blockbuster neupogen market crack open fda become more comfortable re go see biosimilar get lot more easily predict jitendra malik attorney alston bird specialize intellectual property drug approval issue first always hardest get fda be more cautious uncharted territory year biotech revolution not only bring life save new medicine also profit save protection competitor traditional pharmaceutical be assemble machine different chemical ingredient biologic drug be form biological process high tech version fermentation many process be trade secret patent have expiration date reverse engineeringas more company become familiar biotech manufacturing however be able reverse engineer process create biosimilar drug not identical original close enough novartis sandoz unit historically devote traditional generic drug have be pioneer field already selling biosimilar version neupogen sister drug epogen europe many other be line border own product hospira teva pharmaceutical teva have launch own version neupogen europe company be work biosimilar version abbvie abbv blockbuster immunology drug humira include sandoz hospira pfizer prior acquire hospira amgen german pharma giant boehringer ingelheim abbvie announce richly price acquisition pharmacyclic pcyc march analyst figured be drive need blockbuster face humira competitor key biologic face rivalsother drug biosimilar version late stage testing include biogen biib cancer drug rituxan roche rhhby breast cancer treatment herceptin johnson johnson jnj remicade merck mrk be develop biosimilar version sanofi sny popular diabetes drug lantus hospira biosimilar version remicade already have be approve europe be expect be february fda delay advisory panel meeting product due information request pending sponsor application analyst be closely watch biosimilar rollout europe remicade be approve variety ailment psoriasis inflammatory bowel disease ibd rheumatoid arthritis provide test case willing different specialist be use knockoff independent study iosimilar remicade be approve study account remicade sale write leerink analyst jason gerberry december research report specialist ve speak do not plan use remicade ibd indication clinical study report late europe biosimilar version neupogen have take market analyst generally expect same much depend drug be price generic pharmaceutical generally go fraction original drug price drive retail value so much original developer stop marketing product do keep manufacturing biosimilar be more difficult expensive develop so be fewer player less pricing competition novartis still hasn launch zarxio be keep mum price company spokeswoman geena wardaki tell investor business daily email biosimilar general typically expect discount be range reference biologic however depend therapeutic area market channel number competitor reimbursement situation cms vs fda biosimilarson tuesday center medicare medicaid service cms announce physician prescribe medicare part drug be reimburse biosimilar same way original drug average selling price pharmacy dispense part drug exclude original list prefer drug favor biosimilar wish so long provide transitional supply original patient already take imply cms be treat biosimilar effectively interchangeable original further muddy issue already unclear fda rule zarxio be used used approve neupogen boost blood cell various kind cancer patient not technically interchangeable mean doctor prescribe original drug pharmacy fill biosimilar doesn matter so much zarxio drug be administer hospital clinic rather retail pharmacy nonetheless drugmaker find worthwhile file separately approval likely involve study patient switch product say expert matter be deterrent second person come say malik show product be interchangeable doesn necessarily mean applicant road do same thing just piggybac lot case structure original drug be not perfectly know do have spend time convince person same yet question be aggressive payer pharmacy benefit manager pbms be push biosimilar ahead original drug save cost march report analyst gerberry write unnamed payer specialist have tell payer probably leave grace period month doctor get used biosimilar then start lean harder specialist expect policy grandfather stable patient receive tnf therapy remicade same reimbursement new patient new switch likely be require go prior authorization require patient use biosimilar first write gillian woollett senior vice president consult firm avalere health say issue be naming company develop new drug get generic also call nonproprietary name brand name generic name filgrastim case neupogen be used generic drugmaker patent expire name many biologic approve fda even have never be compare also share nonproprietary name be simply name active ingredient not name product biosimilar most other market share nonproprietary name reference product too first approval fda assign maker placeholder nonproprietary name case filgrastim sndz naming thing be important space watch woollett tell investor business daily think be go be brand product biosimilar most originator biologic have brand name again generic drug situation be totally different most generic do not have brand name
873,JNJ,big pharma abbvie deal acquire hot biotech pharmacyclic be meet widespread skepticism abbvie investor thursday send abbvie stock fall thursday abbvie abbv announce cash stock acquisition late wednesday rumor have be swirl afternoon novartis nvs johnson johnson jnj be engage bidding war pharmacyclic pcyc surprised wall street abbvie turn be buyer especially already have partnership pharmacyclic market blood cancer drug imbruvica doesn really make sense be abbvie prevailing pcyc partner natural buyer jnj secure pcyc pay price do asset bernstein analyst geoffrey porge write research note thursday believe jnj be only buyer able secure operational advantage full control buy partner jnj more other buyer have be able maximize synergy reduce product support single commercial organization cash stock deal value pharmacyclic share stock rise thursday stock trade start year conference call analyst early thursday abbvie ceo richard gonzalez affirm bidding war have come contestant didn name justified price cite enormous market potential imbruvica launch late bring pharmacyclic last year abbvie reckon imbruvica bring firm year peak change exist deal split profit evercore isi say assume total worldwide sale make imbruvica biggest selling cancer drug history say analyst mark schoenebaum analyst consensus sale estimate be bullish not bullish latest year available average estimate be call gonzalez break assumption number growth come expansion imbruvica currently approve used second line treatment chronic lymphocytic leukemia cll mantle cell lymphoma well anytime treatment less common condition cll deletion macroglobulemia additional come expansion first line treatment cll lymphoma gonzalez say have very high probability success give clinical trial datum rest come unspecified amount accounting approval other cancer cell more speculative assumption product also work solid tumor do see datum solid tumor be impressed gonzalez say many analyst view abbvie late stage blood cancer candidate potential competitor imbruvica chief scientific officer michael severino say drug potentially work combination expect launch clinical trial prove general executive say acquisition boost abbvie entire cancer business much be change focus abbvie make fortune immunology blockbuster drug humira however humira likely get biosimilar competition amgen amgn pfizer pfe other patent expire call gonzalez affirm abbvie commitment humira defend patent court develop new improve version drug say have nothing do price paid pharmacyclic analyst porge however say premium here be explain abbvie desperation
874,JNJ,stock be still only modestly higher friday midday blowout job report
875,JNJ,nasdaq rise dow jone industrial average climb record high thank part gain goldman sachs gs johnson johnson jnj volume be run higher board stock market today
876,JNJ,ulta beauty ulta have cut gain half beauty supply retailer deliver result view late thursday guidance fourth quarter earning be slightly view friday high stock be nearly past buy point big cup handle
877,JNJ,taser international tasr jump new high fast trade now past buy point cup base clear oct taser already rally thursday news win big order body camera evidence management product
878,JNJ,stretched loss gapping lower late thursday lackluster sale guidance focuse discount retailer also name chief operate officer joel anderson new ceo stock gap day day move average open
879,JNJ,ambarella amba be only fractionally lower pare loss stock be nearly late thursday better expect result upbeat sale outlook stock be still only modestly higher friday midday blowout job report nasdaq rise dow jone industrial average climb record high thank part gain goldman sachs gs johnson johnson jnj volume be run higher board stock market today ulta beauty ulta have cut gain half beauty supply retailer deliver result view late thursday guidance fourth quarter earning be slightly view friday high stock be nearly past buy point big cup handle taser international tasr jump new high fast trade now past buy point cup base clear oct taser already rally thursday news win big order body camera evidence management product stretched loss gapping lower late thursday lackluster sale guidance focuse discount retailer also name chief operate officer joel anderson new ceo stock gap day day move average open ambarella amba be only fractionally lower pare loss stock be nearly late thursday better expect result upbeat sale outlook
880,JNJ,specialty drugmaker mallinckrodt early wednesday beat analyst expectation handily fiscal report stock fall company put provide hope guidance wake food drug administration decision hit best selling drug fiscal fourth quarter end mallinckrodt mnk make share exclude
881,JNJ,specialty drugmaker mallinckrodt beat analyst expectation handily fiscal report didn provide hope guidance wake fda decision hit best selling drug
882,JNJ,mallinckrodt mnk stock be early trading stock market today be now more touch time high nov
883,JNJ,fiscal fourth quarter end mallinckrodt make share exclude time item year earlier quarter cent analyst consensus accord thomson reuter sale rise street estimate
884,JNJ,quick note client earning release company conference call analyst discuss result leerink analyst jason gerberry write beat come combination cost control strength specialty generic business especially generic version johnson johnson jnj adhd drug concerta however last week fda say longer recognize mallinckrodt drug bioequivalent concerta basically push market favor rival actavis act kremer urban development
885,JNJ,gerberry write expect guidance update conference call
886,JNJ,feel month occur just last week mallinckrodt cfo matthew harbaugh say call response analyst question subject need spend more time digest be go play
887,JNJ,indeed mallinckrodt executive say fda decision come total surprise agency normally open such topic discussion beforehand accord ceo mark trudeau trudeau reiterate firm intention challenge decision say evidence be mallinckrodt side
888,JNJ,call analyst be also frustrated lack visibility acthar immunology drug mallinckrodt acquire buy questcor pharmaceutical august questcor be publicly trade wall street grow accustomed get detailed prescription datum market indication
889,JNJ,harbaugh say acthar prescription rise year earlier quarter be somewhat slower historic rate warn read too much number
890,JNJ,be questcor hand close say questcor work calendar year basis work call basis lot apple orange get first quarter so clean mallinckrodt basis
891,JNJ,term overall performance however harbaugh do say fiscal growth be load back half year due concerta issue seasonality
892,JNJ,side sale injectable painkiller ofirmev mallinckrodt acquire buyout cadence pharmaceutical march jump year year acquisition asset have help goose mallinckrodt growth be sluggish company be first spun covidien cov july drive mallinckrodt strong ibd composite rating
893,JNJ,follow amy reeve twitter ibd_areeve specialty drugmaker mallinckrodt beat analyst expectation handily fiscal report didn provide hope guidance wake fda decision hit best selling drug mallinckrodt mnk stock be early trading stock market today be now more touch time high nov fiscal fourth quarter end mallinckrodt make share exclude time item year earlier quarter cent analyst consensus accord thomson reuter sale rise street estimate quick note client earning release company conference call analyst discuss result leerink analyst jason gerberry write beat come combination cost control strength specialty generic business especially generic version johnson johnson jnj adhd drug concerta however last week fda say longer recognize mallinckrodt drug bioequivalent concerta basically push market favor rival actavis act kremer urban development gerberry write expect guidance update conference call feel month occur just last week mallinckrodt cfo matthew harbaugh say call response analyst question subject need spend more time digest be go play indeed mallinckrodt executive say fda decision come total surprise agency normally open such topic discussion beforehand accord ceo mark trudeau trudeau reiterate firm intention challenge decision say evidence be mallinckrodt side call analyst be also frustrated lack visibility acthar immunology drug mallinckrodt acquire buy questcor pharmaceutical august questcor be publicly trade wall street grow accustomed get detailed prescription datum market indication harbaugh say acthar prescription rise year earlier quarter be somewhat slower historic rate warn read too much number be questcor hand close say questcor work calendar year basis work call basis lot apple orange get first quarter so clean mallinckrodt basis term overall performance however harbaugh do say fiscal growth be load back half year due concerta issue seasonality side sale injectable painkiller ofirmev mallinckrodt acquire buyout cadence pharmaceutical march jump year year acquisition asset have help goose mallinckrodt growth be sluggish company be first spun covidien cov july drive mallinckrodt strong ibd composite rating follow amy reeve twitter ibd_areeve
894,JNJ,specialty drugmaker mallinckrodt mnk say thursday fda be longer recognize generic adhd drug equivalent original essentially knock market mallinckrodt be morning trading stock market today malinckrodt stock touch time high nov
895,JNJ,drug question methylphenidate be generic version concerta johnson johnson jnj best selling attention deficit treatment go patent new guideline issue last week regard sameness generic drug brand model fda say be reclassify mallinckrodt drug therapeutically inequivalent
896,JNJ,mallinckrodt objected press release methylphenidate have be market almost year more dose have be administer only adverse reaction record
897,JNJ,face agency precipitous decision mallinckrodt continue defend safety efficacy methylphenidate product mallinckrodt ceo mark trudeau say statement be consider option persuade agency engage meaningful dialogue regard science include potential legal action
898,JNJ,company say soon update guidance account change due report fiscal earning nov
899,JNJ,leerink analyst jason gerberry write note thursday modeled methylphenidate sale fiscal consistent management guidance
900,JNJ,estimate base case ep contribution cent assume operate margin tax rate cost offset write worst case assume opex offset ep contribution be high cent
901,JNJ,sterne agee analyst shibani malhotra see upside actavis act have own generic concerta agreement malhotra estimate actavis drug hold half market rest split mallinckrodt kremer urban development co kudco impax laboratory ipxl also have pending application own version
902,JNJ,kudco product also lose ab rating actavis be poise regain generic concerta market rest provide significant upside current estimate malhotra write research note thursday even kudco retain ab rating actavis benefit lack competition mallinckrodt
903,JNJ,malhotra estimate add annual revenue actavis get generic concerta bring more cent ep
904,JNJ,actavis stock be morning trading thursday
905,JNJ,follow amy reeve twitter ibd_areeve specialty drugmaker mallinckrodt mnk say thursday fda be longer recognize generic adhd drug equivalent original essentially knock market mallinckrodt be morning trading stock market today malinckrodt stock touch time high nov drug question methylphenidate be generic version concerta johnson johnson jnj best selling attention deficit treatment go patent new guideline issue last week regard sameness generic drug brand model fda say be reclassify mallinckrodt drug therapeutically inequivalent mallinckrodt objected press release methylphenidate have be market almost year more dose have be administer only adverse reaction record face agency precipitous decision mallinckrodt continue defend safety efficacy methylphenidate product mallinckrodt ceo mark trudeau say statement be consider option persuade agency engage meaningful dialogue regard science include potential legal action company say soon update guidance account change due report fiscal earning nov leerink analyst jason gerberry write note thursday modeled methylphenidate sale fiscal consistent management guidance estimate base case ep contribution cent assume operate margin tax rate cost offset write worst case assume opex offset ep contribution be high cent sterne agee analyst shibani malhotra see upside actavis act have own generic concerta agreement malhotra estimate actavis drug hold half market rest split mallinckrodt kremer urban development co kudco impax laboratory ipxl also have pending application own version kudco product also lose ab rating actavis be poise regain generic concerta market rest provide significant upside current estimate malhotra write research note thursday even kudco retain ab rating actavis benefit lack competition mallinckrodt malhotra estimate add annual revenue actavis get generic concerta bring more cent ep actavis stock be morning trading thursday follow amy reeve twitter ibd_areeve
906,JNJ,medivation mdvn stock be early thursday company better expect fourth quarter earning biotech benefit strong sale xtandi prostate cancer drug report wednesday close medivation post earning share just cent well consensus analyst estimate revenue nearly triple
907,JNJ,interest rate record lows past several year etfs invest dividend pay stock have be popular income alternative investor remain advantageous now federal reserve be seriously consider hike rate depend specific investment objective fund accord michael rawson research analyst morningstar inc look stock high dividend payout typically underperform economy be do well say company usually invest less future growth utility reit consumer staple therefore don participate much economy be grow very rapidly vanguard high dividend yield index etf vym have asset month yield net fee however be tilt value stock note rawson so be not most favorable be economy be grow so investor look consider dividend etf value stock tilt rawson say important consider etf be tilt higher yielding dividend pay stock tend be value stock do tilt stock grow dividend future company be able increase dividend consistently be usually company very strong brand name very strong market position note example be apple aapl yield dividend hasn be steady dividend growth be reason like vanguard dividend appreciation etf vig look company have raise dividend straight year have lower yield focus quality stock thus have slightly bigger exposure growth company addition have razor thin expense ratio have return average annual past year vs advance top holding be wal mart store wmt pepsico pep johnson johnson jnj coca cola ko fed be likely raise rate think vanguard high dividend yield get hurt more vanguard dividend appreciation rawson say element consider be fund tilt size large cap small cap stock ishare select dividend dvy be highest yielding etfs yield fund be tilt midcap deep value stock make more volatile addition expense ratio make more expensive dividend etfs note morningstar analyst abby woodham report fed raise rate investor consider shift stock more bond say rawson reason person usually hold bond be income diversification stability reason dividend etfs be not always good substitute bond etfs be don have stability bond say investor also need be mindful expense be high tend eat yield etf cheapest etf availableschwab dividend equity etf schd be cheapest dividend etfs expense ratio just nearly asset have pretty attractive yield still maintain focus quality stock look company have paid dividend past year select do well fundamental metric such cash flow debt return equity dividend yield dividend growth return average annual past year top holding be pfizer pfe verizon communication vz chevron cvx exxon mobil xom international fund tend provide higher yield investor need be able stomach higher volatility due currency fluctuation dollar recent strength have hit return nonhedged etfs such emerge market equity income fund dem ishare international select dividend idv
908,JNJ,skin deep success didn satisfy ophelia mitchell america first black model land job first partly fair complexion professional chance remain scarce black frustrated career mind southerner so do something year black be beautiful movement become pioneer modele
909,JNJ,most stock sector leader have already break illumina ilmn be gear make move stock appear thursday sector leader begin look start new flat base striking jan high past few day action shallow double bottom be take shape illumina be
910,JNJ,specialty drug maker mallinckrodt mnk report mixed fiscal result tuesday send stock much quarter end dec mallinckrodt earning exclude time item more double year earlier quarter share beating analyst consensus cent sale rise short street average
911,JNJ,biotech globeimmune gbim say wednesday hepatitis drug develop gilead science gild fail midstage trial globeimmune stock lose half value gilead stock rise globeimmune say gs therapeutic vaccine license gilead didn meet trial primary endpoint reduce hepatitis surface antigen hbsag week
912,JNJ,analyst give mixed reviews wednesday achillion pharmaceutical achn new partnership johnson johnson jnj stock plunge ub jmp security downgrade stock neutral potential massive value create event buyout be limit hepatitis drug deal recently monday achillion pharmaceutical share shot
913,JNJ,small biotech achillion pharmaceutical achn announce late tuesday have enter collaboration johnson johnson jnj develop hepatitis drug potentially worth more agree invest achillion upfront promise development regulatory sale milestone payment company successfully launch pipeline
914,JNJ,investor build equity income portfolio seek etfs hold big dividend payer other focus exchange trade fund consistently grow dividend more important high yield dividend growth stable income stream say lead etf expert investor look fund source cash flow be disappoint find income stream be volatile say ben johnson director global etf research morningstar johnson recently study dividend etf strategy focus large cap screen stock steadily pay grow dividend also generate stable income vs peer dividend drawdown year year decline annual dividend payment be relatively muted even post financial crisis vanguard dividend appreciation vig bellwether etf count ibm ibm johnson johnson jnj top holding stock be classic income play earn most stable possible ibd dividend stability factor ibm have dsf score show stable firm dividend history be year period lower number mean more stable history first trust value line dividend fvd asset hold furniture maker leggett platt leg stock have dsf powershare dividend achiever pfm have asset big stake ibm well altrium group mo tobacco firm have dsf spdr dividend sdy asset hold johnson johnson leggett platt kimberly clark kmb top holding huggy maker have dsf month yield etfs range pfm sdy compare dividend fund investor look yield isolation be run risk yield be volatile time equity income dhs yielded roughly february yield today etps exchange trade product be clearly take more risk other go build income oriented portfolio johnson say less volatile yield say important look fund track benchmark incorporate sort dividend sustainability screen add investor place premium income stability particularly bear market dividend yield vs growthdividend growth provide historical context yield investor etfs grow dividend have better shot cash stream beat rate inflation time vig screen stock have increase dividend least consecutive year have expense ratio lowest dividend focuse etfs sdy look stock have raise dividend past consecutive year have expense ratio fee invest vig be year date wednesday produce annual average gain past year opposed sdy same period
915,JNJ,even better big dividend income stream count here be most reliable dividend payer yield also beat market ibd dividend stability factor show stable company dividend history be year period lower number more stable dividend history johnson johnson jnj be
916,JNJ,ibm ibm announce investment company advance online travel shopping apps work powerful watson computer ibm be part funding round wayblazer travel search discovery company goal redefine consumer plan personalize purchase travel accord ibm press release say wayblazer used
917,JNJ,sometimes drug launch take get ground incyte only approve drug jakafi have be market year really only just get start jakafi sell market jakavi be approve rare bone marrow cancer call myelofibrosis mf thank indication incyte incy revenue be expect pass year compare just year jakafi launch other indication pipeline however really push drug blockbuster territory first expect be approve food drug administration dec be polycythemia vera pv similar somewhat milder disease have potentially larger market meanwhile clinical trial be go really big name cancer pancreatic breast lung colon current consensus estimate have jakafi annual sale hit abroad incyte split take marketing partner novartis nvs sale be expect pass year incyte be base idea research cancer be good investment ceo herve hoppenot tell ibd interview opportunity seizedjakafi be janus associate kinase jak inhibitor regulate signale mechanism cell play important role cell growth immune response jakafi be first jak inhibitor market so far only approve fight cancer pfizer pfe xeljanz approve be also jak inhibitor be used rheumatoid arthritis hoppenot say incyte be originally aim big cancer first mf opportunity unexpectedly come scientist find jak signale play important role disease point company decide move development program very quickly myelofibrosis try prove jak pathway be have impact outcome patient say be able get pivotal study do approval myelofibrosis very rapid way advantage mf market bring firm be small patient pool have other treatment option so incyte have be able market domestically bring big pharma partner thus keep domestic revenue pursue pv be next logical step hoppenot say disease be so similar be disorder mean excess cell be produce bone marrow pv however be much milder sometimes have symptom hoppenot estimate only roughly pv patient be eligible jakafi expect liftoff be fairly slow treat pv isn urgent treat more malignant cancer eventual market be larger mf have fewer sufferer accord leerink estimate disease bring incyte first annual profit next year accord consensus analyst poll thomson reuter incyte turn profit cent share most recently report quarter only milestone payment incyte collect novartis winning reimbursement jakafi europe marketing approval japan start second half next year analyst expect incyte start turn operate profit more consistent way rivalry year however new competition threaten jakafi gilead science gild jak inhibitor momelotinib be late stage trial mf design compare momelotinib jakafi head head result be expect come sometime next year couple smaller player cti biopharma ctic geron gern also have competitor late stage testing nov latter license candidate imetelstat johnson johnson jnj development multiple disease deal potentially worth milestone be realize only datum tell competitive product be incyte have other tool garage incb candidate drug class call ido inhibitor be be test combination most anticipate cancer drug pipeline pd pd inhibitor incyte have partner lead contender field bristol myer bmy astrazeneca azn roche rhhby merck mrk test drug together variety cancer be not licensing deal say hoppenot do mean drug be approve company recommend successful combination drug label incb also garner attention summer american society clinical oncology asco meeting perform well trial combine different related bristol myer drug yervoy treat melanoma leerink analyst michael schmidt write time combo didn appear be effective yervoy combine bristol house pd opdivo do suggest promise combination incb other pd news better expect third quarter report last month induced goldman sachs analyst navdeep singh lift rating incyte neutral sell nearly double price target sell thesis be base more cautious view jakafi launch myelofibrosis mf give safety competition call have not work narrative have shift incy pipeline singh write oct research note add follow newly result asco be more encourage strong underlie growth jakafi mf early datum partnership interest ido inhibitor
918,JNJ,cash be king then information technology sector get crown big lead microsoft msft tech company account cash short term investment hold end third quarter tech sector have cash equivalent health
919,JNJ,pharmacy benefit manager express script announce monday putt abbvie newly approve hepatitis treatment prefer formulary list knock rival treatment gilead science gilead gild stock plunge abbvie abbv fall late friday food drug administration approve abbvie viekira pak combination novel drug older
920,JNJ,johnson johnson have be get leaner meaner hope improve bottom line
921,JNJ,judge earning report strategy seem be work july company dow industrial component report strong second quarter earning profit growth accelerate second straight quarter rise year share sale rise
922,JNJ,sale pharmaceutical segment totale year newly launch hepatitis treatment olysio contribute sale sale prostate cancer treatment zytiga totale year
923,JNJ,xarelto oral anticoagulant be also do well last week johnson johnson jnj partner bayer announce new study evaluate drug new indication
924,JNJ,sale consumer segment edge higher help strong sale tylenol motrin skin care product neutrogena aveeno baby care product overseas sale listerine feminine protection product do well
925,JNJ,meanwhile sale medical device diagnostic unit be sluggish again less
926,JNJ,earlier year johnson johnson sell ortho clinical diagnostic unit private equity firm carlyle group just
927,JNJ,last week wall street journal report be also interested selling cordis unit make product vascular disease include stent catheter unit fetch much
928,JNJ,recently paid quarterly dividend cent share give annual yield have be consolidate gain july flat base be place show early buy point share close wednesday johnson johnson have be get leaner meaner hope improve bottom line judge earning report strategy seem be work july company dow industrial component report strong second quarter earning profit growth accelerate second straight quarter rise year share sale rise sale pharmaceutical segment totale year newly launch hepatitis treatment olysio contribute sale sale prostate cancer treatment zytiga totale year xarelto oral anticoagulant be also do well last week johnson johnson jnj partner bayer announce new study evaluate drug new indication sale consumer segment edge higher help strong sale tylenol motrin skin care product neutrogena aveeno baby care product overseas sale listerine feminine protection product do well meanwhile sale medical device diagnostic unit be sluggish again less earlier year johnson johnson sell ortho clinical diagnostic unit private equity firm carlyle group just last week wall street journal report be also interested selling cordis unit make product vascular disease include stent catheter unit fetch much recently paid quarterly dividend cent share give annual yield have be consolidate gain july flat base be place show early buy point share close wednesday
929,JNJ,top stock leaderboard leader list report quarterly earning close tuesday facebook gilead science here breakdown analyst expect
930,JNJ,social network earning be see jump cent share item be slowdown triple digit growth report previous quarters
931,JNJ,analyst project revenue rise video ad launch late last year be expect provide meaningful growth
932,JNJ,earlier month facebook fb complete acquisition whatsapp deal value whatsapp be largest mobile messaging service worldwide global user facebook have monthly active user june
933,JNJ,facebook have ibd composite rating meaning share outperform stock market measure fundamental technical factor share have rise nearly year be flat stock market today head release result
934,JNJ,analyst project gilead science gild earn share last year be third consecutive quarter triple digit earning growth sale be estimate surge just
935,JNJ,massive year year increase sale earning be due large part hepatitis drug sovaldi launch last december harvoni gilead new improve hepatitis pill launch just month
936,JNJ,gilead share hit new high monday buy point analyst note monday rival merck mrk johnson johnson jnj seem be falter
937,JNJ,gilead stock be nearly year facebook gilead have composite rating share be also relatively flat tuesday
938,JNJ,watch video report ibd tv alissa william detail top stock leaderboard leader list report quarterly earning close tuesday facebook gilead science here breakdown analyst expect social network earning be see jump cent share item be slowdown triple digit growth report previous quarters analyst project revenue rise video ad launch late last year be expect provide meaningful growth earlier month facebook fb complete acquisition whatsapp deal value whatsapp be largest mobile messaging service worldwide global user facebook have monthly active user june facebook have ibd composite rating meaning share outperform stock market measure fundamental technical factor share have rise nearly year be flat stock market today head release result analyst project gilead science gild earn share last year be third consecutive quarter triple digit earning growth sale be estimate surge just massive year year increase sale earning be due large part hepatitis drug sovaldi launch last december harvoni gilead new improve hepatitis pill launch just month gilead share hit new high monday buy point analyst note monday rival merck mrk johnson johnson jnj seem be falter gilead stock be nearly year facebook gilead have composite rating share be also relatively flat tuesday watch video report ibd tv alissa william detail
939,JNJ,ibm introduce watson world game show jeopardy highly intelligent computer outsmart best contestant game show have ever see
940,JNJ,watson be just toddler then grow
941,JNJ,rather compete trivium game ibm ibm watson be help solve complex issue field health care sifting complex datum help doctor institution find answer tough question
942,JNJ,just start
943,JNJ,watson be engage more university industry advance develop humanlike capability
944,JNJ,watson be help oil gas industry boost production help create better build material help chef create new recipe health coach consumer travel agent
945,JNJ,have question watson have answer not always be best answer surely step right direction thing sure say ibm watson represent new era compute
946,JNJ,be just initial cusp new era say john gordon vice president ibm watson group say cognitive compute watson represent be bigger internet term communicate process datum
947,JNJ,fundamentally internet connect information faster ever open new opportunity gordon say watson be take new challenge not connect process information new way allow new era human innovation
948,JNJ,cognitive compute also go name such artificial intelligence augment intelligence machine learn decade research development have go technology draw interest tech elite
949,JNJ,company be field include google googl last year paid acquire specialize machine learn advanced algorithms google have used deep learn enhance search result improve android voice recognition derive more datum image video
950,JNJ,microsoft msft have also invest heavily field have facebook fb microsoft be used machine learn technology enhance feature performance office software facebook be used artificial intelligence make news feed feature more relevant user social network
951,JNJ,diving deeper immense power new compute technology used parallel process neural network explosion big datum analytic advancement computer software
952,JNJ,watson process information more human computer do work require thousand computer decade
953,JNJ,rather be programme anticipate answer action need perform task cognitive compute system be trained used artificial intelligence machine learn algorithms sense predict infer
954,JNJ,system get more intelligent time more information be fed memory bank have more interaction user aids imaging speech recognition
955,JNJ,ibm be leader field field allow computer learn have be programme say david schubmehl research director market research firm idc ll see computer system learn time way human do
956,JNJ,watson computer be different depend work kind information feed memory bank
957,JNJ,watson be also available cloud company essentially rent own personal portion watson platform
958,JNJ,ibm doesn sell watson base company line power system computer do provide computer business partner
959,JNJ,ibm derive revenue sale watson service also take share revenue partner successfully introduce market watson base apps ibm say have hundred commercial partner support thousand developer entrepreneur be develop thousand apps
960,JNJ,re bet share success gordon say expect lot be successful
961,JNJ,ibm establish ibm watson group january ibm be investing group research development collaboration research institution business help commercialize watson ibm also have fund invest startup other want build business top watson
962,JNJ,ibm investment include san diego base pathway genomic past year have receive financing variety investor pathway founder provide genetic testing service used large hospital physician
963,JNJ,year michael nova pathway chief innovation officer call ibm watson group idea want know ibm watson help pathway develop fitness diet tracking app
964,JNJ,fee pathway enormous collection health medical datum watson help user answer health related question pathway app be also expect connect wearable health tracking device such fitbit pull person vital such blood pressure weight pulse user log smartphone ask health question such much exercise do today food stop eating nova expect app be available fourth quarter
965,JNJ,health care be hardest datum problem be nova say need watson board huge advantage be link
966,JNJ,other investment ibm be part funding round wayblazer travel search discovery company goal redefine consumer plan personalize purchase travel
967,JNJ,health care be first market watson ibm have spend most time money
968,JNJ,start health intentionally figure be go be problem solve be meaningful be right place start gordon say amount information produce field be explode
969,JNJ,april ibm unveil watson health cloud unit say provide secure open platform physician researcher insurer other company focuse health wellness
970,JNJ,partner include johnson johnson jnj work ibm develop intelligent virtual coaching solution help prepare patient surgery then deal effect
971,JNJ,johnson johnson also leverage ibm relationship apple aapl deliver new iphone ipad application apple be work ibm integrate watson base apps healthkit researchkit tool system developer
972,JNJ,partner be medical device giant medtronic mdt be collaborate ibm delivery personalize care person diabetes analyze patient info datum medtronic device
973,JNJ,ibm also have watson partnership memorial sloan ketter cancer center md anderson cancer center university texas mayo clinic new york genome center
974,JNJ,re bullish ve see say gordon innovator be build new company watson new era compute ibm introduce watson world game show jeopardy highly intelligent computer outsmart best contestant game show have ever see watson be just toddler then grow rather compete trivium game ibm ibm watson be help solve complex issue field health care sifting complex datum help doctor institution find answer tough question just start watson be engage more university industry advance develop humanlike capability watson be help oil gas industry boost production help create better build material help chef create new recipe health coach consumer travel agent have question watson have answer not always be best answer surely step right direction thing sure say ibm watson represent new era compute be just initial cusp new era say john gordon vice president ibm watson group say cognitive compute watson represent be bigger internet term communicate process datum fundamentally internet connect information faster ever open new opportunity gordon say watson be take new challenge not connect process information new way allow new era human innovation cognitive compute also go name such artificial intelligence augment intelligence machine learn decade research development have go technology draw interest tech elite company be field include google googl last year paid acquire specialize machine learn advanced algorithms google have used deep learn enhance search result improve android voice recognition derive more datum image video microsoft msft have also invest heavily field have facebook fb microsoft be used machine learn technology enhance feature performance office software facebook be used artificial intelligence make news feed feature more relevant user social network diving deeper immense power new compute technology used parallel process neural network explosion big datum analytic advancement computer software watson process information more human computer do work require thousand computer decade rather be programme anticipate answer action need perform task cognitive compute system be trained used artificial intelligence machine learn algorithms sense predict infer system get more intelligent time more information be fed memory bank have more interaction user aids imaging speech recognition ibm be leader field field allow computer learn have be programme say david schubmehl research director market research firm idc ll see computer system learn time way human do watson computer be different depend work kind information feed memory bank watson be also available cloud company essentially rent own personal portion watson platform ibm doesn sell watson base company line power system computer do provide computer business partner ibm derive revenue sale watson service also take share revenue partner successfully introduce market watson base apps ibm say have hundred commercial partner support thousand developer entrepreneur be develop thousand apps re bet share success gordon say expect lot be successful ibm establish ibm watson group january ibm be investing group research development collaboration research institution business help commercialize watson ibm also have fund invest startup other want build business top watson ibm investment include san diego base pathway genomic past year have receive financing variety investor pathway founder provide genetic testing service used large hospital physician year michael nova pathway chief innovation officer call ibm watson group idea want know ibm watson help pathway develop fitness diet tracking app fee pathway enormous collection health medical datum watson help user answer health related question pathway app be also expect connect wearable health tracking device such fitbit pull person vital such blood pressure weight pulse user log smartphone ask health question such much exercise do today food stop eating nova expect app be available fourth quarter health care be hardest datum problem be nova say need watson board huge advantage be link other investment ibm be part funding round wayblazer travel search discovery company goal redefine consumer plan personalize purchase travel health care be first market watson ibm have spend most time money start health intentionally figure be go be problem solve be meaningful be right place start gordon say amount information produce field be explode april ibm unveil watson health cloud unit say provide secure open platform physician researcher insurer other company focuse health wellness partner include johnson johnson jnj work ibm develop intelligent virtual coaching solution help prepare patient surgery then deal effect johnson johnson also leverage ibm relationship apple aapl deliver new iphone ipad application apple be work ibm integrate watson base apps healthkit researchkit tool system developer partner be medical device giant medtronic mdt be collaborate ibm delivery personalize care person diabetes analyze patient info datum medtronic device ibm also have watson partnership memorial sloan ketter cancer center md anderson cancer center university texas mayo clinic new york genome center re bullish ve see say gordon innovator be build new company watson new era compute
975,JNJ,cross border merger boom be boost etfs hold catamaran ctrx dresser rand drc other pharma energy company be hot takeover target merger arbitrage exchange trade fund profit difference stock price deal be announce final purchase price typically upward move cross border merger acquisition have totale roughly
976,JNJ,tap vast field datum facebook fb ibm ibm partner help retailer achieve more personalize target ad ibm combine cloud base marketing datum analytic service facebook ad technology have personalize datum more user social network goal be give brand advertiser clearer
977,JNJ,receptos rcpt stock jump more new high morning trading stock market today company get multiple price target increase bowel disease drug succeed midstage trial receptos announce late monday drug rpc have proven significantly better placebo patient ulcerative colitis uc disease
978,JNJ,share gilead science gild hit new high stock market today biotech prepared deliver report close tuesday analyst note couple potential competitor seem be falter
979,JNJ,analyst poll thomson reuter expect company report earning share year earlier quarter sale be estimate just last year third quarter
980,JNJ,massive year year increase be due hepatitis drug sovaldi launch december analyst expect decline sale sequential basis doctor delay treat patient month launch harvoni gilead next generation hcv pill
981,JNJ,sovaldi fading harvoni just launch isn particular number analyst be champ bit see tuesday isi group analyst mark schoenebaum write earning prep pack client conference call question probably revolve harvoni launch dynamic hcv pipeline potential acquisition possible impact close double irish tax loophole effect gilead be still unclear
982,JNJ,also monday rbc capital market analyst michael yee note event bode well gilead longer term competitive position
983,JNJ,be johnson johnson jnj drug simeprevir call olysio sovriad elsewhere require label change japan patient used die earning report management comment firm plan stay competitive hcv even harvoni launch lead minor panic gilead investor fear price war yee write seem even less likely now
984,JNJ,jnj soon get fda label allow use olysio gild sovaldi write don expect much use combo anymore theoretical positive label update gild already have combo replace regimen price olysio make not feasible view
985,JNJ,give idea much price have be cut week round harvoni cost more round sovaldi alone
986,JNJ,yee also write merck mrk be sound less confident own hcv pipeline conference call discuss earning monday morning company confirm report trial week hcv therapy liver meeting next month commentary be less bullish previous conference call suggest datum help bookend various treatment duration be feasible week treatment be not necessarily relevant long regimen general be competitive
987,JNJ,merck earning modestly beat estimate top line come bit light be more late afternoon monday
988,JNJ,follow amy reeve twitter ibd_areeve share gilead science gild hit new high stock market today biotech prepared deliver report close tuesday analyst note couple potential competitor seem be falter analyst poll thomson reuter expect company report earning share year earlier quarter sale be estimate just last year third quarter massive year year increase be due hepatitis drug sovaldi launch december analyst expect decline sale sequential basis doctor delay treat patient month launch harvoni gilead next generation hcv pill sovaldi fading harvoni just launch isn particular number analyst be champ bit see tuesday isi group analyst mark schoenebaum write earning prep pack client conference call question probably revolve harvoni launch dynamic hcv pipeline potential acquisition possible impact close double irish tax loophole effect gilead be still unclear also monday rbc capital market analyst michael yee note event bode well gilead longer term competitive position be johnson johnson jnj drug simeprevir call olysio sovriad elsewhere require label change japan patient used die earning report management comment firm plan stay competitive hcv even harvoni launch lead minor panic gilead investor fear price war yee write seem even less likely now jnj soon get fda label allow use olysio gild sovaldi write don expect much use combo anymore theoretical positive label update gild already have combo replace regimen price olysio make not feasible view give idea much price have be cut week round harvoni cost more round sovaldi alone yee also write merck mrk be sound less confident own hcv pipeline conference call discuss earning monday morning company confirm report trial week hcv therapy liver meeting next month commentary be less bullish previous conference call suggest datum help bookend various treatment duration be feasible week treatment be not necessarily relevant long regimen general be competitive merck earning modestly beat estimate top line come bit light be more late afternoon monday follow amy reeve twitter ibd_areeve
989,JNJ,celgene rolled more upbeat datum new crohn disease drug send biotech giant share higher tuesday monday celgene celg release abstract phase trial ged also call mongersen show good result patient week take drug share rise monday news tuesday present
990,JNJ,stock future angled lower wednesday add pressure weak housing producer price datum
991,JNJ,dow future nose point fair market value nasdaq future be point
992,JNJ,stock market today again have close eye event europe hope negotiate cease fire ukraine fade report intense fight strategic rail hub debaltseve continue greece say request bailout program extension european central bank be prepared announce not cut emergency funding greek bank accord reuter be wide speculation deal be reach end week
993,JNJ,investor be watch see nasdaq push further new high be look carefully minute federal open market committee jan meeting be release et
994,JNJ,build market tap brake january housing start slow annualize rate commerce department report be december start pace forecast mild dip rate
995,JNJ,build permit gauge future activity backed annualize rate december rate be revise upward economist have forecast january permit increase pace
996,JNJ,price paid producer slip january labor department say be acceleration december dip slowdown project economist strip food energy decline be more tame still weaker expect vs view gain
997,JNJ,low price stock make dramatic move angie list angi soar report healthy fourth quarter result stock have be steep correction july
998,JNJ,australian genetic testing product maker genetic technology gene spiked premarket action less stock end tuesday gain so far february
999,JNJ,sandwich maker potbelly pbpb fly air fleet lessor fly lease fly soar
1000,JNJ,boston scientific bsx spark announce pay johnson johnson jnj settlement related acquisition guidant have claim acquisition complete interfere previous agreement have make guidant
1001,JNJ,boston scientific end tuesday just feb high just week line support stock have clear flat base buy point jan
1002,JNJ,burger joint jack box jack grilled gain fiscal sale earning outperformed consensus expectation management give strong same store sale projection lift earning guidance forecast stock be rumble month uptrend end tuesday just feb high
1003,JNJ,europe stock push modest gain japan tokyo nikkei jump hong kong hang seng tick exchange final trading day ahead day new year holiday shanghai exchange be close holiday next wednesday
1004,JNJ,dollar gain vs euro yen crude slip range putt benchmark west texas intermediate just barrel gold dip fraction ounce
1005,JNJ,et federal reserve report january industrial production factory utilization datum stock future angled lower wednesday add pressure weak housing producer price datum dow future nose point fair market value nasdaq future be point stock market today again have close eye event europe hope negotiate cease fire ukraine fade report intense fight strategic rail hub debaltseve continue greece say request bailout program extension european central bank be prepared announce not cut emergency funding greek bank accord reuter be wide speculation deal be reach end week investor be watch see nasdaq push further new high be look carefully minute federal open market committee jan meeting be release et build market tap brake january housing start slow annualize rate commerce department report be december start pace forecast mild dip rate build permit gauge future activity backed annualize rate december rate be revise upward economist have forecast january permit increase pace price paid producer slip january labor department say be acceleration december dip slowdown project economist strip food energy decline be more tame still weaker expect vs view gain low price stock make dramatic move angie list angi soar report healthy fourth quarter result stock have be steep correction july australian genetic testing product maker genetic technology gene spiked premarket action less stock end tuesday gain so far february sandwich maker potbelly pbpb fly air fleet lessor fly lease fly soar boston scientific bsx spark announce pay johnson johnson jnj settlement related acquisition guidant have claim acquisition complete interfere previous agreement have make guidant boston scientific end tuesday just feb high just week line support stock have clear flat base buy point jan burger joint jack box jack grilled gain fiscal sale earning outperformed consensus expectation management give strong same store sale projection lift earning guidance forecast stock be rumble month uptrend end tuesday just feb high europe stock push modest gain japan tokyo nikkei jump hong kong hang seng tick exchange final trading day ahead day new year holiday shanghai exchange be close holiday next wednesday dollar gain vs euro yen crude slip range putt benchmark west texas intermediate just barrel gold dip fraction ounce et federal reserve report january industrial production factory utilization datum
1006,JNJ,pharmacyclic pcyc stock soar time high wednesday medium report biotech be consider selling big pharmaceutical company pharmacyclic only market product be imbruvica blood cancer drug have draw interest johnson johnson jnj novartis nvs accord report bloomberg cite unidentified source knowledge matter
1007,JNJ,big biotech celgene celg announce monday present datum crohn disease drug ged conference tuesday post abstract top line result high side expectation celgene stock be morning trading stock market today drug be potential blockbuster phase trial compare different dose
1008,JNJ,stock give back modest gain wednesday day nasdaq score solid percentage gain higher volume
1009,JNJ,little more hour remain session dow jone industrial average lose nasdaq fall give nyse nasdaq volume be tracking close tuesday level
1010,JNJ,dow be weigh boee ba slump report earning johnson johnson jnj be bright spot blue chip index earlier today ceo alex gorsky appear fox business network talk plan test ebola vaccine human january
1011,JNJ,stock market today biogen idec biib slump report solid quarter earning sale growth sale cambridge mass base company top drug tecfidera more double didn meet analyst expectation investor also didn news patient take tecfidera die develop rare brain infection know pml
1012,JNJ,elsewhere apple aapl flirted recent time high share rise nearly stock briefly hit new high pull back
1013,JNJ,yahoo yhoo gap rise reclaim buy point way late tuesday search firm google googl microsoft msft report solid earning thank gain mobile business
1014,JNJ,close watch earning security name fortinet ftnt share fall ahead result stock recently find support day move average consolidate gain
1015,JNJ,nxp semiconductor nxpi field communication nfc chip be find apple iphone also report close share lose stock give back modest gain wednesday day nasdaq score solid percentage gain higher volume little more hour remain session dow jone industrial average lose nasdaq fall give nyse nasdaq volume be tracking close tuesday level dow be weigh boee ba slump report earning johnson johnson jnj be bright spot blue chip index earlier today ceo alex gorsky appear fox business network talk plan test ebola vaccine human january stock market today biogen idec biib slump report solid quarter earning sale growth sale cambridge mass base company top drug tecfidera more double didn meet analyst expectation investor also didn news patient take tecfidera die develop rare brain infection know pml elsewhere apple aapl flirted recent time high share rise nearly stock briefly hit new high pull back yahoo yhoo gap rise reclaim buy point way late tuesday search firm google googl microsoft msft report solid earning thank gain mobile business close watch earning security name fortinet ftnt share fall ahead result stock recently find support day move average consolidate gain nxp semiconductor nxpi field communication nfc chip be find apple iphone also report close share lose
1016,JNJ,big cap biotech celgene make name cancer fighter now branch disease immune system biggest test new strategy come weekend unite european week vienna run saturday oct celgene celg be set present phase datum ged treatment crohn disease inflammatory disease gi tract celgene license drug april privately hold nogra pharma upfront payment regulatory development milestone payment sale milestone payment drug launch price raise eyebrow wall street few have hear nogra pharma be most celgene have ever paid upfront licensing deal only information have be publicly release be phase trial have only subject be not placebo controlled celgene however say already know phase datum be worth price ged be potentially therapy demonstrated striking clinical activity phase trial crohn disease scott celgene global head inflammation immunology say press release time date ged release near wall street curiosity optimism have be build accord rbc capital market analyst michael yee combine sale world lead immunology drug abbvie abbv humira johnson johnson jnj remicade come treatment crohn disease cause disease be still mysterious treatment be more management cure accord yee third patient don respond drug do relapse be frequent so potentially huge opportunity celgene drug work still drug have take get much attention recently aug deutsche bank analyst robyn karnauskas assert ged be not modeled wall street consensus number therefore bring huge potential upside then bandwagon have get more crowd nomura security analyst ian somaiya report interview investigator participate clinical trial study be double blind so didn know patient get ged get placebo investigator report patient go clinical remission response time be less half usual week humira take somaiya also observed safety problem strong efficacy expect believe full phase datum reflect clinical site finding confirm strong efficacy see phase trial rapid benefit durable remission clean safety profile somaiya write research note estimate ged reach peak worldwide sale drive upside celg share anticipation drug have boost celgene stock be trading record high week market crash evidence ged be drive celgene rise come stock drop trading day wasn apparent reason short note put late isi group analyst mark schoenebaum report meeting have celgene management new crohn disease drug be unlikely be once daily product schoenebaum write be due theoretical risk fibrotic change long term exposure however company very interested study re treatment intermittent dose month month fibrosis harden thicken bowel wall be common symptom crohn disease idea long term exposure ged make seem have spook investor schoenebaum apparently blame stock drop next day put clarification emphasize word theoretical note note such problem have be report trial go well ged be expect launch be celgene second immunology drug first otezla hit market march psoriatic arthritis be also approve psoriasis larger market street estimate peak annual sale otezla pass
1017,JNJ,stock reversed lower wednesday end day run nasdaq
1018,JNJ,nasdaq fall lose be much wednesday high dow jone industrial average lose johnson johnson jnj be rare winner blue chip index ceo alex gorsky tell fox business network company hope have dose ebola vaccine
1019,JNJ,accord preliminary datum volume end mixed stock market today nasdaq trade be smidge higher nyse volume slip
1020,JNJ,super micro computer smci gap surge reaction late tuesday solid quarterly result thank strong server sale earning more double revenue grow stock touch new high wednesday then fade bit super micro have fail past buy point flat base
1021,JNJ,illumina ilmn rise heavy trade breaking past buy point double bottom base move follow surge tuesday illumina report strong quarterly earning sale monday
1022,JNJ,strong quarterly result also help yahoo yhoo gap rally nearly month high tuesday close internet search portal report rise earning biggest gain year company deliver gain sale first increase quarters
1023,JNJ,biogen idec biib end well session low still lose heavy trading share be much follow mixed quarterly result biotech share also come pressure news patient die take tecfidera multiple sclerosis treatment stock reversed lower wednesday end day run nasdaq nasdaq fall lose be much wednesday high dow jone industrial average lose johnson johnson jnj be rare winner blue chip index ceo alex gorsky tell fox business network company hope have dose ebola vaccine accord preliminary datum volume end mixed stock market today nasdaq trade be smidge higher nyse volume slip super micro computer smci gap surge reaction late tuesday solid quarterly result thank strong server sale earning more double revenue grow stock touch new high wednesday then fade bit super micro have fail past buy point flat base illumina ilmn rise heavy trade breaking past buy point double bottom base move follow surge tuesday illumina report strong quarterly earning sale monday strong quarterly result also help yahoo yhoo gap rally nearly month high tuesday close internet search portal report rise earning biggest gain year company deliver gain sale first increase quarters biogen idec biib end well session low still lose heavy trading share be much follow mixed quarterly result biotech share also come pressure news patient die take tecfidera multiple sclerosis treatment
1024,JNJ,robert wood johnson be medical product whiz be leader brother founder johnson johnson jnj put path become giant amassed sale last year way make sure flourish advertising help johnson marketing master thompson be pal meet young professional new york johnson have desk job medical product brokerage thompson be bookkeeper ad agency be do so badly later buy year later johnson tap thompson develop breakthrough ad johnson johnson game change health care product thompson agency handled medium first consumer product toothpaste call zonweiss johnson learn early pay attention person work hard produce top idea industriousness have owe lot parent influence be parent fear join older brother union army so apprentice pharmacist cousin mother learningjohnson attend prep school family home carbondale pa apprenticeship be largely self taught pharmacy poughkeepsie johnson spend long hour learn trade prepare medicinal plaster forerunner today externally apply medical patch view lot be heal profession customer appreciate effort make well meanwhile figured plaster be make kind remedy dispense johnson be very outgoing person margaret gurowitz chief historian johnson johnson tell ibd trait inquisitiveness lead leave relative seek bigger opportunity new york city be new york johnson sell drug medical product decade then form partnership george seabury also broker say gurowitz work seabury give johnson much need outlet new product development skill organized firm seabury johnson start make plaster india rubber combination say ian ellis today science history many older druggist tell see day day old loft bare arm clothe jumper struggle whitewash brush pail mush spread first benzine plaster succeed produce plaster standard medical formula rubber base effect relegate other form use create new era plaster make used seabury johnson cruised prize product centennial exposition philadelphia johnson attend expo reason other award want hear speech joseph lister british surgeon be stumping america evidence backed antiseptic surgery message be many more patient survive go knife instrument supply clothing be sterilize surgery america tend be unsanitary many doctor do not believe germ theory disease involve thing couldn see physician want trash idea expo say gurowitz notion washing hand surgery say doctor be gentleman gentleman hand be clean gurowitz say take great offense lister idea not johnson recall brother story brutal wound field surgery civil war be win lister inspire lord lister want mass produce aseptic surgery gauze dressing physician use sterile surgery say gurowitz seabury want concentrate expand company exist medical plaster business instead split direction business be just point contention johnson seabury be opinionated difference often accelerate argument disagreement involved even mundane issue such minute board meeting be record seabury figured family help bring brother firm johnson up hire brother seabury johnson find difference irreconcilable break company johnson brother james edward left same time set own medical product business new brunswick hire first employee old seabury johnson familyrobert be bar join noncompete agreement seabury seabury renege agreement not make require payment robert latter joined brother johnson johnson founding firm open way johnson make sell america first mass produce surgical dressing continue make plaster sell sterile dressing mainly retail pharmacy johnson do much own market research channel check go drugstore meeting owner talk want need round meet fred kilmer owner pharmacy new brunswick kilmer share johnson strong interest sterilize medical product procedure become scientific director small businessman kilmer be always look creative new way build business interact public say gurowitz kilmer sell ticket rutger university sport theater event shop way draw more person store kilmer be persuasive writer put skill good use try generate demand doctor sterile product get word outsome physician do want try antiseptic surgery often lack resource technical knowledge gurowitz say be need be manual also layer case antiseptic surgery so johnson johnson publish modern method antiseptic wound treatment give away free medical professional kilmer write part book deal case sterile technique lead higher patient survival rate general practice principle also include surgical case study lead antiseptic surgeon book become lead handbook antiseptic surgery combination company ready use mass produce sterile surgical product manual put antiseptic surgery reach most doctor hospital first time gurowitz say crucial johnson move come involved first aid kit train colorado chat passenger turn be chief surgeon colorado rio grande railway work railroad be so dangerous line have surgeon hand treat injury construction worker engineer chief surgeon hate worker be hurt medical help often be too far away do much good johnson be sure have sterile bandage other supply accessible worker help treat stabilize injured person need do market research write railway surgeon tell company be plan make first aid kit ask need kit gurowitz say datum hand johnson johnson quickly produce kit railroad well general purpose kit same year robert colorado sojourn startup firm employee occupy floor factory build johnson johnson grow operation several worker be largest factory space world johnson die today produce array health care product range prescription drug surgical device band aids go public accord company investor buy worth share back then have jnj stock worth more now alone stock have rocket
1025,JNJ,fda approve gilead science gild hepatitis combo pill harvoni friday afternoon widely expect still crucial step drug expect be megablockbuster gilead also disclose drug price first time week course harvoni be combination ledipasvir sofosbuvir latter already be sell solo
1026,JNJ,earning season be rev here be company high ibd composite rating report quarterly result tuesday johnson johnson jnj report open be expect earn share last year revenue be see rise health care product maker announce late september be buy
1027,JNJ,gilead science gild be california base pharmaceutical company product line include hepatitis drug sovaldi be introduce dec have better cure rate competition week gilead be featured ibd sector leader review mentioned company have lot go hepatitis drug soon
1028,JNJ,part solid approach investing be become aware factor work stock gilead science gild have several thing go current earning growth be huge compare year earlier earning rise revenue rise street expect ep
1029,JNJ,medical giant johnson johnson jnj kick industry earning season strong note sale earning beat early tuesday stock be morning trading stock market today earning exclude time item rise year earlier quarter share beating analyst estimate cent
1030,JNJ,stock surge tuesday open quickly backed away early high
1031,JNJ,nasdaq ease gain leap start trade chipmaker micron technology mu top nasdaq dow jone industrial average be
1032,JNJ,volume rise modestly stock market today nasdaq higher nyse
1033,JNJ,third quarter report drive much morning prevalent action big bank be motion citigroup jpmorgan jpm well fargo wfc deliver result
1034,JNJ,medical health care product giant johnson johnson jnj slip earning beat consensus expectation revenue meet forecast management give positive full year guidance pharmaceutical sale surge diagnostic equipment sale fall
1035,JNJ,ibd list jazz pharmaceutical jazz technology avgo pop more
1036,JNJ,skywork solution swks gap gain management give preliminary result raise ep guidance consensus view supplier chip used apple samsung smartphone put revenue vs consensus company point positive underlie market trend connect everyone everything time
1037,JNJ,downside china base tutor chain tal education xrs fall very strong trade stock slice day line support monday be so far week stock surge tuesday open quickly backed away early high nasdaq ease gain leap start trade chipmaker micron technology mu top nasdaq dow jone industrial average be volume rise modestly stock market today nasdaq higher nyse third quarter report drive much morning prevalent action big bank be motion citigroup jpmorgan jpm well fargo wfc deliver result medical health care product giant johnson johnson jnj slip earning beat consensus expectation revenue meet forecast management give positive full year guidance pharmaceutical sale surge diagnostic equipment sale fall ibd list jazz pharmaceutical jazz technology avgo pop more skywork solution swks gap gain management give preliminary result raise ep guidance consensus view supplier chip used apple samsung smartphone put revenue vs consensus company point positive underlie market trend connect everyone everything time downside china base tutor chain tal education xrs fall very strong trade stock slice day line support monday be so far week
1038,JNJ,employee suffer so do company leader find way elevate face journal american medical association study find depress worker cost employer year due health related productivity loss contribute factor presenteeism be work barely work loss productivity cause depression be extremely difficult track manifest poor performance say graeme cowan author back brink true story practical help overcome depression bipolar disorder bring forward cowan know lowest lows once senior executive johnson johnson jnj consult firm kearney grapple depression year attempt suicide time writing experience research mental health issue finding struggle depression rather suffer silence very bad news employer have big portion workforce struggle reduce capacity tell ibd pick signal manager watch harbinger problem dip performance call sick often miss deadline meeting look tired overwhelmed ask help someone cowan recommend step process simply ask be next listen judgment then encourage action finally follow say extend lifeline employer encourage employee get help putt resource front mental health policy wellness program educational material get ball roll big regret depress individual be didn get accurate diagnosis treatment plan earlier say cowan get move company encourage exercise elevate worker outlook reap reward employee positive mood be more productive sell more be more creative cowan say confront frustration sometimes not depression feel disengagement gnaw professional be case bob epperly author grow former exxon xom executive take too common corporate hit year company suite cut department half outplaced epperly response stuffed feeling moved ahead say explore next year work startup epperly stop stuff feeling pursue inner goal delve yoga improve diet exercise habit attend seminar personal growth enhance start epperly suggest begin activity such meditation seek teacher therapist connect group mind individual share up down life
1039,JNJ,new research note rbc capital market offer bullish take biogen idec biib experimental drug alzheimer disease predict make big splash upcoming international conference alzheimer parkinson disease conference schedule march nice france attract medical scientific professional globe biogen be expect
1040,JNJ,pharmacy benefit manager express script esrx say prescription drug spending rise more last year have accord annual review accord drug trend report spending drug commercially insure rise member last year medicare spending rise member medicaid spending climb
1041,JNJ,report say spending hepatitis drug account more half increase be not big surprise disease be still treat mainly generic drug gilead science gild premium price sovaldi often prescribe tandem johnson johnson jnj also pricey olysio take market october gilead launch harvoni render olysio obsolete cost more sovaldi
1042,JNJ,express script pharmacy benefit management leader be earliest loudest critic sovaldi price amount standard week treatment press release accompany report pbm brag have take bite gilead make exclusive deal abbvie abbv come gilead first serious competitor form viekira pak year end express claim save client year
1043,JNJ,not clear however well be work abbvie analyst tracking prescription datum estimate only have market share datum be incomplete win be fully know abbvie report caveat be express price datum do not include rebate be significant part picture especially hepatitis market lately
1044,JNJ,gilead report last month investor have minor freak company executive guide gross net adjustment rebate level hepatitis franchise
1045,JNJ,express script release also echo comment make ceo january jpmorgan healthcare conference indicated next price war target be pcsk inhibitor new class cholesterol drug expect come market year offering amgen amgn team regeneron pharmaceutical regn sanofi sny
1046,JNJ,drug trend report didn specifically mention do drug end cost year
1047,JNJ,follow amy reeve twitter ibd_areeve pharmacy benefit manager express script esrx say prescription drug spending rise more last year have accord annual review accord drug trend report spending drug commercially insure rise member last year medicare spending rise member medicaid spending climb report say spending hepatitis drug account more half increase be not big surprise disease be still treat mainly generic drug gilead science gild premium price sovaldi often prescribe tandem johnson johnson jnj also pricey olysio take market october gilead launch harvoni render olysio obsolete cost more sovaldi express script pharmacy benefit management leader be earliest loudest critic sovaldi price amount standard week treatment press release accompany report pbm brag have take bite gilead make exclusive deal abbvie abbv come gilead first serious competitor form viekira pak year end express claim save client year not clear however well be work abbvie analyst tracking prescription datum estimate only have market share datum be incomplete win be fully know abbvie report caveat be express price datum do not include rebate be significant part picture especially hepatitis market lately gilead report last month investor have minor freak company executive guide gross net adjustment rebate level hepatitis franchise express script release also echo comment make ceo january jpmorgan healthcare conference indicated next price war target be pcsk inhibitor new class cholesterol drug expect come market year offering amgen amgn team regeneron pharmaceutical regn sanofi sny drug trend report didn specifically mention do drug end cost year follow amy reeve twitter ibd_areeve
1048,JNJ,big pharma pfizer agree buy specialty generic firm hospira thursday deal send hospira stock record high ease slightly close
1049,JNJ,pfizer pfe agree pay share cash hospira hsp sell generic injectable device administer pfizer say buy add cent ep first year deal close expect second half
1050,JNJ,hospira be fold pfizer global establish pharmaceutical gep unit major division widely expect wall street be spun someday
1051,JNJ,addition hospira have potential fundamentally improve growth trajectory gep business vault leadership position large grow patent sterile injectable marketplace combine capability company include enhance manufacturing say gep head john young
1052,JNJ,gep business have be drag revenue most recently report quarter fall year hospira buyout bring pfizer further more lucrative realm hard make specialty product
1053,JNJ,fewer player more power
1054,JNJ,generic market limit number player offer injectable product have lead stronger pricing power better return typical small molecule generic market write morningstar analyst damien conover
1055,JNJ,purchase also bring pfizer portfolio biosimilar product knockoff biologic drug have increasingly filled rank top selling product hospira recently launch biosimilar version johnson johnson jnj blockbuster immunology drug remicade biosimilar version amgen amgn epogen become first biosimilar market
1056,JNJ,hospira earning growth have accelerate last report quarters help give excellent ibd composite rating be expect end recently lose patent protection brand drug precedex capital iq analyst jeffrey loo write thought pfizer offer significantly overvalue hospira give growth outlook
1057,JNJ,pfizer stock rise thursday leerink analyst seamus fernandez write research note stock be deal further enable spinoff gep business
1058,JNJ,also be many street be root good buyout pfizer report last week analyst sound frustrated ceo ian read keep say big deal wasn necessary pfizer growth strategy even company have bid more try buy astrazeneca azn last year
1059,JNJ,deal develop
1060,JNJ,newly launch breast cancer drug ibrance fda approve month ahead schedule tuesday be expect be blockbuster eventually pfizer soft guidance underscore company need deal bmo capital market analyst alex arfaei write time
1061,JNJ,astrazeneca meanwhile announce acquisition own thursday agree pay north american respiratory portfolio actavis act consist drug tudorza pressair daliresp chronic obstructive pulmonary disease
1062,JNJ,most big pharmas season astrazeneca also disclose mixed financial earning plunge cent share miss analyst consensus cent accord thomson reuter revenue fall line estimate
1063,JNJ,company say constant currency basis sale fall midsingle digit year profit rise low single digit analyst estimate generally aren constant exchange rate agree revenue estimate analyst also be expect modest ep decline big pharma pfizer agree buy specialty generic firm hospira thursday deal send hospira stock record high ease slightly close pfizer pfe agree pay share cash hospira hsp sell generic injectable device administer pfizer say buy add cent ep first year deal close expect second half hospira be fold pfizer global establish pharmaceutical gep unit major division widely expect wall street be spun someday addition hospira have potential fundamentally improve growth trajectory gep business vault leadership position large grow patent sterile injectable marketplace combine capability company include enhance manufacturing say gep head john young gep business have be drag revenue most recently report quarter fall year hospira buyout bring pfizer further more lucrative realm hard make specialty product fewer player more power generic market limit number player offer injectable product have lead stronger pricing power better return typical small molecule generic market write morningstar analyst damien conover purchase also bring pfizer portfolio biosimilar product knockoff biologic drug have increasingly filled rank top selling product hospira recently launch biosimilar version johnson johnson jnj blockbuster immunology drug remicade biosimilar version amgen amgn epogen become first biosimilar market hospira earning growth have accelerate last report quarters help give excellent ibd composite rating be expect end recently lose patent protection brand drug precedex capital iq analyst jeffrey loo write thought pfizer offer significantly overvalue hospira give growth outlook pfizer stock rise thursday leerink analyst seamus fernandez write research note stock be deal further enable spinoff gep business also be many street be root good buyout pfizer report last week analyst sound frustrated ceo ian read keep say big deal wasn necessary pfizer growth strategy even company have bid more try buy astrazeneca azn last year deal developingit newly launch breast cancer drug ibrance fda approve month ahead schedule tuesday be expect be blockbuster eventually pfizer soft guidance underscore company need deal bmo capital market analyst alex arfaei write time astrazeneca meanwhile announce acquisition own thursday agree pay north american respiratory portfolio actavis act consist drug tudorza pressair daliresp chronic obstructive pulmonary disease most big pharmas season astrazeneca also disclose mixed financial earning plunge cent share miss analyst consensus cent accord thomson reuter revenue fall line estimate company say constant currency basis sale fall midsingle digit year profit rise low single digit analyst estimate generally aren constant exchange rate agree revenue estimate analyst also be expect modest ep decline
1064,JNJ,canadian drugmaker serial acquirer valeant pharmaceutical international vrx enter tentative agreement buy asset bankrupt biotech dendreon late thursday include dendreon controversial cancer vaccine provenge valeant dendreon enter stalk horse asset purchase agreement valeant be prefer bidder dendreon asset sale valeant agree pay
1065,JNJ,recent flurry deal make drug sector have put spotlight other top rate drugmaker have grow help savvy merger acquisition just past week abbvie abbv agree buy pharmacyclic pcyc beating johnson johnson jnj mallinckrodt mnk announce deal acquire privately
1066,JNJ,health care etfs be top performer year look most heavily trade group reveal slight difference affect performance health care select sector spdr arca xlv have broad coverage include health care equipment supply health care provider service biotechnology pharmaceutical industry fund draw holding
1067,JNJ,eurozone await key announcement european central bank dollar cap powerful third quarter advance vs euro ireland economy month report gdp surge best performance
1068,JNJ,gain be impressive ireland former international monetary fund chief ashoka mody quote telegraph earlier month say country gdp tend be erratic
1069,JNJ,bounce back deep slump always look impressive be mislead say investment be still country have lot debt
1070,JNJ,irish stock exchange index trade not quite early september high tuesday more year peak february yet still ahead year
1071,JNJ,germany frankfurt dax be bit less year cac paris be
1072,JNJ,ishare msci ireland eirl etf be year
1073,JNJ,most eurozone country ireland see export benefit weaker euro dollar recent gain euro still trade better premium soft eurozone inflation number september release tuesday buoy investor hope ecb announce sort quantitative ease measure such measure aim increase supply currency drive value euro lower make european product more competitive global market
1074,JNJ,more important weaker euro ireland have be county corporate tax policy corporate tax rate have attract pantheon heavyweight tech pharmaceutical name ireland gdp growth rise quarter quarter strip revenue form multinational gdp expand accord irish time
1075,JNJ,google googl hold title ireland top exporter year report export euro accord irish exporter association export be bit hazy company book overseas revenue ireland then distribute much capital royalty offshore unit
1076,JNJ,microsoft msft johnson johnson jnj dell dell be next line country top exporter
1077,JNJ,ireland base company packaging leader smurfit kappa book export euro
1078,JNJ,food ingredient maker kerry group also figured prominently export euro
1079,JNJ,ireland top rank stock be drugmaker lead actavis act jazz pharmaceutical jazz shire shpg eurozone await key announcement european central bank dollar cap powerful third quarter advance vs euro ireland economy month report gdp surge best performance gain be impressive ireland former international monetary fund chief ashoka mody quote telegraph earlier month say country gdp tend be erratic bounce back deep slump always look impressive be mislead say investment be still country have lot debt irish stock exchange index trade not quite early september high tuesday more year peak february yet still ahead year germany frankfurt dax be bit less year cac paris be ishare msci ireland eirl etf be year most eurozone country ireland see export benefit weaker euro dollar recent gain euro still trade better premium soft eurozone inflation number september release tuesday buoy investor hope ecb announce sort quantitative ease measure such measure aim increase supply currency drive value euro lower make european product more competitive global market more important weaker euro ireland have be county corporate tax policy corporate tax rate have attract pantheon heavyweight tech pharmaceutical name ireland gdp growth rise quarter quarter strip revenue form multinational gdp expand accord irish time google googl hold title ireland top exporter year report export euro accord irish exporter association export be bit hazy company book overseas revenue ireland then distribute much capital royalty offshore unit microsoft msft johnson johnson jnj dell dell be next line country top exporter ireland base company packaging leader smurfit kappa book export euro food ingredient maker kerry group also figured prominently export euro ireland top rank stock be drugmaker lead actavis act jazz pharmaceutical jazz shire shpg
1080,JNJ,drama continue big biotech gilead science tuesday johnson johnson moved viral disease turf front acquisition
1081,JNJ,johnson johnson jnj disclose buy privately hold alio biopharma cash press release tout alio drug candidate respiratory syncytial virus rsv major cause lung infection have current treatment drug al be midstage clinical testing
1082,JNJ,happen gilead gild also have rsv drug gs phase clinical trial be overshadowed gilead bigger drug rbc capital market analyst michael yee believe have blockbuster potential astrazeneca azn synagis used prevent rsv infection high risk infant draw more year just niche market
1083,JNJ,yee point research note tuesday alio be potential competitor gilead way have nucleotide drug hepatitis virus hcv early stage development
1084,JNJ,gilead megablockbuster sovaldi be first nucleotide drug hcv hit market back december year merck mrk shell buy idenix pharmaceutical also have nuke development
1085,JNJ,not new hep
1086,JNJ,be also hcv game drug olysio be different class drug not directly competitive sovaldi
1087,JNJ,be often prescribe together have help buoy olysio sale launch last november first half year alone sell give success combo not surprising want nuke own
1088,JNJ,clearly think long term call option upside here be alio nuke show log reduction hcv virus have good safety profile yee write course be not layup know development nuke be extremely difficult bar continue progression be very high reminder vertex vrtx be partner prior alio nuke drop development due narrow therapeutic window weak efficacy have sign liver toxicity
1089,JNJ,yee also write be interesting see development read achillion pharmaceutical achn stock boast ibd relative strength rating base largely expectation be next nuke developer be buy investor seem be read negatively achillion stock fall tuesday close
1090,JNJ,still maxim group analyst achillion bull jason kolbert do not sound very worry
1091,JNJ,alio nuke be old news kolbert tell ibd think achn be be bit nonsense nuke show good datum be race
1092,JNJ,high price sovaldi
1093,JNJ,investor analyst be interested future competition sovaldi not just effect market share also sovaldi price have question day
1094,JNJ,gilead charge day treatment typically run week
1095,JNJ,monday government france address issue social security budget bill propose new taxe seller hepatitis drug revenue make france social security have spend more euro drug government call progressive contribution scheme
1096,JNJ,budget still have be approve lawmaker sign european country be continue drive hard bargain gilead roll sovaldi eu approve sovaldi sale january country have own payment system drugmaker have negotiate separately
1097,JNJ,however july france joined other country coordinate strategy drive sovaldi price
1098,JNJ,gilead stock slip tuesday close drama continue big biotech gilead science tuesday johnson johnson moved viral disease turf front acquisition johnson johnson jnj disclose buy privately hold alio biopharma cash press release tout alio drug candidate respiratory syncytial virus rsv major cause lung infection have current treatment drug al be midstage clinical testing happen gilead gild also have rsv drug gs phase clinical trial be overshadowed gilead bigger drug rbc capital market analyst michael yee believe have blockbuster potential astrazeneca azn synagis used prevent rsv infection high risk infant draw more year just niche market yee point research note tuesday alio be potential competitor gilead way have nucleotide drug hepatitis virus hcv early stage development gilead megablockbuster sovaldi be first nucleotide drug hcv hit market back december year merck mrk shell buy idenix pharmaceutical also have nuke development not new hep cj be also hcv game drug olysio be different class drug not directly competitive sovaldi be often prescribe together have help buoy olysio sale launch last november first half year alone sell give success combo not surprising want nuke own clearly think long term call option upside here be alio nuke show log reduction hcv virus have good safety profile yee write course be not layup know development nuke be extremely difficult bar continue progression be very high reminder vertex vrtx be partner prior alio nuke drop development due narrow therapeutic window weak efficacy have sign liver toxicity yee also write be interesting see development read achillion pharmaceutical achn stock boast ibd relative strength rating base largely expectation be next nuke developer be buy investor seem be read negatively achillion stock fall tuesday close still maxim group analyst achillion bull jason kolbert do not sound very worry alio nuke be old news kolbert tell ibd think achn be be bit nonsense nuke show good datum be race high price sovaldiinvestor analyst be interested future competition sovaldi not just effect market share also sovaldi price have question day gilead charge day treatment typically run week monday government france address issue social security budget bill propose new taxe seller hepatitis drug revenue make france social security have spend more euro drug government call progressive contribution scheme budget still have be approve lawmaker sign european country be continue drive hard bargain gilead roll sovaldi eu approve sovaldi sale january country have own payment system drugmaker have negotiate separately however july france joined other country coordinate strategy drive sovaldi price gilead stock slip tuesday close
1099,JNJ,european commission ec approve gilead science gild drug zydelig blood cancer friday send gilead stock much share be flat midday trading stock market today ec approve drug chronic lymphocytic leukemia follicular lymphoma former be be used combination
1100,JNJ,ibd medical biom biotech group be big gainer group be show sign let
1101,JNJ,head thursday be rank group ibd database base month price performance
1102,JNJ,thursday be top perform group abbvie abbv announce plan buy pharmacyclic pcyc cash stock
1103,JNJ,look group be ready roll early february lose straight session find support day move average resume uptrend
1104,JNJ,pharmacyclic be several biotechs have show big sale growth recent quarters blood cancer drug imbruvica be blockbuster food drug administration first approve imbruvica november treat mantle cell lymphoma drug have be approve other indication recent month
1105,JNJ,stock biotech group recently have composite rating higher good bet group see more activity come month big player scoop smaller one compelling pipeline
1106,JNJ,isis pharmaceutical isis isn profitable yet straight quarters accelerate sale growth solid mutual fund sponsorship market capitalization be worth note
1107,JNJ,isis pipeline consist drug treat wide variety disease emphasis cardiovascular metabolic severe rare disease include neurological disorder cancer
1108,JNJ,january company inked potentially lucrative licensing deal johnson johnson jnj janssen biotech unit agree pay front milestone payment develop drug autoimmune disorder tract used isis rna target platform
1109,JNJ,last month isis receive milestone payment biogen idec biib isis be multiyear collaboration biogen advance treatment neurological disease
1110,JNJ,isis be eighth week consolidation show buy point point thursday be only week high
1111,JNJ,elsewhere group small cap newlink genetic nlnk have be busy partnership front newlink partner roche rhhby subsidiary genentech early stage cancer program newlink receive upfront payment genentech more potential milestone
1112,JNJ,infectious disease newlink be work merck mrk ebola vaccine candidate
1113,JNJ,newlink recently clear base buy point close time high
1114,JNJ,meanwhile few large cap name group be back week move average consolidate gain include amgen amgn gilead science gild alexion alxn ibd medical biom biotech group be big gainer group be show sign let head thursday be rank group ibd database base month price performance thursday be top perform group abbvie abbv announce plan buy pharmacyclic pcyc cash stock look group be ready roll early february lose straight session find support day move average resume uptrend pharmacyclic be several biotechs have show big sale growth recent quarters blood cancer drug imbruvica be blockbuster food drug administration first approve imbruvica november treat mantle cell lymphoma drug have be approve other indication recent month stock biotech group recently have composite rating higher good bet group see more activity come month big player scoop smaller one compelling pipeline isis pharmaceutical isis isn profitable yet straight quarters accelerate sale growth solid mutual fund sponsorship market capitalization be worth note isis pipeline consist drug treat wide variety disease emphasis cardiovascular metabolic severe rare disease include neurological disorder cancer january company inked potentially lucrative licensing deal johnson johnson jnj janssen biotech unit agree pay front milestone payment develop drug autoimmune disorder tract used isis rna target platform last month isis receive milestone payment biogen idec biib isis be multiyear collaboration biogen advance treatment neurological disease isis be eighth week consolidation show buy point point thursday be only week high elsewhere group small cap newlink genetic nlnk have be busy partnership front newlink partner roche rhhby subsidiary genentech early stage cancer program newlink receive upfront payment genentech more potential milestone infectious disease newlink be work merck mrk ebola vaccine candidate newlink recently clear base buy point close time high meanwhile few large cap name group be back week move average consolidate gain include amgen amgn gilead science gild alexion alxn
1115,JNJ,specialty drugmaker depome depo pop nearly new high get upgrade roth friday inked deal acquire new pain drug late thursday depome agree buy nucynta franchise johnson johnson jnj janssen pharmaceutical division franchise include tablet extend release tablet oral solution have yet be launch nucynta have be draw year janssen give depome current month sale be run significant revenue stream nucynta deal transform depome write analyst scott henry roth capital partner note upgrading depome buy price increase fine tune product soon approach believe revenue run rate be achievable product depome stock be already move have achieve ibd relative strength rating latest move bring share time high stock market today be more just late morning stock ep rank be lowly operate profit be expect decline year start rise sharply follow amy reeve twitter ibd_areeve related johnson johnson downgrade competition
1116,JNJ,wednesday report fastest quarterly earning growth more year revenue gain continue slow
1117,JNJ,drug health supply distributor fiscal earning share leap fourth straight quarter accelerate growth beating view cent
1118,JNJ,revenue rise help boot alliance wba contract inked last year provide pharmaceutical product top view sale growth slow more prior quarters
1119,JNJ,abc stock end have rise intraday record high
1120,JNJ,re cycling onboard expect revenue growth come evercore isi analyst ross muken tell ibd growth come be still medical distributor market overall
1121,JNJ,be impressive quarter board notably revenue side think have solid result overall say
1122,JNJ,also lift earning outlook share prior view
1123,JNJ,midpoint be roughly line consensus revision be help cent ep beat acquisition mwi veterinary supply company expect add cent ep latter half year
1124,JNJ,only thing investor question be magnitude earning guidance muken say give be not surprised magnitude earning guidance revision
1125,JNJ,company expect revenue wall street consensus
1126,JNJ,fiscal drug unit sale rise specialty sale jump say drug sale gain be due largely pact demand hepatitis drug
1127,JNJ,market hep drug be increasingly competitive gilead gild sovaldi debut december rival treatment johnson johnson jnj abbvie abbv have launch
1128,JNJ,cvs health cvs month say select gilead sovaldi harvoni exclusive hepatitis treatment express script esrx picked abbvie viekira december wednesday report fastest quarterly earning growth more year revenue gain continue slow drug health supply distributor fiscal earning share leap fourth straight quarter accelerate growth beating view cent revenue rise help boot alliance wba contract inked last year provide pharmaceutical product top view sale growth slow more prior quarters abc stock end have rise intraday record high re cycling onboard expect revenue growth come evercore isi analyst ross muken tell ibd growth come be still medical distributor market overall be impressive quarter board notably revenue side think have solid result overall say also lift earning outlook share prior view midpoint be roughly line consensus revision be help cent ep beat acquisition mwi veterinary supply company expect add cent ep latter half year only thing investor question be magnitude earning guidance muken say give be not surprised magnitude earning guidance revision company expect revenue wall street consensus fiscal drug unit sale rise specialty sale jump say drug sale gain be due largely pact demand hepatitis drug market hep drug be increasingly competitive gilead gild sovaldi debut december rival treatment johnson johnson jnj abbvie abbv have launch cvs health cvs month say select gilead sovaldi harvoni exclusive hepatitis treatment express script esrx picked abbvie viekira december
1129,JNJ,soon be acquire medical device giant covidien cov beat analyst fiscal estimate thursday send stock modestly
1130,JNJ,quarter end dec profit rise year earlier quarter share exclude time item beat analyst consensus cent accord thomson reuter sale rise estimate adjust foreign exchange fx headwind sale rise
1131,JNJ,be acquire medtronic mdt covidien didn offer guidance
1132,JNJ,rbc capital market analyst glenn novarro write fx headwind hit top line be expect give johnson johnson jnj stryker syk have already report similar issue covidien turn high quality beat due gross margin gm expansion
1133,JNJ,adjust gms be well estimate consensus believe be partly due fx hedge benefit recall fx benefit gms be basis point last quarter novarro write research note thursday cov operate expense ratio be essentially line estimate
1134,JNJ,overall believe cov report solid quarter operational basis
1135,JNJ,ireland base covidien stock be more morning trading stock market today time high hit jan
1136,JNJ,stock have be climb november medtronic assured investor acquisition be go ahead potential restriction tax inversion deal novarro write expect buyout close late january early february
1137,JNJ,follow amy reeve twitter ibd_areeve soon be acquire medical device giant covidien cov beat analyst fiscal estimate thursday send stock modestly quarter end dec profit rise year earlier quarter share exclude time item beat analyst consensus cent accord thomson reuter sale rise estimate adjust foreign exchange fx headwind sale rise be acquire medtronic mdt covidien didn offer guidance rbc capital market analyst glenn novarro write fx headwind hit top line be expect give johnson johnson jnj stryker syk have already report similar issue covidien turn high quality beat due gross margin gm expansion adjust gms be well estimate consensus believe be partly due fx hedge benefit recall fx benefit gms be basis point last quarter novarro write research note thursday cov operate expense ratio be essentially line estimate overall believe cov report solid quarter operational basis ireland base covidien stock be more morning trading stock market today time high hit jan stock have be climb november medtronic assured investor acquisition be go ahead potential restriction tax inversion deal novarro write expect buyout close late january early february follow amy reeve twitter ibd_areeve
1138,JNJ,big pharma merck mrk be nearly stock market today latest datum hepatitis pipeline underwhelm street sunday annual conference american association study liver disease merck report much anticipate interim datum swift trial analyst thought challenge market leader gilead
1139,JNJ,ve be feel drugmaker merger acquisition have be bust place year professional service firm have number back second quarter report subject release late august company find deal volume pharma life science industry rise total
1140,JNJ,medical giant johnson johnson jnj beat analyst profit estimate tuesday miss topline offer weak guidance send stock more morning trading say earning exclude time item rise year earlier quarter share beating analyst consensus penny accord thomson reuter
1141,JNJ,medical device stock be move wednesday high rate player release preliminary number jpmorgan healthcare conference
1142,JNJ,zeltiq aesthetic zltq startup sell system whittle fat bulge say late tuesday sale be year earlier quarter top analyst consensus company forecast sale ahead consensus estimate last year
1143,JNJ,preliminary result reinforce view zltq continue have significant growth runway underpenetrated market unique fat freeze technology write leerink analyst richard newitter note tuesday reiterate outperform rating
1144,JNJ,zeltiq be founder go public turn profit previous quarters help drive ibd composite rating excellent be expect turn first annual profit year earning cent share midmorning stock market today zeltiq stock be
1145,JNJ,other end size spectrum orthopedic behemoth stryker syk be ep miss expectation late tuesday preliminary range share be analyst consensus firm also say sale rise line estimate
1146,JNJ,stryker say impact foreign exchange rate be anticipate shaving cent ep estimate cent year ep do not provide further guidance
1147,JNJ,give ongoing strengthen dollar do not think syk be alone manage fx headwind generally think investor be brace similar currency impact other medtech result likely be theme other medtech earning kick johnson johnson jnj newitter write
1148,JNJ,have be share cardiovascular giant st jude medical stj pop much wednesday report be merely line market open company say sale rise ep previous guidance range do not offer guidance st jude medical stock be morning trading wednesday
1149,JNJ,follow amy reeve twitter ibd_areeve medical device stock be move wednesday high rate player release preliminary number jpmorgan healthcare conference zeltiq aesthetic zltq startup sell system whittle fat bulge say late tuesday sale be year earlier quarter top analyst consensus company forecast sale ahead consensus estimate last year preliminary result reinforce view zltq continue have significant growth runway underpenetrated market unique fat freeze technology write leerink analyst richard newitter note tuesday reiterate outperform rating zeltiq be founder go public turn profit previous quarters help drive ibd composite rating excellent be expect turn first annual profit year earning cent share midmorning stock market today zeltiq stock be other end size spectrum orthopedic behemoth stryker syk be ep miss expectation late tuesday preliminary range share be analyst consensus firm also say sale rise line estimate stryker say impact foreign exchange rate be anticipate shaving cent ep estimate cent year ep do not provide further guidance give ongoing strengthen dollar do not think syk be alone manage fx headwind generally think investor be brace similar currency impact other medtech result likely be theme other medtech earning kick johnson johnson jnj newitter write have be share cardiovascular giant st jude medical stj pop much wednesday report be merely line market open company say sale rise ep previous guidance range do not offer guidance st jude medical stock be morning trading wednesday follow amy reeve twitter ibd_areeve
1150,JNJ,biotech pharmacyclic pcyc sky-rocket tuesday preliminary sale guidance beat estimate late monday speaking jpmorgan healthcare conference san francisco company official say fourth quarter product revenue be sequentially consensus estimate accord rbc capital market firm also take
1151,JNJ,goldman sachs upgrade eli lilly lly neutral thursday say big pharma have turn corner fall hard patent cliff investment bank downgrade johnson johnson cite increase drug competition believe lly have turn corner improve margin new product launch drive company earning trough
1152,JNJ,special report income investing income investing be filled pothole include chasing yield high yielding stock be tempting accord jim swanson portfolio manager highly regard mfs diversify income fund re fraught risk decline company poor fundamental often have high dividend yield say be seductive situation
1153,JNJ,major stock index nurse modest loss be session lows late afternoon trading tuesday nasdaq lose dow jone industrial average lose nyse nasdaq volume be tracking higher monday level economic news home price stall july accord latest case shiller datum consumer confidence unexpectedly fall lowest read stock market today fast grow name exposure auto market fall heavy volume wall street dissed ford earning guidance monday gentherm thrm plunge harman international har lose day gainer ebay ebay surge news spin paypal unit sometime next year regeneron regn meanwhile add company partner sanofi sny report positive phase ii datum experimental drug dupilumab drug significantly reduce nasal polyp congestion dupilumab be also be look treat eczema asthma regeneron be leaderboard name investor com epam system epam stay rally mode share rise hit low stock be just potential buy point online travel firm expedia expe continue firm week move average second time june share rise strong volume news johnson johnson jnj announce small acquisition buy privately hold alio pharmaceutical
1154,JNJ,medivation mdvn stock rise month high friday biotech company soundly beat estimate late thursday turn corner profitability
1155,JNJ,medivation stock be nearly morning trading stock market today hail distance time high touch feb
1156,JNJ,medivation report profit cent share reverse year earlier loss more double analyst consensus sale jump more average estimate
1157,JNJ,company prostate cancer drug xtandi market collaboration astella have be steep growth curve launch see direct challenger johnson johnson jnj zytiga leerink analyst howard liang note drug have be grow nicely
1158,JNJ,strong continue growth suggest market be not saturation believe datum point address street concern market size liang write research note friday
1159,JNJ,xtandi be approve only patient have already receive chemotherapy september fda be expect approve use earlier treatment drug be also be study breast cancer
1160,JNJ,liang estimate factor drive medivation annual revenue past company be expect produce first annual profit year share accord consensus double digit earning growth foreseeable future
1161,JNJ,follow amy reeve twitter ibd_areeve
1162,JNJ,related
1163,JNJ,earning beat estimate guidance mixed medivation mdvn stock rise month high friday biotech company soundly beat estimate late thursday turn corner profitability medivation stock be nearly morning trading stock market today hail distance time high touch feb medivation report profit cent share reverse year earlier loss more double analyst consensus sale jump more average estimate company prostate cancer drug xtandi market collaboration astella have be steep growth curve launch see direct challenger johnson johnson jnj zytiga leerink analyst howard liang note drug have be grow nicely strong continue growth suggest market be not saturation believe datum point address street concern market size liang write research note friday xtandi be approve only patient have already receive chemotherapy september fda be expect approve use earlier treatment drug be also be study breast cancer liang estimate factor drive medivation annual revenue past company be expect produce first annual profit year share accord consensus double digit earning growth foreseeable future follow amy reeve twitter ibd_areeve related earning beat estimate guidance mixed
1164,JNJ,omnicom group omc biggest advertising company be see profit improve global economy continue grow new york city base firm have report straight quarters accelerate profit increase latest quarter profit current quarter be expect pick further rise cent share revenue have also
1165,JNJ,development stage biotech infinity pharmaceutical infi land key deal develop blood cancer drug duvelisib partnership big pharma abbvie abbv send infinity stock month high stock market today abbvie infinity collaboration include upfront payment milestone payment duvelisib pass
1166,JNJ,ownership apple aapl stock institutional investment firm edge second quarter confidence company performance rise increase follow decline report factset research increase be modest percentage wise number institution add apple portfolio be far more impressive factset
1167,JNJ,stock follow european stock lower wednesday sentiment weaken europe increase sign economic weakness eurozone manufacturing datum show contraction germany france austria greece accord markit economic meanwhile italy lower gdp forecast ahead thursday ecb meeting dow jone industrial average lose weigh boee ba johnson johnson jnj nasdaq fall give russell fall be now recent high distribution day be take shape nyse nasdaq volume be tracking higher tuesday level nasdaq titan facebook fb illumina ilmn baidu bidu lose more home front private employer add job september accord latest datum adp separately ism manufacturing index drop september august drop be little expect stock market today acuity brand ayi be few bright spot share surge company report strong earning fuel strength light emit diode lead product mining utility stock also do well growth stock come heavy selling pressure half stock ibd lose more polaris pii fleetcor flt akorn akrx crash day move average leader ibd transportation equipment manufacturing group also give day line greenbrier gbx tank trinity industry trn lose
1168,JNJ,be shape etfs not too bad thank shire shpg be buy nps pharma npsp maker rare drug roche johnson johnson jnj biogen idec biib have also announce deal zillow be likely merge trulium trla transaction ride coattail banner year
1169,JNJ,biotech macrogenic mgnx cut licensing deal worth much johnson johnson drug development arm monday send stock month high stock market today johnson johnson jnj unit janssen biotech agree pay upfront right macrogenic mgd antibody target
1170,JNJ,biotech isis pharmaceutical isis leap new high stock market today sign licensing deal johnson johnson worth
1171,JNJ,jnj janssen biotech arm agree pay upfront milestone payment develop drug autoimmune disorder tract used isis rna target platform such gi disorder have already filled janssen coffer drug remicade represent new direction isis only market drug present treat high cholesterol
1172,JNJ,collaboration broaden utility drug discovery technology new target gi tract expand administration sense drug local delivery include oral delivery gut say lynne parshall chief operate officer isis company press release
1173,JNJ,isis stock be uptrend especially report positive midstage trial result venous thrombosis preventer isis fxi dec isis have big pharma partner treatment have land big name cancer rare disease inflammatory candidate include roche rhhby biogen idec biib glaxosmithkline gsk
1174,JNJ,company have lose money be not expect break even again
1175,JNJ,isis stock be early afternoon trading monday
1176,JNJ,follow amy reeve twitter ibd_areeve biotech isis pharmaceutical isis leap new high stock market today sign licensing deal johnson johnson worth jnj janssen biotech arm agree pay upfront milestone payment develop drug autoimmune disorder tract used isis rna target platform such gi disorder have already filled janssen coffer drug remicade represent new direction isis only market drug present treat high cholesterol collaboration broaden utility drug discovery technology new target gi tract expand administration sense drug local delivery include oral delivery gut say lynne parshall chief operate officer isis company press release isis stock be uptrend especially report positive midstage trial result venous thrombosis preventer isis fxi dec isis have big pharma partner treatment have land big name cancer rare disease inflammatory candidate include roche rhhby biogen idec biib glaxosmithkline gsk company have lose money be not expect break even again isis stock be early afternoon trading monday follow amy reeve twitter ibd_areeve
1177,JNJ,biotech isis pharmaceutical leap new high monday sign licensing deal johnson johnson worth
1178,JNJ,johnson johnson jnj janssen biotech arm agree pay upfront milestone payment develop drug autoimmune disorder tract used isis rna target platform such gi disorder have already filled janssen coffer drug remicade represent new direction isis isis only market drug present treat high cholesterol
1179,JNJ,collaboration broaden utility drug discovery technology new target gi tract expand administration sense drug local delivery include oral delivery gut say lynne parshall chief operate officer isis company press release
1180,JNJ,isis stock nearly monday be uptrend especially report positive midstage trial result venous thrombosis preventer isis fxi dec
1181,JNJ,isis have big pharma partner treatment have land big name cancer rare disease inflammatory candidate include roche rhhby biogen idec biib glaxosmithkline gsk
1182,JNJ,company have lose money be not expect break even again
1183,JNJ,hot biotech ipo kite pharma kite jump new high monday inked deal amgen amgn worth
1184,JNJ,company develop next generation kite chimeric antigen receptor car cell therapy cancer amgen supply target amgen be pay upfront milestone payment product get approval process launch kite be entitle tiered single digit sale royalty company say
1185,JNJ,deal only cover novel drug candidate not kite current lead drug kte cd be phase testing cell malignancy earlier stage other blood cancer
1186,JNJ,ar cell therapy development have attract increase amount attention fellow drugmaker juno therapeutic juno achieve year biggest biotech ipo valuation debut last month kite go public june kite share soar monday
1187,JNJ,be positive amgn do more deal see more write rbc capital market analyst michael yee research note monday have like also have see deal main cd drug amgn afford commercialize ous outside view
1188,JNJ,yee also note briefing document wednesday fda panel meeting endorse novartis nvs biosimilar version amgen best selling drug neupogen be not look good amgen market exclusivity biotech isis pharmaceutical leap new high monday sign licensing deal johnson johnson worth johnson johnson jnj janssen biotech arm agree pay upfront milestone payment develop drug autoimmune disorder tract used isis rna target platform such gi disorder have already filled janssen coffer drug remicade represent new direction isis isis only market drug present treat high cholesterol collaboration broaden utility drug discovery technology new target gi tract expand administration sense drug local delivery include oral delivery gut say lynne parshall chief operate officer isis company press release isis stock nearly monday be uptrend especially report positive midstage trial result venous thrombosis preventer isis fxi dec isis have big pharma partner treatment have land big name cancer rare disease inflammatory candidate include roche rhhby biogen idec biib glaxosmithkline gsk company have lose money be not expect break even again hot biotech ipo kite pharma kite jump new high monday inked deal amgen amgn worth company develop next generation kite chimeric antigen receptor car cell therapy cancer amgen supply target amgen be pay upfront milestone payment product get approval process launch kite be entitle tiered single digit sale royalty company say deal only cover novel drug candidate not kite current lead drug kte cd be phase testing cell malignancy earlier stage other blood cancer ar cell therapy development have attract increase amount attention fellow drugmaker juno therapeutic juno achieve year biggest biotech ipo valuation debut last month kite go public june kite share soar monday be positive amgn do more deal see more write rbc capital market analyst michael yee research note monday have like also have see deal main cd drug amgn afford commercialize ous outside view yee also note briefing document wednesday fda panel meeting endorse novartis nvs biosimilar version amgen best selling drug neupogen be not look good amgen market exclusivity
1189,JNJ,price action be pretty consistent stock hit week high friday many reversed lower early strength be notable exception dow component johnson johnson jnj extend gain recent flat base share rise fellow dow component home depot hd also hit new high reversed early gain share
1190,JNJ,year biotech medivation launch first drug achievement put ahead more half biotechs trading market wednesday afternoon far wall street be concern become more just biotech drug biotech blockbuster drug august medivation mdvn
1191,JNJ,company always look edge way get create trust team operate integrity big purpose serve other say larry julian author god be ceo approach help motivate person drife succeed here do form bond bring organization together sense purpose say diane swanson kansa state university ethic professor come common mission such serve customer shareholder entire group rally point johnson johnson jnj credo putt health patient client first executive integrity be guide sense purpose swanson tell ibd give incentive publicly reward employee follow firm mission recognize work employee safety outstanding service back action re not hire promote person base integrity then not go work swanson say see big picture succeed long term focuse group mission say julian minneapoli base executive coach know need be make money say also important have purpose transcend bottom line go aspect person show result bill george former ceo medical device maker medtronic mdt christmas bring person life be change firm product show employee big difference effort make julian say such display help turn medtronic unit make drug pump cerebral palsy patient back match action belief doesn do good preach importance safety yet cut cost measure help protect worker watch boss budget hire swanson say employee be watch signal matter take blame buck trend push credit other take responsibility problem many manager do reverse important be able put shoe other employee swanson say make count cheryl bachelder ceo popeye louisiana kitchen plki shift restaurant operator focus serve investor meeting need franchisee be tremendous success story julian say not only do help franchisee make money also increase profit share wealth put power hand person swanson say ll take cue keep culture place ceo be go model integrity purpose have be employee watch learn say build character tony dungy start head coaching career national football league change lose culture take tampa bay buccaneer go team senior leader tell have help young player become best be bring assistant coach share value accountability trust teamwork say want championship have focus first build champion julian say then championship come year later bucs have division title then take indianapoli colt coach super bowl season
1192,JNJ,biotech intercept pharmaceutical icpt be ride high upgrade multiple price target increase issue new datum late monday fatty liver disease drug candidate intercept pharma stock vault early trading stock market today month high monday datum intercept include financial report provide more detail mid stage
1193,JNJ,feel good work flow boost business day energy game do executive silicon valley wall street have common always have too much do not enough time say pravin kothari ceo ciphercloud firm specialize encrypt sensitive information store cloud environment intense
1194,JNJ,pharmacy benefit manager express script announce monday putt abbvie newly approve hepatitis treatment prefer formulary list knock rival treatment gilead science gilead gild stock plunge abbvie abbv fall late friday food drug administration approve abbvie viekira pak combination novel drug older
1195,JNJ,jpmorgan raise price target nevro nyse nvro stock rise monday close time high nevro develop market implantable spinal cord stimulation system call senza design treat chronic pain back leg company raise nov ipo price estimate range june nevro submit premarket approval application food drug administration senza system company plan launch commercially early approve fda system have be commercially available certain european market november nevro report third quarter earning dec revenue rise increase be attributable primarily continue adoption senza system market be available nevro say report net loss compare net loss same period prior year base menlo park calif nevro name medtronic nyse mdt boston scientific nyse bsx st jude medical nyse stj competitor shareholder include johnson johnson nyse jnj follow brian deagon twitter ibd_bdeagon related juno therapeutic ipo hot cancer curer demand
1196,JNJ,jpmorgan raise price target nevro nvro stock rise monday close time high nevro develop market implantable spinal cord stimulation system call senza design treat chronic pain back leg company raise nov ipo price estimate range june nevro submit premarket approval application food drug administration senza system company plan launch commercially early approve fda system have be commercially available certain european market november nevro report third quarter earning dec revenue rise increase be attributable primarily continue adoption senza system market be available nevro say report net loss compare net loss same period prior year base menlo park calif nevro name medtronic mdt boston scientific bsx st jude medical stj competitor shareholder include johnson johnson jnj follow brian deagon twitter ibd_bdeagon related juno therapeutic ipo hot cancer curer demand
1197,JNJ,stock backed early gain be mixed early tuesday investor wrestle jumble economic news
1198,JNJ,dow jone industrial average rise add index reach new high nasdaq shed early gain slip
1199,JNJ,volume be soft second day tracking nyse nasdaq compare same time monday
1200,JNJ,stock market today receive early push commerce department revise gdp estimate much better expect november durable good order be weak federal housing finance agency housing price index tick better expect october
1201,JNJ,personal spending jump november labor department say accelerate gain october economist consensus estimate be slightly smaller jump consumer income rise vs gain october forecast be increase
1202,JNJ,consumer sentiment hold steady december accord university michigan put final consumer sentiment index read smidge vs november better dip economist expect new home sale fall november annualize rate
1203,JNJ,stock gain loss be generally modest drugmaker again pressure be exception merck mrk pfizer pfe johnson johnson jnj post dow only early decline drugmaker hold biggest loss nasdaq
1204,JNJ,retailer be show strength lead dd punch heavy trade stock be buy point double bottom base
1205,JNJ,leader be moderately positive third ibd move higher start trade
1206,JNJ,asbury automotive abg rise drugmaker hold low end list celgene celg drop gilead science gild biogen idec biib amgen amgn fall stock backed early gain be mixed early tuesday investor wrestle jumble economic news dow jone industrial average rise add index reach new high nasdaq shed early gain slip volume be soft second day tracking nyse nasdaq compare same time monday stock market today receive early push commerce department revise gdp estimate much better expect november durable good order be weak federal housing finance agency housing price index tick better expect october personal spending jump november labor department say accelerate gain october economist consensus estimate be slightly smaller jump consumer income rise vs gain october forecast be increase consumer sentiment hold steady december accord university michigan put final consumer sentiment index read smidge vs november better dip economist expect new home sale fall november annualize rate stock gain loss be generally modest drugmaker again pressure be exception merck mrk pfizer pfe johnson johnson jnj post dow only early decline drugmaker hold biggest loss nasdaq retailer be show strength lead dd punch heavy trade stock be buy point double bottom base leader be moderately positive third ibd move higher start trade asbury automotive abg rise drugmaker hold low end list celgene celg drop gilead science gild biogen idec biib amgen amgn fall
1207,JNJ,stock open short week trading quick reversal sudden drop oil price help turn open gain mild loss dow jone industrial average drop fall nasdaq keep fractional loss buffer apple aapl advance volume be soft nasdaq lower nyse oil related issue be take beating early action stock market today price crude benchmark west texas intermediate fall back barrel drag be strong enough reverse premarket gain make halliburton hal schlumberger slb fourth quarter earning report halliburton fall schlumberger be start trade weak oil price be also key positive report delta air line dal launch airline group head early trade delta earning narrowly top expectation company report fuel cost saving increase refinery profit delta spirit airline save surge unite continental holding ual american airline aal alaska air group alk jetblue jblu gain apiece dow johnson johnson jnj slip medical health care good provider report better expect earning revenue stop short projection hurt change currency exchange rate management also raise full year profit guidance analyst expectation illumina ilmn rise retake day line support healthy trade maker large scale genetic screening test equipment drop last week follow brief buy point number china base stock be take hard hit early trade asset manager noah holding noah drop stock have stumble last week be now trading december high bitauto bita also add last week loss diving online car information provider be january high economic news show builder confidence january national association homebuilder housing market index dip be december forecast change
1208,JNJ,stock market be organism strive identify opportunity crisis hold true late summer early fall outbreak ebola virus west africa reach crisis proportion guinea liberium sierra leone first case be discover september liberian native return texas
1209,JNJ,several key drug major drugmaker get endorsement european medicine agency ema friday make commercial approval european union enormous market much more likely
1210,JNJ,bristol myer squibb bmy hepatitis drug daclatasvir now brand daklinza be endorse ema committee medicinal product human use chmp use combination other hep drug notably gilead science gild sovaldi
1211,JNJ,sovaldi daclatasvir perform outstandingly combine clinical trial gilead decide substitute similar drug own make ledipasvir combo expect be approve later year nonetheless bristol executive tell ibd march still see role drug marketplace especially tough treat case
1212,JNJ,chmp also endorse expand label eliquis drug bristol co develop pfizer pfe reduce risk stroke patient atrial fibrillation include deep vein thrombosis pulmonary embolism eliquis launch early last year disappoint street competitor xarelto johnson johnson jnj eat market share bristol pfizer have keep plug away peak annual sale estimate be still run billion
1213,JNJ,endorsement drug be not surprise wall street bristol stock be fraction morning trading stock market today pfizer stock be flat
1214,JNJ,meanwhile regeneron pharmaceutical regn blockbuster eylea look get even bigger chmp endorse expand use include diabetic macular edema type vision loss result diabetes nonetheless regeneron stock be nearly morning trading friday
1215,JNJ,regeneron share have be pressure last week accord rbc capital market analyst adnan butt worry have arise payer particulary medicare medicaid be go mandate use roche avastin eylea cost reason butt write own research do not support theory
1216,JNJ,datum be best anecdotal channel check do not show change pattern hence do not see widespread conversion used label avastin write note wednesday
1217,JNJ,follow amy reeve twitter ibd_areeve several key drug major drugmaker get endorsement european medicine agency ema friday make commercial approval european union enormous market much more likely bristol myer squibb bmy hepatitis drug daclatasvir now brand daklinza be endorse ema committee medicinal product human use chmp use combination other hep drug notably gilead science gild sovaldi sovaldi daclatasvir perform outstandingly combine clinical trial gilead decide substitute similar drug own make ledipasvir combo expect be approve later year nonetheless bristol executive tell ibd march still see role drug marketplace especially tough treat case chmp also endorse expand label eliquis drug bristol co develop pfizer pfe reduce risk stroke patient atrial fibrillation include deep vein thrombosis pulmonary embolism eliquis launch early last year disappoint street competitor xarelto johnson johnson jnj eat market share bristol pfizer have keep plug away peak annual sale estimate be still run billion endorsement drug be not surprise wall street bristol stock be fraction morning trading stock market today pfizer stock be flat meanwhile regeneron pharmaceutical regn blockbuster eylea look get even bigger chmp endorse expand use include diabetic macular edema type vision loss result diabetes nonetheless regeneron stock be nearly morning trading friday regeneron share have be pressure last week accord rbc capital market analyst adnan butt worry have arise payer particulary medicare medicaid be go mandate use roche avastin eylea cost reason butt write own research do not support theory datum be best anecdotal channel check do not show change pattern hence do not see widespread conversion used label avastin write note wednesday follow amy reeve twitter ibd_areeve
1218,JNJ,even re not biotech pharma investor ve probably catch earful news lately virus call hepatitis last december record breaking launch gilead science gild wonder drug sovaldi controversy price tag merck mrk recent buyout formerly neglected biotech idenix pharmaceutical idix
1219,JNJ,year old johnson johnson jnj be still deliver growth income shareholder
1220,JNJ,not band aid bandage baby oil drive growth new brunswick base health care giant operate unit pharmaceutical segment have show consistent growth recent quarters last year pharmaceutical account total sale touch
1221,JNJ,latest quarters revenue pharmaceutical sale rise company have see strong demand remicade treatment inflammatory disease velcade be used multiple myeloma sale new product such zytiga prostate cancer treatment have also show strength
1222,JNJ,johnson johnson have deliver single digit earning growth past quarters sale be flat slightly couple period grow single digit straight quarters analyst poll thomson reuter see earning rise share year profit be slate rise
1223,JNJ,johnson johnson be dividend aristocrat index track performance stock have increase dividend annually least year company have boost shareholder dividend straight year
1224,JNJ,most recently announce hike april raise quarterly dividend cent share cent quarterly dividend have more double past year
1225,JNJ,annualize basis johnson johnson pay share work yield share be trading time high stock remain steady performer have be historically year old johnson johnson jnj be still deliver growth income shareholder not band aid bandage baby oil drive growth new brunswick base health care giant operate unit pharmaceutical segment have show consistent growth recent quarters last year pharmaceutical account total sale touch latest quarters revenue pharmaceutical sale rise company have see strong demand remicade treatment inflammatory disease velcade be used multiple myeloma sale new product such zytiga prostate cancer treatment have also show strength johnson johnson have deliver single digit earning growth past quarters sale be flat slightly couple period grow single digit straight quarters analyst poll thomson reuter see earning rise share year profit be slate rise johnson johnson be dividend aristocrat index track performance stock have increase dividend annually least year company have boost shareholder dividend straight year most recently announce hike april raise quarterly dividend cent share cent quarterly dividend have more double past year annualize basis johnson johnson pay share work yield share be trading time high stock remain steady performer have be historically
1226,JNJ,big cap name lead way stock be higher noon hour approach friday dow jone industrial average hit time high
1227,JNJ,volume swell quadruple witching simultaneous quarterly expiration single stock index future single stock index option
1228,JNJ,dow be top performer major index rise nasdaq gain just year high
1229,JNJ,stock market today dow stock merck mrk caterpillar cat be nearly dupont dd johnson johnson jnj exxonmobil xom be more
1230,JNJ,ibd stock irish drugmaker shire shpg be top performer reject buyout offer abbvie abbv be little change volatile morning
1231,JNJ,worst performer be emerge energy service emes announce secondary offer share discount thursday close price company mine silica hydraulic fracture used oil gas drill
1232,JNJ,auto dealer carmax kmx vault report earning cent share increase year quarter analyst be forecasting cent big cap name lead way stock be higher noon hour approach friday dow jone industrial average hit time high volume swell quadruple witching simultaneous quarterly expiration single stock index future single stock index option dow be top performer major index rise nasdaq gain just year high stock market today dow stock merck mrk caterpillar cat be nearly dupont dd johnson johnson jnj exxonmobil xom be more ibd stock irish drugmaker shire shpg be top performer reject buyout offer abbvie abbv be little change volatile morning worst performer be emerge energy service emes announce secondary offer share discount thursday close price company mine silica hydraulic fracture used oil gas drill auto dealer carmax kmx vault report earning cent share increase year quarter analyst be forecasting cent
1233,JNJ,worry omnicom group second quarter result merger deal france publicis fall advertising publicity giant manage top sale profit forecast last week omnicom group omc report earning rise share exclude item increase revenue
1234,JNJ,medtronic buyout fellow medical device giant covidien get mostly friendly reception wall street monday analyst foresee further round mega merger change industry landscape late sunday medtronic mdt announce have agree buy covidien cov cash stock deal give covidien shareholder ownership new company
1235,JNJ,share medical device maker covidien cov jump stock market today medtronic mdt announce late sunday be buy company medtronic cash stock payment amount share base medtronic close price friday create industry heavyweight annual revenue covidien
1236,JNJ,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
1237,JNJ,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
1238,JNJ,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
1239,JNJ,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
1240,JNJ,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
1241,JNJ,share real estate zillow be hour follow result
1242,JNJ,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
1243,JNJ,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
1244,JNJ,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
1245,JNJ,midst rip roar market many investor tend seek fast growth slow steady income stock be argument be make company provide stable earning reasonable sale growth well dividend payout market recent volatility boost appeal sector be defensive nature such certain medical play johnson johnson jnj be classic income stock new brunswick base health care giant make everything household name product such band aids splenda tylenol medical device prescription drug such wide range product recently be look slim portfolio selling slower grow unit earlier month johnson johnson say receive bound offer carlyle group ortho clinical diagnostic business currently pay cent share quarterly basis annually work dividend yield vs have deliver dividend shareholder more year have grow adjust earning year row analyst expect company lift profit year next year earning growth rate be earning stability factor be scale most stable least stable make dividend aristocrat track company have increase dividend year past consecutive year stock rise last year just ahead gain correct market year sit nearly week high slice week move average last week be near week line level typically find support
1246,JNJ,embattled specialty drugmaker allergan wednesday beat wall street first quarter earning estimate raise guidance company stock slide close future remain doubt allergan agn report earning share year earlier quarter beating analyst consensus cent sale rise line estimate guidance follow similar pattern full year company set sale range bracketing consensus ep range top street last year company make share sale second quarter firm guide sale year again meeting view allergan guide ep consensus vs last year announcement come allergan shareholder be still weigh valeant pharmaceutical vrx hostile takeover attempt launch april tuesday allergan co founder gavin herbert slam takeover bid annual shareholder meeting warning valeant decimate allergan research development budget allergan ceo david pyott refuse take question valeant drama wednesday conference call discuss result instead focuse company continue growth market share gain chief market ophthalmology dermatology aesthetic sale lead product botox grow company forecast full year botox sale last year botox retain market share valeant dysport take most remainder research note wednesday morningstar analyst michael point company benefit johnson johnson jnj decision last month halt development purtox potential competitor botox sale eye drop restasis climb allergan estimate crack year facial aesthetic category jump help launch skin firm injectable juvederm voluma breast aesthetic product line grow even be stagnant last year call pyott say unit growth be still flat company have succeed shift higher end product seri surgical scaffold tissue reconstruction several time call pyott suggest allergan unveil new strategy future response valeant approach shareholder pressure lower spending sale general administrative expense totale revenue quarter slight decline last year pyott acknowledge investor have be ask ll get mid ve be slow go pyott say board have start talk issue month be hold final decision valeant situation be resolve management simply have run business more aggressively not necessarily forfeit traditional method pharmaceutical value creation internal purchase cowen analyst ken cacciatore write note wednesday however have plausibly convince current shareholder make more sense be buy agn stock rather selling
1247,JNJ,big biotech amgen amgn early monday report positive interim result crucial late stage trial blood cancer drug kyproli monday help justify acquisition onyx last year amgen be more early trading stock market today modest rise investor await result important second trial first trial call
1248,JNJ,johnson johnson jnj say thursday receive bound offer private equity firm carlyle group ortho clinical diagnostic business have march decide offer
1249,JNJ,transaction be result discipline approach portfolio management order achieve greatest value johnson johnson ceo alex gorsky say statement
1250,JNJ,diversify medical giant have be work sell slower grow unit ortho clinical diagnostic be still substantial asset annual sale top market share diagnostic industry
1251,JNJ,leerink analyst danielle antalffy say expect more divestiture future
1252,JNJ,diabetes business lifescan blood glucose meter pump be next area ve see meaningful sale growth deceleration margin compression believe be target future strategic alternative write email client jnj have reiterate commitment diabetes believe company have become increasingly drug focuse back successful better expect invokana launch invokana be adult type diabetes
1253,JNJ,stock be flat morning trading stock market today
1254,JNJ,follow amy reeve twitter ibd_areeve johnson johnson jnj say thursday receive bound offer private equity firm carlyle group ortho clinical diagnostic business have march decide offer transaction be result discipline approach portfolio management order achieve greatest value johnson johnson ceo alex gorsky say statement diversify medical giant have be work sell slower grow unit ortho clinical diagnostic be still substantial asset annual sale top market share diagnostic industry leerink analyst danielle antalffy say expect more divestiture future diabetes business lifescan blood glucose meter pump be next area ve see meaningful sale growth deceleration margin compression believe be target future strategic alternative write email client jnj have reiterate commitment diabetes believe company have become increasingly drug focuse back successful better expect invokana launch invokana be adult type diabetes stock be flat morning trading stock market today follow amy reeve twitter ibd_areeve
1255,JNJ,stock open small gain tuesday then moved downward
1256,JNJ,dow jone industrial average be fall nasdaq be volume vs monday pace be run mixed higher nyse lower nasdaq
1257,JNJ,stronger expect quarterly result blue chip goldman sachs gs jpmorgan chase jpm johnson johnson jnj set positive tone market open also open empire state manufacturing survey july trounce view vs estimate accord econoday
1258,JNJ,however retail sale june inched only vs consensus view gain retail stock have be disappointment year sector start year middle pack ibd sector now be bottom third
1259,JNJ,consider consumer spending make economy uptrending stock market weak retail sector isn combination inspire great conviction
1260,JNJ,ibd stock reflect top stock fundamental technical weren make much early progress stock market today typical be stock such social platform provider facebook fb commercial property manager cbre group cbg penny
1261,JNJ,federal reserve chairwoman janet yellen be testify senate banking committee today wednesday testify house financial service committee
1262,JNJ,close chipmaker intel intc railroad operator csx csx internet search provider yahoo yhoo report quarterly result be moderately early trade stock open small gain tuesday then moved downward dow jone industrial average be fall nasdaq be volume vs monday pace be run mixed higher nyse lower nasdaq stronger expect quarterly result blue chip goldman sachs gs jpmorgan chase jpm johnson johnson jnj set positive tone market open also open empire state manufacturing survey july trounce view vs estimate accord econoday however retail sale june inched only vs consensus view gain retail stock have be disappointment year sector start year middle pack ibd sector now be bottom third consider consumer spending make economy uptrending stock market weak retail sector isn combination inspire great conviction ibd stock reflect top stock fundamental technical weren make much early progress stock market today typical be stock such social platform provider facebook fb commercial property manager cbre group cbg penny federal reserve chairwoman janet yellen be testify senate banking committee today wednesday testify house financial service committee close chipmaker intel intc railroad operator csx csx internet search provider yahoo yhoo report quarterly result be moderately early trade
1263,JNJ,maker medical device be come increase pressure owing fundamental power shift american medicine favore insurance company hospital patient change accord moty avisar president medical system maker surgical theater be base patient be force soar medical cost take control health care let say patient be
1264,JNJ,biotech alk report tuesday schizophrenia drug hit goal phase trial file fda approval next quarter stock be morning trading stock market today heavy volume say week treatment drug aripiprazole lauroxil bring statistically significant improvement patient score
1265,JNJ,biotech pharmacyclic pcyc be seesaw stock market today sale beat consensus late thursday company decline update guidance pharmacyclic sale more double year earlier quarter higher consensus loss cent share be well consensus cent analyst
1266,JNJ,drugmaker aim help person live healthier life aren immune patent loss merck mrk have recently face number patent expiration tuesday report sale slow eighth quarter row earning climb cent share third straight quarter gain result beat view
1267,JNJ,drugmaker aim help person live healthier life aren immune patent loss merck mrk have recently face number patent expiration tuesday report sale slow eighth quarter row earning climb cent share third straight quarter gain result beat view
1268,JNJ,business don have weather kick anymore have lead analyst expect improve not spectacular profit revenue growth second quarter earning season kick week first quarter abysmal gross domestic product decline be blame largely polar vortex blizzard profit growth turn better
1269,JNJ,focuse appreciate energetic employee outperform rest tip increase occupational oomph thaw frost most pro have be blindside least once chilly office politic unspoken expectation titanic iceberg career collision seem logically avoidable yet somehow inevitable certain inescapable frustration jesse sostrin tell ibd book job description chip away call hide curriculum work thing re expect understand accomplish aren detailed job description so much unspoken stuff get way professional success say go subsurface figure job job ve get scan organization sign hide curriculum sostrin say observation various player motivation seek input smart way sostrin suggest approach manager soft pedal tack work objective don feel re connect important put focus executive receive such query be wise talk openly ambiguous priority manager encourage candid chat raise stature worker sense get create credibility leader sostrin say create oasis work have dilbert esque moment make small part experience better sostrin say find interest ability intersect organization true need grab sphere influence say warm spirit take more cold hard cash motivate worker re look connection work say cord himelstein vice president marketing communication michael fina employee recognition firm emphasize personalize approach winning rank file ll lose motivation action go unrecognized say shine light size fit appreciation program standard gift year service fall flat himelstein urge firm take thoughtful approach understand behavior re try influence say reward carefully defined outcome such hit performance goal financial target define re go measure success track progress mix movement pause day move little wake overtaxed mind take strategic physical activity break energy level day go truly get back work fully engage so say sanjay gupta president wellness prevention johnson johnson jnj company recommend conduct walking meeting keep exercise ball conference room more active spin sit exert top muscle raise everyone energy level ceo take first step not just say do gupta say culture health start top sign ceo pledge nationwide campaign promote national coalition promote physical activity chief ve sign promise boost own personal fitness provide opportunity employee follow suit supposition boss be work employee follow culture start leader be involved gupta say ve get get more deliberate work
1270,JNJ,stock future show healthy gain early tuesday europe market rebound oil price re-cover lows economic news be fair positive
1271,JNJ,dow future trade point fair market value point hour earlier nasdaq future add early gain be point future moved point even hour earlier level
1272,JNJ,stock market today have eye wednesday afternoon federal open market committee member head day powwow expectation be high policy shift group announce decision wednesday et
1273,JNJ,consumer price be flat november labor department report be gain october line economist expectation core price food energy rise equal october increase meeting consensus projection
1274,JNJ,manufacturing activity new york region slow improve rate december accord new york federal reserve empire state manufacturing survey show performance vs show november be better read expect economist
1275,JNJ,national association home builder release builder confidence index treasury department report long term treasury international capital flow october
1276,JNJ,oil price take modest bounce early trade lift west texas intermediate less brent crude more still trading barrel respectively late day recovery market monday fed rebound european market lead index bounce week lows send dax frankfurt cac paris more midday
1277,JNJ,stock miner steel market be rebound issue vale vale arcelor mittal mt ahead more dow diversify operator mmm old minnesota mining manufacturing co tank more lower earning guidance chevron cvx top index premarket trade gain
1278,JNJ,also notch worst loss stock network ffiv take second hardest hit bit more
1279,JNJ,chipmaker nvidia nvda newell rubbermaid nwl southwestern energy swn top list better
1280,JNJ,flooring retailer lumber liquidator ll bolt higher news report detailed letter kase capital management manage partner whitney tilson declare have cover short position stock
1281,JNJ,tilson have weigh company follow allegation flooring contain unsafe level formaldehyde tilson conclude management probably do not know problem accord bloomberg mean company be sloppy naive not evil tilson write stock end monday news investigation break february
1282,JNJ,lead stock stick moderate move premarket action hawaiian top ibd list slightly more premarket trade dave buster play stake low end loss stock future show healthy gain early tuesday europe market rebound oil price re-cover lows economic news be fair positive dow future trade point fair market value point hour earlier nasdaq future add early gain be point future moved point even hour earlier level stock market today have eye wednesday afternoon federal open market committee member head day powwow expectation be high policy shift group announce decision wednesday et consumer price be flat november labor department report be gain october line economist expectation core price food energy rise equal october increase meeting consensus projection manufacturing activity new york region slow improve rate december accord new york federal reserve empire state manufacturing survey show performance vs show november be better read expect economist national association home builder release builder confidence index treasury department report long term treasury international capital flow october oil price take modest bounce early trade lift west texas intermediate less brent crude more still trading barrel respectively late day recovery market monday fed rebound european market lead index bounce week lows send dax frankfurt cac paris more midday stock miner steel market be rebound issue vale vale arcelor mittal mt ahead more dow diversify operator mmm old minnesota mining manufacturing co tank more lower earning guidance chevron cvx top index premarket trade gain also notch worst loss stock network ffiv take second hardest hit bit more chipmaker nvidia nvda newell rubbermaid nwl southwestern energy swn top list better flooring retailer lumber liquidator ll bolt higher news report detailed letter kase capital management manage partner whitney tilson declare have cover short position stock tilson have weigh company follow allegation flooring contain unsafe level formaldehyde tilson conclude management probably do not know problem accord bloomberg mean company be sloppy naive not evil tilson write stock end monday news investigation break february lead stock stick moderate move premarket action hawaiian top ibd list slightly more premarket trade dave buster play stake low end loss
1283,JNJ,johnson johnson jnj kick medical industry earning season modest upside surprise tuesday send stock morning trading stock market today earning time item totale share year earlier quarter beating analyst consensus cent sale rise
1284,JNJ,stock rebound poor start wednesday major index close session high lead growth stock struggle whole ibd drop more contrast day biggest gainer be concentrated oil exploration defensive group include candy maker electric utility health insurer rise positive reversal
1285,JNJ,stock future tuesday hint third straight session gain be modest
1286,JNJ,nasdaq dow future be future add
1287,JNJ,market uptrend have be pressure recently start heavy volume sell week day friday monday come average volume suggest uptrend hasn yet regain confidence
1288,JNJ,attention stock market today be federal reserve chair janet yellen testimony senate banking committee et focus also be number company report quarterly result
1289,JNJ,open goldman sachs gs report stronger expect quarter investment banker earn share trouncing view fix income trading fall be far less drop expect bloomberg news report goldman share rise pre market action
1290,JNJ,jpmorgan chase jpm also top street target earning rolled share vs view legal fee quarter trim earning cent share stock be pre market trade
1291,JNJ,diversify health product provider johnson johnson jnj deliver adjust earning share top estimate revenue edge view vs consensus estimate share pre market action however didn get much bounce double beat stock be
1292,JNJ,close chipmaker intel intc railroad operator csx csx internet search provider yahoo yhoo report quarterly result
1293,JNJ,world index be mixed stock rise brazil bovespa exchange mexico bolsa index japan nikkei advanced hong kong hang seng index add europe stock be mostly eurozone euro stoxx be
1294,JNJ,comex gold tick west texas intermediate crude oil slip hover just line stock future tuesday hint third straight session gain be modest nasdaq dow future be future add market uptrend have be pressure recently start heavy volume sell week day friday monday come average volume suggest uptrend hasn yet regain confidence attention stock market today be federal reserve chair janet yellen testimony senate banking committee et focus also be number company report quarterly result open goldman sachs gs report stronger expect quarter investment banker earn share trouncing view fix income trading fall be far less drop expect bloomberg news report goldman share rise pre market action jpmorgan chase jpm also top street target earning rolled share vs view legal fee quarter trim earning cent share stock be pre market trade diversify health product provider johnson johnson jnj deliver adjust earning share top estimate revenue edge view vs consensus estimate share pre market action however didn get much bounce double beat stock be close chipmaker intel intc railroad operator csx csx internet search provider yahoo yhoo report quarterly result world index be mixed stock rise brazil bovespa exchange mexico bolsa index japan nikkei advanced hong kong hang seng index add europe stock be mostly eurozone euro stoxx be comex gold tick west texas intermediate crude oil slip hover just line
1295,JNJ,mcdonald mcd johnson johnson jnj be household name offer steady profit growth make classic dividend play income investor fellow dividend aristocrat wide range consumer brand include aveeno band aid tylenol splenda medical device diagnostic equipment pharmaceutical account bulk revenue be
1296,JNJ,most employee complain boss don quit start own company peter rise james wang do get freight forwarding business ground seattle base expeditor international expd be earliest logistic company tap asia freight logistic market go public end year
1297,JNJ,danish pharmaceutical giant nordisk nvo miss sale estimate lower full year revenue forecast thursday profit be line stock be more early trading stock market today
1298,JNJ,make cent share quarter year earlier quarter danish kroner penny analyst consensus sale increase kroner equivalent miss consensus
1299,JNJ,company lower sale growth guidance previous range maintain operate profit growth ceo lar sorensen say know year be challenge pharmacy benefit manager express script esrx take drug victoza novolog prefer treatment list lower reimbursement drug management be also see more competition diabetes market especially new sglt inhibitor class
1300,JNJ,johnson johnson jnj invokana be first class be approve last year astrazeneca azn farxiga be approve january more be come pike astella roche rhhby eli lilly lly
1301,JNJ,be also face generic competition year oral glucose lower drug prandin
1302,JNJ,bright side company say launch tresiba new long act insulin product be go smoothly sale multiply ninefold year earlier quarter have now launch product country be still work fda approval be unexpectedly delay last year agency ask more datum tresiba heart risk
1303,JNJ,sorensen say study fda request be ahead schedule interim analysis datum be available mid
1304,JNJ,stock hold excellent ibd composite rating stock have be consolidate hit time high feb midmorning thursday stock be trading
1305,JNJ,follow amy reeve twitter ibd_areeve
1306,JNJ,related pfizer confirm pursuit pharmaceutical giant nordisk nvo miss sale estimate lower full year revenue forecast thursday profit be line stock be more early trading stock market today make cent share quarter year earlier quarter danish kroner penny analyst consensus sale increase kroner equivalent miss consensus company lower sale growth guidance previous range maintain operate profit growth ceo lar sorensen say know year be challenge pharmacy benefit manager express script esrx take drug victoza novolog prefer treatment list lower reimbursement drug management be also see more competition diabetes market especially new sglt inhibitor class johnson johnson jnj invokana be first class be approve last year astrazeneca azn farxiga be approve january more be come pike astella roche rhhby eli lilly lly be also face generic competition year oral glucose lower drug prandin bright side company say launch tresiba new long act insulin product be go smoothly sale multiply ninefold year earlier quarter have now launch product country be still work fda approval be unexpectedly delay last year agency ask more datum tresiba heart risk sorensen say study fda request be ahead schedule interim analysis datum be available mid stock hold excellent ibd composite rating stock have be consolidate hit time high feb midmorning thursday stock be trading follow amy reeve twitter pfizer confirm pursuit astrazeneca
1307,JNJ,highest rate market big cap biotechs be set report second quarter earning week own unique storyline biogen idec biib subject tuesday new america be first report open wednesday analyst consensus call sale year earlier quarter earning
1308,JNJ,big cap biotech celgene celg report wednesday drug otezla fail trial inflammatory spinal disease stock rebound early drop analyst say news wasn surprise phase study look otezla ankylose spondylitis immunological disease cause pain sometimes fusion spinal cord be not
1309,JNJ,therapeutic anik stock vault time high morning trading stock market today day biotech win fda approval arthritis treatment close tuesday say fda have approve monovisc osteoarthritis knee depuy synthe mitek sport medicine division johnson johnson jnj market
1310,JNJ,specialty drug giant actavis act beat analyst estimate wednesday management project solid future expand product line aid acquisition earning jump year earlier quarter share top analyst consensus cent accord thomson reuter sale gain beating estimate stock rise
1311,JNJ,share johnson johnson jnj be record high even company reputation take blow justice department announce nov settlement more company resolve criminal civil charge illegal marketing medication janssen pharmaceutical subsidiary plead guilty promote antipsychotic drug risperdal unapproved used settlement involved other drug also impose corporate integrity agreement design increase accountability transparency prevent future fraud abuse justice department say say settlement be previously accrue not result additional charge earning johnson johnson also make tylenol band aid diagnostic device other health care product have solid dividend pay cent share quarter good annualize yield nearly be part dividend aristocrat index company have increase payout least straight year latest quarterly result announce oct earn share estimate sale rise also view pharmaceutical business lead quarter growth new drug be exceed high expectation sale prostate cancer drug zytiga surge year year immunology drug simponi stelara grow respectively medical device diagnostic division shed stock be form base possible buy point january share climb price level only second time september
1312,JNJ,nomura analyst ian somaiya raise price target pharmacyclic pcyc gilead science gild lower biogen idec biib survey compete drug chronic lymphocytic leukeumia somaiya write survey doctor treat more cll patient highlighted rapid transition cll market newer oral drug particular
1313,JNJ,stock jump start gate monday accord sort eurozone greece brushed global market bit optimism
1314,JNJ,nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday
1315,JNJ,stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july
1316,JNJ,europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro
1317,JNJ,stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece
1318,JNJ,gps device leader garmin grmn wynn resort wynn climb run head nasdaq
1319,JNJ,head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump
1320,JNJ,newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation
1321,JNJ,very few ibd stock post early decline ambarella amba taser international tasr be stock jump start gate monday accord sort eurozone greece brushed global market bit optimism nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece gps device leader garmin grmn wynn resort wynn climb run head nasdaq head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation very few ibd stock post early decline ambarella amba taser international tasr be
1322,JNJ,day outperformance nasdaq wednesday spark several new high technology sector cavium cavm leader ibd electronic semiconductor fabless group add company product be used variety networking application market such enterprise network datum center consumer suite new product be expect drive
1323,JNJ,stock rebound mildly tuesday lighter trade market defensiveness meanwhile grow more evident few blue chip firm history go back far year show rare stock muscle nasdaq composite edge less higher fraction drop suffer prior session only
1324,JNJ,specialty pharmaceutical company depome depo have be nearly year ceo james schoeneck say have only just begin realize potential drug product portfolio be acquire most recent migraine drug cambia be buy december nautilus neurosciences cambia eventually become
1325,JNJ,nasdaq take beating again friday institutional investor continue take profit growth stock nearly half stock ibd fall more
1326,JNJ,nasdaq plunge be day move average again briefly reclaim support level lose dow jone industrial average ease nyse nasdaq volume be tracking well thursday level stock market today
1327,JNJ,institutional investor rotate growth stock not surprising see scad blue chip name hold well better look chart currently be find dow name such caterpillar cat dupont dd walt disney johnson johnson jnj other
1328,JNJ,economic news economy add job march consensus estimate unemployment rate be unchanged february job growth be revise higher initially report money flow bond market news year treasury yield fall basis point
1329,JNJ,weakness biotech stock have be weigh nasdaq be more same friday ibd medical biom biotech group lose nearly feb high group have lose
1330,JNJ,not surprisingly gold utility stock outperformed
1331,JNJ,bright spot friday be mylan myl share rise news be interested acquire swiss firm meda meda reject proposal
1332,JNJ,bright spot friday be cement maker group rise bloomberg report industry titan swiss firm holcim french firm lafarge be explore possible merger group leader eagle material exp hit time high rise nearly nasdaq take beating again friday institutional investor continue take profit growth stock nearly half stock ibd fall more nasdaq plunge be day move average again briefly reclaim support level lose dow jone industrial average ease nyse nasdaq volume be tracking well thursday level stock market today institutional investor rotate growth stock not surprising see scad blue chip name hold well better look chart currently be find dow name such caterpillar cat dupont dd walt disney johnson johnson jnj other economic news economy add job march consensus estimate unemployment rate be unchanged february job growth be revise higher initially report money flow bond market news year treasury yield fall basis point weakness biotech stock have be weigh nasdaq be more same friday ibd medical biom biotech group lose nearly feb high group have lose not surprisingly gold utility stock outperformed bright spot friday be mylan myl share rise news be interested acquire swiss firm meda meda reject proposal bright spot friday be cement maker group rise bloomberg report industry titan swiss firm holcim french firm lafarge be explore possible merger group leader eagle material exp hit time high rise nearly
1333,JNJ,big cap biotech gilead science beat analyst fourth quarter estimate top bottom line late tuesday offer sale guidance first time didn project sale newly launch much anticipate drug sovaldi market close gilead science gild say profit quarter rise year earlier quarter cent
1334,JNJ,etf investor be typically affluent experience stock market give only household own etfs industry have work cut educate retail investor
1335,JNJ,here be biggest myth truth etfs investor understand avoid mistake
1336,JNJ,myth etf liquidity doesn matter only liquidity underlie holding matter truth be thinly trade etfs have very wide bid ask spread even hold very liquid stock spread be difference lowest price trader be willing sell etf highest price buyer be willing pay wider spread bigger immediate loss buy etf
1337,JNJ,dodd kittsley head institutional product consult ishare recommend investor use limit order get trade execute midpoint bid ask price
1338,JNJ,analytic tool etf com show ipath short enhance msci emerge market etn emsa less asset have bid ask spread be nearly big etn share price most etfs bid ask spread larger share price have less asset
1339,JNJ,low volume etfs be disaster wait happen many case have happened say ron rowland founder capital city asset management allstarinvestor com austin texas wide bid ask spread be just most visible problem unseen problem be inability arbitrage price etf underlie nav net asset value
1340,JNJ,etfs share be create redeem kind exchange prevent etfs trading discount premium nav market maker typically create redeem etfs block share thereby require healthy trading volume
1341,JNJ,not small thinly trade etfs have wide bid ask spread ipath inverse vix short term future etn xxv have less asset bid ask spread be same ishare core small cap ijr asset
1342,JNJ,myth think due diversification etfs be safer stock be buy hold little volatility truth be etfs be volatile individual stock
1343,JNJ,blue chip stock johnson johnson jnj have less market volatility compare volatile sector etfs market vector gold miner gdx ishare nasdaq biotechnology ibb ron delegge editor etfguide com say email other hand diversify health care etf health care select sector spdr xlv have less volatility compare johnson johnson compare volatility always important do apple apple measurement
1344,JNJ,myth etfs be tax efficient truth etfs hold future contract issue tax form instead be hassle deal note etf database analyst jared cumman
1345,JNJ,investor also often overlook fact most popular fund spdr gold share gld ishare silver trust slv be taxed collectible cumman write capital gain be taxed maximum rate instead ordinary
1346,JNJ,etfs link asset class high taxable income reit treasury bond be best keep tax defer account delegge say
1347,JNJ,high turnover actively manage etfs account only etf asset potentially slap investor capital gain distribution say kittsley ishare
1348,JNJ,myth cheapest etfs include offer commission be always best truth be etfs commission free trading have wide bid ask spread so investor end lose difference bid ask price trade
1349,JNJ,low price tag be attractive term end day want select etfs support long term investment goal well meet cost threshold eric pollackov manage director etfs charle schwab say email etf investor be typically affluent experience stock market give only household own etfs industry have work cut educate retail investor here be biggest myth truth etfs investor understand avoid mistake myth etf liquidity doesn matter only liquidity underlie holding matter truth be thinly trade etfs have very wide bid ask spread even hold very liquid stock spread be difference lowest price trader be willing sell etf highest price buyer be willing pay wider spread bigger immediate loss buy etf dodd kittsley head institutional product consult ishare recommend investor use limit order get trade execute midpoint bid ask price analytic tool etf com show ipath short enhance msci emerge market etn emsa less asset have bid ask spread be nearly big etn share price most etfs bid ask spread larger share price have less asset low volume etfs be disaster wait happen many case have happened say ron rowland founder capital city asset management allstarinvestor com austin texas wide bid ask spread be just most visible problem unseen problem be inability arbitrage price etf underlie nav net asset value etfs share be create redeem kind exchange prevent etfs trading discount premium nav market maker typically create redeem etfs block share thereby require healthy trading volume not small thinly trade etfs have wide bid ask spread ipath inverse vix short term future etn xxv have less asset bid ask spread be same ishare core small cap ijr asset myth think due diversification etfs be safer stock be buy hold little volatility truth be etfs be volatile individual stock blue chip stock johnson johnson jnj have less market volatility compare volatile sector etfs market vector gold miner gdx ishare nasdaq biotechnology ibb ron delegge editor etfguide com say email other hand diversify health care etf health care select sector spdr xlv have less volatility compare johnson johnson compare volatility always important do apple apple measurement myth etfs be tax efficient truth etfs hold future contract issue tax form instead be hassle deal note etf database analyst jared cumman investor also often overlook fact most popular fund spdr gold share gld ishare silver trust slv be taxed collectible cumman write capital gain be taxed maximum rate instead ordinary etfs link asset class high taxable income reit treasury bond be best keep tax defer account delegge say high turnover actively manage etfs account only etf asset potentially slap investor capital gain distribution say kittsley ishare myth cheapest etfs include offer commission be always best truth be etfs commission free trading have wide bid ask spread so investor end lose difference bid ask price trade low price tag be attractive term end day want select etfs support long term investment goal well meet cost threshold eric pollackov manage director etfs charle schwab say email
1350,JNJ,stock future rally ahead open boost news more federal reserve stimulus cut fresh monetary support china
1351,JNJ,dow future soar point fair market value be rise nasdaq future point future show strong point gain
1352,JNJ,stock market today dife busy week quarterly report company tuesday economic calendar be relatively quiet forecast be strong housing manufacturing number due thursday
1353,JNJ,wall street journal report federal reserve be likely further taper monthly bond buy effort later month send dollar soar most currency early tuesday
1354,JNJ,global market also receive boost china central bank provide help country financial institution meet cash need ahead february week long lunar new year holiday
1355,JNJ,market remain confirm uptrend nasdaq notch less gain fraction last week leader have be pressure ibd index diving last week leader include nu skin enterprise nus qiwi qiwi break
1356,JNJ,range company include johnson johnson jnj verizon vz new oriental education technology edu be nearly report quarterly result
1357,JNJ,pier import pir jetted premarket action be news immediately apparent company home good retail chain have drop very heavy trade jan report weak holiday sale
1358,JNJ,trucking logistic firm yrc worldwide yrcw also rebound vaulting news company have reach accord international brotherhood teamster extend current bargaining agreement
1359,JNJ,delta air line dal climb atlanta base carrier squeak past consensus earning revenue forecast fourth quarter operate revenue rise rise passenger traffic stock end friday week tight pattern buy point
1360,JNJ,halliburton hal climb report earning jump stronger forecast revenue rise also top view oilfield service heavyweight upside surprise come overseas activity north american operate income revenue decline management target mid single digit revenue growth basis point margin improvement north america
1361,JNJ,oilfield service equipment peer baker hughe bhi rise not quite narrowly clear consensus estimate
1362,JNJ,unilever ul power ahead open help boost european market base food consumer good megalith report forecast sale earning improve operate margin company focus develop economy continue generate result
1363,JNJ,overseas europe market pressed firmly higher asian exchange close healthy gain buoy china monetary support
1364,JNJ,economic calendar be quiet day hour session provide strong dose technology result lead advanced micro device amd cree cree ibm ibm texas instrument txn stock future rally ahead open boost news more federal reserve stimulus cut fresh monetary support china dow future soar point fair market value be rise nasdaq future point future show strong point gain stock market today dife busy week quarterly report company tuesday economic calendar be relatively quiet forecast be strong housing manufacturing number due thursday wall street journal report federal reserve be likely further taper monthly bond buy effort later month send dollar soar most currency early tuesday global market also receive boost china central bank provide help country financial institution meet cash need ahead february week long lunar new year holiday market remain confirm uptrend nasdaq notch less gain fraction last week leader have be pressure ibd index diving last week leader include nu skin enterprise nus qiwi qiwi break range company include johnson johnson jnj verizon vz new oriental education technology edu be nearly report quarterly result pier import pir jetted premarket action be news immediately apparent company home good retail chain have drop very heavy trade jan report weak holiday sale trucking logistic firm yrc worldwide yrcw also rebound vaulting news company have reach accord international brotherhood teamster extend current bargaining agreement delta air line dal climb atlanta base carrier squeak past consensus earning revenue forecast fourth quarter operate revenue rise rise passenger traffic stock end friday week tight pattern buy point halliburton hal climb report earning jump stronger forecast revenue rise also top view oilfield service heavyweight upside surprise come overseas activity north american operate income revenue decline management target mid single digit revenue growth basis point margin improvement north america oilfield service equipment peer baker hughe bhi rise not quite narrowly clear consensus estimate unilever ul power ahead open help boost european market base food consumer good megalith report forecast sale earning improve operate margin company focus develop economy continue generate result overseas europe market pressed firmly higher asian exchange close healthy gain buoy china monetary support economic calendar be quiet day hour session provide strong dose technology result lead advanced micro device amd cree cree ibm ibm texas instrument txn
1365,JNJ,share johnson johnson jnj be midday trading monday pharmaceutical giant say have reach agreement acquire much aragon pharmaceutical privately hold drug discovery company focuse drug hormonally drive cancer term johnson acquire aragon androgen receptor antagonist program johnson pay cash
1366,JNJ,tuesday be shape be ugly day stock market major average re-cover impressively close high busy day headline flow lead way rise dow jone industrial average gain help strong earning coca cola ko johnson johnson jnj nasdaq meanwhile come
1367,JNJ,investor follow big money snag prospective stock winner find way ubiquiti network ubnt diamondback energy fang therapeutic anik today screen day be accelerate mutual fund ownership institutional investor seek top rate stock screen list stock have see increase accumulation recently ubiquiti have notch biggest gain
1368,JNJ,still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher
1369,JNJ,doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow
1370,JNJ,bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate
1371,JNJ,gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market
1372,JNJ,bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon
1373,JNJ,sovaldi set new standard
1374,JNJ,october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply
1375,JNJ,dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing
1376,JNJ,ultimately however do not expect single regimen conquer other not patient be same
1377,JNJ,treat toughest patient
1378,JNJ,daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation
1379,JNJ,decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death
1380,JNJ,decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year
1381,JNJ,respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing
1382,JNJ,barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis
1383,JNJ,believe regimen provide option genotype infected patient bernstein tell ibd
1384,JNJ,abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum
1385,JNJ,next generation regime
1386,JNJ,further road even more drug be way
1387,JNJ,abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine
1388,JNJ,earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen
1389,JNJ,sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink
1390,JNJ,still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future
1391,JNJ,think ll have gilead represent hep market tell ibd abbvie take lion share remain still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon sovaldi set new standardin october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing ultimately however do not expect single regimen conquer other not patient be same treat toughest patient daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis believe regimen provide option genotype infected patient bernstein tell ibd abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum next generation regimesfurther road even more drug be way abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future think ll have gilead represent hep market tell ibd abbvie take lion share remain
1392,JNJ,still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher
1393,JNJ,doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow
1394,JNJ,bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate
1395,JNJ,gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market
1396,JNJ,bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon
1397,JNJ,sovaldi set new standard
1398,JNJ,october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply
1399,JNJ,dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing
1400,JNJ,ultimately however do not expect single regimen conquer other not patient be same
1401,JNJ,treat toughest patient
1402,JNJ,daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation
1403,JNJ,decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death
1404,JNJ,decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year
1405,JNJ,respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing
1406,JNJ,barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis
1407,JNJ,believe regimen provide option genotype infected patient bernstein tell ibd
1408,JNJ,abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum
1409,JNJ,next generation regime
1410,JNJ,further road even more drug be way
1411,JNJ,abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine
1412,JNJ,earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen
1413,JNJ,sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink
1414,JNJ,still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future
1415,JNJ,think ll have gilead represent hep market tell ibd abbvie take lion share remain still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon sovaldi set new standardin october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing ultimately however do not expect single regimen conquer other not patient be same treat toughest patient daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis believe regimen provide option genotype infected patient bernstein tell ibd abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum next generation regimesfurther road even more drug be way abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future think ll have gilead represent hep market tell ibd abbvie take lion share remain
1416,JNJ,good reputation be hard company get easy lose rise social medium make even harder customer trust news slip spread fast here keep rebuild firm reputation discuss leader just mention trust be important need emphasize often
1417,JNJ,analyst have drop profit estimate synthetic biotechnology firm intrexon investor seem be take stride intrexon xon stock have soar year mainly investor hope better result come later royalty collaborator used technology eventually bring product market analyst don expect germantown md base firm post annual
1418,JNJ,stock end modestly higher wednesday hit time high datum suggest economy be pick
1419,JNJ,rise dow jone industrial average nasdaq rise volume be mixed nyse volume tracking lower tuesday nasdaq volume rise accord preliminary datum
1420,JNJ,private employer add job march accord adp pretty much line consensus estimate figure prior month be revise sharply higher datum come ahead friday job report nonfarm payroll be expect increase unemployment rate tick lower
1421,JNJ,order manufacture good rise better expect february biggest increase month
1422,JNJ,stock market today office supply retailer staple spls lead term percentage gain jump heavy volume however stock remain depress well key support line week high
1423,JNJ,meanwhile intuitive surgical isrg continue rebound sharply announce tuesday food drug administration have approve next generation da vinci robotic surgical system stock jump week high more double average daily volume week
1424,JNJ,downside apollo education apol slump slice day move average operator profit university phoenix report revenue latest quarter fall greater expect
1425,JNJ,company also say have receive subpoena education department seek information university phoenix operation northeast stock end modestly higher wednesday hit time high datum suggest economy be pick rise dow jone industrial average nasdaq rise volume be mixed nyse volume tracking lower tuesday nasdaq volume rise accord preliminary datum private employer add job march accord adp pretty much line consensus estimate figure prior month be revise sharply higher datum come ahead friday job report nonfarm payroll be expect increase unemployment rate tick lower order manufacture good rise better expect february biggest increase month stock market today office supply retailer staple spls lead term percentage gain jump heavy volume however stock remain depress well key support line week high meanwhile intuitive surgical isrg continue rebound sharply announce tuesday food drug administration have approve next generation da vinci robotic surgical system stock jump week high more double average daily volume week downside apollo education apol slump slice day move average operator profit university phoenix report revenue latest quarter fall greater expect company also say have receive subpoena education department seek information university phoenix operation northeast
1426,JNJ,big cap drug stock pharmacyclic valeant pharmaceutical celgene be move tuesday new year bring news promise more expansion pharmacyclic pcyc vault say clinical trial imbruvica be halter drug have already meet goal trial compare survival rate patient refractory
1427,JNJ,johnson johnson jnj offer best world investor rise stock price regular dividend increase maker everything baby shampoo tylenol hip joint have increase dividend straight year ibd calculate year dividend growth rate latest increase be announce april
1428,JNJ,biotech firm pharmacyclic pcyc jump new high stock market today report reveal strong launch cancer drug imbruvica late thursday company say imbruvica garner net sale quarter draw just week market be approve mantle cell lymphoma mid november
1429,JNJ,stock remain mixed late tuesday afternoon investor mulled batch quarterly earning report nasdaq be rise dow jone industrial average fall preliminary datum show nyse nasdaq volume tracking lower friday not surprising consider volume be elevated friday due option expiration stock market today traveler co trv johnson johnson jnj verizon communication vz fall quarterly earning report delta airline dal rise beating fourth quarter earning estimate ibd biogen idec biib jump new high retake flat base buy point volume be run average stock initially clear entry jan reversed lower downside chinese social medium stock yy yy slump heavy trade be ibd biggest decliner still buy point late stage cup handle base putt profit take zone elsewhere skecher skx slump be downgrade hold buy bb capital market stock slice day line be now week high
1430,JNJ,stock turn mixed tuesday afternoon follow disappointing earning report thetraveler co trv verizon communication vz johnson johnson jnj
1431,JNJ,nasdaq be halve earlier gain dow jone industrial average fall be little change preliminary datum show nyse nasdaq volume tracking lower friday not surprising consider volume be elevated friday due option expiration
1432,JNJ,stock market today traveler johnson johnson fall verizon be quarterly earning report
1433,JNJ,ibd gun maker sturm ruger rgr be second day heavy volume movie producer harvey weinstein say launch gun campaign stock be now cup base buy point be get support day line
1434,JNJ,elsewhere ibd qihoo technology qihu rise average turnover rebound friday downside reversal china base growth name reclaim week move average last week work new base
1435,JNJ,elsewhere armour ua jump more double average daily turnover try snap session lose streak stock be try reclaim week move average give support level last week stock turn mixed tuesday afternoon follow disappointing earning report thetraveler co trv verizon communication vz johnson johnson jnj nasdaq be halve earlier gain dow jone industrial average fall be little change preliminary datum show nyse nasdaq volume tracking lower friday not surprising consider volume be elevated friday due option expiration stock market today traveler johnson johnson fall verizon be quarterly earning report ibd gun maker sturm ruger rgr be second day heavy volume movie producer harvey weinstein say launch gun campaign stock be now cup base buy point be get support day line elsewhere ibd qihoo technology qihu rise average turnover rebound friday downside reversal china base growth name reclaim week move average last week work new base elsewhere armour ua jump more double average daily turnover try snap session lose streak stock be try reclaim week move average give support level last week
1436,JNJ,nasdaq fall hard friday institutional investor continue take profit growth stock
1437,JNJ,close nasdaq crater take day move average conviction fall dow jone industrial average give nearly preliminary datum show nyse nasdaq volume come well thursday level stock market today
1438,JNJ,growth stock underperform spade half stock ibd fall more
1439,JNJ,institutional investor rotate growth stock not surprising see scad blue chip name hold well better look chart dow include name such caterpillar cat dupont dd walt disney johnson johnson jnj other however even stock not hold early friday gain
1440,JNJ,gold stock outperformed otherwise ugly session new york mercantile exchange june gold rise settle ounce utility stock also do well
1441,JNJ,ibd computer software medical group be day worst performer fall group leader athenahealth athn plunge gain point be now just
1442,JNJ,auto manufacturer group lose hurt weakness tesla motor tsla share fall support week line tesla look promising earlier week be question now
1443,JNJ,weakness biotech stock have be weigh nasdaq be more same friday ibd medical biom biotech group lose feb high group be
1444,JNJ,cement maker provide bright spot friday group rise bloomberg report industry titan swiss firm holcim french firm lafarge be explore possible merger group leader eagle material exp hit time high rise
1445,JNJ,economic news economy add job march consensus estimate unemployment rate be unchanged february job growth be revise higher initially report money flow bond market news
1446,JNJ,year treasury yield fall basis point initial read nasdaq fall hard friday institutional investor continue take profit growth stock close nasdaq crater take day move average conviction fall dow jone industrial average give nearly preliminary datum show nyse nasdaq volume come well thursday level stock market today growth stock underperform spade half stock ibd fall more institutional investor rotate growth stock not surprising see scad blue chip name hold well better look chart dow include name such caterpillar cat dupont dd walt disney johnson johnson jnj other however even stock not hold early friday gain gold stock outperformed otherwise ugly session new york mercantile exchange june gold rise settle ounce utility stock also do well ibd computer software medical group be day worst performer fall group leader athenahealth athn plunge gain point be now just auto manufacturer group lose hurt weakness tesla motor tsla share fall support week line tesla look promising earlier week be question now weakness biotech stock have be weigh nasdaq be more same friday ibd medical biom biotech group lose feb high group be cement maker provide bright spot friday group rise bloomberg report industry titan swiss firm holcim french firm lafarge be explore possible merger group leader eagle material exp hit time high rise economic news economy add job march consensus estimate unemployment rate be unchanged february job growth be revise higher initially report money flow bond market news year treasury yield fall basis point initial read
1447,JNJ,bleary eye workday swilling caffeine drink stay alert better rise shine sleeping edge
1448,JNJ,count sheep many be work sleep deprive fog lot say richard bedrosian do large scale survey prevalence be pretty high range not everyone be aware problem be solve
1449,JNJ,bedrosian be director behavioral health solution development wellness prevention johnson johnson jnj company
1450,JNJ,insomniac worker bedrosian offer tool diagnose sleep problem digital coaching improve nighttime habit
1451,JNJ,really matter detection education tell ibd ideal place screen be workplace
1452,JNJ,check zzzs many person periodically struggle get shut eye sign bigger problem include fatigue memory impairment low motivation error accident tension headach
1453,JNJ,lean alcohol counter sleeping pill conk night caffeine stay awake day
1454,JNJ,typically become self perpetuate cycle bedrosian say
1455,JNJ,fluff pillow tip better rest cut caffeine noon shut electronic hour bedtime keep bedroom dark cool quiet
1456,JNJ,room be sanctuary sleep romance only
1457,JNJ,have build better cocoon re bed bedrosian say
1458,JNJ,ask sandman persistent problem bedrosian recommend cognitive behavior therapy insomnia cbti
1459,JNJ,firm develop digital approach put simply person keep track sleep problem get feedback expert week say
1460,JNJ,many just need information nudge pretty straightforward lend computer base approach say
1461,JNJ,power nap brief afternoon siesta awaken walking dead company see nap strategic advantage
1462,JNJ,ve invest lot nutrition fitness call sleep third pillar say metronaps ceo christopher lindholst
1463,JNJ,firm make gravity chair podlike privacy enclosure specifically snooze
1464,JNJ,google goog nasa be customer be iowa construction firm arizona diamondback baseball team improve productivity alertness also creativity lindholst say
1465,JNJ,save money
1466,JNJ,study estimate insomnia lead direct health care cost year america
1467,JNJ,long term employee wellness be important lindholst say
1468,JNJ,recharge necessary have natural dip rhythm afternoon lindholst say
1469,JNJ,worker typically grab coffee sweet
1470,JNJ,body doesn actually need extra calory say have do be listen body rhythm take brief rest
1471,JNJ,stick minute slumber don go deeper stage sleep say have amazing impact alertness
1472,JNJ,shut need make important decision secret world sleep author penelope lewis present scientific back age old advice sleep
1473,JNJ,answer appear be sleep do lot more just strengthen individual memory write snooze brain bring together piece information unify picture help face dilemma bleary eye workday swilling caffeine drink stay alert better rise shine sleeping edge count sheep many be work sleep deprive fog lot say richard bedrosian do large scale survey prevalence be pretty high range not everyone be aware problem be solve bedrosian be director behavioral health solution development wellness prevention johnson johnson jnj company insomniac worker bedrosian offer tool diagnose sleep problem digital coaching improve nighttime habit really matter detection education tell ibd ideal place screen be workplace check zzzs many person periodically struggle get shut eye sign bigger problem include fatigue memory impairment low motivation error accident tension headach lean alcohol counter sleeping pill conk night caffeine stay awake day typically become self perpetuate cycle bedrosian say fluff pillow tip better rest cut caffeine noon shut electronic hour bedtime keep bedroom dark cool quiet room be sanctuary sleep romance only have build better cocoon re bed bedrosian say ask sandman persistent problem bedrosian recommend cognitive behavior therapy insomnia cbti firm develop digital approach put simply person keep track sleep problem get feedback expert week say many just need information nudge pretty straightforward lend computer base approach say power nap brief afternoon siesta awaken walking dead company see nap strategic advantage ve invest lot nutrition fitness call sleep third pillar say metronaps ceo christopher lindholst firm make gravity chair podlike privacy enclosure specifically snooze google goog nasa be customer be iowa construction firm arizona diamondback baseball team improve productivity alertness also creativity lindholst say save money study estimate insomnia lead direct health care cost year america long term employee wellness be important lindholst say recharge necessary have natural dip rhythm afternoon lindholst say worker typically grab coffee sweet body doesn actually need extra calory say have do be listen body rhythm take brief rest stick minute slumber don go deeper stage sleep say have amazing impact alertness shut need make important decision secret world sleep author penelope lewis present scientific back age old advice sleep answer appear be sleep do lot more just strengthen individual memory write snooze brain bring together piece information unify picture help face dilemma
1474,JNJ,drugmaker actavis act report result line expectation tuesday morning company already lofty share rise new high stock market company profit rise year earlier quarter share meeting analyst consensus sale be hair estimate actavis offer full year
1475,JNJ,drugmaker aptalis holding file go public thursday ipo expect raise half dollar company formerly trade axcan pharma return new incarnation private equity firm tpg capital acquire axcan have merged several other company notably pharmaceutical acquire company have
1476,JNJ,saturday tuesday rep drugmaker world be gathering new orlean present datum blood disease drug american society hematology conference be top rate big cap biotechs abstract be already detail report have potential move stock celgene celg sunday afternoon
1477,JNJ,johnson johnson jnj be quintessential income play company offer slow steady profit growth pay rise dividend be defensive nature root date back late century johnson johnson be titan health care field new brunswick base firm make everything wound care woman health product
1478,JNJ,fda approve pharmacyclic pcyc imbruvica chronic lymphocytic leukemia early wednesday afternoon abruptly send stock nearly stock market today pharmacycli partner johnson johnson jnj unit janssen biotech say agency have approve product treat deadly blood cancer patient receive least prior therapy second indication imbruvica be launch back november be approve mantle cell lymphoma pharmacyclic janssen have apply indication same time so delay approval chronic lymphocytic leukemia cll be unexpected however clinical trial compare survival rate cll patient imbruvica glaxosmithkline gsk arzerra produce such good result company stop trial early jan bode well approval analyst expect imbruvica peak annual sale pass pharmacyclic stock be trading press release come instantly rebound be afternoon trading stock hit time high jan stock be fraction follow amy reeve twitter ibd_areeve
1479,JNJ,firm better expect new home sale stock tack more gain wednesday midpoint
1480,JNJ,nasdaq jump best level early april meanwhile dow jone industrial average rise volume be tracking mixed stock market today nyse trade be run higher nasdaq volume be tracking lower
1481,JNJ,therapeutic anik surge drugmaker be respond news food drug administration approve osteoarthritis treatment monovisc reportedly first single injection type treatment nonanimal source drug be market sport medicine provider depuy mitek division johnson johnson jnj also report result close
1482,JNJ,solarcity scty meanwhile extend gain second day rally record high late monday solar panel installer report preliminary sale view delay earning early march news send share early tuesday stock re-cover solarcity have yet test week line breaking early january
1483,JNJ,papa john international pzza pop time high report sale view late tuesday stock blow past buy point flat base
1484,JNJ,downside jazz pharmaceutical jazz be session low still fall share be much reaction disappointing fourth quarter result drugmaker also announce resignation chief financial officer firm better expect new home sale stock tack more gain wednesday midpoint nasdaq jump best level early april meanwhile dow jone industrial average rise volume be tracking mixed stock market today nyse trade be run higher nasdaq volume be tracking lower therapeutic anik surge drugmaker be respond news food drug administration approve osteoarthritis treatment monovisc reportedly first single injection type treatment nonanimal source drug be market sport medicine provider depuy mitek division johnson johnson jnj also report result close solarcity scty meanwhile extend gain second day rally record high late monday solar panel installer report preliminary sale view delay earning early march news send share early tuesday stock re-cover solarcity have yet test week line breaking early january papa john international pzza pop time high report sale view late tuesday stock blow past buy point flat base downside jazz pharmaceutical jazz be session low still fall share be much reaction disappointing fourth quarter result drugmaker also announce resignation chief financial officer
1485,JNJ,employer outsource payroll process service good chance automatic datum process adp paychex payx handle roseland base automatic datum process be world biggest provider payroll human resource benefit other outsourced business service serve customer more country adp say fortune company use
1486,JNJ,merck agree sell consumer business german giant bayer tuesday continue big pharma recent flurry big deal merck stock fall close bayer stock dip company also announce global collaboration develop market bayer bayry line treatment pulmonary hypertension
1487,JNJ,growth stock have see share selling pressure recent day ibd list top rate growth stock example be nearly march compare decline nasdaq composite money flow growth stock have go somewhere large cap value name have be beneficiary dow
1488,JNJ,modestly higher open wednesday quickly turn tail major average decline again higher volume weak action be enough put market correction nasdaq slump continue string close decisively day move average lose dow jone industrial average give
1489,JNJ,stock end mixed tuesday make feeble attempt rebound sharp sell prior day add dow jone industrial average edge nasdaq dip volume be lower board fall nyse nasdaq compare monday accord preliminary datum apple aapl be dow biggest decliner sink japan nikkei newspaper report tech giant cut production iphone model more plan first month year report cite apple supplier japan abroad apple former market leader be now more week high accumulation distribution rating stand indicate heavy selling elsewhere stock market today gilead science gild rise nearly follow positive result experimental hepatitis drug semiconductor stock be worst performer ibd macom technology solution mtsi make semiconductor auto communication defense industry lose stock erased gain past buy point cup handle base trigger sell signal singapore base chip designer technology avgo drop light trade work handle long consolidation buy point meanwhile wesson swhc be easily biggest winner ibd share jump firearm maker issue bullish guidance late monday rpm international rpm be company due report quarterly earning wednesday economic report schedule wednesday include institute supply management index service sector activity december factory order november trade balance november minute federal reserve dec meeting follow scott stoddard twitter ibd_sstoddard
1490,JNJ,normally healthy biotech stock suffer critical decline friday most other medical name ibd remain fairly stable condition still biotech illness spread other drug stock result biggest loser hailed medical sector include generic ethical drug maker alexion pharmaceutical alxn last week
1491,JNJ,medical product giant abbott laboratory miss sale estimate meeting profit expectation wednesday send abbott stock morning trading stock market today earlier have be much
1492,JNJ,abbott say revenue totale quarter year earlier quarter short analyst consensus earning rise cent share match estimate company say ep be bracketing consensus vs last year
1493,JNJ,leerink analyst danielle antalffy write email client abbott operate leverage allow meet profit goal have miss sale estimate quarters row
1494,JNJ,trend top line miss highlight continue head wind key business primarily nutritional establish product brand generic drug write business be key accelerate long term sale growth profile think investor likely look sign stable improve fundamental here share move meaningfully higher current level
1495,JNJ,bright spot establish product business be key emerge market segment include sale china brazil russia
1496,JNJ,abbott quarter be weaker fellow diversify medical giant johnson johnson jnj report tuesday beat estimate drive strong performance proprietary drug abbott longer have proprietary drug business spun abbvie abbv start last year ep guidance nonetheless miss consensus drive stock tuesday several analyst rise company defense however point early guidance be usually conservative midmorning wednesday jnj stock be flat
1497,JNJ,follow amy reeve twitter ibd_areeve medical product giant abbott laboratory miss sale estimate meeting profit expectation wednesday send abbott stock morning trading stock market today earlier have be much abbott say revenue totale quarter year earlier quarter short analyst consensus earning rise cent share match estimate company say ep be bracketing consensus vs last year leerink analyst danielle antalffy write email client abbott operate leverage allow meet profit goal have miss sale estimate quarters row trend top line miss highlight continue head wind key business primarily nutritional establish product brand generic drug write business be key accelerate long term sale growth profile think investor likely look sign stable improve fundamental here share move meaningfully higher current level bright spot establish product business be key emerge market segment include sale china brazil russia abbott quarter be weaker fellow diversify medical giant johnson johnson jnj report tuesday beat estimate drive strong performance proprietary drug abbott longer have proprietary drug business spun abbvie abbv start last year ep guidance nonetheless miss consensus drive stock tuesday several analyst rise company defense however point early guidance be usually conservative midmorning wednesday jnj stock be flat follow amy reeve twitter ibd_areeve
1498,JNJ,danish drug giant nordisk miss sale estimate lower full year revenue forecast thursday loss support payer hurt stock fall nordisk nvo make cent share quarter year earlier quarter danish kroner penny analyst consensus sale increase
1499,JNJ,pharmacyclic pcyc announce tuesday late stage trial blood cancer drug imbruvica be stop early have already proven effectiveness pharmacyclic stock jump morning trading stock market today trial question be compare survival rate patient refractory chronic lymphocytic leukeumia cll small lymphocytic lymphoma be treat
1500,JNJ,normally healthy biotech stock suffer critical decline friday most other medical name ibd remain fairly stable condition still biotech illness spread other drug stock result biggest loser hailed medical sector include generic ethical drug maker alexion pharmaceutical alxn last week
1501,JNJ,cubist pharmaceutical cbst report positive late stage trial result antibiotic candidate monday send cubist stock year high stock market today
1502,JNJ,drug ceftolozane tazobactam know industry tol taz short be test patient urinary tract infection compare levofloxacin be know commercially johnson johnson jnj levaquin sanofi sny tavanic cubist say tol taz meet trial primary endpoint be inferior levofloxacin fact result suggest superior
1503,JNJ,research note rbc capital market analyst adnan butt say news be better wall street expect bigger hurdle be see be trial tol taz complicate intra abdominal infection result be expect year end
1504,JNJ,analyst have be closely watch cubist pipeline mean breaking dependence flagship drug cubicin sale have lately flattened
1505,JNJ,cubist stock be nearly morning trading breaking flat base have be form late september stock last reach height march stock touch time high cubist pharmaceutical cbst report positive late stage trial result antibiotic candidate monday send cubist stock year high stock market today drug ceftolozane tazobactam know industry tol taz short be test patient urinary tract infection compare levofloxacin be know commercially johnson johnson jnj levaquin sanofi sny tavanic cubist say tol taz meet trial primary endpoint be inferior levofloxacin fact result suggest superior research note rbc capital market analyst adnan butt say news be better wall street expect bigger hurdle be see be trial tol taz complicate intra abdominal infection result be expect year end analyst have be closely watch cubist pipeline mean breaking dependence flagship drug cubicin sale have lately flattened cubist stock be nearly morning trading breaking flat base have be form late september stock last reach height march stock touch time high
1506,JNJ,cubist pharmaceutical cbst report positive late stage trial result antibiotic candidate monday send cubist stock year high stock market today
1507,JNJ,drug ceftolozane tazobactam know industry tol taz short be test patient urinary tract infection compare levofloxacin be know commercially johnson johnson jnj levaquin sanofi sny tavanic cubist say tol taz meet trial primary endpoint be inferior levofloxacin fact result suggest superior
1508,JNJ,research note rbc capital market analyst adnan butt say news be better wall street expect bigger hurdle be see be trial tol taz complicate intra abdominal infection result be expect year end
1509,JNJ,analyst have be closely watch cubist pipeline mean breaking dependence flagship drug cubicin sale have lately flattened
1510,JNJ,cubist stock be nearly morning trading breaking flat base have be form late september stock last reach height march stock touch time high cubist pharmaceutical cbst report positive late stage trial result antibiotic candidate monday send cubist stock year high stock market today drug ceftolozane tazobactam know industry tol taz short be test patient urinary tract infection compare levofloxacin be know commercially johnson johnson jnj levaquin sanofi sny tavanic cubist say tol taz meet trial primary endpoint be inferior levofloxacin fact result suggest superior research note rbc capital market analyst adnan butt say news be better wall street expect bigger hurdle be see be trial tol taz complicate intra abdominal infection result be expect year end analyst have be closely watch cubist pipeline mean breaking dependence flagship drug cubicin sale have lately flattened cubist stock be nearly morning trading breaking flat base have be form late september stock last reach height march stock touch time high
1511,JNJ,acquisition have long be staple drug industry drive force investment decision big pharmas blockbuster drug have go patent ve filled pipeline buy smaller firm new drug smaller player buyout be usually investor chief hope healthy return investment little biotechs be
1512,JNJ,ask several investment strategist share best etf investor consider buy best foreign etfs alan rosenfield manage director harmony asset management scottsdale ariz asset management most street pimco jpmorgan jpm be project growth next year range
1513,JNJ,food drug administration gilead science gild hepatitis pill sovaldi late friday expect still key step drug widely see mega blockbuster
1514,JNJ,analyst foresee very rapid uptake sovaldi sale next year make world best selling drug
1515,JNJ,gilead share edge higher late friday close
1516,JNJ,drug end complicate label different regimen different patient group upshot be first time be treat inject pegylate interferon current standard treatment cause flu symptom
1517,JNJ,fda still recommend take interferon sovaldi oral drug ribavirin week patient disease genotype type be most common patient ineligible interferon have liver cancer take just sovaldi ribavirin combo be recommend week patient genotype
1518,JNJ,gilead be still testing other interferon combination therapy sovaldi ribavirin ledipasvir have notch cure rate patient group
1519,JNJ,be hope sovaldi mark begin new era hepatitis treatment ceo john martin say statement
1520,JNJ,gilead price sovaldi week expect week regimen cost estimate note isi group analyst mark schoenebaum
1521,JNJ,sale estimate keep rise drug keep produce good trial result have hepatitis many don know re infected virus subsist decade symptom advanced case cause serious liver damage federal official have urge more american notably baby boomer get test
1522,JNJ,abbvie abbv have oral hepatitis therapy late stage test launch see bristol myer bmy merck mrk johnson johnson jnj also have oral regimen pipeline food drug administration gilead science gild hepatitis pill sovaldi late friday expect still key step drug widely see mega blockbuster analyst foresee very rapid uptake sovaldi sale next year make world best selling drug gilead share edge higher late friday close drug end complicate label different regimen different patient group upshot be first time be treat inject pegylate interferon current standard treatment cause flu symptom fda still recommend take interferon sovaldi oral drug ribavirin week patient disease genotype type be most common patient ineligible interferon have liver cancer take just sovaldi ribavirin combo be recommend week patient genotype gilead be still testing other interferon combination therapy sovaldi ribavirin ledipasvir have notch cure rate patient group be hope sovaldi mark begin new era hepatitis treatment ceo john martin say statement gilead price sovaldi week expect week regimen cost estimate note isi group analyst mark schoenebaum sale estimate keep rise drug keep produce good trial result have hepatitis many don know re infected virus subsist decade symptom advanced case cause serious liver damage federal official have urge more american notably baby boomer get test abbvie abbv have oral hepatitis therapy late stage test launch see bristol myer bmy merck mrk johnson johnson jnj also have oral regimen pipeline
1523,JNJ,latest earning season book ibd see significant change vs start report period numerous newcomer other rise quickly list today ibd include recent addition kapstone paper packaging ks ubiquiti network ubnt therapeutic anik meantime alexion pharmaceutical alxn shot early
1524,JNJ,peter georgescu be child romania world war ii communist take nearly destroy life arrest grandfather kill imprison father put brother grandmother labor camp work hour day
1525,JNJ,georgescu come america be know hardly english yet rise ceo run new york ad giant young rubicam wonder drive person evil see romania
1526,JNJ,know source georgescu find year person do have do survive have cheat steal do even person have become more civil revert corner
1527,JNJ,instinct come georgescu chairman emeritus young rubicam author constant choice tell ibd thought left romania left evil realize nice good person sometimes do terrible thing
1528,JNJ,gain edge georgescu used lesson strive do right thing become president young rubicam international operation
1529,JNJ,travele asia see company do business country bribery be common local firm be thrill do business be honest do say do
1530,JNJ,crucial component success other company be willingness promote value conduct way reflect value georgescu say
1531,JNJ,make hard choice executive show vital firm value be use guide tough decision leader fire top performer indiscretion speak volume
1532,JNJ,draw line once don have do again maybe year say marianne jenning professor emeritus business ethic arizona state university powerful signal
1533,JNJ,practice preach leader need set example come follow rule live firm value jenning say set tone rest firm ceo follow same rule other do come expense other policy
1534,JNJ,live value build principle culture state clearly act constantly georgescu say point johnson johnson jnj long standing example company have be able do credo put customer first have guide
1535,JNJ,young rubicam also benefit operate true principle particularly internationally be very conscious have be ivory soap pure say be conscious be look see do say
1536,JNJ,follow reinforce daily company stand culture georgescu say
1537,JNJ,hire person agree principle fire don live
1538,JNJ,once learn young employee young rubicam have send email racial joke offender be contrite have be good employee recall boss decide live firm tolerance policy fire trio
1539,JNJ,interact leader chat employee office have feel re approachable re human jenning say closer get have major ethical issue more close door atmosphere see peter georgescu be child romania world war ii communist take nearly destroy life arrest grandfather kill imprison father put brother grandmother labor camp work hour day georgescu come america be know hardly english yet rise ceo run new york ad giant young rubicam wonder drive person evil see romania know source georgescu find year person do have do survive have cheat steal do even person have become more civil revert corner instinct come georgescu chairman emeritus young rubicam author constant choice tell ibd thought left romania left evil realize nice good person sometimes do terrible thing gain edge georgescu used lesson strive do right thing become president young rubicam international operation travele asia see company do business country bribery be common local firm be thrill do business be honest do say do crucial component success other company be willingness promote value conduct way reflect value georgescu say make hard choice executive show vital firm value be use guide tough decision leader fire top performer indiscretion speak volume draw line once don have do again maybe year say marianne jenning professor emeritus business ethic arizona state university powerful signal practice preach leader need set example come follow rule live firm value jenning say set tone rest firm ceo follow same rule other do come expense other policy live value build principle culture state clearly act constantly georgescu say point johnson johnson jnj long standing example company have be able do credo put customer first have guide young rubicam also benefit operate true principle particularly internationally be very conscious have be ivory soap pure say be conscious be look see do say follow reinforce daily company stand culture georgescu say hire person agree principle fire don live once learn young employee young rubicam have send email racial joke offender be contrite have be good employee recall boss decide live firm tolerance policy fire trio interact leader chat employee office have feel re approachable re human jenning say closer get have major ethical issue more close door atmosphere see
1540,JNJ,johnson johnson jnj report fourth quarter earning wall street analyst estimate tuesday sale miss expectation diversify medical personal care product maker guide earning lower maker wide array medical product counter medication tylenol surgical implant such hip knee replacement say ep rise
1541,JNJ,market seesaw manage close mostly higher tuesday lead stock show spunk nasdaq have fight back midday loss afternoon advance hold close bell bullish reversal give chart watcher comfort nasdaq close gain rise
1542,JNJ,johnson johnson jnj division janssen therapeutic announce monday fda approve treatment drug resistant tuberculosis sirturo janssen say sirturo bring first new mechanism treatment tb year disease have long be treat generic antibiotic particular mutation tb treat know multidrug resistant tb have be designate
1543,JNJ,gilead science gild hepatitis drug sofosbuvir win european advisory panel vote earlier wall street expect friday send stock more time high stock market today eu committee medicinal product human use chmp recommend approve sofosbuvir now brand sovaldi follow accelerate review procedure drug
1544,JNJ,buzz first full coupon campaign be launch coca cola next year coupon be redeem soda fountain nationwide suddenly coke coupon french term meaning cut become household word print coupon be still most widely used digital coupon have catch
1545,JNJ,food drug administration approve pharmacyclic pcyc cancer drug ibrutinib wednesday only clear disease company have apply treat
1546,JNJ,fda approve drug now rename imbruvica treat mantle cell lymphoma rare form lymphoma currently treat celgene celg revlimid takeda velcade
1547,JNJ,only second product be approve agency new breakthrough therapy designation allow decision be make only phase clinical trial instead however didn mention part pharmacyclic application ask approval chronic lymphocytic leukemia
1548,JNJ,analyst michael yee speculate fda be wait datum ongoing clinical trial call resonate expect january make final decision cll
1549,JNJ,recall think inclusion resonate datum actually be positive give physician randomize datum glaxosmithkline gsk ofatumamab base prescribe decision better attribution side effect drug write mail client say possible delay be immaterial estimate also note fda comment have include serious safety warning
1550,JNJ,delay also leave bit more wiggle room gilead science gild cll candidate idelalisib reportedly do so well phase trial gilead end early last month
1551,JNJ,drug be co market johnson johnson jnj division janssen pharmaceutical
1552,JNJ,ibd report last month hope ibrutinib be blockbuster more double pharmacyclic stock price year now trade time high hit oct pharmacyclic stock be fraction morning trading stock market wednesday stock be afternoon trading fda news break food drug administration approve pharmacyclic pcyc cancer drug ibrutinib wednesday only clear disease company have apply treat fda approve drug now rename imbruvica treat mantle cell lymphoma rare form lymphoma currently treat celgene celg revlimid takeda velcade only second product be approve agency new breakthrough therapy designation allow decision be make only phase clinical trial instead however didn mention part pharmacyclic application ask approval chronic lymphocytic leukemia analyst michael yee speculate fda be wait datum ongoing clinical trial call resonate expect january make final decision cll recall think inclusion resonate datum actually be positive give physician randomize datum glaxosmithkline gsk ofatumamab base prescribe decision better attribution side effect drug write mail client say possible delay be immaterial estimate also note fda comment have include serious safety warning delay also leave bit more wiggle room gilead science gild cll candidate idelalisib reportedly do so well phase trial gilead end early last month drug be co market johnson johnson jnj division janssen pharmaceutical ibd report last month hope ibrutinib be blockbuster more double pharmacyclic stock price year now trade time high hit oct pharmacyclic stock be fraction morning trading stock market wednesday stock be afternoon trading fda news break
1553,JNJ,biotech medicine co mdco modestly beat estimate wednesday analyst focuse upcoming drug launch transform company trick pony major player stock rise rise medicine co report sale year earlier quarter more wall street expect
1554,JNJ,scientific instrument maker dhr beat analyst expectation affirm guidance thursday morning send stock more time high stock market say profit totale cent share year earlier quarter beating analyst estimate penny sale rise edge consensus view
1555,JNJ,medical giant johnson johnson jnj beat analyst expectation result full year outlook tuesday morning give investor early glimpse quarter overall health care environment earning season begin share be fraction midday trading stock market rise much early trading tuesday
1556,JNJ,make share quarter year earlier quarter beating wall street consensus cent sale rise estimate company guide full year ep range few cent previous guidance squarely consensus last year profit be share
1557,JNJ,analyst widely expect pharmaceutical business power growth recently launch drug surpass already high expectation sale prostate cancer drug zytiga surge year year immunology drug simponi stelara grow respectively anticoagulant xarelto launch less year nearly triple sale face competition bristol myer squibb bmy pfizer pfe eliquis
1558,JNJ,contrast revenue consumer division rise just fraction medical device diagnostic md shed conference call analyst cfo dominic caruso say be due sluggish macroeconomy remain pretty much same previous quarter press consumer government budget
1559,JNJ,company be still process integrate synthe orthopedic company buy last year michel orsinger former ceo synthe have become chairman combine puy synthe business say trauma spine product line miss expectation partly due cheap compete product
1560,JNJ,immediate analyst reaction look bigger picture
1561,JNJ,overall jnj continue ride back strong pharma performance recent product launch continue exceed expectation write leerink swann danielle antalffy email client consensus md sale perpetuate concern broader medtech utilization trend remain weak strong surgical sale actually signal potentially positive volume trend overall
1562,JNJ,related ibd income investor column look medical giant johnson johnson jnj beat analyst expectation result full year outlook tuesday morning give investor early glimpse quarter overall health care environment earning season begin share be fraction midday trading stock market rise much early trading tuesday make share quarter year earlier quarter beating wall street consensus cent sale rise estimate company guide full year ep range few cent previous guidance squarely consensus last year profit be share analyst widely expect pharmaceutical business power growth recently launch drug surpass already high expectation sale prostate cancer drug zytiga surge year year immunology drug simponi stelara grow respectively anticoagulant xarelto launch less year nearly triple sale face competition bristol myer squibb bmy pfizer pfe eliquis contrast revenue consumer division rise just fraction medical device diagnostic md shed conference call analyst cfo dominic caruso say be due sluggish macroeconomy remain pretty much same previous quarter press consumer government budget company be still process integrate synthe orthopedic company buy last year michel orsinger former ceo synthe have become chairman combine puy synthe business say trauma spine product line miss expectation partly due cheap compete product immediate analyst reaction look bigger picture overall jnj continue ride back strong pharma performance recent product launch continue exceed expectation write leerink swann danielle antalffy email client consensus md sale perpetuate concern broader medtech utilization trend remain weak strong surgical sale actually signal potentially positive volume trend overall related ibd income investor column look
1563,JNJ,stock future dump early gain turn mixed ahead tuesday open surprise drop new york region manufacturing october outweighed hint progress budget deal senate generally positive corporate earning report future give narrow early gain be point dow future shed point gain
1564,JNJ,johnson johnson jnj be set kick medical industry earning season open tuesday wall street seem be turn more bullish stock
1565,JNJ,analyst be expect modest growth quarter drug giant consensus analyst poll thomson reuter call profit share year earlier quarter sale stock be trading flat afternoon trading monday have gain previous trading day analyst discuss prospect upcoming drug launch
1566,JNJ,friday goldman sachs analyst jami rubin upgrade stock neutral sell note success several recent drug launch bode well simeprevir ibrutinib product currently await fda approval simeprevir be hepatitis drug eventually hope combine drug just acquire glaxosmithkline gsk form oral therapy hepatitis ibrutinib be treatment blood cancer develop pharmacyclic pcyc win breakthrough therapy designation fda speed review process
1567,JNJ,good news gilead science gild rival idelalisib drug last week goldman sachs analyst navdeep singh set peak annual sale estimate ibrutinib
1568,JNJ,most popular rating stock be still hold company have be face difficult macroeconomy even stock have climb start year rubin however write see bright term future pharmaceutical industry overall show sign converge red hot sibling biotech johnson johnson jnj be set kick medical industry earning season open tuesday wall street seem be turn more bullish stock analyst be expect modest growth quarter drug giant consensus analyst poll thomson reuter call profit share year earlier quarter sale stock be trading flat afternoon trading monday have gain previous trading day analyst discuss prospect upcoming drug launch friday goldman sachs analyst jami rubin upgrade stock neutral sell note success several recent drug launch bode well simeprevir ibrutinib product currently await fda approval simeprevir be hepatitis drug eventually hope combine drug just acquire glaxosmithkline gsk form oral therapy hepatitis ibrutinib be treatment blood cancer develop pharmacyclic pcyc win breakthrough therapy designation fda speed review process good news gilead science gild rival idelalisib drug last week goldman sachs analyst navdeep singh set peak annual sale estimate ibrutinib most popular rating stock be still hold company have be face difficult macroeconomy even stock have climb start year rubin however write see bright term future pharmaceutical industry overall show sign converge red hot sibling biotech
1569,JNJ,gilead science gild stock jump nearly morning trading thursday promising news blood cancer drug idelalisib
1570,JNJ,late wednesday gilead announce have stop idelalisib clinical trial early have already proven positive risk benefit profile treatment chronic lymphocytic leukemia cll combine biogen idec biib rituxan idelalisib be already await fda approval hodgkin lymphoma gilead be continue test other used
1571,JNJ,be obviously good news gilead analyst ponder implication pharmacyclic pcyc johnson johnson jnj ibrutinib be await fda approval cll be expect be blockbuster
1572,JNJ,single agent ibrutinib appear more efficacious cll medacorp key opinion leader view combination datum date idelalisib ibrutinib rituxan be equivalent write leerink swann howard liang note thursday
1573,JNJ,liang also say ibrutinib trial idelalisib trial be randomize mean gilead likely be able meet european union requirement pharmacyclic do
1574,JNJ,analyst mark schoenebaum isi group write email client idelalisib start compete ibrutinib early month ibrutinib launch say current consensus forecast idelalisib indication be number likely go term
1575,JNJ,schoenebaum note much depend yet be report datum toxicity duration treatment ibrutinib be particularly strong gilead hasn say release datum liang expect be american society hematology conference december
1576,JNJ,pharmacyclic stock be morning trading thursday
1577,JNJ,related analyst initiate coverage pharmacyclic bullish report gilead science gild stock jump nearly morning trading thursday promising news blood cancer drug idelalisib late wednesday gilead announce have stop idelalisib clinical trial early have already proven positive risk benefit profile treatment chronic lymphocytic leukemia cll combine biogen idec biib rituxan idelalisib be already await fda approval hodgkin lymphoma gilead be continue test other used be obviously good news gilead analyst ponder implication pharmacyclic pcyc johnson johnson jnj ibrutinib be await fda approval cll be expect be blockbuster single agent ibrutinib appear more efficacious cll medacorp key opinion leader view combination datum date idelalisib ibrutinib rituxan be equivalent write leerink swann howard liang note thursday liang also say ibrutinib trial idelalisib trial be randomize mean gilead likely be able meet european union requirement pharmacyclic do analyst mark schoenebaum isi group write email client idelalisib start compete ibrutinib early month ibrutinib launch say current consensus forecast idelalisib indication be number likely go term schoenebaum note much depend yet be report datum toxicity duration treatment ibrutinib be particularly strong gilead hasn say release datum liang expect be american society hematology conference december pharmacyclic stock be morning trading thursday related analyst initiate coverage pharmacyclic bullish report
1578,JNJ,tuesday bring bonanza mostly bullish third quarter earning report high rate drug stock more legal worry questcor pharmaceutical qcor stomp analyst estimate report close sale totale year earlier quarter past consensus compile thomson reuter profit time item jump
1579,JNJ,tuesday bring bonanza mostly bullish third quarter earning report high rate drug stock more legal worry questcor pharmaceutical qcor stomp analyst estimate report close sale totale year earlier quarter past consensus compile thomson reuter profit time item jump
1580,JNJ,major average lose ground again thursday better expect retail sale be offset larger expect jump weekly jobless claim
1581,JNJ,dow jone industrial average lose fuel weakness cisco system csco walt disney procter gamble pg johnson johnson jnj fall nasdaq ease less nyse volume be tracking higher wednesday nasdaq volume be flat
1582,JNJ,stock market today facebook fb pop news be add replace teradyne ter facebook be back week move average continue work right side possible base
1583,JNJ,meanwhile several china name be hold well include hotel operator china lodging group htht share rise firm week move average breaking cup handle pattern august
1584,JNJ,ipo news hilton worldwide hlt have solid debut pricing wednesday night share rise
1585,JNJ,downside former leader lululemon athletica lulu run more trouble institutional selling stock continue share plummet month low company report tepid earning offer weak fiscal fourth quarter guidance
1586,JNJ,ahead earning report close restoration hardware rh ease not picture technical health ahead result recent cup handle pattern didn go anywhere monday stock fall day move average heavy volume major average lose ground again thursday better expect retail sale be offset larger expect jump weekly jobless claim dow jone industrial average lose fuel weakness cisco system csco walt disney procter gamble pg johnson johnson jnj fall nasdaq ease less nyse volume be tracking higher wednesday nasdaq volume be flat stock market today facebook fb pop news be add replace teradyne ter facebook be back week move average continue work right side possible base meanwhile several china name be hold well include hotel operator china lodging group htht share rise firm week move average breaking cup handle pattern august ipo news hilton worldwide hlt have solid debut pricing wednesday night share rise downside former leader lululemon athletica lulu run more trouble institutional selling stock continue share plummet month low company report tepid earning offer weak fiscal fourth quarter guidance ahead earning report close restoration hardware rh ease not picture technical health ahead result recent cup handle pattern didn go anywhere monday stock fall day move average heavy volume
1587,JNJ,beauty product seller avon product avp have be attempt make few ugly year result be start show now avp be early stage management turnaround story well fargo analyst write upgrade new york base company outperform market perform price target range be
1588,JNJ,obesity drug stock vivus vvus orexigen therapeutic orex pop stock market thursday cowen upgrade former launch coverage outperform rating latter
1589,JNJ,analyst simo simeonidis write team have recently do survey physician primary care obesity specialist say vivus qsymia show strongest efficacy weight loss drug eventually lead market simeonidis also approve recent change company management include appointment former johnson johnson jnj executive seth fischer ceo last month
1590,JNJ,change be bring shareholder revolt follow qsymia weak launch last year many observer criticize tiny biotech strategy try market major drug big pharma partner fischer be currently talk potential partner
1591,JNJ,separately leerink swann analyst marko kozul publish note thursday say tracking patent office suggest qsymia be get significant expansion intellectual property protection have be key issue vivus qsymia be combination drug be already patent add take month process be finalize
1592,JNJ,kozul reiterate outperform rating price target simeonidis upgrade vivus outperform set price target early afternoon trading stock be nearly
1593,JNJ,simeonidis launch coverage orexigen outperform rating price target orexigen drug contrave be still clinical trial simeonidis write unique formula combine strong marketing partner takeda give chance nascent market also comment be buyout target orexigen stock rise midday trading
1594,JNJ,simeonidis also launch coverage arena pharmaceutical arna obesity drug belviq come market june give market perform rating price target say belviq have marginal efficacy safety issue arena share drop more trading just obesity drug stock vivus vvus orexigen therapeutic orex pop stock market thursday cowen upgrade former launch coverage outperform rating latter analyst simo simeonidis write team have recently do survey physician primary care obesity specialist say vivus qsymia show strongest efficacy weight loss drug eventually lead market simeonidis also approve recent change company management include appointment former johnson johnson jnj executive seth fischer ceo last month change be bring shareholder revolt follow qsymia weak launch last year many observer criticize tiny biotech strategy try market major drug big pharma partner fischer be currently talk potential partner separately leerink swann analyst marko kozul publish note thursday say tracking patent office suggest qsymia be get significant expansion intellectual property protection have be key issue vivus qsymia be combination drug be already patent add take month process be finalize kozul reiterate outperform rating price target simeonidis upgrade vivus outperform set price target early afternoon trading stock be nearly simeonidis launch coverage orexigen outperform rating price target orexigen drug contrave be still clinical trial simeonidis write unique formula combine strong marketing partner takeda give chance nascent market also comment be buyout target orexigen stock rise midday trading simeonidis also launch coverage arena pharmaceutical arna obesity drug belviq come market june give market perform rating price target say belviq have marginal efficacy safety issue arena share drop more trading just
1595,JNJ,janssen pharmaceutical subsidiary johnson johnson jnj have acquire hepatitis drug candidate glaxosmithkline gsk janssen biotech partner medivir announce tuesday morning
1596,JNJ,glaxo have develop drug gsk partnership vertex pharmaceutical vrtx never launch phase trial janssen however plan test combination simeprevir drug medivir janssen develop be await regulatory approval be used combination standard therapy interferon ribavirin accord press release janssen hope glaxo drug take place interferon cocktail
1597,JNJ,whole point be jnj try develop oral possibly once daily hcv combo compete simplest easiest regimen write rbc capital market analyst michael yee client note
1598,JNJ,yee view current simplest easiest regimen be gilead science gild sofosbuvir ribavirin also be fda review write news shouldn interfere expect strong launch sofosbuvir next year take least other competitor finish testing approval process
1599,JNJ,market seem agree be trading cent stock market tuesday morning gilead have be slip hit time high be
1600,JNJ,related offer steady stock janssen pharmaceutical subsidiary johnson johnson jnj have acquire hepatitis drug candidate glaxosmithkline gsk janssen biotech partner medivir announce tuesday morning glaxo have develop drug gsk partnership vertex pharmaceutical vrtx never launch phase trial janssen however plan test combination simeprevir drug medivir janssen develop be await regulatory approval be used combination standard therapy interferon ribavirin accord press release janssen hope glaxo drug take place interferon cocktail whole point be jnj try develop oral possibly once daily hcv combo compete simplest easiest regimen write rbc capital market analyst michael yee client note yee view current simplest easiest regimen be gilead science gild sofosbuvir ribavirin also be fda review write news shouldn interfere expect strong launch sofosbuvir next year take least other competitor finish testing approval process market seem agree be trading cent stock market tuesday morning gilead have be slip hit time high be related offer steady stock
1601,JNJ,medical giant johnson johnson jnj be due report quarterly result early tuesday company prepare changeover leadership
1602,JNJ,analyst poll thomson reuter expect company report first quarter financial nearly identical last year revenue be earning share lot have happened then series product recall lawsuit induced longtime ceo william weldon announce resignation february company select vice chairman alex gorsky succeed shareholder meeting set april already inherit predecessor problem however last week justice department let be know want talk gorsky allegation kickback psychotic drug risperdal
1603,JNJ,however hasn be bad news win several key drug approval past year include stroke preventer xarelto recent note morningstar analyst damien conover say aftermath recall didn look too bad base consumer survey most company key brand have take only minor hit enable company return counter drug market share level be only slightly lower pre recall level once manufacturing be back line expect direct consumer advertising begin
1604,JNJ,analyst say be flat see growth pick bit rest year average see full year profit rise share sale
1605,JNJ,johnson johnson share be fraction early trading monday medical giant johnson johnson jnj be due report quarterly result early tuesday company prepare changeover leadership analyst poll thomson reuter expect company report first quarter financial nearly identical last year revenue be earning share lot have happened then series product recall lawsuit induced longtime ceo william weldon announce resignation february company select vice chairman alex gorsky succeed shareholder meeting set april already inherit predecessor problem however last week justice department let be know want talk gorsky allegation kickback psychotic drug risperdal however hasn be bad news win several key drug approval past year include stroke preventer xarelto recent note morningstar analyst damien conover say aftermath recall didn look too bad base consumer survey most company key brand have take only minor hit enable company return counter drug market share level be only slightly lower pre recall level once manufacturing be back line expect direct consumer advertising begin analyst say be flat see growth pick bit rest year average see full year profit rise share sale johnson johnson share be fraction early trading monday
1606,JNJ,share pharmacyclic pcyc jump new high stock market thursday deutsche bank jpmorgan launch coverage bullish rating stock have double price start year deutsche bank analyst robyn karnauskas write wall street be still underestimate potential pharmacyclic drug candidate ibrutinib
1607,JNJ,johnson johnson jnj receive positive news prostate cancer drug welcome event consumer health care giant have suffer series product recall departure senior executive independent datum monitoring committee recommend zytiga prostate cancer patient have not undergo chemotherapy drug already have fda approval
1608,JNJ,johnson johnson offer investor first look state medical industry modestly beat consensus estimate raise guidance share rise nearly early trading eventually close fraction johnson johnson jnj make share year earlier quarter beating
1609,JNJ,sometime early next year biotech pharmacyclic pcyc be expect launch first drug ibrutinib treat blood cancer go wall street expect be sweet vindication ceo robert duggan turnaround plan
1610,JNJ,august food drug administration accept pharmacyclic application ibrutinib not only be approve designate breakthrough therapy agency create designation earlier year way drug represent substantial improvement exist therapy serious condition get approval process faster usual
1611,JNJ,deadline approval
1612,JNJ,promise speed fda still hasn set deadline decide approve ibrutinib
1613,JNJ,analyst be generally expect decision come first quarter overwhelmingly expect answer be yes
1614,JNJ,believe drug transform treatment many blood cancer analyst robyn karnauskas deutsche bank write report initiate coverage stock
1615,JNJ,ibrutinib be follow other drug celgene celg revlimid biogen idec biib rituxan achieve blockbuster sale poorer efficacy less durability response poorer safety profile compare ibrutinib say
1616,JNJ,karnauskas set sale estimate blockbuster say wall street estimate be too low consensus have be rise past month however stock
1617,JNJ,trading nickel dime early pharmacyclic crested oct get catch recent biotech stock selloff
1618,JNJ,be stock nadir september duggan take helm company co founder richard miller
1619,JNJ,miller be highly respect biotech founding idec now merged biogen idec pharmacyclic lead drug candidate xcytrin brain cancer be turn fda
1620,JNJ,duggan start investing pharmacyclic selling own startup computer motion intuitive surgical isrg have become board chairman tell ibd recent interview favore turn away xcytrin focuse class drug call bruton tyrosine kinase inhibitor pharmacyclic have acquire struggle genomic firm celera
1621,JNJ,say think entirely possible world time strength drug ve license celera usher new era medicine truly become ally patient clinician don hurt process help duggan say
1622,JNJ,patient median age
1623,JNJ,be especially important patient chronic lymphocytic leukemia cll median age diagnosis be year
1624,JNJ,accord karnauskas current treatment include rituxan offer patient trade toxicity effectiveness old age body have lot more trouble handle toxicity note phase study drug only newly diagnosed patient relapse patient have drop due adverse event even treatment go year
1625,JNJ,good datum be still future duggan take pharmacyclic fact be so hard raise capital december march lend company own money
1626,JNJ,unit be marketing partner
1627,JNJ,trial result rolled however investor begin come also land company johnson johnson jnj janssen biotech marketing partner
1628,JNJ,have objective company be build organization stay control pharmacyclic chief operate officer maky zanganeh tell ibd janssen be be really willing give control control control regulatory issue
1629,JNJ,zanganeh point pharmacyclic be do drug manufacturing
1630,JNJ,pharmacyclic current fda filing seek approval ibrutinib use second line treatment cll small lymphocytic lymphoma mantle cell lymphoma
1631,JNJ,company be also testing diffuse large cell lymphoma multiple myeloma latter be disease make celgene fortune
1632,JNJ,ibrutinib not be competition wednesday gilead science gild stop trial own cll candidate idelalisib early datum be already so good
1633,JNJ,news briefly depress pharmacyclic stock analyst point still don have precise safety duration datum idelalisib
1634,JNJ,friday goldman sachs analyst navdeep singh give ibrutinib vote confidence lift peak sale estimate year upgrading stock buy neutral sometime early next year biotech pharmacyclic pcyc be expect launch first drug ibrutinib treat blood cancer go wall street expect be sweet vindication ceo robert duggan turnaround plan august food drug administration accept pharmacyclic application ibrutinib not only be approve designate breakthrough therapy agency create designation earlier year way drug represent substantial improvement exist therapy serious condition get approval process faster usual deadline promise speed fda still hasn set deadline decide approve ibrutinib analyst be generally expect decision come first quarter overwhelmingly expect answer be yes believe drug transform treatment many blood cancer analyst robyn karnauskas deutsche bank write report initiate coverage stock ibrutinib be follow other drug celgene celg revlimid biogen idec biib rituxan achieve blockbuster sale poorer efficacy less durability response poorer safety profile compare ibrutinib say karnauskas set sale estimate blockbuster say wall street estimate be too low consensus have be rise past month however stock trading nickel dime early pharmacyclic crested oct get catch recent biotech stock selloff be stock nadir september duggan take helm company co founder richard miller miller be highly respect biotech founding idec now merged biogen idec pharmacyclic lead drug candidate xcytrin brain cancer be turn fda duggan start investing pharmacyclic selling own startup computer motion intuitive surgical isrg have become board chairman tell ibd recent interview favore turn away xcytrin focuse class drug call bruton tyrosine kinase inhibitor pharmacyclic have acquire struggle genomic firm celera say think entirely possible world time strength drug ve license celera usher new era medicine truly become ally patient clinician don hurt process help duggan say patient median age be especially important patient chronic lymphocytic leukemia cll median age diagnosis be year accord karnauskas current treatment include rituxan offer patient trade toxicity effectiveness old age body have lot more trouble handle toxicity note phase study drug only newly diagnosed patient relapse patient have drop due adverse event even treatment go year good datum be still future duggan take pharmacyclic fact be so hard raise capital december march lend company own money unit be marketing partnera trial result rolled however investor begin come also land company johnson johnson jnj janssen biotech marketing partner have objective company be build organization stay control pharmacyclic chief operate officer maky zanganeh tell ibd janssen be be really willing give control control control regulatory issue zanganeh point pharmacyclic be do drug manufacturing pharmacyclic current fda filing seek approval ibrutinib use second line treatment cll small lymphocytic lymphoma mantle cell lymphoma company be also testing diffuse large cell lymphoma multiple myeloma latter be disease make celgene fortune ibrutinib not be competition wednesday gilead science gild stop trial own cll candidate idelalisib early datum be already so good news briefly depress pharmacyclic stock analyst point still don have precise safety duration datum idelalisib friday goldman sachs analyst navdeep singh give ibrutinib vote confidence lift peak sale estimate year upgrading stock buy neutral
1635,JNJ,johnson johnson jnj fourth quarter earning climb exclude time item cent view health care giant issue tepid guidance part effect stronger dollar sale climb largely line view sale slip part due quality control problem force temporary closure
1636,JNJ,update stock vacillate mostly lower finish monday
1637,JNJ,speech fed chairman ben bernanke see modest economic growth next year reiterate interest rate stay low extend period ease fear rate hike also note obstacle include weak labor market tight credit
1638,JNJ,nyse composite fall partly due weak financial gold stock nasdaq fall dow tick fraction turnover drop sharply major exchange
1639,JNJ,china automotive system caas erased morning gain fall nearly triple average trade be biggest percentage loser ibd hit stock be still past buy point week tight pattern
1640,JNJ,mercadolibre meli fall nearly twice average volume marked third straight day heavy trade stock pull back straight week gain remain past buy point week tight pattern
1641,JNJ,side asiainfo holding asia gap soar time average trade chinese software security product maker agree buy fellow chinese telecom software security firm linkage technology
1642,JNJ,hour news fedex fdx raise fiscal earning outlook share earlier view cent cent share rise fellow shipper up up edge
1643,JNJ,earning expect tuesday include autozone azo block hrb kroger kr talbot tlb
1644,JNJ,index end mostly lower
1645,JNJ,vincent mao
1646,JNJ,update stock close mostly lower seesaw session monday
1647,JNJ,nyse composite fall nasdaq fall meanwhile dow squeeze tiny gain volume drop sharply exchange
1648,JNJ,consumer product maker computer manufacturer jewelry retailer be monday worst group fertilizer maker fiber optic alternative energy group be best performer
1649,JNJ,index reverse late trade
1650,JNJ,vincent mao
1651,JNJ,update index turn lower hit new session lows late trading monday dollar index rebound
1652,JNJ,nasdaq be drag big cap techs apple aapl slip fall further south day move average tech icon confirm buy music service firm lala com didn disclose term
1653,JNJ,amazon com amzn reversed earlier gain fall priceline plcn lose baidu com bidu edge more near day move average
1654,JNJ,meanwhile nyse composite fall dow volume be still tracking sharply lower board
1655,JNJ,smartheat heat extend gain pace end session decline firm make plate heat exchanger china industrial residential commercial market earning grow triple digit percentage latest quarters analyst see profit surge current period
1656,JNJ,tech pharmacal hitk also extend gain surge fast trade drugmaker report earning wednesday open analyst see profit vaulting cent share
1657,JNJ,index improve afternoon trade
1658,JNJ,vincent mao
1659,JNJ,update stock continue climb afternoon trading monday bernanke comment slow recovery ease rate hike fear retreat dollar also help
1660,JNJ,most index hit new session high dow rally gain boee ba verizon vz unite technology utx boost blue chip index
1661,JNJ,meanwhile nyse composite picked
1662,JNJ,nasdaq edge do not hit new intraday high
1663,JNJ,turnover be again tracking vastly lower board
1664,JNJ,china agritech cagc ramp new record high have gain more clear buy point cup handle base dec
1665,JNJ,group mate china green agriculture cga rally rebound session pullback organic fertilizer producer be featured monday new america china green have gain nearly early october low
1666,JNJ,randgold resource gold bounce back loss rise fast trade analyst see gold producer earning surge
1667,JNJ,newmont mining nem also shake earlier loss gain active trading
1668,JNJ,downside china automotive system caas erased earlier gain fall heavy trading stock be session peak
1669,JNJ,mercadolibre meli come pressure third straight session lose brisk trade stock be now just past buy point week tight pattern
1670,JNJ,index tick bernanke speech
1671,JNJ,vincent mao
1672,JNJ,update stock perked fed chairman ben bernanke begin speech economic club washington
1673,JNJ,bernanke project modest growth note head wind such tight credit weak job market soft consumer spending
1674,JNJ,dow rally nasdaq nyse composite rise volume be sharply lower major exchange
1675,JNJ,sirona dental system siro reversed early loss rise year high stock be now past buy point cup handle base last week dental equipment maker deliver surge earning still miss view
1676,JNJ,encore capital group ecpg gain best level more year stock recently find support week move average late october debt collector trounce view pop earning
1677,JNJ,gold producer take beating yellow metal dive second straight session
1678,JNJ,iamgold iag gap lose buenaventura bvn also fall just day move average
1679,JNJ,barrick gold abx give downgrade cite concern additional environmental analysis need firm cortez hill project credit suisse cut share neutral outperform
1680,JNJ,elsewhere iii apparel group giii reversed year high drop stock clear week consolidation last week
1681,JNJ,market slightly higher midday
1682,JNJ,jonah keri
1683,JNJ,update stock cling slender gain midday monday nasdaq be dow add nyse composite be flat
1684,JNJ,volume remain lower board add market uncertain tone fall nyse nasdaq compare same period friday
1685,JNJ,tech pharmacal hitk ramp average trade drugmaker stock eclipse day move average
1686,JNJ,software maker ebix ebix advanced rapid turnover company announce expand credit line bank america firm also say be target annualize revenue run rate operate margin better
1687,JNJ,downside bare escentual bare skid nearly time regular volume cosmetic maker slice day line
1688,JNJ,stock retain modest gain
1689,JNJ,update stock vacillate mostly lower finish monday speech fed chairman ben bernanke see modest economic growth next year reiterate interest rate stay low extend period ease fear rate hike also note obstacle include weak labor market tight credit nyse composite fall partly due weak financial gold stock nasdaq fall dow tick fraction turnover drop sharply major exchange china automotive system caas erased morning gain fall nearly triple average trade be biggest percentage loser ibd hit stock be still past buy point week tight pattern mercadolibre meli fall nearly twice average volume marked third straight day heavy trade stock pull back straight week gain remain past buy point week tight pattern side asiainfo holding asia gap soar time average trade chinese software security product maker agree buy fellow chinese telecom software security firm linkage technology hour news fedex fdx raise fiscal earning outlook share earlier view cent cent share rise fellow shipper up up edge earning expect tuesday include autozone azo block hrb kroger kr talbot tlb index end mostly lowerby vincent mao update stock close mostly lower seesaw session monday nyse composite fall nasdaq fall meanwhile dow squeeze tiny gain volume drop sharply exchange consumer product maker computer manufacturer jewelry retailer be monday worst group fertilizer maker fiber optic alternative energy group be best performer index reverse late tradeby vincent mao update index turn lower hit new session lows late trading monday dollar index rebound nasdaq be drag big cap techs apple aapl slip fall further south day move average tech icon confirm buy music service firm lala com didn disclose term amazon com amzn reversed earlier gain fall priceline plcn lose baidu com bidu edge more near day move average meanwhile nyse composite fall dow volume be still tracking sharply lower board smartheat heat extend gain pace end session decline firm make plate heat exchanger china industrial residential commercial market earning grow triple digit percentage latest quarters analyst see profit surge current period tech pharmacal hitk also extend gain surge fast trade drugmaker report earning wednesday open analyst see profit vaulting cent share index improve afternoon tradeby vincent mao update stock continue climb afternoon trading monday bernanke comment slow recovery ease rate hike fear retreat dollar also help most index hit new session high dow rally gain boee ba verizon vz unite technology utx boost blue chip index meanwhile nyse composite picked nasdaq edge do not hit new intraday high turnover be again tracking vastly lower board china agritech cagc ramp new record high have gain more clear buy point cup handle base dec group mate china green agriculture cga rally rebound session pullback organic fertilizer producer be featured monday new america china green have gain nearly early october low randgold resource gold bounce back loss rise fast trade analyst see gold producer earning surge newmont mining nem also shake earlier loss gain active trading downside china automotive system caas erased earlier gain fall heavy trading stock be session peak mercadolibre meli come pressure third straight session lose brisk trade stock be now just past buy point week tight pattern index tick bernanke speechby vincent mao update stock perked fed chairman ben bernanke begin speech economic club washington bernanke project modest growth note head wind such tight credit weak job market soft consumer spending dow rally nasdaq nyse composite rise volume be sharply lower major exchange sirona dental system siro reversed early loss rise year high stock be now past buy point cup handle base last week dental equipment maker deliver surge earning still miss view encore capital group ecpg gain best level more year stock recently find support week move average late october debt collector trounce view pop earning gold producer take beating yellow metal dive second straight session iamgold iag gap lose buenaventura bvn also fall just day move average barrick gold abx give downgrade cite concern additional environmental analysis need firm cortez hill project credit suisse cut share neutral outperform elsewhere iii apparel group giii reversed year high drop stock clear week consolidation last week market slightly higher middayby jonah keri update stock cling slender gain midday monday nasdaq be dow add nyse composite be flat volume remain lower board add market uncertain tone fall nyse nasdaq compare same period friday tech pharmacal hitk ramp average trade drugmaker stock eclipse day move average software maker ebix ebix advanced rapid turnover company announce expand credit line bank america firm also say be target annualize revenue run rate operate margin better downside bare escentual bare skid nearly time regular volume cosmetic maker slice day line stock retain modest gain
1690,JNJ,share johnson johnson jnj hit new high stock market monday medical giant prepared report earning early tuesday analyst poll thomson reuter be expect similar sale growth compare last quarters profit growth be see accelerate bit consensus call revenue
1691,JNJ,pfizer inc pfe free report announce be re organize business business segment separate consumer healthcare business standalone unit begin pfizer report new business unit innovative medicine establish medicine consumer healthcare presently pfizer have report segment innovative health essential health present innovative health unit be call innovative medicine other include current innovative health business unit innovative medicine include new hospital medicine business unit create sterile injectable infective medicine be presently record pfizer essential health unit also biosimilar now be include oncology inflammation immunology business segment innovative medicine unit essential health unit be rename establish medicine unit continue include pfizer legacy brand have lose lose market exclusivity include lyrica lipitor norvasc viagra certain generic medicine lipitor norvasc viagra have already lose patent exclusivity lyrica be expect lose same december year pfizer expect significant reduction impact patent protection loss post lyrica loss exclusivity last year pfizer have say loss exclusivity loe hurt sale negative impact go next year loe impact reduce further post go approximately not be more potentially lower loe impact pfizer be optimistic establish medicine unit generate sustainable modest revenue growth consumer healthcare unit be now part innovative health include pfizer counter drug pfizer be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year pfizer ultimately opt retain business pfizer be have tough time find buyer consumer healthcare segment march british company reckitt benckiser group glaxo gsk free report pull discussion pfizer buy consumer health segment investor believe split make sale easier also speculate pfizer sell generic unit couple year news business re organization come day pfizer defer recent price increase several prescription drug be criticize trump be concern price hike company soon trigger market wide increase price drugmaker jnj free report merck mrk free report other year so far pfizer share have increase decrease industry pfizer currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1692,JNJ,dow endure volatile week marked key geopolitical development begin week treasury secretary make encourage remark progress trade negotiation china however later week president trump expressed dissatisfaction progress trade talk also cancel much await summit north korea leader kim jong result stock gain lose alternate session last week dow gain point last friday close session nearly unchanged trade negotiation unite state china continue weigh investor sentiment president donald trump say doubt negotiation have positive outcome also bond yield reach highest level last week index decline last week trade talk unite state china remain focus week continue weigh investor sentiment moreover high interest rate too push stock lower week year note yield crossed mark first time dent investor confidence see investor panic yield hit psychological level trigger fear equity become less appeal dow index gain nearly point monday dow also close mark first time march trade tension unite state china decline treasury secretary steve mnuchin sunday say be putt trade war hold industrial be biggest gainer stand benefit most trade war be avert share boee ba free report caterpillar cat free report unite technology utx free report jump respectively index decline tuesday erase early gain president trump say wasn satisfied progress unite state china trade talk moreover trump also say highly await summit unite state north korea not happen meanwhile white house say order get fresh nuclear deal unite state iran need stop enrich uranium withdraw support militant group middle east statement cause stock plummet further index gain wednesday lead lead rally share boee gain share mcdonald mcd surge stock gain minute fed meeting conclude earlier month hint policy maker aren worry inflation briefly run target level further such occurrence not result faster interest rate hike rate sensitive stock rally news broader market be able pare earlier loss result geopolitical tension close black index decline thursday president trump scrap summit north korea leader kim jong schedule next month have be maiden face face encounter north korean leader sit president energy stock emerge biggest loser day oil price decline follow unexpected increase domestic crude inventory share exxon mobil xom chevron cvx free report decline respectively lead blue chip index finish red component move index general electric company ge free report recently enter definitive agreement wabtec corporation wab free report lead manufacturer rail equipment agreement company merge operate segment ge transportation wabtec completion synergistic deal zack rank hold general electric obtain cash company shareholder own ownership interest combine company remain stake combine company be retain wabtec shareholder notably deal be likely close early latest move combine ge transportation digital solution railroad marine drill wind mining industry wabtec extensive range electronic solution result market capability be stronger add momentum development implementation innovative solution key market help improve safety efficiency productivity offering notably combine company have large global install base more locomotive create significant opportunity aftermarket service growth read general electric transportation unit merge wabtec johnson johnson inc jnj free report partner glaxosmithkline plc gsk free report announce european commission ec have grant marketing approval juluca make europe first drug hiv treatment johnson johnson have zack rank juluca combine approve hiv drug tivicay mg edurant mg single once daily pill treatment virologically suppress hiv infection juluca gain approval unite state november last year generate sale first quarter read glaxo drug hiv regimen juluca get eu approval merck co inc mrk free report announce pivotal study keynote evaluate keytruda chemotherapy combination first line metastatic squamous small cell lung cancer nsclc meet dual primary endpoint overall survival os progression free survival pfs drug combination chemotherapy demonstrated significantly longer os pfs versus chemotherapy alone merck supplemental biologic license application sbla seek continue approval keytruda combine eli lilly lly free report alimta platinum chemotherapy treat metastatic squamous nsclc be review unite state sbla be file base encourage datum phase iii study keynote company plan share datum keynote study fda expand sbla include patient squamous histology company present detailed datum keynote study upcoming annual meeting american society clinical oncology next month stock have zack rank see complete list today zack rank strong buy stock here pfizer inc pfe free report announce fda have grant breakthrough therapy designation rare disease candidate tafamidis candidate be be develop treatment transthyretin cardiomyopathy ttr cm designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient benefit patient current treatment option designation tafamadis be primarily base encourage top line datum phase iii attr act study demonstrated significant reduction combination cause mortality frequency cardiovascular related hospitalization ttr cm patient read pfizer tafamadis get breakthrough therapy designation separate development zack rank pfizer announce phase iii study evaluate epilepsy drug lyrica pregabalin pediatric patient meet primary endpoint read pfizer epilepsy drug lyrica succeed pediatric study microsoft corporation msft free report recently unveil new gamepad xbox adaptive controller be aim ensure gaming everyone controller price be personalize requirement gamer controller comprise big programmable button mm port round back connect blow tube pedal other accessory zack rank microsoft blog development story date back almost feature copilot release xbox witness creative use company imagination inspire developer bring inclusivity boost engagement consequently bolster user base go forward read microsoft unveil xbox controller specially able gamer performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlookcomment president trump have guide market lower more occasion week only nature fed minute have prove be encourage investor otherwise absence major earning report geopolitical event have weigh heavily investor sentiment give backdrop only be natural investor turn economic report encouragement several key piece datum be line release next week include important gdp report most be encourage nature stock soon return winning way look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1693,JNJ,worst first half performance dow jone have show strength start second half be especially true blue chip index have best day month jul push back index positive territory year gain come back strong job report earning optimism trade tension read winning lose sector etfs june job datum further index close day move average first time nearly week positive sign short term momentum trend such proxy version spdr dow jone industrial average etf dium free report be spotlight head earning season dium be largest most popular etfs large cap space aum more average daily volume share hold blue chip stock fund be widely spread component hold less share industrial information technology financial consumer discretionary healthcare be top sector dium charge bps annual fee have zack etf rank buy medium risk outlook let delve earning picture likely set movement fund come day earning trendstotal earning be expect grow same period last year higher revenue zack sector expect have double digit earning growth represent third consecutive quarter double digit earning growth trend be currently expect continue second half year read safe sound etf strategy nearly fourth blue chip firm be expect announce result week next jpmorgan chase jpm free report be expect release result jul unitedhealth group unh free report johnson johnson jnj free report goldman gs free report be schedule report jul international business machine ibm free report american express axp free report report jul other company procter gamble company pg free report come report jul general electric ge free report have earning release slate jul earning methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate stock be best avoid uncover best stock buy sell re report earning esp filter jpmorgan have zack rank earning esp indicate reasonable chance beating estimate quarter company deliver average positive earning surprise last quarters see positive earning estimate revision couple cent past day be report quarter stock have vgm score unitedhealth have zack rank earning esp stock see earning estimate revision yet be report quarter past day deliver positive earning surprise last quarters stock have top vgm score johnson johnson also have reasonable chance beating estimate quarter zack rank earning esp witness negative earning estimate revision penny past month be report quarter deliver positive earning surprise last quarters stock have vgm score read biotech etfs surge biogen positive drug trial result goldman have zack rank earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise company witness positive earning estimate revision cent past day yet be report quarter have vgm score international business machine have zack rank earning esp indicate reasonable chance beating estimate quarter stock deliver positive earning surprise last quarters average beat see earning estimate revision cent past day be report quarter stock have vgm score american express have zack rank earning esp indicate less chance beating estimate quarter company deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter stock have vgm score procter gamble company have zack rank earning esp earning surprise track last quarters be good average beat stock see negative earning estimate revision couple cent past day be report quarter have vgm score read consumer staple etfs ride high trade war fear general electric have zack rank earning esp company deliver positive earning surprise last quarters witness negative earning estimate revision cent past day yet be report quarter have vgm score bottom earning most blue chip company schedule come week renew strength stock market investor closely monitor movement dow etf grab opportunity surge stock want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1694,JNJ,biogen inc biib free report share be market trading thursday positive top line datum mid stage study evaluate pipeline candidate ban treatment early alzheimer disease ad biogen be develop ban humanize beta amyloid antibody collaboration japan eisai co ltd amyloid be protein form plaque brain person alzheimer candidate be be investigate see slow progression memory problem associate amyloid top line result final analysis phase ii study demonstrated statistically significant slow disease progression key clinical endpoint adcom month treatment patient receive highest treatment dose mg kg biweekly ban compare placebo meanwhile treatment high dose month also lead reduction amyloid beta accumulate brain study include dose regimen datum marked important breakthrough biogen eisai challenge ad market lead share price increase however so far year biogen share have decline almost inline industry decline same time frame late datum announce same study fail show early positive result raise investor concern candidate chance success independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint study fail show early positive result company say blind study be be conduct patient mild cognitive impairment mci due ad mild alzheimer dementia collectively know early alzheimer disease continue comprehensive final analysis be conduct month detailed datum study be expect be present future conference alzheimer fatal illness cause progressive decline memory have always be highly challenge area not much progress be make spite significant investment fund resource several company have fail develop safe effective treatment option deadly brain disease last month lilly lly free report swiss partner astrazeneca azn free report discontinue late stage study alzheimer disease candidate lanabecestat recommendation idmc idmc say study be unlikely meet primary goal completion back november lilly say not seek approval investigational ad treatment solanezumab follow disappointing result late stage study year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage ad due safety concern february year merck discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal ad success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate ad due lack efficacy january pfizer say end effort alzheimer parkinson disease area long back pfizer have shelved late stage ad candidate bapineuzumab iv fail phase iii study setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale biogen currently carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1695,JNJ,biggest news week be novartis nvs free report announcement plan spin eye care division alcon new public company committee medicinal product human use chmp european medicine agency ema give positive recommendation grant marketing approval several drug week astrazeneca azn free report relatively new cancer drug lynparza imfinzi be grant marketing approval japan recap week most important storiesnovartis spin alcon novartis announce intention spin eye care division alcon separately trade standalone company novartis have acquire alcon novartis be conduct strategic review business long include retain business separation sale spin initial public offer decision spin alcon look prudent business be not perform management expectation alcon management believe create standalone company capital market exit create additional shareholder value divestiture unit also help novartis focus drug business novartis plan retain ophthalmic pharmaceutical part pharmaceutical portfolio concurrently company announce initiate share buyback program be execute end read more novartis spin alcon separate trading company chmp give positive opinion several drug bristol myer bmy free report pd inhibitor opdivo gain positive chmp opinion recommend expand approval adjuvant treatment adult patient melanoma chmp also give nod astrazeneca new formulation once weekly bydureon pre filled bcise device help improve glycaemic control new formulation be already approve unite state sanofi sny also gain positive chmp opinion cablivi caplacizumab treatment rare blood disorder call acquire thrombotic purpura cablivi be add sanofi portfolio latest acquisition ablynx novartis filing look label expansion car therapy kymriah cell malignancy be also give positive opinion chmp final decision european union product be expect come month astrazeneca gain japan approval new cancer drug astrazeneca parp inhibitor lynparza gain approval second indication japan lynparza olaparib tablet be already approve advanced ovarian cancer be now approve japan treatment patient unresectable recurrent brca mutate metastatic breast cancer patient have receive prior chemotherapy also astrazeneca new pd inhibitor be approve japanese regulatory authority locally advanced unresectable small cell lung cancer nsclc imfinzi be already approve unite state indication application eu be review decision expect second half read more astrazeneca new cancer drug get approval japan merck keytruda sbla get priority review merck mrk free report supplemental biologic license application sbla look expand label keytruda first line treatment metastatic squamous nsclc difficult treat lung cancer patient population be grant priority review fda fda decision be expect oct sbla filing be base datum keynote study remind investor datum present study steal limelight annual meeting american society clinical oncology earlier month datum study show combination keytruda chemotherapy lead significant improvement overall survival os progression free survival regardless pd expression read more merck keytruda get priority review difficult lung cancer bristol myer leukemia drug get eu nod expand indication bristol myer announce european commission have give marketing approval leukemia drug sprycel new patient population new formulation sprycel be now approve powder formulation administration pediatric patient philadelphia chromosome positive ph chronic myeloid leukemia cml chronic phase cp adamis get strong partner novartis adamis pharmaceutical admp free report announce exclusive distribution agreement novartis symjepi injection mg market emergency treatment acute allergic reaction include anaphylaxis deal novartis generic arm sandoz gain commercial right symjepi unite state exchange upfront fee potential performance base milestone payment company share profit equally meanwhile approval sandoz also get commercial right symjepi injection mg be presently fda review share adamis surge day partnership swiss pharma giant be announce read more adamis surge follow novartis deal symjepi nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform last trading session stock record increase last week glaxo gsk free report gain most past month too glaxo have be biggest gainer jnj free report decline most see last pharma stock roundup here pharma stock roundup ptct unveil promising datum rhhby acquire rest fmi next pharma world watch earning bigwig pharma world later month begin jul make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1696,JNJ,large cap pharmaceutical sector comprise biggest drugmaker world be strong start however sector take backseat due reason market instability few negative update pipeline well regulatory front also older drug company be not perform mark induce drop revenue zack large cap pharma industry have decline so far year zack composite gain overall sector be expect rebound second half year believe new product sale be ramp back rise demand successful innovation product line expansion strong clinical study result frequent fda approval upside turn bring sector back track year also many company have accelerate cost save initiative enable investment new product well defend exist product portfolio optimize long short term growth cost saving drive earning performance importantly merger acquisition activity be gain momentum tax reform place new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be spur merger activity year optimistic outlook rest year here highlight stock prove be good buy stock sport zack rank strong buy buy have see share price earning estimate rise term see complete list today zack rank stock here large cap pharma stocksh lundbeck hluyy free report share danish drugmaker have rally past month zack consensus estimate current year ep have be revise upward respectively last day lundbeck have zack rank company witness solid revenue growth first quarter headwind exchange rate generic erosion also strengthen pipeline inclusion parkinson disease candidate foliglurax acquisition prexton therapeutic currently mid stage development pfizer inc pfe free report zack rank stock have be work strengthen suite product buyout licensing deal company new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance pfizer also boast strong pipeline expect approximately drug approval include product blockbuster potential pfizer grow immuno oncology portfolio offer strong growth prospect share company have increase past month earning estimate have also moved north respectively past day abbvie inc abbv free report abbvie key arthritis drug humira be perform well strong demand trend new competition moreover drug imbruvica market partnership johnson johnson jnj free report be approve hematological cancer have multibillion dollar potential company be explore possibility label expansion solid tumor autoimmune disease mavyret hepatitis virus have become major growth driver abbvie short span market moreover abbvie boast impressive late stage pipeline label expansion new exist product expect next few year several pivotal datum readout regulatory milestone be also anticipate additionally company carry zack rank share price have also gain past month consensus estimate company current next year bottom line have also be raise respectively past day make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1697,JNJ,novartis nvs free report announce generic arm sandoz obtain approval zessly biosimilar version johnson johnson jnj free report remicade europe zessly be approve use indication brand drug include rheumatoid arthritis adult crohn disease pediatric crohn disease adult ulcerative colitis pediatric ulcerative colitis ankylose spondylitis psoriatic arthritis plaque psoriasis approval european commission be base review comprehensive development program include analytical preclinical clinical datum confirm zessly match remicade term safety efficacy quality approval be card chmp have give positive opinion same march approval strengthen sandoz already strong biosimilar portfolio market biosimilar omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state rixathon biosimilar rituximab approve europe treat blood cancer immunological disease also approve eu riximyo duplicate marketing authorization erelzi biosimilar approve europe treat multiple inflammatory disease zessly approval sandoz now have approve biosimilar portfolio zessly be third biosimilar have be approve ec last month sandoz fda also approve biosimilar erelzi however launch be pending unite state due ongoing litigation amgen amgn free report note sandoz acquire biosimilar infliximab pfizer pfe free report february eu country norway iceland liechtenstein form european economic area novartis share have decline year compare industry fall however sandoz continue face pricing pressure sale be project decline upcoming quarters zack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1698,JNJ,eli lilly company lly free report announce fda have approve inclusion additional datum label psoriasis injection taltz latest approval taltz label now include datum psoriasis involve genital area impact roughly psoriasis patient course disease taltz be already market treatment adult patient moderate severe plaque psoriasis be candidate systemic therapy phototherapy well active psoriatic arthritis taltz work specifically target il protein play role drive underlie inflammation psoriasis drug record sale first quarter label expansion expand eligible patient population drug drive sale go forward approval genital psoriasis be base datum study evaluate patient moderate severe psoriasis involve genital area study taltz demonstrated significant improvement compare placebo week severity psoriasis affect genital area overall psoriasis genital itch impact genital psoriasis sexual activity such patient many other drug novartis nvs free report cosentyx jnj free report tremfya abbvie abbv free report humira be approve treat plaque psoriasis lilly claim taltz be now first only fda approve treatment genital psoriasistaltz be also be study late stage study axial year date lilly share have decline compare industry decline lilly currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1699,JNJ,abbvie abbv free report announce combination regimen blockbuster cancer drug imbruvica ibrutinib fail phase iii study dbl evaluate first line treatment diffuse large cell lymphoma dlbcl drug fail improve event free survival ef compare current standard care dlbcl be aggressive form hodgkin lymphoma nhl type blood cancer new therapy have be approve decade treatment naive patient chop combination rituximab doxorubicin vincristine prednisone chemotherapy be standard care patient share abbvie slide jul follow news company share have decrease year date compare industry decline phase iii study be conduct collaboration johnson johnson jnj free report evaluate imbruvica combination chop versus chop placebo together primary endpoint study be superiority ef combination regimen be investigate treatment dlbcl patient have germinal center cell gcb activate cell abc subtype patient subtype commonly have poorer treatment outcome greater unmet medical need however datum study demonstrated improvement certain patient sub population be clinically meaningful be analyze further company present detailed analysis study future scientific conference publish peer review medical journal separate press release abbvie partner roche rhhby free report announce submission supplemental new drug application snda label expansion leukemia drug venclexta venetoclax snda be seek approval venclexta combination hypomethylating agent hma low dose cytarabine ldac treat newly diagnosed patient acute myeloid leukemia aml be ineligible intensive chemotherapy snda be file base datum separate early stage study evaluate venclexta combination mha ldac venclexta label be expand last month monotherapy combination roche biogen biib free report rituxan treatment relapse refractory chronic lymphocytic leukemia small lymphocytic lymphoma second later line setting abbvie inc price abbvie inc price abbvie inc quoteabbvie currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1700,JNJ,expect johnson johnson jnj free report healthcare bellwether beat expectation report second quarter result jul market open last report quarter company deliver positive earning surprise performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson stock have depreciate year so far compare unfavorably decline record industry factor considerj sale improve first quarter be pharmaceutical segment continue positive momentum see second half consumer segment sale improve positive sale trend be expect continue second quarter fact be quite confident pharma segment continue perform better market year impact biosimilar sale key arthritis drug remicade sale consumer medical device segment be expect improve believe new product segment successful label expansion cancer drug imbruvica darzalex contribution recent acquisition continue drive top line growth core product stelara zytiga simponi simponi aria invega sustenna be expect contribute growth however past quarters revenue pulmonary arterial hypertension pah product add june acquisition actelion decline sequentially due lower sale tracleer outside unite state due generic competition be less likely pah revenue improve second competition be expect hurt sale remicade outside unite state please note market remicade partnership merck mrk free report however do not expect biosimilar entrant zytiga prezista risperdal consta invega sustenna unite state however full year guidance include impact generic procrit tracleer well remicade biosimilar regard newly launch tremfya say first quarter conference call uptake product have be strong drug record sale first quarter be expect be higher be report quarter expect discuss initial sale number erleada newly approve prostate cancerdrug second quarter conference call medical device segment sale be expect rise consistently vision care cardiovascular unit diabetes care unit however continue remain weakin consumer segment beauty counter product be expect do well domestic baby care product sale likely remain weak recent acquisition well new product be likely provide support however higher investment new product launch continue hurt profit earning whispersour proven model show be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp be zack consensus estimate stand share uncover best stock buy sell re report earning esp filter zack rank have zack rank combination zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other large drug biotech stock also have right combination element beat earning time amgen inc amgn free report earning esp zack rank company be schedule release result jul see complete list today zack rank stock here abbvie inc abbv free report have earning esp zack rank company be slate release result jul hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1701,JNJ,pacira pharmaceutical inc pcrx free report report encourage preliminary sale figure lead drug exparel preliminary number exparel sale come second quarter rise approximately year year company report daily sale grow month april june respectively compare year period growth drug sale primarily be attribute expand adoption exparel opioid pain management therapy various surgical procedure zack consensus estimate total sale include collaborative licensing milestone revenue royalty revenue exparel sale second quarter be peg preliminary result already suggest revenue beat pacira share price have increase so far begin april compare industry gain remind investor fda have approve label expansion exparel include administration nerve block prolong regional analgesia earlier april pacira partner johnson johnson jnj free report be focuse launch exparel expand indication meanwhile june pacira inked agreement china base nuance development exparel china agreement pacira receive upfront payment close transaction be eligible additional regulatory sale milestone payment pacira be develop exparel use pain management post spinal fusion various other surgery expand label pediatric patient pacira pharmaceutical inc price pacira pharmaceutical inc price pacira pharmaceutical inc quotezack rank stock considerpacira currently carry zack rank sell better rank stock same sector include acelrx pharmaceutical inc acrx free report collplant holding ltd clgn free report carry zack rank buy see complete list today zack rank strong buy stock here estimate acelrx loss have narrow past day stock have surge year date estimate collplant loss have narrow past day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1702,JNJ,fortive corporation ftv free report have sign definitive agreement acquire gordian warburg pincus cash gordian be software company provide construction facility cost datum subscription base model also offer related software service expertise wide range industry vertical solution aid management construction project workflow handle construction maintenance requirement such plan design procurement operation construction connect owner contractor conclusion deal fortive be able enhance product offering further deal enable company foray highly grow global market construction management software latest report research market particular market be expect grow cagr reportedly current total addressable market size construction software be latest move aid company reap benefit high growth potential market fortive anticipate return investment span year expand product acquisition be sync company strong focus expansion product portfolio gordian solution expand fortive field solution portfolio belong professional instrumentation segment already include robust product fluke qualitrol further complement company industrial scientific division belong industrial technology segment consequently note gordian product strengthen segment fortive notably mentioned product perform well last report quarter be expect continue drive fortive performance segment geographical region come price performance share fortive have return year date basis industry decline strategic acquisition key catalystfortive strategic acquisition partnership have play important role shape growth trajectory past few year gordian acquisition be expect be complete third quarter be likely be accretive earning be expect contribute total revenue fortive aid top line growth recently company also make bound offer acquire advanced sterilization product unit johnson johnson jnj free report help company enter global infection control market moroever fortive buyout orpak industrial scientific emaint landauer have be aid segmental regional performance quarter completion note deal continue help company gain momentum market serve better customer consequently aid customer expansion fortive corporation revenue ttm fortive corporation revenue ttm fortive corporation quotezack rank other stock fortive carry zack rank buy other top rank stock broader technology sector be te connectivity tel free report ametek ame free report stock carry zack rank see complete list today zack rank strong buy stock here long term earning growth rate te connectivity ametek be peg respectively look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1703,JNJ,reform financial demographic be pretty rampant china right now ride have be rocky economy growth drop year low last year little respite sight chinese economy expand sequentially mark weakest pace expansion first quarter also lag market expectation naturally government be adopt host accommodative measure boost economy probably part demographic reform beij be plan end decade old infamous policy pertain birth limit report bloomberg reform be expect take effect china be actually gradually ease child policy recent time china have slightly loosen policy relax limit couple partner be only child china scrap child policy altogether allow couple have child move put effect policy be expect have put birth however concern china agee population resultant shortage worker consumer prompt move china work age population drop lowest level last year also fall first time number person older rise population state council last year estimate china population cross result slow population growth decline number worker threat china economic growth state run pension program article publish reuter investor note china have long be work step domestic consumption reduce focus export intend move slower more balanced growth economy effective move be now scrapping restriction be expect translate huge demographic gain road however former division chief national family plan commission indicated scrapping birth limit have little effect tendency china decline birth decision come late investor note number birth fall loosen birth limit still expect positive move long term impact likely baby boom stock marketa expect company selling baby related good service be immediate beneficiary end policy baby related stock rally china follow news course company selling product related baby care see surge long run real estate education sector also get lift highlight stock pertain baby product gain possible reform china family plan norm procter gamble company pg free report procter gamble company be beauty hair personal care grooming health care fabric care home care baby feminine family care baby wipe diaper pant last segment notably pg derive considerable sale greater china be thus expect gain significantly change child birth policy pg have zack rank hold johnson johnson jnj free report company be renown name baby care product other health care offering huge global exposure make watch china news zack rank stock have momentum score value score growth score look china etf worldbe short long term chinese economy likely reap considerable benefit putt spotlight china etfs well read reason bet china etfs now china consumer etf chiq end birth limit translate higher consumption long term make chiq solid bet stock product offer exposure consumer sector china product have zack etf rank buy deutsche tracker harvest csi china share small cap etf ashs free report product be combination china share smaller capitalization etf attempt replicate performance csi index track small cap company shanghai shenzhen stock exchange fund currently have zack etf rank kraneshare zack new china etf kfyp free report news revolve government reform look etf related china year plan seem decent idea fund track zack new china index offer exposure company list mainland china hong kong unite state primary business business be important current year plan central chinese government read follow etfs china national congress begin want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1704,JNJ,glaxosmithkline plc gsk free report partner jnj free report announce european commission ec have grant marketing approval juluca make europe first drug hiv treatment juluca combine approve hiv drug tivicay mg edurant mg single once daily pill treatment virologically suppress hiv infectionjuluca gain approval unite state november last year generate sale first quarter tivicay novel investigational integrase strand transfer inhibitor insti be market viiv healthcare hiv company majorly own glaxo pfizer pfe free report edurant be nucleoside reverse transcriptase inhibitor nnrti market janssen pharma arm juluca have be develop partnership viiv healthcare janssen approval eu be expect march year committee human use medicinal product chmp european medicine agency ema have give positive opinion recommend approval juluca year so far share have decline glaxo have go say time frame industry have witness decline juluca first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen juluca approval be base datum phase iii sword study datum study show combination tivicay edurant antiretroviral be effective drug antiretroviral regimen maintenance therapy hiv patient have already achieve viral suppression remind investor gilead gild free report also gain fda approval single tablet hiv regimen triple therapy year biktarvy gain fda approval february year regulatory application be review eu str be fix dose combination drug bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf glaxo carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1705,JNJ,response president donald trump tweet monday pfizer inc pfe free report say defer recent price increase several prescription drug maximum end year chief executive officer ceo ian read announce decision follow extensive discussion president last week new york base company have announce increase list price several drug effective jul be second time year pfizer increase price medicine pfizer raise price medicine average be agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include january hike pfizer defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio reduce price drug first tweet monday president criticize pfizer price increase trump warn administration act response pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas latest statement read say price medicine return pre jul level soon technically possible also say price be defer president drug pricing blueprint go effect end year be sooner meanwhile price cut company remain effect tweet tuesday president appreciate pfizer decision hope other follow suit incidentally pfizer announcement price hike come only few week trump claim pharma company soon take massive price cut voluntarily however have be sign such price cut pfizer face criticism price hike be concern price hike company soon trigger market wide increase price drugmaker jnj free report merck mrk free report lilly lly free report other year so far pfizer share have increase decrease industry pfizer currently carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1706,JNJ,amgen inc amgn free report announce positive top line result late stage study evaluate safety efficacy abp biosimilar version jnj free report merck mrk free report remicade compare reference product treatment moderate severe rheumatoid arthritis ra abp be tnf monoclonal antibody datum phase iii study show abp be inferior compare remicade base primary endpoint be assessment acr week acr american college rheumatology criterium be used measure effectiveness various arthritis medicine clinical study acr score mean person ra have improve datum show be clinically meaningful difference abp remicade amgen share have gain so far year decrease register industry amgen have biosimilar product portfolio amgen biosimilar version abbvie abbv free report ra drug humira amjevita be approve fda september eu march same indication humira amjevita be first biosimilar version humira be approve fda well amgen first biosimilar medicine be approve amgen begin selling amjevita most country eu year unite state january amgen have collaborate allergan worldwide development oncology antibody biosimilar medicine biosimilar version roche avastin mvasi be already approve unite state eu biosimilar version herceptin kanjinti be review unite state eu biosimilar version rituxan abp be late stage development several amgen own drug be face biosimilar competition biosimilar be already have negative impact key product neupogen neulasta eu unite state neupogen be already face biosimilar competition other key drug neulasta epogen start face biosimilar competition year entry additional biosimilar unite state have negative impact company top line sensipar also lose patent exclusivity march generic be launch soon amgen currently carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1707,JNJ,week astrazeneca azn free report novartis nvs free report eli lilly lly free report announce regulatory pipeline update line extension market drug astrazeneca asthma drug fasenra fail meet primary endpoint late stage study evaluate expand indication chronic obstructive pulmonary disease copd lilly migraine candidate galcanezumab meet same late stage study evaluate indication prevention episodic cluster headache novartis multiple sclerosis ms drug gilenya gain fda approval use adolescent cgrp antibody aimovig also gain fda approval prevention migraine zoetis zts free report lilly announce acquisition deal recap week most important storieslilly buy small cancer biotech lilly have agree buy early phase oncology asset ak aurka pharma expand oncology pipeline lilly make upfront payment acquire share aurka pharma be lilly second cancer acquisition less week last week lilly have announce cash deal tobuy immuno oncology biotech armo bioscience read more eli lilly buy aurka pharma expand cancer pipeline development migraine candidate galcanezumab meet primary endpoint late stage study evaluate indication prevention episodic cluster headache galcanezumab be already review unite state migraine prevention decision expect third quarter year however separate phase iii study evaluate galcanezumab patient chronic cluster headache do not meet primary endpoint read more eli lilly cluster headache candidate succeed phase iii zoetis buy abaxis zoetis announce definitive agreement buy california base abaxis be lead global provider veterinary point care diagnostic instrument approximately share cash deal be aim enhance zoetis presence animal health diagnostic market diagnostic category be fast grow portion animal health industry have grow compound annual growth rate approximately last year read more zoetis inks deal acquire abaxis novartis aimovig get fda nod novartis partner amgen amgn free report gain fda approval cgrp antibody aimovig prevention migraine fda approval aimovig be now first only fda approve treatment migraine work block calcitonin gene related peptide receptor cgrp play critical role migraine attack meanwhile lilly teva pharmaceutical industry ltd teva free report be also await fda approval cgrp migraine candidate galcanezumab fremanezumab year novartis ms drug gilenya gain fda approval treatment child adolescent age relapse form multiple sclerosis approval expand patient population boost sale gilenya drug record sale first quarter represent year year growth rate constant currency basis read more novartis multiple sclerosis drug get fda nod adolescent astrazeneca fasenra fail meet endpoint phase iii copd study astrazeneca respiratory biologic medicine fasenra benralizumab fail meet primary endpoint late stage study evaluate new indication severe copd fasenra be already approve unite state eu japan add maintenance treatment patient severe eosinophilic asthma top line result pivotal phase iii galathea study show treatment fasenra do not result statistically significant reduction exacerbation compare placebo patient moderate very severe copd read more astrazeneca asthma drug fasenra fail copd study astrazeneca announce weak first quarter result miss zack consensus estimate earning sale due lower sale cholesterol drug crestor maintain previously issue outlook pfizer biosimilar retacrit get fda nod pfizer pfe free report retacrit be biosimilar version anemia drug amgen epogen jnj free report procrit gain fda approval indication reference product include treatment anemia due chronic kidney disease ckd pfizer already market biosimilar europe last year fda advisory committee have recommend approval retacrit read more pfizer get fda nod amgen anemia drug biosimilar fda name drugmaker block approval generic fda issue list company week say be used certain gaming tactic delay generic competition market drug fda say company be prevent generic player obtain necessary sample brand product be require secure approval generic drug inability secure such sample slow approval process list include big name shire novartis mylan astrazeneca teva biomarin gilead bayer other fda decision publish such list be part broader effort congress encourage approval low cost generic drug nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week decline bristol myer rise most past month glaxo gsk free report have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup lly buy cancer biotech azn roche announce update next pharma world watch fda decision many pipeline drug line extension market product month more stock news be bigger iphoneit become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1708,JNJ,dow snap record streak win traverse turbulent week trade war related concern continue weigh investor president trump express doubt success upcoming negotiation china additionally spike year treasury yield also spook market spark fresh inflationary concern such fear be also stoke encourage retail sale number last week dow increase last friday mark seventh straight session gain be blue chip index longest winning streak nov notably healthcare stock be initially follow news president trump unveil new healthcare plan however broad market re-cover later announcement be not follow stringent measure low inflation datum weak dollar also boost investor confidence equity index gain last week be blue chip index largest weekly gain march energy tech stock be major driver stock market oil price first rally last wednesday wake unite state decision exit iran nuclear deal increase fuel rally energy stock once again meanwhile apple inc aapl free report share jump celebrity investor warren buffett berkshire hathaway brk free report announce have buy share apple first quarter consequently share apple rise time high dow index gain monday increase eighth consecutive session marked blue chip index longest winning streak sep stock gain first trading day week trade fear subside president donald trump tweet sunday be consider relax stringent sanction have be impose chinese tech giant zte corp last month index lose tuesday yield year treasury note hit year high turn occur retail sale increase consecutive month raise inflationary fear moreover commerce secretary wilbur ross ambassador china terry branstad comment trade tension unite state china be far index gain wednesday reverse previous day broad base decline particular retail stock gain strong sale datum april macy inc free report first quarter earning report moreover russell benchmark index small cap stock hit time high overall most stock close green investor appear ignore concern regard rise yield government bond geopolitical tension index lose thursday president trump comment trade talk unite state china not be successful trump state be successful tend doubt ahead second round trade talk country meanwhile decline technology share negate gain make energy stock component move index home depot inc hd free report post fiscal first quarter adjust earning share escalate record year quarter figure also beat zack consensus estimate home depot have zack rank hold net sale grow year quarter however top line lag zack consensus estimate include impact adoption asu pertain revenue recognition home depot expect sale growth nearly fiscal accompany increase comp further company estimate earning share fiscal be nearly read home depot earning beat estimate sale lag walmart inc wmt free report first quarter fiscal earning share come ahead zack consensus estimate surge year year include time item earning slump cent share walmart have zack rank total revenue advanced surpass zack consensus estimate nearly currency neutral basis total revenue advanced consolidated operate income slip approximately operate income margin contract basis point constant currency basis operate income decline roughly read walmart earning sale jump online sale cisco system csco free report deliver third quarter fiscal gaap earning cent share come ahead zack consensus estimate penny further figure rise year quarter revenue increase year year marginally surpass zack consensus estimate fourth quarter fiscal revenue be expect grow year year basis zack consensus estimate revenue be peg represent year year growth gaap earning be anticipate cent cent share zack consensus estimate earning be cent translate year year growth stock have zack rank buy see complete list today zack rank strong buy stock here pfizer inc pfe free report announce fda have grant approval retacrit biosimilar version blockbuster drug amgen inc amgn free report epogen johnson johnson jnj free report procrit zack rank pfizer already market biosimilar europe retracrit be indicated treatment anemia due chronic kidney disease anemia due hiv infected patient anemia due effect concomitant chemotherapy anemia post chemotherapy drug be also approve reduction allogeneic red blood cell rbc transfusion patient undergo elective cardiac nonvascular surgery retacrit become first biosimilar erythropoiesis stimulating agent approve unite state procrit generate sale epogen sale be sale number suggest bright prospect retacrit be lower cost alternative treatment option patient used procrit epogen read pfizer get fda nod amgen anemia drug biosimilar general electric company ge free report power service business recently enter agreement saudi cement upgrade latter ge gas turbine hofuf plant base kingdom saudi arabia general electric have zack rank deal ge power upgrade turbine install advanced gas path agp solution enable saudi cement boost power output efficiency notably deal mark first installation ge power agp technology solution boost power generation productivity cement industry globally currently enable saudi cement boost power output total turbine read general electric upgrade saudi cement ge gas turbine jpmorgan chase co jpm free report want set joint venture brokerage china company be seek approval security regulator country jpmorgan have zack rank gao li spokeswoman china security regulatory commission recently state morgan broke hong kong ltd unit jpmorgan submit application acquire stake chinese security venture li also inform application be efficiently review regulator move bank come china pledge open financial market foreign investor april chinese authority release guideline give permission foreign company own maximum local security joint venture read jpmorgan seek china approval joint venture performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlookmarket have endure volatile week marked trade inflation related concern even encourage economic report such strong retail sale number have only serve fuel inflationary fear gain have only come investor have choose ignore concern next week feature crucial economic datum housing durable order encourage news front help propel stock higher day ahead more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1709,JNJ,glaxosmithkline plc gsk free report hiv company viiv healthcare announce late stage study testing drug hiv regimen dolutegravir tivicay lamivudine epivir meet primary endpoint phase iii study gemini gemini evaluate drug regimen treatment nave have not receive prior antiviral therapy hiv infected adult compare drug regimen dolutegravir tenofovir alafenamide fumarate emtricitabine study demonstrated dolutegravir lamivudine regimen be inferior standard drug regimen hiv control mean drug hiv regimen control hiv treatment nave patient effectively drug regimen share glaxo be almost thursday response positive news year so far glaxo share have gain industry decline share glaxo also receive boost week mylan myl free report application get approval generic version glaxo blockbuster respiratory drug advair be reject second time fda full result study be present future medical meeting regulatory application get drug regimen dolutegravir lamivudine approve be expect be file later year glaxo have several phase iii study ongoing evaluate drug regimen hiv treatment study conduct global research center include approximately hiv infected man woman drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen thereby reduce long term toxicity concern juluca be glaxo first only approve drug regimen gain approval eu last month unite state november last year generate sale first quarter glaxo have develop juluca partnership jnj free report juluca combine approve hiv drug glaxo tivicay dolutegravir mg edurant rilpivirine mg single once daily pill treatment virologically suppress hiv infection viiv healthcare be hiv company majorly own glaxo pfizer pfe free report japanese pharma company shinogi have minor stake viiv healthcare glaxo currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1710,JNJ,dow traverse tough week suffering loss consecutive session initially investor be wary outcome fed ecb meeting outcome meeting president trump north korea kim jong be also eagerly await ultimately talk have little impact market proceedings comment ecb be also largely welcome investor however fed rate hike lead loss bourse last week dow gain last friday investor concern related global trade war summit fade away blue chip index post third straight positive trading session close highest level march notably procter gamble co pg free report be major advancer blue chip index gain index gain last week biggest weekly gain march dow post third straight weekly advance global trade war tariff related conflict however index end lower last tuesday trade tension dent investor confidence notably dow close best single day percentage gain apr last wednesday dow index gain merely point monday investor be apprehensive outcome meeting president donald trump north korean counterpart kim jong additionally market eagerly await outcome meeting major central bank index lose point tuesday gain consecutive session notably verizon communication inc vz free report be major decliner blue chip index loss nearly however movement index be modest direction investor be closely await outcome meeting fed ecb meanwhile investor concern regard trade war geopolitical conflict wane least time be president donald trump north korea leader kim jong inked agreement denuclearize korean peninsula stop war game index decline wednesday federal reserve announce second rate hike year indicated central bank raise rate more aggressively go forward be second rate hike be line market expectation fed official now expect rate hike year compare march meeting index lose thursday financial weigh index share jpmorgan chase co jpm free report lose be largest drag blue chip index however broader market moved higher strong retail sale jobless claim number investor also welcome ecb comment program bond purchase component move index boee company ba free report recently win modification contract provide full rate production lot aircraft navy contract be award naval air system command patuxent river boee have zack rank buy majority work be carry el segundo st loui mi rest be perform various location unite state work related deal be expect be complete june read boee win navy deal aircraft merck co inc mrk free report have receive fda accelerate approval label expansion blockbuster pd therapy keytruda include advanced cervical cancer second line set company need evaluate drug confirmatory study indication gain continue approval eligible patient treatment cervical cancer be select base fda approve test pd expression tumor combine positive score cp approval come bit earlier expect date jun fda have grant priority review label expansion regulatory application march read merck keytruda get fda approval cervical cancer separate development zack rank merck announce fda accelerate approval pd inhibitor keytruda third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma read merck keytruda get fda nod lymphoma indication caterpillar inc cat free report report rise global retail sale month end deceleration rise witness april average sale growth note past month year separate development caterpillar announce board director have approve increase quarterly dividend cent share increase dividend be paid aug shareholder record jul stock have zack rank strong buy see complete list today zack rank stock here walt disney company free report avenger infinity war recently crossed gross collection globally day release debut apr only other movie avatar titanic star war force awaken have reach milestone avenger infinity war have collect jun make fifth highest gross movie domestically zack rank hold disney hold record biggest domestic debut ever open weekend internationally movie have collect notably avenger infinity war be third biggest western release ever china gross collection release country read disney avenger infinity war collect globally johnson johnson jnj free report have accept offer private equity firm platinum equity sale lifescan diabetes device unit company have announce receipt bound offer platinum equity march johnson johnson have zack rank lifescan unit make blood glucose monitoring product generate revenue last year move be line strategic plan diabetes business company have be plan streamline core asset last year part streamline effort have announce close operation corporation diabetes care unit last october read accept platinum equity offer lifescan unit exxon mobil corporation xom free report have accelerate development liza phase commence development drill offshore guyana development drill first well plan phase be initiate facilitate start production schedule liza prospect operated zack rank exxonmobil be locate mile kilometer offshore guyana stabroek block spread acre square kilometer exxonmobil co venturer have encounter estimate recoverable resource more oil equivalent barrel stabroek block read exxon mobil expedite liza phase development process performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week dow have endure difficult week thing seem be look investor geopolitical tension have be dial follow trump kim talk secondly ecb plan taper bond purchase have be welcome investor further even market moved lower fed rate hike move have be largely price meanwhile economic indicator continue remain encourage several key piece datum especially housing be line release next week most be encourage nature stock soon return winning way wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1711,JNJ,suspension controversial medical device tax year medical device industry be currently ride high optimism advame medical device industry lobbying group strongly advocate relief note tax repeal provide huge impetus company channelize turnover strategic consolidation research development also help create new job opportunity accord article publish daily news tax go effect january save device company much year suspension medical device market be undergo substantial transformation age population longer expectancy life grow healthcare awareness emerge economy combine powerful long term tailwind include merger acquisition product innovation have be contribute growth sector boom continue be yet be see far benefit tax repeal have be redirect now meanwhile accord mark bonifacio president bonifacio consult service private equity strategic oem original equipment manufacturer buyer be compete asset sector medical contract manufacturing broaden portfolio investing new technology strongly state start be sluggish respect be due uncertainty change global healthcare market fate obamacare medical device tax now doubt be gradually get clear industry be once again head year significant activity year biggest deal seem be card wall street journal latest rumore news related mammoth medtech space boston scientific bsx stryker corporation syk free report report say rival consider bid consolidation analyst seem be optimistic rumore deal believe colossal merger medtronic mdt free report covidien abbott st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space follow company consolidation st jude medical january abbott recently close acquisition alere successful wrap transaction combine company be anticipate emerge lead player point care diagnostic space mega consolidation recent time be medical device major becton dickinson co medical surgical diagnostic patient care device provider bard completion deal january becton dickinson be way expand new area vascular access segment piccs peripherally insert central catheter midline drug delivery port baxter international bax purchase thrombin topical preveleak surgical sealant specialty pharmaceutical company mallinckrodt plc mnk free report varian medical var free report also inked major deal company recently sign agreement acquire australia base global life science company sirtex medical limit total deal value investment strengthen company position interventional oncology therapy apart effort gain foothold emerge economy company recently acquire cooperative cl enterprise lead distributor radiotherapy equipment taiwan johnson johnson jnj free report subsidiary depuy synthe inked deal acquire medical enterprise distribution apart boston scientific announce several strategic acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth divestment medical device major continue offload core business line asset be similar one acquire merger focus main segment divesture have be mandate federal trade commission ftc other international trust regulator restrict chance monopoly market earlier month johnson johnson get offer fortive corporation sell subsidiary ethicon inc advanced sterilization product business unit fortive jnj accept proposal be step streamline business strategic roadmap better resource utilization higher shareholder return apart accord massdevice report medtronic recently divest stake lifetech scientific china everbright ltd unnamed investor bd also divest soft tissue core needle biopsy line aspira product line merit medical divestment be related acquisition bard april henry schein hsic announce decision spin company major segment global animal health business believe initiative remain part henry schein strategic plan focus more dental medical business accord company transaction enable make most opportunity dental space order deliver quality clinical care advanced wellness prevention apprehend china drug distribution reform slow company growth region accord reuter report cardinal health sell china business shanghai pharmaceutical hold follow announcement major buyout abbott divest eye care business abbott medical optic amo johnson johnson streamline newly add business line marketer aesthetic treatment system cynosure sell hologic notably hologic acquire outstanding cynosure share approximately emerge market healthcare scenario bright survey report gallup analytic last july reveal adult cite healthcare second major problem face country new presidential administration follow new healthcare reform announcement december gallup poll reveal past decade marked biggest increase uninsured rate meanwhile explode population rise middle class increase governmental awareness health issue emerge geography be face huge demand modern cheaper healthcare option go report guardian international finance corp ifj datum show develop country account global death chronic disease indicate enormous market opportunity recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india fifth largest medtech market world currently record annual growth pace india emerge strong competitor japan germany give huge potential region long back johnson johnson have set manufacturing center brazil china india company emerge market medical device segment continue grow time faster develop market abbott continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report fourth quarter fiscal business latin america middle east africa eastern europe china show sustain strength grow double digit overall medtronic long term outlook emerge market be encourage boston scientific emerge market business register growth first quarter reflect significant increase growth business china be once again remarkable year year key pick spacein medical instrument space be positive abiom inc abmd intuitive surgical inc isrg free report carry zack rank strong buy see complete list today zack rank stock here medical product stock baxter international surmodic inc srdx free report boston scientific orasure technology inc osur free report be also well poise zack rank buy weak linkswe advise investor stay away company offer little growth opportunity term include company estimate revision trend reflect bearish sentiment stock do not look inspiring moment be nephew plc snn tg therapeutic inc tgtx free report nxstage medical inc nxtm free report insys therapeutic inc insy free report carry zack rank sell orthofix international ofix free report eagle pharmaceutical inc egrx hold zack rank strong sell zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
1712,JNJ,week video cover company management have make key decision future respective company johnson johnson jnj free report international paper ip free report johnson johnson jnj free report have largest market capitalization healthcare company just company earning report beat top bottom line expectation earning revenue improve year year most importantly pharma segment account almost half company total revenue have sale improve earning report stock price begin fall worry increase competition generic drug negatively impact pharma sale jnj have nice pipeline new drug high expectation cancer stroke prevention medication segment be susceptible encroachment generic competitor counter threat management announce have available acquisition further management comment be not look make big splash rather be look make many smaller acquisition acquisition be expect bolster drug pipeline next several year add good news jnj recently announce accept platinum equity offer sell lifescan business diabetes treatment deal be expect close late moreover management reveal fortive corp make offer purchase advanced sterilization product business accept close early proceed sale unit be expect go acquisition pool share repurchase program be used increase dividend payment currently jnj be very unique group call dividend king company have increase dividend payment year past consecutive year company have current annual dividend yield price earning consensus grapha see graph stock price have be steady upwards trend third quarter market peaked january stock price then fall next several month due generic competition worry johnson johnson price consensus johnson johnson price consensus johnson johnson quotemany analyst have state jnj current stock price provide great buy opportunity plenty upside growth potential be due sale underperform asset acquisition power strong dividend payment overall long term outlook company be very strong international paper ip free report have be do very well past several quarters most recent earning report company beat zack consensus earning revenue estimate earning grow revenue improve revenue beat expectation be not overly impressive improve revenue management announce increase pricing company primary product printing paper cellulose fiber containerboard move be expect accelerate cash flow earning next several quarters further first month company have see box shipment improve indicate upswing pricing have not impact demand subsequent sale new cash flow be expect be funneled share repurchase initiative increase company dividend currently company have annual dividend yield new pricing power have cause analyst estimate increase next quarters fy fy see table be not time increase target price estimate have be repeatedly increase past day company currently carry zack rank buy have vgm score therefore long term outlook company be very solid medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1713,JNJ,week eli lilly lly free report announce cash deal tobuy immuno oncology biotech armo bioscience inc jnj free report multiple myeloma drug darzalex gain fda approval combination use first line set roche rhhby free report announce couple regulatory pipeline update pd inhibitor tecentriq astrazeneca azn free report sell right schizophrenia product parp inhibitor lynparza gain marketing approval eu recap week most important storieslilly expand immunotherapy pipeline armo eli lilly announce definitive agreement buy california base immuno oncology biotech armo bioscience share approximately cash deal acquisition add armo lead product candidate pegilodecakin lilly cancer pipeline pegilodecakin pegylate il be be study late stage study pancreatic cancer well early stage study lung renal cell cancer melanoma other solid tumor type armo bioscience go public january year lilly have well layer oncology strategy involve build key cancer treatment cyramza lartruvo verzenio foundational agent focuse develop new standard care change therapy combination regimen include immuno therapy armo bioscience acquisition add promising next generation immunotherapy pipeline asset lilly portfolio be line strategy transaction be expect close end second quarter darzalex get fda nod first line set multiple myeloma drug darzalexgain fda approval first line set latest approval darzalex now be prescribe combination bortezomib melphalan prednisone vmp treatment ofpatient newly diagnosed multiple myeloma be ineligible autologous stem cell transplantation theapproval first line set expect year be expect darzalex saleswill improve further go forward also announce datum phase iii study evaluate investigational compound esketamine nasal spray combination newly initiate oral antidepressant niod patient treatment resistant depression compare placebo nasal spray niod combination demonstrated statistically significant clinically meaningful rapid reduction depressive symptom treatment flexibly dose esketamine nasal spray niod compare placebo niod study adult however study conduct elderly patient age older esketamine arm witness clinically meaningful effect compare placebo arm study narrowly miss statistical significance primary efficacy endpoint result be present annual meeting american psychiatric association astrazeneca sell seroquel right luye pharma astrazeneca announce agreement sell seroquel seroquel xr treatment schizophrenia bipolar disease right uk china other international market luye pharma group total consideration be include upfront payment well certain future payment astrazeneca transaction expect close second quarter be part company effort focus main therapy area oncology cardiovascular renal metabolism respiratory sale seroquel seroquel xr have be decline drug be face generic competition november seroquel xr record sale represent year year decline astrazeneca merck parp inhibitor lynparza tablet gain euapproval use maintenance therapy platinum sensitive relapse ovarian cancer regardless patient brca mutation status approval thus expand eligible patient population lynparza approval same indication unite state be receive august last year roche tecentriq focus roche supplemental biologic license application sbla label expansion pd inhibitor tecentriq be grant priority review fda latest application roche be look get tecentriq approve combination avastin bevacizumab carboplatin paclitaxel first line treatment advanced squamous small cell lung cancer nsclc fda decision be expect sep tecentriq be presently market treatment second line metastatic nsclc label expansion first line set boost drug sale further tecentriq be also approve treatment patient suffering locally advanced metastatic urothelial carcinoma muc be not eligible cisplatin chemotherapy drug record sale chf news tecentriq roche announce late stage study evaluate drug combination cotellic heavily pre treat patient advanced metastatic colorectal cancer crc do not meet primary endpoint overall survival os compare regorafenib nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week bristol myer bmy free report decline lilly rise most past month glaxo gsk free report have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup mixed mrk pfe fda nod kymriah indication next pharma world watch fda decision many pipeline drug line extension market product month medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1714,JNJ,geron corporation gern free report share have soar past month significantly outperform industry decline stock see turnaround year fall geron be focuse develop cancer therapy base telomerase inhibitor company pipeline consist only candidate imetelstat be be develop treatment hematologic myeloid malignancy myelofibrosis mf myelodysplastic syndrome mds notably geron have collaborate johnson johnson jnj free report subsidiary janssen imetelstat geron have approve product portfolio top line solely comprise license fee royalty currently imetelstat be be evaluate mf phase ii imbark study mds phase ii iii imerge study december geron present preliminary datum part phase ii iii imerge study datum show imetelstat achieve rbc transfusion independence rbc ti reduce requirement rbc transfusion certain interval patient population have not receive prior treatment lenalidomide hypomethylating agent least week moreover geron expand part imerge enrolled additional patient refine mds population confirm clinical benefit safety observed earlier fda grant fast track designation imetelstat base datum part imerge october meanwhile clinical benefit potential overall survival benefit observed third internal review march support continuation phase ii imbark study modification however be plan amend protocol study allow long term treatment patient investor be solely banking continuation success study geron price have start rally earning release next week anticipation positive update imetelstat geron corporation price geron corporation price geron corporation quotezack rank key picksgeron carry zack rank hold few better rank stock pharma sector include protagonist therapeutic inc ptgx free report catabasis pharmaceutical inc catb free report protagonist sport zack rank strong buy catabasis carry zack rank buy see complete list today zack rank stock here protagonist loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat catabasis loss estimate narrow cent last day company come positive earning surprise precede quarters average beat stock have rally so far year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1715,JNJ,johnson johnson jnj free report have most diverse revenue stream industry pharmaceutical division account almost half revenue company have several multus dollar drug cover broad range area such neuroscience cardiovascular metabolism immunology oncology pulmonary hypertension infectious disease vaccine however several product segment be face generic competition stock have depreciate year so far compare unfavorably decline record industry domestic pharma segment sale witness positive trend second half be soft first half year be likely see positive impact trend first quarter result zack consensus estimate pharmaceutical segment be last quarter segment sale beat consensus estimate believe new product continue share gain key product label expansion drug imbruvica xarelto stelara darzalex meaningful contribution swiss biotech actelion buy june support top line continue share gain drive sale imbruvica cancer indication xarelto blood thinner zytiga prostate cancer stelara psoriasis meanwhile strong adoption newer indication crohn disease continue contribute stelara growth also gain fda approval zytiga first line set february drive sale drug higher first quarter please note market imbruvica partnership abbvie inc abbv free report also strong adoption outside market accelerate adoption unite state line therapy drive sale darzalex positive likely offset loss sale drug invokana due higher manage care discounting meanwhile biosimilar competition be expect continue hurt key arthritis drug remicade sale outside unite state market remicade partnership merck mrk free report regard newly launch tremfya say fourth quarter conference call uptake product have be decent drug record sale last quarter be expect be higher be report quarter also discuss initial sale uptake juluca call first dual treatment hiv develop partnership glaxosmithkline gsk free report gain fda approval last november juluca be review eu meanwhile expect discuss plan erleada newly approve prostate cancer drug first quarter conference call overall expect pharmaceutical segment remain strong consumer medical device segment continue improve read more begin pharma earning store carry zack rank buy see complete list today zack rank strong buy stock here johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1716,JNJ,tax filing deadline april few day away investor still have time make contribution individual retirement account ira tax year ira allow investor buy individual stock bond etfs mutual fund etfs be become increasingly popular investor due low cost transparency tax efficiency etfs be excellent tool retirement investor well provide easy way build diversify portfolio low cost further income pay etfs be better place ira income be shelter taxe investing retirement investor need assess investing goal time horizon risk tolerance read earning weight etfs tap year growth investor need remember performance investment portfolio depend mostly asset allocation investor allocate money major asset class such stock bond alternative asset cash low cost broad diversify fund be more suitable retirement investor core long term investment rather costly narrow focuse niche etfs mainly be used shorter term tactical trading vehicle expense ratio etf be important consideration retirement investing long term cheaper fund significantly outperform more expensive counterpart other thing remain same read etf way hedge portfolio volatility here be etfs be excellent long term investment retirement account ishare core total stock market etf itot free report itot be convenient way get exposure entire stock universe range smallest largest company extremely low cost just basis point hold more stock basket be core hold long term focuse portfolio apple aapl free report microsoft msft free report amazon amzn free report be top holding ishare core dividend growth etf dgro free report product hold company have history consistently grow dividend be likely continue grow dividend holding be weight dividend dollar believe company uninterrupted dividend growth record usually have solid balance sheet strong cash flow so strategy outperform market time also provide stability downside protection market downturn addition grow income stream etf doesn have lot exposure rate sensitive sector be good choice investor worry rise rate environment have low expense ratio johnson johnson jnj free report pfizer pfe free report apple aapl free report be top holding read blackrock launch gun free etfs schwab large cap value etf schv free report numerous academic study have show value stock have deliver higher return lower volatility compare growth stock long term almost market study give proven performance long term value stock fund be predominant part core portfolio schv provide broad exposure large cap stock value style characteristic have expense ratio just basis point dividend yield be quite attractive microsoft morgan jpm free report johnson johnson jnj free report be top holding ishare core msci total international stock etf ixus free report well diversify portfolio have exposure international stock ixus be excellent way get exposure large mid small cap equity international develop emerge market have low expense ratio bps hold more stock basket top holding include tencent nestle samsung want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1717,JNJ,fifa world cup russia kick thursday team usa first time be huge disappointment first time broadcast partner fox foxa free report american soccer fan wake wednesday news north america win right host world cup beating morocco here be everything need know bid economic impact company stand benefit hint fox be already celebrate north america fifa announce vote award world cup canada mexico joint bid reason here be pretty simple money north america be expect generate revenue profit fifa be huge organization make money world cup morocco reportedly couldn offer half figure soccer largest govern body be also pressure award tournament more controversial host russia qatar north american bid include host city candidate include canada mexico rest spread dalla los angele new york new jersey be city vie right host final current plan be set host match canada mexico set hold number seem little soccer fan world cup see world biggest sporting event expand field first time team total match current format north american bid note expect top game mean open game country semifinal final compare favorably super bowl ticket sale well overall hospitality figure committee project overall economic impact be roughly worth ticket sale expect company clear winner world cup bid be fox spanish language network telemundo be own nbcuniversal cmcsa free report broadcast power win television right tournament roughly combine back then somewhat quietly fifa award fox telemundo right world cup open bidding move spark outrage espn free report other network foxsport president coo eric shank north america winning bid worldcup tremendous day lot hard have paid https co nbcpi pic twitter com ysvfkbotrr fox business foxbusiness june fox reportedly only paid more current contract face be somewhat crazy move fox have not even broadcast first world cup game time know country host tournament diving little deeper answer be somewhat clear fifa didn want legal trouble fox shocking move world cup qatar be host fall winter due heat concern directly conflict nfl season other programming fox telemundo now own right world biggest sporting event home soil mean live game primetime be trully amazing opportunity likely have fox telemundo fifa marketing partner giddy medium landscape drive more more netflix nflx free report amazon amzn free report world month advert live primetime be almost invaluable current fifa world cup sponsor spend upwards year include coca cola ko free report visa budweiser bud free report mcdonald mcd free report adida addyy more say major base company now have even more incentive get world cup aside big opportunity staple nike nke be chance armour uaa break world cup scene team base sponsorship everyone youtube tv googl free report twitter twtr free report other tech company work way somehow meanwhile johnson johnson jnj free report free report other giant be current official sponsor soccer bottom line soccer have be suppose sport future host world cup today world most popular sport sit just baseball basketball american favorite sport accord gallup poll basketball be favore baseball meanwhile soccer jump highest spot ever annual poll lot change year especially money pour mls nfl rating decline hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1718,JNJ,vivus inc vvus free report report loss cent share first quarter wider loss cent report year period narrower zack consensus estimate cent quarterly revenue plunge year period mainly due lower product sale moreover company do not record license milestone payment quarter compare time payment year period vivus market drug have not be perform well steady decline sale management have take certain business initiative put company growth track include leadership transition acquisition right drug debt restructure so far year vivus share have outperformed industry stock decline period industry witness decrease quarter company weight management drug qsymia generate net product sale year period due reduction qsymia inventory wholesaler unfavorable impact change revenue recognition methodology exclude impact change revenue recognition methodology sale fall only supply royalty revenue stendra spedra be quarter due timing order selling general administrative expense be year year research development expense decrease almost report quarter company paid license fee selten pharma related acquisition tacrolimus year period exclude license cost expense increase continue development cost tacrolimus new ceoin april company announce appointment john amos new chief executive officer ceo be also add board member kenneth suh be appoint ceo scott oehrlein chief operation officer willow biopharma wholly own subsidiary vivus pancreaze acquisitionin company announce agreement janssen subsidiary johnson johnson jnj free report acquire right latter exocrine pancreatic insufficiency epi drug pancreaze unite state canada vivus have pay janssen close deal transaction be expect close second quarter pancreaze delay release capsule be approve epi inability properly digest food due lack digestive enzyme make pancreas owing cystic fibrosis other condition press release company state pancreaze cash flow be positive be expect boost vivus revenue debt enter agreement athyrium capital management new line credit issuance senior secure note note bear interest period year be interest free period note be issue successful completion pacreaze acquisition concurrently vivus repurchase athyrium convertible note face value issue earlier be due discount par objectivesvivus remain focuse improve qsymia stendra sale innovative strategy expansion new geography company be track file investigational new drug application tacrolimus develop treatment pulmonary arterial hypertension company be also focuse expand commercial portfolio acquisition cash flow positive drug vivus inc price consensus ep surprise vivus inc price consensus ep surprise vivus inc quotezack rank stock considervivus currently carry zack rank sell couple better rank stock biotech sector be ligand pharmaceutical lgnd free report enanta pharmaceutical inc enta free report ligand sport zack rank strong buy enata carry zack rank buy see complete list today zack rank stock here ligand earning share estimate moved remain stable last day company deliver positive earning surprise trail quarters average beat company share have rally year date enanta earning share estimate have significantly increase cent last day company come average beat stock have surge so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1719,JNJ,theravance biopharma tbph free report report first quarter loss share narrower zack consensus estimate loss year loss total revenue quarter surge year year upside mainly be attribute amortization upfront fee related global development agreement janssen subsidiary johnson johnson jnj free report td moreover top line surpass zack consensus estimate theravance share be follow earning release however share have underperform industry year time stock have lose compare industry decrease quarterly detailsvibativ generate revenue first quarter year period revenue collaboration be compare year earlier quarter research development expense be year period selling general administrative expense rise increase expense be due higher employee related cost stock base compensation pipeline other updatesin february theravance enter global collaboration agreement janssen jointly develop commercialize pan janus kinase inhibitor td treatment inflammatory intestinal disease phase ii study phase iib iii study be likely be initiate second half evaluate td crohn disease ulcerative colitis respectively january theravance partner mylan myl free report announce new drug application nda pipeline candidate revefenacin td have be accept fda treatment adult chronic obstructive pulmonary disease response regulatory body be expect nov company be prepare commercial launch drug potential approval company collaboration partner alfasigma velusetrag td opted acquire right candidate opt decision global right develop manufacture commercialize velusetrag be transfer alfasigma upfront fee future milestone payment royalty theravance have decide not pursue further development velusetrag part pipeline strategy outlook continue expect operate loss exclude cash share base compensation range theravance biopharma inc price consensus ep surprise theravance biopharma inc price consensus ep surprise theravance biopharma inc quotezack rank key picktheravance currently carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank strong buy stock here ligand earning share estimate moved remain stable respectively last day company pull positive earning surprise last quarters average beat company stock be so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1720,JNJ,first quarter result pharma bigwig pfizer pfe free report merck mrk free report allergan agn free report steal limelight week other novartis nvs free report gain fda approval second indication car therapy kymriah abbvie abbv free report submit regulatory application eu psoriasis candidate risankizumab merck pd inhibitor keytruda gain fda priority review status yet label expansion application recap week most important storiesmixed result merck pfizer pharma giant beat estimate earning miss same sale pfizer re affirm previously issue guidance merck raise outlook earning sale company witness relatively weaker top line performance quarter merck strong sale keytruda gardasil bridion be partially offset lower sale other key therapy rotateq zepatier zostavax meanwhile loss market exclusivity several drug also hurt top line pfizer top line be hurt decline sale key drug lyrica prevnar prevenar enbrel loss exclusivity product viagra pristiq continue supply shortage legacy hospira product allergan beat estimate earning revenue first quarter raise guidance earning sale novartis kymriah get fda approval second indication novartis supplemental biologic license application sbla look get car therapy kymriah approve second indication be grant approval fda latest approval kymriah suspension have be approve intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma more line systemic therapy include diffuse large cell lymphoma dlbcl high grade cell lymphoma dlbcl arise follicular lymphoma kymriah be first car therapy obtain fda approval august treatment patient year age cell precursor be refractory second later relapse separately novartis announce fda have give complete response letter bla propose biosimilar version roche cancer drug rituxan merck keytruda news merck supplemental biologic license application sbla look get overall survival datum phase iii keynote study include label pd inhibitor keytruda be grant priority review fda fda give decision sep study evaluate keytruda combination lilly alimta pemetrexed platinum chemotherapy cisplatin carboplatin first line treatment patient metastatic squamous nsclc regardless pd expression combination treatment improve overall survival regardless pd expression include patient tumor test negative pd notably combination therapy be grant accelerate approval fda aforementioned indication approval be base tumor response rate pfs datum keynote study hence positive readout keynote confirmatory study help company gain continue approval combo therapy support uptake sale merck also announce interim datum pivotal lung cancer study keytruda meet pre specify secondary endpoint overall response rate orr early cohort participant phase keynote study evaluate keytruda combination carboplatin paclitaxel nab paclitaxel first line treatment metastatic squamous nsclc abbvie submit application psoriasis candidate eu abbvie submit marketing application european regulatory authority investigational interleukin il inhibitor risankizumab treatment moderate severe plaque psoriasis marketing authorization application maa be support datum pivotal phase iii study datum study have show more half patient receive risankizumab achieve complete skin clearance year meanwhile abbvie also announce commencement self tender offer common stock price not less share not more share unite therapeutic acquire steadyme unite therapeutic corporation uthr free report announce definitive merger agreement steadyme ltd unite therapeutic acquire latter include contingent payment deal unite therapeutic add steadyme drug device pipeline product trevyent pulmonary arterial hypertension pah patient portfolio product have pose competition unite therapeutic remosynch implantable pump be review unite state trevyent be single use pre filled pump have be develop steadyme deliver day supply treprostinil subcutaneously used steadyme patchpump technology treat pah steadyme receive refuse file letter fda want further information steadyme intend resubmit nda end allergan ubrogepant succeed phase iii study allergan announce second pivotal phase iii study evaluate oral cgrp acute migraine treatment ubrogepant meet co primary endpoint phase iii datum show ubrogepant display strong efficacy clean side effect profile achieve ii study evaluate efficacy safety orally administer ubrogepant mg mg treat single migraine attack moderate severe headache intensity study datum demonstrated significant greater percentage patient treat ubrogepant dose be free pain hour initial dose compare treat placebo also statistically significant greater percentage ubrogepant patient take mg dose experience absence most bothersome migraine associate symptom photophobia phonophobia nausea hour initial dose compare treat placebo however mg dose fail demonstrate statistical significance endpoint seek label expansion pah drug jnj free report actelion submit supplemental new drug application snda fda seek approval label expansion pah drug opsumit macitentan include treatment patient chronic thromboembolic pulmonary hypertension cteph also announce definitive agreement acquire private biotech benevir biopharm benevir make oncolytic immunotherapy utilize proprietary stealth oncolytic virus platform have potential treatment solid nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock decline last week astrazeneca rise pfizer decline most last month glaxo be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup nvs jnj sale earning top mrk bmy active aacr next pharma world watch pipeline regulatory update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1721,JNJ,year world health day be celebrate apr world health organization have be organize event decade year be focuse make healthcare service accessible everyone theme universal health coverage everyone everywhere official int half world do not have access essential healthcare service moreover rise healthcare cost be push many person poverty organization want bring person healthcare coverage globally bid accomplish goal many philanthropic activity be carry several trust foundation globe give increase population incidence disease grow awareness healthcare coverage initiative drug sector be expect grow consequently company healthcare space be expect witness higher sale year come stock considerahead world health day suggest company investor add portfolio have choose stock carry zack rank strong buy buy vgm score stand value growth momentum have witness positive current year earning estimate revision past day market cap more see complete list today zack rank stock here plc gsk free report new product have be perform encouragingly meanwhile back back approval new product trelegy ellipta shingrix juluca have strengthen glaxo competitive position underperform broader industry glaxo share have picked year past couple month analyst have become bullish stock upward estimate revision earning glaxo earning estimate increase last day company hold zack rank have vgm score read more reason glaxo stock be great pick glaxosmithkline plc price glaxosmithkline plc price glaxosmithkline plc quoteamgen inc amgn free report newer drug prolium xgeva kyproli be perform well amgen be also progress pipeline expect approval launch migraine candidate aimovig year company restructure plan be make leaner more cost efficient amgen share have also outperformed industry year so far stock have be witness solid activity estimate revision front zack consensus estimate earning trend past day share zack consensus estimate increase same period company hold zack rank have vgm score amgen inc price amgen inc price amgen inc quotejohnson johnson jnj free report sale accelerate second half relatively softer first half backed higher sale pharmaceutical segment improve performance medical device new product segment label expansion drug imbruvica darzalex contribution recent acquisition mainly actelion be likely drive top line growth analyst have great expectation company year have be revise earning estimate upward past day earning estimate increase last day company hold zack rank have vgm score johnson johnson price johnson johnson price johnson johnson quotehorizon pharma public limit company hznp free report sale guidance be encourage company orphan rheumatology business unit have continue show strong growth moreover analyst have become increasingly bullish company past couple month upward estimate revision earning horizon pharma earning estimate increase last day company hold zack rank have vgm score read more be horizon pharma public great stock value investor right now horizon pharma public limit company price horizon pharma public limit company price horizon pharma public limit company quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1722,JNJ,biotech major amgen inc amgn free report gain fda approval include positive overall survival datum multiple myeloma late stage aspire study kyproli label final datum phase iii aspire study present july last year show triple combination regimen kyproli significantly improve overall survival os patient relapse refractory multiple myeloma overall survival datum study show patient relapse refractory multiple myeloma live month longer treat kyproli celgene celg free report revlimid lenalidomide dexamethasone krd compare treat revlimid dexamethasone rd median os month krd versus median os month rd datum also show krd reduce risk death compare rd kyproli proteasome inhibitor be already approve use combination revlimid dexamethasone patient relapse multiple myeloma overall survival datum help drive usage boost sale amgen share have gain so far year decrease register industry similar application be also review eu april committee medicinal product human use chmp european medicine agency ema grant positive opinion recommend inclusion os datum aspire study label kyproli early amgen gain fda approval include overall survival datum head head endeavor study label approval include os result aspire study kyproli label now include os datum phase iii study drive sale drug future quarters kyproli have become key revenue driver amgen drug record sale first quarter represent growth year year drive increase demand robust uptake outside market kyproli represent significant commercial potential sale be likely be drive launch additional country expansion additional indication longer duration treatment amgen also have collaboration jnj free report study combination kyproli darzalex multiple clinical study treatment multiple myeloma amgen currently carry zack rank hold better rank biotech stock be biomarin pharmaceutical inc bmrn free report zack rank buy see complete list today zack rank strong buy stock here biomarin earning share estimate increase last day average earning surprise trail quarters be company share have rise year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1723,JNJ,pfizer inc pfe free report report first quarter adjust earning share cent beat zack consensus estimate cent earning rise year year lower tax rate share count due aggressive share repurchase quarter make weaker sale performance higher cost pharma heavyweight record revenue miss zack consensus estimate revenue however rise year quarter report basis due positive impact currency change currency movement benefit pfizer first quarter revenue however operational basis exclude impact currency revenue decline year year international revenue rise operational basis revenue decline segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report basis operational basis year period ibrance eliquis do well quarter ih segment revenue be hurt lower sale enbrel lyrica prevnar prevenar meanwhile unfavorable customer buy pattern somewhat hurt sale ibrance xeljanz certain other product ibrance revenue rise quarter xeljanz sale rise lyrica sale decline eliquis alliance revenue direct sale rise chantix sale rise quarter revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare previous quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada global prevnar prevenar revenue decline higher international sale make decline unite state prevnar revenue tank unite state due lower government purchase last year pediatric indication continue decline revenue adult indication however prevenar revenue rise international market revenue consumer healthcare segment pfizer be consider selling rise global oncology revenue increase global vaccine revenue decline internal medicine decline inflammation immunology franchise decline additionally portfolio rare disease rise pfizer segment sale decline operationally revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state lyrica europe lower revenue legacy hospira product due product shortage viagra sale decline due generic competition begin december however business biosimilar emerge market do well quarter biosimilar revenue rise operationally emerge market revenue grow operationally pfizer launch inflectra biosimilar version johnson johnson jnj free report merck mrk free report blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market adjust selling informational administrative si expense decline operationally quarter adjust expense rise quarter pfizer buy back share worth include open market share repurchase accelerate share repurchase agreement execute march guidancerevenue be expect range adjust earning share be expect range mid point adjust ep be expect increase revenue be expect increase research development expense be likely be range si spending be project range adjust tax rate be expect be basis point less due expect advantage tax reform takepfizer first quarter result be mixed beat estimate earning miss same revenue meanwhile re affirm previously issue guidance share pfizer fall pre market trading lower expect sale quarter top line be hurt decline sale key drug lyrica prevnar prevenar enbrel also loss exclusivity product viagra continue supply shortage legacy hospira product hurt revenue year so far pfizer share have increase decrease industry pfizer face top line headwind form genericization key drug supply shortage legacy hospira product pricing pressure rise competition however believe new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance pfizer look well poise record profit growth pfizer also boast strong pipeline expect approximately drug approval next year include product have blockbuster potential pfizer carry zack rank buy see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1724,JNJ,design provide broad exposure total market etfs category equity market fidelity dividend etf rise rate fdrr free report be smart beta exchange trade fund launch be smart beta etfs product be base market cap weight index be strategy design reflect specific market segment market whole have traditionally dominate etf industry market cap weight index work great investor believe market efficiency provide low cost convenient transparent way replicate market return re kind investor rather try beat market good stock selection then smart beta fund be best choice fund class be know tracking cap weight strategy cap weight index try choose stock have better chance risk return performance be base specific fundamental characteristic mix other such characteristic even space provide many choice investor think simplest methodology equal weighting more complicate one fundamental volatility momentum base weighting not have be able deliver first rate result fund sponsor fund be sponsored fidelity have amassed asset make larger etfs total market etfs fee expense particular fund seek match performance fidelity dividend index rise rate fidelity dividend index rise rate reflect performance stock large mid capitalization dividend pay company be expect continue pay grow dividend have positive correlation return increase year treasury yield cost other expensescost be important factor select right etf cheaper fund significantly outperform more expensive cousin other fundamental be same operate expense annual basis be fdrr make par most peer product space fund have month trail dividend yield sector exposure top holdingseven etfs offer diversify exposure minimize single stock risk investor also look actual holding fund luckily most etfs be very transparent product disclose holding daily basis look individual holding apple inc aapl free report account total asset follow microsoft corp msft free report johnson johnson jnj free report fdrr top holding account total asset management performance riskso far year etf have lose be last year fdrr have trade past week period etf have beta standard deviation trail year period holding effectively diversify company specific risk bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
1725,JNJ,healthcare industry be enter period significant change software new technology be gradually begin revolutionize industry drug biotech company constantly strive bring differentiate high quality medicine vaccine consumer healthcare product many person possible bring successful drug market company spend million dollar several year research development activity however many candidate fail study never reach patient biotech medical research drug discovery involve significant expenditure be thus very important research landscape change major advance science technology be transform way scientist conduct research disease be likely improve diagnosis treatment future here discuss emerge technology pharma biotech industry have start adopt slowly be poise transform sector save time cost artificial intelligence machine intelligence ai be simulation human intelligence process machine especially computer system drug biotech company be analyze huge amount datum database apply artificial intelligence machine learn identify pattern way human artificial intelligence drive solution be enable pharma biotech company identify appropriate patient population reduce eliminate need study case even predict outcome virtual patient several collaboration have be form past couple year big pharma biotech player ai drive company primarily startup novel biological target molecule pharma player used ai example last year glaxo gsk free report collaborate external company exscientia uk specialist machine learn insilico medicine leader ai lead drug discovery harness ai also last year roche rhhby free report pharma arm genentech form research partnership gn healthcare power cancer drug development latter ref causal machine learn simulation ai platform astrazeneca azn free report also collaborate boston base berg last year use artificial intelligence discover novel target therapeutic treat neurological disorder such parkinson disease jnj free report pfizer pfe free report novartis nvs free report have collaboration ibm ibm free report watson health unit leverage latter ai solution application drug discovery accelerate primarily cancer research effort company pfizer glaxo carry zack rank buy see complete list today zack rank strong buy stock here artificial intelligence have be tout next big emerge technology biotech industry drastically reduce time cost take develop new life save drug significant amount time be invest identify potential disease target testing drug candidate hit target use ai be estimate drug design timeframe be cut year year also drastically reduce cost ai be relatively early stage be used biotech drug discovery other purpose broad scale adoption be expect bio printingthree dimensional printing printing be prototyp technology different material be fuse computer control create dimensional object add biology cell process become new technique bioprinting printer be used manufacture human tissue muscle well organ bone be implanted live human printing technology also know additive manufacturing be lead major innovation medicine manufacturing particularly personalize medicine compare conventional manufacturing system bioprinter offer benefit high production rate better precision accuracy reduce material wastage save cost still new pharmaceutical drug research development printing have be use medical device sector many year be mainly used make dental implant custom prosthetic first print prescription drug spritam treat epilepsy be approve fda launch unite state be make private company aprecia pharmaceutical used zip dose technology be expect printing have great potential revolutionize field drug manufacturing be used printing drug tablet personalize dosage drug different release rate printing live tissue texas base nano bioscience develop novel assay vasoactivity used core cell culture platform magnetic bioprinting partnership astrazeneca glaxo be work project decide invest printing drug internet medical thing iomt internet medical thing bring together medical device application technology procure vital datum real time chronic disease require frequent monitoring be track effectively so patient receive timely proper treatment wearable device apple watch fitbit samsung health help user achieve fitness health target well be future healthcare pharma medical device company look innovate keep technology help patient physician better monitor track disease accord report ally market research iot healthcare market reach worldwide register cagr be have potential transform healthcare industry term delivery affordability reliability pharma tech company be now take thing step further collaborate make device track chronic lifestyle associate disease diabetes be become rampant fact scope innovation area contact lense detect glucose level device monitor caloric intake bioelectronic medicine treat wide range chronic disease robotic assist surgery be seemingly endless conclusionwhile healthcare space be grow leap bound emerge technology mount concern privacy datum protection governance prevail also many ai bioprinting research company overestimate achievement something drug biotech company be wary nonetheless nascent technology hold ample promise proper execution definitely prove be trump card space today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1726,JNJ,allergan plc agn free report hungary base partner gedeon richter plc have announce positive top line result third pivotal study evaluate company schizophrenia drug vraylar cariprazine expand indication entity be look get vraylar approve treatment adult major depressive episode related bipolar disorder notably vraylar be already approve unite state eu acute therapy manic mixed episode associate bipolar disorder well schizophrenia additionally fda approve drug november expand use maintenance therapy treatment schizophrenia share allergan have inched year so far industry decrease phase iii rgh md study be investigate dose vraylar mg mg adult patient major depressive episode associate bipolar disorder bipolar depression compare placebo study meet primary well secondary endpoint vraylar mg dosage show significantly greater improvement placebo montgomery asberg depression rating scale madrs baseline week mg dose fail reach statistical significance however drug be generally well tolerate trial also note total patient vraylar treatment discontinue trial due adverse event comparison treat placebo remind investor last december allergan gedeon produce positive top line result second pivotal phase iii rgh md program examine vraylar treatment bipolar depression study also meet primary endpoint base report datum company be plan submit regulatory application fda second half allergan have licensing agreement gideon richter hungarian multinational pharmaceutical biotechnology company co develop market vraylar unite state well canada schizophrenia drug perform well record sale compare be likely be key driver allergan top line national alliance mental illness bipolar disorder be most common mental disease third most frequent cause hospitalization unite state youth adult age year moreover adult country be affected bipolar disorder hence approval drug expand indication provide company access wider patient population base suffering bipolar issue other player bipolar disorder schizophrenia treatment market include astrazeneca plc azn free report seroquel xr johnson johnson jnj free report risperdal consta plc alk free report aristada allergan plc price allergan plc price allergan plc quote zack rankallergan carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1727,JNJ,astrazeneca azn free report announce fda have approve diabetes drug bydureon exenatide extend release injectable suspension adjunctive basal insulin approval allow use drug add therapy basal insulin treat type ii diabetes patient receive more antidiabetic medicine addition diet exercise inadequate glycemic control drug be originally approve treatment october fda approve extend release version bydureon bcise patient uncontrolled diabetes treat other oral agent astrazeneca share have return so far year industry decline approval be base datum duration study evaluate bydureon add therapy insulin glargine metformin drug achieve mean reduction hba level compare placebo patient mean baseline hba moreover patient bydureon arm reach hba level less patient placebo arm however bydureon compete several other diabetes drug include johnson johnson jnj free report invokamet xr have achieve better effectiveness reduce hba level clinical study separate press release astrazeneca announce fda have grant priority review regulatory application seek approval cd recombinant immunotoxin candidate moxetumomab pasudotox biologic license application bla be submit company seek approval candidate treatment hairy cell leukaemia hcl adult patient second later line set decision fda be expect third quarter bla be submit base datum phase iii study evaluate moxetumomab pasudotox patient relapse refractory hcl datum show candidate meet primary endpoint durable complete response study press release astrazeneca partner merck mrk free report announce european medicine agency have accept marketing authorization application maa parp inhibitor lynparza seek approval metastatic breast cancer drug be already approve treat ovarian cancer eu maa include datum phase olympiad study evaluate lynparza chemotherapy patient negative metastatic breast cancer harbore germline brca mutation drug achieve significant improvement progression free survival compare chemotherapy vs month lynparza also reduce risk disease progression death maa be likely get approval ema fda have already approve lynparza similar indication january base olympiad study datum approval certainly boost prospect drug give advantage other drug parp inhibitor segment unite state eu other parp inhibitor include clovis oncology inc clvs free report rubraca tesaro zejula be approve only ovarian cancer drug be also be develop breast cancer indication astrazeneca plc price astrazeneca plc price astrazeneca plc quotezack rankastrazeneca carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1728,JNJ,shire plc shpg free report share have be rally japan base takeda pharmaceutical announce takeover intention shire stock have gain almost close mar press release issue takeda have confirm be consider possible offer buy shire boost core therapeutic area acquisition also help takeda have greater presence unite state however be certainty takeda make offer need be confirm later apr shire share have lose so far year underperform industry decline period investor be speculate bidding war follow takeda announcement previously several company have be rumore acquire shire include pfizer inc pfe free report shire have strong hold attention deficit hyperactivity disorder adhd market major revenue generator company company have drug adhd portfolio however company face competition result presence generic johnson johnson jnj free report concerta novartis nvs free report ritalin la adderall xr moreover sale shire ulcerative colitis drug lialda be also fall due generic competition meanwhile shire be also look strategic alternative neuroscience franchise include adhd portfolio drug hence shire consider offer make takeda likely create company sale tune however many analyst be skeptical impact deal takeda finance company have similar market cap also remain concern benefit add shire haemophilium portfolio takeda product line investor be likely remain focuse further announcement make takeda shire plc price shire plc price shire plc quotezack rankshire currently have zack rank hold see complete list today zack rank strong buy stock here hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1729,JNJ,equity market be go rough patch be lot uncertainty trade negotiation recent concern facebook datum breach be weigh tech sector have increase appeal dividend investing read stock etfs juicy dividend yield bother market tech freefalla day record massive gain talk negotiation china unite state relate trade market suffer huge loss lead tech stock dow jone industrial average fall moreover standard poor fall technology heavy nasdaq slide investor flocked safety social medium company be major loser recent datum debacle introduce fresh concern activity sector participant twitter inc twtr free report slump end trading mar citron research say be shorting stock owing company reliance licensing user datum moreover facebook fb free report slump further mark zuckerberg prepare testify front congress facebook have be fall follow report datum mining firm cambridge analytica firm work president trump campaign unethically obtain datum facebook user permission not be pleasant experience zuckerberg team go front congress be necessary smart strategic step facebook head beltway public fury continue grow cambridge datum leak cnbc article cite daniel ife head technology research gbh insight trade uncertainty tension washington beij be ease sign negotiation china unite state relate trade be naive sit back relax hope negotiation win have major impact global financial market owing recent volatility market allocate portion portfolio safe dividend fund seem appeal option read etfs buy trade war fear abate moreover investor expect unite state withdraw iran nuclear deal john bolton be appoint national security adviser bring back sanction iran weigh capability export crude oil market result rise geopolitical risk increase appeal dividend investing such scenario dividend pay security provide consistent income investor uniqueness security be increase return political uncertainty weigh market more so apart high dividend security exhibit less volatility be stable mature company let now discuss few etfs focuse provide exposure equity relatively high dividend yield flexshare quality dividend index fund fund seek provide exposure company provide high dividend maintain quality factor utilize constraint minimize risk have aum charge fee basis point year sector look fund have high exposure information technology financial industrial allocation respectively fund top holding be boee co ba free report pfizer inc pfe free report apple inc aapl free report allocation respectively fund have return year have lose year date have dividend yield quality dividend growth fund dgrw free report fund seek provide exposure large establish company provide high dividend apply quality screen have aum charge fee basis point year sector look fund have high exposure information technology industrial health care allocation respectively fund top holding be exxon mobil corp xom free report johnson johnson jnj free report microsoft corporation msft free report allocation respectively fund have return year have lose year date have dividend yield schwab dividend equity etf schd free report fund seek provide cheap exposure company provide high dividend have aum charge fee basis point year sector look fund have high exposure consumer staple information technology industrial allocation respectively fund top holding be intel corp intc free report exxon mobil corp procter gamble pg free report allocation fund have return year have lose year date have dividend yield have zack etf rank hold medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1730,JNJ,johnson johnson jnj free report announce fortive corporation ftv free report have offer acquire advanced sterilization product asp business unit surgical system instrument subsidiary ethicon fortive have propose bound offer aggregate value unit offer comprise cash retain net receivables have day offer plan consult various work council offer be accept transaction be expect close early asp be global leader provide offering include capital consumable software use innovative sterilization disinfection solution protect patient hospital acquire infection business unit generate sale fiscal be process streamline business part strategic roadmap better resource utilization drive shareholder return earlier march company receive bound offer private equity firm platinum equity lifescan diabetes device unit firm have offer approximately unit have already announce close corporation october share have lose so far year compare industry decrease fortive expect create global market leader potential acquisition asp have large install base very strong brand also help company expand reach attractive medical sterilization disinfection market strong growth potential fortive state acquisition be line long term strategy expect deal be accretive earning first full year operation johnson johnson price johnson johnson price johnson johnson quotezack rank stock considerj currently carry zack rank hold couple better rank stock pharma sector include lundbeck hluyy free report eli lilly company lly free report lundbeck sport zack rank strong buy lilly carry zack rank buy see complete list today zack rank stock here lundbeck earning estimate increase last day company come average quarter positive surprise company stock have gain so far year lilly earning estimate increase last day company come positive earning surprise trail quarters average beat make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1731,JNJ,johnson johnson jnj free report announce have receive bound offer approximately private equity firm platinum equity lifescan diabetes device unit lifescan unit make blood glucose monitoring product generate revenue last year stock have decline year so far compare unfavorably gain record industry have time jun offer fail expire accept offer transaction be expect close end year sale diabetes care franchise decline due price decline competitive pressure have be evaluate potential strategic option diabetes care unit specifically lifescan corporation calibra medical early last year fact october announce close operation corporation diabetes care unit exit insulin pump business stop manufacturing vibe onetouch ping insulin pump say deal medical device maker medtronic inc mdt free report patient used insulin pump be offer option transfer medtronic pump carry zack rank hold better rank large cap pharma stock include abbvie inc abbv free report pfizer inc pfe free report zack rank buy see complete list today zack rank strong buy stock here abbvie earning share estimate have moved almost last day share company have shot year pfizer earning share estimate have moved last day share price company have increase past year more stock news be bigger iphoneit become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1732,JNJ,point person life need assist medical device age have hip replacement knee replacement pacemaker current context nothing appear be more apt remark make aimee mullin american athlete consider grow prominence orthopedic industry seem prosthetic generation be indeed new market intelligence report bis research publish cision global orthopedic device market be worth be estimate be worth end cagr joint reconstruction replacement device segment be highest revenue generator north america have highest share orthopedic device market be expect lead same encouragingly asia pacific be also estimate catch cagr niche space grand view research report publish becker healthcare thus investor be keen place bet healthcare space long term gain orthopedic market undoubtedly hold immense potential here take look major factor have be drive global orthopedic industry last couple year major market moversagee populaceone major factor drive orthopedic market be age population report publish global market insight population be expect be globally poor life stylepoor eating habit smoking drink lack physical activity also drive demand orthopedic market rise healthcare expenditure unhealthy lifestyle practice expand treatment option have be drive demand report center medicare medicaid service publish advisory board healthcare spending be project rise represent gdp base assumption affordable care act continue rise incidence diabetesdiabete obesity also fuel growth market globally diabetes market be expect touch cagr transparency market research report positive tiding regulatory orthopedic market be ride high recent fda nod product launch zimmer biomet holding inc zbh free report reach new milestone field total shoulder arthroplasty recent fda approval sidusstem free shoulder system furthermore company launch vitality vital spinal fixation system unite state global launch persona partial knee system nuvasive inc nuva free report announce receipt fda clearance company precice system nuvasive specialize orthopedic nso further nephew snn free report announce full commercial release cruciate retain journey ii xr total knee arthroplasty tka unite state japan recently robotic surgery boost technology company be try expand robot rather complex surgery report technavio global orthopedic surgical robot market be estimate witness cagr view abovemention factor number bigwig be spending lump sum continuously innovate develop device improve efficacy side effect regard most noteworthy be stryker corporation syk free report mako be stryker robotic arm assist surgery platform recently stryker launch robotic arm assist total knee arthroplasty application use mako system medical device major johnson johnson jnj free report recently announce acquisition orthotaxy be privately hold developer software enabled surgery technology include differentiate robotic assist surgery solution printing technology orthopedic device company be try leverage be printing report future market insight publish cision orthopedic implant application category global print medical device market be expect be worth time frame cagr regard stryker tritanium tl curved posterior lumbar cage be print interbody fusion cage intend use aid lumbar fixation device recently win fda nod stock focuswe have select company believe be well poise give encourage prospect orthopedic market stryker corporation company have long term earning growth rate current quarter estimate revision trend stock have be encourage estimate move upward compare downward movement past month resultantly zack consensus estimate increase share company year historical growth rate be also favorable compare industry stryker share price movement past year have be favorable company yielded return almost better industry orthofix international ofix free report company have long term earning growth rate company year earning growth rate also compare favorably past month share orthofix have outperformed industry belong stock have gain compare industry rise company recently announce fda approval limit market launch forza xp expandable spacer system johnson johnson company have long term earning growth rate estimate revision current year have be solid estimate move upward compare movement opposite direction past month resultantly consensus estimate increase share company year historical growth rate also compare favorably industry share have increase past month compare favorably increase witness industry more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1733,JNJ,geron corporation gern free report report loss cent share fourth quarter be wider zack consensus estimate loss cent flat year period quarterly revenue surge year quarter revenue however miss zack consensus estimate revenue comprise royalty license fee revenue receive various imetelstat license agreement share be hour trading mar moreover so far year geron share have outperformed industry rise period compare industry gain research development expense decline due lower cost proportionate share clinical development cost imetelstat general administrative expense rise due increase stock base compensation consult cost partially offset lower legal cost company end quarter cash investment compare end third quarter resultsrevenue full year be significantly year period note revenue year quarter have include upfront payment johnson johnson jnj free report subsidiary janssen related licensing agreement company report loss cent year narrower year loss cent expense be expense be pipeline updategeron sole pipeline candidate imetelstat be be evaluate mid stage study imerge imbark myelodysplastic syndrome mds myelofibrosis mf respectively geron be conduct study collaboration december geron present preliminary datum part phase ii iii imerge study datum show imetelstat achieve rbc transfusion independence rbc ti reduce requirement rbc transfusion certain interval patient population have not receive prior treatment lenalidomide hypomethylating agent least week rbc ti be achieve patient subset least week base datum expand part study include more patient refine mds indication confirm clinical benefit safety observed earlier october fda grant fast track designation imetelstat base datum part imerge meanwhile clinical benefit potential overall survival benefit observed third internal review march support continuation phase ii imbark study modification however be plan amend protocol study allow long term treatment patient amendment be base primary analysis datum study be expect second quarter also notify geron continuation study base analysis be expect third quarter geron corporation price consensus ep surprise geron corporation price consensus ep surprise geron corporation quotezack rank stock considergeron currently carry zack rank hold better rank stock pharma sector include horizon pharma public limit company hznp free report ligand pharmaceutical incorporate lgnd free report stock carry zack rank buy see complete list today zack rank strong buy stock here horizon pharma earning estimate increase last day company deliver positive earning surprise trail quarters average beat ligand earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share be so far year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1734,JNJ,week be relatively light far development pharma sector be concern key highlight be priority review merck mrk free report keytruda advanced cervical cancer delay final datum astrazeneca azn free report key lung cancer study success abbvie abbv free report late stage study breakthrough therapy designation jnj free report cancer candidate recap week most important delay final datum mystic study final overall survival datum astrazeneca pivotal phase iii mystic study imfinzi first line lung cancer indication have be delay second half year datum be previously expect be present first half july last year study fail meet primary endpoint progression free survival read more astrazeneca final datum key lung cancer study delay merck keytruda get priority review indication merck supplemental filing look expand label pd therapy keytruda treat advanced cervical cancer have be accept priority review fda decision be expect jun be regulatory submission keytruda accept fda read more merck keytruda get priority review cervical cancer abbvie second late stage study elagolix meet endpoint abbvie neurocrine bioscience second pivotal phase iii study pipeline candidate elagolix meet primary endpoint elaris uf ii study be evaluate elagolix reduce heavy menstrual bleed premenopausal woman uterine fibroid datum study demonstrated elagolix combination low dose add back therapy reduce heavy menstrual bleed woman uterine fibroid compare placebo month read more abbvie uterine fibroid candidate succeed phase iii top line datum first study elagolix uterine fibroid be announce february study also meet primary endpoint read more abbvie uterine fibrosis candidate meet goal study cancer candidate get breakthrough therapy designation late stage pipeline candidate erdafitinib gain breakthrough therapy designation fda treatment urothelial cancer type bladder cancer read more erdafitinib get breakthrough therapy status nyse arca pharmaceutical index be marginal last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform merck emerge biggest gainer last trading session glaxo gsk free report share decline most last month astrazeneca have gain merck decline see last pharma stock roundup here mrk sign new cancer deal derm acne candidate fail next pharma world watch regulatory pipeline news pharma stock hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1735,JNJ,medical device tax suspension jan be very few amendment have garner maximum number bipartisan vote house enactment tax have be quite menace medical device industry statement advanced medical technology association lobbying group tax have significant negative impact medical innovation employment consider house place suspension tax january december only bring back jan recently house come bill tax cut include abatement infamous medical device tax medtech fraternity have be cheer latest repeal share price net margin performance medical device manufacturer be show different story let delve deeper glitzy be repeal medtech innumerable report claim repeal ramp domestic production increase hire skilled professional lower nation overdependence offshore production further medtech bigwig be expect enhance improve margin launch product reduce capital depreciation invest early stage medtech company execute clinical trial turn fuel next generation medical device industry reinvest profit tax saving notably johnson johnson jnj free report shell lump sum medical device sale tax meanwhile medical device giant stryker corporation syk free report report net earning paid approximately medical device excise tax nearly earning datum med device online report tax didn exist analyst believe company have used cash expand improve pipeline draw heavy criticism compelling democrat republican lift tax history say different storysince tax be abolish end company be expect rake profit also put impressive show bourse start however price performance margin trend contradict expectation fact tax repeal news create quite stir analyst back deal blow share medical device manufacturer datum show broader medical product industry have underperform market last year industry cut sorry figure comparison here take sneak peek net margin trend company last tax repeal single metric determine profitability business accurately investor count net margin get fair idea amount profit company be make decline net margin post tax repeal amendment throw light enormous risk cost associate compliance requirement medtech manufacturer also raise question tax repeal provide impetus medtech space do nothing significant year back stock grapple decline price net marginhere have medtech stock have witness significant margin contraction tax repeal draw attention share price net margin performance company follow tax abolition past year medtronic plc mdt free report have be observed underperform broader market latest share price movement stock lose compare unfavorably gain company have be face escalate cost expense be weigh margin also company reiteration guidance projection favorable foreign currency translation fail lift investor spirit past year henry schein inc hsic free report have underperform index stock have lose be disappoint continue deterioration company gross operate net margin thank higher cost sale expense also tough competitive landscape pricing pressure weigh stock healthcare product service distribution industry be highly competitive consist principally national regional local distributor north american dental product market company face stiff competition patterson dental business patterson company inc benco dental supply dentsply sirona inc xray free report share price movement have be disheartening past year company have lose period lackluster margin trend same time frame indicate company failure garner profit post tax repeal day comedentsply expect gross operate margin remain flat decline slightly level underlie margin rate improvement be expect be offset adverse foreign exchange target inventory equipment reduction allscript healthcare solution inc mdrx free report have underperform broader market term price past month notably stock have return compare rally further company margin have contract significantly past year allscript also expect modest increase operate expense company face sluggishness international market competition larger player bruker corporation brkr free report have underperform broader market term price past year stock have return just much lower market further company margin have decline steeply past year bruker conduct business international market result currency fluctuation continue result foreign currency transaction loss latest medtech tax overhaul paint different picture stock history repeat analysis clearly show broader industry hasn react positively tax repeal amendment be legislate consider repeal effect medtech space trend be expect continue time well however medtech industry have be favore massive change consumer behavior lately couple change market dynamic lead dramatic transformation healthcare system last couple year be evident rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model further strategic application artificial intelligence sphere healthcare provide boost productivity medtech space company have adopt ai technology witness reduction healthcare cost be expect record strong margin expansion well never know current favorable trend turn table medtech industry more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
1736,JNJ,vertex pharmaceutical incorporate vrtx free report report first quarter earning share cent beat zack consensus estimate cent come ahead year earning cent strong product revenue lead higher profit quarter vertex report revenue first quarter beating zack consensus estimate however sale be year year due significantly lower collaborative revenue company have receive upfront payment germany base merck kgaa year period licensing oncology program cf drug sale remain strongvertex first quarter revenue consist sale cystic fibrosis cf product kalydeco orkambi symdeko collaborative royalty revenue cf product revenue be first quarter year year due continuous expansion patient population kalydeco sale surge orkambi lumacaftor ivacaftor deliver sale year year growth be support continue approval expand population uptake globally quarter vertex receive approval third cf drug symdeko unite state drug have contribute top line cost riseadjust research development expense increase first quarter due higher cost related phase iii development triple combination cf regimen adjust selling general administrative sg expense increase mainly drive worldwide investment support treatment cf patient revenue guidancevertex provide guidance revenue primarily drive cf drug sale company expect revenue be range guidance combine adjust research development selling general administrative sg expense be maintain range pipeline regulatory updatesvertex remain focuse develop triple combination regimen treatment cf company have advanced next generation cftr corrector vx vx phase iii stage february fda approve symdeko treatment cf patient age older have copy del mutation have least mutation be responsive symdeko drug be review eu similar indication ongoing phase iii study be evaluate symdeko child age year similar mutation label expansion kalydeco include patient age year be review unite state well europe decision fda be expect august meanwhile vertex be also evaluate drug phase ii study treatment infant month similarly vertex be also seek approval orkambi patient age year regulatory application be review unite state europe decision expect august unite state phase iii study be initiate second half evaluate drug patient age month less month moreover january european commission approve line extension orkambi include use child cf age year have copy del mutation apart cf vertex be also develop treatment sickle cell disease thalassemia influenza pain management first quarter vertex announce positive datum phase ii proof concept study evaluate pain candidate vx acute pain follow bunionectomy surgery other phase ii study be evaluate candidate neuropathic pain pain osteoarthritis knee phase iii study pimodivir combination standard care treatment patient influenza be be conduct collaboration janssen pharmaceutical subsidiary johnson johnson jnj free report takevertex first quarter result reflect strong performance cf product help beat estimate count share rise almost hour trading response strong quarterly result robust increase share price last year vertex share price have increase so far year decrease industry vertex cf pipeline be quite strong broad portfolio next generation cf corrector approval symdeko further strengthen franchise triple combination cf regimen be consider crucial long term growth triple combo regime be successful vertex address significantly larger cf patient population almost patient future however competition be increase several major company be express interest cf vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate quotezack rank key picksvertex carry zack rank buy couple better top rank stock biotech sector be ligand pharmaceutical lgnd free report protagonist therapeutic ptgx free report company sport zack rank strong buy see complete list today zack rank stock here ligand earning share estimate moved last day company deliver positive earning surprise trail quarters average beat company share have rally year date protagonist therapeutic loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1737,JNJ,abbvie abbv free report announce top line result phase iii illuminate pcyc study meet primary endpoint improvement progression free survival pfs study evaluate cancer drug imbruvica ibrutinib combination gazyva obinutuzumab previously untreated chronic lymphocytic leukemia small lymphocytic lymphoma cll sll patient compare chlorambucil obinutuzumab year date share abbvie have increase industry decline imbruvica be jointly develop market abbvie subsidiary pharmacyclic llc johnson johnson jnj free report subsidiary janssen biotech be currently approve unite state treat patient mantle cell lymphoma mcl have receive least therapy earlier cll patient deletion be also approve european union treatment mcl significantly january imbruvica be approve patient marginal zone lymphoma mzl require systemic therapy have receive least prior cd base therapy illuminate study meet primary endpoint clinically statistically significant difference pfs patient treat imbruvica obinutuzumab versus receive chlorambucil obinutuzumab assessed independent review committee irc pharmacyclic janssen be sharing primary analysis datum study regulatory authority plan present datum future publication medical congress base datum approve fda imbruvica obinutuzumab be first chemotherapy free cd combination first line cll treatment zack rank stock considerabbvie have zack rank hold better rank stock same space be illumina inc ilmn free report ligand pharmaceutical lgnd free report illumina sport zack rank strong buy ligand carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ligand earning share estimate have be revise upward past day company come positive earning surprise trail quarters average beat company share have rally year date abbvie inc price abbvie inc price abbvie inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1738,JNJ,make debut smart beta exchange trade fund fidelity dividend etf rise rate fdrr free report provide investor broad exposure total market etfs category equity market be smart beta etfs etf industry have long be dominate product base market cap weight index strategy create reflect market particular market segment good option investor believe market efficiency market cap weight index offer low cost convenient transparent way replicate market return be investor think possible beat market great stock selection group likely invest class fund know smart beta track cap weight strategy index attempt select stock have better chance risk return performance base certain fundamental characteristic combination such characteristic smart beta space give investor many different choice equal weighting simplest strategy more complicate one fundamental volatility momentum base weighting however not methodology have be able deliver remarkable return fund sponsor indexfdrr be manage fidelity fund have amassed make larger etfs total market etfs particular fund seek match performance fidelity dividend index rise rate fee expense fidelity dividend index rise rate reflect performance stock large mid capitalization dividend pay company be expect continue pay grow dividend have positive correlation return increase year treasury yield cost other expensessince cheaper fund tend produce better result more expensive fund assume other factor remain equal be important investor pay attention etf expense ratio operate expense annual basis be fdrr make par most peer product space fdrr month trail dividend yield be sector exposure top holdingsit be important delve etf holding investing many upside kind fund diversify exposure minimize single stock risk most etfs be very transparent product disclose holding daily basis look individual holding apple inc aapl free report account total asset follow microsoft corp msft free report johnson johnson jnj free report top holding account approximately fdrr total asset management performance riskso far year etf have add roughly be last year fdrr have trade past week period etf have beta standard deviation trail year period holding effectively diversify company specific risk bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
1739,JNJ,share johnson johnson jnj free report decrease market close apr beating zack consensus estimate earning revenue be primarily due fact top selling drug remicade witness decline sale owing recent competition unite state company revenue increase year year basis first quarter come ahead consensus mark increase sale be drive primarily strong sale cancer drug favorable foreign exchange trend recent acquisition activity june jnj biggest ever acquisition buy swiss company actelion johnson johnson report gaap earning share ep first quarter year year sequential basis beat zack consensus estimate segment sale company report increase sale geographical segment sale increase year quarter international sale increase moreover business segment basis company report improvement segment consumer pharmaceutical medical device revenue increase respectively company be face headwind related sale key drug remicade zytiga certain new drug be expect make loss blood cancer drug darzalex imbruvica deliver strong sale growth quarter however company high dependence pharma segment be concern consumer medical device segment fail register attractive growth still expect adjust earning share range increase revenue guidance range expect earlier current scenario believe be prudent discuss follow etfs have relatively high exposure johnson johnson see health care etfs here health care select sector spdr fund xlv free report fund seek provide exposure healthcare stock track health care select sector index have aum charge moderate fee basis point year sector look fund have high exposure pharmaceutical health care equipment supply health care provider service exposure respectively fund top holding be johnson johnson unitedhealth unh free report pfizer pfe free report allocation respectively fund have return year lose year date xlv currently have zack etf rank hold medium risk outlook read healthy earning unitedhealth etfs watch vanguard healthcare etf vht free report fund seek provide exposure healthcare stock track msci investable market health care index have aum charge moderate fee basis point year sector look fund have high exposure pharmaceutical biotech health care equipment exposure respectively fund top holding be johnson johnson pfizer unitedhealth allocation respectively fund have return year year date vht currently have zack etf rank medium risk outlook ishare healthcare etf iyh free report fund seek provide exposure healthcare stock track dow jone health care index have aum charge moderate fee basis point year sector look fund have high exposure pharmaceutical biotech health care equipment exposure respectively fund top holding be johnson johnson unitedhealth pfizer allocation respectively fund have return year year date iyh currently have zack etf rank medium risk outlook be year chart compare performance etfs discuss jnj source yahoo financewant key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1740,JNJ,equity market be face widespread volatility thank trade negotiation recent geopolitical risk owing strike syrian chemical facility market shrug fear stem syrium attack propose sanction russia earning season be underway long term impact such factor increase appeal dividend investing read stock etfs juicy dividend yield headline market turbulence have bring portfolio reallocation back play tension washington beij have be bother market quite time now talk negotiation have be do round nothing be say certain sail market volatility allocate portion portfolio safe dividend fund seem judicious option read etfs buy trade war fear abate moreover recent chemical attack syrium have increase tension pertain russia relation recent missile strike syrian chemical plant lead coalition france have complicate situation anatoly antonov russia ambassador unite state tell wall street journal warn such action not be left consequence responsibility rest washington london paris insult president russia be unacceptable inadmissible event response russia iran syrium market take hit actual war concern instead only trade war odd happen be low be advisable safeguard portfolio such severe event be such volatile time be difficult beat algorithmic trading outlet be programme start selling merely read news headline indicate adverse event move interest rate cme fed watch tool currently forecast more rate hike many analyst believe have already be price wall street such scenario dividend pay security provide consistent income investor uniqueness security be increase return political uncertainty weigh market more so apart high dividend security exhibit low volatility be stable mature company let now discuss few etfs focuse provide exposure equity relatively high dividend yield vanguard dividend appreciation etf vig free report fund seek provide exposure company offer high dividend have aum charge fee basis point year sector look fund have high exposure industrial consumer service health care allocation respectively fund top holding be walmart wmt free report johnson johnson jnj free report microsoft corp msft free report allocation respectively fund have return year year date have dividend yield have garner inflow first week april etf com datum vanguard high dividend yield etf vym free report fund seek provide exposure large establish company provide high dividend have aum charge fee basis point year sector look fund have high exposure information technology financial health care allocation respectively fund top holding be microsoft corp jp morgan chase co jpm free report johnson johnson allocation respectively have return year have lose year date have dividend yield have garner inflow first week april etf com datum schwab dividend equity etf schd free report fund seek provide cheap exposure company pay high dividend have aum charge fee basis point year sector look fund have high exposure consumer staple information technology industrial allocation respectively fund top holding be exxon mobil corp xom free report intel corp intc free report pfizer inc pfe free report allocation respectively fund have return year have lose year date have dividend yield have garner inflow first week april etf com datum want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1741,JNJ,stock market continue winning streak second consecutive day support robust first quarter earning result strong economic datum major index close highest level month moreover index close day move average important metric calculate short term price momentum security dow jone industrial average dji close gain point index inx increase close meanwhile nasdaq composite index ixic close increase total share be trade tuesday lower last session average share advance issue outnumber decliner nyse ratio nasdaq advancer have edge decliner ratio cboe vix decline close do benchmark perform dow gain stock stock index close green stock trade red notably blue chip index close highest level mar return positive zone year first time mar increase lead gain technology select sector spdr xlk consumer discretionary select sector spdr xly sector benchmark index end positive territory gain more notably breach day move average close level first time mar tech heavy nasdaq composite also gain drive sharp increase share price netflix inc nflx free report record high level follow blockbuster result first quarter netflix also lead overall technology sector surge tuesday tech stock surge fabulous netflix result netflix first quarter earning revenue not only beat respective zack consensus estimate also rise year year read more netflix earning revenue crush estimate netflix add subscriber well consensus estimate consequently stock price increase stock touch intraday high be also week high netflix carry zack rank buy seethe complete list today zack rank stock here highly impressive result netflix have domino effect tech sector tech giant twitter inc twtr free report alphabet inc googl free report microsoft corp msft free report apple inc aapl free report amazon com inc amzn free report gain respectively earning momentum remain strongfirst quarter earning continue show broad base momentum company various sector have start declare robust result unitedhealth group inc unh free report first quarter earning revenue top zack consensus estimate company revise financial outlook adjust net earning have be raise previously project band consequently stock price rise read more unitedhealth earning revenue top view lift goldman sachs group inc gs free report first quarter earning revenue outpaced zack consensus estimate however management expect halt second quarter share buyback utilize fund future investment especially new acquisition consequently stock price drop read more goldman sachs earning impress improve trading likewise johnson johnson jnj free report first quarter earning revenue surpass zack consensus estimate management maintain previously issue adjust earning guidance fail live investor expectation result stock price fall read more top earning estimate raise sale guidance economic datum accord commerce department housing start rise seasonally adjust annual rate unit march beating consensus estimate however single family homebuilding largest component housing market fall unit march federal reserve measure industrial production rise march better consensus estimate rebound utility demand february weather related decline surge mining more offset tepid output machinery food product moreover industrial capacity use rise march reach notably march read be highest level year stock make headlinesunited continental earning beat fy view bullishunite continental holding inc ual free report report better expect result first quarter read more sm energy issue yield spending update guide sm energy company sm free report release production realize price total capital spending view first quarter read more hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1742,JNJ,strong start drug sector struggle bit next few month probably market instability few negative update pipeline regulatory front first month year january april biotech industry significantly underperform biotech industry decline compare decline however industry have bounce back past month rise better increase better expect first quarter pull biotech industry medicalsector total market cap index report result total earning company be higher revenue beating ep estimate beating revenue estimate several positive pipeline regulatory update also contribute rise acquisition strategic collaboration deal have also be rise consistently year tax reform place new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be spur merger activity fact drug biotech sector have be best perform industry stock market outlook biotech drug sector be quite positive rest year here take look stock share price have increase past month stock carry zack rank strong buy buy see complete list today zack rank stock here biomarin pharmaceutical inc bmrn free report company share price have increase past month stock carry zack rank biomarin receive fda approval pegvaliase reduce blood phenylalanine phe level pku patient be second product approval biomarin less year first be brineura mid impressive rare disease pipeline be also progress well biomarin key orphan disease drug vimizim kuvan continue do well backed strong underlie patient demand trend biomarin expect sustain growth drug ligand pharmaceutical incorporate lgnd free report company share price have increase past month company benefit numerous licensing agreement year so far ligand have enter worldwide omniab platform license agreement glenmark pharmaceutical latter be able use full omniab platform fully human mono multispecific antibody ligand also enter worldwide omniab platform license agreement fer pharmaceutical venbio partner year ligand also carry zack rank vivus inc vvus free report share price company have increase past month vivus enter agreement janssen subsidiary johnson johnson jnj free report acquire right latter exocrine pancreatic insufficiency epi drug pancreaze unite state canada be first company expect be series product acquisition design generate revenue strengthen financial position pancreaze have positive cash flow be expect boost vivus revenue company carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1743,JNJ,pfizer inc pfe free report announce fda have approve label expansion jak inhibitor xeljanz tofacitinib include new indication moderately severely active ulcerative colitis uc drug be approve treatment adult patient recommend dose mg twice daily least week approval be expect fda drug advisory committee have adopt positive vote meeting march recommend approval supplemental new drug application snda file july last year seek label expansion xeljanz uc xeljanz be already market treatment rheumatoid arthritis active psoriatic arthritis first quarter xeljanz sale be year period label expansion uc indication be likely boost sale further share pfizer have lose so far year compare decrease industry belong approval be base datum pivotal study octave induction octave induction octave sustain demonstrated statistically significant greater proportion patient achieve remission treat xeljanz compare placebo pfizer be currently evaluate xeljanz open label long term extension study octave open however be several blockbuster drug inflammatory segment approve uc include johnson johnson jnj free report remicade simponi abbvie abbv free report humira shire shpg free report lialda moreover many biotech company be develop candidate treatment uc hence competition be likely increase segment pfizer inc price pfizer inc price pfizer inc quotepfizer currently have zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1744,JNJ,dow open slightly higher wednesday morning investor look rebound brutal day trading tuesday see tech stock drop en masse international trade fear cool now stock dow fared better selloff tech heavy nasdaq suggest investor be shift sector exposure favor consumer staple industrial right now tech recent volatility seem stem combination profit take new skepticism surround internet privacy wake facebook fb free report latest datum scandal famous fang stock facebook amazon amzn free report netflix nflx free report alphabet googl free report have be worst performer still bullish tech selloff present interesting buy opportunity especially sign point strong earning season sector however be look move cash tech space lower risk play mind dow stock include plenty attractive option today check dow stock buy now traveler company inc trv free report insurance giant have exposure nearly industry key market make largest most well know brand business company be also look strong back improve earning outlook solid financial position trv full year ep estimate have trend higher recently zack consensus estimate fiscal period gain past day positive revision activity have earn stock zack rank buy meanwhile company continue be cash cow bring cash share right now trv used financial strength reward shareholder offer dividend yield insurance not be most exciting industry investor start flock cash heavy income play trv soon johnson johnson jnj free report healthcare consumer good be likely outside problem area investor be most cautious right now improve earning outlook attractive valuation make appeal bet right now zack consensus estimate jnj full year earning have gain cent past day lift stock zack rank buy jnj be also trading forward month earning represent lowest earning multiple past year company be also income pick offer dividend yield boee company ba free report boee be sell concern china target company retaliation trump latest batch tariff report official be negotiating chinese regulator cool fear say investor now scoop zack rank strong buy stock discount boee owe strong zack rank improve earning outlook company be also well position benefit encourage news instance recently learn american airline aal drop deal airbus meaning boee likely snag contract worth boee have sunk nearly past month trade negotiation go well stock rebound just fine want more market analysis author make sure follow ryan_mcqueeney twitter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1745,JNJ,abbvie inc abbv free report share have outperformed large cap pharma industry past month stock have return timeframe industry decline abbvie outperformance be backed decent quarterly result optimistic outlook stronger underlie business performance rest year positive pipeline news flow regulatory update be repute name pharmaceutical sector abbvie come existence jan abbott laboratory free report divest pharmaceutical divisionhere be reason invest stock favorable rank earning surprise record abbvie have zack rank buy see complete list today zack rank strong buy stock here have be consistently beating earning expectation earning surpass expectation last quarters average positive surprise company be expect record earning sale growth respectively meanwhile estimate increase respectively past day valuation look reasonable outperformance abbvie valuation look fairly reasonable currently abbvie currently have forward month price earning ratio be lowest level past year compare highest level median level past year be apparently upside left space also look inexpensive compare industry current well median ratio industry be respectively price earning forward month chart key drug humira go strong abbvie flagship product humira be approve several inflammatory indication rheumatoid arthritis humira continue witness strong demand trend launch drug new mechanism action competition indirect biosimilar currently approve indication humira sale have increase consistently backed robust demand trend product continue see strong growth dermatology market company expect humira sale approach biosimilar version humira be already approve fda settlement amgen amgn free report samsung bioepis biosimilar entry unite state be set thus delay direct biosimilar competition country strong oncology portfolio abbvie work rigorously expand accelerate presence oncology key drug oncology portfolio be imbruvica be currently approve quite few indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease several study imbruvica be ongoing evaluate drug alone combination different patient segment abbvie expect imbruvica peak sale more revenue abbvie have develop imbruvica partnership jnj free report abbvie be also study cancer drug venclyxto venclexta expand label address broader relapse refractory chronic lymphocytic leukemia cll patient population expand earlier line therapy broaden other hematologic malignancy multiple myeloma acute myeloid leukemia june regulatory application seek approval combination venclexta roche rhhby rituxan relapse refractory cll be approve unite state label expansion include broader patient population boost venclexta commercial potential meanwhile acquisition drugmaker stemcentrx add key late stage candidate rovalpituzumab tesirine rova abbvie portfolio rova be currently registrational study first second line small cell lung cancer sclc phase arm basket study rova neuroendocrine tumor be also ongoing promising pipeline abbvie have deep pipeline consist several interesting late stage candidate promising candidate include elagolix endometriosis risankizumab inflammatory disease depatux glioblastoma multiforme abbv early alzheimer disease progressive supranuclear palsy psp upadacitinib inflammatory disease company expect move tumor candidate clinical development several pivotal datum readout regulatory milestone be expect second half year include fda decision risankizumab elagolix regulatory application mavyret perform expectation abbvie week pan genotypic ribavirin free once daily hepatitis hcv treatment mavyret gain approval unite state eu canada japan mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor mavyret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history mavyret perform expectation first year launch record sale almost positive sale trend continue drug record sale first quarter less year market mavyret already command share unite state conclusion abbvie face share challenge form slower sale hcv drug potential biosimilar competition humira regular pipeline setback rise competition however believe abbvie be well position overcome headwind today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1746,JNJ,johnson johnson jnj free report announce fda have grant breakthrough therapy designation late stage pipeline candidate erdafitinib treatment urothelial cancer type bladder cancer designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient benefit patient current treatment option designation erdafitinib be primarily base efficacy finding phase ii study evaluate advanced urothelial cancer indication show overall response rate stock decline year so far compare unfavorably gain record industry urothelial cancer start urothelial cell line bladder be usually characterize serious outcome due often rapid progression tumor lack efficacious treatment be sixth most common form cancer unite state be estimate more new case bladder cancer be diagnosed year press release have robust pipeline company expect launch file approval more new blockbuster product company be target more line extension exist new drug well help lessen impact genericization key product pharma portfolio key late stage candidate company pipeline include esketamine treatment resistant depression niraparib prostate cancer imetelstat myelofibrosis other regulatory filing unite state esketamine be expect niraparibis expect next year please note imetelstat be be develop partnership geron corporation gern free report important new drug guselkumab tremfya be approve last year plaque psoriasis also first dual treatment hiv juluca dolutegravir rilpivirine receive approval unite state november last year candidate be review eu juluca have be develop partnership viiv healthcare hiv company majorly own glaxo gsk free report pfizer pfe free report meanwhile symtuza darunavir base once daily single tablet regimen treatment hiv be review unite state symtuza be approve eu september last year carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1747,JNJ,last week senator tina expressed concern big pharma company plan use large corporate tax saving reward shareholder instead bring cost expensive drug benefit consumer senator question letter ceo big pharma company pfizer pfe free report merck mrk free report johnson johnson jnj free report abbvie abbv free report abbott lab free report plan use extra cash please note conference call hold earlier year most big pharma company discuss plan do extra cash save new tax bill company plan invest extra cash capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback not many talk take step lower prescription drug cost apart key announcement week include failure dermira inc derm free report acne candidate pivotal late stage study merck oncology collaboration japan eisai expansion jardiance clinical study eli lilly lly free report fda committee back pfizer xeljanz third indication recap week most important storiesdermira share sink acne candidate fail share dermira plunge announce acne candidate olumacostat glasaretil surprisingly fail meet primary endpoint pivotal phase iii study clareo clareo company say likely stop olumacostat glasaretil development follow failure read more dermira acne candidate fail pivotal trial share sink merck jointly develop eisai cancer drug lenvima similar last year profit sharing deal astrazeneca azn free report merck announce oncology collaboration japan eisai co ltd deal company jointly develop commercialize eisai tyrosine kinase inhibitor lenvima monotherapy combination merck pd therapy keytruda several type cancer deal merck give eisai upfront payment company share global development marketing cost well gross profit lenvima equally read more merck pay upfront co develop eisai cancer drug pfizer xeljanz snda get fda committee back pfizer supplemental new drug application include ulcerative colitis uc indication label receive back fda advisory committee fda drug advisory committee gidac vote unanimously favor jak inhibitor fda decision be expect june xeljanz be already approve treat rheumatoid arthritis active psoriatic arthritis record sale represent growth year year astrazeneca look forxiga eu approval type diabetes astrazeneca application look get sglt inhibitor forxiga approve new indication oral adjunct treatment insulin type diabetes patient be accept european medicine agency forxiga be presently approve monotherapy well combination therapy treat type diabetes approve forxiga become first sglt inhibitor approve europe treatment oral treatment adjunct insulin read more astrazeneca forxiga label expansion filing accept eu glaxo present asthma hiv datum glaxo gsk free report present datum osmo study new respiratory medicine nucala american academy allergy asthma immunology aaaai world allergy organization wao joint congress orlando datum study show patient asthma be uncontrolled xolair witness improve asthma control switch glaxo new respiratory medicine nucala glaxo also present interim datum phase iiib study inspiring investigational hiv candidate dolutegravir medical conference boston read more glaxo encourage asthma hiv datum medical meeting meanwhile glaxo gain approval expand european label once daily laba ics combination treatment relvar ellipta now relvar ellipta be used eu patient asthma be already adequately controlled ics laba label update doctor prescribe asthma patient switch once daily relvar ellipta current twice daily ics laba experience comparable benefit lung function safety profile lilly boehringer expand jardiance clinical study lilly partner boehringer ingelheim announce plan initiate phase iii emperial study evaluate effect lilly sglt inhibitor jardiance exercise ability heart failure symptom person chronic heart failure irrespective have type ii diabetes presently ongoing phase iii emperor outcome study be evaluate effect jardiance long term morbidity mortality outcome person heart failure emperial study investigate treatment jardiance help improve everyday life person live chronic heart failure read more lilly boehringer expand jardiance heart failure program nyse arca pharmaceutical index be last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session major stock rise largest gainer be glaxo lilly last month bristol myer bmy free report gain merck decline see last pharma stock roundup here azn imfinzi get fda nod mrk buy australian firm next pharma world watch regulatory pipeline news pharma stock don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
1748,JNJ,share bristol myer squibb company bmy free report fall investor be not much impressed company initial result phase iii study checkmate study be evaluate opdivo mg kg low dose yervoy mg kg combination first line advanced small cell lung cancer nsclc patient high tumor mutational burden tmb mutation megabase mut mb combination demonstrated superior benefit co primary endpoint progression free survival pfs versus chemotherapy initial result show year pfs rate be more triple combination versus chemotherapy vs overall response rate combination be chemotherapy arm responder have ongoing response year chemotherapy grade treatment related adverse event rate opdivo low dose yervoy combination be versus chemotherapy result be encourage investor be disappoint merck mrk free report keytruda seem have fared better opdivo yervoy combination merck announce result phase iii study keynote evaluate pd therapy keytruda combination pemetrexed alimta cisplatin carboplatin first line treatment metastatic nonsquamous nsclc result show keytruda pemetrexed platinum chemotherapy combination significantly improve overall survival os reduce risk death half compare chemotherapy alone consequently share bristol myer decline first line nsclc market competition be stiffening quite few company try capture additional market share share company have gain only past year underperform industry growth concurrently bristol myer announce obtain fda approval opdivo yervoy injection intravenous use first immuno oncology combination therapy previously untreated patient intermediate poor risk advanced renal cell carcinoma phase iii trial checkmate demonstrated significant unprecedented increase os abovemention combination patient population compare current standard care pfizer pfe free report sutent moreover opdivo demonstrated sustain os advantage standard care patient recurrent metastatic squamous cell carcinoma head neck checkmate patient treat opdivo experience reduction risk death year minimum follow note opdivo be currently approve several country include unite state eu japan several cancer indication opdivo continue be launch globally approval label expansion drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc label expansion additional indication give product access higher patient population increase commercial potential drug significantly bristol myer announce worldwide collaboration johnson johnson jnj free report janssen pharmaceutical inc janssen factor xia fxia inhibitor program include development former factor xia fxia inhibitor bms note bms investigational anticoagulant compound be be evaluate prevention treatment major thrombotic condition company be expect advance bms phase ii trial second half study secondary stroke prevention zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1749,JNJ,strength earning season least early stage have help bolster market index continue ahead tuesday market open well dow future look loss push back green first time roughly week ahead today open bell new housing start permit result march have hit tape see seasonally adjust annualize read new start last month estimate february start be revise originally report today multus family unit be stronger expect last month single family housing start have be carry load recent time fall region midwest see gain northeast south west take step backward permit forward indicator future housing start multus family home spiked suggest continuation multus family home strength earning highlightswhile await earning report bell today ibm unite continental other ahead bell see result key big name industry line outperformed expectation wall street major goldman sachs gs free report follow strength late last week other big bank post earning share expect well strongly year share revenue reach easily surpass expect year quarter more gs earning click here zack rank hold rate johnson johnson jnj free report top earning estimate cent share quarterly sale reach outpace expect zack consensus pharmaceutical rise quarter year year share be more today pre market more jnj earning click here unitedhealth unh free report have be carry zack rank sell rating go morning earning report also surprised upside share beat zack consensus have be expect revenue narrowly top estimate healthy subscription growth year year more unh earning click here
1750,JNJ,tuesday april strength earning season least early stage have help bolster market index continue ahead tuesday market open well dow future look loss push back green first time roughly week ahead today open bell new housing start permit result march have hit tape see seasonally adjust annualize read new start last month estimate february start be revise originally report today multus family unit be stronger expect last month single family housing start have be carry load recent time fall region midwest see gain northeast south west take step backward permit forward indicator future housing start multus family home spiked suggest continuation multus family home strength earning highlightswhile await earning report bell today ibm unite continental other ahead bell see result key big name industry line outperformed expectation wall street major goldman sachs gs free report follow strength late last week other big bank post earning share expect well strongly year share revenue reach easily surpass expect year quarter more gs earning click here zack rank hold rate johnson johnson jnj free report top earning estimate cent share quarterly sale reach outpace expect zack consensus pharmaceutical rise quarter year year share be more today pre market more jnj earning click here unitedhealth unh free report have be carry zack rank sell rating go morning earning report also surprised upside share beat zack consensus have be expect revenue narrowly top estimate healthy subscription growth year year more unh earning click here mark vickerysenior editorquestion comment article author click here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1751,JNJ,powershare dividend achiever portfolio pfm free report be launch be passively manage exchange trade fund design offer broad exposure large cap value segment equity market fund be sponsored invesco powershare have amassed asset make average size etfs attempt match large cap value segment equity market large cap valuelarge cap company typically have market capitalization overall be usually stable option less risk more sure fire cash flow mid small cap company value stock be know lower average price earning price book ratio investor also note lower average sale earning growth rate value stock have outperformed growth stock nearly market consider long term performance growth stock be more likely outpace value stock strong bull market costssince cheaper fund tend produce better result more expensive fund assume other factor remain equal be important investor pay attention etf expense ratio annual operate expense etf be make more expensive product space have month trail dividend yield sector exposure top holdingseven etfs offer diversify exposure minimize single stock risk investor also look actual holding fund luckily most etfs be very transparent product disclose holding daily basis etf have heaviest allocation consumer staple sector portfolio industrial information technology round top look individual holding exxon mobil corp xom free report account total asset follow microsoft corp msft free report johnson johnson jnj free report top holding account total asset management performance riskpfm seek match performance nasdaq broad dividend achiever index fee expense nasdaq broad dividend achiever index be design identify diversify group dividend pay company have increase annual dividend more consecutive fiscal year etf have lose so far year be last year past week period have trade etf have beta standard deviation trail year period make medium risk choice space holding effectively diversify company specific risk dividend achiever portfolio carry zack etf rank hold be base expect asset class return expense ratio momentum other factor thus pfm be good option seek exposure large cap etfs area market investor also want consider other etf option space ishare russell value etf iwd free report vanguard value etf vtv free report track similar index ishare russell value etf have asset vanguard value etf have iwd have expense ratio vtv charge bottom linean increasingly popular option retail institutional investor passively manage etfs offer low cost transparency flexibility tax efficiency be also excellent vehicle long term investor learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
1752,JNJ,pass new tax bill corporate tax rate have come be likely boost profit margin moreover cash repatriation window allow bill help company bring cash stash foreign location time tax rate leave company extra spending power most big pharma company discuss plan use extra cash save new tax bill fourth quarter conference call extra cash mostly be invest capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback however majority company do not mention effort regard lower prescription drug cost last week senator tina letter big pharma company expressed concern big pharma company plan used billion dollar save tax cut offer tax bill pass december be concern fact company be favore investor instead used saving bring prescription drug cost major life save drug be protected patent be steeply price thus make drug affordable help consumer lower medical cost senator have send letter ceo pfizer inc pfe free report merck co inc mrk free report johnson johnson jnj free report abbvie inc abbv free report abbott laboratory free report provide detail intend utilize major saving tax overhaul price major prescription drug have sky-rocket past year pinch hard citizen medical bill have soar moreover government also have pay higher cost drug be cover medicare concern senator be thus justified move restrict use tax saving boost shareholder be welcome move consumer moreover large player other industry have similar plan have undercut president donald trump plan create job boost wage senator be also work make cheaper generic drug available market faster introduce new legislation report kdal large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returndon even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
1753,JNJ,theravance biopharma tbph free report report fourth quarter loss share wider zack consensus estimate loss year loss total revenue quarter plunge year year compare prior year figure downside mainly be attribute lower sale company sole market product vibativ telavancin however top line surpass zack consensus estimate theravance share be more feb hour trading follow earning release report wider loss moreover share have underperform industry year time stock have lose versus industry increase quarterly detailsvibativ generate revenue fourth quarter year period sale decrease mainly due impact generic competition unite state revenue collaboration be compare year earlier quarter research development expense be year period mainly due increase employee related cost advancement company priority pipeline program partially offset reduction external expense selling general administrative expense rise primarily higher employee related cost resultsfull year sale slump year year however number beat zack consensus estimate full year loss share be wider year tally loss be also wider consensus mark loss pipeline other updatesearlier february theravance enter global collaboration agreement janssen subsidiary johnson johnson jnj free report jointly develop commercialize pan janus kinase inhibitor td treatment inflammatory intestinal disease pursuant mentioned contract theravance be entitle receive upfront payment be also eligible get potential payment remain collaboration completion phase ii activity also january theravance partner mylan myl free report announce new drug application nda pipeline candidate revefenacin td have be accept fda treatment adult chronic obstructive pulmonary disease response regulatory body be expect nov nda acceptance be support positive datum replicate pivotal phase iii efficacy study single month open label active comparator safety trial october company report positive datum phase iii evaluation project operate loss range theravance biopharma inc price consensus ep surprise theravance biopharma inc price consensus ep surprise theravance biopharma inc quote zack rank key picktheravance carry zack rank hold better rank stock health care sector be regeneron pharmaceutical regn free report sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1754,JNJ,johnson johnson jnj free report have most diverse revenue stream industry pharmaceutical division account almost half revenue company have several multus dollar drug cover broad range area such neuroscience cardiovascular metabolism immunology oncology pulmonary hypertension infectious disease vaccine however many peer be face generic competition pricing pressure product pharmaceutical segment stock have depreciate year so far compare unfavorably decline record industry pharma segment sale picked second half be soft first half be likely see positive impact trend second quarter result zack consensus estimate pharma segment sale be believe new product continue share gain key product label expansion drug imbruvica xarelto stelara darzalex meaningful contribution acquisition support top line continue share gain drive sale imbruvica cancer indication xarelto blood thinner zytiga prostate cancer stelara psoriasis please note market imbruvica partnership abbvie abbv free report zack consensus estimate total imbruvica sale be strong adoption witness newer indication crohn disease continue contribute stelara growth zytiga be approve first line set february contribute strong performance drug first quarter trend expect continue second quarter also strong adoption outside market accelerate adoption unite state line therapy be likely drive sale darzalex importantly darzalex be approve first line set add significantly sale second quarter positive offset loss sale drug invokana due higher manage care discounting market share decline due competitive pressure meanwhile biosimilar competition be expect hurt sale key arthritis drug remicade outside unite state please note market remicade partnership merck mrk free report zack consensus estimate total remicade sale be note inventory build seasonality issue hurt sale xarelto first quarter remain be see issue persist second quarter well regard newly launch tremfya say first quarter conference call uptake product have be strong drug record sale first quarter be expect be higher be report quarter meanwhile expect discuss initial sale number erleada newly approve next generation oral androgen receptor ar inhibitor prostate cancer second quarter conference call overall second quarter sale pharmaceutical segment be expect remain strong consumer medical device segment continue improve read more set pharma earning motion currently carry zack rank hold better rank large cap pharma stock be lundbeck hluyy free report sport zack rank strong buy see complete list today zack rank stock here share lundbeck have gain year so far earning estimate have go past day medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1755,JNJ,biggest news week be pfizer pfe free report announcement plan re organize business new segment effective next year jnj free report be order st loui jury pay approximately nearly dozen woman lawsuit related talc base product merck mrk free report abbvie abbv free report bristol myer bmy free report provide update cancer drug pfizer re organize business unit pfizer be re organize business business segment separate consumer healthcare business standalone unit begin pfizer report new business unit innovative medicine establish medicine consumer healthcare presently pfizer have report segment namely innovative health essential health present innovative health unit be call innovative medicine unit now include biosimilar new hospital business unit infective sterile injectable be presently report essential health essential health unit now be rename establish medicine unit include pfizer legacy brand have lose lose market exclusivity read more pfizer reorganize business new unit pay talc lawsuit be order jury st loui court pay damage woman allege talc base product include baby powder contain asbestos cause develop ovarian cancer damage comprise compensatory damage punitive damage official statement say verdict be unfair appeal also say talc product neither contain asbestos cause cancer face more case talc product trump slam pfizer price hike pfizer defer increase tweet president donald trump slam pfizer raise price several prescription drug effective jul trump say pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas warn administration respond day tweet be publish pfizer issue statement say defer price increase president drug pricing blueprint go effect end year be earlier abbvie imbruvica lymphoma study fail abbvie announce late stage study evaluate cancer drug imbruvica first line treatment diffuse large cell lymphoma dlbcl fail meet primary endpoint study evaluate addition imbruvica chop combination rituximab doxorubicin vincristine prednisone be exist standard care dlbcl aggressive form hodgkin lymphoma nhl versus chop placebo however study datum show add imbruvica chop do not improve event free survival ef target patient population imbruvica be presently fda approve indication include cell blood cancer well chronic graft versus host disease drug abbvie market partnership record sale first quarter include sale international profit sharing abbvie also file supplemental new drug application snda fda label expansion venclexta venetoclax first line treatment acute myeloid leukemia aml abbvie be look get venclexta approve combination hypomethylating agent hma low dose cytarabine ldac aml patient be ineligible intensive chemotherapy read more abbvie imbruvica fail phase iii blood cancer study merck keytruda sbla get priority review merck supplemental biologic license application sbla look expand label keytruda previously treat patient advanced hepatocellular carcinoma hcc most common type liver cancer be grant priority review fda fda decision be expect nov sbla filing be base datum phase ii keynote study read more merck keytruda get fda priority review liver cancer bristol myer opdivo yervoy combo get fda nod colorectal cancer bristol myer announce accelerate approval combination immuno oncology drug opdivo yervoy type colorectal cancer combination be now approve previously treat patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer opdivo yervoy combination be also approve other tumor type first line treatment intermediate poor risk advanced renal cell carcinoma unresectable metastatic melanoma read more bristol myer combo drug get fda nod colorectal cancer cti biopharma slump study failure share cti biopharma ctic free report slump monday pivotal study evaluate combination regimen cancer drug pixuvri hodgkin lymphoma fail improve progression free survival pixuvri have conditional approval europe monotherapy treatment multiply relapse refractory aggressive cell nhl however be yet receive approval unite state read more cti biopharma fall failure pivotal lymphoma study nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record increase last week astrazeneca azn free report gain most past month glaxo have be biggest gainer jnj free report decline most see last pharma stock roundup here pharma stock roundup nvs divest eye care unit chmp give nod several drug next pharma world watch earning bigwig pharma world later month begin jul medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1756,JNJ,big bank be start second quarter earning season week result pharma giant be due next few week make good time shift attention report cycle tariff concern trade wo be concern pharma company revenue be generate foreign market overall earning number be expect be upbeat healthcare sector have jump last month better rally sign sector success become more evident last month nyse arca pharmaceutical index nasdaq biotechnology index gain respectively johnson johnson jnj free report novartis ag nvs free report schedule report jul jul respectively be good time figure be better stock stock carry zack rank hold see complete list today zack rank strong buy stock here other major earning schedule next week include unitedhealth group incorporate unh free report microsoft corporation msft free report price johnson have see gain last month novartis have advanced so johnson johnson be winner respect better return rival novartis broader industry rise same period most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major novartis ev ebitda value be overvalue compare broader industry have valuation however johnson johnson hold edge novartis industry here lower ev ebitda value dividend yieldover year johnson johnson novartis have offer dividend yield respectively industry dividend yield be industry dividend yield be slightly higher pharma giant individual stock johnson johnson have take lead here too net marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention allegedly exorbitant drug pricing help sector maintain steep margin net margin value novartis underperform bigger rival johnson johnson have net margin value broader industry net margin value be equal johnson johnson return equityreturn equity roe be key financial ratio pharma company entity employ huge amount capital bring product market respect used roe help evaluate company ability generate ample profit equity capital broader industry have roe come stock johnson johnson roe be clearly advantage industry novartis have roe earning history esp estimate more comprehensive earning history johnson johnson have deliver positive surprise quarters average earning surprise other hand novartis have deliver positive surprise prior quarters average earning surprise consider earning esp johnson johnson have esp novartis have esp johnson johnson earning estimate current year have increase last day same metric novartis have decline conclusionour comparative analysis show novartis hold edge johnson johnson consider only earning history however consider price performance valuation roe net margin johnson johnson be advantage novartis additionally johnson johnson also have better dividend yield novartis more comprehensive look estimate revision johnson johnson be clearly better stock clinch case favor johnson johnson point time be have better esp be lead indicator likely positive surprise be be wise bet johnson johnson novartis prepare report earning next week medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1757,JNJ,pfizer inc pfe free report be reportedly raise price almost drug effective july be second time drug giant have raise price drug year scrutiny drug price have increase trump assume office however softer drug pricing policy form last month expect other company follow suit increase price be nearly majority drug agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include price hike january trump announce plan control drug price unite state however group investor believe plan be not likely have major impact profit large pharma company instead include provision direct negotiation medicare pharma company trump target intermediary certain small pharma company foreign country thus medicare be major customer drug pay nearly dollar value prescription filled medicare have negotiate lower price directly manufacturer president also expect increase competition streamline approval related regulatory process promote faster approval generic biosimilar plan allow more substitution addition medicare drug list single source generic contain price rise give sponsor more negotiation power manufacturer also instruct company display list price advertising plan also focus more transparency related pricing availability generic moreover announcement price hike pfizer come week trump claim pharma company take massive price cut voluntarily soon pfizer have defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio also reduce price drug meanwhile price hike company soon trigger market wide increase drug price thus pfizer move again stir opposition related drug price rise especially large pharma company pfizer stock price several other large cap pharma company moved north jul include johnson johnson jnj free report eli lilly company lly free report abbvie inc abbv free report rise drug price certainly help company boost profit so far year large cap pharma industry have decline rise expect investor remain focuse other pharma company announcement related drug price subsequent move government restrict further hike look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1758,JNJ,johnson johnson jnj free report kick pharma earning strong note beating zack consensus estimate count first quarter drug consumer product giant up previously issue sale outlook share be pre market trading year so far share have decline compare unfavorably decline witness industry earning beatj first quarter earning come share beating zack consensus estimate increase year period adjust earning exclude amortization expense special item include item report first quarter earning share compare earning year period sale beat slightlysale come beating zack consensus estimate sale also increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis better increase see be pharmaceutical segment continue positive momentum see second half consumer segment sale improve first quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow operational increase new product imbruvica cancer darzalex multiple myeloma continue perform well core product xarelto stelara zytiga simponi simponi aria invega sustenna also contribute growth please note market imbruvica partnership abbvie inc abbv free report organically exclude impact acquisition divestiture sale increase operational basis slightly less growth see previous quarter quarter record pulmonary arterial hypertension pah revenue less previous quarter acquisition swiss biotech actelion june last year diversify revenue pah category add sale growth first quarter however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report be quarter sale decline however international sale rise biosimilar competition pharma segment achieve clinical milestone quarter include fda approval prostate cancer drug erleada treatment man metastatic castration resistant prostate cancer line extension already market prostate cancer drug zytiga combination prednisone first line set medical device segment sale come year period include operational increase positive currency movement domestic market sale rise year year international market sale increase operational increase year year consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market rise year period meanwhile international segment record increase reflect operational increase positive currency impact outlook maintain previously issue earning guidance increase sale range still expect adjust earning share range reflect operational growth rate however now expect revenue range higher reflect operational constant currency sale growth rate range previously quite few key product portfolio remicade concerta face generic competition believe new product plaque psoriasis drug tremfya guselkumab cancer drug darzalex imbruvica zytiga currency tailwind contribution acquisition help deliver strong sale profit first quarter year lead raise sale outlook whole year fact be quite confident pharma segment continue perform better market year impact biosimilar remicade sale tell chief financial officer dominic caruso bloomberg meanwhile announce global supply chain initiative annually save approximately pre tax cost meanwhile alex gorsky chairman chief executive officer say company invest more capital investment unite state next year new tax law leave extra cash hand large pharma company allow invest innovation capital build zack rank stock considerj carry zack rank hold johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotea better rank stock be pfizer inc pfe free report have zack rank buy see complete list today zack rank strong buy stock here share pfizer have gain year so far breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1759,JNJ,johnson johnson jnj free report bellwether healthcare company have strong presence pharmaceutical medical device consumer care market world new jersey base company be well know baby care product brand tylenol addition drug remicade concerta however many peer jnj be face generic competition pricing pressure product pharmaceutical segment scenario investor focus remain late stage pipeline candidate commercial potential well performance new product apart usual top bottom line number jnj have pretty good earning track record company deliver positive earning surprise last quarters average positive surprise estimate movement have be stable past day currently jnj have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat jnj beat first quarter earning company report ep consensus call ep revenue beat revenue also slightly beat expectation johnson johnson post revenue compare consensus estimate key statistic pharmaceutical segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market up sale outlook maintain previously issue earning guidance increase sale range still expect adjust earning share range reflect operational growth rate however expect revenue range higher expect previously reflect operational constant currency sale growth rate range previously zack consensus estimate earning share revenue be respectively stock price impact share rise pre market trading johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson quotecheck back later full jnj earning report later best worst zackstoday be invite download full minute list zack rank strong buy free charge list have averaged stellar gain year download zack rank strong sell even list hold many stock seem be solid have historically perform market see critical buy sell free
1760,JNJ,achillion pharmaceutical inc achn free report report loss cent share fourth quarter wider zack consensus estimate loss cent loss cent share year quarter company generate revenue report quarter however report revenue fourth quarter earn agreement johnson johnson jnj free report be terminate share achillion have underperform industry year date company share lose compare industry decrease research development expense increase nearly year period increase be due higher clinical trial expense lead pipeline candidate manufacturing formulation expense next generation factor inhibitor candidate general administrative expense increase year year achillion paid underwriting fee related sale common stock company generate revenue full year have report revenue year period loss share widen year year cent expense increase almost year due increase clinical cost related preclinical manufacturing cost partially offset reduce preclinical manufacturing cost expense rise primarily due higher legal consult fee company provide sg expense guidance range respectively company expect expense decrease due restructure plan net loss be expect be range cent cent earning result company announce operational restructure plan focus exist factor inhibitor candidate reduce expense achillion also reduce workforce restructure plan company plan save achillion be plan complete phase ii study most advanced candidate glomerulopathy immune complex mediate ic mpgn interim datum plan third quarter more study be plan evaluate meanwhile interim datum ongoing phase ii study evaluate monotherapy paroxysmal nocturnal hemoglobinurium pnh be plan fourth quarter add study be plan evaluation combination alexion pharmaceutical alxn free report pnh drug soliris eculizumab interim datum be expect fourth quarter company also target complete phase study next generation factor inhibitor fourth quarter achillion pharmaceutical inc price consensus ep surprise achillion pharmaceutical inc price consensus ep surprise achillion pharmaceutical inc quotezack rank stock pharma carry zack rank hold stock healthcare sector worth consider be exelixis exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate increase cent cent last day company deliver positive earning surprise trail quarters average beat company share be past year zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1761,JNJ,have be month last earning report johnson johnson jnj free report share have lose time frame underperform market recent negative trend continue lead next earning release be jnj due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver beat earning miss sale issue outlookj fourth quarter earning come share beating zack consensus estimate increase year period higher sale higher net other income lower tax rate make higher operate cost quarter adjust earning exclude amortization expense special item include charge approximately related recent tax law change include item report fourth quarter net loss share versus earning share year period sale come slightly miss zack consensus estimate nonetheless sale increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis better see third quarter first half expect sale growth accelerate second half backed higher sale pharmaceutical segment improve performance medical device fourth quarter sale grow unite state international market reflect operational growth currency favorably impact report international sale growth segment segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow operational increase new product imbruvica darzalex continue perform well other growth driver be core product xarelto stelara zytiga invega sustenna organically exclude impact acquisition divestiture sale increase operational basis outperform growth see third quarter imbruvica sale rise quarter drive largely higher market share market growth several indication unite state strong uptake outside unite state stelara sale rise quarter stelara gain market share quarter drive share gain psoriasis market well newer crohn disease market simponi simponi aria sale rise quarterdarzalex sale rise quarter darzalex enjoy strong uptake outside market accelerate adoption unite state line therapy xarelto sale rise quarter backed increase market share zytiga sale rise quarter due improve market share grow metastatic castration resistant prostate cancer market invega sustenna sale rise quarter record pulmonary arterial hypertension pah revenue less third quarter strong demand uptravi opsumit be partially offset expect decline tracleer outside unite state due generic competition transition patient assistance foundation actelion acquisition add sale growth invokana invokamet sale decline due increase discount manage care contract loss market share sale remicade decline quarter sale decline meanwhile international sale decline due biosimilar competition regard newly launch tremfya say uptake product have be decent record sale fourth quarter medical device segment sale come year period include operational increase positive currency movement exclude impact acquisition divestiture operational basis worldwide sale increase operational growth be drive continue strong performance vision care cardiovascular well improve growth surgery make weaker sale performance diabetes care unit domestic market sale rise year year international market sale increase operational increase year year consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment exclude impact acquisition divestiture adjust operational sale growth be worldwide slower growth domestic baby care product due competitive pressure be offset growth beauty counter product sale domestic market decline year period meanwhile international segment record increase reflect operational increase positive currency impact margin discussioncost good sell percentage sale decline basis point mostly due favorable product mix selling marketing administrative expense be bps year year sale due investment new product research development cost percentage sale rise bps prior year quarter resultsfull year sale rise fall slightly short zack consensus estimate operationally sale rise year be line upper end guide range adjust earning be share zack consensus estimate year year earning be higher end guidance range share outlook issuedj issue mixed guidance earning range be consensus estimate sale fall slightly short same expect adjust earning share range reflect operational growth rate company guidance exceed then zack consensus estimate share currency fluctuation be expect favorably impact earning share cent expect revenue range reflect operational constant currency sale growth rate range however sale guidance fall slightly short then zack consensus estimate organic sale growth exclude impact acquisition divestiture be expect be range slightly higher see fall short fourth quarter currency fluctuation be expect favorably impact sale basis point expect pharmaceutical segment remain strong consumer medical device segment continue improve believe new product segment label expansion drug imbruvica darzalex contribution acquisition mainly actelion support top line growth adjust pre tax operate margin be expect increase approximately basis point expectation increase investment company say tax rate earning be lower allow increase investment adjust tax rate guidance be range company do not expect biosimilar entrant zytiga prezista risperdal consta invega sustenna unite state however company be confident absorb impact potential zytiga headwind be earlier expect generic launch have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter look back additional day see even more upward momentum have be move last month johnson johnson price consensus johnson johnson price consensus johnson johnson quotevgm scoresat time jnj have nice growth score however momentum be do bit better charting somewhat similar path stock be allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable momentum investor look value growth outlookestimate have be trend upward stock magnitude revision look promising interestingly jnj have zack rank hold expect line return stock next few month
1762,JNJ,be second half year time analyze first half turn be pharma biotech stock term fda decision regulatory body approve novel drug first half be less year period figure however several fda decision line second half higher number drug be approve rest year key fda approval first half include amgen amgn free report novartis first cgrp antibody aimovig erenumab prevention migraine jnj free report next generation oral androgen receptor ar inhibitor erleada apalutamide pre metastatic prostate cancer crpc vertex pharmaceutical vrtx free report third medicine treat underlie cause cf symdeko be combination tezacaftor ivacaftor biomarin pharmaceutical palynziq treat pku drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst let take look few important regulatory event schedule month july fda decision indivior schizophrenia injection rbp jul fda be expect give decision indivior plc invvy free report rbp have be develop treatment schizophrenia rbp be once monthly injectable risperidone give used atrigel delivery system indivior be zack rank hold stock see complete list today zack rank strong buy stock here progenic pharmaceutical azedra review progenic pharmaceutical pgnx free report new drug application nda look get pipeline candidate azedra approve treatment patient suffering malignant rare neuroendocrine tumor paraganglioma be review fda be expect give decision jul month delay previous fda action date march azedra be add progenic portfolio acquisition molecular insight pharmaceutical decision insys therapeutic pain candidate jul fda be also expect give decision insys therapeutic insy free report buprenorphine sublingual spray moderate severe acute pain be important remember fda advisory committee vote approval company have file new drug application nda september last year base positive datum pivotal study candidate fda accept nda review december assign pdufa date jul be quite possible unfavorable vote committee influence fda decision delay approval drug fda panel back new indication glaxo nucala end month fda panel be expect give opinion glaxo gsk free report label expansion filing eosinophilic asthma drug nucala mepolizumab new indication chronic obstructive pulmonary disease copd latest filing glaxo be look get nucala approve add maintenance treatment copd eosinophilic phenotype nucala be presently approve treat severe eosinophilic asthma eosinophilic granulomatosis polyangiitis egpa glaxo hadfiled supplemental biologic license application sbla label expansion nucala include use copd november last year fda take recommendation panel advisory committee account review application be not bound follow same today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1763,JNJ,month have go last earning report johnson johnson jnj free report share have lose time frame recent negative trend continue lead next earning release be jnj due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver top first quarter earning estimate raise sale guidancej first quarter earning come share beating zack consensus estimate increase year period adjust earning exclude amortization expense special item include item report first quarter earning share compare earning year period sale come beating zack consensus estimate sale also increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis better increase see be pharmaceutical segment continue positive momentum see second half consumer segment sale improve first quarter sale grow domestic market international market reflect operational growth positive currency impact segment segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow operational increase new product imbruvica darzalex continue perform well core product stelara zytiga simponi simponi aria invega sustenna also contribute growth organically exclude impact acquisition divestiture sale increase operational basis slightly less growth see previous quarter strong performance be lead company oncology portfolio imbruvica sale rise quarter drive largely higher market share line therapy market growth unite state stelara sale rise quarter stelara gain market share quarter drive share gain psoriasis market well newer crohn disease market simponi simponi aria sale rise quarterdarzalex sale rise quarter darzalex enjoy increase penetration outside market market growth unite state approval first line set expect year be expect be driver darzalex sale go forward xarelto sale rise quarter sale be softer previous quarter due inventory build seasonality issue however company say drug continue witness market share gain zytiga sale rise quarter due improve market share grow metastatic castration resistant prostate cancer market zytiga be approve first line set february be key driver zytiga strong performance first quarter invega sustenna sale rise quarter record pulmonary arterial hypertension pah revenue less previous quarter strong demand uptravi opsumit be partially offset expect decline tracleer outside unite state due generic competition transition patient assistance foundation actelion acquisition add sale growth first quarter invokana invokamet sale decline due higher manage care discounting sale remicade decline quarter sale decline due rebate adjustment however international sale rise biosimilar competition regard newly launch tremfya say uptake product have be strong tremfya record sale first quarter compare previous quarter be quite confident pharma segment continue perform better market year impact biosimilar remicade sale medical device segment sale come year period include operational increase positive currency movement exclude impact acquisition divestiture operational basis worldwide sale increase operational growth be drive continue strong performance vision care well advanced surgery business make weaker sale performance diabetes care orthopedic particularly hip knee spine domestic market sale rise year year international market sale increase operational increase year year consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment exclude impact acquisition divestiture adjust operational sale growth be worldwide acceleration fourth quarter slower growth domestic baby care product due competitive pressure be offset growth beauty counter product sale domestic market rise year period meanwhile international segment record increase reflect operational increase positive currency impact margin discussioncost good sell percentage sale decline basis point mostly due favorable product mix selling marketing administrative expense be bps year year sale investment new product be due lower cost relative sale growth pharmaceutical unit research development cost percentage sale rise bps prior year quarter sale outlook raisedj maintain previously issue earning guidance increase sale range still expect adjust earning share range reflect operational growth rate currency fluctuation be expect favorably impact earning share cent however revenue be expect range higher reflect operational constant currency sale growth rate range previously organic sale growth exclude impact acquisition divestiture be expect be range versus previously currency fluctuation be expect favorably impact sale basis point adjust pre tax operate margin be expect increase approximately basis point previously bps expectation increase investment adjust tax rate guidance be range company do not expect biosimilar entrant zytiga prezista risperdal consta invega sustenna unite state however company be confident absorb impact potential zytiga headwind be earlier expect generic launch however guidance include impact generic procrit tracleer well remicade biosimilar new cost saving initiativej announce global supply chain initiative annually save approximately pre tax cost be substantially deliver discussion regard specific future action be ongoing say company invest more capital investment unite state next year represent increase prior year more new tax law leave extra cash hand large pharma company allow invest innovation capital build have estimate be move then turn fresh estimate have trend downward past month have be revision higher current quarter compare lower johnson johnson price consensus johnson johnson price consensus johnson johnson quotevgm scoresat time jnj have strong growth score be lag bit momentum front charting somewhat similar path stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be primarily suitable growth investor also be suitable look momentum lesser degree value outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift notably jnj have zack rank hold expect line return stock next few month
1764,JNJ,pfizer inc pfe free report announce fda have grant approval retacrit biosimilar version blockbuster drug amgen inc amgn free report epogen johnson johnson jnj free report procrit pfizer already market biosimilar europeretracrit be indicated treatment anemia due chronic kidney disease anemia due hiv infected patient anemia due effect concomitant chemotherapy anemia post chemotherapy drug be also approve reduction allogeneic red blood cell rbc transfusion patient undergo elective noncardiac nonvascular surgery retacrit become first biosimilar erythropoiesis stimulating agent approve unite state procrit generate sale epogen sale be sale number suggest bright prospect retacrit be lower cost alternative treatment option patient used procrit epogen however procrit already face biosimilar competition drug novartis nvs free report binocrit europe pfizer share have decline so far year compare favorably fall record industry approval be support comprehensive datum package demonstrated high level similarity retacrit epogen procrit last year fda sadvisory committee have recommend approval retacritpfizer have enter collaboration switzerland base pharma retacrit certain channel retacrit be third approve biosimilar pfizer commercial portfolio include inflectra biosimilar version remicade company be also develop different biosimilar candidate several mid late stage study trump administration continue rally exorbitantly high drug price fda have be actively approve generic biosimilar expensive brand drug bid bring price competition see several such approval expect trend continue year pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1765,JNJ,geron corporation gern free report be expect report fourth quarter result mar last report quarter company deliver positive earning surprise geron share have outperformed industry past year stock have gain industry witness decline say time frame pipeline focusgeron revenue solely comprise license fee royalty have approve product portfolio moreover have only candidate pipeline imetelstat hence investor focus remain update related geron be develop imetelstat collaboration johnson johnson jnj free report treat patient hematologic myeloid malignancy myelofibrosis mf myelodysplastic syndrome mds acute myelogenous leukemia aml late stage study imetelstat be ongoing imbark phase ii treatment mf imerge phase ii iii treatment mds follow second internal review datum imbark imerge april last year study continue unmodified november geron initiate dose expand part ongoing phase ii iii imerge study expand part be be conduct confirm clinical benefit safety observed earlier janssen decide continuation part imerge base datum expand part janssen be expect evaluate mature datum imbark study include assessment overall survival internal review datum be expect first quarter however continuation study depend protocol specify primary analysis be do third quarter reach pre specify number death expect company provide update path forward imetelstat development fourth quarter conference call surprise historygeron performance last quarters have be fairly decent company surpass expectation thrice meeting same once average positive surprise last quarters be earning whispersour proven model do not conclusively show geron be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank geron zack rank increase predictive power esp esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision geron corporation price consensus geron corporation price consensus geron corporation quotestock warrant lookhere be couple health care stock want consider model show have right combination element post earning beat quarter exelixis exel free report be schedule release result feb market close company have earning esp zack rank see complete list today zack rank stock here exact science exas free report have earning esp zack rank company be schedule release result feb market close hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1766,JNJ,dow rebound strongly first trading day enter correction territory last week index gain monday investor look buy cheap energy stock key gainer dow continue gain tuesday wednesday initial concern higher expect consumer price datum ultimately dow gain fifth consecutive day thursday track post biggest weekly increase november last week dow increase last friday tumultuous week fear gauge cboe volatility index vix decrease close however remain time higher last year average key index make recovery last hour trading end positive territory movement lack specific catalyst even blue chip index register increase more pointsdure last week market slip correction territory dow witness point drop period lose process market suffer huge loss week follow concern bond be become more attractive investment equity rise bond yield diminish appeal stock especially valuation hover historically high level tighter labor market strong wage growth prospect rise inflation raise rate hike prospect early fed next policy meeting march turn weigh investor sentiment higher rate environment optimism steady economic growth higher inflation weigh bond price dow index increase monday movement come investor look buy cheap energy stock key gainer domestic oil price re-cover last week decline opec monthly report project global oil demand increase barrel day bpd year better previous outlook bpd additionally president trump sign law bipartisan budget deal provide massive spending boost pentagon infrastructure turn have positive impact key index index gain third consecutive day tuesday add register gain tuesday dow remain time high level register jan additionally trading volume day be comparatively lower investor wait bureau labor statistic consumer price report wednesday further clue inflation index increase wednesday register longest stretch gain more week market manage rebound decline initially follow better expect consumer price report key inflation metric strong earning season steady economy help key index shrug yearly decline close positive territory index increase thursday end positive territory fifth straight trading day be dow best such feat december index be now year be way post biggest weekly increase november movement lack specific catalyst part day gain be fuel strong earning resilient economy component move index cisco system inc csco free report deliver second quarter fiscal gaap earning cent share beating zack consensus estimate cent further figure increase cent year quarter cent cisco have zack rank hold revenue increase year year marginally surpass zack consensus estimate acquisition contribute basis point bps revenue growth quarter security infrastructure platform application revenue increase quarter third quarter fiscal revenue be expect rise year year basis gaap earning be anticipate cent cent share zack consensus estimate earning be peg cent revenue be gaap gross margin be expect range operate margin be anticipate quarter read cisco earning top estimate view strong caterpillar inc cat free report report rise global retail sale month end january par performance witness december level last see august be drive improvement region machine resource industry construction industry report positive gain seventh consecutive month respectively january zack rank buy caterpillar performance be drive increase asia pacific sale region have be consistent contributor company post first positive read august latin america register growth october europe africa middle east eame sale be north america sale also go read caterpillar january sale momentum sustain visa inc free report recently announce have enter definitive agreement acquire fraedom have be partnership visa year transaction be subject customary close condition be expect be complete first half fraedom be software service technology company specialize provide payment transaction management solution financial institution corporate customer visa intellilink spend management core platform visa commercial small business client already used fraedom technology stock have zack rank see complete list today zack rank strong buy stock here johnson johnson jnj free report subsidiary janssen biotech announce fda have approve new drug application nda apalutamide treatment man metastatic castration resistant prostate cancer nmcrpc apalutamide zack rank next generation oral androgen receptor ar inhibitor be market trade name erleada fda decision come much earlier expect please note december last year nda be grant priority review fda fda grant priority review response be expect april erleada nda submission be base positive datum phase iii spartan study last week present positive datum spartan study american society clinical oncology genitourinary cancer symposium meeting datum study show erleada apalutamide significantly reduce risk metastatis death increase median metastatis free survival more year patient nmcrpc read get fda nod new prostate cancer treatment revise goldman sachs group gs free report be talk acquire new york base startup clarity money article bloomberg bank plan fuse personal finance service startup offer digital consumer lend platform marcus goldman sachs goldman sachs have zack rank person familiar matter disclose deal have be finalize so far also be possibility deal come nothing launch october marcus goldman sachs have be deliver good result so far platform exceed bank expectation lend loan year end read goldman expand online lend platform offering exxonmobil corporation xom free report recently announce oil gas reserve grow owing growth several place shale unite arab emirate guyana zack rank exxonmobil report reserve update follow fourth quarter earning fail meet expectation company add barrel oil equivalent boe reserve mark production replacement bring company total prove reserve boe exxonmobil believe prove reserve hold significant development opportunity grow shareholder value come year total prove reserve be liquid increase current production rate company reserve be expect last year read exxonmobil announce prove reserve growth performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlookmarket seem have rebound strongly grave loss suffer last week investor have overcome initial jitter have push index willingness big great bargain cheap result benchmark be back positive territory be coast best weekly gain give trader have choose focus broad fundamental namely strong economy excellent earning result market be likely continue recovery week ahead wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1767,JNJ,be first big week earning season mean ll get lot big cap company report include several dow component company various industry lead charge several have best chart not only week entire earning season not easy beat quarter year ve do mean survive various economic condition have management forward think vision keep winning streak best big cap earning chart johnson johnson jnj free report have keep earning beat streak alive hasn miss year share be stock market have pull back get boost earning unitedhealth group unh free report have best chart wall street share be recent time high be change growth stock be just pause big cap name move higher still ibm ibm free report have beat quarters row share have be stagnant several year worry revenue growth blockchain be ibm savior intuitive surgical isrg free report have be hottest medical stock last year have beat quarters row share have pause be buy opportunity lam research lrcx free report hasn miss year be great performer volatility have hit share earning report be just boost need investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1768,JNJ,abbvie inc abbv free report announce extension research development agreement calico life science jointly develop candidate treat age related disease include cancer calico be san francisco bay area base biotech company backed alphabet inc googl free report company first enter deal partnership have produce more dozen early stage program latest agreement collaboration have be extend year calico be responsible early program continue advance program phase iia abbvie continue support calico early stage have option manage late stage development commercial activity company be sharing cost profit equally contribute additionally collaboration deal strengthen abbvie grip oncology segment be abbvie have strong position oncology market drug imbruvica market partnership jnj free report imbruvica currently approve quite few indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease several study imbruvica be ongoing evaluate drug alone combination different patient segment abbvie expect imbruvica peak sale more revenue abbvie be also study chronic lymphocytic leukemia cll drug venclyxto venclexta expand label address broader relapse refractory cll patient population expand earlier line therapy other hematologic malignancy multiple myeloma aml datum phase iii murano study venclexta roche rhhby free report rituxan relapse refractory cll present last september show combination lead profound improvement progression free survival compare treanda rituxan regulatory application seek approval combination use broader patient population be approve unite state earlier month label expansion indication expand patient population venclexta significantly boost commercial potential abbvie share have decline year so far compare industry decline abbvie currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1769,JNJ,abbvie inc abbv free report announce fda have grant priority review lymphoma drug imbruvica ibrutinib snda treatment waldenstrm wm combination rituxan rituximab market genentech subsidiary roche group rhhby free report snda be base positive datum phase iii study innovate evaluate imbruvica combination rituxan show positive outcome line wm treatment include patient untreated relapse refractory wm phase iii study enrolled patient relapse refractory treatment naive wm patient receive intravenous rituxan mg once weekly consecutive week follow second weekly rituxan course post month interval receive imbruvica mg placebo once daily permanently discontinue treatment primary endpoint be progression free survival measure safety tolerability treatment line base datum approve snda expand drug label indication wm first chemotherapy free combination treatment option notably imbruvica be first class bruton tyrosine kinase inhibitor drug be already approve unite state follow indication such chronic lymphocytic leukemia small lymphocytic lymphoma waldenstrm previously treat mantle cell lymphoma previously treat marginal zone lymphoma previously treat chronic graft versus host disease drug be be jointly develop market pharmacyclic llc get acquire abbvie janssen biotech unit johnson johnson jnj free report also mark abbvie humira drug be key growth driver revenue base imbruvica also appear have great potential blockbuster drug first quarter drug net revenue be year year end year global revenue exceed sale unite state likely cross share abbvie have decrease year date compare industry decline abbvie currently carry zack rank hold better rank stock same sector be lundbeck hluyy free report sporting zack rank strong buy see complete list today zack rank stock hereh lundbeck earning estimate have be revise upward past day stock have soar year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1770,JNJ,geron corporation gern free report report loss cent share first quarter narrower year loss cent quarterly revenue fall year quarter revenue comprise royalty license fee revenue receive various imetelstat license agreement company state active imetelstat license agreement reduce number product sale licensee decrease share be pre market trading however so far year geron share have significantly outperformed industry rise industry decline research development expense decline decline be due decrease stock base compensation lower cost proportionate share clinical development cost imetelstat collaboration janssen subsidiary johnson johnson jnj free report general administrative expense rise due consult cost legal cost company end quarter cash investment compare end fourth quarter pipeline updategeron sole pipeline candidate imetelstat be be evaluate mid stage study imerge imbark myelodysplastic syndrome mds myelofibrosis mf respectively geron be conduct study collaboration december geron present preliminary datum part phase ii iii imerge study datum show imetelstat achieve rbc transfusion independence rbc ti reduce requirement rbc transfusion certain interval patient population have not receive prior treatment lenalidomide hypomethylating agent least week rbc ti be achieve patient subset least week base datum expand part study include more patient refine mds indication confirm clinical benefit safety observed earlier october fda grant fast track designation imetelstat base datum part imerge meanwhile clinical benefit potential overall survival benefit observed third internal review march support continuation phase ii imbark study modification however be plan amend protocol study allow long term treatment patient amendment be base primary analysis datum study be expect second quarter also notify geron continuation study base analysis be expect third quarter geron corporation price consensus ep surprise geron corporation price consensus ep surprise geron corporation quotezack rank key picksgeron currently carry zack rank buy couple other stock consider biotech sector be ligand pharmaceutical lgnd free report enanta pharmaceutical inc enta free report ligand sport zack rank strong buy enata carry zack rank see complete list today zack rank stock here ligand earning share estimate moved remain stable last day company deliver positive earning surprise trail quarters average beat company share have rally year date enanta earning share estimate significantly increase cent last day company come average beat stock have surge so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1771,JNJ,pfizer inc pfe free report report fourth quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year drive higher international sale lower cost share count pharma heavyweight deliver revenue also beat zack consensus estimate revenue rise year quarter report basis operational basis revenue be flat year year sale detailcurrency movement benefit pfizer fourth quarter revenue february pfizer divest hospira infusion system business icu medical exclude currency headwind revenue prior year quarter sale rise operationally strong performance newer product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis somewhat offset lower sale enbrel viagra loss exclusivity product supply shortage legacy hospira product international revenue rise operational basis meanwhile revenue decline segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report basis operational basis year period pfizer ih revenue be drive persistently strong momentum eliquis globally xeljanz lyrica ibrance chantix champix primarily unite state ibrance revenue rise quarter drive strong revenue however ibrance sale be softer prior quarter time price adjustment hurt international sale xeljanz sale rise lyrica sale rise eliquis alliance revenue direct sale rise chantix sale rise quarter revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare third quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada total viagra ih sale decline due generic competition begin december global prevnar prevenar revenue rise higher international sale make decline unite state prevnar revenue tank unite state due continue decline revenue eligible adult patient population however prevenar revenue rise international market due favorable timing government purchase emerge market pediatric indication consumer healthcare revenue decline global oncology revenue increase global vaccine revenue rise internal medicine rise inflammation immunology franchise rise additionally portfolio rare disease decline pfizer be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision be expect year also be retain business pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state lyrica europe lower revenue legacy hospira product due product shortage divesture however business biosimilar emerge market do well quarter biosimilar revenue rise operationally emerge market revenue grow operationally pfizer launch inflectra biosimilar version johnson johnson jnj free report merck mrk free report blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market adjust selling informational administrative si expense decline operationally quarter adjust expense also decline resultsfull year sale be flat year year operational basis sale marginally beat zack consensus estimate be line guidance range adjust earning share full year exceed zack consensus estimate well guide range earning rise year year guidancerevenue be expect range zack consensus estimate be peg adjust earning share be expect range zack consensus estimate share mid point adjust ep be expect increase revenue be expect increase research development expense be expect range si spending be project range adjust tax rate be expect be takepfizer fourth quarter result be expectation beat estimate earning revenue meanwhile issue upbeat guidance also pfizer say plan invest approximately capital project unite state next year increase access foreign cash follow tax reform however initial gain share pfizer fall premarket trading believe lower sale unite state sequentially softer performance ibrance quarter hurt investor sentiment past year pfizer share have increase compare unfavorably increase industry top line headwind form genericization key drug supply shortage legacy hospira product pricing pressure rise competition pfizer achieve adjust earning growth new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance meanwhile pfizer look well poise record profit growth pfizer carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
1772,JNJ,abbvie inc abbv free report report impressive result fourth quarter company surpass earning revenue estimate period importantly raise earning expectation response share climb almost pre market trading abbvie share have soar year time significantly outperform industry rally company report fourth quarter earning share beating zack consensus estimate bottom line grow year year earning also surpass previous expectation company post revenue report quarter marginally beating zack consensus estimate top line also increase year year exclude favorable impact foreign exchange rate fluctuation operational revenue jump revenue report higher growth compare previously expect rise operational basis quarter detailkey drug humira record sale growth operational basis revenue come sale unite state increase humira sale ex market be operational basis report basis growth major market category drive upside increase competition new class drug well indirect biosimilar competition international market fourth quarter net revenue imbruvica stand year year sale imbruvica be compare year figure abbvie record international profit sharing johnson johnson jnj free report other product have deliver impressive performance include duodopa show revenue growth operational report basis product call creon witness ascent revenue operational report basis hcv chronic hepatitis virus product record sale significantly operational report basis respectively adjust sg expense inched expense escalate quarter adjust operate margin be sale report quarter resultsfull year sale jump year year sale outpaced zack consensus estimate revenue growth be slightly higher previous expectation earning share exceed zack consensus estimate full year bottom line reflect growth compare year figure moreover report earning be slightly higher past projection outlookabbvie raise adjust ep range compare predict earlier earning guidance reflect year year surge mid point zack consensus estimate current year earning be peg share abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quote zack rank key picksabbvie carry zack rank hold better rank stock health care sector be nordisk nvo free report sucampo pharmaceutical inc carry zack rank buy see complete list today zack rank strong buy stock here nordisk earning share estimate have increase last day company deliver positive earning surprise trail quarters average beat company share price have surge year sucampo earning share estimate have moved north last day company pull positive earning surprise last quarters average beat company share price have soar year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1773,JNJ,merck co inc mrk free report pfizer inc pfe free report report upbeat first quarter result fact pharma giant manage outpace earning estimate miss revenue front however company top bottom line rise year year merckha zack rank buy pfizer possess zack rank hold now let see stock be better position term fundamental post earning see complete list today zack rank strong buy stock here other major earning come other pharma giant abbott free report johnson johnson jnj free report earning performancein first quarter merck report adjust earning share surpass zack consensus estimate cent bottom line increase year period meanwhile company revenue fall short zack consensus estimate increase year year read more merck beat earning lag sale raise outlook pfizer post first quarter earning cent share beating zack consensus estimate only cent earning advanced year period due lower tax rate share count moreover revenue increase year year miss zack consensus estimate read more pfizer stock fall sale miss earning beat price have witness rise past month pfizer have advanced only so merck be clear winner respect better return rival merck broader industry decline same period most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major pfizer ev ebitda ratio be overvalue broader industry have ev ebitda value other hand ev ebitda ratio merck be underpriced pfizer industry net marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention exorbitant drug pricing help sector maintain steep margin net margin value pfizer perform better rival merck have net margin value comparison broader industry have net margin value debt equity debt equity ratio be good indicator financial health company good proxy debt servicing capacity context capital intensive industry pharma be indicator company long term sustainability merck debt equity ratio be significantly high compare industry ratio comparatively lower ratio pfizer evidently have better leverage condition earning history estimate revisionsmerck deliver positive surprise last quarters average earning surprise comparison pfizer deliver earning beat trail quarters post average positive earning surprise consider estimate revision merck earning estimate current year have improve past day meanwhile pfizer earning estimate have decline same period conclusionin comparative analysis find pharma giant have certain positive pfizer hold better leverage position have higher net margin however term valuation merck be more underpriced pfizer further merck have comparatively higher price performance pfizer moreover merck also hold edge pfizer consider average positive earning surprise estimate revision clinch case favor merck point time be have better zack rank pfizer respect analysis clearly indicated merck be better position pfizer thus call investor attention post earning look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1774,JNJ,abbvie abbv free report announce hike quarterly dividend authorization new share buyback program board abbvie stock rise more thursday response news dividend be increase cent share cent share cash dividend be payable shareholder record apr new quarterly dividend amount annual dividend share imply dividend yield please note be second dividend hike abbvie less month october last year abbvie announce hike quarterly dividend cent share cent share abbvie hike quarterly dividend fact inception abbvie have hike dividend fourth quarter conference call hold last month management hint shareholder return be likely go company cash position have improve follow recent tax reform fact abbvie have perform exceptionally well past year support series positive news stock have return past year compare favorably gain record industry abbvie meet primary endpoint several pivotal study key phase iii murano study venclexta roche rhhby free report rituxan relapse refractory chronic lymphocytic leukemia phase iii study evaluate oral jak selective inhibitor upadacitinib rheumatoid arthritis also phase iib study atopic dermatitis pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara humira moderate severe chronic plaque psoriasis meanwhile abbvie gain regulatory approval unite state europe japan competitive hcv medicine mavyret fda approval sixth indication cancer drug imbruvica fact mavyret launch have be stronger expect inform company fourth quarter conference call abbvie also settle patent dispute amgen amgn free report delay launch latter biosimilar version abbvie blockbuster arthritis drug humira unite state most country eu october agreement have remove major overhang abbvie share moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market several pivotal datum readout regulatory milestone expect bullish run stock continue importantly humira have be generate solid sale base strong demand trend drug trend expect continue year imbruvica abbvie second most important drug be also do consistently well have multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease factor bode well stock abbvie carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1775,JNJ,johnson johnson jnj free report subsidiary janssen biotech announce fda have approve new drug application nda apalutamide treatment man metastatic castration resistant prostate cancer nmcrpc apalutamide next generation oral androgen receptor ar inhibitor be market trade name erleada fda decision come much earlier expect please note december last year nda be grant priority review fda fda grant priority review response be expect april erleada nda submission be base positive datum phase iii spartan study last week present positive datum spartan study american society clinical oncology genitourinary cancer symposium meeting datum study show erleada apalutamide significantly reduce risk metastatis death increase median metastatis free survival more year patient nmcrpc stock have return past year compare favorably gain record industry give be fda approve treatment available patient population erleada approval be significant boost company cancer portfolio also erleada approval have strengthen prostate cancer franchise especially key drug zytiga approve treat metastatic crpc face patent challenge several company amneal apotex dr reddy rdy free report mylan myl free report teva teva free report other be look fda approval generic version zytiga last month announce pto issue final written decision party review ipr generic manufacturer invalidate patent zytiga zytiga be key driver revenue growth last year zytiga sale rise due improve market share grow metastatic castration resistant prostate cancer market do not expect biosimilar entrant zytiga year be confident guidance organic sale growth absorb impact potential zytiga headwind such earlier expect generic launch addition erleada early approval somewhat make lose sale zytiga case generic be launch year apalutamide be add portfolio august aragon acquisition carry zack rank hold johnson johnson price consensus johnson johnson price consensus johnson johnson quote be reissue article correct mistake original article issue thursday february longer be rely wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1776,JNJ,global medical device industry have demonstrated strong sustainable growth recent past banking age population increase incidence chronic lifestyle disease increase adoption artificial intelligence ai big datum application upbeat consumer sentiment increase business investment sector appear be pink health go kpmg datum medical device industry global annual sale be forecast rise more year reach nearly cision report say unite state be largest medical device market world present rake more revenue several socio political hazard economic dip medical device company have be ride high innovation increase consolidation emerge market expansion tax cut undoubtedly have be very profitable investment space late here be few major development abolition medtech tax bipartisan year suspension medical device tax impose excise tax medtech manufacturer mark temporary relief be again put effect jan repeal be expect boost hire investment america base medical device manufacturer thus instilling investor optimism ratification tax repeal amendment have encourage massive investment sector uptrend continuesapart tax relief medtech fraternity have also be ride high ongoing merger acquisition trend space fact various report suggest have be key catalyst drive healthcare space late datum provide biospectrum asia activity medtech space surge increase value aggregate more major acquisition recent past include becton dickinson company bdx free report acquisition bard johnson johnson jnj free report buyout actelion pbm health insurer health insurer have be look collaborate pharmacy benefit manager medtech space streamline cost drug supply chain buoy continue capital inflow strategic policy key medical device player have expand customer basis moderate leverage enhance cash flow have also alleviate pricing pressure competition medtech space regard latest buyout announcement express script cigna ci free report come just month drug chain pharmacy giant cvs health corp cvs free report announcement acquire nation third largest health insurer aetna be important digital revolution medtechlatest trend robotic surgery big datum analytic bio printing printing electronic health record ehr predictive analytic real time alert revenue cycle management service medtech space be gain prominence various report suggest strategic application ai sphere healthcare provide impetus productivity company adopt ai technology have witness reduction healthcare cost have also experience improve patient outcome more rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model have be drive profit medical device company late trade war fear grip medtechthe sector have be identify trump imposition higher tariff be now investor radar healthcare include medical equipment be sector likely bear brunt trade dispute go datum provide article christian jone mondaq medtech firm unite state currently sell annually china nation import china total medical device export medical device last year totale create worldwide trade surplus needless say medical device lobby be extremely apprehensive propose tariff chinese product significantly affect international trade zack industry rankwithin zack industry classification medical device be broadly group medical sector zack sector further sub divide industry expand level medical instrument medical product medical dental supply medical info system rank industry zack sector base earning outlook fundamental strength constituent company zack industry rank be top zack classify industry medical info system top medical dental supply top medical instrument bottom medical product backtesting show top zack rank industry outperform bottom factor more analyze zack industry rank different medical device segment be say apart certain medical product stock term outlook aforementioned medical device subsector be overall positive price price performance major zack categorize sub industry be follow past day have gain med instrument space have rise stock space have be trading be varian medical system inc var free report steris plc ste free report edward lifescience corp ew free report medical product subsector industry rank indicated bearish tone sector have increase period player space be haemonetic corp hae free report baxter international inc bax free report boston scientific bsx free report zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
1777,JNJ,johnson johnson jnj free report subsidiary janssen biotech announce fda have approve new drug application nda apalutamide treatment man metastatic castration resistant prostate cancer nmcrpc apalutamide next generation oral androgen receptor ar inhibitor be market trade name erleada fda decision come much earlier expect please note december last year nda be grant priority review fda fda grant priority review response be expect april erleada nda submission be base positive datum phase iii spartan study last week present positive datum spartan study american society clinical oncology genitourinary cancer symposium meeting datum study show erleada apalutamide significantly reduce risk metastatis death increase median metastatis free survival more year patient nmcrpc stock have return past year compare favorably gain record industry give be fda approve treatment available patient population erleada approval be significant boost company cancer portfolio also erleada approval have strengthen prostate cancer franchise especially key drug zytiga approve treat metastatic crpc face patent challenge several company amneal apotex dr reddy rdy free report mylan myl free report teva teva free report other be look fda approval generic version zytiga last month announce pto issue final written decision party review ipr generic manufacturer invalidate patent zytigazytiga be key driver revenue growth last year zytiga sale rise due improve market share grow metastatic castration resistant prostate cancer market do not expect biosimilar entrant zytiga year be confident guidance organic sale growth absorb impact potential zytiga headwind such earlier expect generic launch addition erleada early approval somewhat make lose sale zytiga case generic be launch year apalutamide be add portfolio august aragon acquisition carry zack rank hold hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1778,JNJ,johnson johnson jnj free report fourth quarter result be mixed beat estimate earning miss same sale announce fourth quarter result jan market open expect sale growth accelerate second half year backed higher sale pharmaceutical segment improve performance medical device organically exclude impact acquisition divestiture sale increase operational basis fourth quarter better increase see third quarter first half meanwhile acceleration underlie sale growth pharma segment see third quarter continue fourth quarter pharmaceutical segment sale rise year year fourth quarter also drug medical device giant issue bullish profit outlook estimate adjust earning share range reflect operational growth rate company guidance exceed then zack consensus estimate share positive factor share have decline earning release seem be investor disappointment revenue guidance expect revenue range reflect operational constant currency sale growth range however sale guidance fall slightly short then zack consensus estimate organic sale growth exclude impact acquisition divestiture be expect be range slightly higher see be short record fourth quarter organic sale growth outlook fall short investor expectation result share price drop understand investor concern project decline revenue growth however do believe outlook be conservative consider have history issue cautious outlook especially begin year believe be several tailwind year coax improve projection year progress new drug be approve last year guselkumab tremfya unite state well eu plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state juluca be review eu also gain fda approval several line extension lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene celg free report multiple myeloma drug pomalyst sixth indication imbruvica other please note market imbruvica partnership abbvie inc abbv free report line extension expand eligible patient population drug drive sale higher newly approve product also contribute sale also submit regulatory application label expansion key drug include darzalex first line set multiple myeloma xarelto chronic coronary artery disease peripheral artery disease invokana include cardiovascular indication zytiga earlier stage metastatic prostate cancer get fda nod line extension year provide top line support launch year expect file approval depression candidate esketamine apalutamide pre metastatic prostate cancer symtuza darunavir base once daily single tablet regimen hiv be approve fda also several pivotal datum readout regulatory milestone be expect meanwhile pharma segment sale accelerate second half weak first half management seem confident positive trend continue also say call consumer medical device segment continue improve believe new product segment label expansion drug imbruvica darzalex contribution acquisition mainly actelion support top line growth wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1779,JNJ,expect pfizer inc pfe free report beat expectation report fourth quarter full year result jan market open last quarter company deliver positive earning surprise pharma giant have fairly decent record earning surprise company earning surpass expectation last quarters miss result average positive surprise pfizer share have rise past year compare unfavorably increase industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner be likely contribute meaningfully top line however loss exclusivity associate generic competition product primarily pristiq unite state vfend lyrica develop europe supply shortage legacy hospira product divesture hospira infusion system unit continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition prevnar prevenar vaccine franchise be likely see lower sale lower demand be expect hurt sale viagra third quarter call pfizer say be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue time acquire hospira september pfizer have estimate take couple year integrate manufacturing plant resolve majority supply chain issue company also state remediation business have take longer expect expect supply shortage hurt sale fourth quarter meanwhile bottom line be likely be drive cost saving share buyback leukemia treatment besponsa inotuzumab ozogamicin approve eu june unite state august relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be approve third quarter xeljanz sutent bosulif be approve line extension fourth quarter ixifi pfizer second biosimilar version johnson johnson jnj free report blockbuster drug remicade be also launch december new product line extension bring additional sale fourth quarter also expect management update plan new approve oral sglt inhibitor steglatro ertugliflozin tablet conference call apart be approve monotherapy treat type ii diabetes steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other health care stock worth consider model have right combination element beat earning time abbvie inc abbv free report be schedule release result jan company have earning esp zack rank see complete list today zack rank stock here merck co inc mrk free report have earning esp zack rank company be schedule report earning feb pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1780,JNJ,expect johnson johnson jnj free report healthcare bellwether beat expectation report first quarter result april market open last quarter company deliver positive earning surprise performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be stock have depreciate year so far compare unfavorably decline record industry factor considerj sale growth accelerate second half backed higher sale pharmaceutical segment improve performance medical device expect pharmaceutical segment remain strong consumer medical device segment likely continue improve believe new product segment label expansion drug imbruvica xarelto stelara darzalex meaningful contribution swiss biotech actelion buy june last year support top line zack consensus estimate sale pharmaceutical segment be however fourth quarter revenue pulmonary arterial hypertension pah product add actelion acquistion decline sequentially be be see pah revenue improve meanwhile biosimilar competition be expect continue hurt sale key arthritis drug remicade outside unite state however do not expect biosimilar entrant zytiga prezista risperdal consta invega sustenna unite state year regard newly launch tremfya note conference call uptake product have be decent drug record sale be expect be higher be report quarter meanwhile expect discuss plan erleada newly approve prostate cancer drug conference call also discuss initial sale uptake juluca first dual treatment hiv develop partnership glaxosmithkline gsk free report receive fda approval november last year juluca be review eu medical device segment sale be expect continue rise vision care cardiovascular unit diabetes care unit continue remain weak zack consensus estimate sale medical device segment be consumer segment global consumer category slowdown many company market continue hurt sale however recent acquisition well new product likely provide support zack consensus estimate sale consumer segment be meanwhile higher investment new product launch continue thwart profit earning whispersour proven model show be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be uncover best stock buy sell re report earning esp filter zack rank have zack rank combination zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other large drug biotech stock have right combination element beat earning time amgen inc amgn free report earning esp zack rank company be schedule release result apr see complete list today zack rank stock here abbvie inc abbv free report have earning esp zack rank company be slate release result apr today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1781,JNJ,karyopharm therapeutic inc kpti free report share increase more apr company announce oral selective inhibitor nuclear export compound selinexor kpt have be grant fast track designation fda company be look get candidate approve treatment patient penta refractory multiple myeloma have receive least prior line therapy fda grant fast track designation expedite candidate development well faster review treat serious unmet medical condition designation candidate be expect be grant priority review once file new drug application news be huge positive company come ahead datum phase iib storm study selinexor expect end april study be evaluate selinexor low dose dexamethasone penta refractory multiple myeloma patient positive datum trial allow company submit regulatory application fda second half also pave way selinexor accelerate approval unite state give indication karyopharm share have rally year date industry decrease remind investor karyopharm be also evaluate selinexor several mid later phase study multiple cancer indication most advanced be phase iii study candidate combination johnson johnson jnj free report velcade multiple myeloma patient company be also plan evaluate selinexor subject gynecological malignancy notably last october karyopharm enter exclusive license agreement japanese company ono pharmaceutical develop commercialize selinexor human oncology indication japan south korea taiwan hong kong southeast asian country go forward expect investor focus remain company further update selinexor karyopharm therapeutic inc price karyopharm therapeutic inc price karyopharm therapeutic inc quote zack rank key pickskaryopharm carry zack rank sell better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report infinity pharmaceutical inc infi free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have soar year infinity loss share estimate narrow cent cent cent last day company deliver positive surprise trail quarters average beat medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1782,JNJ,spell high volatility drive uncertainty global trade policy threat rise price essential commodity wall street be look respite upcoming earning season be expect be strongest year term earning revenue such solid quarterly profit provide support market earning expectation be rise late mostly due recently pass tax reform bill sharply trim corporate tax rate upbeat economic scenario home abroad be also primary factor help earning pick pace give positive trend investing blue chip stock be likely make most earning season seem judicious blue chip be such stock be position report impressive earning result mostly have strong balance sheet solid cash flow earning growth expect be strongerblue chip be expect soar high earning season unfold total earning sector be estimate improve same period last year higher revenue such uptick follow earning growth revenue improvement last quarter mark best quarterly performance more year read more earning take wall street storm top pick gain be likely be broad base nearly sector expect report year year earning growth auto conglomerate energy sector be poise report highest earning growth sector material construction industrial product technology financial retail wholesale medical name few be expect contribute significantly catalyst strong recent tax code overhaul strengthen economy certainly help blue chip company make more money upcoming earning season republican backed tax efficaciously defy opposition democrat pass biggest overhaul tax code trim corporate taxe same time income bring back overseas be taxed instead current time low tax rate foreign profit help blue chip bring fund hold overseas back unite state help such company carry combination share buyback dividend payment activity also face high tax burden make big gainer tax rate go strong economic growtheconomic recovery be also likely give boost profitability american blue chip company trump economy be pink health unemployment rate remain year low march worker hourly wage rise cent month unite state same time add average job month faster average gain same period consumer sentiment march reach highest level courtesy healthy job market global economy too be estimate expand rate year year come top promising growth rate world bank blue chip buy head earning seasonblue chip be poise strong earning season mostly response corporate tax cut policy robust economic growth home abroad call investing fundamentally sound blue chip company make most earning season have thus zero such stock flaunt zack rank buy traveler company inc trv free report provide range commercial personal property casualty insurance product service business government unit association individual consider more comprehensive earning history traveler company have average quarter positive earning surprise company such positive earning surprise be more likely positively surprise future zack consensus estimate current year earning rise last day wasn enough company have earning esp positive earning esp zack rank have result positive earning surprise time past decade company be expect report earning result quarter end march apr visa inc free report operate payment technology company connect consumer business bank government enable use digital currency instead cash check bearing mind more inclusive earning history visa have average quarter positive earning surprise zack consensus estimate current year earning climb last day visa have earning esp company be schedule report earning result quarter end march apr see complete list today zack rank strong buy stock here johnson johnson jnj free report together subsidiary research develop manufacture sell various product health care field look more comprehensive earning history johnson johnson have average quarter positive earning surprise zack consensus estimate current year earning also rise last day johnson johnson have earning esp company be slate report earning result quarter end march apr cisco system inc csco free report design manufacture sell internet protocol ip base networking other product related communication information technology industry consider more comprehensive earning history cisco system have average quarter positive earning surprise almost zack consensus estimate current year earning go last day cisco system have earning esp even negative earning esp couple zack rank have produce positive earning surprise time last year company be schedule report earning result quarter end april medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1783,JNJ,economy have be rally donald trump election victory trump tax reform be recently sign law increase optimism investor faster pace economic growth prospective pass other policy president however better expect job growth investor be bet faster rate rise inflation cause havoc market such situation investor generally flock traditional defensive investment however investment fail protect investor most recent downturn market correctionper datum release labor department wage grow year year january compare prior month highest pace april introduce fear investor rise rate inflation make comeback move interest rate fed be widely expect hike interest rate multiple time year tame inflation give market be bet fed hike rate more time suggest earlier cme fed watch tool be chance basis point rate hike march read way build rate proof portfolio etfs result enter correction territory decline more record high set january spook investor weigh risk appetite turn make investor reallocate portfolio defensive fund volatility etfs be go investment vehicle time high market uncertainty investment fared well high political uncertainty geopolitical risk bring low volatility play favor low volatility etfs generally include utility staple stock try investor high dividend yield fund invest stock be view bond investor steady business strategy be know protect investor uncertain time reason do not work recent selloff be rise rate expectation be instance powershare low volatility portfolio splv free report have lose so far february high dividend fund be know be negatively correlated rise rate be good play combat market uncertainty however bond yield record high year yield touch appeal bond equity decline instance quality dividend growth fund dgrw free report have lose so far february result be surprise defensive fund fail be positive territory sell cause fear rise rate fed keep raise rate so call defensive investment not be able protect investor wrath correction instance utility select sector spdr fund xlu free report have lose so far february consumer staple select sector spdr fund have lose period let now discuss few etfs focuse provide exposure discuss sector powershare low volatility portfolio splv free report fund be popular etf target large cap company low volatility have aum charge fee basis point year sector look fund have high exposure financial utility industrial allocation respectively fund top holding be honeywell international inc hon free report berkshire hathaway brkb coca cola co ko free report allocation fund have return year have lose year date have zack etf rank hold medium risk outlook quality dividend growth fund dgrw free report fund seek provide exposure large establish company provide high dividend apply quality screen have aum charge fee basis point year sector look fund have high exposure information technology industrial health care allocation respectively fund top holding be exxon mobil xom johnson johnson jnj free report microsoft corporation msft free report allocation respectively fund have return year have lose year date have zack etf rank medium risk outlook consumer staple select sector spdr fund xlp free report fund seek provide exposure staple stock have aum charge low fee basis point year fund top holding be procter gamble pg coca cola co pepsico inc pep free report allocation respectively fund have return year have lose year date xlp have zack etf rank sell medium risk outlook utility select sector spdr fund xlu free report xlu be most popular fund utility space fund have aum be relatively cheaper bet charge fee basis point year have allocation nextera energy nee free report duke energy duk free report dominion energy free report fund have return year have lose year date have zack etf rank medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1784,JNJ,johnson johnson jnj free report subsidiary janssen announce fda have grant approval prostate cancer drug zytiga abiraterone acetate combination prednisone treat early stage prostate cancer notably zytiga be earlier approve unite state eu treat metastatic castration resistant prostate cancer mcrpc treatment experience patient chemotherapy contain docetaxel latest nod regulatory body drug label have be expand treat newly diagnosed patient metastatic high risk castration sensitive prostate cancer cspc zytiga be approve treatment newly diagnosed cspc patient eu november company also submit regulatory filing combination therapy japan canada mexico switzerland singapore philippine give indication share have outperformed industry year time stock have increase compare favorably industry rally fda approval expand patient population be support encourage datum pivotal phase iii latitude study evaluate zytiga prednisone combination cspc patient prior experience cytotoxic chemotherapy datum trial demonstrated statistically significant improvement overall survival give patient population combination regimen show reduction death risk compare placebo be important note zytiga be most important successful product company oncology portfolio drug sale surge fourth quarter owing improve share grow metastatic castration resistant prostate cancer market be highest prescribe oral medication unite state patient metastatic crpc approval combination therapy cspc patient population increase zytiga sale future quarters incidentally market drug cspc patient have receive docetaxel therapy be pfizer pfe free report japanese company astella pharma combine xtandi enzalutamide zytiga be face patent challenge unite state company anticipate impact generic competition drug year also be confident absorb effect potential zytiga headwind be earlier expect generic launch johnson johnson price johnson johnson price johnson johnson quote zack rank key picksj carry zack rank hold better rank stock health care sector be exelixis inc exel free report xoma corporation xoma free report xoma sport zack rank strong buy exelixis carry zack rank buy see complete list today zack rank stock here exelixis earning share estimate have be revise upward cent cent last day company pull positive surprise trail quarters average beat share price company have soar year time xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1785,JNJ,total earning total healthcare market capitalization be revenue growth not only be growth rate impressive earning revenue beat ratio respectively be great too robust number have push healthcare stock higher average gain response earning announcement most notable player johnson johnson jnj free report be first major drug company report earning jan follow pfizer pfe free report eli lilly company lly free report jan jan respectively other major drug company merck mrk free report bristol myer squibb company bmy free report report feb feb respectively industry prime post solid result earning revenue beat johnson johnson earning world biggest maker healthcare product continue long streak earning beat earning share come couple cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate johnson johnson issue outlook earning share revenue read healthcare etfs focus post jnj result pfizer earning drug giant come earning revenue beat earning share cent come cent zack consensus estimate revenue be also ahead estimate annual basis earning share revenue rise respectively pfizer guide revenue range earning share merck earning focusmerck beat earning estimate miss revenue earning share come cent surpass zack consensus estimate cent improve year quarter revenue inched year year be zack consensus estimate merck issue revenue guidance earning share guidance bristol myer earning focusbristol myer top estimate front report earning share cent penny zack consensus estimate year earning cent revenue grow edge past zack consensus estimate company provide earning share guidance see healthcare etfs here eli lilly earning focuseli lilly also surpass earning revenue estimate earning outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly raise earning guidance maintain revenue outlook range etf pharma etfs see terrible trading past month latest global market rout string earning beat bolster confidence space compelling investor cash beaten price have highlighted detail fund have zack etf rank hold suggest room upside day ahead read inverse equity etfs bet historic selloff powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest more share bmy pfe jnj lly etf have lose month ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket focus firm account least share product have amassed asset base trade moderate volume share day expense ratio come fund have lose month read new pharma etf pill investor need know first trust nasdaq pharmaceutical etf ftxh free report fund track nasdaq smart pharmaceutical index hold security basket pfizer johnson johnson account more share merck bristol myer eli lilly makeup more ftxh have lower level aum share averaged daily volume charge bps annual fee have shed same time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1786,JNJ,johnson johnson jnj free report have accept offer private equity firm platinum equity sale lifescan diabetes device unit company have announce receipt bound offer platinum equity march lifescan unit make blood glucose monitoring product generate revenue last year stock have decline year so far compare unfavorably decrease record industry move be line strategic plan diabetes business company have be plan streamline core asset last year part streamline effort have announce close operation corporation diabetes care unit october last year company have arrange deal medical device maker medtronic inc mdt free report transition patient insulin pump medtronic pump meanwhile also receive offer fortive corporation ftv free report earlier month advanced sterilization product business moreover sale diabetes care franchise decline due price decline competitive pressure thus streamline asset be likely boost margin well cash position company johnson johnson price johnson johnson price johnson johnson quotezack rankj currently carry zack rank hold eli lilly company lly free report be better rank large cap pharma stock carry zack rank buy see complete list today zack rank strong buy stock here lilly earning share estimate moved last day share company be year so far hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1787,JNJ,eli lilly company lly free report swiss partner astrazeneca azn free report announce discontinuation late stage study alzheimer disease ad candidate lanabecestat recommendation independent datum monitoring committee idmc idmc say amaranth study evaluate lanabecestat early alzheimer disease daybreak alz study mild alzheimer disease dementia be unlikely meet primary endpoint completion lead decision discontinue study oral beta secretase cleave enzyme bace inhibitor company claim recommendation stop study be not base safety concern lilly do not expect incur significant cost related discontinuation maintain previously issue earning guidance meanwhile partnership lilly astrazeneca develop bace inhibitor remain intact lilly astrazeneca be also develop treatment alzheimer disease antibody target beta amyloid early stage study year date lilly share have rise industry decline be not first failure lilly alzheimer disease market november lilly amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease fatal illness cause progressive decline memory be challenge note several company have fail regard year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage alzheimer disease due safety concern february year merck mrk free report discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal alzheimer disease success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate alzheimer disease due lack efficacy late biogen alzheimer disease study ban fail show early positive result raise investor concern candidate chance success alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch lilly currently carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1788,JNJ,total earning total healthcare market capitalization be revenue growth growth rate seem unimpressive compare other sector earning revenue beat ratio respectively be also not great most notable player johnson johnson jnj free report be first major drug company report earning apr follow eli lilly company lly free report bristol myer squibb company bmy free report apr apr respectively other major drug company merck mrk free report pfizer pfe free report report industry bigwig come earning revenue beat earning focusjohnson world biggest maker healthcare product continue long streak earning beat earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year edge past estimate johnson johnson raise revenue guidance maintain earning share outlook reflect growth read healthcare etfs focus johnson johnson earning drug giant surpass earning estimate lag revenue earning share cent come cent zack consensus estimate revenue fall shy estimate annual basis earning share revenue rise respectively pfizer expect revenue range earning share merckmerck also beat earning estimate miss revenue earning share come surpass zack consensus estimate cent improve year quarter revenue inched year year be estimate merck increase revenue guidance earning share guidance bristol myersbristol myer top estimate front report earning share cent cent zack consensus estimate ahead year earning cent revenue grow edge past zack consensus estimate company raise earning share guidance see healthcare etfs here eli lillyeli lilly also surpass earning revenue estimate earning outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue guidance earning guidance etf anglepharma etfs see terrible trading past month mediocre result fail boost confidence space push many fund week lows have highlighted detail fund have zack etf rank hold ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period read be spdr pharmaceutical etf xph free report hot etf right now vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket focus firm account more share product have amassed asset base trade moderate volume share day expense ratio come fund have lose month powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest least share bmy pfe lly etf have lose month first trust nasdaq pharmaceutical etf ftxh free report fund track nasdaq smart pharmaceutical index hold security basket pfizer johnson johnson account more share merck bristol myer eli lilly make more ftxh have lower level aum share average daily volume charge bps annual fee have shed same time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1789,JNJ,pfizer inc pfe free report announce positive top line result phase iii comparative study evaluate pf company biosimilar version roche rhhby free report blockbuster leukemia drug rituxan mabthera rituximab notably rituxan be approve treat blood cancer include hodgkin lymphoma follicular lymphoma diffuse large cell lymphoma chronic lymphocytic leukemia well immunological disease rheumatoid arthritis share pfizer have gain year time underperform industry rally phase iii reflection study be design compare efficacy safety pharmacokinetic immunogenicity pf compare rituxan study meet primary endpoint demonstrate equivalence overall response rate first line treatment patient cd positive low tumor burden follicular lymphoma mark pfizer fifth propose biosimilar monoclonal antibody mab show positive trial result significantly pfizer biosimilar capability be substantially boost acquisition hospira december company launch ixifi second biosimilar version johnson johnson jnj free report merck co inc mrk free report blockbuster drug remicade unite state remind investor pfizer be evaluate biosimilar molecule various developmental stage incidentally biosimilar product late stage development include biosimilar version roche avastin abbvie humira also herceptin biosimilar version be review unite state well eu importantly novartis teva file regulatory application last year unite state biosimilar version rituxan september june respectively pfizer inc price pfizer inc price pfizer inc quote zack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1790,JNJ,market close mostly higher tuesday even nasdaq surge record high boost encourage earning netflix also hit record close dow edge lower due mixed corporate earning top component meanwhile congress approve bill keep government funded come week halter day government dow jone industrial average dji decrease less close rise close tech laden nasdaq composite index close gain fear gauge cboe volatility index vix increase close total share be trade wednesday higher last session average share advancer outnumber decliner nyse ratio nasdaq ratio favore advance issue netflix surge push nasdaq record territoryshare netflix nflx free report surge tuesday breaking market capitalization first time inception such feat be make possible company report add new international membership alone fourth quarter tech behemoth report earning share cent line zack consensus estimate cent year quarter revenue climb year year well estimate most strength come global stream revenue be year year read more such event bode well technology sector tech laden index nasdaq amassed point finish record post fresh record increase point close fresh record tuesday marked record so far january most number record close month major sector end positive territory real estate utility stock lead advancer utility select sector spdr etf xlu real estate select sector spdr xlre surge respectively gain broad market index be rather broad base make possible spate stupendous corporate earning so far current earning season company have beat earning expectation further company report earning fourth quarter surpass sale expectation dow edge lower mixed earning dow lose point finish day red briefly hit intraday high earlier session blue chip index suffer decline follow mixed corporate earning top component share johnson johnson jnj free report plunge report mixed fourth quarter earning company beat fourth quarter earning company report ep consensus call ep however revenue slightly miss expectation johnson johnson post revenue compare consensus estimate read more share procter gamble company pg free report decline report fourth quarter earning report net sale surpass zack consensus estimate top line grow year level foreign exchange have positive impact sale organically revenue grow back increase organic volume however price have negative impact sale read more further share verizon communication inc vz free report dip report mixed financial number fourth quarter top line beat zack consensus estimate bottom line lag same quarterly gaap net income be compare year quarter adjust earning share cent lag zack consensus estimate cent read more meanwhile share traveler company inc trv free report rally report fourth quarter earning surpass analyst expectation fourth quarter core income share comfortably beat zack consensus estimate whopping however bottom line deteriorate year year read more such mixed earning performance weigh heavily blue chip index lead lower see complete list today zack rank strong buy stock here congress approve government funding billfollow day government shutdown congress finally approve bill monday keep government funded week come right republican assured democrat immigration bill work bring floor matter few week vote house approve funding bill president trump sign monday night bill seek keep government funded feb stock make headlinesunited continental earning surpass decline yunited continental holding ual free report report better expect earning revenue fourth quarter read more canadian national earning revenue misscanadian national railway company cni free report fourth quarter earning fall short zack consensus estimate read more magellan reward unitholder distribution hikemagellan midstream partner mmp free report board director recently announce increase quarterly cash distribution fourth quarter read more hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1791,JNJ,earning season have commence johnson johnson jnj free report be first drug company report jan open bell world biggest maker health care product continue long streak earning beat offer decent outlook earning share come couple cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate company lag revenue estimate robust sale blood cancer treatment darzalex imbruvica well plaque psoriasis treatment tremfya johnson johnson issue outlook expect earning share come well ahead zack consensus estimate revenue be expect range high end be well zack consensus estimate see healthcare etfs here market impactdespite strong result share jnj drop much day mark biggest intraday decline august drop come circuit court appeal federal circuit upheld ruling company patent top selling arthritis drug remicade be invalid blow come just week jnj lose patent blockbuster prostate cancer drug zytiga currently stock have zack rank hold vgm score further johnson johnson belong solid industry zack rank top result investor closely watch movement stock keep close eye etfs have double digit allocation diversify drug maker have highlighted health care select sector spdr fund xlv free report most popular healthcare etf xlv follow health care select sector index fund manage nearly asset base trade heavy volume share expense ratio come annually total fund hold security basket jnj take top spot asset pharma account share sector look healthcare provider service biotech healthcare equipment supply make double digit exposure have zack etf rank hold medium risk outlook read healthcare etfs watch earning unfold ishare healthcare etf iyh free report fund offer exposure security tracking dow jone health care index here again johnson johnson dominate fund return total asset term industrial exposure pharma take top spot follow biotech healthcare equipment product have amassed nearly asset base charge bps annual fee trade good volume share day have zack etf rank medium risk outlook ishare edge msci multifactor healthcare etf hcrf free report etf follow msci usa health care diversify multiple factor capped index target company potential outperform broad healthcare sector hold stock basket jnj be top firm allocation industrial look manage health care pharmaceutical health care equipment biotechnology take double digit exposure product have accumulate asset base trade paltry volume share day average charge bps annual fee have zack etf rank ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index here too johnson johnson take top spot accounting share product have aum charge bps fee expense volume be lower exchange share day fund have zack etf rank high risk outlook read lie store pharma etfs vanguard health care etf vht free report etf track msci investable market health care index hold stock basket johnson johnson occupy top position allocation pharma take largest share biotech healthcare equipment round top spot vht be also popular liquid etfs aum average daily volume share charge bps annual fee have zack etf rank medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1792,JNJ,sandwich netflix nflx free report strong quarterly earning report bell yesterday texas instrument txn free report unite air line ual free report follow today close see fresh group earning hit tape week mark first several hundred publicly trade company bring result last quarter healthcare drug device package good giant johnson johnson jnj free report put mixed report earning beating estimate revenue fall tad short zack rank hold company report share surpass zack consensus cent revenue quarter fall slightly have be look however pharma unit grow year year full year earning guidance well ahead expect say revenue guidance full year be currently zack consensus more jnj earning click here competitor procter gamble pg free report report positive result fiscal report ahead today open bell earning share beat consensus estimate revenue outpace anticipate zack rank company report organic growth revenue volume more pg earning click here domestic telecom leader verizon vz free report also post mixed outcome period reverse company miss bottom line expectation cent share cent quarterly sale surpass zack consensus verizon also zack rank stock report post paid churn come total retail connection rise year year more vz earning click here paper sanitary product manufacturer kimberly clark kmb free report also beat bottom line expectation report share have be look share zack rank company fall just short full year guidance be well ahead zack consensus more kmb earning click here finally zack rank buy rate insurer traveler trv free report far outpaced expectation share report share morning be roughly year year however revenue top expect headline number be solid underwriting profit company fall more trv earning click here
1793,JNJ,tuesday january sandwich netflix nflx free report strong quarterly earning report bell yesterday texas instrument txn free report unite air line ual free report follow today close see fresh group earning hit tape week mark first several hundred publicly trade company bring result last quarter healthcare drug device package good giant johnson johnson jnj free report put mixed report earning beating estimate revenue fall tad short zack rank hold company report share surpass zack consensus cent revenue quarter fall slightly have be look however pharma unit grow year year full year earning guidance well ahead expect say revenue guidance full year be currently zack consensus more jnj earning click here competitor procter gamble pg free report report positive result fiscal report ahead today open bell earning share beat consensus estimate revenue outpace anticipate zack rank company report organic growth revenue volume more pg earning click here domestic telecom leader verizon vz free report also post mixed outcome period reverse company miss bottom line expectation cent share cent quarterly sale surpass zack consensus verizon also zack rank stock report post paid churn come total retail connection rise year year more vz earning click here paper sanitary product manufacturer kimberly clark kmb free report also beat bottom line expectation report share have be look share zack rank company fall just short full year guidance be well ahead zack consensus more kmb earning click here finally zack rank buy rate insurer traveler trv free report far outpaced expectation share report share morning be roughly year year however revenue top expect headline number be solid underwriting profit company fall more trv earning click here mark vickerysenior editorquestion comment article author click here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1794,JNJ,glaxosmithkline gsk free report partner pfizer inc pfe free report announce hiv focuse joint venture company viiv healthcare have initiate phase iii program evaluate drug hiv regimen dolutegravir tivicay lamivudine epivir study evaluate drug regimen maintenance viral suppression achieve hiv infected patient drug regimen tenofovir alafenamide fumarate taf base regimen remind investor glaxo be also evaluate drug base regimen cabotegravir johnson johnson jnj free report rilpivirine phase iii study treat adult virally suppress hiv infection moreover company be also evaluate cabotegravir monotherapy prevention hiv infection sexually active woman hiv treatment generally be drug base regimen latest entrant market be gilead science inc gild free report once daily single tablet regimen biktarvy bictegravir emtricitabine tenofovir alafenamide approve earlier month however glaxo be try reduce number medicine hic treatment regimen compromise efficacy conventional drug regimenshare glaxosmithkline have underperform industry so far year stock have lose industry rally period phase iii tango study investigate drug regimen treatment hiv phase iii program be design evaluate inferior antiviral activity combination regimen week compare continuation taf base regimen study also evaluate long term antiviral activity tolerability safety combination therapy week glaxo be also evaluate combination regimen gemini study patient hiv have receive prior treatment datum gemini tango study be anticipate note glaxo newest hiv medicine juluca be single tablet contain dolutegravir rilpivirine juluca be first drug regimen approve fda meanwhile several company interested develop drug treat life threaten disease competition have intensified manifold space glaxosmithkline plc price glaxosmithkline plc price glaxosmithkline plc quotezack carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1795,JNJ,theravance biopharma inc tbph free report share increase almost feb announce global collaboration agreement janssen subsidiary johnson johnson jnj free report jointly develop commercialize pan janus kinase jak inhibitor td treatment inflammatory intestinal disease notably td be be evaluate phase ib study moderate severe active ulcerative colitis august company announce positive result trial also plan initiate phase iib iii adaptive design induction maintenance program td year give indication additionally theravance be plan start phase ii study candidate crohn disease pursuant mentioned agreement theravance be entitle receive upfront payment be also eligible get potential payment remain collaboration completion phase ii activity moreover janssen be responsible develop td crohn disease phase ii theravance lead candidate development ulcerative colitis conclusion phase iib iii program janssen theravance share profit respective ratio potential sale unite state expense related potential phase iii program theravance share have underperform industry year time stock have lose versus industry increase theravance be focuse used target jak inhibitor treatment range inflammatory intestinal disease patient unite state be affected ulcerative colitis crohn disease respectively hence successful development candidate offer huge boost company top line apart td theravance pipeline include promising candidate revefenacin revefenacin be review unite state treatment copd theravance biopharma inc price theravance biopharma inc price theravance biopharma inc quote zack rank key pickstheravance carry zack rank hold better rank stock health care sector be exelixis inc exel free report xoma corporation xoma free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate have be revise upward cent cent last day company pull positive surprise trail quarters average beat share price company have surge year time xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1796,JNJ,geron corporation gern free report be expect report first quarter result last report quarter company deliver negative earning surprise geron share have significantly outperformed industry so far year stock have gain industry witness decline say time frame pipeline focusgeron revenue solely comprise license fee royalty have approve product portfolio moreover have only candidate pipeline imetelstat hence investor focus remain update related geron be develop imetelstat collaboration johnson johnson jnj free report treat patient hematologic myeloid malignancy myelofibrosis mf myelodysplastic syndrome mds acute myelogenous leukemia aml late stage study imetelstat be ongoing imbark phase ii treatment mf imerge phase ii iii treatment mds fourth quarter geron expand part imerge enrolled additional patient refine mds population confirm clinical benefit safety observed earlier consequently research development expense be expect be higher side soon be report quarter janssen decide continuation part ii imerge base datum expand part march geron announce phase ii imbark study be continue modification base clinical benefit potential overall survival benefit observed third internal review however be plan amend protocol study allow long term treatment patient decision continuation study be expect be announce third quarter note do not provide update imetelstat report first quarter result last month investor be solely banking continuation success study expect company provide update path forward imetelstat development first quarter conference call surprise historygeron performance last quarters be mixed company surpass expectation twice meeting same once miss once average positive surprise last quarters be earning whispersour proven model do not conclusively show geron be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank geron zack rank increase predictive power esp esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision geron corporation price ep surprise geron corporation price ep surprise geron corporation quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter aptevo therapeutic inc apvo free report have earning esp zack rank company be expect release first quarter result see complete list today zack rank stock here array biopharma inc arry free report have earning esp zack rank company be schedule release first quarter result medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1797,JNJ,last year turn be pretty good pharma biotech stock far fda decision be concern regulatory body approve novel drug easily surpass total tally landmark decision last year include approval couple gene base therapy cancer novartis nvs free report kymriah gilead science gild free report yescarta therapy have potential change way look cancer treatment just quarter go year fda have already grant approval new treatment key approval include jnj free report next generation oral androgen receptor ar inhibitor erleada apalutamide pre metastatic prostate cancer crpc vertex pharmaceutical incorporate vrtx free report third medicine treat underlie cause cf symdeko be combination tezacaftor ivacaftor gilead once daily single tablet hiv regimen biktarvy novartis lutathera certain neuroendocrine tumor drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst let take look few important regulatory event schedule month april note month fda have already approve pacira pharmaceutical exparel new indication nerve block regional analgesia clovis oncology parp inhibitor rubraca maintenance therapy recurrent ovarian cancer second indication novartis kymriah apr fda be expect give decision novartis supplemental biologic license application bla look approval kymriah second indication latest filing novartis be look get kymriah approve treatment adult patient relapse refractory diffuse large cell lymphoma dlblc most common form hodgkin lymphoma have fail more prior therapy kymriah be approve treatment deadly cancer call acute lymphoblastic leukemia last august accord company annual report dlblc patient do not respond initial therapy relapse month treatment indicate significant market potential kymriah dlblc indication fda decision mallinckrodt label expansion amitiza child mallinckrodt plc mnk free report supplemental new drug application snda look get constipation drug amitiza approve paediatric functional constipation year be review fda be expect give decision apr amtiza be add mallinckrodt portfolio february acquisition sucampo pharmaceutical amitiza be already approve chronic idiopathic constipation cic adult irritable bowel syndrome constipation ib adult woman opioid induced constipation oic patient chronic cancer pain accord company press release amitiza approve paediatric functional constipation be first only prescription medication specifically approve such patient have limit treatment option address disease fda panel back gw pharmaceutical epidiolex incyte lilly olumiant fda panel be expect give opinion gw pharmaceutical lead cannabinoid pipeline candidate epidiolex next week gw pharmaceutical be look get epidiolex approve adjunctive treatment seizure associate lennox gastaut syndrome lgs dravet syndrome be highly treatment resistant form childhood onset epilepsy fda grant priority review epidiolex nda response fda be expect jun epidiolex represent blockbuster potential especially be approve possible indication fda panel be also expect give opinion month incyte lilly lly free report olumiant baricitinib treatment adult patient moderately severely active rheumatoid arthritis april company have receive complete response letter crl fda baricitinib fda require additional clinical datum thenda olumiant be re submit january olumiant have already be launch select european country japan fetch sale fda take recommendation panel advisory committe account review application be not bound follow same fda decision rigel tavalisse ultragenyx burosumab april fda be expect give decision rigel pharmaceutical nda tavalisse fostamatinib treatment chronic immune itp apr rigel be prepare launch oral spleen tyrosine kinase syk inhibitor second quarter approve exist therapy treat chronic itp include steroid blood platelet production booster tpos splenectomy however still disease remain inadequately treat many patient mean approve tavalisse enjoy significant market potential fda decision expect apr be ultragenyx pharmaceutical bla burosumab treat pediatric adult patient link xlh burosumab be approve treat xlh trade name crysvita eu february fda decide prometic ryplazim fda decision expect apr be canadian biotech prometic life science biologic license application bla ryplazim treatment congenital plasminogen deficiency ryplazim enjoy orphan drug fast track designation fda say indication bristol myer opdivo yervoy combo get fda approval bristol myer bmy free report have file sbla look get blockbuster drug opdivo approve combination cancer drug yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc fda decision be expect apr clinical study combination have demonstrated superior overall survival os compare current standard care sunitinib intermediate poor risk patient bode well drug give potential target market pd inhibitor be presently approve several country include unite state eu japan several cancer indication label expansion boost opdivo sale further opdivo generate sale almost bristol myer be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1798,JNJ,fda refusal review plc alk free report depression candidate alk week be major setback company decision send stock tumble more alk once daily oral medication have be develop major depressive disorder mdd patient have not respond standard antidepressant therapy fda refuse review candidate state new drug application nda do not have enough evidence oral medication work fdawa opinion additional study be conduct ascertain drug effectiveness propose indication go say unexpected pipeline setback shift investor focus company market be develop drug treatment depression latest pipeline setback have shift investor focus market depression type depression be medical condition affect brain individual depression feel melancholic have intricacy enjoy routine activity factor such stress brain chemistry be most common cause depression also be genetic be different form depression such persistent depressive disorder perinatal depression disorder psychotic depression seasonal affective disorder bipolar depression psychotic depression persistent depressive disorder bipolar disorder be most severe form depression accord estimate person worldwide be affected depression have be see carry suicidal tendency thus rise press need develop drug condition know antidepressant drug be instrumental identify sign symptom ailment several pharma biotech company be involved develop selling depressantdrug stock focuslet look company be actively pursue development treatment various type depression allergan plc agn free report zack rank hold stock look well position depression market company have quite few product portfolio include vraylar schizophrenia bipolar disorder viibryd major depressive disorder saphris bipolar disorder drug be also several label expansion study earlier week allergan announce pivotal study evaluate vraylar treatment adult major depressive episode associate bipolar disorder bipolar depression meet primary endpoint moreover allergan moved rapastinel nmda receptor modulator phase iii development major depressive disorder rapastinel potentially game change treatment be expect be launch drug be expect generate revenue rapastinel be grant breakthrough therapy status adjunction major depressive disorder fda allergan be also evaluate flagship product botox treatment major depressive disorder allergan have outperformed industry year date company share have moved industry decline johnson johnson jnj free report healthcare giant have strong presence neuroscience segment be core therapeutic area company have product risperdal consta schizophrenia bipolar disorder portfolio most promising candidate pipeline be esketamine investigational antidepressant medication blockbuster potential esketamine nmda receptor antagonist have novel mechanism action get breakthrough therapy designation fda major depressive disorder imminent risk suicide esketamine have be grant breakthrough therapy designation treatment resistant depression regulatory application indication unite state be expect be file year zack rank buy stock have underperform industry year date company stock have lose compare industry decline see complete list today zack strong buy rank stock here eli lilly company lly free report pharmaceutical giant lilly major drug cymbalta be used treatment major depressive disorder generalized anxiety disorder fibromyalgia neuropathic pain neuroscience portfolio lilly include drug prozac treatment major depressive disorder obsessive compulsive disorder bulimia nervosa panic disorder zyprexa treatment schizophrenia acute mixed manic episode associate bipolar disorder bipolar maintenance lilly zack rank stock have underperform industry company share have decline compare industry sdecline sage therapeutic inc sage free report sage be company work development cns treatment company portfolio include novel pipeline candidate target critical cns receptor system gaba nmda company lead program brexanolone sage be late stage development super refractory status epilepticus rare severe seizure disorder well postpartum depression ppd brexanolone have be grant breakthrough therapy designation unite state priority medicine designation eu treatment postpartum depression sage be schedule move phase ii placebo controlled study therapeutic indication mdd ppd essential tremorand parkinson disease sage zack rank stock underperform industry year date company share have lose compare industry decline today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1799,JNJ,major bourse make remarkable comeback apr dow jone gain more point trough peak initially bourse have plunge key technical level china retaliate threat impose tariff number american good stock rebound investor gauge tariff threat be merely negotiating tactic side win risk full blow trade war trade conflict dent corporate profit impede economic expansion president trump also downplay fear tariff announce china unite state trade war worry dissipate broader market move north investing stock make most recovery seem judicious wall street massive dow jone rebound point plunge finish session point apr blue chip index thus register best single session comeback feb blue chip have slip end tech heavy nasdaq stage biggest intraday turnaround feb tumble end gain nasdaq logged gain be day apr gain point nasdaq rise point eventually erase steep open loss such gain close day move average second straight day indicate encourage long term trend particular gain back back session first time mar nasdaq meanwhile end positive territory year lead initial loss concern potential trade war unite state china have unnerved investor china ministry commerce plan impose tariff product include soybean airplane affect worth good american soybean manufacturer be likely face steep loss export almost yearly agricultural sale china investor be also selling share airline manufacturer boee company ba free report heavy equipment maker caterpillar inc cat behemoth have huge business operation china thus revenue profit be vulnerable trade dispute china retaliate trump administration levy duty chinese export worth list include video monitor electromagnet used mri machine aerospace product machinery levy tariff china punish second largest economy theft trade secret include software patent trade war worry investor soon realize country do not want full blow trade war tit tat tariff threat trade war be big worry corporate america profit be hurt trade restriction be put also deal heavy blow economy result widespread unemployment forget market pundit expect earning result be quite impressive trump economy be good shape jobless rate year low total earning company be estimate improve same period last year higher revenue highest quarterly earning growth pace year such uptick follow earning growth revenue improvement last quarter read more look ahead earning season white house also play notion trade war trump chief economic advisor larry kudlow tell reporter be willing resolve trade dispute minimum hassle come trump know action be not tough rhetoric forget be suppose impose hefty tariff foreign steel aluminum choose give exemption country mexico canada european union south korea australia brazil argentina top ally threaten retaliation top winner not only do major index end more last trading session also have scope scale higher reduce trade war fear have thus select stock make most encourage trend stock also flaunt zack rank strong buy buy tandem diabetes care inc tndm free report design develop commercialize various product person insulin dependent diabetes unite state company have zack rank zack consensus estimate current year earning moved last day stock expect growth rate current quarter year be respectively company yielded return apr addus homecare corporation adus free report provide personal care service elderly chronically ill disabled person individual be risk hospitalization unite state company have zack rank zack consensus estimate current year earning rise last day stock expect growth rate current quarter year be respectively company yielded return apr tailor brand inc tlrd free report operate specialty apparel retailer unite state company have zack rank zack consensus estimate current year earning moved last day stock expect growth rate current quarter year be respectively company return apr see complete list today zack rank stock here tellurian inc tell free report develop own operate natural gas business deliver natural gas customer company have zack rank zack consensus estimate current year earning moved last day stock project growth rate current quarter year be respectively company have yielded return apr johnson johnson jnj free report develop manufacture sell various product health care field company have zack rank zack consensus estimate current year earning climb last day stock estimate growth rate current quarter year be respectively company have yielded return apr today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1800,JNJ,johnson johnson jnj free report report mixed fourth quarter result beating zack consensus estimate earning slightly miss same sale drug consumer product giant issue decent outlook share be pre market trading fact past year share have return compare favorably increase witness industry earning beatj fourth quarter earning come share beating zack consensus estimate increase year period adjust earning exclude amortization expense special item include charge related recent tax law change include item report fourth quarter net loss share versus earning share year period sale miss slightlysale come slightly miss zack consensus estimate nonetheless sale increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis better see third quarter first half pharmaceutical segment continue positive momentum see third quarter fourth quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be core product xarelto stelara zytiga invega sustenna please note market imbruvica partnership abbvie inc abbv free report quarter record pulmonary arterial hypertension pah revenue acquisition swiss biotech actelion june last year diversify revenue pah category add sale growth however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition pharma segment achieve clinical milestone quarter include approval tremfya guselkumab eu november plaque psoriasis juluca dolutegravir rilpivirine first dual treatment hiv unite state please note juluca have be develop partnership glaxosmithkline gsk free report juluca be review eu tremfya be approve unite state july last year quarter also gain fda approval several line extension lower dose xarelto new indication simponi aria psoriatic arthritis ankylose spondylitis use adolescent stelara medical device segment sale come year period include operational increase positive currency movement domestic market sale rise year year international market sale increase operational increase year year consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market decline year period meanwhile international segment record increase reflect operational increase positive currency impact resultsfull year sale rise fall slightly short zack consensus estimate adjust earning be share zack consensus estimate year year earning be higher end guidance range share outlook issuedj issue decent guidance earning range be consensus estimate sale fall slightly short same expect adjust earning share range reflect operational growth rate company guidance exceed thezack consensus estimate share expect revenue range reflect operational constant currency sale growth rate range however sale guidance fall slightly short zack consensus estimate acceleration underlie sale growth see third quarter continue fourth quarter quite few key product portfolio remicade concerta face generic competition believe new product segment label expansion drug imbruvica darzalex contribution actelion lead better sale trend second half compare first half profit outlook be also quite upbeat carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1801,JNJ,alzheimer fatal illness cause progressive decline memory have always be highly challenge area not much progress be make spite significant investment fund resource tuesday lilly lly free report swiss partner astrazeneca azn free report say be discontinue late stage study alzheimer disease candidate lanabecestat recommendation independent datum monitoring committee idmc idmc say study be unlikely meet primary goal completion prompt decision stall study oral beta secretase cleave enzyme bace inhibitor several company have fail develop safe effective treatment option deadly brain disease year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage ad due safety concern february year merck mrk free report discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal ad success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate ad due lack efficacy january pfizer pfe free report say end effort alzheimer parkinson disease area long back pfizer have shelved late stage ad candidate bapineuzumab iv fail phase iii study late biogen biib free report ad study ban fail show early positive result raise investor concern candidate chance success clinical stage company axovant science suffer major setback september investigational ad candidate fail meet co primary efficacy endpoint late stage study company decide discontinue development mg dose treatment ad lilly decide november not seek approval investigational ad treatment solanezumab follow disappointing result late stage study candidate be be evaluate see slow progression memory problem associate amyloid protein form plaque brain person alzheimer accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval be somewhat underlie cause severe neurological ailment alzheimer not be clear disease cancer also alzheimer progress go unnoticed year time symptom ailment become evident significant function be already lose make develop drug treat disease difficult interest still alive setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale biogen novartis nvs free report eisai astrazeneca amgen be presently work alzheimer disease treatment biogen ad pipeline comprise mid well late stage candidate different mechanism action include tau candidate biib amyloid aducanumab candidate well bace inhibitor elenbecestat program candidate be be develop collaboration eisai meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be collaborate ac immune development alzheimer disease treatment lilly astrazeneca be also develop treatment alzheimer disease antibody target beta amyloid early stage study earlier year fda propose new guideline be aim lower clinical study goal alzheimer disease drug aim treat earlier stage patient have not yet display functional disability clinical abnormality strategy be part fda ongoing effort expand access safe effective treatment option many serious condition effort fda also reinvigorate research effort alzheimer drug repeat failure lilly merck carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1802,JNJ,merck co inc mrk free report report first quarter adjust earning share beat zack consensus estimate cent earning rise year year attributable slightly higher sale lower cost quarter include charge related formation collaboration eisai first quarter earning share be cent compare earning cent share year quarter revenue quarter rise year year sale however slightly miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale rise year year quarter pharmaceutical segment generate revenue exclude fx impact year year mainly strong sale pd inhibitor keytruda gardasil bridion offset lower sale other key therapy rotateq zepatier hepatitis zostavax prevention shingle previous quarters loss market exclusivity several drug also hurt top line keytruda largest product merck portfolio bring sale first quarter sequentially year year sale continue be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve first line set keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer keytruda development program be also progress well several regulatory decision new indication unite state well europe pending year label expansion approve expand patient population drive sale higher zepatier bring sale year quarter due increase competition decline volume be expect continue bridion sugammadex injection generate sale quarter year year drive strong global demand meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cancida lose exclusivity europe zetia lose market exclusivity unite state december vytorin lose exclusivity april decline almost quarter remicade sale decline quarter merck market brand version remicade outside unite state johnson johnson jnj free report market rheumatoid arthritis drug country cancida sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin sale isentress decline quarter januvia janumet diabetes franchise sale rise higher international sale be partially offset lower sale due continue pricing pressure gardasil gardasil sale rise lower sale unite state be offset commercial launch china strong growth europe continue transition dose regimen impact volume unfavorably unite state zostavax sale decline quarter face strong competition glaxo gsk free report newly approve shingle vaccine shingrix merck animal health segment generate revenue exclude fx impact year quarter primarily drive higher sale companion animal product growth ruminant poultry business gross margin decline cost increase adjust gross margin come basis point bps year quarter marketing administrative expense be report quarter research development spend decrease quarter due lower licensing cost partially offset increase investment pipeline early drug development guidance raisedmerck raise outlook revenue range previously zack consensus estimate stand revenue guidance include approximately positive impact currency fluctuation company now expect adjust earning range raise previous guidance zack consensus estimate be peg share adjust earning guidance include approximately positive impact currency fluctuation adjust operate expense be still expect increase year year low mid single digit rate takemerck first quarter result be mixed company beat estimate earning miss same sale also raise guidance share be pre market trading so far year merck share have outperformed industry merck share have rise period decrease industry eye be performance keytruda be be tout key long term growth driver merck drug continue robust performance strong demand trend several label expansion slate year sale be expect increase further however significant decline sale zostavax zepatier due rise competitive pressure remain concern meanwhile generic competition several drug pricing pressure continue be overhang top line merck co inc price consensus ep surprise merck co inc price consensus ep surprise merck co inc quotezack rank key pickmerck carry zack rank buy ligand pharmaceutical incorporate lgnd free report be better rank stock health care sector sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate moved remain stable last day company deliver positive surprise trail quarters average beat share price company have increase year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1803,JNJ,protagonist therapeutic inc ptgx free report announce have discontinue phase iib study propel ulcerative colitis uc candidate ptg protagonist be small biotech company focuse develop treatment inflammatory bowel disease crohn disease thalassemia ptg be most advanced candidate company pipeline share company fall follow news fact protagonist share be so far year underperform industry decline period discontinuation decision be base plan interim analysis propel study independent datum monitoring committee committee deem study not be able achieve primary endpoint clinical remission interim analysis be do datum first patient have complete week treatment ptg total patient population study be however company be conduct extensive review datum study have notified stop further treatment patient currently study protagonist have also postpone decision initiate phase ii iii ptg patient chronic pouchitis await full review interim datum propel study apart ptg company be develop candidate ptg ptg separate phase study treatment crohn disease beta thalassemia respectively company have worldwide license collaboration agreement johnson johnson jnj free report development ptg moreover ptg enjoy orphan drug designation unite state protagonist therapeutic inc price protagonist therapeutic inc price protagonist therapeutic inc quotezack rank other stock currently sport zack rank strong buy other top rank stock health care sector include horizon pharma public limit company hznp free report ligand pharmaceutical incorporate lgnd free report stock carry zack rank buy see complete list today zack rank stock here horizon pharma earning estimate increase last day company deliver positive earning surprise trail quarters average beat ligand earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share have increase so far year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1804,JNJ,glaxosmithkline plc gsk free report have withdraw race buy pfizer pfe free report consumer healthcare segment last october pfizer have say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year ultimately opt retain businessglaxo chief executive officer emma walmsley say management be interested deal improve company return not compromise priority capital allocation pfizer be have tough time find buyer consumer healthcare segment last week british company reckitt benckiser group also pull discussion pfizer buy latter consumer health segment reckitt benckiser backed glaxo be see frontrunner buy pfizer unit share glaxo be friday response positive news glaxo stock have rise year so far decline industry separate press release pfizer announce shingle vaccine shingrix have gain regulatory approval japan eu please note shingrix be approve unite state canada october last year also shingrix enjoy preferential recommendation center disease control prevention advisory committee immunization practice acip last year acip recommend shingrix prevention shinglesover merck mrk free report zostavax yet release glaxo announce committee medicinal product human use chmp europe have grant positive opinion recommend approval juluca drug regimen dolutegravir rilpivirine once daily single pill hiv juluca become first drug pill be approve europe final decision european commission eu be expect end second quarter juluca be approve unite state november last year juluca have be develop glaxo pfizer hiv focuse company viiv healthcare partnership johnson johnson jnj free report glaxo carry zack rank buy see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1805,JNJ,plc alk free report announce submission new drug application nda fda pipeline candidate alk nda seek fda approval candidate usage adjunctive treatment major depressive disorder mdd approve be first therapeutic option patient depression novel mechanism action remind investor october fda have grant fast track status alk adjunctive treatment mdd patient inadequate response standard antidepressant therapy fast track designation fda facilitate development expedite review drug be intend treat serious condition address medical need share have underperform industry year time stock have gain compare industry increase notably nda submission be support encourage efficacy safety datum package more clinical trial conduct more patient aforementioned indication candidate have demonstrated antidepressant activity safety tolerability development program june company initiate phase iiib study mdd patient evaluate alk subject enrolled trial have earlier show inadequate response commonly prescribe depression drug company press release be annually diagnosed mdd unite state large number do not get sufficient relief first line standard antidepressant therapy hence approval drug provide company access huge patient population base look new treatment apprehend serious mental illness revenue continue be drive proprietary product vivitrol aristada partner product namely johnson johnson jnj free report risperdal consta invega sustenna xeplion invega trinza trevicta acorda therapeutic acor free report ampyra fampyra astrazeneca azn free report bydureon notably company progress pipeline candidate target major cns central nervous system disorder such schizophrenia addiction depression multiple sclerosis have be impressive successful development subsequent other interesting candidate alk phase iii schizophrenia alk phase iii multiple sclerosis alk phase iii help physician transition patient physical dependence opioid vivitrol lend huge boost company plc price plc price plc quote zack rankalkerme carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1806,JNJ,amgen amgn free report announce receive positive opinion committee medicinal product human use chmp european medicine agency recommend addition update overall survival os datum phase iii head head study label multiple myeloma drug kyproli carfilzomib phase iii endeavor study be conduct patient datum trial demonstrated combination kyproli dexamethasone kd lead superior overall survival compare takeda pharmaceutical velcade dexamethasone vd second line multiple myeloma set finding show combination therapy reduce risk death increase os month compare vd give patient population importantly january amgen announce fda have approve supplemental new drug application snda include os datum endeavor program kyproli label fda decision come much earlier expect initially expect april year note kd regimen be already approve unite state eu other country base primary analysis progression free survival endeavor study overall survival datum approve help drive usage kyproli boost sale remind investor kyproli be also approve unite state single agent treat patient multiple myeloma have receive least prior therapy include velcade agent significantly amgen collaborate johnson johnson jnj free report november study combination kyproli darzalex multiple clinical study address case multiple myeloma term agreement first study phase iii registrational trial evaluate combo therapy kyproli darzalex dexamethasone compare kyproli dexamethasone alone patient multiple myeloma have undergo prior line therapy have be initiate amgen share have outperformed industry year time stock have rally compare favorably industry increase incidentally kyproli become part amgen portfolio follow acquisition onyx register sale first month compare year figure drug label expansion immensely expand patient population well commercial potential company press release multiple myeloma be aggressive disease accounting approximately percent cancer moreover patient be annually diagnosed multiple myeloma europe almost case prove be fatal hence market opportunity combination therapy be huge eu cater unmet need patient additional option apprehend life threaten disease amgen inc price amgen inc price amgen inc quote zack rank key picksamgen carry zack rank hold better rank stock health care sector be xoma corporation xoma free report exelixis inc exel free report xoma sport zack rank strong buy exelixis carry zack rank buy see complete list today zack rank stock here xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month exelixis earning share estimate have be revise upward cent cent last day company pull positive surprise trail quarters average beat share price company have soar year time hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1807,JNJ,novartis ag nvs free report announce committee medicinal product human use chmp european medicine agency ema adopt positive opinion marketing authorization propose biosimilar johnson johnson jnj free report remicade infliximab chmp recommend approval biosimilar indication brand drug rheumatology dermatology note remicade be approve treat crohn disease adult child ulcerative colitis rheumatoid arthritis psoriatic arthritis ankylose spondylitis plaque psoriasis positive opinion be base comprehensive datum package be expect confirm biosimilarity infliximab original drug analytical preclinical clinical datum match quality efficacy safety earlier phase iii confirmatory study rheumatoid arthritis reflection meet primary endpoint demonstrate equivalent efficacy propose sandoz biosimilar infliximab reference medicine measure american college rheumatology acr response week novartis share have decline year compare industry fall novartis generic arm sandoz be leader biosimilar market product market biosimilar include omnitrope human growth hormone binocrit erythropoiesis stimulating agent used treat anemia filgrastim neutropenia brand name zarzio outside unite state zarxio unite state rixathon biosimilar rituximab approve europe treat blood cancer immunological disease also approve eu riximyo duplicate marketing authorization erelzi biosimilar approve europe treat multiple inflammatory disease fda also approve biosimilar erelzi however launch be pending unite state due ongoing litigation amgen amgn free report ema be due review chmp opinion note sandoz acquire biosimilar infliximab pfizer pfe free report february eu country norway iceland liechtenstein form eea term pfizer retain manufacturing right infliximab pf country outside eea meanwhile sandoz have quite number biosimilar pipeline tentative approval further boost company generic division company have also file approval biosimilar adalimumab pegfilgrastim eu apart froma strong generic portfolio novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space zack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1808,JNJ,abbvie inc abbv free report post impressive result first quarter better expect earning revenue moreover company raise expectation bottom line response share too climb almost pre market trading share abbvie have surge year time significantly outperform industry rise company report earning share first quarter beating zack consensus estimate also figure grow year year earning also surpass previous expect range company post revenue quarter review marginally trumping zack consensus estimate top line also increase year year exclude favorable impact foreign exchange rate fluctuation operational revenue rise revenue show higher growth compare previous projection mid range operational basis quarter detailkey drug humira record sale growth operational basis revenue come sale unite state increase humira sale ex market be operational basis report basis growth major market category drive upside stiffer competition new class drug well indirect biosimilar contest international market first quarter net revenue imbruvica be year year sale imbruvica gross compare year figure abbvie logged international profit sharing johnson johnson jnj free report other product have deliver impressive performance include duodopa show revenue growth operational report basis product call creon witness ascent revenue operational report basis hcv chronic hepatitis virus product record sale significantly compare last report adjust sg expense increase expense escalate first quarter adjust operate margin be sale notably first quarter earning abbvie announce intention commence tender offer purchase share common stock cash value company expect initiate same early outlookabbvie raise adjust ep range compare predict earlier earning guidance reflect year year surge mid point zack consensus estimate metric current year be peg share abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quote zack rank key picksabbvie carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report infinity pharmaceutical inc infi free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have surge year infinity loss share estimate have narrow cent cent cent last day company deliver positive surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1809,JNJ,johnson johnson jnj free report bellwether healthcare company have strong presence pharmaceutical medical device consumer care market world new jersey base company be well know baby care product brand tylenol addition drug remicade concerta however many peer jnj be face generic competition pricing pressure product pharmaceutical segment scenario investor focus remain late stage pipeline candidate commercial potential well performance new product apart usual top bottom line number jnj have pretty good earning track record company deliver positive earning surprise last quarters average positive surprise estimate have go slightly past day currently jnj have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat jnj beat fourth quarter earning company report ep consensus call ep revenue miss revenue slightly miss expectation johnson johnson post revenue compare consensus estimate key statistic pharmaceutical segment sale rise year year reflect operational growth positive currency impact sale rise domestic international marketsissu outlook issue mixed guidance earning range be consensus estimate sale fall slightly short same expect adjust earning share range company guidance range top zack consensus estimate stand share revenue guidance be range however sale guidance fall short zack consensus estimate stock price impact share rise pre market trading check back later full jnj earning report later johnson johnson price consensus johnson johnson price consensus johnson johnson quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1810,JNJ,strong global economy newly pass tax law have bring new attention bottom line world most powerful company report season not feel effect new force investor be certainly focuse intently latest earning announcement right now wave fourth quarter earning report be only just pick so far wall street have be impressed friday pre market announcement member have report tally average earning growth rate higher revenue course investor be always look find company be poise post better expect earning result experience strong post earning gain luckily zack premium customer utilize earning esp screener order search stock be expect beat zack earning esp expect surprise prediction look find earning surprise focuse most recent analyst estimate be do generally speaking analyst post estimate right earning release mean have fresh information potentially be more accurate analyst thought company month positive earning esp pair zack rank hold better ranking help feel confident potential earning beat fact year backtest have reveal methodology have accurately produce positive surprise time today be give reader very special treat free look strongest stock be pop earning esp screener right now check johnson johnson jnj free report johnson johnson be world largest manufacturer pharmaceutical personal healthcare item company be schedule release fiscal fourth quarter earning report market open jan jnj be currently sporting zack rank hold have earning esp base latest consensus estimate expect see johnson johnson report earning share revenue result represent year year growth respectively la vegas sand corp lvs free report la vegas sand be casino operator company property portfolio include historic venetian resort sand expo convention center venetian macau la vegas sand be schedule release latest quarterly result close bell jan lvs be currently zack rank buy have earning esp accord latest consensus estimate la vegas sand be project post earning share revenue represent year year growth respectively sei investment company seic free report sei investment be lead global provider asset management investment technology solution company innovative solution help corporation financial institution financial advisor affluent family create manage wealth sei be schedule release latest report jan stock be currently zack rank strong buy have earning esp base latest consensus estimate sei be expect report earning share revenue result represent year year growth respectively want more analysis author make sure follow ryan_mcqueeney twitter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1811,JNJ,healthcare be perform well start new year thank encourage industry trend favorable policy environment notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain nearly so far bullish trend be likely continue head earning season big name johnson johnson jnj free report pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read tax bill etf investor need know let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stocksjnj have zack rank earning esp indicate lower chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive momentum style score value growth style score johnson johnson be slate release earning jan open bell see healthcare etfs here pfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see positive earning estimate revision penny be report quarter deliver average negative earning surprise past quarters have impressive growth value momentum style score respectively pfizer be schedule report earning jan open bell merck be expect report result feb market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision couple cent past day be report quarter merck have value growth momentum style score respectively amgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day quarter be report stock have solid value style score growth momentum style score look dull amgen report earning feb market close read wave push biotech etfs higher abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter stock have solid value growth style score momentum style score be unimpressive company be schedule report jan open bell gilead be expect release earning feb market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision cent past month be report quarter have solid value style score growth momentum style score look ugly bristol myer likely report earning feb open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have solid momentum growth style score respectively unfavorable value style score sum earning surprise well card healthcare sector be expect witness earning growth fourth quarter suggest upside healthcare etfs particular etfs have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1812,JNJ,novartis nvs free report announce fda have approve line extension il inhibitor drug cosentyx moderate severe scalp psoriasis fda approval come back positive efficacy safety outcome dedicate phase iii study scalp patient scalp psoriasis note drug be approve similar indication europe june be already approve treatment plaque psoriasis psoriatic arthritis psa ankylose spondylitis press release scalp psoriasis be difficult treat form psoriasis affect half approximately patient disease line extension drug be important achievement treatment scalp psoriasis topical agent phototherapy be challenge due presence hair other factor novartis share have return past year compare industry gain same period scalp study evaluate subcutaneous administration cosentyx mg week datum show significant improvement patient compare placebo cosentyx performance be impressive achieve multus blockbuster drug status back strong growth approve indication sale drug increase surpass mark drug have show superiority clinical study johnson johnson jnj free report stelara amgen amgn free report enbrel treat psoriasis novartis be also conduct head head clinical trial exceed surpass evaluate superiority cosentyx versus abbvie abbv free report humira psa propose biosimilar humira respectively superiority drug stelara enbrel have help gain market share potential superiority humira biosimilar line extension scalp psoriasis certainly boost prospect drug novartis ag price novartis ag price novartis ag quotezack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1813,JNJ,merck co inc mrk free report report fourth quarter adjust earning cent share beat zack consensus estimate cent earning rise year year slightly higher sale lower taxe higher other income make higher cost quarter include provision related tax reform fourth quarter loss share be cent compare loss cent share fourth quarter revenue quarter rise year year sale however slightly miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale rise year year lose sale market due network cyber attack june hurt top line however sale quarter be boost addition sale terminate december vaccine joint venture sanofi sny free report europe approximately quarter pharmaceutical segment generate revenue exclude fx impact year year continue strong sale pd inhibitor keytruda bridion offset lower sale key vaccine hpv vaccine gardasil gardasil unite state zostavax prevention shingle previous quarters loss market exclusivity several drug also hurt top line keytruda second largest product merck portfolio bring sale fourth quarter sequentially year year sale continue be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve first line set keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer keytruda development program also significantly advanced regulatory approval new indication unite state europe japan approval expand patient population drive sale higher zepatier bring sale previous quarter bridion sugammadex injection generate sale quarter year year drive strong demand meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cancida lose exclusivity europe zetia lose market exclusivity unite state december vytorin lose exclusivity april decline quarter remicade sale decline quarter merck market brand version remicade outside unite state johnson johnson jnj free report market rheumatoid arthritis drug country cancida sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin sale isentress also decline quarter januvia janumet diabetes franchise remain soft quarter januvia janumet franchise record sale quarter year quarter higher global volume partially offset impact continue pricing pressure isentress sale decline quarter lower volume demand due competitive pressure hurt sale isentress gardasil gardasil sale rise lower sale unite state be offset commercial launch china strong growth europe unfavorable timing public sector purchasing partial replenishment borrow dose gardasil gardasil center disease control prevention cdc adversely impact gardasil sale unite state however sale rise europe be boost addition sale terminate vaccine joint venture sanofi zostavax sale decline quarter face strong competition glaxo gsk free report newly approve shingle vaccine shingrix merck animal health segment generate revenue exclude fx impact year quarter primarily drive higher sale companion animal product primarily bravecto companion animal vaccine growth ruminant business gross margin decline cost increase adjust gross margin come basis point bps year quarter marketing administrative expense be flat report quarter research development spend increase quarter due increase investment pipeline early drug development higher business development expense also raise cost quarter resultsfull year sale miss zack consensus estimate revenue be guidance range sale rise year year adjust earning be share beat zack consensus estimate share well guidance range earning rise year year guidancerevenue be expect range zack consensus estimate stand revenue guidance include approximately positive impact currency fluctuation company expect adjust earning range zack consensus estimate be peg share adjust earning guidance include approximately negative impact currency fluctuation adjust operate expense be expect increase year year low mid single digit rate merck also say expectation improve cash position follow tax reform plan invest approximately next year capital expenditure approximately investment be make unite state takemerck fourth quarter result be mixed company beat estimate earning miss same sale also issue line guidance share be slightly pre market trading past year merck share have underperform industry merck share have decline period compare unfavorably increase industry eye be performance keytruda be be tout key long term growth driver merck drug continue robust performance strong demand trend however significant decline sale zostavax due rise competitive pressure be concern meanwhile generic competition several drug pricing pressure continue be overhang top line merck carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1814,JNJ,bristol myer squibb company bmy free report first quarter earning cent share exceed zack consensus estimate cent year quarter earning cent total revenue be slightly higher zack consensus estimate increase record year period strong sale opdivo eliquis contribute top line report quarter share company be almost pre market trading possibly better expect earning however bristol myer share have decline so far year compare unfavorably industry decrease quarterly detailsrevenue be year year adjust foreign exchange impact revenue increase unite state outside country ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year sale drug be label expansion drug pediatric patient unite state last november presumably do not have much impact sale rheumatoid arthritis drug orencia be first quarter melanoma drug yervoy contribute top line report quarter sale drug be opdivo be approve multiple cancer indication generate revenue year period sale cardiovascular drug eliquis be report quarter year year multiple myeloma drug empliciti record sale year year however performance key drug virology unit continue disappoint sale baraclude decline reyataz sustiva franchise deteriorate year year respectively hepatitis franchise lose year quarter sale contribute mere revenue research development expense quarter decrease marketing selling administrative expense decline gross margin be quarter compare year quarter due change product mix regulatory quarter april fda approve opdivo yervoy combination regimen treat intermediate poor risk advanced renal cell carcinoma patient have not receive prior treatment march fda have grant priority review supplemental biologic license application sbla seek approval combination regimen treat microsatellite instability high mismatch repair deficient metastatic colorectal cancer also april fda grant priority review sbla seek approval opdivo monotherapy patient small cell lung cancer third later line set new dose regimen opdivo mg week be also approve majority indication april bristol myer collaborate johnson johnson jnj free report subsidiary janssen develop commercialize factor xia inhibitor program include bms treat major thrombotic condition same month bristol myer privately hold illumina inc announce collaboration utilize latter next generation sequence technology february bristol myer squibb nektar therapeutic nktr free report enter strategic development collaboration nektar lead immuno oncology program nktr collaboration company develop commercialize nktr combination opdivo opdivo yervoy more indication tumor type well potential combination other cancer agent respective company third party company plan initiate study renal cell carcinoma melanoma mid pipeline updatein april bristol myer announce datum phase iii study checkmate show superior progression free survival first line small cell lung cancer nsclc treat opdivo yervoy combination compare chemotherapy january bristol myer announce positive datum phase ii checkmate study evaluate combination opdivo yervoy patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer mcrc company also announce datum phase iii study checkmate evaluate opdivo chinese population datum show drug achieve superior overall survival previously treat patient nsclc compare docetaxel datum long term follow phase iii study checkmate show opdivo reduce risk death metastatic squamous cell carcinoma head neck minimum year follow compare standard chemotherapy march bristol myer pfizer inc pfe free report announce datum real world datum analysis different direct oral anticoagulant include eliquis xarelto boehringer ingelheim pradaxa datum show eliquis achieve significantly lower rate stroke systemic embolism major bleed compare xarelto pradaxa guidance updatedbristol myer increase adjust earning expectation company now project earning range share previously zack consensus estimate earning be peg company expect worldwide revenue increase mid single digit takebristol myer beat earning expectation primarily robust sale opdivo eliquis quarter increase guidance adjust earning be also encourage be positive bristol myer effort develop pipeline especially opdivo several label expansion application opdivo be review unite state europe potential approval further boost prospect blockbuster drug also superiority eliquis real world datum analysis be expect further boost sale drug bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotebristol myer carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1815,JNJ,share johnson johnson jnj free report hit new week high jan eventually close day stock hit new high probably reuter news state chinese bidder be plan buy diabetes care unit country deal be worth billiona be stock have have great run past year share have rally year industry have register increase promising datum several pivotal study rapid progress pipeline line extension year keep stock growth trajectory positive trend be likely continue well company receive approval new drug last year guselkumab tremfyain unite statesas well eu plaque thefirst dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state juluca be review eu also receive fda approval several line extension lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene corporation celg free report multiple myeloma drug pomalyst sixth indication imbruvica other investor note market imbruvica partnership abbvie inc abbv free report line extension expand eligible patient population drug drive sale sale company pharma segment accelerate third quarter trend be likely continue fourth quarter well asin believe new product segment label expansion drug imbruvica xarelto darzalex contribution recent acquisition mainly actelion support top line growth year expect file approval depression candidate esketaminewhile pre metastatic prostate cancerand symtuza darunavir base once daily single tablet regimen be approve fda several pivotal datum readout regulatory milestone expect bullish run stock be likely continue johnson johnson price johnson johnson price johnson johnson quote zack rank have zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1816,JNJ,johnson johnson jnj free report healthcare bellwether report fourth quarter result jan open bell last quarter company report positive earning surprise share have gain past year outperform increase witness industry belong earning beat expectation last quarters average positive surprise let see thing be shape announcement factor considerwe believe strong performance pharmaceutical segment well positive contribution acquisition actelion abbott medical optic pull top line fourth quarter however higher investment product launch put pressure profit third quarter domestic pharma segment sale decelerate first half however sale growth accelerate third quarter be likely see continuation positive trend fourth quarter probably believe new product segment label expansion drug imbruvica xarelto darzalex meaningful contribution swiss biotech actelion buy june support top line however biosimilar competition be expect hurt sale key arthritis drug remicade outside unite state new drug be approve last year include tremfya guselkumab unite state july well eu november plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state november juluca be review eu regard tremfya say third quarter conference call have be well receive physician patient drug be likely contribute sale soon be report quarter expect update plan juluca fourth quarter conference call medical device segment sale continue gain mainly inclusion abbott medical optic acquisition diabetes care unit be however expect remain weak hurricane texas florida puerto rico hurt sale growth last report quarter due lose surgery day third quarter call company have say supply disruption be not anticipate be not clear time surgical procedure miss third quarter be re-cover fourth pricing issue india system outage europe also hurt sale extent remain be see issue be resolve time consumer segment global consumer category slowdown many company market continue hurt sale however recent acquisition well new product be likely provide support model proven model do not conclusively show be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be uncover best stock buy sell re report earning esp filter zack rank zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considera couple stock large cap pharma sector have positive earning esp favorable zack rank be merck co inc mrk free report earning esp zack rank company be schedule release result feb pfizer inc pfe free report be schedule release result jan company have earning esp zack rank see complete list today zack rank stock here johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson quotezack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1817,JNJ,dow endure volatile week index hit fresh record high fall bank share lead loss index monday index slip tuesday follow positive news major component surge treasury yield lead loss index wednesday ultimately index surge record high thursday follow investor optimism economic growth last week dow gain last friday due optimism build implementation gop tax bill such broad base gain ensure improvement major benchmark negating effect dismal economic datum nonfarm payroll month december come lower consensus estimate job addition further trade deficit increase november settle be highest deficit january ism service index december decline point index add impressive point friday finish session milestone second straight day marked third straight record close last trading session best open week gain blue chip index be rather broad base last week index gain marked dow best weekly run dec period dow touch psychological level first time be index fastest point rise inception optimism strong market performance contribute gain favorable economic datum include upbeat manufacturing report record construction spending boost market dow index lose almost nearly point monday due fall bank share snap winning run marked end day streak gain blue chip index hit intraday record earlier session suffer broad base loss finish negative territory share major bank such goldman sachs group inc gs free report jpmorgan chase co jpm free report decline respectively weigh dow bank share decline analyst estimate be time charge fourth quarter earning bank suffer due implementation tax reform index increase tuesday follow report boee company ba free report have deliver record number airplane push dow record territory such event lead share boee gain contribute much point dow blue chip index amassed point finish record also contribute dow gain be increase share johnson johnson jnj free report gain add point dow index lose wednesday yield year benchmark note surge follow report china be consider halter purchase treasury market also suffer loss report canada surface government expect trump pull nafta soon meanwhile cost import good unite state surge year high index gain point thursday hit time high follow investor optimism economic growth share boee gain emerge largest contributor dow aircraft manufacturer likely be major beneficiary higher economic growth meanwhile ppi index decline move lower first time more year component move indexboee delivery show rise commercial shipment decline defense shipment year year basis company report commercial delivery jet higher delivery figure be company delivery guidance zack rank hold boee deliver model airplane follow delivery model boee deliver unit model compare unit year other delivery include compare unit respectively defense space business boee delivery be year total delivery consist apache helicopter new remanufacture chinook helicopter new renew read boee commercial defense jet delivery meanwhile boee defense space security unit recently secure modification contract worth production increment lot small diameter bomb sdb term deal company purchase additional quantity sdbs read boee win fms deal build small diameter bomb apple inc aapl free report announce be work feature provide increase parental control smartphone usage child announcement be make follow apprehension apple shareholder jana partner llc california state teacher retirement system regard role company shape child future bloomberg zack rank apple response criticism also mentioned iphone other apple product run io have be offer parent tool enable control child access company also offer ask buy feature require consent parent buy good service add bloomberg company be focuse make vigilance stricter new tool read apple develop tool increase parental control merck co inc mrk free report japanese partner easai co ltd announce fda have grant breakthrough therapy designation btd combination regimen zack rank merck pd therapy keytruda easai multiple receptor tyrosine kinase inhibitor lenvima company be develop combination potential treatment advanced metastatic renal cell carcinoma rcc kidney cancer be btd keytruda second lenvima designation aim expedite development review drug intend treat serious life threaten condition provide patient access soon possible read merck keytruda combo get breakthrough therapy status meanwhile merck announce phase iii study evaluate pd therapy keytruda monotherapy treatment high risk melanoma meet primary endpoint recurrence free survival rfs read merck keytruda succeed high risk melanoma study chevron corporation cvx free report effort divest stake south africa business china petroleum chemical corporation snp free report better know sinopec have be approve country competition commission notably sinopec acquire stake asset subsidiary soihl hong kong hold limit completion deal soihl manufacturer supplier petroleum petrochemical product enter south african petroleum market stock have zack rank strong buy see complete list today zack rank strong buy stock here pfizer inc pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff decision end neuroscience discovery program mainly affect employee facility andover cambridge groton ct zack rank pfizer however intend continue development pain candidate tanezumab be develop late stage study partnership eli lilly lly free report label expansion effort pain drug lyrica rare disease program read pfizer stall alzheimer parkinson cut job coca cola co ko free report affiliate chile local bottler brand enter agreement buy novaverde sa move be line strategy invest newer revenue generate platform company specialize juice canned fruit vegetable mainly brand guallarauco coca cola have zack rank embotelladora andina coca cola del valle new venture coca cola chile enter stock purchase agreement ownership novaverde share be transfer completion deal coca cola del valle new venture own share coca cola chile embotelladora andina own share respectively gain ownership share embotelladora andina direct indirect ownership novaverde be approximately be already shareholder coca cola del valle new venture deal be value accord reuter report read coca cola chilean arm buy novaverde diversify portfolio performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlookdespite recent hiccup market continue be fuel expectation strong economic growth bullish fourth quarter earning recently release datum manufacturing construction have also bear such sentiment several economic report be line release next few day release reveal critical insight retail sale industrial production housing most report be encourage nature market be likely maintain upward trajectory week ahead zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1818,JNJ,abbott free report have be hog limelight development flagship sensor base continuous glucose monitoring cgm system freestyle libre system company have be witness solid growth global diabetes care business primarily back solid contribution freestyle libre accordingly be leave stone unturned cash grow popularity cgm system eliminate need daily finger stick development freestyle librefollow fda approval september freestyle libre flash glucose monitoring system abbott recently achieve major milestone center medicare medicaid service cms grant freestyle libre approval medicare coverage post approval freestyle libre have become only user calibration cgm device medicare coverage available person diabetes unite state meanwhile abbott have be steadily progress development diabetes care segment last september company announce receipt national reimbursement freestyle libre mark milestone company notably freestyle libre system be partially fully cover country include france germany japan moreover company announce receipt health canada license freestyle libre flash glucose monitoring system june drive diabetes care segment see revenue growth third quarter continue acceptance freestyle libre internationally believe latest cms reimbursement grant boost company performance domestic arena well expect freestyle libre contribute abbott top line japanese canadian development french health ministry approve national reimbursement device last market potentialan agee population unhealthy lifestyle rise awareness expenditure healthcare be likely drive growth further diabetes market moreover report mordor intelligence global market diabetes care device be project reach value cagr give bullish market sentiment believe recent regulatory approval freestyle libre have come opportune moment however market be dominate well establish player johnson johnson jnj free report be most prominent space johnson johnson have tie base corporation successfully develop innovate insulin delivery system share price abbott have be gain investor confidence consistently positive result last month company share price have outperformed broader industry stock have gain comparison broader industry gain zack rank key picksabbott carry zack rank hold few better rank stock broader medical sector be bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate have gain year intuitive surgical have long term expect earning growth rate stock carry zack rank have surge year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1819,JNJ,focus week be annual jpmorgan healthcare conference several biotech pharma company provide preliminary look result also provide pipeline update well outlook recap week most important storieskey takeaway jpmorgan healthcare conference several pharma company be present annual jpmorgan healthcare conference largest most informative healthcare investment symposium industry key update pfizer pfe free report say expect be rich datum delivery year bristol myer squibb company bmy free report also provide look pipeline include opportunity opdivo company also say business development remain important priority focus be deal make sense financial perspective asset technology be strategically align priority be potentially merck mrk free report be also lookout business development deal exercise financial discipline company say be look opportunity licensing deal bolt acquisition add drug technology address unmet medical need read more key takeaway pfizer other drug stock healthcare conference allergan be also present conference preliminary financial outlook read more allergan sale guidance lower expect glaxosmithkline gsk free report meanwhile be look strengthen pharma pipeline prioritize development capital focus core respiratory hiv infectious disease potential therapy immuno inflammation oncology area glaxo be zack rank buy stock see complete list today zack rank strong buy stock here nordisk go public ablynx proposal nordisk nvo free report confirm be look acquire belgium base biopharma company ablynx nordisk have initially propose acquire ablynx share cash however company come back revise offer ablynx reject first proposal nordisk latest offer include upfront cash payment share contingent value right cvr worth share total equity valuation approximately offer too have be reject ablynx company board announce proposal fundamentally undervalue ablynx growth prospect look ablynx pipeline show company well be position launch first product caplacizumab vwf acquire thrombotic purpura attp year caplacizumab be currently review eu regulatory application be file unite state first half estimate annual market opportunity attp life threaten blood clot disease be expect be company also have broad range partnership potential generate more milestone royalty other pipeline candidate also address significant market opportunity currently be rumor additional bidder eu approval caplacizumab well change scenario far nordisk be concern acquisition make sense caplacizumab be good fit company hematology portfolio deal also give boost nordisk pipeline especially give continue pricing pressure diabetes care particularly unite state read more nordisk confirm bid ablynx face rejection sanofi regeneron boost investment dupixent cemiplimab sanofi sny free report partner regeneron have decide boost investment development cemiplimab pd antibody oncology dupixent il il pathway block antibody type allergic disease base decision investment cemiplimab shoot least increase approximately initial agreement company contribute equally cemiplimab be be study monotherapy well combination other therapy wide range cancer include advanced skin cancer small cell lung cancer cervical cancer lymphomas regulatory application cemiplimab advanced cutaneous squamous cell carcinoma be schedule be submit european union unite state first quarter meanwhile dupixent currently approve eczema have potential be evaluate additional indication include chronic obstructive pulmonary disease peanut allergy grass allergy patient have multiple allergic condition be addition ongoing development pediatric atopic dermatitis pediatric asthma eosinophilic esophagitis nasal polyposis regeneron sanofi be currently seek fda approval dupixent uncontrolled persistent asthma patient least year old candidate benefit additional investment be regn il antibody potential atopic dermatitis asthma chronic obstructive pulmonary disease development update merck merck provide late stage datum pd therapy keytruda monotherapy surgically resect high risk melanoma keytruda meet primary endpoint recurrence free survival rfs merck also announce fda have accept regulatory application doravirine investigational nucleoside reverse transcriptase inhibitor nnrti treatment hiv infection adult response agency be expect oct fda also grant breakthrough therapy designation eisai lenvima lenvatinib combination keytruda treatment patient advanced metastatic renal cell carcinoma rcc breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint read more merck keytruda combo get breakthrough therapy status merck stock be last year compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock johnson johnson jnj free report be pfizer decline last month bristol myer be glaxo decline see last pharma stock roundup here allergan announce job cut pfizer inks deal next pharma world watch usual pipeline regulatory update zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1820,JNJ,fourth quarter earning season be finally underway investor be already get excited upcoming report market move tech company netflix nflx free report nevertheless see many major report noteworthy consumer face brand other industry so investor want be pay attention news come week see report world biggest most relevant company meaning investor need be prepared ensue movement be likely occur market accord latest report sheraz mian head zack equity research department acknowledge earning expert earning growth be expect be positive zack sector growth rate be project hit double digit energy technology construction industrial product basic material automotive group investor remember always use zack earning calendar plan schedule earning dividend announcement other important financial release handy tool be perfect stop shop properly prepare market event have impact own portfolio today ve make task even easier used earning calendar look ahead next week select biggest report watch make sure keep eye company prepare report week january johnson johnson inc jnj free report personal healthcare pharmaceutical behemoth johnson johnson be schedule release latest quarterly result market open january company basically never miss earning estimate share have gain respectable past year jnj be currently sporting zack rank hold approach report date base latest consensus estimate expect see johnson johnson report earning share revenue result represent year year growth respectively believe new product segment label expansion drug imbruvica darzalex contribution recent acquisition support company top line ford motor company free report automotive manufacturing giant ford be slate announce latest quarterly earning result market close january company have meet surpass estimate consecutive quarters stock have drop wake management warning profit be softer expect still ford be currently zack rank buy primarily favorable term outlook base current consensus estimate ford be expect post earning share revenue mark growth respectively year period nevertheless update company forward look guidance likely be drife stock wake report starbucks corporation sbux free report coffee king starbucks be schedule release latest quarterly earning report close bell january starbucks be pretty consistent earning performer year year comparison have tighten stock have gain just past week sbux be sporting zack rank hold approach release report accord latest consensus estimate starbucks be project post earning share revenue result represent year year growth respectively digital initiative mobile pay delivery service third party loyalty partnership stimulate stronger sale trend americas china remain key growth market company want more stock market analysis author make sure follow ryan_mcqueeney twitter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1821,JNJ,johnson johnson jnj free report have most diverse revenue stream industry pharmaceutical division account almost half revenue company have several multus dollar drug cover broad range area such neuroscience cardiovascular metabolism immunology oncology pulmonary hypertension infectious disease vaccine however several product segment be face generic competition share have gain past year outperform increase witness industry belong domestic pharma segment sale decelerate first half however sale growth accelerate third quarter be likely see continuation positive trend fourth quarter probably zack consensus estimate pharmaceutical segment be last quarter segment sale beat consensus estimate believe new product segment label expansion drug imbruvica xarelto stelara darzalex meaningful contribution swiss biotech actelion buy june support top line pharma segment also continue benefit easier comp second half compare first continue share gain be likely drive sale imbruvica cancer indication stelara psoriasis strong adoption newer indication crohn disease be expect contribute stelara growth also strong adoption outside market accelerate adoption unite state line therapy be likely drive sale multiple myeloma product darzalex positive offset loss sale drug invokana due higher manage care discounting also gain fda approval several line extension second third quarters lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene celg free report multiple myeloma drug pomalyst sixth indication imbruvica other line extension expand eligible patient population drug drive sale fourth quarter new drug be approve last year include tremfya guselkumab unite state july well eu november plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state november juluca be review eu regard tremfya say third quarter conference call have be well receive physician patient drug be likely contribute sale soon be report quarter expect update plan juluca fourth quarter conference call however biosimilar competition be expect hurt sale key arthritis drug remicade outside unite state please note market remicade partnership merck mrk free report overall strong performance pharmaceutical segment well positive contribution acquisition actelion abbott medical optic pull top line quarter meanwhile higher investment product launch continue hurt profit have be case third quarter read more set pharma earning motion carry zack rank hold see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1822,JNJ,week company novartis nvs free report merck mrk free report johnson johnson jnj free report be news merck provide datum keytruda novartis be news gain priority review status label expansion car therapy kymriah recap week most important storiesmerck keytruda shine st line lung cancer study merck score week pd therapy keytruda combination alimta pemetrexed cisplatin carboplatin meeting primary endpoint overall survival os progression free survival pfs late stage study first line treatment patient metastatic squamous small cell lung cancer nsclc interim analysis conduct independent datum monitoring committee show keytruda combination result significantly longer os pfs compare alimta platinum chemotherapy alone read more merck strong confirmatory phase iii lung cancer study priority review label expansion novartis kymriah novartis first company gain fda approval car therapy kymriah say agency have grant priority review company regulatory application seek expand label product novartis be look get kymriah approve treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl be ineligible relapse autologous stem cell transplant asct kymriah also get accelerate assessment status european medicine agency ema treatment child young adult cell acute lymphoblastic leukemia adult patient dlbcl be ineligible asct read more novartis sbla car therapy kymriah accept fda unfavorable ipr decision suffer setback week patent trademark office pto issue final written decision parte review ipr related sole unexpired patent list cover company prostate cancer therapy zytiga abiraterone acetate fda orange book generic drug company argentum pharmaceutical have challenged claim patent be due expire aug issue statement regard pto decision say be evaluate option rehearing appeal court appeal federal circuit zytiga bring sale first month novartis sandoz global partnership biocon biosimilar sandoz novartis division be enter global partnership biocon development manufacture multiple biosimilar immunology oncology company share responsibility end end development manufacturing global regulatory approval number product have cost profit share arrangement responsibility be divide partnership allow company address next wave biosimilar opportunity globally sandoz biocon have have success biosimilar space sandoz portfolio include biosimilar market various country world company be currently seek fda approval biosimilar version abbvie blockbuster immunology drug humira regulatory application biosimilar be recently accept review fda pfizer gilead clinical trial collaboration pfizer pfe free report have enter clinical trial collaboration kite gilead gild free report company safety efficacy kite car cell therapy yescarta axicabtagene ciloleucel be evaluate combination pfizer utomilumab fully humanize bb agonist monoclonal antibody patient refractory large cell lymphoma phase ii study be expect commence year pfizer be zack rank buy stock see complete list today zack rank strong buy stock here company stock be last year compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock merck be bristol myer squibb bmy free report decline last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here nordisk reveal bid acquire ablynx pfizer other healthcare conference next pharma world watch usual pipeline regulatory update well fourth quarter earning announcement january make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1823,JNJ,investing sound large cap pharma stock seem judicious be fundamentally lucrative ensure steady stream cash inflow investor drug sector have good run bounce back drug pricing issue dampen performance importantly sector see considerable increase new drug approval last year fda approve novel drug last year more double tally large cap pharma industry witness impressive rally decline run be propel encourage quarterly result increase demand new product sale successful innovation product line expansion strong clinical study result continue strong performance legacy product also boost sector factor be expect play instrumental role well take large cap drug sector new high industry be already so far year notably large cap pharma industry carry zack industry rank place top zack industry back testing show top zack rank industry outperform bottom half factor more pass tax overhaul bill congress be cherry top slash corporate tax rate be likely further boost profit margin moreover cash repatriation window allow bill help company bring cash stash foreign location leave company extra cash hand lead strategic deal merger acquisition year be relatively fewer most drug company large market cap have see share price rise so far here present company johnson johnson jnj free report abbvie inc abbv free report zoetis inc zts free report nordisk nvo free report outperformed industry last year have potential repeat same performance johnson company stock be compare favorably gain record industry company have zack rank hold see complete list today zack rank strong buy stock here company share be boost approval drug tremfya plaque psoriasis juluca hiv several line extension major drug include xarelto simponi aria stelara imbruvicain trend be expect continue have several regulatory application label expansion key drug review potential approval line extension certainly boost company growth prospect meanwhile be several pivotal datum readout regulatory milestone line moreover pharma segment growth accelerate third quarter slow first half due number factor include competition key drug remicade concerta upside be expect continue stock company be company hold zack rank buy company report series positive news include promising datum several pivotal study regulatory approval unite state europe japan competitive hcv medicine mavyret fda approval sixth indication imbruvica settlement humira patent dispute amgen inc amgn free report abbvie also expect several pivotal datum readout regulatory milestone be expect further aid company datum readout pivotal phase iii trinity study rova third line later small cell lung cancer be important catalyst stock moreover fda decision be expect new drug application nda elagolix endometriosis be grant priority review october last year abbvie blockbuster drug humira have be perform well competitive pressure company expect drug performance continue boost topline imbruvica be also do consistently well multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease nordiskshare company increase company carry zack rank company be grant approval expand label diabetes drug victoza include treatment major adverse cardiovascular event adult type ii diabetes august moreover new diabetes drug fiasp receive approval september treat adult diabetes december fda approve ozempic semaglutide once daily pre filled pen improve glycaemic control type ii diabetes patient also receive approval rebinyn hemophilia unite state refixia treatment adolescent adult same indication europe company expect launch ozempic approval same europe certainly boost company revenue moreover company serve almost half insulin market quarter diabetes market grow diabetes market certainly boost topline company share rise company sport zack rank strong buy company have diversify portfolio livestock companion animal product company increase share dermatology product dog market companion animal business have be perform well launch apoquel cytopoint company acquire nexvet biopharma last year boost pipeline solution chronic pain management dog cat company also expand reach poultry diagnostic product major european market zoetis topline be expect benefit cytopoint be launch europe fourth quarter company expect cattle herd size increase drive growth strong product portfolio consistently successful pipeline development anticipate growth demand drug company likely attract investor attention year well zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1824,JNJ,amgen inc amgn free report announce fda have approve regulatory application include overall survival os datum head head endeavor study label multiple myeloma drug kyproli please note fda decision come much earlier expect be initially expect april amgen have submit supplemental new drug application snda fda july last year regulatory application eu seek approval include os datum endeavor study be also submit same month datum present endeavor study earlier have demonstrated combination kyproli dexamethasone lead superior overall survival compare takeda velcade dexamethasone second line multiple myeloma set kyproli dexamethasone arm reduce risk death increase os month compare combination velcade dexamethasone kyproli be already approve patient population overall survival datum help drive usage boost sale other ongoing study kyprolisinclude phase iii arrow study be evaluate weekly dose regimen kyproli relapse refractory multiple myeloma patient phase iii aspire study evaluate triple combination regimen kyproli celgene celg free report revlimid lenalidomide dexamethasone krd patient relapse multiple myeloma compare revlimid dexamethasone rd amgen have also form collaboration jnj free report study combination kyproli darzalex multiple clinical study treatment multiple myeloma kyproli generate sale third quarter record year year growth drive higher demand robust uptake outside market share amgen be more wednesday past year amgen share have return compare increase register industry amgen carry zack rank hold better rank biotech stock be vertex pharmaceutical incorporate vrtx free report zack rank strong buy see complete list today zack rank stock here vertex stock have return past year earning estimate have go almost past day zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1825,JNJ,fourth quarter earning season be full swing financial figure member index already jan latest earning preview total earning index member jump year quarter drive improvement revenue beat ratio be bottom line top line positive note ongoing earning phase seem have begin well drug biotech sector major large cap player johnson johnson jnj free report kick season earning beating estimate sale slightly miss same few other large pharma company release earning result last week picture look quite encourage pharma bigwig have report last week be novartis nvs free report abbvie abbv free report surpass earning sale estimate quarter review novartis raise sale guidance abbvie increase previously issue earning expectation year major player biotech sector biogen biib free report announce mixed performance report period earning lag estimate sale exceed same however celgene corp celg free report outpaced metric expectation fourth quarter drug biotech stock remain growth trajectory courtesy slew fda approval rise demand new product sale successful innovation product line expansion strong clinical report well continue robust performance legacy product moreover impressive factor regular acquisition be expect drive sector growth well also earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning period discussion pharma biotech giant be schedule report earning number jan let see thing be shape company upcoming release eli lilly company lly free report lilly be schedule release fourth quarter earning market open company deliver positive surprise last quarter lilly earning performance have be modest earning miss expectation last quarters beating same remain thus bring average beat proven model show lilly be likely beat earning quarter combination lilly zack rank increase predictive power esp solid zack rank positive earning esp make confident earning beat impending report zack consensus estimate quarter be report be peg share uncover best stock buy sell re report earning esp filter expect sturdy uptake new product trulicity taltz basaglar cyramza jardiance lartruvo upside be likely make decline sale establish product zyprexa alimta ciali strattera effient fourth quarter read more lilly report earning card vertex pharmaceutical inc vrtx free report vertex be slate release fourth quarter earning market close company track record have also be impressive so far deliver positive surprise trail quarters average beat third quarter vertex come positive surprise however proven model do not conclusively show vertex be likely beat earning quarter company favorable zack rank hold increase predictive power esp earning esp leave surprise prediction inconclusive zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here vertex cystic fibrosis cf drug kalydeco orkambi perform consistently first quarters expect uptrend be reflect result soon be report quarter read more vertex report earning card don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
1826,JNJ,discourage result phase ii study evaluate abbvie abbv free report promising cancer candidate rovalpituzumab tesirine rova third line later small cell lung cancer sclc grab headline week other news include purchase offer jnj free report diabetes device unit successful study result announce heron therapeutic hrtx free report roche rhhby free report recap week most important storiesabbvie rova fall short key lung cancer study abbvie promising cancer candidate rovalpituzumab tesirine rova fall short expectation phase ii trinity study evaluate third line later small cell lung cancer sclc abbvie say not seek accelerate approval rova third line set consult fda rova be add abbvie portfolio follow acquisition stemcentrx june abbvie have significant confidence rova potential failure trinity have raise skepticism rova potential have bring question viability stemcentrx deal read more abbvie stock fall weak lung cancer study outcome get offer lifescan unit say have receive bound offer private equity firm platinum equity lifescan diabetes device unit have time jun offer fail expire have be evaluate potential strategic option diabetes care unit specifically lifescan corporation calibra medical early last year read more get offer lifescan diabetes device unit pfizer get fda priority review expand label xtandi pfizer pfe free report japanese partner astella gain fda priority review regulatory filing be look expand label prostate cancer drug xtandi include early stage patient population regulatory application add metastatic castration resistant prostate cancer crpc indication drug label be base result prosper study xtandi fda grant priority review decision be expect july read more pfizer xtandi label expansion filing get priority review meanwhile british company reckitt benckiser group pull discussion pfizer buy latter consumer health segment last october pfizer have say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year ultimately opt retain business glaxo also say have withdraw race buy pfizer unit heron htx succeed phase iii heron therapeutic pipeline candidate htx meet primary endpoint pivotal phase iii study evaluate post operative pain control follow bunionectomy hernia repair respectively top line datum study show treatment htx lead statistically significant reduction pain intensity opoid use hour follow surgery candidate be also superior bupivacaine solution be current standard care local anesthetic postoperative pain control read more heron pain candidate meet endpoint pivotal studiesroche tecentriq succeed lung cancer combo study roche tecentriq meet co primary endpoint progression free survival phase iii study evaluate pd inhibitor combination chemotherapy carboplatin abraxane first line treatment advanced squamous small cell lung cancer nsclc tecentriq be already market treatment second line metastatic nsclc label expansion first line set boost drug sale further however roche await overall survival datum study continue read more roche tecentriq phase iii combo study meet primary endpoint novartis tasigna get fda nod label expansion novartis nvs free report leukemia drug tasigna be grant fda approval use pediatric year age older population first second line treatment philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp glaxo begin new combo study benlysta glaxo gsk free report have initiate late stage study bliss believe evaluate systemic lupus erythematosus medicine benlysta combination roche rituxan benlysta previous late stage study have demonstrated consistent efficacy reduce disease activity sle aim new combination study be achieve clinical remission sle patient apart demonstrate low disease activity read more glaxosmithkline initiate phase iii combo study nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform week astrazeneca azn free report be only stock record gain last trading session decline bristol myer bmy free report be last month astrazeneca be biggest gainer merck mrk free report be biggest loser decline see last pharma stock roundup here abbv elagolix meet study goal mrk keytruda focus next pharma world watch regulatory pipeline news pharma stock look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1827,JNJ,dow traverse rough water once again week period be marked trouble facebook inc fb free report fed latest policy statement concern facebook datum security policy arise follow whistleblower damage revelation week investor also remain focuse central bank latest policy meeting trade war related concern also surface china prepare retaliate trump latest action front last week dow increase last friday follow better expect reading industrial output industrial production surge february comfortably surpass consensus estimate period marked highest read october investor braced higher volatility due friday be quadruple witching day meanwhile news surface trump soon fire national security advisor mcmaster index lose last week period president trump fire secretary state rex tillerson former ceo exxon mobil inc xom free report further special counsel robert mueller reportedly subpoena trump organization trump business related document factor trade war fear weigh investor sentiment president trump be expect levy fresh tariff chinese import announce trade deficit china be reduce significantly process dow index decrease monday follow concern facebook policy regard privacy user datum share facebook decline single session monday post worst dip day march dow lose point finish negative territory component save boee ba free report finishing red decline blue chip index turn negative trading share caterpillar cat free report decline emerge worst perform dow component meanwhile market watcher also speculate possibility rate hike post culmination fed day fomc meet wednesday index gain tuesday support rally energy share oil price settle highest level month meanwhile investor closely follow fomc policy meeting share facebook continue decline federal trade commission decide probe datum debacle have take market storm dow gain point tuesday end positive territory day lose more point earlier session day gain blue chip index be buoy surge share boee nike nke free report gain respectively index increase wednesday follow much expect quarter point rate hike fed however federal open market committee fomc adhere december forecast rate hike central bank also increase gdp projection pave way future rate hike meanwhile exist home sale rebound february follow back back decline month prior current period dow lose almost point end negative territory wednesday share apple aapl free report decline add blue chip index wo however dow surge more point session high index slump thursday specter damage trade war china trigger broad selloff consequently dow finished lowest point feb second lowest close record so far year currently index be lower time high achieve earlier year additionally fed latest policy statement raise question path interest rate hike also weigh market be ongoing trouble facebook factor drag tech stock lower meanwhile president trump lead attorney resign position heighten political uncertainty component move index nike third quarter earning share cent be flat year year surpass zack consensus estimate cent marked rd straight earning beat nike have zack rank hold revenue swoosh brand owner have increase beating zack consensus estimate be primarily drive double digit growth international location global nke direct business partly offset soft north american wholesale revenue sale grow currency neutral basis go forward company state overall outlook fiscal remain unchanged exclude time impact tax reform fourth quarter fiscal company expect report revenue growth high single digit backed persistent strength international region reversal trend north america read nike rally earning sale beat buy zodiac apple be reportedly develop next generation microled screen own use secret manufacturing facility company california headquarters bloomberg company be currently make small number screen testing purpose zack rank apple foray microled display manufacturing have take market surprise be likely company have be plan venture microled display technology quite time company have acquire luxvue technology developer microled screen technology way back rumor mill have now start buzz apple bring display manufacturing house make sense longer be dependent asia base manufacturer supply display screen read apple reportedly produce microled screen oled stock fall caterpillar be plan close facility texas panama be also mull shutdown engine manufacturing plant illinois reuter report move lead layoff job be sync company strategy cut cost consequently boost margin equip company better handle business cycle move affect work tool facility waco tx demonstration centre panama work texas plant be shift wamego ks affect regular contract position stock have zack rank buy see complete list today zack rank strong buy stock here exxon mobil recently commence potential gulf coast project intend grow capacity produce polypropylene ton year company start detailed engineering work project foresee rise demand high performance lightweight durable plastic exxon mobil have zack rank final decision multus facility expect come online be make year construction period be expect create more job once project come online generate excess permanent job read exxon mobil follow strategy boost polypropylene general electric company ge free report operate segment ge transportation announce have secure order refurbish locomotive several north american railroad disclose name client zack rank sell ge also deliver modernize locomotive previously order canadian pacific railway limit cp free report norfolk southern corporation nsc free report respectively year read ge transportation get order modernize locomotive johnson johnson jnj free report announce have receive bound offer approximately private equity firm platinum equity lifescan diabetes device unit lifescan unit make blood glucose monitoring product generate revenue last year zack rank have time jun offer fail expire accept offer transaction be expect close end year read get offer lifescan diabetes device unit walmart inc wmt free report be extend agreement handy accord source let customer hire helper walmart store install assemble purchase television furniture read walmart stay firm game expand alliance handy further accord report company inked deal fedex fdx subsidiary fedex office add new fedex office location certain walmart store next year read walmart play card add fedex shop select store performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have lose next week outlook market have endure quite few rough week recently seem have yet recover completely february correction phase datum related debacle facebook trump trade war have do little ease investor fear time meanwhile fed recent action have be largely predictable line concern surround future rate hike continue linger time investor look upcoming economic report include crucial gdp datum solace week ahead look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1828,JNJ,abbvie inc abbv free report announce disappointing result pivotal phase ii study evaluate promising cancer candidate rovalpituzumab tesirine rova third line later small cell lung cancer sclc abbvie say not seek accelerate approval rova third line sclc set consult fda abbvie stock crash more thursday response news stock have return year so far compare favorably decrease record industry trinity study be single arm study comparator be evaluate efficacy rova treatment patient relapse refractory sclc high expression protein dll have receive least previous treatment regimen include least platinum base regimen sclc be characterize poor outcome very few treatment choice available study best overall response rate be objective response rate be only median duration response be month median overall survival rate be month probability survival month be result be much lower company have hope not significant enough be prioritize accelerate approval however phase iii study rova first second line setting meru tahoe respectively be ongoing however investor concern success remain study increase failure trinity rova be add abbvie portfolio follow acquisition stemcentrx june abbvie have significant confidence rova potential believe candidate have blockbuster potential abbvie have past guide peak sale rova failure trinity have raise scepticism rova potential have bring question viability stemcentrx deal rova be also be evaluate early stage arm basket study neuroendocrine tumor rova be key candidate abbvie oncology pipeline abbvie key cancer drug present be imbruvica market partnership jnj free report imbruvica currently approve quite few indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease abbvie be also conduct study cancer drug venclyxto venclexta expand label address broader relapse refractory chronic lymphocytic leukemia cll patient population expand earlier line therapy broaden other hematologic malignancy multiple myeloma aml datum phase iii murano study venclexta roche rhhby free report rituxan relapse refractory cll present september last year show combination lead profound improvement progression free survival compare teva pharma teva free report treanda rituxan regulatory application seek approval combination use be review unite state abbvie carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1829,JNJ,re interested broad exposure large cap value segment equity market look further powershare dividend achiever portfolio pfm free report passively manage exchange trade fund launch fund be sponsored invesco powershare have amassed asset make average size etfs attempt match large cap value segment equity market large cap valuecompany find large cap category typically have market capitalization tend be stable company predictable cash flow be usually less volatile mid small cap company value stock be know lower average price earning price book ratio investor also note lower average sale earning growth rate consider long term performance value stock have outperformed growth stock almost market however be more likely underperform growth stock strong bull market costscost be important factor select right etf cheaper fund significantly outperform more expensive counterpart other fundamental be same annual operate expense etf be make more expensive product space have month trail dividend yield sector exposure top holdingseven etfs offer diversify exposure minimize single stock risk investor also look actual holding fund luckily most etfs be very transparent product disclose holding daily basis etf have heaviest allocation consumer staple sector portfolio industrial information technology round top look individual holding exxon mobil corp xom free report account total asset follow johnson johnson jnj free report microsoft corp msft free report top holding account total asset management performance riskpfm seek match performance nasdaq broad dividend achiever index fee expense nasdaq broad dividend achiever index be design identify diversify group dividend pay company have increase annual dividend more consecutive fiscal year etf have lose so far year be last year past week period have trade etf have beta standard deviation trail year period make medium risk choice space holding effectively diversify company specific risk dividend achiever portfolio carry zack etf rank hold be base expect asset class return expense ratio momentum other factor thus pfm be good option seek exposure large cap etfs area market investor also want consider other etf option space vanguard value etf vtv free report ishare russell value etf iwd free report track similar index vanguard value etf have asset ishare russell value etf have vtv have expense ratio iwd charge bottom linewhile excellent vehicle long term investor passively manage etfs be popular choice institutional retail investor due low cost transparency flexibility tax efficiency learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
1830,JNJ,vertex pharmaceutical incorporate vrtx free report report fourth quarter earning share cent beat zack consensus estimate cent come ahead year earning cent strong product revenue lead higher profit quarter lower operate expense ratio year year vertex report revenue fourth quarter almost year year drive strong product revenue revenue also beat zack consensus estimate fourth quarter sale strongvertex fourth quarter revenue consist sale cystic fibrosis cf product kalydeco orkambi collaborative royalty revenue cf product revenue be fourth quarter year year kalydeco sale surge follow approval treat expand population kalydeco be approve use cf patient year older have residual function mutation cftr gene august kalydeco be approve cf patient year older have residual function mutation result splice defect cftr gene line extension increase eligible patient population kalydeco orkambi lumacaftor ivacaftor deliver sale year year growth be support continue uptake globally especially pediatric patient unite state cost riseadjust research development expense increase fourth quarter due higher cost related development triple combination cf regimen adjust selling general administrative sg expense increase resultsvertex full year revenue increase year year mainly drive upfront payment earn germany base merck kgaa strong cf portfolio sale upfront payment be part collaboration agreement vertex license oncology program merck kgaa adjust earning be year year share adjust expense increase year year however exclude upfront payment related acquisition cftr potentiator vx concert pharmaceutical inc cnce free report adjust sg expense increase year year include cost related potential launch tezacaftor ivacaftor combination unite state increase be also due increase investment support global orkambi kalydeco stock repurchase earning release vertex announce board have authorize share repurchase program buy back common stock tune guidancevertex provide guidance combine operate cost combine adjust research development selling general administrative sg expense be anticipate range increase operate expense reflect anticipate cost related development triple combination treat cf plan launch tezacaftor ivacaftor combination pipeline regulatory updatesin december vertex announce datum phase iii study arrival evaluate kalydeco child age year have mutation cftr gene show improvement multiple endpoint include measure pancreatic function base datum vertex plan file regulatory application approval kalydeco child age year first quarter january european commission approve line extension orkambi include use child cf age year have copy del mutation approval increase target patient population patient company have plan file regulatory application approval orkambi child age cf have copy del mutation first quarter vertex be also seek approval combination tezacaftor kalydeco ivacaftor cf patient age older have copy del mutation have least residual function mutation regulatory application be review unite state europe decision be expect unite state feb europe second half company be also develop triple combination regimen treat cf be capable treat almost patient vertex have select next generation corrector vx vx advance separate phase iii triple combination study candidate evaluate combination tezacaftor kalydeco apart cf vertex be also develop treatment sickle cell disease thalassemia influenza pain management fourth quarter company initiate phase iii study pimodivir combination standard care treatment patient influenza study be be conduct collaboration janssen pharmaceutical subsidiary johnson johnson jnj free report takevertex fourth quarter result reflect strong performance cf product company beat estimate count sale cf drug rise share rise hour trading response strong quarterly result past year vertex share price have increase massive compare favorably increase industry vertex cf pipeline be quite strong broad portfolio next generation cf corrector triple combination cf regimen be consider crucial long term growth triple combo regime be successful vertex address significantly larger cf patient population almost patient future however competition be increase several major company be express interest cf vertex carry zack rank hold see complete list today zack rank strong buy stock here vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1831,JNJ,earning season have start gather steam latest earning preview member accounting index have already release financial figure apr total earning member have report result already be same period last year higher revenue beating ep estimate beating revenue estimate proportion company beating ep revenue estimate be ongoing earning phase seem have also begin encouragingly drug biotech sector major large cap player johnson johnson jnj free report kick season strong note beating zack consensus estimate earning well sale large cap player report earning last week be novartis nvs free report also surpass earning revenue expectation quarter also biogen inc biib free report release result week surpass earning miss sale expectation higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning quarter review pharma biotech giant be schedule report earning result apr let see thing be shape company upcoming release abbvie inc abbv free report be slate releaseresult market open company deliver positive earning surprise last report quarter moreover company performance have be impressive recent past earning surpass expectation trail quarters average positive earning surprise proven model show abbvie be likely beat earning be report quarter have right combination key ingredient positive earning esp zack rank hold zack consensus estimate company earning quarter review be peg share company key drug humira be likely remain key growth driver first quarter backed strong demand trend drug abbvie expect humira sale reflect rise low teen band imminent earning release internationally growth rate be project mid single digit range operationally other drug namely duopa creon be also likely maintain encourage performance soon be report quarter read more be beat card abbvie earning abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote alexion alxn free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise alexion be likely beat earning be report quarter have positive earning esp zack rank buy zack consensus estimate quarterly earning be peg share see complete list today zack rank strong buy stock here alexion blockbuster drug soliris continue perform well company be work expand soliris label additional indication alexion recently announce acquire sweden base wilson therapeutic transaction be expect close second quarter acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder alexion be look diversify portfolio reduce dependence blockbuster drug soliris deal strengthen alexion rare disease pipeline late stage candidate read more be beat store alexion earning season alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quote bristol myer squibb bmy free report be slate report result open bell company deliver positive earning surprise last quarter company deliver positive earning surprise trail quarters average beat model show bristol myer be likely beat estimate quarter combination bristol myer zack rank positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share bristol myer blockbuster immuno oncology drug opdivo be expect remain main sale driver first quarter follow several line extension soon be report quarter company announce encourage result phase iii study evaluate opdivo first line small cell lung cancer label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact read more be beat store bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quote vertex pharmaceutical incorporate vrtx free report be slate report result market close vertex track record have be impressive so far company deliver positive earning surprise last quarters average positive earning surprise last quarters be last report quarter vertex deliver positive earning surprise model show vertex be likely beat estimate quarter combination bristol myer zack rank positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter vertex cystic fibrosis cf drug kalydeco orkambi perform well sale rise almost expect positive trend continue soon be report quarter also boost vertex cf franchise fda approve vertex third cf drug symdeko be combination tezacaftor ivacaftor february expect company provide update symdeko plan initial uptake company be also likely provide full year revenue guidance include symdeko sale call read more be beat store vertex earning season vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quote investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1832,JNJ,re interested broad exposure large cap value segment equity market look further oshare ftse quality dividend etf ousa free report passively manage exchange trade fund launch fund be sponsored oshare investment have amassed asset make average size etfs attempt match large cap value segment equity market large cap valuelarge cap company typically have market capitalization consider more stable option large cap company boast more predictable cash flow be less volatile mid small cap counterpart value stock have lower average price earning price book ratio also have lower average sale earning growth rate value stock have outperformed growth stock nearly market consider long term performance growth stock be more likely outpace value stock strong bull market costsinvestor also pay attention etf expense ratio lower cost product produce better result higher cost assume other metric remain same annual operate expense etf be make more expensive product space have month trail dividend yield sector exposure top holdingseven etfs offer diversify exposure minimize single stock risk be still important look fund holding investing luckily most etfs be very transparent product disclose holding daily basis etf have heaviest allocation consumer staple sector portfolio information technology industrial round top look individual holding johnson johnson jnj free report account total asset follow exxon mobil corporation xom free report intel corp intc free report top holding account total asset management performance riskousa seek match performance ftse qual vol yield factor capped index fee expense ftse qual vol yield factor capped index measure performance publicly list large capitalization mid capitalization dividend pay issuer unite state etf have lose so far year be last year past week period have trade etf have beta standard deviation trail year period make medium risk choice space holding effectively diversify company specific risk ftse quality dividend etf hold zack etf rank buy be base expect asset class return expense ratio momentum other factor ousa be outstanding option investor seek exposure large cap etfs segment market be other additional etfs space investor consider well vanguard value etf vtv free report ishare russell value etf iwd free report track similar index vanguard value etf have asset ishare russell value etf have vtv have expense ratio iwd charge bottom linewhile excellent vehicle long term investor passively manage etfs be popular choice institutional retail investor due low cost transparency flexibility tax efficiency learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
1833,JNJ,first quarter earning season start solid note show sign yet report cycle emerge strong latest earning preview member accounting index have already release financial figure apr total earning index participant jump year quarter drive improve revenue beat ratio be bottom line top line further good news be ongoing earning phase seem have also begin encouragingly drug biotech sector major large cap player johnson johnson jnj free report kick season strongly beating zack consensus estimate earning well sale first quarter large cap player have report earning performance last week be novartis nvs free report also surpass earning revenue expectation quarter remind investor drug biotech sector face severe volatility last couple month due broader market pressure mainly drive china trade war sector be still likely improve year progress expect surge new product sale sync rise demand apart successful innovation product line expansion strong clinical study result more frequent fda approval consistently sturdy performance key product grow demand drug especially address rare treat disease agee populace increase healthcare expenditure be factor keep sector well place also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning period discussion pharma biotech giant be schedule report earning number apr let see thing be shape company upcoming release eli lilly company lly free report eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quote lilly be slate release first quarter earning market open company deliver positive surprise last quarter moreover company performance have be impressive recent past earning surpass expectation trail quarters average positive surprise however proven model do not conclusively show lilly be likely beat earning quarter company favorable zack rank buy increase predictive power esp earning espof leave surprise prediction inconclusive company require positive esp be confident probable surprise zack consensus estimate quarterly earning be peg share lilly strong uptake new product trulicity taltz basaglar cyramza jardiance lartruvo compensate sale decline establish product namely zyprexa alimta ciali strattera effient expect uptrend find reflection result soon be report quarter read more lilly lly free report report earning card biogen inc biib free report biogen inc price ep surprise biogen inc price ep surprise biogen inc quote biogen be also slate release first quarterearning market open company track record have also be impressive so far deliver positive surprise trail quarters average beat however biogen come negative surprise fourth quarter moreover proven model do not conclusively show biogen be likely beat earning quarter company favorable zack rank hold increase predictive power esp earning esp leave surprise prediction inconclusive zack consensus estimate be peg share see complete list today zack rank strong buy stock here sale biogen multiple sclerosis drug improve patient growth major european market well growth strong emerge market drive international tecfidera sale inventory build quarter benefit sale expect momentum continue impending result soon be report quarter read more store biogen biib free report earning season amgen inc amgn free report amgen inc price ep surprise amgen inc price ep surprise amgen inc quote amgen be schedule release first quarter earning market close company deliver negative surprise previous quarter amgen earning performance have be quite robust metric beating expectation last quarters miss same remain average beat proven model show amgen be likely beat earning quarter combination amgen zack rank increase predictive power esp positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg share uncover best stock buy sell re report earning esp filter amgen latest product prolium kyproli xgeva blincyto be likely perform well backed higher demand upside make weak sale stiff competition mature brand such enbrel aranesp epogen neulasta neupogen be report quarter read more amgen amgn free report report earning be beat card today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1834,JNJ,market rally be heating year dow jone index breach new milestone hit second trading session new year close first time dow jone close easily set record fastest point rise history top jan euphoria surround new tax legislation be fuel rally be massive tax cut likely create economic surge boost job growth reflation trade further accelerate earning save company billion dollar lead increase dividend buyback activity pave way increase merger acquisition read biggest etf story continue bizarre jump oil price weak dollar improve global growth round upbeat economic datum especially area manufacturing construction spending retail be add strength further report cycle be strong start earning company have report result same period last year higher revenue beating ep estimate beating revenue estimate overall total earning revenue be project grow respectively rally have be broad base winner be spread many corner space have highlighted few etfs stock surge time high recent session be compelling choice investor seek ride current trend equity market have zack rank strong buy buy hold suggest lead continue month ahead spdr dow jone industrial average etf dium free report be largest most popular etf mega cap space aum average daily volume share track dow jone industrial average index charge investor expense ratio etf hit time high represent gain year have zack etf rank read solid start await dow etf earning vanguard mega cap etf mgc free report aum etf offer exposure largest stock represent approximately top market capitalization tracking crsp mega cap index charge bps annual fee trade lower average daily volume share product touch time high have return past year have zack etf rank guggenheim top etf xlg free report fund follow top etf index measure cap weight performance largest company index reflect performance mega cap stock have be able manage asset worth trade small volume share day average expense ratio come etf reach time high have surge year have zack etf rank ishare russell top value etf etf offer exposure large company be thought be undervalue market relative comparable company easily be do tracking russell top value index iwx have aum average daily volume share charge bps annual fee have gain past year hit fresh high fund have zack etf rank read value investing set shine tax reform cheap etfs berkshire hathaway inc brk free report nebraska base hold company provide property casualty insurance reinsurance well life accident health reinsurance operate railroad system north america stock have see solid earning estimate revision cent year past day expect growth rate have market cap hit time high have gain past year stock have zack rank solid industry rank top see complete list today zack rank stock here johnson johnson jnj free report new jersey base company be engage research development manufacture sale range product healthcare field have see positive earning estimate revision couple cent year past day expect growth rate share jnj have surge year hit fresh high stock have market cap zack rank also flaunt solid industry rank top boee company ba free report world largest illinois base aerospace company be lead manufacturer commercial jetliner defense space security system stock have see solid earning estimate revision cent year past day expect growth rate have rise past year hit time high stock have market cap zack rank wal mart store inc wmt free report arkansa base company operate retail store various format worldwide earning estimate revision have go cent current fiscal year expect growth rate stock hit time high have gain year have market cap zack rank stock also boast solid industry rank top read strong holiday retail sale etf stock pick want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1835,JNJ,wall street have sizzling start trump tax overhaul bolster optimism strong corporate earning improve economy earning season underway investor be bet new tax legislation result big saving corporation give boost earning dow jone industrial average have be biggest beneficiary trump era thus proxy version spdr dow jone industrial average etf dium be spotlight climb last year dow jone soar initial day trading read biggest etf story continue dium be largest most popular etfs large cap space aum average daily volume share hold blue chip stock fund be widely spread component none hold more share industrial information technology financial consumer discretionary healthcare be top sector dium charge bps annual fee have zack etf rank buy medium risk outlook let delve earning picture likely set movement fund come day earning trendstotal earning be expect be same period last year higher revenue be higher earning growth revenue growth additionally revision trend have be favorable earning estimate hold better relative other comparable period earning estimate have moved percentage point start period nearly fourth blue chip firm be expect announce result week next jpmorgan chase jpm free report be expect release result jan read etfs stock favorite sector earning unitedhealth group unh free report be schedule report jan goldman gs free report jan international business machine ibm free report american express axp free report report jan other company procter gamble company pg free report johnson johnson jnj free report come report jan general electric ge free report have earning release slate jan earning methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter jpmorgan have zack rank earning esp make surprise prediction difficult company deliver average positive earning surprise last quarters see negative earning estimate revision couple cent past day be report quarter stock have vgm style score unitedhealth have zack rank earning esp indicate less chance beating estimate quarter stock have see upward earning estimate revision penny yet be report quarter deliver positive earning surprise last quarters stock have top vgm style score goldman have zack rank earning esp make surprise prediction difficult earning surprise track past quarters be robust average positive surprise company witness negative earning estimate revision cent past day yet be report quarter have miserable vgm style score read prepare etfs international business machine have zack rank earning esp indicate reasonable chance beating estimate quarter stock deliver positive earning surprise last quarters average beat see earning estimate revision past day be report quarter stock have good vgm score american express also have zack rank earning esp indicate reasonable chance beating estimate quarter company deliver positive earning surprise last quarters average beat see positive earning estimate revision cent past month be report quarter stock have good vgm style score procter gamble company have zack rank earning esp indicate reasonable chance beating estimate quarter earning surprise track last quarters be good average beat stock witness earning estimate revision past day be report quarter have vgm style score johnson johnson also have reasonable chance beating estimate quarter zack rank earning esp witness negative earning estimate revision penny past month be report quarter deliver positive earning surprise last quarters stock have vgm style score general electric have zack rank earning esp company suffer huge negative earning surprise last quarter witness negative earning estimate revision cent past day yet be report quarter have vgm style score read steer clear ge bet industrial etfs instead bottom earning most blue chip company schedule come week stock market extend bull run investor closely monitor movement dow etf grab opportunity surge stock price want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1836,JNJ,quite few pharmaceutical industry merger include large deal be card now tax reform be place tax bill be sign law president donald trump december last tax rate corporate now go boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate also tax cut be expect prevent inversion be rampant drug industry change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal week senior executive largest pharmaceutical biotech company discuss impact tax reform merger acquisition plan use excess cash jp morgan healthcare conference ceo say brent saunder chief executive officer ceo allergan agn free report say first half year be likely see smaller deal such celgene celg free report bigger high profile merger large pharmaceutical biotech company probably happen latter half year next year last week celgene announce have offer buy small cancer drug developer impact biomedicine read more celgene acquire impact biomedicine boost pipeline lilly lly free report ceo dave rick chief financial officer dominic caruso say tax cut american company compete better foreign counterpart operate better tax environment caruso say new tax law provide more flexibility ease analysis term get transaction do same line merck mrk free report ceo meg tirrell say have access overseas cash give more financial flexibility think different way go transaction tirrell however confidently say even new tax law be implement company have enough power balance sheet make bolt acquisition want do michel vounatsos biogen biib free report ceo smartly argue tax overhaul spur activity rationale activity not be cash available go say be look set potential target gilead ceo john milligan say tax reform be good company allow plan long term fda approval process be quite lengthy meanwhile maintain goal investing replenish pipeline also say excess cash allow clean balance sheet repay debt conclusion overall be quite clear drug industry be optimistic tax reform fuel greater activity be major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buyout strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline matter company look buy drug biotech stock be current sale performance latter drug product prospect sale growth quality pipeline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1837,JNJ,alzheimer disease ad area be focus once again pfizer inc pfe free report say be drop plan develop treatment alzheimer parkinson disease accord news source pfizer expect decision result elimination position neuroscience discovery early development program expect additional detail be available company presentation annual jpmorgan healthcare conference today pfizer have have long association alzheimer disease research area company become part dementia discovery fund be form speed development new treatment neurological disease bring together major pharma company uk government alzheimer research uk fund be involved financing new early stage drug development project however alzheimer have always be highly challenge area not much progress be make investment lot fund resource fact pfizer have face major setback way back development effort alzheimer disease treatment company partner johnson johnson jnj free report decide discontinue development bapineuzumab iv follow late stage failure other company eli lilly company lly free report merck mrk free report have also stumble effort develop treatment alzheimer lilly decide november not seek approval investigational ad treatment solanezumab follow disappointing result late stage study candidate be be evaluate see slow progression memory problem associate amyloid protein form plaque brain person alzheimer meanwhile evaluation merck investigational alzheimer disease treatment verubecestat be halter phase ii iii study epoch february base interim analysis external datum monitoring committee edmc study fail study be ongoing result expect february biogen also suffer setback recently independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint phase ii study failure show early positive result come major disappointment biogen be develop candidate association eisai clinical stage company axovant science axon free report suffer major setback september investigational alzheimer disease candidate fail meet co primary efficacy endpoint late stage study company decide discontinue development mg dose treatment alzheimer disease last year company share be compare decline industry belong accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval road setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale company be currently work alzheimer disease treatment include biogen novartis nvs free report astrazeneca eisai amgen amgn free report biogen aducanumab be most important candidate company pipeline candidate currently couple late stage study biogen be also work elenbecestat bace inhibitor phase iii program candidate be be develop collaboration eisai lilly also have quite few alzheimer disease candidate pipeline include lanabecestat be be develop collaboration astrazeneca datum readout expect meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be also collaborate ac immune development alzheimer disease treatment company pfizer lilly merck be zack rank hold stock see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1838,JNJ,glaxosmithkline plc gsk free report focus core business pharmaceutical vaccine consumer healthcare glaxo enjoy strong fundamental form diversify base presence different geographical area uk base company reshape business follow completion part conditional transaction novartis nvs free report march deal glaxo sell oncology asset novartis acquire novartis vaccine business exclude influenza vaccine here be reason invest stock year good rank solid vgm score glaxo carry zack rank buy favorable vgm score back test result show stock vgm score combine zack rank strong buy offer best upside potential see complete list today zack rank stock here rise share price estimate underperform broader industry glaxo share have picked year glaxo stock have rise year so far compare favorably flat trajectory industry meanwhile estimate rise respectively past day pharma giant have be consistently beating earning expectation earning surpass expectation last quarters average positive surprise new drug vaccine do well glaxo newer respiratory hiv drug vaccine be do well continue boost revenue new product generate glaxo pharmaceutical vaccine sale continue boost revenue significantly glaxo have expect new pharmaceutical vaccine product include contribution shingrix deliver sale annum however product almost reach target significant progress pipeline glaxo have make significant progress late stage pipeline glaxo receive approval key new drug shingrix vaccine shingle enjoy preferential recommendation acip trelegy ellipta provide medicine single inhaler treat copd juluca dolutegravir rilpivirine first drug regimen once daily single pill hiv back back approval new product have strengthen glaxo competitive position juluca have be develop glaxo partner pfizer inc pfe free report hiv focuse company viiv healthcare partnership johnson johnson jnj free report glaxo be also work expand label market product nucala additional face share challenge stiff competition genericization pricing pressure slow growth emerge market meanwhile top selling respiratory product advair be also expect face generic competition unite state year hurt sale however look glaxo strong pipeline consistent outperformance new hiv drug vaccine new product cost cut bring back track year hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1839,JNJ,emerge market investment have take backseat late thank nonstop blow economy linger geopolitical tension gulf debt policy related hazard latin america missile test north korea have lead stock investor reconsider outlay market earlier proclaim offer better growth opportunity unite state go msci emerge market index last year annualize growth rate be just other hand gdp capita growth rate last year unite state be international monetary fund world economic outlook database face such adversity goldman sachs statement bloomberg last week address emerge market stock world best bet have create quite stir investment world accord report follow selloff february other market correction investor be keen put money riskier asset emerge economy time msci index have not show significant improvement then comment sheila patel chief executive officer international gsam have force investor think again take asset market go bloomberg report goldman sachs be particularly bet indian healthcare firm consumer stock argentine debt expect india government boost spending public health prime minister narendra modi political risk be ignore investor pessimism mexico argentina be overdo report say emerge market healthcare scenario way better unite patel particularly talk grow prospect indian healthcare market datum show prospect broader emerge market be equally encourage contrary healthcare scenario unite state be muddle survey report gallup analytic last july reveal adult cite healthcare second major problem face country new presidential administration follow new healthcare reform announcement december gallup poll next month state past decade marked biggest increase uninsured rate new healthcare reform bring term scenario remain pretty unclear now meanwhile explode population rise middle class increase governmental awareness health issue emerge geography be face huge demand modern cheaper healthcare option go report guardian international finance corp ifj datum show develop country account global death chronic disease indicate enormous market opportunity emerge market opening medtechper recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india fifth largest medtech market world currently record annual growth pace india emerge strong competitor japan germany other emerge geographical region latin america even face economic stagnation hold enormous potential january report medtech intelligence central south american nation significantly increase capita spending healthcare give huge potential region long back johnson johnson jnj free report have set manufacturing center india china brazil company emerge market medical device segment continue grow time faster develop market abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report second quarter fiscal business china latin america southeast asia show sustain strength grow double digit overall medtronic long term outlook emerge market be encourage boston scientific bsx free report emerge market business register organic growth fourth quarter reflect significant increase growth business china be once again remarkable year year growth pace emerge market have decline pre financial crisis year however market have historically play crucial role large corporation hedge international trade risk accord bcg report go forward emerge market gdp be project grow faster develop economy market account total consumer spending more investor point view be imprudent immense growth potential emerge economy due occasional rough spot today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1840,JNJ,market finished record level tuesday bank healthcare stock rally further report boee have deliver record number airplane push dow record territory nasdaq increase sixth consecutive session meanwhile report national federation independent business show small business optimism decline december dow jone industrial average dji increase close rise close nasdaq composite index close gain fear gauge cboe volatility index vix increase almost close decliner outnumber advancer nyse ratio nasdaq ratio favore decline issue gain boee push dow highershare boee ba free report surge tuesday follow report aero giant deliver record commercial airplane mark fresh record airplane maker surpass earlier record unit company also announce have book order commercial airplane be seventh highest annual total lead highest ever order backlog rise airplane end such backlog be worth year production such event lead share boee gain contribute much point dow blue chip index amassed point tuesday finish record also contribute dow gain be increase share johnson johnson jnj free report gain add point dow see complete list today zack rank strong buy stock here further dow jone transportation average djt close record level surge support gain index be share matson inc matx free report hunt transport service inc jbht free report gain respectively nasdaq post record gain point close record sixth straight session mark best start year major sector broad market index only end positive territory healthcare financial lead advancer real estate laggard however loss real estate be more make gain financial healthcare stock health care select sector spdr etf xlv financial select sector spdr etf xlf gain respectively meanwhile nasdaq add point also close record sixth straight session highest period gain tech laden index be broad base market also gain traction due optimism surround strong market rally kick economic dataon economic datum front national federation independent business nfib report index small business optimism tank point month december such decline come right republican tax bill be implement decline be owe sluggishness imbalance labor market have impact hire unite state moreover capex december increase only marginally further dampen small business sentiment stock make headlinesunited continental december traffic guidance alteredunite continental holding inc ual free report wholly own subsidiary unite airline report dismal traffic number december read more robust holiday show fail woo inc jwn free report have conclude dull strong note report modest improvement sale comparable store sale comp combine month november december primarily comprise holiday season read more sm energy sell powder river basin asset msm energy company sm free report have inked definitive agreement divest bulk powder river basin resource read more lennar earning miss revenue top higher demandlennar corporation len free report miss expectation earning final quarter fiscal surpass same time row read more look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1841,JNJ,pfizer inc pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff decision end neuroscience discovery program mainly affect employee facility andover cambridge groton ct pfizer however intend continue development pain candidate tanezumab be develop late stage study partnership eli lilly lly free report label expansion effort pain drug lyrica rare disease program share pfizer have rise past year compare unfavorably increase industry successful development therapy treatment alzheimer disease be challenge note several company have fail regard fact pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation november lilly amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lillyalso suffer major setback august have halt development phase iii alzheimer candidate semagacestat last month biogen inc biib free report announce alzheimer disease study ban fail show early positive raise investor concern candidate chance success pfizer plan use saving terminate program re allocate spend potentially more fruitful pipeline project pfizer expect approximately drug approval next year product have blockbuster potential include line extension cancer drug xtandi ibrance well rheumatoid arthritis drug xeljanz half potential blockbuster be expect receive approval pfizer carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1842,JNJ,incyte corporation incy free report announce new week year follow datum phase iii response study jakafi study compare efficacy safety jakafi best available therapy bat patient polycythemia vera pv be resistant intolerant hydroxyurea hu primary response be composite endpoint proportion patient achieve hematocrit hct control defined phlebotomy eligibility week week spleen volume reduction least baseline week study meet primary endpoint show jakafi be superior bat control hematocrit hct reduce spleen volume week datum study show durable primary response jakafi patient pv be resistant intolerant hu overall safety profile jafaki remain consistent week response datum publish earlier fact week follow response study confirm patient initially respond jakafi treatment have probability maintain primary hematocrit hct response greater week be respectively thus confirm jakafi be effective long term treatment option patient pv be hu resistant intolerant so far year incyte share have decline industry growth jakafi be incyte sole market product be first class jak jak inhibitor be approve unite state treatment patient polycythemia vera pv have have inadequate response be intolerant hydroxyurea also jakafi be approve treatment patient intermediate high risk myelofibrosis mf include primary mf post pv mf post essential thrombocythemia mf incyte market drug unite state be market novartis nvs free report jakavi outside country label have be update several time approval march fda approve supplemental labele jakafi include additional safety datum well efficacy analysis response study assessed durability response jakafi treat patient week incyte corporation price incyte corporation price incyte corporation quotezack rank stock considerincyte have zack rank hold better rank health care stock same space be sucampo pharmaceutical johnson johnson jnj free report company hold zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date johnson johnson earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have increase year date today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1843,JNJ,begin expectation be pretty high pharma biotech sector finally see lot merger acquisition however do not happen few high value deal be announce focus be mostly small bolt acquisition licensing deal agreement accord mergermarket global pharma medical biotech trend report global pharma medical biotechnology sector be range span deal so far year decline year period dip be mostly attributable pharma medical sector key deal announce year include gilead gild free report kite johnson johnson jnj free report actelion acquisition boost value transaction biotech sector biotech stock continue command hefty premium be concern key question now face sector be activity remain sluggish be surge deal tax reform work activity be expect increase upcoming quarters tax reform cash repatriation be expect lead boost area biotech remain highly seek sector company innovative technology pipeline remain demand disease area nonalcoholic steatohepatitis nash immuno oncology central nervous system disease see quite bit activity treatment orphan disease gene editing technology be also demand be several large drugmaker be lookout deal company be look replace sale blockbuster product be face loss patent exclusivity other be look build pipeline acquisition well licensing agreement expectation be high big player sanofi sny free report pfizer merck amgen amgn free report announce deal company gilead be also expect be lookout additional acquisition target major deterrent however be high valuation bidding war keep key player sideline backdrop here be look biotech stock find radar company lookout acquisition target incyte corporation incy free report wilmington base incyte be company be often consider attractive acquisition target thank flagship product jakafi promising pipeline jakafi jak jak inhibitor look well position growth jakafi revenue be expect range incyte be also work expand jakafi label additional indication include steroid refractory acute graft versus host disease gvhd datum expect first half essential thrombocythemia et rare blood cancer lead life threaten complication company have several catalyst line include potential approval baricitinib resubmission new drug application moderate severe rheumatoid arthritis expect january well advancement immuno oncology pipeline company immuno oncology pipeline include ido inhibitor epacadostat pi delta inhibitor incb jak inhibitor itacitinib incb other epacadostat be late stage development melanoma datum due first half have immense commercial potential epacadostat be be evaluate several other type cancer well juno therapeutic inc company juno share have be upward trend follow gilead kite acquisition announcement earlier year juno be focuse development innovative cellular immunotherapy treatment cancer company be consider potential acquisition target juno cell base cancer immunotherapy be base chimeric antigen receptor high affinity cell receptor technology company have several cell base candidate pipeline target variety cell malignancy well multiple solid tumor multiple myeloma company suffer major setback development erstwhile lead pipeline candidate due safety issue include patient death juno be now focuse jcar next generation car cell product target cd jcar be currently registrational study hodgkin lymphoma nhl company expect file approval second half juno share be year date compare gain record industry belong bluebird bio inc blue free report bluebird be clinical stage company work develop gene therapy serious genetic disease cell base immunotherapy cancer company pipeline include lenti currently phase ii iii study treatment cerebral lentiglobin currently study treatment transfusion dependent thalassemia severe sickle cell disease company lead oncology program bb bb be bcma car program be be develop collaboration celgene incyte juno bluebird be zack rank hold stock see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1844,JNJ,week be rule cancer datum presentation drug company annual meeting american association cancer research aacr chicago other jnj free report novartis nvs free report kick pharma earning strong note beating zack consensus estimate earning sale first quarter recap week most important storiesj beat earning raise sale guidance first quarter earning come share sale be number increase year year quite few key product portfolio remicade concerta face generic competition believe new product plaque psoriasis drug tremfya guselkumab cancer drug darzalex imbruvica zytiga currency tailwind contribution acquisition help deliver strong sale profit first quarter year lead raise sale outlook whole year read more top earning estimate raise sale guidance novartis first quarter earning come share beat zack consensus estimate revenue increase year year beat zack consensus estimate strong performance key drug cosentyx entresto lead impressive performance quarter novartis re iterated previously issue guidance read more novartis beat earning revenue estimate merck present successful keytruda datum aacr merck mrk free report present full datum pivotal keynote study evaluate keytruda combination alimta pemetrexed platinum chemotherapy cisplatin carboplatin first line treatment patient metastatic squamous nsclc regardless pd expression datum show keytruda combo significantly improve overall survival reduce risk death half compare chemotherapy alone january merck have announce study meet primary endpoint progression free survival pfs os co primary endpoint notably combination therapy be grant accelerate approval fda aforementioned indication approval be base tumor response rate pfs datum keynote study hence positive readout keynote confirmatory study help company gain continue approval combo therapy support uptake sale read more merck keytruda better survival lung cancer combo study merck also present update datum phase iii eortc keynote study evaluate keytruda monotherapy high risk stage iii melanoma patient adjuvant set datum study demonstrated adjuvant treatment keytruda increase recurrence free survival rfs reduce risk disease recurrence death placebo surgery such patient read more merck keytruda reduce death risk melanoma patient separately merck astrazeneca azn free report announce final overall survival os datum phase iii study evaluate parp inhibitor lynparza metastatic breast cancer aacr median os be month lynparza arm compare chemotherapy bristol myer opdivo focus bristol myer bmy free report present initial result phase iii study checkmate evaluate combination pd inhibitor opdivo yervoy first line treatment advanced nsclc patient high tumor mutational burden initial result show year pfs rate be more triple combination versus chemotherapy vs however result be encourage investor be disappoint merck keytruda seem have fared better opdivo yervoy combination read more bristol myer merck nsclc study fare better opdivo also demonstrated statistically significant overall survival primary endpoint benefit compare chemotherapy late stage study checkmate evaluate predominantly chinese population previously treat small cell lung cancer opdivo reduce risk death versus chemotherapy read more bristol myer report positive datum nsclc trial opdivo development opdivo be approve combination yervoy treatment intermediate poor risk advanced renal cell carcinoma previously untreated patient also bristol myer supplemental biologic license application sbla expand use opdivo monotherapy previously treat patient small cell lung cancer sclc be grant priority review fda fda be expect give decision aug separately bristol myer strike collaboration illumina inc develop commercialize companion diagnostic bristol myer oncology immunotherapy bristol myer also inked deal johnson johnson development bristol myer factor xia fxia inhibitor bms prevention treatment major thrombotic condition company be expect advance bms phase ii trial second half roche hemlibra get btd new indication swiss pharma giant roche rhhby free report haemophilium drug hemlibra be grant breakthrough therapy designation fda treatment haemophilium factor viii inhibitor base positive datum phase iii haven study hemlibra emicizumab be approve routine prophylaxis bleed episode person haemophilium factor viii inhibitor eu february unite state november last year have be successfully launch unite state read more roche hemophilia drug get breakthrough therapy designation shire agree sell oncology unit shire announce definitive agreement sell oncology business french company servier dublin ireland drug giant plan return proceed sale shareholder share buyback japan takeda consider take shire latter oncology business be key area interest takeda read more shire sell oncology unit ahead takeda potential offer shire however thursday reject takeda third offer pound share well say undervalue shire growth prospect pipeline meanwhile allergan agn free report issue press release same day say be early stage consider possible offer shire however later day issue press release say do not intend make offer shire bayer sell stake singapore temasek germany bayer have strike deal sell stake singapore investment company temasek total gross proceed euro latest purchase temasek own approximately bayer stock equity sale raise fund bayer upcoming merger seed maker company astrazeneca tagrisso get fda nod first line set astrazeneca lung cancer drug tagrisso gain fda approval first line treatment adult patient metastatic nsclc tumor have egfr mutation snda be base datum phase iii flaura study similar label expansion application be review eu now tagrisso be approve unite state european union japan china second line treatment option patient egfr mutation positive nsclc read more fda nod astrazeneca tagrisso first line nsclc nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform last trading session merck be biggest gainer last week rise bristol myer decline last month astrazeneca have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup nvs buy avexis pfe abbv drug succeed phase iii next pharma world watch first quarter earning result several drug giant other pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1845,JNJ,johnson johnson jnj free report kick pharma earning season strong note beating zack consensus estimate earning sale first quarter performance be drive continue positive momentum second half improvement consumer segment sale do perform earning share beat zack consensus estimate quarterly revenue be also beat consensus mark buoy strong performance company up previously issue sale outlook read more top earning estimate raise sale guidance pharmaceutical segment sale grow year year first quarter due strong sale domestic international market favorable currency impact sale market rise quarter international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well oncology sale increase quarter constitute almost quarter pharmaceutical sale core product xarelto stelara zytiga simponi simponi aria invega sustenna also contribute growth imbruvica sale rise drug be market partnership abbvie inc abbv free report edurant sale rise prezista sale increase however concerta sale continue decline due generic competition sale risperdal consta also fall sale invokana invokamet decline due higher manage care discounting blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report fall pharma segment achieve clinical milestone quarter include fda approval prostate cancer drug erleada treatment man metastatic castration resistant prostate cancer line extension already market prostate cancer drug zytiga combination prednisone first line set certainly boost sale now expect revenue range higher expect previously overall expect pharmaceutical segment remain strong consumer medical device segment continue improve expect other company merck amgen inc amgn free report pfizer lilly follow suit novartis report encourage resultsnovartis ag nvs free report also report week swiss pharma giant beat earning revenue estimate drive strong performance key drug cosentyx entresto novartis report core earning share beating zack consensus estimate record year quarter revenue increase beating zack consensus estimate read more novartis beat earning revenue estimate sale innovative medicine division grow drive volume growth cosentyx entresto however entry generic gleevec unite state europe impact sale unfavorably cosentyx sale increase drive strong growth indication expand access entresto sale increase drive increase uptake oncology franchise exclude gleevec grow drive promacta revolade tafinlar mekinist jakavi recent launch however sale sandoz division be due price erosion unite state however year so far share have lose novartis share be decrease witness industry other pharma bigwig report solid result too pfizerpfizer top line be expect be favorably impact new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner soon be report quarter moreover line extension xeljanz sutent bosulif receive fourth quarter be also expect bring more sale however loss exclusivity associate generic competition pristiq unite state lyrica europe product shortage legacy hospira likely affect sale negatively blockbuster drug enbrel sale continue decline quarter due biosimilar competition company sale be expect increase low single digit level zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale currently stand represent year year growth pfizer carry zack rank buy merckmerck blockbuster drug keytruda lynparza bridion injection be expect boost revenue first quarter keytruda sale be gain momentum approval launch keytruda new indication especially first line lung cancer however rise competitive pricing pressure be expect hurt sale zostavax zepatier januvia isentress animal health franchise sale be likely remain strong first quarter merck carry zack rank see complete list today zack rank strong buy stock here zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale be represent year year increase eli lilly lly sale lilly diabetes drug trulicity jardiance be expect grow drive market share gain other new drug such cyramza taltz lartruvo be also expect boost top line due continue strong demand verzenio be also expect generate higher sale first quarter however patent expiry country cymbalta strattera effient axiron zyprexa evista competitive pressure mainly immuno oncology agent alimta hurt sale drug expect strong uptake new product offset decline sale establish product quarter too zack consensus estimate sale earning be peg respectively zack consensus estimate sale stand represent rise year year lilly carry zack rank bristol myer squibb company bmy several label expansion bristol myer blockbuster cancer drug opdivo drive company sale last year be expect do so year well moreover cardiovascular drug eliquis also demonstrated strong performance expect trend continue quarter label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact however genericization plavix avapro avalide baraclude unite state due loss exclusivity be significantly hurt company top line company also face stiff competition immuno oncology space hiv business continue face competitive pressure zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale be peg represent rise year year bristol myer carry zack rank new product majority company be do well be expect offset decline sale legacy drug due loss exclusivity moreover most company boast deep promising pipeline also new tax law boost prospect strategic merger acquisition licensing deal collaboration smaller company strengthen company product portfolio wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1846,JNJ,dow experience particularly volatile week earning result take center stage index gain week first trading day thank primarily robust earning strong economic datum geopolitical tension ease however dow decline next session earning come mixed treasury yield surge highest level year last week dow decline last friday earning result major bank fail live investor high expectation also panic selling take place news syrium surface moreover investor be concern possibility russia lower house parliament be consider draft legislation allow kremlin ban list product be retaliation recent sanction group russian tycoon official index gain last week gain come back strong expectation earning otherwise volatile market market open higher monday continue bull run next day trade related tension ease white house say trade dispute china be resolve hold talk market close lower wednesday day gain follow president donald trump tweet warning russia possible military strike syrium however wall street rebound thursday geopolitical tension ease dow index gain monday drive robust first quarter earning result ease geopolitical tension least time be notably blue chip index close day move average dow breach psychological barrier first time mar close level first time mar indicate positive investor sentiment index increase tuesday support robust first quarter earning result strong economic datum notably blue chip index close highest level mar return positive zone year first time mar housing start rise industrial production increase march index lose wednesday drive plunge share price international business machine corp ibm free report ibm report impressive result primarily due time tax gain investor be look greater profit management be diversify cloud artificial intelligence company moreover company also state mainframe sale momentum not continue rest year consequently share price plunge mark largest decline year meanwhile energy stock gain surge oil price transportation sector start strong earning session index decline thursday real estate consumer staple technology stock drag broader market corporate earning be mixed bag even treasury yield surge highest level year day loss drag dow red year once again however stock manage curb loss end trading follow report president trump not be subject probe be conduct special counsel robert mueller component move index american express company axp free report report first quarter adjust earning share ep beating zack consensus estimate moreover bottom line witness marked year year improvement american express have zack rank hold revenue come ahead zack consensus estimate top line increase year year higher card member spending loan fee income growth business line base first quarter result solid trend remain year company foresee full year earning share high end range revenue be expect increase least read amex earning top higher card member spending goldman sachs group inc gs free report report first quarter earning share comfortably beating zack consensus estimate further bottom line witness year year improvement goldman net revenue be year year quarter review moreover revenue figure handily outpaced zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here ibm deliver first quarter gaap earning share beat zack consensus estimate nickel earning share ep increase year quarter plunge sequentially revenue outpaced zack consensus estimate climb year year basis however revenue decline sequentially constant currency cc revenue remain flat zack rank ibm reiterate ep forecast gaap ep be expect be least almost figure be expect first half mean ep least second quarter zack consensus estimate be currently peg read ibm beat earning revenue reiterate outlook johnson johnson jnj free report first quarter earning come share beating zack consensus estimate increase year period adjust earning exclude amortization expense special item include item report first quarter earning share compare earning year period sale come beating zack consensus estimate sale also increase year quarter reflect operational increase positive currency impact zack rank still expect adjust earning share range reflect operational growth rate however now expect revenue range higher read top earning estimate raise sale guidance procter gamble company pg free report report fiscal third quarter core earning share beat zack consensus estimate cent bottom line increase prior year quarter zack rank report net sale surpass zack consensus estimate top line grow year level give strong sale beauty fabric homecare business cincinnatus ohio base company maintain projection year expect organic sale growth range fiscal however expect organic sale be low end range sale growth be expect be read procter gamble earning top estimate view raise unitedhealth group inc unh free report report first quarter earning share beating zack consensus estimate bottom line also rise year year unitedhealth record revenue outpaced zack consensus estimate moreover top line compare favorably year figure unitedhealth revise financial outlook back solid first quarter result now expect current year net earning share estimate earlier adjust net earning have be raise previously project band read unitedhealth earning revenue top view lift jpmorgan chase co jpm free report report first quarter earning share handily outpaced zack consensus estimate report figure be prior year quarter jpmorgan have zack rank net revenue report be quarter year quarter also top zack consensus estimate rise rate loan growth increase trading revenue be main reason improvement be partially offset lower investment banking revenue read jpmorgan earning beat better rate trading performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlooktension related trade dispute seem have firmly recede background point focus be now squarely earning be more mixed bag be earlier estimate however only real worry investor have point be ongoing spike treasury yield major earning release line next week manage satisfy investor expectation dow soon return winning way wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1847,JNJ,abbvie inc abbv free report share be expect be northbound carry momentum achieve last year stock be compare favorably gain record industry abbvie carry zack rank buy see complete list today zack rank strong buy stock here last year share price surge be support series positive news abbvie meet primary endpoint several pivotal study key phase iii murano study venclexta roche rhhby free report rituxan relapse refractory chronic lymphocytic leukemia phase iii study evaluate oral jak selective inhibitor upadacitinib rheumatoid arthritis also phase iib study atopic dermatitis pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara humira moderate severe chronic plaque psoriasis meanwhile abbvie gain regulatory approval unite state europe japan competitive hcv medicine mavyret fda approval sixth indication cancer drug imbruvica abbvie also settle patent dispute amgen amgn free report delay launch latter biosimilar version abbvie blockbuster arthritis drug humira unite state most country eu october agreement have remove major overhang abbvie share moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market factor likely support rally several pivotal datum readout regulatory milestone expect bullish run stock continue important catalyst stock be datum pivotal phase iii trinity study rova third line later small cell lung cancer sclc first half year important regulatory milestone be fda decision elagolixin second quarter please note new drug application nda elagolix endometriosis be grant priority review fda october last year importantly humira have be generate strong sale new competition abbvie raise long term target humira sale october base strong demand trend drug imbruvica abbvie second most important drug be also do consistently well have multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease factor bode well stock wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1848,JNJ,sanofi inc sny free report announce start new phase iii study evaluate investigational biologic isatuximab combination other cancer medicine treatment multiple myeloma rare blood cancer first study ikema compare combination isatuximab amgen amgn free report kyproli carfilzomib dexamethasone kyproli dexamethasone second study imroz evaluate combination isatuximab dexamethasone celgene celg free report multiple myeloma drug revlimid lenalidomide japanese firm takeda velcade bortezomib combination velcade revlimid dexamethasone ikema study include patient relapse refractory multiple myeloma have be previously be treat line therapy imroz evaluate cancer combination newly diagnosed multiple myeloma patient not eligible transplant primary endpoint be progression free survival studiesplease note isatuximab be already be evaluate monotherapy phase iii study relapse refractory multiple myeloma phase ii acute lymphoblastic leukemia sanofi share have rise so far year compare unfavorably gain record industry sanofi carry zack rank sell better rank large cap pharma stock be johnson johnson jnj free report carry zack rank buy see complete list today zack rank strong buy stock here share have rise year so far earning estimate have go past day wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1849,JNJ,eli lilly company lly free report announce top line datum phase iii study rainfall evaluate cyramza ramucirumab first line treatment patient advanced gastric cancer study meet primary endpoint progression free survival pfs fail improve overall survival os result be present future medical meeting company have also announce not seek regulatory approval first line set base datum study cyramza be presently approve single agent combination chemotherapy drug paclitaxel treat advanced metastatic gastric stomach junction gej adenocarcinoma patient disease have progressed prior therapy drug be also approve treat metastatic small cell lung cancer metastatic colorectal cancer tradename folfiri share lilly have gain past month outperform industry rise period rainfall study evaluate cyramza combination cisplatin capecitabine fluorouracil first line treatment negative metastatic gastric gej adenocarcinoma versus company be hopeful positive pfs lead os benefit treat advanced gastric cancer be challenge be further underscored fact major advance chemotherapy have be achieve treat metastatic gastric cancer moreover initial datum phase iii study cyramza present esmo congress show drug meet pfs endpoint patient advanced urothelial carcinoma press release gastric cancer be fifth most common form cancer world disease be expect affect new patient cause death unite sate alone eli lilly company price eli lilly company price eli lilly company quotezack rank stock considerlilly carry zack rank hold better rank stock pharma sector include johnson johnson jnj free report acadium pharmaceutical inc acad free report therapeutic inc cort free report stock carry zack rank buy see complete list today zack rank strong buy stock here earning estimate increase last day company deliver positive earning surprise trail quarters average beat company share have return so far year acadium loss estimate narrow last day company come positive earning surprise trail quarters average beat company share have return so far year earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1850,JNJ,celsion corporation clsn free report announce fda have accept design phase ii study ovation ii ovarian cancer clear initiation study evaluate dna base immunotherapy gen localize treatment stage iii iv ovarian cancer newly diagnosed patient share company open higher jan follow announcement fact celsion share be past month significantly outperform industry gain period fda have clear study base compelling datum dose escalate phase ib ovation study evaluate gen ovarian cancer candidate achieve comparable progression free survival pfs patient versus neoadjuvant chemotherapy ovation ii study be also dose escalation study phase part be design find suitable dose gen evaluate dose mg select dose be evaluate phase ii part study primary endpoint study be achieve least improvement pfs patient treat gen combination neoadjuvant chemotherapy compare neoadjuvant chemotherapy alone company expect initiate study first half celsion be also develop candidate combination johnson johnson jnj free report doxil roche hold ag rhhby free report avastin patient platinum resistant ovarian cancer apart gen immunotherapy cancer program celsion portfolio be thermodox lead pipeline candidate be currently be investigate phase iii study primary liver cancer phase ii study recurrent chest wall breast cancer company have approve product portfolio thus investor remain focuse pipeline progress celsion corporation price celsion corporation price celsion corporation quotezack rank key pickcelsion carry zack rank buy sucampo pharmaceutical inc be top rank health care stock carry zack rank see complete list today zack rank strong buy stock here sucampo earning share estimate have increase cent last day company deliver positive earning surprise trail quarters average beat company stock be past month zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1851,JNJ,roche hold ag rhhby free report member genentech announce fda have converted accelerate approval avastin receive previously treat glioblastoma most aggressive form brain cancer full approval full approval be base datum phase iii eortc study avastin base treatment increase time disease progression death compare chemotherapy alone study however do not meet primary endpoint be significant increase overall survival avastin base treatment however show patient be able completely stop intake corticosteroid treatment avastin arm compare control arm evidence study show avastin treatment delay disease progression reduce need corticosteroid lead conversion provisional approval full apart recent approval drug be already approve unite state various indication include first second line treatment metastatic colorectal cancer advanced nonsquamous small cell lung cancer nsclc metastatic kidney cancer advanced cervical cancer recurrent ovarian cancer so far year share company have increase compare industry gain however drug have be face competition have be witness decline sale september amgen amgn free report partner allergan agn free report announce fda approve biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi be first cancer biosimilar approve unite state be also first biosimilar avastin same country zack rank stock considerroche carry zack rank sell top rank health care stock same space be johnson johnson jnj free report sporting zack rank buy see complete list today zack rank strong buy stock here johnson johnson earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1852,JNJ,key announcement week include fda approval eye disease drug well diabetes treatment label expansion exist product regulatory pipeline update be also provide company astrazeneca azn free report johnson johnson jnj free report recap week most important storiesaerie rhopressa gain fda approval aerie pharmaceutical aeri free report get boost earlier expect fda approval rhopressa lower elevated intraocular pressure iop patient open angle glaucoma ocular hypertension approval be expect consider favorable advisory panel vote october approval come couple month ahead feb pdufa prescription drug user fee act goal date rhopressa be first product aerie portfolio company expect launch product mid second quarter read more aerie get early fda approval lead drug rhopressa merck pfizer diabetes drug get fda nod sglt inhibitor steglatro ertugliflozin have be develop merck mrk free report pfizer pfe free report gain fda approval treatment type ii diabetes steglatro be enter highly crowd diabetes market already have other sglt inhibitor form invokana farxiga jardiance steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan priority review astrazeneca tagrisso label expansion astrazeneca supplemental new drug application snda use tagrisso osimertinib first line treatment patient metastatic small cell lung cancer nsclc tumor have egfr mutation have be grant priority review fda approval indication expand patient population significantly read more astrazeneca tagrisso label expansion filing accept fda janssen car deal priority review apalutamide janssen biotech have inked worldwide collaboration license agreement legend biotech usa inc legend biotech ireland limit subsidiary genscript biotech corporation development manufacture chimeric antigen receptor car cell drug candidate lcar lcar specifically target cell maturation antigen bcma be currently regulatory review china multiple myeloma mm meanwhile clinical study be be plan unite state term deal global net trade sale exclude greater china area be record janssen company split cost profit equally greater china janssen legend have cost sharing profit split arrangement deal term also include upfront payment janssen additional payment achievement development regulatory sale milestone be latest agreement field car have be attract lot interest recent quarters janssen also announce get priority review status fda new drug application nda apalutamide company investigational next generation oral androgen receptor ar inhibitor treatment man metastatic castration resistant prostate cancer crpc fda grant priority review response be april give be fda approve treatment currently available patient population timely approval be boost company cancer portfolio have gain year date compare rally industry belong allergan provide update vraylar seysara allergan agn free report provide couple update pipeline front company partner gedeon richter say vraylar cariprazine meet primary endpoint late stage adult major depressive episode associate bipolar disorder bipolar depression company plan seek label expansion indication second half read more allergan vraylar positive bipolar disease phase iii allergan also announce nda seysara have be accept review allergan partner paratek pharmaceutical be look get antibiotic approve treatment moderate severe acne vulgaris patient year age older approval come second half fda expand label pfizer bosulif grant btd bavencio fda have give nod label expansion pfizer bosulif use newly diagnosed chronic phase ph chronic myelogenous leukemia ph cml patient bosulif initial approval be use patient chronic accelerate blast phase ph cml resistance intolerance prior therapy expand indication increase addressable patient population significantly accord american cancer society new cml case be diagnosed unite state pfizer also announce fda have grant breakthrough therapy designation btd bavencio avelumab use combination inlyta treatment nave patient advanced renal cell carcinoma rcc avelumab be partner merck kgaa breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint be second time bavencio have receive btd hard treat cancer first time be treatment patient metastatic merkel cell carcinoma mmcc disease have progressed least previous chemotherapy regimen label expansion clinical trial collaboration bmy opdivo bristol myer squibb bmy free report pd immune checkpoint inhibitor opdivo gain fda approval yet indication regulatory agency grant approval opdivo intravenous use adjuvant treatment patient completely resect melanoma lymph node involvement metastatic disease opdivo be already approve wide range indication alone well combination other agent be currently several study well fact company also announce clinical trial collaboration taris biomedical evaluation safety tolerability preliminary efficacy taris tar gemris combination opdivo phase ib study evaluate combination patient muscle invasive bladder cancer mibc be schedule radical cystectomy opdivo be prioritize brand bristol myer portfolio product bring sale first month bristol myer be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be slightly last trading session major stock merck be lilly bristol myer decline last month bristol myer be glaxo decline see last pharma stock roundup here teva announce major job cut lilly provide outlook next pharma world watch regulatory pipeline news pharma stock look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1853,JNJ,johnson johnson jnj free report stock be compare favorably gain record industry last year share price surge be support series positive news include promising datum several pivotal study rapid progress pipeline line extension positive trend be likely continue year well drive stock new drug be approve last year guselkumab tremfya unite state well eu plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state juluca be review eu also gain fda approval several line extension lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene celg free report multiple myeloma drug pomalyst sixth indication imbruvica other please note market imbruvica partnership abbvie inc abbv free report line extension expand eligible patient population drug drive sale higher future quarters also submit regulatory application label expansion key drug include darzalex first line set multiple myeloma xarelto chronic coronary artery disease peripheral artery disease invokana include cardiovascular indication zytiga earlier stage metastatic prostate cancer get fda nod line extension year factor likely support rally several pivotal datum readout regulatory milestone expect bullish run stock be likely continue year expect file approval depression candidate esketamine apalutamide pre metastatic prostate cancer symtuza darunavir base once daily single tablet regimen hiv be approve fda domestic pharma segment sale decelerate first half number key growth driver remicade concerta face competition however sale growth accelerate third quarter be likely see positive impact trend fourth quarter result probably believe new product segment label expansion drug imbruvica xarelto stelara darzalex contribution recent acquisition mainly actelion support top line growth factor bode well stock carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1854,JNJ,sanofi inc sny free report announce head head study compare toujeo insulin glargine long act insulin nordisk nvo free report tresiba long act insulin insulin degludec have meet main objective study show extent toujeo lower blood glucose level adult patient diabetes be similar tresiba other assess similarity difference efficacy secondary objective bright study involve evaluation important safety aspect such total number participant low blood sugar event full result study be expect be present next year sanofi share have rise so far year compare unfavorably gain record industry toujeo be already market unite state eu injection record sale growth first month be key new product sanofi portfolio please note sanofi diabetes franchise be significant pressure key product lantus face increase competitive pressure payor level biosimilar competition several european market japan moreover biosimilar version lantus hit market december last year so far lantus sale have decline unite state due lower average net price due exclusion cvs health corporation cvs free report unite health formulary plan diabetes sale have decline so far fact diabetes franchise sale be expect decline accelerate rate fourth quarter due cvs unite health formulary exclusion plan continue lower average pricing difficult comparison last year sanofi carry zack rank sell seethe complete list today zack rank strong buy stock here better rank large cap pharma stock be johnson johnson jnj free report carry zack rank buy share have rise year so far earning estimate have go past day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1855,JNJ,amgen inc amgn free report announce fda have approve regulatory application seek approval include datum cardiovascular outcome study fourier label pcsk inhibitor repatha label expansion repatha now be prescribe prevent heart attack stroke coronary patient establish cardiovascular disease year so far amgen share be better increase register industry datum phase iiifourier study present first quarter have reveal significant reduction myocardial infarction stroke treatment repatha compare current best therapy alone repatha significantly reduce risk hard mace heart attack stroke cardiovascular death compare standard treatment statin therapy individual component risk heart attack stroke coronary be nominally reduce respectively repatha however repatha do not show improvement cardiovascular death risk have raise investor concern then notably repatha gain fda approval august treatment patient incapable manage ldl cholesterol acceptable level be approve country include unite state japan canada overall member country european union give indication however uptake drug have not be very encourage so far due higher pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical inc regn free report also face similar issue pcsk inhibitor praluent fourier datum hold key commercial success repatha broaden use drug cardiovascular indication approve be include repatha label patient access drug improve amgen file regulatory application unite state eu include fourier datum repatha label june july fda have grant priority review regulatory application amgen currently carry zack rank hold see complete list today zack rank strong buy stock here better rank large cap pharma stock be johnson johnson jnj free report have zack rank buy share have rise year so far earning estimate have go past day zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1856,JNJ,share merck mrk free report decline large cap pharma industry surge industry rally be backed strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring large cap drug sector back track last year pharma giant astrazeneca azn free report nordisk nvo free report johnson johnson jnj free report lead front outperformed industry however merck miss opportunity suffer notable pipeline setback october merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing october company also announce delay readout important lung cancer study be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer raise investor concern delay readout give competitor chance gain strength lung cancer market october merck also withdraw regulatory application europe be look get keytruda approve first line combination therapy lung cancer september merck discontinue development hcv combination program mk mk say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group july keytruda be see key long term growth driver merck such setback do not bode well company remain be see strong performance new drug particularly keytruda strong vaccine animal health business cost save effort help merck pick keytruda second largest product merck portfolio be gain strong momentum new indication first line lung cancer fact keytruda be continuously grow expand new indication market globally keytruda development program also significantly advanced several key regulatory approval further drive sale merck global restructure program aim reduce cost structure increase efficiency intend reduce number manufacturing site include animal health site consolidate other facility company expect annual saving once restructure program be complete merck carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1857,JNJ,pharma biotech industry be plague drug pricing issue last year however bounce back make considerable headway year courtesy slew fda approval particularly large cap player industry rake stellar return not forget same space post decline year earlier upbeat quarterly result rise demand new product sale successful innovation product line expansion strong clinical study result well continue strong performance legacy product propel large cap drug sector new high year moreover encourage factor be expect drive sector growth meanwhile jubilant republican pass tax overhaul bill first time year bill slash corporate tax rate such tax reduction be likely further boost profit margin company large cap pharma sector more cash left hand turn also be used striking strategic deal be be remember merger acquisition activity lag previous year notably large cap pharma sub industry carry zack industry rank place top zack industry backtesting show top zack rank industry outperform bottom half factor more banking such positive trend investing sound large cap pharma stock seem judicious top such stock be fundamentally lucrative ensure steady stream cash inflow have hence select such company have outperformed broader index year be also poise continue winning streak head new year johnson johnson inc jnj free report new jersey base biotech giant johnson johnson have outperformed year share company have rally broader market have increase stock earning be further expect grow company track record product launch have be impressive year be make fast progress achieve goal more approval new blockbuster product moreover company be target more line extension exist well new drug october receive fda approval line extension simponi aria psoriatic arthritis ankylose spondylitis additionally contribution recent acquisition mainly actelion generate positive sentiment investor continuous development have lead consistent rise share company carry zack rank hold abbvie inc abbv free report illinois base company also outperformed so far year share company have surge period rally price movement be support series positive news past few month abbvie present promising datum several pivotal study gain key regulatory approval settle humira patent dispute amgen stock earning be further estimate increase next year abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret secure approval unite state eu canada third quarter additionally august abbvie clinch nod regulatory agency imbruvica address sixth indication other meanwhile company announce positive datum phase iii murano study venclexta roche rhhby free report rituxan relapse refractory cll september later october too abbvie announce pivotal head head phase iii study evaluate risankizumab versus johnson johnson stelara humira treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint several pivotal datum readout regulatory milestone be expect mentioned factor bode well stock company be zack rank player astrazeneca plc azn free report uk base giant outperformed year company share increase period have announce quite few progression regulatory pipeline front year drive steady appreciation share price astrazeneca also have promising late stage pipeline include immuno oncology candidate imfinzi approve bladder cancer currently be evaluate multiple cancer be key drug pipeline company have new molecular entity phase iii trial regulatory review apart several lifecycle management program last month fasenra benralizumab have be approve unite state treatment asthma be review eu chronic obstructive pulmonary disease copd month fda have accept application label expansion market drug tagrisso osimertinib first line treatment adult patient metastatic nsclc additionally regulatory filing tagrisso label expansion be accept eu november similar indication december astrazeneca also announce positive top line datum phase iv study evaluate market drug tudorza pressair expand indication copd cardiovascular risk factor company carry zack rank nordisk nvo free report nordisk have be news past few month base encourage progress diabetes pipeline constant improvement corresponding approval have lead regular surge share company be rank player share company have soar so far year outpace index stock earning be further project rise october endocrinologic metabolic drug advisory committee fda vote ratio favor approval semaglutide improve glycaemic control adult type ii diabetes meanwhile late last year company also file semaglutide eu give indication moreover september fda approve fiasp fast act insulin aspart treat adult diabetes august fda approve label expansion company diabetes drug victoza drug be now approve reduce risk major adverse cardiovascular event adult type ii diabetes same month label expansion lessen risk severe hypoglycaemia tresiba be endorse committee medicinal product human use eu tresiba label update boost company sale conclusiona series datum readout upside regulatory pipeline front stock year be likely help continue bullish run next year surpass broader market well more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1858,JNJ,last week issue article mentioned merger acquisition be quite lean pick significantly propose tax reform be finally approve reform aim cut corporate tax rate boost profit large drug biotech company change tax code also allow company bring back huge cash hold overseas time tax rate change definitely leave more cash hand drug biotech company also focus drug pricing take backseat large drug biotech company struggle organic growth be lot chatter possible increase large give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline article discuss mid large cap name be logical acquisition target next year company pfizer pfe free report merck mrk free report johnson johnson jnj free report other matter buy drug biotech stock be current sale performance drug product prospect future sale growth quality pipeline company discuss have most factor go favor acquisition small cap drug biotech company be very difficult predict quite frequent hence have be exclude discussion biomarin pharmaceutical inc bmrn free report company product pipeline portfolio include rare disease drug be great demand be less competitive space expensive treatment bring huge profit biomarin be such drug developer market cap be biomarin key orphan disease drug vimizim kuvan continue do well backed strong underlie patient demand trend biomarin expect sustain growth drug brineura earlier expect approval year treatment child cln disease form batten disease be also huge boost biomarin impressive rare disease pipeline be also progress well approval pegvaliase treatment expect pipeline believe late stage candidate vosoritide achondroplasia most common form dwarfism bmn hemophilia have blockbuster potential biomarin have already be target takeover speculation company gilead gild amgen amgn roche be interested buy biomarin vertex pharmaceutical inc vrtx free report vertex so far have be tremendous year positive datum read out regulatory approval lead increase eligible patient population approve cystic fibrosis cf kalydeco orkambi cf be vertex main area focus consistent expansion patient population vertex cf product revenue have increase quarter quarter company be optimistic positive trend cf sale continue gain additional reimbursement approval orkambi ex market get approval launch tezacaftor vx ivacaftor combination medicine meanwhile company have also make decent clinical progress multiple cf study year have meaningful pipeline catalyst market cap vertex be incyte corporation incy free report incyte strong oncology portfolio make lucrative target company gilead amgen bristol myer market cap incyte be more primary reason incyte be ripe buyout be product market jakafi iclusig jakafi jak inhibitor be first only product be approve polycythemia vera pv myelofibrosis mf rare blood cancer jakafi be see strong sale performance drive strong patient demand indication order expand patient population increase commercial potential drug company be work expand label further iclusig be approve chronic myeloid leukemia acute lymphoblastic leukemia meanwhile incyte pipeline boast candidate immune therapy epacadostat be study combination pd agent merck bristol myer other olumiant rheumatoid arthritis approve europe regulatory application be file unite state january alexion pharmaceutical inc alxn free report biomarin alexion be also focuse development life transform drug treatment patient ultra rare disorder key drug be soliris approve severe ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus have be consistently do well meanwhile alexion be work expand drug label include additional indication approve boost further sale growth have other drug rare disease call strensiq kanuma be emerge growth driver alexion also have robust pipeline several candidate development include soliris follow candidate alxn roche pfizer novartis be interested buy alexion market cap alexion be more today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1859,JNJ,world aids day take place year december person world come together fight hiv support live hiv commemorate have die aids related disease everybody slogan world aids day be everybody count goal be ensure access affordable high quality care service person hiv strong health care system well integration hiv tuberculosis hepatitis service accord information provide world health organization more person have lose life due hiv so far person die last year hiv related cause end approximately person be live hiv number newly infected hiv patient be currently available treatmentswhile be cure hiv present virus be controlled use effective antiretroviral arv drug accord adult child hiv be currently lifelong arv person live hiv be receive antiretroviral therapy art combination art combine more atv drug have be find be effective suppress viral replication person body thereby allow immune system strengthen regain capacity fight infection hiv drug landscape have evolved year drug vary mechanism action be approve year include multus class combination product atripla complera stribild nucleoside reverse transcriptase inhibitor nrtis combivir epivir truvada viread nucleoside reverse transcriptase inhibitor nnrtis edurant sustiva protease inhibitor pis prezista reyataz norvir hiv integrase strand transfer inhibitor insti isentress tivicay well fusion inhibitor entry inhibitor ccr co receptor antagonist accord new hiv infection fall hiv related death decline third art save life however only hiv infected person be aware status remain significant need spread awareness disease availability rapid diagnostic test rdts detect presence absence hiv antibody accord globaldata hiv market unite state france germany italy spain uk japan brazil china be expect grow be significant need new alternative arv treatment option come better tolerability higher efficacy lower rate treatment discontinuation here be look few key player hiv market drug stock focusjohnson johnson jnj free report be key player hiv market company introduce several medicine therapeutic area last year company partner glaxosmithkline plc gsk free report recently gain fda approval juluca first complete single pill drug regimen treatment hiv infection certain adult live disease be virologically suppress once daily antiretroviral be combination tivicay insti edurant nnrti maintain safety efficacy traditional drug regimen nrti simpler treatment regimen make compliance easier hiv patient need stay consistent treatment regimen order keep viral count low company be currently seek fda approval partner gilead science inc gild free report darunavir base single tablet regimen str once daily regimen comprise darunavir mg cobicistat mg emtricitabine mg tenofovir alafenamide mg taf be also work hiv vaccine company bill melinda gate foundation national institutes health be conduct efficacy study investigational mosaic hiv preventive vaccine be significant unmet need vaccine hiv lot progress have be make treat manage disease almost person become infected year develop vaccine hiv have prove be challenge due unique property virus include ability mutate rapidly moreover genetic diversity multiple strain subtype prevalent different part world be additional hurdle be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong gilead science inc hiv be primary area focus gilead company hiv portfolio include drug genvoya truvada atripla descovy odefsey complera stribild contribute approximately total sale first month gilead taf base product genvoya descovy odefsey remain key growth driver gilead be currently seek fda approval investigational fix dose combination bic ftc taf fda expect respond feb meanwhile company expect complete mg cohort phase study gs tlr agonist hiv cure year end late stage study evaluate descovy pre exposure prophylaxis prep be schedule complete third quarter company hepatitis virus hcv franchise see decline sale gilead be focuse hiv franchise growth company hcv product be expect generate sale however competition market be intense moreover company be face competition generic product well gilead be zack rank hold stock stock have gain year date compare rally industry belong glaxosmithkline glaxo be majority stakeholder viiv healthcare global specialist hiv company be set partnership pfizer inc pfe free report now have shionogi shareholder well key product hiv portfolio include triumeq tivicay glaxo be work bring new growth driver hiv business juluca be recent addition glaxo be explore new treatment paradigm drug regimen new modality long act injectable new mechanism action include maturation inhibitor broadly neutralising antibody company be work dolutegravir lamivudine combination also be naive patient long act cabotegravir rilpivirine combination viiv have commence late stage study long act cabotegravir prevention hiv infection sexually active woman study compare cabotegravir injection give month daily oral pre exposure prophylaxis prep emtricitabine tenofovir disoproxil fumarate glaxo zack rank stock have decline year date compare rally industry belong merck mrk free report merck have presence hiv market form isentress isentress hd hiv integrase inhibitor use combination other antiretroviral agent company hiv franchise bring sale first month year period mainly due lower demand unite state due competitive pressure merck hiv pipeline have couple late stage candidate mk doravirine nnrti mk doravirine lamivudine tenofovir disoproxil fumarate dor tc tdf company expect file regulatory approval doravirine single entity tablet fix dose combination tablet dor tc tdf year end merck zack rank stock have decline year date compare rally industry belong medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1860,JNJ,glaxosmithkline plc gsk free report have announce start large late stage african study experimental long act injection prevention hiv viiv healthcare hiv company majorly own glaxo pfizer pfe free report say phase iii study hptn evaluate long act cabotegravir monotherapy prevention hiv infection sexually active woman viiv healthcare be conduct study public private funding collaboration national institute allergy infectious disease niaid bill melinda gate foundation niaid part national institutes health nih be sponsor study viiv healthcare gilead gild free report be provide medicine study enrol more woman age sub saharan african country order prevent hiv infection uninfected person present use oral retroviral medication need be take day compare cabotegravir injection be administer month approvedglaxo share have decline year so far underperform increase witness industry viiv healthcare be already conduct hptn study cabotegravir hiv uninfected man transgender woman have sex man also co funding niaid meanwhile cabotegravir be also be evaluate late stage study drug regimen johnson johnson jnj free report edurant rilpivirine third study initiation announce earlier week last week glaxo partner announce fda approval first dual treatment hiv juluca tivicay dolutegravir edurant rilpivirine juluca have be develop partnership viiv healthcare janssen hiv have be key therapeutic area glaxo new hiv drug tivicay triumeq have be record consistently strong sale gain market share glaxo hiv sale rise constant exchange rate first month meanwhile significant portion expenditure go develop hiv medicine treat prevent hiv glaxoha zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1861,JNJ,week company nordisk nvo free report eli lilly company lly free report be news provide regulatory update nordisk gain approval new type ii diabetes drug fda expand label lilly taltz recap week most important storiesnovo nordisk diabetes drug get fda nod nordisk get major boost fda approve company new type ii diabetes drug ozempic ozempic once weekly glp agonist be approve use adjunct diet exercise improve glycemic control adult type ii diabetes mellitus approval come shortly fda advisory panel have vote favor approve drug ozempic enter highly crowd market have be show lead clinically meaningful statistically significant reduction hba compare placebo januvia sitagliptin bydureon exenatide extend release lantus insulin glargine ozempic be also associate weight loss ozempic be expect enter market early represent blockbuster potential read more nordisk semaglutide get fda approval diabetes positive datum abbvie imbruvica rituxan combo wm johnson johnson jnj free report partner abbvie present datum combination btk inhibitor imbruvica rituxan treatment newly previously treat patient waldenstrm wm primary endpoint progression free survival pfs be achieve late stage study imbruvica be approve different indication include chronic lymphocytic leukemia previously treat mantle cell lymphoma wm well chronic graft versus host disease read more abbvie imbruvica succeed combo study rituxan be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong sanofi present toujeo head head datum end vaccine development sanofi sny free report present positive datum toujeo head head study versus insulin degludec effect toujeo blood sugar level be find be similar insulin degludec read more sanofi toujeo meet key objective head head study sanofi also announce have decide end development clostridium vaccine base plan interim analysis show chance vaccine meeting primary endpoint late stage study be low be latest blow company vaccine segment be face issue dengue vaccine dengvaxia due safety concern earlier week philippine fda ask company suspend sale distribution marketing dengvaxia withdraw market pending compliance directive agency second indication approve lilly taltz lilly taltz ixekizumab gain fda approval second indication agency give nod use drug treatment adult active psoriatic arthritis psa taltz be initially approve treatment adult patient moderate severe plaque psoriasis be candidate systemic therapy phototherapy taltz work specifically target il protein play role drive underlie inflammation psoriasis read more lilly taltz get approval label expansion fda nod first herceptin biosimilar fda grant approval mylan myl free report biocon biosimilar version roche rhhby free report blockbuster cancer drug herceptin trastuzumab remind investor earlier year july fda oncologic drug advisory committee odac have vote favor approve biosimilar ogivri have be approve indication reference product herceptin include treatment positive breast gastric cancer cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock lilly be bristol myer decline last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here pfizer merck kgaa drug fail study teva ceo announce change next pharma world watch regulatory pipeline news pharma stock several company be present annual meeting american society hematology ash december datum approve pipeline drug wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1862,JNJ,portola pharmaceutical inc ptla free report announce fda have extend review period biologic license application bla reversal agent factor xa inhibitor andexxa andexanet alfa day result regulatory body now announce decision instead previously set deadline feb notably andexxa have be develop patient treat direct indirect factor xa inhibitor reversal anticoagulation be need due life threaten uncontrolled bleed portola share have significantly outperformed industry so far year stock have soar compare broader industry increase review date be extend accommodate resubmission additional datum provide portola august resubmission be request fda complete response letter issue portola last august letter fda have request extra information related product manufacturing importantly regulatory body have also ask more datum support inclusion direct factor xa inhibitor lixiana edoxaban indirect factor xa inhibitor lovenox enoxaparin product label hence view fda have logically ask additional time review application remind investor bla be base positive datum phase iii annexa study have evaluate safety efficacy andexxa reverse anticoagulant activity factor xa inhibitor xarelto rivaroxaban johnson johnson inc jnj free report eliquis apixaban bristol myer squibb company bmy free report older healthy volunteer significantly andexxa enjoy orphan drug status unite state andexxa be also review eu marketing application file third quarter response regulatory body be expect first half company press release more patient treat oral factor xa inhibitor be admit hospital due excessive bleed have also be estimate more patient take injectable factor xa inhibitor lovenox unite state benefit antidote annually currently approve antidote factor xa inhibitor yet be urgent gape unmet need same market go ahead expect investor focus remain further detail andexxa regulatory aspect portola pharmaceutical inc price portola pharmaceutical inc price portola pharmaceutical inc quotezack rank key pickportola carry zack rank hold better rank stock health care sector be therapeutic incorporate cort free report carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have be revise upward cent cent last day company deliver positive earning surprise trail quarters average beat share price company have sky-rocket year date zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1863,JNJ,share biogen inc biib free report decline almost company alzheimer candidate ban fail meet criterium success base month interim analysis primary endpoint mid stage trial company be develop candidate collaboration eisai co ltd so far year share biogen have gain compare industry growth phase ii study study involve patient prodromal mild alzheimer disease positive biomarker brain amyloid pathology study used bayesian adaptive randomization design allow automatic change design study early success study explore efficacy dose response ban interim analysis month evaluation base eisai house develop alzheimer disease composite score adcom month comprehensive assessment treatment placebo active arm bayesian analysis month indicated success be judge higher probability achieve least reduction rate decline adcom versus placebo interim analysis assessed potential futility stopping safety neither condition be meet study continue full analysis month biogen state month blind study continue further analysis follow predefined study protocol comprehensive final analysis be conduct month look demonstrate clinically significant result datum study be expect second half biogen be look strengthen ad other disorder pipeline notably company alzheimer disease ad pipeline comprise candidate different mechanism action include tau candidate biib bms potential ad well progressive supranuclear palsy psp amyloid aducanumab candidate well bace inhibitor elenbecestat program however successful development therapy treatment alzheimer disease be challenge note several company have fail develop treatment same november eli lilly company lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study consequently lilly decide drop development candidate meanwhile pfizer pfe free report shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch biogen inc price biogen inc price biogen inc quotezack rankbiogen carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1864,JNJ,report tech giant amazon meeting generic drugmaker make round company pfizer pfe free report teva pharmaceutical industry ltd teva free report be news former report late stage datum latter announce leadership organizational change recap week most important storiesis amazon talk generic drugmaker accord cnbc report tech giant amazon be preliminary discussion generic drugmaker include mylan myl free report novartis generic arm sandoz enter pharmacy market not much information be available be lot speculation discussion industry watcher way tech giant be plan enter market drug wholesaler retailer pfizer merck kgaa bavencio fail late stage study pfizer merck kgaa suffer setback effort expand label checkpoint inhibitor bavencio avelumab therapy fail meet primary endpoint superior overall survival os compare physician choice chemotherapy late stage study be be conduct evaluate bavencio third line treatment unresectable recurrent metastatic gastric junction gej adenocarcinoma patient disease progressed follow prior therapeutic regimen regardless pd expression company continue evaluate bavencio first line switch maintenance set gastric cancer accord information provide company gastric cancer be fifth most common cancer world third most common cause cancer death survival advanced disease be poor usually less year third line set be difficult treat population read more pfizer merck kgaa bavencio fail gastric cancer study leadership organizational change teva teva new ceo have announce change organization well leadership structure company key change be generic specialty medicine segment now operate single segment region north america europe growth market generic specialty organization also be merged global group newly form marketing portfolio function be set change dr michael hayden dr rob koreman dipankar bhattacharjee be exit teva effective dec several new appointment be also announce detailed restructure plan be unveil mid december teva have many challenge ahead pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track generic competition copaxone mg be major setback stock teva have lose value year date versus decline record industry mylan biosimilar eu review mylan partner biocon say european medicine agency ema have accept marketing application biosimilar version roche herceptin trastuzumab amgen neulasta pegfilgrastim herceptin be used treatment certain positive breast gastric cancer neulasta be used reduction duration neutropenia low count neutrophil type white blood cell incidence fever associate neutropenia adult patient treat chemotherapy certain type cancer marketing application have be withdraw earlier follow audit be conduct european inspect authority biocon drug product facility biocon say have complete corrective preventive action capas base audit be verify inspection part regulatory review process meanwhile company get response fda regulatory application biosimilar version herceptin december earlier year july fda oncologic drug advisory committee odac have vote favor approve biosimilar fda be not require do so usually follow recommendation advisory panel partner commence hiv vaccine efficacy study focus world aids day today johnson johnson jnj free report bill melinda gate foundation national institutes health have initiate first efficacy study investigational mosaic hiv preventive vaccine study evaluate vaccine efficacy safety reduce incidence hiv infection woman sub saharan africa be significant unmet need vaccine hiv lot progress have be make treat manage disease almost person become infected year develop vaccine hiv have prove be challenge due unique property virus include ability mutate rapidly moreover genetic diversity multiple strain subtype prevalent different part world be additional hurdle note efficacy study evaluate different vaccine candidate be be conduct south africa be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong viiv start late stage study hiv prevention viiv healthcare global specialist hiv company majority own glaxosmithkline gsk free report pfizer shionogi limit shareholder have commence late stage study long act cabotegravir prevention hiv infection sexually active woman study compare cabotegravir injection give month daily oral pre exposure prophylaxis prep emtricitabine tenofovir disoproxil fumarate cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock bristol myer bmy free report be astrazeneca decline last month bristol myer be glaxo decline see last pharma stock roundup here fda approve glaxo hiv drug roche present datum next pharma world watch regulatory pipeline news pharma stock response fda regard approval status mylan biocon biosimilar version roche blockbuster cancer drug herceptin trastuzumab be december nordisk nvo free report key player diabetes market also get know approval status latest type ii diabetes product offer semaglutide month medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1865,JNJ,roche rhhby free report member genentech announce interim result phase iii study evaluate tecentriq avastin chemotherapy first line treatment advanced squamous small cell lung cancer nsclc iii impower study show tecentriq avastin chemotherapy reduce risk disease worsening death compare be treat avastin chemotherapy earlier november roche have already mentioned iii impower study have meet co primary endpoint progression free survival pfs concurrent present release company also announce month landmark pfs rate percentage lung cancer patient survive year disease progress be almost double tecentriq avastin chemotherapy arm compare avastin chemotherapy arm same be secondary endpoint study be overall response rate orr rate tumor shrinkage combination tecentriq avastin chemotherapy tumor shrinkage rate be compare avastin chemotherapy arm tecentriq study be first phase iii combination trial cancer immunotherapy show improvement progression free survival first line treatment advanced lung cancer company expect submit encourage result regulatory authority potential label expansion tecentriq also roche expect present result co primary endpoint overall survival os first half so far year share company have increase compare industry gain separate release roche also announce positive interim result phase iii haven study evaluate hemlibra emicizumab prophylaxis dose once week adult adolescent year age older haemophilium inhibitor factor viii study show hemlibra prophylaxis administer injection skin once week show meaningful bleed control person haemophilium compare current treatment regimen require more frequent intravenous infusion roche hold ag price roche hold ag price roche hold ag quote zack rank stock considerroche have zack rank sell better rank health care stock same space be sucampo pharmaceutical johnson johnson jnj free report therapeutic inc cort free report hold zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date johnson johnson earning share estimate have moved last day company come positive earning surprise trail quarters average beat share price company have increase year date searning share estimate have moved cent cent cent cent last day company pull positive earning surprise trail quarters average beat share price company have increase year date zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1866,JNJ,quite few pharmaceutical industry merger be card propose tax reform be finally approve senate pass amend tax reform bill last week thereby successfully pass second stage bill now be present conference committee representative house senate come together draft final bill tax reform propose cut tax rate corporate boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare contrary expectation increase pharma biotech merger acquisition focus be mostly small bolt acquisition licensing deal agreement gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal year rise investor expectation trump action drug price not be onerous previously fear be lot chatter possible increase meanwhile major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buy asset strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace drug biotech company have regularly try merge acquire competitor mega merger deal achieve critical mass sale marketing meanwhile smaller biotech research firm investigate new therapy interesting pipeline candidate have also attract attention larger counterpart last few year focus drug pricing take backseat possibility repatriation fund hope be high activity pick company pfizer pfe free report merck mrk free report be expect take lead support robust cash flow balance sheet wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1867,JNJ,abbvie inc abbv free report partner janssen johnson johnson jnj free report pharmaceutical subsidiary announce combination study evaluate key cancer drug imbruvica waldenstrm wm rare form hodgkin lymphoma meet primary endpoint interim datum phase iii innovate study show combination imbruvica roche rhhby free report rituxan lead improve progression free survival pfs treatment naive previously treat patient wm compare rituxan alone base early positive result independent datum monitoring committee idmc recommend unblinded study abbvie plan discuss positive interim datum regulatory be already approve monotherapy treatment wm fact include wm imbruvica be presently approve distinct patient population include mantle cell lymphoma mcl small lymphocytic lymphoma sll chronic lymphocytic leukemia cll marginal zone lymphoma mzl chronic graft versus host disease gvhd imbruvica be add abbvie pipeline acquisition pharmacyclic have become key revenue driver abbvie abbvie expect record imbruvica global revenue more sale unite state expect cross first month imbruvica have record sale represent growth year year fact abbvie expect imbruvica peak sale more revenue present cll segment be largest revenue contributor imbruvica growth expansion hodgkin lymphoma nhl other indication be major growth driver future imbruvica have multus dollar potential abbvie be explore potential expand label solid tumor autoimmune disease imbruvica be phase iii study diffuse large cell lymphoma follicular lymphoma abbvie be position imbruvica pipeline molecule treatment feature several company sponsored study abbvie share have gain so far year compare favorably gain only record industry share price surge be support series positive news past few month abbvie present promising datum several pivotal study gain regulatory approval unite state europe japan competitive hcv medicine mavyret receive fda approval sixth indication imbruvicaand settle humira patent dispute amgen inc amgn free report abbvie carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1868,JNJ,abbvie inc abbv free report announce fourth pivotal phase iii study evaluate investigational il inhibitor risankizumab treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint top line datum immhance study show significant portion patient treat risankizumab achieve high level skin clearance nearly half patient treat risankizumab achieve complete skin clearance versus placebo week treatment continuous treatment risankizumab week risankizumab patient maintain response year datum show patient achieve better disease improvement time continuous treatment risankizumab rather withdraw therapy initial response result study support regulatory filing candidate week result study be present international congress psoriasis gene clinic meeting london abbvie have license risankizumab boehringer ingelheim abbvie be responsible future development candidate remind investor october abbvie have announce pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara abbvie humira treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint top line datum present study show risankizumab achieve significantly greater response clear almost clear skin versus stelara humira placebo week treatment risankizumab be also be evaluate phase ii study other immunological disorder crohn disease psoriatic arthritis abbvie share have gain so far year compare favorably gain only record industry share price surge be support series positive news past few month abbvie present promising datum several pivotal study gain regulatory approval unite state europe japan competitive hcv medicine mavyret receive fda approval sixth indication imbrivicaand settle humira patent dispute amgen inc amgn free report abbvie carry zack rank hold see complete list today zack rank strong buy stock here better rank large cap pharma stock be lundbeck hluyy free report carry zack rank buy share lundbeck have rise so far year earning estimate have go past day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1869,JNJ,allergan plc agn free report announce fda have approve supplemental new drug application snda label expansion schizophrenia capsule vraylar cariprazine maintenance treatment notably vraylar be already approve unite state acute treatment schizophrenia bipolar disorder be also approve europe give indication share allergan have decline year so far compare favorably industry decrease fda approval be base new datum week study prevention relapse adult patient schizophrenia datum study demonstrated long term treatment vraylar delay time relapse compare placebo course week significantly vraylar have perform expectation record sale year drug be likely be key driver allergan top line growth company press release approximately person be affected schizophrenia unite state also disease relapse patient year maintenance treatment be take hence vraylar label expansion maintenance therapy cater hugely unmet need patient require long term treatment option disease other player bipolar disorder schizophrenia treatment market be astrazeneca plc azn free report seroquel xr johnson johnson jnj free report risperdal consta plc alk free report aristada allergan plc price allergan plc price allergan plc quotezack rankallergan carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1870,JNJ,eli lilly company lly free report announce fda have approve label expansion psoriasis drug taltz include treatment active psoriatic arthritis psa adult note taltz be presently approve treat moderate severe plaque psoriasis adult have systemic therapy phototherapy drug have grow more first month contribute significantly revenue volume approval expand label unite state be expect further boost growth lilly stock price have increase past year outperform industry gain come back news fda approval taltz label expansion be base datum phase iii study spirit spirit evaluate drug active psa patient have not receive antirheumatic drug therapy have fail tumor necrosis factor tnf inhibitor respectively drug achieve reduction more composite measure disease activity acr more half patient population study week drug mg ml be inject single agent combination disease modify antirheumatic drug methotrexate however taltz face competition several drug especially novartis nvs free report cosentyx drug work target il cosentyx be also approve psa plaque psoriasis psa be chronic form inflammatory arthritis be painful progressive well press release approximately person unite state be affected disease apart cosentyx johnson johnson jnj free report stelara abbvie inc abbv free report humira other be fight market share eli lilly company price eli lilly company price eli lilly company quotelilly carry zack rank hold see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1871,JNJ,year world aids day be celebrate dec raise public awareness acquire immuno deficiency syndrome popularly know aids day be observed make person aware proper cure prevention disease regard year theme day year be right health day also commemorate have die aids related illness world aids day be official global public health campaign marked world health organization accord globally person be suffering hiv aids end total be child less year old aids be pandemic disease cause due infection human virus hiv virus weaken immune system destroy cell fight disease infection eventually lead aids medicine treatment hiv be call antiretroviral therapy art slow put check progression virus currently company be investigate new medicine treat prevent ultimately cure hiv scientist also be explore new treatment paradigm drug regimen make therapy drug drug improve long term safety profile new mechanism action improve medical understand hiv significant effort make lead government medical body prevent treat hiv aids disease still have limit treatment option person die aids related illness totale start epidemic base statistic be not surprising several healthcare company be investing significant amount expenditure develop treatment device hiv aids stock watch world aids day here be key pharma company hiv market investor rely glaxosmithkline gsk free report have long standing commitment hiv aids company have develop widely used antibiotic amoxycillin year be first medicine approve treat hiv sale older hiv product epzicom selzentry have be decline however newer hiv drug triumeq tivicay be witness consistent increase sale gain market share meanwhile significant portion expenditure be be used develop hiv medicine treat prevent hiv last week glaxo partner johnson johnson announce fda approval juluca combination glaxo edurant dolutegravir tivicay rilpivirine single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen week viiv healthcare hiv company majorly own glaxo pfizer pfe free report announce start large late stage african study evaluate long act prevention hiv sexually active woman approve cabotegravir injection be administer month opposed presently available oral retroviral medication need be take day already viiv healthcare have start conduct hptn study cabotegravirin hiv uninfected man transgender woman have sex man co funding national institute allergy infectious disease niaid meanwhile cabotegraviris also be evaluate late stage study drug regimen withedurant third study initiation announce earlier week furthermore glaxo be develop drug regimen ofdolutegravir lamivudine gilead gild free report be dominant player hiv market impressive portfolio fact gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya happen be bestseller surpass truvada atripla fourth quarter currently gilead bictegravir single table regimen str hiv treatment be priority review unite state fda be expect announce decision february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone combination be also review eu company work develop hiv drug be johnson johnson jnj free report company partner glaxo recently receive fda approval first drug regimen juluca discuss further company bill melinda gate foundation national institutes health be conduct efficacy study investigational mosaic hiv preventive vaccine study evaluate vaccine be safe be able reduce incidence hiv infection woman sub saharan africa hiv have significant unmet need woman girl account person live hiv eastern southern africa otherssome other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress mylan myl free report also recently receive tentative fda approval combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate meanwhile merck be develop investigational nucleoside reverse transcriptase inhibitor doravirine single entity tablet combination fix dose tablet other antiretroviral agent lamivudine tenofovir disoproxil fumarate tdf company plan file regulatory application same end conclusionaid hiv be life threaten disease have limit medical cure however be numerous company be develop drug treatment care person suffering hiv be risk become infected hiv thereby make space competitive johnson johnson sport zack rank strong buy glaxo gilead carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1872,JNJ,minerva neurosciences inc nerv free report announce have initiate phase iii study min evaluate lead pipeline candidate monotherapy treatment negative symptom patient diagnosed schizophrenia minerva share price have decline so far year industry witness gain phase iii study design be week placebo controlled monotherapy study testing dose min mg mg schizophrenia patient negative symptom patient be require have moderate severe negative stable positive symptom month prior enrollment patient be also require have specify minimum threshold baseline score positive negative syndrome scale panss negative sub scale order be eligible study primary endpoint study be achieve improvement panss score top line datum study be expect first half week study be follow open label extension study period week design phase iii study be similar successfully complete phase iib study phase iib study show improvement schizophrenic patient negative symptom treat min compare placebo approve product portfolio minerva be dependent progress pipeline moreover major collaboration agreement company doesn have source fund continue burn cash research development process company expect incur operate loss go forward cash available be expect fund operation next month only setback development min adversely impact minerva share meanwhile minerva have license agreement janssen pharmaceutical subsidiary johnson johnson jnj free report co development orexin receptor antagonist min treat schizophrenia minerva neurosciences inc price minerva neurosciences inc price minerva neurosciences inc quotezack rank stock considerminerva neurosciences carry zack rank hold couple better rank stock pharma sector include celldex therapeutic inc cldx free report acadium pharmaceutical inc acad free report stock carry zack rank buy see complete list today zack rank strong buy stock here celldex loss estimate narrow cent cent cent last day company deliver positive earning surprise trail quarters average beat acadium loss estimate narrow last day company come positive earning surprise trail quarters average beat medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1873,JNJ,pfizer inc pfe free report germany base partner merck kgaa announce phase iii study evaluate key pipeline candidate avelumab treatment gastric cancer third line set fail meet primary endpoint javelin gastric trial study evaluate avelumab monotherapy treatment unresectable recurrent metastatic gastric junction gej adenocarcinoma patient disease progressed follow prior therapeutic regimen regardless pd expression study fail demonstrate superior overall survival primary endpoint avelumab treatment chemotherapy study evaluate avelumab use hard treat patient population fail other gastric cancer study javelin gastric continue be evaluate avelumab first line switch maintenance set share pfizer have rise year compare increase large cap pharma industry avelumub human pd antibody receive fda approval metastatic merkel cell carcinoma mcc rare form skin cancer march advanced bladder cancer be market trade name bavencio bavencio be also approve eu japan september mcc meanwhile avelumab be be evaluate different type cancer monotherapy combination other portfolio asset pfizer have also initiate avelumab double triple combination study chemotherapy target therapy have avelumab combination therapy immuno oncology agent development currently avelumab be be develop more type tumor include gastric junction head neck hodgkin lymphoma small cell lung ovarian renal cell carcinoma other study be part javelin development program bavencio be consider be key long term growth driver pfizer pfizer carry zack rank hold see complete list today zack rank strong buy stock heresome better rank large cap pharma stock include johnson johnson jnj free report lundbeck hluyy free report carry zack rank buy share have rise year so far earning estimate have go past day share lundbeck have rise so far year earning estimate have go past day investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1874,JNJ,merck co inc mrk free report announce committee medicinal product human use chmp european medicine agency ema have give positive opinion recommend marketing approval prevymis letermovir merck be look get prevymis approve eu prevention cytomegalovirus cmv reactivation disease adult cmv seropositive recipient allogeneic hematopoietic stem cell transplant hsct merck expect decision european commission month remind investor only last week prevymis receive approval fda prevention cmv infection common potentially serious viral infection allogeneic hsct recipient cmv infection be associate increase mortality hsct patient merck say prevymis be first new cmv medicine be approve unite state year merck intend launch drug unite state next month list price day tablet injection merck share have decline year increase industry other key pipeline candidate merck include doravirine hiv new drug application nda filing expect end year mk be be develop phase ii study refractory chronic cough idiopathic pulmonary fibrosis ipf cough merck pfizer pfe free report have develop diabetes candidate ertugliflozin regulatory application be review unite state eu company have file separate ndas ertugliflozin monotherapy twoforfixed dose combination metformin januvia sitagliptin respectively decision fda be expect next month merck carry zack rank hold see complete list today zack rank strong buy stock here better rank stock industry be johnson johnson jnj free report ligand pharmaceutical incorporate lgnd free report zack rank buy share be earning estimate have go past day share ligand pharmaceutical have rise year so far earning estimate have increase past day today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1875,JNJ,achillion pharmaceutical inc achn free report announce fda have grant orphan drug designation lead factor inhibitor candidate treatment glomerulopathy serious renal disorder note orphan drug designation be grant drug capable treat rare disease affect less person unite state status make eligible year marketing exclusivity unite state follow approval designation also make company eligible certain other benefit include tax credit related clinical trial expense exemption fda user fee assistance fda clinical trial design share achillion have underperform industry so far year stock have lose contrast industry gain preliminary datum announce last month phase ii study evaluate demonstrated potential treat reduce proteinurium excess protein urine treatment duration daysachillion also announce initiation phase bioavailability study evaluate extend release oral tablet formulationsof endpoint study be achieve once twice daily dose regimen interim result expect mid apart company be also develop phase ii study patient paroxysmal nocturnal hemoglobinurium pnh candidate also enjoy orphan drug status indication achillion have plan initiate phase ii study first half evaluate long term potential combination alexion pharmaceutical inc alxn free report soliris treat pnh remind investor achillion face major setback johnson johnson jnj free report sell stake achillion last month follow termination global license collaboration agreement develop hepatitis treatment september approve product portfolio achillion have lose future revenue form milestone payment achillion pharmaceutical inc price achillion pharmaceutical inc price achillion pharmaceutical inc quotezack rank stock carry zack rank buy stock investor consider be therapeutic incorporate cort free report stock carry zack rank see complete list today zack rank strong buy stock here earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1876,JNJ,allergan plc agn free report partner gedeon richter announce positive top line result second pivotal phase iii study schizophrenia drug vraylar study evaluate vraylar cariprazine treatment adult patient major depressive episode associate bipolar disorder bipolar depression notably vraylar be already approve unite state eu acute treatment manic mixed episode associate bipolar disorder well schizophrenia additionally fda approve drug last month expand use maintenance therapy treatment schizophrenia share allergan have decline year so far compare favorably industry decrease phase iii rgh md study be investigate dose vraylar mg mg total patient bipolar depression study meet primary endpoint show significant improvement patient compare placebo drug be generally well tolerate study however also note total number patient be treat vraylar discontinue trial due adverse event comparison treat placebo base report datum company be plan submit regulatory application fda second half significantly allergan have licensing agreement gideon richter hungarian multinational pharmaceutical biotechnology company co develop market vraylar unite state well canada vraylar have perform well first month record sale compare register same period year drug be likely be key driver allergan top line national alliance mental illness bipolar disorder be most common mental disease third most common cause hospitalization unite state youth adult age year moreover adult country live bipolar disorder hence approval drug expand indication provide company access wider patient population base bipolar issue other player bipolar disorder schizophrenia treatment market include astrazeneca plc azn free report seroquel xr johnson johnson jnj free report risperdal consta plc alk free report aristada allergan plc price allergan plc price allergan plc quotezack rankallergan carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1877,JNJ,equity have have stellar run strong growth rise optimism president donald trump tax reform however latest development political landscape unite state spell trouble republican positive trumpgdp growth unite state be revise third quarter compare previous quarter third quarter read be revise initial read be strongest quarterly growth read year farm payroll increase november labor department moreover unemployment rate come year low come positive trump seek brand leader mass risk involvedhowever not well trump administration democrat doug jone defeat republican roy moore senate election alabama deep red state vote overwhelmingly trump november presidential election moore have be accuse sexual abuse child molestation have be factor relatively low support receive have show country way be unify jone say entire race have be dignity respect campaign have be rule law add gop senate majority have slim moore defeat create difficulty trump administration pass key legislation senate pass republican tax reform be increase concern difference version house senate moreover geopolitical risk weigh market last month north korea launch hwasong missile improve technology fly japan latest show force owing high uncertainty market believe be best opt low volatility hence now discuss few etfs focuse provide exposure low volatility space equity market ishare edge msci min vol usa etf usmv free report fund be popular etf provide exposure company low risk have aum charge fee basis point year sector look fund have high exposure information technology health care consumer staple allocation respectively dec fund top holding be johnson johnson jnj free report visa inc class free report mcdonald corp mcd free report allocation dec fund have return year year date dec have zack etf rank hold medium risk outlook powershare low volatility portfolio splv free report fund be popular etf target large cap company low volatility have aum charge fee basis point year sector look fund have high exposure utility financial industrial allocation respectively dec fund top holding be honeywell international inc hon free report coca cola co ko free report pepsico inc pep free report allocation dec fund have return year year date dec have zack etf rank medium risk outlook powershare midcap low volatility portfolio xmlv free report fund be popular etf target mid cap company minimum volatility have aum charge fee basis point year sector look fund have high exposure utility real estate financial allocation respectively dec fund top holding be jack henry associate inc jkhy free report westar energy inc great plain energy inc allocation dec fund have return year year date dec want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1878,JNJ,johnson johnson jnj free report partner glaxosmithkline gsk free report recently announce fda approval juluca combination glaxo tivicay rilpivirine edurant dolutegravir single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen approval juluca have shift investor focus hiv disease space let see company be try tap huge market note hivhiv stand human virus weaken immune system destroy cell fight disease infection eventually lead aids acquire syndrome medicine treatment hiv be call antiretroviral therapy art slow put check progression virus globally person be live hiv aids end total be child less year old improve medical understand hiv prevention treatment well significant effort make lead government medical body hiv aids still have cure notably person die aids related illness reach total number start epidemic company develop hiv drugsmarkete therapy hivseveral pharmaceutical company be marketing drug therapy treat hiv gilead gild free report be dominant player hiv market impressive portfolio company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya be bestseller surpass truvada atripla fourth quarter company glaxosmithkline have long standing commitment hiv infectious disease company have develop widely used antibiotic amoxycillin year develop first medicine approve treat hiv azt company other market hiv drug include triumeq tivicay other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress pharmaceutical company mylan myl free report have receive tentative approval fda combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate treat hiv pipeline company be work develop new drug treat prevent possibly cure hiv scientist be explore new treatment paradigm drug regimen make therapy drug improve safety profile new mechanism action gilead str bictegravir hiv treatment be priority review unite state fda be expect announce decision next february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone merck be develop investigational nucleoside reverse transcriptase inhibitor mk doravirine hiv infection plan tofile regulatory application fix dose combination same single entity tablet fix dose combination tabletconsist fix dose combination doravirine dor lamivudine tc tenofovir disoproxil fumarate tdf late glaxo be also develop drug regimen be dolutegravir cabotegravir rilpivirine increase number company be develop drug treat life threaten disease competition have intensified manifold space meanwhile be be see juluca fare market be reissue article correct mistake original article issue tuesday nov longer be rely
1879,JNJ,senate republican reveal tax plan entail deferment corporate tax cut year such delay raise concern president trump ability pass law aggravate wall street end week winning streak lower taxe be major campaign promise make trump help push major index series record high presidential election add high valuation corporate debt plague broader market decade long bull run be question near end wake such uncertainty pick stock isn easy be way reduce chance make bad investment such scenario stock be undisturbed market gyration provide steady earning growth have higher market capitalization make solid bet tax overhaul senate seek delay tax reduction plan hasn go well investor lower corporate tax rate strengthen labor market revitalize economy also encourage world ingenious entrepreneur establish business unite state top senate add plan impose minimum income intangible asset intellectual property multinational company generate significant portion profit intellectual property be line fire notable be company tech sector tech bank affected mosttech company meanwhile benefit immensely lower tax rate tax earning improve lead repatriation trillion dollar hold abroad such company tech company use extra cash research development merger acquisition hence possible delay much anticipate corporate tax cut result bout selling tech stock bank weren spare be lower corporate taxe bolster investment be boon lender add trouble bank be flattest yield curve decade affect already weak interest income nation largest lender week winning streak come endin fact broader equity market register first weekly loss month investor remain wary congressional republican fail make inroad pass tax cut stock dow jone fall point close nov index decline finishing index record week winning streak longest meanwhile index small cap stock russell fall post steepest weekly decline august volatility have back market cboe volatility index vix gauge used option trading datum measure imply volatility stock jump close vix also end week slightly average touch record low week earlier other potential red flagsnot only delay tax reform market be flash several warning sign biggest roadblock be lofty valuation bull market already stretch back march result cyclically adjust price earning cape ratio be well second highest valuation century lyn alden founder lyn alden investment strategy atlantic city nj now lag valuation see late dot com bubble also remember be too much risk bull run gain be concentrated certain stock accord david winter ceo adviser portfolio manager fund such stock include alphabet googl free report amazon com amzn free report apple aapl free report ebay facebook microsoft corp netflix priceline pcln salesforce crm starbucks corp sbux have gain average so far year have also contribute almost third return end last not least corporate debt ceiling be rise jp morgan recent guide market corporate debt percentage gross domestic product gdp touch highest recent history time buy ultra safe stock solid market apprehend healthy pullback strong run investing stock be immune market gyration seem judicious best way go do be create portfolio ultra safe stock essentially have low beta make less volatile market trade case low beta range also have large market capitalization market capitalization value more help provide steadily increase earning growth have much risk collapse additionally such stock flaunt zack rank strong buy buy exxon mobil corporation xom free report explore produce crude oil natural gas recently company have zack rank beta exxon mobil expect growth current year be higher industry project growth company expect growth next year be solid visa inc free report operate payment technology company currently stock have zack rank beta visa expect growth current year be more industry project growth company expect growth next year be steady johnson johnson jnj free report research develop manufacture sell various product health care field company currently possess zack rank beta johnson johnson expect growth current year be higher industry project growth company expect growth next year be promising see complete list today zack rank stock here este lauder company inc el free report manufacture market skin care makeup fragrance hair care product currently stock have zack rank beta este lauder company expect growth current year be more industry project growth company expect growth next year be steady dollar tree inc dltr free report operate variety retail store company have zack rank beta dollar tree expect growth current year be higher industry project growth company expect growth next year be solid make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1880,JNJ,impax laboratory inc report third quarter adjust earning cent share beating zack consensus estimate cent however earning be cent year period due higher cost expense total revenue decrease year year mainly due lower generic division sale revenue however surpass zack consensus estimate report quarter impax share fall almost thursday follow earning announcement nonetheless year date impax share be industry decline quarter detaildure report quarter impax generic division revenue decrease year quarter decrease revenue be due lower sale metaxalone fenofibrate oxymorphone partially offset higher sale epinephrine auto injector product acquire teva pharmaceutical new product launch however revenue impax specialty pharma division be year year largely due higher sale rytary zomig sale be adjust research development expense fall report quarter due closure research development facility middlesex nj adjust selling general administrative expense sg increase other detailsin july company receive approval generic version attention deficit hyperactivity disorder drug novartis nvs free report focalin xr mg johnson johnson jnj free report concerta mg fda approval generic focalin xr complement portfolio generic focalin xr include mg capsule be already market concurrent earning release company announce completion phase iib study parkinson disease candidate ipx candidate be extend release formulation carbidopa levodopa cd ld achieve average hour reduction time compare immediate release cd ld subsequent quarter october impax privately hold generic drug maker amneal pharmaceutical enter stock deal merge form new publicly trade company amneal pharmaceutical inc combine company have diverse pipeline more product file fda active stage development deal be expect close first half add impax standalone adjust earning first month generate double digit revenue earning growth next year meanwhile fda approve company abbreviated new drug application seek approval sanofi sny free report chronic kidney disease drug renvela outlook company update full year adjust earning expectation range cent cent share previously cent cent share company expect adjust gross margin range previously adjust research development expense include patent litigation expense generic brand division be forecast be range previously company maintain adjust selling general administrative expense estimate range takeimpax generic division have be unfavorably impact pricing pressure prevailing market however company cost control initiative announce early year have improve margin be expect bring more improvement moreover merger amneal also bring synergy moreover approval full dose range generic concerta well generic renvela be expect have positive impact impax revenue go forward impax laboratory inc price consensus ep surprise impax laboratory inc price consensus ep surprise impax laboratory inc quotezack rankimpax currently carry zack rank sell see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1881,JNJ,earning remain focus week company astrazeneca azn free report report third quarter result meanwhile company roche rhhby free report merck co inc mrk free report be news due regulatory update recap week most important storiesmixed result astrazeneca astrazeneca third quarter result be mixed company miss earning beating revenue company have several pipeline event line come quarters include datum cancer drug lynparza imfinzi well regulatory submission moxetumomab pasudotox leukemia selumetinib thyroid cancer other read more astrazeneca miss earning tweak ep view fda nod merck cmv drug merck gain fda approval prevymis letermovir prevention cytomegalovirus cmv infection disease adult allogeneic hematopoietic stem cell transplant hsct patient common potentially serious viral infection allogeneic hsct recipient level cmv infection be associate increase mortality hsct patient merck say prevymis be first new cmv medicine be approve unite state year merck intend launch drug december list price day tablet injection merck be zack rank hold stock see complete list today zack rank strong buy stock here sanofi sign ms deal worth sanofi sny free report have enter agreement principia biopharma inc latter clinical stage blood brain barrier cross oral btk inhibitor prn have potential be develop treatment multiple sclerosis ms other central nervous system cns disease sanofi be willing shell include upfront payment balance be payable achievement milestone principia also earn royalty product sale moreover company have option co fund late stage development cost exchange higher royalty global sale profit loss sharing arrangement unite state sanofi already have presence ms market form lemtrada aubagio glaxo file nucala label expansion unite state glaxosmithkline plc gsk free report be look expand label il antagonist nucala mepolizumab be currently approve fda add maintenance treatment patient severe asthma age year older eosinophilic phenotype glaxo be now seek fda approval drug be used add maintenance treatment patient have chronic obstructive pulmonary disease copd eosinophilic phenotype accord information provide company copd be estimate affect person world be currently fourth lead cause death world however give prevalence become third lead cause death glaxo have also file fda approval nucala treatment adult patient eosinophilic granulomatosis polyangiitis egpa roche lung cancer drug get fda nod first line set roche gain fda approval lung cancer drug alecensa alectinib first line treatment person specific type lung cancer label expansion be base phase iii datum show alecensa significantly extend time person live disease worsening compare xalkori crizotinib risk cancer spread grow brain central nervous system be also significantly lower alecensa arm approval expand patient population alecensa significantly treatment previously be approve second line set roche also gain fda approval melanoma drug zelboraf treatment erdheim chester disease ecd rare blood disease roche have gain year date compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline marginally week major stock eli lilly lly free report be astrazeneca be last month johnson johnson jnj free report be glaxo decline see last pharma stock roundup here pfizer teva earning novartis seek new indication kymriah next pharma world third quarter earning season almost watch regulatory pipeline news pharma stock more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1882,JNJ,total earning total healthcare market capitalization be revenue growth earning growth appear solid compare many other sector earning revenue beat ratio respectively look disappointing most notable player johnson johnson jnj free report be first major drug company report earning oct follow eli lilly company lly free report bristol myer squibb company bmy free report oct oct respectively other major drug company merck mrk free report pfizer pfe free report report oct oct respectively industry prime post solid result earning revenue beat johnson johnson earning world biggest maker healthcare product continue long streak earning beat earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year edge past zack consensus estimate johnson johnson raise full year earning share guidance revenue guidance read healthcare etfs focus johnson johnson earning pfizer earning drug giant come earning beat line revenue earning share cent come couple cent zack consensus estimate revenue be line estimate year year basis earning share revenue rise respectively pfizer narrow revenue guidance range raise earning share guidance range merck earning focusmerck beat earning estimate miss revenue earning share come surpass zack consensus estimate improve year quarter revenue decline year year be zack consensus estimate merck raise revenue guidance earning share guidance year bristol myer earning focusbristol myer miss earning beat revenue report earning share cent couple cent estimate revenue grow edge past zack consensus estimate company raise earning share guidance see healthcare etfs here eli lilly earning focuseli lilly top zack consensus estimate front earning outpaced zack consensus estimate couple cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue earning guidance now expect revenue range compare previous expectation earning share range versus expect previously etf string earning beat fail boost pharma etfs see rough trading past month have highlighted detail fund have zack etf rank hold high risk outlook powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest share focus firm etf have lose month ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month read lie store pharma etfs spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take nearly share product be same period vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket johnson johnson pfizer bristol myer eli lilly account least share merck make asset product have amassed asset base trade moderate volume share day expense ratio come fund have lose month want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1883,JNJ,pipeline regulatory update be focus week fda approve first drug hiv treatment unite state european commission ec grant approval johnson johnson jnj free report tremfya expand label novartis nvs free report tasigna recap week most important storiesj glaxo hiv drug get fda nod glaxosmithkline gsk free report gain fda approval first drug hiv treatment unite state juluca combine approve hiv drug tivicay mg edurant mg single once daily pill maintenance treatment virologically suppress hiv infection company expect make drug available pharmacy december juluca mark begin new era hiv treatment other company gilead also work bring better treatment market read more glaxo get fda approval first drug hiv regimen eu nod psoriasis drug janssen cilag international nv company gain eu approval psoriasis drug tremfya use adult moderate severe plaque psoriasis be candidate systemic therapy approval be expect consider committee medicinal product human use chmp have adopt positive opinion september drug be approve unite state earlier year july psoriasis market be pretty crowd person world be estimate suffer psoriasis include european case be consider moderate severe tremfya be currently late stage development treatment psoriatic arthritis johnson johnson be zack rank buy stock see complete list today zack rank strong buy stock here roche present datum hemophilia cancer drug roche rhhby free report present positive datum recently approve hemophilia drug hemlibra late stage study haven adult adolescent age year older hemophilia inhibitor factor viii study meet primary endpoint well key secondary endpoint hemlibra significantly reduce bleed roche also present positive datum combination cancer drug tecentriq avastin patient type advanced lung cancer drug chemotherapy be find significantly cut risk disease worsening death first line treatment patient roche intend submit datum fda well other regulatory agency datum be not fully mature roche say initial observation show encourage overall survival os datum next os analysis be schedule first half read more roche report positive datum tecentriq combination study label expansion novartis cancer drug ec have expand label novartis tyrosine kinase inhibitor tki tasigna nilotinib so be used treatment pediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp pediatric patient ph cml cp resistance intolerance prior therapy include gleevec imatinib approval indication be expect give positive chmp opinion issue september treatment option be limit child cml be significant unmet need patient population read more novartis receive ec nod tasigna label expansion seek label expansion darzalex janssen cilag international nv be look expand label immunotherapy darzalex so be used combination velcade bortezomib melphalan prednisone treatment adult patient newly diagnosed multiple myeloma be ineligible autologous stem cell transplant approval expand patient population significantly regulatory application have be submit unite state well eu fda approval make fifth indication darzalex unite state first frontline set read more seek darzalex label expansion first line set have gain year date compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock astrazeneca azn free report be merck mrk free report decline last month bristol myer bmy free report be glaxo decline see last pharma stock roundup here fda nod astrazeneca severe asthma drug bayer sign deal loxo next pharma world watch regulatory pipeline news pharma stock more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1884,JNJ,dow experience relatively sluggish holiday shorten week suffering loss trading session investor continue remain concern trump administration ability push tax cut meanwhile tech stock notch strong gain also fed november minute reflect central bank concern sluggish inflation last week dow decline point last friday investor remain cynical trump administration ability pass bill senate end year be mainly senate version tax plan be quite different house panel several way tax cut wo news probe russia interference election also weigh dow index lose last week mark second successive weekly decline tax wo continue worry investor gain be capped further share general electric company ge free report plummet year low release weak ep guidance halved dividend moreover oil price decline iea slash global crude demand forecast meanwhile senate finance committee announce major amendment version tax bill strong earning result wal mart store inc wmt cisco system inc csco free report help curb gain index dow index gain monday verizon communication inc vz free report share increase well fargo analyst jennifer fritzsche raise telecom giant price target fritzsche also project stronger dividend outlook company meanwhile investor continue focus prospect republican tax overhaul plan index increase tuesday follow gain technology healthcare sector share apple inc aapl free report increase yesterday other tech giant facebook inc fb free report alphabet inc googl free report gain respectively exist home sale rise october september seasonally adjust rate index lose wednesday fed minute hint term rate hike be more less certain future hike occur slower expect pace due sluggish inflation minute take more dovish tone previous discussion indicate member be concern persist soft interest rate build financial bubble market be close thursday thanksgiving day holiday component move indexapple have purchase canada base ar headset maker vrvana boost augment reality effort techcrunch report vrvana be best know totem headset combine ar virtual reality technology read apple expand ar acquire headset maker vrvana development zack rank apple have remove host apps include skype china store follow government notification skype be also not available other third party app store tencent holding ltd qihoo technology co ltd however user have app install be able access service add report read aapl free report withdraw skype china app store apple withdraw skype china app store
1885,JNJ,pfizer inc pfe free report announce fda have approve label expansion janus kinase jak inhibitor xeljanz tofacitinib dose mg twice daily mg once daily extend release xr formulation latest approval xeljanz now be administer treat adult patient active psoriatic arthritis psa have inadequate response conventional synthetic disease modify antirheumatic drug csdmard tumor necrosis factor inhibitor respectively notably xeljanz mg twice daily be approve unite state second line treatment option patient moderate severely active rheumatoid arthritis ra have have inadequate response tolerate methotrexate mtx drug be approve europe china march ra significantly be first only jak inhibitor approve unite state moderate severe ra active psa share pfizer have gain so far year underperform industry rally supplemental new drug application snda xeljanz be file fda year aforementioned indication approval be base encourage datum phase iii opal oral psoriatic arthritis trial study broaden xeljanz opal broaden opal trial evaluate efficacy safety xeljanz adult patient psa program achieve primary efficacy endpoint statistically significant improvement twice daily xeljanz mg compare placebo month measurement american college rheumatology response change baseline health assessment questionnaire disability index score overall safety result study be find be consistent observed broader rheumatology development program xeljanz remind investor company be also look get drug label expand include treatment adult patient suffering moderate severe active ulcerative colitis response fda be expect march next year additionally pfizer be conduct phase iiib iv head head study compare xeljanz abbvie abbv free report humira february company announce top line result assessment outcome trial demonstrated inferiority combo therapy comprise xeljanz mtx compare other combo agent humira mtx thus meeting primary endpoint be encourage pfizer label expansion effort xeljanz sale surge year year first month drug label expansion boost further sale blockbuster drug approve treat psa ra include johnson johnson jnj free report remicade amgen inc amgn free report enbrel pfizer market outside unite state canada pfizer press release company announce have start phase iii study evaluate efficacy safety once daily janus kinase jak inhibitor pf treatment moderate severe atopic dermatitis initiation surface first trial jak atopic dermatitis efficacy safety global development program pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1886,JNJ,month discussion house republican have finally pass much controversial tax reform bill vote nov member senate finance committee vote approve version tax package nov pave way full senate hold debate bill once session resume post thanksgiving however republican be go make effort get bill sign president trump christmas overwhelmed house victory trump say cabinet meeting re go give american person huge tax cut christmas hopefully be great big beautiful christmas present meanwhile investor keen medtech space be closely follow development hope final tax stature result abolition infamous medtech tax delve deeper let take look primary objective bill brief house senate billsas article thomas kaplan alan rappeport publish new york time house bill propose reduction corporate tax rate also shrink number tax bracket bill intend introduce international tax system nation more consistent tax structure rest world also revoke scale back many well accept deduction include state local taxe bill also focus double standard deduction claim most tax payer same time root lift child tax credit simultaneously call complete eradication estate tax allowance roughly property tax deduction meanwhile senate bill raise child tax credit also cut top marginal tax rate also tax cut individual be suppose expire end same time plan do not propagate complete repeal estate taxe fact call abolishment individual mandate provision affordable care act aca majority person be require have health insurance pay penalty consider difference bill be challenge task republican come neutral ground decide final structure tax reform bill boon bane medtech accord business insider report republican tax plan repeal itemize deduction apply healthcare expense affect family high healthcare expenditure expense not be deduct taxe hence most person refrain opt expensive healthcare medtech procedure report hill say section republican tax bill plan impose excise tax good manufacture overseas subsidiary company tax code puerto rico be consider foreign land imply parent company have pay excise taxe purchase subsidiary island regard fda recently find puerto rico gross domestic product be drive pharmaceutical medical device undoubtedly latest tax plan have create uproar medtech player witness huge reduction turnover follow approval bill reduction corporate taxe lead extensive research development creation expensive cut edge medtech product question effectiveness loom large be higher number uninsured lesser deduction healthcare expense industry be likely witness shrink customer base post enactment indicate decline demand expensive medical procedure device matter policy shape prove beneficial challenge other player medtech space meanwhile best investor stay sideline tax situation stabilize bill mum medical device tax community have be hopeful trump propose policy entail abolition infamous medical device sale tax dread tax be commonly address fund aca dealt heavy blow medical device industry enactment tax be impose selling price instead net profit amount stupendous sum wipe almost quarter profit medical technology company realize severe linkage effect tax medtech bigwig well small player house senate temporarily suspend year begin thus reimposition tax jan be much fear medical device stalwart report fiercemedical device release time reveal johnson johnson jnj free report make payment medical device sale tax medtronic plc mdt free report covidien nephew plc snn free report shell respectively year situation smaller company have be much context abiom inc abmd free report ceo michael minogue quote article cheryl swanson publish motley fool be quite pertinent state don think tax innovator tax group company provide innovation healthcare be smart idea biggest concern have unprecedented be tax company be not yet profitable industry company be not yet profitable be go have detrimental effect job growth survival datum provide medical device trade group ken blackwell article publish daily caller partial year repeal medtech tax have result rise research development investment medtech player comeback tax lead rise taxe largely discourage activity undoubtedly future medtech industry depend republican decision medical device tax today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1887,JNJ,astrazeneca plc azn free report report third quarter core earning cent american depositary share ad miss zack consensus estimate cent core earning decline year year constant exchange rate cer lower product sale gross margin higher sg cost hurt profit quarter total revenue rise cer report quarter revenue also beat zack consensus estimate revenue however gain mainly payment merck mrk free report oncology collaboration company announce july jointly commercialize develop lynparza selumetinib meanwhile product sale decline quarter due generic competition face legacy product key growth platform represent total revenue be quarter cer key growth platform emerge market new cardiovascular metabolic disease cvmd new oncology japan perform well quarter however respiratory sale decline report quarter growth rate mentioned be year year basis cer product sale declineproduct sale decline quarter due lower sale unite state well europe offset strong performance emerge market china crestor sale decline sale unite state europe due entry multiple generic version drug market seroquel xr sale decline due competition generic launch quarter onglyza sale decline due competitive pressure dpp class symbicort sale be quarter due lower sale unite state europe sale decline due continue pricing pressure manage care access ics laba class also competition other class lama laba combination medicine nexium record sale however legacy product record growth quarter include farxiga forxiga daliresp daxas faslodex iressa pulmicort newer medicine lynparza sale rise sale unite state gain label expansion approval august treatment second line ovarian cancer europe sale be push higher number successful launch brilinta brilique sale be report quarter year year sequentially brilinta maintain leadership position brand oral platelet market unite state europe china brilinta continue display impressive performance tagrisso launch record sale sequentially new medicine movantik moventig record sale quarter less previous quarter bevespi lama laba pressurize meter dose inhaler launch commercially unite state january record sale quarter less second quarter lama laba class grow more slowly anticipate pd inhibitor imfinzi launch second line bladder cancer unite state do not generate sale third quarter second quarter regulatory application seek label expansion imfinzi treat earlier stage lung cancer be grant priority review fda last month imfinzi be key candidate company immuno oncology pipeline be beingevaluat multiple cancer alone combination other regimen last month astrazeneca expand clinical trial collaboration incyte incy free report evaluate incyte investigational selective ido enzyme inhibitor epacadostat combination imfinzi compare imfinzi alone early lung cancer regional sale decline primarily due generic competition crestor seroquel xr pricing pressure symbicort unite state european market witness decline sale revenue emerge market be primarily back strong growth china establish row market sale be flat other core gross margin decline basis point bps core selling general administrative sg expense rise quarter core research development expense be flat outlookwhile astrazeneca retain previously issue sale outlook slightly refine core earning guidance astrazeneca continue expect total revenue decline low mid single digit percentage range however core earning be expect favorable end previously issue guidance decline low mid percentage base average exchange rate first half currency movement be still expect adversely impact top line low single digit percentage minimally impact core ep astrazeneca third quarter performance be mixed share rise pre market trading thursday company brighten earning outlook moreover company have announce quite few positive development regulatory pipeline front so far year latest such development be accelerate approval calquence treatment mantle cell lymphoma aggressive form blood cancer last month backed positive news flow so far year astrazeneca share have gain compare favorably industry growth astrazeneca plc price consensus ep surprise astrazeneca plc price consensus ep surprise astrazeneca plc currently carry zack rank hold see complete list today zack rank strong buy stock here better rank company large cap pharma industry be johnson johnson jnj free report carry zack rank buy share be earning estimate have go past day today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1888,JNJ,pfizer inc pfe free report announce fda have approve ixifi second biosimilar version johnson johnson jnj free report blockbuster rheumatoid arthritis ra drug remicade infliximab notably ixifi be chimeric human murine monoclonal antibody tumor necrosis factor ixifi receive nod approve indication remicade include ra ulcerative colitis plaque psoriasis psoriatic arthritis ankylose spondylitis crohn disease share pfizer have rise so far year underperform industry rally approval be base encourage datum phase iii study reflection biologic license application be file fda april notably february pfizer have divest right development manufacturing ixifi european economic area eea novartis generic arm sandoz however pfizer retain manufacturing right ixifi country outside eea remind investor pfizer first biosimilar product remicade inflectra be launch last november unite state company have exclusive right inflectra unite state certain other territory september pfizer file lawsuit district court allege be resort unfair practice prevent sale inflectra available wholesale acquisition cost be lower reference product pfizer allege complaint file district court eastern district pennsylvania have enter biosimilar exclusion contract insurer contract boost insurer not cover inflectra thus make difficult access patient protect reference product pfizer also claim anticompetitive contract discount be offer hospital purchase remicade condition do not buy biosimilar version pfizer claim unfair practice benefit sale reference product key revenue generator latter pfizer be evaluate biosimilar molecule various stage development biosimilar product late stage development include biosimilar version roche rhhby free report rituxan avastin abbvie abbv free report humira biosimilar version herceptin be review unite state eu europe pfizer market nivestim biosimilar version amgen neupogen retacrit well biosimilar version amgen epogen pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1889,JNJ,regeneron pharmaceutical inc regn free report announce fda have accept review company supplemental biologic license application sbla label expansion eylea injection company be seek approval week dose interval eylea injection patient wet age related macular degeneration wet amd base physician assessment action date set fda be aug so far year share company have rally compare industry gain note eylea be approve unite state eu japan other country treatment neovascular age related macular degeneration wet amd diabetic macular edema dme macular edema follow retinal vein occlusion include macular edema follow central retinal vein occlusion macular edema follow branch retinal vein occlusion eylea injection be indicated treatment patient neovascular wet age related macular degeneration amd recommend dose eylea be mg administer intravitreal injection week monthly first week month follow mg once week month eylea be dose once month most patient additional benefit be not see dose plan be also approve treatment macular edema follow retinal vein occlusion rvo recommend dose eylea be mg administer intravitreal injection week monthly also treat person suffering diabetic macular edema dme diabetic retinopathy dr patient dme recommend dose be mg administer intravitreal injection week monthly first injection follow mg once week month sbla submission be base integrate analysis year result view view phase iii study investigate treatment eylea patient wet amd integrate study find patient study have eylea dose interval extend week begin second year week treatment patient be able maintain week dose interval best correct visual acuity bcva gain be assessed end second year week second year result confirm sustainability vision gain achieve eylea less monthly dose frequency thus approve indication mean patient have take fewer injection eylea label expansion additional indication give eylea access higher patient population increase commercial potential drug meanwhile novartis nvs free report be develop brolucizumab treat neovascular wet amd candidate november demonstrated inferiority eylea phase iii study long last effect patient moreover have show superior improvement reduction retinal thickness due fluid accumulation versus eylea potential approval brolucizumab hurt regeneron product sale ophthotech corp opht free report be also develop pipeline candidate zimura phase iia study treat wet amd datum expect late next year regeneron pharmaceutical inc price regeneron pharmaceutical inc price regeneron pharmaceutical inc quotezack rank key pickregeneron carry zack rank hold better rank health care stock same space be johnson johnson jnj free report sporting zack rank buy see complete list today zack rank strong buy stock here johnson johnson earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1890,JNJ,abbvie inc abbv free report share have gain so far second half year compare favorably gain only record industry share price surge be support series positive news past few month abbvie present promising datum several pivotal study gain key regulatory approval settle humira patent dispute amgen resolution amgen lawsuitabbvie announce resolution patent dispute amgen inc amgn free report september have delay launch latter biosimilar version abbvie blockbuster arthritis drug humira unite state most country eu october agreement have remove major overhang abbvie share company be still face patent challenge boehringer ingelheim gain approval biosimilar version humira cyltezo august moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market key regulatory approvalsabbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada third quarter mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history august abbvie gain approval sixth indication imbruvica drug be approve chronic graft versus host disease gvhd serious potentially life threaten condition high unmet medical need cgvhd be first indication imbruvica outside cancer also imbruvica be first treatment specifically approve cgvhd positive datum studiesabbvie announce positive datum phase iii murano study venclexta roche rhhby free report rituxan relapse refractory cll last month datum show venclexta rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll label expansion indication expand patient population venclexta significantly boost commercial potential abbvie oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment ra highly statistically significant clinically meaningful result dose mg mg upadacitinib compare placebo upadacitinib also meet primary endpoint phase iib study treatment adult patient atopic dermatitis also know eczema company plan advance candidate phase iii study next year datum upadacitinib study be announce september october abbvie announce pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara humira treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint several pivotal datum readout regulatory milestone expect bullish run stock continue next year importantly humira have be generate strong sale new competition abbvie raise long term target humira sale october base strong demand trend drug imbruvica abbvie second most important drug be also do consistently well have multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease factor bode well stock abbvie carry zack rank hold seethe complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1891,JNJ,jp morgan have launch new fund focuse provide exposure equity space invest company low volatility jpmorgan minimum volatility etf jmin track jp morgan minimum volatility index fund characteristic fund utilize rule base methodology select stock base volatility have aum seek provide exposure low risk equity minimize unsystematic risk charge basis point fee year have top holding nvr inc walmart store inc brownforman corp exposure respectively dec bear less concentration risk just little be allocate top holding sector look fund have high exposure health care consumer good utility exposure respectively dec market impact senate vote favor tax reform be multiple hurdle tax reform become law trump call senate vote major victory republican party unbeatable have somebody don know right now re unbeatable say trump house senate differ radically want establish tax reform multiple compromise be need come conclusion instance house want abolish estate tax senate want raise be significant negotiation make reconcile plan appeal low volatility fund increase be increase uncertainty regard trump deregulation plan increase investor appeal safety turn make shift low volatility fund competition fund face high competition other fund focuse provide exposure same space discuss few etfs seek provide exposure corner see total market etfs here ishare edge msci min vol usa etf usmv free report fund seek provide exposure company be more less immune volatility have aum charge fee basis point year sector look fund have high exposure information technology health care consumer staple allocation respectively dec fund top holding be mcdonald corp mcd free report johnson johnson jnj free report visa inc free report allocation dec fund have return year year date dec have zack etf rank hold medium risk outlook powershare low volatility portfolio splv free report fund seek provide exposure company be more less immune volatility have aum charge fee basis point year sector look fund have high exposure utility financial industrial allocation respectively dec fund top holding be honeywell international inc hon free report coca cola co ko free report pepsico inc pep free report allocation dec fund have return year year date dec have zack etf rank medium risk outlook spdr russell low volatility focus etf onev free report fund seek provide exposure company be more less immune volatility track russell low volatility focuse factor index have aum charge fee basis point year sector look fund have high exposure financial service consumer discretionary producer durable allocation respectively dec fund top holding be equity residential eqr free report sysco corporation syy free report baxter international inc bax free report respective allocation allocation dec fund have return year year date dec have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1892,JNJ,jp morgan have launch new fund focuse provide exposure equity space invest company offer high dividend jpmorgan dividend etf jdiv track jp morgan dividend index fund fund utilize rule base methodology select stock base volatility yield have aum seek provide exposure higher yielding equity minimize unsystematic risk charge basis point fee year have top holding dowdupont inc dwdp hollyfrontier corp hfc free report digital realty trust inc dlr exposure respectively nov bear less concentration risk just little be allocate top holding sector look fund have high exposure utility financial consumer good exposure respectively nov market impactmoreover market anticipate interest rate hike december meeting fed cme fed watch tool be chance basis point rate hike chance basis point rate hike december fund be expect be significantly impact higher interest rate reduce appeal dividend focuse fund however janet yellen have warn faster rate hike cause inflation go fed target moreover newly elect fed chair jerome powell be see dovish lead not steer much current policy be increase uncertainty regard trump tax reform deregulation plan increase investor appeal safety turn make shift dividend focuse fund fund face high competition other fund focuse provide exposure same space discuss few etfs seek provide exposure corner see total market etfs here vanguard dividend appreciation etf vig free report fund seek provide exposure company provide high dividend have aum charge fee basis point year sector look fund have high exposure industrial health care consumer service allocation respectively oct fund top holding be microsoft corp msft free report johnson johnson jnj free report pepsico inc pep free report allocation respectively fund have return year year date nov have dividend yield have zack etf rank buy medium risk outlook ishare select dividend etf dvy free report fund seek provide exposure company track record pay dividend consecutive year have aum charge fee basis point year sector look fund have high exposure utility consumer discretionary financial allocation respectively nov fund top holding be lockheed martin corp lmt free report cme group inc class cme mc donald corp mcd free report allocation respectively nov fund have return year year date nov have dividend yield have zack etf rank hold medium risk outlook spdr dividend etf sdy free report fund seek provide exposure company provide high dividend have aum charge fee basis point year sector look fund have high exposure consumer staple industrial financial allocation respectively nov fund top holding be tanger factory outlet center inc skt free report inc free report national retail property inc nnn free report allocation respectively nov fund have return year year date nov have dividend yield have zack etf rank medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1893,JNJ,johnson johnson jnj free report announce submission regulatory application fda european medicine agency ema seek label expansion multiple myeloma mm drug darzalex first line set potential approval allow darzalex be used combination proteasome inhibitor mm drug velcade bortezomib melphalan prednisone treat mm treatment nave patient have autologous stem cell transplantation bone marrow approve be fifth indication drug be encourage effort expand darzalex label further drug generate sixth company total oncology sale first month note darzalex be first approve november monotherapy mm patient treat least prior line therapy follow approval past year combination therapy second third line setting share have outperformed industry so far year company share have gain compare industry gain have submit top line datum phase iii alcyone study support regulatory application geography datum study show darzalex combination therapy reduce risk disease progression death compare treatment bortezomib melphalan prednisone standard care alone present datum annual meeting american society hematology schedule be hold dec dec note license darzalex genmab subsidiary janssen hold worldwide right develop manufacture commercialize drug have pay milestone payment genmab national cancer institute new patient be likely be diagnosed mm cause death unite state alone darzalex compete other approve market treatment mm include celgene corporation celg free report revlimid amgen inc amgn free report kyproli bristol myer bmy free report emplicti johnson johnson price johnson johnson price johnson johnson quotej carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1894,JNJ,johnson johnson jnj free report partner glaxosmithkline gsk free report announce fda approval juluca drug complete regimen tivicay rilpivirine edurant dolutegravir single tablet treatment hiv infection tivicay novel investigational integrase strand transfer inhibitor insti be market viiv healthcare hiv company majorly own glaxo pfizer pfe free report edurant other hand be nucleoside reverse transcriptase inhibitor nnrti market janssen pharma arm juluca have be develop partnership viiv healthcare janssen year so far share price be compare favorably increase witness industry come back latest news juluca approval be base datum phase iii sword study datum study publish february year show combination dolutegravir rilpivirine antiretroviral be effective drug antiretroviral regimen maintenance therapy hiv patient have already achieve viral suppression juluca first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen remind investor gilead gild free report bictegravir single table regimen str hiv treatment be priority review unite state fda be expect announce decision february next year str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone combination be review eu well gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1895,JNJ,tax reform have be grab headline election campaign last year however plan have be modify quite few time congressional vote expect week move tax reform bill forward let revisit aspect bill impact biotech pharma industry corporate tax bill current form propose cut tax rate corporate be higher originally propose point cut also help company save considerable amount tax payment unite state bill also propose full exemption future dividend income company foreign subsidiary currently foreign income be repatriate be taxed full credit local levy however change allow foreign subsidiary send cash back parent company just pay local taxe leave extra cash hand company fund capital expenditure acquisition share buyback other lower tax rate inflow foreign income lead rise merger acquisition have be relatively low so far pharma sector acquisition so far year include johnson johnson jnj free report buyout actellion gilead science inc gild free report takeover kite pharma minimum tax foreign earningswhile bill cut tax rate remove tax dividend foreign subsidiary propose implement minimum tax foreign income current tax plan company defer tax payment parking foreign profit host country however minimum tax be impose be deferral route skip taxe company have pay taxe difference minimum tax local taxe year increase tax bill base company propose tax improve competitiveness foreign pharma company swiss giant astrazeneca azn free report novartis nvs free report base counterpart however rate tax have yet be decide cash repatriation current tax plan allow multinational company keep foreign cash host country thereby defer tax liability unite state however propose minimum tax stop deferral system company have hoard cash low tax country be allow repatriate much lower rate move also increase domestic cash company biotech company utilize extra cash fund clinical study make strategic acquisition strengthen portfolio tax reform propose expense capital expenditure exclude cost structure plant warehouse current year rather defer year allow currently large pharma company areexpect have huge pile cash available potential tax reform acquisition set manufacturing facility help company lower tax bill term however reform partially limit deduction interest debt tax calculation deduction limit be yet be set moreover presently company claim tax credit half research cost related development drug rare disease credit get eliminate reform pass hurt small biotech company have recoup development cost senate budget committee have vote bill full vote house many be still sceptical tax reform many still believe add country fiscal deficit also argue lower federal revenue result lower taxe strain healthcare fund moreover healthcare cost be expect increase future unite state see increase number age person further dent healthcare fund congress be still divide impact tax reform long term investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1896,JNJ,effort enhance shareholder value merck mrk free report declare hike quarterly dividend cent cent share paid last quarter increase dividend be paid jan shareholder record dec raise dividend rate bring merck annual dividend share imply yield be better industry average concurrently board director merck also sanction new stock buyback plan notably first month company complete purchase equity merck financial strength enable continue repurchase program initiate dividend payout sep company cash cash equivalent be increase repurchase authorization new dividend payout be expect boost investor confidence stock merck strategy return wealth shareholder demonstrate growth potential stable liquidity position meanwhile merck have global restructure program progress aim reduce cost structure increase company efficiency intend decrease number manufacturing site include animal health consolidate other facility instead company expect annual saving once restructure program be complete merck have also divest segment consumer care business so focus core area expertise however merck share have decline year so far underperform industry rally company have also suffer notable pipeline setback year hurt share price performance october merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month company also postpone readout important lung cancer study be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer raise investor concern delay readout give competitor chance gain strength lung cancer market october merck also withdraw regulatory application europe be look get keytruda approve first line combination therapy lung cancer september merck discontinue development hcv combination program mk mk cite hcv market be extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group july drug be see key long term growth driver merck such setback do not bode well company remain be see strong performance company new drug particularly keytruda strong vaccine animal health business cost save effort help merck pick here merck company inc price merck company inc price merck company inc quotezack rank key picksmerck carry zack rank hold better rank stock health care sector be johnson johnson jnj free report ligand pharmaceutical inc lgnd free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here johnson johnson earning share estimate have moved last day company come positive earning surprise trail quarters average beat share price company have surge year date ligand earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have surge year date achillion loss share estimate have narrow cent cent cent cent last day company come positive earning surprise trail quarters average beat investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1897,JNJ,astrazeneca plc azn free report announce committee medicinal product human use chmp european medicine agency ema have give positive opinion recommend marketing approval respiratory disease candidate benralizumab astrazeneca be look get benralizumab approve add maintenance treatment severe eosinophilic asthma adult candidate be also review unite state response fda expect year meanwhile benralizumab be also be evaluate treatment chronic obstructive pulmonary disease copd late stage study chmp opinion be base positive datum pivotal study sirocco calima show significant reduction exacerbation improvement lung function treatment benralizumab meanwhile phase iii study zonda show add benralizumab standard care lead statistically significant clinically relevant reduction daily maintenance oral corticosteroid ocs use benralizumab dose regimen compare placebo so far year astrazeneca share have gain compare favorably industry growth astrazeneca respiratory product market include symbicort pulmicort tudorza duaklir other sale respiratory portfolio have decline so far year other benralizumab promising respiratory treatment pipeline include tralokinumab phase iii study severe asthma pt also phase iii study treatment copd remain be see candidate improve astrazeneca respiratory sale approval astrazeneca carry zack rank hold see complete list today zack rank strong buy stock here better rank stock industry be johnson johnson jnj free report pdl biopharma inc pdli free report ligand pharmaceutical incorporate lgnd free report zack rank buy share be earning estimate have go past day share pdl biopharma have increase year so far earning estimate have increase past day share ligand pharmaceutical have rise year so far earning estimate have increase past day make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1898,JNJ,achillion pharmaceutical inc achn free report report loss cent share third quarter narrower zack consensus estimate loss cent year quarter company have report loss cent share company generate revenue report quarter be case year quarter share achillion have underperform industry year date company share lose industry register increase research development expense decrease nearly year period due lower cost related preclinical study manufacturing lower legal fee well general administrative expense remain flat year year pipeline company be develop most advanced candidate paroxysmal nocturnal hemoglobinurium pnh immune complex mediate ic mpgn glomerulopathy unite state phase ii study factor inhibitor treatment patient pnh be ongoing interim analysis have show clinically meaningful complement inhibition factor favorable tolerability profile company expect announce update interim result year end phase ii study be expect start first half study evaluate candidate combination alexion pharmaceutical inc alxn free report soliris potential long term treatment pnh patient already be treat soliris moreover company initiate phase ii study september patient evaluate effect factor inhibitor complement pathway company have plan start phase ii study first half evaluate candidate patient biopsy confirm ic mpgn achillion evaluate potential extend release formulation phase study be expect start later year meanwhile achillion be plan advance number next generation factor inhibitor preclinical clinical study include phase study expect start end september johnson johnson jnj free report terminate worldwide license collaboration arrangement company related development hepatitis treatment achillion lose strong partner termination achillion pharmaceutical inc price consensus ep surprise achillion pharmaceutical inc price consensus ep surprise achillion pharmaceutical inc quotezack rank stock pharma carry zack rank hold stock health care sector worth consider be exelixis inc exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate remain stable cent increase cent cent last day company deliver positive earning surprise trail quarters average beat company share be so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1899,JNJ,geron corporation gern free report report loss cent share third quarter be narrower zack consensus estimate loss cent year quarter company have record loss cent quarterly revenue be significantly year quarter however revenue year quarter include upfront payment johnson johnson jnj free report subsidiary janssen related licensing agreement revenue also miss zack consensus estimate revenue comprise royalty license fee revenue receive various imetelstat license agreement share fall hour trading wednesday however so far year geron share have outperformed industry rise period compare industry gain research development expense decline due lower cost proportionate share clinical development cost imetelstat general administrative expense rise due increase stock base compensation company end quarter cash investment compare end second quarter pipeline updategeron develop cancer therapy base telomerase inhibitor company sole pipeline candidate imetelstat be mid stage study be be evaluate hematologic myeloid malignancy myelofibrosis mf myelodysplastic syndrome mds geron be conduct study collaboration last year janssen announce unfavorable finding plan internal reviews initial datum study imetelstat imbark phase ii treatment mf imerge phase ii iii treatment mds follow internal review april year study imbark phase ii mf imerge phase ii iii mds evaluate imetelstat be continue unmodified fourth quarter more patient be enrolled part imerge refine mds indication confirm clinical benefit safety observed earlier discussion be currently fda datum package propose refinement trial design part imerge decide proceed part imerge larger patient phase iii study patient enrollment be expect begin fourth quarter last month fda grant fast track designation imetelstat base datum part imerge meanwhile imbark study clinical benefit potential overall survival benefit observed internal review support continuation thestudy modification datum study be expect third quarter geron corporation price consensus ep surprise geron corporation price consensus ep surprise geron corporation quotezack rank stock considergeron currently carry zack rank hold couple better rank stock pharma sector include inc agen free report exelixis inc exel free report stock carry zack rank buy see complete list today zack rank strong buy stock here loss estimate remain stable narrow last day company deliver positive earning surprise trail quarters average beat exelixis earning share estimate remain stable cent increase cent cent last day company deliver positive earning surprise trail quarters average beat company share be so far year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1900,JNJ,glaxosmithkline gsk free report partner pfizer inc pfe free report announce hiv focuse company viiv healthcare have initiate phase iii program evaluate combination long act injectable cabotegravir johnson johnson jnj free report rilpivirine treat adult virally suppress hiv infection share glaxosmithkline have underperform industry so far year stock have lose compare unfavorably industry rally period atla trial comprise third phase iii study undertake viiv healthcare investigate drug regimen treatment hiv phase iii program be design evaluate inferior antiviral activity combination regimen week administer week versus week study also evaluate pharmacokinetic safety tolerability combination therapy preliminary datum study be anticipate notably viiv healthcare be form november glaxosmithkline pfizer partner be later joined shionogi october remind investor phase iii atla study be already evaluate monthly dose combination regimen virally suppress patient flair study be evaluate combination first line set outcome study be expect notably last week glaxosmithkline partner jnj free report announce fda approval juluca drug complete regimen tivicay rilpivirine edurant dolutegravir single tablet treat hiv infection most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen meanwhile several company be work develop regimen treat hiv gilead gild free report bictegravir single table regimen str be priority review unite state fda be expect announce decision february next year uninitiated mylan have receive tentative approval treat hiv fda combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate company increasingly develop drug treat life threaten disease competition have intensified manifold space glaxosmithkline plc price glaxosmithkline plc price glaxosmithkline plc quotezack carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1901,JNJ,drug pricing issue cripple performance last year drug biotech industry small correction recently have witness turnaround year stock large market cap have do particularly well decline last year large cap pharma industry have rise year so far number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring large cap drug sector back track year most drug company larger market cap have see share price rise year astrazeneca azn free report nordisk nvo free report novartis nvs free report johnson johnson jnj free report have even outperformed industry however couple large cap pharma company have witness downside year discuss merck co inc mrk free report merck be very few company share be last year notwithstanding industry decline other way round year share merck have decline year so far merck have suffer notable pipeline setback year october merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month company also announce delay readout important lung cancer study be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer raise investor concern delay readout give competitor chance gain strength lung cancer market october merck also withdraw regulatory application europe be look get keytruda approve first line combination therapy lung cancer september merck discontinue development hcv combination program mk mk say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group july keytruda be see key long term growth driver merck such setback do not bode well company remain be see strong performance new drug particularly keytruda strong vaccine animal health business cost save effort help merck pick here glaxosmithkline plc gsk free report share glaxo be year so far stock be rise trajectory announcement third quarter resultson oct third quarter conference call glaxo expressed interest purchase pfizer pfe free report consumer healthcare business latter plan put sale however glaxo interest buy pfizer unit raise investor concern acquirer possibly sacrifice portion dividend payment due potential buyout share decline sharply thereafter meanwhile persistent challenge stiff competition genericization pricing pressure slow growth emerge market have be hurt sale pricing pressure competitive dynamic be hurt sale glaxo respiratory franchise particularly older product meanwhile top selling product advair be also expect face generic competition unite state next year further hurt sale slowdown sale consumer healthcare segment year be also concern see glaxo strong pipeline consistent outperformance new hiv drug vaccine new product trelegy ellipta shingrix juluca have boost portfolio lately cost cut bring back track next year merck glaxo have zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1902,JNJ,equity market be go rough patch be lot political uncertainty market predict odd timely pass president donald trump tax reform bill have increase appeal dividend investing read way play grow dividend etfs trump impactthere be increase uncertainty regard trump ability pass promise legislation relate tax reform deregulation economic fundamental have be strong uncertainty tax reform have push market lower washington post report senate republican leader be weigh impact year delay reform house approve version bill be significant difference bill senate version market be therefore worry create hindrance timely pass legislation read house pass tax bill likely etf winner loser trump aim cut stringent regulation improve ease do business especially target cut lot dodd frank act think restrict business growth however have be major development space market be worry ability pass promise legislation geopolitical risk have be rise north korean supreme have be relatively silent past few week have be other development global market have be concern investor saudi arabian crown prince moham bin salman look tighten grip power order crackdown arrest royal minister investor moreover houthi force yeman fire missile riyadh international airport missile be intercept midway debris land airport see act war saudi foreign minister adel jubair tell cnn saudi arabia accuse iran provide necessary support rebel increase geopolitical risk have lead increase price oil investor appeal safety such scenario dividend pay security provide consistent income investor uniqueness security be increase political uncertainty weigh market more so apart high dividend security exhibit less volatility be stable mature company let now discuss few etfs focuse provide exposure equity relatively high dividend yield flexshare quality dividend index fund qdf free report fund seek provide exposure company provide high dividend maintain quality factor utilize constraint minimize risk have aum charge fee basis point year sector look fund have high exposure information technology financial industrial allocation respectively fund top holding be well fargo co wfc free report boee co ba free report apple inc aapl free report allocation respectively fund have return year year date nov have dividend yield quality dividend growth fund dgrw free report fund seek provide exposure large establish company provide high dividend apply quality screen have aum charge fee basis point year sector look fund have high exposure information technology health care industrial allocation respectively nov fund top holding be johnson johnson jnj free report apple inc microsoft corporation msft free report allocation respectively nov fund have return year year date nov have dividend yield currently have zack etf rank buy medium risk outlook schwab dividend equity etf schd free report fund seek provide cheap exposure company provide high dividend have aum charge fee basis point year sector look fund have high exposure information technology consumer staple industrial allocation respectively sep fund top holding be intel corp intc free report microsoft corporation home depot inc hd free report allocation respectively nov fund have return year year date nov currently have zack etf rank hold medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1903,JNJ,unite therapeutic corporation uthr free report report fda have grant month pediatric exclusivity pulmonary arterial hypertension pah drug adcirca tadalafil delay generic competition drug additional month pediatric exclusivity have push back patent expiry oral pde inhibitor patent be otherwise set expire month mean generic version drug be approve then share unite therapeutic be monday response positive development however look unite therapeutic share price movement show stock have underperform industry year so far unite therapeutic stock have decline period industry rise remind investor unite therapeutic buy exclusive right commercialize adcirca treatment pah unite state eli lilly lly free report november tadalafil be also sell lilly ciali erectile dysfunction additional exclusivity adcirca be base study datum submit lilly fda separately unite therapeutic be require pay higher royalty sale adcirca effective next month previously announce amendment licensing agreement royalty rate adcirca sale be unite therapeutic also have make milestone payment net product sale adcirca generate sale month year year meanwhile company have more pah product portfolio remodulin tyvaso orenitram product unite therapeutic have varied range therapy target pah market lately growth orenitram tyvaso remodulin have slow due competition mainly actelion new drug uptravi selexipag actelion be now part johnson jonson jnj free report also patient be stay longer front line oral ambition combination therapy adcirca gilead gild free report letairis delay transition inhaled injectable therapy tyvaso remodulin thereby hurt demand meanwhile remodulin account more unite therapeutic total sale start face generic competition june unite therapeutic carry zack rank hold see complete list today zack rank strong buy stock here zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1904,JNJ,be not much activity cancer space week however see drug get regulatory nod european commission ec zejula receive approval monotherapy maintenance treatment recurrent ovarian cancer patient be set give astrazeneca azn free report merck mrk free report lynparza run money parp inhibitor space europe other hand novartis nvs free report tasigna receive approval label expansion first line set paediatric patient chronic myeloid leukemia meanwhile johnson johnson jnj free report submit regulatory application label expansion darzalex first line therapy multiple myeloma unite state europe moreover roche hold rhhby free report announce encourage result phase iii study evaluate tecentriq combination chemotherapy stage iv squamous small cell lung cancer nsclc recap week most important storiestesaro zejula approve europe european commission have grant marketing authorization zejula maintenance treatment woman recurrent ovarian cancer be first parp inhibitor receive approval europe do not require brca mutation other biomarker testing drug be already market unite state same indication zejula now compete lynparza be already approve europe however zejula have edge lynparza require brca mutation status europe zejula have perform well unite state launch similar adoption drug europe aid company read more tesaro ovarian cancer drug zejula get approval eu tesaro inc price tesaro inc price tesaro inc quotenovartis tasigna get label expansion europe ec approve label expansion tasigna include paediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp label also include ph cml cp resistance intolerance prior therapy include imatinib gleevec tasigna be already approve adult similar indication accelerate phase cml second later line set read more novartis receive ec nod tasigna label expansion novartis ag price novartis ag price novartis ag quotej seek darzalex label expansion submit regulatory application unite state europe seek label expansion darzalex first line set treat multiple myeloma mm drug approve be used combination proteasome inhibitor mm drug velcade bortezomib melphalan prednisone treatment nave patient have autologous stem cell transplantation bone marrow darzalex contribute almost sixth total oncology sale potential label expansion approval geography further boost prospect read more seek darzalex label expansion first line set johnson johnson price johnson johnson price johnson johnson quoteroche tecentriq impress phase iii combination study roche announce encourage result phase iii impower study evaluate tecentriq nsclc patient study be evaluate efficacy safety tecentriq combination chemotherapy carboplatin paclitaxel avastin combination tecentriq avastin chemotherapy achieve statistically significant clinically meaningful reduction risk disease worsening death compare avastin chemotherapy person stage iv nsclc study be conduct patient do not receive prior therapy read more roche report positive datum tecentriq combination study roche hold ag price roche hold ag price roche hold ag quoteapart celldex therapeutic inc cldx free report announce initiation phase ii study pipeline candidate cdx combination eli lilly lly free report erbitux study evaluate candidate patient advanced head neck squamous cell carcinoma more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1905,JNJ,weak performance due drug pricing issue pharma industry have bounce back year minor correction recently merck co inc mrk free report be very few company share be last year notwithstanding industry decline other way round year share merck have decline year increase large cap pharma industry let discuss merck have suffer notable pipeline setback year october merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month company also announce delay readout important lung cancer study say be include overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer delay readout study raise investor concern delay readout give competitor chance gain strength lung cancer market october merck also withdraw regulatory application europe be look get keytruda approve first line combination therapy lung cancer please note october share merck be result back back pipeline setback september merck discontinue development hcv combination program mk mk say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group july keytruda be see key long term growth driver merck such setback do not bode well company remain be see strong performance new drug particularly keytruda strong vaccine animal health business cost save effort help merck pick here merck carry zack rank hold see complete list today zack rank strong buy stock heremost other large cap pharma stock include astrazeneca azn free report jnj free report eli lilly lly free report bristol myer be year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1906,JNJ,fda approve novel drug last year have give approval drug so far include september key approval year include novartis kymriah first gene therapy unite state lilly verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month october flexion gain approval first drug specialty pharma company flexion therapeutic flxn free report be await fda approval first product zilretta company be focuse development novel local therapy treatment patient musculoskeletal condition begin osteoarthritis oa expect decision agency oct flexion be look get zilretta approve treatment oa related knee pain zilretta opioid provide oa patient new alternative treatment option approval flexion already have sale leadership team place say pre approval inspection patheon manufacturing facility be conclude observation flexion stock have gain year date substantially outperform rally industry belong alexion soliris label be expand again alexion pharmaceutical alxn free report be work expand label flagship product soliris eculizumab soliris currently approve unite state serious ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus bring sale first half year alexion have key catalyst come decision fda expect oct regard approvability soliris refractory generalized myasthenia gravis gmg eu approval indication come august make first only complement base therapy approve ultra rare subset gmg gmg indication represent incremental growth opportunity soliris alexion share be year date compare industry rally alexion be zack rank hold stock see complete list today zack rank strong buy stock here crl likely ptc translarnaptc therapeutic ptct free report be expect decision fda regard approval status translarna treatment nonsense mutation duchenne muscular dystrophy nmdmd approve eu translarna be yet gain approval unite state company have initially file new drug application nda unite state december however february fda issue refusal file rtf letter say nda be not sufficiently complete allow substantive review company be tell phase iib phase iii act dmd study be negative do not provide sufficient evidence effectiveness adequate information abuse potential translarna ptc file nda first quarter be assign fda action date oct however chance gain approval seem low consider translarna fail gain support fda advisory panel last week panel find drug be effective find submit datum inconclusive say more datum be need support efficacy give situation believe fda issue complete response letter crl ask additional datum ptc share be year date compare industry rally apart company quite few other company be await decision fda industry bellwether johnson johnson jnj free report be seek fda approval mg dose xarelto reduce risk recurrent venous thromboembolism vte fda grant priority review response be oct cancer focuse company tesaro tsro free report be expect decision fda intravenous iv formulation rolapitant oct company have receive crl earlier year iv formulation specialty pharma company acelrx pharmaceutical acrx free report expect response fda regard nda sufentanil sublingual tablet mcg oct be review treatment moderate severe acute pain medically supervised setting meanwhile aerie pharmaceutical aeri free report rhopressa be evaluate fda advisory panel treatment patient open angle glaucoma ocular hypertension oct today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1907,JNJ,astrazeneca plc azn free report announce fda have grant approval new indication breast cancer drug faslodex label faslodex now be expand include combination use eli lilly lly free report new cdk inhibitor verzenio abemaciclib treat woman hr advanced metastatic breast cancer disease have progressed endocrine therapy fda approval be base monarch study datum show faslodex improve progression free survival month compare faslodex placebo share london unite kingdom base pharma giant have gain so far year compare favorably industry growth august faslodex have receive fda approval label extension first line monotherapy set treatment postmenopausal woman hr advanced breast cancer approval faslodex be only approve advanced breast cancer later line treatment believe fda approval new indication faslodex month improve sale drug future quarters drug have generate sale so far year year also please note be second time faslodex have be approve use combination cdk inhibitor be already market combination pfizer pfe free report ibrance astrazeneca carry zack rank hold better rank stock large cap pharma sector be johnson johnson jnj free report zack rank buy see complete list today zack rank strong buy stock here share be so far year earning estimate have go past day zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1908,JNJ,third quarter earning season draw close focus be back deal regulatory approval pipeline update week company astrazeneca azn free report bayer bayry free report be news former announce fda approval severe asthma drug bayer sign cancer focuse deal loxo oncology recap week most important storiesfda approval astrazeneca severe asthma drug astrazeneca continue deliver pipeline company score couple fda nod week regulatory body grant approval company respiratory biologic fasenra benralizumab add maintenance treatment severe asthma patient age year disease be drive eosinophilic inflammation read more astrazeneca asthma drug benralizumab approve fda moreover astrazeneca get positive opinion committee medicinal product human use chmp european medicine agency ema fasenra read more astrazeneca get positive chmp opinion asthma candidate astrazeneca also gain fda approval use cancer drug faslodex expand patient population faslodex now be used combination eli lilly lly free report cdk inhibitor verzenio abemaciclib woman hr advanced metastatic breast cancer mbc disease have progressed endocrine therapy study result have show month progression free survival pfs combination treatment mark second fda approval faslodex cdk inhibitor treatment be already approve use combination pfizer cdk inhibitor ibrance palbociclib fda advisory panel meeting pacira exparel snda specialty pharma company pacira pharmaceutical inc pcrx free report announce supplemental new drug application snda exparel use nerve block regional analgesia be discuss fda anesthetic analgesic drug product advisory committee aadpac meeting be schedule be hold feb final response fda regard approval snda be expect apr read more pacira exparel snda be review fda advisory committee bayer oncology deal loxo bayer enter collaboration agreement loxo company focuse development highly selective medicine patient genetically defined cancer deal see bayer shell see company collaborate global development loxo highly selective trk inhibitor larotrectinib loxo patient trk fusion cancer agreement term include upfront payment loxo receive achievement certain regulatory commercial milestone additional milestone related loxo development cost be split equally company company co promote unite state loxo receive tiered double digit royalty net sale sale milestone totale ex territory larotrectinib be schedule be file fda approval late early janssen biotech licensing deal zymework janssen biotech johnson johnson jnj free report company have enter licensing agreement zymework development next generation bispecific antibody therapeutic deal janssen get worldwide royalty bearing license research develop commercialize bispecific antibody used zymework azymetric efect platform zymework be entitle upfront payment development milestone commercial milestone payment well tiered royalty potential sale janssen also have option add more bispecific program deal mean additional money zymework johnson johnson be zack rank buy stock see complete list today zack rank strong buy stock here chmp positive merck drug merck mrk free report get positive opinion chmp prevymis recently gain approval unite state merck be seek eu approval prevymis prevention cytomegalovirus cmv reactivation disease adult cmv seropositive recipient allogeneic hematopoietic stem cell transplant hsct chmp give positive opinion chance gain approval look high decision regard eu approval be expect month read more merck get chmp nod infection candidate prevymis update datum bristol myer immuno oncology combination bristol myer squibb bmy free report announce update result combination opdivo bms selective once daily oral ido inhibitor ongoing phase iia dose escalation expansion study study show maximum tolerate dose combination be mg mg dose be determine be recommend dose base safety pharmacodynamic datum moreover company say encourage response be observed heavily pre treat patient advanced cancer objective response rate orr disease control rate dcr be respectively bladder cancer cohort orr dcr be respectively cervical cancer cohort bristol myer also announce expansion label blockbuster drug sprycel now be used treatment child ph chronic phase cp chronic myeloid leukemia cml bristol myer have gain year date compare rally industry belong cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock astrazeneca be merck decline last month bristol myer be glaxo decline see last pharma stock roundup here astrazeneca earning roche merck drug get fda nod next pharma world watch regulatory pipeline news pharma stock zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1909,JNJ,johnson johnson jnj free report present new datum large canvas outcome program type ii diabetes drug invokana sglt inhibitor demonstrate improve renal outcome datum be present annual meeting american heart association scientific session california publish circulation so far year johnson johnson share price have increase compare favorably rally industry belong new analysis canvas show reduction risk composite renal endpoint patient group history cv disease secondary prevention only risk factor cv disease primary prevention also invokana demonstrated reduction risk hospitalization due heart failure hhf patient group new adverse event be report additional analysis remind investor june company report datum canvas program demonstrated invokana be successful reduce risk cardiovascular cv outcome type ii diabetes patient have establish cardiovascular cv disease be risk cv disease invokana reduce major adverse cv event mace compare placebo mace be composite endpoint cv death fatal myocardial infarction fatal stroke however study also show drug increase risk amputation last month submit supplemental new drug application snda fda label expansion invokana include cardiovascular indication base datum canvas program many pharma company be work hard get label diabetes medicine update include cardiovascular benefit death cardiovascular disease be significantly higher adult diabetes compare addition positive cv outcome label diabetes drug give sale shot arm eli lilly company lly free report receive fda eu approval last year include cv risk reduction datum empa reg outcome study label jardiance additionally august nordisk nvo free report victoza liraglutide be approve fda new indication reduce risk major adverse cardiovascular cv event adult type ii diabetes establish cv disease however merck co inc mrk free report be deny approval fda include cardiovascular outcome datum tecos trial label dpp iv inhibitor januvia sitagliptin other medicine contain januvia astrazeneca bydureon also fail reduce cardiovascular risk phase iiib iv cardiovascular outcome study exscel johnson johnson price johnson johnson price johnson johnson quotezack rankjohnson johnson carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1910,JNJ,geron corporation gern free report be schedule report third quarter result nov market close last report quarter company deliver positive earning surprise geron share have underperform industry so far year stock have lose industry witness gain say time frame pipeline remain focusgeron revenue solely comprise license fee royalty have approve product portfolio moreover have only candidate pipeline imetelstat hence investor focus remain update related geron be develop imetelstat collaboration johnson johnson jnj free report treat patient hematologic myeloid malignancy myelofibrosis mf myelodysplastic syndrome mds acute myelogenous leukemia aml late stage study imetelstat be ongoing imbark phase ii treatment mf imerge phase ii iii treatment mds follow second internal review datum imbark imerge april study continue unmodified part imerge enroll more patient fourth quarter refine mds indication confirm clinical benefit safety observed earlier janssen decide continuation part imerge base ongoing fda interaction datum package propose refinement trial design submit april datum expand part imbark result suggest clinical benefit potential overall survival benefit observed support continuation trial modification janssen be expect evaluate mature datum imbark study next year include assessment overall survival internal review datum be expect first quarter however continuation study depend protocol specify primary analysis be do third quarter reach pre specify number death expect company provide update path forward imetelstat development third quarter conference call surprise historygeron performance last quarters have be mixed company surpass expectation thrice meeting same once average positive surprise last quarters be earning whispersour proven model do not conclusively show geron be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank geron zack rank increase predictive power esp esp make surprise prediction difficult quarter note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be couple health care stock want consider model show have right combination element post earning beat quarter clovis oncology inc clvs free report be schedule release result nov market close company have earning esp zack rank see complete list today zack rank stock here exact science corporation exas free report have earning esp zack rank company be schedule release result oct wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1911,JNJ,third quarter earning season be strong start result company have report number show earning revenue growth pace be accelerate first quarters particular revenue growth have show significant momentum evident proportion positive revenue surprise total earning index third quarter be expect be higher revenue oct company account index total market capitalization have report result result reveal earning company be year quarter increase revenue beat earning estimate beat revenue estimate medical sector medical sector have perform relatively well date quarter be not go be different estimate company have report so far beat revenue company surpass earning expectation go forward sector be expect record year year growth revenue earning bellwether sector johnson johnson jnj free report report better expect third quarter result raise outlook swiss giant novartis ag nvs free report too beat earning sale back new drug cosentyx entresto eli lilly company lly free report also report better expect result third quarter here have major biotech giant be set report third quarter result oct let see thing be shape gilead science inc gild free report be expect beat expectation report market close zack model stock need have positive earning esp zack rank strong buy buy hold beat zack consensus estimate gilead track record be pretty mixed company beating estimate last miss last quarter company beat expectation overall company record average positive earning surprise gilead currently carry zack rank earning esp combination zack rank positive esp make confident earning beat uncover best stock buy sell re report earning esp filter strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue third quarter well genvoya have already become most prescribe regimen treatment nave switch patient launch drive hcv product sale taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy specifically genvoya be now company bestselling hiv product treatment nave patient share zack consensus estimate genvoya stand strong uptake truvada use pre exposure prophylaxis set be also expect boost sale read more be gilead poise beat earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotebristol myer squibb company bmy free report be likely beat expectation report result market open bristol myer track record have be positive so far company deliver positive earning surprise last quarters miss expectation company average positive earning surprise last quarters be company currently carry zack rank earning esp see complete list today zack rank stock here bristol myer high profile immuno oncology drug opdivo be expect be primary sale driver third quarter meanwhile rheumatoid arthritis drug orencia receive approval treat psoriatic arthritis unite state well europe july moreover june bristol myer announce availability subcutaneous administration option orencia patient moderately severely active polyarticular juvenile idiopathic arthritis label expansion new administration option be expect fuel growth drug read more be beat store bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotecelgene corporation celg free report be schedule report result open bell celgene have excellent track record company beating earning estimate last quarters last quarter company beat expectation overall company have deliver average positive surprise celgene currently carry zack rank esp combination zack rank positive esp make confident earning beat expect company beat estimate once again back strong performance key drug revlimid drug perform well first half combat challenge uneven buy pattern coverage gap continue momentum core indication label expansion global launch help product keep contribute top line zack consensus estimate drug currently stand read more be celgene poise beat earning season celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotealexion pharmaceutical inc alxn free report be schedule report result open bell last quarter company earning surpass zack consensus estimate also alexion track record be excellent have consistently beaten expectation last quarters average positive earning surprise company currently carry zack rank esp make surprise prediction difficult alexion blockbuster drug soliris continue perform well alexion continue identify treat consistently high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be also work expand soliris label additional indication label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quotezack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1912,JNJ,anthem inc antm free report third quarter adjust net income share surpass zack consensus estimate bottom line also jump year year operate revenue miss zack consensus estimate top line however grow year year due premium rate increase well higher enrollment medicaid medicare local group insure self funded business operational updatemedical enrollment increase year year member rise be primarily record commercial specialty business well fully insure self funded local group business medicare medicaid enrollment also contribute appreciation upside be partially offset decline membership national account individual business total expense increase nearly report quarter mainly due rise benefitexpense increase selling expense year year basis anthem benefit expense ratio deteriorate basis point bps prior year quarter be largely due year waiver health insurance tax however impact retroactive revenue adjustment medicaid business improve medical cost performance individual large group business be offset selling general administrative sg expense ratio increase bps year quarter be due year waiver health insurance tax impact fix cost leverage operate revenue growth however rise be partially offset increase spend support growth initiative quarter segment specialty businessoperate revenue be third quarter year year operate gain totale year year due increase spend support growth initiative quarter impact year waiver health insurance tax decrease be partially offset improve medical cost performance local group individual business operate margin be bps year year government businessoperate revenue be third quarter prior year quarter operate gain be year year downside reflect increase spend support growth initiative quarter impact year waiver health insurance tax however deterioration be partially offset timing impact retroactive revenue adjustment medicaid business operate margin be decline bps year year other operate revenue be third quarter prior year quarter segment report operate loss narrower operate loss prior year quarter improvement be primarily drive lower expense related terminate cigna acquisition operate margin be bps year year anthem inc price consensus ep surprise anthem inc price consensus ep surprise anthem inc quotefinancial updatea sep anthem have cash cash equivalent year end sep long term debt decline year end sep shareholder equity be year end operate cash flow be first month reflect year year growth share repurchase dividend updatedure quarter anthem repurchase share common stock first month repurchase share common stock sep have approximately share repurchase authorization remain third quarter anthem paid quarterly dividend cent share represent distribution cash totale oct audit committee declare third quarter dividend cent share payable dec shareholder record close business dec guidance anthem expect adjust net income range share previous quarter company expect same be more company have lower guidance medical enrollment medical membership be now expect range compare previous expectation fully insure membership self funded membership be likely be band previously guide range respectively operate revenue be project range unchanged previous guidance benefit expense ratio be expect be earlier projection adjustment bps sg ratio be expect be compare earlier projection adjustment expect operate cash flow be more compare previous projection more zack rank performance other presently carry zack rank hold see complete list today zack rank strong buy stock here other player medical sector have report third quarter earning so far abbott laboratory free report johnson johnson jnj free report unitedhealth group incorporate unh free report beat respective zack consensus estimate zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1913,JNJ,expect pfizer inc pfe free report beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise pharma giant have mixed record earning surprise company earning surpass expectation last quarters miss other result average negative surprise pfizer share have rise year so far compare unfavorably increase zack classify industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner contribute top line meaningfully however loss exclusivity associate generic competition product pristiq vfend zyvox celebrex expiration few co promotion agreement continue hamper top line growth sale blockbuster drug enbrel continue decline quarter due biosimilar competition lower sale trend prevnar prevenar vaccine franchise be likely continue sale viagra be also likely be affected lower demand zack consensus estimate prevnar enbrel be respectively call management say penetration inflectra pfizer biosimilar version jnj free report blockbuster rheumatoid arthritis drug remicade unite state have be slower expect be experience access challenge national commercial payer fact september pfizer file lawsuit district court allege wasresorting unfair practice prevent sale inflectra do not discuss much inflectra impact brand drug sale lawsuit call expect update pfizer upcoming investor call meanwhile bottom line be likely be drive cost saving share buyback however new product launch expense investment be expect hurt profit pfizer acute lymphoblastic leukemia candidate bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march advanced bladder cancer bavencio be also approve eu japan september leukemia treatment besponsa inotuzumab ozogamicin relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be also approve fda third quarter besponsa be also approve eu june expect management record sale new cancer drug quarter earlier month pfizer say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction update matter be expect investor call model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent share zack consensus estimate cent share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quoteother stock considera couple stock pharmaceutical sector also have positive earning esp favorable zack rank be merck co inc mrk free report schedule release result oct have earning esp zack rank see complete list today zack rank stock here bristol myer squibb company bmy free report schedule release result oct have earning esp zack rank zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1914,JNJ,biogen inc biib free report well know name multiple sclerosis ms market surpass expectation earning sale third quarter company revenue be drive continue strong performance newest drug spinraza spinal muscular atrophy better expect result biogen share be almost pre market trading be probably due fact sale multiple sclerosis franchise be expectation increasingly competitive market however note biogen share have gain so far year compare unfavorably industry increase third quarter earning share be comfortably beat zack consensus estimate earning also rally year year sale come year period sale also surpass zack consensus estimate top line exclude hemophilia revenue grow year year company spun hemophilia business february year quarter detail biogen ms revenue be quarter include approximately royalty sale roche ms drug ocrevus tecfidera sale increase year period however drug record sequential drop revenue include sale ex sale unite state tecfidera inventory level third quarter be relatively flat compare year level hurt sale report quarter third quarter tysabri revenue be ex decrease year year sequentially believe ocrevus launch have put pressure tysabri sale quarter combine interferon revenue avonex plegridy third quarter be ex year period avonex revenue decline year period plegridy contribute third quarter revenue year year sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well higher discount allowance zinbryta launch collaboration abbvie inc abbv free report august last year contribute revenue third quarter sequentially newly launch spinraza bring revenue revenue third quarter register growth sequentially drug witness strong demand unite state company be work expand access patient quarter biogen record biosimilar revenue compare second quarter company market benepali biosimilar reference amgen inc amgn free report enbrel europe benepali record revenue register growth rate sequentially biogen also market flixabi biosimilar reference johnson johnson jnj free report blockbuster drug remicade record revenue report quarter compare second quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period third quarter spend decrease report quarter sg spend decline year year collaboration month biogen announce restructure collaboration arrangement eisai neurimmune improve long term value alzheimer candidate aducanumab be presently phase iii study concurrent earning release biogen announce renegotiation agreement neurimmune make time payment exchange reduction neurimmune royalty rate potential sale aducanumab re negotiate deal thus increase aducanumab profit potential oct biogen partner eisai refine exist alzheimer collaboration biogen already have agreement eisai develop phase iii bace inhibitor phase ii amyloid beta antibody ban alzheimer disease however biogen have announce eisai have exercise option jointly develop commercialize aducanumab company now receive aducanumab potential profit unite state europe japan biogen inc price consensus ep surprise biogen inc price consensus ep surprise biogen inc quotezack rankbiogen currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1915,JNJ,biotech stock bounce back strongly year poor show last year challenge rise competition slowdown growth mature product generic competition certain key drug strong clinical result faster fda approval success new product significant contribution establish drug have lead rally biotech sector nasdaq biotechnology index gain so far year be sharp contrast last year performance index be however strong performance investor be keen know rally continue factor drive same company be likely see continue demand product give accelerate increase age population proportionate increase disease moreover fda have approve far more drug so far do whole hence faster drug approval process strong pipeline innovative treatment impressive result increase health care spending support further growth sector momentum biotech sector be likely continue good idea avoid few stock possibly lose momentum soon significant year date gain small biotech stock avoid avoid stock have represent significant share price gain be bit tricky however have take help zack stock screener identify stock stop rally term shortlist stock vast universe biotech sector have picked stock carry zack rank sell strong sell moreover have also take consideration stock witness negative estimate revision current year last day be likely plunge further be dump keryx inc kerx free report new york base company focus treat patient suffering renal disease company share have rise so far year however currently carry zack rank further last day loss share estimate widen company label expansion effort only market drug auryxia bode well growth supply interruption auryxia hurt sale future quarter keryx inc price keryx inc price keryx inc quotejuno therapeutic inc washington base company focus development immuno oncology treatment company share have gain significant so far year share company mainly rise september year speculation be acquire soon acquisition kite pharma gilead however currently carry zack rank have vgm score further last day loss share estimate widen almost juno be major player field cell base immunotherapy be several other company be look develop bring immunotherapy treatment market car space have many company include novartis kite pharma bluebird bio intrexon johnson johnson jnj free report work treatment note juno lag kite pharma novartis race bring car product market hence competition immunotherapy space weigh heavily stock term juno therapeutic inc price juno therapeutic inc price juno therapeutic inc quoteabeona therapeutic inc abeo free report delaware base company focus develop gene therapy life threaten rare genetic disease company share show significant gain so far year however currently carry zack rank have vgm score further last day loss share estimate widen company lead gene therapy eb abo recently receive breakthrough therapy orphan drug designation respectively fda abeona share significantly rise july company announce have receive guidance fda commence pivotal phase iii eb however many company be work bring gene therapy market therefore candidate face intense competition target space approve abeona therapeutic inc price abeona therapeutic inc price abeona therapeutic inc quotemore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1916,JNJ,plc alk free report announce positive top line result phase iv study aristada aripiprazole lauroxil extend release injectable suspension treatment schizophrenia study show patient switch aristada mg mg mg monthly mg week experience statistically significant clinically meaningful improvement schizophrenia symptom end month compare inadequate response intolerance be johnson johnson jnj free report invega sustenna further datum evaluation demonstrated differentiate efficacy safety profile aristada treatment schizophrenia have significant unmet medical need additionally highlight unique attribute aristada have strong efficacy safety profile unmatched range dose duration note drug be injectable atypical antipsychotic month week month dose option treatment schizophrenia drug provide number option help clinician tailor treatment individual need patient drug be originally approve oct second quarter aristada sale come compare second quarter aristada be grow impressively long act injectable lai market evident improvement double digit however share have underperform industry year date stock have decline industry gain same time frame company be also evaluate candidate alk phase iii treatment schizophrenia june company announce positive preliminary top line result phase iii study enlighten evaluate antipsychotic property alk versus placebo efficacy study be anticipate company also expect result enlighten pivotal month phase iii study evaluate weight patient stable schizophrenia receive olanzapine alk plc price plc price plc quotezack rank stock consideralkerme currently carry zack rank hold better rank stock health care sector include alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report sporting zack rank strong buy see complete list today zack rank stock here alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
1917,JNJ,market enjoy month spectacular gain power strong earning performance hope surround tax reform significant progress be make new tax law month further raise hope investor meanwhile bullish tech earning be highlight thirdquarter earning season characterize notable revenue growth ecb cut bond purchase extend duration monetary stimulus package october performancelast month dow nasdaq increase respectively dow post seventh straight month gain be nasdaq fourth straight monthly gain benchmark have post biggest monthly rise february moreover also happen be dow longest streak such gain april also longest meanwhile house representative pass budget bill moreover house representative clear budget blueprint majority republican voting favor move further ecb announce plan extend quantitative ease program also release federal open market committee minute clearly hint rate hike december president trump choose not certify iran compliance nuclear deal strike dow breach dow gain point oct surpass psychological milestone midday trading first time also marked dow fastest ascent point milestone mid july history span century dow have register fourth point increase year first time economist believe such stellar show blue chip index have partially be due optimism build hope tax cut new tax code be formulate president trump gain have also be part due strong corporate earning broadly encourage economic condition bullish domestic dataeconomic datum release august be largely encourage nature ism manufacturing index soar september mark highest increase ism service index september come mark highest level aug construction spending surge month august surpass consensus estimate increase period index gain last year ppi september increase cpi increase retail sale unite state month september increase mark highest increase more year consumer spending surge september mark highest level almost year such rally be attribute fact resident hurricane ravage texas florida replace flood damage automobile first estimate gdp look economy expand solid seasonally adjust annual rate third quarter accord commerce department datum such expansion come heel growth second quarter also mark first time consecutive quarters growth more mid economy however report do not specify much impact hurricane harvey irma have growth economy economist comment primary factor such growth be increase consumer spending backed broadly encourage economic condition strong government outlay main engine economy grow quarter gain second quarter moreover business investment increase inventory rise also trade sector advanced pce price index increase logging annual gain be improvement pace record second quarter hurricane cause job loss unemployment slipsaccording bureau labor statistic economy lose job month september mark first time economy have lose job month economist state devastate hurricane harvey irma be primary reason such job loss analyst comment many person be job highest figure last year worst affected sector be restaurant industry many person lose job meanwhile government raise estimate job opening month august initially unemployment rate decrease september august consensus estimate period show unemployment rate remain unchanged unemployment be now lowest level report bls state metric be not affected hurricane third quarter earning come third quarter earning be clear momentum revenue front growth notably accelerate other recent period total revenue member have report result friday oct be same period last year compare top line growth same group company precede quarter read strength earning season impressive third quarter earning tech heavyweight such microsoft corp msft free report alphabet inc googl free report amazon com inc amzn free report intel corp intc have be highlight earning season share ibm ibm free report soar oct company post better expect earning result share netflix nflx free report surge oct company report strong third quarter earning health care stock be send higher oct gain johnson johnson jnj free report unitedhealth group incorporate unh free report share gain respectively company post earning beat latest quarter notable disappointment jpmorgan jpm free report decline oct company fix income trading revenue dip come third quarter year meanwhile citigroup free report decline company cost credit increase due global consumer banking well high credit reserve build oct share general electric ge free report nosedive miss third quarter earning estimate wide margin top line growth tax reform make end september president trump aide unveil tax reform effectively lower taxe business individual proposal seek decrease corporate tax rate moreover pass business taxe be slash first definitive move tax reform house representative pass budget legislation oct however few member president trump team vote bill democrat object part tax reform proposal democrat opposed passage bill term move vehicle achieve partisan tax reform vote late oct senate approve budget blueprint fiscal year such outcome unlock procedure used tax code be change used only republican vote moreover tax bill now be used lower project revenue almost year period ultimately house representative pass budget blueprint oct report bloomberg surface oct legislator house be involved formulation new tax code be consider possible phase corporate tax rate cut effectively reduce current rate corporate tax fomc minutesminute federal open market committee fomc release oct confirm rate hike take place december third instance federal reserve official remain largely divide raise interest rate majority banker vouch favor raise rate one debate increase rate reason hike rate time inflation be lower target cause major setback economy meeting end fed choose leave interest rate unchanged range decide start unwinding balance sheet much anticipate unwinding humungous balance sheet fed be announce federal reserve open market committee last month fed be slate begin gradual unwinding process month plan trim asset month however fed panel announce rate hike end further hike expert therefore speculate come december fed meet final time year end star performer octoberi run screen research wizard company follow parameter click here sign free trial research wizard today percentage price change last week greater equal forward price earning ratio current financial year less equal pick stock be good value choicesexpect earning growth current financial year greater equal zack rank less equal ascertain stock have show average return last year see performance zack portfolio strategy here zack performance here be top stock make screen health insurance innovation inc hiiq free report operate developer administrator cloud base individual health insurance plan ancillary product price gain last week expect earning growth current year health insurance innovation hold zack rank buy stock have rocky brand inc rcky be lead designer manufacturer marketer premium quality footwear apparel price gain last week rocky brand have expect earning growth current year be more stock hold zack rank strong buy see complete list today zack rank strong buy stock here lgi home inc lgih be engage design construction entry level home texas arizona florida georgia south carolina new mexico north carolina washington colorado tennessee price gain last week expect earning growth current year lgi home hold zack rank stock have braskem bak free report be producer seller thermoplastic resin price gain last week braskem hold zack rank expect earning growth current year be more stock have winning streak continue november stock have notch record gain october set several new milestone process power gain be expectation surround tax reform strong third quarter earning result momentum be likely continue month november economic datum gdp number particular have also remain strong go forward only likely impediment market be sluggish inflation level initial reaction next rate hike bar few minor hiccup issue stock likely continue record bust streak november more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1918,JNJ,issue update report catalyst pharmaceutical inc cprx free report sep catalyst pharma be development stage company focuse development therapy target rare neurological disease disorder such lambert eaton myasthenic syndrome lem epilepsy initially infantile spasm tourette syndrome present coral gable fl base company have candidate development firdapse cpp catalyst pharma share have outperformed industry year date stock have surge compare industry gain same time frame company expect report top line result second phase iii study firdapse treatment lambert eaton myasthenic syndrome lem second half resubmit new drug application nda end earlier receive refusal file letter fda connection nda firdapse notably agency determine company nda be insufficient preliminary review consequently catalyst pharma be require conduct additional study agency requirement addition result previously submit phase iii datum october reach agreement fda special protocol assessment spa protocol design clinical endpoint statistical analysis approach be take second phase iii study evaluate firdapse meanwhile company be work develop firdapse additional indication february catalyst initiate investigator sponsored phase ii iii study firdapse symptomatic treatment musk antibody positive mg march company report top line datum phase ii iii trial potential approval firdapse label expansion help generate revenue company additionally catalyst pharma be explore possibility develop cpp gaba inhibitor treatment epilepsy initially infantile spasm treatment other select neurological indication such complex partial seizure tourette disorder however market epilepsy treatment be highly competitive crowd give presence product pfizer pfe free report neurontin lyrica johnson johnson jnj free report topamax novartis nvs free report trileptal catalyst pharmaceutical inc price consensus catalyst pharmaceutical inc price consensus catalyst pharmaceutical inc quotezack rankcatalyst pharma currently carry zack rank hold see complete list today zack rank strong buy stock here new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
1919,JNJ,dow experience substantial gain week power primarily strong earning expectation bullish result index ignore trump hawkish comment iran surge higher monday index hit new intraday record tuesday ultimately close point wednesday thursday index overcome specter anniversary crash end positive territory last week index gain last friday follow release retail sale datum post highest read more year month september retail sale increase meanwhile president trump decertify iran nuclear deal also plan terminate subsidy obamacare health insurer index gain last week be dow fifth consecutive week gain mean time release federal open market committee minute clearly hint rate hike december moreover minute state majority fed official vote favor rate hike jobless claim plummet week low business resume texas florida area pummeled destructive hurricane moreover broad base market gain traction ahead begin third quarter earning season investor remain hopeful streak strong earning release dow index gain monday strong expectation third quarter earning lead broad base gain market dow amassed point monday end positive territory however trump comment iran nuclear deal weigh investor sentiment share jpmorgan chase co jpm free report rally contribute most dow ascent index increase tuesday slew strong corporate earning lead gain healthcare stock dow gain point tuesday surpass psychological milestone midday trading first time blue chip index also hit fresh intraday record also marked dow fastest ascent point milestone mid july history span century blue chip index register fourth point increase year first time index gain wednesday close point first time ever blue chip index have close first time aug dow post fourth straight daily rise include gain past trading session upbeat corporate earning result mostly technology financial company help broader equity market gain traction index inched marginally higher thursday overcome initial loss more point dow be able overcome selling pressure anniversary crash strong earning result help index stay afloat influence political tension europe poor economic datum emanate china component move index american express company axp free report report adjust third quarter earning share ep beating zack consensus estimate earning witness sharp year year improvement american express have zack rank buy revenue come ahead zack consensus estimate top line increase year year higher net interest income card member spending company guide earning share higher range earlier guidance account continue strength business read american express earning top grow view international business machine corp ibm free report report third quarter gaap earning share beat zack consensus estimate couple cent earning share ep be penny better year figure surge sequentially ibm have zack rank hold revenue surpass zack consensus estimate be almost flat year year basis constant currency cc revenue decline moreover revenue fall sequentially ibm reiterate ep forecast gaap ep be expect be least company also anticipate free cash flow remain flat read ibm beat earning revenue reiterate ep view johnson johnson jnj free report third quarter earning come share beating zack consensus estimate increase year period include amortization expense special item report third quarter earning share year period sale come beating zack consensus estimate sale increase year quarter reflect operational increase positive currency impact zack rank rate expect adjust earning share range compare expect previously revenue guidance be raise range compare expect previously read beat earning actelion buyout drife sale unitedhealth group inc unh free report report third quarter net operate earning share comfortably beating zack consensus estimate increase year year zack rank unitedhealth post net revenue line zack consensus estimate revenue be year year company report medical care ratio basis point year year encourage strong earning performance company raise outlook earning company now expect gaap net earning approach share versus share earlier adjust net earning share versus previous guidance read unitedhealth beat earning higher membership goldman sachs group inc gs free report third quarter result record positive earning surprise company report earning share comfortably beating zack consensus estimate further bottom line witness year year improvement goldman net revenue climb year year quarter review furthermore revenue handily outpaced zack consensus estimate stock have zack rank see complete list today zack rank strong buy stock here traveler company inc trv free report third quarter core income cent share comfortably beat zack consensus estimate cent whopping however bottom line plunge year year total revenue zack rank sell traveler improve nearly year quarter also revenue surpass zack consensus estimate read traveler earning surpass estimate slump verizon communication inc vz free report report mixed financial number third quarter quarterly gaap net income be compare year quarter adjust earning share be cent report quarter line zack consensus estimate verizon have zack rank however total revenue increase year year beating zack consensus estimate total operate expense quarter review be year year read verizon earning line revenue beat estimate performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week dow have notch historically impressive gain week power primarily strong expectation third quarter earning season actual report number have also be impressive large factor alone have help market ignore trump hawkish pronouncement dismal development abroad such trend be likely continue next week encourage gdp report slate release period add further positive momentum market proceedings wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1920,JNJ,johnson johnson jnj free report kick third quarter earning season pharmaceutical sector strong note company beating earning revenue focus remain strong earning result company allergan agn free report be also news regard patent litigation recap week most important storiesj result impress raise outlook earning result be strong company beating earning revenue segment consumer medical device pharmaceutical do well oncology record robust growth result include contribution pulmonary hypertension product become part company portfolio follow acquisition actelion base solid third quarter result raise outlook year well read more beat earning actelion buyout drife sale company have gain year date compare rally industry belong sanofi dupixent top allergic inflammatory disease study sanofi partner regeneron pharmaceutical announce positive phase ii result dupixent dupilumab adult active moderate severe eosinophilic esophagitis chronic allergic inflammatory disease patient receive dupixent weekly report significant improvement ability swallow versus placebo read more sanofi regeneron dupixent succeed phase ii study market be huge dupixent gain timely approval give lack fda approve treatment dupixent have orphan drug status unite state indication dupixent have blockbuster potential be currently approve eczema be be evaluate additional indication apart eosinophilic esophagitis fact last month company have announce positive top line datum late stage study dupixent uncontrolled persistent asthma regeneron sanofi be also collaborate aimmune therapeutic clinical stage company focuse development treatment potentially life threaten food allergy clinical collaboration aimmune ar be evaluate adjunctive dupixent peanut allergic patient mid stage study be schedule commence next year study be sponsored regeneron aimmune provide clinical supply ar food challenge material datum merck keytruda priority review lynparza snda merck mrk free report present update overall survival os datum pd therapy keytruda first line treatment patient suffering metastatic small cell lung cancer high level pd company say additional month available datum continue show reduction risk death keytruda compare chemotherapy keytruda more double median os compare chemotherapy year follow keytruda be key product merck portfolio drug bring sale first half merck partner astrazeneca also announce have be grant priority review fda supplemental new drug application snda use parp inhibitor lynparza tablet patient gbrca negative metastatic breast cancer mbc have be previously treat chemotherapy neoadjuvant adjuvant metastatic setting response agency be expect first quarter nordisk diabetes drug get fda panel support nordisk nvo free report get boost fda advisory panel endocrinologic metabolic drug advisory committee voting unanimously favor approve once weekly semaglutide use type ii diabetes patient give favorable vote chance gain fda approval look pretty high second quarter call nordisk have say expect decision fda year end semaglutide approval be major positive company drug expect be key growth driver nordisk be zack rank buy stock see complete list today zack rank strong buy stock here priority review bmy drug label expansion bristol myer squibb company bmy free report immuno oncology therapy opdivo have be grant priority review fda label expansion treatment melanoma patient be high risk disease recurrence follow complete surgical resection opdivo prioritize brand bristol myer portfolio bring sale first half read more bristol myer get priority review opdivo label expansion adverse ruling allergan restasis patent litigation allergan continue make headline related blockbuster eye drug restasis time round company announce have receive adverse ruling district court eastern district texas regard patent cover drug court find patent be invalid allergan intend appeal ruling say fda be yet approve generic version drug however ophthalmology focuse company imprimis pharmaceutical announce be work make lower cost alternative restasis available company say initial prescription be cent month supply refill start month include shipping accord allergan restasis patent be schedule expire aug allergan enter settlement agreement generic challenger recently innopharma have be adopt different way protect restasis generic competition company come fire enter agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect drug generic competition restasis be allergan second best selling drug bring sale almost lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent deal have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug impax combine amneal specialty pharma company impax laboratory be merge privately hold generic company amneal pharmaceutical stock transaction merger combine company have high value generic product pipeline grow specialty business deal be expect boost impax stand alone earning share first month generate double digit revenue earning share growth year follow close transaction annual cost synergy be expect be achieve year merger be expect go first half read more impax laboratory amneal pharmaceutical agree merge cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be week sector react positively result major stock be bristol myer decline last month bristol myer be see last pharma stock roundup here pfizer mull option consumer healthcare lly pipeline setback next pharma world watch earning result company novartis eli lilly lly free report bristol myer other come week wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1921,JNJ,healthcare sector have be spotlight lately president donald trump target drug company accuse charge extremely high price read etfs focus imf up global growth forecast market mover prescription drug price be control drug price have go roof trump say meeting add drug company frankly be get away murder want bring price other country be pay latest executive order trump aim scrapping key component obamacare president say want end subsidy insurer cost year help million low income american pay medical expense uncertainty be reduce extent news political party come bipartisan deal start do round senator party say reach deal stabilize obamacare short term allow insurer subsidy however change deal be card have be pass congress sign trump first solution be year year ll get intermediate hump trump say let now discuss etfs focuse provide exposure healthcare sector health care select sector spdr fund xlv free report fund seek provide exposure healthcare stock track health care select sector index have aum charge moderate fee basis point year have holding bear significant concentration risk almost asset be allocate top holding read keep portfolio healthy biotech etfs sector look fund have high exposure pharmaceutical biotech health care provider service exposure respectively sep fund top holding be johnson johnson jnj free report pfizer pfe free report unitedhealth unh free report allocation respectively sep fund have return year year date oct xlv currently have zack etf rank buy medium risk outlook vanguard healthcare etf vht free report fund seek provide exposure healthcare stock track msci investable market health care index have aum charge moderate fee basis point year have holding bear significant concentration risk almost asset be allocate top holding sector look fund have high exposure pharmaceutical biotech health care equipment exposure respectively sep fund top holding be johnson johnson pfizer unitedhealth allocation respectively sep fund have return year year date oct vht currently have zack etf rank medium risk outlook bottom linexlv be more popular vht be evident higher aum however vht be more appeal investor owing cheaper expense ratio vht also have more diversify exposure term number holding moreover vht outperformed xlv year date basis year vht return more xlv so far year year return more xlv want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1922,JNJ,earning revenue beatshare johnson johnson jnj free report increase market close oct beating zack consensus estimate earning revenue company revenue increase third quarter year year basis sequential basis come ahead consensus mark increase sale be drive primarily strong sale cancer drug recent acquisition activity earlier year june jnj biggest ever acquisition buy swiss company actelion johnson johnson report gaap earning share ep third quarter year year sequential basis beat zack consensus estimate segment sale company report increase sale geographical segment sale increase international sale increase moreover business segment basis company report improvement segment consumer pharmaceutical medical device revenue increase respectively company increase revenue guidance full year range update adjust ep guidance industry factorsin latest executive order trump aim scrapping key component obamacare president say want end subsidy insurer cost year help million low income american pay medical expense moreover trump take dig drug pricing accuse company get away murder charge sky high drug price uncertainty be reduce extent news political party come bipartisan deal start do round senator party say reach deal stabilize obamacare short term allow insurer subsidy however change deal be card have be pass congress sign trump first current scenario believe be prudent discuss follow etfs have relatively high exposure johnson johnson see health care etfs here health care select sector spdr fund xlv free report fund seek provide exposure healthcare stock track health care select sector index have aum charge moderate fee basis point year read keep portfolio healthy biotech etfs sector look fund have high exposure pharmaceutical biotech health care provider service exposure respectively sep fund top holding be johnson johnson jnj free report pfizer pfe free report unitedhealth unh free report allocation respectively oct fund have return year year date oct xlv currently have zack etf rank buy medium risk outlook vanguard healthcare etf vht free report fund seek provide exposure healthcare stock track msci investable market health care index have aum charge moderate fee basis point year sector look fund have high exposure pharmaceutical biotech health care equipment exposure respectively sep fund top holding be johnson johnson pfizer unitedhealth allocation respectively sep fund have return year year date oct vht currently have zack etf rank medium risk outlook ishare healthcare etf iyh free report fund seek provide exposure healthcare stock track dow jone health care index have aum charge moderate fee basis point year sector look fund have high exposure pharmaceutical biotech health care equipment exposure respectively oct fund top holding be johnson johnson pfizer unitedhealth allocation respectively oct fund have return year year date oct iyh currently have zack etf rank medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1923,JNJ,glaxosmithkline plc gsk free report partner innoviva inc announce triple combination therapy be grant marketing authorization eu maintenance therapy treatment patient chronic obstructive pulmonary disease copd once daily single inhaler triple therapy be market trade name trelegy ellipta be approve treatment moderate severe copd patient be already be treat combination inhaled corticosteroid ics long act beta adrenergic agonist laba require additional bronchodilation trelegy ellipta be approve unite state september year eu approval be expect be european medicine agency ema committee medicinal product human use chmp have grant positive opinion recommend marketing approval trelegy ellipta september trelegy ellipta combination fluticasone furoate ics umeclidinium long act muscarinic antagonist lama vilanterol laba therapy provide patient convenient dose option remove need multiple inhaler product be expect bring blockbuster sale trelegy ellipta be deliver glaxo ellipta dry powder inhaler glaxo share have decline year so far underperform increase witness industry please note share theravance biopharma inc tbph free report be more thursday biotech have economic interest royalty glaxo pay innoviva global sale trelegy ellipta glaxo have zack rank hold better rank stock large cap pharma sector be johnson johnson jnj free report zack rank buy see complete list today zack rank strong buy stock here share be so far year earning estimate have go almost past day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1924,JNJ,pfizer inc pfe free report report third quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year drive slightly higher sale lower cost share count pharma heavyweight deliver revenue be line zack consensus estimate revenue rise year quarter report well operational basis sale detailcurrency movement hurt pfizer third quarter revenue slightly divestiture hospira infusion system business hurt sale quarter february pfizer divest hospira infusion system business icu medical inc icui free report exclude currency headwind revenue sale rise strong performance newer product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis offset lower sale enbrel viagra prevnar prevenar vaccine franchise loss exclusivity product international revenue rise operational basis meanwhile revenue be flat segment report segment be pfizer innovative health ih pfizer essential health pfizer ih sale grow report operational basis year period pfizer ih revenue be drive persistently strong momentum ibrance eliquis globally growth lyrica xeljanz primarily unite state ibrance revenue rise quarter xeljanz rise lyrica sale rise eliquis alliance revenue direct sale rise revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow september medivation acquisition also contribute revenue xtandi record alliance revenue quarter compare second quarter be partially offset continue decline revenue prevnar unite state lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside unite state canada total viagra ih sale decline lower demand wholesaler destock ahead potential generic competition december hurt sale viagra global prevnar prevenar revenue decline prevnar revenue tank unite state due continue decline revenue eligible adult patient population however prevenar revenue rise international market due favorable timing government purchase emerge market consumer healthcare revenue rise global oncology revenue surge drive ibrance global vaccine revenue rise internal medicine rise inflammation immunology franchise rise additionally portfolio rare disease decline earlier month pfizer say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision be expect next year pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product primarily pristiq unite state vfend lyrica europe lower revenue legacy hospira product due product shortage divesture however business biosimilar emerge market do well quarter pfizer launch inflectra biosimilar version johnson johnson jnj free report merck blockbuster ra drug remicade november last year inflectra record sale unite state globally other biosimilar bring sale outside market emerge market revenue grow operationally adjust selling informational administrative si expense decline operationally quarter adjust expense also decline guidance pfizer raise adjust earning guidance tighten revenue expectation year revenue be expect range compare expect previously zack consensus estimate be peg adjust earning share be expect range compare expect previously zack consensus estimate be peg share mid point adjust ep be expect increase previously research development expense be expect range previously si spending be project range previously takepfizer third quarter result be mixed beat earning estimate deliver line sale however company raise adjust earning guidance year share be pre market trading so far year pfizer share be compare unfavorably increase industry pfizer continue face headwind form genericization key drug lose alliance revenue pricing pressure rise competition be hurt top line nonetheless believe new product ibrance contribution acquisition cost cut effort share buyback help company achieve guidance pfizer also boast strong pipeline expect multiyear wave potential new product launch product line extension bavencio be be consider key long term growth driver pfizer bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march year advanced bladder cancer bavencio be also approve eu japan september mcc other leukemia treatment besponsa inotuzumab ozogamicin relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be also approvedby fda third quarter besponsa be also approve eu june pfizer carry zack rank hold see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1925,JNJ,merck co inc mrk free report announce be discontinue further development next generation hepatitis hcv program mk mk market be become extremely crowd mk be oral triple combination regimen uprifosbuvir combination grazoprevir ruzasvir develop treatment chronic hcv infection mk be combination ruzasvir uprifosbuvir merck share have rise year so far compare increase industry company now focus grow sale key hcv drug market zeptier be approve use ribavirin treat chronic hcv genotype infection zepatier once daily fix dose combination tablet contain ns inhibitor elbasvir ns protease inhibitor grazoprevir be gradually become key top line driver merck cancer drug keytruda medicine record sale second quarter much higher first quarter attributable strong underlie demand trend unite state europe japan company continue launch zepatier globally however remind investor second quarter conference call management have warn zepatier uptake go forward be impact ongoing decline overall patient volume many market increase competition hcv market be get crowd be thus see increase pricing pressure gilead science inc gild free report market blockbuster hcv drug sovaldi harvoni other well know name market be abbvie inc abbv free report viekira pak bristol myer daklinza johnson johnson jnj free report olysio moreover other company be also look bring new improve shorter duration hcv treatment market abbvie pan genotypic shorter duration hcv regimen glecaprevir pibrentasvir mavyret receive approval unite state canada eu july august meanwhile gilead already market epclusa oral pan genotypic single tablet hcv regimen meanwhile gilead single tablet regimen str sovaldi velpatasvir voxilaprevir vosevi receive approval unite state eu canada july august vosevi become first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor merck carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1926,JNJ,equity market be go turbulent time be lot volatility uncertainty owing rise geopolitical risk political uncertainty have increase appeal dividend investing geopolitical risk have be rise north korea conduct seventh nuclear test continental ballistic missile fly japan sep kim jong action have create huge unrest number asian economy unite state response continuous missile test president donald trump maiden general assembly speech threaten completely destroy north korea prompt north korean leader kim jong unite state highest level hard line countermeasure history moreover north korea foreign minister state trump comment indicate unite state have declare war north korea declare war country have right make countermeasure include right shoot bomber even be not yet airspace border country foreign minister ri yong say however white house have reject accusation latest development make investor flock safe haven investment lead decline tech stock read safe haven currency etfs gain latest north korea threat trump actionsthere be increase uncertainty regard trump ability pass promise legislation relate tax reform deregulation economic fundamental have be strong be renew doubt capability trump administration trump introduce new travel ban restriction citizen nation be muslim majority start oct citizen chad iran libya syrium venezuela yeman somalia north korea be ban travele unite state however person hold permanent residency visa be exempt ban renew visa once expire moreover trump administration be be highly criticize separate development adviser trump have be find be used personal email address official government purpose be ironical give trump stance investigation hillary clinton use personal server prior presidential election read trump widen north korea sanction etfs focus such scenario dividend pay security provide consistent income investor uniqueness security be increase political uncertainty weigh market more so apart high dividend security exhibit less volatility be stable mature company let now discuss few etfs focuse provide exposure equity relatively high dividend yield flexshare quality dividend index fund qdf free report fund seek provide exposure company provide high dividend maintain quality factor utilize constraint minimize risk have aum charge fee basis point year sector look fund have high exposure information technology financial industrial allocation respectively jun fund top holding be merck co inc mrk free report well fargo co wfc free report boee co ba free report allocation respectively sep fund have return year year date sep quality dividend growth fund dgrw free report fund seek provide exposure large establish company provide high dividend apply quality screen have aum charge fee basis point year sector look fund have high exposure information technology health care industrial allocation respectively sep fund top holding be johnson johnson jnj free report apple inc aapl free report microsoft corporation msft free report allocation respectively sep fund have return year year date sep have dividend yield currently have zack etf rank buy medium risk outlook schwab dividend equity etf schd free report fund seek provide cheap exposure company provide high dividend have aum charge fee basis point year sector look fund have high exposure consumer staple information technology industrial allocation respectively jun fund top holding be verizon communication inc vz free report pfizer inc pfe free report intel corp intc free report allocation respectively sep fund have return year year date sep currently have zack etf rank hold medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1927,JNJ,benchmark finished higher tuesday slew strong corporate earning lead gain healthcare stock dow close record level blue chip index touch psychological milestone first time year history meanwhile industrial production september rebound straight month lull dow jone industrial average djia close gain index inx increase close meanwhile nasdaq composite index ixic close decrease little half point total share be trade tuesday lower last session average share decline issue outnumber advancer nyse ratio nasdaq decliner outnumber advancer ratio cboe vix increase close dow breach dow gain point tuesday surpass psychological milestone midday trading first time blue chip index also hit fresh intraday record also marked dow fastest ascent point milestone mid july history span century blue chip index have register fourth point increase year first time largest so far economist believe such stellar show blue chip index have partially be due optimism build hope tax cut new tax code be formulate president trump gain have also be part due strong corporate earning broadly encourage economic condition boee ba free report caterpillar cat free report have contribute most dow significant point ascent aug blue chip index surpass mark first time add point respectively year stock have rally respectively so far most recent exuberance dow however be support share goldman sachs gs free report home depot hd free report add point point respectively see complete list today zack rank strong buy stock here strong earning catapult market highera slew strong quarterly earning set tone gain broader market investor be also observe such high stock valuation actually support earning strong earning bank healthcare stock also contribute significantly gain advanced point close record high major sector end positive territory healthcare stock lead gainer health care select sector spdr etf xlv gain tuesday health care stock be send higher gain johnson johnson jnj free report unitedhealth group incorporate unh free report share gain respectively company post earning beat latest quarter johnson johnson report better expect third quarter result beating zack consensus estimate earning sale drug consumer product giant raise sale profit outlook send share pre market trading fact year so far share price be be almost line increase witness industry read more meanwhile unitedhealth group inc report third quarter net operate earning share comfortably beating zack consensus estimate increase year year higher revenue strength segment optum membership growth lead outperformance unitedhealth have tradition guide conservatively then beating own estimate surprise investor company surpass expectation report quarters quarter review be exception read more economic dataindustrial production month september surge surpass consensus estimate increase figure rebound september suffering consecutive decline earlier industrial production be push higher increase output construction utility sector output chemical industry be hampered hurricane harvey irma stunt production texas florida lead chemical lower overall manufacturing production gain september meanwhile capacity utilization increase august stock make pacific earning line revenue misscanadian pacific railway limit cp free report report line earning lower expect revenue third quarter read more exxonmobil initiate polyethylene line mont belvieuoil giant exxonmobil corporation xom free report petrochemical unit exxonmobil chemical company have bring online polyethylene line plastic plant mont belvieu tx read more hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1928,JNJ,johnson johnson jnj free report report better expect third quarter result beating zack consensus estimate earning sale drug consumer product giant raise sale profit outlook send share pre market trading fact year so far share price be be almost line increase witness industry earning beatj third quarter earning come share beating zack consensus estimate increase year period include amortization expense special item report third quarter earning share year period sale beatsale come beating zack consensus estimate sale increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis third quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow organically exclude impact acquisition divestiture sale increase operational basis new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be core product xarelto stelara invega sustenna sale concerta zytiga improve quarter quarter record pulmonary arterial hypertension pah revenue acquisition swiss biotech actelion june diversify revenue pah category however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition regard mention pfizer inc pfe free report file lawsuit district court recently lawsuit pfizer allege resort unfair practice prevent sale inflectra pfizer biosimilar version remicade be launch unite state november last year pharma segment achieve clinical milestone quarter include label expansion unite state pulmonary arterial hypertension pah drug tracleer pediatric use imbruvica chronic graft versus host disease gvhd drug first indication outside cancer market imbruvica partnership abbvie inc abbv free report call company also mentioned not file global regulatory application rheumatoid arthritis candidate sirukumab remind investor last month receive complete response letter crl fda sirukumab want additional safety datum medical device segment sale come year period include operational increase positive currency movement sale gain mainly inclusion abbott medical optic acquisition add operational sale growth exclude impact acquisition divestiture operational basis worldwide sale increase domestic market sale rise year year international market sale increase operational increase year year operational growth be drive wound closure product general surgery business product cardiovascular business acuvue contact lense vision care business make weaker sale performance diabetes care consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market decline year period slower growth baby care product due competitive pressure be partially offset growth beauty counter product international smoking cessation aids meanwhile international segment record increase reflect operational increase positive currency impact guidance raisedj raise adjust earning sale outlook year expect adjust earning share range compare expect previously revenue guidance be raise range compare expect previouslyour takea indicated last quarter sale growth accelerate third quarter lead company post first positive sale surprise almost year higher sale pharmaceutical segment well positive contribution actelion deal pull top line quarter actelion acquisition add impressive operational sale growth quarter quite few key product portfolio remicade concerta be face generic competition believe new product segment label expansion drug imbruvica darzalex contribution actelion lead better sale trend go forward carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1929,JNJ,pfizer inc pfe free report japanese partner astella announce prostate cancer drug xtandi meet primary endpoint late stage study expand label drug include early stage patient top line datum phase iii prosper study show treatment xtandi androgen deprivation therapy adt lead statistically significant improvement metastasis free survival mfs primary endpoint man castration resistant metastatic prostate cancer crpc compare adt alone many prostate cancer patient metastatic crpc earlier stage prostate cancer experience disease progression adt however presently fda approve treatment option be available cater condition patient develop metastatic disease xtandi be presently approve treatment metastatic crpc patient have previously receive docetaxel approve metastatic patient population label xtandi be expand cover patient crpc share pfizer be almost response positive news however pfizer share have underperform industry year so far stock have return period compare unfavorably increase industry pfizer plan discuss prosper study datum fda other regulatory authority also present detailed datum future medical meeting xtandi be add pfizer portfolio acquisition medivation september pfizer sell xtandi unite state partnership astella latter own marketing right outside market pfizer record xtandi alliance revenue second quarter first december pfizer astella have announce phase iv study plato evaluate efficacy safety continue treatment xtandi do not meet primary endpoint plato study evaluate xtandi johnson johnson jnj free report zytiga prednisone compare zytiga prednisone alone xtandi be key drug prizer oncology portfolio pipeline new york base pharma giant be aggressively work expand label market cancer drug xtandi ibrance xalkori xtandi be several study include late stage study hormone sensitive prostate cancer be also mid stage development treatment advanced breast cancer hepatocellular carcinoma pfizer carry zack rank hold see complete list today zack rank strong buy stock here stock considerbetter rank drug biotech stock include alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report zack rank share alexion be year date zack consensus estimate have climb respectively past day regeneron share year so far estimate have moved have increase past day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1930,JNJ,amgen amgn free report partner allergan agn free report announce fda approve biosimilar version roche rhhby free report cancer drug avastin bevacizumab treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer biosimilar be market trade name mvasi mvasi be first cancer biosimilar approve unite state be also first bevacizumab biosimilar country notably amgen have also submit regulatory application same eu remind investor july fda oncologic drug advisory committee have unanimously vote recommend approval mvasi amgen share have outperformed industry so far year stock have plunge versus broader industry rally approval be support comprehensive datum package demonstrated similarity mvasi bevacizumab datum also include result phase iii comparative efficacy safety immunogenicity study confirm clinically meaningful difference mvasi reference product amgen allergan be also develop biosimilar version roche herceptin abp review unite state eu rituxan abp phase iii amgen biosimilar version abbvie humira amjevita be approve fda september last year however amjevita have not be launch yet due ongoing litigation other development include amgen biosimilar version alexion soliris lilly erbitux johnson johnson jnj free report merck remicade interestingly biosimilar endeavor offer lucrative opportunity annual revenue worth amgen company have also collaborate japan daiichi sankyo biosimilar japan accelerate approval biosimilar number pharmaceutical biotech company be work bring biosimilar market many biosimilar be market eu very few be available unite state last november pfizer have launch inflectra biosimilar version remicade sandoz also market zarxio first biosimilar be approve unite state product be turn biosimilar amgen neupogen july merck have launch reneflexis biosimilar version remicade unite state august last year sandoz have gain fda approval erelzi biosimilar version amgen enbrel however product be hold due ongoing litigation be yet be unveil unite state amgen inc priceamgen inc price amgen inc quotezack rankamgen currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1931,JNJ,presidential campaign donald trump have stress tax reform promise bring corporate tax be top priority president unite state keep word trump propose change tax rate individual corporate stimulate economic growth well employment growth tax plan propose lower current corporate tax rate highest world be expect favorably impact post tax earning company territorial tax system tax only domestic income have also be propose american company so create level play field also suggest elimination special tax break company major reform propose be repatriation trillion dollar hold cash reserve overseas company global operation time tax reportedly similar tax move be make bring overseas cash reserve bush administration time tax number company repatriate amount exceed current tax code allow tax repatriation rate however give tax credit amount tax paid overseas country anticipate reform have be propose create new job aid economic growth expand investment more cash available company tax cut repatriation however extent step be successful be uncertain large portion repatriate cash be used fund share buyback dividend payment buyback fuel stock rally be actual economic growth tax reform be expect benefit company have operation globe similar buyback time be also expect help stock grow large cap pharma company base unite sate major operation worldwide include amgen inc amgn free report gilead science other be sit huge pile cash reserve stash overseas country repatriation benefit large drug biotech company more tax saving due rate cutsmoreover repatriation cash hold overseas create surplus domestic cash reserve fuel merger acquisition sector industry have see only major acquisition year actelion johnson johnson jnj free report kite pharma inc gilead science inc gild free report be expect close end let discuss impact tax reform drug biotech giant johnson johnsonjohnson johnson be well know brand world cater wide variety medical need company have paid tax effective rate respectively therefore revision tax rate not bring huge positive change post tax earning june end have cash reserve almost year end company have used major chunk cash reserve hence be expect be least impact reform company have strong presence oncology hematology cardiovascular disease inflammation bone health nephrology market effective tax rate amgen be respectively hence tax rate cut have minimal effect amgen have nearly overseas cash fiscal end bloomberg report total cash reserve company have change minimally first month so repatriation reform initiate buyback moreover tax have more domestic cash reserve total overseas cash be repatriate increase domestic cash also be used acquire new drug technology car therapy gilead sciencesgilead recently announce plan acquire kite pharma nearly add latter car therapy candidate pipeline gilead be plan complete acquisition combination cash debt bloomberg report gilead have cash reserve overseas country end repatriation help company pay debt quickly effective tax rate have be suggest minimal impact due tax rate cut make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1932,JNJ,sep issue update research report impax laboratory inc impaxis company focuse development obesity treatment be base hayward impax anaphylaxis treatment epinephrine auto injector have show notable growth sale opioid analgesic oxymorphone boost growth prospect note impax have acquire certain generic product teva pharmaceutical industry ltd teva free report last year meanwhile launch generic version merck co inc mrk free report cardiovascular drug vytorin april be expect further boost impax revenue drug register sale first month approval generic version johnson johnson jnj free report concerta july also help sale growth end june company have abbreviated new drug application anda pending fda approval anda generic pipeline impax likely be able take advantage upcoming patent expiration pharma industry effort save cost impax initiate several process improve efficiency margin focus growth opportunity company have start consolidate stopping manufacturing pack facility company be also modify generic portfolio so eliminate low value product streamline operation company expect action save annualize cost tune end however generic industry be face pricing pressure have negatively impact revenue company marketing generic drug impax have lower earning guidance anticipation dampen revenue stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1933,JNJ,johnson johnson jnj free report announce fda have deny approval investigational rheumatoid arthritis ra treatment sirukumab il inhibitor want additional safety datum fda issue complete response letter crl biologic license application bla sirukumab be file september last year company be look get sirukumab approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard regulatory application be review eu japan well propose trade name sirukumab be plivensia so far year share price have increase compare unfavorably gain record industry belong crl be somewhat expect last month fda arthritis advisory committee have not recommend approval sirukumab raise safety concern panel be concern increase mortality rate evaluate dose mg mg sirukumab fda crl have ask additional clinical datum further evaluate safety candidate plan meet fda follow discussion crl be expect delay drug approval be previously expect happen year july year partner sirukumab base drug giant glaxosmithkline plc gsk free report inform termination collaboration remind investor eli lilly company lly free report partner incyte corporation incy free report have also receive crl experimental jak inhibitor baricitinib treat ra fda demand additional datum however august company inform re submit nda baricitinib much faster previously expect not be require conduct additional study nda be expect be re submit january next year ra be common chronic life long autoimmune disease affect person unite state carry zack rank hold see complete list today zack rank strong buy stock here hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1934,JNJ,key highlight pharma sector include complete response letter crl fda johnson johnson jnj free report investigational rheumatoid arthritis ra treatment fda approval merck mrk free report bristol myer squibb bmy free report cancer drug recap week most important storiescrl ra drug janssen biotech get crl fda sirukumab treatment moderately severely active ra agency have ask additional datum safety sirukumab do not come surprise consider investigational treatment fail get support fda advisory panel last month give safety concern raise panel request additional datum be more less expect intend meet agency determine requirement gain approval il inhibitor meanwhile company have submit new drug application nda first darunavir base single tablet regimen treatment hiv approval make combination only complete regimen potential deliver advantage single table regimen high genetic barrier resistance darunavir demonstrated safety profile taf fda nod merck keytruda merck pd therapy keytruda have gain fda approval yet indication cancer therapy be already available wide range indication now be used previously treat patient recurrent locally advanced metastatic gastric junction gej adenocarcinoma tumor express pd mark tenth new indication keytruda year period keytruda be key product merck portfolio drug bring sale first half company be work expand label drug be currently more study cover wide range cancer treatment setting read more merck keytruda get fda nod advanced gastric cancer merck be zack rank hold stock see complete list today zack rank strong buy stock here allergan announce share buy back cfo departure allergan agn free report continue work return capital shareholder company announce intention buy back share worth come shortly company complete share buyback program allergan also reaffirm commitment increase cash dividend year reiterate commitment maintain investment grade credit rating pay debt company also announce departure tessa hilado executive vice president chief financial officer cfo be retire company once successor be appoint bristol myer opdivo get approval bristol myer also gain approval indication immune oncology therapy opdivo latest approval opdivo now be used treatment hepatocellular carcinoma patient previously treat nexavar sorafenib make opdivo first only immuno oncology agent be approve patient population read more bristol myer opdivo get approval liver cancer company also gain approval japan use opdivo treatment unresectable advanced recurrent gastric cancer have progressed chemotherapy gastric cancer be highly prevalent asian country be second most commonly diagnosed cancer japan bristol myer also enter clinical trial collaboration abbvie combination opdivo abbvie investigational antibody drug conjugate abbv be evaluate meet overexpressing small cell lung cancer nsclc bristol myer stock have gain year date compare rally industry belong priority review aradigm drug aradigm get priority review linhaliq treatment cystic fibrosis bronchiectasis ncfbe patient chronic infection pseudomona aeruginosa aeruginosa response agency regard approval status drug be jan ncfbe severe chronic rare disease affect more person unite state person europe drug currently approve treatment condition be significant unmet need aradigm share be news cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index be so far week major stock lilly lly free report be pfizer pfe free report be last month bristol myer be glaxo gsk free report decline see last pharma stock roundup here pfizer file suit supernus hit study update next pharma world watch usual pipeline regulatory update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1935,JNJ,allergan plc agn free report announce fda have issue refusal file rtf letter supplemental new drug application snda vraylar cariprazine company be look get vraylar label expand include new datum support drug use maintenance treatment vraylar be presently approve europe treatment schizophrenia allergan share price be year so far compare favorably industry decrease fda say snda be not sufficiently complete allow substantive review company plan meet fda official understand additional information be require remind investor earlier march fda have accept company snda vraylar snda be base datum phase iii study evaluate vraylar maintenance efficacy adult schizophrenia datum study show vraylar have significantly delay time relapse compare placebo also relapse occur nearly twice many placebo patient comparison treat vraylar vraylar have perform expectation record sale year drug be likely be key driver allergan top line growth other player bipolar disorder schizophrenia treatment market include astrazeneca plc azn free report seroquel xr johnson johnson jnj free report risperdal consta plc alk free report aristada separate press release allergan announce new datum centaur phase iib study evaluate pipeline candidate cenicriviroc cvc treat liver fibrosis adult patient nash phase iib datum support continue development cenicriviroc cvc ongoing phase iii aurora study evaluate safety efficacy candidate liver fibrosis adult patient nash centaur study demonstrated significant difference fibrosis improvement be observed cvc placebo second year patient administer cvc couple year patient switch cvc year remain placebo year such patient receive cvc achieve combine endpoint reduction fibrosis least stage worsening nash find lie straight comparison remain placebo allergan plc price allergan plc price allergan plc quotezack rankallergan currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1936,JNJ,pfizer inc pfe free report say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make next year ultimately opt retain business pfizer share have underperform industry year so far stock have return period compare unfavorably increase industry consumer healthcare segment include several counter otc healthcare medicine vitamin personal care product be sell prescription important product be advil pain relief tablet centrum multivitamin be top selling consumer healthcare brand globally segment record sale almost first half represent growth year year chief executive officer ceo ian reed say consumer unit be not core prescription drug business potential value be more fully realize outside company regard core pharmaceutical business august pfizer say expect approximately drug approval next year include product have blockbuster potential include line extension xtandi ibrance xeljanz xr half potential blockbuster be expect receive approval fund potential spin pharmaceutical consumer healthcare business make easier company achieve goal be be apprehend consumer health biggy nestle reckitt benckiser procter gamble pg free report glaxosmithkline gsk free report johnson johnson jnj free report be interested buy unit pfizer put sale pfizer carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1937,JNJ,novartis ag nvs free report announce long last skin clearance rate cosentyx plaque psoriasis patient phase iii study evaluate drug year cosentyx be first only fully human il inhibitor achieve sustain skin clearance rate year reinforce long term favorable impact datum study show cosentyx maintain psoriasis area severity index pasi pasi measure skin clearance year year patient moderate severe plaque psoriasis datum study be present european academy dermatology venereology eadv congress geneva switzerland share company have outperformed industry have surge so far year industry increase drug be approve unite sate treatment adult active ankylose spondylitis active psoriatic arthritis psa moderate severe plaque psoriasis launch drug have be prescribe more patient cosentyx achieve blockbuster status record sale first half generate solid sale long term safety efficacy datum drug be expect further boost growth meanwhile second quarter drug be grant approval europe label update include week datum clear study demonstrated long term superiority cosentyx compare johnson johnson jnj free report stelara psoriasis also patient recruitment be underway new head head clinical trial exceed evaluate superiority cosentyx versus abbvie abbv free report humira psa novartis expect next growth phase begin drive cosentyx psoriasis psoriatic arthritis ankylose spondylitis indication entresto kisqali deep pipeline candidate baf amg rth moreover approval kymriah ctl august make novartis first company bring car cell therapy treat cancer go forward expect approval new drug label expansion exist one bode well novartis novartis ag price consensus novartis ag price consensus novartis ag quotezack rank stock have zack rank hold aduro biotech inc adro free report be better rank biomedical company zack rank buy see complete list today zack rank strong buy stock here aduro loss estimate narrow last day company deliver average earning beat trail quarters trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1938,JNJ,abbott free report recently announce receipt national reimbursement freestylelibre glucose monitoring system national health service nhs business service authority notably be major breakthrough diabetic business development have widen illinois base medical device major customer base diabetes management begin nov abbott flagship glucose monitoring system be available reimbursement nhs england wale nhs scotland health social care northern ireland abbott grant reimbursement also make freestylelibre system widely available person be diagnosed diabetes also management expect be roughly person have diabetes be yet be diagnosed reimbursement approval mark milestone abbott freestyle libre system stand partially fully cover country include france germany japan notably freestyle libre system be presently review fda await approval unite state meanwhile abbott have be move steadily development diabetic segment recently company announce receipt national reimbursement freestyle libre japan moreover company recently announce receipt health canada license freestyle libre flash glucose monitoring system further stimulate growth diabetes care sale segment be second quarter continue consumer acceptance freestyle libre internationally expect freestyle libre further contribute abbott top line japanese canadian development french health ministry recently approve national reimbursement device apart july company partner bigfoot biomedical solidify footprint rapidly grow diabetes therapeutic market report mordor intelligence global market diabetes care device be project reach value cagr consider market potential abbott slew latest development diabetes care segment recent national reimbursement grant accelerate top line however diabetes market be dominate many well establish player johnson johnson jnj free report be most prominent space johnson johnson also have tie base corporation successfully develop innovate insulin delivery system share price have be gain investor confidence consistently positive result last month abbott share price have outperformed broader industry stock have gain comparison broader industry gain company have also outperformed gain market same time frame zack rank key picksabbott carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1939,JNJ,integra lifescience holding corporation iart free report recently sign definitive agreement sell company certain neurosurgery asset healthcare product service provider natus medical incorporate baby free report total deal value form part company effort fulfill certain close condition propose acquisition johnson johnson jnj free report codman neurosurgery business integra have decide sell global camino icp monitoring product line include san diego manufacturing facility natus medical natus also get hold right related integra fix pressure shunt well right codman duraform dural graft implant standard evd catheter csf collection system announce entire set divestiture integra have also discuss imminent financial impact company approximately revenue be earn neurosurgery product line associate divestiture take net divestiture codman acquisition account company preliminary basis estimate fourth quarter revenue contribution approximately full year integra expect codman neurosurgery contribute revenue net divestiture overall codman neurosurgery business be expect remain accretive integra adjust earning share contribute least cent however full year integra expect minimal contribution codman neurosurgery adjust earning share notably integra propose acquisition codman declare february provide company global reach neurosurgery connote core expertise integra specialty surgical solution integra codman neurosurgery exist portfolio new product pipeline advanced hydrocephalus neuro critical care be go complement acquirer lead product pipeline tissue ablation dural repair cranial stabilization post completion acquisition consolidated portfolio offer complete solution neurosurgery scale invest bring new technology table patient worldwide notably report radiant insight global neurosurgery market be expect witness estimate cagr take consideration huge growth prospect believe integra initiative strengthen foothold particular niche be well time overall integra lifescience have be consistently trading broader industry last month stock have rally year date substantially outperform gain industry zack rank key pickintegra currently carry zack rank hold better rank medical stock be edward lifescience corporation ew free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1940,JNJ,achillion pharmaceutical inc achn free report announce have receive notice termination global license collaboration agreement develop hepatitis treatment partner janssen subsidiary johnson johnson jnj free report remind investor agreement janssen be sign provide achillion strong experience partner major source fund termination agreement believe investor have become wary due uncertainty fund achillion share achillion tumble monday fact achillion share have fall so far year underperform industry gain period achillion janssen be develop jnj treat patient hepatitis janssen take decision discontinue further development hepatitis treatment regimen jnj believe be several highly effective therapy available indication ongoing phase iia study be evaluate jnj triple combination regimen simeprevir al achillion odalasvir datum study announce april demonstrated treatment regimen have ability shorten treatment duration patient moreover jnj demonstrated cure rate only week therapy publish journal hepatology janssen complete study plan stop further development thereafter achillion state now focus develop factor inhibitor treatment patient paroxysmal nocturnal hemoglobinurium pnh interim result study announce august show clinically meaningful complement inhibition favorable tolerability profile multiple phase ii study be plan evaluate second half study include pnh patient sub optimal response alexion pharmaceutical inc alxn free report soliris patient rare renal disorder separate press release achillion announce promotion current executive vice president joseph truitt chief operate officer appoint avner ingerman senior vice president head ophthalmology dr ingerman have year experience pharmaceutical industry be previously employ ohr pharmaceutical inc regeneron pharmaceutical inc regn free report achillion pharmaceutical inc price consensus achillion pharmaceutical inc price consensus achillion pharmaceutical inc quoteachillion currently have zack rank sell see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1941,JNJ,equity market be go turbulent time be lot volatility uncertainty owing rise geopolitical risk political uncertainty have increase appeal dividend investing geopolitical risksnorth korea conduct sixth nuclear test hydrogen bomb be mount continental ballistic missile sep kim jong action have create huge unrest number asian economy unite state president donald trump have be suggest kim jong threat be meet military action threaten harm territory ally ambassador nikki haley say north korea be beg war have urge impose strictest sanction rogue nation read safe haven currency etfs gain dollar lose geopolitical uncertainty political risksthere be increase uncertainty regard trump ability pass promise legislation relate tax reform deregulation economic fundamental have be strong be renew doubt capability trump administration economic growth unite state be better initially expect market commerce department economic growth be second quarter compare earlier estimate read etfs watch oil price rise debt limit deal however latest show bipartisanship trump side democrat increase debt ceiling fund government mid december come disappointment fellow republican be push longer extension hour deal be pass paul ryan state shorter debt limit extension give democrat immense leverage republican once debate start again mid december such scenario dividend pay security provide consistent income investor uniqueness security be increase political uncertainty weigh market more so apart high dividend security exhibit less volatility be stable mature company let now discuss few etfs focuse provide exposure equity relatively high dividend yield vanguard dividend appreciation etf vig free report fund be low cost etf seek provide exposure large establish company provide high dividend have aum charge fee basis point year sector look fund have high exposure industrial consumer service consumer good allocation respectively jul fund top holding be microsoft corporation msft free report johnson johnson jnj free report pepsico inc pep free report allocation respectively jul fund have return year year date sep currently have zack etf rank buy medium risk outlook quality dividend growth fund dgrw free report fund seek provide exposure large establish company provide high dividend apply quality screen have aum charge fee basis point year sector look fund have high exposure information technology health care industrial allocation respectively sep fund top holding be johnson johnson apple inc aapl free report microsoft corporation allocation respectively sep fund have return year year date sep currently have zack etf rank medium risk outlook ishare core dividend growth etf dgro free report fund seek provide cheap exposure company provide high dividend have aum charge fee basis point year sector look fund have high exposure information technology health care financial allocation respectively sep fund top holding be pfizer inc pfe free report apple inc microsoft corporation allocation respectively sep fund have return year year date sep currently have zack etf rank hold medium risk outlook want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1942,JNJ,dow endure significant loss holiday shorten trading week market be close monday labor day holiday index endure worst day loss several week tuesday follow rise tension north korea index rebound wednesday president donald trump conclude agreement congress debt ceiling issue however loss key component drag index lower thursday last week index gain last friday market watcher play chance possible rate hike fed follow desultory nonfarm payroll datum august total job be add economy august significantly lower consensus estimate job addition payroll addition be lower expect unemployment rate increase reach meanwhile ism manufacturing index hit year high month august index gain last week period hurricane harvey pummeled houston force major oil refinery area shut moreover north korea test fire ballistic missile japan raise geopolitical tension unite state meanwhile speaking cnbc secretary state steven mnuchin say trump administration have present detailed tax plan congress expect sign law year end dow weekmarket be close monday labor day holiday dow suffer loss more point tuesday register worst day drop aug end day winning streak such loss be incur investor rotate relatively riskier asset due escalate tension pyongyang washington likelihood fallout hurricane name irma coast florida send home insurer lower index gain wednesday president trump reach agreement key member congress extend debt ceiling deadline be do aid relief funding victim hurricane harvey however category hurricane irma gain momentum be slate land fall coast florida weekend news irma come send timeshare vacation stock lower meanwhile fed vice chairman announce plan retire mid october cite personal reason index lose thursday drag share walt disney company free report goldman sachs group inc gs free report disney share lose ceo bob iger announce company earning guidance full year be be revise downward share goldman sachs also decline weigh heavily dow broader market close marginally lower investor rotate financial seek telecom consumer discretionary stock component move index unite technology corporation utx free report recently inked definitive agreement acquire iowa base avionic firm rockwell collin inc col free report strategic transaction be likely create industry behemoth unrivaled competitive advantage be largest aircraft equipment manufacturer world individual capacity zack rank hold unite technology acquire rockwell collin share combination cash stock term agreement rockwell collin shareholder be entitle receive share cash balance amount unite technology share equate purchase price include rockwell collin net debt company expect fund transaction secondary debt offer available cash maintain solid investment grade credit rating transaction be likely close third quarter subject mandatory approval other customary close condition read unite technology inks accretive rockwell merger deal boee co ba free report recently announce be company receive aerospace system air platform technology research program contract unite state air force have ceiling value notably boee be final company receive award pentagon contract company be responsible provide quality research affordable revolutionary capability warfighter be award air force research laboratory patterson air force base boee expect complete task aug work be carry company hazelwood ms facility utilize fiscal research development fund finish task stock have zack rank buy see complete list today zack rank stock here johnson johnson jnj free report announce fda have approve label expansion oral pulmonary arterial hypertension pah medicine tracleer johnson johnson have zack rank consequently mg tablet tracleer be now approve use pediatric patient age year older idiopathic congenital pah improve pulmonary vascular resistance pvr be expect result improvement exercise ability approval tracleer have become first medicine unite state be approve use pediatric patient mg oral suspension formulation pediatric use be expect be available fourth quarter year presently tracleer be market mg dosage adult patient still be available read pah drug label expand pediatric use merck co inc mrk free report announce pd therapy keytruda have receive approval european commission first second line treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer keytruda have be approve first line therapy patient receive standard care chemotherapy contain cisplatin keytruda be also approve second line treatment patient have be previously treat platinum contain chemotherapy read merck keytruda get eu approval bladder cancer separate development zack rank merck announce acquire germany base rigontec privately hold immuno oncology focuse biotech upfront cash payment almost euro rigontec be leader retinoic acid inducible gene rig target therapeutic be novel immuno oncology treatment approach deal completion date be not yet disclose subject certain close condition apart upfront payment base achievement certain milestone merck also make additional contingent payment worth approximately euro read merck opt buy german immuno oncology biotech pfizer inc pfe free report announce fda have grant approval mylotarg adult patient newly diagnosed cd positive acute myeloid leukemia aml drug also receive approval treat relapse refractory cd positive aml adult well child year older pfizer have zack rank approval be expect fda oncologic drug advisory committee have vote favor mylotarg approval july however be note label drug include box warning hepatotoxicity include severe fatal hepatic veno occlusive disease approval be grant base datum multiple investigator lead clinical trial include alfa aml mylofrance alfa phase iii study evaluate mylotarg combination chemotherapy newly diagnosed aml patient drug show significant improvement event free survival ef achieve month compare month chemotherapy read pfizer acute leukemia drug mylotarg approve fda performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have decline tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week investor seem be weigh several concern domestic foreign origin tension north korea continue simmer hurricane be likely make landfall weekend such crisis occur even texas recover effect hurricane harvey give such backdrop only encourage economic datum help market return winning way week ahead more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1943,JNJ,abbvie inc abbv free report report mixed result third quarter company surpass earning estimate post line revenue period importantly company raise long term sale expectation blockbuster rheumatoid arthritis drug humira rise competition market response share nudge almost pre market trading year so far abbvie share have surge significantly outperform industry rally company report third quarter earning share beating zack consensus estimate bottom line grow year year company post revenue report quarter have meet zack consensus estimate revenue also increase year year exclude favorable impact foreign exchange rate fluctuation operational revenue climb quarter detailkey drug humira record sale growth operational basis revenue come sale unite state rally humira sale ex market be operational basis report basis growth major market category drive upside increase competition new class drug well indirect biosimilar competition international market third quarter net revenue imbruvica stand year year sale imbruvica be compare year figure abbvie record international profit sharing johnson johnson jnj free report other product deliver impressive performance include duodopa show revenue growth operational report basis product call creon witness increase revenue operational report basis hcv chronic hepatitis virus product record sale operational report basis respectively downside be attributable intense pricing competitive pressure hcv market adjust sg expense be expense escalate quarter adjust operate margin be sale report quarter abbvie announce hike quarterly dividend cent share cent share increase payment begin dividend payable february next year outlookabbvie raise adjust earning range compare expect previously earning guidance reflect year year growth mid point zack consensus estimate be currently peg share long term guidanceabbvie project adjust ep range show approximate rally mid point revise range outlook abbvie estimate humira generate global sale higher predict previously several company be work biosimilar version humira amgen amgn free report humira biosimilar receive fda approval september launch be delay due settlement patent dispute abbvie make humira free competition few more year also abbvie have robust intellectual property be expect generate positive sentiment investor zack rank key picksabbvie currently carry zack rank hold better rank stock health care sector be eli lilly company lly free report carry zack rank buy see complete list today zack rank strong buy stock here eli lilly earning share estimate increase last day company deliver positive earning surprise trail quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1944,JNJ,merck co inc mrk free report report third quarter adjust earning share beat zack consensus estimate earning rise year year other item adjust earning exclude charge related new oncology collaboration britain astrazeneca azn free report revenue quarter decline year year sale also miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale decline year year lose sale market due network cyber attack june hurt top line quarter meanwhile unfavorable comparison third quarter last year hurt sale quarter pharmaceutical segment generate revenue exclude fx impact year year continue strong sale pd inhibitor keytruda be offset lower sale key product diabetes drug januvia hpv vaccine gardasil gardasil previous quarters loss market exclusivity several drug also hurt top line keytruda bring sale third quarter sequentially year year sale continue be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer meanwhile keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe key recent approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer new approval have expand patient population believe drive sale third quarter zepatier bring sale previous quarter bridion sugammadex injection generate sale quarter year year drive strong uptake follow launch unite state meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cubicin lose patent protection unite state june zetia lose market exclusivity unite state december vytorin lose exclusivity april decline quarter remicade sale decline quarter merck market brand version remicade outside unite state johnson johnson jnj free report market rheumatoid arthritis drug country cubicin sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin sale isentress januvia janumet diabetes franchise also decline quarter januvia janumet franchise record sale quarter year quarter due continue pricing pressure isentress sale decline quarter lower volume demand due competitive pressure hurt sale isentress gardasil gardasil sale decline production shutdown follow cyber attack result supply constraint adversely impact sale unite state however sale rise europe boost addition sale terminate vaccine joint venture sanofi sny free report asia pacific backed strong demand merck animal health segment generate revenue exclude fx impact year quarter primarily drive higher sale companion animal product primarily bravecto companion animal vaccine contribution valle acquisition gross margin cost rise adjust gross margin come basis point bps year quarter attributable favorable effect product mix offset cost related cyber attack marketing administrative expense increase report quarter research development spend increase quarter guidancemerck raise previously issue adjust earning guidance raise sale guidance marginally second time year company expect adjust earning range compare expect earlier adjust earning guidance include less negative impact currency fluctuation compare favorably approximately previously revenue be expect range compare earlier forecast include negative currency impact less versus approximately previously operate expense be still expect increase year year mid single digit rate increase cost be attributable increase investment ongoing launch remediation expense related cyber attack well additional cost associate new oncology collaboration astrazeneca takemerck third quarter result be mixed company beat estimate earning miss same sale relatively weaker sale performance merck raise previously issue adjust earning guidance also up sale guidance marginally share be pre market trading response lower sale merck multiple medicine year so far merck share have underperform industry merck share have rise year compare unfavorably increase industry eye be performance keytruda be be tout key long term growth driver merck drug continue strong performance sale cross mark quarter however company have suffer notable pipeline setback year earlier month merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month merck discontinue development hcv program say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group julymerck carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1945,JNJ,wall street be scaling multiple high trump pro growth reform dow jone industrial average have be outperformer election last year be strong rotation leadership large cap domestic space have benefit dow jone more other large cap counterpart read high beta etfs stock market beating return notably dow jone have return election day compare gain trump rally be now closer become greatest year investor be gear earning season proxy version spdr dow jone industrial average etf dium free report be spotlight dium be largest most popular etfs large cap space aum average daily volume share hold blue chip stock fund be widely spread component none hold more share industrial financial information technology consumer discretionary healthcare be top sector dium charge bps annual fee have zack etf rank hold medium risk outlook let delve earning picture likely set movement fund come day earning trendstotal earning be expect be same period last year higher revenue double digit growth first quarters year earning growth last quarter year currently expect be high single digit growth be track be lowest year earning season have get underway nearly fourth blue chip firm expect announce result week next jpmorgan chase jpm free report be expect release result oct read buy etfs stock earning unfold international business machine ibm free report be schedule report oct goldman gs free report unitedhealth group unh free report johnson johnson jnj free report report oct other company american express axp free report come earning report oct general electric ge free report procter gamble company pg free report have earning release slate oct earning methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter jpmorgan have zack rank earning esp indicate less chance beating estimate quarter company deliver positive earning surprise last quarters average beat see earning estimate revision past day be report quarter however stock have vgm style score international business machine have zack rank earning esp indicate reasonable chance beating estimate quarter stock deliver positive earning surprise last quarters average beat however see negative earning estimate revision cent past day be report quarter stock have vgm score goldman have zack rank earning esp make surprise prediction difficult earning surprise track past quarters be robust average positive surprise company witness negative earning estimate revision couple cent past day yet be report quarter have miserable vgm style score read fed reverse qe financial etfs stock buy unitedhealth have zack rank earning esp indicate less chance beating estimate quarter stock have see downward earning estimate revision penny yet be report quarter deliver positive earning surprise last quarters stock have good vgm style score johnson johnson also have less chance beating estimate quarter zack rank earning esp witness positive earning estimate revision cent past month be report quarter deliver negative earning surprise last quarters stock have solid vgm style score american express also have zack rank earning esp indicate less chance beating estimate quarter company deliver positive earning surprise last quarters average beat see positive earning estimate revision penny past month be report quarter stock have vgm style score general electric have zack rank earning esp however earning surprise track past quarters be robust average positive surprise company also witness solid earning estimate revision cent past day yet be report quarter have miserable vgm style score procter gamble company have zack rank earning esp indicate high chance beating estimate quarter earning surprise track last quarters be good average beat nevertheless stock witness negative earning estimate revision cent past day be report quarter have vgm style score read winning etf strategy bottom earning most blue chip company schedule come week stock market extend bull run investor closely monitor movement dow etf grab opportunity surge stock price want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1946,JNJ,hepatitis be infectious disease cause hepatitis virus hcv primarily affect liver gilead science inc gild free report market blockbuster hcv drug sovaldi harvoni other well know name market be abbvie inc abbv free report viekira pak bristol myer bmy free report daklinza johnson johnson jnj free report olysio accord center disease control prevention cdc person unite state be live chronic hepatitis infection many remain unaware be infected be new hepatitis case year unite state many go unreported consider number be not surprise quite few pharma biotech company be work bring new improve shorter duration hcv treatment market market be thus get crowd see increase pricing pressure lot have happened hcv space late september gilead science sovaldi receive approval china component combination antiviral treatment regimen be first gilead hcv drug be approve china meanwhile gilead single tablet regimen str sovaldi velpatasvir voxilaprevir vosevi receive approval unite state eu canada july august vosevi become first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor gilead share have outperformed industry year date stock have rally compare industry gain same time frame stock carry zack rank hold see complete list today zack rank strong buy stock here meanwhile abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada past couple month mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history abbvie share have outperformed industry year date stock have rally compare industry gain same time frame stock carry zack rank however last week pharmaceutical giant merck mrk free report announce be discontinue further development next generation hepatitis hcv program mk grazoprevir ruzasvir uprifosbuvir mk ruzasvir uprifosbuvir company make decision base review available phase ii efficacy datum heavily crowd hcv market merck share have underperform industry year date stock have gain compare industry gain same time frame stock carry zack rank merck giant johnson johnson also discontinue development investigational hcv treatment regimen jnj combination direct act antiviral al odalasvir simeprevir company take decision consider be several highly effective therapy available indication johnson johnson share have underperform industry year date stock have gain compare industry gain same time frame stock carry zack rank be believe discontinuation merck combination hcv regimen act favor gilead abbvie gilead abbvie benefit lack additional competition enter market least term however company continue face challenge form decline patient volume intense pricing pressure lack additional entrant market also slow rate decline sale do zack investment idea come be welcome download full minute list zack rank strong buy stock free charge be better place start own stock search access full list avoid zack rank strong sell other private research see stock free
1947,JNJ,pharmaceutical sector have be grab investor attention late nyse arca pharmaceutical index gain large cap pharmaceutical industry year date outpace gain new drug approval tax reform be expect provide further impetus stock however factor drug pricing competition biosimilar continue act major deterrent other hand company eli lilly company lly free report be resort workforce reduction leaner cost structure front apart johnson johnson jnj free report acquisition actelion ltd june nothing much have happened space merck co mrk free report recently announce acquire germany base rigontec privately hold immuno oncology focuse biotech boost immune oncology pipeline nevertheless propose tax reform be expect boost cash balance company turn be used merger acquisition here have picked largest drug company look well poise growth be prudent choice add portfolio base switzerland novartis ag nvs free report be leader health care solution wide array drug service novartis have presence field oncology neuroscience ophthalmology generic novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu improve formulation exjade recent fda approval kisqali advanced metastatic breast cancer breakthrough gene transfer treatment kymriah suspension acute lymphoblastic leukemia have further boost portfolio approval be major boost novartis give potential car therapy space growth driver cosentyx entresto more offset impact generic erosion mainly due glivec cosentyx achieve blockbuster status believe approval new drug label expansion exist one boost top line go forward novartis currently carry zack rank buy see complete list today zack rank strong buy stock here novartis stock have gain year date strength oncology drug approval first car therapy continue boost performance pfizer inc pfe free report lead pharmaceutical company unite state focus development wide range product include human animal biologic well small molecule medicine vaccine consumer health care product pfizer be look drive growth licensing deal collaborative agreement company be look expand label approve drug ibrance xeljanz xalkori eliquis pfizer also boast strong pipeline moreover pfizer be evaluate various biosimilar molecule several stage development give potential market share company have moved last month compare favorably industry gain pfizer presently carry zack rank earning estimate company have be static past day bagsvrd denmark base nordisk nvo free report be global leader diabetes market company be also key player hemophilia care growth hormone therapy hormone replacement therapy obesity company portfolio include drug levemir novorapid victoza novomix novomix novomix novoseven norditropin additionally obesity drug saxenda liraglutide mg be launch unite state uptake have be encourage victoza be currently market leader glp segment expect victoza continue be significant contributor company top line august fda approve new indication victoza reduce risk major adverse cardiovascular cv event adult type ii diabetes establish cv disease believe label expansion drug further boost top line company currently carry zack rank company share have rally year date company earning estimate have moved last day headquarter leverkusen germany bayer ag bayry free report be life science company core competency area health care agriculture bayer have be consistently make effort transform pure life science company drug launch last few quarters be expect continue drive top line bayer be look label expansion oncology drug stivarga be approve treatment metastatic colorectal cancer metastatic stromal tumor company have inked several strategic deal undertake meaningful acquisition recent past bayer be look acquire cash transaction combine business be expect boost bayer crop science business provide accretion bottom line bayer currently carry zack rank buy company share have gain year date earning estimate company have moved north last day bottom line challenge form pricing pressure competition remain healthcare sector nevertheless pick outperformer space backed solid zack rank positive price movement lead investor gain earning season stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1948,JNJ,most healthcare community have start rejoice capitol hill regulatory apprise recent past way full obamacare repeal proposal republican prime agenda healthcare roster fall flat face be intense thing get even stagier skinny repeal bill also fail get passable support senate believe immense support retain affordable care act aca obamacare come heel latest cost estimate release congressional budget office cbo staff joint committee taxation jct republican bill primarily promise improve insurance coverage exist law significantly lower american premium cost estimate reveal something totally contrary report aca be repeal number uninsured person increase present uninsured number apart average premium nongroup market individual policy purchase marketplace directly insurer increase trouble time medtech twist turn continue unfold capitol hill thus boost chance exist healthcare policy scenario medical device space be get gloomier such political conundrum market watcher be keep tab medtech space community have be quite hopeful change power trump propose policy always talk abolition infamous medical device sale tax dreadful tax be commonly address fund aca simply take toll entire medical device industry enactment tax be impose selling price instead net profit amount stupendous sum wipe almost quarter profit medical technology owner report fiercemedical device release time reveal johnson johnson jnj free report make payment medical device sale tax medtronic mdt free report legacy covidien nephew snn free report paid respectively year be story industry forerunner position smaller company be much let alone make profit be fact struggle survive realize severe linkage effect tax medtech bigwig well small player finally begin house senate temporarily suspend year only now medtech player find face similar situation begin policy remain intact note voter be favor aca be also talk abolishment cadillac tax excise tax high cost healthcare plan dreadful fiscal revenue generate mean democrat unfortunately trump administration have be target complete annulment cadillac tax future have not come concrete plan replace medtech tax yet future medtech fraternity thus hang balance medtech community perceive be accord medtech community suspension medtech tax have directly address issue lack opportunity research development innovation pipeline development increase investment need accelerate patient provider access innovative health care product have also help boost job creation quality patient care accordingly be go shelve tax go article peter sullivan publish hill follow congress failure approve repeal exist healthcare law trade group medical device company be launch new campaign push lawmaker repeal obamacare tax medical device await medtech player political cacophony market watcher have bearish stance space ponder medical device stock stand gain lose due political gridlock find retention repeal obamacare actually create vicious circle sector hand obamacare stay medtech profit be hit significantly thus pose challenge research development be quite expensive other hand repeal obamacare lead intensive research development creation expensive cut edge medtech product be question effectiveness be higher number uninsured industry be likely witness shrink customer base post enactment indicate decline demand expensive medical procedure device matter policy shape prove be beneficial well challenge same time player space investor meanwhile be hopeful fact overall impact exist policy amendment retention not be appalling apparently seem simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1949,JNJ,biogen inc biib free report announce datum long term study alzheimer disease ad candidate aducanumab datum study show continue benefit rate amyloid decline year period patient prodromal mild alzheimer disease treat aducanumab share be monday response promise show amyloid candidate company say result recently conduct analysis long term extension lte ongoing phase ib study prime aducanumab be consistent previously report datum prime prime be randomize double blind placebo controlled multiple dose phase ib study be conduct evaluate safety tolerability pharmacokinetic pharmacodynamic aducanumab patient suffering prodromal mild ad so far year biogen share have rise industry record increase biogen be conduct other phase iii study engage emerge aducanumab treatment early ad result lte study support design engage emerge study biogen be look strengthen ad other disorder pipeline biogen ad pipeline comprise candidate different mechanism action include tau candidate biib bms potential ad well progressive supranuclear palsy psp amyloid aducanumab candidate well bace inhibitor elenbecestat program however successful development therapy treatment alzheimer disease be challenge note several company have fail develop treatment same november last year eli lilly company lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly suffer major setback aug have halt development phase iii alzheimer candidate semagacestat meanwhile pfizer pfe free report shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch biogen have zack rank hold see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1950,JNJ,biotech stock have bounce back strongly year poor show last year challenge rise competition slowdown growth mature product generic competition certain key drug strong clinical result faster fda approval success new product significant contribution establish drug have lead rally biotech sector nasdaq biotechnology index gain so far year be sharp contrast last year performance index be however strong performance investor be keen know rally continue factor drive same company be likely see continue demand product give accelerate increase age population proportionate increase disease moreover fda have approve far more drug so far do whole hence faster drug approval process strong pipeline innovative treatment impressive result increase health care spending support further growth sector momentum biotech sector be likely continue good idea avoid few stock possibly lose momentum soon significant year date gain small biotech stock avoid avoid stock have represent significant share price gain be bit tricky however have take help zack stock screener identify stock stop rally term shortlist stock vast universe biotech sector have picked stock carry zack rank sell strong sell moreover have also take consideration stock witness negative estimate revision current year last day be likely plunge further be dump keryx inc kerx free report boston base company focus treat patient suffering renal disease company share have rise so far year however currently carry zack rank further last day loss share estimate widen company label expansion effort only market drug auryxia bode well growth company sole dependence product revenue be concern keryx inc price keryx inc price keryx inc quotejuno therapeutic inc washington base company focus development immuno oncology treatment company share have gain significant so far year share company mainly rise september year speculation be acquire soon acquisition kite pharma gilead however currently carry zack rank have vgm score further last day loss share estimate widen almost juno be major player field cell base immunotherapy be several other company be look develop bring immunotherapy treatment market car space have many company include novartis kite pharma bluebird bio intrexon johnson johnson jnj free report work treatment note juno lag kite pharma novartis race bring car product market hence competition immunotherapy space weigh heavily stock term juno therapeutic inc price juno therapeutic inc price juno therapeutic inc quoteabeona therapeutic inc abeo free report delaware base company focus develop gene therapy life threaten rare genetic disease company share show significant gain so far year however currently carry zack rank have vgm score further last day loss share estimate widen company lead gene therapy eb abo recently receive breakthrough therapy orphan drug designation respectively fda abeona share significantly rise july company announce have receive guidance fda commence pivotal phase iii eb however many company be work bring gene therapy market therefore candidate face intense competition target space approve abeona therapeutic inc price abeona therapeutic inc price abeona therapeutic inc quote be reissue article correct mistake original article issue sep longer be rely
1951,JNJ,dow mop gain week buoy announcement federal reserve decline tension unite state north korea lead gain index monday index moved higher tuesday speculation fed declare be trimming balance sheet actual announcement lead further gain wednesday ultimately index snap day stretch gain thursday stock lose luster follow fed announcement last week dow gain last friday mark sixth consecutive session gain stock be buoy rally bank stock even investor digest missile launch japan north korea bank share surge follow strong inflation number come expectation raise speculation rate hike fed retail sale drop august biggest decline month index gain last week investor sentiment improve impact hurricane irma be weaker expect dow also post biggest day percentage gain mar speaking investment conference treasury secretary state trump administration expect tax reform materialize year end also north korea threaten raze japan unite state nuclear weapon issue fresh sanction country dow index gain hit fresh record high north korea fear ebb follow secretary treasury rex tillerson announcement unite state be look peaceful solution problem country further investor focuse federal open market committee fomc day meeting give rise speculation fed start unwinding balance sheet boost treasury yield lead broad base gain financial sector index increase tuesday day fomc meeting kick meanwhile president donald trump make debut speech unite nation general assembly urge member state combat rogue nation north korea iran index gain wednesday federal reserve announce begin trimming balance sheet october fed also decide keep benchmark interest rate unchanged indicated rate hike be likely december such statement lead gain financial share benefit bank index lose thursday bring end successive day gain period index experience average increase point stock lose luster fed hint rate hike unwinding balance sheet be offing end year share apple inc aapl free report procter gamble co pg free report lose respectively contribute primarily day loss index component move index apple little snafu stage demonstrate new facial recognition feature mega edition iphone not only result wave troll meme social medium also give competitor opportunity take potshot tech giant report facebook fb free report ad post huawei take jab used clown iphone facial recognition state fail often person real artificial intelligence ai phone come oct refer upcoming device mate apple mega event sep company suffer major embarrassment phone craig federighi be used demonstrate face id feature do not unlock software chief be force use backup work be require read apple mock huawei take iphone mate development zack rank hold apple have acknowledge latest apple watch os series have issue cellular connectivity assured engineer be work problem fix be soon available future software release apple comment come several prominent reviewer lambaste watch repeat failure connect lte apple have tout build cellular usp watch read apple say watch have connectivity issue fix offing boee co ba free report have win modification contract worth provide new preliminary design activity requirement presidential aircraft par program contract be award air force life cycle management center patterson air force base contract boee complete preliminary design work modification aircraft replace age vc boee used presidential support aircraft work be schedule be complete dec be execute seattle wa read boee win air force contract par program additionally boee announce have secure contract air force provide support service minuteman iii weapon system contract company provide operation maintenance testing technical datum delivery support minuteman iii stock have zack rank buy see complete list today zack rank strong buy stock here johnson johnson jnj free report announce european medicine agency ema committee medicinal product human use chmp have grant positive opinion recommend approval pipeline candidate guselkumab treatment moderate severe plaque psoriasis eu johnson johnson have zack rank sell drug be approve unite state july year be market trade name tremfya treatment immune system related skin disorder decision european commission ec be expect later year read psoriasis drug guselkumab get chmp nod eu jpmorgan chase co jpm free report recently make undisclosed investment bill com largest business business payment network unite state move be part company effort enable business client do away paper check instead make receive payment electronically bill com technology be likely be integrate zack rank jpmorgan digital system early association benefit bank customer allow have access bill com network comprise almost user read jpmorgan partner bill com eradicate paper payment pfizer inc pfe free report announce fda advisory committee give mixed opinion regard regulatory application be file expand label cancer drug sutent sutent be presently market first line treatment advanced renal cell carcinoma rcc latest supplemental new drug application snda be accept fda year pfizer be look get label extend include use patient high risk rcc recurrence read pfizer sutent label expansion get mixed fda committee view meanwhile pfizer have file lawsuit district court allege johnson johnson be resort unfair practice prevent sale inflectra pfizer biosimilar version merck co inc mrk free report blockbuster rheumatoid arthritis drug remicade pfizer biosimilar version be available wholesale acquisition cost wac be lower reference product read pfizer sue accuse prevent inflectra uptake performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week outlookdespite gain make prior announcement fed hawkish stance have ultimately rob stock much luster have end long stretch gain such narrative be unlikely continue much longer next week feature release several crucial economic report include important gdp datum positive sign front be enough help stock return winning way trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1952,JNJ,expect plethora earning report have hit tape morning include more bigger wall street bank other household brand put simply result be mostly good ultimately mixed thus far let try slog ve find hour
1953,JNJ,goldman sachs gs free report beat estimate top bottom line share be selling follow earning report drastically lower fix income revenue earning share beat zack consensus estimate sale well ahead expect be drop fix income commodity currency ficc staple goldman sachs holding second quarter row poor performance segment
1954,JNJ,bank america bac free report also top estimate cent share beat cent respectively zack consensus tax windfall related sale consumer credit card business help achieve quarterly beat top line be least fifth quarter row post earning beat north carolina base bank major
1955,JNJ,healthcare product retailer johnson johnson jnj free report beat earning estimate cent share quarter revenue miss expect however guidance sale earning fiscal be revise upward earning report help jnj share rise immediately follow result
1956,JNJ,defense contractor giant lockheed martin lmt free report surpass zack consensus earning revenue share beat anticipate quarterly sale beat expect company aeronautic segment grow year year help boost lockheed result quarter share be trading today pre market
1957,JNJ,zack rank buy rate healthcare provider unite health unh free report top earning estimate revenue marginally surpass consensus earning share beat cent quarter sale be smudge expect company have raise forecast fiscal mark least fifth quarter row earning beat share be modestly hour
1958,JNJ,johnson johnson jnj free report report mixed second quarter result earning beat expectation sale miss same however drug consumer product giant raise sale profit outlook send share more pre market trading year so far share price be compare favorably increase witness zack classify large cap pharma industry earning beatj second quarter earning come share beating zack consensus estimate increase year period include time item report second quarter earning share year period sale miss againsale come miss zack consensus estimate sale increase year quarter reflect operational increase negative currency impact organically exclude impact acquisition divestiture sale increase operational basis second quarter sale grow domestic market international market reflect operational growth partially offset negative currency impact sale segment sale decline year year reflect operational growth negative currency impact higher sale international market offset weaker performance sale domestic market decline international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be xarelto stelara invega sustenna however sale invokana invokamet decline also concerta decline zytiga sale fall importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition regard mention pfizer inc pfe free report launch inflectra injection biosimilar version remicade late last november do not have significant impact remicade sale past quarters management be expect comment impact biosimilar second quarter sale conference call pharma segment achieve clinical milestone quarter include fda approval darzalex be used combination celgene corporation celg free report pomalyst pomalidomide dexamethasone third line treatment multiple myeloma importantly last week announce fda approval pipeline candidate guselkumab treatment moderate severe plaque psoriasis drug be market trade name tremfya meanwhile last month complete previously announce acquisition swiss biotech actelion diversify revenuesto pulmonary arterial hypertension pah category actelion pah drug add top line quarter medical device segment sale come year period include operational increase negative currency movement sale gain mainly inclusion abbott medical optic acquisition exclude impact acquisition divestiture operational basis worldwide sale increase sale domestic market rise year year international market sale increase operational increase year year operational growth be drive advanced surgery business product cardiovascular business acuvue contact lense vision care business make weaker sale performance diabetes care consumer segment record revenue report quarter year year operational increase foreign currency movement negatively impact sale segment sale domestic market grow year period slower growth baby care product be partially offset growth counter product meanwhile international segment record decline reflect operational decline negative currency impact guidance raisedj raise earning guidance increase lower end sale outlook expect adjust earning share range include currency impact compare expect previously revenue guidance be range compare expect previouslyour takedespite third consecutive sale miss look optimistic better sale performance second half chief executive officer alex gorsky say sale growth accelerate second half year importantly sale medical device segment be pick make lower sale international consumer pharmaceutical segment quarter sale domestic pharma segment have decelerate year key growth driver have slow due competition quite few product portfolio remicade concerta be face generic competition however believe new product tremfya label expansion drug imbruvica darzalex contribution actelion lead better sale trend remain half year carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quote trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1959,JNJ,novartis ag nvs free report report second quarter core earning share beating zack consensus estimate record figure be penny lower year figure revenue decline volume growth be offset negative impact generic competition pricing beat zack consensus estimate billiona look novartis share price movement last month show stock outperformed zack classify large cap pharma industry share have rally compare gain record industry growth rate mentioned be year year basis constant exchange rate quarter detailnovartis operate segment innovative medicine pharmaceutical alcon ophthalmology unit sandoz generic innovative medicine division record sale generic competition pricing pressure impact sale segment primarily due entry generic gleevec europe nevertheless growth product cosentyx entresto promacta revolade jakavi tafinlar mekinist gilenya boost sale psoriasis cosentyx sale surge back strong growth approve indication entresto too have solid quarter sale benefit continue access improvement expansion sale force reimbursement europe oncology franchise grow drive mainly promacta revolade jakavi tafinlar mekinist sale sandoz division be volume growth be offset price erosion mainly sale decline due pricing pressure retail generic prior year launch timing sale grow mainly drive zarxio sale alcon division be surgical sale increase drive growth cataract consumable vitreoretinal intraocular lense return growth globally vision care sale be fuelled continue double digit growth daily total outlook expect net sale be broadly line level include impact continue genericization gleevec glivec europe management have earlier estimate impact generic competition sale be approximately pipeline updatenovartis pipeline candidate progress have be encourage oncology portfolio continue gain traction breast cancer drug kisqali receive positive chmp opinion first line option hr advanced metastatic breast cancer combination inhibitor europe drug be already approve company also receive fda approval rydapt treatment newly diagnosed flt mutate acute myeloid leukemia aml type systemic mastocytosis addition zykadia receive fda ema approval first line use alk positive advanced small cell lung cancer nsclc tafinlar mekinist receive fda approval treatment braf mutant metastatic nsclc ctl be unanimously recommend approval fda oncologic drug advisory committee july treatment pediatric young adult patient relapse refractory cell acute lymphoblastic leukemia meanwhile cosentyx be grant approval europe label update include week datum clear study demonstrate long term superiority cosentyx compare johnson johnson jnj free report stelara psoriasis sandoz receive approval launch major biosimilar eu erelzi biosimilar amgen inc amgn free report enbrel rixathon biosimilar version roche holding rhhby free report mabthera treat blood cancer immunological disease ema also accept propose biosimilar adalimumab infliximab sandoz generic version asthma drug advair diskus be accept fda novartis ag price ep surprise novartis ag price ep surprise novartis ag quoteour takenovartis second quarter result be encourage company beat earning sale estimate however sandoz performance be disappointing battle pricing pressure first half novartis announce be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company throw more light plan alcon end positive note growth driver cosentyx entresto more offset impact generic erosion mainly due glivec cosentyx hit blockbuster status recent approval kisqali fda panel recommendation ctl also bode well company portfolio zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1960,JNJ,tuesday july expect plethora earning report have hit tape morning include more bigger wall street bank other household brand put simply result be mostly good ultimately mixed thus far let try slog ve find hour goldman sachs gs free report beat estimate top bottom line share be selling follow earning report drastically lower fix income revenue earning share beat zack consensus estimate sale well ahead expect be drop fix income commodity currency ficc staple goldman sachs holding second quarter row poor performance segment bank america bac free report also top estimate cent share beat cent respectively zack consensus tax windfall related sale consumer credit card business help achieve quarterly beat top line be least fifth quarter row post earning beat north carolina base bank major healthcare product retailer johnson johnson jnj free report beat earning estimate cent share quarter revenue miss expect however guidance sale earning fiscal be revise upward earning report help jnj share rise immediately follow result defense contractor giant lockheed martin lmt free report surpass zack consensus earning revenue share beat anticipate quarterly sale beat expect company aeronautic segment grow year year help boost lockheed result quarter share be trading today pre market zack rank buy rate healthcare provider unite health unh free report top earning estimate revenue marginally surpass consensus earning share beat cent quarter sale be smudge expect company have raise forecast fiscal mark least fifth quarter row earning beat share be modestly hour mark vickerysenior editorquestion comment article author click here
1961,JNJ,stock be little change monday investor refrain place big bet ahead busy earning week investor gear key quarterly earning result major player include goldman sachs group inc gs free report bank america corp bac free report microsoft corporation msft free report international business machine corp ibm free report johnson johnson jnj free report qualcomm inc qcom free report ebay inc ebay free report be release week netflix inc nflx free report be expect report earning market close monday dow end red hit record high friday nasdaq be able eke slight gain notch day winning streak look issue currently face market make sure read today ahead wall street article dow jone industrial average dji decline meagre close drop just finish utility lead advancer health care lag tech heavy nasdaq composite index however gain close advance issue outnumber decliner nyse see complete list today zack rank strong buy stock here earningsgiven stock market record run year wall street be keep close eye quarterly earning be excellent earning season turn boost operate earning share trail month improve second quarter economic growth strong manufacturing service survey moderate uptick wage growth be expect help corporate america post relatively high profit margin earning growth be expect be lead energy financial information technology read more wall street see terrific earning top gainer accord estimate total second quarter earning cohort be expect be same period last year higher revenue follow earning growth revenue growth highest least year sam stovall chief investment strategist cfra research further add history show final tally be better actual ep exceed initial estimate last quarters have do so average percentage point move total earning cohort be anticipate increase higher revenue gain higher revenue entire year total earning index be expect be higher revenue be way more earning growth higher revenue record last year read more bank earning spotlight meanwhile world largest asset manager blackrock inc blk free report quarterly profit come expectation blackrock report second quarter adjust earning share lag zack consensus estimate lower expect result be primarily due rise operate expense lower investment advisory performance fee read more blackrock earning lag estimate expense rise stock make headlinesspirit airline june load factor fall trasm view raisedspirit airline save free report see rise traffic measure revenue passenger mile rpms approximately jun year year basis read more qualcomm lose eu case slap daily fine qualcomm inc largest manufacturer wireless chipset base technology have be fine euro day lose court bid european union eu read more trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1962,JNJ,johnson johnson jnj free report bellwether healthcare company have strong presence pharmaceutical medical device consumer care market world new jersey base company be well know baby care product brand tylenol addition drug remicade concerta however many peer jnj be face generic competition pricing pressure product pharmaceutical segment scenario investor focus remain late stage pipeline candidate commercial potential well performance new product apart usual top bottom line number jnj have pretty good earning track record company deliver positive earning surprise last quarters average surprise estimate have remain stable past day currently jnj have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat jnj beat second quarter earning company report ep consensus call ep revenue miss revenue be however slightly expectation johnson johnson post revenue compare consensus estimate key statistic pharmaceutical segment sale decline year year reflect operational growth negative currency impact up view raise sale earning guidance expect adjust earning share range compare expect previously revenue guidance be range compare expect previouslystock price impact share rise more pre market trading check back later full jnj earning report later johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson quote trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1963,JNJ,only company be report week many biggest name street be include technology giant big health insurer element fang not easy beating earning quarter year take mastery business wall street company have master not only do have perfect earning track record chart be best street earning star perfect surprise record netflix nflx free report have beat year row more just earning medium giant investor be watch growth number subscriber cost well lockheed martin lmt free report have be fire defense stock just keep produce earning beat unitedhealth group unh free report have best chart street remember obamacare be go be doom private insurer fact just opposite have happened happen trumpcare johnson johnson jnj free report have be most consistent earning performer dow industrial share recently break set year high visa free report also have best chart street just quietly go business quarter quarter be watch financial sector want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today click here free day trial today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1964,JNJ,achillion pharmaceutical inc achn free report share fall almost market trading tuesday follow announcement johnson johnson jnj free report sell stake company remind investor have terminate global license collaboration agreement achillion develop hepatitis treatment earlier september decision be take part strategy focus area greatest unmet medical need termination agreement be major setback achillion have market drug be dependent fund company have lose future revenue form milestone payment achillion share be so far year underperform industry remain flat period separate press release achillion also announce promising preliminary datum group phase ii study factor inhibitor renal disease candidate demonstrated potential treat glomerulopathy serious renal disease study be evaluate candidate patient immune complex mediate ic mpgn phase ii study be evaluate candidate separate group patient ic mpgn group evaluate dose mg thrice daily day patient proteinurium study also measure ratio fragment intact plasma also decrease rapidly compare baseline course study higher fragment be believe be responsible kidney damage loss function see disease time presently fda approve therapy be available treat however promise show candidate be boost company indicate potential treatment development achillion be currently select patient enrollment group study moreover company have plan initiate separate phase ii study evaluate ic mpgn patient month first half other ic mpgn achillion be also develop paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome dry age related macular degeneration august company have announce positive datum phase ii study pnh patient achillion have plan initiate phase ii study evaluate candidate combination alexion pharmaceutical inc alxn free report soliris potential long term treatment pnh patient already be treat soliris achillion pharmaceutical inc price achillion pharmaceutical inc price achillion pharmaceutical inc quotezack rank key pickachillion carry zack rank buy sucampo pharmaceutical inc be better rank health care stock sporting zack rank strong buy see complete list today zack rank stock here sucampo earning share estimate have increase last day company deliver positive earning surprise trail quarters average beat hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1965,JNJ,johnson johnson jnj free report announce have submit supplemental new drug application snda fda label expansion diabetes drug invokana include cardiovascular indication base datum large canvas outcome program application include indication risk reduction cardiovascular event type ii diabetes patient also apply invokana fix dose combination invokamet invokamet xr filing be base datum canvas program evaluate invokana sglt inhibitor compare placebo cv event type ii diabetes patient have establish cardiovascular cv disease be risk cv disease primary endpoint study be defined major adverse cardiovascular event mace include cv death nonfatal myocardial infarction nonfatal stroke study show invokana be successful reduce risk heart attack stroke canvas program comprise nearly identical large outcome study call canvas canvas however study also show drug increase risk amputation so far year johnson johnson share price have increase compare unfavorably gain record industry belong many pharma company be work hard get label diabetes medicine update include cardiovascular benefit death cardiovascular disease be significantly higher adult diabetes compare diabetes addition positive cv outcome label diabetes drug give sale shot arm eli lilly company lly free report receive fda approval last year include cv risk reduction datum empa reg outcome study label jardiance update label include cardiovascular indication be launch jan american diabetes association ada have also update diabetes treatment guideline european commission also approve jardiance label update cardiovascular indication august nordisk nvo free report victoza liraglutide be approve fda new indication reduce risk major adverse cardiovascular cv event adult type ii diabetes establish cv disease fda decision be base result landmark leader trial demonstrated victoza statistically significantly reduce risk cardiovascular death fatal heart attack fatal stroke versus placebo add standard care absolute risk reduction however merck co inc mrk free report be deny approval fda include cardiovascular outcome datum tecos study label dpp iv inhibitor januvia sitagliptin other medicine contain januvia astrazeneca bydureon also fail reduce cardiovascular risk phase iiib iv cardiovascular outcome study exscel johnson johnson price johnson johnson price johnson johnson quotejohnson johnson carry zack rank sell see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1966,JNJ,integra lifescience holding corporation iart free report have finally come news complete codman neurosurgery business acquisition johnson johnson jnj free report development be expect heel last month major asset divestment initiative company whopping purchase have be consider major breakthrough integra provide company global reach neurosurgery thus connote core expertise company specialty surgical solution integra expect complete say asset divestment soon form part certain close condition codman acquisition notably integra have sign definitive agreement sell company certain neurosurgery asset healthcare product service provider natus medical incorporate baby free report total deal value company have also decide sell global camino icp monitoring product line include san diego manufacturing facility natus medical additionally natus get hold right related integra fix pressure shunt well right codman duraform dural graft implant standard evd catheter csf collection system earlier announce set divestiture natus integra have discuss imminent financial impact company approximately revenue be earn neurosurgery product line associate divestiture take net divestiture codman acquisition account company preliminary basis estimate fourth quarter revenue contribution approximately full year integra expect codman neurosurgery contribute revenue net divestiture overall codman neurosurgery business be anticipate remain accretive integra adjust earning share contribute least cent however full year integra expect minimal contribution codman neurosurgery adjust earning share integra lifescience holding corporation price consensus integra lifescience holding corporation price consensus integra lifescience holding corporation quoteper integra codman neurosurgery exist portfolio new product pipeline advanced hydrocephalus neuro critical care be go complement acquirer lead product pipeline tissue ablation dural repair cranial stabilization post closure buyout consolidated portfolio offer complete solution neurosurgery scale invest well bring new technology table patient worldwide notably report radiant insight global neurosurgery market be project witness estimate cagr take consideration huge growth prospect believe integra initiative strengthen foothold particular niche area be well time overall integra have be consistently trading broader industry last month stock have rally year date thus substantially outperform industry gain period zack rank other key pickintegra currently carry zack rank buy top rank medical stock be idexx laboratory inc idxx free report also carry same bullish zack rank see complete list today zack rank strong buy stock here idexx laboratory have positive earning surprise last quarters stock have roughly surge year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1967,JNJ,late last week merck mrk free report announce decision discontinue development couple candidate hepatitis virus hcv program mk grazoprevir ruzasvir uprifosbuvir mk ruzasvir uprifosbuvir company decision be base review available phase ii efficacy datum grow competition hcv market merck have market product hcv market form zepatier elbasvir grazoprevir bring sale first month include favorable adjustment rebate accrual due mix business merck continue work expand zepatier utilization world uptake be impact ongoing decline overall patient volume many market increase competition gilead abbvie hcv spotlightmerck announcement have now put spotlight firmly gilead science gild free report abbvie abbv free report key player market gilead be undisputed leader hcv market hcv product bring sale first half company revolutionize treatment paradigm hcv market introduction sovaldi cut duration treatment few week instead prior standard care week moreover need peg interferon injection come several side effect be reduce eliminate completely gilead launch harvoni next first once daily single tablet regimen treatment most prevalent hcv genotype unite state be follow launch epclusa first oral pan genotypic single tablet regimen treatment adult genotype chronic hcv infection year gilead gain approval yet hcv treatment vosevi gilead rule hcv market quite few year sale be decline give intense pricing pressure grow competition pricing scrutiny decline patient population approval newer hcv product have result rapid increase number patient be treat cure follow decline number patient seek care be able access hcv treatment gilead expect hcv net product sale range announce result represent quite drop last year hcv product sale meanwhile abbvie hcv product include mavyret glecaprevir pibrentasivr viekira pak ombitasvir paritaprevir ritonavir tablet co package dasabuvir tablet viekira xr dasabuvir ombitasvir paritaprevir ritonavir mavyret be approve recently viekira sale be first half mavyret company next generation hcv offer be meaningful contributor sale other hcv drug include bristol myer squibb company bmy free report daklinza daclastavir janssen therapeutic olysio simeprevir remind investor merck be not only company have take decision halt development hcv candidate last month johnson johnson jnj free report have announce decision terminate collaboration agreement achillion pharmaceutical achn free report hcv janssen pharmaceutical say be discontinue development investigational hcv treatment regimen jnj combination direct act antiviral al odalasvir simeprevir merck drop investigational hcv treatment gilead abbvie benefit lack additional competition enter market least term company continue face challenge decline patient volume intense pricing pressure lack additional entrant market slow rate decline sale gilead have be work expand hcv market encourage baby boomer get test accord company have be increase hcv antibody screening baby boomer start initiative increase testing have lead increase diagnosis person be newly diagnosed hcv represent significant opportunity exist player hcv market gilead abbvie be zack rank hold stock see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1968,JNJ,abbott free report recently announce receipt fda approval freestyle libre flash glucose monitoring system unite state approval be likely widen illinois base medical device major customer base diabetes management company aim make product commercially available person diabetes unite state end flagship product be available major retail pharmacy end user prescription basis meanwhile abbott have be steadily progress development diabetic segment recently company announce receipt national reimbursement freestyle libre mark milestone company notably freestyle libre system be partially fully cover country include france germany japan moreover company recently announce receipt health canada license freestyle libre flash glucose monitoring system drive growth diabetes care sale segment see revenue growth second quarter continue consumer acceptance freestyle libre internationally believe latest fda nod boost company performance domestic arena well expect freestyle libre contribute abbott top line japanese canadian development french health ministry have approve national reimbursement device report mordor intelligence global market diabetes care device be project reach value cagr give bullish market sentiment believe recent regulatory approval freestyle libre have come opportune moment however diabetes market be dominate many well establish player johnson johnson jnj free report be most prominent space johnson johnson also have tie base corporation development insulin delivery system share price have be gain investor confidence consistently positive result last month abbott share price have outperformed broader industry stock have gain contrast broader industry decline company have also outperformed gain market same time frame zack rank key picksabbott carry zack rank hold few better rank medical stock medical sector be orthofix international ofix free report owen minor inc omi free report orthofix international owen minor sport zack rank strong buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month owen minor have long term expect earning growth rate stock have gain last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1969,JNJ,key highlight week include lawsuit file pfizer pfe free report accuse johnson johnson jnj free report adopt exclusionary contract other anticompetitive practice prevent biosimilar uptake meanwhile company glaxosmithkline gsk free report supernus pharmaceutical supn free report be news regulatory pipeline update recap week most important storiessupernus study update supernus provide update first phase iii study spn be be evaluate treatment impulsive aggression ia patient age year have attention deficit hyperactivity disorder adhd base plan interim analysis company have decide drop lower dose mg study patient be randomize receive mg dose placebo investor be disappoint update share be read more supernus drop spn lower dose test phase iii trial chmp positive psoriasis drug tremfya guselkumab get positive opinion eu committee medicinal product human use chmp recommend marketing authorization treatment adult moderate severe plaque psoriasis be candidate systemic therapy timely approval make tremfya first biologic selectively block interleukin il cytokine play key role plaque psoriasis accord information press release person europe be estimate suffer psoriasis tremfya gain fda approval earlier year july pfizer file suit biosimilar pfizer have file lawsuit district court eastern district pennsylvania related provide patient physician access lower cost biosimilar accord lawsuit have adopt exclusionary contract other anticompetitive practice deny access undermine benefit price competition biologic market order maintain monopoly connection remicade infliximab be accuse lawsuit inappropriately exclude biosimilar competitor pfizer have launch inflectra biosimilar version remicade late biosimilar available eu many year be relatively recent entrant unite state be yet have significant impact reference product sale read more pfizer sue accuse prevent inflectra uptake glaxo innoviva copd treatment get fda nod glaxo partner innoviva get boost fda approval once daily single inhaler triple therapy trelegy ellipta treatment appropriate patient chronic obstructive pulmonary disease copd combination inhaled corticosteroid ics long act muscarinic antagonist lama long act beta adrenergic agonist laba trelegy ellipta provide patient convenient dose option be expect bring blockbuster sale read more glaxo innoviva triple combo therapy get fda nod copd glaxo stock have gain year date compare rally industry belong teva divest woman health business teva teva free report recently get new chief executive officer ceo be take step get performance back track company announce sale remain asset specialty global woman health portfolio plan divestiture segment bring total proceed be used teva pay debt decision sell woman health business be part teva effort divest core segment focus key strategic area company also announce amendment usd jpy term loan revolve credit facility teva be currently go tough time company be hit generic pricing erosion company need work pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track roche abbvie cancer drug positive late stage study roche rhhby free report partner abbvie be look expand label cancer therapy venclexta venclyxto result late stage study murano show venclexta rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll independent datum monitoring committee have recommend unblind study base positive result label expansion indication expand patient population venclexta significantly boost commercial potential read more roche announce positive datum leukemia drug roche be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index slip last trading session major stock bristol myer squibb bmy free report gain slip last month bristol myer be glaxo decline see last pharma stock roundup here achillion slump end hcv deal teva get new ceo next pharma world watch usual pipeline regulatory update bristol myer pd inhibitor opdivo be priority review use patient hepatocellular carcinoma hcc prior treatment nexavar sorafenib fda be expect give response sep meanwhile be expect response fda investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor however plivensia fail get support fda arthritis advisory committee safety concern quite likely agency ask additional information grant approval trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1970,JNJ,not news corporate earning be good earning season be spotlight incrementally new positive earning backdrop
1971,JNJ,share expedia inc expe free report decline company chief executive officer dara khosrowshahi announce be join uber ceo biogen inc biib free report share surge follow positive result alzhiemer drug study share gilead science inc gild free report increase enter agreement kite pharma inc acquire company whopping cash johnson johnson jnj free report share increase almost announce favorable result phase study blood thin drug xarelto
1972,JNJ,johnson johnson jnj free report subsidiary janssen announce datum pivotal phase iii study show blood thinner xarelto have significantly reduce major cardiovascular event patient stable coronary peripheral artery disease cad pad study be be currently conduct expand xarelto label rivaroxaban mg twice daily combination aspirin mg once daily versus aspirin alone xarelto be presently market anticoagulant reduce risk stroke blood clot patient atrial fibrillation af not cause heart valve problem be also approve unite state treat deep vein thrombosis vte pulmonary embolism share have outperformed industry year date stock increase industry gain period randomize phase iii compass study part ongoing explorer clinical research program meet primary endpoint datum study demonstrated xarelto aspirin combination reduce combine risk cardiovascular death stroke heart attack patient stable cad pad compare aspirin alone finding also show massive decrease stroke fall cv death trial be conduct center country also pad patient treat combination therapy have significantly fewer major adverse limb event compare take aspirin alone however risk major bleed be find be significantly higher patient receive treatment xarelto aspirin regimen currently be new indication seek study xarelto part explorer clinical development program notably xarelto have be develop partnership bayer ag bayry free report drug be launch more country be market bayer outside unite state company press release cad be find be develop third half middle age populace lifetime develop country estimate approximately adult age year have evidence pad therefore approval xarelto additional indication provide company access huge globally potential market remind investor june announce fda have grant priority review snda xarelto label expansion include mg dose reduce risk recurrent vte xarelto be currently approve mg dose formulation only last month committee medicinal product human use chmp issue positive opinion label update regard use mg once daily dose xarelto combination inhibitor treatment patient valvular atrial fibrillation af require oral anticoagulation undergo percutaneous coronary intervention pci stent placement final decision european commission be expect end johnson johnson pricejohnson johnson price johnson johnson quotezack rank stock considerj currently carry zack rank hold better rank stock pharma sector be aduro biotech inc adro free report acadium pharmaceutical inc acad free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate reduce last day company deliver positive surprise trail quarters average beat acadium loss share estimate narrow last day company come positive earning surprise last quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1973,JNJ,minerva neurosciences inc nerv free report announce amendment license agreement janssen pharmaceutical subsidiary johnson johnson jnj free report related co development orexin receptor antagonist min jnj have be approve eu notably minerva enter agreement janssen june execution be dependent sanction certain term eu subsequently condition have now be meet amendment be expect take effect aug pursuant agreement minerva be entitle receive upfront payment janssen additionally minerva also receive amount start phase iii insomnia study min completion enrollment study also amount have be waive janssen be due minerva phase ii development candidate share minerva have significantly underperform industry year date stock have plunge compare industry decrease period remind investor january company announce positive top line result phase iia study min give indication trial be conduct patient insomnia disorder minerva other pipeline candidate include min currently clinical development major depressive disorder mdd min phase iib study schizophrenia min parkinson disease significantly july minerva complete public offer have generate net proceed approximately company expect fund finance raise public stock offer current financial resource together support clinical study project take place end other pipeline candidate include min minerva neurosciences inc priceminerva neurosciences inc price minerva neurosciences inc quotezack rank stock considerminerva currently carry zack rank buy other stock worth consider pharma sector be aduro biotech inc adro free report acadium pharmaceutical inc acad free report carry zack rank see complete list today zack rank strong buy stock here aduro biotech loss share estimate reduce last day company deliver positive surprise trail quarters average beat acadium loss share estimate narrow last day company come positive earning surprise last quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1974,JNJ,portola pharmaceutical inc ptla free report recently announce fda have accept resubmit biologic license application bla reversal agent factor xa inhibitor andexxa andexanet alfa decision regulatory body be expect feb andexxa have be develop patient treat direct indirect factor xa inhibitor reversal anticoagulation be need due life threaten uncontrolled bleed notably andexxa be also review eu marketing application file third quarter portola share have significantly outperformed industry so far year stock have soar compare broader industry decrease resubmission include additional information request fda complete response letter crl issue portola august last year letter fda have request information related product manufacturing have also ask more datum support inclusion direct factor xa inhibitor lixiana edoxaban indirect factor xa inhibitor lovenox enoxaparin product label remind investor bla be base positive datum phase iii annexa study evaluate safety efficacy andexxa reverse anticoagulant activity factor xa inhibitor xarelto rivaroxaban johnson johnson inc jnj free report eliquis apixaban bristol myer squibb company bmy free report older healthy volunteer significantly andexxa enjoy orphan drug status unite state company press release more patient treat oral factor xa inhibitor be admit hospital due excessive bleed have also be estimate more patient take injectable factor xa inhibitor lovenox unite state benefit antidote year currently approve antidote factor xa inhibitor yet be high unmet need same market go ahead expect investor focus remain further detail andexxa regulatory aspect portola pharmaceutical inc priceportola pharmaceutical inc price portola pharmaceutical inc quotezack rank stock considerportola currently carry zack rank hold better rank stock pharma sector be acadium pharmaceutical inc acad free report carry zack rank buy see complete list today zack rank strong buy stock here acadium loss estimate narrow last day company come positive earning surprise trail quarters average beat simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1975,JNJ,karyopharm therapeutic inc kpti free report announce positive datum phase ii portion phase ii iii seal study demonstrate superiority liposarcoma candidate selinexor improve progression free survival pfs compare placebo company oral selective inhibitor nuclear export compound be be evaluate patient advanced unresectable liposarcoma have receive prior treatment karyopharm share be more wednesday fact share company be have rise year date outperform industry gain datum phase ii study demonstrated selinexor achieve primary endpoint pf pfs reduce risk progression death liposarcoma patient separate assessment world health organization candidate prolong pfs detailed analysis study be present future medical meeting company have already initiate phase iii portion seal study mg selinexor administer patient disease progression intolerability be compare placebo fda approve pfs be primary endpoint study top line datum study be available liposarcoma be rare form cancer occur soft tissue body especially fatty tissue disease be generally treat surgery combination radiation therapy hence oral dose medicine be better option patient however be drug be administer intravenously treat advanced liposarcoma patient include johnson johnson jnj free report yondelis eisai co ltd esaly free report halaven karyopharm be also evaluate selinexor several mid later phase study multiple cancer indication most advanced be phase iii study candidate combination velcade multiple myeloma patient selinexor be also be evaluate patient gynecological malignancy karyopharm therapeutic inc price consensus karyopharm therapeutic inc price consensus karyopharm therapeutic inc quotezack rank stock have zack rank hold alexion pharmaceutical inc alxn free report be better rank stock biotech sector sporting zack rank strong buy see complete list today zack rank stock here alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1976,JNJ,pfizer inc pfe free report have file lawsuit district court allege johnson johnson jnj free report be resort unfair practice prevent sale inflectra pfizer biosimilar version merck co inc mrk free report blockbuster rheumatoid arthritis drug remicade pfizer biosimilar version be available wholesale acquisition cost wac be lower reference product pfizer share be wednesday share be however pfizer share have underperform industry year so far stock have return period compare unfavorably increase industry pfizer allege complaint file district court eastern district pennsylvania have enter biosimilar exclusion contract insurer contract encourage insurer not cover inflectra thereby make easily accessible patient protect reference product pfizer also claim anticompetitive contract be be offer hospital encourage discount purchase remicade condition do not buy biosimilar version pfizer claim unfair practice benefit sale reference product be key revenue generator latter remind investor second quarter conference call hold august pfizer have say inflectra penetration unite state have be slower expect be experience access challenge national commercial payer other hand have say second quarter conference call hold july rate penetration inflectramay be modest latest lawsuit suggest be responsible slow sale inflectra please note april year samsung bioepis biosimilar version remicade also receive fda approval pfizer have launch inflectra unite state november last year biosimilar be also market ex market inflectra generate sale unite state globally second quarter biosimilar be essentially cheaper version expensive biologic drug be complex make traditional generic drug biosimilar have be available eu quite be regulatory pathway biosimilar unite state long time however change pass biologic price competition innovation act bpci act part affordable care act president obama sign law march several pharma well biotech company be involved development biosimilar first biosimilar gain approval unite state be sandoz zarxio biosimilar version amgen inc amgn free report neupogen zarxio be launch unite state september inflectra be second biosimilar gain approval other approve biosimilar country include sandoz erelzi biosimilar amgen enbrel amgen amjevita biosimilar version abbvie humira however have not be launch yet due ongoing litigation earlier month fda approve first cancer biosimilar amgen allergan mvasi biosimilar version roche blockbuster cancer drug avastin biosimilar be expect reduce health care cost provide large number patient access much need biologic treatment however so far biosimilar have not see much commercial success be yet make significant dent reference product sale unite state fight drug giant be likely aid effort lower drug price increase biosimilar availability pfizer carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1977,JNJ,earning season biotech pharma sector kick week industry bellwether johnson johnson jnj free report report second quarter result tomorrow market open swiss pharma giant novartis nvs free report be news recently related favorable fda advisory panel recommendation car cell therapy also be report second quarter result tomorrow jul member index total market capitalization have report result look earning preview article show total earning company be year quarter revenue be far medical sector be concern revenue be expect increase earning be expect decline be contrast first quarter earning rise revenue growth overall sentiment pharma biotech stock have improve significantly investor focuse more fundamental issue drug pricing make sense avoid drug company be sell rank stock do not look well position ahead earning have zero stock have sell rank zack rank sell strong sell have negative earning esp second quarter valeant pharmaceutical international inc vrx free report canada base specialty pharma company valeant have be headline mainly due drug pricing controversy relationship philidor zack rank stock miss earning expectation last quarters revenue expectation first quarter have negative earning esp second quarter company have be work simplify operate model reduce debt be report result aug earning estimate be last day flexion therapeutic inc flxn free report burlington base flexion be specialty pharmaceutical company focuse development novel local therapy treatment patient musculoskeletal condition begin osteoarthritis zack rank stock miss loss estimate last quarters have negative earning esp second quarter loss estimate june quarter be respectively last day flexion be expect report second quarter result aug ignyta inc san diego base ignyta be focuse precision medicine oncology zack rank stock post wider expect loss last quarters have negative earning esp second quarter loss estimate june quarter be respectively last day ignyta be expect report second quarter result aug therapeutic inc anik free report bedford base be global integrate orthopedic medicine company zack rank stock miss first quarter earning estimate have negative earning esp second quarter earning estimate june quarter be last day full year estimate be period be report second quarter result jul year date company share be underperform zack categorize medical biomedical genetic industry be almost uncover best stock buy sell re report earning esp filter see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1978,JNJ,johnson johnson jnj free report healthcare bellwether announce fda have approve pipeline candidate guselkumab treatment moderate severe plaque psoriasis drug be market trade name tremfya drug be approve accelerate process follow filing priority voucher share have gain so far year significantly ahead increase witness zack classify large cap pharma industry come back latest news fda approval be base study phase iii voyage voyage navigate evaluate efficacy safety guselkumab il human monoclonal antibody administer subcutaneous injection treatment adult moderate severe plaque psoriasis datum voyage trial announce earlier have show significantly higher proportion patient moderate severe plaque psoriasis treat guselkumab achieve high rate skin clearance compare receive placebo patient receive guselkumab achieve least clearer skin versus placebo voyage trial evaluate guselkumab versus abbvie inc abbv free report humira study demonstrated statistically significant efficacy guselkumab compare humira week be maintain week treatment almost patient treat humira achieve least clearer skin versus guselkumab navigate study evaluate efficacy safety switch guselkumab moderate severe plaque psoriasis patient be not achieve clear almost clear skin other plaque psoriasis medicine stelara datum study show patient switch guselkumab show significantly greater improvement skin clearance compare patient continue receive stelara company press release american suffer disease overproduction skin cell cause itch pain burn sensation skin tightness hence approval guselkumab have give company access wide patient population guselkumab be review eu japan plaque psoriasis indication phase iii head head study tremfya novartis ag nvs free report cosentyx moderate severe plaque psoriasis be ongoing meanwhile phase ii trial evaluate guselkumab moderate severely active psoriatic arthritis be also ongoing have previously mentioned tremfya have blockbuster potential rake sale more other tremfya expect key pipeline candidate sirukumab rheumatoid arthritis also gain fda approval year sirukumab be also review eu carry zack rank hold better rank stock same space be astrazeneca plc azn free report sporting zack rank strong buy see complete list today zack rank stock here share astrazeneca have rally so far year also earning estimate moved same climb last day earning performance have be pretty impressive well consistent positive surprise company deliver average earning beat last quarters more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1979,JNJ,third quarter report cycle be full swing corporate earning have be reassure so far quarter expect momentum continue go ahead oct member accounting index total market capitalization have report result accord earning preview total earning index member be year quarter improvement revenue growth revenue be impressive ahead previous quarter growth significantly higher quarter average beat ratio be earning revenue more half company have beaten ep revenue estimate report total earning company third quarter be expect grow year year higher revenue meanwhile broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning only big name biotech pharma sector have report thus far johnson johnson jnj free report swiss base novartis ag nvs free report result be better expect company raise sale profit outlook year well novartis also beat estimate revenue earning quarter let take look pharma biotech company be set report third quarter result oct amgen inc amgn free report amgen be schedule release earning market close have deliver positive earning surprise last quarter amgen beat expectation last quarters average positive surprise quarter amgen have earning esp zack rank hold do not conclusively show amgenis likely beat estimate quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter higher demand amgen new drug be expect offset lower sale mature brand company key drug neulasta be face competition newer cancer therapy threat biosimilar also lurk several company be look launch generic version drug read more card amgen earning season glaxosmithkline plc gsk free report london base glaxo be schedule announceresult open bell tomorrow glaxo have beaten estimate last quarters meet same result average positive surprise last report quarter glaxo deliver positive surprise company have earning esp zack rank indicate be poise deliver beat time see complete list today zack rank strong buy stock here glaxo hiv product be expect drive sale pharmaceutical segment quarter moreover newly launch respiratory drug be expect offset decline sale seretide advair avodart meanwhile slowdown consumer segment due market condition impact divesture be expect continue read more glaxo earning deliver beat yet again vertex pharmaceutical incorporate vrtx free report company specially focus cystic fibrosis cf report result tomorrow market close last quarter vertex deliver positive earning surprise company come average positive earning surprise trail quarters company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg cent share approval label expansion cf drug kalydeco unite state august have broaden patient population drive sale drug moreover re imbursement agreement ireland italy orkambi be also positive read more be beat card vertex earning today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1980,JNJ,centene inc cnc free report report third quarter adjust net income share beat zack consensus estimate earning also improve year year primarily back higher revenue operational quarter total revenue grow year year primarily drive growth health insurance marketplace business expansion new program many state be partially offset moratorium health insurer fee lower membership commercial business california revenue surpass zack consensus estimate end quarter manage care membership reflect increase third quarter health benefit ratio hbr quarter be compare prior year quarter improvement basis point bps be result new expand health plan higher hbr increase higher acuity member premium rate reduction california medicaid expansion effective jul third quarter adjust selling general administrative expense ratio be bps year year improvement reflect leverage expense higher revenue total operate expense increase prior year quarter centene corporation price consensus ep surprise centene corporation price consensus ep surprise centene corporation quotefinancial updatea sep centene have cash cash equivalent year end total asset grow year end sep centene long term debt totale year end first month cash inflow operation be compare prior year period guidancecentene expect adjust earning diluted share be range previously guide range total revenue be expect be range compare earlier guidance hbr be expect range unchanged previous guidance adjust selling general administrative expense ratio be expect range unchanged previous guidance diluted share outstanding be expect be zack rank performance other peerscentene currently sport zack rank strong buy see complete list today zack rank stock here other player medical sector have report third quarter earning so far abbott laboratory free report johnson johnson jnj free report unitedhealth group incorporate unh free report beat respective zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1981,JNJ,third quarter report cycle be positive start evident accelerate revenue growth trend meanwhile proportion positive surprise be average quarter also estimate revision trend next quarter have be mostly favorable estimate have actually go past couple week oct member accounting index total market capitalization report result accord latest earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning biotech pharma bigwig only johnson johnson jnj free report have report third quarter result so far report better expect third quarter result raise sale profit outlook sale growth accelerate third quarter lead company post first positive sale surprise almost year here have biotech pharma giant be set report third quarter result oct let see thing be shape quarter eli lilly company lly free report lilly be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning miss expectation last quarters beating same other bring average negative surprise quarter lilly have earning esp zack rank hold zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter new product trulicity cyramza taltz jardiance have support top line past few quarters expect trend continue third quarter well however decline sale alimta cymbalta zyprexa be expect continue due loss exclusivity read more eli lilly report earning store biogen inc biib free report biogen well know name multiple sclerosis ms market be also schedule announce result open bell biogen earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be last quarter company deliver positive earning surprise company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg share see complete list today zack rank strong buy stock here global patient growth be likely drive prescription trend sale biogen ms drug tecfidera however rise competition roche rhhby free report newly launch ms drug ocrevus hurt sale tysabri modestly investor focus also be spinraza performance read more biogen earning deliver beat again novartis ag nvs free report swiss pharma giant be expect report market open last quarter novartis deliver positive earning surprise company post average positive earning surprise trail quarters company have earning esp zack rank zack consensus estimate be peg share new product cosentyx entresto be expect boost top line however loss exclusivity key drug novartis portfolio be expect continue hurt company top line investor focus novartis earning call be update related newly approve car therapy kymriah acute lymphoblastic leukemia read more card novartis earning season make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1982,JNJ,investor seek momentum have vanguard healthcare etf vht free report radar now fund recently hit new week high share vht be approximately week low share be more gain ahead etf let take look fund term outlook get better idea be head vht focusvht focus provide exposure healthcare stock equity market charge basis point fee year have top holding johnson johnson jnj free report pfizer pfe free report unitedhealth unh free report allocation respectively sep see health care etfs here move earning season be strong start company sector beating estimate latest executive order trump aim scrapping key component obamacare president say want end subsidy insurer cost year help million low income american pay medical expense however uncertainty be reduce extent news political party come bipartisan deal start do round senator party say reach deal stabilize obamacare short term allow insurer subsidy turn lead rally healthcare stock more gain ahead currently vht have zack etf rank buy medium risk outlook moreover etf have weight alpha so be promising outlook ahead want ride surge etf shade further want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1983,JNJ,oct issue update report immunogen inc imgn free report immunogen be development stage biotechnology company focuse develop target cancer therapeutic used proprietary antibody drug conjugate adc technology immunogen have make significant progress regard lead pipeline candidate mirvetuximab soravtansine candidate be currently phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer tumor express high medium level fr alpha additionally have receive prior treatment regimen successful development subsequent approval be huge boost company ovarian cancer market represent huge potential notably combination regimen mirvetuximab soravtansine ovarian cancer be phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche avastin merck keytruda immunogen report initial datum forward ii study demonstrate candidate have potential complement currently available therapy indication notably mirvetuximab soravtansine enjoy orphan drug status unite state eu treatment ovarian cancer platinum resistant ovarian cancer market provide immense commercial potential immunogen be set face intense competition approval establish product roche avastin johnson johnson jnj free report doxil also several company be work introduce treatment market target disease apart mirvetuximab soravtansine immunogen be work develop couple other candidate include imgn imgn notably imgn be be evaluate phase study treat acute myeloid leukemia datum expect later year other hand company plan move imgn clinical development year end treat hematological malignancy include acute myeloma leukemia aml immunogen have agreement several big healthcare company include amgen inc bayer eli lilly company lly free report novartis nvs free report roche sanofi takeda contract turn allow other company use immunogen adc technology provide fund form license milestone fee royalty clinical material revenue research development support fee today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1984,JNJ,johnson johnson jnj free report announce european medicine agency ema committee medicinal product human use chmp have grant positive opinion recommend approval pipeline candidate guselkumab treatment moderate severe plaque psoriasis eu drug be approve unite state july year be market trade name tremfya treatment immune system related skin disorder decision european commission ec be expect later year so far year share price have increase compare favorably gain record industry belong application eu be base study phase iii voyage voyage navigate evaluate efficacy safety guselkumab il human monoclonal antibody administer subcutaneous injection treatment adult moderate severe plaque psoriasis datum voyage trial show significantly higher proportion patient moderate severe plaque psoriasis treat guselkumab achieve high rate skin clearance compare receive placebo patient receive guselkumab achieve least clearer skin versus placebo voyage trial evaluate guselkumab versus abbvie inc abbv free report blockbuster drug humira study demonstrated statistically significant efficacy guselkumab compare humira week be maintain week treatment almost patient treat humira achieve least clearer skin versus guselkumab navigate study evaluate efficacy safety switch guselkumab moderate severe plaque psoriasis patient be not achieve clear almost clear skin other plaque psoriasis medicine stelara datum study show patient switch guselkumab show significantly greater improvement skin clearance compare patient continue receive stelara meanwhile phase iii head head study tremfya novartis ag nvs free report cosentyx moderate severe plaque psoriasis be ongoing also phase iii study evaluate guselkumab moderate severely active psoriatic arthritis be also ongoing have previously mentioned tremfya have blockbuster potential rake sale more carry zack rank hold stock considera better rank biotech stock be alexion pharmaceutical inc alxn free report sporting zack rank strong buy see complete list today zack rank stock here share alexion have gain year date zack consensus estimate increase respectively past day new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
1985,JNJ,neos therapeutic inc neos free report announce fda have approve third attention deficit hyperactivity disorder adhd drug adzenys extend release oral suspension patient year older drug be approve once daily treatment company share be friday announcement news stock have outperformed industry so far year neos therapeutic share have rise industry rise same period fda approval give adhd patient option different dosage form other product adhd portfolio include adzenys xr odt orally disintegrate tablet cotempla xr odt adzenys xr odt adzenys be prescription drug stimulate central nervous system cns treat adhd patient year older cotempla xr odt be also cns stimulant treat adhs pediatric patient year company say adzenys xr odt be approve january be fastest grow alternative dosage form product treatment adhd company expect launch drug first half note dosage form adzenys be bioequivalent form shire plc shpg free report adderall xr remind investor shire be market leader adhd segment receive approval new adhd drug mydayis june adzenys xr odt record sale first half register sequential growth second quarter adhd space be largest fastest grow segment market be many drug available indication include johnson johnson jnj free report concerta pfizer inc pfe free report quillivant neos therapeutic inc price consensus neos therapeutic inc price consensus neos therapeutic inc quoteneo therapeutic have zack rank hold see complete list today zack rank strong buy stock here new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
1986,JNJ,america dominant equity market index power past first time sep bull market rage rally have be largely drive rebound technology share rise bank stock upbeat corporate earning stable economic growth also continue buoy investor sentiment benchmark index be mode right now even north korea kim jong couldn stall rally hurricane irma meantime lose steam investor choose ignore perhaps largest ever equifax datum breach earthquake mexico banking such bullish trend investing sound stock list index be judicious push past index flaunt biggest company planet include apple inc aapl free report johnson johnson jnj free report exxon mobil corporation xom free report begin day back foot crawl back end trading session point higher record stock index also capped biggest weekly advance january week rise stock have soar more past year other post world war ii time economic growth national bureau economic research surge bottom july economy be strike great recession mean have invest benchmark index dark day be worth today fact index biggest gain be april march internet related stock moved north index also perform exceptionally well donald trump be elect president post whopping market value trump election last november say howard silverblatt senior index analyst dow jone index tech bank stock propel market time rebound technology share rally bank stock help achieve milestone chipmaker gain traction thank nvidia corporation nvda free report jump record high evercore isi raise price target stock broader technology sector be boost apple iphone maker share increase first gain unveil new iphone sep consumer price meantime rise august biggest month gain january have push year year increase july inflationary pressure firm august bring end successive month soft datum inflation gradually climb fed target level expectation future rate hike strengthen accord cme group be chance fed raise borrow cost december meeting week earlier bank stock gain higher chance interest rate hike month higher longer term interest rate boost bank profit increase spread bank earn funding longer term asset such loan shorter term liability focus robust fundamental investor also continue focus corporate earning be expect increase year least economy continue expand steady pace healthy corporate earningstotal earning member be expect increase same period last year higher revenue year total earning member be expect increase higher revenue follow paltry earning growth higher revenue last year read more earning season get underway solid economic growthwhen come economic growth gdp expand second quarter fastest rate growth more year uptick consumer outlay business investment give economy boost increase spending good service push consumer expenditure say quarter consumer spending biggest driver economy picked higher income consumer low inflation additionally empire state factory gauge hit month new order component report come strong reach highest point october nfib small business optimism index too remain healthy read political ruction hurricane fear subsideinvestor have more less programme ignore north korea tension rogue nation fire missile japan second time month north korea defy effort global nation force abandon course south korea immediately respond conduct simulate strike air base pyongyang white house meanwhile want unite nation impose oil embargo north korea same time freeze kim jong asset response regime sixth nuclear test last week wall street also breathe sigh relief hurricane irma shift direction ease fear widespread devastation florida irma gradually lose strength once make landfall florida key sep be downgrade tropical storm top winnersbanking such positive have select solid stock have not only gain significantly sep also have scope gain further traction stock sport zack rank strong buy buy such stock also boost vgm score here stand value growth momentum score be weight combination metric such score allow eliminate negative aspect stock select winner genworth financial inc gnw free report provide mortgage insurance product allow person purchase home company offer individual group long term care insurance product meet consumer need long term care genworth financial have zack rank vgm score zack consensus estimate current year earning increase last day company gain sep expect growth rate current next quarters be respectively signet jeweler ltd sig free report be retailer diamond jewelry company have zack rank vgm score zack consensus estimate current year earning increase last day company gain sep expect growth rate next quarter be boee co ba free report be aerospace company company segment include commercial airplane defense space security bds such boee military aircraft bma network space system ss global service support gs boee capital bcc boee have zack rank vgm score zack consensus estimate current year earning increase last day company gain sep expect growth rate next quarter be see complete list today zack rank stock here abercrombie fitch co anf free report be specialty retailer primarily sell product store direct consumer operation well various wholesale franchise licensing arrangement company have zack rank vgm score zack consensus estimate current year earning increase last day company gain sep expect growth rate current next quarters be more respectively caterpillar inc cat free report be manufacturer construction mining equipment diesel natural gas engine industrial gas turbine diesel electric locomotive company have zack rank vgm score zack consensus estimate current year earning increase last day company gain sep expect growth rate current next quarters be nearly respectively new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
1987,JNJ,issue update report catalyst pharmaceutical inc cprx free report aug fact catalyst pharma be development stage company focuse development therapy target rare neurological disease disorder such lambert eaton myasthenic syndrome lem epilepsy initially infantile spasm tourette syndrome present coral gable fl base company have candidate development firdapse cpp company expect report top line result second phase iii study firdapse treatment lambert eaton myasthenic syndrome lem second half resubmit new drug application nda end earlier receive refusal file letter fda connection nda firdapse notably agency have determine company nda be insufficient preliminary review consequently catalyst pharma be require conduct additional study agency requirement addition result previously submit phase iii datum oct reach agreement fda special protocol assessment spa protocol design clinical endpoint statistical analysis approach be take second phase iii study evaluate firdapse meanwhile company be work develop firdapse additional indication catalyst initiate investigator sponsored phase ii iii study firdapse symptomatic treatment musk antibody positive mg feb mar company report top line datum phase ii iii trial potential approval firdapse label expansion help generate revenue company additionally catalyst pharma be explore possibility develop cpp gaba inhibitor treatment epilepsy initially infantile spasm treatment other select neurological indication such complex partial seizure tourette disorder however market epilepsy treatment be highly competitive crowd give presence product pfizer pfe free report neurontin lyrica johnson johnson jnj free report topamax novartis nvs free report trileptal zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1988,JNJ,issue update report pacira pharmaceutical inc pcrx free report aug fact share company have rally zack classify industry fall year date basis pacira pharmaceutical inc be specialty pharmaceutical company focuse development manufacture proprietary pharmaceutical product primarily use hospital ambulatory surgery center notably company flagship product exparel be launch product be liposome injection bupivacaine be indicated single dose administration surgical site produce postsurgical analgesia january pacira inked co promotion agreement depuy synthe sale inc market promote use exparel orthopedic procedure market expect collaboration significantly expand use exparel broad range surgical procedure fact parsippany nj base company effort expand exparel label boost sale oral surgery chronic pain be encourage september company have launch exparel oral surgeon community treat pain follow oral maxillofacial procedure currently expect label expansion injection oral surgery benefit oral maxillofacial surgeon prosthodontist endodontist give ability produce analgesia single dose administration day follow surgery prior april company have initiate randomize controlled study exparel total knee arthroplasty tka march company announce positive topline datum study additionally pacira be conduct phase iv study exparel spinal fusion surgery result expect fourth quarter also be launch series phase iv study soft tissue procedure study assess company flagship product part multimodal protocol section colon cancer breast reconstruction surgery meanwhile pacira remain track resubmit supplemental new drug application snda fda later turn seek expansion exparel label include indication administration nerve block snda be base pivotal efficacy study furthermore company announce positive top line datum study july company believe datum study meet requirement fda state complete response letter issue march january pacira sign agreement depuy synthe sale inc subsidiary johnson johnson jnj free report market promote use orthopedic procedure market however pacira drug depocyt sale have be decline downturn be almost first half compare year quarter company also announce discontinue production depocyt due persistent technical issue specific depocyt hence be heavily dependent exparel growth account significant chunk revenue hence decline exparel sale adversely impact company top line pacira pharmaceutical inc price consensus pacira pharmaceutical inc price consensus pacira pharmaceutical inc quotezack rank stock considerpacira currently carry zack rank hold better rank stock health care sector include enzo inc sanofi sny free report enzo sport zack rank strong buy sanofi hold zack rank buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date sanofi earning share estimate increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1989,JNJ,geron corporation gern free report report loss cent share second quarter be narrower zack consensus estimate loss cent year quarter too company have record loss cent share rise hour trading wednesday however so far year geron share have underperform industry share geron rise period industry witness gain quarterly revenue come compare year quarter revenue miss zack consensus estimate revenue comprise royalty license fee revenue receive various imetelstat license agreement research development expense decline due lower cost proportionate share clinical development cost imetelstat general administrative expense decline due reduce consult cost company end quarter cash investment compare end first quarter pipeline updategeron be develop cancer therapy base telomerase inhibitor company currently have candidate pipeline imetelstat be be develop treatment hematologic myeloid malignancy myelofibrosis mf myelodysplastic syndrome mds geron have collaboration johnson johnson jnj free report subsidiary janssen imetelstat sep janssen announce unfavorable finding plan internal reviews initial datum study imetelstat imbark phase ii treatment mf imerge phase ii iii treatment mds however apr geron inform janssen have complete second internal datum review study result review trial be continue imerge janssen say benefit risk profile imetelstat treat patient support continue development lower risk mds indication geron mentioned janssen decide proceed part imerge larger patient phase iii study patient enrollment begin fourth quarter year last month geron announce part imerge be expand enroll additional patient refine mds population confirm clinical benefit safety observed current result imbark result suggest clinical benefit potential overall survival benefit observed support continuation trial modification janssen be expect evaluate mature datum imbark study next year include assessment overall survival last month geron say expect janssen examine overall survival make continuation decision third quarter geron corporation price consensus ep surprise geron corporation price consensus ep surprise geron corporation quotestock considergeron currently carry zack rank hold better rank stocksin pharmaceutical sector be regeneron pharmaceutical inc regn free report alexion pharmaceutical inc alxn free report zack rank strong buy see complete list today zack rank stock here share regeneron have increase year so far earning estimate have increase past day share alexion have rise year so far earning estimate have increase past day simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1990,JNJ,be busy week fda oncologic drug advisory committee odac review several experimental treatment week include novartis nvs free report car cell drug meanwhile french pharma giant sanofi sny free report announce be acquire vaccine company recap week most important storiesfda panel support novartis car drug novartis get huge boost fda advisory panel voting unanimously favor company experimental car cell therapy ctl novartis be look get treatment approve pediatric young adult relapse refractory cell acute lymphoblastic leukemia positive vote be major milestone company become first launch car cell therapy fda follow advisory panel advice ctl be currently priority review advisory panel issue positive recommendation believe chance gain approval be high read more novartis car therapy drug recommend fda panel so far novartis have outperformed zack categorize large cap pharmaceutical industry share gain industry be fda nod psoriasis treatment jnj free report tremfya gain fda approval treatment moderate severe plaque psoriasis make drug first only biologic approve selectively block only il cytokine play key role plaque psoriasis psoriasis market be pretty crowd tremfya demonstrated superior result skin clearance compare humira head head analysis week tremfya be currently late stage study treatment active psoriatic arthritis phase iii program evaluate efficacy compare cosentyx treatment moderate severe plaque psoriasis mar pdufa date pfizer xeljanz label expansion pfizer pfe free report snda xeljanz have be accept review fda response expect mar timely approval make xeljanz first oral janus kinase jak inhibitor be available person live moderately severely active ulcerative colitis uc pfizer also get favorable vote fda advisory panel acute myeloid leukemia aml drug mylotarg newly diagnosed patient final decision fda be sep mylotarg be initially approve be subsequently withdraw market late stage study fail show clinical benefit moreover higher rate fatality result treatment related toxicity be observed mylotarg arm priority review lilly advanced breast cancer drug lilly lly free report get priority review fda cdk inhibitor abemaciclib company be look get abemaciclib approve monotherapy combination therapy fulvestrant patient advanced breast cancer give priority review status lilly get response fda first quarter currently approve cdk inhibitor include pfizer ibrance novartis kisqali read more lilly breast cancer drug get priority review status fda lilly also enter settlement agreement generic player settle patent infringement lawsuit related ciali tadalafil unit dose patent settlement agreement patent be previously set expire apr now end sep ciali be approve treatment erectile dysfunction ed frustrate urinary symptom benign prostatic hyperplasia bph ciali sale be lilly say adcirca tadalafil patent remain protected nov pediatric exclusivity be grant adcirca be approve pulmonary arterial hypertension read more lilly settle patent litigation ciali generic firm sanofi buy vaccine company sanofi fail effort acquire medivation actelion announce be acquire protein science base privately hold vaccine biotech company include upfront payment achievement certain milestone acquisition sanofi be look expand flu portfolio addition egg base vaccine protein science flublok quadrivalent influenza vaccine qiv be approve fda oct be only recombinant protein base flu vaccine approve agency acquisition be schedule close third quarter sanofi be zack rank buy stock see complete list today zack rank strong buy stock here mylan herceptin biosimilar get favorable panel vote mylan myl free report get boost biosimilar version herceptin trastuzumab get favorable recommendation fda advisory panel panel vote support eligible indication reference product include breast cancer metastatic adjuvant setting biosimilar version have be develop collaboration biocon cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock astrazeneca azn free report be lilly gain almost last month astrazeneca be bristol myer be see last pharma stock roundup here mrk keytruda mm combo study clinical hold bayer revise outlook next pharma world watch second quarter earning result company be report jul more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1991,JNJ,strengthen focus image guide volumetric intensity modulate radiotherapy cancer patient varian medical system inc var free report announce have initiate treatment latest halcyon radiotherapy treatment system europe notably treatment be provide year old male head neck cancer belgium base university hospital leuven uz leuven just month hospital have order new system halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide platform receive clearance ce mark european directive allow varian start selling system unite state europe company unveil halcyon radiotherapy treatment system astro conference vienna third quarter notably treatment used halcyon platform be cost effective short duration system have be ergonomically design provide user friendly platform clinical staff patient halcyon fortify varian global footholdvarian have long term goal treat cancer patient year highly exclusive radiotherapy treatment end third quarter management varian announce halcyon have receive order country north america varian strike strategic deal petcure deliver halcyon unit veterinary oncology network management regulatory clearance china japan follow next year furthermore varian receive order halcyon system icon group australia company book several order country india morocco romania russia turkey market prospectsvarian have be take initiative gain customer broad spectrum product especially target emerge market strong revenue opportunity oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership deal be positive varian datum market market reveal global radiotherapy market be project reach worth cagr other company eyee emerge marketsthe ongoing political uncertainty unite state deteriorate economic condition europe automatically shift focus several medtech player emerge geography china india latin america other johnson johnson jnj free report have set manufacturing center brazil china india have be do business china nearly year be expand further back synthe acquisition thermo fisher tmo free report be also leave stone unturned expand presence emerge market company garner total revenue high growth asia pacific emerge market abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strong growth country colombia mexico peru argentina today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1992,JNJ,johnson johnson jnj free report be first large cap pharma stock report earning result season oct beat zack consensus estimate earning revenue third quarter also raise sale profit outlook share be more tuesday sale growth accelerate third quarter lead company post first positive sale surprise almost year higher sale pharmaceutical segment well positive contribution actelion deal pull top line quarter acquire swiss biotech actelion june year overall pharma sector have witness great turnaround year drug pricing issue cripple performance last year decline last year large cap pharma industry have rise year so far outpace gain same time frame new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval new drug approve alone continue strong performance legacy product have play pivotal role bring sector track year factor be likely drive sector rest year probably next challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug better expect result especially strong performance pharmaceutical segment have raise optimism strong quarterly performance pharma sector mainly large cap company let have closer look expect big pharma stock report month early next month company be expect deliver earning beat quarter pfizer inc pfe free report pfizer be schedule announce third quarter result oct market open zack rank hold earning esp chance stock beating zack consensus estimate third quarter be high uncover best stock buy sell re report earning esp filter new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be expect contribute pfizer top line meaningfully however loss exclusivity associate generic competition product pristiq vfend zyvox celebrex expiration few co promotion agreement continue hamper top line growth blockbuster drug enbrel sale continue be soft quarter due biosimilar competition pfizer surpass zack consensus estimate trail quarters show chart pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotebristol myer squibb company bmy free report bristol myer be schedule release result oct market open similar pfizer quantitative model indicate earning beat bristol myer zack rank stock have earning esp see complete list today zack rank strong buy stock here bristol myer high profile immuno oncology drug opdivo be likely drive company top line be report quarter opdivo sale be drive melanoma second line small cell lung cancer renal cell carcinoma indication recent label expansion classical hodgkin lymphoma head neck cancer indication also boost drug sale bristol myer outpaced zack consensus estimate trail quarters reflect chart bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotemerck company inc mrk free report merck be schedule release result oct market open zack rank earning esp chance stock beating zack consensus estimate third quarter be high merck new product keytruda cancer zepatier hcv bridion sugammadex injection likely drive revenue quarter well keytruda sale unite state be gain particularly strong momentum new indication first line lung cancer keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe new approval expand patient population be expect drive sale further however genericization increase competition likely remain overhang merck outpaced zack consensus estimate trail quarters reflect chart merck company inc price ep surprise merck company inc price ep surprise merck company inc plc gsk free report brentford uk base glaxosmithkline be expect report result oct glaxosmithkline be also expect outperform third quarter due zack rank buy earning esp glaxo pharmaceutical vaccine business segment be expect perform well glaxo pharmaceutical segment be expect continue be drive strong sale new hiv product tivicay triumeq however many glaxo key drug lovaza avodart be face decline sale due generic competition moreover sluggish sale growth consumer healthcare segment due slowdown market condition impact divesture negatively impact top line third quarter notably company surpass zack consensus estimate trail quarters show chart glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quoteeli lilly company lly free report eli lillyis slate announce third quarter result oct market open zack rank earning esp chance earning beat be report quarter be high continue trend past few quarters new product trulicity cyramza taltz jardiance be likely support top line report quarter however sluggish performance alimta cymbalta zyprexa be expect continue third quarter due loss exclusivity notably eli lilly surpass zack consensus estimate trail quarters show chart eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotenovartis ag nvs free report swiss company novartis be schedule report result oct market open novartis be not expect beat estimate third quarter due zack rank earning esp recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space moreover new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie humira amgen enbrel cosentyx achieve blockbuster status however weak alcon business generic competition several key drug be expect hurt revenue quarter notably novartis outpaced zack consensus estimate trail quarters reflect chart novartis ag price ep surprise novartis ag price ep surprise novartis ag hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1993,JNJ,fair share buoyancy wall street year be attribute dow jone industrial average blue chip index have be continually hit record high latest be mark touch oct index actually set astounding rally trump crossed new point threshold fourth time year top first time year history nov apart occasional dip trump policy related uncertainty be look back year index hit more record high result spdr dow jone industrial average etf dium free report be year oct instrumental stocksstock act tailwind last month be like boee company ba free report unitedhealth group inc unh free report johnson johnson jnj free report apple aapl free report mcdonald mcd free report oct international business machine corp ibm free report major component dium post beat line jnj too beat zack consensus estimate earning sale unitedhealth comfortably beat zack consensus estimate membership growth lead outperformance unh jnj be oct ibm add more hour trump tax reform proposal end september trump reveal much talk tax plan suggest comprehensive tax cut individual corporation key suggestion be cut corporate tax rate slash number individual tax bracket goldman see earning company get boost bank america lynch believe new rate benefit earning quite expectedly dow jone exhibit nice stretch hope tax reform read etfs benefit trump tax plan upswing manufacturing sectordomestic factory activity jump more year high september thank higher new order uptick manufacturing number act strong tailwind dow jone industrial average forward growth opinion dow jone base etf dium invest weight highest allocation industrial sector read etfs play upbeat global manufacturing good news oil patch furthermore have be noticed lately dow jone share deep relationship oil price movement energy sector rally spread optimism broader market whole most case particular day oil surge spurt dow jone be steeper vice versa such scenario american petroleum institute api record steep drawdown barrel crude oil inventory platt analyst survey expect stockpile fall barrel week end oct etfs be benefit other diainvestor note leverage dow etf play favore investor obvious reason choice be proshare ultra dow ddm free report proshare ultrapro dow udow free report dow jone related fund outperformed base fund spy last month read minute guide most popular leverage etfs want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1994,JNJ,biogen inc biib free report well know name multiple sclerosis ms market surpass expectation earning sale second quarter drugmaker also raise revenue guidance sale newest drug spinraza spinal muscular atrophy witness faster expect adoption share biogen rise almost pre market trading response strong result however note biogen share have inched so far year compare unfavorably industry increase biogen report second quarter earning share beat zack consensus estimate however earning decrease year year sale come year period sale also surpass zack consensus estimate top line exclude hemophilia revenue grow year year company spun hemophilia business february quarter detail biogen ms revenue grow year year second quarter stable global share tecfidera sale rally year period drug record sequential surge revenue include sale ex sale tecfidera revenue benefit seasonal recovery unit volume discount well allowance second quarter tysabri revenue be flat year year same decrease sequentially ex note tysabri revenue first quarter benefit approximately ex market due agreement price reimbursement committee italian national medicine agency aifa related tysabri sale benefit be miss second quarter lead sequential decline combine interferon revenue avonex plegridy second quarter be ex year period avonex revenue decline year period plegridy contribute second quarter revenue year year sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well higher discount allowance zinbryta launch collaboration abbvie inc abbv free report august last year contribute revenue second quarter compare first quarter newly launch spinraza bring revenue revenue second quarter register massive growth sequentially drug witness strong demand spinraza revenue include approximately related inventory build company be work expand access patient notably jun spinraza be grant marketing authorization eu treatment spinal muscular atrophy sma be also approve japan canada recently quarter biogen record biosimilar revenue compare first quarter company market benepali biosimilar reference amgen inc amgn free report enbrel europe benepali record revenue thus register growth rate sequentially biogen also market flixabi biosimilar reference johnson johnson jnj free report blockbuster drug remicade record revenue report quarter compare first quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period second quarter spend soar report quarter sg spend decrease year year quarter company repurchase share worth share repurchase program outlookbiogen raise earning revenue outlook biogen now expect earning range share old guidance share revenue be now expect range comapr earlier guidance increase prior guidance be primarily attribute faster anticipate adoption spinraza term percentage total revenue company sg expense be expect be respectively biogen inc price consensus ep surprisebiogen inc price consensus ep surprise biogen inc quotezack rankbiogen currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1995,JNJ,be enter peak period second quarter report cycle week quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview beat revenue earning estimate compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig johnson johnson jnj free report report mixed second quarter result beating earning miss sale other hand novartis nvs free report second quarter result be encourage company top earning sale estimate jul lilly lly free report biogen inc biib free report release second quarter result company beat earning revenue estimate lilly raise previously issue adjust earning sale outlook biogen also raise earning sale outlook let take look pharma giant be set report second quarter result jul let see thing be shape quarter gilead science inc gild free report gilead be schedule release earning close bell have deliver positive earning surprise last quarter gilead earning performance have be mixed earning miss expectation last quarters beating remain result average positive surprise quarter gilead have earning esp zack rank hold indicate likely beat quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter hiv other antiviral product be expect boost sale however hcv franchise continue be pricing pressure read more be gilead poise beat earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotevertex pharmaceutical inc vrtx free report vertex be also schedule announce result close bell vertex average positive earning surprise last quarters be last report quarter vertex post positive surprise company have earning esp zack rank strong buy be thus expect beat earning estimate quarter see complete list today zack rank stock here investor focus vertex second conference call be triple combination cystic fibrosis cf regimen be crucial long term growth vertex datum vx vx phase ii vx phase triple combination study present last week have show combination lead pronounce improvement lung function read more be beat card vertex earning vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate plc gsk free report company be expect report market hour glaxosmithkline report line earning last quarter glaxo performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank glaxo pharmaceutical vaccine segment be expect drive sale second quarter well meanwhile consumer healthcare segment have slow due impact general sale tax continue slowdown nutrition category india challenge economic condition other international market nigerian beverage business divestment factor impact second quarter result well read more lie store glaxo earning season glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quotemore stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1996,JNJ,geron corporation gern free report be expect report second quarter result next week company earning come line zack consensus estimate last report quarter let see thing be shape upcoming announcement geron share outperformed industry rise so far year industry witness gain focus imetelstat geron have approve product portfolio top line solely comprise license fee royalty such scenario investor focus remain company sole pipeline candidate imetelstat geron collaboration johnson johnson jnj free report janssen biotech be develop candidate treat patient hematologic myeloid malignancy myelofibrosis mf myelodysplastic syndrome mds acute myelogenous leukemia aml april geron provide positive update late stage study imetelstat imbark phase ii treatment myelofibrosis mf imerge phase ii iii treatment myelodysplastic syndrome mds owing favourable update trial be continue unmodified geron inform janssen have complete second internal review datum study imbark imerge imetelstat janssen say benefit risk profile imetelstat treat patient support continue development lower risk mds indication imbark latest clinical benefit potential overall survival benefit observed support continuation trial modification trial assess safety efficacy imetelstat treatment relapse refractory mds also include assessment overall survival also datum suggest mg kg be appropriate start dose studyjanssen be expect take decision regard initiation phase iii stage imerge study later year decision regard continue development imetelstat relapse refractory mf indication next year expect company provide update path forward imetelstat development program second quarter conference call surprise historygeron performance last quarters have be mixed company surpass expectation thrice meeting same once average positive surprise last quarters be geron corporation price ep surprise geron corporation price ep surprise geron corporation quoteearning whispersour proven model do not conclusively show geron be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank geron zack rank increase predictive power esp esp make surprise prediction difficult quarter note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be couple health care stock want consider model show have right combination element post earning beat quarter arena pharmaceutical inc arna free report be expect release result aug company have earning esp zack rank see complete list today zack rank stock here vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1997,JNJ,benchmark turn mixed performance monday be largely due fact bond yield increase lead investor exit utility telecom stock also sale johnson johnson fall release new drug renflexis merck co also weigh dow other hand nasdaq end green tech rally continue ahead major earning sector slate week dow jone industrial average djia decline point close index inx fall slide point close apart nasdaq composite index ixic close add point total share be trade monday lower last session average share decline issue outnumber advancer nyse ratio nasdaq ratio favore advancer bond yield go utility yield year treasury note increase have negative ramification safe haven such utility telecom selloff bond be responsible surge rate lead investor offload utility telecom stock favor safer fix income counterpart result weigh index johnson johnson disappoint share price tankshare johnson johnson jnj free report fall monday be largely due fact merck co mrk free report together south korean partner samsung bioepis co ltd have start selling renflexis less expensive alternative version johnson johnson rheumatoid arthritis drug remicade unite state drug sell astounding discount list price remicade move be tout bring price widely sell medicine general trend price generic medicine show once multiple biosimilar drug become accessible price drop rapidly due stiff competition rival furthermore come jolt healthcare heavyweight pfizer inc launch inflectra late last year percent discount list price later drop discount tech stock show stellar close record high monday primarily due splendid performance broad base gain technology stock come just earning release faang stock such amazon com inc amzn free report facebook fb free report be due later week year facebook apple inc aapl free report amazon netflix inc nflx free report alphabet inc googl free report have gain primary reason nasdaq recent gain have be splendid performance netflix share jump add subscriber july exist home sale exist home sale have take hit due acute shortage property time demand be high house be sale market last month skid year median house price have also increase year time additionally national association realtor announce monday exist home sale drop unit last month stock make headlinescore laboratory earning top estimate sale lagcore laboratory clb free report report second quarter adjust diluted earning share surpass zack consensus estimate read more hibbett dim view eclipse entry ecommerce stock fallshibbett sport inc hibb free report announce comparable store sale comp second quarter fiscal fall much read more more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1998,JNJ,second quarter report cycle seem have get good start abundance positive surprise particularly revenue front meanwhile earning revenue growth also better expectation jul member accounting index total market capitalization report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig only johnson johnson jnj free report swiss company novartis ag nvs free report have report so far report mixed second quarter result beating earning miss sale be third consecutive sale miss due slowdown pharmaceutical product sale however be optimistic sale growth accelerate second half other hand novartis second quarter result be encourage company beat earning sale estimate however sandoz performance be disappointing due pricing pressure here have pharma giant be set report second quarter result jul let see thing be shape quarter eli lilly company lly free report lilly be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning miss expectation last quarters beating other result average negative surprise eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quarter lilly have earning esp zack rank buy zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter new product trulicity cyramza taltz jardiance have support top line past few quarters expect trend continue second quarter well however decline sale alimta cymbalta zyprexa be expect continue due loss exclusivity read more be beat card eli lilly earning previous article show lilly be likely beat earning quarter however estimate change thereafter be not certain beat earning season biogen inc biib free report biogen well know name multiple sclerosis ms market be also schedule announce result open bell biogen earning performance have be pretty impressive so far have deliver back back positive surprise average earning beat last quarters be last quarter company deliver positive earning surprise biogen inc price ep surprise biogen inc price ep surprise biogen inc company have earning esp zack rank hold see complete list today zack rank strong buy stock here biogen expect relatively stable demand key ms drug tecfidera tysabri patient growth ex market offset modest decline due rise competition drug roche ocrevus read more biogen keep earning streak alive amgen inc amgn free report biotech giant be expect report market hour amgen deliver positive earning surprise last quarter amgen performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be amgen inc price ep surprise amgen inc price ep surprise amgen inc company have earning esp zack rank amgen growth drug prolium xgeva continue do well biosimilar competition slowdown sale mature product put pressure sale growth read more amgen report earning card more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1999,JNJ,illinois base global medical device company abbott laboratory free report partner bigfoot biomedical solidify footprint rapidly grow diabetes therapeutic market leverage abbott freestyle libre glucose sense technology collaboration result innovation marketing insulin delivery system alliance help company develop patient friendly insulin delivery system calibration glucose sensor management important trial combine technological system be project initiate clinical research site abbott have be move steadily development diabetic segment recently company announce receipt health canada license freestyle libre flash glucose monitoring system further stimulate growth diabetes care sale segment be first quarter continue consumer acceptance freestyle libre internationally expect freestyle libre further contribute abbott top line canadian development french health ministry recently approve national reimbursement device report mordor intelligence global market diabetes care device be project value witness cagr moreover insulin delivery device market be expect see cagr roughly thus consider market potential abbott current development diabetes care segment collaboration seem be lucrative strategically align believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth diabetes market however market be dominate many well establish player johnson johnson jnj free report be most prominent space johnson johnson also have tie base corporation successfully develop innovate insulin delivery system moreover abbott have be gain investor confidence consistent positive result past month company share price have outperformed zack categorize medical instrument sub industry stock have gain higher broader industry gain company have also outperformed gain market same time frame zack rank other key picksabbott currently have zack rank buy few other top rank medical stock be edward lifescience corporation ew free report abiom inc abmd free report notably edward lifescience sport zack rank strong buy abiom carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month abiom have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2000,JNJ,good news be here investing friend earning result be not only clear present result be better expect most household name stock ahead bell morning quarter rife stress nation capital natural disaster here abroad other stock market headwind stronger expect earning be provide good tonic morning goldman sachs gs free report tear cover ball figuratively speaking wall street investment giant easily surpass top bottom line estimate share beat expect revenue top zack consensus estimate be also higher record year quarter mark fourth quarter last goldman sachs have beaten earning estimate quarter trail average morgan stanley ms free report also beat expectation earning revenue investment bank top line bring versus expect earning share cent easily outpace cent anticipate investment banking revenue particular grow company household product giant johnson johnson jnj free report beat earning estimate solid dime share top line result also come expectation versus zack consensus guidance fiscal be also raise pharma sale quarter grow impressive fifth straight earning beat least unite healthcare unh free report also post positive surprise ahead today open bell share best expect revenue quarter rise year year growth medical enrollment other side street harley davidson hog free report illustrated difficulty today market just meeting cent share expect zack consensus year result sale do top expect number be report baby boomer buy fewer bike look be culprit here related news peter fonda be year old new import export result import export price beat expectation morning last month consensus well unrevised headline previous month export perform even better opposed expect import year year be line export be time last year more grist interest rate hike mill know fed be pay attention
2001,JNJ,tuesday october good news be here investing friend earning result be not only clear present result be better expect most household name stock ahead bell morning quarter rife stress nation capital natural disaster here abroad other stock market headwind stronger expect earning be provide good tonic morning goldman sachs gs free report tear cover ball figuratively speaking wall street investment giant easily surpass top bottom line estimate share beat expect revenue top zack consensus estimate be also higher record year quarter mark fourth quarter last goldman sachs have beaten earning estimate quarter trail average morgan stanley ms free report also beat expectation earning revenue investment bank top line bring versus expect earning share cent easily outpace cent anticipate investment banking revenue particular grow company household product giant johnson johnson jnj free report beat earning estimate solid dime share top line result also come expectation versus zack consensus guidance fiscal be also raise pharma sale quarter grow impressive fifth straight earning beat least unite healthcare unh free report also post positive surprise ahead today open bell share best expect revenue quarter rise year year growth medical enrollment other side street harley davidson hog free report illustrated difficulty today market just meeting cent share expect zack consensus year result sale do top expect number be report baby boomer buy fewer bike look be culprit here related news peter fonda be year old new import export result import export price beat expectation morning last month consensus well unrevised headline previous month export perform even better opposed expect import year year be line export be time last year more grist interest rate hike mill know fed be pay attention mark vickerysenior editorquestion comment article author click here today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2002,JNJ,achillion pharmaceutical inc achn free report report loss cent share second quarter line zack consensus estimate year quarter company have report loss cent share company generate revenue report quarter have be case year quarter share achillion surge almost hour trading aug company announce positive interim result most advanced factor inhibitor pipeline candidate however stock have underperform industry year date company share lose industry register increase research development expense increase nearly year period due increase clinical trial cost related pipeline candidate increase expense also include higher manufacturing cost related cost related ophthalmic factor inhibitor compound development however increase be partially offset decrease cost related manufacturing general administrative expense be due increase corporate legal fee consult fee partially offset decrease corporate taxe pipeline updatein april achillion initiate patient dose phase ii study evaluate key pipeline candidate factor inhibitor treatment patient paroxysmal nocturnal hemoglobinurium pnh company complete month dose quarter enter long term extension trial interim result study announce together earning release show clinically meaningful complement inhibition favorable tolerability profile candidate have show improvement ldh hemoglobin fatigue score other marker response moreover company plan initiate phase ii study later year patient rare renal disorder include dense deposit disease ddd gn meanwhile achillion be plan advance number next generation factor inhibitor preclinical clinical study end also achillion be evaluate triple combination simeprevir odalasvir al phase ii omega study patient hcv genotype infection cirrhosis study be be conduct johnson johnson jnj free report subsidiary janssen datum expect second half achillion pharmaceutical inc price consensus ep surprise achillion pharmaceutical inc price consensus ep surprise achillion pharmaceutical inc quotezack rank stock pharma carry zack rank hold couple better rank stock pharma sector include summit therapeutic plc smmt free report enzo inc stock carry zack rank buy see complete list today zack rank strong buy stock here summit loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat share price be so far year enzo loss estimate narrow cent cent last day company come positive earning surprise trail quarters average beat stock be so far year more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2003,JNJ,second quarter earning season be near last leg picture so far appear be quite encourage few turbulent quarters earning second quarter show solid strength aug approximately company index total market capitalization have report result deep look result show earning company report be year year higher revenue have top earning estimate have beat revenue estimate result blended beat growth second quarter come back strong contribution finance technology energy sector growth be expect persist second half well even pace growth have be sluggish total earning index be currently same period last year higher revenue much better earning growth project start quarter go forward estimate growth be project start july do medical sector perform medical sector have more less combat overall decline financial market maintain momentum so far company sector have report result earning be higher revenue result blended beat industry bellwether johnson johnson jnj free report report mixed second quarter result beating earning miss sale estimate biotech giant gilead science gild free report biogen inc surpass expectation earning sale second quarter raise annual guidance let take look pharma biotech company be set report second quarter result aug acadium pharmaceutical inc acad free report be schedule report close bell company have dismal track record acadium have miss estimate trail quarters beat once report line result remain quarter result average negative surprise currently company have zack rank hold earning esp current rank increase predictive power esp esp make unlikely stock beat estimate quarter uncover best stock buy sell re report earning esp filter fda approval nuplazid apr be major boost company drug be approve treatment hallucination delusion associate parkinson disease psychosis drug have show promising growth launch read more acadium pull surprise earning season acadium pharmaceutical inc price ep surprise acadium pharmaceutical inc price ep surprise acadium pharmaceutical inc quotejazz pharmaceutical public limit company jazz free report be schedule report result close bell jazz have encourage earning track record company have top estimate last quarters average positive earning surprise currently company have zack rank earning esp investor focus be performance jazz lead product xyrem cataplexy excessive daytime sleepiness investor also be look company pipeline progress defitelio sale ramp xyrem face issue related patent litigation company business development plan be also expect draw attention read more jazz pharma spring surprise earning jazz pharmaceutical plc price ep surprise jazz pharmaceutical plc price ep surprise jazz pharmaceutical plc quotekite pharma inc be expect report result market open company have mixed record earning surprise have report positive earning surprise negative surprise other last fourquarter bring average surprise positive currently company have zack rank esp approve product portfolio investor focus primarily be kite pharma cash burn pipeline update kite pharma lead drug axicabtagene ciloleucel be currently priority review treat aggressive hodgkin lymphoma fda decision expect nov read more card kite pharma earning kite pharma inc price ep surprise kite pharma inc price ep surprise kite pharma inc plc mnk free report be set report second quarter result mallinckrodt have deliver average positive earning surprise trail quarters mallinckrodt currently carry have zack rank esp combination mallinckrodt zack rank positive esp make reasonably optimistic earning beat mallinckrodt be currently focuse reshape product portfolio strategic acquisition core asset divestiture acthar ofirmev inomax drive upside view however mallinckrodt specialty generic segment continue be laggard weakness be expect persist stiff competition continue hurt volume price read more mallinckrodt deliver beat earning season mallinckrodt plc price ep surprise mallinckrodt plc price ep surprise mallinckrodt plc quoteendo international plc endp free report be expect report second quarter open bell company have deliver positive surprise trail quarters record average positive surprise endo currently carry zack rank sell esp caution stock zack rank strong sell go earning announcement continue be challenge year endo generic base business legacy brand pain franchise be expect decline further further jul endo have withdraw opioid pain medication opana oxymorphone hydrochloride extend release market follow fda request june move come wake widespread opioid abuse epidemic read more card endo earning season endo international plc price ep surprise endo international plc price ep surprise endo international plc quote trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2004,JNJ,total earning total healthcare market capitalization be revenue growth earning growth be weak compare many other sector earning revenue beat ratio respectively be particularly encourage fact healthcare be fourth sector surprised investor most earning trail aerospace technology material most notable player johnson johnson jnj free report be first major drug company report earning july follow eli lilly company lly free report bristol myer squibb company bmy free report july july respectively other major drug company merck mrk free report pfizer pfe free report report july august respectively industry prime post solid result earning beat few lag revenue front johnson johnson earning world biggest maker healthcare product continue long streak earning beat narrowly miss top line estimate earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate johnson johnson raise full year earning share guidance revenue guidance zack consensus estimate be peg earning share revenue time earning release jnj have gain date earning announcement read brighten outlook healthcare etfs focus pfizer earning drug giant beat earning miss revenue earning share cent come couple cent zack consensus estimate revenue fall shy estimate annual basis earning share rise revenue decline pfizer expect revenue range raise lower end earning share guidance zack consensus estimate be correctly peg revenue earning share share pfe be earning announcement merck earning focusearning share come surpass zack consensus estimate cent improve year quarter revenue inched year year be zack consensus estimate merck raise revenue guidance reiterate earning share projection year zack consensus estimate be currently peg revenue earning share stock have lose follow earning announcement bristol myer earning focusbristol myer report earning share cent penny ahead estimate increase year quarter revenue grow edge past zack consensus estimate company raise low end earning share guidance year zack consensus estimate time earning announcement be peg share bmy be date earning announcement see healthcare etfs here eli lilly earning focusearning eli lilly outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue earning guidance now expect revenue range compare previous expectation earning share range versus expect previously zack consensus estimate time earning release be peg revenue earning share share lly have lose earning release etf string earning beat fail boost pharma etfs see rough trading past day have highlighted detail powershare dynamic pharmaceutical fund pjp be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see moderate volume share day fund charge bps fee expense hold stock fund invest share focus firm etf have lose past day have zack etf rank hold rating high risk outlook read lie ahead pharma etfs second half ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top hold basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed past day have zack etf rank buy rating high risk outlook spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period have zack etf rank high risk outlook vaneck vector pharmaceutical etf etf follow mvis list pharmaceutical index hold stock basket johnson johnson take top spot basket asset pfizer bristol myer merck eli lilly collectively account asset product have amassed asset base trade moderate volume share day expense ratio come fund have lose past day have zack etf rank medium risk outlook read etfs buy avoid healthcare bill failure want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2005,JNJ,week company pfizer pfe free report allergan agn free report teva teva free report report second quarter result pfizer report mixed quarter allergan top expectation teva however have tough quarter meanwhile bristol myer bmy free report announce immune oncology io focuse deal include acquisition recap week most important storiesa look earning result big company pfizer allergan teva report second quarter result week pfizer surpass earning estimate miss revenue raise concern company top line growth prospect prevnar enbrel sale decline quarter pfizer be face key loss exclusivity loe viagra later year lyrica end read more pfizer surpass earning estimate miss sale meanwhile allergan top earning sale estimate raise outlook well read more allergan earning sale top restasis sale teva share fall dismal quarter company miss earning sale reflect performance generic business continue deterioration venezuela generic business be hit accelerate price erosion lower volume mainly due customer consolidation higher competition delay new product launch teva lower outlook year slash dividend well company also expect exit market globe year end be cut headcount close actavis generic business deal teva have lose value year date versus decline industry abbvie drug get fda nod cgvhd johnson johnson jnj free report abbvie btk inhibitor imbruvica gain fda approval first cancer indication chronic graft versus host disease cgvhd adult failure more systemic line therapy make imbruvica first only approve treatment patient population mark sixth indication imbruvica stock have gain year date outperform rally industry belong bristol myer acquisition deal worth bristol myer announce be acquire ifm therapeutic venture backed biotech company work treatment modulate novel target innate immune system treat cancer autoimmunity inflammatory disorder acquisition bristol myer gain full right ifm preclinical sting stimulator interferon gene nlrp agonist program be focuse cancer sting agonist program include lead asset nlrp agonist program include potential first class pipeline candidate acquisition schedule close third quarter strengthen bristol myer immune oncology io pipeline deal see bristol myer shell upfront additional payment be make first product program achievement certain milestone additional milestone payment be make further product result program bristol myer sign io focuse deal week company sign clinical collaboration agreement clovis oncology immunotherapy opdivo be evaluate combination clovis parp inhibitor rubraca mid late stage study different type tumor meanwhile opdivo label be expand week treatment adult pediatric year older patient microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc have progressed follow treatment oxaliplatin irinotecan accelerate approval be grant basis overall response rate orr duration response however note merck keytruda gain approval earlier year patient msi dmmr wider patient population merck label include patient solid tumor have progressed follow prior treatment have satisfactory alternative treatment option well colorectal cancer patient disease have progressed follow treatment certain chemotherapy drug ra drug fail get fda advisory panel support investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor fail get support fda arthritis advisory committee safety concern company be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person fda be not require do so usually follow advice advisory panel consider safety concern raise panel agency well ask additional information grant approval pfizer drug get advisory panel support pfizer supplemental new drug application snda jak inhibitor xeljanz mg twice daily xeljanz xr mg once daily treatment adult patient active psoriatic arthritis psa get support fda arthritis advisory committee advisory panel vote favor approve propose dose xeljanz psa indication decision fda be dec xeljanz currently approve ra bring sale first half priority review astrazeneca btk inhibitor astrazeneca azn free report investigational btk inhibitor acalabrutinib be grant priority review fda company be look get drug approve use patient relapse refractory mantle cell lymphoma mcl have receive least prior therapy response agency be expect first quarter acalabrutinib be also give breakthrough therapy designation btd indication astrazeneca imfinzi also get btd week treatment patient locally advanced unresectable small cell lung cancer nsclc disease have not progressed follow platinum base chemoradiation therapy positive datum lilly migraine drug lilly lly free report present late stage datum investigational migraine drug lasmiditan say meet primary endpoint well key secondary endpoint result be consistent result present earlier late stage study lilly expect file fda approval second half lilly be zack rank buy stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock pfizer be lilly lose last month be astrazeneca gain see last pharma stock roundup here nvs earning merck drug get tentative fda nod next pharma world watch usual pipeline regulatory update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2006,JNJ,pacira pharmaceutical inc pcrx free report incur second quarter loss cent share include impact stock base compensation wider zack consensus estimate loss cent year loss cent higher cost soft revenue hurt earning quarter revenue rise year year miss zack consensus estimate revenue be estimate higher exparel revenue be offset lower other product collaboration revenue however company remain encourage progress johnson johnson jnj free report partnership co promote exparel enter jan sale medical education team actively support exparel orthopedic space pacira share price have increase year date compare zack classify industry gain quarter detailpacira top line comprise product revenue collaborative licensing milestone revenue royalty revenue exparel generate revenue year year depocyt other product revenue come collaborative licensing milestone revenue be royalty revenue be research development expense include impact stock base compensation be selling general administrative sg expense increase recent company remain track resubmit supplemental new drug application snda fda later seek expansion exparel label include indication administration nerve block snda be base pivotal efficacy study company believe datum study meet requirement fda state complete response letter issue mar pacira be also evaluation exparel treatment total knee arthroplasty tka mar company announce positive topline datum phase iv study study meet co primary endpoint postsurgical pain opioid reduction active comparator bupivacaine exparel group achieve statistically significant reduction curve auc visual analog scale vas score compare do not receive exparel outlookpacira reiterate guidance project exparel sale range expense exclude stock base compensation be expect band sg expense exclude stock base compensation be anticipate be range also stock base compensation be expect be range pacira pharmaceutical inc price consensus ep surprise pacira pharmaceutical inc price consensus ep surprise pacira pharmaceutical inc quotezack rank stock considerpacira currently carry zack rank sell better rank pharma stock same space include exelixis inc exel free report enzo inc exelixis enzo sport zack rank buy see complete list today zack rank strong buy stock here exelixis pull positive earning surprise trail quarters average beat share price company have increase year date enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2007,JNJ,astrazeneca plc azn free report announce have enter agreement dispose theremaining right anaesthetic medicine aspen global incorporate agi mauritian subsidiary aspen group upfront consideration remind investor astrazeneca have divest right anaesthetic medicine outside market agi collaboration agreement sign june new deal agi acquire remain right intellectual property manufacturing know related astrazeneca anaesthetic medicine comprise diprivan emla xylocaine xylocard xyloproct marcaine naropin carbocaine citanest meanwhile astrazeneca continue manufacture supply medicine agi next year also company be entitle sale base milestone payment sep nov however new agreement agi not pay royalty astrazeneca be condition older agreement notably new deal be expect close fourth quarter so far year astrazeneca share have gain compare favorably industry growth astrazeneca have be regularly divest core asset marketing right treatment so focus resource main therapy area include oncology respiratory june company sell global right migraine treatment drug zomig outside japan grnenthal german pharmaceutical company march sell right inhaled respiratory medicine tudorza duaklir copd circassia pharmaceutical also enter deal sanofi sny vaccine unit sanofi pasteur development medi prevention respiratory syncytial virus rsv associate illness newborn infant same month again february enter agreement tersera therapeutic selling commercial right zoladex unite state canada last year astrazeneca divest outside right rhinocort aqua nasal spray indicated allergic allergic rhinitis affiliate johnson johnson jnj free report global right develop commercialize experimental crohn disease drug medi allergan plc agn free report right brand well authorize generic verison beta blocker heart medicine toprol xl aralez pharmaceutical inc astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2008,JNJ,abbvie inc abbv free report be schedule release second quarter earning open bell jul abbvie share have rally so far year industry have record increase last quarter company deliver positive surprise note abbvie earning history be mixed bag pharmaceutical company deliver positive surprise last quarters record line earning other average earning beat last quarters be abbvie inc price ep surpriseabbvie inc price ep surprise abbvie inc quotelet see thing be shape company quarter factor considerat first quarter conference call management reveal expect second quarter earning range share revenue be expect grow report basis currency headwind be expect hurt revenue company key drug humira be likely remain main growth driver second quarter increase awareness favorable clinical datum additional indication expansion new market be expect help product continue make significant contribution top line quarter abbvie also expect humira sale growth mid high teen range internationally humira sale be expect rise mid single digit range operational basis humira be do well company be concern product long term prospect owing potential biosimilar competition area focus be performance imbruvica add abbvie portfolio follow acquisition pharmacyclic drug record strong sale past few quarters trend expect continue imbruvica have multus dollar potential company be look expand drug label solid tumor autoimmune disease company expect imbruvica sale growth approach second quarter imbruvica have huge commercial potential investor know revenue be share johnson johnson jnj free report have collaboration agreement pharmacyclic other drug duopa creon be also expect continue perform well soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue be adversely impact intense pricing competitive pressure hcv market notably last month company announce committee medicinal product human use chmp recommend marketing approval investigational hepatitis virus hcv combo regimen glecaprevir pibrentasvir candidate be market trade name maviret decision european commission be expect third quarter approval definitely provide company stronger presence competitive dynamic hcv market earning whispersour proven model do not conclusively show abbvie be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp abbvie be most accurate estimate be peg share zack consensus estimate stand higher uncover best stock buy sell re report earning esp filter zack rank abbvie zack rank increase predictive power esp earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be better rank health care stock want consider model show have right combination element post earning beat quarter nordisk nvo free report be schedule release result aug company have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report schedule release result aug have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2009,JNJ,pfizer inc pfe free report report second quarter adjust earning share cent beat zack consensus estimate cent earning also rise year year other hand revenue miss expectation pharma heavyweight deliver revenue fall short zack consensus estimate again revenue decline year period due currency headwind divestiture hospira infusion system business feb pfizer divest hospira infusion system business icu medical sale detailcurrency movement impact pfizer second quarter revenue sale growth be flat operational basis exclude revenue sale rise operational basis lower sale enbrel prevnar prevenar vaccine franchise loss exclusivity product offset strong performance key product ibrance breast cancer xtandi prostate cancer xeljanz rheumatoid arthritis international revenue decline flat operational basis meanwhile revenue be flat segment second quarter pfizer reorganize report segment pfizer innovative health ih pfizer essential health pfizer ih sale grow operationally year period pfizer ih revenue be drive persistently strong momentum ibrance eliquis globally growth lyrica xeljanz primarily ibrance revenue rise quarter xeljanz rise lyrica sale rise eliquis alliance revenue direct sale rise revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow sep medivation acquisition also propel revenue xtandi record alliance revenue quarter compare first quarter be partially offset continue decline revenue prevnar lower revenue enbrel viagra enbrel revenue decline key european market due biosimilar competition pfizer have exclusive right amgen inc amgn free report blockbuster rheumatoid arthritis ra drug enbrel outside canada viagra sale decline due lower sale international market due reduce demand global prevnar prevenar revenue decline prevnar revenue tank due high initial capture rate eligible adult patient population follow successful launch result smaller remain catch opportunity second quarter compare year quarter unfavorable timing government purchase pediatric indication also hurt sale eucrisa crisaborole topical ointment treatment atopic dermatitis eczema be buy part jun anacor acquisition be launch first quarter ointment record sale second quarter consumer healthcare revenue rise global oncology revenue surge drive ibrance global vaccine revenue decline internal medicine rise inflammation immunology franchise decline additionally portfolio rare disease decline pfizer segment sale record decline operationally exclude revenue sale decline revenue be hurt loss exclusivity associate generic competition product pristiq generic version launch mar vfend zyvox celebrex lyrica lower revenue legacy hospira product divesture however business biosimilar do well quarter pfizer launch inflectra biosimilar version johnson johnson jnj free report merck co inc mrk free report blockbuster ra drug remicade november last year inflectra record sale globally other biosimilar bring sale outside market adjust selling informational administrative si expense be flat operationally quarter adjust expense rise guidance pfizer raise lower end adjust earning guidance retain revenue expectation year revenue be expect range adjust earning share be expect range compare expect previously higher previously anticipate royalty income certain product lower interest cost lead increase lower end profit outlook mid point revenue be expect be slightly level adjust ep be expect increase previously research development expense be still expect range si spending be project range key drug key pipeline candidate bavencio avelumab receive accelerate fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer candidate be be study different type cancer include several combination therapy other immuno oncology agent pipeline candidate besponsa inotuzumab ozogamicin be approve eu june monotherapy relapse refractory cd positive cell precursor acute lymphoblastic leukemia candidate be review fda decision expect later month takepfizer second quarter result be mixed beat earning estimate miss same sale share decline slightly pre market trading company continue struggle sale performance pfizer share be so far year compare unfavorably increase industry pfizer continue face headwind form genericization key drug lose alliance revenue pricing pressure rise competition be hurt top line product viagra lyrica chantix lose exclusivity couple year nonetheless believe new product ibrance contribution acquisition cost cut effort share buyback help company achieve guidance pfizer also boast strong pipeline expect approximately drug approval next year include product have blockbuster potential bavencio be be consider key long term growth driver pfizer pfizer carry zack rank hold see complete list today zack rank strong buy stock here pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2010,JNJ,fda approve treatment last year have give approval drug so far include july key approval year include gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month august new indication bristol myer opdivo bristol myer squibb bmy free report be look get label pd inhibitor expand use patient mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer crc prior oxaliplatin irinotecan base chemotherapy regulatory application be currently priority review response expect aug opidivo be currently approve wide range indication bring sale first half bristol myer have lose value year date ytd versus growth industry ra drug support fda panel fda arthritis advisory committee be meeting tomorrow discuss bla johnson johnson jnj free report investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor company be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person new treatment option have enter market last couple decade ra patient be still not adequately manage many left fewer therapeutic option due loss response available agent poor compliance due inconvenient dose earlier week fda have release briefing document meeting indicate lot emphasis be place safety profile drug especially imbalance cause death plivensia placebo approve plivensia enter pretty crowd market give presence drug humira actemra kevzara other once monthly dose schedule give advantage share have gain ytd outperform industry rally fda follow eu path give green signal abbvie maviret abbvie abbv free report also have important regulatory event come fda expect respond approval status company latest hepatitis virus hcv offer month maviret investigational pan genotypic regimen glecaprevir pibrentasvir be once daily ribavirin free treatment have potential provide faster path virologic cure major hcv genotype gt maviret represent blockbuster potential help abbvie gain major market share once approve launch note maviret gain eu approval just last week share abbvie have gain ytd outperform industry rally third time lucky dynavax heplisav be great week clinical stage immunology company dynavax technology corp dvax free report get favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult positive vote be third time lucky company have previously receive complete response letter heplisav nov other feb fda decision agency be expect aug approve dynavax plan launch vaccine early next year dynavax share shot positive panel vote be whopping ytd significantly outperform industry rally pfizer xeljanz be review fda advisory panelpfizer pfe free report have regulatory event month first be fda advisory panel meeting other pdufa date fda arthritis advisory committee be meeting aug discuss supplemental new drug application snda submit company jak inhibitor xeljanz xeljanz xr treatment adult patient active psoriatic arthritis efficacy safety datum benefit risk consideration be discuss panel xeljanz currently approve ra bring sale meanwhile fda be expect give response regard approval status pfizer besponsa recently gain approval eu approve besponsa provide new treatment option adult patient relapse refractory cell precursor acute lymphoblastic leukemia aggressive type blood cancer poor prognosis adult accord information provide pfizer year overall survival rate patient relapse refractory adult be less pfizer stock have gain ytd lag industry belong pfizer be zack rank hold stock see complete list today zack rank strong buy stock here other fda decision schedule month include response regard agio pharmaceutical inc agio free report partner celgene celg free report idhifa priority review relapse refractory acute myeloid leukemia aml idh mutation aug meanwhile fda be expect decide approval status valeant eye drug vesneo latanoprostene bunod ad treatment levodopa induced dyskinesia person parkinson disease aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2011,JNJ,dow continue trade tight band week dominate earning investor refrain post big bet monday lead index end mostly unchanged earning result guide dow fortune next trading day week however be deal retail major lead loss key component hence index thursday last week dow close record high third time row last friday stock index register record close year increase tech stock gain jpmorgan chase co jpm free report citigroup free report well fargo wfc free report post better expect earning result share banking behemoth fall report decline trading sale investor also digest couple poor economic report retail sale inflation lead market participant believe federal reserve turn dovish index gain last week even major benchmark post solid gain index overcome series bottleneck tech overvaluation fear russia involvement election climb back record territory dow index decline meager monday investor refrain place big bet ahead busy earning week investor gear key quarterly earning result major player be slate release week index decline tuesday weigh goldman sachs group inc gs free report share banking behemoth slip report staggering drop second quarter bond trading revenue meanwhile share netflix inc nflx free report hit record high follow larger expect subscriber addition second quarter netflix gain help other benchmark close green dow gain wednesday benchmark close record high wednesday boost partly broad base gain technology share meanwhile ibm corp ibm free report disappointing quarterly result limit dow advance nevertheless blue chip index still manage finish record high deal sear holding corp shld amazon com inc amzn free report weigh home improvement retailer thursday turn drag dow lower home depot inc hd free report lose however share microsoft corp msft free report gain momentum expectation better expect quarterly result banking strong cloud performance tax benefit component move index american express company axp free report report adjust earning share ep beating zack consensus estimate cent however earning witness sharp year year decline stock have zack rank hold better expect result be mainly backed lower tax rate effect share buyback however compare year year bottom line suffer year earning reflect gain record sale costco wholesale corp cost co brand portfolio company reaffirm earlier ep guidance revenue come slightly ahead zack consensus estimate year year read american express earning beat view intact goldman sachs report earning share beating zack consensus estimate further bottom line witness year year improvement zack rank strong sell rate goldman net revenue edge year year quarter review however revenue outpaced zack consensus estimate result be primarily drive higher equity revenue low expense however lower fix income revenue be headwind notably quarter witness challenge market make environment reduce level volatility low client activity level read goldman equity revenue low cost drive earning ibm report second quarter gaap earning share increase year quarter beat zack consensus estimate cent revenue miss zack consensus estimate decrease year year constant currency cc revenue decline however revenue improve sequentially zack rank rate ibm reiterate forecast gaap earning be expect be least share company now anticipate free cash flow remain flat read ibm beat earning revenue outlook unimpressive unitedhealth group inc unh report second quarter net operate earning share comfortably beating zack consensus estimate increase year year zack rank buy rate unitedhealth post net revenue line zack consensus estimate revenue be year year company raise outlook gaap net earning range share previous guidance adjust net earning range share versus previous guidance stock have zack rank buy see complete list today zack rank strong buy stock here johnson johnson jnj free report second quarter earning come share beating zack consensus estimate increase year period include time item report second quarter earning share year period sale come miss zack consensus estimate sale increase year quarter reflect operational increase negative currency impact raise earning guidance increase lower end sale outlook expect adjust earning share range include currency impact compare expect previously revenue guidance be range compare expect previously read beat earning lag sale up view traveler company inc trv free report second quarter core income share miss zack consensus estimate also bottom line deteriorate year year total revenue zack rank sell rate traveler improve nearly year quarter revenue surpass zack consensus estimate read traveler earning miss revenue beat estimate jpmorgan chase report second quarter earning share easily surpass zack consensus estimate also figure reflect rise year period notably result include legal benefit stock have zack rank manage net revenue quarter be year quarter also compare favorably zack consensus estimate solid loan growth higher interest rate support net interest income further investment banking fee record rise read jpmorgan earning beat loan growth higher rate performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week dow fortune be likely be guide earning result upcoming week well be also safe assume policy related development not have major impact market proceedings future such event investor turn key economic release guidance day ahead release schedule next week be datum housing durable order gdp report be likely influence market direction heavily day ahead make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2012,JNJ,johnson johnson jnj free report bellwether healthcare company have strong presence pharmaceutical medical device consumer care market world new jersey base company be well know baby care product brand tylenol addition drug remicade concerta however many peer jnj be face generic competition pricing pressure product pharmaceutical segment scenario investor focus remain late stage pipeline candidate commercial potential well performance new product apart usual top bottom line number jnj have pretty good earning track record company deliver positive earning surprise last quarters average surprise estimate have go slightly past day currently jnj have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat jnj beat third quarter earning company report ep consensus call ep revenue beat revenue be also expectation johnson johnson post revenue compare consensus estimate higher sale new product well positive contribution recent acquisition actelion pull top line quarter key statistic pharmaceutical segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market up view raise adjust earning sale outlook year expect adjust earning share range compare expect previously revenue guidance be raise range compare expect previously stock price impact share rise pre market trading johnson johnson price consensus johnson johnson price consensus johnson johnson quotecheck back later full jnj earning report later look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2013,JNJ,earning season kick high gear week many big name dow component name want know be happen certain industry be sure tune week earning healthcare railroad chemical restaurant advertising big financial be just few industry be represent big name be bellwether stock report set tone industry possibly even broader market company have best earning chart week not easy beat consensus quarter quarter company be able do keep streak alive quarter start earning season bang best earning chart start week unitedhealth group unh free report have best look chart wall street period hasn miss year share be high doesn have exposure obamacare exchange so set continue ascent csx csx free report have only miss once year railroad be always first railroad report have have own company specific problem quarter not be much bellwether quarter johnson johnson jnj free report just keep chug take perfect year record earning season share look want break beat propel higher omnicom group omc free report have perfect year record share be high now advertising be usually first signal recession do weak share signal morgan stanley ms free report have miss just twice last year share be year high keep momentum want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today free click here join dave more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2014,JNJ,janssen subsidiary johnson johnson jnj free report announce fda have approve label expansion plaque psoriasis drug stelara use adolescent year age older drug be approve adult indication company believe label expansion be significant achievement plaque psoriasis develop age year approximately third patient moreover number treatment available adolescent be limit patient be administer only dose year starter dose stelara have become lead therapeutic option share company be so far year almost line industry performance industry have gain same time frame latest approval stelara be base datum phase iii study evaluate subcutaneous administration drug adolescent patient datum show drug achieve minimal psoriasis clear skin least third patient safety datum be also consistent be achieve adult patient be almost person suffering psoriasis unite state american academy dermatology moreover national center biotechnology information state majority psoriasis patient suffer plaque psoriasis number represent huge opportunity drug follow label expansion moreover approval stelara have gain edge compete drug abbvie inc abbv free report humira novartis ag cosentyx celgene corporation celg free report otezla be only approve adult plaque psoriasis patient however pfizer inc pfe free report enbrel compete stelara adolescent segment johnson johnson price consensus johnson johnson price consensus johnson johnson quotejohnson johnson carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2015,JNJ,few month line republican complete full year power unfortunately political power change healthcare community hasn have many opportunity rejoice survey report gallup analytic last month reveal adult cite healthcare second major problem face country new presidential administration fact debate repeal affordable care act aca obamacare have be rage now report peaked reach congress august consider prevailing uncertainty implementation health policy respite term seem unlikely medtech unite state blur pictureneedless say current crisis medtech industry integral part broader healthcare space show sign abate few month back company space be hopeful promise cancellation medtech tax obamacare new government unquestionably latest political development have land medtech space uncertain territory investor be mull retain exist medtech stock forego holding favor company other industry boost financial resource say spite future hold believe investor stick medtech space have show sign prosperity recent time globally yes read right even consider dull performance medical device market still hold lead position almost third world market share rise regulatory legislative uncertainty global growth have be quite encourage industry grow pace last see financial crisis emerge market hold immense uncertainty unite state worsening economic condition europe automatically shift focus emerge geography china india latin america other emerge economy be see rise uptake medical device largely due grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage make market happy hunting ground global medical device player add rise healthcare spending improve healthcare infrastructure growth continue go recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india medtech market fifth largest world be currently demonstrate annual growth continue india give good competition japan germany other emerge geography latin america even face general economic stagnation hold enormous potential january report medtech intelligence central south american nation significantly increase capita spending healthcare period accord world bank datum guatemala increase spending brazil chile colombia uruguay paraguay ecuador lower domestic production latin america have make open market exporter investment emerge market player look sensiblein such scenario believe be wise investor be keen medtech stock keep eye company have turn emerge market happy hunting ground expertise network wonder stock cash enormous growth potential emerge geography have perfectly shield political turmoil unite state let look few medtech player significant emerge market presence give huge potential region long back johnson johnson jnj free report have set manufacturing center brazil china india company medical device segment emerge market be grow time faster develop market have be do business china nearly year be expand further here back synthe acquisition johnson johnson price consensus johnson johnson price consensus chart johnson johnson quote abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina abbott laboratory price consensus abbott laboratory price consensus chart abbott laboratory quote medtronic mdt free report last report first quarter fiscal business china latin america southeast asia show sustain strength grow double digit overall medtronic remain confident long term outlook emerge market company be focuse develop new public private partnership well execute channel optimization strategy medtronic plc price consensus medtronic plc price consensus chart medtronic plc quote boston scientific bsx free report emerge market business register organic growth second quarter significant increase growth business china be once again remarkable year year company be currently look forward much better performance ahead china banking recent approval synergy china boston scientific corporation price consensus boston scientific corporation price consensus chart boston scientific corporation quote thermo fisher tmo free report too be leave stone unturned expand presence emerge market company garner total revenue high growth asia pacific emerge market thermo fisher scientific inc price consensus thermo fisher scientific inc price consensus chart thermo fisher scientific inc quote wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2016,JNJ,johnson johnson jnj free report healthcare bellwether report third quarter result oct open bell last quarter company report positive earning surprise share have gain so far year underperform increase witness zack classify industry company have consistently surpass earning expectation earning beat expectation last quarters average positive surprise let see thing be shape announcement factor considerat conference call chief executive officer alex gorsky have say company sale earning growth accelerate second half year organically exclude acquisition divestiture purchase price adjustment sale grow first half year company expect organic sale growth second half year pharma segment be expect benefit easier comp third fourth quarters compare first half continue growth imbruvica darzalex new product launch tremfy approve unite state july plaque psoriasis better performance stelara well xarelto meaningful contribution swiss biotech actelion buy june positive offset loss sale drug invokana due higher manage care discounting however biosimilar competition be expect continue hurt key arthritis drug remicade sale outside unite state management be expect comment pfizer inc pfe lawsuit be file district court recently lawsuit pfizer allege be resort unfair practice prevent sale inflectra pfizer biosimilar version remicade be launch unite state november last year remind investor conference call have say rate penetration inflectra be modest medical device segment increase contribution new product strong growth vision care be expect lead better sale trend however weaker macroeconomic dynamic consumer category geographic market continue put pressure sale consumer segment meanwhile investor call management also provide update complete response letter crl receive rheumatoid arthritis candidate sirukumab last month want additional safety datum model proven model do not conclusively show be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be uncover best stock buy sell re report earning esp filter zack rank zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considera couple stock large cap pharma sector have positive earning esp favorable zack rank be eli lilly company lly have earning esp zack rank company be schedule release result oct pfizer inc pfe be schedule release result oct company have earning esp zack rank see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2017,JNJ,market notch record high follow release federal open market committee minute wednesday minute clearly indicated rate hike december moreover minute state majority fed official vote favor rate hike meanwhile dow post time record close support rally share johnson johnson mcdonald dow jone industrial average djia close gain index inx increase close meanwhile nasdaq composite index ixic close increase advance issue outnumber decliner nyse nasdaq advancer outnumber decliner cboe vix decrease close benchmark finished record dow gather point wednesday notch time record close such gain be buoy rally share johnson johnson jnj free report mcdonald corp mcd free report gain respectively blue chip index have advanced so far year see complete list today zack rank strong buy stock here amassed almost point hit record close major sector end gain real estate utility lead advancer real estate select sector spdr xlre utility select sector spdr etf xlu advanced respectively fed minute confirm rate hike decemberminute federal open market committee fomc release wednesday confirm rate hike december third instance federal reserve official remain largely divide raise interest rate majority banker vouch favor raise rate one debate increase rate reason hike rate time inflation be lower target indication healthy economy cause major setback economy such persistent disagreement fed official make difficult investor understand future rate hike unfold meanwhile majority policymaker opined impact hurricane harvey irma have economy likely fade short time further also comment inflation soon hit target rate meeting end fed choose leave interest rate unchanged range decide start unwinding balance sheet much anticipate unwinding humungous balance sheet fed be announce federal reserve open market committee last month fed be slate begin gradual unwinding process month plan trim asset month however fed panel announce rate hike end further hike expert therefore speculate come december fed meet final time year end moreover recent speech cleveland fed chairwoman janet yellen caution raise interest rate gradually reason lead overheat economy also financial instability such claim yellen be second kansa city fed president george say wait inflation rate hit level rather turn be mistake stock make raise guidance september traffic fallallegiant travel company algt free report have report traffic number september read more jetblue september traffic fall hurricane mar jetblue airway corporation jblu free report report unimpressive traffic datum month september read more delta air line earning beat view impressivedelta air line inc dal free report begin third quarter earning season airline space bright note read more wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2018,JNJ,second quarter earning season pharma sector kick week industry bellwether johnson johnson jnj free report swiss pharma giant novartis nvs free report report result meanwhile merck mrk free report gain tentative approval fda follow biologic basal insulin company launch immediately due ongoing patent infringement case recap week most important storiesa look novartis result industry bellwether swiss pharma giant novartis report second quarter result earlier week surpass earning expectation revenue fall short company raise outlook year operational sale growth expect accelerate second half factor help include earlier launch tremfya more moderate erosion remicade business compare previous expectation well continue strong performance key drug contribution new product medical device segment be also expect pick back half year strong growth vision care segment expect continue consumer segment however continue be impact weaker macroeconomic dynamic read more beat earning lag sale up view novartis second quarter result be better expect company beating earning revenue entresto cosentyx continue perform well sandoz sale decline reflect pricing pressure meanwhile alcon performance improve encourage company raise alcon sale outlook low single digit growth read more novartis top earning sandoz face pricing pressure novartis stock have gain year date outperform rally industry belong tentative approval merck follow basal insulin merck get tentative approval fda biosimilar version sanofi sny free report blockbuster diabetes drug lantus lusduna nexvue insulin glargine injection technically follow biologic basal insulin have be develop merck funding samsung bioepis however merck have launch product due automatic month stay result patent infringement lawsuit initiate sanofi sep merck launch product expiry stay period favorable court ruling occur first note biosimilar version lantus be already market form lilly lly free report boehringer ingelheim basaglar enter market mid dec lantus sale decline first quarter include decline reflect lower average net price patient switch toujeo impact formulary exclusion pricing pressure increase once merck product enter market sanofi merck be zack rank buy stock see complete list today zack rank strong buy stock here sanofi nanobody deal ablynx sanofi have enter research collaboration global exclusive licensing agreement belgian company ablynx focuse development nanobody base therapeutic treatment various immune mediate inflammatory disease deal sanofi gain access certain nanobody ablynx exist portfolio well ablynx scientist proprietary nanobody platform sanofi make upfront payment other financial detail include milestone payment well tiered royalty collaboration sanofi be look expand drug discovery pipeline immunology eu nod astrazeneca kyntheum astrazeneca azn free report psoriasis treatment kyntheum gain approval eu iceland liechtenstein norway company say partner leo pharma gain approval use biologic medicine treatment moderate severe plaque psoriasis adult be candidate systemic therapy kyntheum be approve trade name siliq feb black box warning regard risk patient suicidal thought behavior cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock astrazeneca be gain last month astrazeneca be gain see last pharma stock roundup here fda panel vote novartis car drug sny buy vaccine co next pharma world watch second quarter earning result company lilly bristol myer bmy free report astrazeneca other make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2019,JNJ,earning season have commence johnson johnson jnj free report be first drug company report earning july open bell world biggest maker health care product continue long streak earning beat offer upbeat outlook full year however lag revenue estimate again sluggish drug sale result detailearning share come cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate weak drug sale arthritis treatment remicade diabetes medicine invokana cancer drug zytiga be company top selling treatment be responsible revenue miss johnson johnson raise full year earning share guidance revenue guidance expect sale profitability pick second half year strong demand newer pricey treatment such cancer drug darzalex imbruvica zack consensus estimate be currently peg earning share revenue see healthcare etfs here market impactfollow result share jnj rise close july currently stock have zack rank buy vgm score further johnson johnson belong solid industry zack rank top result investor closely watch movement stock keep close eye etfs have largest allocation diversify drug maker have highlighted health care select sector spdr fund xlv free report most popular healthcare etf xlv follow health care select sector index fund manage nearly asset base trade heavy volume share expense ratio come annually total fund hold security basket jnj take top spot asset pharma account share sector look biotech healthcare provider service healthcare equipment supply make double digit exposure have zack etf rank strong buy rating medium risk outlook read top rank healthcare etfs long term investor ishare healthcare etf iyh free report fund offer exposure security tracking dow jone health care index here again johnson johnson dominate fund return total asset term industrial exposure pharma take top spot follow biotech healthcare equipment product have amassed nearly asset base charge bps annual fee trade good volume share day have zack etf rank medium risk outlook vanguard health care etf vht free report etf track msci investable market health care index hold stock basket johnson johnson take top spot allocation pharma take largest share biotech healthcare equipment round top spot vht be also popular liquid etfs aum average daily volume share charge bps annual fee have zack etf rank medium risk outlook fidelity msci health care index etf fhlc free report fund provide exposure healthcare stock aum be do tracking msci usa imi health care index here too jnj be top firm nearly allocation pharma account share biotech healthcare equipment supply healthcare provider service round top spot double digit exposure etf have expense ratio volume be good share day fhlc have zack etf rank hold rating medium risk outlook ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index johnson johnson be top firm accounting share product have aum charge bps fee expense volume be lower exchange share day fund have zack etf rank buy rating high risk outlook read lie ahead pharma etfs second half want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2020,JNJ,share johnson johnson jnj free report gain company second quarter earning come share beating zack consensus estimate share bank america corp bac free report fall company sale trading revenue fall second quarter adversely affected slide fix income divisionshare unitedhealth group inc unh free report increase company report second quarter net operate earning share comfortably beating zack consensus estimate share chipotle grill inc cmg free report drop company confirm several customer fall ill eating outlet virginia
2021,JNJ,gilead science inc gild free report announce fda have approve vosevi sovaldi velpatasvir mg voxilaprevir mg tablet drug be single tablet regimen str re treatment chronic hepatitis virus hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sovaldi contain regimen ns inhibitor approval come back positive datum phase iii study polaris polaris study study evaluate week vosevi direct act antiviral experience chronic hcv infected patient cirrhosis compensate cirrhosis however vosevi have be warn product label regard risk hepatitis virus hbv reactivation hcv hbv co infected patient nevertheless approval make vosevi first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor approval be expect boost gilead strong hcv portfolio gilead have strong presence hcv market due blockbuster hcv drug sovaldi harvoni sovaldi continue be very important product company harvoni label have be expand twice approval be now approve use broader range patient population hcv portfolio get huge boost epclusa gain approval jun eu jul become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection initial uptake epclusa have be encourage formulary reviews be track gilead expect launch epclusa other large eu market once pricing reimbursement be place second half boost sale further last month committee medicinal product human use chmp adopt positive opinion company marketing authorization application maa vosevi follow accelerate assessment procedure gilead hcv franchise be pressure due intense competition pricing issue hcv product sale be weaker expect mainly due fewer new patient start harvoni lower revenue patient harvoni sovaldi epclusa have be face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report daklinza johnson johnson jnj free report olysio company expect persistent decline hcv patient start be primary factor year year decrease revenue increase competition impact patient share pricing share gilead have underperform zack classify medical biomedical genetic industry year so far stock lose period industry gain nevertheless hiv franchise gilead be perform well be expect help company combat persistent decline hcv franchise zack rank gilead currently carry zack rank hold see complete list today zack rank stock here look stock skyrocket upsizack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2022,JNJ,have already crossed halfway mark second quarter report cycle earn season have show broad base growth record earning quarter jul member accounting index total market capitalization report result accord earning preview company beat count compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue medical segment have also perform well so far earning increase revenue report total earning company second quarter be expect grow year year higher revenue plenty result still come actual earning growth quarter exceed mark follow earning growth first quarter increase revenue highest almost year johnson johnson jnj free report begin earning season pharma sector mixed second quarter result performance novartis nvs free report lilly lly free report biogen inc biib free report be encourage company beat earning revenue estimate lilly biogen also raise earning revenue estimate other pharma bigwig report last week abbvie inc abbv free report report better expect result earning sale surpass expectation lymphoma drug imbruvica record record growth merck co inc mrk free report also beat estimate earning sale second quarter mainly backed strong sale pd inhibitor keytruda let take look pharma biotech company be set report second quarter result aug let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning open bell deliver positive earning surprise last quarter pfizer earning performance have be mixed earning miss expectation last quarters beating same twice result average negative surprise quarter pfizer have earning esp zack rank hold indicate likely beat zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotenew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be likely contribute top line meaningfully read more be beat card pfizer earning aerie pharmaceutical inc aeri free report aerie pharma be schedule announce result close bell aerie pharma have miss estimate past quarters have average negative earning surprise company have earning esp zack rank buy see complete list today zack rank strong buy stock here aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc approve product portfolio aerie depend heavily late stage candidate rhopressa roclatan aerie have submit regulatory application rhopressa expect submit same eu second half hence expect investor focus remain pipeline update read more card aerie earning season incyte corporation incy free report company be expect report market open incyte deliver earning surprise last quarter incyte performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank zack consensus estimate be peg loss cent share incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quotemore stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2023,JNJ,abbvie inc abbv free report report better expect result second quarter company surpass earning sale expectation year so far abbvie share have rally thus favorably compare industry increase company report second quarter earning share marginally beat zack consensus estimate share earning grow year year company post revenue report quarter again narrowly surpass zack consensus estimate revenue also increase year year operational basis revenue increase quarter detailkey drug humira record sale growth operational basis revenue come sale increase humira sale ex market be operational basis report basis growth major market category drive upside increase competition new class drug well indirect biosimilar competition international market second quarter net revenue imbruvica stand year year sale imbruvica be compare year figure abbvie record international profit sharing johnson johnson jnj free report other product deliver impressive performance include duodopa show revenue operational report basis product call creon report revenue operational report basis hcv product viekira record sale sequentially sale be also operational report basis respectively due intense pricing competitive pressure hcv market adjust sg expense dip expense escalate quarter adjust operate margin be sale report quarter outlookabbvie reiterate previously issue outlook company maintain adjust ep range thus reflect year year growth mid point abbvie inc price consensus ep surpriseabbvie inc price consensus ep surprise abbvie inc quotezack rank key picksabbvie currently carry zack rank hold better rank stock health care sector be eli lilly company lly free report sanofi sny free report carry zack rank buy see complete list today zack rank stock here eli lilly earning share estimate inched last day company share have shot so far year sanofi earning share estimate increase last day company deliver positive earning surprise trail quarters average beat share company have rise so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2024,JNJ,second quarter earning season be strong start july approximately company index total membership have report result deep look result show earning company report so far be year year higher revenue have top earning estimate have beat revenue estimate however pace growth be first quarter line quarter average have improve quarter average go forward estimate third quarter be go estimate growth be start quarter pharma sector have more less combat overall decline financial market maintain momentum last week industry bellwether johnson johnson jnj free report report mixed second quarter result beating earning miss sale swiss major novartis ag nvs free report report encourage second quarter result meanwhile biotech giant biogen inc biib free report surpass expectation earning sale second quarter raise annual guidance let take look biotech company be set report second quarter result jul bristol myer squibb company bmy free report be schedule report open bell last quarter company beat earning estimate bristol myer have decent track record so far company earning beat estimate trail quarters average positive surprise currently company have zack rank hold earning esp current rank increase predictive power esp esp make unlikely stock beat quarter uncover best stock buy sell re report earning esp filter bristol myer high profile immuno oncology drug opdivo be expect continue drive company top line be report quarter first quarter see stability second line lung cancer recent fda approval merck co inc mrk free report keytruda first line treatment metastatic nonsquamous nsclc impact sale read more offing bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotecelgene corporation celg free report be schedule report open bell last quarter company beat expectation celgene key product revlimid be expect continue be main growth driver first quarter drive share gain important market longer treatment duration newly diagnosed multiple myeloma mm other key product pomalyst imnovid abraxane otezla continue perform well second quarter call investor be expect remain focuse company performance label expansion effort update pipeline front celgene have submit new drug application fda idhifa relapse refractory aml nda idhifa be grant priority review prescription drug user fee act pdufa action date aug celgene track record have be pretty decent company toppingearning estimate thrice trail quarters overall company have deliver average positive surprise currently company carry zack rank earning esp indicate likely earning beat quarter read more be celgene poise beat earning season celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotealexion pharmaceutical inc alxn free report be schedule report result open bell last report quarter company earning surpass zack consensus estimate alexion blockbuster drug soliris continue perform well label expansion drug additional indication be expect boost revenue new product strensiq be do well kanuma lag expectation management be reassess strategy drug go forward alexion track record be excellent company have consistently top expectation last quarters average positive earning surprise currently company carry zack rank earning esp indicate be likely beat estimate quarter read more be beat store alexion earning season alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2025,JNJ,johnson johnson jnj free report healthcare bellwether announce fda have approve label expansion oral pulmonary arterial hypertension pah medicine tracleer consequently mg tablet tracleer be now approve use pediatric patient age year older idiopathic congenital pah improve pulmonary vascular resistance pvr be expect result improvement exercise ability approval tracleer have become first medicine be approve use pediatric patient mg oral suspension formulation pediatric use be expect be available fourth quarter year presently tracleer be market mg dosage adult patient still be available remind investor tracleer other pah drug include opsumit ventavis veletri uptravi be add portfolio acquisition swiss biotech actelion acquire actelion june year diversify former revenue pah category actelion newer drug opsumit uptravi have be well receive be poise become blockbuster drug however tracleer older medicine be face competitive pressure believe label expansion pediatric use improve sale tracleer go forward pah be chronic life threaten disease characterize increase blood pressure pulmonary artery pah market be highly attractive give low diagnosis rate low penetration exist therapy significant unmet medical need other actelion unite therapeutic corporation uthr free report hold strong position pah market many approve product remodulin adcirca tyvaso orenitram pfizer pfe free report revatio be used same indication well arena pharmaceutical inc arna free report have ralinepag pipeline be also be develop pah so far year share price have increase compare favorably gain record industry belong carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today
2026,JNJ,pfizer inc pfe free report partner bristol myer squibb company bmy free report present finding phase iv study eliquis demonstrated oral anticoagulation potential achieve maintain normal heart rhythm cardioversion study emanate compare eliquis standard care heparin reduce occurrence acute stroke systemic embolism major bleed clinically relevant major bleed cause death valvular atrial fibrillation nvaf patient undergo cardioversion remind investor eliquis be already approve reduction risk stroke systemic embolism patient nvaf treatment deep vein thrombosis dvt pulmonary embolism pe reduction risk recurrent dvt pe follow initial therapy prophylaxis dvt lead pe patient have undergo hip knee replacement surgery however drug be not approve reduction stroke nvaf patient undergo cardioversion pfizer have underperform industry so far year stock have gain period industry gain come back latest news cardioversion procedure be associate concern clot blood heart travel brain stroke other body part systemic embolism emanate study show be stroke eliquis group compare stroke heparin arm however systemic embolism be observed drug group eliquis also reduce number major bleed event clinically relevant major bleed event compare heparin current standard care heparin coumadin require monitoring potential dose adjustment administer reduce risk stroke however eliquis be administer fix dose mg twice daily note eliquis be anticoagulant increase risk bleed become serious potentially fatal company also announce datum real world analysis eliquis nvaf patient separate press release analysis eliquis show lower risk stroke lower rate major bleed compare coumadin nvaf patient well select high risk patient sub population eliquis face competition anticoagulant segment johnson johnson jnj free report xarelto boehringer ingelheim pradaxa approval portola pharmaceutical inc ptla free report bevyxxa june competition be expect intensify stroke event be major concern nvaf patient finding show eliquis become prefer treatment same boost potential drug pfizer bristol myer try get label eliquis expand include finding give drug edge other market blood thinner pfizer inc price consensus pfizer inc price consensus pfizer inc quotecurrently pfizer carry zack rank hold see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2027,JNJ,dow enjoy strong week gain ride stellar earning result index decline monday due spike bond yield dim attraction such safe haven stock telecom utility index close green successive day close thursday record level fed decision refrain raise rate end day policy meeting also lift investor sentiment last week dow lose last friday general electric company ge post decline second quarter earning revenue furthermore decline oil price adversely affected energy share turn weigh broader market petro logistic opec be expect increase crude production barrel day bpd month such expectation increase production level oversupply concern drag oil price lower index decline last week dismal performance ibm ibm free report goldman sachs gs weigh dow again amazon sear deal adversely affected home depot hd free report turn weigh dow other benchmark end week gain dow dow decline monday largely due fact bond yield increase lead investor exit utility telecom stock also share johnson johnson jnj free report fall drag blue chip index be largely due fact merck co mrk free report together south korean partner samsung bioepis co ltd have start selling renflexis less expensive alternative version johnson johnson rheumatoid arthritis drug remicade unite state index gain tuesday follow stellar earn result mcdonald corp mcd caterpillar inc cat oil price rise follow saudi decision curb oil export be broad gain technology stock tech rally continue index increase wednesday boost strong earning result fed decision not raise rate end day meeting splendid second quarter earning boee company ba free report help close dow record high dow outperformed other benchmark close record high thursday ride rally share boee company verizon communication inc vz free report blue chip index gain however technology stock take batter share apple inc aapl free report swoon due now familiar speculation overvaluation tech stock component move index company mmm free report report strong second quarter result healthy year year increase earning revenue gaap earning report quarter be share compare share year earlier quarter however report earning miss zack consensus estimate penny net sale quarter be year quarter miss zack consensus estimate zack rank hold rate raise earlier guidance read slightly miss earning organic growth caterpillar deliver upbeat quarter adjust earning share second quarter logging improvement year year also ahead zack consensus estimate revenue improve year year quarter surpass zack consensus estimate give upbeat first half performance improve order activity discipline cost control zack rank buy rate caterpillar have hike revenue guidance range prior range read caterpillar top earning revenue raise view coca cola company ko free report report second quarter adjust earning cent share surpass zack consensus estimate cent net revenue decline year year due currency headwind negative impact structural item zack rank buy rate coca cola expect organic revenue rise company expect adjust ep decline prior year comparable ep read coca cola healthy drive help earning beat boee report adjust earning share second quarter beating zack consensus estimate gaap basis boee report earning share loss cent share year quarter company revenue amount report quarter miss zack consensus estimate report figure also decline year year stock have zack rank buy see complete list today zack rank strong buy stock here dupont record adjust earning share second quarter share year result top zack consensus estimate zack rank rate dupont logged net sale roughly year year higher volume also surpass zack consensus estimate read dupont earning revenue trounce estimate mcdonald post robust result second quarter bottom top line outpaced zack consensus estimate adjust earning share ep surpass zack consensus estimate improve year quarter mcdonald have zack rank revenue decline year year mainly due impact company strategic refranchise initiative constant currency figure decline however same surpass zack consensus estimate nearly nearly read mcdonald top earning solid comp growth general electric report second quarter earning cent share beat zack consensus estimate cent total consolidated revenue report quarter decrease year year surpass zack consensus estimate ge have zack rank strong sell general electric reaffirm guidance company continue anticipate operate earning be organic growth read ge excel earning revenue estimate affirm view procter gamble company pg fiscal fourth quarter core earning cent share beat zack consensus estimate cent bottom line also increase prior year quarter report net sale surpass zack consensus estimate top line however remain unchanged compare year level procter gamble have zack rank cincinnatus base company expect organic sale growth range fiscal core earning share growth be project compare fiscal core earning share read procter gamble top earning revenue estimate unite technology corporation utx free report report second quarter earning share beating zack consensus estimate bottom line also come higher year tally net sale report quarter come outpace zack consensus estimate addition top line come higher prior year figure zack rank rate unite technology raise lower end full year earning guidance adjust earning be currently anticipate lie share range previously estimate range read unite technology top earning lift view verizon post second quarter adjust earning cent share line zack consensus estimate total revenue increase year year beating zack consensus estimate verizon have zack rank total operate expense second quarter be year year operate income come compare year quarter read verizon earning line revenue beat estimate visa inc report third quarter fiscal end jun earning cent share beating zack consensus estimate cent also bottom line improve year year net operate revenue surpass zack consensus estimate also revenue climb year year visa have zack rank fiscal visa largely reaffirm guidance adjust earning share growth be project be normal dollar basis read visa beat earning revenue tweak view microsoft corporation msft free report report fourth quarter fiscal earning cent share beat zack consensus estimate cent earning share ep increase constant currency cc year year basis sequential basis revenue adjust window deferral impairment restructure charge increase sequentially year quarter cc further exceed zack consensus estimate read azure office help microsoft top earning performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain tickerlast day performance month performancemmm gs ibm hd ba unh mcd trv jnj aapl next week outlookmost dow component earning have be bullish nature keep tone rest second quarter earning result bunch key earning way shift turn somewhat economic datum follow release gdp datum today come better expect market be likely focus economic fundamental give growth be slate pick second half year stock be likely receive further catalyst gain day ahead hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
2028,JNJ,unite therapeutic corporation uthr free report report adjust earning share include stock base compensation benefit exclude charge second quarter be better share year quarter unite therapeutic say have set aside potential settlement department justice doj resolve investigation related contribution profit organization provide financial assistance patient thereby violate federal security law quarter company record charge estimate loss contingency relation matter also record impairment charge related cost method investment privately hold company experience event trigger impairment analysis include charge stock base compensation benefit company incur loss share miss zack consensus estimate revenue report quarter rise year year beat zack consensus estimate stronger sale pulmonary arterial hypertension pah franchise pull top line quarter better expect sale performance share decline almost thursday response potential settlement expense look unite therapeutic share price movement show stock have underperform industry year so far unite therapeutic stock have decline period industry rise quarter detailunite therapeutic market product treatment pah remodulin tyvaso adcirca orenitram orenitram report sale quarter year year adcirca sale be year year tyvaso sale totale year year remodulin sale be year year however sale tyvaso remodulin improve sequentially quarter unituxin treatment pediatric patient high risk neuroblastoma sale be year year lately growth unite therapeutic pah drug orenitram tyvaso remodulin have slow due competition last quarter company have say patient be stay longer front line oral ambition therapy adcirca gilead science inc gild free report letairis delay transition inhaled injectable therapy tyvaso remodulin thereby hurt demand meanwhile drug be also face strong competition actelion now part johnson johnson jnj free report new drug uptravi selexipag initial treatment pah be typically orally deliver drug follow prostacyclin therapy first quarter earning call management have say longer use oral therapy result large backlog patient eligible prostacyclin therapy pah medicine suggest sale trend improve sale tyvaso remodulin orenitram improve second quarter first quarter level management believe be see early sign transition ambition regimen back pah drug research development expense include stock base compensation benefit increase due higher cost support pipeline cardiopulmonary cancer drug develop organ manufacturing project selling general administrative sg expense include stock base compensation benefit decline lower consult marketing cost offset higher legal cost pipeline updateunited therapeutic be work medical device maker medtronic inc mdt free report get implantable pump deliver remodulin remosynch approve fda order launch remosynch unite therapeutic medtronic be pursue parallel regulatory filing related device drugwe remind investor april unite therapeutic announce regulatory issue delay plan launch remosynch company now expect launch remosynch sometime first half year expect previously unite therapeutic be also work deka development pre filled semi disposable pump system subcutaneous delivery remodulin remunity launch expect clinical study remopro pain free new chemical entity version treprostinil be expect begin year other phase iii pipeline program include oral combination therapy orenitram oreniplus freedom ev study tysuberprost esuberaprost combination tyvaso tyvaso ild tyvaso be evaluate patient pah associate idiopathic pulmonary fibrosis orenileft pah left ventricular diastolic dysfunction unite therapeutic be also develop dinutuximab active ingredient unituxin small cell lung cancer phase iii other high risk form cancer gd express cell tumor such ovarian cancer several sarcomas unite therapeutic carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2029,JNJ,expect pfizer inc pfe free report beat expectation report second quarter result aug market open last quarter company deliver positive earning surprise pharma giant have mixed record earning surprise company earning surpass expectation last quarters miss other result average negative surprise pfizer share rise year so far compare unfavorably increase zack classify industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be likely contribute top line meaningfully xeljanz mg take twice daily be approve eu mar boost drug sale be report quarter also revenue blockbuster prostate cancer drug xtandi add pfizer portfolio follow sep medivation acquisition be likely propel revenue hospira acquisition be expect be important growth driver well also pfizer launch inflectra biosimilar version johnson johnson jnj free report blockbuster drug remicade nov inflectra record sale globally first quarter biosimilar generate more sale soon be report quarter however pfizer continue face headwind form loss exclusivity key product pristiq zyvox celebrex expiration few co promotion agreement continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition prevnar prevenar vaccine franchise be expect continue see lower sale lower demand continue hurt sale viagra meanwhile bottom line be drive cost saving share buyback however new product launch expense investment be expect hurt profit second quarter call investor focus be expect remain performance new product pipeline progress include biosimilar immuno oncology importantly key cancer candidate bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc mar advanced bladder cancer drug bring revenue second quarter management be expect shed light launch be progress conference call acute lymphoblastic leukemia candidate besponsa be also approve eu late jun expect management comment plan conference call model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent share zack consensus estimate cent share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considera couple stock pharmaceutical sector also have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report earning esp zack rank company be schedule release result jul hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
